Principles and Practice of Pharmaceutical Medicine

Second Edition
Principles and Practice of Pharmaceutical Medicine

Second Edition

Edited by

Lionel D. Edwards
Novartis and Pharma Pro Plus Inc. New Jersey, USA

Andrew J. Fletcher
Temple University School of Pharmacy, Philadelphia, USA

Anthony W. Fox
EBD Group Inc., California, USA and Munich, Germany and Skaggs SPPS, University of California, San Diego

Peter D. Stonier
Consultant in Pharmaceutical Medicine, Richmond, Surrey, UK

John Wiley & Sons, Ltd
# Contents

Preface to the First Edition ix
Preface to the Second Edition xi
About the Editors xiii
Contributors xv

## SECTION I: OVERVIEW OF PHARMACEUTICAL MEDICINE

1 The Practice and Practitioners of Pharmaceutical Medicine 3
*Anthony W. Fox*

2 Pharmaceutical Medicine as a Medical Specialty 7
*Michael D. Young and Peter D. Stonier*

3 Clinical Research Education and Training for Biopharmaceutical Staff 25
*Peter Marks*

## SECTION II: DRUG DISCOVERY AND DEVELOPMENT

4 Introduction 41

4 Drug Discovery: Design and Serendipity 43
*Ronald R. Cobb and Leslie J. Molony*

5 Pharmaceutics 51
*Anthony W. Fox*

6 Nonclinical Toxicology 63
*Frederick Reno*

7 Informed Consent 75
*Anthony W. Fox*

8 Phase I: The First Opportunity for Extrapolation from Animal Data to Human Exposure 79
*Stephen H. Curry, Dennis McCarthy, Helen H. DeCory, Matthew Marler and Johan Gabrielsson*

9 Phase II and Phase III Clinical Studies 101
*Anthony W. Fox*

10 Phase IV Drug Development: Post-Marketing Studies 119
*Lisa R. Johnson-Pratt*
CONTENTS

11 Site Management
Barry Miskin

12 Good Clinical Practices
Wendy Bohaychuk and Graham Ball

13 Quality Assurance, Quality Control and Audit
Rita Hattemer-Apostel

14 The Unique Role of Over-the-Counter Medicine
Paul Starkey

SECTION III: SPECIAL POPULATIONS AND REQUIRED SPECIAL STUDIES

15 Drug Research in Older Patients
Lionel D. Edwards

16 Drug Development Research in Women
Lionel D. Edwards

17 Clinical Research in Children
Lionel D. Edwards

18 Racial and Ethnic Issues in Drug Registration
Lionel D. Edwards, J.M. Husson, E. Labbé, C. Naito, M. Papaluca Amati,
S. Walker, R. Williams and H. Yasurhara

19 Hepatic and Renal Failure
Anthony W. Fox

20 Drug Interactions
Anthony W. Fox and Anne-Ruth van Troostenburg de Bruyn

21 Orphan Drugs
Bert Spilker

SECTION IV: APPLIED ASPECTS OF DRUG DEVELOPMENT

22 Biotechnology Products and Development
David A. Shapiro and Anthony W. Fox

23 Pharmacoeconomics: Economic and Humanistic Outcomes
Raymond J. Townsend, Jane T. Osterhaus and J. Gregory Boyer

24 Pharmacoepidemiology and the Pharmaceutical Physician
Hugh H. Tilson

25 Statistical Principles and Application in Biopharmaceutical Research
Dan Anbar

26 Data Management
T.Y. Lee and Michael Minor
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>Patient Compliance: Pharmionics, a New Discipline</td>
<td>Jean-Michel Métry</td>
<td>355</td>
</tr>
<tr>
<td>28</td>
<td>Monitoring Drug Concentrations in Clinical Practice</td>
<td>Anthony W. Fox</td>
<td>375</td>
</tr>
<tr>
<td>29</td>
<td>Generics</td>
<td>J.D. Gabriel Lopez and J.D. Thomas Hoxie</td>
<td>381</td>
</tr>
<tr>
<td>30</td>
<td>Complementary Medicines</td>
<td>Anthony W. Fox</td>
<td>387</td>
</tr>
<tr>
<td>SECTION V: DRUG REGULATION</td>
<td></td>
<td>393</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>United States Regulations</td>
<td>William Kennedy</td>
<td>395</td>
</tr>
<tr>
<td>32</td>
<td>Special US Regulatory Procedures: Emergency and Compassionate INDs and Accelerated Product Approvals</td>
<td>Anthony W. Fox</td>
<td>407</td>
</tr>
<tr>
<td>33</td>
<td>The Development of Human Medicines Control in Europe from Classical Times to the Year 2000</td>
<td>John P. Griffin</td>
<td>415</td>
</tr>
<tr>
<td>34</td>
<td>Medicines Regulation in the European Union</td>
<td>Anne-Ruth van Troostenburg de Bruyn and Giuliana Tabusso</td>
<td>443</td>
</tr>
<tr>
<td>35</td>
<td>Japanese Regulations</td>
<td>Etienne Labbé</td>
<td>487</td>
</tr>
<tr>
<td>36</td>
<td>Drug Registration and Pricing in the Middle East</td>
<td>Edda Freidank-Mueschenbornfs</td>
<td>509</td>
</tr>
<tr>
<td>SECTION VI: MEDICAL SERVICES</td>
<td></td>
<td>517</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Medical Affairs</td>
<td>Gregory P. Geba</td>
<td>519</td>
</tr>
<tr>
<td>38</td>
<td>Drug Labeling</td>
<td>Anthony W. Fox</td>
<td>529</td>
</tr>
<tr>
<td>39</td>
<td>Drug Surveillance</td>
<td>Howard J. Dreskin and Win M. Castle</td>
<td>535</td>
</tr>
<tr>
<td>40</td>
<td>Data Mining</td>
<td>Mirza I. Rahman and Omar H. Dabbous</td>
<td>545</td>
</tr>
<tr>
<td>41</td>
<td>Risk Management in Product Approval and Marketing</td>
<td>Anthony W. Fox</td>
<td>557</td>
</tr>
</tbody>
</table>
CONTENTS

42 Publishing Clinical Studies
   Anthony W. Fox 565

43 Organizing and Planning Local, Regional, National and International Meetings and Conferences
   Zofia Dziewanowska and Linda Packard 575

44 Drug Withdrawals from the Market – Causes and Consequences
   Ronald D. Mann 579

SECTION VII: LEGAL AND ETHICAL ASPECTS OF PHARMACEUTICAL MEDICINE 585
   Introduction 585

45 Introduction to Bioethics for Pharmaceutical Professionals
   Andrew J. Fletcher 587

46 Pharmaceutical Medicine and the Law
   Sarah Croft and Timothy Pratt 595

47 Pharmaceutical Product Liability
   Han W. Choi and Howard B. Yeon 605

48 Patents
   Gabriel Lopez 619

49 Fraud and Misconduct in Clinical Research
   Jane Barrett 631

SECTION VIII: BUSINESS ASPECTS 643
   Introduction 643

50 The Multinational Corporations: Cultural Challenges, the Legal/Regulatory Framework and the Medico-commercial Environment
   R. Drucker and R. Graham Hughes 645

51 Advertising and Marketing
   Jonathan Belsey 653

52 Middle East, India, China and the Far East: Pharmaceutical Medicine in the East
   Gamal Hammad 665

53 Financial Aspects of Clinical Trials
   R.G. Hughes and N. Turner 689

54 Outsourcing Clinical Drug Development Activities to Contract Research Organizations (CROs): Critical Success Factors
   John R. Vogel 701

55 The Impact of Managed Care on the US Pharmaceutical Industry
   Robert J. Chaponis, Christine Hanson-Divers, and Marilyn J. Wells 725

Appendix: Useful Internet Links 745

Index 749
Preface to the First Edition

Pharmaceutical medicine is a relatively new, but rapidly growing, academic discipline. As these trends continue into the 21st century, pharmaceutical physicians are increasingly regarding consultancy work and contract research organization (CRO) affiliation as good career opportunities, and now recognize the need for continuing education and training in this broad spectrum discipline.

As editors, we would like to thank our contributors for their expertise, their dedication, and their vision. We would like to thank and acknowledge the work and counsel of our colleague Robert Bell, MD, MRPharmS, who helped us greatly during the early part of this project. We would also like to thank and acknowledge the enormous help, encouragement, and patience of the team at John Wiley & Sons, Inc., UK, with whom we have worked closely over these past few years, among whom we have particularly stressed (!) Michael Davis, Deborah Reece, Hannah Bradley, Lewis Derrick, and Hilary Rowe.

Lastly, we would like to thank our families, and friends, who have withstood the frequent telephone calls, e-mails, and meetings, often late into the night. Indeed, to all who made this project possible, both authors and non-authors, we thank you. We are certain that this specialty, and our patients, even though we may help them vicariously, will benefit because of your contributions.

Andrew Fletcher
Lionel Edwards
Tony Fox
Peter Stonier
Preface to the Second Edition

Since the first edition of this book, pharmaceutical medicine has only become more diverse and has also become widely accepted as a recognized medical specialty, for example, with its first graduates of specialist training in the United Kingdom, to add to those of Switzerland, and Mexico. This has been accompanied by pharmaceutical medicine’s rapid progress toward specialty recognition within the European Community, and many changes in the pharmaceutical environment. So, we have taken this book further with this second edition. There are new chapters on European regulations, risk management, the Middle East, Asia and other topical subjects in pharmaceutical medicine. Those chapters that did appear in the first edition have all been brought up to date.

But this book is for all those working in pharmaceutical medicine, regardless of their degrees, titles or affiliations. Although it comprehensively covers the internationally harmonized syllabus for the Diplomas in Pharmaceutical Medicine that are awarded in Belgium, Switzerland and the United Kingdom, this book will also usefully serve those teaching other types of certificates and (usually Master’s) degrees in this field, as well as being a vade mecum for those who are not undertaking academic courses.

We would again like to thank the team at John Wiley and Sons, Inc., Chichester (UK). Hannah Bradley got this second edition started, but then went off on a tour around the world; the editors strenuously deny that they are the reason why. Lucy Sayer and Juliet Booker have since piloted the ship to the dock-side, successfully cajoling us into getting this edition done before its second decade. Not least, we would like to thank you, the reader, for your continued support and suggestions. So here is our second edition, it is more than a simple update, and it is even less US-centric than before.

Lionel Edwards
Andrew Fletcher
Tony Fox
Peter Stonier
About the Editors

LIONEL D. EDWARDS, MB, BS, LRCP, MRCS, DipRCOG, FFPM, is Senior Director of Medical Affairs for Novartis USA, and President of Pharma Pro Plus Inc., a drug development consulting company. Dr. Edwards has been involved in all aspects of clinical trials for over 33 years on many different research drug and devices in 10 therapeutic areas. Previously, he was Vice President of Clinical Research at Bio-Technology Pharmaceutical Corporation, a small biotechnology firm operating both in the United States and internationally. Prior to this, he worked at Noven Inc., a small Skin Patch Technology firm with large internationally licensed partners – CIBA and Rhone Poulenc Rorer. He was Assistant Vice President, International Clinical Research at Hoffman-La Roche, Senior Director of Schering-Plough International Research, and Director of US Domestic Gastrointestinal, Hormonal, and OTC Research Departments.

Dr. Edwards chaired the PMA Special Population Committee, and also sat on the Institute of Medicine Committee for Research in Women, sponsored by the US National Instutes of Health. He also served on the efficacy subcommittee Topic 5 (Acceptability of Foreign Clinical Data) for the International Committee on Harmonization (ICH).

Dr. Edwards is a Fellow of the Faculty of Pharmaceutical Medicine and an Adjunct Professor at Temple University Graduate School of Pharmacology. He has taught for the Pharmaceutical Education & Research Institute for over 12 years and was on the teaching faculty of the National Association of Physicians. He is a founder member of the American Academy of Pharmaceutical Physicians. Dr. Edwards has homes in New Jersey and Florida.

ANDREW J. FLETCHER, MB, BChir, (Cantab), MS (Columbia), DipPharmMedRCP, FFPM was formerly the Senior Assistant Editor of The Merck Manual, and is Adjunct Professor of Pharmaceutical Health Care at Temple University School of Pharmacology. He graduated from Cambridge University and St. Bartholomew’s Hospital, London, briefly trained in Neurosurgery, joined CIBA-Geigy in the UK as Medical Advisor, then European Medical Director for Syntex, and joined Merck, first in the international division after graduating in business studies from Columbia University, New York City, then as Assistant Editor of The Merck Manual. He teaches pharmaceutical medicine, bioethics and medical and scientific writing at Temple University’s School of Pharmacy. He is a founder member and former trustee of the Academy of Pharmaceutical Physicians and Investigators (formerly the American Academy of Pharmaceutical Physicians). Dr. Fletcher resides in Ohio.

ANTHONY (‘Tony’) W. FOX, BSc, MBBS, FFPM, FRCP, MD(Lond), DipPharmMedRCP, CBiol, FIBiol, is President of EBD Group, a consultancy with offices in San Diego and Munich. From the Royal London Hospital, after general clinical training, he was Rotary International Fellow at Emory University (Atlanta) and CIBA-Geigy Fellow at Harvard. Industrial positions at Procter & Gamble and (then) Glaxo Inc. came next. He has also been a clinical and regulatory Vice President within a small pharmaceutical company. Among many societies, Tony was a Charter Member, Trustee, and Education VP of the American Academy of Pharmaceutical Physicians, and is a liveryman guardant of the Worshipful Society of Apothecaries of London. He is an Adjunct (i.e. honorary) Associate Clinical Professor in the Skaggs School of Pharmacy and
Pharmaceutical Sciences, at the University of California, San Diego. His publications span several areas of pharmaceutical medicine, for example, regulation, pharmacology, clinical trials, pharmacovigilance, analgesics, migraine, genotoxicology, and metabolism, and he is named as inventor on several patents. He is on the editorial boards of several journals, and serves in a more senior capacity for two of them. Tony is proud to be an Essex man, researches the history of that County, and has been elected as a fellow of the Royal Geographical and the Royal Numismatic Societies.

PETER D. STONIER, BA, BSc, PhD, MBChB, MRCPsych, FRCP, FRCPE, FFPM has 29 years experience in pharmaceutical medicine. He is a graduate of Manchester Medical School, qualifying in 1974, following a BSc degree in physiology (University of Birmingham) and a PhD in protein chemistry (University of Sheffield). He is a pharmaceutical physician and was Medical Adviser with the UK Hoechst Group of companies from 1977, serving as Medical Director and Board Director until 2000. Currently, he is Director of Education and Training of the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians of the UK. He is Medical Director of Amdipharm Plc, and of Medical Resource Provider Axess Ltd. Formerly, he was President of the International Federation of Associations of Pharmaceutical Physicians (IFAPP) and Chairman of the British Association of Pharmaceutical Physicians. He is a past-President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, UK. He is Visiting Professor in pharmaceutical medicine at the University of Surrey, which under his direction introduced the first MSc degree in Pharmaceutical Medicine in 1993, which is now part of the Postgraduate Medical School of the University. His publications include edited works in human psychopharmacology, pharmaceutical medicine, clinical research, medical marketing, and careers in the pharmaceutical industry. He is a member of the Association of Pharmaceutical Physicians and Investigators (APPI). Professor Stonier has been elected a Fellow of the Royal Society for the encouragement of Arts, Manufactures and Commerce.
Contributors

Anbar, Dan  ClinPro Inc., 1661 Route 22 West, Round Brook, NJ 08805, USA.
Email: dan.anbar@clinproinc.com


Barrett, Jane  2 Falcon Way, Wokingham, Berkshire RG41 3HD, UK.
Email: janebarrett@doctors.org.uk

Belsey, Jonathan  JB Medical, The Old Brickworks, Chapel Lane, Little Cornard, Sudbury, Suffolk CO10 0PB, UK.
Email: jbelsey@jbmedical.com


Boyer, J. Gregory  Accreditation Council for Pharmacy Education, Chicago, IL, USA

Castle, Win M.  Formerly of GlaxoSmithKline, Philadelphia, PA, USA.
Email: winwinsituation@earthlink.net

Chaponis, Robert J.  US Medical Operations, Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA.
Email: robert.j.chaponis@pfizer.com

Choi, Han W.  Oracle Investment Management Inc., 200 Greenwich Ave 3rd Fl., Greenwich, CT 06830, USA.
Email: hchoi@oraclepartners.com

Cobb, Ronald R.  RiverWood BioConsulting Inc., 8909 SW 75th Street, Gainesville, FL 32608, USA

Croft, Sara  Shook, Hardy and Bacon International LLP, London, UK and Shook, Hardy and Bacon LLP, Kansas City, MO, USA

Curry, Stephen H.  Department of Pharmacology and Physiology, University of Rochester, Rochester, NY 14627, USA.
Email: stephenhcurry@earthlink.net

Dabbous, Omar H.  Health Economics & Clinical Outcomes Research, Medical Affairs, Centocor Inc., 800 Ridgeview Drive, Horsham, PA 19044, USA.

DeCory, Heleen H.  UCB, 755 Jefferson Road, Rochester, NY, USA

Dreskin, Howard J.  7809 Via Optuntia, Carlsbad, CA 92009, USA. Formerly of GlaxoSmithKline, Philadelphia, PA, USA.
Email: howard.dreskin@adelphia.net
**Drucker, R.** Technomark Consulting Services Ltd, King House, 11 Westbourne Grove, London W2 4UA, UK. Email: rdrucker@technomark.com

**Dziewanowska, Zofia** Ligand Pharmaceuticals Inc., 10275 Science Center Drive, San Diego, CA 92121, USA. Email: zofia@ligand.com

**Edwards, Lionel D.** Novartis Pharmaceuticals Corporation, US CD&MA, Building 501/Room 216, One Health Plaza, East Hanover, NJ 07936-1080, USA. Email: lionel.edwards@novartis.com

**Fletcher, Andrew J.** Temple University School of Pharmacy, PHARM-QA/RA, 3307 North Broad Street, Philadelphia, PA 19140, USA. Email: andrew.fletcher@temple.edu

**Fox, Anthony W.** EBD Group Inc., 2032 Corte del Nogal #120, Carlsbad, CA 92011, USA and Neuhauser Straße 3, Munich, D-80331, Germany. Email: awfox@ebdgroup.com;

**Freidank-Müsch enborn, Edda** International Regulatory Affairs, Engelhard Arzneimittel GmbH, Herzbergstrasse 3, 61138 Niederdorfelden, Germany. Email: e.mueschenborn@engelhard-am.de

**Gabrielsson, Johan** AstraZeneca R&D, Wilmington, DE, USA

**Geba, Gregory P.** Novartis Pharmaceuticals Corporation, One Health Plaza, Building 701, East Hanover, NJ 07936-1080, USA. Email: gregory.geba@novartis.com

**Griffin, John P.** John Griffin Associates Ltd, Quartermans, Digswell Lane, Digswell, Welwyn, Hertfordshire AL7 1SP, UK. Email: JQmans5@aol.com

**Hammad, Gamal** 24 Cassiobury Park Avenue, Watford, Hertfordshire WD18 7LB, UK. Email: haithamgbr@talk21.com

**Hanson-Divers, Christine** Cary, NC, USA

**Hattemer-Apostel, Rita** Verdandi AG, Wiesergasse 2, 8049 Zurich, Switzerland. Email: rha@verdandi.ch

**Hoxie, Thomas** Hoxie & Tso LLP, 374 Millburn Avenue, Suite 300E, Millburn, NJ 07041, USA

**Hughes, R. Graham** Technomark Consulting Services Ltd, King House, 11 Westbourne Grove, London W2 4UA, UK. Email: rghughes@technomark.com

**Husson, J.M.** Paris, France

**Johnson-Pratt, Lisa R.** Wynnewood, PA, USA. Email: lisa_johnsonpratt_md@merck.com

**Kennedy, William** Consultant, Delaware, USA; formerly V.P. Regulation Affairs. Email: consultkennedy@aol.com

**König, Anja** International Regulatory Affairs, Engelhard Arzneimittel GmbH, Herzbergstrasse 3, 61138 Niederdorfelden, Germany. Email: an.koenig@engelhard-am.de
Labbé, Etienne  UCB S.A., Allée de la Recherche, 60, 1070 Brussels, Belgium.
Email: Etienne.Labbe@UCB-Group.com

Lee, T.Y.  ACER/EXCEL Inc., USA.

Lopez, Gabriel  6 Pleasantville Road, New Vernon, NJ 07976, USA.
Email: lopezg4@yahoo.com

Marler, Matthew  Department of Psychiatry, University of California, San Diego, CA, USA

McCarthy, Dennis  AstraZeneca R&D, Wilmington, DE, USA

Mann, Ronald D.  42 Hazleton Way, Waterlooville, Hampshire PO8 9BT, UK.
Email: ronmann@professormann.com

Marks, Peter  Pfizer Inc., 50 Pequot Avenue, MS 6025-C4247, New London, CT 06320, USA.
Email: Peter.Marks@pfizer.com

Métry, Jean-Michel  AARDEX Ltd, Untermueli 6, Postfach 2026, 6302 Zug, Switzerland.
Email: jm.metry@aardex.ch

Minor, Michael  ACER/EXCEL Inc., USA

Miskin, Barry  University of Florida, College of Medicine, PO Box 8068, Jupiter, FL 33468, USA.
Email: miskinmd@aol.com

Molony, Leslie J.  RiverWood BioConsulting Inc., 8909 SW 75th Street, Gainesville, FL 32608, USA.
Email: Imolony@riverwoodbio.com

Naito, C.  Teikyo University, Japan

Osterhaus, Jane T.  Wasatch Health Outcomes, Park City, UT and Carlsbad, CA, USA.
Email: jtosterhaus@mindspring.com

Packard, Linda  Formerly American Academy of Pharmaceutical Physicians, Research Triangle Park, NC, USA

Papaluca Amati, M.  EMEA, London, UK

Pratt, Timothy  Shook, Hardy and Bacon International LLP, London, UK and Shook, Hardy and Bacon LLP, Kansas City, MO, USA

Rahman, Mirza I.  Health Economics & Clinical Outcomes Research, Medical Affairs, Centocor Inc., 800 Ridgeview Drive, Horsham, PA 19044, USA.
Email: mrahman@cntus.jnj.com

Reno, Frederick  Merritt Island, FL, USA. Email: fred_reno@msn.com

Shapiro, David A.  Integrated Quality Resources, PO Box 8530, Rancho Santa Fe, CA 92067, USA.
Email: dshapiro@idun.com

Spilker, Bert  Bert Spilker Associates, 8004 Overhill Road, Bethesda, MD 20814-1145, USA.
Email: bspilker@comcast.net

Starkey, Paul  Formerly SmithKline Beecham Healthcare, Parsippany, NJ, USA.
Email: pgvstar@aol.com

Stonier, Peter D.  5 Branstone Road, Kew, Richmond, Surrey TW9 3LB, UK.
Email: peterstonier@btinternet.com
CONTRIBUTORS

Tabusso, Giuliana  
Via Melchiorre Gioia 47, 20124 Milan, Italy.
Email: giulianatabusso@libero.it

Tilson, Hugh H.  
Office of the Dean, School of Public Health, University of North Carolina, Chapel Hill, NC 27599-7400, USA.
Email: hugh_tilson@unc.edu

Townsend, Raymond J.  
Elan Pharmaceuticals, 7475 Lusk Boulevard, San Diego, CA 9212, USA.
Email: ray.townsend@elan.com

Tilson, Hugh H.  
Office of the Dean, School of Public Health, University of North Carolina, Chapel Hill, NC 27599-7400, USA.
Email: hugh_tilson@unc.edu

Turner, Nadia  
Astra-Zeneca Pharmaceuticals, Macclesfield, UK

van Troostenburg de Bruyn, Anne-Ruth  
Takeda Global R&D Centre (Europe), Arundel Great Court, 2 Arundel Street, London WC2R 3DA, UK.
Email: vantoar@tiscali.co.uk

Vogel, John R.  
John R. Vogel Associates Inc., 328 Pualoa Nani Place, Kihei, HI 96753, USA.
Email: vogelj001@hawaii.rr.com; john@jrvogel.com

Walker, S.  
Centre of Medicine Research, Carlshalton, UK

Wells, Marilyn J.  
Hampton University, Hampton, VA 23668, USA

Williams, R.  
US Pharmacopia, Rockville, MD, USA

Yasurhara, H.  
Teikyo University, Japan

Yeon, Howard B.  
Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Email: hyeon@partners.org

Young, Michael D.  
MDY-Associates, Philadelphia, PA, USA.
Email: MichaelDYoungMD@aol.com
SECTION I
Overview of Pharmaceutical Medicine
Pharmaceutical medicine is unquestionably a young medical specialty. The first university chair in pharmaceutical medicine is less than 10 years old, and there are no great buildings or institutions dedicated to it, unlike venerable medical specialties such as chest medicine, neurology, physiology, pharmacology and so on. Possibly because of its youth, this is a specialty that can be misunderstood by those outside it. Even among practitioners of pharmaceutical medicine, there can be surprise when they consider their own diversity.

Nonetheless, elements of what we recognize today as the practice of pharmaceutical medicine have existed for a long time. Withering’s identification of Digitalis purpurea as a treatment for what was then called ‘dropsy’ and the clinical trial of citrus fruit conducted by Lind are examples of drug discovery and investigation. Sequential clinical trial designs have been borrowed from as far a-field as the discipline of engineering and date from the mid-twentieth century. The techniques shared with the fields of epidemiology and public health are obvious and also well established. Every prescription written in ordinary clinical practice is a clinical trial of some sort, where \( n = 1 \), because human beings are anisogenetic; this even applies to identical twins as they age or are exposed to different environments. Ever since the need to demonstrate efficacy, tolerability and purity in drug products (and their equivalents in diagnostics and devices), pharmaceutical medicine has become evidence based; it is interesting to note that the more venerable medical specialties are now imitating the supposed ‘new kids on the block’ with the recent emphasis on evidence-based approaches to the patient.

It is therefore not surprising that the diverse and overlapping discipline of pharmaceutical medicine is populated by practitioners with varied educational backgrounds. There can be no doubt that clinical experience is always a good prelude to a career in pharmaceutical medicine. But dental surgeons, medical practitioners, nurses, pharmacists, physiotherapists, psychologists and many other members of the allied health professions have all found satisfying careers in this specialty.

Few medical specialties involve working in teams with as large a number of other professions as of pharmaceutical medicine. For example, general practitioners regularly work with nurses, health visitors, administrators, hospital colleagues and social workers; radiologists might add radiographers and physicists to this list and delete the health visitors and social workers. But, by way of comparison, the following list of nouns, all of which have their own professions, comprise pharmaceutical
medicine (in no particular order): ethics, chemistry, pharmacology, computational modeling, pharmaceutics, project planning, toxicology, regulatory affairs, logistics, quality control engineering, biostatistics, pharmacogenomics, clinical trials, politics, economics, public relations, teaching, pharmacovigilance, marketing, finance, technical writing, data automation, actuarial analysis, information science, publishing, public health, international aid and development, intellectual property and other types of laws. However, this is not an exhaustive list. Surely, there can be no other industry with as many diverse professionals as this one where all have the welfare of other human beings as their ultimate concern? And for those with a life-long thirst to learn on a cross-disciplinary basis, this breadth of intellectual interaction is a magnet.

Conversance with, if not advanced capability in, these specialties should therefore be an early goal of any career in pharmaceutical medicine. Those who remain in the industry thereafter usually value their initial generalist experience. But eventually, for most practitioners, the opportunity will exist either to remain as a generalist in pharmaceutical medicine or to sub-specialize within one or more areas in the list shown above.

But, perhaps the greatest difference between this specialty and all other specialties is the value placed on versatility, adaptability, communication skills and teamwork. Physicians and pharmacists must learn that in pharmaceutical medicine, they are unlikely to be as predominant as decision makers as they were in clinical practice. Those who can become an expert in some subject and be respected for it by people both inside and outside the company, even though they may never have heard of that particular disease or drug before three months ago, will do well if they can match such knowledge with superior inter-personal skills. Knowing when to lead, when to follow and when to get out of the way, rather than presuming a leadership role in all situations, will always be valued in this specialty.

Finally, what about those who do not stay in the specialty? Any clinician who spends just two or three years in pharmaceutical medicine but then returns to his or her clinical calling, will have benefited, if only having learned something about oneself and what one does not like to do at work! But, nonetheless, there will usually be an opportunity to gain some management experience and skills and to look at the therapeutic enterprise from a different angle: Appropriate scepticism with regard to the wanted and unwanted effects of drugs, and the ways they may be properly and improperly promoted, is best learned inside the industry and applied outside it. ‘Clinical re-entry’ after two or three years of pharmaceutical medicine will not be associated with being out of date in terms of knowledge and skills base, although re-entry after 10 years almost certainly will. Those attempting the latter should anticipate the need for re-training.

1.1 Organizations and educational systems

Most countries in the developed world have one or more national societies or academies devoted to the specialty of pharmaceutical medicine. All hold education and training as central to their mission, whereas some societies will engage in regulatory or political debates when particular issues arise.

The first formal post-graduate qualification to acquire in pharmaceutical medicine is a Diploma in Pharmaceutical Medicine (DipPharmMed). It requires two years of part-time study and tests the knowledge basis for the specialty. This diploma has been examined by the Royal Colleges of Physicians (RCP) in the United Kingdom for more than 30 years, and its possession qualifies the holder for membership in the Faculty of Pharmaceutical Medicine (MFPM). The Belgian Academy has more recently introduced a diploma which is recognized reciprocally with that in the United Kingdom, and accordingly, there is periodic exchange of examiners. Switzerland is likely to be the next, and progress toward an analogous goal (‘Board certification’) is being made in North America. At least two years’ experience in clinical medicine and prescribing is a matriculating qualification for these diplomas; in countries where the roles of pharmacists, physician’s assistants and nurses include prescribing responsibility, these
professionals should enquire from the relevant Academy or Royal College whether they may also sit this examination.

Beyond the diploma, the European Economic Area (the European Union plus Iceland, Norway and Liechtenstein) will probably soon recognize pharmaceutical medicine as a medical specialty on the official list and national medical registers. Achieving the Certificate of Specialized Training (CSST) will require completion of a modular, part-time program of Higher Medical Training (HMT) for which the diploma will be the matriculating qualification. Whether or not holding the CSST, it will also become possible to revalidate specifically as a pharmaceutical physician.

International compatibility and recognition of these qualifications would seem essential in a profession whose activities are being increasingly globalized. Many employment opportunities in pharmaceutical medicine are with companies that have become international conglomerates. Intra-company transfers and international job applications can only be facilitated by universally recognized and accredited qualifications.

Many other qualifications are also of benefit in pharmaceutical medicine, even if the holder was already a physician, nurse or pharmacist. These will be more or less specific to that long list given above, many of which have their own diplomas and university degrees. Human resources departments have to be well informed about the diversity of formal recognitions that may be held by those who can contribute to the industry and its regulation.

Lastly, is there any evidence for all this optimism? In the year 2000, the American Academy of Pharmaceutical Physicians (AAPP) polled its members on their career choices and factors associated with satisfaction. More than 90% of the members indicated overall satisfaction with their choice of pharmaceutical medicine. This proportion was higher than any other that has been reported by learned societies from similar surveys in other medical sub-specialties in the United States.

Further reading

Useful web sites on careers and/or qualifications (http://): www.fpm.org; www.acrp.org.
Medicine is an art that has been practiced since time immemorial. The use of herbs and natural medicaments to relieve pain or to aid the sick in coping with their afflictions has been a part of all societies. In the Western world, medicine has developed at least since the time of the Greeks and Romans – the Hippocratic oath reminds us of this nearly 2500-year history. However, the progress of medicine has been very different from that of many other arts within society. It has come of age after an incredibly long maturation period. As a function capable of offering a successful treatment for a human ailment, medicine is very much a development of the last 100–150 years. Indeed, the major advances have come in the last 50–75 years.

The role of physicians in society has changed over the centuries. It may have reached its nadir during the early renaissance, when the general attitude was, as Shakespeare said, ‘Trust not the physician; his antidotes are poison’. From nineteenth century onwards, with their growing diagnostic understanding and their therapeutic agents becoming increasingly effective, physicians have come to be increasingly valued. Today, much of the practice of medicine in all of its subspecialities is based on a physician’s diagnosis and treatment with drugs, devices or surgery. This radical change to an era of focused treatments, after aeons of using homespun remedies and then watching hopefully for the crisis or the fever to pass, has accompanied the recent revolutions in the understanding of biological processes and in technical and biotechnical capabilities. These developments have allowed us to produce pure therapeutic agents and establish their safe and effective use.

The exponential growth in scientific knowledge, particularly over the last 100 years, has brought about a paradigm shift in our approach to pharmaceuticals. Until the twentieth century, the sale and use of medicines and medical devices was almost entirely unregulated by governments. It was a case of caveat emptor, with only the drug taker’s common sense to protect against the dangers of the so-called patent medicines and ‘snake oils’. The obvious abuses in these situations eventually led to government intervention, professional regulation and requirements that drugs be pure and unadulterated. With advances in science and in the ability to define and establish drug efficacy came a requirement to demonstrate that drugs were also safe. Finally, as late as the second half of the twentieth century, came the legal requirement to establish that pharmaceuticals were effective before they were marketed. These legal requirements reflected changes in social attitudes and
expectations grounded in the questions that the development of biological and basic sciences had made it possible to ask and to answer. The response to these changes has led to the development of the speciality of pharmaceutical medicine.

Pharmaceutical medicine can be defined as ‘the discipline of medicine that is devoted to the discovery, research, development, and support of ethical promotion and safe use of pharmaceuticals, vaccines, medical devices, and diagnostics’ (by-laws of the Academy of Pharmaceutical Physicians and Investigators, APPI). Pharmaceutical medicine covers all medically active agents from neutraceuticals, through cosmeceuticals and over-the-counter (OTC) pharmaceuticals, to prescription drugs. Furthermore, the speciality is not confined to those physicians working within what is classically considered the pharmaceutical industry but includes those involved in the clinical management or regulation of all healthcare products. It is the basic speciality for physicians within the cosmetics and nutrition industry for those in the device industry and for those in ‘not-for-profit’ companies, such as those responsible for the national blood supplies and/or for specialized blood products. Furthermore, it is the fundamental discipline for physicians who are in government health ministries, insurance companies, National Health Trusts or HMO management, drug regulatory agencies or any other oversight or regulatory function for healthcare.

In the early part of this quarter-century, for a medicine to be adopted and to sell, it was sufficient that science could conceive of a new treatment, that technology could deliver that treatment, and that clinical research could prove it effective and safe for the physician to use. This is no longer the case. Over the past three decades, we have seen the emergence of two major influences in decisions about new advances in healthcare. These are the payer–providers and the patient–consumers. Their role in the decision-making process has increased rapidly in the last 25 years, as can be seen in Figure 2.1.

With an increasing proportion of society’s healthcare budget spent on pharmaceuticals, even a growth in the percentage of the gross national product that governments are willing to allocate to healthcare has been unable to meet the demands of unbridled development. This has made the payer/provider a major determiner of the use of pharmaceuticals. All possible treatments cannot be freely available to all and a cost-to-benefit consideration has to be introduced. This, in turn, has ensured that pharmaceutical medicine involves pharmacoconomics training and even media training to deal with what, for some, may be seen as the rationing and/or the means-testing of access to the totality of healthcare options. These are significant ethical and social issues, and physicians within the pharmaceutical industry or the health regulatory agencies will inevitably be required to provide a perspective, both internally and to those outside.

The second new decision maker in the provision of healthcare has arrived even more recently as a crucial component. These are the end-user or patient groups. The rising status of the physician since the nineteenth century has encouraged a paternalistic doctor–patient relationship, with the physician clearly in the lead. In recent times, the nature of this relationship has come under question. The advent of holistic medical concepts focused on the whole patient, and taking into account the entirety of an individual patient’s life has forced changes in the focusing of any therapeutic interaction. The general increase in educational standards within the developed world and the massive increase in available information culminating today with the electronic media and the Internet has inevitably produced a more informed patient. This has empowered the patient and led to the formation of all kinds of public interest and patient groups. Furthermore, the ability in this century to think in terms of the maintenance of good health and even of the abolition of disease (e.g. smallpox and polio) has changed the patient’s and society’s
attitudes to what they can and should expect of physicians. Today, we are very much moving towards a balance in the therapeutic interaction, if not to a patient–doctor relationship. This change is a seminal one for the delivery of healthcare and for the development of new therapeutic agents.

For prescription drugs, the major factor bringing about the involvement of patient groups was probably the revolution in the new drug evaluation process caused by the AIDS epidemic. This terrible affliction occurred at a time when groups within society were forming to fight for their recognition and/or rights quite independent of the occurrence of a life-threatening disease. Nonetheless, within the Western world, it is clear that these groups rapidly came to form a vanguard for patients rights with respect to AIDS. They challenged the paternalism within medicine and insisted on access and full disclosure of what was going on in pharmaceutical medicine and within academic medical politics. Without this openness such patients would have lost confidence in pharmaceutical companies, the academia and the medical and regulatory establishments. Having forced a re-evaluation and a greater respect for patients’ needs, AIDS Coalition to Unleash Power (ACTUP) and others have brought patient representatives into the drug development process. Such educated and involved patients have, in their turn, come to understand the scientific methodology and the requirement for the adequate testing of new drugs. Indeed, the requirements have consequently become much more acceptable to patients in general. Nevertheless, there is no doubt that these proactive patient representative groups have forever changed the role of the patient in the development of therapeutics and of healthcare within society.

Pharmaceutical medicine is the discipline that specializes within medicine in overseeing the process of developing new therapeutics to improve the standard of health and the quality of life within society. Inevitably, then, it was one of the first medical specialities to feel this change in patients’ view of the quality of their care. An integral part of all progress in healthcare is evaluating the needs of patients and society and the gaps in the present provisions for those needs. To oversee this progress, pharmaceutical medicine involves the combination of the following: first, the medical sciences to evaluate disease; second, the economic sciences to evaluate the value with respect to costs; and third, the ethical and social sciences to evaluate the utility of any new drug to patients and to society as a whole.

As with all products, truly successful therapeutic agents are those that meet all the customers’ needs. In today’s and tomorrow’s world, the concept that all that is needed is for medicines to meet the scientific requirements of being effective and safe is essentially an anachronism. It is not just the scientific factors and customers that must be satisfied. Table 2.1 shows that the two other critical factors or influences outlined in Figure 2.1 produce many more customers to be served.

As members of the public become generally more and more informed, it is inevitable that they will want to take more of a role in deciding on their own health and how any disease that they might have is to be treated. It is important to realize that this is likely to change the demand for healthcare. Some of the focus will shift to areas not classically considered as diseases or to health areas considered today as an inevitability of life or a condition for which the patient should ‘just take charge’. Typical examples will be, on the one hand, an increased focus on the quality of life or on the effects of ageing (such as cognitive dysfunction, menopause, osteoporosis and waning immunological function, with consequent increase in vulnerability to disease), and, on the other hand, disorders such as

<table>
<thead>
<tr>
<th>Table 2.1 Controlling factors in the adoption of new therapeutic agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Influences</strong></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Medical science</td>
</tr>
<tr>
<td>Physicians</td>
</tr>
<tr>
<td>Healthcare providers</td>
</tr>
<tr>
<td>National health services/HMOs</td>
</tr>
<tr>
<td>Consumers</td>
</tr>
<tr>
<td>Pharmacists</td>
</tr>
</tbody>
</table>


obesity, attention deficit, hyperactivity and even anorexia/bulimia. As the patients or their representatives respond and ‘take charge’, we should not be surprised to see a change in what are considered therapeutic modalities and how they are made available. We might expect a demand for products that do not need prescriptions (e.g. minerals, nutraceuticals and cosmeceuticals) or for patients to be able to self-diagnose and use prescription drugs moved to a ‘pharmacy only’ or to a full OTC status. Some of these moves may well fit within one or more governments’ desire to reduce the national pharmaceutical bill and hence may be something that has both patient and provider endorsement.

Those seeking to develop therapeutic products will need to understand these dynamic interactions and the consequent potential changes in one or more of society’s approaches to its healthcare. Indeed, this is another opportunity for pharmaceutical medicine to expand. The speciality should cover all pharmacologically active treatments, all disease preventions and all health maintenance modalities. The objective is to maximize patient benefits and extend product life cycles, as well as company sales. Clearly, pharmaceutical medicine requires an ability to read the direction society is taking and an understanding that, on a global basis, various societies can take different attitudes to how they will regulate and/or classify a therapeutic agent. However they are classified or regulated, new therapeutic agents will continue to be needed, health benefits to deliver now and to be potentially significant revenue generators for a business, allowing investment in future therapeutics. This is the basic cycle (Figure 2.2) that drives the pharmaceutical industry.

The R&D process is moving forward as biomedical science progresses and disease processes are better understood. The process of developing a therapeutic agent is much more than a better understanding of a disease leading to a new approach to its management. The process includes the following: first, state-of-the-art technical manufacturing sciences to ensure a drug substance is pure; second, appropriate and innovative pre-clinical science to ensure that a new chemical entity is as safe as possible before being used by humans; third, the most sophisticated clinical evaluation methodology, which must establish the efficacy and safety of a new treatment in humans and include a multi-disciplinary approach to medical, social and economic issues of quality of life and cost–benefit. Finally, the process includes the business management of social and political issues inherent in establishing, communicating and assuring the value of the new drug within a global economy.

The amount spent on R&D by the pharmaceutical industry has grown logarithmically over the past few decades, and now the industry outspends the National Institutes of Health in the United States (Figures 2.3 and 2.4).

Similar growth in R&D investment has been seen outside United States, for example in the United Kingdom. With such a massive R&D effort,
the process has inevitably become subdivided into several functional sections, the following being the most obvious:

- **Basic chemical or structural research**: Exploring the genetic basic of a disease or the microstructure of a receptor or enzyme active site, and from that, developing tailored molecules to provide specific interactions and potential therapeutic outcomes.

- **Pre-clinical research and development**: Using biological systems, up to and including animal models, to explore the causes of diseases and the potential safety and efficacy of new therapeutic agents.

- **Clinical development**: Using humans, both the healthy and those with a disease, to evaluate the safety and efficacy of a new drug. This section is itself, by convention, subdivided into three phases.

- **Regulatory and societal development**: Ensuring that the entire development of each new therapeutic is seen in the context of its need to meet governmental requirements and that the appropriate value-added components (e.g., quality of life, cost–benefit, evidence-based medicine, relative competitive positioning) over and above the basic demonstration of safety and efficacy are integrated into the product’s database.

- **Post-market approval medical affairs**: This involves the promotion of each product by marketing and sales functions and the oversight of this process by pharmaceutical physicians. Two other critical post-marketing components are as
follows: first, continued learning about the safety and efficacy of the product in normal medical practice, as opposed to clinical trials; and second, the development of new or improved uses of the product as more is learned about it and as medical science progresses.

So, the whole process of developing a new drug is extremely expensive and time-consuming. It is also a very difficult and risky process. Indeed, the majority of initial new product leads never reach the level of being tested on humans, and over 80% of the products that are tested on humans never become licensed drugs. Of course, all of the many failed research and development efforts must be paid for, as well as the relatively few successful projects. As Figure 2.3 shows, this can only be done from the earnings on the new treatments that are developed. This, and the need to return to shareholders a profit on their long-term investment in the R&D process, are the basic factors in the cost of new drug. A major role of pharmaceutical medicine is to ensure that the value of new therapies is clearly demonstrated so that society can see the cost–benefit of new medicines.

Overall, the process of moving from a research concept through development to a marketed drug and then further refining the drug’s value throughout what marketing would call the product’s life cycle involves many disciplines. It can be seen in the terms shown in Figure 2.5. The basic responsibility for establishing and maintaining the safety and efficacy of a drug involves knowing where all of these differing functions can have an effect on the risks and the benefits of medicines for patients.

In the 1950s and 1960s, random screening and serendipity was the basis of the approach to new drug discovery. The structure–activity relationships were rudimentary and used simplistic pharmacophores and animal ‘models of diseases’. This approach had essentially thousands of chemicals chasing a few models to hopefully find a new drug. The 1970s and 1980s have seen the impact of receptor science. They have seen the development of protein chemistry and elucidation of many enzymes and cell surface structures. Finally, the

![Figure 2.5](image-url)
1990s have seen the impact of enabling biomolecular technologies, such as combinatorial chemistry, genomics and high-throughput screening, and computer-assisted drug design, and so in the 1990s, we have basic pharmaceutical discovery being carried out at the molecular and disease mechanism level. As such, we now have many models to evaluate and have probably reversed the development paradigm to one that Dr Stanley Crooke, the Chief Executive Officer of Isis, has described as ‘target-rich but chemical-poor’.

Inevitably, in today’s world, where science seems to be producing amazing advances almost weekly, the focus is on R&D and further improvements in healthcare in the future. This should not cause us to take our eye off the needs of today and the ability of today’s medicines to be used most effectively. The value of a new therapeutic agent is not maximal at the time of its first approval. Much can be done after market approval to ensure that a new drug’s utility is both fully understood and actually realized. The physicians within pharmaceutical medicine need to oversee and lead this process. This requires that they are trained in economics and business as well as medicine. Indeed, some may well go on to specialized courses in those areas leading to diplomas and even university degrees.

The rapid advances in the biosciences and our gains in the understanding of diseases offer the opportunity of new benefits or uses for drugs to be developed after they have been marketed. Consequently, there is a real and ongoing role for those in pharmaceutical medicine to follow the advances of medical sciences and improve the value of the drugs of today within the medical and healthcare practices of tomorrow. This ‘evergreening’ process is analogous to physicians in their practice learning about a therapy and, as they come to know more about the use of the treatment and their practice dynamics change, modifying the use of that therapy to the maximum benefit of patients.

The management of a drug on the market is a professional challenge for which no medical school trains its physicians. The overall process and skill is an important part of the training within the specialty of pharmaceutical medicine. This effort may include the issues of quality-of-life evaluations, together with the appropriate development of evidence-based medicine, of outcomes research and cost–utility sciences. All of these are techniques needed within pharmaceutical medicine. Used appropriately, they can help not only to establish the curative value of a new medicine but also to ensure that the therapy gets delivered optimally.

Just as is one’s personal practice of medicine, there is no more rewarding experience than the optimal use of a treatment modality in a complex clinical case with a successful outcome and a happy patient; there is an equivalent reward in pharmaceutical medicine for a physician who positions a product to deliver the best benefit for all patients, convinces all those delivering the care to use the product, and sees a consequent real improvement in society’s level of healthcare. In the past, many good therapeutic agents have not been used as or when they should have been. This was not because patients in trials have not been benefited, rather because the value message had not been positioned adequately for the care providers and/or for those who have to manage the healthcare resources of our societies. Even when well developed and appropriately used for their approved indication, many drugs take on a new lease of life as medical sciences change and new therapeutic uses become possible; for example lidocaine was a very well-known local anaesthetic and was in use for decades when it found a new role as an antiarhythmic within the new context of cardiac resuscitation and coronary care units.

By the same token, as medicine progresses, the acceptability and safety of a drug can change. It is a basic axiom of pharmaceutical medicine that no drug can ever be considered completely safe. This is true no matter how much human-use data is available. For example, PhisoHex (hexachlorophene) gained broad usage as a skin wash and scrub to combat the spread of infection. It was used in paediatric and neonatal units in hospitals, by nurses and surgeons, as a scrub and was even sold over the counter as a teenage acne remedy. Notwithstanding all this, it became a safety issue. This was because, as medical science advanced, more and more premature babies were able to survive. The skin of these babies was
more permeable than that of full-term babies, children or adults. There was therefore a new potentially ‘at-risk’ group. Hexachlorophene toxicity in humans was considered to have resulted, and this led to the product being modified or removed in many markets worldwide.

The scale of the response to this issue provides a case history that highlights another skill and training required within pharmaceutical medicine, namely crisis management. This is a very important technique which is critical in addressing substantive health issues. In a relatively recent history of healthcare, there have been several such issues, for example Zomax, Oralflex, Tylenol tampering, toxic shock syndrome, Reye’s syndrome, the Dalcon shield, contaminated blood supply, silicon implants and the so-called ‘generic drug scandal’, to mention but a few.

Today, as much as being a leader in R&D, it is part of the role of a pharmaceutical physician to recognize new opportunities and to be alert for any emerging evidence of potential added benefits and/or new safety issues, as products and those of competitors are used more broadly outside the confines of clinical trials.

Many of the areas of expertise needed in pharmaceutical medicine overlap with the expertise of other medical disciplines. The most obvious overlap perhaps seemed to be with clinical pharmacology. Indeed, clinical pharmacologists have a real interest in the R&D of the pharmaceutical industry and their training is good for entry into the industry. However, clinical pharmacology is by no means the entirety of pharmaceutical medicine. Indeed, some pharmaceutical physicians will work in even more basic and theoretical science settings, whilst others will work in more commercial settings. Of course, many within the speciality can and do focus on the development of disease models and the evaluation of new chemical entities in these diseases. The most modern methods in such areas are vital to the successful development of new drugs, and the continued and continuous interaction between the industry and academia is absolutely necessary.

Indeed, the distinction between academia and pharmaceutical medicine is becoming blurred. The pharmaceutical industry R&D effort is now leading to Nobel prizes being awarded to those in the industry for pioneering work on subjects as diverse as prostaglandins, anti-infectives, and pharmacological receptors such as the histamine and the β-adrenergic receptor. The direct interaction within a company between those involved in basic research on receptors, active sites or genetic code reading sites, those synthesizing new molecules, and those testing them in the clinic, leads to the potential for a very fruitful research effort.

Naturally, the industry as a prime inventor has the opportunity to carry out seminal work with entirely unique concepts, even if many of them do not become therapies for humans. Human is a unique animal which can, and does, exhibit unique responses to a new chemical entity. No pre-clinical work can be entirely predictive of a successful response in the clinic, and there can, in the end, be no substitute for human testing. Some products fail because of safety problems specific to humans, and some because the early promise of efficacy in model systems is not realized in humans.

Those who join this new speciality may come from many medical backgrounds and can well spend much of their time doing things other than pharmacology. In a very real way, those in pharmaceutical medicine are practicing medicine. They are responsible for the products of the pharmaceutical industry that are in use today. As such, they are influencing the health of far more people globally than they ever could in the context of their own individual clinical practice.

Any discussion of the discipline of pharmaceutical medicine today would be incomplete without a comment on the impact of biotechnology and the burgeoning biotechnology revolution. This is a revolution that is driven in a very different way than that in which the pharmaceutical industry has classically been run. The prime drivers are a multitude of small venture capital companies which are espousing the very cutting edges of research in biologics, genetics and technology. They are largely managed by a combination of bioscientists and financiers. In this context, the role of pharmaceutical medicine takes on its most extreme variants. At one end are physician/scientists, who are the research brain of the venture, and at the other
end are physicians/businessmen, who are the money-raising voice of the venture. In either of these settings, pharmaceutical medicine is needed and the specialist will apply all of the training components that, as already indicated, compose this new discipline.

The biotechnology industry is carrying forward some of the best and brightest projects of the world’s leading academic institutions. It is moving pure research concepts through applied research into development and finally to the production of remarkable new therapeutic products. This industry has already created two or three new companies of substance, with sales of over $1 billion per year and a capitalization measured in billions. More than these obvious and huge successes, the industry has spawned literally thousands of venture capital efforts and new companies developing drugs, devices, diagnostics and all manner of medical technologies. Amazingly, this is an industry which has come into being in the last decade or two. Like the PC and software industry, it is revolutionizing society’s approach to new product development and even to what a new therapeutic agent actually is. Already, companies are finding that the major transition points in the therapeutic product development process, from molecular to biochemical system, to cellular system, to organ model, to intact organism, to mammalian model, to humans, are all real watersheds. Pharmaceutical medicine provides the required understanding of each of these processes and particularly of the transition points. In a very real sense, the success of these emerging companies will be determined by the quality of their pharmaceutical medicine efforts.

The new discipline of pharmaceutical medicine is a speciality which has only very recently become recognized in its own right as a speciality within medicine. Indeed, the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians was only founded in 1989 in the United Kingdom and the Academy in the United States even more recently in 1993. Like many new ventures, this new medical speciality is not seen by all today as one of the premiere medical roles. However, there is a growing involvement of academics within the pharmaceutical industry and Nobel prize-winning work is being done within the industry. Furthermore, there is a growing understanding within academia that in the past someone else was capitalizing on their intellectual endeavours, so we are seeing more medical and bioscience academics patenting their discoveries and going into business. As this progress continues, the two disciplines of research and business are coming to realize that neither can do the other’s work. Pharmaceutical medicine is the natural common pathway and the integrating speciality which will fill this need and will deliver the healthcare advances of the future. If this is so, then pharmaceutical medicine will become a leadership medical function in the twenty-first century. The speciality lies at the conjunction of changing societal needs for healthcare, the burgeoning biosciences and the understandings of how to provide improved quality of life and cost–utility for patients today. The expertise it contains and provides includes basic sciences, such as chemistry and mathematics, applied sciences, such as engineering, economics and business, biological sciences, such as pharmacology and toxicology, and the medical sciences from paediatrics to geriatrics and from family medicine to the individual subspecialities. As such, pharmaceutical medicine is one of the most challenging, exciting and rewarding areas of medicine. It is a career for those who wish to be in the vanguard of research on multiple fronts.

2.1 Education and training in pharmaceutical medicine

Doctors working with the pharmaceutical industry as pharmaceutical physicians are encouraged to undertake training in pharmaceutical medicine which is the medical discipline or speciality which encompasses their work in medical departments of the pharmaceutical and related healthcare companies, in clinical research units and regulatory bodies. Courses covering general and specialized aspects of pharmaceutical medicine have been established for many years in a number of European countries and elsewhere around the world.
2.2 Some background to pharmaceutical physician education and training

Training opportunities currently available and recommended for pharmaceutical physicians in the international field of pharmaceutical medicine in a global industry have increased enormously in recent years and space available here cannot possibly cover them all exhaustively. A recommended source of specific training opportunities originates from the professional bodies that support, deliver and endorse training opportunities. Many commercial training companies run competitive alternatives, and the trainee is advised to consider all the options that are appropriate to their individual training as well as experience of others.

The desire to learn through continuous improvement is matched by the desire to improve through continuous learning. Adequate training can fulfill these needs, but it is important to apply rules of measures and evaluation. Only by assessment of training through competency measurement can the trainee be nurtured into a position of excellence.

The curriculum vitae offers a simple way to keep track of training received, but a more detailed record should be kept by trainees themselves to illustrate specific examples of how the skills and knowledge gained from training have been implemented. With this information, the individual can identify outstanding training needs and, more significantly, highlight achieved goals, thus increasing their career opportunities.

All trainees should become aware of the expected learning cycle and their training needs with the scope of career options. A proactive trainee should insist on an induction programme when starting a new company whatever their status and experience.

The term trainee may seem pejorative to those doctors who embark on industry careers with high levels of educational and professional qualifications, experience and expertise, and who have gained their positions through competitive selection and expectations of effective contribution. It is used firstly because there is no ready alternative and secondly because in the context of the rapidly changing technological, managerial and organizational industrial setting, continuing education and training are an inherent career-long learning process, regardless of seniority, longevity or trajectory: ‘we are all trainees now’.

The learning cycle

A simple cycle of events can be assessed continuously as part of an active career plan. Continuing professional development (CPD) demands that, at whatever level, training is reviewed and acted upon. There will never be a situation when there are no training needs, and this is worthwhile exercise to apply to all activities when considering training opportunities.

Relating the essential components of learning, knowledge, skills, attitudes and behaviour, to the learning cycle of experience, reflection and deliberate testing can help clarify training needs within career objectives. Thus, identify learning needs, analyse training needs, set learning objectives, design and implement training, evaluate training.

The evaluation of training, set against the original objectives, should allow a competency level to be assigned. This may be set by the manager or the employer, and if not, it is worthwhile to include a grade in a personal development plan (e.g. basic, competent, distinguished, expert). Personal development plans should feature a combination of performance assessment, career plan and business need.

Induction

Following an analysis of training needs, built around experience, curriculum vitae and job description, an induction programme for a new post or role can be developed. As trainee, trainer or manager, it is worthwhile applying a simple template to ensure that key information is understood and all new staff are benchmarked to accepted quality standards. Review of training needs will highlight unfamiliar tasks that must be
taken on board quickly and efficiently and are of benefit to all parties.

A knowledge and skills profile offers the best headlines for an induction template. It is important that the extension of knowledge and skills goes beyond the simple ‘doing of the job’. There are five main characteristics to cover.

General knowledge at the corporate level, for example:

- pharmaceutical business (local and global);
- organization of company (national and international);
- product portfolio.

Job-specific roles and responsibilities, for example:

- sales techniques;
- clinical research practices;
- regulatory requirements.

Therapeutic and product knowledge, for example:

- indication and related disorders;
- physiology and pharmacology;
- formulations and competitors.

Other technical requirements, for example:

- marketing plans;
- medical responsibilities;
- statistics, pharmacokinetics.

Transferable skills, for example:

- presentation skills;
- time management;
- teambuilding, leadership.

Such an induction program cannot be immediate unless the company organizes a full 2–4-week induction programme prior to starting the job. It is essential that the many topics to be covered are prioritized by setting key objectives. Other aspects to consider are resources, including budget and specialized needs. Self-development may well be essential, when resources are limited, but care must be taken to be efficient with training opportunities and not cause conflict with active roles and responsibilities. Development of competency comes with time and experience.

There is a subtle difference between competence and competency worthy of clarification. Competence is a standard obtained with a particular skill, whereas competency reflects a manner of behaving when performing that skill. As such, competences refer to ranges of skills, whereas competencies refer to the behaviours adopted in competent performance. As the individual measures his or her competences and competencies, they and their trainer must be aware of the difference.

**Appraisal and personal development**

Following induction, the individual and sponsor company have a joint responsibility for ensuring personal development. The benefits to both parties may be obvious, yet progress must be monitored continually to guarantee that both parties are satisfied with agreed goals and targets. In the events of dissatisfaction, continual review allows prompt action and reassessment of goals. Measurement of training needs is usually performed at appraisal, and the individual should expect appraisals to be stretching and challenging, if performed properly. Appraisals should decide a career plan based on knowledge, skills and performance to date, that is recorded competencies.

The sponsor company will consider training an investment. It does not wish to train the individual to take a career step out of the company but must take the risk that this may occur. Appraisal will measure the adequacy of training for the role or for the future role of the appraisee. A sponsor company will want to be sure that the training has a clear link with corporate business needs, that training is the
most effective solution to a learning need and, through continued appraisal, realize that benefits of training are evaluated beyond course satisfaction.

The usual appraiser will be the line manager of the appraisee, although it is important that a relationship exists between these two and the sponsor company departments of human resources and training. Often, the latter belongs to the same department. A company template for appraisal and subsequent training plans – a career plan – is likely to be in place to enable consistency and efficient measurement across individuals, teams and departments. If working individually without a career plan, it may be worth using such an example as a guide.

Whether an appraiser or an appraisee, the first training to be undertaken may well be a short course ensuring everyone uses the appraisal process in the same manner.

The appraisal will cover many more areas than training and development needs, for example performance output and relationships, yet ultimately outcomes from appraisal will focus around the careers plan and what has to be done to achieve agreed goals. The training cycle remains the same, and the five categories listed under induction may also be used to cover more focused training needs.

At appraisal, it is important to recognise that it is not only the appraisee who is being measured. Appraisal is an opportunity to record and assess support and performance of the appraiser, other staff and the training personnel, perhaps through use of multisource feedback (360° assessment).

CPD is a useful tool for identifying and measuring ‘lifelong learning’; in other words, it can be described as the data that supports the curriculum vitae and gives direction to the career plan.

CPD allows for:

- planning short-term learning needs;
- recognising previously unseen learning opportunities;
- involving the employer to match personal needs with business needs;
- collating a portfolio of evidence to demonstrate competencies;
- keeping up to date with the chosen profession;
- collating a portable record of progress and achievement;
- increasing awareness of potential career options;
- analysing strengths and weaknesses;
- reflecting on learning and promoting self-awareness and motivation;
- focusing on development needs and career ambitions.

### Regulations and training records

Aside from personal development needs and the business requirements of corporate progress, the pharmaceutical industry is one of the most highly regulated in the world. The strict regulation extends to matters concerning training and development, and the majority of disciplines will find themselves governed by formal guidelines and legal requirements for the quality and quantity of training before and during the specific function. In the scientific areas, these are usually as GXPss such as Good Laboratory Practice (GLP) or Good Clinical Practice (GCP), whilst sales and marketing personnel have to adhere strictly to Codes of...
Practice, and regulatory staff must be completely aware of and work within all aspects across the regulatory and legal framework.

The medical profession is incorporating CPD into plans for demonstrating continuing competency to practise, based on annual appraisals and, for example in the United Kingdom, a proposed 5-yearly assessment for revalidation in order for a practitioner to remain on the general medical register and be certified to practise. Everyone should undertake a professional and ethical obligation to remain up to date with best practice standards in the role that they perform.

Apart from direct observation, which must also be undertaken, the sponsor company management, sponsor company auditors and external inspection units can only be sure of correct adherence to formal training requirements by correct and meticulous record keeping. All training and development in the pharmaceutical industry must be recorded and maintained.

The responsibility for keeping the training logs of staff vary from company to company, being held either by the human resources or training departments or by the manager of the department to which the individual belongs. However, it is recommended that each individual keeps a copy of their own records where they can; this can form part of their personal CPD plan and is inherently part of the information supporting their curriculum vitae. It is important to be able to verify the effectiveness of the training undertaken. The simplest form of record, which details title, date and attendees, does not inform an inspector, of any kind, whether the training was of value or not.

The most usual way of tracking value is by comparing the training data against the actual performance changes at appraisal. Again, this may be viewed as purely a top-level assessment and can raise more questions than it answers. It is recommended to introduce a direct competency measurement to the evaluation of training. Here, a manager, coach or trainer will identify the training need prior to training, and through witnessing, the trainees ‘put into practice’ what they have learnt, be able to verify through dated signature the success or failure of the training. It is important, however, that the training records are not made too complex, leading to a maze of information, which serves to confuse rather than to clarify.

Training sources

Whether self-supporting or with the aid of a ‘training-aware’ sponsor company, the ambitious trainee has a number of options available in order to satisfy the identified training needs. Most of the larger sponsor companies will run consolidated in-house courses covering a vast array of topics from specific skills training, for example GXPs, therapy areas, IT to challenging transferable skills, for example problem solving, time management, cultural communication.

In addition, their training programmes will be indexed to competency measurement and appraisal. In smaller companies and as individuals, such in-house programmes may not be available. This need not be a disadvantage. A greater spectrum of training experience may give greater value to a personal portfolio and offer a wider outlook of the bigger picture. The marketplace offering commercial courses to support any of the training needs for all of the disciplines within pharmaceutical medicine is huge.

Commercial courses are not usually inexpensive, and a considered decision must be made based on previous experience or advice from another source when applying to become a delegate.

As has been highlighted, networking in the industry is essential. Training may be competitive between the commercial companies themselves, but information on ‘good’ and ‘bad’ courses is usually shared across sponsor companies. Human resources or heads of specific departments are good sources of relevant information. The most effective commercial training companies are often those that can tailor their training material to the needs of the trainees, and this material can be customized to specific sponsor company requirements when a group or team is involved. Clearly, the best source of specific training comes from the professional bodies supporting pharmaceutical medicine. In the majority of cases, their primary objective is education based in order to maintain the highest possible standards for their profession.
2.4 Education and training programmes in pharmaceutical medicine

In recent years, a common syllabus has become established through the International Federation of Associations of Pharmaceutical Physicians (IFAPP) from which core curricula for courses have been derived and form the basis for examinations for diplomas and degrees where these have been established. The syllabus in pharmaceutical medicine covers medicines regulations, clinical pharmacology, statistics and data management, clinical development, healthcare marketplace, drug safety and surveillance, the medical department, therapeutics and drug discovery.

The first postgraduate course in pharmaceutical medicine was inaugurated in 1975 in the United Kingdom by AMAPI (now BrAPP) and was transferred to the University of Cardiff in 1978. Since that time several similar courses have been founded in European universities, most from a close cooperation between pharmaceutical physicians, often represented by the national Association of pharmaceutical physicians and academia.

Although there are national variations, to undertake training where there is an outcome by examination to obtain a diploma or degree, doctors must be registered in their country of medical qualification, must have undertaken a prescribed number of years of approved clinical training prior to taking a post in pharmaceutical medicine and must have spent a prescribed number of years, usually two, working in pharmaceutical medicine prior to obtaining the diploma or degree.

More recently, pharmaceutical medicine has been recognized and listed as a medical speciality in four countries, Switzerland, Mexico, United Kingdom and Ireland, resulting in accreditation of the physician specialists as the outcome of their training.

It might be expected that the content of courses following the syllabus in pharmaceutical medicine would be quite similar. However, cultural differences and local academic standards and practices have induced major differences in the structure of courses and the techniques of assessment and examination. As it is in the interest of pharmaceutical medicine in general and pharmaceutical physicians in particular, working in the international field of medicines development and maintenance, that there should be mutual recognition between countries of the diplomas in pharmaceutical medicine given by awarding bodies, a process of harmonization and approval of courses has been established by IFAPP.

In 2002, the Council for Education in Pharmaceutical Medicine (CEPM) was inaugurated by IFAPP with the objectives, inter alia, of contributing to the harmonization of existing postgraduate courses in pharmaceutical medicine and promoting mutual recognition of equivalent educational qualifications between countries.

Europe

The CEPM has approved diploma courses in pharmaceutical medicine in United Kingdom (2), Switzerland, Belgium, Spain (2) and Sweden. The Faculty of Pharmaceutical Medicine (London) has recognised two diplomas, in Belgium and Switzerland, as equivalent to the United Kingdom.

United Kingdom

The Diploma in Pharmaceutical Medicine was established in 1976 by the three Royal Colleges of Physicians of the United Kingdom. The diploma is awarded by examination once a year by the board of examiners of the RCPs’ Faculty of Pharmaceutical Medicine. The examination is knowledge based and comprises MCQs, short questions, essays and an oral.

Two international courses are available in the United Kingdom which cover the syllabus for the diploma. The University of Cardiff in conjunction with BrAPP offers the postgraduate course in pharmaceutical medicine which is the world’s longest-running such course. This is a 2-year part-time residential structured training programme for registered physicians consisting of 10 modules, five per year; each module lasts three days, and the full course counts 200 hours of teaching.
The Postgraduate Medical School of the University of Surrey, as part of its Master of Science programmes, offers eight core modules (of the 12 needed for the MSc) as covering the syllabus for the Diploma in Pharmaceutical Medicine. These are 3-day modules, which are part of the full 15–18-month cycle. They comprise 192 face-to-face teaching hours and may be taken as part of the MSc programme or separately.

The University of Surrey offers a taught Master of Science programme in Pharmaceutical Medicine which involves 12 modules, including eight core and four selected from a number of options. The MSc is gained following satisfactory completion of the module assignments and a 25 000-word dissertation in an area of pharmaceutical medicine.

In 2002, pharmaceutical medicine became a listed medical speciality in the United Kingdom, and the specialist training programme was established to become the basis of accredited education and training in pharmaceutical medicine for physicians. This is a competency-based in-work programme over four years which incorporates the Diploma in Pharmaceutical Medicine as the speciality knowledge base and six practical modules – medicines regulation, clinical pharmacology, statistics and data management, clinical development, healthcare marketplace and drug safety surveillance. A generic module provides interpersonal and management skills and working to the principles of Good Pharmaceutical Medical Practice, ensuring that pharmaceutical physicians practise to high standards of competency, care and conduct in their work, common to the ethics and professionalism of all doctors.

The supervised in-work programme is complemented by module- and topic-based courses. Progress and achievement is assured through in-work and course-based assessments, regular educational and performance appraisal and an annual independent evaluation, the Record of In-Training Assessment (RITA), by the RCPs and Faculty of Pharmaceutical Medicine. The outcome is the Certificate of Completion of Training, a recognised European credential of specialist training common to all medical specialities.

**Switzerland**

Pharmaceutical medicine is a recognised medical speciality since 1999 by the FMH, the Swiss Medical Regulatory body. The Swiss Association for Pharmaceutical Physicians (SwAPP) offers, through the European Center of Pharmaceutical Medicine (ECPM) Diploma in Pharmaceutical Medicine, a postgraduate qualification of theoretical and practical training in pharmaceutical medicine. To qualify, physicians must have full membership of SwAPP and provide documentary evidence of five years supervised post-graduate training, two years of which must be in relevant professional activity and three years in pharmaceutical medicine, including two years in clinical development and one year in drug safety, medical-scientific information and registration.

The committee for postgraduate training (KWF) is responsible for the design of the training programme and approval of training courses and centres. Training centres are medical departments in pharmaceutical companies, clinical research institutes and hospitals, official institutions and development departments in clinical research organizations.

Theoretical training comprises 360 hours. The diploma examination for physicians comprises written papers, MCQs and oral. The diploma is recognized by the Faculty of Pharmaceutical Medicine as equivalent to that in the United Kingdom.

**Belgium**

The Free University of Brussels (ULB) has offered the Diploma in Pharmaceutical Medicine since 1992 in conjunction with ABEMEP, the national association of pharmaceutical physicians. This is a non-residential course consisting of eight modules. All modules are taught each year, but students can spread their training over 1–3 years. Each of the modules takes one full week every month between November and June, leading to 280 hours of teaching.

Oral and written examinations are organized at least once a year; it is not required to follow the
course to register for the examination, provided the candidate has adequate experience in pharmaceutical medicine.

Physicians passing the examinations are awarded the Diploma in Pharmaceutical Medicine, which is recognized by the Belgian College of Pharmaceutical medicine, established in 2000 by two Belgian Royal Academies of Medicine. Holders are added to a specialist register held by the Belgian College of Pharmaceutical Medicine.

The diploma is recognised by the Faculty of Pharmaceutical Medicine (London) as being equivalent to that of the United Kingdom.

Ireland

The Association of Pharmaceutical Physicians in Ireland (APPI) is the leading force in establishing Higher Medical Training in Ireland. APPI gained acceptance for pharmaceutical medicine as a speciality from the Irish Committee for Higher Medical Training (ICHMT) of the Royal College of Physicians of Ireland. This was accepted by the Irish Medical Council in 2004, and the medical speciality was approved by the Ministry of Health in 2005. APPI is working with other new specialities on the practicalities of establishing the new speciality, and it has constructed the curriculum and will work through the ICHMT on the necessary training requirements for specialist accreditation for pharmaceutical physicians.

France

The EUDIPHARM programme was established in 1999 based on the University of Lyon with funding from the European Union. The programme involves the participation of 14 universities in 11 countries of the EU. There is an international teaching faculty involving many from the United Kingdom, Sweden, Germany and Italy. The course is at variance with other courses in pharmaceutical medicine in that during the first year, all students attend three residential seminars of 3-week duration, representing a basic training module with 18 sub-modules.

In the second year, students elect to specialize in one of the series of subspeciality options, namely drug development, regulatory affairs, post-marketing monitoring, medical marketing, attending three to four modules, each of 2-week duration. In the first year, all courses are at the University of Lyon, but in the second year, students move around the various participating universities. To obtain the diploma, the candidate sits written and oral examinations and submits a dissertation. The total number of teaching hours is estimated at 325.

Spain

The University of Barcelona offers a 2-year non-residential course consisting of 14 modules between 4-30 hours depending on the subject. Courses are taught at the university one day per week from January to June each year, representing a total of 222 hours of teaching. Written examinations are conducted twice a year. Successful candidates receive a Diploma in Pharmaceutical Medicine.

The University of Madrid offers a 2-year non-residential course which consists of 14 modules from October to June and totalling 300 hours of teaching at the University. Examinations, written and oral, are conducted once a year; to register for the examinations, students must have attended at least 75% of the courses. Successful candidates receive a Diploma in Pharmaceutical Medicine.

Portugal

The University of Lisbon has, since 1999, offered a 6-month non-residential course in pharmaceutical medicine taught every year from January till June. The course has 11 modules with two 2-day sessions per month, representing a total of 176 hours of teaching. Assessments are made at the end of each module, and only those students who have passed the 11 assessments and have attended 100% of the course are allowed to submit a dissertation of 20,000 words at the end of the course. Successful candidates receive a Diploma in Pharmaceutical Medicine recognized by the Portuguese National Board of Physicians, where the ‘Pharmaceutical
Industry’ is listed as a postgraduate competence (‘capacidade’).

**Sweden**

There is a 2-year diploma course in pharmaceutical medicine given at the Karolinska Institute and the Medical Products Agency, Stockholm, organized for pharmaceutical physicians in conjunction with the Swedish Board of Pharmaceutical Medicine.

**Germany**

There is a Diploma in Pharmaceutical Medicine in Germany which is provided by the DGPharMed (German Society for Pharmaceutical Medicine).

Since 2005, the University of Essen-Duisburg has offered a 2-year course leading to a Master of Science in pharmaceutical medicine. The course has 450 hours of teaching in 18 modules and a further 1350 hours are planned for homework. The last six months are needed for preparation of a thesis, its presentation and oral examination. Although only recently available, this course has longer heritage, having being transferred from the University of Witten-Herdecke, which since 1997 offered a course leading to a Diploma in Pharmaceutical Medicine.

**Italy**

In pharmaceutical medicine, efforts are being made to establish a diploma course at the University of Pisa supported by the Italian Association of Pharmaceutical Physicians (SSFA).

**Non-European**

**Mexico**

Mexico granted pharmaceutical medicine speciality status in 1999. There is a 2-year specialist training programme organized by the National Polytechnic Institute, Faculty of Medicine, Postgraduate Studies Section, leading to a specialist qualification in Pharmaceutical Medicine. There is an entry examination to the programme, which then includes 17 subjects (84 credits) over four semesters. There are practical rotations through pharmaceutical industry departments in the fourth semester.

**Argentina**

The University of Buenos Aires offers a postgraduate education programme in pharmaceutical medicine, comprising 420 teaching hours and 240 practice hours.

**Brazil**

The Federal University of Sao Paulo offers a postgraduate course in pharmaceutical medicine comprising 200 teaching hours and 160 practice hours.

**Acknowledgements**

The authors wish to thank Gareth Hayes, Dr Ibrahim Farr and Drs Herman Lahon and Juan Lahuerta of the Council for Education in Pharmaceutical Medicine for their contributions and advice.

**References**


3 Clinical Research Education and Training for Biopharmaceutical Staff

Peter Marks

3.1 Introduction

The biopharmaceutical industry is a highly regulated industry where many of the activities and tasks performed by company staff are defined by regulations and guidelines issued by international regulatory authorities. The training requirements for clinical staff of pharmaceutical companies or sponsors can be relatively well defined.

The International Conference on Harmonization (ICH) Guideline for Good Clinical Practices (GCP), for example, describes a minimum standard for the ethical and scientific standards for designing, conducting and reporting clinical research. The ICH GCP Guideline is the unified standard for the European Union (EU), Japan and the United States to facilitate mutual acceptance of clinical data. The ICH GCP Guideline, together with other ICH Guidelines, provides operational definitions of the core competencies needed by clinical staff to conduct world-class clinical research.

One of the principles of ICH GCP is that ‘each individual involved in conducting a trial should be qualified by education, training and experience to perform his or her respective task(s)’. Specifically, regarding the selection and qualifications of monitors, the ICH GCP Guideline states that ‘monitors should be appropriately trained and should have the scientific and/or clinical knowledge needed to monitor the trial adequately’. Most major pharmaceutical firms have always had varying degrees of in-house education and training for staff, supplemented (as appropriate) by external workshops, courses and training meetings. The ICH GCP Guidelines help formalize the desired elements of education programs to comply with current GCP requirements.

3.2 What is a competency-based training program?

Few people come to the pharmaceutical industry from academia and health-related positions with the requisite knowledge and skills necessary to plan, conduct and report clinical research to regulatory authority standards. This knowledge and skill usually need to be provided by sponsors to all levels of new staff by the way of in-house training.

One approach to education and training in the industry is what is called ‘competency-based training’. A competency is a skill, knowledge or behavior required to undertake effectively the tasks and responsibilities for which an individual is responsible.
A competency-based education and training system (CBETS) details the essential knowledge and skills needed by sponsor’s staff to complete the requirements of GCP. The concept of a CBETS is different to traditional educational and training approaches. Traditional approaches tend to address the training needs of individuals based on their job descriptions. For example, within a sponsor company, a monitor will receive training on how to monitor a clinical trial and a physician will receive training in protocol development. In this traditional education and training model, the required tasks are functionally defined. The monitor may not learn much about preparing protocols and the physician may not learn much about monitoring. However, each may be intimately involved in both tasks.

The CBETS asks what tasks the sponsor needs to do to meet its drug development goals. The primary tasks of clinical research and good clinical practice can be described rather precisely. Once one knows what the major tasks are and what activities are needed to accomplish these tasks, one can then ask what knowledge and skills are needed by staff for the tasks and, finally, what education and training should be provided to communicate the knowledge and skills. A CBETS only asks who is going to do these tasks. Only when the tasks and activities are fully defined is it necessary to ask who is going to do it and how competent they need to be to complete the tasks. In the example provided above, it is useful for the physician to have a fundamental knowledge of the monitoring process even though he or she will not be performing the tasks. The physician may, however, be supervising the monitors. It is appropriate for the monitor to receive advanced training in the requirements of monitoring as this is one of their major functions. In terms of protocol development, the physician and monitor each need competencies to perform the tasks of developing the protocol. The CBETS is applicable to behavioral and management training, as well as technical training.

Education and training programs in the pharmaceutical industry should be designed to provide the competencies necessary to prevent or remove obstacles to staff performance.

3.3 Competency-based training program for staff associated with conducting clinical trials

The following is a description of the typical knowledge and competencies needed to plan, conduct and report clinical research in a regulated environment. Each competency is described along with the knowledge and skills a sponsor’s representative would need to be successful in completing the task.

General clinical competencies

Understanding the drug development process

New clinical staff should understand the overall drug development process. Before new investigational products can be given to the public, extensive preclinical and toxicological studies are performed. Staff who will be responsible for the clinical portion of investigational product’s development need to have an understanding of the work that has been undertaken to progress the compound through to the clinical phases. Many clinical investigators are also involved in basic research and often will expect the sponsor’s representative to be able to discuss the total background on the investigational product.

This includes understanding the vision, mission and objectives of the sponsor. Most sponsors have a company-specific clinical development strategy and product development system. Individuals new to the industry should understand the strategy and function of the major departments comprising the development process, as well as understanding the decision-making approach of the sponsor’s management bodies.

To gain this knowledge, new staff members should attend appropriate orientation programs on drug development and, if recommended, Pharmaceutical Education and Research Institute, Inc. (PERI), Drug Information Association (DIA) overview courses on investigational drug development or equivalent international courses. There is considerable literature available that discusses the drug development process such as the ‘Guide to
Clinical Trials’ and ‘Multinational Investigational Drug Companies’ by Bert Spilker. Many regulatory authorities also provide useful literature and guidelines on registration expectations. New staff should carefully review and discuss with experienced sponsor management and have internal documentation explaining the company’s systems and processes. Senior-level staff can also attend the noted and advanced course on international investigational product development and regulatory issues sponsored by Tufts University at the Tufts Center for the Study of Drug Development.

Understanding good clinical practices

Understanding the responsibilities and obligations of sponsors in terms of good clinical practices is fundamental knowledge essential to conduct clinical research. Currently, most pharmaceutical firms reference the ICH GCP Guideline as the minimum standard for conducting clinical trials. There are excellent PERI or DIA overview courses covering good clinical practices.

The responsibilities and obligations include knowledge of the elements of informed consent, the role and responsibilities of Institutional Review Boards/Independent Ethics Committees (IRB/IEC) and the importance of Clinical Study Quality Assurance.

Understanding the regulations of the countries in which drug development will occur

Although the US Food and Drug Administration (FDA) historically has been the dominant regulatory authority in the world, in recent years, the other regions (e.g. EU and Japan) have emerged to challenge that dominance. As multinational companies consider conducting a larger proportion of trials outside the United States, knowledge of global regulations has become increasingly important.

An understanding of the regulatory structure, operations and functions is very important to individuals new to the pharmaceutical industry or new to clinical development.

Knowledge and skills are required for communication with the regulatory agencies; covering, for example, End-of-phase II Meetings, IND/CTA Annual Report, Advisory Committee Meetings, Pre-NDA/BLA/MAA Meetings, Clinical Hold, IND/CTA Termination and regulatory inspections.

Competencies associated with planning clinical development

Conceptualization and development of clinical development plans (CDPs)

Developing an international CDP to answer questions defined by the investigational product target profile is a key activity of senior-level industry personnel. This competency requires an understanding of toxicology and clinical pharmacology to identify clinical target profile criteria. The CDP defines the critical path for the clinical program and the clinical budget. The CDP also defines investigational drug development assessment and decision points, and the project resource (personnel and budget) estimates.

CDPs will cover

- preparing the clinical section of IND/CTA submission;
- preparing clinical reports needed to support IND/CTA submissions;
- clinical research and scientific methodology;
- exploratory INDs (in the United States)/pilot efficacy studies;
- phase I studies;
- phase II studies;
- phase III studies;
- phase IV studies;
- pharmacokinetic and bioavailability studies;
dose-ranging studies;

• dose-titration studies;

• marketing and safety surveillance studies;

• studies supporting over-the-counter switches (see a separate chapter in this book).

The goal of these plans is to provide a lean, efficient NDA/BLA/MAA with the minimum studies needed for registration and approval in the world markets. The medical, scientific, regulatory and marketing opinions must be weighed and balanced in the plans.

Understand and conceptualize clinical study design

To create a CDP successfully, the individual must know the basic concepts of research design and statistics, the concepts of clinical research and investigational drug development; possess an in-depth understanding of the concepts of clinical pharmacology, pharmacokinetics, pharmacodynamics, toxicology, state-of-the-art therapeutic medicine and methodology, FDA/EU/ICH therapeutic research guidelines and regulatory issues; and understand basic concepts of project planning and scheduling. Knowledge of new methodology (e.g. better use of PK/PD modeling/simulations and computer-assisted trial design), ‘right-sizing’ trials and alternative statistical designs (e.g. futility analyses, adaptive designs) are becoming essential as companies look to improve efficiency and reduce costs of the clinical development process.

Preparation of the investigator’s brochure (IB)

The IB is a compilation of clinical and preclinical data on the investigational product that is relevant to the study of the investigational product in human subjects and the investigator’s assessment of risk in participating in the study. The sponsor compiles clinical information for the preparation of the IB.

Clinical staff or a medical writing group may perform the preparation of an IB. The activities included in preparing the IB include

• coordination of the compilation of clinical and preclinical data from contributing departments (e.g. Clinical Pharmacology, Toxicology);

• describing the physical, chemical and pharmaceutical properties and formulation;

• preparing a clear, concise summary of the information relating to the safety and effectiveness of the investigational product;

• providing a detailed description of possible risks and benefits of the investigational product;

• defining a clear rationale for the dosage and dosing interval.

To prepare an IB, the sponsor’s representative must understand the fundamental purpose and uses of the IB, the basic format and content of sponsor IBs, the clinical pharmacology and toxicology findings, the investigational product–disease relationships, the international regulatory requirements governing IBs and the indications and safety profile of the investigational product.

Design and preparation of clinical protocols

The clinical protocol describes the objectives, design, methodology, statistical considerations and organization of the trial. The sponsor is usually responsible for developing the protocol in industry-sponsored clinical trials. However, internal and external content experts (e.g. specialists, key opinion leaders) are frequently consulted. Protocols must be written ensuring medical soundness and clinical practicality.

Frequently, the sponsor uses a template to complete the sections of the protocol. The tasks of developing a protocol include

• defining clear protocol objectives;
identifying primary efficacy and safety parameters;

determining appropriate subject selection criteria;

identifying correct dosages and route.

This could be a two-step process where the protocol summary containing all the key elements is prepared and approved, triggering key operational activities such as case report form (CRF) and database design, manufacturing and packaging of investigational product supply. While these activities are being carried out, the full protocol text can be refined to meet regulatory requirements and investigator needs.

To prepare appropriate protocols, staff must understand research design and statistical inference for clinical research, state-of-the-art research designs (e.g. adaptive designs, futility analyses) and trials, therapeutic area guidelines, good clinical practice, regulatory requirements, guidelines and country-specific issues, national and international medical practices, sponsor protocol review and approval procedures and possess in-depth investigational product–disease knowledge.

Clinical protocols are the building blocks of the CDP and the NDA/BLA/MAA. Protocols specify the conditions that permit and lead to meaningful and credible results in clinical programs. Operationally, protocols provide a written agreement between the sponsor and the investigator on how the trial is going to be conducted. This agreement allows the sponsor to ensure that the study will be done to the highest ethical and medical standards and that the quality of the data can be relied upon as credible and accurate.

All clinical protocols and supporting documents are reviewed and approved internally by a group of senior Clinical Research & Development managers. This group assesses the overall study design and ability of the study to meet its objectives, as well as the quantity and quality of the data. In addition, the group reviews the procedures for the safety and welfare of the subjects to ensure compliance to good clinical practices and ethical principles.

The quality of a clinical protocol can be assessed by how well the elements of the protocol are prepared. The elements of clinical protocols are described in Table 3.1.

The extent of a Background section will vary with the drug’s stage of development. New clinical data not already included in the IB should be emphasized. The Rationale provides a concise statement of the reasons for conducting the study and the basis for the dosage selection and duration that will be used in the trial. Quality protocols should target relevant information in the Background and convincing rationale for the study.

Every protocol must state a primary, quantifiable study objective. Secondary objectives should be limited in scope and related to the primary question. Objectives must be specific and capable of answering a key clinical question required by the CDP.

The study design is an important element in assessment of quality protocols. The overall purpose of the study design is to reduce the variability or bias inherent in all research. Good study design will always address control methods that reduce experimental bias. These control methods will often include treatment blinding, randomization and between- or within-patient study designs. The Schedule of Assessments describes a schedule of time and events and provides a complete

<table>
<thead>
<tr>
<th>Table 3.1 Elements of clinical protocols</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background and rationale</td>
</tr>
<tr>
<td>Study objectives</td>
</tr>
<tr>
<td>Experimental design and methods</td>
</tr>
<tr>
<td>Schedule of assessments</td>
</tr>
<tr>
<td>Subject selection criteria</td>
</tr>
<tr>
<td>Trial procedures (screening, trial period, follow-up, assessments)</td>
</tr>
<tr>
<td>Adverse event reporting</td>
</tr>
<tr>
<td>Trial medication</td>
</tr>
<tr>
<td>Premature withdrawal</td>
</tr>
<tr>
<td>Subject replacement policy</td>
</tr>
<tr>
<td>Criteria for excluding data</td>
</tr>
<tr>
<td>Data analysis/statistical methods</td>
</tr>
<tr>
<td>Quality control/assurance</td>
</tr>
<tr>
<td>Data handling and record keeping</td>
</tr>
<tr>
<td>Ethics (e.g. IRB/IEC approval)</td>
</tr>
<tr>
<td>Definition of end of trial</td>
</tr>
<tr>
<td>Sponsor discontinuation criteria</td>
</tr>
<tr>
<td>Signatures</td>
</tr>
</tbody>
</table>
profile of the overall trial design. Good Quality Schedule of Assessments sections also include acceptable time windows around the variables being collected that can minimize protocol deviations.

The inclusion and exclusion criteria are described in the Subject Selection part of the protocol. To a large extent, the success or failure of a particular clinical trial can often be traced back to how well these criteria were developed. Good protocol authors strive to include the most appropriate patient population to satisfy the study objective and still include those kinds of patients who will ultimately receive the drug. Therefore, selection criteria can be unreasonable and unnecessary in some cases and vague and not specific in other cases. The management of concomitant medications is particularly problematic. The protocol must attempt to define those medications that are permitted for intercurrent illnesses and those that are prohibited as they will interfere with the interpretation of the test medication. Although there are no easy answers, quality protocols are able to justify with some precision the rationale for each inclusion and criteria. How these criteria are applied is handled in the Screening for Study Entry section.

The efficacy and safety parameters describe how and when the variables are going to be recorded, usually in relation to drug administration and follow-up periods. How adverse events are managed and recorded are particularly important to the sponsor and to regulatory authorities. Protocol authors should ensure that the study defines the criteria for success or failure of treatment. End points should be clear and defined. As many clinical phenomena are open to interpretation, protocols should provide definitions of variables and time windows for their collection. If the assessments are purely subjective, provision for observer triuing must be provided. Addressing these issues will improve the quality and meaningfulness of the results of the study. Training on such assessments at investigator meetings before the trial starts proves a valuable investment.

The description of the management of trial medication is often a source of confusion. Protocols must include clear directions for dosing intervals and adjustments. Because patients will never follow a protocol precisely in all cases, provisions for missing doses or ‘what if’ situations should be anticipated. Good protocols always include, in addition, adequate compliance checks of drug consumption by the subjects of the study.

Protocols should predetermine how subjects will be replaced following dropping out of the study. This is important because the means by which subjects are replaced can adversely affect the statistical analysis. Similarly, a decision concerning the conditions under which a subject would not be evaluable must be stated explicitly before the study starts. This is intended to minimize intentional or unintentional data manipulation.

The Quality Control/Assurance section addresses the sponsor’s conduct of periodic monitoring visits to ensure that the protocol and GCPs are being followed. The sponsor’s representatives (monitors or Clinical Research Associates; CRAs will review source documents to confirm that the data recorded on CRFs are accurate – this is a fundamental requirement of quality clinical research. This section also alerts the investigator and clinical institution that the sponsor’s representatives (for monitoring and/or audit purposes) and possibly appropriate regulatory authorities (for inspections) will require direct access to source documents to perform this verification. It is important that the investigator(s) and his or her relevant personnel are available during the monitoring visits and possible audits or inspections, and that sufficient time is devoted to the process.

The Data Handling and Record Retention section of the protocol will address the requirement to maintain data (whether on a paper CRF or using an electronic data collection tool (DCT)) of each trial subject. It will address expectations of ownership of the completed CRF data, the investigator’s responsibility to ensure accuracy and completeness of data recording. This section will also address the requirements for retention of records at the trial site in accordance with relevant guidelines and regulatory requirements.

The Ethics section of the protocol deals with the fundamental requirement for prospective IRB/IEC approval of the trial protocol, protocol amendments, informed consent forms and other relevant documents (e.g. subject recruitment advertisements).
The section will also detail the requirements for obtaining informed consent from trial subjects.

For trials conducted in the EU, the protocol must include a definition of the end to the trial (in an EU member state or in all participating countries).

The Sponsor Discontinuation section of the protocol provides a reminder to the investigator that the trial may be terminated prematurely as a result of a regulatory authority decision, a change in opinion of the IRB/IEC, drug safety problems or at the discretion of the sponsor. In addition, most sponsors will reserve the right to discontinue development of the investigational product at any time.

**Design of the format and content of Case Report Forms CRFs**

The CRF is the document used to record all of the protocol-specified data to describe individual subject results. Many sponsors use standard modules to prepare the CRF and are increasingly using electronic data capture technology.

To prepare successful CRFs, the sponsor’s staff must know typical clinical practices, therapeutic conventions, investigator and staff needs, data management and analysis plans, project-specific definitions and procedures, CRF completion problem areas, remote data/electronic entry and review and approval procedures for CRFs. Ideally, CRFs should be pretested with internal and external experts (e.g. investigational sites).

The quality of a clinical trial can be influenced by how well the CRF is designed. If the investigator’s staff cannot enter the protocol data as required, the sponsor will have a considerable challenge in trying to interpret the results. There are a number of design principles that facilitate the use of CRFs in clinical trials. These principles include the concepts of standardization and minimization. The sponsor standardizes the design of CRFs in one consistent international format. This permits uniform databases, consistency in collection and more rapid data entry/capture. In addition, standardization facilitates the monitoring process and therefore increases accuracy of the data. Although efficiency is an important variable in the design process, the systems must also be sufficiently flexible to account for the variances between projects. Finally, an important principle of both protocol and CRF design is to collect only the data needed to satisfy the objectives of the protocol. The inherent temptation to collect more data must be resisted.

There are several CRF design characteristics that define quality CRFs. Some of these include

- limiting the amount of space or blank fields for free text;
- providing instructions on the CRF or within the electronic tool for its completion;
- consistent layout of information within the CRF;
- simple, unambiguous language, particularly for multinational trials;
- collecting only raw data, letting the computer do transformation calculations;
- intensive monitor training in the use of the CRFs.

High-quality CRF design is probably the cheapest investment in big returns on a clinical trial.

**Packaging and labeling of investigational product**

The investigational product is the active ingredient or placebo being tested in a clinical trial. Forecasting investigational drug supplies is important in that it must be done well in advance of the start date of the clinical trial. To make this forecast, it is necessary to estimate, from the CDP, the bulk investigational product supply needs. Oftentimes, the protocol summary provides the trigger to begin packaging and labeling of investigational supplies for the trial.

To successfully handle drug supplies, the sponsor’s representative must know
the procedures for ordering bulk investigational product supplies;
models for bulk investigational product quantity estimation;
investigational product packaging time frames;
protocol-specific and country-specific requirements for packaging and shipping investigational product supplies;
procedures for packaging international investigational product supplies;
investigational product supply tracking systems;
investigational product ordering and packaging processes;
general investigational product formulation and packaging processes and configurations;
protocol design;
randomization procedures;
investigational product dispensing and accountability.

Identification and selection of clinical investigators for study placement and conducting pre-study evaluation visits

Selecting investigators: The proper selection of clinical investigators is one of the key success factors for any clinical program. The investigator (sometimes referred to as the principal investigator) has the primary responsibility for the success of the trial. His or her leadership and direction of sub-investigators and study staff are critical in performing the requirements of today’s trials. Time spent in learning who the best investigators are is well spent and pays significant dividends in the end.

To successfully identify and select clinical investigators, the sponsor’s representatives need to identify internal and external sources of potential investigators, define investigator selection criteria, protocol requirements, expected cost of the study, investigator and facility qualifications, interview potential investigators and, finally, schedule and conduct pre-study site evaluation visits.

The International Clinical Team (ICT) has an important role in determining the quality selection of clinical investigators. Selection criteria will be based upon the needs of the CDP and the individual protocols. Quality investigators can be identified by

- previous clinical research experience;
- previous performance on sponsor and other company trials;
- their reputation among peers and the quality of their publications;
- the experience and training of their support staff;
- the quality and reputation of their research facilities.

Potential sources of quality investigators are shown in Table 3.2.

Many physicians may need to be considered before the best investigators can be identified. Preliminary contact should be done by telephone. Only those investigators who satisfy the primary selection criteria need to be visited.

Pre-study visits: The purpose of the pre-study visit is to evaluate the investigator’s interest and ability to conduct the study to the required sponsor

Table 3.2 Sources of quality investigators

| Clinical leaders/therapeutic area heads |
| Country company heads/medical directors |
| Consultants |
| Colleague recommendations |
| Investigator recommendations |
| Scientific and medical literature |
| Physician directories |
| Speakers at professional meetings |
standards. Normally, the monitor or CRA conducts this. Special attention is paid to the quality of the investigator’s staff and facilities, as well as to the availability of the required patient population. In conducting the pre-study site evaluation visit, the sponsor’s representative determines whether or not the investigator is qualified by training and experience to conduct the trial.

The pre-study visit is a professional exchange of information. The investigator is informed of the preclinical and clinical background of the drug. Of primary importance to the investigator is the rationale for use of the drug and the expected safety profile. Much can be inferred from the investigator’s preparation and questions about the investigational drug. The protocol should be explained, including the requirements for the patient population, the study design and a description of the safety and efficacy variables.

Other aspects of the study are also discussed with the investigator, such as the completion of the CRF, access to source documents and management of drug supplies. The nature and form of informed consent are reviewed. In these discussions, the sponsor’s representative is attempting to identify aspects of the study that present difficulties or problems for the investigator. Quality investigators usually have clear understanding and strategy for the above activities. Examples of the questions that require answering during pre-study visits are shown in Table 3.3.

Some objective measure of the availability of the correct patient population is important during a pre-study visit. The sponsor’s representative can often best accomplish this through a chart or hospital census review.

<table>
<thead>
<tr>
<th>Table 3.3 Pre-study visit questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>How will the protocol specifically operate at the prospective center?</td>
</tr>
<tr>
<td>How will informed consent be obtained? By whom?</td>
</tr>
<tr>
<td>How will source documents be managed?</td>
</tr>
<tr>
<td>How will adverse events be handled and followed up? Serious and nonserious events?</td>
</tr>
<tr>
<td>How many studies is the investigator conducting currently?</td>
</tr>
</tbody>
</table>

The time spent doing this aspect of a clinical trial will invariably result in better and more timely results in clinical programs.

Assuming that the outcome of the pre-study visit(s) is successful, the sponsor’s representative will need to develop and negotiate study contracts and secure essential documents.

**Competencies associated with conducting clinical research**

**Investigator meeting**

Sponsors now try to conduct many initiation activities via an investigator meeting. Such meetings (which may be in person or utilize videoconferencing or internet technology) can be used to orient all investigators to the fundamental practical requirements of the protocol and trial (CRF completion, investigational product handling, discussion of audits/inspections, etc.). These meetings provide an opportunity to ensure common understanding of issues, subjective grading systems and so on. However, investigator meetings tend not to be attended by all the staff who will be involved in the conduct of the trial at the institution. Inevitably, this means that the sponsor’s representative has to conduct study initiation activities at the institution with some key staff.

**Conducting study initiation**

The study initiation visit is sometimes confused with the pre-study visit. The purpose of the study initiation visit is to orient the study staff (sub-investigators, study coordinators, etc.) to the requirements of the protocol. At the point of the study initiation visit, the study site should be fully ready to begin all aspects of the trial. The monitor must ensure that the study medication and materials are available at the site. In addition, all essential documentation must be completed and available. Key study documentation is shown in Table 3.4.

All study staff who will have direct involvement in the trial should participate in the study initiation visit or investigator meeting. This usually includes
the investigator and sub-investigator(s), the study coordinator or research nurse, pharmacist and laboratory personnel or specialists as needed.

During the meeting, all major points and requirements of the protocol are reviewed and discussed. Procedures for subject enrollment are particularly important as this is the area that may cause most of the problems for the site. During the presentation, participants may raise important medical or logistical issues that have or have not been anticipated by the protocol authors. It is important to note these concerns and communicate them to the protocol authors, as appropriate.

The sponsor’s representative should be competent in the basic medical and scientific issues of the investigational product and protocol, know the target disease or symptoms, be able to train the investigative staff on the conduct of the study, confirm facility capabilities, conduct the site initiation meeting, describe adverse event reporting requirements and be able to resolve protocol issues during and after meeting.

**Conducting clinical trial monitoring**

Clinical trial monitoring includes those activities that ensure that the study is being conducted according to the protocol. Monitoring permits an in-process assessment of the quality of the data being collected. The first alert to safety issues is often revealed during the process of monitoring the clinical trial.

Monitoring clinical studies involves the act of overseeing the progress of a clinical trial. Monitors ensure that the study is conducted, recorded and reported in accordance with the protocol. This is accomplished by the review of paper CRFs or paper copies of electronic DCTs on-site for possible errors, inconsistencies and omissions. The monitor identifies errors and discrepancies that require discussion with the investigator or staff and any safety questions or issues. The monitor compares CRFs with source documents (source document verification or SDV), confirming that source data are consistent with CRF entries, identifies all serious adverse events (SAEs), resolves previous and current data queries and confirms completeness of investigator records and files.

To be a successful monitor, the sponsor representative should know how to interpret hospital/clinic records/charts, laboratory tests and interpretations, query resolution procedures, protocol and CRF data requirements, medical nomenclature, SAE procedures and health authority requirements. In addition, a monitor needs to have excellent interpersonal communication and problem-solving skills.

Clinical monitoring requires clinical, interpretive and administrative skills. The monitor needs to confirm subject selection and patient enrollment compliance. Quality monitoring will always include and confirm the following activities:

- properly obtained informed consent;
- adherence to the protocol procedures and inclusion/exclusion criteria;
- transcription of data from source documents to the CRF that is both consistent and logical;
- identification of any safety issues including SAEs;
- proper accountability and reconciliation of drug supplies;
- continued adequacy of facilities and staffing.

The frequency of clinical monitoring depends on the actual accrual rate of the subjects. Complex studies may need to be visited more frequently depending on the accrual rate of subjects, the

---

**Table 3.4  Key study documentation**

<table>
<thead>
<tr>
<th>Document Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved protocol and CRF</td>
</tr>
<tr>
<td>Informed Consent Form and Subject Information Sheet</td>
</tr>
<tr>
<td>Investigator’s CV</td>
</tr>
<tr>
<td>Written IRB/IEC approval</td>
</tr>
<tr>
<td>Local regulatory approval</td>
</tr>
<tr>
<td>Signed study contract</td>
</tr>
<tr>
<td>Laboratory ranges and accreditation</td>
</tr>
</tbody>
</table>

---
amount of data and the number of visits. Generally, most investigators should be monitored every four to six weeks. The monitors should anticipate sufficient time for good monitoring practices.

Following a monitoring visit, the monitor will prepare a monitoring report for sponsor records and follow up correspondence to the trial site.

The monitor may need to plan intervention and possible replacement of nonperforming or non-compliant trial centers.

**Managing drug accountability**

The sponsor is responsible for providing the investigator with investigational product. Both the sponsor and investigator have a role in drug accountability.

The sponsor’s representative inspects storage of investigational product supplies, checks study site investigational product dispensing records, checks randomization and blinding and maintains records of investigational product shipments.

The monitor reconciles investigational product shipped, dispensed and returned, arranges for shipment of investigational product to core country or investigative sites, checks investigational product supplies at site against enrollments and withdrawals, maintains investigational product accountability records, resolves investigational product inventory problems, implements tracking system for investigational product management on a study and project level, arranges for the return and/or destruction of unused or expired investigational product supplies and ensures final reconciliation of investigational product supplies.

Good clinical practices require sponsors to be able to account for the drug supplies prepared and shipped to the investigator, the investigator’s use of those supplies and the return and destruction of remaining drug supplies. Planning drug supplies is a detailed and complex activity. Bulk and formulated drug requests must be made at least six months in advance of the need for those supplies. This is to account for the ordering of intermediates or finished drug, purchasing of comparator agents and for quality control testing.

Drug packaging should follow as consistent a format as possible within a project, and must be identical within multicenter trials. Regulatory documents required for investigational drug use in the core countries must be anticipated and made available when needed, for example methods/certificates of analysis, stability data and customs declarations.

The typical requirements for drug labels are described in Table 3.5.

<table>
<thead>
<tr>
<th>Local language</th>
<th>Route of administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of investigator</td>
<td>Dosage</td>
</tr>
<tr>
<td>Study number</td>
<td>Dosage form</td>
</tr>
<tr>
<td>Bottle number</td>
<td>Quantity or volume</td>
</tr>
<tr>
<td>Lot number</td>
<td>Storage precautions</td>
</tr>
<tr>
<td>Drug name or code</td>
<td>Directions for use</td>
</tr>
<tr>
<td>Manufacturer name</td>
<td>Note: ‘For Clinical Trial’</td>
</tr>
<tr>
<td>Manufacturer address</td>
<td>Caution statement</td>
</tr>
<tr>
<td>Local affiliate name</td>
<td>Expiry date</td>
</tr>
</tbody>
</table>

Once the study is underway, the investigator’s staff must account for the use of the investigational drug. Subjects should return unused medication and empty containers to the investigator. The amount of drug dispensed and the amount used by the patients are compared for discrepancies. This provides a measure of compliance by the study subjects. Monitors must also check that drug supplies are being kept under the required storage conditions.

Study drug must be dispensed according to the randomization schedule. Failure to do so can result in some of the data having to be discarded during statistical analysis. This issue can prove to be problematic when a single site is studying patients at different locations. Finally, the double-blind code must not be broken except when essential for the management of adverse events. The breaking of treatment codes can make that patient’s data unusable for efficacy analyses.

**Handling adverse drug events (ADEs)**

Safety concerns are present throughout the drug development process. From the filing of INDs/CTAs through the conduct of clinical trials to the
approval process of the NDA/BLA/MAA and the marketing of the drug, safety is the primary concern of any clinical program.

Management of safety is a principal responsibility of the sponsor monitor. The monitor has responsibility for informing the investigator about the safety requirements of the study. This will include a discussion of expected and unexpected adverse events, how to report adverse events should they occur and how to characterize the adverse events in terms of project-specific definitions.

Monitors are expected to review CRFs and source documents with particular attention to potential safety problems. On the CRF, the adverse event section and laboratory result section are reviewed for important findings. Often, the investigator makes relevant notes in the comment section of the CRF. In source documents, safety issues may be uncovered in the progress notes of hospital charts or the interpretative reports of various diagnostic tests, for example chest X-rays and EKGs. Safety problems can manifest themselves in many ways. Monitors must be alert to exaggerated changes from baseline with expected pharmacological effects, acute and chronic effects and multiple drug treatment reactions.

Monitors are often the first company representatives to learn about an adverse event. The timeliness of reporting the event to sponsor safety group is important in satisfying regulatory reporting requirements. In general, the expectation is that the sponsor will learn of the event within 24 h of its occurrence. The monitor should immediately notify appropriate safety staff of serious ADEs that are unexpectedly discovered. These strict timelines are designed to keep us in compliance with the regulatory authorities. Failure to adhere to the reporting timelines required for regulatory authorities is evidence of negligence on the part of the sponsor. The sponsor monitor is responsible for assuring adherence to reporting systems for managing SAEs and for ensuring that the investigator’s staff is aware of these requirements of being in compliance with the regulatory authorities.

The sponsor monitor is responsible for the timely follow-up of all SAEs. The cases must be followed to completion. The monitor needs to collect all required follow-up information on ADEs.

To be successful, monitors need to be competent in

- basic medicine and therapeutics;
- recognizing clinical signs and symptoms;
- interpretation of laboratory findings;
- medical practice, nomenclature and terminology;
- relevant regulatory requirements;
- protocol requirements.

The sponsor needs to provide ongoing review of safety data for investigational products.

**Closing down the center**

Closing down a study is important because it may represent the sponsor’s last best chance to obtain the data required in the trial. The study closedown (closeout) visit usually occurs after the last subject has completed the trial including any posttreatment follow-up visits. Drug supplies should be reconciled, and the integrity of the double-blind treatment codes should be confirmed. Any outstanding queries should be resolved and documented.

Arrangements for retaining source data should be confirmed with the investigator. In addition, the investigator should notify the IRB/IEC of the completion of the study. When the final draft of the clinical study report is available, it should be given to the investigator for signature. In multicenter trials, a single lead investigator may sign a pooled study report.

**Reviewing, editing and verifying in-house case report data and databases**

While the goal of monitoring is to provide ‘clean’ CRFs, it is necessary to review CRFs for
Consistency and unrecognized errors once they are received in-house. The use of computer edit and logic checks supports this effort, where computer output is verified against CRF data. Discrepancies are identified and CRF queries are generated for resolution.

The goal of managing CRFs is to get the data from the CRFs to a clean database in the fastest time possible while maintaining the highest level of quality. To accomplish this task, CRFs must be ready for data entry at the site. CRFs must be cleaned on an ongoing basis during the study. To do this, efficient systems must be incorporated to simplify the query process. The approach used by some sponsors permits electronic exchange of CRF data between the investigator, monitor and data entry personnel. SDV is still a fundamental requirement even when utilizing electronic data capture and exchange. Computerized checking programs and edit checks make the process more value-added for the monitors.

Clinical teams should design database before the trial begins, reduce the amount of data collected, use standardized CRFs and complete the review process on an ongoing basis. The philosophy is ‘do it right, first time’ at the source.

To be successful, the staff must know how to prepare CRFs for data entry, be able to verify database consistency with original records and CRFs and assure that queries are handled effectively.

### Competencies associated with reporting clinical research

#### Preparing clinical study reports

The requirements for reporting clinical trials to international regulatory authorities are similar in intent but differ in detail. Sponsors approach preparation of NDA/BLA/MAA documentation in a modular format. Each module satisfies a specific documentation need. The modules are generally organized as follows:

- Module I: Includes a basic summary of the study not unlike a publication. It includes study rationale, objectives, methods, results and conclusions. Module I also has a large appendix which includes list of investigators, drug lot numbers, concomitant diseases and medications, intent-to-treat analysis, patient listings of adverse events and relevant laboratory abnormalities and publications on the study.

- Module II: Includes the protocol and any modifications, CRF, detailed methodology and the glossary of original terminology and preferred terms.

- Module III: Presents the detailed efficacy findings including the intent-to-treat analysis population and the efficacy data listings.

- Module IV: Presents the detailed safety findings including the intent-to-treat analysis population and the safety data listings.

- Module V: Includes individual center summary reports, quality assurance measures, statistical methods and analyses and randomization lists.

The skills necessary to prepare a clinical study report include:

- Advanced research design, methodology and statistics;

- Preparation and review of study tabulations;

- Ability to confirm that study tabulations conform to protocol design;

- Ability to verify study tabulations against computer data listings;

- Clarification of outstanding issues regarding data analysis and presentation;

- Drafting of assigned study report sections according to the clinical study report prototype;

- Interpretation of adverse events;

- Interpretation of laboratory findings;
• interpretation of efficacy findings;

• ability to ensure that the conclusions are supported by the data;

• ability to ensure that reports satisfy regulatory requirements;

• developing clear, simple graphs, tables, figures to illustrate and support findings;

• ability to write a clear, concise report that accurately summarizes and interprets the results.

Preparing annual safety reports

Sponsors are required to submit annually to regulatory authorities a summary of safety findings of investigational products. This involves verification of AE tabulations against computer data listings and the preparation of safety tables. The current findings are reviewed and compared with AE data from the past reporting period.

The sponsor’s representatives must be able to clarify any outstanding issues regarding safety interpretation and presentation of the data. As this information is of critical importance to the regulatory authorities, the annual report must be written in a clear, concise manner that accurately summarizes and interprets the safety results. The annual report should provide clear, simple graphs, tables and figures to illustrate and support safety findings.

Following the submission of the annual report, safety findings are usually integrated into an updated version of the IB.

To be able to prepare annual reports, the sponsor’s representative should know how the reports satisfy regulatory authority requirements. The clinical representative should be able to interpret clinical safety and laboratory findings. The ability to understand computer-generated clinical output and the organization and structure of the NDA/BLA/MAA safety database is important.

The annual report and NDA/BLA/MAA safety update review and approval procedures must be understood, as well as the procedures for the preparation of the IB.

Preparing clinical sections of NDA/BLA/MAA

The knowledge and skill needed to prepare an NDA/BLA/MAA include the ability to

• verify individual study tabulations against overall summary computer listings;

• prepare brief descriptions of the studies;

• interpret critical clinical safety and efficacy results;

• interpret laboratory findings;

• develop clear tables, figures to illustrate and support clinical findings;

• summarize, interpret and integrate the overall safety and efficacy results;

• prepare NDA/BLA/MAA clinical study summaries, benefit/risk summary, expert reports and Package Insert.

In addition, an understanding of electronic NDA/BLA/MAAs and regulatory authority data presentation requirements are useful.

The expert report usually generates considerable discussion within a project. The sponsor often prepares this document under the guidance of an external expert. Although internal experts are acceptable, it should be remembered that the regulatory authorities are looking for an individual who knows the drug thoroughly and can express an unbiased opinion of its medical importance. The expert report is not just a summary but also a critical assessment of the clinical evaluation of the drug. The expert report provides an independent assessment of the risk-to-benefit ratio of the drug and its use. The text is limited to 25 pages, but may include ‘unlimited’ number of attachments. Many companies have been creative in font size and two-sided preparation of the document.
Certain trends and directions can be recognized in the preparation of NDA/BLA/MAAs. The ICH has the long-term goal of harmonizing the content of European, US and Japanese NDA/BLA/MAAs. EU registration dossiers are becoming more detailed in the process, and are expected to include integrated summaries in the future. The US FDA will accept more non-US data for drug approval as common high standards for clinical trials become well established in the world. Finally, electronic NDA/BLA/MAAs will be the norm and are already required in the United States.

Lastly, how and where are Competencies Taught?

Quite apart from established in-house training programs, there is a wide selection of vendors offering competency-based training. The format of their programs may include:

- workshops, seminars and lectures;
- self-instructional manuals;
- computer-based training systems;
- videotape libraries;
- job aids;
- preceptorships and mentoring programs;
- educational organizations such as PERI and DIA;
- professional meetings and conferences.

Most vendors advertise widely in the trade journals, and many of their courses are tailored to meet the several certifications that are now available in clinical research or regulatory affairs.
SECTION II
Drug Discovery and Development

Introduction

How does a chemical become a medicine? A better question, given the huge attrition rates in drug development, might be: What governs whether a chemical becomes a medicine? This section of the book covers all those disciplines and processes that are needed for this putative transmogrification.

This can also be called the ‘pre-marketing’ phase of the drug life cycle. It should be noted that although all this is necessary, it is certainly not sufficient for commercial success.

Importantly, these chapters have had to be designed to present the general case. Two major limitations then automatically arise. The larger limitation is that whole disciplines can be essentially product specific; hence, there is little about preclinical pharmacology in this section because a general case cannot be extensively presented. The smaller limitation is well illustrated by the discipline of toxicology. In this case, the general principles are fairly easily to enunciate, and have been codified by the International Conference on Harmonization. However, the toxicology program for almost every new chemical entity deviates from these general principles because special studies are needed in pursuit of product-specific issues that are uncovered while doing the ‘standard’ tests. Neither can such custom-designed studies be generalized here.

Regulatory affairs are so fundamental to preclinical and clinical development that it deserves a section of this book to itself. However, this is a purely artificial distinction which must not be allowed to obscure the crucial, intimate and interactive relationship between regulation and the other disciplines that are described in this section.

Lastly, there is some cross-referencing and overlaps between some of the chapters in this section. Much in this section would also apply to late phase III and phase IV drug development. This is intentional and again reinforces how an integrated approach must be taken in drug development for there to be any chance at all of eventual success.
4 Drug Discovery: Design and Serendipity

Ronald R. Cobb and Leslie J. Molony

4.1 Introduction

How is it that medicines are discovered? In ancient times, and even today, tribal people knew the healing or hallucinogenic properties of indigenous plants and animals. The knowledge was accumulated through generations, recorded by chant and living memory and was derived largely from human experience. Although many of the drugs in use today were discovered by chance, most drug discovery scientists engage in directed research, based on a series of steps, each requiring substantial scientific input. Although available facilities, resources, technology focus or even corporate culture can define the procedures followed by researchers at particular institutions, there are some obvious, generally applicable milestones in this process that facilitate the discovery of therapeutics.

Targeted medicines and their implications

The understanding and use of medicines by physicians and healers have evolved significantly, keeping in step with technological and biological breakthroughs. From the use of herbal remedies to toxic chemotherapeutic substances (Vinca alkaloids being an example of both!), today’s ideal case is a medicine directed at an identified pathological process, and/or specific receptors controlling these pathologies. Well-targeted medicines are often substantially safer, and are likely to have fewer adverse events (side effects) in a larger patient population than those with multiple pharmacological properties.

Research and development leading to a new, well-targeted pharmaceutical product is a long, complex and expensive process. Historically, the cost of a new drug has been escalating by close to $100M every five years. In 2005, the estimated cost to bring a new drug from the laboratory bench into the marketplace was US$800 millions (about £670 millions or £450 millions). Average development time is 7–10 years, although some ‘blockbuster’ drugs have taken 20 years. In the universe, of all commercial products, these are among the longest of all development cycles, permitting patent exploitation among the shortest periods.

Hence, the drug discovery and development process is a two-part exercise in mitigating the economic punishment to product sponsors while maximizing the probability that something that can be developed successfully is actually found. As few as 1% of promising lead molecules will be tested in human beings; fewer than one-third of those tested
will become marketed products, and among those only about a half will produce financial returns that are disproportionately higher than their costs of development.

Despite the high risk and escalating costs to develop new medicines, the benefits of pharmaceuticals to human healthcare provide both financial as well as humanitarian motivation to pharmaceutical companies and to the individual drug discovery scientists.

### 4.2 Designing a drug discovery project

‘Chance favors the prepared mind.’ – Anon.

All drug discovery projects depend on luck to be successful, but research and careful planning can improve chances of success and lower the cost. Project teams can streamline the discovery process by using the tools that can lead to a discovery most directly. These tools are drawn from the repertoires of modern biology, chemistry, robotics and computer simulations. In comparison with older processes of in vivo screening of huge numbers of molecules, however, these innovations have not been associated with shortening of the development time of 7–10 years (see Figure 4.1). Some think that modern biology as well as other fields have only increased the numbers of ‘hits’ overall, whereas others think that an increase in speed of discovery has compensated for an increase in regulatory stringency during the last two decades.

### The ‘Unmet Clinical Need’ as a market niche

Usually, scientists are directed to research new targets in specific therapeutic areas based on unmet clinical needs and market opportunities that are foreseen in the medium-to-long term. Both medical and business considerations are weighed. Larger companies will rarely fund internal research for drug discovery of orphan drug products (or products targeting diseases with few patients). On the other hand, small market niche needs are often sufficient for smaller companies (often researching in biotechnology).

Once a medical need and market niche are identified, and a particular therapeutic area chosen, the biological research begins. It is during this first stage of drug discovery that anecdotal clinical observations, empirical outcomes and ‘data’ from folk medicine are often employed, if only as direction-finding tools.
Once a direction is chosen, it must be validated scientifically, within a defined biological system. Human disease or pathology is usually multifactorial, and the first task of the researcher is to narrow down the search by defining the molecular mechanisms better; optimally this will be a small number of pathophysiologically observable processes, for example the pinpointing of one or two types of cells which are etiological.

From that cellular stage, the researcher next defines specific molecular targets, such as receptors on or specific isoenzymes in those cells, which create the destructive phenotype. Is there an anomaly in a cell derived from a tumor, to use a cancer example, which renders that tumor cell unique from normal cells derived from the same tissue? If the difference is significant and can be reproducibly observed in the laboratory, it can be exploited for drug discovery. In other diseases, the cell which is identified can be normal but activated to a destructive state by stimulation with disease pathogens. In rheumatoid arthritis, for example, the normal T-lymphocyte is stimulated to react to antigens present in the joint, thus developing a destructive phenotype.

The wider effects of inhibiting, modifying or eliminating this new molecular target on the organism must also be considered. An enzyme that is essential to life is a ‘no-hoper’ from the point of view of the drug developer. The perfect target is organ-, tissue- or cell-specific, thereby limiting effects to the system involved in the disease. The choice of a target for a disease will be critical to the outcome and performance of the drug, and will determine what organs or tissues will be susceptible to side effects. The ideal molecular drug target is also one which is proprietary, whether having been discovered in-house or in-licensed.

At this stage, an assessment is made as to whether the medicine that could result is likely to be palliative or ‘disease-modifying’. Disease-modifying drugs (DMD) are those which directly and beneficially deflect the natural history of the disease. Nonsteroidal anti-inflammatory drugs and methotrexate are examples of each of these in patients with rheumatoid arthritis. Then probability of one or the other can alter economic assessments of the research program, and lead to a go-no-go decision in some cases.

Combining basic and applied research

Molecular targets are not always obvious, even though cellular and histological disease pathologies have been well described in the literature. At this point, the researcher returns to the laboratory bench to design critical experiments (see Figure 4.2).

The design and use of highly specific, monoclonal antibodies (MAs) to proteins (or receptors) derived from diseased tissue is a common approach to probing for the correct molecular target. One refinement of this approach is to use a variety of these MAs to screen hybridoma supernatants for activity in preventing a cellular manifestation of the disease of interest. Taking cancer as an example, malignant cells often contain over-expressed, mutated or absent ‘oncogenes’ (i.e. genes which code for particular proteins or receptors in normal cells, but are mutated, and thus cause pathological overactivity or underactivity of those gene products in tumor cells). Two well-known examples of oncogenes are the \( RAS \) and \( SRC \) oncogenes, which code for the production of RAS and SRC proteins, respectively. Normal RAS protein regulates cellular division and coordinates the nuclear changes to alterations in the cellular architecture required for mitosis (cytoskeleton and cell motility). Meanwhile, SRC protein is a key signaling molecule which alters cell growth by modulating the activation of the epidermal growth factor (EGF) receptor by its ligand. Many drug discovery efforts have, therefore, targeted SRC, RAS, the EGF receptor or any of their associated enzymes. Thus, for example, RAS inhibitor discovery projects include prevention of the enzymatic event which allows translocation of RAS from the cytosol to the plasma membrane in cancer cells as one way to prevent the effects of RAS.

Taking another example, consider the case of a novel approach to treating inflammatory disease. In 1997, a cell or molecular biologist beginning such a research program might have found reports in the literature of transgenic mice which, when genetically engineered to cause monocytes to express constant levels of the cytokine (TNF), develop arthritis, as well as some of the early clinical trials using anti-tumor necrosis factor
(TNF) antibodies in human rheumatoid arthritis. There would also have been a lot of data available concerning cellular infiltrates in joint effusions, with monocytes and T-lymphocytes being the most prevalent. High concentrations of other mediators of inflammation, such as interleukin-1β, leukotrienes and phospholipases had also been reported in rheumatoid joints. The scientist might then conclude that inhibitors of TNF receptor activations, rather than antibodies to the ligand (TNF) itself, could also benefit inflammatory arthropathy. A range of ways how this might be accomplished would then present itself: irreversible antagonism of the TNF receptor, interruption of that receptor’s transduction mechanism or prevention of the expression of either TNF itself, or its TNF receptor, in the nucleus or ribosome.

The investigator might then seek the counsel of marketing experts and physicians regarding the use of the antibodies, and again review the clinical trial data available through the literature on the anti-TNF antibodies. Such antibodies will be competing products for a long time in the future, given that it is difficult to obtain regulatory approval for ‘generic’ biotechnology products, regardless of the patent situation. But the antibodies are also unattractive drugs. They are not orally available, and they elicit of immune responses after several doses (anti-anti-TNF antibody humoral response). Thus, these criteria would then be applied when sorting through the alternative modes of attack on the TNF receptor. An orally bioavailable, non-peptide drug might become the goal.

The next question to be answered is whether a priori the receptor itself, or one of the associated regulatory enzymes, is likely to be specifically targetable using an oral, non-peptide drug. Little literature on this subject was available in 1997, and no competitor seems to have taken this approach. The company’s laboratories are then set to work.

Each individual laboratory (‘lab’) working on TNF as a therapeutic target approaches the problem from a different direction. For example, one lab may seek to inhibit transcription factor activation by phosphorylation or proteolysis, and to examine the sorts of compound that may be capable of this. Another group might seek to interfere
with the binding of the transcription regulatory complex to DNA.

A key decision in each lab is when to incur the expense, and time to clone the molecular target and set up the robotized in vitro assays which can screen compounds with a high rate of throughput. The best assays are those which relate directly to cellular events, which allow screening of huge numbers of chemical compounds and which predict in vivo responses. Other assays during this exploratory stage may be used as secondary screens for candidates identified by the first one, if at rather slower throughput.

**Genomics and molecular biological approaches**

The Human Genome Project has had a significant effect on target identification. One by-product was that gene expression profiling technologies were invented which allowed for direct comparisons of mRNA levels in normal and diseased cells (e.g. ‘gene microarrays’ or ‘gene chips’; Cunningham, 2000; Clarke et al., 2001). Technologies such as these allow the pharmaceutical researcher to compare the expression levels of nearly all the genes in the genome in one experiment, and in an automated fashion. Gene expression profiling is useful not only in target identification as described here but also in finding significant use in later stages of drug development such as toxicology, surrogate marker generation and mechanism of action studies (see Figure 4.3).

‘Antisense oligonucleotides’ are short, single-stranded DNA molecules that are complementary to a target mRNA (Baker and Monia, 1999; Crooke, 1999; Kolter et al., 2000). Once bound to the mRNA of interest, it is targeted for cleavage and degradation resulting in a loss of protein expression. There are several naturally occurring catalytic RNAs including ‘hammerhead’, ‘hairpin’ and ‘hepatitis delta virus’ introns and the RNA subunit of RNAase P (Khan and Lal, 2003). Catalogues exist where the researcher can simply look up which genes a particular antisense sequence will map to, and the use of fluorescent tags can then be used to probe the location of disease-producing mutants.

But the pharmaceutical researcher should not rely entirely on gene expression profiling for target identification, even though the technology is very powerful. Gene expression does not automatically lead to predictable protein synthesis. Protein

![Drug screening flowchart](image-url)
activity and abundance does not always correlate with mRNA levels (Chen et al., 2002; Gygi et al., 1999).

The ‘one-gene-one-protein’ hypothesis is now well and truly dead. Proteins hugely outnumber genes in all mammals. The term Proteomics has been coined to describe the analogous study of proteins within particular cells or tissues (Figeys, 2003; Petricoin et al., 2002; Tyers and Mann, 2003; Zhu et al., 2003). Moreover, many proteins are modified after translation in ways that are crucial in regulating their function. Thus, the application of proteomics also extends far beyond the target identification stage in drug development.

Further exploitation of this genomic and proteomic can be obtained by making comparisons of these data with epidemiological observations in human populations. Patterns of familial disease, with mapping to differences between individuals in terms of DNA or mRNA, can identify which of many genetic variations is the etiology. This is known as ‘Linkage Analysis’, and, ultimately, the precise chromosomal location, relative to the location of other known genes, can be found using a technique known as ‘positional cloning’. An example of new target identification using these methods was the identification of ApoE as a causative factor in Alzheimer’s disease (Pericak-Vance, 1991).

Mutations which cause disease can arise spontaneously. Genetic mapping methods utilizing positional cloning can help identify disease-causative genes and their proteins in animals which have spontaneously developed diseases similar to those of humans. An example of this type of technology is the ob/ob genetic mouse, which is obese and has mutations in a gene for a peptide hormone known as leptin. A similar mouse, the Agouti strain, is also obese and has defects in melanocortin receptors, which develops type II diabetes, and therefore can be used as an animal model of that disease in humans. Of course, human disease is rarely as simple as a single genetic defect, so these models must be used with some caution when testing drugs or when identifying the causative genes. Pathophysiological studies of organisms that have been engineered to contain (transgenic ‘splice in’), or to be free from (‘knock out’) the identified gene is an extension of this concept (see also below).

The sequencing of genes does not directly identify new molecular targets for disease. But what it does do is to permit the rapid identification of target proteins, because their codes are known. Usually, only a few trial peptides need then be synthesized, shaving months off of the discovery process. In turn, this allows rapid identification and cloning of new targets for assay development.

### 4.3 Whole tissue studies

Pharmacologists are often able to develop tissue and whole animal models of human disease. In some instances, studies on isolated tissues, such as blood vessels, heart muscle or brain slices, will allow a tissue- or organ-specific understanding of the effects of potential new drugs. Cardiovascular pharmacologists often study isolated arteries which are maintained in a physiological salt solution. Electric stimulation can induce contraction of the vascular smooth muscle, and the effects of hypertensive drugs on vascular contraction can then be measured. Historically, these systems were often used as primary drug screening tools. Because these methods are much less direct than molecular screening, they are now relegated to secondary or tertiary roles as validation of the targets or drugs discovered, using assays that directly employ the molecular or cellular targets. Whole animal models are often seen as critical decision-making points for a newly discovered drug.

Human pathology is inevitably more complex than those of rats and mice. Thus, it is often necessary to induce a pathological state by introduction of a pathogen or stimulant directly into a healthy animal. The development of new animal models is a time-consuming process and must be overseen by the appropriate ethics committees and expert veterinarian advice.

Why are in vivo (whole animal) studies still important to drug discovery? All the new technology, as well as mathematical modeling using computers, has reduced but not eliminated the need for animal experimentation. Computer models still cannot accurately predict the effects of chemical compounds on the cell, let alone in systems with higher orders of complexity, that is whole tissues,
organs and organisms, with their emergent properties that define the discipline of complex systems biology. In vivo cells operate in a dynamic and communicative environment, where an effect of a drug in one place may well lead to corresponding or compensatory changes elsewhere. The summation of these innumerable responses often defeats the predictions of high-throughput screens and three-dimensional drug-receptor ‘design the key for the lock’ calculations.

In vivo target validation also still requires the use of animal models. It is now possible to monitor multiple targets within the same cells by intercrossing independently derived strains of mice that have been engineered to express different target genes and/or to lack one or more target genes. These models provide a powerful genetic approach for determining specific events and signaling networks that are involved in the disease process.

4.4 Other sources of compounds

Pharmacognosy is the science of identifying potential drugs that are naturally formed within plants or animals. It is not yet an abundant source of molecules, although The Pacific Yew did recently yield paclitaxel for ovarian cancer. One large pharmaceutical company has concluded an agreement with a Central American country to preserve its entire flora and give the company exclusive rights to any pharmacophores within it.

Combinatorial chemistry

The breakthroughs in technology that have allowed sequencing of genes ‘on a chip’ and high-throughput screening of compounds in microtiter plate format have also caused a revolution in chemical synthesis, known as combinatorial chemistry.

Biological therapeutics

The chapter on biotechnology drugs enlarges on this subject in more detail, but suffice it to say here that vaccines, antibodies, proteins, peptides and gene therapies all now exist. These biological drugs bring with them specific, regulatory, clinical trials and manufacturing difficulties. Gene therapy, in particular, carries human safety risks that do not apply to other classes of therapy, for example the infective nature of some types of vector that are employed, and the potential for incorporation of the test genetic material into the genome in males, leading to expression of gene products in offspring.

New uses for old drugs

Lastly, opportunities still exist for astute clinicians to find new uses for old drugs, and for these newly discovered uses to lead to new and unexpected drugs. The recent approval of bupropion as a smoking cessation agent is a good example of a chance observation while the drug was being used for its initial indication, which was as an antidepressant. This has led to realization of the influence of nicotine on depression, and investigational drugs of a new class, based on this alkaloid molecule, are now being designed. Viagra is another good example of a drug that was originally designed for one therapeutic action and wound up becoming a blockbuster drug in another therapeutic area.

4.5 Summary

This chapter began with a survey of the modern methods of drug discovery. Pharmaceutical physicians should be aware of some of the techniques employed and the rapid rate at which genetic information is becoming available. It should be noted that this modern revolution has not quite completely swept away the occasional new drug found by serendipity or astute clinical observation.

References


### Further Reading


5 Pharmaceutics

Anthony W. Fox

5.1 Introduction

It is a triumph of modern pharmaceutics that most of us do not give a thought to the difference between a white powder and a tablet, and think that ‘a drug is a drug is a drug’. This huge presumption is doubtless because we do not, any more, make pharmaceutical (or Gallenical) formulations ourselves, and precious few of us have even observed that complicated process. Nevertheless, it is important to understand some elements of this science because of the following:

• Packaged white powders are probably not marketable, and overcoming Gallenical problems is a *sine qua non* for product success.

• A suitable formulation permits the conduct of clinical trials.

• Formulations constrain clinical trial design. Among other things, likely bioavailability must be compared with toxicology coverage, well-matched placebos may or may not be available, and special procedures may be required (e.g. masking colored intravenous infusions).

• Product storage and stability (or lack thereof) can bias clinical trials results, and dictate shelf-life in labeling.

• Formulation can strongly influence patient acceptability and compliance.

For all these reasons, and more, marketing and clinical input on suitable formulations should be included in the earliest considerations of project feasibility, and it behooves the clinical researcher to be able to provide such input in an informed manner. Equally, we should understand the constraints, difficulties and regulatory ramifications that all of our colleagues experience, including those in the research pharmacy. At the end of the day, product licences are awarded and NDAs are approved typically after the resolution of at least as many questions about ‘chemistry, manufacturing, and controls’ (for which read ‘pharmaceutics’) as about clinical efficacy and safety.
5.2 The constituents of a medicine

‘A drug is not a drug is not a drug’ because, when administered to a human being, in the general case, it contains

- active compound at a dose that is precise and within a limited tolerance (sometimes as a racemate);
- manufacturing impurities;
- one or more excipients;
- degradants of the active compound;
- degradants of the impurities;
- degradants of the excipients.

**Impurities**

An impurity is defined as a compound which is the by-product of the manufacturing process used for the active compound that has not been removed prior to formulation. Impurities can have their own toxic potential, and control of impurity content is therefore a highly important feature in any NDA.

**Excipients**

An excipient is defined as a material that is deliberately incorporated into the formulation to aid some physicochemical process, for example for a tablet, integrity, dissolution, bioavailability or taste; excipients are typically chosen from among many compounds without pharmacological properties (e.g. lactose), although there are examples where pharmacokinetics change with the excipient used. There are specialized examples of excipients, for example propellants are excipients that assist in the delivery of inhaled drugs to the respiratory tract. For intravenous infusions or ophthalmic products, the excipients are usually pH buffers or preservatives, and for dermatological products, they may include emollients and solvents.

**Degradants**

A degradant is defined as a compound that cumulates during the storage of bulk drug or finished formulation. For example, the vinegar-like odor of old aspirin tablets is due to acetic acid, which is a degradant due to hydrolysis of acetylsalicylate, which is an ester.

**Formulation-associated intolerability**

Many tablets carry printed identification markings or are color coated; dyestuffs are special excipients, and allergies to them have been documented. Formulations also have more subtle, but nonetheless differential characteristics such as whether the tablet was compressed at a higher or lower pressure. Lastly, differential efficacy exists among differently colored placebos, and this should therefore also be expected for active formulations.

Impurities and degradants may possess their own toxicological properties. Early in development, the structures of these impurities and degradants may be poorly characterized. Typically, both bulk drug and finished product become more refined as clinical development progresses. Thus, in order to preclude any new toxicology problems developing later during clinical development, it is common practice to use the less pure bulk drug for toxicology studies. This is commonly accomplished by using drug removed from the production process before the last step, for example before the last recrystallization. This usually guarantees that a lower purity, that is mixture with greater molecular diversity than the drug of interest, will be tested toxicologically than that to which patients will actually be exposed.

The evasion of formulation and toxicological testing by ‘herbal medicine’ manufacturers is completely illogical in this context. For example, the Butterbur (or Bog Rhubarb; *Petasites hybridus*) contains well-characterized carcinogens. Butterbur extract tablets are sold as chronic oral therapies...
for bladder dysfunction and migraine prevention, and claimed to be innocuous on grounds of chemical purity but without much biological, toxicological testing. Similarly, oral melatonin has an absolute bioavailability of about 15% maximum and was eventually withdrawn in the United Kingdom and Japan after safety concerns arose (DeMuro et al., 2000). The types and amounts of degradants and impurities in these products are unknown.

### 5.3 Formulation choice

The formulation chosen for particular drugs is not random, but the degree to which it is critical varies from drug to drug. For example, hydrocortisone is available for at least seven routes of administration, as tablets, several creams and ointments, intraocular solutions, suppositories, intrarectal foams, injections and eardrops. Even newer drugs, with fewer indications than hydrocortisone, seek greater market acceptability by providing a variety of alternative formulations (e.g. sumatriptan is available as an injection, intranasal spray, suppository and tablets).

One commonly used principle is to target drug delivery to the organ where beneficial effects are likely to occur. This can achieve

- relatively fast onset of effect;
- locally high drug concentrations;
- relatively low systemic drug concentration, avoiding toxicity;

probably the most common applications of this principle are the administration of beta-adrenergic agonists bronchodilators by inhalation and the use of topical hydrocortisone creams.

### Formulation characterization

Various physicochemical properties of bulk drug can be measured. Some will be reasonably familiar from medical school biochemistry, for example the one or more pK values for active drug or excipients, or the pH of drug solutions in specified aqueous solutions. The log $P$ is a measure of lipophilicity, usually measured as the octanol/water distribution coefficient when the aqueous phase is buffered at pH 7.4. Powder density is the ratio of weight and volume occupied by a powder; some powder particles pack together more efficiently; the familiar comparison between table salt and talcum powder is an illustration. Particle size and distribution is often measured using infrared devices. Maximum solubility ($x\text{ mg ml}^{-1}$) in various solvents is also often helpful not only to those whose task is to make drugs into prescribable pharmaceutical formulations but also to toxicologists estimating a maximum feasible dose in a given species by a particular route of administration. Hygroscopicity is a measure of the capability of a drug to absorb water from the atmosphere; such drugs gain weight with time, are often less stable than drugs lacking this property, and may thus predicate an aluminium foil packaging. Standard manuals such as Merck Index provide many of these data.

### 5.4 Specific formulations

**Oral formulations** include tablets, syrups, wafers and suspension according to the excipients used. **Binders** are used to hold the various components together, and examples would be starch or polyvinylpyrrolidone (to which dogs exhibit a species-specific allergy). **Bulking agents** (sometimes called diluents, or, confusingly for a solid formulation, diluents) include lactose and cellulose; these increase tablet weight, which can improve production uniformity. Silica and starch may also be used to improve the flow of powder in mass production, when they are known as pro-glidants. Stearic acid salts are used to enable tablets to escape from the press when finished, this being an unusual use of the term lubricant. **Coatings** are often sugars or cellulose and may be employed when a drug tastes foul. Particular color schemes can be created with dyestuffs or iron oxide.

Most wafer formulations dissolve in the mouth and are actually converted into a solution for
swallowing and gastrointestinal absorption (e.g. rizatriptan wafer). Benzocaine lozenges are intended for the same purpose but to dissolve more slowly, thus bathing the esophagus as a symptomatic treatment (for example) for radiation esophagitis; a similar approach is used with antifungal drugs.

**Bioequivalence and generic products**

Although the subject of their own chapter in this book, it should be emphasized here that there is no regulatory requirement for innovative and generic drugs to have identical excipients. Exemption from demonstration of efficacy for generic products is obtained only when bioequivalence with a prototype, approved product is demonstrated.

The standards for bioequivalence are similar worldwide, but as a specimen we can use the *Code of Federal Regulations*, Title 21 (21CFR), parts 320.1–320.63) in the United States. The regulation states that bioequivalence is ‘…demonstrated if the product’s rate and extent of absorption, as determined by comparison of measured parameters, for example concentration of active drug ingredient in the blood, urinary excretion rates, or pharmacological effects, do not indicate a significant difference from the reference material’s rate and extent of absorption’.

The data that have traditionally been most persuasive have been a pharmacokinetic comparison of the generic and reference drugs in humans. The commonest study design is to compare two oral formulations with the following optimal design features (21CFR, part 320.26):

- Normal volunteers in the fasting state.
- Single-dose, randomized, crossover with well-defined reference material.
- Collection of blood samples for at least three half times of elimination and at a frequency that captures distribution phase, $C_{\text{max}}$ and $T_{\text{max}}$, all at identical times post-dose for each formulation being compared.
- When there are major metabolites, then collections should accommodate at least three half times of their elimination.

In this case, the $T_{\text{max}}$, $C_{\text{max}}$, AUC and the half time of elimination for parent drug and principal metabolites become the end-points of the study. For combination therapies, these end points have to be measured and fulfilled for all active components, and the therapies should not be administered separately.

The regulation does not define what a significant difference might be, although a commonly applied standard seems to be a formulation whose mean $T_{\text{max}}$, $C_{\text{max}}$ and AUC is within 20% of the reference material and is also within the 95% confidence interval. However, these limits are tightened when

- the therapeutic ratio of the drug is low;
- the solubility of the drug is $<5$ mg ml$^{-1}$;
- tablet dissolution *in vitro* is slower than 50% in 30 min.;
- the absolute bioavailability is $<50$%;
- there is extensive first pass metabolism that makes rate of absorption, as well as extent, a factor governing exposure;
- there are special physicochemical constraints such as chelation, complex formation or crystallization to consider (see 21CFR, part 320.33).

There are also alternative ways to demonstrate bioequivalence. It may be possible to demonstrate bioequivalence using well-validated *in vitro* or animal methods, and these appear at 21CFR, part 320.24(ii)–(iii). For example, two oral formulations can be compared with an intravenous dose of equal or unequal size. If the drug is concentrated in the urine but has negligible concentration in the blood (e.g. nitrofurantoin antibiotics), then urine sampling with a frequency that matches the blood samples could be employed. Multiple-dose
bioequivalence study designs are also available. Rarely, the testing of bioequivalence at steady state in patients is needed because normal volunteers would face an undue hazard, and patients cannot ethically be withdrawn from therapy (antiretroviral agents are one example). Chronopharmacological effect can also be exploited, that is using pharmacodynamic data with a frequency and timing of end points in much the same way as that for the blood samples described above. This can be useful for drugs that are not intended to be absorbed systemically, for example, the rate of onset and offset of local anesthesia to a standardized experimental injury.

The Clinical Trials Directive now requires the filing of a clinical trial application for bioequivalence studies in normal volunteers or patients. In the United States, an IND is always needed if the generic drug is without an approved innovator in the United States, is radioactive or is a cytotoxic. However, when single- or multiple-dose studies in normal volunteers do not exceed the approved clinical dose sizes and there will be retention samples available for inspection, then there can be exemption from the need to file an IND. An IND is needed for a multiple-dose bioequivalence study, when it is not preceded by a single-dose study. The usual protections for human subjects are required, and, of course, these include an approval from the Institutional Review Board.

Sustained release oral formulations

By definition, sustained release formulations differ pharmaceutically and pharmacokinetically from the innovator drug. The excipients and particle sizes (usually larger) of the formulation are designed to dissolve more slowly and are almost always drugs for chronic diseases. The common advantages are reduction in dose frequency (and thus, hopefully, improved patient compliance; see that chapter in this book) or reduction of \( C_{\text{max}} \) for a standard AUC, which can improve tolerability when adverse events are plasma concentration related. Regulatory approval of these formulations usually hinges on the following factors [see 21CFR, part 320.25(f)]:

- Equivalence of area under the time–plasma concentration curve AUC to a prototype ‘rapid release’ drug.
- Steady-state plasma concentrations that do not exceed and are usually within a narrower range than that of the prototype.
- Absence of any chance of ‘dose dumping’, because the gross weight of active drug in a single slow-release capsule will always exceed that of a single dose of the prototype.
- Consistency of performance from dose to dose.

There are various formulation tactics. Active drug granules of larger size have smaller surface area to volume ratios and dissolve more slowly. These granules can also be coated with different thicknesses of polymer, and mixtures of these can be contained within a single capsule. Osmotically driven tablets slowly release drug through a small aperture during the entire traverse of the small bowel. The tablets can be compacted with layers that have different rates of dissolution and can also be designed to release their contents only in relatively alkaline environments (i.e. beyond the ampulla of Vater). It is illogical to seek sustained release formulations for drugs with relatively long half times of elimination (amiodarone, frovatriptan).

Oral transmucosal formulations

The best drugs for oral transmucosal administration are those that have high potency and do not taste bad. For example, among opioids, buprenorphine and fentanyl are the two drugs that have been successfully developed using this type of formulation. The formulations and excipients include sublingual pellets, chewable gums and sugary solids held on a stick, somewhat like a lollipop.
Gases

The physics of gases and the partial pressure at which they can achieve anesthesia is beyond the scope of this chapter. For one thing, this huge subject begs the question of how the state of anesthesia can be measured, and this is one of the more difficult clinical trial end points. One wit, a famous British cardiothoracic anesthesiologist, has commented, ‘If you can tell me what consciousness is, then I will tell you what anesthesia is’!

Gases are usually administered either ‘pure’ (i.e. with limits on impurities) or in combination with excipients, for example oxygen, air or helium in the gas stream which is vaporizing a liquid halogenated hydrocarbon (validated vaporizers, usually designated for use with a single active compound, are required). When the route of administration includes mechanical ventilator (including a hand-squeezed bag), then drug economy, occupational exposure of the staff, carbon dioxide scrubbing and other pharmacokinetic problems emerge that are rarely encountered elsewhere. Gas flow can be measured with various devices, and exhaled gas concentrations (including carbon dioxide) can now be measured instantaneously. A rare adverse event, malignant hyperthermia, is associated with the inhalation of halogenated hydrocarbons (as well as some depolarizing neuromuscular junction blocking drugs), and this can be treated with intravenous dantrolene (Strazis and Fox, 1993).

There are some uses for gaseous drugs outside of surgery. Nitrous oxide and oxygen mixtures are sometimes used as analgesics during labor or when transferring patients in pain by road or helicopter. In very cold weather, nitrous oxide can liquefy, reducing the delivered dose; shaking the container helps.

Helium/oxygen mixtures are used to improve oxygenation in patients with subtotal airways obstruction, exploiting the superior flow (proglidant) properties of the lighter gas. The use of this mixture as prophylaxis against nitrogen narcosis at high inspired pressures (deep sea divers) or to minimized fire hazard is also well described. Fire hazard due to oxygen (arguably a gaseous drug under some circumstances) is important. Patients are often burned when on oxygen therapy for lung disease which they are encouraging with an illicit cigarette. The disastrous fire inside the command capsule of Apollo 3, during a launch rehearsal on Pad 39B at Cape Kennedy, started in a pure oxygen, normal pressure, atmosphere. Reduction in total atmospheric pressure and excipient nitrogen has since been employed in all pressurized American space vehicles, but they still contain supra-atmospheric partial pressures of oxygen, and a fire was recently reported in the Russian–American Space Station.

Metered dose inhalers and nebulized drugs

In general, and with a few rare exceptions (see below), the inhaled route of administration is the most difficult that is commonly encountered. Metered dose inhalers and nebulizers are considered together here because they are both aerosols of drug solution.

In textbooks for a general audience, it is customary to insert, at this point, a graph that relates aerosol particle size to the penetration by drugs of various levels of the airway. Particles >10 μm are stated to commonly impact in the pharynx, those <5 μm are assumed to be ideal for alveolar delivery and those <0.05 μm are said not to deposit in the lung at all, being liable to be exhaled. This is an oversimplification.

Particle deposition is actually dependent on a large number of factors, attested to by a vast literature in the fields of respiratory medicine, pulmonary physiology and industrial hygiene. These factors include (with example studies)

- coughing (Camner et al., 1979);
- mucociliary action (Lippmann et al., 1980);
- exercise and minute ventilation (Bennett et al., 1985);
- mucous production and ability to expectorate (Agnew et al., 1985);
- apnoeic pause at the end of inhalation (Legath et al., 1988);
• whether or not the patient is actually having an asthma attack (Patel et al., 1990);
• breathing pattern, airway calibre, device spacers and reservoirs (Bennett, 1991);
• the physicochemical properties of the drug(s) (Zanen et al., 1996);
• lung morphometry (Hoffmann, 1996);
• sampling techniques on which exposure calculations are based (Cherrie and Aitken, 1999).

The reality is that it is impossible to measure accurately the lung deposition of inhaled drugs in humans.

Much vaunted in vitro studies actually use apparatuses that do not model well the anatomy of the human respiratory tree, let alone one with disease. The British Association for Lung Research has recognized this complexity and issued a consensus statement (Snell and Ganderton, 1998) which recommends, at a minimum, a five-stage collection apparatus, examination of a range of particle sizes 0.05–5 μm, a range of flow rates and patterns to mimic the various physiological states, the development of an apparatus modeled on the shape of the human pharynx, regional lung assessments in three dimensions, the concomitant use of swallowed activated charcoal in to minimize systemic absorption of drug that was swallowed after affecting the oropharynx and further development of better statistics for analyzing the data.

The metered-dose inhaler has been in use for about 50 years and forms the mainstay for the treatment of asthma, as well as chronic bronchitis with a reversible component. Great technical challenge has been experienced in the last few years due to the need to change excipients (propellants) in metered-dose inhalers, so as to avoid non-fluorohydrocarbon materials. In comparison with domestic refrigerators, industrial refrigeration plants and cattle-generated methane, this contribution to protecting the atmospheric ozone layer must be negligible. Nonetheless, these huge drug re-development costs are now being borne by healthcare systems worldwide. In this case, although a bioequivalence approach has been taken when changing the propellant, clinical studies have mostly relied on efficacy parameters, again because of the inability to quantitate lung deposition, while avoiding systemic drug absorption. Inhaled insulin is studied on the basis of both pharmacodynamic and pharmacokinetic parameters.

A wide variety of nebulizers are now available. They all have their own physicochemical properties. In the absence of the ability to quantitate lung deposition, most modern labels specify the combination of a new drug with particular nebulizer device (the labeling for alpha-dornase was the first to exhibit this change in regulatory policy). The corollary is that product development plans should decide, as early as possible, which nebulizer is intended for the marketplace, and that device should be used in all inhalational toxicology studies and subsequent clinical trials.

### Intranasal formulations

The absorptive capacity of the nasal mucosa has been known for centuries: nicotine (Victorians using snuff) and cocaine (aboriginal peoples since time immemorial) are the two historical examples of systemic drug absorption via the nose. The opposite pharmacokinetic aspiration is illustrated by anti-allergy and decongestant drugs which are now administered via the noses in the developed world literally by the tonne: here, the intent is to treat local symptoms and avoid significant systemic exposure of drugs with varied pharmacology such as alpha-adrenergic agonists, antihistamines and corticosteroids. These products also contain buffers and preservatives.

There is particular interest in the nasal mucosa because it can provide systemic absorption of drugs that otherwise must be administered by injection. These are often polypeptide drugs. Calcitonin and vasopressin-like drugs (nonapeptides) for diabetes insipidus in patients with panhypopituitarism are examples.

There is a specific guidance document from the International Conference on Harmonization which discusses the demonstration of bioequivalence for
nasal sprays and aerosols. While the intent of this guideline is to facilitate the development of generic products for use by this route of administration, it has been challenged on several scientific and technical grounds (e.g. Harrison, 2000).

**Transdermal and topical formulations**

The principal distinction between transdermal and topical drugs is that only the former is intended for systemic delivery. Both are subject to the same skin irritant testing prior to human exposures; preclinical and clinical skin irritancy testing is reasonably stereotypical and commodity priced.

Biologically, the skin is designed to be a barrier. Evading this barrier is not easy, because drugs must traverse both live dermis and dead epidermis. Lipophilic drugs tend to form a reservoir in the former, even after traversing the hydrophobic latter. As in oral transmucosal administration, potent drugs, with modest requirements for mass absorbed and reasonable lipophilicity, are the best candidates for transdermal delivery. Fentanyl, nicotine and scopolamine are good examples.

**Suppositories** are probably the clearest illustration of cross-cultural differences in pharmaceuticals. A surgeon on a famous ocean liner has commented that ‘Part of the problem stocking one’s pharmacy is that one needs three times as many products as when working on land: Tablets for the Brits, shots (injectables) for the Yanks, and suppositories for the French!’

However, this route of administration is eminently logical, in several circumstances. For the acute treatment of migraine, oral drugs are often vomited (sumatriptan). For treating acute asthma, children often cannot use an inhalational device properly (theophylline). For perioperative antibiotics, patients are often nil by mouth (metronidazole). For inflammatory bowel disease and proctitis, this is simply a topical administration.

Diazepam and paraldehyde administered rectally are effective for terminating a seizure, especially in children, without the need to find a vein. Use a glass syringe for paraldehyde.

**Vaginal pessaries** are suppositories designed for a more acidic environment than that found in the rectum. Topical uses include treatments for *Candida albicans*, and *Trichomonas* infections, as well as for preparation of the cervix prior to induction of labor. Contraceptive devices are outside of the scope of a chapter on pharmaceutics, although the nonoxyl containing sponge pessary is a unique formulation. At the time of writing (May 2006), there is controversy over whether mifepristone is associated with greater clinical hazard when administered *per vagina* in comparison with being swallowed.

**Injectates (s.c., i.m, i.v.)**

The solubility of a drug and the compatibility of a particular solvent with the site of injection are interrelated factors governing the suitability of this route of administration and the pharmaceutical formulation that is employed. The route of administration may also be governed by tolerability aspects associated with the formulation. If a drug cannot be dissolved in a concentrated manner in a suitable vehicle, then often dose size must increase. For example, intravenous injections of penicillin-type antibiotics are much more comfortable than when the same dose is administered intramuscularly.

Intravenous formulations are probably the least demanding of all injectates; the human vein is quite robust, although venous irritancy is often encountered in clinical trials. A surprising example of this robustness is seen when inducing anesthesia with thiopental sodium (sodium thiopentone). The upper limb veins tolerate these alkaline solutions with impunity, but the solutions are very damaging when administered occasionally and iatrogenically into the cubital fossa; a solution at pH 9 can cause serious injury to the structures at the elbow, including the median nerve.

Organic solvents are often used to enhance the rate of absorption from subcutaneous or intramuscular sites of administration. For example, benzyl alcohol and sodium benzoate are used to dissolve diazepam, and extravasation of this formulation is not as serious a problem as for thiopental.

Water-soluble drugs are usually also hygroscopic. If not shipped and stored as solutions,
then an anhydrous environment is needed for product stability. This is most easily achieved as a lyophilized powder in an evacuated and sealed glass vial. This can be reconstituted with water or saline immediately prior to injection. Lyophilizates in stoppered vials can also be subjected to gamma irradiation to ensure sterility. Stability studies should include not only the range of temperatures and humidities (see below) but also with the vials inverted.

Rarely, adverse events are reported when an apparently innocuous formulation is administered via wrong route. Usually, these problems arise because of excipients that the typical physician takes little interest in. As one example, intravenous remifentanil is formulated with glycine, and hence it is not well suited for intrathecal administration. The intravenous administration of liquid enteral diets is occasionally achieved in spite of all precautions with non-Luer equipped tubing and prominent labeling; profound metabolic acidosis is the result.

The development of an injectate is often one tactic used for obtaining a patent. Even though a composition of matter patent (i.e. the structure of the drug molecule itself) may be old, the development of a nonobvious injectate and its method of use for a new indication, may be sufficient to obtain a further patent and thus extend effective proprietary coverage. Such patents are usually stronger in North American than in European jurisdictions.

### Packaging

The selection of an inert package is an essential part of the pharmaceutical development of a drug. There are many standard stoppers, plastic and glass bottles, and so on with which regulatory authorities are very familiar and for which drug master files are already in place. Stability studies must be conducted, of course, in the same sorts of packaging.

Packaging, nonetheless, degrades, and over a period of months or years an apparently impervious material may permit the ingress of water. Foil wraps are generally available for all tablets and are usually the most impervious of all materials; however, these can be inconvenient for patients with arthritis. PVC blister packs are at the other end of the spectrum: Padfield (1985) has provided one example where a 0.8% increase in tablet weight within a PVC package occurred within 12 weeks.

Drugs, both investigational and prescription, are today transported over great distances. Airlines often advertise their cargo holds as pressurized and temperature controlled, but even so require special arrangements for the conveyance of livestock. The potential for condensation during unloading at a humid airport, or degradation because the pallet sat for several hours on the unshaded tarmac in Dakkar, is great.

### 5.5 Stability testing

Stability testing of drugs is its own subspecialty. In brief, it is the research pharmacist’s duty to stress test drugs in storage using factorial combinations of

- low and high temperatures;
- low and high humidity;
- exceeding the labeled drug shelf life;
- in contact with all feasible components of the packaging (e.g. both the glass and the stopper of a vial, the latter by inverted storage);
- exposure to bright and subdued light (in some case clear and amber glass bottles).

It is these data that justify approval and continued marketing of a drug that complies with the ‘quality’ criterion of the oft-quoted triad ‘safety, efficacy, quality’. This is usually not a trivial exercise.

### 5.6 Innovation in pharmaceutics

Innovation has always been a very visible activity in pharmaceutics. As noted above, we very rarely administer powders out of paper cones today. Particular drugs have driven innovation, even though the new formations later find broader use.
For example, the dry-powder inhaler was initially devised for sodium cromoglycate (which is almost insoluble), but it is now also helping to solve the metered-dose inhaler with hydrofluorocarbon propellant problem. The intravenous emulsion of propofol was unique, again being invented out of necessity, but is now also used for antifungal agents. There are several other examples of truly unique formulations or routes of administration that we may expect to be further exploited in the future. AIDS-associated infective retinitis is treated with a drug administered by intraocular injection, and the current parlous state of retinal detachment treatments suggests that this route of administration may find wider use.

What are we likely to see in the future? Novel pharmaceutical formulations seem to fall into two groups, those being used for gene therapy and those being used elsewhere.

Investigational gene therapies are comprised of two components: the DNA itself (the ‘construct’) and usually a method of delivery (‘the vector’). Naked DNA can be injected but its expression is inefficient. Vectors may include viruses. However, such viruses have to be human, and their attenuation sometimes is lost after administration, leading to very serious adverse events. Nonviral vectors can include targeted liposomes, microspheres and emulsions.

Needleless injectors have been available for decades, yet still seem to be underused (the needleless injector used by Dr ‘Bones’ McCoy of the ‘USS Enterprise’ is clockwork, develops several thousand pounds pressure per square inch, and feels like a mild middle-finger percussion when used over the deltoid). It turns out that cell membranes become transiently leaky when exposed to high voltages: otherwise insoluble or excluded drugs can enter the cell under these conditions, and the device that performs this is known as an electroporator.

5.7 Summary

The objective of this chapter has been to provide some appreciation of the complexity of pharmaceutical development. Understanding the vocabulary will help participation in team meetings where pharmaceutical and clinical development must be coordinated. A chapter on this scale will never equip the generalist to conduct pharmaceutical development. But, at the very least, it should now be clear that a drug is not a drug is not a drug.

References


Testing new pharmaceutical agents for tolerability in nonclinical studies is a critical aspect of any development program. Usually, in the ‘discovery’ stage, in vivo or in vitro studies establish the pharmacological profile of the new drug and a rationale for its potential clinical efficacy. At this stage, the potential agent can be considered a new chemical entity (NCE) or perhaps an analog or metabolite of an existing one. Preliminary studies are also made with respect to drug absorption, metabolism and excretion. In many companies, drug metabolism is a separate entity from the toxicology function but, for the sake of completeness of this chapter, a discussion of this important research area will be included. At some point, a decision is made to move the agent into the ‘development’ phase, and the initiation of nonclinical toxicology studies necessary to establish safety for initial clinical trials is started.

6.1 International harmonization

Initially, over a period of four decades or so, individual regulatory authorities in the United States, Japan and across Europe established their own guidelines for the types and extent of preclinical studies required prior to various types of human exposure to investigational products. Although often providing detailed guidances, these jurisdictions rarely said the same thing, and designing a single nonclinical toxicology program that would be universally accepted was difficult, if not impossible. The International Conference on Harmonization (ICH), a tripartite group that consists of regulators and pharmaceutical company representatives from the three geographical areas, has now been meeting for several years with the aim of harmonizing many aspects of the drug development process including preclinical toxicology. The ICH guidelines (in either draft or final form) for nonclinical studies are now applicable in all three geographical areas and will be identified throughout this chapter.

6.2 Good laboratory practices

In addition, all nonclinical toxicology studies that are intended to support clinical trials or marketing applications must be conducted in compliance with Good Laboratory Practices guidelines.
(GLP; Federal Register, December 1978; also see Williams and Hottendorf, 1997). These define technical matters such as laboratory methods, documentation, data handling, instrument calibration and much more connected with the actual conduct of toxicology testing at the bench level.

6.3 Considerations related to the clinical development plan

The nature, timing and extent of the initial nonclinical toxicology program depend on the clinical development plan that it must support. The ICH guidelines further specify the extent and duration of nonclinical studies that are required to initiate or continue clinical studies (Federal Register, November 1997, and see below). Therefore, it is important that the clinical development plan, at least the initial stages, be clearly delineated.

Initial clinical studies

Usually, the initial clinical goals are to study tolerability and to provide initial pharmacokinetic assessments. These studies may only involve single doses of the drug administered to normal volunteers. Such a clinical study would require a restricted set of toxicity studies to support safe use of drug in this situation. On the contrary, some companies achieve economies by having the initial toxicology program to be sufficient to support not only initial clinical studies but also phase II. The toxicology studies may then involve repeated doses over a period of weeks. Thus, the initial clinical studies must be determined before the nonclinical program can be designed. One small exception to this is that recent guidances provide a certain amount of relief from standardized toxicological testing, when the clinical exposure is a ‘microdose’, usually defined as less than 100 μg in absolute mass or less than 30 nanomoles of a polypeptide, and without the use of any excipient that is not on the ‘generally recognized as safe (GRAS)’ list.

Initial proof of principle

In most cases, a proof of principle (i.e. initial indication of clinical efficacy) during early phase II clinical studies will require clinical treatment for some period of time, ranging from days (diagnostic agents, etc.) to weeks or months (for other types of drug). As exposure of patients in clinical trials (in most cases) cannot last beyond the duration of the animal studies, careful consideration of the development schedule must be made so that no delays are caused through lack of toxicological coverage. This requires that the appropriate preclinical reports are available prior to the planned initiation of the clinical trial.

Enrollment of women

Most regulatory agencies now request that women be enrolled into the clinical studies as early in phase II as possible. Since thalidomide, reproduction and teratology studies have been required prior to enrollment of large numbers of women in clinical studies, in some cases, depending on the proposed indication for the drug, postmenopausal or otherwise reproductively incapable women can be enrolled. However, the timing of the enrollment of women needs to be understood well in advance so that the lack of appropriate nonclinical reports does not hinder clinical development.

6.4 Consideration of regulatory strategy

The European Clinical Trials Directive has now standardized the submissions to regulatory authorities needed for phase I studies within the European Community. The data in support of such submissions are now more or less the same as for an IND in the United States, and there is comparable institutional review board/ethics committee review and oversight on both sides of the North Atlantic. The preclinical manager must keep a close eye on the pace of such studies so that the preclinical testing for phase I in humans, which is usually rate limiting, causes as little delay as possible.
6.5 Initial nonclinical considerations

Formulation Aspects

It is desirable to carry out pivotal nonclinical studies using the proposed clinical route of administration and with a formulation that best approximates that anticipated for initial clinical usage (this is unlikely to be the exact formulation that is eventually marketed). Factors such as method of synthesis, excipients and appropriate vehicles usually evolve from bench-scale drug supplies and simple vehicles to more sophisticated pharmaceutical formulations (‘Gallenicals’) as the program proceeds.

Scale-up of manufacturing processes can result in bulk drug with different impurity profiles. As adverse effects may be due to parent drug, metabolites or impurities, this factor must be carefully considered when preparing preclinical plans to support human exposure. Furthermore, tablets or capsules cannot be given to most animal species, and the nonclinical studies are therefore carried out using dosing solutions or suspensions. The type of formulation can affect the pharmacokinetics of the drug, thus altering the toxicological profile, making comparison of animal and human pharmacokinetics, in the context of the formulations used, into a critical element in the evaluation of human safety.

Impurities/stability

Early-stage small-scale synthesis methods will often create a different profile of impurities or degradants than drug supplies produced by scaled-up processes. Every batch of drug used in nonclinical studies must have a certificate of analysis that clearly specifies the purity levels and the quantities of impurities (which may include residual solvents, unreacted starting materials or degradants). The impurities must be reviewed in terms of the potential contribution that they can make to toxic effects that may be manifested in the nonclinical studies. There are ICH guidelines that pertain to impurities and to the extent to which additional toxicity studies need to be performed with impurities (Federal Register, 4 January 1996; 19 March 1996). In general, a useful tactic is to conduct toxicological studies with samples of material that are intentionally less pure than those to which human beings will be exposed, so that ceilings for exposure to both parent molecule and the impurities and may be simultaneously as high as possible.

Of equal importance is the stability of the drug in the nonclinical formulation. This can determine whether the nonclinical formulations must be prepared daily or weekly. If drugs are to be given orally, it is obvious that they must be resistant to degradation of gastric acids and must be stable in the formulation itself (water, carboxymethylcellulose suspensions, etc.). As will be discussed in more detail later, this requires the availability of an analytical method at the earliest stages of development.

Drug requirements

The amount of bulk drug that is typically required to carry out the nonclinical studies may be a big surprise in comparison to that needed for initial clinical studies. Although many biologically derived drugs may require relatively small quantities, due to the potency of the material or the limited number of nonclinical studies that are possible (see below), a typical program needed for ‘first time in man’ drugs that are relatively nontoxic may require 2–3 kg of active drug. For many companies, this can be difficult from either a manufacturing standpoint (small quantities synthesized prior to scale-up) or cost.

Analytical methods for dose and plasma determinations

GLP regulations require confirmation of the potency of all formulations used in nonclinical studies. Furthermore, current ICH guidelines also require toxicokinetic data (i.e. animal pharmacokinetics determined at one or more time points during a nonclinical toxicology study). Both the potency and the toxicokinetic assays require an analytical method to determine the parent drug...
(and possible major metabolites) in solvents and plasma. Such assays need to be separately validated for each nonclinical species, as well as for each biological substrate (blood, urine, cerebrospinal fluid, etc.).

### Appropriate species

The selection of the animal species for the nonclinical program is often not straightforward, especially in the early stages of development. At this stage, there is often little, if any, information on which to make a scientific judgment about which species might be the most appropriate, i.e. which species will best predict response in humans. In these cases, regulatory agencies have a default position requiring the use of both a rodent and a non-rodent species. The typical approach would be to use a rat and a dog for the general toxicity studies, and mice or rabbits (the latter are now classed as lagomorphs and not as rodents) for other more specialized studies. Topical formulations are another special case, and the rabbit is commonly employed.

Primates may be needed when it becomes clearer that the parameters of interest (hematology, blood chemistry, histopathology, etc.) can only be studied in species that are phylogenetically closer to *H. sapiens*. This is often the case when candidate drugs are proteins (e.g. animal-derived monoclonal antibodies), and antibody formation may be major issue and may dictate the choice of species. For example, it may be known that only the chimpanzee does not develop neutralizing antibodies to the drug, which would lead one to select that species as the nonclinical model.

### 6.6 Toxicological support pre-IND and for phase I clinical studies

The preliminary evaluation of the safety assessment of any new drug requires multiple studies, some of which evaluate general and multiple endpoints (such as general toxicity studies). Other studies evaluate more specific and defined endpoints (such as mutagenicity studies and safety pharmacology studies). Drugs that are derived from a biological origin, such as proteins, monoclonal antibodies or drugs produced by biological vectors (or what are generally referred to as ‘biotechnology products’), present additional problems that require a significantly modified approach. The ICH guidelines recognize that unique approaches may be needed, and it has addressed this in a further guideline (Terrell and Green, 1994; ICH, 1997). This section will elaborate on those studies that are needed to support the safety of a typical xenobiotic agent; the same general principles follow for biotechnology products, although they are usually necessary but not sufficient.

There are two types of guidelines that must be considered in initiating the nonclinical program. The first relates to the types of studies required; the second relates to protocol requirements for the studies themselves.

### Types of study

The types of studies needed are dictated by national regulatory requirement, although ICH has promulgated an international guideline (*Federal Register*, 25 November 1997) that is progressing through the final review stage at present. These studies, outlined in Tables 6.1 and 6.2, vary somewhat by the phase of the clinical trial and may still vary among countries where the trial is being conducted. The US Food and Drug Administration (FDA) has also published guidelines that outline the requirements necessary to initiate initial clinical studies (FDA, 1995). This latter document focuses more on the extent of study documentation required than on the study types and allows for data to be submitted that is not in final report form.

The following sections briefly describe the studies that would typically be performed to support initial studies in humans. Additional specialized studies might be needed to study the potential for an effect that might be characteristic of drugs in the particular class in question (e.g. antibody determinations for some biological products, neurotoxicity studies for drugs acting on the central nervous system, etc.).
Acute toxicity studies

Single-dose studies in animals are an important first step in establishing a safety profile, with the general aim of exploring a feasible dose range. Note that finding the LD50 (the acute dose of a test material causing a 50 % mortality in the test animals) is no longer required or scientifically necessary. Identification of an upper dose without drug-related effects, the dose that produces some level of exaggerated pharmacological effect (not necessarily death) that helps identify potential side effects, and other doses in between helps all further toxicological (and clinical) tolerability assessments. These studies can be designed using ‘up-and-down’ (Dixon) protocol designs or other tactics to reduce the time and number of animals required. These studies may then guide dose selection for the first repeated-dose studies. Various guidelines for the performance of these studies are available, and the ICH has also published its own guideline (Federal Register, 26 August 1996).

Repeated-dose toxicity studies

Repeated-dose studies are designed to identify safe levels of the drug following treatment regimens that are designed to provide continuous exposure of the animals to the test drug. Ideally, the route of

Table 6.1 Duration of repeated-dose toxicity studies to support phase I and phase II clinical trials in the EU and phase I, II and III clinical trials in the United States and Japan

<table>
<thead>
<tr>
<th>Duration of clinical trial</th>
<th>Rodents</th>
<th>Non-rodents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single dose</td>
<td>2–4 weeks&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2 weeks</td>
</tr>
<tr>
<td>2 weeks</td>
<td>2–4 weeks&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2 weeks</td>
</tr>
<tr>
<td>1 month</td>
<td>1 month</td>
<td>1 month</td>
</tr>
<tr>
<td>3 months</td>
<td>3 months</td>
<td>3 months</td>
</tr>
<tr>
<td>6 months</td>
<td>6 months</td>
<td>6 months&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>&gt;6 months</td>
<td>6 months</td>
<td>Chronic&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>In Japan, if there are no phase II clinical trials of equivalent duration to the proposed phase III trials, then nonclinical toxicology studies of the durations shown in Table 6.2 should be considered.

<sup>b</sup>In the EU and the United States, two-week studies are the minimum duration. In Japan, two-week non-rodent and four-week rodent studies are needed. In the United States, with FDA concurrence, single-dose toxicity studies with extended examinations can support single-dose human exposures.

<sup>c</sup>Data from six months of administration in non-rodents should be available before clinical exposures of more than three months. Alternatively, if applicable, data from a nine-month non-rodent study should be available before clinical treatment duration exceeds that supported by other toxicology studies.

Table 6.2 Duration of repeated-dose toxicity studies to support phase III clinical trials in the EU, and product marketing in all jurisdictions

<table>
<thead>
<tr>
<th>Duration of clinical trial</th>
<th>Rodents</th>
<th>Non-rodents</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 weeks</td>
<td>1 month</td>
<td>1 month</td>
</tr>
<tr>
<td>1 month</td>
<td>3 months</td>
<td>3 months</td>
</tr>
<tr>
<td>3 months</td>
<td>6 months</td>
<td>3 months</td>
</tr>
<tr>
<td>&gt;3 months</td>
<td>6 months</td>
<td>Chronic</td>
</tr>
</tbody>
</table>

<sup>a</sup>The table reflects the marketing recommendations in all three ICH regions, except that a chronic non-rodent study is recommended for clinical use >1 month in Japan.
administration should be the same as that planned in humans, whereas the animal studies should involve higher doses and longer durations of exposure than those planned clinically. The type and duration of specific studies, and those that are needed relative to different stages of clinical development, were mentioned previously (Federal Register, 25 November 1997). Protocols must specify the number of animals per group, numbers of groups and experimental procedures to be carried out, and standard versions of these have been available for some time. In general, for initial repeated-dose studies, protocols require the use of three dose groups plus a control, and a minimum of 10 rodents and 3 non-rodents per sex per group. Doses must be selected that will allow for the identification of toxic effects at the highest dose as well as at a no-effect level at the middle or lowest dose.

Usual experimental procedures include the determination of body weights and food consumption on at least a weekly basis, evaluation of hematology and blood chemistry parameters during the treatment period, ophthalmoscopic examinations, the recording of macroscopic examinations at necropsy and the determination of organ weights. A complete histopathological examination of tissues from animals is required. In rodent studies, this can take the form of examination of all high-dose and control animals and the examination of target organs at the two lower doses. In non-rodent studies, it is typical to examine tissues from all animals in the study.

It is crucial that plasma concentrations of drug are measured in these studies to allow for determination of effects on the basis of exposure. Frequently this is a more appropriate measure of comparing effects in animals and man, as rates of absorption, distribution and excretion can vary extensively between these species. This aspect, now commonly referred to as ‘toxicokinetics’, has been outlined in an ICH guideline (Federal Register, 1 March 1995). This guideline specifies minimum requirements in terms of number of time points examined, number of animals per time point, and the requirements for calculation of various pharmacokinetic parameters such as $C_{\text{max}}$, AUC and so on. These will become important for comparison with human data as it becomes available later.

**Mutagenicity studies**

Mutagenicity studies are highly specialized but, in general, include studies of genetic mutation, clastogenesis and nuclear maturation. There are multiple hereditary components in both somatic and germinal cells that may be affected by drugs. During 1970s, it was thought naïvely that these studies may be replacements for the long and costly carcinogenicity studies that are required for many drugs. Although this goal was never realized, mutagenicity studies nonetheless provide useful indications of the ability of a drug to alter genetic material, which may later be manifested in studies of carcinogenic or teratogenic effects (Kowalski, 2001). Genotoxicity studies are relatively inexpensive and may also serve, early in the drug development process, to assure drug developers and regulators that no obvious risk of such adverse effects exists, albeit knowing that more definitive studies to evaluate teratogenic and carcinogenic effects will not come until later.

An exhaustive review of various components of a mutagenicity evaluation will not be attempted in this chapter. Multiple guidelines are available. Those issued by the ICH include general guidelines (Federal Register, 24 April 1996) and specifics related to the core battery of studies required (Federal Register, 3 April 1997). Tennant et al. (1986) have summarized the correlation between the results of a battery of mutagenicity assays and the probability of the material producing a positive carcinogenic response in long-term rodent studies. Obviously, mutagenicity studies cannot predict nongenetic carcinogenicity or teratogenicity (e.g. estrogen-induced breast tumors in rodents).

Positive results in one or more mutagenicity assays do not necessarily translate into human risks. Mechanistic studies may show that such responses would not occur in the human cell population or that the concentrations at which positive responses occurred may far exceed any concentration of drug that may occur in the clinical setting. Many drugs are in the market...
Pharmacokinetic studies

In the early stages of drug development, it is important to identify important parameters that relate to the absorption and excretion pathways for the drug. In the later stages of development, studies on the extent of tissue distribution and the identification of metabolites become important. Another reason why this is important is that it assists the investigator in knowing that the appropriate species has been selected for the nonclinical toxicology program. It is important to human safety evaluation that the nonclinical models chosen are representative of the metabolism of the drug in humans. Therefore, it is necessary to have pharmacokinetic information early in the program, so that it can be compared to the data generated in the early clinical studies.

Drug metabolism is a highly specialized field and is increasing in sophistication all the time. A relatively new technique that is available to the preclinical investigator is the use of in vitro methods to establish and confirm similar mechanisms in drug metabolism between animals and humans (see Chapter 10). These procedures involve the use of liver slices and/or liver hepatocyte homogenates and can be done in human and animal cultures at the earliest stages of drug development.

Toxicokinetic data are generally obtained from repeated-dose toxicity studies and generally determine whether (a) the plasma concentrations of the drug increase in a linear fashion over the range of the increasing doses used in the studies; (b) plasma concentrations increase over time, suggesting an accumulation of the drug in plasma or tissues; (c) there is a relationship between the plasma concentrations of the drug (or metabolites) and the toxicity associated with higher levels of the drug; and (d) the effects are more closely related to peak concentrations or to overall exposure (measured by the area under the concentration time curve, AUC).

Toxicokinetic data are generally collected on the first day of dosing in a repeated-dose study and near the last day of dosing, that is during the last week, of a 90-day toxicity study. In rodent studies, satellite groups of animals are required due to the blood volumes needed for assay. For larger non-rodents, the main study animals can usually provide the samples. Guidelines have been made available that cover most aspects of collection and analysis of these data (Federal Register, 1 March 1995).

Lastly, pharmacokinetic assessment requires tissue distribution studies in nonclinical models to determine the extent of localization of the drug in tissues. In some situations, where single-dose tissue distribution studies suggest drug localization, a tissue distribution study following repeated dosing may be indicated. The conditions under which such studies may be necessary have been delineated in an ICH guideline (Federal Register, 1 March 1997).

Safety pharmacology

Studies related to safety pharmacology (sometimes confusingly termed ‘general pharmacology’ studies) tend now to be performed earlier in the drug development process than was previously the case. Although in some respects considered an aspect of the discipline of pharmacology, the purpose of safety pharmacology is to evaluate the potential pharmacological properties that may be unrelated to the intended indication for the drug. An example of this would be significant effects of a drug on the cardiovascular system that may actually be under development for the treatment of gastric ulcers. In such a case, there is a specific guidance for examining in animals the potential for a test substance to cause changes in hemodynamics and QT prolongation on the ECG.

Most major developed countries have stated guidelines indicating that safety pharmacology
studies are required. Table 6.3 lists the guidelines from major countries. As can be seen from these guidelines, it is not always clear when such studies are required. All of the major organ systems need to be evaluated, and therefore studies need to be performed that would identify potential effects on the central nervous, cardiovascular and gastrointestinal systems, as well as an evaluation of renal function and possibly immunogenicity.

Like many other disciplines, there are a multitude of protocols and procedures that can be followed for each safety pharmacology study. A detailed review of each available procedure is outside the purview of this discussion.

Nonclinical summary documents

Prior to the initiation of initial studies in humans, it is important that all of the nonclinical information available is made into an integrated summary. This information must be included in the clinical investigators’ brochure so that the clinical protocol can be modified to include relevant biochemical or other markers to minimize human risk. The regulatory authority and ethics committees are further target audiences, and the company may wish to use this for formal, internal proceedings to justify the decision to proceed with initial human exposure.

6.7 Toxicological support for phase II and III studies

Nonclinical toxicology studies required to support phase II and phase III stages of the program depend on a variety of factors. First, as shown in Tables 6.1 and 6.2, the ultimate clinical regimen, that is the duration of therapy or treatment, determines the ultimate duration of the animal studies. For example, a diagnostic agent or a drug with a three- to four-day exposure (such as an anesthetic agent) may require little in the way of additional repeated-dose toxicity studies beyond what is already conducted prior to phase I. But drugs intended for chronic therapy, for example a new antihypertensive agent, may require much more. As the longer term studies take time, they must begin well in advance in the phase II clinical program if toxicology testing is not to introduce delay into the development process.
Chronic toxicity studies

As discussed above, the extent of additional repeated-dose studies are generally outlined in Tables 6.2 and 6.3. The maximum duration of chronic studies is generally 6 months, although the ICH guidelines describe situations where studies of 9–12-month duration may be necessary in a non-rodent species.

Protocols for these studies are similar to those for studies of shorter duration, except that a minimum of 10–15 rodents per group and 4 non-rodents per sex per group are required. Toxicokinetic measurements are still required. The usual in-life and postmortem observations are performed.

Reproduction and teratology studies

Thalidomide demonstrated the need to evaluate new drugs in reproductive toxicology studies. Some of the earliest guidelines were issued by the US FDA (the ‘Goldenthal guidelines’). An ICH guideline now covers the performance of these studies (Federal Register, 22 September 1994), as amended in 1995 to address possible effects on male reproduction.

In general, three phases of the reproductive process are evaluated. These cover the principal aspects of reproductive biology, namely conception and implantation, organ formation and teratogenesis and finally the development of offspring of exposed maternal animals allowed to proceed to term.

Fertility and implantation

The first phase (historically referred to as ‘Segment I’ study, and now under ICH as ‘Stage A’) evaluates the effect of the new drug on the fertility and the early implantation stages of embryogenesis. In these studies, breeding animals of one species (usually rats or rabbits) of both sexes will be treated for two or more weeks prior to mating, and then the females will be further dosed until day 6 of gestation.

Teratogenesis

The second stage (historically Segment II, now ICH Stage B) is the teratology study (sometimes termed ‘the developmental toxicity study’). This is also done in rats and rabbits. The maternal animal is exposed to test medication during the period of organogenesis, and the pregnant animals are typically sacrificed shortly prior to term for detailed anatomical study of the fetus.

Developmental studies postpartum

The third stage (Segment III or ICH Stage C) evaluates treatment during late gestation, parturition and lactation. Behavioral and neurodevelopmental assessments in the offspring are often made in Segment III studies. In some cases, two of the studies can be combined and still satisfy the ICH guideline.

The period in the drug development process at which results of these studies are required still varies somewhat from country to country, as is discussed in the ICH guideline (see Hoyer, 2001, for the current situation and additional perspective).

Carcinogenicity studies

Carcinogenicity studies involve the treatment of rodents for long periods approximating to the complete life span (18 months to 2 years) to determine whether the test material possesses the capability to initiate or promote the development of tumors. The relevance of these models to the human situation has been debated for many years. Carcinogenicity studies have been required for all drugs where clinical therapy may extend for six months or longer. Although the scientific debate about the relevance of these studies continues, they remain obligatory by regulation.

Several different ICH guidelines have been issued that address the various aspects of carcinogenicity testing of drugs, including when studies are needed (duration of clinical therapy; Federal Register, 1 March 1996). Other features of the new drug may mandate carcinogenicity testing, such as
structure–activity similarities to known carcinogens, evidence of preneoplastic lesions in repeated-dose nonclinical studies, or long-term tissue sequestration of the drug. Another guideline (Federal Register, 1 March 1995) addresses the complex issue of the selection of doses for these studies; this responds to much criticism of the prior recommendation to use the maximum tolerated dose (which had been suggested by the National Toxicology Program; Haseman and Lockhart, 1994). The current ICH guideline recommends a high dose causing up to 25-fold greater plasma AUC in rodents compared to the AUC in humans at steady state. A subsequent amendment to this guideline (Federal Register, 4 December 1997) adds a further proviso that the highest dose in a carcinogenicity study need not exceed 1500 mg kg\(^{-1}\) per day when (a) there is no evidence of genotoxicity and (b) the maximum recommended human dose is no more than 500 mg per day. The basis for species selection, circumstances needing mechanistic studies and exploitation of pharmacokinetic information in carcinogenicity testing is described in yet another guideline (Federal Register, 21 August 1996).

Modern protocols for carcinogenicity studies have changed little since they were first established in the early 1970s. In recent years, the use of mice (historically the second of the two required species in addition to rats) has come under scrutiny because they may be inappropriate models, with unusual sensitivity to certain classes of chlorinated hydrocarbons. The most recent ICH guideline (Federal Register, 21 August 1996) allows for the option of using transgenic mice and study designs of somewhat shorter duration.

Of growing importance is the interaction of factors that are critical to a successful toxicology program. For example, if a transgenic mouse model is selected, then the choice of strain is important and may depend on whether the drug is non-genotoxic (TG.AC model) or genotoxic (p53 model). Metabolic and pharmacokinetic data are important to ensure that the selected models handle and metabolize the drug in a fashion at least reasonably similar to humans and may vary for the same drug according to the toxic effect of interest. Perhaps the most important factor is the relevance of the doses selected to those in humans. Although this has been a subject of controversy for years, a recent ICH guideline allows for the use of toxicokinetic measurements, and states that doses that produce an AUC in the carcinogenicity model that are 25 times that seen in humans at steady state may no longer have to be used under some circumstances. A recent review of the status of carcinogenicity testing (Reno, 1997) addresses the many factors that should be considered in a carcinogenicity program.

### Special studies

It is not uncommon in drug development programs for specific toxicities to be uncovered. In most cases, additional studies are then carried out that will attempt to elucidate additional information with regard to the mechanism of the effect. For example, the identification of a non-specific behavioral effect (e.g. tremors and/or convulsions) may trigger the performance of a neurotoxicity study, which includes an exhaustive evaluation of the potential effects on the central and the peripheral nervous tissues. The identification of an effect on reproduction may warrant the performance of detailed studies to identify the specific mechanism or phase of the reproductive cycle that is affected. In-depth metabolic studies may prove that the effect is related to a metabolite in animals that has no relevance to man, and prevent the abandonment of an otherwise promising drug. It is rare that a drug development program does not involve some type of special study.

### 6.8 Product licence/new drug application requirements

#### Format and content of the application

Although differing in format for each application, an integrated summary that interrelates the pharmacology, pharmacokinetic and toxicology study information, and what significance the data has to human safety, is paramount (Peck et al., 1992).
A well-written integrated summary can be beneficial not only to the agency reviewer but also to the sponsor. Some of the information in this summary is also needed for the product’s package insert. Crucially, it should include comparisons between effects seen in animals and the likelihood that such findings would be expected in clinical usage. These comparisons are often quantitative and must be made both on a milligram per kilogram and a surface area (mg m$^{-2}$) basis (Voisin et al., 1990).

**Expert reports**

The European Community, and other countries, requires several expert reports in each dossier, one of which examines the nonclinical toxicology of the new drug. These documents are typically about 20–30 pages long and again summarize all the toxicology data, as well as the clinical implications.

Much from the integrated summaries described above may be reused in this report, with the exception of the expert, who must personally sign the report. Expert reports contain the expert’s curriculum vitae, and part of the regulatory review process is to evaluate whether the expert is actually qualified for this role. The choice of expert is important, and his/her independence is crucial because the role is that of a reviewer and not of a sponsor. Experts may nonetheless be drawn from within the sponsoring company with appropriate protections, although those from outside may carry more credibility in some jurisdictions.

**6.9 Final comments**

The objective of his chapter has been to provide an overview of the objectives and philosophy of the nonclinical toxicologist in the drug development process. None will deny the crucial role of this field of science in drug development and that its activities must anticipate (often by dozens of months) what the clinical department will want to do. Toxicology can also provide information of direct importance in terms of the limits on doses to which humans should be exposed and which clinical tests should be followed with care. Although a typical set of scenarios has been described, it is to be remembered that no individual drug development case will be typical.

**References**


7 Informed Consent

Anthony W. Fox

7.1 Introduction

There is a tendency to assume that the principles of informed consent are self-evident. In fact, evidence that this is not the case comes from many sources, such as ethics committees that are frequently dissatisfied with proposed informed consent documents, and sophisticated Western governments that, from time to time have conducted clinical trials without it (e.g. the Tuskegee travesty). A recent gene therapy accident in the eastern United States, which led to the death of the participant, led to litigation which was centered not around whether the clinical trial was unduly hazardous but rather on whether the consent that the patient gave was truly and fully informed.

Informed consent was first formulated under international law through the Declaration of Helsinki, and in response to the atrocities of the Second World War. The principles of informed consent are under continuous review and discussion (e.g. Marsh, 1990). This is to be expected when reasonable standards of informed consent are dependent not only on the design of a particular study but also on environmental factors, the current state of medicine and particular local characteristics of clinical trials populations, all of which are themselves continuously changing.

7.2 Ethical basis

Although discussed in detail elsewhere in this book, the two ethical principles guiding informed consent are those of autonomy and equipoise. Autonomy is the concept that the patient is an individual that is under no duress, whether subtle or obvious, actual or inferred, and is competent to make a choice according to his or her free will. Clinical trials conducted on persons in custody, or on subordinate soldiers, may both be violations of the patient’s autonomy. Equipoise is the concept that the investigator, and those sponsoring the trial, are truly uncertain as to the outcome of the study; in practical terms, this is a guarantee to the patient that an unreasonable hazard cannot result from unfavorable randomization because the treatment options are not known to be unequally hazardous.
The large majority of clinical trials use a written informed consent document. In the absence of any special circumstances, the essential elements of such a document are as follows:

1. A clear statement that the study is a research procedure.

2. A clear statement that participation is voluntary and that there will be no repercussions either in the patient’s relationship with the investigator, or with the patient’s other care givers, should the patient decide not to take part in the study;

3. A description of the scope and aims of the research, and whether or not there may be benefits to patients exposed to the test medications. The foreseeable risks and discomforts should also be disclosed. The possibility of placebo treatment and the probability of being treated with each test therapy should be stated.

4. Clear descriptions of alternative therapies or standard therapies or procedures (if any), in order that the patient can judge whether to enter the study.

5. The methods for compensation that may be available in the case of injury (these often have marked international variations).

6. Name and telephone number of persons that the patient may contact in case of any difficulty during the study. Also, the identity of person(s) of whom the patient may ask questions during the day-to-day conduct of the study and an expression of willingness on the part of the investigator to provide answers to any questions that the patient may have.

7. A confidentiality statement. This should include the degree to which the patient’s identity could be revealed to an inspecting regulatory authority, and whether information from communicated to the patient’s primary care or referring physician. In any case, there should be an assurance that no patient identity information will be made public.

8. A statement of the circumstances under which the patient will be withdrawn from the study (e.g. noncompliance with test procedures).

9. A clear statement that the patient may withdraw from the study at any time and for any reason, again without repercussions to his or her relationship with any clinical care giver.

10. A statement that the patient will be required to give a full and accurate clinical and treatment history on study entry and periodically thereafter (according to the study design).

11. Assurance that any new information that arises (e.g. in other studies) and which may alter the assessment of hazard of study participation will be communicated to the patient without delay.

12. A statement about the number of patients taking part in the study, and a brief summary of how many patients in the past have been exposed to the test medication.

Written informed consent documents should be signed by both the patient and the investigator, and ideally the patient should sign before an impartial witness. Informed consent documents should be written in a language that is understandable to the patient, and ideally at a level of complexity that could be understood by a young adolescent of average intelligence from the same community as the patient. There should be adequate time for the patient to review the document. All written informed consent documents should be approved by an ethics committee or an institutional review board (IRB).

Informed consent, in law, must be informed but
Ethics committees and IRBs may sanction specific methods for the documentation of oral informed consent. This is a very rare clinical situation.

**Surrogate informed consent**

Some patients are incapable of providing informed consent, whether written or not. These patients are often in demographic subgroups which are medically underserved. Consequently, these are patients for whom there is encouragement to the pharmaceutical industry by governments, activists and others to increase research into experimental therapies. Children, those with various types of neurological disease (e.g. Alzheimer’s disease), and emergency patients (e.g. unconscious head injury, stroke, multiple trauma, etc.) are good examples. Many of these patients have a very poor prognosis, and they epitomize the concept of unmet medical need. For these patients, clinical research would be impossible if written informed consent was an essential prerequisite.

For children, most ethics committees agree that provision of written informed consent by a parent or guardian is acceptable. If the child is of sufficient age, then his or her concurrence may also be sought; although this is not sufficient evidence of informed consent, the refusal to provide concurrence by a child that is likely to be competent to understand the clinical trial conditions should be sufficient to exclude the child from a study.

In the case of studies in incompetent adults, again most Ethical Committees will accept a legal guardian or custodian in lieu of the patient himself or herself, provided that there is sufficient evidence that the custodian has a bona fide and independent interest in the patient’s welfare. Again, forms of concurrence can be employed when possible. The ordering of a patient’s participation in a clinical trial by a Court Order would usually be a form of duress and could thus violate the concept of autonomy described above.

**When informed consent is impossible**

Emergency patients have as much right to taking

For example, patients with acute head injury and a low Glasgow Coma Score have a dismal prognosis, and therapeutic interventions (if ever likely to be successful) must be instituted quickly. Under these conditions, there is often not even the time to find relatives to provide surrogate informed consent. Even if relatives can be found quickly enough, then their emotional state may not be suited to becoming truly informed before giving consent.

Experiments are now under way to investigate whether some substitute for informed consent may be used. One set of guidelines suggests that such clinical trials can be conducted when

1. there is clinical and public agreement that the disease merits clinical investigation with the investigational therapy;

2. there has been advertising and publicity in the likely catchment area of suitable patients that such a study is being undertaken;

3. the ethics committee or the IRB has approved, in detail, the methods used in pursuit of local publicity;

4. an independent, clinically experienced individual will confirm that the patient is a member of the well-defined population that is the subject of the clinical research, and that it is not unreasonable to include the patient in the study for any other reason;

5. no relative (if any is available in a timely fashion) objects.

It is likely that these guidelines will be refined, possibly on an international basis, in the near future.

**7.5 Responsibility of parties to informed consent**

It is the responsibility of all parties to the informed consent that all parties remain within its ethical
document is essentially an agreement between ethics committee, investigator and patient. However, for example, an investigator is responsible for the patient’s role in the informed consent; if the investigator suspects that the patient is not truly informed, even in the absence of any deficiency on the part of the investigator, then the investigator should nonetheless police the patient’s part of the agreement. This is entirely different from the notion of a contract, where each party to the contract is responsible only for fulfilling its own commitments (see Meisel and Kuczewski, 1996).

Audit of some of the elements listed above may also form part of the duty of a regulatory authority. For example, in the United States, FDA will audit IRBs and issue citations if the IRB is not ensuring that written informed consent documents are complete and appropriate. FDA will also audits study sites, and disciplines investigators (including prosecution), who do not ensure that appropriate informed consent procedures are being followed. Some FDA reviewing divisions will ask for, and require changes to, informed consent document prior to allowing an IND to become active.

Although under law it is not the primary responsibility of the typical pharmaceutical company, it nonetheless behoves pharmaceutical physicians to ensure that appropriate informed consent is being obtained in all company-sponsored studies. Many companies recognize this within their own Standard Operating Procedures, and creation of patient files that require a copy of the signed informed consent. Investigators will often be grateful if the company will draft an informed consent document that complies with the guidelines, which the investigator can submit to the ethics committee or IRB.

References


Successful preclinical drug discovery programs frequently reach a point where there is a need to choose one or two candidates from among a whole pharmacological class of new drugs for phase I testing (Welling and Tse, 1995). There is thus a crucial need to make reliable and rapid predictions of human responses from animal data.

Although drug discovery is primarily designed to find compounds with desired efficacy, the choice from among multiple compounds potentially offering efficacy often comes down to those with the most favorable pharmacokinetics (Welling and Tse, 1995). Thus, compounds are chosen using animal data, partly because of suitable bioavailability, half-life and tissue penetration characteristics. As we shall discuss below, the possibility of multiphasic plasma level decay patterns following intravenous dosing is an important element in this selection process.

Pharmacokinetics, related when possible to the observed drug effects, is a powerful and critical component of the pivotal step from animal research to human research in the drug development process. Data for chosen compounds will commonly also have been subjected to simultaneous modeling of pharmacokinetic and pharmacodynamic data from animals, again in an effort to optimize the chances that the drugs chosen will have the properties in humans specified in a prediscovery product profile. Meanwhile, the pharmacodynamic information available typically includes data from receptor-binding studies, in vitro functional assays and in vivo pharmacological screening experiments. The essence of this crucial step of drug development, taking the new drug into human beings, is the making of valid predictions of in vivo drug effects from in vitro data.

The collection of in vitro data from animal materials and extrapolation (a) from physical properties to in vitro data, (b) from in vitro data to nonhuman in vivo data, and (c) from nonhuman in vivo data to clinical in vivo responses can be done more efficiently using online analysis and simulations. This chapter seeks to show how rapid progression may be achieved for new chemical entities through this process, using in vitro and in vivo data and advanced modeling procedures. This must be seen in the context of the entire drug discovery process, which, on a larger scale, is designed to find potent, safe drugs (in humans), based on animal data (Figure 8.1). We anticipate a time when in vitro pharmacodynamic data will be routinely combined with in vitro drug metabolism data in a rational prediction of drug responses in healthy human volunteers, with consequent acceleration of the drug discovery effort, and therefore a general
trend for more efficient use of resources in early clinical development.

### 8.1 The in vitro/in vivo prediction

The challenge is to predict systemic clearance, volume of distribution and oral bioavailability in humans from a combination of *in vitro* and *in vivo* preclinical data. If this prediction can become reliable, then phase I studies become more confirmatory. The use of human hepatocytes and isolated enzymes can form a critical part of the *in vitro* database.

Clearance of almost all drugs is by renal, metabolic and/or biliary mechanisms. There are rare exceptions, such as anesthetic gases that are exhaled unchanged. However, in this chapter we shall concentrate on the typical situation. Physicochemical properties, especially lipophilicity, frequently govern the clearance route; lipophilicity is commonly measured as log \( D_{7.4} \), where this variable equals \( \log_{10} \left( \frac{\text{drug in octanol}}{\text{drug in aqueous buffer}} \right) \) at \( \text{pH} = 7.4 \), in a closed system at equilibrium. Generally, compounds with a log \( D_{7.4} \) value below 0 have significant renal clearance values, whereas compounds with log \( D_{7.4} \) values above 0 will usually be eliminated principally by hepatic metabolism (Smith *et al.*, 1996). Molecular size also has some effect on these clearance routes. For example, compounds with molecular weights greater than 400 Da are often eliminated through the bile unchanged, whilst smaller lipophilic compounds will generally be metabolized.

#### Elementary aspects of clearance

The common, clinical measurement of drug clearance involves taking serial venous blood samples. As time passes after \( T_{\text{max}} \) (the time when drug concentration reaches its peak), parent drug concentrations continuously decline. Modeling of drug disappearance is essentially a descriptive process and requires actual human exposures. Unsaturated elimination mechanisms, in the absence of drug sequestration, can be modeled as simple, first-order elimination, using a constant \( (k) \) with units of \( \text{h}^{-1} \); plasma concentration \( (C) \) is then modeled by equations of the general form:

\[
C = Ae^{-kt}
\]

where \( A \) is the concentration of drug at time \( (t) 0 \) (assuming that there was instantaneous and homogenous equilibration of the dose into the circulating compartment). As the number of compartments increases, then so does the number of terms of the form shown on the right-hand side of the equation shown above.

The *elimination rate* always has units of \( \text{mass/time} \) for any elimination process. For first-order processes, the elimination rate at any one moment is represented by a tangent to the elimination curve for any specified time \( t \) or drug concentration \( C \).

In contrast, zero-order elimination processes are occasionally encountered. These usually represent saturation by the drug of the elimination mechanism(s). These ‘drug disappearance’ curves are straight and thus described simply by:

\[
C = A - bt
\]

where the elimination rate \( (b) \) does not change with time or drug concentration. If followed for long enough, most drugs that are subject to zero-order elimination eventually fall to such low
concentrations that the elimination mechanism becomes unsaturated, and first-order elimination then supervenes; good examples include ethanol and sodium dichloroacetate (Hawkins and Kalant, 1972; Curry et al., 1985; Fox et al., 1996).

The elimination rate for zero-order processes may also be treated as a maximal rate of reaction \( V_{\text{max}} \), and thus this type of data may be subject to ordinary Michaelis–Menten analysis (see further, below). Note that first-order elimination curves are so common that ‘drug disappearance’ curves are routinely analyzed as semi-logarithmic plots (which linearizes the curve). The literature is sometimes ambiguous in its use of the term ‘linear data’, authors may or may not assume that the semi-logarithmic transformation is to be taken as read.

When the elimination rate is known, then clearance \( (Cl) \) is defined simply as:

\[
Cl = \frac{\text{elimination rate}}{C}
\]

where \( C \) is again the drug concentration. Note that in first-order elimination processes, the elimination rate of the drug (with units of mass/time) changes with time (and drug concentration), and thus only instantaneous clearances, specifying time or drug concentration, can be stated.

Urinary clearance, obviously, may only partly explain the rate of drug disappearance from plasma. In any case, the urinary clearance of an agent may be found from the familiar equation:

\[
Cl = \frac{(U \times V)}{P}
\]

where \( U \) is the urinary concentration, \( V \) is the volume of urine excreted during a specified time period, and \( P \) is the average plasma concentration during that time period. For inulin and sodium iothalamate, but not for creatinine or urea, the urinary clearance is a good measure of glomerular filtration rate.

These elementary aspects of clearance may be revised in any textbook (e.g. Curry, 1980; Benet et al., 1996). The purpose of the remainder of this section is to show how much more informative the concept of clearance may be and to provide an illustration of its use.

**Prediction of human drug clearance**

For those compounds that are predominantly cleared by metabolism, human blood clearance can be predicted using simple enzyme kinetic data (Houston, 1994; Ashforth et al., 1995; Iwatsubo et al., 1996; Obach, 1996a). These predictions may be strengthened by comparing preclinical \textit{in vivo} data with the predictions made from \textit{in vitro} data using tissues from the same preclinical species (Rane et al., 1977). As an illustration, consider compound X (anonymized but real). This compound has a molecular weight less than 400 and a log \( D_{7.4} \) value of approximately 0.5, suggesting that it could undergo both renal and hepatic clearances. Preclinical \textit{in vivo} studies indicate that compound X is eliminated largely unchanged in the urine in the rat (~90%). Several oxidative biotransformation pathways have nonetheless been identified. In common with studies of compound X clearance in humans, simple \textit{in vitro} enzyme kinetic studies were used in conjunction with knowledge from rat \textit{in vivo} data. The general strategy for prediction of kinetic studies is shown in Figure 8.2.

Using liver microsomes from different species, the intrinsic clearance \( (Cl'_{\text{int}}) \) for each species can be determined and then scaled to hepatic clearance. This is typically done by first determining \textit{in vitro} \( K_m \) (the Michaelis–Menten constant) and \( V_{\text{max}} \) (the
maximal rate of metabolism) for each metabolic reaction, using substrate saturation plots (using the familiar algebra and, because of enzyme saturation, finding that \( \text{Cl}_{\text{int}}^\prime = V_{\text{max}}/K_m \)). However, for compound X, the situation is more complicated because we know that the \( \text{Cl}_{\text{int}}^\prime \) (drug disappearance) actually is due to several combined biotransformation pathways (i.e., \( \text{Cl}_{\text{int}}^\prime \) (total) = \( \text{Cl}_{\text{int}}^\prime \) (total) + \( \text{Cl}_{\text{int}}^\prime \) (int) + \( \text{Cl}_{\text{int}}^\prime \) (int2) + \( \text{Cl}_{\text{int}}^\prime \) (int3) + \( L \)), thus complicating any \( K_m \) and \( V_{\text{max}} \) determinations from a simple substrate saturation plot.

To determine the \( \text{Cl}_{\text{int}}^\prime \) of compound X, we are able to use the in vitro half-life method, which is simpler than finding all the component \( \text{Cl}_{\text{int}}^\prime \) values. When the substrate concentration is much smaller than \( K_m \), the Michaelis–Menten equation simplifies from velocity \( (V) = V_{\text{max}}([S])/(K_m + [S]) \), because \([S]\) (substrate concentration) becomes negligible. Furthermore, under these conditions, the in vitro half-life \( (T_{1/2} = 0.693/K_{el}) \) can be measured, and this, in turn, is related to the Michaelis–Menten equation through the relationship velocity \( V = \text{volume} \times K_{el} \) (where volume is standardized for the volume containing 1 mg of microsomal protein). When both \( V \) and \( V_{\text{max}} \) are known, then \( K_m \) is also found. Although simpler than finding a complicated \( C_{\text{int}}^\prime \), one caveat of the in vitro half-life method is that one assumes that the substrate concentration is much smaller than \( K_m \). It may be necessary to repeat the half-life determinations at several substrate concentrations, and even model the asymptote of this relationship, because very low substrate concentrations that are beneath biochemical detection may be needed to fulfill the assumptions needed to simplify the Michaelis–Menten equation.

Note also that in this in vitro application, intrinsic clearance, like all conventional mathematical evaluation of clearances, has units of \( \text{volume} \times \text{time}^{-1} \). It is obtained from \( V_{\text{max}} \) and \( K_m \) measurements, where \( V_{\text{max}} \) has units of mass \( \times \text{time}^{-1} \). The definition of intrinsic clearance as \( V_{\text{max}} \times K_m^{-1} \) should not be confused with the historically prevalent calculation of \( k_{el} \) (the first-order rate constant of decay of concentration in plasma), calculated from \( k_{el} = V_{\text{max}}/K_m \), where \( V_{\text{max}} \) is the zero-order rate of plasma concentration decay observed at high concentrations and \( K_m \) is the concentration of plasma at half-maximal rate of plasma level decay.

Once the in vitro intrinsic clearance has been determined, the next step, scaling in vitro intrinsic clearance to the whole liver, proceeds as follows:

\[
\text{in vivo} \, \text{Cl}_{\text{int}}^\prime = \text{in vitro} \, \text{Cl}_{\text{int}}^\prime \times \text{weight microsomal protein/g liver} \times \text{weight liver/kg body weight}
\]

The amount of microsomal protein per gram liver is constant across mammalian species (45 mg \( g^{-1} \) liver). Thus, the only species-dependent variable is the weight of liver tissue per kilogram body weight.

In vivo, hepatic clearance is determined by factoring in the hepatic blood flow \( (Q) \), the fraction of drug unbound in the blood \( (fu) \) and the fraction of drug unbound in the microsomal incubations \( (fu_{\text{inc}}) \) against the intrinsic clearance of the drug by the whole liver (the in vivo \( C_{\text{int}}^\prime \)). The \( fu \) and \( fu_{\text{inc}} \) are included when the drug shows considerable plasma or microsomal protein binding (Obach, 1996b). Several models are available for scaling in vivo intrinsic clearance to hepatic clearance, including the parallel tube model or sinusoidal perfusion model, the well-stirred model or venous equilibration model and the distributed sinusoidal perfusion model (Wilkinson, 1987).

Thus far, for compound X, we have obtained good results in this context with the simplest of these, the well-stirred model (see Table 8.1 for the equations, with and without significant plasma

---

**Table 8.1** Equations for predicting hepatic clearance using the well-stirred model

<table>
<thead>
<tr>
<th>In the absence of serum or microsomal protein binding</th>
<th>In the presence of significant serum protein binding</th>
<th>In the presence of both serum and microsomal protein binding</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{Cl}<em>{\text{hepatic}} = Q \times \text{Cl}</em>{\text{int}}^\prime )</td>
<td>( \text{Cl}<em>{\text{hepatic}} = Q \times fu \times \text{Cl}</em>{\text{int}}^\prime )</td>
<td>( \text{Cl}<em>{\text{hepatic}} = Q \times fu \times \text{Cl}</em>{\text{int}}^\prime \times fu_{\text{inc}} )</td>
</tr>
<tr>
<td>( Q + \text{Cl}_{\text{int}}^\prime )</td>
<td>( Q + fu \times \text{Cl}_{\text{int}}^\prime )</td>
<td>( Q + fu \times \text{Cl}<em>{\text{int}}^\prime \times fu</em>{\text{inc}} )</td>
</tr>
</tbody>
</table>
and/or microsomal protein binding). Using this well-stirred model, it has proved possible to predict the hepatic clearance from \textit{in vitro} intrinsic clearance rates in rat, dog and human (Table 8.2). The hepatic clearance value for the rat (0.972 ml min$^{-1}$ mg$^{-1}$ protein) was approximately one-tenth the actual clearance found \textit{in vivo}; well in agreement with the observation that \textit{in vivo} compound X was eliminated by the rat, largely unchanged, by the kidneys (~90%).

To predict hepatic clearance of compound X in humans, human \textit{in vitro} intrinsic clearance could then be scaled to hepatic clearance, using a technique that had been validated in rat (Ashfortt \textit{et al.}, 1995). Renal clearance is subject to an allometric relationship and can generally be scaled across species (see below). The predicted \textit{in vivo} renal Cl for rat (estimated by multiplying the predicted hepatic Cl by 9) may be scaled allometrically to obtain a prediction for the human \textit{in vivo} renal clearance. Total or systemic Cl in humans can then be estimated by adding the two clearance parameters (hepatic and renal) together; in practice, for compound X, later first-in-human data revealed an actual \textit{in vivo} Cl nearly identical to the predicted total Cl (2.15 vs. 1.87–2.45 ml min$^{-1}$ kg$^{-1}$, respectively; Table 8.2). Here, then, is a real-world example of, first, how rat \textit{in vitro} and \textit{in vivo} preclinical data were used to develop and validate a scaling method for compound X in rat; and second, how the scaling method successfully predicted \textit{in vivo} overall drug clearance in humans.

However, if the same methods are used for compound X in dog, things initially appear to be different. Scaling the \textit{in vitro} intrinsic clearance to hepatic Cl using the rat-validated method, in conjunction with allometric scaling of renal Cl, resulted in a five-fold under-prediction of the total or systemic clearance \textit{in vivo}. However, further metabolism studies in the dog \textit{in vivo} revealed that compound X undergoes significant additional biotransformation, particularly \textit{N}-methylation, which is unique (as far as we are aware) to this species, and invalidates some of our \textit{in vitro} assumptions. This canine biotransformation pathway was not detected by our initial microsomal studies because there are no \textit{N}-methyl transferases in microsomes. Thus, although we did not successfully predict dog systemic clearance for compound X, our scaling tactics did eventually teach us about a new clearance mechanism, and how important this was for the systemic clearance of compound X in dog.

This is an example of how \textit{in vitro} studies can be combined with \textit{in vivo} preclinical data, leading to useful prediction of human systemic drug clearance. Nonetheless, several caveats are encountered in such scaling exercises, which warrant restating.

The first caveat is that all clearance pathways (hepatic, renal, biliary or other) must be taken into consideration. If a compound undergoes a high level of hepatic clearance, then \textit{in vitro}--\textit{in vivo} scaling may be used to predict the fraction of systemic clearance expected from this pathway. If a compound undergoes a high level of renal elimination, allometric scaling may be also used to predict the clearance attributed to this pathway.

The second caveat is that, in order to accurately predict hepatic clearance, the correct \textit{in vitro} system must be chosen. If the candidate drug is primarily oxidatively metabolized, then liver

<table>
<thead>
<tr>
<th></th>
<th>Predicted \textit{in vivo} hepatic Cl (ml min$^{-1}$ kg$^{-1}$)</th>
<th>Predicted \textit{in vivo} renal Cl (ml min$^{-1}$ kg$^{-1}$)</th>
<th>Predicted \textit{in vivo} total Cl (ml min$^{-1}$ kg$^{-1}$)</th>
<th>Actual \textit{in vivo} Cl (ml min$^{-1}$ kg$^{-1}$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>0.972</td>
<td>8.75</td>
<td>9.72</td>
<td>8.17–10.7</td>
</tr>
<tr>
<td>Human</td>
<td>0.223</td>
<td>1.93</td>
<td>2.15</td>
<td>1.87–2.45</td>
</tr>
<tr>
<td>Dog</td>
<td>0.463</td>
<td>3.74</td>
<td>4.20</td>
<td>21.2–22.5</td>
</tr>
</tbody>
</table>

Predicted values were scaled from \textit{in vitro} half-life data using liver microsomes and the well-stirred model of hepatic extraction. Hepatic Cl predictions were corrected for plasma and microsomal protein binding. Predicted total Cl was obtained by adding in renal Cl estimates which were, in turn, scaled allometrically ($Y = aW^{0.75}$).
microsomes will be sufficient. However, if the potential for non-microsomal biotransformation exists, then a different in vitro system, such as hepatocyte suspensions, should be used. In the illustration above, it turned out, as far as clearance of compound X is concerned, human is specifically like a rat and unlike a dog.

The third caveat is that one must consider the variability in the expression of metabolizing enzymes between individuals. Oxidative metabolism (seen in vivo and in microsomal enzymes), and especially cytochrome P₄₅₀s, vary tremendously between human individuals (Meyer, 1994; Shimada et al., 1994). Had we used a single donor microsomal sample, rather than pooled liver microsomes (a pool consisting of at least eight individual donors), to scale in vitro data to in vivo hepatic clearance, we might have made greatly misleading predictions (note that oxidative, initial drug metabolism is sometimes called ‘phase I metabolism’ in the literature, causing ambiguity with the stage of drug development or type of clinical trial).

**Volumes of distribution**

**Review of elementary concepts**

Volume of distribution is a theoretical concept that may or may not correspond to the anatomical compartment(s) which drugs or metabolites may access after dosing. When size of the dose \( D \) is known, and when drug concentration \( C \) may be found by sampling biological fluids, then, in the simplest case, the volume of distribution \( VD \) is:

\[
VD = D / C
\]

Clinical protocols can usually only prescribe the sampling of a subset of compartments when a drug is known to distribute widely in the body. For example, a lipophilic drug may penetrate lipophilic organs such as brain, and, obviously, brain sampling simply for pharmacokinetic purposes is usually possible only in animals. In such cases, blood concentrations fall far lower than if the dose had distributed solely into the circulating compartment; \( C \) becomes very small, and \( VD \) becomes correspondingly very large. The opposite effect would require the drug to be restricted to a fraction of the compartment that is sampled, essentially suggesting that too few compartments have been postulated, and the effect is almost never encountered. Again, see Curry (1980) or Benet et al. (1996) for expansion of these elementary aspects of volume of distribution.

**Prediction of human volumes of distribution**

The free (not plasma protein bound) volume of distribution of experimental drugs is generally considered to be constant for all species. Thus, the volume of distribution in humans can easily be predicted through a simple proportionality between in vitro plasma protein binding data in humans and and in a preclinical species, and in vivo volume of distribution in that same preclinical species:

\[
VD_{\text{human}} = \frac{VD_{\text{pre-clinical species}} \times fu_{\text{human}}}{fu_{\text{pre-clinical species}}}
\]

where \( fu \) is fraction unbound \( V_0 \) plasma proteins. Table 8.3 shows the predicted volume of distribution of a single intravenous bolus dose of compound X in humans; this is found by using the above equation, an in vitro estimate of protein binding data for rat and dog plasmas and the observed volumes of distribution for these two species in vivo. For humans, \( VD_{\text{human}} \) was predicted to be 3.48–4.59 kg⁻¹ using the rat data and 3.01–5.06 kg⁻¹ using the dog data.

<table>
<thead>
<tr>
<th>Fraction of compound X unbound in the plasma (fu)</th>
<th>In vivo volume of distribution (l kg)</th>
<th>Predicted volume of distribution in humans (l kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>3.02–3.97</td>
<td>3.48–4.59</td>
</tr>
<tr>
<td>Human</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Dog</td>
<td>3.82–6.43</td>
<td>3.01–5.06</td>
</tr>
</tbody>
</table>
Elementary aspects of oral bioavailability

The oral bioavailability \( F \) of a drug is dependent on (a) the absorption of the drug from the gastrointestinal (GI) tract and (b) the capability of the liver to clear the drug during its first pass through the portal venous system. Oral bioavailability may be described as the fraction of the total oral dose for which systemic exposure is achieved. It is a measurement of the extent of exposure and contrasts with the rates of absorption or elimination discussed above.

Clinically, \( F \) is found by comparing the systemic exposures that result after intravenous and (usually) oral doses of the same drug. Note that this comparison need not be for doses of the same size (an important consideration when assessing the tolerability aspects of a proposed normal volunteer study). It is, in fact, preferable to achieve concentrations in the same range from the two doses. Typically, \( C_{\text{max}} \) for a standard dose is going to be higher after bolus intravenous dosing (IV) than after oral administration (PO), and adverse effects of new agents are likely to be concentration dependent. The relevant equation is:

\[
F(\%) = \left( \frac{AUC_{\text{PO}} \times \text{Dose}_{\text{IV}}}{AUC_{\text{IV}} \times \text{Dose}_{\text{PO}}} \right) \times 100\
\]

where \( AUC \) is the area under the time–plasma concentration curve after each of the respective administrations (the dose terms cancel when equally sized doses are administered by both routes of administration). A residual of less than 15% (sometimes 10%) of the total \( AUC \) is a commonly used standard for timing the last plasma sample. These studies are usually conducted under standard conditions and using crossover protocols, although, occasionally, a double-label study may be used to measure \( F \) instantaneously. Comparison of generic with innovator’s formulations, and slow-release with rapidly absorbed formulations, may be done using equations of the same form. Similarly, subcutaneous and intravenous injections can be compared. With very rare exceptions, the intravenous administration of a dose is assumed to be 100% bioavailable. For example, very short-acting drugs, for example some arachidonate derivatives, remifentanil, esmolol and adenosine, may be metabolized during their first return circulation after intravenous administration and still not achieve 100% ‘bioavailability’. Also, the concept is not applicable to topically acting drugs. However, assessing the bioavailability of these drugs by any other route of administration is usually pointless, unless there is some highly specialized issue, for example absorption after intrathecal administration or potential for drug abuse.

Fluctuation of plasma drug concentration is an important aspect of the bioavailability of slow-release formulations, which almost always have lower \( C_{\text{max}} \) values for a standard dose size than, albeit similar AUC to, a more rapidly absorbed tablet. Assuming that the assay can handle the inevitably lower plasma concentrations, a useful measure of fluctuation, after the initial absorption phase of the curve and during the next four half-lives of elimination, is:

\[
\frac{(C_{\text{max}} - C_{\text{min}})}{C_{\text{avg}}}\]

where \( C_{\text{avg}} \) is the average concentration during the specified time period; whether to use the arithmetic or geometric average is a controversy, with respected protagonists on both sides.

Prediction of oral bioavailability

Oral bioavailability can be predicted using the following equation:

\[
F = Fa \left( 1 - \frac{Cl}{Q} \right)
\]

where \( Fa \) represents the fraction of drug absorbed through the intestinal lining, \( Cl \) is the hepatic clearance (predicted from in vitro studies, see earlier section) and \( Q \) is the hepatic blood flow in humans (see, for example Rane et al., 1977). Octanol/water partitioning has traditionally been used to predict the fraction absorbed through the intestinal lining. Recently, Caco-2 cell permeability studies have replaced the use of octanol/buffer partitioning studies. Yee (1997) established a
relationship between Fa and Caco-2 cell permeability, expressed as the apparent permeability constant ($P_{\text{app}}$), as follows:

- If $P_{\text{app}} < 10^{-6}$ cm s$^{-1}$, then $Fa = 0 - 20\%$
- If $1 \leq P_{\text{app}} \leq 10 \times 10^{-6}$ cm s$^{-1}$, then $Fa = 20 - 70\%$
- If $P_{\text{app}} > 10^{-5}$ cm s$^{-1}$ then $Fa \geq 70\%$

The use of Caco-2 cell permeability studies has resulted in more accurate oral bioavailability predictions. Using the predicted hepatic clearance for compound X in humans (see above), estimating $Fa$ by extrapolation from the Caco-2 cell $P_{\text{app}}$ and assuming hepatic blood flow for humans (see, for example Rane et al., 1977) of 20 ml min$^{-1}$ kg$^{-1}$, the human oral bioavailability of 69–98% is predicted for compound X. This compares well with the known oral bioavailability of this compound in rats and dogs (83 and 72%, respectively).

### 8.2 Prediction from animals to humans in vivo

#### Elementary aspects

Allometric scaling is an empirical method for predicting physiological, anatomical and pharmacokinetic measures across species in relation to time and size (Boxenbaum, 1982; Ings, 1990; Boxenbaum and DiLea, 1995). Allometric scaling is based on similarities among species in their physiology, anatomy and biochemistry, coupled with the observation that smaller animals perform physiological functions that are similar to larger animals, but at a faster rate. The allometric equation is $Y = aW^b$, and a log transformation of this formula yields the straight line:

$$\log Y = b \log W + \log a,$$

where $Y$ is the pharmacokinetic or physiological variable of interest, $a$ is the allometric coefficient (and $\log a$ is the intercept of the line), $W$ is the body weight and $b$ is the allometric exponent (slope of the line).

One of the first applications of allometric scaling was the use of the toxicity of anticancer agents in animals to predict toxicity in humans children. It was observed that the toxic dose of a drug is similar among species when the dose is compared on the basis of body surface area (Freireich et al., 1966). For most vertebrate species, the body weight/volume ratio varies very little, but the surface area/volume ratio increases as species become smaller. Allometric correction of dose multiples in toxicology (compared with proposed human doses) is thus important, especially when small rodents provide the principal toxicology coverage.

Body surface area ($Y$) is related to body weight ($W$, in kg) by the formula:

$$Y = 0.1 W^{0.67}$$

This allometric relationship between body surface area and species body weight then allows for a simple conversion of drug doses across species (Figure 8.3), and allometrically equivalent doses of drugs (mg kg$^{-1}$) can be calculated for any species (Table 8.4). The conversion factor (km) is simply the body weight divided by the body surface area. Thus, using the km factors, the dose in Species 1 (in mg kg$^{-1}$) is equivalent to ($km_{\text{species2}}/km_{\text{species1}}$) times the dose in Species 2 (in mg kg$^{-1}$). For example, a 50 mg kg$^{-1}$ dose of drug in mouse would be equivalent to a 4.1 mg kg$^{-1}$ dose in humans, that is approximately one-twelfth of the dose (Table 8.4). Likewise, the conversion factor can be used to calculate equivalent doses between any species. An equivalent dose in milligram per kilogram in rat would be twice that for mouse.

#### Allometric approaches to drug discovery

Using limited data, allometric scaling may be useful in drug discovery. We assume that, for the formula $Y = aW^b$, the value of the power function $`b`$ (or slope of the line from a log vs. log plot) is drug independent, unlike the intercept `$a$`, which is drug dependent. By doing this, we can use data from a single species (rat) to successfully predict the pharmacokinetics of compound X in humans.
and cats. This method could be expected to save time and money in the drug discovery process by enabling us to do the following:

1. Select the correct dose in an animal model of disease. These studies are expensive and time consuming. The selection of the wrong dose in an animal model, especially in a model in a larger species such as cat, could lead to invalid results, either through toxicity (if the dose is too high) or inactivity (if the dose is too low).

2. Provide confidence that the pharmacological model will predict efficacy in humans. If a drug is effective in therapeutic models using different species and these animals receive equivalent exposures (as measured by the maximum plasma concentration, $C_{\text{max}}$, or area under the plasma concentration curve, AUC), then the clinician can choose a dose for trials with confidence.

3. Eliminate unnecessary doses and plasma samples in the first trials in humans.

The discovery process for compound X, which is efficacious in a number of in vivo models, is again an illustration of how allometric considerations can enhance the development process. The whole brain concentrations of this compound are in equilibrium with plasma concentrations within 5 min after dosing, and it is also eliminated from the brain in equilibrium with the declining plasma concentration. We also know that compound X is $\sim 80\%$ orally bioavailable in rats and dogs (see above) and has linear (first-order elimination) and predictable pharmacokinetics in animals.

Next, this compound was tested in a model of excitotoxicity, in which the neurotoxin malonate was injected into the striatum of rats. A subcutaneous injection of compound X at 9 mg kg$^{-1}$ caused an $80\%$ reduction in the lesion activity produced by malonate. The $C_{\text{max}}$ plasma levels of compound X at this dose would be about 1500 ng ml$^{-1}$.

In a study using spontaneously hypertensive rats, a dose of 12 mg kg$^{-1}$ of compound X was also neuroprotective [these rats were subjected to 2 h of focal ischemia by occlusion of the right middle cerebral artery (MCA), followed by 22 h of reperfusion]. With the assumption of 100\% systemic absorption, the expected plasma $C_{\text{max}}$ at this dose was 2000 ng ml$^{-1}$. In this model, there was a significant reduction (greater than 30\%) in cortical infarct volume, compared with saline controls, when the drug was given at the time of occlusion and at 0, 0.5, 1 and 1.5 h post-MCA occlusion.

Using the data from the neuroprotection models from rats, we then scaled a dose to the cat that was

### Table 8.4  Equivalent surface area dosage conversion factors

<table>
<thead>
<tr>
<th>Species</th>
<th>Body weight (kg)</th>
<th>Body surface area (kg m$^{-2}$)</th>
<th>Factor ($K_m$)</th>
<th>Approximate human dose equivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>0.02</td>
<td>0.0067</td>
<td>3.0</td>
<td>1/12</td>
</tr>
<tr>
<td>Rat</td>
<td>0.100</td>
<td>0.0192</td>
<td>5.2</td>
<td>1/7</td>
</tr>
<tr>
<td>Dog</td>
<td>8.0</td>
<td>0.400</td>
<td>20</td>
<td>1/2</td>
</tr>
<tr>
<td>Monkey</td>
<td>2.5</td>
<td>0.217</td>
<td>11.5</td>
<td>1/3</td>
</tr>
<tr>
<td>Human</td>
<td>60</td>
<td>1.62</td>
<td>37</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Dose in species 1 (mg kg$^{-1}$) = dose in species 2 (mg kg$^{-1}$).
expected to achieve a neuroprotective plasma concentration of 1500 ng ml$^{-1}$. To do this, we predicted the volume of distribution ($V_{\text{cat}}$) using data collected from the volume of distribution in rat ($V_{\text{rat}}$). For our calculations, we used a value of 0.938 for the power function $b$ (see Ings, 1990, Table 2). In doing this, we made the standard assumption that in the formula $Y = aW^b$ the value of the power function $b$ was compound independent and that the function $a$ was compound dependent (Ings observed that the power function $b$ is reasonably constant for each pharmacokinetic parameter). Substituting into the allometric formula, $\log(V_{\text{cat}}) = b \log W + \log a$, we found:

$$\log 0.4261 = 0.938 \log 0.3kg + \log a$$

Thus,

$$\log a = 0.120.$$ 

By substituting back into the formula and using a cat weight of 4 kg, we found:

$$V_{\text{cat}} = 4.81 \text{ or } 1.211 \text{ kg}^{-1}.$$ 

Our formula for calculating the dose to be administered was:

$$Dose_{\text{cat}} = Dose_{\text{rat}}(V_{\text{cat}}/V_{\text{rat}})$$

The formula for predicting the plasma half-life was:

$$T_{1/2\text{cat}} = T_{1/2\text{rat}}(W_{\text{cat}}/W_{\text{rat}})^{y-x}$$

in which $y$ is as defined earlier and $x$ is a clearance parameter (Boxenbaum and Ronfeld, 1983). The measured plasma half-life in the rat was 4.53 h. Filling in the formula (Boxenbaum and Ronfeld, 1983), we predicted a plasma half-life of 7.3 h in the cat ($= 4.53 \times (4/0.3)^{0.938-0.75}$). The measured plasma half-life in the cat was 6 h. We knew from data collected in the rat that a dose of 3.06 mg kg$^{-1}$ administered over 15 min would give a plasma $C_{\text{max}}$ of 1500 ng ml$^{-1}$ of plasma. This equated to a dose in the cat of 2.6 mg kg$^{-1}$ over 15 min or 175 $\mu$g kg$^{-1}$ min$^{-1}$ for 15 min.

When we performed studies to determine the $C_{\text{max}}$ in cats following a dose of 2.6 mg kg$^{-1}$ administered over 15 min, our predicted values were very close to the actual values, with a measured $C_{\text{max}}$ of 1240 $\pm$ 100 ng ml$^{-1}$.

Data from the rat can also be used to predict the pharmacokinetics of compound X in humans. As with the cat, we made our predictions prospectively by assuming, that for the formula $Y = aW^b$, the value of the power function $b$ (or slope of the line from a log vs. log plot) was drug independent and that the intercept function $a$ was drug dependent. We assigned values of 0.75, 0.938 and 0.25 for clearance, volume of distribution and plasma half-life, respectively, using the data taken from the literature and discussed above. The intercept function $a$ was then determined for each parameter by substituting the pharmacokinetic data from rats, that is clearance = 0.54 1h$^{-1}$ kg$^{-1}$, $V_1 = 1.421$ kg$^{-1}$, $V_{\text{dss}} = 3.33$ kg$^{-1}$. We estimated the pharmacokinetic parameters for humans by substituting the calculated intercept function back into the formula and solving for $Y$ for a 70-kg human. The prediction of the plasma half-life in humans was determined by three separate methods. For our predictions, we also assumed that the protein binding was the same in rats and in humans and that the metabolism of compound X was similar in both the species. Clearly, approaches such as this could be a routine part of drug discovery.

The values estimated by allometric scaling were compared with those observed in the single-dose human volunteer study (Table 8.5). We predicted that for compound X in humans, the plasma

<table>
<thead>
<tr>
<th>Pharmacokinetic parameter</th>
<th>Predicted</th>
<th>Actual</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clearance</td>
<td>0.138 h$^{-1}$ kg$^{-1}$</td>
<td>0.123</td>
</tr>
<tr>
<td>Half-life$^a$</td>
<td>14.5 h</td>
<td>13.6 h</td>
</tr>
<tr>
<td>$V_1$</td>
<td>1.011 kg$^{-1}$</td>
<td>1.021 kg$^{-1}$</td>
</tr>
<tr>
<td>$V_{\text{dss}}$</td>
<td>2.41 kg$^{-1}$</td>
<td>2.11 kg$^{-1}$</td>
</tr>
</tbody>
</table>

$^a$Plasma half-life is the average from three values by three different methods: (a) $T_{1/2\text{human}} = (0.693 \times V_1)/Cl_1$; (b) $T_{1/2\text{human}} = T_{1/2\text{rat}}(W_{\text{human}}/W_{\text{rat}})^{y-x}$; and (c) $\log T_{1/2\text{human}} = \log a + b \log W_{\text{human}}$. 

Table 8.5 Predicted and actual pharmacokinetic parameters for humans
half-life would be 14.5 h, the plasma clearance be $0.1381 \text{ h}^{-1} \text{ kg}^{-1}$ and the $V_1$, $V_{dss}$ and $V_{db}$ be 1.01, 2.37 and 2.561 kg$^{-1}$, respectively. The predictions using rat data were within 15% of the actual mean values in human volunteers. A complex Dedrick plot of the rat and the human data showed nearly superimposed concentration–time curves (Figure 8.4).

This illustrates how allometric scaling is a useful part of the drug discovery process: we avoided studying irrelevant doses and saved time. Ideally, allometric scaling should be done using pharmacokinetic data from at least four species, even though accurate predictions can be made using data from a single species. If possible, information about differences in metabolism among species should be considered when making predictions.

8.3 Pharmacokinetic/pharmacodynamic models

Elementary aspects

The possibility that time since dose changes the relationship between pharmacological effect size and drug concentrations in plasma has been known for a long time (Levy, 1964, 1966; Levy and Nelson, 1965; Wagner, 1968; Curry, 1980). The pioneering work was done by Levy and his colleagues in the 1960s on single dose–plasma level–effect relationships and on the duration of action of drugs as a function of dose. Brodie and colleagues had shown even earlier how complicated the relationships are when drugs with multicompartiment distribution are studied in this context (e.g. Brodie, 1967). Lasagna and colleagues, using diuretics, found that depending on whether a cumulative effect (24-h urine production) or an ‘instant’ effect (rate of urine flow at a particular time) were measured, different relationships of response were possible (Murphy et al., 1961). Nagashima et al. (1969) demonstrated the relative time courses of anticoagulant concentration and effect. Thus, the relationship between effect size and concentration of drug in plasma should not be expected to be constant or simple, and it can vary with time.

The objectives of modern analysis of drug action are to delineate the chemical or physical interactions between drug and target cell and to characterize the full sequence and scope of actions of each drug (Ross, 1996). Preclinical models describing the relationship between the concentration of drug in blood or plasma and drug receptor occupancy or functional response provide clinically useful tools regarding potency, efficacy and the time course of effect.

Potency is an expression of the activity of a compound, in terms of either the concentration or amount needed to produce a defined effect. $E_{\text{max}}$ is the maximal drug-induced effect. $EC_{50}$ is the concentration of an agonist that produces 50% of the maximal possible response. An $EC_{50}$ can be described for drug concentrations using $in vitro$ assays, or as a plasma concentration $in vivo$. $IC_{50}$ is the concentration of an antagonist that reduces a specified response to 50% of its former value.

A measure of the tendency of a ligand and its receptor to bind to each other is expressed as $K_d$ in receptor occupancy studies. $K_d$ is the equilibrium constant for the two processes of drug–receptor combination and dissociation. $K_d$ may be found for both agonists and antagonists, although sometimes the former poses more technical challenge due to alterations to the conformation of the binding site. In contrast, efficacy is a relative measure,
amongst different agonists, describing response size for a standard degree of receptor occupation (Jenkinson et al., 1995). When an agonist must occupy 100% of available receptors to cause $E_{\text{max}}$, its efficacy may be said to be unity. If occupation of all receptors achieves a response that is less than $E_{\text{max}}$, then the agonist’s efficacy is less than 1 and equal to the ratio of observed maximal effect/maximal effect for an agonist with efficacy 1 (we call these partial agonists or agonist–antagonists). Some agonists need occupy only a subset of the available receptors, in order to achieve $E_{\text{max}}$, and these have efficacy greater than unity. In the latter case, the concentration–response curve lies to the left of the concentration–receptor occupancy curve (e.g. Minneman et al., 1983). Drugs with efficacy $\geq 1$ are also called full agonists.

Below, we present some model relationships between observed concentration and effect size, as examples from a considerable volume of literature. The reader is referred to key texts for comprehensive coverage of this topic (e.g. Smolen, 1971; Gibaldi and Perrier, 1982; Dayneca et al., 1993; Levy, 1993; Lesko and Williams, 1994; Colburn, 1995; Derendorf and Hochhaus, 1995; Gabrielsson and Weiner, 1997; Sharma and Jusko, 1997).

**Pharmacokinetic–pharmacodynamic (PK/PD) modeling**

**Single-compartment, time-independent PK/PD models**

The simplest model is where (a) the drug distributes into a single compartment, represented by plasma, and (b) the effect is an instantaneous, direct function of the concentration in that compartment. In this situation, the relationship between drug concentration ($C$) and a pharmacological effect ($E$) can be simply described by the linear function:

$$E = SC$$

where $S$ is a slope parameter. If the measured effect has some baseline value ($E_0$), when drug is absent (e.g. physiological, diastolic blood pressure or resting tension on the tissue in an organ bath), then the model may be expressed as:

$$E = E_0 + SC$$

The parameters of this model, $S$ and $E_0$, may be estimated by linear regression. This model does not contain any information about efficacy and potency, cannot identify the maximum effect and thus cannot be used to find $EC_{50}$.

When effect can be measured for a wide concentration range, the relationship between effect and concentration is often observed to be curvilinear. A semi-logarithmic plot of effect versus log concentration commonly linearizes these data within the approximate range 20–80% of maximal effect. This log transformation of the concentration axis facilitates a graphical estimation of the slope of the apparently linear segment of the curve:

$$E = m \ln(C + C_0)$$

where $m$ and $C_0$ are the slope and the hypothetical baseline concentration (usually zero, but not for experiments of add-on therapy or when administering molecules that are also present endogenously), respectively. In this equation, the pharmacological effect may be expressed, when the drug concentration is zero, as:

$$E_0 = m \ln(C_0)$$

As mentioned earlier, for functional data based on biophase, plasma or tissue measurements, we often represent potency as $EC_{50}$; and when two compounds are compared with respect to potency, the one with the lowest $EC_{50}$ value has the highest potency. A general expression for observed effect, by analogy with the Michaelis–Menten equation (above) is:

$$E = \frac{E_{\text{max}}C}{EC_{50} + C}$$

There are various forms of this function for agonist (stimulatory) and antagonist (inhibitory) effects. For example, if there is a baseline effect ($E_0$),
then this may be added to the right-hand side of the equation:

\[ E = E_0 + \frac{E_{\text{max}} C}{EC_{50} + C} \]

Alternatively, the relationship between concentration and effect for an antagonist, including a baseline value, is:

\[ E = E_0 - \frac{I_{\text{max}} C}{IC_{50} + C} \]

In the \( E_{\text{max}} \) model above, plasma concentration and \( EC_{50} \) are raised to the power of \( n \) (Hill factor) equal to 1. A more general form of the equation is the sigmoid curve:

\[ E = \frac{E_{\text{max}} C^n}{EC_{50}^n + C^n} \]

where, by addition of a single parameter \( (n) \) to the \( E_{\text{max}} \) model, it is possible to account for curves which are both shallower and steeper than when \( n = 1 \) (i.e. unlike the ordinary \( E_{\text{max}} \) models). Note that the sigmoidicity parameter \( (n) \) does not necessarily have a direct biological interpretation and should be viewed as an extension of the original \( E_{\text{max}} \) model to account for curvature.

The larger the value of the exponent, the more curved (steeper, concave downwards) is the line. A very high exponent can be viewed as indicating an all-or-none effect (e.g. the development of an action potential in a nerve). Within a narrow concentration range, the observed effect goes from all to nothing or vice versa. An exponent less than unity \( (<1) \) sometimes indicates active metabolites and/or multiple receptor sites.

The corresponding inhibitory sigmoid \( E_{\text{max}} \) model is functionally described as follows:

\[ E = E_0 - \frac{I_{\text{max}} C^n}{IC_{50}^n + C^n} \]

\( In \) \( vivo \), these models, analogous to the classical dose or log dose–response curves of \( in \) \( vitro \) pharmacology, are limited to direct effects in single-compartment systems. These models make no allowance for time-dependent events in drug response.

**Complex PK/PD and time-dependent models**

The most common approach to \( in \) \( vivo \) pharmacokinetic and pharmacodynamic modeling involves sequential analysis of the concentration versus time and effect versus time data, such that the kinetic model provides an independent variable, such as concentration, driving the dynamics. Only in limited situations could it be anticipated that the effect influences the kinetics, for example effects on blood flow or drug clearance itself.

Levy (1964), Jusko (1971) and Smolen (1971, 1976) described the analysis of dose–response time data. They developed a theoretical basis for the performance of this analysis from the data obtained from the observation of the time course of pharmacological response, after a single dose of drug, by any route of administration. Smolen (1976) extended the analysis to application of dose–response time data for bioequivalence testing.

In dose–response time models, the underlying assumption is that pharmacodynamic data gives us information on the kinetics of drug in the biophase (i.e. the tissue or compartment precisely where the drug exhibits its effect). In other words, apparent half-life, bioavailability and potency can be obtained simultaneously from the dose–response–time data. Considering such a model, assuming \( (a) \) first-order input/output processes and \( (b) \) extravascular dosing, the kinetic model then drives the inhibition function of the dynamic model. It is the dynamic behavior which is described by the response model. A zero-order input and first-order output governs the turnover of the response. This permits us to consider situations where the plasma concentration represents delivery of the drug to an effect compartment; the time course of drug concentration and of effect (both in the biophase) is different from that simply observed in plasma concentrations.

The amount of drug in a single hypothetical compartment after an intravenous (IV) dose is usually modeled with mono-exponential decline
and is analogous to the ‘plasma disappearance’ curve (above):

$$X_{IV} = D_{IV} e^{-Kt}$$

The amount of drug in a single hypothetical compartment after an extravascular dose is then modeled with first-order input/output kinetics:

$$X_{po} = \frac{K_a F D_{po}}{K_a - K} \left[ e^{-K(t-t_{lag})} - e^{K_a(t-t_{lag})} \right]$$

Concentration–time effect modeling is illustrated by the following example, which was chosen to illustrate a single dose of drug causing the reversal of a symptom (pain). Many other types of examples exist.

The plasma kinetics of the analgesic were describable by the following expression after the intravenous bolus dose, with $C_0 = 45.0$ and $K = 0.50$ h\(^{-1}\):

$$C = 45.0 e^{-0.50t}$$

In the same study, effect measurements were recorded during 80 min, as shown in Figure 8.5.

Often, drug effects do not parallel changes in plasma concentration. This can result from distribution phenomena, such as when the effect occurs outside the plasma compartment (e.g. the sedative effect of a dose of benzodiazepine which occurs in the brain), or when the effect recorded reflects, for example, a chain of biochemical events triggered by the presence of drug (e.g. the aborting of a migraine attack by a serotoninergic drug). In relation to the first of these possibilities, a model, sometimes called a ‘link model’ (also called the ‘effect-compartment’ or the ‘effect-distribution’ model), allows estimation of the in vivo pharmacodynamic effect from nonsteady-state effect ($E$) versus time and concentration ($C$) versus time data, within which potential exists for observed $E$ and $C$ to display temporal displacement with respect to each other (Segre, 1968; Wagner, 1968; Dahlstrom et al., 1978; Sheiner et al., 1979). The rate of change of drug amount ($A_e$) in a hypothetical effect compartment can be expressed as:

$$\frac{dA_e}{dr} = k_{le} A_1 - k_{e0} A_e$$

where $A$ is the amount of drug in the central compartment of a pharmacokinetic model, linked to the effect compartment, with first-order rate constants $k_{le}$ and $k_{e0}$. The corresponding expression for the amount of drug in the effect compartment, for a

![Figure 8.5 Observed effect-time data for an analgesic](image-url)
one-compartment model with bolus input of dose (D) is:

\[ A_e = \frac{k_{le}D}{k_{e0} - K} \left[ e^{-Kt} - e^{-k_{el}t} \right] \]

where \( K \) is the elimination rate constant. The concentration of drug in the effect compartment, \( C_e \), is obtained by dividing \( A_e \) by the effect compartment volume, \( V_e \):

\[ C_e = \frac{k_{le}D}{V_e(k_{e0} - K)} \left[ e^{-Kt} - e^{-k_{el}t} \right] \]

At equilibrium, the rates of drug transfer between the central and effect compartments are equal:

\[ k_{1e}A = k_{e0}A_e \]
\[ k_{1e}V_eC = k_{e0}V_eC_e \]

If the partition coefficient, \( K_p \), equals \( C_e/C \) at equilibrium (steady state), then we can rearrange the above equation:

\[ V_e = \frac{k_{1e}V_1}{K_p k_{e0}} \]

Substituting for \( V_e \) in the above equation (i.e. \( k_{1e} = k_{e0} \)) yields:

\[ C_e = \frac{k_{e0}DK_p}{V_1(k_{e0} - K)} \left[ e^{-Kt} - e^{-k_{el}t} \right] \]

At equilibrium, \( C \) will be equal to \( C_e/K_p \) by definition, and thus:

\[ C_e = \frac{k_{e0}D}{V_1(k_{e0} - K)} \left[ e^{-Kt} - e^{-k_{el}t} \right] \]

This is how the link-model relates the kinetics in plasma to the kinetics of drug in the effect compartment. When used together with the \( E_{\text{max}} \) model for estimation of the maximal drug-induced effect, the concentration at half-maximal effect (apparent \( EC_{50} \)) and the rate constant of the disappearance of the effect (\( k_{e0} \)):

\[ E = \frac{E_{\text{max}}C_e^n}{EC_{50}^n + C_e^n} \]

Computer fitting of the equations to the effect data and estimation of the rate constant for the disappearance of the effect, \( k_{e0} \), \( EC_{50} \) and \( E_{\text{max}} \) follows, assuming the sigmoidicity factor (\( n \)) to be equal to unity.

At steady state, \( C_e \) is directly proportional to the plasma concentration (\( C \)), as \( C_e = K_p C \). Consequently, the potency (\( EC_{50} \)) obtained by regressing the last two equations represents the steady-state plasma concentration producing 50% of \( E_{\text{max}} \).

Note that the effect equilibration rate constant (\( k_{e0} \)) may be viewed as a first-order distribution rate constant. It can also be thought of in terms of the rate of presentation of a drug to a specific tissue, determined by, for example, tissue perfusion rate, apparent volume of the tissue and eventual diffusion into the tissue. The results of the data fitting in this exercise with the analgesics are \( E_{\text{max}} \) 4.5; \( EC_{50} \) 0.61 ng·ml\(^{-1} \) and \( k_{e0} \) 0.07 h\(^{-1} \).

Effect compartment or link models are limited by their applicability to situations in which the equilibrium between plasma and response is due to distributional phenomena. In reality, there is often a delay between occurrence of maximum drug concentration in the effect compartment and maximum intensity of effect caused by slow development of the effect rather than slow distribution to the site of action. In this situation, indirect or ‘physiological substance’ models are more appropriate (Dayneka et al., 1993; Levy, 1994; Sharma and Jusko, 1997). Warfarin is a good example, where this drug inhibits the prothrombin complex activity (PCA) (inhibition of production of effect). This is illustrated by the following example, which relates changes in \( S \)-warfarin concentration to the observed PCA. The dose was intravenous. The change in PCA is shown in Figure 8.6. The plasma kinetics of \( (S) \)-warfarin were described by the following mono-exponential expression:

\[ C_{w(s)} = 1.05 e^{-0.0228t} \]

and the equation for the turnover of clotting factor \( [P] \) was:

\[ \frac{dP}{dt} = k_d \frac{P_o}{C_{w(s)}^{n} + IC_{50s}} - P \]
In this equation, $k_d$ is the apparent first-order degradation rate constant (also called $k_{out}$). This constant can be obtained experimentally from the slope of a $\ln(P)$ versus time plot, after administration of a synthesis-blocking dose of coumarin anticoagulant (Nagashima et al., 1969; Pitsui et al., 1993). $P_0$ is the baseline value of the prothrombin time, $C_w(s)$ is the concentration of ($S$)-warfarin and $IC_{50s}$ is the concentration of warfarin at 50% of maximal blocking effect. It was also possible to estimate the half-life of the apparent first-order degradation.

An alternative model, including a lag-time to allow for distributional effects embedded in the observed time delay of the onset of the effect after warfarin administration, was published by Pitsui et al. (1993). Setting the baseline value of clotting factor activity in the absence of warfarin ($P_0$) to a fixed mean of three predose measurements, the program can estimate that parameter.

The model equations are as follows:

$$\frac{dPCA}{dt} = \frac{K_{in}}{I(C_w(s))} - k_d \times P$$

where $I(C_w(s))$ is the inhibition function of warfarin (see next equation). It is appropriate to substitute $K_{in}$ with $k_d \times P_0$. Inhibition of synthesis (rate in) has an impact on the peak (trough) level rather than the time to the peak. This is similar to a constant rate of drug infusion into a one-compartment system. The time to steady state is only governed by the elimination rate constant and not the rate of infusion. At steady state:

$$\frac{dR}{dt} = \frac{K_{in}}{I(C_w(s))} - k_{out}P = 0$$

If the baseline condition for PCA with no inhibition of drug is:

$$PCA = P_0$$

then the steady-state condition for the pharmacological response ($PCA_{ss}$) with drug present becomes:

$$PCA_{ss} = \frac{P_0}{I(C)} = P_0 \frac{1}{1 + \frac{C_w(s)}{IC_{50s}}}$$

and where $I(C_w(s))$ is a function of $C_w(s)$, $n$ and $IC_{50s}$, then:

$$I(C_w(s)) = 1 + \frac{C_w(s)^n}{IC_{50s}}$$

As stated before, the intensity of a pharmacological response may not be due to a direct effect of the drug on the receptor. Rather, it may be the net result of several processes only one of which is influenced by the drug. The process that is influenced by the drug must be identified and an attempt be made to relate plasma drug concentration to changes in that process. Warfarin provides a good example of this, as the anticoagulant (hypothrombinemic) effect is an inhibition of the synthesis of certain vitamin K-dependent clotting factors.

Initial parameter estimates were obtained from the PCA versus time data. The baseline value (120 s) was obtained from the intercept on the effect axis. This value is the ratio $K_{in}/k_d$. From the intercept and slope, $K_{in}$ was calculated to be 3.5 s h$^{-1}$. The plasma concentration at the time of the trough of the effect corresponded approximately with the EC$_{50}$ value. Thus, $IC_{50} = 0.35$ mg 1$^{-1}$, $k_d = 0.3$ h$^{-1}$, $n = 3.5$, and

![Figure 8.6 Observed PCA time course following the administration of an intravenous bolus dose of warfarin](image-url)
$P_0 = 130 \text{ s and } t_{lag} = 0 \text{ h}$. The computer fitting gave $0.262 \pm 9.46$ for the IC$_{50}$, $0.033 \pm 17.9$ for $k_{dt}$, $2.68 \pm 39.6$ for $n$ and $121 \pm 58$ for $P_0$ (limits are CV%) with no lag time. Precision increased when a finite lag time was included in the fitting.

As stated earlier, these are two of the many examples that can be chosen to illustrate principles. These two cases, however, are especially relevant to the relationship between animal work and phase I studies in which only the simplest effects, such as counteraction of a painful stimulus or raising/lowering of a physiological parameter such as PCA, are likely to be commonly measured. The reader is again referred to standard texts for more thorough treatment of models of this kind (Sharma and Jusko, 1997).

8.4 Commentary

We have not sought in this chapter to describe phase I studies as such. This is a postgraduate textbook, and we wish to convey how in vitro and in vivo data of various kinds may be used to help extrapolate observed drug effects from simple experimental systems to the more complex clinical situation. The ultimate need is to obtain useful predictions of response in healthy human subjects (phase I studies) from observed drug effects in animals or in the test tube.

What are the strengths and weaknesses of these approaches? The use of intrinsic clearance in vitro permits predictions between species for the particular enzyme/route of metabolism concerned. If humans have qualitatively different routes of metabolism for any particular compound, then this will weaken the predictive value of the in vitro observation. Similarly, allometric scaling works best for compounds with a high component of nonenzymatic elimination, such as our model compound with approximately 90% excretion as unchanged drug. This prediction weakens as variations in rates of enzymatic reactions become more important. The PK–PD modeling approaches use the existing in vivo data to calculate constants which can be applied to other in vivo data but does not, in its present form, link in vitro and in vivo data.

Significantly, none of these approaches uses drug-receptor binding data. Although $K_d$ values are generated during initial screening of the scores of compounds emerging from medicinal chemistry laboratories, it has been a traditional problem that relative efficacy remains unknown (this does not detract from their value in chemical, structure–activity analyses). Neither does any of these approaches uses results of in vitro functional assays which emerge from screening of the compounds in biochemistry laboratories. It should be added that there are exceptions, however: drug–receptor binding constants and EC$_{50}$ values from in vivo studies in animals were used by Danhof and Mandema (1995) to model drugs effects at benzodiazepine receptors and effects on EEG (Figure 8.7). Rowley et al. (1997) have taken a similar approach with NMDA antagonists.

Prospectus

In the future, models will exist which will link constants for in vitro binding to cloned human receptors ($K_d$), data from in vitro functional assays (IC$_{50}$) and animal and human in vivo EC$_{50}$ values. A composite prediction matrix will be applied rapidly and accurately to the process of synthesis of new compounds for phase I testing.

In the shorter term, what can we now do to expedite the drug selection process? Figure 8.8 represents a flow chart illustrating one form of metabolism/pharmacokinetics input into the drug discovery process. Arrows (indicating the flow of work and communication) pointing to the right represent perceived progress, whereas arrows pointing to the left represent ‘disappointments’ (and other feedback) leading to corrections and revisions. The numbered asterisks indicate continuations. The ‘flow of time’ is from left to right and from the top panel to the bottom panel. The rectangles indicate tasks that are to be completed, and rectangles in a column within a panel represent work done by different departments which may be simultaneous or not simultaneous but does not require much interaction between the investigators involved. Unlike the flow chart of a computer program, after which the diagram is modeled, most of the decisions
are made in discussions among committee members and may not necessarily be based on hard and fast criteria. Also, unlike a computer flow chart, the decision concerning a particular drug will usually be based in part on the results of work with other compounds that have the same indication.

In the boxes representing tasks to complete in the phase I study in humans, we have used the symbol 1 to represent work that can be expedited by good validated preclinical data. The symbol 2 represents the tasks that can be expedited by online pharmacokinetic modeling. Among the pharmacokinetic questions that will be asked online in the phase I trial are the following:

1. As the doses are escalated, do the kinetics of the drug appear to be linear or nonlinear over the dose range?

2. With repeated dosing, is there any evidence of a change in kinetics, for example a higher elimination rate that might be indicative of autoinduction?

3. Does the drug accumulate in tissues more than predicted with repeated dosing?

4. If preclinical work identified metabolite(s) to measure in humans, are the pharmacokinetics of metabolite(s) linear and as predicted?

5. Does the relationship between concentration and effect change with dose, time and duration of treatment?

We expect that the task lists represented by some of the boxes will increase. For example, within the box including ‘in vitro intrinsic clearance’, there may be in vitro predictors of oral availability and measures of potentially toxic metabolites. The ‘in vivo pharmacokinetics’ in rats may include an increasing number of compartments whose concentrations are measured by microdialysis and may include measures of a few selected metabolite concentrations.

This diagram is not a comprehensive guide to drug discovery. However, it does show that the chemists discover new chemical entities with desirable properties. In vitro biochemistry is followed by initial in vivo work in the rat which is conducted with pharmacokinetic support and in vitro drug metabolism in parallel. Compounds meeting pre-arranged criteria proceed through

Figure 8.7  Correlation \( (r = 0.993, p < 0.001) \) between benzodiazepine-free drug concentrations EC\(_{50}\) units producing 50% of the maximal EEG effect (change in amplitudes in the \( \alpha \) frequency band, as determined by aperiodic EEG analysis) and affinity to the GABA–benzodiazepine receptor complex \( (K_i) \). Binding to the benzodiazepine receptor was determined on basis of displacement of \(^{3}H\)flumazenil in washed brain homogenate at 37 °C for six drugs B, IA, M, F, O, and C. (Reproduced with permission from Danhof and Mandema, 1995)
Figure 8.8 Flow diagram for involvement of pharmacokinetic and pharmacodynamic mode/computer-generated feedback into the iterative process of drug discovery from medicinal chemistry to the decision to enter phase II trials. This is not a comprehensive flow diagram for all aspects of drug discovery – it is restricted to the components of the process discussed in this chapter. This flow diagram emphasizes efficient involvement of in vitro and in vivo experimental science and computer modeling, in review of data obtained in phase I studies, in the decisions related to selection of the best compound for patient studies.
pharmacological screening to general pharmacology and toxicology, all with pharmacokinetic support, which involves the development of pharmacokinetic and pharmacodynamic models. As a chemical series develops, correlations such as that in Figure 8.6 are developed. Eventually, a compound or compounds is/are chosen for phase I studies.

In this scheme, phase I is influenced by pharmacokinetic and pharmacodynamic modeling. This modeling is used to refine the phase I protocol, providing advice on sampling times, doses and warning signs of difficulty if they occur, as well as permitting comparison of, for example, EC$_{50}$ data from humans with EC$_{30}$ data from animals and in vitro/in vivo comparisons. The objective is expeditious choice of the best compound, with the ever-present limitations on information available. Note that this scheme can involve feedback from phase I to renewed chemical synthesis, as well as choice of a second or third compound for human testing.

Currently, phase I studies themselves tend to be quite straightforward and focus on single compounds. Typically, after adequate preclinical characterization of a candidate drug and 14-day and/or 3-month multiple-dose toxicology studies in two mammalian species, a very low dose is chosen for the first human exposure to the drug. In later exposures, the dose is escalated according to some prearranged criteria until the drug concentrations in plasma associated with undesirable properties in animals are reached and/or until some other limiting response is threatened or observed in the human volunteers. Doses may be single or short multiple-dose series. Simple physiological and biochemical measurements are routinely made in order to monitor for safety. If possible, responses to the drug are also measured when relevant to the intended therapeutic use. A drug successfully passes to phase II if, with appropriate plasma levels, responses are predictable, reversible, related to the known pharmacological mechanisms of the drug and there is a viewpoint among the investigators concerned that the drug could safely be given in initial studies to patients from its target population. Hopefully, all or most of what is observed in phase I is in line with predictions based on the pharmacokinetic and pharmacodynamic properties of the drug in animals.

Once phase I is complete, the humans become the first-choice test species, under all but the most specialized of circumstances (e.g. effects on reproduction). In this context, phase I serves as the interface between preclinical research and clinical development, and the validity of the predictions from animals to humans involved is of paramount importance.

We believe that with enhanced integrated study of animals and humans and with data feedback based on computer models, the process of drug discovery from synthesis to proof of safety in humans could be dramatically improved in its efficiency. This is beyond what has traditionally been expected from departments of drug metabolism and pharmacokinetics (Welling and Tse, 1995). The time saved could be used to permit a larger number of compounds with better prospects, from a single research program, to be compared in phase I studies. Consequently, the extremely costly testing programs in patients which follow phase I could be started sooner and conducted better.

References


Levy G. 1964. ‘Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects’. *J. Pharm. Sci.* **53**: 342.


9 Phase II and Phase III Clinical Studies

Anthony W. Fox

9.1 The phases of drug development: an obsolete model

In former times, it was assumed that developmental drugs proceeded in stepwise fashion from phase I, through phase II, to phase III, prior to filing a PLA or NDA. Phase I was conducted in ‘normal volunteers’ (although some medical students might hardly characterize this term!). Phase II trials were initial studies in selected patients, and phase III was seen as wide-scale studies in broader patient populations. After approval, certain studies, to find new indications, address special patient subpopulations, for marketing purposes or to otherwise broaden product labeling might or might not be conducted. All postapproval studies were termed stage IV.

In modern practice, the distinctions between phases I, II, III, and IV are very often blurred. Three principal and interlocking pressures have caused this blurring: time, finance and an evolving regulatory environment.

Of these three pressures, the most important is time. Strategies such as the overlapping of development ‘phases’, as well as the use of early dose-ranging studies as pivotal, and choosing doses based on surrogate end points are technical responses to this challenge.

Financial pressures, even for the largest pharmaceutical companies, are generally much greater than in the past. The technical response is to maximize resources, avoiding any and all redundant clinical studies.

The regulatory pressures come both from the regulatory authorities and from within the pharmaceutical companies themselves. Regulatory authorities have increased their scientific sophistication during the last 30 years. The questions that are now asked of companies, and the earlier stages of drug development when these questions are asked, have driven change in clinical study design. Increasingly sophisticated data are now developed at earlier stages of drug development.

In the later stages of the development of successful drugs, the interval between PLA or NDA filing and product launch is not wasted. The term ‘phase IIIb’ has been invented for the conduct of phase IV-type studies during the pre-approval period. Furthermore, in some companies, the old ‘phase IV’ is now divided into phases IV and V, without any generally agreed definitions except, perhaps, that the studies are run by different teams.
Quite apart from these general trends blurring the distinctions between phases I, II and III, there are (and always have been) sound medical or pharmacological reasons for doing so. Good examples might be the following:

- It would be unreasonable to study the pharmacokinetics of relatively toxic agents, at potentially therapeutic doses, in normal volunteers due to the near-certainty of the adverse events. Typically, this information can be gained in patients with diseases potentially responsive to these agents. Thus, the first-in-man studies in this case are ‘phase II’, using the classic nomenclature. Cytotoxic and antiviral drugs are two important classes of agent where this is commonly the case.

- There is little point in testing the tolerability of drugs in normal volunteers, when only patients with the disease of interest are able to demonstrate a relevant pharmacodynamic effect. The doses at which tolerability must be confirmed are unknown until the exposure of patients can indicate the doses that may be effective. The development of potent opioids such as alfentanil, sufentanil and remifentanil as anesthetic agents are a good example.

- There are some diseases which have neither animal model nor relevant pharmacodynamic or surrogate end point in normal volunteers. Such diseases may also alter the pharmacokinetics of the drug, thus invalidating anything that might be learned from normal volunteers. A good example is the migraine syndrome. No animal species has migraine, and normal volunteers cannot report an anti-migraine effect. Nausea, vomiting and gastric stasis are common during migraine attacks and may be expected to alter the pharmacokinetics and effectiveness of oral therapies.

There is nonetheless little hope that the phase I–III aphorism will die. Nevertheless, it is quite wrong to assume that these ‘classical’ terms and definitions still apply to how drugs are developed according to modern practice. The classical four-phase strategy of drug development is far too stereotyped, simplistic and pedestrian to have survived into the modern era of drug development. None of today’s successful companies actually use such a strategy. We are simply shackled with an outmoded terminology.

### 9.2 Concepts of bias and statistical necessities

Bias is a general consideration in clinical trial design, regardless of the type of trial being conducted. It is considered here as an overarching issue, to be applied to the systematic description of the types of study design considered below.

The word bias has many definitions, but in this context, it is best described as a distortion of, or prejudice toward, observed effects that may or may not truly be due to the action of the test drug(s). Many things can distort the true measurement of drug action, and bias is the trialist’s most unremitting enemy. This enemy comes from many quarters (Table 9.1). The clinical trialist must be sufficiently humble to realize that he or she, himself or herself, may be a source of bias.

The pharmaceutical physician may not be expected to be a specialist statistician, and statistics are not the subject of this chapter. However, the ability to talk to and understand statisticians is absolutely essential. *Sine qua non*: *Involve a good statistician from the moment a clinical trial is contemplated*. Furthermore, the pharmaceutical physician should be confident of a sound understanding of the concepts of type I and type II error, and the probabilities \( \alpha \) and \( \beta \) (e.g. Freiman *et al.*, 1978). This is one of your best defences against bias.

### 9.3 Prospective definitions: the only way to interpret what you measure

It does not require a training in advanced statistics to hold a common sense and accurate approach to creating clinical hypotheses, translate them into the precise quantities of a measured end point and then
to interpret the results. Although the finer points of
statistics are presented elsewhere in this book, it is
common sense that the only way to interpret what
you measure is to define this whole process before
the experiment starts.

Thinking carefully about what might actually
constitute an observed response before you mea-
sure it removes at least one important source of
bias. That bias is the clinical trialist himself/herself.
There has been too little emphasis in recent
years on the fundamentals of end points, their
variability and how they are measured. Further-
more, the relationship between what is measured
and its clinical relevance is always debatable: the
tendency is to measure something that can be
measured, rather than something that needs valida-
tion as clinically relevant. Good examples include
rheumatological studies: counts of inflamed joints
before and after therapy may be reported, but do
not reveal whether the experimental treatment or
the corresponding placebo caused some of the
patients to recover the ability to write or others
the ability to walk (Chaput de Saintonge and Vere,
1982).

Most clinical trialists experience the urge, espe-
cially in early studies, to collect every piece of data
that they possibly can, before and after every drug
exposure. This urge comes from natural scientific
curiosity, as well as a proper ethical concern,
because the hazard associated with clinical trials
is never zero. It behooves us to maximize the
amount of information gained in return for the
risk that the patient takes for us, and for medicine
in general.

Consequently, large numbers of variables are
typically measured before and after drug (or
placebo) administration. These variables all exhibit
biological variation. Many of these variations have
familiar, unimodal, symmetrical distributions which
are supposed to resemble Gaussian (normal), Chi-
squared, f, binomial and so on, probability density
functions. An intrinsic property of biological vari-
ables is that when measured one hundred times,
then, on the average and if normally distributed,
5% of those measurements will be more than ±2
standard deviations from the mean (there are corol-
laries for the other probability density functions). This
meets a typical, prospective ‘p < 0.05, and
therefore it is significant’ mantra. It is also true
that if you measure one hundred different variables,
on two occasions only, before and after administra-
tion of the test material, then, on the average, 5% of
those variables are going to be significantly different
after treatment (this masquerades sometimes in

<table>
<thead>
<tr>
<th>Table 9.1</th>
<th>Some example sources of bias in clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poorly matched placebos subtle or obvious non-randomization of patients</td>
<td></td>
</tr>
<tr>
<td>Failure of double-blinding, for example when pharmacodynamic effects cannot be controlled</td>
<td></td>
</tr>
<tr>
<td>Prompting of prejudiced subjective responses non-uniform medical monitoring</td>
<td></td>
</tr>
<tr>
<td>Protocol amendments with unequal effects on treatment groups</td>
<td></td>
</tr>
<tr>
<td>Peculiarities of the study site itself (e.g. psychotropic drug effects in psychiatric institutions which fail to predict effects in out-patients)</td>
<td></td>
</tr>
<tr>
<td>Differing medical definitions across languages, dialects or countries (e.g. ‘mania’)</td>
<td></td>
</tr>
<tr>
<td>CRF with leading questions, either toward or away from adverse event reporting</td>
<td></td>
</tr>
<tr>
<td>Informal, ‘break the blind’ games played at study sites</td>
<td></td>
</tr>
<tr>
<td>Selective rigor in collection and storage of biological samples</td>
<td></td>
</tr>
<tr>
<td>Selectively incomplete data sets for each patient</td>
<td></td>
</tr>
<tr>
<td>Inappropriate use of parametric or non-parametric statistical techniques</td>
<td></td>
</tr>
<tr>
<td>Failure to adequately define end-points prospectively, and retrospective ‘data dredging’</td>
<td></td>
</tr>
<tr>
<td>Acceptance of correlation as evidence of causation</td>
<td></td>
</tr>
<tr>
<td>Averaging of proportionate responses from non-homogenous treatment groups, also known as Simpson’s paradox (see Spilker, 1991)</td>
<td></td>
</tr>
<tr>
<td>Unskeptically accepting anecdotal reports tendency to publish only positive results</td>
<td></td>
</tr>
</tbody>
</table>

CRF: case report form; the term ‘controlled’ is used in its technical sense (see Section 9.2 of this chapter).
findings among ‘selected secondary end points’). A sound interpretation, of course, is based upon only those end points that were selected before the experiment began, and comparing these with those for which no such statistical differences were found.

9.4 Historical clinical trials

Any general work must include these classic bits of history. Perhaps unusually, clinical trials appear to be a European scientific invention. There is no evidence that either the ancient world or the mediaeval Arabs carried out prospective studies (although there are some anachronisms in recent fiction). Sir John Elwes of Marcham Manor (Berkshire, now Denman College of the Women’s Institute) was a famous miser. After injuring both legs, Elwes gambled with his apothecary that the latter’s treatment of one leg would result in slower healing than the other leg which would be left untreated. The apothecary duly lost his fee with a wound that took an extra two weeks (Milledge, 2004). The precise date of this clinical trial is uncertain, but it must have been close to what is generally accepted as the earliest clinical trial, conducted by Lt. James Lind, RN.

Thomas (1997) has pointed out that sailing men-of-war frequently went many months without docking (for example, Nelson spent 24 unbroken months on HMS Victory while blockading French ports, and it is said that Collingwood once went 22 months without even dropping anchor). Scurvy was rampant in the Royal Navy, often literally decimating ships’ crews. Sailors survived on the poor diets carried aboard for long months, with water-weevils and biscuit-maggots constituting important dietary protein! Before Lind’s time, the Dutch had already learned to treat scurvy by replenishing their ships at sea with fresh fruit and vegetables. This was also known by Cook; when in command of H.M. Barque Endeavour, men were flogged for not eating their vegetables.

Lind had been pressed into the Royal Navy as a Surgeon’s Mate in 1739 and with some experience as an apprentice surgeon in Edinburgh. It is a nice irony that the first prospective clinical study with $n > 1$ was actually conducted by a surgeon!

The clinical trial was held at a single site, H.M.S. Salisbury, a frigate in the English Channel during the early summer of 1747 (Lind, 1753; Frey, 1969; Thomas, 1997). The experimental controls included that all 12 patients met the same inclusion criteria (putrid gums, spots on the skin, lassitude and weakness of the knees). All patients received the same diet except for the test materials. All treatments were administered simultaneously (parallel group). Compliance with therapy was confirmed by direct observation in all cases. The trial had six groups, with $n = 2$ patients per group.

The test medications were (daily doses): (a) cider (1 quart), (b) elixir of vitriol (25 drops), (c) vinegar (two spoonfuls plus vinegar added to the diet and used as a gargle), (d) sea water (‘a course’), (e) citrus fruit (two oranges, plus one lemon when it could be spared) and (f) nutmeg (a ‘bigness’). Lind noted, with some disdain, that this last treatment was tested only because it was recommended by a surgeon on land. The famous result was that within six days, only 2 of the 12 patients had improved, both in the citrus fruit group, one of whom became fit for duty and the other at least fit enough to nurse the remaining 10 patients.

We should note the absence of dose standardization and probably of randomization because Lind’s two seawater patients were noted to have ‘tendons in the ham rigid’, unlike the others. However, the result had been crudely replicated by using $n = 2$ in each group. If we accept that the hypothesis was that the citrus-treated patients alone would improve (Lind was certainly skeptical of the anecdotal support for the other five alternative treatments), then, using a binomial probability distribution, the result has $p = 0.0075$. But statistics had hardly been invented, and Lind had no need of them to interpret the clinical significance of this brilliant clinical trial.

Lind was not quick to publish his most famous treatise reporting this clinical trial (Lind, 1753). Indeed, in 1748, his Edinburgh MD thesis was on an entirely unrelated subject. Subsequently, Lind was Treasurer of the Royal College of Surgeons of Edinburgh, and then appointed physician to the Royal Naval Hospital, Haslar (a fifth of his first
6000-odd admissions were for scurvy). He subsequently developed a large private practice, but little fame amongst his peers, and was buried at Gosport in 1794. The Royal Navy was even slower to act on his findings, not instituting citrus juice in sailors’ diets, until the year after Lind’s death, following much administrative resistance but no scientific controversy (Bardolph and Taylor, 1997). The British, especially those in the Royal Navy, are still known as ‘limeys’, which is the unique example of a national nickname based on a therapy proven by clinical trial.

Thus, Lind illustrates some other aspects of clinical trials: first, he had little academic kudos, although he was clearly qualified by experience and training (a requirement of trialists by law in the United States). Second, he did not publish his results rapidly. Third, his results were not implemented promptly in the interests of the public health. It is important to realize that these undesirable aspects of clinical trials persist to this day.

9.5 Limitations of controlled clinical trials

Progress in therapeutics has not always arisen from controlled clinical trials. Chance observations have historically led to huge advances. Today’s three most commonly used cardiovascular drugs are good examples: digoxin is a component of digitalis (famously reported by Withering after observing the treatment of a dropsical lady by a gypsy), aspirin is derived from the willow tree bark first reported by the Revd. Edmund Brown to treat his own malarious fevers, and warfarin is the result of a University of Wisconsin investigation into a hemorrhagic disease of cattle. Lest we forget, Jenner’s experiments would be ethically impossible today: they included deliberate exposure to smallpox, and aspirin is a drug that would probably fail in a modern preclinical toxicology program due to chromosomal breaks and gastrointestinal adverse effects due to systemic exposures in rodents. Modern clinical trials are therefore not necessarily the holy grail of therapeutic progress.

Statistical theory must also be held not only with respect but also with healthy skepticism. It should be remembered that the development of statistics, as they have come to be applied to clinical trials, has arisen from a variety of nonmammalian biological sources. Experimental agriculture stimulated the early giants (Drs. Fisher and Yates) to explore probability density functions. While epidemiological studies have confirmed much that is similar in human populations, it is unknown whether these probability density functions apply uniformly to all disease states. Any statistical test that we employ makes assumptions that are usually not stated.

9.6 The clinical development plan

It is impossible to consider clinical trial protocol design in isolation. All clinical protocols should be written after a clinical development plan has been agreed by the diverse membership of the clinical development team. The clinical development plan should itself follow the construction of a hypothetical drug label. The goals of such a plan might be as limited as to provide for the start of phase II, or as complex as mapping an entire route from first-in-man studies to product registration. The path from the present status to the overall goal can then be understood. It may be added that, within a large company, this is also a good way for clinical and marketing departments to communicate.

9.7 Protocols, case report forms, and investigators’ brochures

Other chapters describe the regulatory governance of clinical trials, and little needs to be added here. These clinical trial documents are central to these processes. Equally, the regulatory requirements (which still vary from country to country), and the documents needed to support them, must be taken into account when constructing the clinical development plan.
9.8 Objectives and prerequisites of phase II studies

Gallenical forms

A good rule of thumb is that pivotal clinical trials for registration purposes ought to be conducted with the same formulation and manufacturing process that is proposed to be taken to market. Although the nuances of pharmaceutical constructs are described in Chapter 5, it is important to understand the sometimes grave consequences when this rule of thumb is not observed.

Most regulatory authorities will want reassurance that the pharmacokinetic (PK) properties of the marketed product closely resemble those in which the pivotal studies are carried out. This is not unreasonable: if the PK properties differ, then so may dose size and frequency. Occasionally, a phase III study will be 'bridged' to the marketed formulation by the demonstration, for example, that two different tablets have the same PK profile. However, the risk is that different formulations will not turn out to possess the same PK profile: either new pivotal studies will have to be conducted with the new formulation or registration will be delayed until the new formulation is adapted so that it does match the phase III test material. For inhaled drugs, this is especially difficult. Time and money is often lost in both cases. It is a risky gamble to leave development of the final formulation until the end of a clinical development plan.

Informed consent

This is considered in detail in Chapter 7. The clinical trialist should remember, however, that he or she ultimately carries the ethical responsibility for this document, regardless of what corporate lawyers and others may wish to do with it. Typically, Institutional Review Boards in the United States are more likely to be tolerant of long forms than ethics committees in Europe.

Toxicological coverage is covered in more detail in Chapter 6. However, the clinical trialist is encouraged to consider this for every protocol. A useful method is to start with the general case:

What is the relationship between duration and dose sizes of animal studies and the clinical protocol-specified dose size and duration? This exercise ought to be conducted using methods that standardize both for body weight and body surface area across species. Next, review closely all the prior human exposure to the test drug (if any) to see whether any unexpected signals for investigation may be found. Lastly, consider from the known pharmacology of the drug whether there are likely to be any particular tolerability issues for which special monitoring methods are needed, and think laterally.

For example, what is likely to be the adverse effects of a potassium channel-blocking drug being investigated for a central nervous system indication? The answer may lie in all the excitable tissues that contain potassium channels. Is there any preclinical evidence that the drug discriminates between potassium channels in different tissues? Are there changes in the EEG or ECG that may be found in the nonhuman database or among prior human exposures to the test agent that escaped being reported because ‘not thought to be clinically significant’?

9.9 Common phase II/III study designs

Many initial studies are conducted in an uncontrolled fashion. Eminent professors will treat a few of their patients with a test medication (perhaps under an investigators’ IND in the United States) and form opinions about the worth (or otherwise) of a new therapy. Although this may be grist for the mill of press releases and fund raising for small companies, these uncontrolled observations often mistakenly become a cast-iron credo for the sponsoring company. An observed effect – any effect – is viewed as better than none, and the relative lack of scientific controls permits large biases to arise.

The first risk from this haphazard start to clinical development is that potentially good options for a test compound may be needlessly rejected. The professor’s patient population may not include a disease state or disease subtype for which the new drug is actually well suited. Equally, efficacy and
tolerability may be dose-dependent, and this can only be assessed when studied in a systematic fashion. Lastly, most drugs are just one of a series of compounds which share closely related properties in preclinical testing. It is impossible to know which of these is the most promising, when only one has been tested.

Assuming that reasonable tolerability, reasonable understanding of pharmacokinetics and (preferably) a relevant pharmacodynamic effect has been observed in normal volunteers (see Chapter 8), then the first task is to reassess all of these in a relevant disease state. This is slower and uses more patients than the professor’s uncontrolled observations. But at the end of a small number of such small studies, there ought to be good information about the feasibility of a pivotal clinical trials program and, if not, then the feasible course corrections (e.g. alternative indications). Note that one such course correction may be ceasing to develop the drug, and switching to another member in the series. Arguably, the appropriate ‘killing’ of drugs is the most valuable thing that a phase II program can accomplish before too much time and money has been wasted.

When choosing a clinical trial design (Table 9.2), economic factors include numbers of patients, time that will elapse, drug supply and total cost. Although these economies are important and relevant in all design choices, they should also be factored against the end points that may or will be measured. The relevance of an end point and its sensitivity to detect a drug-related effect may be primarily dependent upon the duration of patient exposure. For example, a short period of observation is unlikely to detect a difference in time to next seizure in a study of antiepileptic drug with an add-on design in patients who are only moderately disabled by epilepsy. On the other hand, the identification of a PK interaction between a new and an established therapy in the same population may only require very short observation periods.

There are several common classes of study design. These classes apply to almost all phases of drug development. No list of trial designs can be

### Table 9.2 Basic trial designs and the factors that are suited and unsuited to each

<table>
<thead>
<tr>
<th>Trial type</th>
<th>Factors suited</th>
<th>Factors unsuited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parallel-group, single</td>
<td>Episodic disease</td>
<td>Rare disease</td>
</tr>
<tr>
<td>treatment</td>
<td>Imperfect placebo matching</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blinding difficult (e.g. surgical procedures, psychotropic drugs)</td>
<td></td>
</tr>
<tr>
<td>Parallel-group, chronic</td>
<td>Stable disease state</td>
<td>Unethical to use active comparator or placebo</td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td>Untreated washout not ethical</td>
</tr>
<tr>
<td>Crossover with washout</td>
<td>Stable disease state</td>
<td>Complicated tolerability profile</td>
</tr>
<tr>
<td></td>
<td>Ethical to use placebo after active</td>
<td>Many concomitant disease factors</td>
</tr>
<tr>
<td>Sequential</td>
<td>Rare disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Homogeneous disease state</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urgent need to save life</td>
<td></td>
</tr>
<tr>
<td>‘N of 1’</td>
<td>Stable disease state</td>
<td>Few or no feasible alternative therapies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tolerability issues not closely related to efficacy variable</td>
</tr>
<tr>
<td>‘Large simple’</td>
<td>Very common disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Easily measured end-points</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Well-understood drug</td>
<td></td>
</tr>
<tr>
<td>Open label</td>
<td>Tolerability issues only</td>
<td>Spontaneous adverse event frequency high</td>
</tr>
<tr>
<td>Within-patient dose ranging</td>
<td>Stable disease state</td>
<td>Drug tolerance</td>
</tr>
<tr>
<td>Combination therapy</td>
<td>Intolerable high initial dose</td>
<td>Unethical to use single therapy</td>
</tr>
<tr>
<td></td>
<td>A priori reason to expect favorable drug interaction</td>
<td></td>
</tr>
</tbody>
</table>
exhaustive, because almost all clinical trials are different. What follows is an attempt to briefly review the classes of clinical trial design that will encompass a large majority of studies, and to comment on their economy and end point possibilities.

Parallel-group studies are typically thought of as the most straightforward design case. In fact, a bewildering array of variations exists within this class.

In the simplest case of parallel-group study, a group of patients presenting sequentially are randomized to one of two equally sized treatment groups, until a prospectively determined total number of patients has been recruited. All these patients are followed for a predetermined period of time, or until some end point is achieved. The database is quality assured and locked before the randomization code is broken. The patients are then sorted according to their treatment, the end point measurements are subjected to a statistical test and an interpretation of the effect (or absence thereof) of the drug is made. What could possibly go wrong?

The answer is that little can go wrong when there are ample patients, plenty of drug available, the choice of dose size has been perfect, the end points are incontrovertible, the measurements are possible using a rational or absolute scale, there is ample toxicological coverage for all the dose sizes employed and the trialist has an unlimited budget! This combination of Utopian conditions never exists.

The ascending dose-ranging cohort design is one variant within the parallel-group class. It is best suited when there is no cast-iron assurance of tolerability for all the dose sizes of interest. Patients are randomized in cohorts to either active or placebo treatment; frequently there are fewer placebo-treated patients in each cohort.

The objective is to cumulate tolerability experience as dose size gradually increases. If the treatments in the first cohort prove to be well tolerated, then the next cohort is randomized in the same way except that the active-treated patients receive a larger dose size. Note that this judgment can be made without breaking the blind. A comparable number of placebo-treated patients to any single active-treatment group can be cumulated across several cohorts, each cohort having fewer placebo-treated patients in each cohort. This economizes on patient numbers in comparison to randomizing each cohort in a 1:1 fashion, and may also economize on both drug and patients if two doses are found to be similarly effective and well tolerated, albeit not the highest dose that was projected.

Sequential cohorts do not usually economize on time. Treatment codes can be broken at the end of each cohort (and not introduce bias into observations of succeeding cohorts). Sometimes, this can lead to early closure of the study when the desired pharmacodynamic effect is observed at a lower dose than the maximum projected by the study. However, the deliberations of safety committees at the end of each cohort can often be time-consuming.

Within-patient dose titration designs may be conceptualized as the application of an ascending dose cohort design within a single patient. The advantages of such designs are when immediate high-dose therapy is contraindicated for tolerability reasons, and when there is likely to be large variations between patients in the tolerability and efficacy of the test drug.

Patients are reviewed during and after completion of a course of therapy which may include programmed changes in dose size. If the drug is well tolerated they may progress to a course of therapy at higher dose. A prospective limit on dosing and the number of courses of treatment is made (e.g. according to toxicology coverage). Dosing may be curtailed at any time when either there is unreasonable intolerance of the drug, or when acceptable efficacy and simultaneous tolerability have been observed. This is not unlike the approach to therapy under ordinary clinical circumstances. For example, patients with epilepsy are often treated by dose alterations. Another advantage of this design is that at the end of the study, the range of tolerated and efficacious doses can be examined among all treated patients in comparison to demographic factors, disease subtypes and so on.

The greatest difficulty with ascending-dose, within-patient designs is usually in treatment masking. Double-blind requirements have to take into account a wide variety of dose sizes, and that contemporaneous placebo formulations will be needed. Some studies of this type are hybridized with a crossover strategy (see below). Dose tailing at the end of the study may be viewed as the same
procedure in reverse, although may be conducted open-label and more rapidly (guided by suitable PK information) than when therapy is being introduced.

Sources of bias in this study design arise from the exposure of patients to lower doses first. Patients obligatorily must tolerate, and fail to respond to, lower doses before being exposed to higher doses. Any degree of treatment familiarization, tachyphylaxis or patient withdrawal rate biases dose–response curves to the right (i.e. tend to overestimate the ED50) in comparison to a parallel-group study in the same patients with the same end points.

**Crossover studies**

Generally, crossover studies are more complicated than parallel-group designs. Patients are exposed to more than one test medication, in sequential treatment periods, perhaps with periods of no therapy intervening between those of active therapy. Active therapies may be different drugs, or different doses of the same drug, or, in complicated studies, both.

The most famous problem is eliminating carryover effects (‘washout’). Ideally, end points should be measured and unambiguously attributable to one of the test regimens. This requires no residual effects of the previous regimen(s) (see Laska et al., 1983). If this involves intervening placebo treatment periods in between test medications, then clearly this approach is not possible when placebos are ethically unjustifiable.

Usually, patients are randomized to a particular treatment order, and all patients are eventually exposed to the same variety of treatments. Large numbers of treatment periods, assigned using a Latin square, have been reported; however, the logistics and patient retention in such studies are usually difficult, and these ideal designs are likely to be successful only when treatment periods are short; ideal designs are commonest for normal volunteer studies (e.g. Amin et al., 1995).

In later phase studies, if there are still numerous treatments or dose sizes that need to be tested, then ‘partial crossover’ designs can be used. These expose patients to a random subset of all the study treatments, again in a random order. ‘Partial crossover’ designs necessarily require the availability of large numbers of patients. However, there can be economies of the amounts of test drug needed, and the time needed to conduct the study in comparison to an equivalent, complete, crossover design. Shorter durations of patient participation are also usually associated with less missing data and fewer patients lost for administrative reasons. Overall patient recruitment is more efficient.

Clinical trialists should be wary of using randomized, crossover designs when there are likely to be appreciable numbers of patients who are withdrawn before completing the study. This can cause serious imbalance among treatment groups and seriously jeopardize the likelihood of achieving a statistically robust result. Crossover studies with three or more periods have a substantial advantage over two-period designs, when the amount of missing data is likely to be large and statistical salvage is necessary (Ebbutt, 1984).

**9.10 Minimization trials**

Less common are trial designs that specifically and adaptively minimize the number of patients needed while preserving design integrity for appropriate statistical analysis. Early ‘Evolutionary’ designs are now being succeeded by independent treatment allocation in pursuit of this goal. All minimization designs involve arduous statistical planning, and the clinical trialist should seek expert help from the outset.

Evolutionary designs were devised by Dixon and Armitage. Although the statistical analysis is rather different, they have the same objective, which is to detect a treatment effect at the earliest moment possible, using the fewest possible patients, while retaining statistical robustness. Both types are suited for exploratory clinical research and diseases which are rare.

The Dixon ‘Up-Down’ technique was first described in the statistical literature in 1947. It is designed to estimate an ED50 in clinical trials or toxicological tests, when a quantal response is measured (see Figure 9.1). However, it should be
remembered that continuous responses can be converted into quantal responses with appropriate, prospective efficacy criteria. For example, blood pressure is a continuous variable, but a drug may be deemed effective or ineffective by stating prospectively that a desired response is quantal positive after a 15 mmHg fall in diastolic blood pressure within 60 days of commencing therapy. Theoretically, this strategy can be implemented with groups of patients treated in the same way instead of individuals. Sometimes, this technique is termed an ‘adaptive’ trial design, because dose size is adapted according to the response of the previous patient or group of patients.

The Armitage technique or ‘sequential analysis’ was originally employed in the testing of explosive ordnance. Patients or groups of patients are paired and then treated with alternative therapies. A control chart is developed that records the result of each comparison with time, and crossing a boundary on the chart after an unpredictable number of paired comparisons gives the trial result. For a trial of a new therapy that can both benefit and harm the patient, a typical probability control chart forms a ‘double-triangle’ pattern, as shown in Figure 9.2.

The original methods have been extended in many ways. The design of control charts is always prospective, and their shape depends upon the \textit{a priori} expectations of the development team. For example, when it is important to test only the tolerability of a compound, the chart can have an ‘open top’: this is when it is important for the
development team to detect drug toxicity early, but not efficacy. Similarly, depending upon the hypotheses under test, control charts can be rhomboidal, parallelogram or of many other shapes. Whitehead (1999) is the best entry to the literature on this specialized topic.

**Contemporaneous independent treatment allocation**

Taves (1974) has described a study design that requires an independent coordinator who allocates each patient, as he or she is recruited to one or other treatment group. The independent coordinator allocates each patient so as to minimize the difference between the two treatment groups according to prospectively defined patient characteristics, for example, age, sex, genotype, disease state or stage, or concomitant therapy. This allocation is therefore also based upon the cumulating characteristics of the treatment groups as has developed during the study to date. Patients are therefore not allocated to a treatment group by the chance of a randomization schedule.

Bias in minimization trials can be avoided when three conditions are met. Firstly, those performing the clinical trial itself, that is administering test medications and measuring end points, should be double-blind and unaware of which treatment the patient has received. Secondly, the independent coordinator need only allocate patients to anonymous groups A or B, and the study pharmacist need be the only person who knows which treatments these codes represent. Thirdly, the criteria for which the treatment groups should be balanced must be prospectively identified and rigidly adhered to, using a recorded, quantitative system of scoring the factors.

In its simplest form, this class of minimization designs usually results in treatment groups of nearly equal size. By equitably assigning patients to three or more treatment groups, and yet having identical treatments for two or more of these, unbalanced sample sizes can be created. This is of use when, for example, it may be desirable to expose fewer patients to placebo than to active therapy, especially when conducting a trial of compounds whose properties are fairly well known or may be predicted with some confidence.

Note that minimization trials can only alter power calculations when assumptions of the size of worthwhile differences in effect are also prospectively defined. For example, from a clinical point of view, a small-sized improvement in outcome (perhaps a few percent of patients more than that observed for placebo treatment) may be viewed as very worthwhile in an extremely heterogeneous patient population when subjected to multivariate analysis (this is common in large, simple studies; see below). On the other hand, when designing a minimization study, the assumption is that the treatment groups will be devoid of relevant differences in baseline characteristics and, therefore, clinical significance might only be assumed to follow from a large-sized difference in patient response. The size of the difference that is assumed to be of interest, as it increases, may compensate for the reduction in variability amongst study group samples, and thus have less than expected impact on the sample sizes needed to conduct the clinical trial.

Minimization designs are probably under-used by the pharmaceutical industry. This approach is not well designed for pivotal clinical trials nor for diseases with large numbers of prognostic factors, where, in any case, large numbers of patients are especially needed for a tolerability database. If the controlled clinical trial is a gold standard, then it would be wrong to assert that the independent treatment allocation design is the ‘platinum standard’ (pace Treasure and MacRae, 1998). The interested reader is referred to a good published example (Kallis et al., 1994), and to more detailed statistical treatments (Pocock and Simon, 1975; Freedman and White, 1976).

### 9.11 The ‘large simple study’ and stratification designs

These similar classes of study require large numbers of patients. The choice between them lies in being able to ‘hedge one’s bets’ with a partial indication approval, versus ‘all or nothing’ with huge logistical costs and potentially huge rewards.
Stratification studies

In pivotal studies, large numbers of patients are studied so that their diverse clinical characteristics can imitate better the ordinary patient population than in earlier, more selective trials. When a variety of concomitant factors (e.g. other diagnoses, wider degree of disease severity, concomitant medications, etc.) are suspected, and may interact with drug tolerability or efficacy, then patients may be stratified into randomization groups according to the presence or absence of such factors. For example, patients with Crohn’s disease might be stratified according to whether or not they also have cutaneous manifestations, and each stratum then randomized to active or placebo for a total of four treatment groups, although with only two test treatments. Separate statistical analyses for the strata can then be planned, and the study size adjusted accordingly. The efficacy of the new drug may be found to be restricted to a (some) particular patient subset(s). Regulatory authorities will often approve indications with caveats based on such subsets. For example, in the United States, one indication for aprotonin is ‘...to reduce perioperative blood loss ... in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high, for example impaired hemostasis, presence of aspirin or coagulopathy of other origin’. The risk of stratification studies is that conservative regulatory authorities will want to see statistical significance in all patient subsets before allowing a short, broad indication in labeling.

The ‘Large, simple study’ is a recently recognized alternative to stratification, pioneered by Peto. Large numbers of unselected patients are subjected to a single randomization. If enough patients are recruited, and if the randomization is truly unbiased, then the large sample sizes will allow all the potentially interacting variables (concomitant drugs, concomitant diseases, demographic variables, etc.) to balance out between the treatment groups.

The ‘simple’ part of this approach is that, in fundamental terms, the case report form can be very short. There is no need to collect lots of information about the patient’s clinical condition because there is no use for these data. Trials of cardiovascular drugs, on an almost epidemiological scale, have been the most significant example of this alternative approach. Literally, tens of thousands of patients have been recruited under these protocols with case report forms having fewer than 10 pages for each patient. Dr Robert Temple (1997; Director of the Office of Drug Evaluation I, at FDA) has commented that it may even be possible to conduct large simple studies in treatment IND situations, thus permitting the generation of efficacy data outside of orthodox ‘phase III’ clinical trial programs. However, in this case the end point would have to be just as simple, for example, survival or death of the patient, during a documented period of observation; Kaplan-Meier analysis and other epidemiological approaches may also be applied to such databases.

Although the conditions under which large simple trials can provide efficacy data are fairly well worked out, it is important to consider whether (or which) tolerability issues can be precisely addressed in this way. If a tolerability factor (adverse event) relates to the efficacy variable of interest (e.g. a fatal adverse event in a patient survival study), then a simple case report form may provide relevant information. However, if the adverse event type is rare or unanticipated (e.g. the test drug causes unanticipated, significant anaemia in 0.1% of patients, and the protocol and case report form do not collect hemoglobin values before and after treatment), then it is very likely that the adverse event will be missed. Large simple studies can thus create undue confidence in product tolerability (‘thousands of patients were exposed to the agent during clinical trials’).

9.12 Treatment withdrawal and other specialized designs

There are rare cases where established treatments are without strong evidence-based support. Two good examples exist for digoxin: the treatment of mild heart failure and the treatment of cardiac asthenia, a diagnosis that is especially common in Europe, and for which relatively small doses are prescribed. When the effect of such treatments on
the natural progression of disease is unknown, then it can be ethical to recruit patients into a study with inclusion criteria that include that they are already being treated with the drug of interest. Almost any of the designs discussed above may then be used, where patients are randomized either to remain on the treatment of interest or to be withdrawn from that treatment. All the usual needs for precisely defined prospective end points and sound statistical advice before starting the study apply.

Early-phase clinical trials in patients with cancer often use a two-stage design that has been promoted by Gehan and others (Gehan, 1979; Ellenberg, 1989). With progressive, fatal diseases, the problem of preventing an untoward number of patients from being treated with a useless therapy increases. These two-stage designs usually include a small number of open-label treated patients (usually $n \leq 14$) in the first stage. The proportion and degree of tumor responsiveness are then used to fix the number of patients in the second stage of the design which may use an active comparator or no therapy as the alternative treatment, depending upon whether an active comparator therapy can be identified. Such studies cannot produce fundamental evidence of efficacy, but in the hands of experienced statisticians and development teams can predict whether wider trials are justified.

### 9.13 Stopping clinical trials

#### Safety issues

Stopping a clinical trial because of an emergent safety problem, either by a medical monitor or by a safety committee, is always a unique situation. Little useful, generalizable guidance can be provided here. These are decisions that are always taken in consultation, and the safety of potential future trial recruits must be the paramount concern (including the abrupt cessation of therapy). Trial suspension is usually the best immediate option, allowing time for collective thought, notification of regulatory authorities and wider consultations as appropriate.

#### Efficacy issues

Pocock (1992) has succinctly summarized most of the situations that obtain when it is considered whether to stop a clinical trial. Efficacy, like safety, can cause ethical concerns to the pharmaceutical physician when he or she suspects that patients will be exposed to alternative therapies which are suboptimal.

Interim efficacy analyses usually make a mess! These analyses require either that the overall size of the trial has to be greater than if no interim analysis was performed, or that a smaller $\alpha$ must be accepted as indicating statistical significance at the end of the whole study.

Pharmaceutical physicians will hear loud complaints about these drawbacks of interim analyses, especially from senior management with purely commercial backgrounds. Everyone will want to know as soon as possible whether ‘the drug is working’, but lax scientific thinking is behind these complaints. Common statements are: ‘We don’t want to stop the study at the halfway stage, we just want to see how it is going’. When asked why, the answer is usually something like: ‘There would be no point in spending more money on the study if there is no chance of achieving a statistically significant result’. This is a popular misrationalization: the decision not to stop a study is a decision to allow it to continue. Any interim decision introduces a bias on the dataset that is eventually analyzed.

Spectacularly effective drugs may achieve a very small $\alpha$ at the time of the interim analysis. Stopping the trial by reason of the unethical basis for treating the patients with anything else is a rare and pleasant event for the clinical trialist. However, in that spectacular success, the pharmaceutical physician should ask whether a minimization design would have achieved the same thing with even fewer patients, and thus actually feel chastened.

It is not the purpose of this chapter to delve into the mechanics of statistics. However, a few comments about the relationships between values for $\alpha$ at the stage of an interim and complete statistical analysis of a clinical trial may be in order. There are several statistical points of view on this subject, and
regulatory authorities have a habit of believing only the most conservative.

At the time of writing, the O’Brien and Fleming rule is becoming an acceptable standard. As a rule of thumb, pharmaceutical physicians should expect statisticians to provide alternatives that obey a simple subtraction rule. For example, clinicians might agree that the study should stop due to great efficacy when \( p = 0.01 \) at an interim analysis, when sufficient patients (power of 0.8) to detect such a difference have been recruited. In that case, if the study continues after the interim analysis fails to achieve \( p < 0.01 \), then it will be required to achieve approximately \( p < 0.04 \) for the whole patient population in the final statistical analysis in order to demonstrate the efficacy of the test drug. Even so, Pocock and Geller (1986) have shown that trials stopped by reason of efficacy at an interim stage are likely to have exaggerated the size of the difference between treatment groups. Marketing departments should be aware of this error in their extrapolations to the commercial worth of the product.

9.14 Bayesian trial designs

A typical Bayesian design might be where, for example, there are several drugs with preclinical rationale for the treatment of cancer; as none of them are clinically proven, one of the test treatments is placebo. Patients are then recruited sequentially into the study, and the results (e.g. tumor size reduction) are recorded. After a while, the proportions of patients responding to each treatment are compared using a sophisticated probabilistic method which takes into account the uncertainties associated with small and unequal treatment group sizes. The randomization code is then adjusted to favor more patients being allocated to the treatments that have started out looking better than the others, while very poor, placebo-equivalent treatments might be dropped altogether. Eventually, the several test therapies are reduced to two, and a definitive demonstration of superiority or nonsuperiority for that pair of treatments can be reported.

The difficulties with interim analyses do not arise when a Bayesian approach to the original design has been taken (Berry, 1985). The Bayesian methodology essentially revises the proportionate patient allocation among the test therapies according to the latest and best information available (e.g. Berry, 1995): essentially, after some minimum number of patients have entered the trial, an interim analysis is done every time another patient completes the trial. The important distinction between Bayesian and sequential designs (above) is that although patient numbers required to complete a sequential design study are undefined at the beginning, the treatment allocations are nonetheless according to a fixed randomization schedule. Thus, the sequential designs are still, essentially, a frequentist methodology, and not Bayesian.

Bayesian approaches currently find little understanding on the part of regulatory authorities, and thus are, probably unduly, little utilized by clinical trialists. However, Bayesian methods are finding increased uses in specialized areas, for example, trials of cancer chemotherapy and studies in rare disease. The potential benefits of Bayesian methods include the use of fewer patients to demonstrate efficacy, as well as potential seamlessness of phase II and phase III development when the number of drugs or dose sizes of interest has been reduced during the trial from several to one or two; patients recruited after this transition may be regarded as patients in a pivotal trial by an enlightened regulatory authority.

The generalist cannot be expected to be able to generate Bayesian statistical plans for himself or herself. These require an experienced statistician, and it may be added a statistician who is not, himself or herself, philosophically opposed to Bayesian rather than frequentist thinking. The decision to employ a Bayesian design for a clinical trial will be viewed as courageous in most companies, and there will be many clinical trials for which an orthodox, frequentist approach will be selected for several good reasons. Overall, the generalist should be advised that, when considering a new trial, he or she should at least consider whether a Bayesian approach might help. If this option is rejected then that is fine, but the brief consideration,
as a matter of routine, might occasionally lead to a superior trial design.

### 9.15 Series of published cases

Some diseases are so rare that the prospects of conducting a clinical trial are remote. It is unlikely that enough patients could ever be collected at any reasonably small number of study sites for any useful randomization. These diseases may be found in the literature as case reports. In these cases, probably the best that can be accomplished is to collect and retrospectively analyze as many such cases as possible. If the drug of interest has been used in a sufficient number of patients, then retrospective risk ratios for benefit and harm can be calculated. This may be the strongest evidence that can ever be collected about a particular drug under these rare conditions, albeit never as strong as a controlled clinical trial. One example is the effectiveness of dantrolene in malignant hyperthermia (Strazis and Fox, 1993).

### 9.16 Objectives and prerequisites of pivotal clinical trials

Licensing requirements typically are greater than reporting data from multicenter ‘phase III’ studies. Special populations may require small-scale studies to supplement a traditional two-study, large-scale registration development scheme. Similarly, if (in the United States) the proposed indication has an approved Orphan Drug designation, then small-scale ‘phase II-type’ studies may be all that is possible due to disease rarity. Furthermore, even for conventional indications, the resource implications of pivotal studies are usually much greater than any earlier phase of development, and efficient resource utilization becomes exponentially more important than before. The incorporation of pharmacoeconomic and humanistic outcomes alongside the primary registration end points is becoming essential, and preparatory work is best done in conjunction with the smaller, earlier studies and must also factor treatment compliance.

### 9.17 Benefit–risk analysis

The cumulation of all the data from the clinical trials of a new drug product, assuming a fairly orthodox regulatory strategy for a typical dossier or NDA, will form the largest fraction of the application. However, these data are also needed for derivative documents within the application, one of which is a benefit–risk analysis, which forms the last part of an Integrated Safety Summary (Section 9 of the NDA), and is a central objective of the expert report in European applications. These benefit–risk assessments must be derived from the clinical study reports and summaries elsewhere in the applications.

All clinicians constantly weigh benefit–risk in their daily practice. Their assessment of this ‘ratio’ in everyday practice, using approved drugs, is usually not as numerical as it sounds. In practice, clinicians make prescribing decisions based upon (a) a subset of the published information that might be available about the drug (labeling, drug representatives, comments from colleagues, etc.), (b) their current and prior experience with this particular patient and (c) prior experience with other patients. This prior experience, even if personal, may or may not be consciously recalled. Furthermore, we all operate algorithms taught us by others whom we respect, and thus we use others’ experience with drugs and patients, quite apart from the often hard-learned lessons from our own therapeutic adventures (pace ‘evidence-based medicine’).

Clinical trialists also weigh benefit–risk every time a protocol is written. Often, unlike for approved drugs, there is much less information to go on. In early clinical development, extrapolations are obligatory. However, unlike in general medical practice, these extrapolations are often not from clinical experience, but rather from pharmacokinetic models or animal data, or at best from patients who are clearly dissimilar from that proposed in the new trial. This is obligatory: if the
answers to the clinical trial questions were known, then there would be little point in doing the trial.

There are highly mathematical approaches to benefit–risk assessment. When a single (binary) end point of interest can be balanced against a single adverse event of concern, then the number of patients required and the number of required therapeutic events can be defined, and the confidence intervals can be calculated to examine what the true benefit–risk ratio might be (e.g. for GUSTO, Willan et al., 1997). The number needed to treat, number needed to harm (and corresponding reciprocals) can be used to compare drugs for this purpose. However, this is a highly unusual and artificial situation, and the sophisticated statistical answers that result are unlikely to have more than a partial impact on the more nonnumerical approach taken by clinicians.

Usually, however, the clinical trialist has to stick out his or her neck, based upon a highly personal, nonnumerical assessment of benefit–risk. The highly mathematical approaches usually work best in retrospect, and this is the situation neither of the clinician who must decide whether to prescribe nor the clinical trialist who must decide whether to commit patients to a particular study design, both being prospective decisions. Furthermore, both in clinical trials and general medical practice, it is a rare situation where the benefit to the patient arises from a single binary variable, and there are no drugs which possess a single type of adverse event, whose probability may be confidently, prospectively estimated for any given patient. Even the simplest case, a drug with substantial history and experience, cannot fit the contrived mathematical approach described above. Penicillin has three adverse events of primary interest (anaphylaxis, bacterial drug resistance and sodium load at high doses). The mechanism by which infection recedes, if it is to recede, is only partly due to the action of the drug, because the extreme variability introduced by the concomitant condition of the patient. Whether to prescribe penicillin is a common decision for doctors and dentists: the mathematical analysis of the benefit–risk ‘ratio’ is unlikely to affect most prescribing decisions.

The informed consent document is where we ask patients to make their own benefit-risk assessments, albeit with some guidance (Marsh, 1990). Certainly, the mathematical approach cannot be expected on the part of the patient nor will it be useful in a balanced and fair communication with the patient about the nature of the clinical trial.

Benefit–risk, then, is a central part of the practice of pharmaceutical medicine and its regulation. It can almost never be reduced to a numerical exercise. Benefit–risk assessments of clinical trial data are an important part of all new drug applications. Good people will differ in their benefit–risk assessment even when using the same body of clinical trials data.

9.18 Summary

This chapter has attempted to provide a philosophy of clinical trials. The place of clinical trials in the overall development plan and what the clinical trialist must know about rather than be able to actually implement himself or herself has been emphasized. Almost all clinical trials are unique because of the infinite combinations of hypothesis to be addressed, pharmacological properties of the drug under investigation, the types of patients who are likely to be available and likely users of the resulting data. The major categories of trial designs have been surveyed in some detail; it is hoped that, when challenged with testing any clinical hypothesis, a good clinical trialist would consider all these broad categories, select that most relevant to the clinical situation and then refine the proposed trial design from that point. Some of the subtle interactions between statistical, financial and psychological aspects of trial design have been hinted at. The clinical trialist will only really grow in this discipline through experience and good mentorship.

References


10 Phase IV Drug Development: 
Post-Marketing Studies

Lisa R. Johnson-Pratt

10.1 Objectives of the phase IV clinical development program

Phase IV studies (in some companies subdivided into phases IV and V) are mostly conducted after initial product approval (although, occasionally, some may begin prior to product launch, with the risk that the product is not approved on schedule, but with the potential to gain a competitive advantage).

The range of purposes of phase IV studies is broader than earlier phases of drug development. There is usually no need to provide pivotal evidence of efficacy (unless a new, second indication for the drug is sought). Table 10.1 summarizes the typical goals and tactics of phase IV studies.

The phase IV studies in some companies are carried out by the original development team that also did phases II and III. Some companies view this as desirable because these are the people with that repository of information, for the entire history of the drug, who can spot or remember small events that might merit further study in phases IV and V. Some of those people will enjoy following the drug through its entire life cycle, and will be glad for that opportunity. However, others are either unwilling or unable to evolve from a more regulation-oriented to a more market-oriented approach to clinical trials, and when these are in the majority, some companies will then set up a separate department, and thus achieve an essentially phase-oriented departmental structure.

Types of phase IV studies

The typical characteristics of phase IV studies, in comparison with phases I, II and III, therefore are that they are larger, less technically complicated, have fewer inclusion/exclusion criteria and are more likely to include subjective or qualitative end points (e.g. quality of life or patient satisfaction). Rigorous, placebo-controlled, parallel-group studies still find a place, however, when a supplemental licence application for a new indication is being investigated. As a particular marketplace becomes more crowded, the competition for places in formularies and for reimbursements increases, and some phase IV studies are designed specifically to provide information for consumer and healthcare delivery organizations, whether nationalized or not; placebo-controlled studies are usually inadequate for this purpose (unless the product is unique). Table 10.2 summarizes some
of the nuances and challenges of conducting phase IV trials.

The type of investigator that one seeks during phase IV development must clearly correspond to the nature of the study. Usually, larger numbers of investigators who each contribute fewer patients than the phase II and III investigators are sought. If such individuals are local or national thought leaders, who will eventually advocate for the product, then so much the better. But even at the local level, it is these investigators who might be found on hospital formulary committees, develop local treatment algorithms, see high volumes of patients and are active in local medical societies.

**Comparative superiority trials**

Well-designed, head-to-head, active comparator studies are also always to be preferred over the

<table>
<thead>
<tr>
<th>Table 10.1 Typical goals and tactics of phase IV clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extension of tolerability information</td>
</tr>
<tr>
<td>Competitive efficacy claims</td>
</tr>
<tr>
<td>New indications</td>
</tr>
<tr>
<td>Ethnopharmacology</td>
</tr>
<tr>
<td>Outcomes assessment</td>
</tr>
<tr>
<td>Pharmacovigilance</td>
</tr>
<tr>
<td>Market expansion</td>
</tr>
</tbody>
</table>

The draft ICH Guidance on pharmacovigilance (ICH E2E, 11 November 2003) is likely to cause greater emphasis on the penultimate item in this list.

<table>
<thead>
<tr>
<th>Table 10.2 Practical aspects of phase IV clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of study</td>
</tr>
<tr>
<td>Active comparators</td>
</tr>
<tr>
<td>Obtaining active comparator drug</td>
</tr>
<tr>
<td>Blinding, reformulations and bioequivalence</td>
</tr>
<tr>
<td>Disclosure of trade secrets to competitors</td>
</tr>
<tr>
<td>Placebo-control justifications</td>
</tr>
<tr>
<td>Use of appropriate dose ranges</td>
</tr>
<tr>
<td>Risks demonstrating superiority of competitor</td>
</tr>
<tr>
<td>Equivalence trials</td>
</tr>
<tr>
<td>Usually large patient populations needed</td>
</tr>
<tr>
<td>Cannot demonstrate superiority</td>
</tr>
<tr>
<td>Scientific demonstration of a negative</td>
</tr>
<tr>
<td>‘Standard of care’ context challenged</td>
</tr>
<tr>
<td>Mega-trials</td>
</tr>
<tr>
<td>Statistical complexity</td>
</tr>
<tr>
<td>Few inclusion/exclusion criteria</td>
</tr>
<tr>
<td>Representativeness to treated population known only toward the end of the trial</td>
</tr>
<tr>
<td>Open-label</td>
</tr>
<tr>
<td>Prescriber and patient biases</td>
</tr>
<tr>
<td>Scientifically limited</td>
</tr>
<tr>
<td>New indication</td>
</tr>
<tr>
<td>Similarity to phase III designs (q.v.)</td>
</tr>
<tr>
<td>Drug interactions</td>
</tr>
<tr>
<td>Almost unlimited alternatives</td>
</tr>
<tr>
<td>Special patient populations</td>
</tr>
<tr>
<td>See other chapters</td>
</tr>
<tr>
<td>New formulations</td>
</tr>
<tr>
<td>Bioequivalence</td>
</tr>
</tbody>
</table>
meta-analytical comparisons of placebo-controlled studies of different drugs, which were conducted at different times and in different places. The general aim is to compare the new drug with a widely recognized ‘gold standard’. This ‘gold standard’ might be the prototypical drug in the same pharmacological class (e.g. a clinical trial comparing a new cephalosporin with an old one), or it could be an hitherto dominant therapy or procedure (e.g. comparing a proton pump inhibitor with an H₂ antagonist, or conservative management with a new drug versus surgery). Sometimes, a change in pharmaceutical formulation may have occurred, and, even after approval, there may be questions over its superiority, patient preference or economic advantage compared with the formulation that was initially approved (see Makuch and Johnson, 1986, 1989).

**Open-label studies**

Conducting open-label studies can be a liberating and fascinating experience. When both the patient and the prescriber know the treatment being administered, many of the complexities of early-phase studies go away. Furthermore, when it is appreciated that double-blind clinical trials are always an abstraction from the ordinary clinical situation, to observe how one’s new drug actually works in that latter environment is often eye-opening; one common and pleasant experience is to see with one’s own eyes how conservative was the estimate of product efficacy prior to its approval.

This ‘real-world’ environment can be studied at length and relatively cheaply, too. Longitudinal study designs (e.g. the Framingham Study or the UK Physicians Cohort Study) can assess multiple effects of treatment: pathological, economical, quality of life and even epidemiological impacts can be assessed. One can also find out what sort of patient one’s drug will be prescribed to, which may or may not resemble the patient population pre-PLA/NDA, and which may suggest unknown benefits and hazards of the new therapy.

The open-label trial approach is, however, not without its critics. Friedman *et al.* (1985) drew attention to the need to observe whether

- the cohort being followed represents the larger population for whom the drug is being prescribed;
- the treatment groups are truly comparable, as patients are often matched on only one or at most a small number of clinical characteristics.
- the need to check that randomization, or at least patient allocation, has not become unbalanced or biased as a result of some unspecified factor.

Another difficult aspect in the design of open-label studies is how one assesses those patients who withdraw from the study. The reasons for withdrawal can be at least as varied as in double-blind studies (intolerability, administrative difficulties, coincidental emergent disease or concomitant therapies, etc.). However, in addition, in an open-label design, patients may develop an opinion on the superiority of one or other treatment for reasons that may or may not be explicit. If completion of a course of therapy is one end point of the study, then all withdrawals can be accounted treatment failures, and the statistical handling is fairly straightforward. However, if there is another end point, and if withdrawals are imbalanced between the treatment groups and unrelated to product intolerability, then the situation becomes a lot more clouded. Under these latter conditions, the entire trial may have to be abandoned when it becomes apparent that the trial design cannot answer the hypothesis under test one way or the other.

On the positive side, open-label trials are usually easy to administer, and patient recruitment and longevity within each treatment group can easily be monitored as the study progresses. Investigators have greater freedom in entering and allocating patients, and this is often more comfortable than a placebo-controlled situation in the ordinary clinical setting.

**Equivalence trials**

Sometimes, the demonstration of equivalency is sufficient, especially when the competing product cannot be expected to be inferior, or when a successor
product can be marketed at a lower price than the innovator. In the special case of generic products, at the very end of a drug’s life cycle when patent coverage has expired, equivalence need only be demonstrated pharmacokinetically (usually involving only a small number of normal volunteers and the relevant, specific types of regulatory applications). However, when the new product is challenging the position of an older one, then equivalency trials usually require very large numbers of patients (often hundreds per treatment group). The overall tactic is to show that with a well-powered study (e.g. $\beta = 0.925$) there is no clinical or statistical difference between the two treatments. The size of the clinical difference that is worth detecting is *sine qua non* defined prospectively and forms the basis for the power calculations, and hence study size.

*Mega-trials*

When it is suspected that there may only be small differences between active treatments, and when placebo controls are unavailable for clinical or ethical reasons, then it is often necessary to resort to large-scale studies (‘mega-trials’). A good, famous example was the clinical trial known by the acronym GUSTO, where streptokinase and recombinant tissue plasminogen activator (t-PA) were compared for acute coronary thrombosis (for a commentary, see Hampton, 1996).

Unlike more orthodox studies, mega-trials do not attempt to control for large numbers of confounding variables. Instead, huge numbers of patients (tens of thousands) are randomized, ‘the cards are allowed to fall where they may’, and faith is placed in the notion that a large $n$ will automatically lead to well-balanced treatment groups. This is not always the case, and imbalance can often be demonstrated between treatment groups of even several thousands when enough concomitant confounding factors are analysed (Charlton, 1966).

*Safety surveillance*

The draft ICH Guidance E2E issued 11 November 2003 provides a framework for the pharmacovigilance of new drug products. Each new product should have a pharmacovigilance *specification*, which basically describes the clinical hazard landscape for the new product, as far as it can be known at the time of approval. The specification is essentially a problem statement. Each specification should then be accompanied by a pharmacovigilance *plan*. The plan might include routine adverse event reporting and periodic safety updates to be provided to regulators, and/or recommendations for clarifications to product labeling. In special cases, however, a post-marketing surveillance study might be recommended, and this forms another type of phase IV study.

It is typical before conducting a post-marketing surveillance study to obtain the view of the regulatory authorities on its design. The study may have been a condition of product approval, and it is both reasonable and wise to ensure that the study design can be expected to provide the information that is needed both by the sponsor and the regulators. Unblinded designs that imitate the ordinary clinical situation are the norm.

*New indications*

As in the early phases of drug development, the identification of new indications for old drugs can be both rational and serendipitous. Rarely, even adverse events can be exploited as new indications, and the hair-growing properties of the antihypertensive drug called minoxidil is a famous example.

Finding a new indication is an obvious opportunity to increase market size by enlarging the potential pool of patients that can benefit from the product. In this case, two pivotal, well-controlled phase IV studies demonstrating efficacy will usually be required, at a minimum. If there is the potential for a new type of clinical hazard to be associated with new disease being studied, then a safety database, of a size that regulators will find acceptable, will be needed for the supplemental application, too. Clearly, whenever such a project is contemplated, then a financial assessment is needed of the balance between the cost of the program, the probability of success and the size of the eventual revenue increment that may or may not justify it.
The finding of a new, nonobvious use for an old drug can also be patented. This type of patent is known as a ‘Method of Use’ patent, and its eventual enforcement is probably easier in the United States than in other jurisdictions. Nonetheless, the view of the corporate patent attorney on any proposed phase IV exploration for a new indication should always be sought.

Stimulation of the process of finding new uses for old drugs is often done when companies offer investigator research grants. It is fairly common that individual prescribers will have bright ideas about the use of medical products, and indeed some specialties use most drugs ‘off-label’ (e.g. intensive care physicians, anesthesiologists and pediatricians). Small grants to such individuals, in order to observe such niche uses under organized circumstances can lead to new indications. At the very least, such programs encourage disclosure of new ideas to the company and allow for some review of the safety aspects of what these inventive individuals are getting up to!

New dosage forms

Initial dosage forms are usually those that are most easily developed, most stable and at least reasonably acceptable to adult patients. Such formulations can often be improved upon, whether for matters of convenience (e.g. a bioequivalent melt-in-the-mouth wafer that, unlike a tablet, does not require access to water for its administration) or to enlarge the patient population that might use the product (e.g. a linctus instead of a tablet for use in children or to permit smaller increments in dose adjustment). Again, when there are serious physicochemical constraints on formulations, the discovery of a new one can itself be patentable.

A variety of regulatory approaches are needed when adding to the range of formulations, and each, in turn, dictates a different phase IV clinical trial design. When the route of administration does not change (e.g. the wafer vs. tablet example above), then orthodox bioequivalence and absence of formulation-dependent intolerability might be all that is needed. A pseudo-phase I approach during phase IV might then be all that is required.

On the contrary, the new formulation might be deliberately designed not to be bioequivalent. Slow-release formulations are, by definition, not bioequivalent but often associated with therapeutic superiority due to reduced probability of \( C_{\text{max}} \)-related adverse events and better compliance because of reduced dosage frequency. In this case, efficacy data will normally be required of the scale and rigor of the earlier phase III program.

It should be noted that the company might be wise to consider, when developing new formulations, that the minimum database acceptable to regulators might be insufficient for their own purposes. The decision to launch a new formulation has to be based not only on its technical success but also according to a financial analysis of the type referred to above for new indications. Crucial information on that question can usually only be obtained by studying the new formulation using one of the other authentic phase IV approaches described in this chapter.

Special populations

Special populations have their own chapters in this book, to which the reader is referred. In the United States, many product approvals now come with the condition that future studies in children are mandatory. This is probably the commonest special population that phase IV development units now routinely deal with.

Other, newly identified special populations result from pharmacovigilance signals, unexpected use of the product in an unanticipated population, requirements for regulatory filings in non-ICH nations, or even the spread of disease into new geographical areas. Traditional pharmacokinetic approaches are usually the first step in assessing whether these events will alter product efficacy or safety.

Drug interactions

These are essentially another form of special population, and almost all drugs can exhibit at least...
some interactions. Many PLA/NDAs will contain studies of particular drug interactions that seem relevant at the time, especially when combination therapy is the norm, or when there are biochemical predictions that a new drug will interact with older therapies (e.g. cytochrome P450 isoenzyme findings in *vitro*). Pharmacokinetic studies are typically done at small scale. But, in addition, the phase IV team might be asked to do a retrospective case-controlled analysis of the existing clinical trials database trawling for differences between patients who were and were not on a particular concomitant therapy.

**The clinical–marketing interface**

As mentioned, one purpose of a phase IV clinical trial program is to gather new indications or information that can lead to a competitive advantage. Optimization of the clinical–legal interface is critical to ensure success. It is the marketing team that is the keeper of the strategy, aware of the competitive environment (both current and future competitors; within and outside of the class of the drug under development) and closest to the commercial environment that the drug will have to compete in (e.g. Formulary issues; pricing concerns). In order to ensure that the product is commercially successful, it is important for the clinical team to embrace this information when developing a phase IV clinical trial program. It is especially important when entering a very competitive, highly developed market place (e.g. Diabetes or hypertension) where there are multiple treatment options or a lack of perceived difference between members of a particular drug class. It is also important for new classes when there will be a within-class competitor launching within a short timeframe. In these cases, the label may be similar, especially in the United States where there has been a trend in recent years to have drugs within the same class have similar labeling verbiage (i.e. ‘class labeling’). In the absence of ‘current’ labeling differences between competitors, it is sometimes the robustness of the phase IV clinical trial program that will differentiate competitors, as it is seen as a harbinger of future indications or positive data. These programs also highlight to the scientific and community the ‘commitment’ that the company has to the drug and the disease state.

For these reasons, it is critical that the clinical and marketing teams collaborate extensively on the phase IV development program, usually via a standing commercialization team with representatives from other functional areas that will provide sound input into the program to increase its chance of success (e.g. Regulatory and legal). The marketing team should provide the commercialization team with a clear understanding of the market environment, including past promotional behavior of key competitors, so that a robust needs assessment can be formulated. Once the commercial case has been made, the clinical teams should provide a scientific risk assessment that includes the likelihood of success of achieving the desired outcome. If the ultimate goal of a given study is for promotional purposes, it is helpful for the marketing team to provide examples of how that data are intended to be promoted to ensure that the trial is designed to ultimately allow for those promotional messages.

With the financial stakes so high, it is no longer acceptable for clinical teams to view their roles as purely scientific. Success for a product is no longer dependent solely on approval of indications. In our information-driven society, consumers of scientific information are always looking for new information to continue to support their use of a product. Effective collaboration between clinical development and marketing teams in the context of phase IV trials can go a long way toward optimizing sales of an effective drug.

**The clinical–legal interface**

Concern about product liability can both decline and increase as phase IV proceeds. If, on the one hand, the sudden exposure of large numbers of patients to a new drug (i.e. large in comparison to those in the PLA/NDA) does not result in a flurry of serious adverse events, nor any signal of a qualitatively new type of adverse event, then there is reassurance that the label is probably doing its job properly.
However, when anything new is discovered about a drug in phase IV, then, by definition, it will not be in the product label. Furthermore, sometimes, when such a signal is observed, a retrospective trawl through the preclinical and clinical databases can often uncover consistent information whose significance had not been earlier realized. In this case, a ‘gap’ exists between what is known about a drug and what information has been provided to prescribers.

The gap may exist for a very short period of time because of a prompt change in product labeling, and the company will have done everything that is appropriate as fast as it possibly could. In some cases, the ‘gap’ might exist due to a very rarely occurring adverse event of questionable direct association with the product, which does not warrant inclusion into the label.

However, on other occasions the ‘gap’ will need to be urgently addressed. The range of actions that might be needed, in increasingly alarming order, are

- design/implement purpose-built phase IV study
- change in label at next routine printing
- more urgent change in labeling
- issuance of ‘Dear Prescriber/Doctor/healthcare professional’ letter
- institution of restrictive access program
- product withdrawal.

The phase IV development program will almost always generate information that is relevant in choosing from among these alternative actions. The corporate lawyers will always be depending on the phase IV clinicians to determine the appropriate course of action due to their knowledge of the post-marketing trial program, results and how that information has been communicated to the medical community.

10.2 Conclusion

Phase IV clinical trials, in all their many forms, are the natural extension from the constrained environment of phase II and III drug development, as well as a pivotal, interfacing position between the marketing, research, regulatory and legal departments. Indeed, such distinctions can be seamless, especially when there is no change in development team post-approval, or when phase IV is actually begun before approval. The variety of questions that phase IV teams must answer are many and varied. This can be a liberating, stimulating and educational assignment for those who have hitherto worked only in early-phase product development.

References and further reading

The investigative site serves a critical function in the clinical development process. As the physical location where clinical trials are conducted, its purpose is to produce clean, reproducible clinical data in a timely and safe manner. The site generates these data by performing the study protocol on human subjects that it recruits. By providing this valuable service, sites play a major role in moving investigational products through the clinical phases on their way to regulatory submission, and ultimately, to market.

This chapter describes different kinds of investigative sites around the globe and makes the case that operating a successful site requires an infrastructure that enables the generation of good quality data. The infrastructure must include critical business functions such as budgeting, patient recruitment, regulatory oversight, audit preparation and the keeping of metrics on site performance. Investigators and clinical research coordinators well trained in good clinical practice (GCP) are also key to site success.

### 11.1 Types of investigative sites

As the clinical trials industry becomes increasingly global, research is taking place in a variety of venues (Figure 11.1), ranging from academic medical centers to phase I units. To some degree, the location of the study is dictated by the complexity of the protocol, the types of procedures required and the availability of experienced staff. But there can be other factors at play that determine where a clinical trial occurs.

In many locales, clinical trials take place largely at academic medical centers, regardless of complexity, using investigators who are part of a national health service. In other regions, such as the United States, there are many public and private clinical trial options. Data suggest that in the United States, approximately 35% of studies take place at academic medical centers (Figure 11.2). The rest occur at a combination of public and private, dedicated and part-time investigative sites.

The dedicated site functions with a staff and infrastructure in place to enable the conduct of clinical trials on a full-time basis. It is essentially a business. The elements needed to operate the dedicated site successfully are described in the Basic Infrastructure section below.

Some dedicated sites maintain loose affiliations with non-competing sites to share leads about upcoming studies. Others belong to a site management organization (SMO), which is a formal affiliation offering centralized management,
contract negotiation, accounting and patient recruitment services.

With more than one-third of US-based clinical trials taking place in part-time sites, they are a popular option. They are generally defined as trial locations in which the investigator(s) conducts a limited amount of clinical trials annually, usually less than four or five. They offer community-based, actual use settings, a feature that sponsors find attractive (Zisson, 2002), and can be profitable because they tend to require less infrastructure than their dedicated site counterparts.

Investigators may opt for part-time site status when they have commitments such as private practice and academic appointments that restrict their available time for clinical research. Also, they may simply prefer to conduct just a few studies each year to supplement income or to indulge a research interest.

There is a hot market for phase I sites. Because pharmaceutical sponsors seek to limit costs and risk by weeding out weak drug candidates earlier, they are increasing their investments in phase I studies. Data suggest that phase I spending is rising more rapidly than other sectors of the clinical development market (Korieth, 2004).

Phase I is a collection of small safety studies using approximately 20–100 subjects to research the drug’s pharmacokinetics and pharmacological effects. Substantial investment in staff and equipment is required to conduct these studies as the phase I site often houses inpatients, and therefore, operates 24 h a day. With the exception of some trials for cancer and other serious illnesses such as HIV, the studies use healthy volunteers.

Phase I sites are found in many countries but have been prevalent in Europe, particularly the United Kingdom. Prior to the implementation of the European Directive on Clinical Trials on May 1, 2004, an investigational new drug application (IND) for studies on healthy volunteers was not required in Europe, as it was and continues to be in the United States. Europe’s then more lenient regulatory environment attracted business (Neuer, 2000), but with the advent of the European Directive, regulatory approval by ethics committee is now required to begin phase I testing.

### 11.2 Basic infrastructure

Clinical trials cannot take place without an infrastructure designed to support the research function. With research studies becoming more complex and entailing more procedures per subject (Figure 11.3), it is critical that the staff at the investigative site have an appreciation of what it takes to perform good-quality clinical research in a timely, ethical and fiscally responsible manner.

The basic infrastructure, particularly for dedicated sites, includes (Miskin and Neuer, 2002)

- clinical investigator
- study coordinator
- Director of clinical operations
- quality assurance
- writing of standard operating procedures (SOPs)
- regulatory affairs
• data management and increased use of electronic data capture (EDC)
• accommodation for record storage

Clinical investigator

The clinical investigator is ultimately responsible for clinical research conducted at the site. According to FDA and GCP regulations (Sections 312.60 and 312.64, respectively) the investigator has broad-based responsibilities for protecting the rights and safety of study volunteers. This is accomplished through activities such as obtaining informed consent, administering study drug, maintaining and storing medical records and reporting adverse and serious adverse events.

Physicians report that they participate in clinical research mostly because it is scientifically rewarding, but they are also attracted to the financial rewards and the opportunities to improve patient care (Lamberti, 2005). With clinical trials numbering in the tens of thousands, there is industry-wide concern that there may be a 15% shortfall in the number of qualified US investigators in the next few years (Zisson, 2001). There are several factors contributing to this dilemma.

First, the number of evaluable subjects per new drug application (NDA) continues to rise and is now in the range of 5300, a dramatic increase from the 3200 needed for NDAs submitted in the mid-1980s (Lamberti, 2005). To meet this demand, more investigators per study need to be recruited.

Second, the percentage of US investigators participating in clinical trials has always been low, in the range of 5% of physicians, and this number seems to be declining. A recent study from the Tufts Center for the Study of Drug Development indicates that only 3% of US board certified physicians are principal investigators (Tufts University, 2005).

To complicate matters further, there is a high rate of dropout among investigators. Many conduct one or two trials and choose to never conduct another one, leading to a dilemma in which 50% of US principal investigators have opted out of the clinical trials business. The reasons cited are that clinical research interferes too much with other responsibilities such as private practice medicine or academic obligations, or they lack the infrastructure to handle today’s rigorous trials.

There is good news, however. The Tufts Center study reveals that the number of investigators in many regions of the world is actually rising. In addition, there are now certification programs for investigators, so it is possible that those who invest in preparing for and receiving certification by examination may be less likely to drop out. Certification programs are offered by the Drug Information Association (DIA) and through the Association of Clinical Research Professionals (ACRP) affiliate, the Academy of Pharmaceutical Physicians and Investigators (APPI). Certification offered through DIA is the Certified Clinical Investigator (CII) (see www.diahome.org). The ACRP-APPI designation is Certified Clinical Trial Investigator (CCTI) (see www.acrpnet.org).
Study coordinator

The study coordinator is generally considered the linchpin in the day-to-day activities of clinical research. Without this key individual, sites would be hard pressed to perform studies in a quality and timely fashion because the coordinator’s responsibilities define clinical trial conduct.

The coordinator’s job is detail-oriented and includes responsibilities such as (Miskin and Neuer, 2002)

- patient recruitment activities
- completing case report forms (CRFs)
- transmitting study data
- scheduling patient visits
- meeting with principal investigators
- meeting with study monitors
- shipping samples to laboratories
- maintaining inventory and accountability of the investigational product
- closing out the study
- participating in preparing proposals for soliciting new studies
- participating in budget preparation
- attending investigator meetings
- participating in ongoing training
- collecting metrics.

Today’s quality sites often encourage study coordinators to become certified either by the Association of Clinical Research Professionals (ACRP), an international organization with chapters in some half-dozen countries. The ACRP certification is known as ‘Certified Clinical Research Coordinator’ (CCRC), and SoCRA’s certification is the ‘Certified Clinical Research Professional’ (CCRP).

To achieve either of these designations, the coordinator must sit for an examination following specified amounts of either full-time or part-time experience by the date of the examination as defined by either organization (www.acrpnet.org and www.socra.org). The examinations test knowledge in study conduct, regulations and ethical issues.

A major issue in clinical research today is that of the overwhelmed study coordinator. Because of the ever growing number of details that comprise clinical studies, coordinators can easily become bogged down and, ultimately, very frustrated. This situation can lead to a decline in work quality or a high level of employee turnover. According to a recent survey, 53% of study coordinators have been in their jobs for three years or less (Borfitz, 2004). This poses real challenges in terms of experience level, knowledge of GCP and familiarity with site operations.

Sites interested in retaining their trained and certified coordinators are exploring ways to improve retention. This includes offering good compensation and benefits, offering ongoing training and making decisions to hire more full- or part-time coordinators if the workload expands beyond the capacity of the existing staff complement.

Director of clinical operations (DCO)

The DCO is the point person for daily clinical operations. He is the individual who interfaces with sponsors, investigators, study coordinators and other professional staff on a regular basis to oversee clinical and budgetary status of ongoing and upcoming studies. Because of the intense, close attention to detail that the job demands, it makes sense to fill this position with a highly detail-oriented individual with an understanding of the clinical trials process.
For small or part-time sites that cannot justify a full-time DCO, a well-trained coordinator can assume this function.

Quality assurance

Putting systems in place to assure product quality is a standard business process. According to the International Standardization Organization (ISO 9000), quality assurance is defined as a set of activities whose purpose is to inspire the confidence of customers and managers that all quality requirements are being met for a product or service (ISO 9000 definitions).

The investigative site should have a keen interest in adopting quality assurance methods to ensure its clients—sponsors and CROs—that it is achieving its goal of turning out a quality product, clean data. The way to accomplish this goal is by assigning an individual to review the site’s adherence to GCP guidelines, its handling of clinical data, its attention to patient safety and protection and its adherence to standard operating procedures (SOPs). The QA professional should establish specific time intervals for routine review of CRFs, certainly at study start-up and once a month thereafter. Because mistakes in data collection and reporting are most likely to occur at study start-up, it is a good idea for the QA manager to review the first three to five charts.

Attention to detail will also serve to improve the outcomes of visits from study monitors. As a representative of the sponsor or CRO, the monitor’s job is to ensure that the study protocol is being adhered to and that the clinical data are properly collected, recorded and forwarded (Miskin and Neuer, 2002). A quality site treats the monitor with respect and provides a quiet space in which the monitor can work.

Writing of SOPs

The writing and implementation of SOPs form the framework of a quality operation by defining expectations and providing a consistent approach to drug development at the sponsor, CRO and site levels (Hamrell and Wagman, 2001). SOPs for the site are best developed with input from all levels of site management, and should describe how each member of the clinical research team is to complete various tasks. The SOP should state its objective, mention to whom it applies, define terms or abbreviations, describe tasks in a step-by-step manner, include appropriate checklists or forms and list any associated SOPs (Miskin and Neuer, 2002). Because the industry is not static but is constantly changing, it is a good idea for the head of quality assurance to review the SOPs annually to evaluate the need for updates.

Standardizing procedures becomes particularly relevant as sites grow internally or eventually expand into more than one location. In addition, employee turnover is inevitable, so the SOPs can serve as a basic element of the training program for new hires.

There is a whole host of SOP topics for the investigative site, ranging from study management to patient recruitment to handling of accounts receivable. Some study management SOPs appear in Figure 11.4 (Miskin and Neuer, 2002).

Regulatory affairs

Clinical trials cannot operate without regulatory oversight. Regulatory agencies from each country or region promulgate guidelines and regulations for conduct of ethical clinical research by industry and government sponsors. As part of that chain, investigative sites share the responsibility for conforming to federal guidelines and regulations, and do so by receiving training that defines what their responsibilities entail.

At the site level, there is a growing amount of regulatory responsibility, particularly in countries that have adopted ICH GCP guidelines or similar regulations. Everything from submissions to institutional review boards (IRBs) or ethics committees, completion of the Statements of Investigator Form 1572 and financial disclosure forms (US), maintaining of the regulatory binder and the
credentials of investigators and sub-investigators, adverse event reporting and participation in site inspections are some of the many responsibilities assumed by the regulatory affairs department.

Generally, small and part-time sites cannot justify creating a position for a full-time regulatory manager, but once the number of studies conducted annually approaches eight or more, a full- or part-time regulatory affairs position needs to be created. Without this function firmly in place, it becomes increasingly difficult to maintain site quality. Signals that staffing in regulatory affairs needs to be increased include the failure to submit important regulatory documents in accordance with established timelines, difficulty in keeping regulatory binders up-to-date and failure to report adverse event (AE) and serious adverse events (SAE) to sponsors or ethics committees as required.

Data management and increased use of electronic solutions

As clinical trial protocols increase in complexity, there is an industry-wide shift toward adoption of electronic solutions to improve critical functions, most notably the collection, handling, analysis and storing of clinical data and the reporting of adverse and serious adverse events.

Traditionally, the collection of data at the investigative site has been and, to a large extent, continues to be accomplished using paper and pen, but in recent years, there is growing emphasis on electronic methods. Estimates vary as to the percentage of electronic solutions used to collect and submit clinical data, but they are generally in the range of 15–20% of clinical trials (Borfitz, 2004). This number is expected to increase over time as more pharmaceutical sponsors commit to implementing electronic data capture (EDC) in virtually all of their clinical trials (Bleicher, 2005).

For the investigative site, shifting away from paper in favor of electronic solutions means that staff must be trained in both types of data collection during this transition phase. The quality assurance department should create SOPs for both methods because the capturing and handling of clinical data are completely different for ‘paper-based’ and ‘electronic studies’. In a paper-based study, clinical source data are handwritten onto paper CRFs that are mailed, faxed or overnighted to the sponsor or CRO. In a study using EDC, data are entered electronically into a secured Web-based CRF that is sent via the Internet to the sponsor or CRO. Data that are missing, placed in the wrong field or out of range are immediately spotted, thereby reducing the number of queries. And, to facilitate the more rapid sending of electronic data to sponsors or CROs, allowing near real time viewing of those data, the site should implement high-speed Internet access.

Regulatory pressures are also driving increased use of electronic solutions (Beyster et al., 2005). Regulatory agencies around the globe are requiring that more trial-related information be submitted electronically. For example, on May 1, 2004, European Medicines Agency (EMEA), the regulatory body for the EU member states, started

---

**Figure 11.4** Some study management SOPs (Source: Miskin and Neuer, How to Grow Your Investigative Site, 2002)
requiring suspected serious unexpected adverse reactions (SUSARs) be reported electronically to Eudra Vigilance, the European data processing network. The Food and Drug Administration (FDA), the US regulatory agency, has established the Adverse Event Reporting System (AERS), a database that accepts electronic individual case safety reports. In addition, FDA is moving toward requiring electronic submission of NDAs, amended new drug applications (ANDAs) and biologics license applications (BLAs) using industry-accepted standardized formats for data submission.

These trends have implications for the investigative site. First, GCP guidelines require investigators to report SAEs immediately to the sponsor unless otherwise indicated in the protocol or investigator’s brochure (Figure 11.5). AEs are to be reported to sponsors in accordance with the protocol. Complying with these reporting requirements can be greatly facilitated if they are done electronically. Second, to enable sponsors to conform to the growing number of electronic submission requirements, the clinical trial data that are collected from dozens of sites across the globe are more easily compiled and analyzed if the sites use standardized electronic formats.

Accommodation for record storage

Clinical trials generate vast amounts of paperwork, all of which must be stored during and after the trials. With trials sometimes lasting for several years and generally requiring more patients per trial (Lamberti, 2005), storage requirements are important regulatory and cost considerations for the investigative site.

According to ICH GCP guideline 4.9.5, records are to be retained until at least two years after the last approval of a marketing application. Records may be retained for even longer periods if required by applicable regulatory requirements or if required by the sponsor.

Trial-related documents can be stored offsite once a trial is completed, but generally, while a study is ongoing, it is more convenient to keep them onsite. In particular, a visiting study monitor will expect to have direct access to trial documents, so having them readily available is important.

It is a good idea for the investigative site to plan for excess document storage capacity in a location that is dry and can be locked. Storing documents in the basement of a building without special protection from water damage or rodent destruction is not a good idea and is actually a violation of GCP. ICH GCP guideline 4.9.4 states that the investigator is responsible for storing documents in a manner that will prevent their accidental or premature destruction.

11.3 Clinical site challenges

Once basic infrastructure is in place, the challenge of conducting successful clinical research begins. Basic infrastructure provides the necessary framework, but the essence of clinical research is defined by specific tasks such as

- patient recruitment and retention
- budgeting
- FDA audits.

Patient recruitment and retention

The recruiting of study volunteers and retaining them throughout the study remains one of the
industry’s key bottlenecks. Data suggest that in North America, for example, more than 90% of clinical trials must extend the enrollment period beyond established timelines because of incomplete enrollment (Borfitz, 2004).

Patient recruitment and enrollment target goals are set by the sponsor but become the responsibility of the selected investigative sites once they commit to conducting specific trials. If a site contracts to enroll 15 patients, for instance, it is committed to reaching that goal.

Oftentimes, a site expects to fill its enrollment quota from its own internal patient database, but statistics suggests that most of the time, this approach is less than successful. To improve their chances for recruitment success, site managers need to determine how to go about recruiting and enrolling patients if the database falls short.

Sites in some regions of the world, such as the United States, attempt to boost enrollment through active patient education and recruitment campaigns, including advertising the study in electronic and print media as well as the Internet. Other locales have been more conservative, generally relying on practitioners to inform patients of appropriate clinical trial opportunities. That approach is starting to change, however, as more countries are allowing patient recruitment activities in their regulatory guidelines.

The EU, for example, permits patient recruitment activities for the member states as described in a detailed guidance put forth by the European Commission in April 2004 (European Commission, 2004). Section 7.4 of the guidance, entitled ‘Advertising for Trial Subjects’, lists various aspects to be included in advertisements (Figure 11.6), provided they are reviewed and approved by an ethics committee.

Once patients are recruited, retaining them becomes the next hurdle. Data suggest that only 70% of subjects enrolled in phases I–III trials complete those trials (Lamberti, 2005). That retention figure is likely to increase if study volunteers are satisfied with the care and treatment they are receiving (Miskin and Neuer, 2002). Proper treatment starts from the beginning, from the minute volunteers enter the site, extends to follow-up reminder telephone calls or postcards about upcoming visits and continues by making them feel valued at every step of the process, essentially treating them like important customers (Neuer, 2003).

Budgeting

The clinical trials industry is a competitive business. Although thousands of clinical trials are ongoing at any given time, there are thousands of investigative sites competing for that business. Yet, despite the strong competition, sites need to avoid rushing to accept studies before taking the time to determine if they make financial sense.

The clinical staff and financial manager need to evaluate (Gersch et al., 2001)

- the study of study visits;
- the number and cost of procedures, that is physical examinations, chest X-rays, electrocardiograms, stress tests and blood draws, including...
the cost of processing, packing and shipping the samples to a central laboratory;

- supplies and equipment needed to conduct the trial;
- cost of recruiting subjects;
- the amount of screening or ‘prestudy’ work involved to determine study eligibility and if the site will be paid for that work, even for prospects who ultimately fail to qualify for the study;
- personnel costs and time for performing procedures, collecting and forwarding clinical data to the sponsor or CRO;
- records retention fee;
- administrative or overhead costs such as rent, utilities, office supplies.

Many sites report cash flow problems either because they accepted studies with insufficient budgets, the sponsor or CRO is very slow to pay for work already done, or the site failed to negotiate reimbursement for prestudy work. Regarding slow pay, a recent study of 111 investigative sites revealed that 71% of respondents reported that it is taking ‘somewhat longer’ or ‘much longer’ to receive payment from sponsors or CROs as compared to three years earlier (Lamberti, 2005). There is also research to suggest that prestudy work can quickly reach $10,000 US before successful enrollment of the first subject (Silva, 2005), so during the budget negotiation process, sites should request compensation for screening costs whether they result in screen failures or subject enrollment.

If a budget is presented by the sponsor as ‘nonnegotiable’, it is the site’s responsibility to determine the feasibility of accepting the budget as is, or attempt to negotiate a few favorable points such as receiving several thousand dollars in start-up expenses (Figure 11.7) or adding a line item for patient recruitment costs.

**FDA audits**

Clinical sites should be in the habit of operating as if everyday is inspection day. Operating in top form is not only in the best interest of the study volunteers, it also prepares the sites for FDA inspection, an inevitability if they are conducting studies for compounds or devices to be submitted to FDA. The purpose of inspections is to ensure the protection of research subjects and the integrity of data submitted to the agency in support of a marketing application.

Generally, inspections are done by appointment and begin with an opening interview with the investigator and study coordinator(s). The inspector will tour the facility, and review charts as well as the regulatory binder.

FDA conducts the following three types of inspections through its Bioresearch Monitoring Program (Information Sheets, 1998):

- **Study-oriented**
- **Investigator-oriented**
- **Bioequivalence study.**

The *study-oriented* inspection is conducted almost exclusively to audit trials that are important to product evaluation such as NDAs and product license applications (PLAs) pending before FDA. The inspection consists of two parts: the facts surrounding the conduct of the study (Figure 11.8) and the auditing of study data.

---

**Figure 11.7** Start-up expenses [Source: Miskin and Neuer, How to Grow Your Investigative Site, 2002]
The investigator-oriented inspection is initiated for several reasons. Some include: the investigator conducted a study that is pivotal to product approval; representatives of the sponsor have reported to FDA that they are having difficulty getting case reports from the investigator or have some other concern with the investigator’s work; a study volunteer complains about protocol or subject rights violations; an investigator has participated in a large number of studies or has done work outside his or her specialty areas.

Most inspections are of the study-oriented or investigator-oriented types. The bioequivalence study inspection is conducted when one study may be the sole basis for a drug’s marketing approval.

At the end of the site inspection, the inspector(s) conducts an exit interview with the investigator and appropriate staff. If the inspector uncovered any significant issues, he or she may issue Form FDA-483, an ‘inspectional observations’ form documenting deviation from GCP. The investigator will need to respond to the 483 and take corrective action.

Following the inspection, the clinical investigator will receive one of three types of letters:

1. **NAI (No Action Indicated)**: A notice that no significant deviations from the regulations were observed. This letter does not require any response from the clinical investigator.

2. **VAI (Voluntary Action Indicated)**: An informational letter that identifies deviations from regulations and good investigational practice. This letter may or may not require a response from the clinical investigator. If a response is requested, the letter will describe what is necessary and provide the name of a contact person.

3. **OAI (Official Action Indicated)**: Identifies serious deviations from regulations requiring prompt correction by the clinical investigator. The letter will provide the name of a contact person. In this case, FDA may inform both the study sponsor and the reviewing IRB of the deficiencies. The agency may also inform the sponsor if the clinical investigator’s procedural deficiencies indicate ineffective monitoring by the sponsor.

The vast majority of inspections, some 77%, result in ‘VAI’. Of the other two categories, 16% result in ‘NAI’ and 7% in ‘OAI’ (Lamberti, 2005).

The number of annual inspections has been growing steadily, and in 2004, reached a total of 242 for US clinical investigators and 82 for foreign clinical investigators (2004 Report to Nation). The top five deficiencies, led by protocol violations, appear in Figure 11.9.

### 11.4 Final thoughts

The purpose of the investigative site is to produce clean clinical data by performing a protocol on study volunteers. Sites that achieve this goal do so by building an infrastructure that supports the many functions involved in generating those data. The infrastructure includes standard business practices such as quality assurance, writing of SOPs, regulatory affairs and data management. It must also include study coordinators and investigators who are well trained in GCP.

Because the conduct of clinical trials is a competitive business, sites should document their performance in terms of quality and timeliness. This
entails keeping metrics of on time completion of patient recruitment and enrollment, retention rates of study volunteers, success rates with different kinds of patient recruitment media and numbers of studies completed in various therapeutic areas.

Sponsors looking to select sites for clinical trials can use these metrics to distinguish performing sites from nonperformers. In addition, sponsors are increasingly using metrics to identify sites with a higher probability of achieving trial objectives on time (Anderson, 2004).

By reaching objectives, sites begin to form relationships with sponsors who recognize and appreciate the contribution they make to the clinical development of investigational compounds and devices.

References


The aim of this chapter is to describe the general framework for conducting good clinical practices (GCP)-compliant clinical research. As it is difficult to cover this broad topic in such a short chapter, the authors will focus on those areas that are most discussed, most problematic and most critical to achieving a GCP-compliant clinical study. Thus, there is particular emphasis on ethical issues, source data verification and data integrity, monitoring and safety review, and study medication/device management.

12.1 The current rules for conducting clinical research

Conducting GCP-compliant clinical research is a serious undertaking, and this has been recognized by numerous authorities internationally. It is difficult to achieve a fully GCP-compliant clinical study, but the expectation today is that the greatest effort will be made nevertheless and the documentation to provide evidence of this effort must be available.

The basic tenets of GCP

GCP is an international ethical and scientific quality standard for the designing, conducting, recording and reporting clinical trials that involve the participation of human subjects. Compliance with the 13 core principles of this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with principles have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.

The primary reason for the presence of GCP is to safeguard human rights, as the welfare of current study subjects and future patients is at stake. Therefore, systems must be in place (such as ethics committee review and informed consent) to protect study subjects. Collecting honest and accurate data is also a major objective of GCP to ensure that data have integrity and that valid conclusions may be drawn from those data. Further, data should be reproducible, that is if the study were to be conducted in a similar population using the same procedures, the results should be the same. To assure the integrity and reproducibility of research
results, the whole process should be transparent, that is everything must be documented so that an external reviewer may verify that the research was actually conducted as reported by the researchers.

**The general regulatory framework for GCP**

The regulatory framework for compliance with research procedures has essentially developed on an international basis only in the last two decades, except for the United States where rules were first established in the 1930s. Today, countries in the European Union, other countries in Europe (e.g. Switzerland) and Japan have regulations on GCP. Other countries have regulations controlling clinical studies, with guidelines on GCP, such as Australia and Canada. In the 1990s, an attempt was made to harmonize GCP requirements in the form of the ICH GCP document which has since been adapted in regulation by many countries. Some countries have no guidelines or regulations, but guidance for researchers has been provided by organizations such as the Council for the International Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO). (A brief list of existing regulations and guidelines is presented at the end of this chapter.) Regulatory authority review and/or approval is usually necessary in all countries before, during and after clinical studies. With the advent of the EU Clinical Trials Directive, compliance with the principles of GCP is now a legal obligation in Europe for all trials of investigational medicinal products. Further, it is now a legal requirement in Europe for these investigational medicinal products to be manufactured, handled and stored to the standards of Good Manufacturing Practice (GMP) in order to prevent exposure of subjects to defective medicines.

In the past few years, there has been increasing interest in regulatory inspection of GCP compliance to ensure validity of the data and protection of study subjects and to compare the practices and procedures of the investigator and the sponsor/contract research organization (CRO) with the commitment made in the application to undertake a study. Although inspection has been a regulatory requirement in the United States for many years, inspectorates have only just started in countries such as Austria, Denmark, France, Finland, Germany, Japan, The Netherlands, Norway and Sweden. There are problems in finding good inspectors, in deciding on the final standards for inspections and in imposing sanctions for noncompliance. An interesting recent development has been the initiation of inspections in Europe by the central regulatory authority, the European Medicines Agency (EMEA). Regulation of compliance with requirements by ethics committees is also developing in some parts of the world (e.g. France and Denmark). To date, the US Food and Drug Administration (FDA) is the only authority that is actively checking on the activities of institutional review boards (IRBs) by inspection and licensing.

For noncompliance with regulations, only the United States has imposed serious sanctions to date. The ‘blacklist’ (list of all investigators who have been found to be noncompliant and were barred from clinical research for FDA submissions) is publicly available through freedom of information rules. The United States has vast experience (thousands of inspections) compared to the handful of inspections in other countries.

Within a research organization, other independent review, auditing, is undertaken internally to check on compliance with standards and basically to pre-empt the inspectors. Auditing may be conducted at any time during a clinical study to ensure continued compliance with GCP. Almost all aspects of GCP could be audited. Auditing, by definition, must be undertaken by personnel who are independent of the research being audited.

### 12.2 Setting up clinical studies

To ensure that the standards for clinical research are established before studies begin and to check on compliance with those standards, many fundamental systems and processes must be defined by study sponsors and CROs. These are outlined in Table 12.1.

The sponsor/CRO has a duty to place a study safely. That is, the sponsor (or the delegated CRO) must assess and choose a site where study subjects
will not be harmed. Some companies report that, in practice, they have little choice in this process, as the marketing department has already selected the investigators. Another rationale for apparent lack of choice is that there are too few patients or investigators in a particular therapeutic area. None of these reasons is as important as compliance with the basic GCP principle, which requires the sponsor/CRO to assess, select and choose safe settings for research.

Setting up clinical studies is a lengthy process, as there are many documents to prepare [e.g. protocols and case report forms (CRFs)], study facilities to be assessed (e.g. study sites, CROs, clinical laboratories, phase I units), regulatory review to be considered and negotiations and agreements with study sites (e.g. contracts, finances, confidentiality, indemnity, insurance) to be undertaken. In addition, as will be dealt with in subsequent sections, ethical aspects of the study must be considered (e.g. ethics committee and IRB review and informed consent requirements), and study medications/devices must be organized.

### Protocols and CRFs

The protocol, with the accompanying CRF, is the key document governing a clinical study. It formally describes how a clinical study will be conducted and how the data will be evaluated, and it must include all the information that an investigator should know in order to properly select subjects, collect safety and efficacy data and prescribe the correct study medication/device. Protocols must be prepared in accordance with a specified and standardized format that is described in guidelines and regulations (the reader is particularly advised to refer to the ICH GCP document). Protocols are usually prepared, at least initially, by the sponsor or the delegated CRO, although investigator input is obviously necessary.

Any document used to collect research data on clinical study subjects may be generically classed as a data collection form. These completed forms provide evidence of the research conducted. The most common type of data collection form is the CRF. Other types of data collection forms include...
diary cards, dispensing records, quality-of-life forms and so on. The CRF must allow for proper analysis of the data and proper reporting of the data in the final clinical study report, and it must reflect the protocol exactly: no more and no less data must be collected. Thus, a CRF must be created for each clinical study and must be prepared in parallel with the protocol. CRFs are usually also prepared by sponsors/CROs because of the demanding requirements for their design and contents.

Table 12.2  Selection of study sites

The following items should be assessed at study sites by sponsor/CRO monitors before studies begin:

Study site personnel, for example qualification, experience, training, availability; specific allocation of responsibilities

Facilities, for example offices, wards, archives, pharmacy, clinical laboratory; study medication/device storage areas; clinical laboratories; access to source documents; ethics committee/IRB requirements

Suitable study subject population, for example access to suitable subjects in sufficient numbers; method of subject recruitment; source, for example from investigator’s subject population, or be referred by other physicians and, if referred, means by which investigator will obtain adequate evidence of medical history; use of advertisements; potential subject enrollment (recruitment) rate

Table 12.3 highlights some of the responsibilities of the main investigator GCP which might be included in contracts.

12.3 Ethical considerations

Part of the selection process for a study site involves confirming that ethics committee/IRB review will be safe and that all study subjects will be properly informed prior to consent to study participation. If the sponsor/CRO cannot obtain documented evidence of compliance with these two fundamental requirements, it is not safe to work with that site.

Ethics committee/IRB review

All clinical studies require review by an independent ethics committee/IRB before, during and after the study. Before any study subject is treated, review by the committee must be documented in compliance with international guidelines and the local regulations of the country in which the research is conducted. Clinical studies begin (for the study subjects) whenever the study subjects undertake any procedure that they would not normally undergo: ethics committee/IRB review must be sought before these events. Thus, if a study requires screening procedures, washout from normal treatment and even completion of a questionnaire that poses personal questions, the study begins when those procedures are undertaken. It is a common misconception that studies begin only when study subjects are randomized to treatment.
Prior to selection of a clinical study site, the sponsor/CRO must confirm and document, in the pre-study assessment visit report, that the investigator has access to a local ethics committee/IRB. Local committees cannot be bypassed: the only official exception to this requirement is France, where, by regulation, a central committee may rule for all sites in a multicenter study. However, in the United States, it appears to be common practice for a central IRB to rule for the widely

<table>
<thead>
<tr>
<th>Table 12.3</th>
<th>Investigator GCP responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>The following investigator responsibilities must be declared in agreements or contracts:</td>
<td></td>
</tr>
<tr>
<td>Adhere to the protocol exactly. No changes to the protocol may be undertaken without following a formal protocol amendment procedure and without agreement by the sponsor/CRO.</td>
<td></td>
</tr>
<tr>
<td>Be thoroughly familiar with the properties of the clinical study medications/devices as described in the investigator brochure.</td>
<td></td>
</tr>
<tr>
<td>Have sufficient time to personally conduct and complete the study. If more than one investigator is involved at a specific study site, the specific responsibilities must be described for each investigator. The investigator must ensure that no other studies divert study subjects, facilities or personnel from the study under consideration.</td>
<td></td>
</tr>
<tr>
<td>Maintain the confidentiality of all information received with regard to the study and the investigational study medication/device.</td>
<td></td>
</tr>
<tr>
<td>Submit the protocol, information sheet and consent form, and other required documentation, to an ethics committee/IRB for review and approval before the study begins. During the study, the investigator is also responsible for submitting any new information, for example protocol amendments, safety information, which might be important for continuing risk assessment by the ethics committee/IRB.</td>
<td></td>
</tr>
<tr>
<td>Obtain informed consent from each study subject prior to enrolment into the study.</td>
<td></td>
</tr>
<tr>
<td>Inform the subjects primary care physician, e.g. general practitioner or family physician, of proposed study participation before enrolment into the study.</td>
<td></td>
</tr>
<tr>
<td>Maintain study subject clinical notes, that is source documents, separately from the CRFs. The source documents must support the data entered into CRFs and must clearly indicate participation in a clinical study. If the study subject is referred by another physician, the investigator must ensure that sufficient evidence is available in the clinical notes to support the eligibility of the study subject.</td>
<td></td>
</tr>
<tr>
<td>Maintain a confidential list identifying the number/code and names of all subjects entered into the study.</td>
<td></td>
</tr>
<tr>
<td>Allow authorized representatives of the sponsor/CRO and regulatory authorities direct access to study subject clinical notes (source documents) in order to verify the data recorded on CRFs.</td>
<td></td>
</tr>
<tr>
<td>Ensure CRFs are complete and accurate.</td>
<td></td>
</tr>
<tr>
<td>Allow monitoring visits by the sponsor/CRO at a predetermined frequency. During these monitoring visits, the monitor must be allowed to communicate with all site personnel involved in the conduct of the clinical study.</td>
<td></td>
</tr>
<tr>
<td>Report all AEs and SAEs to the sponsor/CRO and follow the special reporting requirements for SAEs.</td>
<td></td>
</tr>
<tr>
<td>Maintain the security and accountability of clinical study supplies, ensure that medications/devices are labeled properly, maintain records of clinical study medication/device dispensing, including dates, quantity and use by study subjects; and return or disposition (as instructed by the sponsor/CRO) after completion or termination of the study.</td>
<td></td>
</tr>
<tr>
<td>Archive all CRFs and documents associated with the study for a minimum of 15 years. Notify the sponsor/CRO of any problems with archiving in potential unusual circumstances, for example investigator retires, relocates, dies; study subject dies, relocates and so on.</td>
<td></td>
</tr>
<tr>
<td>Provide reports of the study’s progress whenever required.</td>
<td></td>
</tr>
<tr>
<td>Review the final clinical report, and sign and date the signature page after review.</td>
<td></td>
</tr>
<tr>
<td>Allow an independent audit and/or inspection of all study documents and facilities.</td>
<td></td>
</tr>
<tr>
<td>Agree to the publication policy.</td>
<td></td>
</tr>
<tr>
<td>Agree to the sponsor’s/CRO’s ownership of the data.</td>
<td></td>
</tr>
<tr>
<td>Agree to the stated time frames for the study, for example start and completion of recruitment, submission of completed CRFs.</td>
<td></td>
</tr>
<tr>
<td>Work to GCP as defined by the ICH, FDA and local regulations.</td>
<td></td>
</tr>
</tbody>
</table>
geographically separated areas in the country, and researchers may not inform the local IRB.

Normally, the sponsor/CRO will prepare all necessary documentation for submission by the investigator to the ethics committee/IRB (it is not usual procedure for the sponsor/CRO to directly submit items to the committee, unless requested to do so by the committee). Whatever the local variations, the sponsor/CRO is usually responsible for ensuring the submission of the items in Table 12.4. Some committees require other additional items.

The membership of an ethics committee/IRB will vary nationally and regionally. However, the sponsor/CRO is only permitted to conduct studies that are approved by ethics committees/IRBs that have a sufficient number of qualified members to enable a medical and scientific review of the proposed study and a review of all other ethical aspects of the study. Generally, ethics committees also have to be diverse in composition. Details of the membership of the ethics committee/IRB should be obtained and reviewed by the sponsor/CRO, prior to initiating the study, to ascertain the above and to determine that there is no serious conflict of interest (e.g. investigator voting on her/his study).

The sponsor/CRO should also request a written copy of the working procedures of the ethics committees/IRBs. These procedures should provide sufficient information to assure sponsors/CROs, investigators, auditors and inspectors of the integrity and independence of the ethics committee/IRB. Unfortunately, today, it is still difficult to obtain working procedures from many committees.

Ethics committees/IRBs also have responsibility for review during and after clinical studies (Table 12.5). In other words, committee review is an ongoing responsibility that extends beyond the initial submission and review of documents to proceed with the study.

### Informed consent

Potential study subjects may enter a clinical study conducted by the sponsor/CRO only after being properly informed and consenting to participate. The researchers must consider who does what, when, what sort of information must be provided and how this will all be documented. The general principles for the conduct of informed consent are noted in Table 12.6 (see also Chapter 7). All information sheets and consent forms should include the items listed in Table 12.7, and they must be provided before study participation. Obtaining informed consent is a complex issue, and it is not easy to comply with these requirements.

#### 12.4 Monitoring and safety assessment

The conduct of clinical studies is a cooperative undertaking between the sponsor/CRO and the investigator; each is responsible for ensuring that the study is in conformity with the protocol and in accordance with all applicable laws and regulations, and, of course, that study subjects are protected at all times. This responsibility involves regular and conscientious review of the progress of the study by the sponsor/CRO and by the investigator and study site personnel.

### Monitoring

One of the most important means of quality control of a clinical study is managed by frequent and thorough monitoring. A monitor’s aim is first to protect the agenda of the sponsor/CRO who employs him/her. Monitors (often referred to as CRAs or Clinical Research Associates or Assistants in the pharmaceutical industry) must ensure maintenance of proper standards, compliance with the protocol, accurate and complete data capture and standardization across sites in a multicenter study. Basically, monitors will undertake the review noted in Table 12.8.

In general, study sites should be visited by a monitor at least every four to six weeks. The frequency of monitoring visits will be defined for each individual study and will depend on details such as the study phase, treatment interval and overall duration, enrolment rate, complexity of the study methodology, occurrence of adverse events (AEs) or other significant events, and the nature of the
The following items should be reviewed by ethics committees/IRBs before clinical studies begin:

Protocol (including annexes, such as the CRF)

Consent procedures (described in the protocol and the appended information sheet and consent form), which specify who will provide information and who will obtain consent, how consent will be documented, and whether or not a witness will be present

Consent form/information sheet. Most committees will be particularly interested in these documents to ensure that all necessary information is provided to study subjects

Suitability of investigator and facilities, including support personnel. Some committees may request a copy of investigator and other site personnel CVs. The committee will be particularly interested in allocation of resources, whether the investigator has enough time and study subjects to conduct the study, and whether use of resources for clinical studies will detract from normal medical care requirements

Delegation of responsibility by investigators

Source of study subjects and means of recruitment. The committee will wish to know if study subjects are known to investigators and, if not (i.e. referred patients), how investigators will confirm eligibility and whether primary care practitioners will be informed. The committee will wish to determine that advertisements are not unduly coercive or misleading or too ‘inviting’

Appropriateness (eligibility) of study subjects (described in the protocol)

Primary care physician to be informed of study participation

Number of subjects to be studied and justification for sample size (this information should be in the protocol). The committee will be interested in how many subjects will be exposed to the risk of treatment. In a multicenter study, the local ethics committee/IRB should be informed of the number of subjects to be enrolled at each site and the total number of subjects to be enrolled in the study

Investigator brochure or other authorized summary of information (e.g. pre-clinical and clinical summaries) about the investigational products, including comparator products and placebo. If the study medication/device is a marketed product, the ethics committee/IRB must review the most current data sheet, product monograph and so on. The brochure is particularly important for confirming the formal declared safety profile of the study treatment and therefore is of great assistance to committees in assessing the relevance of AEs. Also, the committee can verify, by reviewing the brochure or product labeling, that the information sheet for obtaining consent provides sufficient information with regard to safety

Evidence of regulatory submission and review/approval (if applicable). Committees particularly wish to know whether the drug/device is on the market in their country or in other countries, and the details of the stage of the submission

Adequacy of confidentiality safeguards, with regard to protection of identification of the study subject (described in the protocol and the appended information sheet and consent form)

Insurance provisions, if any, for injury to study subjects (described in the protocol or provided as a separate document). Committees must confirm that there is insurance for protection of the study subjects

Indemnity/insurance provisions for the sponsor/CRO, investigator, institution and so on (as relevant to the study and if required by local regulations)

Payments or rewards to be made to study subjects, if any. Committees must determine that the amount, and schedule of payments, is not unduly coercive

Benefits, if any, to study subjects

Payments or rewards to be made to investigators. Many committees are beginning to realize that the financial interests of the investigator might have a strong influence on some aspects of the study, particularly recruitment patterns

Assurance of quality/stability of medication/device to be administered

Review decision of other ethics committees/IRBs in multicenter studies

Duration of study

Plans to review data collected to ensure safety
study medication/device. At the beginning of a study, monitoring may be even more frequent. The most time-consuming task at the study site is the review of source documents to confirm entries in CRFs and compliance with the protocol.

The monitor will be ever-vigilant for protocol violations which can occur during a study and which can have a serious impact on eligibility and evaluability. Many researchers confuse the terms ‘protocol violations’ and ‘protocol amendments’. It is important to appreciate the differences between these terms and understand how to avoid protocol violations and how to manage protocol amendments. Perhaps the easiest way to explain the difference is to stress that violations are not planned changes (hopefully) to the protocol, whereas protocol amendments are planned changes and are enacted through a formal approval process.

---

**Table 12.5** Review by ethics committees/IRBs during and after clinical studies

The following items should be reviewed by ethics committees/IRBs during and after clinical studies:

- Serious and/or unexpected AEs, if any occur during the study, including the follow-up period
- Protocol amendments, if any, and reasons for amendments
- Protocol violations which impact on subject safety, if any
- Discontinuation of study, if applicable, and any reasons for premature discontinuation
- Any new significant information, for example information arising from other studies, results of interim analyses, marketing approvals, changes in local procedures, updated investigator brochure, supply problems, during study, if any
- Amendments to consent forms/information sheets, if any
- Annual reports of the study. More frequent review may be necessary, depending on the working procedures of each individual ethics committee
- Final clinical report/summary of study. Some ethics committees/IRBs also review publications, if any

---

**Table 12.6** Principles for the conduct of informed consent

The following principles for conducting informed consent should be implemented for all clinical studies:

Informed consent must be obtained from each study subject. The person receiving the information and giving consent must sign the consent form. This is usually the study subject, but may be the study subject’s legally acceptable representative (depending on national regulations) in the event that the study subject is incapable of providing informed consent, for example the subject is unable to write or understand the consent documents, or the study subject is in a ‘vulnerable’ population, for example children, elderly. Informed consent must be obtained before the start of the study.

The person providing the information and obtaining consent must sign the consent form. This person should be an investigator who must be qualified to adequately inform the study subject, and her/his signature also indicates personal involvement in the consent process. If other personnel, for example study nurses assist in providing information or obtaining consent, they should also sign the consent form, clearly describing their role in the consent procedure.

A witness or patient advocate should be present during the consent procedure at the times of providing information and giving consent, and should sign the consent form. The witness will ensure that there was no coercion in the obtaining of informed consent and that the study subject was given adequate time to consider participation in the study. The witness must be able to confirm that the consent procedure was adequate and must have no vested interest in the clinical study, that is the witness should be impartial, independent, or neutral, as far as this can be achieved. The relationship of the witness to the study subject and to the investigator and the study should be documented.

All participants should personally date their signatures and all dates should precede the start of the study (for each subject).
Table 12.7  Information to be provided to study subjects before obtaining consent to participate in clinical studies

The information sheets and consent forms should contain the following items:

1. Information about the consent procedure:
   - Consent to be given by the study subject’s free will
   - Adequate time (which should be defined in advance in the protocol) must be allowed for the study subject to decide on participation in study
   - Adequate time must be allowed to ask questions
   - Statement that participation is entirely voluntary
   - Statement that refusal to participate will involve no penalties or loss of usual benefits
   - Description of circumstances under which participation would be terminated
   - Right to withdraw at any time without prejudice or consequences
   - Study subject is allowed to keep the written explanation (information sheet and consent form) for future reference

2. Information about the study and medications/devices:
   - Instructions on use and storage of study medication/device, if relevant
   - Name of sponsor/CRO
   - Explanation that the study is a research procedure
   - Description of study type and research aims
   - Description of study medications/devices
   - Description of procedures to be followed
   - Description of experimental procedures to be followed, if any. Experimental procedures might include those which are not normally used for the presentation under consideration or procedures which are new or have never been used before
   - Comparator treatments (including placebo) described. It is important to explain ‘placebo’ in simple terms
   - Randomization procedures. Randomization is not easily understood by many subjects and should also be explained in simple terms
   - Expected duration of participation
   - Required number of visits
   - Reason for selection of suitable subjects
   - Approximate number of other study subjects participating in the study

3. Information about the risks/benefits:
   - Foreseeable risks, discomforts, side effects and inconveniences
   - Known therapeutic benefits, if any. The benefits must not be ‘oversold’
   - Availability of alternative therapies. If there are other treatments, this must be explained so that the subject does not feel the new treatment is the only option
   - Any new findings, which might affect the safety of the study subject, and that become available during participation in the study, will be disclosed to the study subject
   - Assurance of compensation for treatment-induced injury with specific reference to local guidelines (it must not be expected that the study subject is familiar with the guidelines, and therefore the guidelines must be explained and/or attached)
   - Terms of compensation
   - Measures to be taken in the event of an AE or therapeutic failure
   - Financial remuneration, if any. Patients, whether receiving therapeutic benefit or not, are not usually paid for participation in clinical research, except for incidentals such as travel costs. Healthy volunteers are usually paid a fee for participation, but this payment should never be offered to induce the prospective subjects to take risks they would not normally consider
   - Explanation of additional costs that may result from participation, if any (this normally only occurs in the United States)

(continued)
process (if violations are deliberate or planned, a case of fraud should be considered!).

### Reporting and recording safety events

An issue over which site personnel and monitors will be particularly watchful is the observation and recording of safety information. In many studies, safety information is under-reported because of the tendency to make judgments that are often based on subjective and biased clinical opinion. It seems difficult to teach clinical researchers to operate as ‘scientists’: that is, to observe and record all observations before making judgments. The monitor and all clinical research personnel must ensure that all safety information is documented. This means that all AEs occurring in clinical studies must be recorded in CRFs, their significance must be assessed and other information must be provided for reporting AEs externally (e.g. to regulatory authorities and ethics committees/IRBs). This applies to any study treatment (including comparator agents, placebo and nonmedical therapy) and any stage of the study (e.g. run-in, washout, active treatment, follow-up).

All research personnel must search for clues about safety events from many sources, such as information in clinical records at the study sites; information in data collection forms (e.g. CRFs, diary cards, quality-of-life forms, psychiatric rating scales, etc.), occurrence of missed and/or unscheduled visits, dropouts and withdrawals; use of any concomitant medications/devices; and abnormal laboratory data. AEs may also occur simply as a result of study procedures and study participation. Information about definitions of AEs and requirements for reporting AEs must be clearly stated in the protocol and explained to the site staff, who must also be educated in the correct procedure and immediate requirement for reporting any AE suspected to be serious or unexpected as per the regulatory definitions.

All investigators and other study site personnel, ethics committees/IRBs and possibly study subjects must be informed of all new significant safety information, including all events occurring with any treatment (e.g. washout, investigational product, comparator, placebo, etc.) in the study, even if these occurred in another study with the same treatment or in another country. Significant safety information includes all SAEs and any other events
Table 12.8 Objectives of monitoring visits

The following tasks should be undertaken by the sponsor/CRO monitor at each study site visit:

Verify accuracy and completeness of recorded data in CRFs, including diary cards, quality of life forms, registration forms, consent forms, etc., by comparing with the original source documents (clinic or hospital records). Where discrepancies are found, arrangements must be made for corrections and resolution. Resolve any outstanding queries, ensuring completion of any issued data queries, since the last monitoring visit.

Verify compliance with entry criteria and procedures, for all study subjects, as specified in the protocol. If subjects are found to be ineligible or un evaluable, these events must be immediately brought to the attention of the investigator. There may also be implications for payment to the study site and requirements for reporting to ethics committees/IRBs. Finally, and most seriously, there could be implications for subject safety.

Review all AEs, including clinically significant laboratory abnormalities, that have occurred since the previous visit. If a serious or unexpected AE has occurred, which was not correctly reported by the investigator, the monitor must ensure that the correct reporting procedure is followed immediately.

Evaluate the subject recruitment and withdrawal/dropout rate. If recruitment is less than optimal, suggest ways in which it can be increased. In particular, query the reasons for withdrawals/dropouts, or unscheduled visits, in case these are related to AEs.

Confirm that all source documents will be retained in a secure location. Source documents must be legible and properly indexed for ease of retrieval. Check the study site file to ensure that all appropriate documents are suitably archived. Check that the investigator files are secure and stored in a separate area which is not accessible to individuals not involved in the study.

Conduct an inventory and account for study medications/devices and arrange for extra supplies, including other items, such as CRFs, blank forms and so on, if necessary. Resolve discrepancies between inventory and accountability records, and medication/device use, as recorded in the CRFs. If a pharmacy is involved in the study, the pharmacy and pharmacist must be visited. Check that the medication/device is being dispensed in accordance with the protocol. Check that the medication/device is being stored under appropriate environmental conditions and that the expiry dates are still valid. Check that the medication/device is securely stored in a separate area that is not accessible to individuals not involved in the study. Check that any supplies shipped to the site since the last visit were received in good condition and are properly stored. If applicable, ensure that randomization procedures are being followed, blind is being maintained, randomization codebreak envelopes are intact (sealed and stored properly) and a chronological sequence of allocation to treatment is being followed.

Verify correct biological sample collection (especially number, type, and timing), correct procedures for assays (if applicable), and labeling, storage and transportation of specimens or samples. All clinical laboratory reports should be checked for identification details, validity and continued applicability of reference ranges, accuracy of transcription to CRFs (if any), comments on all out-of-range data, and investigator signatures and dates.

The dates of sample collection, receipt, analysis and reporting should be checked to ensure that samples are analyzed promptly, and that investigators are informed of results and review them promptly.

Ensure continued acceptability of facilities, staff and equipment. Ensure that the reference range, documentation of certification and proficiency testing, licensing, and accreditation, for the clinical laboratory are still current. Document any changes in clinical site personnel and, if changes have occurred, collect evidence of suitability of new personnel. Ensure that new staff are fully briefed on the requirements of the protocol and study procedures and arrange any training of new personnel, if necessary. Document any changes in overall facilities and equipment and if changes have occurred, collect new evidence of suitability, maintenance, calibration and reason for change of new equipment.

Advise the investigator and other site personnel of any new developments, for example protocol amendments, AEs, which may affect the conduct of the study.
Collecting data with integrity

Collecting data that are accurate, honest, reliable and credible is one of the most important objectives of conducting clinical research. It is difficult to achieve. However, in general, data in CRFs are not credible to the regulators unless they can be supported by the ‘real’ documents (i.e. the source documents maintained at the study site for the clinical care of the study subject).

Source data verification

Source data verification is the process of verifying CRF entries against data in the source documents. Source data verification is only carried out at the study site, usually by the sponsor/CRO monitor (auditors will also conduct source data verification on a sample of CRFs; inspectors may conduct source data verification on a sample or all CRFs).

Source documents (and the data contained therein) comprise the following types of documents: patient files (medical notes where summaries of physical examination findings, details of medical history, concurrent medications/devices and diseases are noted), recordings from automated instruments, traces (e.g. ECGs, EEGs), X-ray films, laboratory notes and computer databases (e.g. psychological tests requiring direct entry by patient onto computers or direct entry of patient information onto computers by physicians).

The primary purpose of source documents is for the care of the study subject from a clinical perspective: the primary purpose of CRFs is to collect research data. CRFs (and other data collection forms) generally cannot substitute as source documents. Data entered in CRFs should generally be supported by source data in source documents, except as specifically defined at the beginning of the study. Nevertheless, some data entered in CRFs may be source data (e.g. multiple blood pressure readings, psychiatric rating scales, etc.) and would not be found elsewhere. This may be acceptable, if these data would not normally be entered in medical records, and if knowledge of such data is not required by the investigator or other clinicians who concurrently or subsequently treat the study subject (the protocol should specify which data will be source data in the CRF).

How much information is expected to be documented in source documents? This is a difficult issue, but one that must be discussed and resolved before the CRFs are completed. Some guidelines are provided in Table 12.9.

Direct access to source documents is required for all studies – direct access means monitors, auditors, other authorized representatives of the sponsor/CRO and inspectors are permitted to view all relevant source documents needed to verify the CRF data entries. Other restricted methods of access to source documents (e.g. ‘across-the-table’, ‘back-to-back’, ‘interview method’) are not acceptable, as they do not allow proper verification of the data in CRFs. To ensure direct access, the study subject consent form must clearly indicate that permission for access has been granted by the study subject.

Other review to assure data integrity

After retrieval from the study site, there are further means of assessing CRFs. First, there is the initial review at the sponsor/CRO premises: this process is sometimes referred to as ‘secondary monitoring’. Thereafter, review by the data management department is another extremely important means of quality control. It is a lengthy and complex process and there are few guidelines and regulations for reference. These processes will inevitably result in queries about the data. It is critical that all data review procedures be prompt. As time goes by, it becomes more and more difficult to correct data. Slow processing usually means that data lose credibility.
Table 12.9  Source data verification

For all study subjects, source data verification requires a review of the following items:

- Existence of medical records/files at the study site. There must be a medical file, separate from the CRF, which forms a normal part of the clinical record for the study subjects. The medical file should clearly indicate the full name, birth date, and hospital/clinic/health service number of the study subject.
- Eligibility of study subjects. The medical file must show compliance with the inclusion and exclusion criteria. At a minimum, demographic characteristics, for example sex, weight and height, diagnoses, for example major condition for which subject was being treated, and other ‘hard’ data, for example laboratory results within a specified range or normal chest X-ray, should be clearly indicated. All required baseline assessments must be evident. If the medical file has little or no information concerning medical history, it would not support selection of the subject.
- Indication of participation in the study. The medical file should clearly show that the subject was in a clinical study in case the information is necessary for future clinical care.
- Consent procedures. The original signed consent form should be maintained with the subject’s medical files or in the investigator files and an indication that consent was obtained (with the date specified) should be noted in the medical files. Signatures and dates must be checked carefully to ensure that the correct individuals were involved in the consent procedure and that consent was obtained prior to any study intervention.
- Record of exposure to study medication/device. The medical file should clearly indicate when treatment began, when treatment finished, and all intervening treatment dates.
- Record of concomitant medications/devices. All notations of previous and concomitant medication/device use must be examined. All entries in the CRF should be verifiable in the medical file by name, date(s) of administration, dose and reason (or indication). All entries in the medical file during the time period specified by the protocol must be noted in the CRF. Concomitant medication/device use must be explicable by an appropriate indication and must be consistent from visit to visit. The reasons (indications) for use of concomitant medications/devices, newly prescribed during the study period, must be noted as AEs. The medical history should be reviewed to determine whether medical conditions arising during the study already existed at baseline. The dispensing records, which are normally separate from the medical file, must also be examined to determine consistency.
- Visit dates. All visit dates should be recorded in the medical file. Interim visit dates recorded in the medical file, but not in the CRF, should be noted by the monitor in case they signify occurrence of AEs or protocol violations. The final visit date should be so indicated, for example ‘study finished’ or ‘withdrew from study’.
- AEs. All AEs noted in the medical file during the time period specified by the protocol must be recorded in the CRF. The monitor must also carefully check other documents (e.g. diary cards, quality of life forms) for sources of information about AEs. Occurrence of out-of-range laboratory values, which are considered to be clinically significant by the investigator, must be reported and assessed as AEs.
- Major safety and efficacy variables (to be decided and documented in advance). It is not necessary for all measured variables to be recorded in the medical file. Present and future clinical care of the study subject is the most important factor in determining whether or not measured variables should be recorded in the medical file. The investigator should record what he/she would normally record to care for the study subject, but also take into account any recording needed because of the special circumstances of a clinical study. The entire medical file should be reviewed to ensure that no additional information exists in the medical file that should have been recorded in the CRF.

To ensure that the integrity of clinical research data is maintained and that there is total agreement between the data recorded on CRFs, the data entered in the computer, the data recorded in data listings and cross-tabulations, the data entered into statistical and clinical study reports and finally the data in the sponsor/CRO and investigator archives, it is essential that the data must only be changed by following a formal procedure. Thus, requests for data clarification and all resolution of queries must be documented. All data changes must be authorized by the investigator ultimately. Obviously, the
sponsor/CRO cannot arbitrarily make changes of data.

Archiving

Systems must be in place to ensure that documents will be securely retained for a long period of time. The purpose of archiving is to safeguard all documentation that provides evidence that a clinical study has been conducted in accordance with the principles of GCP. Archives at both the sponsor/CRO and investigator sites must be reasonably secure with regard to indexing, controlled access, fire-resistance, flood-resistance and so on.

The investigator must be held responsible for ensuring that all source documents, especially records acquired in the normal practice of care and treatment of a study subject, are safely archived and available for inspection by authorized company personnel or regulatory authorities. Further, the investigator must archive all necessary documents for a minimum of 15 years – the usual industry standard. All appropriate clinical study documents should be archived by the sponsor/CRO, essentially for the lifetime of the product. The specific documents to be retained are described in the ICH GCP document.

12.6 Managing study medications/devices

Management of clinical study medications and devices is a complicated activity, and many clinical researchers report that they are not particularly interested in this aspect of clinical studies: they assume that it is all handled by other personnel in the manufacturing facility. Meanwhile, personnel in the manufacturing facility usually report that they assume no further responsibility once the supplies are released!

Preparation of study medications/devices

The preparation of study medications or devices and often rate limiting in initiating the study, particularly with double-blind designs. Requisition, labeling and packaging are some of the important considerations.

Requisition of study medication/device (including placebo and comparator products, if relevant) must be initiated at an early stage to allow sufficient time to procure the study medications/devices and to prepare the final labeling and packaging, taking into account any special circumstances for blind studies and for import requirements.

The principles of safe labeling and packaging require compliance with the following principles: the contents of a container can be identified; a contact name, address and telephone number is available for emergencies and enquiries; and the study subject (or the person administering the medication/device) is knowledgeable about storing and administering the study medication/device, and that the packing process can be audited against a standard operating procedure.

Shipment of study medications/devices

Clinical study medications/devices should not be dispatched to study sites until all pre-study activities have been completed and regulatory requirements have been satisfied. The receipt of each shipment of study medication/device should be confirmed in writing by the investigator or pharmacist (or other authorized personnel), who will be instructed to return a completed ‘acknowledgement of receipt form’ immediately. The recipient at the study site will be instructed to contact the sponsor/CRO immediately if there are any problems (e.g. missing or broken items, defects in labeling, evidence of excursion from temperature ranges) with the shipment. The recipient must be particularly instructed to record the exact date of receipt of the clinical supplies at the study site. This information is necessary so that the monitor can determine that the supplies were secure and correctly stored environmentally during the entire period of shipment.

After the clinical study supplies have been sent to the study site, the monitor must verify as soon as possible that the supplies have arrived satisfacto-
subjects until the monitor has checked their condition. The monitor will verify that the amount shipped matches the amount acknowledged as received. If there is a lack of reconciliation, or if the shipment is not intact, recruitment may be delayed until the situation is resolved.

Control of study medications/devices at study sites

Evidence of careful control at the study site is imperative, and naturally it is difficult to standardize the situation across many study sites and many countries. Security, correct storage and accurate documentation of dispensing and inventory are necessary. Systems to ensure and assess compliance with the required use of the product being studied must be established. Monitors must be trained to check on these features and ensure that all site personnel are fully briefed.

The expectations with regard to maintenance of study medications/devices at study sites focus on security and appropriate environmental conditions. Concerns for security require that supplies be maintained under locked conditions. All agreements between the sponsor/CRO and the study site must specify that supplies are only for clinical study subjects – this information must also be clearly stated on the labeling. The main concern for appropriate environmental conditions is usually temperature requirements, but other factors (e.g. light, humidity) might also be important. Terms such as ‘room temperature’ and ‘ambient temperature’, which have different meanings in different countries, should always be avoided and specific temperatures must be stated. At each monitoring visit, the monitor will ensure that the correct procedures are being followed.

Compliance with medication/device use (by the study subject) should be assessed in all studies. If supplies are dispensed to subjects for self-administration, methods to assure compliance (e.g. diary cards, instructions on labeling, supervised administration) and methods to check compliance (e.g. tablet counts, plasma/urine assays, diary card review) must be in place. At each study visit, the study subjects should be asked to the investigator, who will check the supplies for assessment of compliance and store them for return to the sponsor/CRO. The monitor will review all relevant documents (e.g. source documents, CRFs, medication/device inventory, dispensing forms) to ensure that the data in the CRFs reflect the subjects’ compliance with the study medications/devices.

Overall accountability of study medications/devices

Overall accountability must be documented and reviewed. A reconciliation of the initial inventory and the final returns must be undertaken and all discrepancies must be explained. Final disposition and destruction must be carefully documented to also allow assessment of possible detrimental environmental impact. All unused and returned medications/devices, empty containers, devices, equipment and so on, which are returned to the investigator by the study subjects, must be stored securely and under correct environmental conditions at the study site until retrieved by the monitor. The monitor will check the supplies returned and verify that they reconcile with the written specifications. All discrepancies and the reasons for any non-returns must be documented and explained.

Generally, destruction of returned study medications/devices by the sponsor/CRO may not take place until the final report has been prepared and until there is no further reason to question the accountability of the study medication/device. The actual destruction process must be documented in a manner which clearly details the final disposition of the unused medications/devices and the method of destruction. The information is particularly necessary in case of any query regarding environmental impact. In exceptional circumstances, unused study medications (e.g. cytotoxics, radio-labeled products) may be destroyed at the study site, with appropriate documentation.

Randomization and blinding

Randomization procedures are employed to ensure that study subjects entered into a comparative
(or masking) procedures (e.g. single-blind or double-blind) further minimize bias by ensuring that outcome judgments are not based on knowledge of the treatment. If the study design is double blind, it is essential that all personnel who may influence the subject or the conduct of the study are blinded to the identity of the study medication/device assigned to the subject, and therefore they do not have access to randomization schedules.

12.7 Summary

The code of GCP was established to ensure subject safety and arose because of biases inherent in clinical research (e.g. pressures to recruit subjects for payment, publication, etc.), which needed some counterbalance. It is hoped the reader will appreciate that GCP is not ‘bureaucratic nonsense’ (as argued by some researchers) but a logical, ethical and scientific approach to standardizing a complex discipline.

12.8 Sources of international guidelines/regulations for GCP

Australia


European Union


Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products.


United Kingdom


Conduct of Investigator Site Audits, ABPI, 1993.

Good Clinical (Research) Practice, ABPI, 1996.

Good Clinical Trial Practice, ABPI, 1995.

Introduction to the Work of Ethics Committees, ABPI, 1997.

Patient Information and Consent for Clinical Trials, ABPI, 1997.

Phase IV Clinical Trials, ABPI, 1993.


United States

Regulations

Code of Federal Regulations [CFR], 21 CFR Ch I, Food and Drug Administration [FDA], Department of Health and Human Services [DHHS]:


Compliance Program Guidance Manuals for FDA Staff:


Information Sheets:


Inspection and Warning Letters:


**Forms:**


**International ICH:**


**WHO:**


Other related publications by the authors


Bohaychuk W, Ball G. 1998. *101 GCP SOPs for Sponsors and CROs* (available from authors, paper and diskette).


The aim of this chapter is to describe the general framework for quality management (QM) in clinical trials. Quality assurance (QA), including audits, and quality control (QC) are components of QM, and their contribution to quality and integrity of clinical data is widely recognized, in particular, in clinical research conducted according to good clinical practice (GCP). As it is difficult to cover all aspects of quality and auditing in one chapter, the particular emphasis of this chapter is on approaches to QM and general procedures for QA, QC and audit. This should allow the readers to develop QM systems for clinical trials which are tailored to their specific environment and organization.

13.1 Introduction

QM is not a new discipline in industry, but the concepts evolved and were refined over many decades and have been implemented in nearly all areas, in manufacturing industries, service providers as well as nonprofit organizations. It, therefore, comes as no surprise that QM found its way into pharmaceutical medicine, in particular, in clinical research and GCP.

Research and development of pharmaceuticals is a time-consuming and complex process, demanding a good understanding of medical and regulatory requirements paired with the ability to manage sophisticated clinical trials which are often to be conducted within an ambitious time schedule. Competition is fierce and time-to-market often dictates the ‘pulse’ of drug development. Over the years, clinical studies have become increasingly difficult because of heightened requirements stipulated by regulatory agencies, development and evolution of GCP guidelines and regulations and technical advancements in data and document management.

The need for outsourcing parts or even all drug development activities to contract research organizations (CROs) and specialized external providers contributes to the complexity of developing new pharmaceuticals.

Clinical research is a global business and multinational trials with globally dispersed investigator sites are one sign of it. Local, national and international requirements for conducting clinical studies must be respected and, because of the variety of countries and languages involved, familiarization with those requirements is not always an easy undertaking, but essential. And, to add to the above, regulatory frameworks are subject to continuous refinement and revision. Monitoring of these changes is mandatory and requires regular
review and update of internal processes and standard operating procedures (SOPs).

An effective QM system for clinical research helps assure that studies are planned, conducted, analyzed, reported and managed in compliance with GCP guidelines and ethical principles as noted in the Declaration of Helsinki, so that dependable trial results are achieved while ensuring that trial participants are protected.

13.2 Quality management

Surprisingly, ‘quality’ or ‘quality management’ are not included in the glossary included in the International Conference on Harmonization (ICH) GCP (1995), although definitions for ‘Quality Assurance’, ‘Quality Control’ and ‘Audit’ are to be found in this guideline. Useful explanations related to quality are also included in ISO 9000:2005 (2005), the ‘generic’ standard that can be applied to any organization (large or small), including whether its ‘product’ is actually a service in any sector of activity. Let us review some of the ISO definitions.

Quality

In ISO 9000:2005 (2005), quality is defined as ‘The degree to which a set of inherent characteristics fulfils needs or expectations that are stated, generally implied or obligatory’.

Hence, the standards for conducting clinical trials must be known before they can be applied. Standards are either international (e.g. ICH GCP), European (e.g. European Union Clinical Trials Directive (2001) and GCP Directive (2005)), national (i.e. national drug laws and GCP regulations) or even more local, such as State laws in the United States (Isidor and Kaltmann, 1999). Apart from the regulations, the clinical trial protocol, SOPs and other internal or external instructions document procedures how the trial should be carried out from start to finish. Compliance with these standards is expected.

Without clear standards prepared within an organization, or without adequate knowledge of existing standards, compliance with GCP requirements, ethical principles and the trial procedures may be suffering, up and until the point that regulatory authorities reject the data because data validity and adherence to ethical standards cannot be demonstrated.

Quality management

ISO 9000:2005 (2005) defines quality management as ‘The coordinated activities to direct and control an organization with regard to quality’. ICH GCP does not contain a definition for QM.

QM is not a new concept; it is rooted in medieval Europe in the late thirteenth century where guilds were responsible for developing strict rules for product and service quality. Inspection committees enforced the rules by marking flawless goods with a special mark or symbol (Hattemer-Apostel, 2003; ASQ, 2006). This was the start of ‘quality control’, a process to assess finished products to evaluate whether they fulfilled pre-established criteria. The statistical evaluation of data paved the way to focus on improving the manufacturing process rather than inspecting the final product by preventing errors instead of correcting them, that is ‘assuring quality’ instead of ‘inspecting quality into a product or service’. The benefits of QA soon led to the insight that quality is an attribute that can be managed. On one hand, quality can be influenced in that investments in process quality impact the outcome of the product or service. On the other hand, quality has increasingly become a task of management. ISO 9000:2005 (2005) describes the role of senior management and emphasizes the importance of leadership by top management in implementing quality management.

The absence of the term ‘quality management’ in clinical research regulations and guidelines is surprising. Neither the US Code of Federal Regulations nor European documents, such as the most recent European (EU) Clinical Trials Directive 2001/20/EC (2001) and the EU GCP Directive 2005/28/EC (2005), describe the requirement for a comprehensive quality management system. ‘quality assurance’ is found in the US Food and Drug Administration’s (FDA) inspection guide for sponsors, CROs and monitors (FDA Compliance
Program Guidance Manual, 2006), stating: ‘Clinical trial quality assurance units (QAUs) are not required by regulation. However, many sponsors have clinical QAUs that perform independent audits/data verifications to determine compliance with clinical trial SOPs and FDA regulations’.

Regulatory agencies have not yet made it mandatory to implement a comprehensive quality management system in clinical research; however, they expect that a QA function be established.

Quality assurance

ICH GCP (1995) defines QA as ‘All those planned and systematic actions that are established to ensure that the trial is performed and the data are generated, documented (recorded) and reported in compliance with GCP and the applicable regulatory requirement(s)’. In clinical development of pharmaceuticals, QA usually describes the audit function within a company; however, QA should not be limited to auditing.

According to ISO 9000:2005 (2005), QA activities are not confined to auditing, but comprise all activities suitable to ensure that company procedures are designed so that the product or service will comply with pre-established quality requirements: ‘The part of quality management focused on providing confidence that quality requirements will be fulfilled’. This definition emphasizes that QA activities are future-oriented and should focus on improving systems and procedures to be followed to ensure that these are set up in such a way that produces a quality result or service.

The conduct of audits is not a mandatory requirement in GCP. ICH GCP (1995) mentions in section 5.19: ‘If and when sponsors perform audits, as part of implementing quality assurance’ – this is not interpreted as an obligation to establish an audit program. Similarly, FDA does not mandate the conduct of audits (FDA Compliance Program Guidance Manual, 2006).

Quality control

The ICH GCP (1995) definition for QC is ‘The operational techniques and activities undertaken within the quality assurance system to verify that the requirements for quality of the trial-related activities have been fulfilled’. ISO 9000:2005 (2005) uses a more precise definition which nicely contrasts the above definition for QA. Quality control is ‘The part of quality management focused on fulfilling quality requirements’.

QC activities in clinical research are manifold and comprise all activities undertaken by operational departments (such as clinical monitoring, project management, data management, etc.) to ensure that activities are performed in compliance with the trial protocol, SOPs and other procedure guides. These in-process quality controls are vital to the quality of the documents prepared (e.g. trial protocols, study reports) and the integrity of the trial conduct.

Compliance

‘Adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements and the applicable regulatory requirements’ – this is how ICH GCP (1995) defines compliance.

A myriad of laws, regulations and guidelines specify the requirements to be adhered to when conducting clinical trials. Responsibilities of clinical investigators, sponsors, CROs, independent ethics committees (IECs), monitors and auditors are described, including also activities such as pharmacovigilance/safety reporting, data management/statistics, notification of trials at regulatory authorities and so on.

It is important to be aware of the enforceability of requirements laid down in documents (e.g. legal requirements vs. industry best practice) and the geographic coverage of guidance documents (e.g. FDA regulations vs. EU Directives) (Hattemer-Apostel, 2004). Without dependable knowledge on the applicable regulatory requirements it is unlikely that GCP compliance can be achieved. Key steps toward compliance are

1. know the regulatory framework and keep abreast of changes;
2. train employees and colleagues, and implement the requirements in the standard processes; and

3. follow the rules and provide sufficient documentation so that compliance can be verified.

### 13.3 Implementing quality assurance

QA’s task to identify noncompliance with regulatory requirements, the trial protocol and internal procedures such as SOPs is not always an easy job. Communicating deficiencies and highlighting inadequate procedures is certainly a benefit for the company as a whole, but the individual may not appreciate being confronted with audit findings (Winchell, 2004). In order to be efficient and effective in QA, the following should be observed.

### Organization and independence of QA

According to ICH GCP (1995) and FDA (FDA Compliance Program Guidance Manual, 2006), the audit function must be independent of routine monitoring or quality control functions, so that auditors are able to provide an unbiased, objective assessment. Being involved in designing, conducting, monitoring or analyzing a clinical study would undermine the requirement of independence.

QA’s independence from operations should be identifiable in the organizational charts of a company or CRO. The reporting line of QA should go directly to senior management and in no case to any operational function. To preserve the independence of the audit function, audits are also often outsourced to external contractors; however, this is no GCP requirement.

### SOPs for QA

The requirement of having SOPs for all functions in clinical research also applies to QA and is emphasized in ICH GCP (1995) in section 5.19.3 (‘The sponsor should ensure that the auditing of clinical trials/systems is conducted in accordance with the sponsor’s written procedures on what to audit, how to audit, the frequency of audits, and the form and content of audit reports.’) and by FDA (FDA Compliance Program Guidance Manual, 2006) (‘Obtain a copy of any written procedures (SOPs and guidelines) for QA audits and operation of the QAU.’).

The number of SOPs and their topics depend on the scope of audits performed, the set up and size of the QA department and whether audits are outsourced to external contractors which may decrease the scope of audits conducted by internal QA members. The QA department may also be tasked with activities such as SOP management and staff training; SOPs would also be needed for these areas.

### Qualification of QA auditors

The need to use qualified and trained employees in all areas of clinical research also affects the QA department. As QA auditors are verifying the work of their colleagues and are evaluating compliance with regulations, they must have a dependable knowledge of the clinical trials regulatory framework and practical work experience in clinical research to be credible in their role (Hattemer-Apostel, 2000a).

There is no standard professional education for QA auditors and, therefore, practical experience is indispensable before embarking on the QA job. Before joining the QA department, the QA candidate may have worked in clinical monitoring, data management, pharmacovigilance, regulatory affairs, training and other areas of clinical research.

ISO 19011:2002 (2002) lists the following personal attributes for auditors (and includes further information on desired auditor qualifications):

- **Ethical**, that is fair, truthful, sincere, honest and discreet.
- **Open-minded**, that is willing to consider alternative ideas or points of view.
- **Diplomatic**, that is tactful in dealing with people.


**Observant**, that is actively aware of physical surroundings and activities.

**Perceptive**, that is instinctively aware of and able to understand situations.

**Versatile**, that is adjusts readily to different situations.

**Tenacious**, that is persistent, focused on achieving objectives.

**Decisive**, that is reaches timely conclusions based on logical reasoning and analysis.

**Self-reliant**, that is acts and functions independently while interacting effectively with others.

The standard also outlines the following areas in which QA auditors should be competent:

1. **Audit principles, procedures and techniques**: This includes knowledge on the ethical and professional conduct of audits, interaction with auditees and co-auditors, confidentiality, fair presentation of results and observations in an audit report and the need to be objective throughout the audit process and to base conclusions only on audit evidence.

2. **Management system and reference documents**: This comprises the SOPs, working instructions and other internal documents to demonstrate that the company’s processes and procedures comply with GCP and regulatory requirements.

3. **Organizational situations**: Organizational charts, internal reporting lines and relationships with external service providers and partners fall into this category.

4. **Applicable laws, regulations and other requirements relevant to the discipline**: The QA auditor should be aware of international GCP regulations, regulatory requirements in the relevant countries where clinical trials are conducted as well as any protocol requirements and trial-related procedures and contracts.

5. **Quality-related methods and techniques**: Knowledge of methods applied in quality management, for example use of checklists and forms to record audit observations, sampling techniques, interview techniques, verification of information and writing audit reports must be acquired by the auditor. Communication skills, both oral and written, are essential for QA auditors to ensure adequate communication with auditees and management.

6. **Processes and products, including services**: QA auditors must possess a good understanding of all processes in clinical research and drug development and be familiar with the terminology and abbreviations used related to clinical trials.

**Training of QA auditors**

Induction training in QA may comprise the general audit procedures employed at the company, key audit SOPs and documentation requirements in QA. A thorough review of the regulatory framework for GCP is recommended, as QA auditors are expected to be experts for clinical trial regulations and all GCP aspects. It would impair the QA auditors’ credibility if they knew less than the auditees of the requirements that must be adhered to in drug development.

Auditing cannot be learned in a theoretical course and on-the-job training is mandatory. It is recommended that the QA auditor be accompanied during the first audits to learn from an experienced and competent auditor and to qualify for conducting audits alone (Hattemer-Apostel, 2000b).

With the changing regulatory environment and evolving internal company processes, continual training is also required in QA. Attending internal and external trainings and seminars, meeting QA peers to exchange experiences and discuss audit situations and interpretation of regulations refines the QA auditor’s knowledge (Hattemer-Apostel, 2001). It goes without saying that QA auditors, like everyone in clinical research, should maintain a training file to document their qualification.
13.4 Scope of QA activities

Internal consulting

QA auditors are often consulted for advice in GCP because of their broad and profound expertise in the regulations. As they acquire knowledge in many areas and oversee a variety of different clinical trials, QA auditors are often requested for information and clarification. This way of interaction with employees and auditees is an opportunity for preventing errors before they occur and for fostering communication between operational staff and QA. Auditors remain aware of day-to-day challenges in clinical research and learn early on about potential misinterpretations.

Auditing

QA auditors’ core responsibility is to conduct audits in the various areas in clinical research. This requires the set up of an audit program which should be based on the clinical development plan for the substance(s), previous experience gained in audits and the importance of the trials in the light of a marketing submission. Ideally, the audit program should cover all clinical trials.

ICH GCP (1995) defines an audit as ‘A systematic and independent examination of trial-related activities and documents to determine whether the evaluated trial-related activities were conducted, and the data were recorded, analyzed and accurately reported according to the protocol, sponsor’s SOPs, GCP and the applicable regulatory requirement(s)’.

The benefit of audits can be maximized if they are performed during the active phase of a clinical trial (e.g. when trial subjects are recruited and treated), so that deficiencies can still be corrected.

Training

QA auditors are often actively involved in providing training on GCP and regulatory topics related to clinical research. They gain first-hand experience regarding interpretations, shortcoming and problem areas when conducting audits. This knowledge is a valuable resource to tap in trainings.

QA auditors should assess, for example during audits, if adequate programs for induction training and continual education are established and followed. It has been observed that in some companies the QA department has been made responsible for maintaining the training files for all employees and for ensuring that training plans are available and training courses are attended.

SOP management

QA auditors are often tasked with responsibilities related to SOP management, such as maintaining originally signed versions, managing the dissemination (electronic and as hard copies), organizing SOP reviews (scheduled and ad hoc) and, sometimes, even writing SOPs for departments other than QA.

SOP review by QA auditors is certainly recommended before issue to ensure the SOPs are consistent with applicable international, country-specific and regional regulations, ICH guidelines (not limited to ICH GCP) and company policies and procedures.

SOPs are considered controlled documents and as such require a system which controls the distribution of SOPs to ensure that only current versions are accessible for use. Outdated documents should be retrieved and identified as historical. It is QA’s responsibility to verify that this system is being followed and is effective. Deficiencies in the SOP system are usually attributed to a lack of control and weaknesses of a company’s QM system.

Inspection readiness

The frequency of GCP inspections is increasing with many countries having established GCP inspectorates over the past years. Inspections can occur at sponsors, at investigator sites, laboratories, CROs and other external providers. GCP inspectors may assess compliance with regulations, protocol requirements and SOPs at various
time points related to a clinical trial: before a trial starts (e.g. to evaluate the adequacy of the selected site), during an ongoing trial (i.e. surveillance inspection) or as part of a Marketing Authorization Application (MAA) (i.e. pre-approval inspection) (European Union Clinical Trials Directive, 2001; GCP Directive, 2005).

The assistance of QA auditors in preparing, managing and following up GCP inspections is vital. Auditors are familiar with audit and inspection situations and know how to interact with inspectors. The presence of QA auditors during regulatory inspections (in-house as well as at external facilities) is strongly encouraged. A wealth of information about approaches, needs and expectations of GCP inspectors can be gained. This knowledge may be very helpful for preparing forthcoming inspections and for formulating responses to inspection reports.

Inspection readiness is another area where the QA function can contribute considerably to establish systems and procedures which ensure that a company is always ready for an inspection. This includes a dependable SOP system in full compliance with guidelines and regulations, up-to-date training programs and documented training for all employees with complete training files, current CVs for all persons involved in clinical research, current organizational charts and job descriptions, contracts in place with all external providers and so on. QA auditors can help establish and maintain a state of inspection readiness in the company.

Suspected misconduct and fraud

Misconduct or fraud is a rare occurrence in clinical research, but when misconduct or fraud is confirmed the consequences can be disastrous (Lock et al., 2001; Eichenwald and Kolata, 2004). Fraudulent practices in clinical trials can lead to subjects being exposed to safety risks, to submitted or published clinical data being jeopardized and, if the product has been licensed based on false data, this may result in compromised patient safety. Therefore, any suspected case of misconduct or fraud should be taken seriously and be assessed – this is when QA auditors should be involved.

Anyone who has access to or responsibility for collecting, transcribing, monitoring or reporting data and who is motivated to deceive can commit fraud. Although misconduct and fraud is reported to occur rather at investigator sites than elsewhere, this should not preclude from finding obscure and questionable situations and documentation in other areas.

It is important to distinguish clearly between misconduct, fraud and honest error. FDA provides the following examples for fraud:

1. **Altered data**: Data that have been legitimately obtained, but that have been subsequently changed to bias the results.

2. **Omitted data**: The non-reporting of data, which has an impact on study outcome, for example, the non-reporting of adverse events.

3. **Fabricated data**: Data that have been deliberately invented without performing the work, for example making entries in case record forms when no data were obtained or patients not seen.

QA auditors should help investigate suspected fraud or misconduct by means of data and document review and audits at the concerned sites. Their independent and objective perspective of the situation will be important to provide an unbiased view and a valid assessment. Investigations of fraud should always be conducted by two auditors.

Training on how to detect and, even more important, prevent fraud is another area where QA should be involved (Hattemer-Apostel, 2004). QA auditors should play an active role in fraud prevention and awareness training measures so that all employees are adequately sensitized to reliably identify such occurrences.
aligned to the drug development program so that the audits are placed in accordance with the complexity and the importance of the clinical trials for a regulatory submission. Application of risk assessment and management methods may be helpful to identify high-risk areas in the company’s clinical research environment.

For example, first-in-man studies and pivotal trials are more likely to be audited than phase IV trials, and external providers selected for the first time who are responsible for key areas in clinical trials should be audited with a higher priority than CROs with a long history and reliable performance.

Audit plan

For each individual audit, it is useful to prepare an audit plan to provide the auditee with an overview on the audit components and the conduct of the audit. An audit plan may also be useful as a basis for agreement between the sponsor, the (external) QA auditor and the audit team. It is common practice in clinical research to draw up an audit plan and distribute this information prior to the audit.

ISO 19011:2002 (2002) suggests including the following information in the audit plan:

- Type and scope of the audit; organizational and functional units and processes to be audited.
- Audit objectives and reason for conducting the audit, if appropriate.
- Audit criteria and reference documents.
- Identification of the client/sponsor and trial protocol.
- Date(s) and location(s) of audit activities at the site together with expected time and duration of activities, including any audit-related meetings.
- Names, roles and responsibilities of the audit team members and technical experts accompanying the audit team, if appropriate.

The following details may also be addressed in the audit plan, as required:

- Language in which the audit will be conducted and the audit report will be written where this is different from the language of the auditor and/or the auditee.
- Structure of the audit report.
- Travel arrangement for auditors, where required, and logistic arrangements at facilities at the site (e.g. pharmacy, packaging area, laboratory, etc.).
- Confidentiality agreements.
- Follow-up activities to the audit.

Audit-related correspondence

For announced audits, it is good business practice to inform the auditee in writing of the planned audit and to agree on a mutually feasible audit date. Once the audit is scheduled, the audit plan should be sent with a cover letter to the auditee, audit team members, technical experts (if involved) and the client/sponsor (in case of third party audits).

After the audit, a letter to the auditee should confirm that an audit has taken place and to thank the site staff for their availability and assistance during the audit. The letter should not include deficiencies or observations made during the audit; however, follow-up procedures can be outlined. For unannounced audits, only the audit confirmation letter is mandatory.

QA should keep records of all correspondence with the auditee and should check during the audit that the announcement letter and audit plan were received at the auditee’s site.

Audit team

Prior to the audit, the audit team needs to be established if the audit is conducted by more than one
auditor. The lead auditor must be nominated and responsibilities for the individual team members should be clearly assigned, considering competence and expertise. The same is true if technical experts (internal or external) are involved in the audit. Technical experts should be independent of the auditee and activities to be audited. In any case, the responsibility for the audit will rest with the lead auditor and the audit team.

Audit tools

Recording audit observations is an essential part of the audit to enable the auditor to prepare detailed, accurate and complete audit reports which are based on factual observations. Checklists, audit questionnaires and sampling plans are useful tools and should be prepared prior to the audit. Generic checklists may be a good start and can be refined as required for each audit to account for trial-specific issues. Source data verification (SDV) templates are always trial-specific as each clinical trial is unique. Although checklists and questionnaires are very useful to record audit observations, they should never restrict the extent and scope of audit activities and allow for flexibility during the audit.

Opening meeting

An opening meeting should be held with the auditee and his/her management, if appropriate, and those responsible for the functions and processes to be audited, in order to confirm the audit plan and the sequence of reviews and topics and to present the audit procedures. The purpose of the meeting is also to confirm that documents to be audited and individuals to be interviewed are available.

Communication during the audit

Depending on the duration of the audit, interim meetings with the auditees may be necessary to discuss interim results, ideally at the closure of each audit day. For the audit team, it is very useful to confer periodically to exchange audit observations and information to assess the audit progress. The lead auditor is responsible for communication with the auditee.

The auditee and/or the sponsor should be informed without delay in case serious deficiencies are uncovered which may pose a high risk for either trial participants or the clinical data. Likewise, if the audit scope cannot be covered during the scheduled time for the audit, the auditee and/or the sponsor must be notified and appropriate action should be determined (e.g. extension of the audit time or modification of the audit plan, etc.).

Audit notes, audit evidence, audit findings and audit conclusions

Audit notes are indispensable to allow QA auditors to write an accurate report after the audit. Detailed notes allow the auditor to prepare a meaningful audit report which is based on verified observations. All information collected during an audit is considered audit evidence. Information sources in an audit are, for example, document review, interviews and observation of activities. If applicable, sampling techniques may be applied, for example for SDV and verification of information in tables and listings. Audit observations are only considered audit findings if it is determined after comparison with audit criteria that these are not or insufficiently fulfilled. And finally, audit conclusions can be drawn to assess whether the audit findings impact the validity of the clinical data and the safety of the trial subjects.

Closing meeting

It is good auditing practice at the termination of the audit to conduct a closing meeting with the auditee to present the audit findings and conclusions. This is also the last opportunity for the auditee to clarify potential misunderstandings by the audit team and to provide requested documentation. The lead auditor should chair this meeting and, if applicable, address follow-up activities.
Audit report

ICH GCP (1995) defines an audit report as ‘A written evaluation by the sponsor’s auditor of the results of the audit’. Format and layout of audit reports vary greatly between companies and can range from a simple list of audit findings to a detailed description of all audit areas, observations and conclusions. The lead auditor is responsible for preparing the audit report and should be assisted by the entire audit team. Ideally, the audit report should be prepared as soon as possible after the audit. The report should be a complete and accurate representation of the audit conducted, and not include opinions or assumptions.

The following details are typically included (ISO 19011:2002, 2002):

- type and scope of the audit;
- audit objectives and reason for conducting the audit, if appropriate;
- identification of the auditee and organizational and functional units and processes audited;
- identification of the client/sponsor and trial protocol;
- identification of the audit team leader, and members and technical experts, if required;
- date(s) and location(s) of audit activities at the site; start and stop dates of the audit;
- audit criteria and reference documents;
- audit findings and conclusions.

Further details may be useful:

- audit plan and any deviation to the audit plan;
- list of auditees and interview partners;
- recommendations for improvement and recommended follow-up activities;
- distribution list for the audit report;
- statement of the confidential nature of the contents.

The lead auditor should sign and date the final audit report which should then be disseminated to the recipients as agreed with the sponsor.

It may be useful to remind the recipients of the confidential nature of audit reports which means that they should not be made publicly available or distributed to persons outside the company. Regulatory authorities should not routinely be provided with audit reports. Audit reports should be securely filed (ideally with the QA department) and not included in the Trial Master File (TMF).

Audit certificate

According to ICH GCP (1995), an audit certificate is ‘A declaration of confirmation by the auditor that an audit has taken place’. It is kind of a ‘neutral’ document and does not make reference to deficiencies or findings observed during the audit. It merely documents that an audit has taken place and is issued by the lead auditor at the termination of the audit.

Audit follow-up

The value of an audit would be considerably reduced if no corrective or preventive follow-up activities emerged from an audit report in case of identified deficiencies or recommendations for improvement. The auditee and/or recipient of the audit report are responsible for initiating follow-up activities. In case of serious or critical observations made during the audit, QA auditors are often asked to review the corrections planned to resolve a problem.

Archiving

Like all documentation in clinical research, archiving is also required for QA documents, such as correspondence, audit notes, reports and certificates.


13.6 Brief outline of audit types

Audits are conducted either for a specific trial or to evaluate an entire system in clinical research and development. Both approaches are value-adding and ensure that clinical trials are conducted according to accepted principles, that trial participants are treated ethically and the trial data are valid.

Trial-related audits focus on a particular trial to assess compliance with the protocol, with related SOPs and applicable GCP regulations. Of particular interest is how trial participants are informed of the trial, the study activities conducted at the investigator sites and the procedures of clinical data handling, recording, processing, analysis and reporting.

Systems audits are not specifically conducted for a particular trial, but may use a clinical trial as a guidance to assess the system. These audits evaluate whether a system (e.g. clinical monitoring) is capable of delivering the desired result (e.g. adequate oversight of investigator sites and appropriate documentation of monitoring activities). To this end, the adequacy and practicality of processes and procedures followed within a system is analyzed and SOPs, working instructions and process descriptions are assessed for their suitability to lead to consistent services, documentation and output. SOPs are checked for compliance with GCP regulations and guidelines, and the education, training and qualification of involved personnel are reviewed during systems audits. And finally, the interfaces to other internal departments and to external service providers and contractors are evaluated to identify potential process weaknesses or gaps which may impair or even invalidate the clinical trial and its data.

Trial-related audits

Protocol audit

Protocol audits are best scheduled when the protocol is still in draft stage, immediately prior to finalization. The purpose of protocol audits is to assess if the protocol complies ICH GCP (1995), ICH E3 (1995), ICH E9 (1998), the Declaration of Helsinki (2006), national regulations (e.g. FDA CFR requirements (FDA 21 CFR Part 50; FDA 21 CFR Part 54; FDA 21 CFR Part 56; FDA 21 CFR Part 312; FDA 21 CFR Part 314)) and company SOPs regarding format and contents of protocols. The audit also evaluates if trial procedures are accurately, completely, clearly and consistently described in the protocol so that misinterpretations are prevented.

If a generic subject information sheet and informed consent form are attached to the protocol, these documents should also be reviewed for compliance with any requirements for informed consent, such as GCP, SOPs and the Declaration of Helsinki, and for consistency with the trial protocol. The information sheet and informed consent forms must be written in a language understandable to the trial participant and should include information on data protection/privacy. Further information on protocol and informed consent audits is available in literature (Bohaychuk and Ball, 1999; DGGF, 2003).

Case report form (CRF) audit

CRF audits should also be conducted on a draft version, just before finalization of the CRF. As the CRF is ‘the’ data collection tool in a clinical trial, errors and inconsistencies in its contents and design and inconsistencies with the trial protocol may lead to serious problems if they are not identified prior to the CRF being used. This holds true for paper CRFs and electronic CRFs, as well as the use of remote data entry (RDE) or web-based data collection and transmission tools. The latter requires careful consideration of related guidelines (FDA 21 CFR Part 11; FDA Guidance for Industry, 1999).

The focus of the CRF audit is on consistency with the protocol, ease of completion (e.g. module-based style, chronology of events) and compliance with SOPs and any requirements outlined by data management (DGGF, 2003).

TMF audit

TMF audits can be conducted at any stage of a clinical trial, for example before shipping investigational medicinal products (IMPs) to a clinical...
site, in preparation for an investigator site audit or at trial termination and before archiving to ensure completeness of the essential documents as per ICH GCP (1995).

Complete, consistent and accurate trial documentation is the basis for any inspection by regulatory authorities or sponsor/client audit and is a proof that the study was conducted according to GCP regulations, the trial protocol and SOPs. The TMF plays a vital role in providing confidence to auditors and inspectors that the clinical data are valid and that the trial was conducted properly.

Although it may be possible in studies with only few investigator sites to conduct a 100% review of the TMF contents, large trials require a sampling approach.

TMF audits may be conducted to review the filing system for trial documentation. Combining the TMF audit with an assessment of the archiving system allows evaluating the retrieval procedures of trial documents to ensure that the documents are accessible at any time within the agreed archival period.

**Investigator site audit**

Investigator site audits are probably the most frequent type of audits conducted by clinical QA departments and, therefore, deserve particular attention. The purpose of investigator site audits is to assess compliance with the GCP regulations (with a focus on the country-specific regulatory requirements) and the protocol. Further, the safety of the trial participants, the ethical conduct of the trial and the validity, completeness and accuracy of the data collected and recorded are verified during the audit.

Preparing for the site audit requires the review of key trial documents before visiting the site for the on-site part of the audit. The QA auditor should review at least the trial protocol (and amendments), the current investigator’s brochure (to the extent necessary). Ideally, the following documents should be studied as well before the audit: any site-related documents including the IEC submission and approval, approved informed consent form used at the site, monitoring reports for the site, serious adverse event (SAE) reports and shipment forms of IMP and study materials, previous audit reports related to the site and relevant SOPs followed for clinical monitoring.

At the investigator site, after an opening meeting to introduce the audit team, the auditees and the audit process, interviews with the site staff are conducted to determine procedures followed for recruiting and consenting trial subjects, method of recording source data and maintaining source documents, communication and interaction between site personnel, sponsor and any external providers. Also, delegation of responsibilities and tasks is discussed at this stage of the audit.

During the time on site, facilities for storage and archival of IMPs, biological samples and trial-specific equipment are reviewed. These facilities should be secure and protect the items stored against loss or deterioration. Access should be restricted to authorized personnel and should be controlled. Storage and archival facilities for documents (e.g. investigator binder, trial records, CRFs and source data) should be secure for the duration of the trial and the archiving period. Storage facilities for IMPs must be environmentally monitored (e.g. temperature, light and humidity) and storage conditions must be recorded to allow for retrospective assessment of storage conditions. Biological samples must be kept at required temperatures, for example in the refrigerator or in –20°C or –80°C freezers. Regular maintenance, cleaning and calibration is required and should be documented. If any specific equipment is required for the trial, records should be verified regarding maintenance, calibration, quality control and SOPs.

Another important component of investigator site audit is to review the investigator site file for completeness to verify if all trial-related documents are available at the site. Chapter 8 of ICH GCP (1995) lists the documents to be expected at the site. In addition, country-specific regulations may require additional documents to be included, such as the FDA form 1572 ‘Statement of Investigator’ for investigators involved in Investigational New Drug (IND) trials. A particular focus of the document review is placed on ethics committee correspondence and approval; regulatory authority correspondence and notification/approval;
documentation of IMP shipments, accountability, reconciliation and destruction; and randomization code break envelopes to determine that they are complete and intact. Any code breaking must be fully documented.

Verification of informed consent forms for all trial participants is a key task during audits. The auditor should check if an informed consent form is present for all trial subjects and has been signed by the subject and the investigator prior to any trial-related activity.

A major component of investigator site audits is devoted to verify the validity of the clinical data generated and recorded at the investigator site. This step includes the audit of a sample of CRFs against source documents and original medical records. The purpose of the review is to determine if the trial procedures followed at the site are complying with protocol requirements, if the data gathered is complete and accurately transcribed onto the CRF or electronic forms and if the clinical monitoring and SDV process is satisfactory (FDA Guidance for Industry, 1988; DGGF, 2003). If computerized systems are used at the site to capture data, these should also be reviewed to ensure security, retrievability and validity (FDA 21 CFR Part 11; FDA Guidance for Industry, 1999).

The investigator site audit concludes with a closing meeting with the investigator and key site personnel to review key audit findings and to suggest corrective and preventive action, if required.

Database audit

Following collection of the CRFs from the investigator sites, the clinical data are transcribed or transmitted on to an electronic database. Data entry and verification, data cleaning and consistency checks and coding of medical terminology such as adverse events, concomitant medication and medical history are procedures which are prone to error. Therefore, periodic checks, in-process quality control steps, should be implemented in the data management process. An audit of the database by QA helps ensure that data integrity and validity have not been impaired during data management procedures.

Clear procedures (SOPs) for conducting such audits must be established, detailing the sampling procedures for CRFs and acceptable error rates. Information is available in literature on error levels and data verification procedures (DGGF, 2003; Zhang, 2004; Society of Clinical Data Management, 2005).

For the database audit to be meaningful, the database should only be audited in a ‘frozen’ or ‘defined’ state and prior to database lock so that eventual changes are possible after the audit without requiring a database ‘unfreeze’. When comparing CRFs and data queries against the database entries, data entry, data validation and coding procedures should be taken into account. It is important to ensure that no changes were made to the clinical data without proper justification and complete documentation. Depending on the number and volume of CRFs to be verified, database audits can be quite time-consuming.

Report audit

The study report is the essence of the clinical trial and summarizes trial data and their interpretation. Since trial reports are part of the package submitted to regulatory authorities for obtaining marketing authorization, the contents must be valid, complete and accurate. Trial report audits verify that all necessary components and attachments are included in the report. Ideally, the last draft version is subject to audit, thus avoiding rework which may be necessary after audits of early drafts which are substantially changed until they are considered final. In addition, all QC checks and activities should have been completed prior to the audit.

Apart from compliance with SOPs for biostatistics and report writing, the statistical analysis plan, the trial protocol, regulatory requirements and guidelines (ICH E3, 1995; ICH E9, 1998; ISO 9000:2005, 2005), QA auditors check the internal consistency of the trial report and appendices and between data in tables, figures and graphs and numbers cited in the text. All numbers and percentages must be substantiated by attached tables and listings. In summary, the trial report should be an accurate representation of the clinical data. Allocation of trial
subjects to the datasets analyzed and to treatment groups must be traceable and comply with the randomization scheme and the outcome of the data review meeting, if such a meeting occurred.

In contrast to GLP regulations, GCP does not require an audit for all trial reports. The number of report audits may depend on the audit plan, the importance of the trial for a regulatory submission and the confidence in the procedures followed for evaluating clinical study data and writing reports, just to name a few.

**Systems audits**

The purpose of systems audits is to assess procedures and systems across clinical studies and departments to evaluate that adequate procedures are followed which are likely to produce a quality product or result.

Systems audits focus on the verification of quality control steps incorporated in the procedures, on interfaces between different functions and departments and on relationship to external providers. While noncompliance may be detected in systems audits, such audits aim to assess the capability of a system to deliver a quality output.

Based on the above-described trial-related audits, systems audits can be composed of such ‘core audit elements’ and ‘enriched’ by additional elements to form a systems audit. In general, the scope of any study-related audit can be broadened into a systems audit. The following paragraphs describe selected systems audit; further information is available in literature (DGGF, 2003).

**Phase I/clinical pharmacology unit**

Early-phase clinical trials, including first-in-man studies, are often conducted in dedicated phase I CROs or clinical pharmacology units. Because of the very limited information on the drug’s toxicological and pharmacological effects on one hand and the importance of the trials to the entire drug development program on the other hand, audits of such trials are a valuable component of the audit program.

In addition to the components verified for investigator site audits, the QA auditor should check the quality management and SOP systems, compliance with particular requirements for early-phase clinical trials (FDA Guidance for Industry, 1995, 2006; Draft FDA Guidance for Industry, 2006; ABPI), recruitment and informed consent procedures for volunteers (e.g. volunteer panels or database), medical oversight (particularly on dosing days) and access to resuscitation equipment and proximity to emergency units and typical facilities for phase I trials (e.g. sleeping and recreational rooms, standardized meals).

**Clinical monitoring**

Clinical monitoring is one of the core activities in clinical research and regular verification of the capability of the monitoring processes is recommended. A systems audit in clinical monitoring can be based on investigator site audits where clinical monitoring activities are assessed in detail. In addition, the systems audit should verify if adequate SOPs are available for clinical monitoring which comply with GCP requirements (FDA Guidance for Industry, 1988). The SOPs should also address procedures for SDV and document and facility review. Training procedures and documentation for monitors should be reviewed to ensure that CRAs are adequately trained in GCP, SOPs and protocol procedures. This includes the review of activities such as co-monitoring or supervised visits.

The systems audits should also evaluate procedures followed for investigator site selection and initiation, the scope and frequency of monitoring visits and the SDV procedures applied as well as the timing of and process for conducting close-out visits. Handling of safety information (AEs, SAEs) by clinical monitors at the site and in-house is also an important area to review. Documentation of monitoring visits is essential, and the audit should therefore evaluate the contents of monitoring reports and their timely preparation and also check if contacts with the investigator sites between monitoring visits are adequate recorded.
Data management, statistics and medical writing

This late phase in clinical trials ‘offers’ many opportunities to introduce errors and inconsistencies in the clinical trial data as obtained on the CRFs by the investigator sites. No stage before included so many steps for data processing, coding, cleaning, programming, analysis and reporting and requires seamless interaction of many contributors.

Systems audits in this late phase in clinical trials aim at assessing related procedures to ensure that capable procedures exist for managing and cleaning clinical trial data, for conducting statistical analyses and for preparing the final study report which represents properly the data collected and reported in the clinical trial. Such systems audits are performed across functional boundaries. Such systems audit can be combined with a database audit and/or an audit of the final study report.

Typical aspects of such audits are the capability of SOPs and project-specific instructions for data management, statistical analyses and medical writing to provide an error-free report containing clinical trial data that are traceable to the original CRFs. This includes verification if software used in data management, for statistical analyses and report generation is fully validated and validation is adequately documented. Audit of the reconciliation process between clinical and safety database is another key area of the audit. All programs written, including database set up and statistical analyses programs must be validated and approved prior to use. Adequate procedures for database freeze/lock and unfreeze/unlock should be established together with proper documentation so that post-final database updates are fully traceable and do not render the clinical trial data invalid. Conclusions drawn in the final study report must be valid and substantiated by clinical data included in the report. Documentation related to data management, statistics and medical writing must be securely archived and, ideally, be part of the TMF. All personnel involved in data handling, analyses and reporting must be adequately trained.

Further details on and requirements to review during such systems audits are provided in literature (FDA 21 CFR Part 11; FDA Guidance for Industry, 1999; Rondel et al., 2000; DGGF, 2003; Society of Clinical Data Management, 2005).

Computerized systems

Systems audits in computerized systems validation (CSV) are closely related to data collection and management, statistics and pharmacovigilance, as these areas are fully dependent on operating validated and properly functioning systems.

The objective of QA is to provide assurance to management that computer systems are appropriately validated so that clinical trial data integrity is maintained. This includes verification of the system development life cycle (SDLC) documentation (or alternative documentation for systems which have been in place for a long time and are not validated according to current requirements) and adequate testing and user acceptance testing of specified requirements. System security (logical and physical) must be evaluated as part of the systems audit, including access to server rooms and backup procedures. Handling and access to audit trails is a critical component of any CSV audit. System documentation, instruction manuals and appropriate training records for anybody involved in computer systems (either as developer or as user) must be available.

Revalidation and change control procedures for hardware and software should be checked during the audit.


Investigational medicinal products

The systems audit should follow the route of the IMPs and verify that all drug shipments between manufacturer, CRO, investigator sites, pharmacies (if applicable) and trial participants are fully documented, providing information on the nature of the drug, the amount, batch number(s), subject kit number(s) storage conditions and expiry/retest date. Certificates of analysis should be available for all batched of IMP (active and placebo) and comparators. Labeling should comply with GMP requirements as requested for the countries involved in the trial and release of the drug should be documented – if required by a ‘Qualified Person’. All procedures related to IMP should be adequately described in SOPs. Finally, accountability and reconciliation information for the study medication should be consistently performed during and after the clinical trial and be traceable. All involved persons must be trained in related GCP and GMP regulations and SOPs and training should be documented.

Pharmacovigilance/safety reporting

Pharmacovigilance is a key area in clinical development, and information on adverse events experienced in clinical trials and after the drug has been launched must be reliably handled and reported within specified timeframes (DGGF, 2003). Companies must have a clearly defined pharmacovigilance system established even before they have a product in the market and are still in the drug development phase to be able to make proper assessments of the safety of a new drug and to meet regulatory obligations for safety reporting. Systems audits in pharmacovigilance are useful to evaluate all processes and SOPs related to pharmacovigilance and to assess the interaction with investigator sites, CRAs and related in-house personnel involved in handling safety information. QA auditors verify if the pathways and timeframes for reporting AEs and SAEs are followed and that all required recipients of such safety information are notified as needed (e.g. http://eudravigilance.emea.eu.int). SOPs and, if required, protocol-specific instructions should be available to describe the management of AE information. Sufficient and transparent documentation is required to demonstrate the timely and satisfactory handling of AE reports, including expedited reporting, where required. The QA auditor should also assess the training of involved personnel and, where needed, review the validation documentation of computerized systems utilized in pharmacovigilance.

Training

As already mentioned in the descriptions above, training and education are key components in systems audits. ICH GCP (1995) requires that ‘each individual involved in conducting a trial should be qualified by education, training and experience to perform his or her respective task(s)’. Related requirements can be found in several paragraphs of ICH GCP.

Systems audits of the training department/function should assess whether procedures and SOPs are in place for all aspects of training. For each employee in clinical drug development, training records should be available to document the training and demonstrate the qualification and experience. Training files should be archived when employees leave the company. The training records should also include a current job description and previous versions should be retained. A CV should be available and maintained. Attendance at internal and external training courses and conferences/meetings should be documented. Ideally, training programs are outlined for induction and continual training.

Closely related to training files are organizational charts which should be available for all company departments/functions involved in clinical drug development. Organizational charts must be updated when necessary; previous versions should be maintained.

Archiving

At the termination of each clinical trial, the study-related documents should be archived so that they
can be accessed in the future if needed, for example, in case of regulatory inspections (ISO 9000:2005, 2005; GCP Directive, 2005). Subject to archiving are also SOPs, AE reports/pharmacovigilance documentation, staff records, equipment and validation records and audit files.

Systems audits in archiving should verify that SOPs and procedures are in place for timely archiving and adequate retrieval of clinical documents. This involves, for example, a dedicated facility/area for long-term storage with adequate access controls and environmental protection (e.g. against loss, flood, vermin or fire). A dedicated person (and a backup) must be responsible for the management and operation of the archive. Documents provided to the archive must be indexed to ensure retrievability. A reasonable timeframe should be specified for documentation to be moved into the archive after trial termination.

Retention times must also be specified as ICH GCP 5.5.1.1 (1995) does not provide a clear rule and only outlines that trial documents 'should be retained until at least two years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least two years have elapsed since the formal discontinuation of clinical development of the investigational product'.

**Audits of external providers**

**CROs, SMOs and AROs**

A multitude of external providers are used to deliver services in clinical trials, for example CROs, site management organizations (SMOs) and academic research organizations (AROs). To ensure that they are capable of providing the services in a reliable manner and to the standards expected in compliance with current regulatory requirements, capability audits are conducted at service providers prior to contracting.

It is good business practice and a sign of due diligence to confirm (prior to outsourcing services) that the systems in place at and procedures followed by the external provider are compatible with the sponsor, that staff at the service provider is adequately trained and qualified and that records exist to demonstrate this. A functioning quality management system including current SOPs and a QA audit program should exist, storage and archiving procedures and facilities should be available. To the extent applicable, required equipment and calibration/maintenance records should be assessed during vendor audits as well as computerized systems, validation records and backup procedures. The systems audit will also evaluate the training records and personnel qualifications.

The audit should also verify procedures in those functional areas which provide services to the sponsor.

Apart from systems audits conducting to assess the capability of an external provider, such audits can also be conducted to verify compliance throughout the clinical trial or retrospectively after trial termination.

**Laboratory**

In the majority of clinical trials, external (central) laboratories are contracted to analyze biological samples which are acquired during the clinical trial. Laboratory results are often critical, for example primary efficacy data, and, therefore, warrant systems audits in laboratories.

Based on the above items listed for CRO audits, the laboratory systems audit should assess if the laboratory participates in routine external quality assessments, whether sample handling is adequate and transparent and the risk of mix-ups is minimized. Proper documentation should be available for all sample movements and adequate space at refrigerators/freezers/cold rooms is mandatory. Refrigerators/freezers/cold rooms must be temperature-monitored, connected to an alarm system, be maintained, cleaned and calibrated as required.

Analytical methods must be adequately validated following regulatory requirements and adequate validation documents should exist. Computerized systems must be validated and the reporting of laboratory results to investigator sites, CROs, monitors and sponsors should be clearly described.
### 13.7 Conclusion

QA activities are manifold and require a broad set of skills and a dependable knowledge of GCP regulations and clinical development processes. Possible areas of occupation for QA auditors are diverse: some are focusing on auditing and specialize to become an expert in a specific area; others would like to be flexible and conduct a variety of audits. Moving into training and consulting is a valid opportunity and even moving out of QA into operational functions is possible. Most important, though, for QA auditors is to skill to work with a variety of functional areas and cross-functional, to be detailed but also not to lose sight of the overall picture. Auditors should be able to deal with conflicts and critical situations which may emerge in auditing clinical trials and systems.

Regulatory authorities expecting QA programs being established at sponsors and external service providers. However, this should not be the only reason for implementing a proper QA program at the company. QA auditors can help ensure the integrity and validity of clinical trial data from the beginning to the end, from trial planning until the final study report, through trial-related and systems audits, training and consulting. While QA’s contribution may not be easily measurable, their investment in error prevention, compliance assessments and contribution to inspection readiness is a considerable benefit to the company and adds value to the processes and procedures. Management support and adequate resources, however, are mandatory to ensure that QA auditors and programs are effective.

Last but not least, one should not forget that it is not QA who is ultimately responsible for the quality of the services and products, but it is the individual involved in the clinical research process.

### References

ABPI. Medical experiments in non-patient volunteer studies. Available at http://www.abpi.org.uk.


PIC/S Aide-Mémoire GMP Particularities in the Manufacture of Medicinal Products to be Used in


14 The Unique Role of Over-the-Counter Medicine

Paul Starkey

14.1 The expanding place of self-medication

In recent years, the role of over-the-counter (OTC) medication in the overall health system has increased dramatically. The increased interest in and availability of OTC medications is being driven by several factors:

1. There is a growing recognition of the capability of patients to treat themselves in a rational and safe manner. The older authoritarian model of medicine is being gradually replaced by a more participative model.

2. There is an increasing desire by patients to participate in their own medical care. This is not just a result of changes in philosophy but also of the dramatic increase in average educational level over the past half-century. The world increasingly possesses a well-informed and intellectually capable population that demands an active and inclusive role in its own healthcare.

3. The quantity of information now available to the average person, both through formal education and through the media, has increased substantially, giving increasing awareness of treatment options.

4. There is a growing need to contain medical costs. OTC drugs are not only cheaper than prescription drugs, due to their simpler and more efficient distribution channels, but they also eliminate the need for an expensive visit to the doctor for each episode of illness. The professional intervention required to prescribe pharmaceuticals represents the dominant cost in the handling of many common types of illness.

5. There is a need to increase treatment effectiveness, which is not ordinarily considered an advantage of self-medication. Increase in effectiveness depends on the generally more rapid availability of OTC medications compared to prescription medications, so that treatment may begin sooner. This can significantly shorten the total length of suffering, especially when the natural course of a disease is brief or when severe discomfort makes prompt therapy especially helpful.

An example of this last phenomenon is in the treatment of vaginal candidiasis. Prior to the OTC
availability of topical anti-fungals, it was often necessary for a woman who had already recognized the symptoms of the disease to call and arrange a clinician’s appointment. This often took several days. Delaying treatment caused much unnecessary suffering and encouraged disease progression. Many clinicians, recognizing these difficulties, would prescribe over the phone, based solely on the woman’s description of symptoms. Research has shown that the accuracy of the clinician’s diagnosis in this setting is no better than that of the woman herself. This constituted an ideal situation for the switching of an important class of drugs from prescription to OTC status. The patient obtained equally accurate diagnosis and far more rapid treatment for a disease that is very uncomfortable. Severe cases of vaginal candidiasis with heavy discharge are now much less common.

A second example is in the treatment of the common cold. Anticold medications have been available OTC for many years, because of the compelling need for rapid treatment. A cold evolves quickly, the entire illness lasting only a few days. A delay of only a day or two in seeing the clinician for a prescription may eliminate any possibility of obtaining effective treatment for half of the duration of the illness. The prompt availability of self-medication improves treatment efficacy while reducing costs and enhancing patient satisfaction with the medical system.

The above factors have combined to greatly increase public awareness of the importance of self-medication in the total healthcare scheme. The Sponsor should recognize the opportunities for OTC use of medications and the advantages and pitfalls attendant upon such use. As self-medication becomes a central part of the healthcare system, the skillful and appropriate movement of pharmaceuticals from prescription to OTC availability will increasingly become a vital role of the Sponsor in optimizing the nation’s health.

### 14.2 Criteria for OTC use of medicines

The capability for OTC drug labeling is always a matter of careful judgment. The Food and Drug Administration (FDA) has been progressive in defining the requirements for OTC use in recent years. The old tendency to restrict OTC treatment to conditions of short duration and primarily to symptomatic therapy is rapidly disappearing. The suitability of a medication for OTC use is not solely dependent upon its pharmacologic characteristics.

Appropriate labeling and advertising of the medication can have a major impact on the extent to which patients understand its proper use. An OTC product should be envisioned not just as the drug itself but as the whole package of drug, labeling, and advertising, designed to encourage safe and effective self-medication. With this in mind, several vital considerations concern suitability of a drug for OTC marketing.

**Self-diagnosis**

First of all, and nothing to do with the drug itself, *self-treatment implies self-diagnosis*. Only diseases that are self-diagnosable with the assistance of appropriate labeling can be considered for OTC treatment.

Fortunately, there are many common conditions that are indeed self-diagnosable. It should not be assumed that a diagnosis made by a patient is necessarily inferior to that made by a clinician. The patient can actually feel the symptoms as well as observe the signs of a disease – a real advantage in the diagnosis of diseases where symptoms predominate and signs are few. Of course, diseases where diagnosis depends on the interpretation of complicated laboratory tests or sophisticated imaging techniques are usually best diagnosed by the clinician and treated only by prescription.

An example of this is headache, where the diagnosis rests largely on history and symptoms. The patient has lived the history and experienced the symptoms. The clinician has at best a description of these symptoms, which a patient may be able to communicate well or poorly. Even with the most skillful clinician eliciting the history, there is a degradation of information as it moves from patient to clinician. If patients can be educated about the
criteria for diagnosis, they may be as capable of rendering the diagnosis as accurately as the clinician.

Even when a fully adequate description of symptoms and signs is not practicable for patient labeling, this barrier may be surmounted by limiting use to patients who have previously had the condition and had been diagnosed by a professional. Once some diseases have been experienced, they are unmistakable. This approach emphasizes the need for the Sponsor to think creatively in evaluating whether or not a disease can be made self-diagnosable.

OTC products offer an opportunity for real and very meaningful creativity in devising wording and graphics that can explain a diagnosis in a way that lay persons can effectively understand and use. Usually, the best OTC labeling is obtained by an iterative process in which various labeling possibilities are tried out in label comprehension tests. These nonclinical trials do not actually use the drug but simply ask patients, preferably with the disease of interest, read the proposed labeling and then take a test to find out what they understood. The results can be most illuminating and can guide the sponsor far more effective ways of getting the right message across.

**Differential diagnosis**

Once a condition is established as self-diagnosable, a related consideration is the differential diagnosis – the potential consequence of confusing the disease with other similarly presenting ones, possibly resulting in a major delay in treatment. This consideration can often be a dominant factor in determining whether a condition is safely self-treatable. In conditions where minimal consequences are likely from a misdiagnosis, a modest level of diagnostic inaccuracy is tolerable to obtain the benefits of self-medication. If the major downside of misdiagnosis is simply the persistence or modest worsening of symptoms without serious health consequences, even more difficult self-diagnoses may be reasonable. However, it is usually wise to place a time limit on the length of self-treatment without a satisfactory response.

**Drug safety**

When evaluating the safety and tolerability of a drug for possible OTC use, one must first consider the quality of available information. Many drugs, particularly those used for a long time as prescription medications, have extensive safety databases. However, some do not, especially older drugs that predate modern research standards and newer drugs with insufficient usage. Also, with some drugs, the tolerability of one formulation may differ greatly from that of another. One example is benzyl peroxide, in which formulations may vary greatly, even at the same strength but with different excipients. Where such problems mean that there is an inadequate database for an intended OTC formulation, clinical testing will be needed before launch.

Safety is usually the controlling factor in determining suitability for OTC use, and involves several factors:

- The ‘therapeutic window’ (or ‘therapeutic index’, i.e. the size of the difference between therapeutic and toxic doses). This varies widely for both prescription and OTC drugs and is often less of a safety determinant than might be supposed. For example, the prescription drug sucralfate for the treatment of ulcers has extremely low toxicity, whereas OTC systemic decongestants typically have a narrower therapeutic window than have most prescription drugs, as has recently been seen leading to restrictions on ephedrine-containing products in the United States and Europe.

- The effects and consequences of toxicity and overdosage.

- The ease of recognition of early signs of toxicity to allow reduction in dosage or professional assistance.

Safety (negative propensity to cause genuine harm) can be distinguished from tolerability (negative propensity to cause limited adverse effects). Tolerability can limit OTC use even when safety is good. This is particularly true for topical agents such as
anti-acne preparations, most of which are of little safety concern but can produce very substantial irritation.

However, the effect of a drug on the general population is only part of the story. The acceptability of a drug for market, particularly an OTC drug without a clinician intermediary, is often determined by its effect on special populations, including those patients who are particularly sensitive to its effects. Care should be taken to examine atypical patients in a study population, as well as individual adverse reaction reports. Precautions may be required in the labeling for populations at particular risk.

The conclusion that a drug is not acceptable for OTC use based on safety should be reached only after determining that satisfactory labeling cannot be developed. The Sponsor must weigh safety and tolerability against efficacy, both in the general and special populations. Here the responsibility rests directly on the Sponsor, because there will be no other medical professional between the drug and the patient using it.

**Efficacy**

Efficacy is a central issue with all pharmaceutical products. In the context of OTC products, it is traditional to accept a somewhat lesser degree of efficacy in order to improve the safety profile. Also, a lesser standard of efficacy is normally expected by the patient, because OTC medication tends to be a first step in therapy. Failure to obtain satisfactory efficacy typically results in the patient seeking professional advice, at which point more powerful treatments can be prescribed. This does not mean, however, that OTC drugs should not be effective for the conditions they treat.

**Dosage selection**

The extent of efficacy will depend considerably on dosage. In the past, there was an automatic tendency to reduce the dosage to half or less of prescription strength. Today, it is widely realized that dosage should not be reduced simply as a matter of course; rather, a considered judgment on optimum dosage should be made. It is being progressively appreciated by both the pharmaceutical industry and the regulatory agencies that inappropriate reduction of dosage can result in reduced efficacy with little or no safety and tolerability benefits, thus leading to needlessly ineffective treatment. The goal is to provide the lowest effective dose. It is vital to retain medically meaningful efficacy that will provide patients with satisfying results if self-treatment is to fulfill its proper role in the medical care system.

### 14.3 The unique characteristics of the OTC field from the Sponsor’s viewpoint

The role of the clinician working in the OTC division of a major pharmaceutical company is substantially different from that played in the research or medical affairs departments dealing with drugs intended for prescription. One might assume that OTC work is simpler and less involved than that related to prescription medications. In many ways, the opposite is true.

Clinicians overseeing OTC products must be generalists, requiring a broad expertise in medicine, toxicology and regulatory affairs. The OTC clinician deals with a vast variety of drugs from many different areas of medicine, including some that are little taught in medical school and never encountered while working as a junior hospital doctor. This contrasts with research on new chemical entities, where the clinician generally focuses on a single therapeutic area, enjoys a large support staff that provide him/her with in-depth assistance and uses a limited number of research protocols and techniques that can be thoroughly mastered. In contrast, the OTC clinician must be an expert on smoking cessation one day, gastroenterology the next and dermatology the next.

The regulations governing OTC medications are substantially different from those in the prescription field, and the OTC clinician is typically more involved in regulatory matters than his/her non-OTC colleagues. The OTC clinician must also be
concerned with detailed issues of formulation and manufacturing.

Because staff are fewer and the hierarchy simpler, the OTC clinician has much more general authority, with broad responsibility for in-line, new and forthcoming products. On the prescription side, this would not be true of any job short of the Vice President of Clinical Research.

Another difference concerns marketing. Typically in the prescription area, interaction with the marketing department is infrequent, although sometimes intense. In the OTC area, it is constant. The clinician educates the marketing department on medical issues surrounding a particular drug and on the opportunities and limitations that these present. In particular, the clinician must understand the needs of the brand managers and be able to offer guidance. For instance, when difficulties occur in the implementation of marketing plans, the clinician must be able to assist in developing alternative strategies. An OTC business is subject to intense market pressures. The clinician must help the marketers deal with them effectively by frequently playing the roles of educator and creative thinker, as well as medical expert.

One of the most surprising aspects of the clinician’s role in OTC medication development is the very high degree of creativity that is required. With prescription medication, one must work with whatever compounds have been previously developed by chemistry and toxicology. These are brought to the clinician for clinical testing. There is seldom any input by the clinician into drugs he/she will be required to work on. Sometimes the project on which the clinician will be spending years of his/her life is of considerable medical interest, in other cases it is not. No matter what the case, the clinician will be able to exercise only minimal control over what compounds he/she is working on at any given time. Although it is possible for the clinical development of a new chemical entity to be poorly handled, it is not possible for the clinical researcher to add any characteristic that the particular chemical entity did not possess when it was synthesized.

In contrast to this, in the OTC area, the clinician is actually in a position to greatly influence the choice of compounds on which he/she and the company will do research. He/she can even creatively discover new indications suitable for OTC therapy. The OTC clinician typically enjoys major input into all decisions involved in the company’s commitment to particular compounds and formulations. This is true for OTC switch and for new formulations of older products. The formulators in an OTC operation seek extensive input from their medical colleagues, and the corporation looks to the clinician for more than just straightforward opinions. Creativity is required and he/she has an opportunity to devise concepts that are actually developed by the company.

Because the development cycle of OTC drugs is much shorter than that of prescription compounds, the clinician is often able to see an idea of his/her own brought to fruition in the form of an actual product. Typically, it requires only three years or less for the development of an OTC drug, as opposed to 7–10 years for a new chemical entity. The skillful use of medical knowledge and its creative application to new products can make all the difference in the medical and business success of an OTC company.

The extent to which the OTC clinician is a key decision maker is especially clear in dealing with the release to market of new formulations of drugs that have monograph status. Here the Sponsor makes direct judgments on the safety and marketability of products without the intervention of a regulatory agency. The US FDA has provided for the direct marketing of a wide variety of OTC drugs which it has pre-approved in the so-called ‘monograph’ system. The underlying concept of this system is that there are many drugs that have long been on the OTC market and for which abundant information already exists. Therefore, it would be redundant and wasteful for a new NDA to be submitted each time a new formulation of one of these compounds is to be brought to market. The FDA has provided a series of numerous monographs, each one of which deals with a particular narrow therapeutic area, ranging from acne and antihelmintics to hormones and weight control. The therapeutic area is discussed in some detail and specific requirements for well-established drugs in that area are set forth. As long as a new formulation remains within the exact requirements set forth in the monograph for type of drug, dosage, indication
and labeling statements, a compound may be formulated and marketed on the judgment of the Sponsor alone. No further pre-approval or examination of any application to the FDA is necessary. However, if the requirements set forth in the monograph for a particular compound are to be changed in any way by a different dosage, a new indication or by changes in labeling, the formulation no longer is covered by the monograph and it is necessary to submit a full NDA. As long as the monograph requirements are strictly met, the clinician in charge will make the final judgment on whether a new formulation is satisfactory for market. This system exists only in the United States and it provides for a striking amount of speed and flexibility in the OTC marketing of products.

However, it also places a very substantial amount of responsibility on the Sponsor. You can never appreciate the value of having a regulatory agency review your work and make the final decision to allow marketing until you do not have them and must take the responsibility yourself. This is particularly true with regard to the tolerability of new formulations. It is unlikely that major safety problems will arise with well-known drugs dosed at well-known levels for indications that are thoroughly understood. However, with topical drugs, where irritation and allergenicity are a problem, the judgment of suitability for market can be difficult. These drugs tend to be very dependent on the contents of individual formulations and be sure of enough information before release them to market.

The need for specific clinical testing must be determined by the clinician in each individual instance. A wide variety of situations may arise, varying from those in which no particular testing is required to those in which an extensive series of tests is needed before full confidence can be felt in a formulation. In short, the American monograph system provides unparalleled speed and flexibility of drug development for those compounds which are covered by it, but especial vigilance is also needed on the part of the OTC clinician. For all the delay and difficulty involved in obtaining approvals from FDA, it does have the major advantage that it provides a second source of learned judgment prior to the marketing of products. Even in the limited scope of monograph drugs, the clinician can often find it necessary to use all his/her abilities to ensure that adequate testing is done and that careful judgments are made before individual formulations are allowed to reach the marketplace.

Because of the monograph system, one of the more striking features of OTC drug development is the speed with which new formulations may be moved from the conceptual stage to actual product realization. This contributes in a major way to job satisfaction, but also creates the need to act with much more speed in advancing one’s own portion of the development efforts. There is a need for the clinician to participate in every phase of early planning of a development program. This is the only way to ensure that it is properly handled and can be quickly executed. Frequently, several companies will be moving forward with similar projects. Both commercial and personal success rely upon being the first to market. Thus, the program must be planned for success on the first try. If major delays in research occur, the product will usually be so far behind competition in reaching the market that it will have little commercial value.

Several factors can accelerate the entire process of research in the OTC area. As it is much quicker and simpler for a product to remain within the monograph requirements, every effort is made to do so if it is possible. For research with monograph drugs, it is perhaps surprising to learn that an investigational new drug (IND) exemption is not always required prior to undertaking research. This is only logical, however, as for a monograph drug there is pre-approval from the FDA to actually launch the product into the market. It would not be sensible to require special pre-approval to perform human research via the IND system. This considerably speeds and simplifies the course of the research effort but again results in greater responsibility for the OTC clinician. The clinician must ensure that the research undertaken will be complete and adequate for both safety and efficacy determination purposes and must make a solo judgment as to the safety of the research subjects involved, with no FDA oversight.

The details of the clinical research process are little different for OTC and prescription work. What changes most is the role of the Sponsor.
This role is greater in scope and responsibility in the OTC area and everything must be done with greater speed.

**14.4 Prescription-to-OTC switch**

One of the most dynamic areas in the pharmaceutical industry today is the prescription-to-OTC switch, commonly called the \textit{Rx-to-OTC switch}. This is the process by which a drug that has previously been used only by prescription is converted to self-medication status. We have already considered the criteria for OTC use of medications and these criteria represent a sound guide in determining what drugs are suitable for switching. There are no hard and fast guidelines for determining which drugs may become suitable for OTC switch, but a consideration of self-diagnosability of the disease state to be treated, the general safety and tolerability of the drug, its ability to show efficacy in the hands of nonprofessionals and a relative absence of problems with masking of symptoms all contribute to making a drug more OTC-able.

The first question that arises when considering the possibility of an OTC switch is, why has the drug not been available OTC before and what can be done to remove the obstruction? It is possible that a drug may simply not have had adequate prescription experience in the past. It takes time to accumulate a substantial use database of real-world experience. This is essential to make it possible to form a judgment about safety in prescription use and, therefore, projected safety in OTC use. What constitutes substantial use is always a relative matter. Typically, at least three years of data accumulation with a widely marketed drug is required to be able to feel some security in making judgments from the adverse reaction database accumulated. For drugs with 1000 sales this can easily take 10 years or more. The fewer problems this database reveals, the better the drug will be as a switch candidate.

It is sometimes possible to accelerate the accumulation of data for a promising OTC candidate by specialized phase IV studies. These studies accelerate the process of data collection by conducting what amounts to a survey amongst clinicians using the drug on a prescription basis. As the sole interest is the gathering of adverse reaction data, with special emphasis on rare and serious events, record forms are kept very minimal, often to a single page. The study design consists simply of a survey done without control groups. Hundreds of clinicians, or even thousands, must be contacted to participate in the survey by submitting brief record forms on patients they treat in their usual manner with the prescription drug. Such a survey can rapidly provide a much more reliable database than spontaneous reporting. With a survey, you get both a frequency of the various side effects and a reasonable estimate of the number of patients treated, which permits the calculation of accurate rates for the adverse effects observed. This is in marked contrast to the data obtained from an entirely spontaneous adverse reaction database, where it is impossible to determine what the efficiency of reporting is. Therefore, it is extremely difficult to estimate correct rates of occurrence of individual adverse effects. The spontaneous databases are more useful for the qualitative evaluation of what can happen with a drug than for the quantitative evaluation of its true frequency. This type of adverse reaction survey study can pave the way for a switch effort in much less time than needed if reliance is placed solely on spontaneous reports for collection of data.

If the principal barrier to switch has been a lack of clinical experience with a drug, this can be remedied by the collection of a large adverse reaction database. Once this is done, it is usually straightforward to establish that the drug is safe in prescription use. This is a major advance on the road to OTC approval, but it certainly does not yet prove that the drug will be safe and effective in the hands of consumers without the benefit of a learned intermediary. In order to establish this additional point, it is almost always necessary to supplement the analysis of adverse reaction databases with clinical studies in realistic conditions, using the labeling composed for the OTC product. We will discuss the peculiar aspects of the design of clinical studies suitable for such purposes later, but for now, it is sufficient to note that they may usually proceed with the objectives of establishing efficacy and side effects \textit{in a fully realistic OTC setting}. 


When starting with a prescription-only medicine, it is extremely important to begin interactions with the regulatory agencies as soon as possible, if only to establish whether or not there are concerns that the company has not anticipated. Obstructions to an Rx-to-OTC switch might not be related to safety or efficacy, and can involve some other peripheral but still highly important considerations. Examples of such problems are indications which the FDA does not regard as self-diagnosable, spread of antibiotic resistance or inability to keep the OTC product out of the hands of children. It should be remembered that Regulators’ principal concern in considering an Rx-to-OTC switch is from a public health perspective. This is in contrast to the usual viewpoint of the pharmaceutical companies, which tends to be focused on the treatment of the individual patient. There is nothing that will facilitate the Rx-to-OTC switch of a drug more powerfully than convincing Regulators that this will contribute toward the health of the public.

Other issues that may concern Regulators are when a precedent is being set. It is possible that the precedent set by one particular Rx-to-OTC switch could be damaging in terms of their overall policy, even when they have relatively little concern about the switch itself; this may be the reason for hesitancy shown in approving ‘Plan B’, a proposed OTC product for emergency contraception by the US FDA. Careful negotiation is called for. The corollary is that if your proposed Rx-to-OTC switch can be shown to follow some sort of precedent, then your road with the regulators will be smoother.

Another broad-scale public health concern which may worry the FDA is the implied message given to the consumer by the OTC availability of a particular compound. This concern is illustrated by the situation with soluble fiber cholesterol-lowering agents of the psyllium-type. These agents have been shown to lower cholesterol but only to a very small degree. It was felt by the FDA that, if they become established with claims of cholesterol reduction, the population may be misled into feeling that they have made a major beneficial intervention in their lipid profile, when, in fact, they have not. The message communicated to the consumer by making these compounds available constitutes a barrier to this Rx-to-OTC switch.

The timing of the Rx-to-OTC switch can be a major contribution to its success. The timing is influenced by both regulatory and commercial considerations. The completeness of the available database is critical, and the time this takes can dictate the timing of a switch. Often, however, it is a commercial factor which is the key to deciding when an Rx-to-OTC switch should take place. Before the end of patent expiration is one obvious opportunity for major benefits to a company to obtain OTC status, and offset the foreseen precipitous decline unit price of the prescription product, and reduction the Sponsor’s share of that segment of the Rx market. Typically, once a drug has become an OTC product, it is sold at a lower unit price with smaller profit margins, but the total volume increases several-fold. On occasion, the rapid growth of an OTC market can be even larger than the original prescription sales.

Unfortunately, in many cases, an Rx-to-OTC switch at the time of patent expiration does not occur and there is a long hiatus before OTC status is secured; this is the consequence of failing to seriously examine the need for an OTC switch early enough. Unlike for monograph products, two years are quite insufficient for the necessary studies and regulatory applications in time for an Rx-to-OTC switch. Thus, realistic expectations of loss of patent coverage must be made to create the greatest opportunity. Organizations often exhibit an ebullience, exhibited in one form as the requirement of its staff to believe and promulgate that their weakest method of use patent will prevail against a generic challenge. This weak patent is inevitably the latest. Long-range revenue projections are created and published accordingly, and woe betide anyone suggesting planning for an Rx-to-OTC switch as a contingency.

Awareness of the OTC potential of the company’s portfolio of drugs, and the time it will take to implement, should be constant.

There are two fundamentally different types of Rx-to-OTC switches from the standpoint of the scope of the research program required. Switch programs can vary from large NDA programs, as extensive and expensive as anything found in the
new chemical entity development, to programs consisting of little more than a single study. What influences the basic size and expense for a proposed Rx-to-OTC switch is whether or not either the indication or the dose of the drug will change.

New indication or dose size

If the indication or the dose is to be changed, you will be involved with an entirely new IND/NDA, which is needed to show the fundamental efficacy and safety of the drug, either at its new dose or in its new indication. Such a program obviously will require several years and involve extensive expenditure.

Same indication and dose size:
actual use studies

In contrast to this are the programs of modest size often required for the switch of drugs that will be taken into the OTC market at their existing prescription dosage and for their existing prescription indications. Here, the regulatory agencies will generally accept the concept that there is no need to prove again the basic safety and efficacy of the drug, because this has already been done in the primary new chemical entity NDA. Such a repetition would not provide useful new data. What will be required is an actual use study, to show that the proposed labeling for OTC use is effective in enabling patients to use the drug properly. Also, it may be necessary to address whatever specific factor it is that has been obstructing the drug from OTC use hitherto.

For example, if there is a question as to whether the prescription indication that will now be taken OTC is self-diagnosable, then a study of self-diagnosis will be required. This occurred with the vaginal antifungal compounds, which were long kept on prescription status because of questions as to whether women could effectively diagnose vaginal candidiasis themselves. Only a single study was required to resolve this issue. It was extremely unusual for the pharmaceutical industry, in that it involved no drugs of any kind. It was simply a study of women’s ability to self-diagnose, but it resolved the one outstanding issue that had blocked OTC approval.

The time required to carry out studies on such special questions can vary, considerably depending on the complexity of the question. However, it is typically a brief program and its budget is commonly small by the standards of the pharmaceutical industry. It is obvious that in the planning and preparation of a switch program, it is essential not to assume that a full safety and efficacy program will be required. Rather, early communication with the regulatory agencies is needed in order to establish what barriers actually exist.

14.5 Special study designs
for the OTC area

The philosophy for OTC study design is significantly different from that of prescription medication studies. With prescription medications, you are typically striving to answer the basic scientific questions of ‘can this drug work effectively’? and ‘is it safe to administer to people’? Therefore, it is appropriate to study these new chemical entities primarily in highly controlled settings with extensive inclusion and exclusion criteria. This provides increased safety for the study participants, who will be using a drug of relatively unknown toxicity. Also, it allows a reduction in the inherent variability of the study population so as to obtain a clearer scientific answer to the questions of basic safety and efficacy. Every effort is made in studies of this type to control for all possible variables and to reduce random real-world circumstances to a minimum.

For drugs being prepared for the self-medication market, it is just the opposite. In this situation, a great deal of evidence is already available about the safety and efficacy of the drug. The key issue is whether the drug can work in the real-world context, with all the inherent happenstance and randomness in an environment that is relatively more chaotic than even outpatient IND/CTA studies. Realism is the key to OTC research design.
Actual use studies are often called ‘slice-of-life’ studies. In the real world, what will this OTC product do? It helps when inclusion and exclusion criteria are minimized, as they are in the supermarket or pharmacy. Every effort should be made to simulate the way in which patients will actually use the drug. Eliminating large segments of this population by strict admission criteria will simply give a result that is irrelevant. In some cases, it may even be necessary to even have patients pay for the drug, in order to assess the motivational factors associated with a purchase (they can be reimbursed post hoc and without their prior information).

In the same philosophical vein, it is important to design the study for minimum interaction with the patient. He/she must be left free to act, guided only by the labeling. Intervention by the investigator will only distort the results.

These types of studies are not unscientific. Even if lacking well-matched placebo-controls among others, there is still a hypothesis under test, and these studies are addressing different sorts of questions. At the stage where a drug is being considered for a switch, the umbrella question is, ‘What impact will this drug have on the public health as it will really be used by the lay public’? – the central question that the Regulators and the Sponsor need to be answered.

Real-world studies are tests of the labeling as much as they are tests of the drug itself. It is essential that the combination of the drug and its OTC labeling work closely together to enable patients to self-treat effectively. Not only is a great deal of creativity necessary in developing effective labeling but appropriate label comprehension studies are also important in ensuring that the best labeling is obtained. The labeling may, in fact, make all the difference between approval of the Rx-to-OTC switch.

Research has shown that patients by and large do read labeling and they do heed it, particularly when they are using OTC products that are unfamiliar to them. Prior to any program being advanced to the stage of the definitive clinical studies, it is wise to develop a variety of different versions of the proposed labeling, so that these versions can be tested in label comprehension studies. These studies are sometimes organized by the medical department and sometimes they are carried out as market research, as they need not involve actual ingestion of drug. They consist of comparative studies in which patients in a realistic setting read the proposed labeling and then are quizzed on their comprehension of it. In this way, it is possible to see whether they understand how the drug ought to be used and whether they have understood key precautions. It is best to check both short-term and long-term comprehension to see how well the patients are able to remember what they have learned. This sort of pre-screening of labeling can be absolutely essential to success and it has saved many careers by avoiding disasters in large-scale definitive studies. Note that Institutional Review Board/ethics committee approval may still be required even when a drug is not being swallowed because, at the very least, there will still be issues of informed consent and confidentiality that must be accorded to participants when documenting their experience of disease.

14.6 Market support studies

The market support study is the second major class of study that is used commonly to research OTC products. These often involve active comparator, head-to-head clinical comparisons between alternative formulations or against competitors. Only authentic differences will emerge as successful claims at the end of the study process.

Locating such possible advantages for quantification in market support studies can be done through usage and attitudes (U and A studies) studies, usually performed by marketing departments. Focus group sessions can be invaluable in discovering the possible existence of advantages for a particular formulation over its competitors, as well as individual interviews, and these are discussed elsewhere in this book.

Careful review and surveillance of the literature is another way in which differences can be identified. The term ‘literature’ should be interpreted loosely; it should include the academic journals, newspapers, magazines, patients’ newsletters and any and all ephemera associated with the disease or drug of interest. Even small differences may be quite
meaningful to patients, even though they may appear minor to the pharmacologist, who is not actually using the drug him/herself. For example, in the case of an antinausea drug, a difference in onset of action of 10–15 min can be very important if you are the one who is nauseated, and yet completely insignificant to the medical reviewer of the original NDA at the regulatory authority. The other side of the coin is that differences that are not meaningful to patients will not generate sales: do not let the scientists run this part of the company! And do not allow expectations grow out of hand; chasing after advantages that never existed in the first place leads to designing studies for bizarre purposes with a very high failure rate.

**New claims**

Once a probable new claim has been identified and the chances of its being scientifically valid have been assessed, two good-quality studies are usually necessary to support them (rarely, a single study may be enough).

A different regulatory *milieu* compared with prescription-only medicines drives what is needed to support a new claim for an OTC product. Typically, after a brief initial period, oversight of the OTC product passes to the government authorities that deal with consumer products and trading in general, rather than the EMEA or FDA (for example, in the United States, this is the Federal Trade Commission). In practice, advertising of OTC products must conform to the standards that might equally apply to, say, washing powder, fashion clothing, ‘herbal remedies’ or shoes. The OTC pharmaceutical industry also tends to be self-enforcing; companies maintain eagle eyes on each other’s advertising as part of the literature surveillance program described above, and often their competitors when unsupported claims are suspected. The possession of scientifically sound studies is of great value in preventing, prosecuting and defending such lawsuits. Thus the medical director for OTC products often find himself or herself under oath, and there is less trepidation when you have carefully prepared a satisfactory scientific basis for the advertising claims that you have approved.

**14.7 Summary**

An OTC product has two components: the gallenical itself and its labeling. New OTC products are developed either by compliance with regulators’ pre-approved monographs or by regulatory approval of Rx-to-OTC switches using the New Drug Application/Marketing Authorization Application procedures. The former is often without direct governmental oversight and places a greater responsibility solely on the Sponsor than the latter. Obstacles to Rx-to-OTC switches may or may not be related to product safety and efficacy, and the information needed to support such applications depends greatly on whether there will be any proposed change in indication or dose size, demonstrating a contribution to the public health, and finding a relevant precedent make success more likely. The clinical data in support of a new OTC product should be obtained under conditions that are as close to the proposed ordinary use of the product as possible; in particular, investigator–patient interaction runs counter to obtaining real-world information about usefulness of labeling, capability for self-diagnosis, likelihood of product selection in the retail environment and product effectiveness. Timing Rx-to-OTC switch applications well is key, and realistic anticipation of prescription product patent expiration usually offers one such opportunity. The volume of sales of OTC products in spite of the generally lower unit price can, on occasion, mitigate the loss of, or even exceed revenues formerly realized by, the corresponding proprietary prescription-only drug.
SECTION III
Special Populations and Required Special Studies

Introduction

In 1993, the US Food and Drug Administration (FDA), Europe’s Committee for Proprietary Medicinal Products (CPMP) and Japan’s Ministries of Health and Welfare (MOHW) issued regulatory requirements for testing and labeling in a ‘special population’, namely the elderly. These were not promulgated in isolation but after consultation with academia and industry. In the United States, initially this was done under the auspices of the American Society of Clinical Pharmacology and Therapeutics. Industry was allowed to participate and was largely credited with aiding the process. The First International Conference on Harmonization (ICH) held in Europe (5–7 November 1991), again involved the regulators and the regulated and, for the first time, involved Japan as a major contributor. As a result of pre-conference, during-conference and post-conference discussions, success was achieved. The ‘elderly’ drug guidance was the forerunner of many future tripartite agreements in the clinical area.

The special populations covered in the following chapters include the four major demographic segments: the elderly, women, children and major ethnic groups; and although any smaller grouping of people or diseases may be labeled ‘special’, only renal and hepatic patients and orphan disease have been included in this section. The four major demographic segments were designated ‘special populations’ because, despite the large size of each segment (globally, women constitute 51% of the population), pharmaceutical research has been sparse in these groups. The basis for this is multifactorial. Different responses to needs and medicinal interventions, compared with that in the White male population, have been only sporadically addressed by the research, academic, and industry pharmaceutical development communities.

In general, globally and especially in the United States, legislation controlling food and drugs (including devices and biologics) has been stimulated by therapeutic disasters. This, often in the United States, caused the implementation of the Food, Drug and Cosmetic Act of 1906, which outlawed the practice of embalming meat for consumption. Further disasters triggered subsequent multiple amendments to the Act.

In special populations, perceived omissions of research and development have also resulted in specific amendments to this Act. On occasion, these amendments have been due to political pressure from special advocate groups rather than a specific therapeutic disaster.

Why did industry ignore these special populations, which represent major markets? First, the
costs of additional research would add to the already enormous cost of drug and devices research. Second, the ever-present fear of litigation resulting from perceived exploitation, coercion and vulnerability of these special populations discouraged industry and the FDA from policies of inclusion.

Other influences determining research directions in drugs and devices were paternalism (protectionism) and the money available for grant projects, guided by the numerical male dominance in the reviewing process of research priorities.

For the pharmaceutical industry, it is ironic that attention to these special populations is now proving 'good business,' either because of an extension of protected patent life or the development of special business units. These units have increased market penetration and retention of drugs for third-party reimbursement and allowed niche dominance. The latest of the four major special populations rulings by ICH, the final rule on Acceptability of Foreign Data, was implemented in July 1998. Although it is the latest, it will not be the last – the future impact of the genome project on each of these major demographic segments, and its influence on genomic pharmacology and gene therapy with regard to these 'special populations', has yet to be felt.

Each chapter will give a limited historical context. The chapters dealing with drug development in women (Chapter 16) and racial and ethnic populations (Chapter 18) explore issues of physiology and metabolism in detail, because of the societal sensitivity and a relative paucity of data in the literature.

The chapters on geriatrics and pediatrics (Chapters 15 and 17) focus mainly on the evolution and requirements of the drug development process, because data on the physiology and metabolism of these groups are both widely known and easily available in the literature.

The chapter on orphan populations described what constitutes an orphan population and an 'orphan drug', the history of legislation, and the current inducements for industry.

Lastly, although the chapter on drug exposure of renal and hepatic impaired patients is an essential part of most clinical programs (as a predictor of drug pharmacokinetics in the elderly), it is included in this section as these volunteer patients are indeed special patients.
15 Drug Research in Older Patients

Lionel D. Edwards

15.1 Demographics

The elderly (over 64 years old) comprise 12% of the US population and 17% of Sweden and Japan. This sector continues to grow. In the United States, it is estimated that the elderly population will grow to 14% by the year 2010 and reach 17% by 2030 (US Bureau of the Census, 1996). This, together with their known sensitivity to medications (Everitt and Avorn, 1986), contributed to acceptance by industry of additional requirements for testing in the elderly.

The US Bureau of the Census, International Database (1996) (National Center for Health Statistics, 1996) projected that, for the year 2020, the less-developed countries would contain only 16.4% of the world population compared to 27.1% in 1996, and that by 2020 the mean age of the population in more developed countries would be 42 years, up from 36 years in 1996. In developed regions, the elderly would outnumber young children by 8:1, for example in Italy, based on current fertility and survival rates, only 2% of the population would be five years or younger, but 40% would be 65 years and older.

There were even more startling projections by the United Nations International Population Division (1996). They projected life expectancy in the ‘developed’ countries to reach 81 years by 2050. For less-developed countries, this would still reach 76 years. However, this increase in the global elderly population would be proportionally offset by a decrease in fertility rate, now under way, from 1.7 births per woman down to 1.4 in the Western world. This is below the replacement rate. For Second World regions, the rate of about 3.3 births per woman would decline to 1.6. Even in the least developed (Third World) countries, five births per woman would fall to two by 2050. Thus, the whole world would actually start to ‘depopulate’ in 40 years.

The social and healthcare impact of these demographics in the United States and across the globe will lead to an increased demand for better medicines directed at a healthy old age. This elderly population have more income than average per capita income. In the United States, 70 million ‘baby-boomers’ are starting to retire to a total of 86.7 million retirees, 21% of the population (US Administration on Aging, 2005). In addition, with more time on their hands to lobby, they are more likely to vote, and can be expected to use their political muscle to make demands on their governments. The governments will respond in the usual knee-jerk reaction – ‘more regulations and controls’ on industry – while increasing funding for
academic research aimed at improving the quality of life and the prolongation of active old age. It will be interesting to see whether a more extended life expectancy, over and above the current projections, will reverse the depopulation trend.

15.2 Impact of an aging population on the society

In developed countries, by 2020, the working population aged 15–65 years will fall from 22% in 1996 to 16%. Those aged 65 years and over will increase to 20 from 16% (US Bureau of Census, 1996). In the United States, 60 years ago, the retirement age for Social Security ‘pension’ was designed for an expected average lifespan of 65 years. Already this has been pushed back to 67 years by year 2004, and additional legislation will probably push the age requirements back to 70 in 10 years’ time, when the ‘baby-boomers’ swell the retired population.

To encourage the healthy older person to continue working beyond 65 years, legislation was passed to remove the penalty (in workers 65–70 years) of the loss of $1 for every $2 earned from Social Security benefits in the United States. In 1999, it was proposed that, because of the high cost of medication and because the older people were the greatest users, they be eligible for drug cost reimbursement under Medicaid. This would give the US Government reimbursement control on more than 58% of drugs prescribed and the power to ‘set prices’, as in other countries (e.g. Canada, the UK, France, Italy, Germany). This has sent a chill through the US pharmaceutical industry. The current situation is that the government will not use this volume to drive prices down. How long this legislation will remain unamended is to be seen.

Of great concern is the social and financial impact of Alzheimer’s disease, whose incidence per capita increases to 32% of the surviving population at ages 80–85 (and declines rapidly after age 85). Many live with this disease for five to eight years before succumbing. This causes enormous detriment to the surviving spouse and family and to family finances, and must eventually impact Medicaid and Medicare Federal and State budgets.

The duration of financial burden of terminal care is 1–4 months in general (1–18 months for Alzheimer’s patients) and, even with what would normally be an adequate pension, this burden can financially ruin the surviving spouse. In the United States alone, Alzheimer’s disease will affect 16 million people by 2050 (Tauzin, 1995).

Immigration from the Third World to the developed countries will increase as countries of aging populations try to replace the loss of their labor pool. This is already happening in Europe and in the United States. This again will put further pressure on Medicare and Medicaid, as many of these immigrants will suffer from tuberculosis, hepatitis and intestinal disease, endemic to many of their home countries. In 1997, 39% of tuberculosis cases in the United States were in foreign-born parents; in California, this rose to 67% (Satcher, 1999) and the annual cost of diagnosis and treatment of the 1 million immigrants was $40 million (Muenning et al., 1999). This will cause further competition for available health dollars.

15.3 Prescribing and adverse events

Studies of drug utilization in the elderly showed that older people receive disproportionate amounts of medication (Rochon and Gurwitz, 1995). A study in rural persons 65 years or older showed that, of 967 interviewed, 71% took at least one prescription drug and 10% took five or more prescription medications. Again, women took more medications than men, and in both groups, the number of drugs increased with age. The elderly comprised 18% of the population but received 45% of all prescription items (Lassila et al., 1996).

One in 10 admissions to acute geriatric units was caused or partly caused by adverse drug reactions. The drugs involved most commonly were benzodiazepines, warfarin, digoxin and nonsteroid anti-inflammatories (Denham and Barnet, 1998). Tamblyn (1996), in his review article, cited reports of adverse events causing 5–23% of hospitalizations, nearly 2% of ambulatory visits and 1 in 1000 deaths in the general population. These rates increase in the elderly. Errors in
prescribing accounted for 19–36% of hospital admissions due to drug-related adverse events. To compound this worrying situation, there is the concomitant use of over-the-counter (OTC) nonprescription drugs. Only 50% of physicians or health workers ask about OTC drug use, yet 40% of all drugs used by the elderly are nonprescription drugs. In all, 69% of the elderly use OTC drugs, and 70% take at least one prescription, as described earlier. In addition, 31% take alcohol frequently (Conn, 1992).

This new potential for adverse drug interaction is enormous. Interaction of NSAIDs and aspirin with anticoagulants, such as warfarin or coumadin, can increase the bleeding tendency, and not just from the stomach. Antacids can decrease the excretion of antidepressant tricyclics, quinidine, pseudephidrine and indomethacin. They can also reduce the absorption of digoxin and β-blocker hypertensive medication. These are only a few of the multitude of interactive drug effects. This is imposed on the reduced efficacy of hepatic metabolism and elimination, and renal excretion in the elderly (on average, about 30% reduction). Thus, drug OTC use can add to the recipe for toxic drug accumulation and, in the latter case of antacids, cause further damage to the kidney by loss of blood pressure control and worsening cardiac failure.

15.4 Practical and ethical issues of drug research in older populations

Traditionally, elderly subjects were frequently excluded from clinical drug development (unless the disease being treated was more prevalent in that age group). The reasons given were that the elderly suffer from too many other diseases, require concomitant medicines, are more frail and are more vulnerable to adverse events. All these can cause ‘static’ in the interpretation of the data, and give undue weightage to adverse events in the labeling and product package insert.

In addition, the elderly can exhibit differences, both physiologically and pathologically compared with the younger population; the contrast in speed of disease progression of prostate cancer in the ‘younger elderly’ compared to the slow rate in the ‘older old’, is an example. The elderly are often confused or demented, making informed consent and their continuation in a study questionable. Lastly, because the elderly indication may represent only a small use of a drug, it is uneconomic to include the elderly in a drug’s development program. These are often the perceived concerns of both investigators and pharmaceutical firms.

What is ‘geriatric’? Strictly defined, it describes a person aged 65 years or over, but aging is neither a homogeneous nor a linear process. There are very fit 80-year-olds who climb mountains, and young children dying from genetic advanced aging (progeria). The elderly therefore cover a spectrum of fitness. So many of the above concerns can be reduced by selecting ‘uncomplicated, healthy’ older patients in phase I studies, who are increasingly available due to the success of medicines and preventative medicine.

However, there is a need to know how medicines behave in the real world – not just their interactions with other medicines but also in other disease states suffered concurrently, which is often the case in a geriatric population and less so in younger age groups.

For the elderly, of equal importance to life extension and cure is improvement or preservation of their activities. Thus, the results of quality of life, disease outcomes and pharmacoeconomic studies are of even greater relevance to this special population and to third-party payers.

15.5 Regulatory response

By the 1980s, most of the new medicines still had little or no information on elderly dosing or contained disclaimers. As a result of this, and the fact that 30% of prescription drugs by then were consumed by just 12% of the population (those over 65 years), a new guideline was issued. Thus, the FDA Guideline on Drug Development in the Elderly (1990) recommended that, if a drug was likely to have significant use in the elderly, then studies should be done in an elderly population. These studies should look at effectiveness and
adverse events by age. In addition, other studies should determine whether older people handle the new drug differently (a 30% decrease in renal excretion and liver metabolism is normal in a healthy elderly person). This guideline also required studies of the pharmacokinetics (PK) and, where possible, pharmacodynamic studies of the new drug in the elderly. The Guideline also urged the study of possible drug interactions with drugs commonly used concurrently in this age group. Digoxin was given as an example. Looking even further forward to the future, the Guideline encouraged the inclusion of patients over 75 years.

Medicines in the elderly had become a world issue and, in 1994, the FDA implemented the ICH tripartite guidance, *Studies in Support of Special Populations: Geriatrics* (*Federal Register*, August 1994). The agency followed up with specific requirements on content and format of labeling for human prescription drugs; addition of a ‘Geriatric Use’ subsection in labeling (*Federal Register*, August 1997). This set out priority implementation lists of drug categories for information in geriatric population and gave the industry one year to comply. It also set out the specific content and format of wording to be used.

### 15.6 Overview of international harmonization conference guidelines

This guideline was very similar to the 1990 FDA guideline in intent. It made the following requests:

1. Studies should be done in new molecular entities (NMEs) or new chemical entities (NCEs) likely to be used in the elderly, either to treat a disease of ageing or because the disease is also common in the elderly.

2. Studies should include patients 65 years and older, and preferably patients aged 75 or older, and advised against arbitrary age cutoff (patients aged 60–65 are not considered elderly).

3. Meaningful numbers, especially in phase III: a minimum of 100 patients was suggested for a non-geriatric-specific disease (e.g. hypertension).

4. Analysis of the database for age-related differences of efficacy, adverse events, dose and (gender) relationships. A geriatric database may contain data from the main phase II and III studies or from a geriatric-specific study.

5. PK studies, either formal PK studies or on a population basis, should be carried out. For the latter, a blood sample is taken from many patients on up to four occasions. The time of dosing is recorded, and the time of samples. The patients must be in ‘steady state’. This way, an adequate population PK plot can be built.

6. PK studies in renal-impaired patients if the drug or metabolites are renally excreted. If the NME is excreted and/or metabolized by the liver, a hepatic-impaired study should be undertaken. These studies do not have to be done in elderly patients (they are usually done on a new NME anyway).

7. Usually, differences in the therapeutic response or adverse events are too small to detect at an equivalent plasma level between ordinary adult and elderly patients to make this a requirement. However, separate studies are requested of sedative hypnotic psychoactive drugs or drugs having a significant CNS effect, and, similarly, if phase II and III studies are suggestive of an age-related difference.

8. Drug interaction studies should be done on digoxin and oral anticoagulants, for these drugs have a narrow therapeutic range and are commonly prescribed in the elderly. These drugs frequently have their serum levels altered by other drugs. Where drugs are heavily metabolized by the liver, the effect of drug enzyme inducers and inhibitors should be explored. Similarly, drugs which will share the same cytochrome P450 enzyme pathways should be tested. Ketoconazole, macrolides and quinidine
are given as examples. Finally, other common drugs most likely to be used with the test drug are recommended to be explored for possible synergistic or antagonistic drug interactions.

15.7 Industry response

A survey conducted by the FDA in 1983 (Abrams, 1993) showed that, for 11 drugs recently approved or awaiting approval of New Drug Applications, in seven applications 30–36% of patients were aged over 60. In one application, a study on a drug for prostate cancer, 76% of patients were, not surprisingly, over 60 years old (Everitt and Avorn, 1986). An additional survey by the FDA in 1988 of 20 NDAs showed similar results but, in addition, analysis by age and PK studies in the elderly were frequently included. A survey by the Pharmaceutical Research and Manufacturers of America (PhRMA) (Tauzin, 1995) showed that 917 medicines were being studied for potential use in the elderly. These include 373 drugs targeting indications of old age, 166 for heart disease and stroke.

A private survey of 19 pharmaceutical companies operating in the United States (Chaponis, 1998) ranked cardiovascular, depression, Alzheimer hypertension, rheumatoid arthritis, osteoarthritis and oncology as the most important therapeutic areas in their company. All of these are commonly found in the elderly. Why did companies target these therapeutic areas in the geriatric population? This drew the response: ‘It’s a growing population,’ from 77% of respondents, and ‘increasing market size’ from 58% of the 27 company respondents. Companies were asked which types of geriatric-based clinical trials they conducted. Safety, efficacy, PK and drug interaction studies were quoted in that order of frequency, which, because of the introduction of the guidelines, is to be expected. However, the next most frequent studies were quality-of-life, pharmacoeconomic, drug disease (outcomes) and patient satisfaction studies. The later studies reflect the elderly and third-party payers’ influences (Chaponis, 1998). In its 2005 survey, PhRMA reported that more than 600 medicines were then being developed for diseases of ageing. This reflects the increasing importance of medicines for the graying population of United States.

15.8 Issues of diseases in the elderly

Hypertension affects about 50% of the elderly population. There is also a unique form called isolated systolic hypertension, which affects 9% of the geriatric population and is growing as the population ages. The challenges of doing studies in this area increase with the age of patients admitted, which correlates with increased concomitant medications and illness and compliance, but otherwise relates well to study designs in the younger age group. This is a major cause of the following three major events causing death in the elderly.

Coronary heart disease caused one in five deaths in 2002 at average age of 65.8 and 70.4 for women (American Heart Association, 2005).

Heart failure is a leading cause of hospitalization of the elderly. About 5 million Americans suffer from this disease, which has a high mortality rate. Control of blood pressure, use of β-blockers, ACE inhibitors and now spironolactone (Pitt et al., 1999) will result in further improvement of mortality which have started to fall from 117 per 110 000 in 1988 to 108 in 1995, according to the Center for Disease Control and Prevention (CDC). Because of its severity, patients are on many concomitant medications apart from the aforementioned drugs, such as diuretics, digoxin, potassium supplements, medicines to improve pulmonary function and antibiotics to control frequent infection in edematous and often emphysematous lungs. Measurements of heart function, and the long duration of these studies and large patient numbers required for mild to moderate heart failure (end point death), make these very challenging and expensive studies.

Stroke thrombotic or hemorrhagic is the third leading cause of death, killing 160 000 persons in the United States each year, 7 out of 10 victims are aged 65 or older. Of those that survive, one-third will be permanently disabled. Some improvements in these figures are hoped for, with earlier use of
thrombolytics in case of cerebral thrombosis. As of 1999, more than 20 new drugs were in development to treat this condition.

Arthritis causing inflammatory and degenerative changes around joints affects 43 million in the United States, and CDC projects that this will rise to 60 million by 2020. It can be caused by more than 100 different diseases, but the commonest are osteoarthritis and rheumatoid arthritis. New medications, such as the anti-tumor necrotic factor α-blockers, raise fresh challenges to clinical study methodology because of limitations on nonclinical toxicity predictors and the application of biologic measurements on a traditional drug appraisal system.

The new nonsteroidal anti-inflammatory drugs, including the Cox II inhibitors, because of the vast range of arthritic diseases, require that careful selection of indications for initial product approval must be undertaken. Rarely do companies have the time or money to develop all the pain indications (acute, chronic use) or to study arthritic diseases prior to product launch. As with hypertension, the numbers of patients required in the database will be large for product approval, especially for safety.

Depression is a frequently missed diagnosis in the elderly. The Alliance for Aging Research says that 15% of Americans aged 65 years and older experience clinically relevant depression. It can amplify the underlying disabilities in stroke, arthritis, Parkinson’s disease, slow or prevent recovery from hip fracture and surgery, and be mimicked or masked by an underactive thyroid. The latest receptor-specific medicines have a very much reduced potential for adverse events and drug interactions. Difficulties can arise from confusion, memory impairment and disorientation, which are common in the depressed elderly. This brings challenges of ensuring both drug compliance and follow-up visits are easier to achieve than with Alzheimer or depressed patients.

Alzheimer’s disease is the eighth leading cause of death in the elderly and already affects some 4 million Americans. The incidence rises from 2% at 65 years to 32% at age 85. The National Institute of Health (NIH) estimates that at least half of the people in nursing homes have this disease. A small study of donezil showed that this treatment avoided the need for home nursing care by half compared to those who did not receive the medicine (Small, 1998).

Clinical studies in this disease are very expensive, often requiring several collaborating disciplines at each investigative site. A gerontologist, a neurologist, a psychologist and a psychiatrist may be required, in addition to the usual support staff. Multiple cognitive tests and behavioral ratings of the patient often involving primary caregiver ratings will be required – all this in addition to the basic Alzheimer’s Disease Assessment Scale (ADAS–COG). These studies, at present, require large numbers of patients to show the often small improvement, as well as months of observation to detect a slowing of progression. These studies require large numbers of patients, and many are conducted at multinational sites. It must be asked if cognitive scales are validated in different cultural backgrounds.

15.9 Issues in the conduct of clinical studies in the elderly

Informed consent

In general, the principles are no different with the elderly than with other adult persons; the elderly are just as subject to the relationship to the researcher if the clinician and researcher are one and the same. Not wishing to offend (by refusal) is very strong in the elderly, and also they are also subject to ‘therapeutic fallacy’, that is they find it hard to accept that, despite repeated descriptions of risks and possible benefits, the treating physician could be really offering them treatment of uncertain benefit or risk.
The elderly are more likely to have cognitive impairment or mild dementia, and to be living alone, in poverty or under institutional care. They are also vulnerable to caregiver abuse, often because of indifference, anger or physical abuse triggered by the patients’ behavior and difficulties derived from their disease.

Hearing or vision problems must be expected; bright light and large print, together with honest and simple language, much used for eliciting the informed consent. Research subjects, whether elderly or not, should be able to understand the informed consent process, feel free to refuse or to withdraw from the study without reprisal and understand the uncertain outcomes of the new drug, the use of placebo and the random allocation of treatment.

The most vulnerable elderly population is found in nursing homes or mental institutions and frequently comprises persons of diminished or fluctuating mental ability. Ironically, regulations governing research in these patients were proposed but never voted upon. The NIH established a policy which allowed a patient, when he/she was still in good cognitive condition, to appoint a ‘Health Care Agent’.

For industry, prior written agreement of a family member with the potential subject to act as ‘guardian’ is preferred but not always attainable. It is best for the researcher him/herself to meet with relatives, nursing staff and residents, and fully explain to them the study purpose, benefit and risks, as well as to the patient. Not infrequently, any of these persons may feel protective of the patient and undermine the research objective. It is wise that all family members who are not involved be sent a letter explaining the research, including a form to be completed if they wish to prevent the patient being involved in research.

Compliance

Compliance in the elderly in general is similar to that of the general population. If more than six drugs are prescribed long term, or more than three doses per day are required, then compliance will suffer (Gately, 1968; Blackwell, 1979). These factors are more common in the elderly. Recommendations for improving compliance in older patients are similar to any other studies, except for one – that the physician should set priorities for which medications are critical to patients’ health in a polypharmacy setting. The medication regimens should be as simple as possible; the caregiver and patient should be educated about the name, dose and reason for all medications. Patients should be given simple instructions on cards, together with suggestions on how to remind themselves – ‘tick-off cards on fridge’, ‘diary notes’ on bathroom mirror for morning dose, or on pantry door ‘with food’ and so on. Patients and their caregivers should be given educational pamphlets about their diseases. They should be encouraged to ask questions or report possible adverse events or strange feelings. Patients should be asked to repeat back instructions. Lastly, there are telephone call services which will call and remind patients to take the medicine, or help organize cabs or transport for follow-up visits, either to the laboratories for blood work and so on, or to the investigator appointments.

Screening and recruitment

The Chaponis (1998) survey of 19 US-based companies reported also that 32% reported difficulty in finding suitable investigative sites for geriatric patients. In addition, those respondents involved in phase IV outcomes, quality-of-life and pharmacoeconomics studies and so on, said that the lack of ‘in-company’ geriatric expertise and resources was a barrier. Locating suitable investigative centers for geriatric studies is only part of the solution and works well for the smaller elderly experience studies. Nonetheless, in clinical studies undertaken for specific diseases in aging, much larger numbers of patients must be enrolled.

Even the large resources of the NIH can be strained. The Systolic Hypertension in the Elderly Person (SHEP) investigation recruited 4736 patients aged 60–96 years (average 72). The patient screening and selection was organized from 16 sites but took 31 months to complete, which had initially been projected to be 24 months.
Nearly 450,000 patients were screened (SHEP Cooperative Research Group, 1991).

Hall (1993) reported on 15 cardiovascular studies funded by the National Heart and Lung Blood Institute (NHLBI) over 10 years. All overran their projected recruitment times by an average of 27%. Overoptimistic projections are the norm, and this norm has been called ‘Lasagna’s Law’ (Spilker and Cramer, 1972). For pharmaceutical clinical physicians and their staff, similar overruns are not excused by management, and raise the temptation to ‘move the target’ by closing recruitment at a lower level. This solution compromises the statistical robustness of the study; both the problem and this solution are career busters. Better to project realistically and plan recruitment and fallback strategies. Hall (1993) also varied the recruitment strategies used; the most successful was community screening. This can be done through appeals to senior centers, churches, shopping centers and major industrial sites (Melish, 1982). Medical chart review is also productive if the condition has a International Classification of Disease (ICD) code and charts are available to the investigators.

For large studies, mass-mailing to registered voters, members of organized groups such as AARP, or members of a disease association can be helpful, with 7–12% response rate (McDermont and Bradford, 1982). Use of media campaigns can result in up to 11% of first protocol visits (Levenkrow and Farquhar, 1982). These need at least 3–6 months of planning for resources to respond to the initial wave of inquiries. The approach can be a newspaper article and advertisements in regional papers, TV and radio. Appeals to community physicians for referrals are usually disappointing, possibly caused by the physician believing that he/she will lose a paying patient to a research clinic.

**15.10 Conclusion**

The growth of the aging population, regulatory overview and increased business opportunities will ensure the growth of clinical research in the elderly. Recent reports of the high level of seniors’ adverse events, many leading to deaths, both in and outside hospitals, will force more monitoring systems for medications. Soon, plastic medicine card chips with imprinted medication recorded by the pharmacist will be required by third-party insurers. This would ensure that all current concurrent medications are captured.

There is a shortage of geriatric specialists, which will take time to be corrected if the 600 drugs under development are to be adequately researched. The rapid growth of sheltered self-care communal housing for active seniors, which guarantee healthcare up to terminal status, illustrates that seniors wish to stay out of nursing homes. Their expectation of the pharmaceutical industry is that it should provide them with medications which allow for an active old age. The industry has heard.

**References**


Federal Register. 1999. ‘Guidelines for the study of drugs likely to be used in the elderly’. Federal Register, March 55 FR; 7777.


Hall WD. 1993. ‘Screening and recruitment of elderly participants into large-scale cardiovascular studies’. In Inclusion of Elderly Individuals into Clinical Trials, Wenger NK (ed.). Marian Mennel Dow: Kansas; 67–71.


16 Drug Development Research in Women

Lionel D. Edwards

16.1 Background

The pharmaceutical industry is in the business of developing, manufacturing and selling drugs, vaccines and devices. Although basic research has become more important in recent years, it is not the primary aim of industry. However, increasingly and usually dictated by opportunity, industry is investing in a highly targeted fashion in some aspects of basic research, but the development of a product is always to the fore. This thrust, however, need not exclude the gathering of basic data, which may prove invaluable to the research process. Regrettably, these data were frequently inaccessible, in some instances owing to the needs of confidentiality, product protection or even legal concerns, but by far the greatest reason is that such data are regarded as a by-product, almost ‘waste data’, for they are not part of the mainstream of product development. Such data are recorded but rarely utilized, frequently residing in notebooks, case records, mainframe databanks, statistical reports or data tabulations in the back of appendices of regulatory submissions.

So it is with gender data: it is collected, analyzed and tabulated by each study and by each drug, but data on drugs of the same class and between each government agency handling multiple applications are virtually inaccessible. Mining these data requires more creative solutions than ‘regulations’. This is now happening.

It has been estimated that the average cost of developing a new medicine is now $805 million (DiMasi, 2003). This estimate mostly comprises costs in development, but includes the loss of other revenue if the development money had instead been invested cumulatively. These costs are passed directly on to the consumer.

Drug costs have risen slowly compared to other health costs, when adjusted for inflation. When compared to other health costs, in 1965, the drug/device cost was less than a dime per health dollar and in 2004, it was less than twelve cents (Health Care Financing Administration). Drug cost is, and must remain, one of the most affordable aspects of treatment. A large component of drug development cost is caused by regulatory needs to test for drug safety and efficacy, both for the USA and foreign agencies. Clearly, the cost of any additional regulation imposed on top of the current burden will also be directly reflected in the eventual cost to the consumer.

Women comprise 51% of the population of most nations. According to the United Nations, the global female population will increase by 48.4%
from 2000 to 2050, compared to males (45.4%). Population of women over 65 years will increase by 24% over 2000–2010 in the United States and 12% in Europe, and even in 2000 women of 80 years outnumbered males by a 2:1 ratio (Source: United Nations Population Database). In western countries, 54% of women are of childbearing potential (15–49 years). Women account for 57% of physician visits (National Disease and Therapeutic Index, 1991). In the age group 20–39 years, women were found to be the biggest users of anti-infectives, especially ampicillin and amoxicillin; antidepressants are prescribed twice as often to women as to men (Stewart, 1998); and of some concern was that tetracycline, a known teratogen, was the eighth most prescribed drug in the 38% of women of childbearing age (FDA, 1986).

As major users, it might be postulated that women, including those of childbearing age, should be the group on which phase I and phase II dosing (early efficacy and safety) should be based. Why is this not so? Critics of the industry, and indeed of the wider research process, claim that it is entrenched discrimination by males, which is disguised as ‘concern and gallantry’. Critics also point out that both medicine and research are dominated by males, who place research into women’s diseases on the back burner of their male priorities and only see data, even on women, from a man’s point of view. They point to a report by Coale (1991) on the ‘missing 100 million women’ in Asia and the Indian subcontinent, who are speculated not to exist because of abortion and medical and nutritional neglect. They also point to the misuse of science (ultrasound or amniocentesis) for sex determination.

While these are extreme examples of societal attitudes, it is true that women have been excluded from many large, well-published studies, such as the Physicians’ Health Study of aspirin in cardiovascular disease (Henrekens, 1989). It is also true that many early studies of drugs in phases I and II were conducted in healthy white males 18–40 years old, and the results then extrapolated to women in phase III studies, primarily aimed at expanded efficacy and safety. Only recently, Paul Williams (1996) confirmed that exercise raised HDL cholesterol in women, many years later than that reported in men. It is, however, in most cases, grossly naive to attribute this to deliberate ‘male discrimination’ to exclude research on women.

It is also frequently mentioned that fear of embryonic malformation, whether or not drug-related, and subsequent litigation is the major determining factor for exclusion of females from therapeutic and basic research projects. This overly simple explanation covers up other difficulties, such as methodology, lack of relevant baseline information and biochemical variables, both hormonal and gender-related. It also ignores the use of information derived from other groups of women, those of no childbearing potential, sterile or post-menopausal, the elderly or children just entering puberty, where the risk of fetal exposure is non-existent or minimal.

### 16.2 The dilemmas

Do women respond to medications differently to men? If so, in what ways and how frequently are these changes clinically meaningful? Review of the literature shows some examples of differences between the sexes in drug handling, particularly with certain classes of drugs. These will be dealt with later, but it is important to bear in mind that, despite some detectable differences, usually no therapeutically significant differences are seen (Edwards, 1991). This is unlikely to be due to lack of compliance, as women are generally more reliable than men, although compliance does fall off to 67% over a few weeks for both genders (Cramer et al., 1990). This does not exclude self-adjustment of dose by female patients, a phenomenon seen in both sexes and probably much more common than reported.

It has also been claimed (because gender data are rarely mentioned in clinical studies, papers or reports) that gender differences are not sought. This presupposes that data are neither collected nor examined. In fact, the opposite is much more likely: 94% of surveyed pharmaceutical firms were found to collect gender data in their studies (Edwards, 1991). The reality is that
findings of no differences are rarely reported, but sometimes this finding may just be a function of small sample size for each individual study or the small degree of difference to be found. It must also be recognized that many drugs were introduced into medicine prior to the current modern-day comprehensive testing programs. Nonetheless, after many years and millions of prescriptions, it is of reassurance that few have shown significant clinically important gender-related differences.

**Differences in disease presentations**

A report from the National, Heart, Lung and Blood Institute (NHLBI, 1996), showed that the age and incidence (1988–1993) of onset of heart disease between genders were different; 24% of the 65–74 year-old males compared to about 18% of females in the same age group. This incidence rose in both genders at 75–84 years to about 28% males and 30% females.

Not only do women develop heart disease later but they also present differently. The signature symptom of a heart attack, severe chest pain, is often absent in women, and pain in the upper back or neck, or breathlessness and nausea, may present either as a single symptom or as multiple symptoms. The American Heart Association states that 44% of women are likely to die in the first year of their heart attack, compared to 27% of men.

It is not surprising that heart attack and angina are misdiagnosed more commonly in women than men during emergency room visits. The range between hospitals of misdiagnosis was 0–11%, with an average 2.3% for angina and 2.1% for heart attacks. The diagnosis was missed in 7% of women under 55 years (Pope et al., 2000).

Finally a large NIH study (The Women’s Health Study of 40 000 women), just completed in 2005, showed that aspirin gave no cardiac protection to women as had previously been assumed, though it did reduce the incidence of ischemic strokes in women over 65 years. This compared to the reduction of heart attacks in men. A subsequent meta-analysis of six studies, including the Women Health Study, confirmed this, and in addition, showed no benefit in reducing ischemic strokes in men (Berger et al., 2006).

**What’s representative?**

An additional dilemma is, what population is ‘representative’ for female dose and efficacy determination? Women of childbearing potential (54%)? These will have possible hormonal cycling changes and those on contraceptive hormones will have even greater changes, added to a possible basic gender difference, either amplifying or even suppressing effects.

The needs of women aged 66 years or more are already represented in regulatory drug testing guidelines in the elderly, Federal Register (Federal Register, 1990), but women 50–65 years old also can lay claim to special consideration, given the special problems associated with combined hormonal loss and age changes (e.g. osteoporosis, loss of possible cardiac estrogen protection and changes in body fat composition and its distribution). Pregnant women, already isolated from drug development by fear of legal tort laws and, indeed, by their physicians' reluctance to even prescribe in early pregnancy, can also stake a claim to require additional studies. Finally, when studying females of childbearing potential, should we include patients on oral contraceptives (OCs), with their large levels of regulated fluctuating but synthetic hormones, or rely on females not taking OCs? The latter option will increase the risk of potential fetal exposure.

It must now be apparent that the female population (51%) contains many potential subgroups, none truly ‘representative’, for all have major physiological differences from each other. For industry to study all groups would be impractical, uneconomical and would gravely slow the drug development process and compromise the number of agents placed into development. To include all groups within one all-encompassing study, unless extremely large, offends a basic research nostrum – that is ‘stabilize, reduce or remove all the variables except the one to be measured’, or the signals many be lost in the static. This is especially true in phase II studies.
16.3 The phantom fetus

Teratogenic issues

The term ‘phantom fetus’ has been used to describe the current apprehension regarding the use of drugs in women of childbearing potential. This apprehension has dominated industrial, and institutional, and private research. The thalidomide tragedy of the 1960s – the 10 000 or so deformed children now grown to adults – continue to haunt us. It must be recognized that, despite careful animal testing, the full potential for teratogenic activity of any drugs in humans will only come to light once the drug is in the marketplace, and then only when sufficient multiple exposures have occurred in pregnant patients and their fetuses. It is extremely unlikely that deliberate drug testing in pregnant women will ever become routine. However, in special circumstances, such as HIV-infected pregnant women, it is justified to include them in appropriate clinical studies. Current predictive animal screening cannot give complete assurance that the potential for teratogenicity will be uncovered in all cases. It must be remembered that the then-current 1956 screens did not discover the teratogenicity of thalidomide, nor the 16-year delayed hyperplasia and neoplasia effects on the cervix and uterus of female adolescents exposed to stilbestrol (given to prevent miscarriages during their mothers’ pregnancies).

Both historically and currently, the major determination of teratogenicity is made from findings from animal screening; many agents have been eliminated from further development, and only rarely does teratogenicity become uncovered in the marketplace. Nonetheless, it requires large numbers of exposures before the more subtle embryotoxic or teratogenic effects are found, as was demonstrated most recently by the ACE inhibitors, which had passed all the screens. Indeed, these events may never be exposed. How could this be? One must take into account the ‘background noise’ level, the so-called ‘natural’ incidence of congenital abnormalities. By far the commonest is Down’s syndrome, whose incidence is known to increase with the age of the mother, although nearly all other abnormalities appear not to increase with maternal age, according to a recent report (Wilson, 1973). Thus, a higher incidence of ‘typical’ drug-induced teratogenic effects serve as an early alert. The commonest abnormalities most frequently associated with drug exposure in the first trimester are neural tube defects, cardiac and renal anomalies, shortening of limbs and digits and failure of closure of the palate and upper lip. More subtle changes associated with exposure to drugs occur in the third trimester, with hearing and eye abnormalities predominating (Wilson, 1973). Any such determinations require many, many thousands of exposures before they become apparent.

However, many millions of women become pregnant before being aware of their pregnancy and have been exposed to environmental chemicals (most of which have never been tested), as well as OTC drugs and prescription drugs. Also, a number of embryos are spontaneously aborted and a delay to the menstrual period of perhaps two or three weeks passes unremarked or sometimes unnoticed in a background of a national miscarriage rate of one in three pregnancies (Yoder, 1984). Teratologists have concluded that there is a threshold dose for any drug before it shows potential teratogenicity (in other words, enough must be given), and the effect tends to increase with the duration of exposure, with higher concentrations in the plasma or tissues and with the timing of the developing fetal tissues and organs (Wilson, 1973). In the first seven to eight days, the embryo is refractory to any teratogenic effect but is most susceptible 20–55 days after conception. Of some reassurance is that most drugs prescribed to women of childbearing age are antibiotics and tend to be for relatively short durations. But the tetracyclines and antiepileptic drugs are known to have effects on the developing fetus and are frequently prescribed to women (Stewart, 1998).

It is an irony that the normal tenet of US and UK law that an individual is ‘innocent until proven guilty’ does not apply to prescribed pharmaceutical products or devices. They must be proven safe and efficacious before they are approved; in other words, they must be proven to be innocent. Thus, it comes as no surprise that industry and other research groups tend to avoid the potential exposure of women of childbearing age in the early clinical development of pharmaceuticals or
devices, for many experimental drugs (perhaps 9 out of 10 tested in man) will never achieve the marketplace.

The potential for pregnancy while on a trial drug

What is the risk of pregnancy occurring in a study participant while a new drug is being developed? The author is not aware of any published figures, but from the author’s experience in industry and from questions to colleagues, pregnancy does occur during drug development, even in those patients apparently taking adequate contraceptive precautions. A typical NDA database for most drugs will involve between 2000 and 4000 patients, of which perhaps one-third are female and exposed to study medication. It is not surprising, therefore, that given an average failure rate of the contraceptive pill of 2%, or even with the most stringent compliance, a failure rate of 0.5/100 women years will result in occasional pregnancy (Trussell et al., 1990). Other methods, such as the diaphragm, condoms and IUDs, can carry even higher failure rates, depending on whether ‘usual’ or ‘perfect compliance’ calculation of 18–6%, 12–2% and 3–0.5%, respectively, are used (Trussell et al., 1990). If we assume an average NDA database of 4000 patients, one-third or more female, it is likely that half of these will be females of childbearing potential (the other half being postmenopausal or elderly). Thus, approximately 660 females of childbearing potential may be exposed to the drug, the comparator or a placebo. In the best circumstances of perfect contraceptive compliance, in a one-year exposure and at a 0.5% failure rate, 3.3 fetuses are likely to be exposed. With a ‘typical compliance’ of the contraceptive pill, a 3% failure rate would leave about 19 fetuses exposed to experimental entities, one-third of which would be lost due to spontaneous miscarriage.

Few patients would be exposed for a full year, but more typically only between two weeks and three months of study medication. Given all the above assumptions, between 0.8 and 5 early embryos will be exposed in a full drug development program. From the author’s personal experience of over 30 years in industry, an average of two children are born exposed to a new chemical entity. This is most likely to occur in phase III studies, which have many more patients and are often of longer duration. Currently, pharmaceutical firms, with the agreement of the FDA, follow up all possible exposures until any resultant child is 12–14 years of age, and a full medical examination (including a full neurological workup) is done at yearly intervals.

The potential for teratogenic damage during drug study programs

As previously mentioned, the best sources for the actual figures for the above calculations reside within the FDA but may, as alluded, be inaccessible. In recent years, figures given by the Agency, for example in elderly drug-testing studies, appear to have been hand-tallied rather than garnered from composite computer access. However, the agency is now involved in a large effort to ‘mine’ data across therapeutic classes, some of which, with meta-analysis, will provide data which individual drug programs never could, nor were designed to show. In time, the ability to access data across drugs and across drug classes will grow as more firms put in computer-assisted NDAs (CANDAs) in appropriate and compatible programs and formats. What is the risk of a fetus being damaged during an ‘average’ NDA drug development program? Obviously small. Clearly, toxic but ‘life-saving’ treatment will carry a heavy embryotoxic risk; anticancer, anti-AIDS drugs and fetal intrauterine surgical procedures are obvious examples, but the clear-cut risks involved are usually deemed acceptable. A more subtle judgment call involves the development of antiepileptic drugs. Let us look at two examples. It has been estimated that exposure of pregnant women to normal therapeutic doses of valproic acid may give rise to 1% fetal abnormality rate involving the neural tube (Lindhaut and Schmidt, 1986) – 10 times the natural incidence. Many of these defects are correctable with modern surgical techniques. Exposure to phenobarbitone also has a reported higher incidence of cleft lip and palate defects (Frederick, 1973): most are surgically correctible. If used in combination,
the incidence of anticonvulsant teratogenic effects are increased (Lindhaut et al., 1984). Would either of these drugs be developed in today’s litigious atmosphere? Its doubtful. But both drugs are valuable in many circumstances; they may be the only drugs suitable for some patients and, indeed, frequently can be life-saving. Certainly, maternal status epilepticus is very injurious to the fetus, often resulting in miscarriage or premature birth.

The incidence of neonatal abnormalities in mothers taking anticonvulsant treatment is 70/1000 live births (Frederick, 1973). This is 2.4 times the ‘spontaneous rate’ in the general population (29 abnormalities/1000 live births). Thus, even using a known ‘low-incidence’ teratogen could cause 40 additional cases/1000 live births, but to determine that accurately would require many thousands of female patient exposures to be detectable against the ‘spontaneous’ background incidence.

So, back to the opening question. What is the likelihood of detecting low-incidence, drug-induced congenital effects in a drug development program? With our presumed database of 4000 patients, only 0.8–5 fetuses would be exposed to a background ‘spontaneous’ risk of 2.9%. Each program could carry a 1 in 33 to 1 in 6 chance of a single ‘spontaneous’ abnormality occurring. If the drug or procedure should have low teratogenic activity (at the level of an anticonvulsant), this risk rises to 1 in 14 to 1 in 2.5 that a child will be born with a congenital abnormality in any drug development program. Both ‘spontaneous’ or drug-induced abnormalities may occur, for example a neural tube defect. Thus, on a single-case basis, the abnormalities will be indistinguishable for drug causality. This, in turn, can lead to litigation, and certainly to a reference in the package label insert.

Wilson has estimated that both drugs and environmental chemical exposures only account for 2–3% of developmental defects in man (Wilson, 1972). Thus, a product-label reference of such an occurrence will be undeserved at least 97% of the time, but also may be the first signal of a teratogenic risk. It may now be appreciated why this 2–3% risk is termed the ‘phantom fetus’ and also why the difficulty in disproving liability dominates the mainstream concerns of research, regulatory authorities and industry alike. This ‘ghost risk’ creates ‘discrimination’ against female patients in drug research. This ‘ghost’ must be exorcised and contained; possible solutions will be discussed later.

16.4 Industry practice: factors in phase I and early phase II testing

Medical journalist Paul Cotton (1990) asked, in a thought-provoking article, is there still too much extrapolation from data on middle-aged white men? Inspection of the demographics of recent NDAs will give us numbers to debate; however, these data are not readily accessible. Most phase I testing is still undertaken in healthy young males, and even for phase I testing of new contraceptives hormonal for women. Why this occurs is multi-faceted.

Timing of mutagenicity fertility and teratogenicity testing

The complete battery of tests with full histology and the development of a final report can take as long as two years. In general, only some of the mutagenicity studies are completed, and perhaps one- to three-month reports of animal testing are available when male phase I dosing volunteer studies commence. All animal studies do not commence at the same time but are usually sequential. Some, such as postexposure weaning and subsequent second-generation drug effect studies, will be time-consuming and expensive. Often, if mutagenicity tests, for example Ames’ test or mouse lymphoma test, are positive (Ames test has 30% false-positive rate), then females will be excluded until more data are collected. Thus, only limited data are available prior to the first human exposure (for further reference Federal Register, 1994, 1996).

Volunteer dose-ranging studies will, by design, include high enough doses to provoke unpleasant
adverse effects; also, information on ‘target organs’ (organs likely to be most affected or harmed) is usually predictable but unconfirmed at this point. Generally, as a result of animal studies, it is thought that the effect of drugs on reproductive function in males is less than that in females and only affects the sperm viability or, rarely, the size and function of the testicles, which is usually reversible. This is unduly optimistic, as one report by Yazigi, Odem and Polakoski (1991) suggest that spermatozoa may not be immobilized or destroyed by cocaine, but may interact, and the spermatozoa themselves have the potential to act as an active transport mechanism for drugs, pesticides and even environmental chemicals to the unfertilized ovum. They may also alter the genetic makeup of either spermatozoa or ovum. In addition, spermatozoa can be made sluggish by calcium channel blockers, leading to male infertility while on medication. Hence, the European guidelines call for male animal testing prior to start of phase II.

The blastocyst (early embryo) is relatively resistant to damage in the first seven days, for up to 75% of cells can be destroyed before tissue differentiation and the embryo can still survive. What might happen if garden pesticides, or house builders’ formaldehyde containing glue and chemicals, are combined into the genetic material? If it is ever confirmed, then we may have the inkling of what makes up the 65% of the ‘unknown’ causes of developmental defects mentioned by Wilson (1972). If it could be shown that the synthetic chemicals are incorporated into the blastocyst, the field of male phase I testing would be transformed, as would that of genetic counseling.

Testing facilities

Largely because early testing of drugs occurred in males rather than females, for reasons discussed above, most commercial and hospital units devoted to human pharmacology testing were set up to deal with a unisex population. They ran one gender study at a time, usually male, in 1993. Sleeping and bathroom facilities in the units’ dormitory accommodations did not provide for mixed gender groups. These were minor but not inexpensive attentions but were quickly adopted following the publication of the FDA Guidelines for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs (Federal Register, 1993).

Standardizing for the menstrual cycle (phase I and early phase II)

Of much greater concern is the issue of standardizing the drug administration to the menstrual cycle. Women of childbearing age do not all have cycles for the same length of days; variations of 24–36-day cycles are not unusual between and within the same women. Thus, unless controlled by OCs, women volunteers could not start and finish in a study all together. Indeed, if OCs were used to standardize cycles, the issue of how really representative of all women of childbearing age this artificial hormone-boosted group might be would be debatable. Evidence suggests that even low-dose contraceptives can affect metabolism (Abernathy and Greenblatt, 1981). The logistics of running phase I single-dose and multiple-dose ranging studies while controlling for a natural menstrual cycle are truly horrendous, both for the phase I testing units and for the volunteer. The duration of any study would be extended by at least one month (the time required for the last patient’s cycle to start), and each patient volunteer would have to be measured separately because of the different days of her cycle. A small but frequently argued point is timing. Which is the preferred day in the cycle for single-dose studies? And for a multiple-dose study (usually only 10–14 days long), which segments of the cycle should be covered? This may seem academic, but in those clinically significant drug classes where women’s responses to drug handling are different to those of men because of biochemical hormone effects (not just gender), then the timing of drug dosing and measurement would be critical.

Too many young volunteer studies

Many volunteer studies, especially at commercial, academic and university clinical units, include
frequently young people of college age. Both males and females will volunteer as financial remuneration, and a free medical check-up and medical care play their part in motivation. The young also have less career and family commitments interfering with their motivation. Time for studying, reading and relaxation within an atmosphere of camaraderie also contributes to the availability of younger volunteers, who, because of their age, also tend to be very healthy. It will readily be appreciated that most drugs or devices are not unique or life saving but hopefully an improvement on existing agents, and indeed this applies to most basic research experiments. Nearly all drug studies in phase I are aimed at gathering data on a potentially safe and possibly efficacious dose range. As a result, it is often hard to recruit older, more mature women for these basic types of essential drug development programs.

What is a representative female population in phase I?

It has been stated that large numbers of mature women are volunteering for the new lipid, heart risk, osteoporosis and arthritis phase 3 studies, due to their concern that women have been represented so poorly as subjects in the past. Phase I studies are of short duration (one to two weeks) but usually require confinement of the volunteers. Because of this time commitment, far fewer mature women volunteer, due to career conflicts or because they are often burdened unequally with family management. Those that do volunteer are generally unattached young female students. Thus, most female volunteers may not be typical of a ‘representative’, mature, childbearing population (if this can ever be defined).

One alternative, a study design of stratification by age and sex, would lead to inordinately long study recruitment times, because the last ‘cell’ (group) always takes a disproportionately long time to fill. The most obvious way out of the quandary for phase I testing would be to maintain a special cadre of ‘safe, standard’ volunteers. How ‘representative’ these much used ‘new-drug volunteers’ would become is debatable. For example, studies in arthritic patients show that these ‘retread’ volunteer patients will differ in their tolerance to pain and in their judgment of efficacy and severity of adverse events, when compared to drug-study ‘naive’ patients (Coles et al., 1988). This ‘training effect’ increases with multiple drug exposure.

By far, the biggest issue of undertaking additional dosing phase I studies on women is expense. Most of these studies cost $100–250 thousands each. Altogether, single, multiple and multiple-dose ranging studies, with food effect studies and extra staff costs, could add $5 million to development costs and very rarely show a difference which would prove clinically relevant. Indeed, the difference may not show up at all in phase I or II gender-to-gender studies due to other variables, for example small numbers, estrogen-cycle levels and OC levels and drug polymorphism.

16.5 Drug handling differences between males and females

Due to space limitations, this subchapter cannot discuss the many reports of apparent gender differences of psychology, different anatomic brain location of functions, skeletal build and muscle-to-fat mass ratios which might have marginal impact upon drug activity. But an analysis of 300 FDA reviewed new drug applications between 1995 and 2000, of 163 that included a gender analysis, 11 drugs showed a greater than 40% difference in pharmacokinetics between male and female, though while listed on the product label, were not accompanied by any variable dosing recommendations. An analysis of 26 bioequivalence studies involving both sexes was undertaken by Chen et al. (2000).

In 39% two data sets (AUC or CMax) difference of 20% or greater was observed and was reduced to 15% after body weight correction, in men.

In general, the between-gender variations did not result in obvious pharmacodynamic dose-response differences, but care must be exercised in drugs having a steep dose–response curve and/or
a low toxicity ceiling (e.g. digoxin) where adjusted dosing is required.

The weight/dose problem

A casual appraisal of ideal weight-for-height tables for males and females (Metropolitan Life Insurance, 1999) shows clear differences between males and females. The mythical ‘average’ 70 kg (154 lbs), male would be 5’10” in height and his female counterpart 5’4” and weight 130 lbs. This is a 28% difference in weight. This mythical male is often used to calculate dose ranges for ‘optimal’ dose determinations, around which phase II and phase III efficacy and safety studies evolve. Even more striking is the range of normal heights and weights, remembering that the same dose is usually prescribed to individuals across the range. In males, this varies from 5’ at 106 lbs to 6’8” at 226 lbs; in females, it varies from 85 lbs at 4’9” to 185 lbs at 6’5”; yet all are ideal weights for their respective heights. For both sexes, this represents a 46% differential in healthy weight while taking the same dose of medication. Why should these great disparities be tolerated by the research community, industry and agencies? Because most drugs work – even over these ranges. First, the majority of the population falls toward the middle of the height–weight levels, rather than the extremes. Second, most drugs have a wide range over which they exert therapeutic effect before efficacy levels off. Third, the level of unacceptable adverse events generally occurs at much higher doses than the therapeutic level for most drugs (there are some notable exceptions, e.g. lithium, digitalis, warfarin, etc.).

For lipophilic drugs, the composition of mass to fat/total body water is a further variable, increasing in women after puberty. The composition of ‘good fat and bad fat’ changes with age, both in increased fat, increased bad fat and its relocation to the fat around the heart and abdomen. The quantity and distribution differs between genders. This may have an effect on lipid-soluble drugs, regarding the level, the time to achieve steady state and the time to eliminate the drug and its metabolites from such fat storage depots.

Different gastric emptying time

Some studies have shown that women demonstrate greater duration in the gastric residence time of medications, which is reflected in an increased lag time of absorption, compared to men. This effect is increased when medication is taken with food, even when adjusted for the timing of the menstrual cycle (Majaverian et al., 1987). This was consistent with other reports that men had faster emptying times for both liquid and digestible solids than women (Majaverian et al., 1988; Wright et al., 1983). The length of time and variability of gastric emptying in women was also reported by Notivol et al. (1984) to be altered in relation to the menstrual cycle and was shortest at mid-cycle (MacDonald, 1965; Booth et al., 1957).

These changes can affect the amount of drug in the blood. Miaskiewicz et al. (1982) showed that, after a single dose of sodium salicylate, absorption was slower and achieved a lower level in women. This has also been shown for ibuprofen. The $T_{\text{max}}$ was observed to be more than 54 min in females, compared to a $T_{\text{max}}$ of 31.5 min in males. Majaverian even showed a delay of 9.5 h before absorption occurred in one woman (Majaverian et al., 1987). Sex differences in plasma salicylate albumin binding capacity have been reported (Miaskiewicz et al., 1982) and, for other agents (Allen and Greenblatt, 1981), $\gamma$-globulin transport systems have been reported to be altered with the menstrual cycle.

Some effects on absorption can be subtle, such as the greater absorption of alcohol in women due to their reduced gastric mucosal and liver alcohol dehydrogenase activity compared to men. This results in higher circulating levels of alcohol, in spite of body weight corrections (Frezza et al., 1990), with obvious implications. Odansetron, on the other hand, is more slowly metabolized by women and thus may be more effective.

Metabolic gender differences

Propranolol is still one of the most frequently used $\beta$ blockers (National Prescription Audit, 1989), but Walle et al. (1985) reported that women had higher
plasma levels of propranolol than men following single oral dosing and, in an additional study, showed that on multiple dosing, propranolol steady state (trough) plasma levels were 80% higher than in men (Walle et al., 1985). This is probably because propranolol is metabolized through three pathways, but in women, the P450 cytochrome oxidation pathways are less effective than in men (Walle et al., 1989).

Methaqualone metabolism has been shown to be significantly increased at the time of ovulation (day 15), almost double than that of day 1, and this was reflected in an area under the curve (AUC) reduced by half on day 15. It is of interest that men, used as a control, only sustained levels at the level of day 1 in women (Wilson et al., 1982).

Both verapamil and erythromycin appear more effective in women than in men; this may be due to higher blood levels resulting from differences in liver metabolism and reduced glycoprotein transport (Meibohm et al., 2002).

Differences between males and females in the amount of free drug found in plasma, and of protein binding, have been reported for diazepam (Abel et al., 1979; Greenblatt et al., 1979) and for imipramine (Kristensen, 1983). In the latter instance, a direct correlation was found with differences in lipoprotein and orosomucoid protein (1-a-acid glycoprotein) fractions (Greenblatt et al., 1980). In women, oxazepam has been found to be eliminated at a slower rate, about 10%, and for temazepam about 25% (Divoll et al., 1981). Chlorodiazepoxide was also found to be less bound to protein and this was even further reduced if women were also on estrogen OCs (Roberts et al., 1979).

Circulating hormones, such as aldosterone and renin, have long been known to fluctuate with the menstrual luteal phase. If an amenorrheic cycle occurs, these changes are not seen (Michelakis et al., 1975). If OCs are given, then an increase of these hormones is also seen in the first part of the cycle (M’Buyamba-Kabunga et al., 1985). Androgens transported on the β-globulin and albumen fraction are influenced by estrogen, which increases their binding. This effect is enhanced by the use of OCs (Clark et al., 1971).

In animals, estrogen has been shown to influence the effect of antidepressants on the brain. Wilson showed that estradiol increased the binding of imipramine to the uptake of serotonin at membrane sites. Estrone had no effect, but the addition of progesterone to low doses of estrogen increased this effect. In all, the greatest effect seen was about a 20% enhancement of imipramine binding (Wilson et al., 1986).

For low therapeutic/toxic drugs such as lithium, this might prove to be an explanation of the reduction in efficacy seen at the end of the menstrual cycle, when these hormone levels fall (Conrad and Hamilton, 1986). It might also explain the reduction in efficacy of other central nervous system drugs such as anticonvulsants (Shavit et al., 1984; Rosciweska et al., 1986) and antimigraine medications, seen with the fluctuation of the menstrual cycle (Gengo et al., 1984).

Young women appear to be the group most at risk of developing extrapyramidal reactions when taking the antinausea drug metoclopramide. This appears to be strongly age- and gender-related (Simpson et al., 1987). Another age- or gender-related effect is seen in older women who have become newly postmenopausal and who are still taking antipsychotic medications, because the symptoms of tardative dyskinesia may appear or even worsen (Smith and Baldessarini, 1973). This is perhaps another example of the loss of estrogen protection.

Many of the examples quoted involve central nervous system drugs. This is very important, as gender-related prescription usage is heavily weighted in this area toward women. The FDA 1985 drug utilization report showed that for benzodiazepines, the increased usage in women outnumbers men by 2:1 (339 vs. 171 prescriptions/1000 women and men, respectively). Twice as many women are treated for depression and anxiety neurosis than men, first described by Raskin (1974), and confirmed by Weissman and Klerman (1977). It is by no means certain that this is solely due to biochemical differences, for women are more likely to seek help than men. Of importance from the prior discussion is that, if women are
the greatest users of these medications, should not
study recruitment members be biased in their
favor? However, some of the psychotropic CNS
drugs also have animal data – and a few, even some
human data – suggesting an increased teratogenic
potential (Physician’s Desk Reference, 1991;
Jefferson et al., 1987). There is no consistent
evidence of class teratogenicity (Elia et al.,
1987), but there is a high association of fractured
hips with the use of psychotropic medicines, even
when corrected for women’s greater age-related
hip fracture rate (Ray et al., 1987). One of the
commonest causes of the elderly being admitted
to institutional care is urinary incontinence.
Women have been found to be more susceptible
than men to medications that can cause inconti-
nence to occur (Diokno et al., 1986).

Adverse event differences

There is increasing evidence that gender is a risk
factor in adverse reactions with female patients at
1.5–1.7-fold greater risk than men (Rademaker,
2002). Although it is true that women take more
medicines than men, but of 8 of 10 prescription
drugs removed from the market, women suffered
more serious adverse reactions. At least four of
these were taken in equal numbers by both genders
(General Accounting Office, 2001).

One of the most striking differences between
male and female responses to drugs is the finding
reported by Martin et al. (1998) in 513 608 patients
with serious adverse events, which occurred in
43.2% males and 55.7% females when adjusted
for age. In women of all ages, Tran et al. (1998)
also reported that, in findings from records of 2367
patients, female patients were at twice greater risk
of adverse reactions than males. More than one
agent was reported to be responsible in 50% of
female patients versus 33.1% of all male patients.
Drugs in both genders most likely to cause an
adverse event were anti-infectives (60.4%) and
nervous system agents (21.5%) (Martin et al.,
1998). The commonest events were skin-related
reactions (49%). It is possible that bare arms and
exposed legs in women may cause more phototoxic
reactions than in men; nonetheless, this cannot be
said of nervous system agents. Clearly, these two
classes of agents need special gender exploration in
clinical development.

Women also have a higher risk of developing
drug-induced cardiac arrhythmia (Ebert et al.,
1998) and life-threatening torsades de points
arrhythmia may occur with drugs such as antihis-
tamines, antibiotics or antipsychotics, making it
important that Cardiac QT studies be conducted
in volunteers of both genders (Woolsey, 2005).

16.6 Government agency
and industry actions on
gender-related research

The Public Health Service Task Force on
Women’s Health Issues (1985) and the National
Institutes of Health (NIH) Guide (1989) both
recommended that biomedical and behavioral
research should be expanded to ensure emphasis
on conditions unique to, or most prevalent in,
women of all age groups: ‘in addition, studies
are needed to study the metabolism and disposi-
tion of drugs and alcohol by age and gender’. The
National Institute for Drug and Alcohol Abuse
(NIDAA) (1990) policy provides detailed, almost
affirmative-action instructions for the inclusion of
women and minorities into study designs, accord-
ing to their prevalence in the diseases being
studied.

Since 1988, the FDA has requested tabulations
of gender, age and racial distributions in NDA
submissions. Many of their senior officials, for
example Drs. Peck and Temple, had forcefully
stated that women should be included in drug
development studies. Indeed, the 1977 guideline,
General Consideration for the Clinical Evaluation
of Drugs, included a policy for the inclusion of
women of childbearing potential in clinical trials
but excluded them, in general, from phase I and
early phase II studies, with exceptions for life-
saving or life-prolonging treatments. Childbearing
potential was strictly defined as ‘any woman cap-
able of becoming pregnant’, including women
using reversible contraceptive precautions and
those with vasectomized partners.
The FDA issued new guidelines in 1993 (Federal Register, 1993), perhaps spurred by its own findings in 1989, and confirmed by the General Accounting Office (GAO), that in only 50% of submissions were gender analysis discussed in NDA submissions. Temple (1992) reported that two FDA surveys demonstrated that women were included routinely and in proportion to the presence in the treatment population, and young women in large numbers (Bush et al., 1993). Not recorded were his concluding remarks, in which he said many NDAs did not adequately discuss gender difference, which would be addressed in the new amended guideline. The FDA, in its discourse in the 1993 guidelines, Revised Policy on Inclusion of Women of Childbearing Potential in Clinical Trials, mentions that it was swayed by a legal precedent. In 1991, the US Supreme Court found on behalf of the plaintiff workers union that their pregnant members had been unfairly excluded from jobs by the Johnson Control Company, because the working conditions exposed their fetuses to potential risk. The court wrote: ‘Welfare of future children should be left to the parents ... rather than to employers who hire them’. Although not quite the same circumstances, the FDA was of the mind that this opinion would also apply to pregnant (informed) women, giving them the right to enter drug trials irrespective of phase of development.

The FDA revised guidelines on this and ethnic differences which appeared in July 1993 in the Federal Register, in essence abolished the prior ban on women of childbearing age from phase I and phase II studies, and stipulated additional topics, including the embryotoxic and teratogenic risk potential, to be covered in the patients’ informed consent.

Earlier, the NIH had issued its own guidelines to its staff, grant applicants and academic centers it supported. It called for all research on human subjects concerning drugs, devices, epidemiology, nondrug device studies and treatment outcomes, to include both genders and minority representatives whenever possible. In phase III studies, ‘women and minorities and their subpopulations in sufficient numbers should be included, such that valid analyses of differences can be accomplished’.

It stipulated that ‘cost was not an acceptable reason for exclusion, and that programs and support for outreach efforts to recruit these groups be undertaken’ (NIH, 1986). Failure to ensure adequate effort to implement could be reason for grant rejection or loss of financial support.

To amplify the female view, both the FDA and NIH during the last decade have appointed women to significant roles. Dr Bernadette Healy headed the NIH and created the Office of Research in Women’s Health; Dr Henny led the FDA until 2001 and within the FDA, Dr Janet Woodcock and Dr Kathy Zoon were appointed to head CDER (drugs), and CBER (biologics), respectively, two of the largest centers perhaps partly in response to an article by LaRosa and Pinn (1993), both women bemoaning the exclusion of women in decisions of research.

The industry is now encouraged by the FDA to include women earlier in the clinical development program, but there are also still good reasons why the FDA might deny inclusion of women of childbearing potential – insufficient toxicology data; a disagreement over the interpretation of such data; agency knowledge of another company’s confidential data indicating a potential risk with a drug class-related compound and, finally, an FDA reviewer’s individual comfort level with ‘high-risk population exposure’. Such an event has now become rarer.

**Pharmaceutical industry practice**

In July 1991, a survey was completed by this author for the Pharmaceutical Manufacturers Association (PMA), Special Populations Committee on the current practice of the industry in handling gender and minority data (Edwards, 1991). Vice-Presidents of headquarters, clinical and regulatory affairs were contacted at 46 companies; 33 companies responded (nearly all the major companies). All 33 responding companies collected gender-related data on the participant patients in clinical studies. Over three-quarters of the companies reported that they deliberately recruit ‘representative’ numbers of women. It should be noted that the term ‘representative’ has not been defined by the
FDA or by industry. However, only 10 companies (30%) frequently or usually collected data on menstrual cycle; 56% replied that the FDA at some time or other had requested the inclusion of women in trials. When women of childbearing potential were included in protocol proposals, 21% of the respondents said that the FDA never disagreed, but 79% had experience of some FDA reviewers at one time or another excluding women of childbearing potential. When excluded, this was usually in the phase I and phase II trials, 58% and 45%, respectively, correspondents reported.

Although this survey was qualitative rather than quantitative, the results should not be dismissed lightly; because the survey was confidential, no respondents or their firms were exposed to open criticism. Because of their experience and senior positions, respondents had reviewed many different drugs and NDA applications. The survey replies were, therefore, likely to be reliable and provide a good approximation of the then-current industry gender practices and the frequency of clinically meaningful differences.

When gender differences in safety or efficacy were found to be clinically significant, most respondent companies (94%) opted to put the data in the product label, the Physicians’ Desk Reference and the product literature (72%), and to publish in the medical journals (69%). Presumably, the two companies that did not amend their labels acted thus because the products were only intended for one-gender use. By December 1999, there were 348 medicines in development for diseases only in women or where women are disproportionately affected (Holden, 2000). Not only has industry stepped up its research efforts, but many large firms have units devoted to women’s healthcare.

Finally, correspondents were asked how frequently gender differences were found; 73% said ‘occasionally’, 3% said ‘frequently’ and the rest said ‘never’. Of those who saw differences, only one-third found these differences to be clinically significant 5% of the time, while 17% of respondents said that significant differences occurred 10% of the time. This was more than expected, and provides further justification for gender testing.

16.7 Possible solutions

The author must stress that the opinions and the suggestions that follow are personal, based on 30 years in industry, from phase I–IV study experience, with five large international pharmaceutical firms.

Women’s inclusion as drug research subjects

Women should be and, indeed, are included into new drug and device development programs when not specifically excluded due to male-only disease or existing pregnancy. If it is predictable that a drug or device will be used in women (though they may not be the majority users), then a ‘reasonable number’ should be included in phase II and phase III studies. If the disease occurs more frequently in women, for example rheumatoid arthritis, then women should be involved in phase I studies. The reality is that of the many hundreds of drugs and devices approved for use today, very few show major gender-related differences in either side effects or efficacy. Clearly, in the drug classes that have been shown to demonstrate significant gender clinical differences, ‘specific’ gender-related studies should be included for investigation drugs and devices. These could be similar to those now undertaken in the elderly. First, a single-dose study should be undertaken. If important differences are found compared to men, a multiple-dose study ought to be undertaken, and then a shorter duration efficacy and safety study in women. Such studies can be conducted later, perhaps concurrently with phase III of the development program.

What do we mean by ‘a reasonable number’? ‘Reasonable’ is that number which would be expected to show a significant gender clinical difference if a real difference is present, and probably will only apply to efficacy and adverse events 5% or larger, because a difference in low-incidence adverse events will not show up until the drug is in the market. This would mean at least 300 women exposed to the new drug. The number of patients should be based on what is judged to be a clinically
significant percentage loss or enhancement of efficacy, for example 30%, dependent on the disease or symptoms.

**Representative population of women**

This can be based on the incidence of disease proportional to gender distribution and can be studied when drug development and toxicity are well-advanced, usually by phase III. Women of childbearing age must be represented if the disease is prevalent in the age group of 15–50 years. Indeed, diseases such as endometriosis can only be studied in such a population, whereas drugs to treat urinary incontinence would be better undertaken in older patients.

In some diseases, such as hypertension, where both sexes are similarly affected, balanced numbers of male and female patients in phase III would not seem out of place, although many investigators are finding recruitment of sufficient numbers of female patients increasingly difficult.

In diseases such as osteoarthritis, where women patients outnumber males (80%), a legitimate case can be made for a ‘female-weighted database’, and also when women are the majority users for medicines, such as psychotropic agents (although they are not necessarily the majority of sufferers). Provision and timing of adequate animal toxicology and fertility data are critical to avoid expensive delays and to allow adequate female recruitment, so these animal data may be advanced on an ‘at-risk basis’, depending on the drug’s clinical significance and its market potential. A list of diseases more prevalent in women is provided in *Medicines in Development for Women* (Holmer, 2004).

**The potential childbearing population**

The probability of potential early embryonic exposure occurring in a drug development program must be expected and confronted because, despite careful pregnancy testing and adequate contraceptive precautions being undertaken, it happens. Levine (1975) in his book suggested that, in the consent form, there should be ‘a statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus if the subject is or may become pregnant) which are currently unforeseeable’.

When a woman of childbearing age participates in a research procedure in which there is a risk to the fetus, the nature of the risk being either known or unknown, she should be advised that, if she wishes to be a subject, she should avoid becoming pregnant. Her plans for avoiding conception should be reviewed during consent negotiations. At times, if her plans seem inadequate and she does not consent to the investigator’s suggestions, it will be necessary to exclude her from the research. She should be further advised that if she deviates from the plans discussed at the outset, she should advise the investigators immediately.

Halbreich and Carson (1989) made the point that not to include women of childbearing age could even increase liability.

The general policy of an academic institution should be to favor the conduct of research involving women and children in testing of new drugs with potential for major therapeutic value to those populations. Such research may expose the institution to risk of liability for damage to subjects; however, that is inherent in research involving human subjects anyway, and there are many ways of minimizing such risks. Not to do such research, while it may serve to protect the interests of the institution as narrowly conceived, would involve a failure to serve the public interest in a much more serious manner by exposing classes of persons to knowable but unknown risks, through the practice of clinical medicines using drugs not thoroughly tested and understood, and withholding drugs that may be of benefit.

It has been suggested that members of female religious orders, women who have had tubal ligation or lesbians could provide a ‘no-risk pregnancy’ pool of volunteers. Although possible, this is not generally a widely applicable solution, because geographic, environmental and volunteer numbers now become added variables.

Should women on OCs enter studies, could the high level of artificial hormones confound the results? Female OC users make up 28% of the potential childbearing population (Ortho, 1991),
and these hormone concentrations (10–20 times higher than the natural hormone levels) may cause drug interactions which cannot occur during ordinary menstrual cycling. Intrauterine devices are currently regaining popularity, subdermal implants have had little influence on contraceptive practice at the epidemiological level.

**Liabilities for fetal damage**

Given all of the above reasons for including women of childbearing potential, the issue of the chilling effect of legal liability for fetal damage on firms and institutions is still present, and the necessary addition to the patient’s informed consent does not help. The Supreme Court in 1992 rejected an attempt to cap the amount juries could award in damages as ‘unconstitutional’, that is would require a constitutional amendment. This is highly unlikely to occur. The consequences of litigation, particularly in obstetrics, were dramatic increases in C section from 18 to 29.1% of all live births; (2005 Center for Disease control) resignations from this specialty, and a broader rejection of ‘high-risk’ or Medicaid patients (O’Reilly et al., 1986; Bello, 1989). A possible solution might be to follow the example of the National Vaccine Injury Act of October 1988, where a trust fund was set up derived from an excise tax imposed on each vaccine. The funds, through an arbitration panel, are used to compensate persons injured by vaccination. It should be noted that a Drugs in Pregnancy Registry has been set up to follow up early embryonic exposure to the anticonvulsants and antiviral drugs acyclovir and retrovir. This is administered by the American Social Health Association (ASHA), Center for Disease Control (CDC) and GlaxoSmithkline. One wonders if it could be expanded (with suitable support) to cover additional agents.

**Current enrollment**

The use of double barrier contraceptive requirements in many clinical studies in women of childbearing potential has resulted in better recruitment. Analysis of regulatory applications by the health authorities in Europe, Japan and United States reported (2003 ICH Working Report) that near equal representation of both women and men were observed.

As a result of this the ICH declined to issue a separate guideline on women as a special population (ICH, 2004). The Office of Research on Women Health (ORWH), National Institute of Health, in February 2005, reported in its monitoring that both NIH recruitment of women and minorities, in the clinical studies, were now reaching substantial proportions. Even in industry-based studies, by 2000, 22% of subjects were female in early-stage studies.

**Data gathering**

Gender data are collected by major pharmaceutical companies; few, however, record the menstrual dates. Frequently, no drug-handling differences between the sexes is detected; much less commonly is the absence commented upon in reports or publications. It is suggested that LMP dates could be included in case report forms, and that publications and reports should contain statements on the presence or absence of gender differences, also giving the patient gender numbers and \( p \)-values. This would allow for later meta-analysis. Both of these suggestions would be inexpensive to implement.

Gender-related data from the FDA are more readily available as the FDA continues to increase its computer ability, and pharmaceutical firms utilize computer-assisted NDAs and increase their efforts to adequately power the studies to find differences. Unified systems and formats would enhance this. The information is included in the Summary Basis for Approval or in the Medical Reviewer’s Report. Either should be available through the Internet at www.fda.gov./cder under ‘New Approvals’.

16.8 Conclusion

Gender-related differences do exist in drug handling, but in general are relatively clinically...
insignificant. Theoretically, because of weight differences, women may receive more medication than men for a standard dose when adjusted to mg kg\(^{-1}\). Greater effects might be expected from the range of normal weights rather than from the effects of gender.

Clinically significant gender effects have been reported with CNS, anti-inflammatory and cardiovascular drugs. It is suggested that women continue to be enrolled into most drug study programs, but that greater thought be given to obtaining ‘representative’ numbers in the early program planning stage. For drugs intended mainly or entirely for women, even phase I testing in women should be usually considered. Single-dose testing, even in women of childbearing potential, poses minimal risk if done early in the cycle, with adequate precautions and ‘consort’ consent to short sexual abstinence. Alternatively, women with tubal ligation could be enrolled for these small studies.

‘Representative’ could be twofold: a reflection of the percentage of women suffering from the disease, or a ‘reasonable or sufficient’ number to show clinically significant differences in efficacy or safety in the main efficacy and safety studies; alternatively, conducting at least one study just in women in phase III. What is a ‘clinically significant effect’ would depend on the drug and disease, but effects with a less than 15% difference get harder to detect and generally will be less meaningful. Again, women of childbearing potential could be included, depending on the age/prevalence of the disease. Women using OCs may be compared not only with males but also with non-OC users. OC and drug interaction studies are currently required for most drugs.

Early embryo drug exposure and the potential liability for any damage continues to influence industry, agencies and some research workers. It must be recognized that, if an agent has human teratogenic potential, it is better to detect this before it achieves the marketplace. Unfortunately, this is unlikely to be detected because the small numbers of women becoming pregnant in any NDA program make it impossible to detect drug-induced effects from spontaneous birth defects. Data in women are needed and the possibility is suggested of an expanded National Register along the lines of the International Clearing House for Birth Defects Monitoring to follow up the expected small number of embryos exposed and a Compensation Panel in the event of proven damage, funded by an excise tax, as with vaccines.

Finally, with all the great strides being made to unravel the human genome and determine the gene structures and their influence, we are much nearer to tailoring drugs to match male and female differences, and with enhanced computer power, this chapter may become moot.

**Acknowledgments**

The author wishes to acknowledge that much of this chapter was supported by a grant from the NIH branch, Office of Protection from Research Risks ($805).

**Recommended reading**


**References**


REFERENCES

219


US General Accounting Office. Most drugs withdrawn in recent years had greater health risks for women. Drug Safety, GAO 01-286R: Washington, DC.


The world population reached 6 billion in June 2000, and half of the world’s population (3 billion) are less than 15 years old. Sadly, the mortality rate of children in Third World countries is 10 times higher than in the developed world. Before 1850, half of the children born in the United States died from infections before five years of age. The introduction of sanitation, antiseptics and, in the last century, vaccines, and lately medicines, have made such early deaths in the United States now very uncommon.

Today, accident is the largest killer of children, accounting for 2500 deaths in children under five years; this compares to 700 deaths from congenital abnormalities, 518 from cancer and 473 from murder. AIDS is the leading infectious cause of death in the under–five-year-olds (200). The major causes of death in the 5–14-year-olds are accidents (3500), cancer (1053) and murder (570). Again, in this age group, AIDS is the leading infectious cause of death (National Center for Health Statistics, 1996).

Many of the childhood cancers are hematologic, and great improvements in survival have been achieved. For example, the acute leukemia survival rate in children has risen from 53% in 1970 to 80% by 1989 (American Cancer Society); and new surgical techniques and new devices are improving and sometimes correcting (even by intrauterine surgery) many previously fatal congenital abnormalities, for example hypoplastic heart.

This chapter will focus on the current regulatory requirements, their background, the clinical study, challenges and the clinical issues of drug research in the pediatric population.

Still estimated that over 2500 studies in the FDA’s pediatric subgroups needed to be conducted over the next three years (Still, 2000). This includes completion of pediatric studies on the FDA priority list of marketed products. Estimates of the annual cost to the industry of these studies vary. The FDA estimated in 1994 that $13.5–20.9 million per year would be spent by industry (Federal Register, 1998). At a press conference, Christopher Jennings, President Clinton’s principal healthcare advisor, said that pediatric label studies would only be about 1% of the development cost of a drug. Dr Henry Miller (1997), a former FDA Director of the Office of Biotechnology, said that applying Jennings’ figure will mean an industry cost of $200 million (1% of the $20 billion spent on R&D). Dr Still, presenting at the 36th Drug Information Association (DIA) Annual Meeting (1999), estimated the cost at $892 million if all five pediatric subgroups were to be studied (based on 1999 study costs).
These additional costs for pediatric studies may be justified if these studies satisfy all global markets. MacLeod (1991) estimated that ‘developing countries’ by the year 2000 will comprise 36% of the total pharmaceutical market and that half of their populations are children (accounting for 18% of the market). In the developed countries, children under 18 years account for 20% of the market. It would seem that the 38% pediatric share of the global market is worth an extra effort.

17.2 Children, the therapeutic orphans

The Food, Drug and Cosmetic Act, first passed in 1906, was dramatically altered by the 1962 Kefauver–Harris amendments as a direct result of the thalidomide tragedy. This amendment required that drugs must be both safe and effective before marketing approval could be given. In addition, adequate animal, toxicology and fertility testing had to be concluded prior to the first dose in humans. Substantial additional testing in animals and in humans was required prior to marketing approval. This led to the era of the Science of Clinical Trial Design. Regrettably, the testing of drugs in children did not advance at a similar pace, and most drugs (unless specifically intended for children) were never tested in children by the sponsors of new medicines.

Physicians were thus forced to use most drugs ‘off-label’ and extrapolate the child dose on a comparative weight basis from that in adults. This often involved parents splitting or crushing tablets, hiding medication in spoonfuls of honey or sprinkling a crushed tablet onto a meal. Each time this happened, a little more confidence in and knowledge of the drug was gained, but each child was a ‘one-off experiment’ and only provided a learning curve for the individual physician. Eventually, academia would publish a series of cases, so giving guidance on dosing and likely toxic effects. Even so, the average pediatrician and family practitioner felt uneasy and legally vulnerable about off-label use.

A few drugs were developed for children in such categories as antibiotics, antihistamines and antiepileptics. But otherwise, few firms undertook studies to develop full pediatric label instructions or even pediatric formulations. Liquid formulations did exist for some drugs, but mainly for use in the elderly. In 1975, Wilson surveyed the 1973 Physician’s Desk Reference for labeling instructions for pediatric patients and pregnant or breast-feeding women. He found that 78% of listed drugs either had no information for pediatric dosing or contained a disclaimer. A subsequent survey by Gilman and Gal (1992) showed that this situation had not improved qualitatively and had also risen to 81%. Eventually, the FDA issued the 1994 rule, which sought to strengthen the 1979 guideline on pediatric labeling requirements (Federal Register, 1994).

The Pediatric Use Working Group, chaired by Miriam Pina (1995) (FDA Division of Pulmonary Drugs) examined the data that the FDA had acquired on 1994 pediatric prescriptions from IMS. From these they identified the top 10 drugs used ‘off-label’ in children: Albuterol, Phenergan, Ampicillin i.m. or i.v., Auralgan otic solution, Lotison, Prozac, Intal, Zoloft, Ritalin (under six years) and alupent syrup (under 6). A combined total of over 5 million of these 10 products were prescribed in 1994.

Clearly, firms needed further encouragement to submit additional pediatric data, so in 1997 Congress passed the FDA Modernization Act (FDAMA). This called for firms to submit data on children to support labeling for a new pediatric subsection before the drug could be approved. This applied to drugs that could be projected to provide therapeutic benefit to substantial numbers of children. In exchange, Congress felt that an inducement was required and wrote into the Act provision for an extension of a drug’s patent life by six months if pediatric studies were done. For a $4 billion drug such as Claritin (Loratidine) six months’ extra exclusivity is not ‘small change’.

The FDA was requested to provide guidance and, in December 1998, it issued the Final Rule Amendments to the Pediatric Subsection § to be implemented April 1999, governing the need for pediatric studies, and extending the requirements to biological drugs and already-marketed drugs. The FDA identified drugs for which supplemental
data were still needed for pediatric labeling. The FDA has issued an annual list of ‘priority drugs’ for which additional pediatric information may be ‘beneficial’.

FDA chose to interpret the patent life extension as applying to all indications, not just to pediatric use. As might be expected, the generic companies continue to appeal this interpretation of the pediatric rule.


Products subject to the rule

For drugs that are new molecular entities (NMEs), a determination should be made by the sponsor of the potential usefulness of the new drug in a pediatric population. If it is likely to generate over 100,000 prescriptions per year, this would indicate the need to develop a pediatric formulation and suitable pediatric studies. If it is likely to generate less than 50,000 prescriptions per year, the sponsor may be granted a waiver by the FDA for pediatric data, and a disclaimer statement allowed. Either way, in a children’s disease, if less than 200,000 patients per year may benefit, then orphan-drug status with 7 per year exclusivity may be applicable. This would then apply only to that pediatric indication.

The requirements of the Pediatric Final Rule now includes marketed drugs and biologics. The FDA has already listed products affected and sent pediatric data requests to firms. The firms had until April 2001 to provide the extra data.

Data to be provided

If considerable data exist, or are planned, for same indications in adults, it may be appropriate to extrapolate safety and efficacy from adults to children. But pharmacokinetic (PK) studies to determine dosing and, if possible, pharmacody-

17.4 Major physiologic variations in pediatrics

In the past, the statement that ‘children are not little people’ dominated research thinking. In general, both in children and in the elderly, drugs and biological products behave similarly to that in the 18–65-year-old population, although this expectation must be adjusted for age-related differences in PK variables, such as immature or aging enzyme metabolism systems as well as elimination rates affected by immature or aging organs of excretion.

In neonates, the gastric pH is biphasic, being high in the first few days after birth and decreasing by day 30, but it takes 5–12 years for the adult pattern and value to emerge (Signer and Fridrich, 1975). On the contrary, the methylation pathway, unimportant in adults, is well developed in children. Furthermore, acetaminophen is less toxic to children than to adults, probably because it utilizes the sulfate metabolic pathway (Rane, 1992).
Most infants are slow acetylators and may accumulate toxic levels of those drugs that are metabolized by this second phase of metabolism route. Renal perfusion and glomerular filtration rates (GFR) vary: for the premature, 2–4 ml min\(^{-1}\); for neonates, 25 ml min\(^{-1}\); and by 1–1.5 years old, 125 ml min\(^{-1}\), which is equivalent to adult clearance rates (Arant, 1978). The potential toxic implication of renal metabolites and elimination of unchanged drug in the very young are obvious (Stewart and Hampton, 1987).

**Dosing**

Without pediatric PK data, dosing in children has depended on extrapolations from the adult data, either by weight or by body surface area. Using weight may result in overdosing neonates but underdosing infants and children. Using body surface area may be better because of its linear increase with age and its good correlation with cardiac output, renal flow and GFR — more so than weight. Neither method compensates for the varying metabolism aforementioned, nor for differences in drug disposition between children and adults.

**Concerns in formulations for pediatrics**

If a drug is to be given by injection, i.m. or i.v., this may require only volume variations. But most drugs developed for adults are given by the oral route, as tablets, capsules or caplets. The adult formulation is usually determined by marketing considerations. Invariably, for children, especially under age seven years, liquid or syrup must be formulated. Most drugs taste bitter or unpleasant (which is why most tablets are sugar coated). Sometimes, it may be impossible to completely mask the taste. A commitment to a pediatric formulation requires a whole gamut of testing and the development of specific product specifications. If the liquid formulation changes the bioavailability (faster or slower absorption), then further efficacy and safety studies may be required. A further concern is that liquid formulations often have a shorter shelf life than tablets. Finally, stability characteristics or other factors may make it impossible to make a liquid or syrup or glycolated elixir, sprinkle beads or powder sachets, and split or crushed tablets in apple sauce may be a last resort. In the latter two cases, an even distribution of active compound and other inactive excipients must be demonstrated. In addition, a lack of effect on bioavailability must be proved if such advice is to appear in the dosing instructions.

**Toxicology**

The plastic nature of immature organs such as kidney, liver, brain and lung may indicate the need for more animal toxicology. Frequently, neonatal acute and subacute toxicology studies are undertaken in two animal species. Because of the small size of both mouse and rat pups, this may prove a challenge to administer the active drug. The common ‘mixing with chow’ is inappropriate in neonates. Dog pups usually provide one of the two species, so a special liquid formulation for animals may be required (if the product is intended for oral delivery), and given by dropper or gavage.

**17.5 Clinical studies**

**Pharmacokinetics (PK)**

The traditional PK study volunteer study in healthy children has proved very hard to set up, because of the attitude of many parents and over-viewing independent review boards (IRBs). Even in pediatric patients, the frequency and total volume requirements for samples for conventional PK studies can cause the same refusals. However, there are pediatric research units that specialize in these studies, with minimum needle sticks, minute blood volumes and IRBs sympathetic to the needs of the pediatric community. The National Institute of Child Health and Human Development has set up a ‘network of pediatric pharmacology units’, usually in academic regional centers, now
numbering 13 units. There are other non-governmental specialized units also available for pediatric PK work.

An alternative method of getting PK data is to take a small extra sample of blood (and urine) at a child’s regular scheduled visit when blood is drawn for routine blood work. The time of day of this sample is predetermined by the time of the administration of the medicine. If samples are obtained from many children, a weight–age-corrected, scatter-plot graph can be constructed and a PK profile be calculated. This is the ‘pharmacokinetic screen’ method. A version of this method is also utilized to gather ethnic data for labeling in adults as well as children, and is called ‘population pharmacokinetics’.

**Recruitment**

One of the major problems in running pediatric clinical trials is the availability of pediatric patients, who tend to be scattered, because they are numerically less likely to have diseases (other than asthma and the usual childhood illnesses). This affects the logistics of screening and subsequent clinic visits. Another hurdle is finding trained pediatric investigators or pediatric pharmacologists, and overseas they are even harder to find. In Europe, there is collaboration between the US-based Pediatric Pharmacology Research Units (PPRU), the European Society of Developmental Pharmacology and the European Network for Drug Investigation in Children (ENDIC). For diseases of children, there are often self-help organizations that can prove invaluable in recruiting children and in reassuring their parents.

A large package of data, and two well-controlled pivotal studies of safety and efficacy are rarely required, with the exception of diseases specific to childhood, such as surfactant studies in respiratory distress syndrome. This is especially the case if the drug has similar effects in both adult and pediatric populations, for example antihistamines.

However, if a disease or drug behaves in different ways in children compared with adults but a large body of safety data exists in adults, then usually only a single efficacy and safety study is required.

**Ethical concerns**

The American Academy of Pediatrics formed a Committee on Drugs to examine ethical issues of pediatric studies for its members and for the guidance of IRBs dealing with pediatric studies. The Committee released its report in 1995. This report (Committee Drugs, American Academy of Pediatrics) is very comprehensive, but amongst its many recommendations the following areas are highlighted.

**Vulnerability**

In this special population, there is a special duty to avoid (unintended) coercion of the patient, parent or guardian. This coercion may arise because the investigator is usually also the treating physician. It would be better to have a colleague explain and obtain the informed consent. There are varying degrees of vulnerability. Patients handicapped either mentally, emotionally or physically are frequently institutionalized and may be supervised as wards of Court or by a social welfare agency. These patients should be rarely used, unless the treatment is for serious disease specific to institutional settings and no other treatment is available.

Emergency situations can arise where it may be impossible to obtain written informed consent from a parent or guardian. Medications for this type of problem will require intense IRB review and overview; only in special circumstances will informed consent be waived, and then it must ‘not adversely affect the rights and welfare of the subject’. (Abramson et al., 1986). The last category is the use of a research medicine in a child close to dying who has either no response to standard therapy or where no alternative therapy exists. The agent to be considered must have some evidence of efficacy (animal proof of concept or clinical data and a good chance of a beneficial result). The risk of unintended coercion of desperate parents is especially to be guarded against.
IRBs’ special emphasis

IRBs have a duty to make sure the study is of value to children in general and in most cases to the patient him/herself; is robust enough to give answers; and attempts to minimize risk and maximize benefit. In reviewing the protocol, the IRBs should involve healthcare specialists who are aware of the special medical, psychological and social needs of the child, and the disease as might be impacted by the study.

In studies conducted on diseases mainly affecting pediatric patients, the development will be entirely in pediatric patients. However, in addition to the appropriate usual toxicology and neonate animal toxicology, the first-in-humans studies for toxicity and safety are usually done in healthy adult volunteers. Clearly, however, drugs such as the surfactants would yield no useful data from adult testing. For these unique pediatric situations, new measurements and end points may need to be developed and validated. Frequently, the FDA will involve an advisory panel to help determine what these might be.

The use of a placebo control

Placebo control is desired whenever possible if using a placebo does not place the pediatric patients at increased risk. The AAP Committee on Drugs (1995) outlined other circumstances:

• No other therapy exists or is of questionable efficacy, and the new agent might modify the disease.

• If the commonly used therapy has a high profile of adverse events and risk greater than benefits.

• When the disease fluctuates frequently from exacerbations to remissions thus the efficacy of the (new) treatment cannot be evaluated.

17.6 Conclusion

The ICH draft guidance on pediatric issues has been published in the Federal Register (2000). This guidance covers pediatric formulation, development, ethics, regional and cultural issues, regulatory expectations, duration and type of studies, and age ranges to be studied. The guidance is similar to the FDA Final Rules (Federal Register, 1994, 1998) with the addition of a fifth group, preterm newborn infants. It also seems better organized and informative, but then, hindsight is always helpful.

The face of pediatric pharmacologic medicine has been changed. In future, for pediatricians there will be less uncertainty and better predictive information available; for children, safer and more effective dosages will result. For the industry, the added cost of research will be more than recouped in a new global market to which previously they could not promote their products. This is supported by the 1998 survey by PhRMA, which showed that medicines and vaccines in development for children were up 28% from the previous year.

The FDA Modernization Act of 1997, the Best Pharmaceutical for Children Act 2002 and the Pediatric Research Act of 2003 have brought about improvements (see chapter on US Regulations).

Meanwhile in Europe similar efforts are underway with the EU issuing the European Draft Document for Pediatric Regulation. It proposes 10-year exclusivity for ‘off patent drugs if required pediatric studies are done, and six months for patented medicines’. This draft is currently under consideration and comment by members states before the EU Commission signs a final regulation.

In addition, the ICH issued the E11 Pediatric guideline on Federal Register 2000. This outlines conduct of studies in children and is utilized by many countries. This guideline also addresses availability of formulations and labeling for children.

As of 2004 there are 158 medicines being actively developed for use in children, including 32 in cancer (still one of the leading causes of death in children 1–14 years); 15 medicines for cystic fibrosis; 11 medicines for infectious disease; and 15 new vaccines (Holmer, 2004). In addition, the Office of Pediatric Therapeutics has been formed in the FDA to monitor and enforce pediatric requests.
Finally, the inclusion of the needs of children in clinical trials, as envisioned by the then FDA Commissioner, Dr Charles Edwards, in 1972 to the American Academy of Pediatrics is almost fulfilled, albeit after 34 years.

References


Federal Register. 1983. 16d.


18 Racial and Ethnic Issues in Drug Registration


18.1 Background

The international need for quicker national approval of significant drugs offering improved therapy, less toxic effects and even cure had been delayed and restricted by differing mandatory regulatory requirements between nations. Thus, by 1980, the need for an international cohesive policy was apparent. Discussions between the regulatory authorities of Europe [European Medical Evaluation Agency (EMEA)] and the United States (FDA) were aimed at the harmonization of regulations governing the approval process of drugs and devices and have been going on since the first International Conference of drug regulatory authorities, which met in October 1980 (Annapolis, USA), and latter under the auspices of the International Conference on Harmonization (ICH). In their first meeting in Brussels (November 1991), the Japanese regulatory authorities [Ministry of Health and Welfare (MHW)] participated as a full member; these three major regional members were joined by representatives from the pharmaceutical industry of Japan (JPMA), Europe (IFHPA) and United States (PhRMA) and observers from the World Health Organization (WHO) Nordic countries and Canada’s HPB, thus covering about 92% of the current regulatory activity and global spending on pharmaceuticals.

The ICH continuing series of meetings has resulted in success in the areas of quality control, toxicology, pharmacology and clinical development, including good clinical practice (GCP) and the recent issue of guidances on the acceptability of foreign clinical data, the Common Technical Document, adoption of MeDRA and electronic submissions.

The clinical area has proved much harder to harmonize because of the lack of clear-cut regional or national concordance on many clinical issues. The very existence of some diseases is in dispute, for example, temporomandibular joint dysfunction and premenstrual syndromes in the United States, hypotension syndrome (Pemberton, 1989) in Europe, and ‘heavy leg’ pre-varicose vein syndrome in Switzerland. The emphasis on treatment, overprevention and the real physical and genetic differences between national populations with variety of healthcare systems can cause disparity of results, observations and conclusions. Again, diversity within a national population, geographic influences, diet, varied measurement standards, religious and cultural effects, and patient–doctor relationships also play a part in making interpretation and agreement difficult.
To date, it is by no means clear that harmonization has reduced the overall burden of regulations for either the regulators or the regulated, but it has already eliminated some inconsistencies. To those ends, ‘Ethnic Factors Influence on the Acceptability of Foreign Data’ was proposed by Japan and Europe and accepted as an ICH 2 topic by the ICH Steering Committee, Washington (24 March 1992). This chapter will give an account of the ethnic issues faced by the working party, ending in the tripartite implementation of the ‘Guidance’ of 1998. A working party made up of representatives from each of three major regions was set up and met many times for two-day working sessions. A major study of approved drug dosage and pharmacokinetics (PK) between the three regions was undertaken by Japan’s MHW and JPMA. A further study, commissioned by IFFPA, was undertaken by the Centre of Medicines Research (CMR, UK). In addition, the type and incidence of spontaneous adverse events reports occurring with eight drugs marketed in the European community were examined for consistency by the EC representative, and concurrently, the data files of one pharmaceutical company of four drugs in different therapeutic areas was examined for any variations of PK, dosage and adverse events between regions by the EFPIA member. Only their major findings are included in this chapter, more information can be found in the individual reports [Naito and Yasuhara, Walker and Harvey; Papaluca; Labbé; Edwards; and Williams (ICH Orlando, 1993)].

Terminology

Race and Ethnicity are often used interchangeable. But the Office of Management and Budget (OMB) issued in 1997 revised recommendations for the collection of race and ethnicity data by Federal Agencies. This led to the issue of a Guidance for Industry (2005) by the FDA adopting the OMB categorization.

The nonbinding recommendations were for the US database if collected separately.

Race would include American Indian/Alaska Native, Asian, Black or African-American, Native Hawaiian or Other Pacific Islanders. Ethnicity would be Hispanic or Latino, or not Hispanic or Latino.

If a combined format is used, then six categories are recommended by adding Hispanic or Latino as a group.

The agency admits that these are arbitrary groupings and not based on anthropomorphic, genealogical or genetic grouping. Indeed if the evolutionary human tree was used as a guide, African, the later evolving Asian/Mongoloid peoples and the last to emerge Caucasians might be a better way to define race. The word ethnicity could be used to describe subgroups either genetic sub-variations or culturally different – for example, Asian Indians and Japanese – thus affecting ethnic ancestral origins.

For the purpose of this chapter, the words race and ethnicity will be used interchangeably.

18.2 Regulatory practice

In the United States, initially, non-US studies, not under the investigational new drug applications (INDs), were considered primarily as a source of supportive safety data. By the early 1970s, it was appreciated that well-controlled non-US clinical data could be utilized to support US new drug applications. US regulations have allowed for the use of non-US data as the sole basis for approval, so long as certain conditions were met, including the stipulation that ‘foreign data are applicable to US populations and US medical practice’ (Food and Drug Administration, 1975, 1985). No specifics were given regarding the definition of ‘applicable’. Thus, clinical data from phases I–III were allowed; but in practice, such data could not be the sole source of safety and efficacy for new drug approvals. The reasons given for not using Japanese data more widely in the United States and Europe involve differences in medical practice, such as the use of different end points, lower dosages, and differences in research methodology, such as the emphasis on a large number of physicians and their experience in phase III, resulting in a large number of investigators with a low ratio of patients enrolled. In Europe, although there may be preference by individual countries to
have local clinical data developed, it did not appear that actual regulations precluded the use of ‘foreign’ (usually US) data in most European countries (Safety Workshop ICH 1, 1992), although some nations (France, Italy and Germany) required some clinical experience in their countries prior to approval.

In Japan, there has been harmonization with the other regions in the area of toxicology (animal studies); the Japanese Ministry of Health, Labor and Welfare (MHLW) accepts appropriate foreign animal data and animal safety studies performed according to ICH guidelines. Indeed, Japan has played a major role, and its then current fertility and reproductive animal studies requirements have been adopted by the other two regions.

However, the acceptance of ‘foreign’ clinical data has been a major issue for all the health authorities for a long time. Previously, all phase II and III clinical studies needed to be performed. Mandatory clinical studies were required in many European countries and in Japan on Japanese people. Phase I studies could be done outside Japan, but only if the drug was in wide use in that country (which had to be a developed country) and if the drug’s performance was unaffected by racial differences in physiology. The Japanese position has been that diet, and perhaps genetics, can play a significant role, and that a drug’s safety or efficacy may be different in the Japanese than in other races (ICH guidelines). Indeed, Japan has played a major role, and its then current fertility and reproductive animal studies requirements have been adopted by the other two regions.

However, the acceptance of ‘foreign’ clinical data has been a major issue for all the health authorities for a long time. Previously, all phase II and III clinical studies needed to be performed. Mandatory clinical studies were required in many European countries and in Japan on Japanese people. Phase I studies could be done outside Japan, but only if the drug was in wide use in that country (which had to be a developed country) and if the drug’s performance was unaffected by racial differences in physiology. The Japanese position has been that diet, and perhaps genetics, can play a significant role, and that a drug’s safety or efficacy may be different in the Japanese than in other races (ICH guidelines). Indeed, Japan has played a major role, and its then current fertility and reproductive animal studies requirements have been adopted by the other two regions.

18.3 Objective differences

Now to first examine those differences which can be quantified more readily.

Population demographics between tripartite areas

The United States is a nation of many racial, ethnic and national origins and is the most heterogeneous population of the three areas. Given the successive waves of European, African and Asian immigrants, themselves imposed upon even earlier waves of Bering Straits immigrants (Native North and South American Indians, and Eskimo), makes the US population the most diverse in the world. Although inter-marriage has occurred, many major racial groups remain regionally or locally clustered and still adhere to cultural aspects of their area of origin. However, many of the smaller distinct racial and ethnic groups may not be represented in the US pharmaceutical databases, either due to the realities of setting up clinical studies or because only small numbers are present in that population. In general, only Caucasians, Blacks, Asians and Hispanics may have measurable populations in a database (Edwards, 1992). As of 1990, American Indians comprise 0.8% of the population, with the other minorities comprising larger or smaller percentage of the population: Hispanic (any race) 9.8%; Pacific Asian 2.9%; Black 12.1% (US Bureau of the Census, 1991). Europe has a Caucasian ‘heterogeneous’ population made up of Anglo-Saxon/Celtic, Germanic, Gaelic, mid-European and ‘Latin’ races. There are sizeable populations of migrant foreign workers, as much as 10% in Germany, and many resident Asian and African citizens of Britain and in France (5%). In contrast, Japan is populated almost entirely by ethnic Japanese, truly homogeneous, although a sizable non-national immigrant population of other guest Asian workers exists.

The definitions of racial groups are not totally satisfactory (e.g. what is ‘Black’?), and ethnicity and geography can wreak havoc on the meaning of ‘representative’ for example Pacific Islanders and Asians make up 9.8% of the Pacific states population and 61.8% of the US state of Hawaii (US Bureau of the Census, 1991). What is Hispanic, other than a language group that contains a combination of genetic groups from Europe, Africa and Native America? Diseases such as stroke are
associated with high levels of Von Willebrand factor (Folsom et al., 1999), found commonly in the Black population sickle cell anemia, thalassemia and glucose dehydrogenase deficiency are ethnically linked, but how do they effect drug metabolism?

The small genetic variation (DNA), only 0.5 of the 11% total variations between individuals of these groups among the three major divisions of humans (Caucasian, Negroid and Mongoloid), makes up the total variation between individuals of these groups (Vessell, 1989). Thus, it would not be a surprise if race gives rise to fewer differences than does individual variation of drug metabolism and dynamics. That is, genes of race have less influence than an individual’s total genetic make-up.

**PK/PD and ethnic differences**

One of the earliest reports of differences was described by Chen and Poth (1929). They noted that the mydriatic response to cocaine was greatest in Caucasians, less in Chinese and least in Blacks. When PK differences were first reported in the literature, they usually involved the genetic polymorphisms of acetylation, the debrisoquine–sparteine and mephenytoin pathways, the second phase of metabolism or selective protein transport systems. Drugs such as clonazepam, hydralazine, sulphonamides, isoniazide, nitrazepam and procainamide undergo acetylation in the liver. Most Asians, especially Japanese (88–93%), are fast acetylators compared to 50% of Caucasians and Blacks (Wood and Zhou, 1991). Fast acetylators may be at greater risk of isoniazide hepatitis from toxic metabolites (Drayer and Reidenberg, 1977), whereas slow acetylators may respond better to treatment (sustained levels) but be at greater risk of toxic reactions. Those drugs which extensively use both acetylation as to second phase of metabolism, and also use either of two cytochromes enzymes in the first phase, are more likely to induce Lupus (Hess, 1982) and/or hypersensitivity reactions (Reider, 1999). The two cytochromes were identified as CYP2D6 and CYP2C19, part of the extensive P450 cytochrome enzyme systems not only found mainly in the liver but also present in other tissues such as gut, lung and brain. Ethnic differences in these two pathways have also been found, CYP2D6 enzymes are lacking in 8% of Caucasians and 1% of Asians. CYP2C19 is lacking in 20% of Asian, 4–8% of Blacks and 3% of Caucasians. These are two of the three commonest first phases, metabolic pathway. The most common CYP3A4 has not demonstrated Ethnic sensitivity.

Perpherazine and over-the-counter (OTC) ingredients codeine and dextromethorphan are made active by the debrisoquine–sparteine oxidative pathway. The percentage of an ethnic or racial population poorly metabolizing by this pathway varies greatly; for example Switzerland 9–10%, Hungary 10%, United States 7%, Nigeria 3–8% and Japan 0.5% (Wood and Zhou, 1991), but if not will gain no pain relief.

Clinically, this has been shown to make a difference in a small study in males, involving 10 Chinese and 9 Caucasian subjects; the Chinese metabolized propranolol more rapidly, clearance was 76% higher, with a lower area under the curve (AUC) and plasma levels lower than that in the Caucasians at all time points. In this study, when dosage was adjusted upwards to equilibrate to Caucasian therapeutic blood levels, a greater response was noted in the Chinese subjects (lower blood pressure and pulse rate) (Zhou et al., 1990). Conversely, the presence of very fast metabolizers in a population may also vary.

The mephenytoin metabolic pathway is utilized by commonly used drugs, such as mephobarbital, hexobarbital, diazepam, imipramine and omeprazole, but only 3–5% of Caucasians and 8% of Blacks are poor metabolizers of mephenytoin, compared to 15–20% of Chinese and Japanese populations (Kupfer et al., 1988). This enzyme’s activity is inhibited by floconazole and fluoxetine and induced by drugs such as barbiturates and nicotine (smoking).

The lack of digestive enzyme lactase in many Hispanics, especially Mexican-Americans and African-Americans, causes lactose intolerance, with nausea, diarrhea and occasionally vomiting. It is understandable that lactose is no longer preferred as a filler (non-active excipient) in tablets and capsules.
Some drugs, such as phenothiazines and tricyclic antidepressants, show greater preference for binding and transport on \(\alpha-1\) acid glycoprotein rather than on albumin. Thus, 44% of Swiss and both US White and Black populations have higher levels of this protein, compared to 15–27% of the Japanese population (Eap and Bauman, 1989; Mendoza, 1991). This might explain the higher fraction of free drug found in Asians (with a greater volume of distribution and clearance), as well as the fact that the metabolism of some benzodiazepines appears to be slower in Asians than in Caucasians (Kumana et al., 1987). One study (Zhang et al., 1990) showed that Chinese subjects who were either poor or extensive mephenytoin metabolizers when taking diazepam (mephenytoin pathway) still metabolized diazepam at the same rate as Caucasian poor metabolizers. The higher proportion of slow metabolizers of mephenytoin pathways is thus not the only difference. However, ethnic differences in the percentage of body fat between the two groups could also account for this. The ‘p’ protein transport system is also being explored for ethnic drug variations, especially in the maintenance of the blood–brain barrier.

As previously noted, drugs such as propranolol and imipramine each have two major pathways, and even poor metabolizers of any significant pathways usually have alternative pathways, which might be expected to show some increased handling ability over time. Thus, in many cases, plasma levels and clinical differences between poor and good polymorphic metabolizers may be insignificant. In others, especially where the therapeutic index is small, it may be critical – usually these drugs are titrated for efficacy and safety and thus, the effect is avoided. In other cases, such as anti-hypertensive agents, the clinical effect of genetic differences may not be seen, because the patient’s dosage is titrated to blood pressure response (Eichelbaum and Gross, 1990) and only a large meta-analysis may show ethnic optimal dosage.

**Prescribing differences**

Of great concern are findings that ethnicity may affect prescribing habits. Sleath et al. (1998) looked at the patient’s ethnicity and the likelihood of a psychotropic being prescribed: they found that Caucasians received medication 20% of the time and non-Whites only 13.5%. A similar finding was made by Khandker and Simoni-Wastilia (1998) concerning any prescription drug. Differences were found at all ages, with Black children receiving 2.7 fewer prescriptions than their Caucasian counterparts. This rose to 4.9 prescriptions in adult Blacks and 6.3 in elderly Blacks. All the patients were on Medicaid, so ability to pay was not a factor. Dinsdale et al. (1995) confirmed a similar pattern in prescriptions issued for analgesics for postoperative pain to be self-administered by the patient, with Caucasians receiving prescriptions significantly more frequently than minorities (\(p = 0.01\)).

**Genetic and ethnic susceptibility**

Therapeutic effects may vary between ethnic populations, due either to a sizeable representation of poor metabolizers present or to a genetic or ethnic-related ‘susceptibility’. Clozapine is associated with the development of agranulocytosis in 20% of Ashkenazi Jews, compared to 1% of the general population treated for schizophrenia. This was found to be highly associated with specific linked genes for agranulocytosis and especially those of Ashkenazi Jewish origin (100%) (Leiberman et al., 1990). Yet again, the best known example was the sensitivity to quinine and its derivatives in Blacks given to prevent malaria, resulted in many deaths in World War II.

Another example of PD differences is that of reports on lithium in the manic phase of bipolar depression. Asian patients, including Japanese, are reported to have therapeutic blood levels at 0.5–0.8 m.eg/l compared to required levels in US Caucasian patients of 0.8–1.2 m.eg/l (Takahashi, 1979; Jefferson et al., 1987; Yang, 1987); these findings, however, are disputed by Chang et al. (1985). African-Americans require less drug, but this is because of higher levels due to a slower clearance rate than Caucasians (Lin et al., 1986; Jefferson et al., 1987).

Asians have been reported to require smaller doses of neuroleptic drugs and to suffer adverse
events at lower doses than Caucasians, even after body weight was accounted for (Lin, 1986: 1991; Wood and Zhou, 1991). With tricyclic agents, the picture is more confusing between Asians and Caucasians, but Asians appear to show more variability overall and African-Americans tend to have higher plasma levels, faster therapeutic effect, but more side-effects than either (Strickland et al., 1991).

Essential hypertension is a symptom of modern society, and its treatment accounts for a sizeable portion of global prescriptions. As a result, there is a great interest in reported ethnic and racial differences reported in the literature. The use of appropriate therapy in Black patients has been best studied. As monotherapy, calcium channel blockers and diuretics appear to be most effective in Blacks, whereas β-blockers and ACE inhibitors produce smaller reductions in blood pressure (Kiowskisi et al., 1985; Freis, 1986; Hall, 1990). However, this may more reflect the lower plasma renin, salt and water retention and intercellular sodium and calcium in Blacks, compared to other groups (Kiowskisi et al., 1988). There are individual exceptions amongst patients and among drugs, even within these classes; for example labetalol, a combined α-blockers and β-blockers, can be equally effective in both African-Americans and Caucasians and, as mentioned previously, the Chinese appear twice as sensitive to propranolol as Caucasians (Oster et al., 1987; Zhou et al., 1990).

**Receptor sensitivity**

Salzman described a downregulation of benzodiazepine and β-blocker receptors linked to ageing. It has been postulated that Asians have fewer benzodiazepine and β-blocker receptors than Caucasians. Downregulation of these receptors with age (Salzman, 1982) has been described and postulated by Zhou et al. (1990), but hard evidence of racial or ethnic differences is still awaited. If the Chinese are more sensitive to propranolol in spite of their high catabolic rate, it might be linked to adrenergic receptor sensitivity.

Looking at the broader picture, part of today’s discovery process is the incorporation of isoenzyme detector screens and computer predictor modeling, to eliminate potential drugs posing major metabolic and ethnic problems or interference patterns. This is being done as part of the screening process for lead candidates prior to preclinical screening. Drugs such as terfenidine and mibebradil would not pass these screens today.

**In-depth drug case studies**

The European Federation Pharmaceutical Association (EFFPA) commissioned a third party, the Centre for Medicines Research (CMR, UK), to collect data on a small number of targeted drugs. By direct appeal to manufacturers through an independent third party, compliance information between regions was made available, as well as PK data. In addition, data on efficacy and safety were also requested from firms operating in the three major areas.

The CMR conducted this study amongst European and American companies to assess the significance of interethnic differences in clinical responsiveness and to determine the implications of such differences for international clinical development. Information was collected for all three phases of clinical development. Data from 21 compounds developed since 1985 in the West and Japan, and covering a wide range of therapeutic categories, were analysed. Overall, there was no indication that the metabolism of any of these drugs was affected by genetic polymorphism. One compound is known to be eliminated by an enzyme which is polymorphic, but there was no evidence of altered phenotype or subset population within any ethnic group. Although three compounds displayed some regional variability in PK, further analysis of the data provided rational explanations for all such perceived differences. All the regional variations were attributable to different pharmaceutical formulations, reduction of initial doses and alteration in sampling times and techniques, and none of these differences had any significant impact on clinical development.

There was considerable regional variation in dosing or frequency of dosing, with a tendency toward lower Japanese doses, due to cultural
differences in medical practice. The type and frequency of adverse reactions observed during clinical trials was generally lower in Japanese subjects, although there was no correlation between reduced adverse reactions and lower doses. Cultural attitudes relating to the use of preferred terms, different assessment methods and reporting differences were provided as explanations for the lower incidence of Japanese adverse reactions. More Western subjects were included in trials for a given indication than Japanese subjects, and Japanese dose-ranging trials were frequently of an open design. Phase III trials were controlled, although regional differences in the numbers of subjects and the use of placebos and reference drugs were observed, placebo controls being more frequent in the United States.

The only apparent difference in clinical effectiveness between the West and Japan was not considered to be significant, for all 21 compounds displayed no geographic differences in risk–benefit assessment (for further details, see Harvey and Walker, 1993).

Other ethnic factors with pharmacologic implications

Differences seen across regions and nations, both in reports of efficacy and incidence of adverse reactions, are much greater than can be accounted for by ethnic variations of PK and PD. Other objective differences are now discussed.

Alcohol

Even modest amounts of alcohol may induce enzyme activity of many hepatic-metabolized drugs; thus, it is conceivable that data derived from a French, Italian or Spanish European population, who regard wine or beer as a ‘digestive’ and part of the daily diet, might enhance, albeit slightly, a higher metabolism of some drugs, thus requiring higher dosages to achieve efficacy. Contrast this with the same drug developed in a Moslem or Mormon society, or in populations who have less tolerance of alcohol, because of poor metabolism due to a reduction or absence of either aldehyde dehydrogenase or gastric alcoholic dehydrogenase (Agarwal, 1990). This reduction or absence of enzyme occurs in Japanese (44%), Eskimos (43%) or South American Indians (41–43%) and to a much lesser degree in other ethnic groups (Mendoza, 1991). Initially, this reduced enzyme might exaggerate possible adverse events with drugs competing for the same metabolic pathway.

Other influences on drug differences

Some curiosities, such as prolongation of ductus arteriosus closure in the neonate at high altitudes and its resistance to indomethacin closure, are interesting but hardly relevant to most populations. Of greater impact is the effect of ultraviolet light on skin. Black pigment gives about 30% protection from sunburn, but Caucasian populations living in tropical areas not only suffer exaggerated sunburn and photosensitivity when ingesting some classes of drugs, for example, tetracyclines and quinolones, but also develop a higher incidence of skin cancers. Concurrent presence of diseases dominating in a region, for example, chronic hepatitis B, which is endemic in Asia and may affect up to 30% of the population, might distort laboratory normals of liver enzyme responses to drugs and population baseline measurements. Heterozygous sickle cell anemia gene confers immunity against falciparum malaria to Africans (Medawar, 1961), but this benefit is unneeded in African-Americans in malaria-free United States, and homozygous genes (two sets) confer illness and sickle cell anemia episodes may confuse drug assessment. Indeed, drugs such as chloroquine give rise to occasional fulminating hepatitis in these patients and diltiazam has been shown to produce greater sensitization of the PR interval in sickle cell C and S patients (Weintraub and Rubio, 1992).

Although nutritional status is good in Japan, much of Asia lives on less than optimal nutrition, and it might be argued that the United States and Europe suffer from nutritional excess, with about 30% of their populations overweight. Either status has implications regarding lipophilic drug storage, metabolism and tissue distribution.
Ethnic variations in diet, additives or salt content may alter metabolism rates. Lin et al. (1986) and Henry et al. (1987) report that antipyrine metabolism was different in rural Asian Indians than in Asian Indian immigrants resident in England for some years. Dietary environmental differences may also account for the findings of Gould et al. (1972) and Kato et al. (1973) of a gradation of heart and stroke incidence, lowest in residents of rural Japan, higher in Japanese in Hawaii and highest in Japanese in California.

High- or low-fat diets can affect ingestion of drugs, as can a high intake of salt affect diuretic efficacy. Findings that some spices may influence metabolism have been reported. Baily et al. (1991) showed that enhanced bioavailability of felodipine can be more than doubled, and to a lesser extent, nifedipine, with concurrent consumption with grapefruit juice compared to water (an effect not seen with orange juice), and many other drugs (Rau, 1997).

18.4 Subjective factors

The previous objective factors can produce, on occasion, a real although usually small/difference in drug levels and effect. The next group of factors to be discussed are largely subjective but still have an even more profound effect on protocol design, execution, measurement, outcome, recording and interpretation of the data collected. The subjective biases of doctors, patients, study monitors, experts, investigators and regulatory assessors are affected in different ways by variations of the three regional medical cultures and practices, and their population cultural values. It is also an area which is poorly researched by comparative studies. Many of the observations reported in this next section came from the experiences of the author or from the literature of anthropology and social biology.

Medical practice

Physicians in Japan try to achieve effectiveness with no adverse effects with what, by US standards, appear to be almost homeopathic doses at times. In Europe, the aim is to achieve effectiveness with some minimal side effects, often by titrating the dose upwards. In the United States, the aim is to achieve optimal effectiveness with acceptable adverse effects and then titrate downwards. Thus, the highest total daily dosage tends to be greater in the United States than in the other two regions.

The pressure to prescribe is greater in the United States than in Europe; for example antibiotic usage...
per capita is twice as great in the United States compared to the United Kingdom, and four times more than in Germany. Caesarian section is 25% of all births in the US but only 8% in Britain. Defensive medicine is only part of the story; the need for an aggressive approach, with the need to cure as opposed to treatment, is a major factor in the United States. Less litigation may reduce this pressure, but this is unlikely to occur. Conversely, fear of litigation also increases drug attribution and reporting of adverse events.

In Japan, concurrent prescribing of different drugs of the same class in small doses is not unusual. Disclosure of cancer diagnosis to the patient is frowned upon in Japan, and reporting of GI side effects by the patient may be discouraged by the culture.

Differences in preferred dose form, availability of suppositories in France, injections in Italy, pills in the United Kingdom and polypharmacy in Japan, reflect medical practice, education and practice conditions. There is great emphasis and concern in Germany over the heart and diet; in France over the liver; in the United Kingdom over viruses; and in the United States over hypertension and obesity. Only in 1999 were oral contraceptives approved in Japan, a brave action, for it may increase the falling rate of Japanese population replacement, shared with Italy and Western nations (excluding the United States). All reflect a different but small emphases on drug development.

In the different regions, the physicians and investigators are held in varying degrees of esteem by their patients. In Japan, the ability to depend on others, to lean and to be leaned on, is considered healthy (Doi, 1973). The doctor is held in great respect by the patient, and both the doctor and patient regard the chief investigator with even greater respect. This can interfere with adverse event reporting (AER) (avoidance of offense) by the patient, and perhaps lack of critical observation by their sub-investigators. These factors can influence the use of placebo, and ‘informed consent format’ in clinical studies. However, great strides are being made in Japan to share the responsibility with the patient for mutual benefit.

Physicians in the three regions deal differently with failure to achieve the desired clinical effect. In the United States, the tendency is to change medications. In other countries, dose titrations of the same medication may be used more frequently. The different approaches reflect both medical school teaching and expectation of the results of therapy. In many areas of Europe, the physicians and investigators are free, to a certain extent, from suspicion of monetary influence because of extensive socialized or government-backed health schemes. This has its pitfalls, but allows a degree of benevolent, autocratic meritocracy to emerge, which resulted in the evolution of the ‘expert system’ for regulation in Europe and the ‘doctor knows best’ for the patient in Japan, which works quite well in those cultures. Again, the reporting, anticipation or recognition of adverse effects may be diminished. This contrasts with the United States, where frequently almost twice the number of adverse events are reported compared to European studies (except Sweden) and, not infrequently, placebo response rates are also increased. It has been postulated that these increased effects spring from both the aggression of American medical practice in search of cure and from the higher doses used. In addition, US physicians often focus on extensive data gathering in an attempt to achieve diagnostic certainty. This leads to increased search for, and investigation of, adverse reactions and their causality. This may also be due to the litigious nature of the US system. The diagnostic approach ‘blitz’ has been heavily impacted by the inroads of managed care to reduce costs.

Ethnic effects on European AER

As part of an ongoing effort by the EC’s General Directorate for Scientific Research, the European ‘concertation’ procedure’s impact on the ability to monitor and detect changes in clinical safety was studied. Some of the information gathered on spontaneous ADRs was made available to the ICH EC Working Party by Dr M. Papaluca, Amanti.

The nature and incidence of serious spontaneous ADRs on three different new agents approved by the 11 EEC, at that time member states (1989–1991) were examined. As expected, the reporting rate varied between regions, according to the
reporting framework and regulatory requirements, but qualitatively, the same serious adverse events were reported appropriately per capita in all member states where the drug was available. It thus appears, for serious ADRs, that ethnic variation in Europe does not influence the pattern of adverse events or its reporting. Other preliminary findings also showed a similarity of serious ADRs in multinational, multicenter European studies, provided that similar methodology and reporting formats are used. These observations did not apply to nonserious ADRs, where marked national differences were seen.

For further discussion, see sections on Evolution of ICH Topics and Ethnic Factors and Clinical Responsiveness (Papaluca, Amanti, 1993).

**National socioeconomic influences**

National reimbursement policies, therapeutic policies on patients and third-party reimbursement differences between nations and national or private insurers can all have an impact on how drugs are used. Obvious examples are the 1999 refusal of the United Kingdom government to reimburse the Glaxo Wellcome antiflu drug Relanza. Advised National Institute for Clinical Excellence only now ‘at risk’ patients (November 2000), because relief of one day of illness (out of an average of six days) did not justify the price. Another example, Germany, France and Italy’s policy on pricing, grants only ‘improved’ drugs a higher price than the advertised therapy, even to the denial of some ‘me-too’ drugs. The pricing policy in Japan, with the compulsory dropping of a company’s drug price after a few years, irrespective of patent life, is a further example. Lastly, the lately rescinded Canadian legislation, basically denying research costs against developers’ taxes and shortening patent life nearly crippled research in Canada and slowed the applications until a price structure had emerged for drugs in the United States and Europe.

Finally, the US population and US third-party insurance, both government and private industry, all pay 30–50% higher prices for the same medicines than Canada, Mexico or Europe. Pressures on the US manufacturers to reduce US prices will have a chilling effect on the development of new medicines and, hence, on the availability of new medicine globally (the United States is the origin of about 60% of the world’s new chemical entities).

**Terminology, diagnosis and other subjective factors**

As previously mentioned, some diseases and syndromes are not universally recognized in the three regions. Until recently, neither AIDS nor depression was diagnosed in Japan. Conditions such as ‘cardiac fatigue’ and ‘postural hypotension’ in Germany; ‘liver crisis’ in France; ‘heavy leg syndrome’ (pre-varicose-vein development) in Switzerland; and ‘anxiety neurosis’ in the United States are unique to these regions. The end points for treatment may also be different, for example that for blood pressure in Japan is 160/95; in Europe 140/90; and in the United States 130/80. Indeed, even in the same language, ‘I am in the pink’ and ‘I feel blue’ have opposite meanings, and used in self-rating scales but have no or different meanings for the United States and United Kingdom, respectively.

The end result of these differences, although apparent rather than real, may be why the recommended dose of captopril (an ACE Inhibitor, antihypertensive drug) is 75–450 mg per day in the United States and 37.5–122.5 mg per day in Japan (with overall adverse events of 39% and 3.8% respectively). With a nonsteroidal anti-inflammatory agent, overall adverse events were 45–51% in the United States and 24% in Japan at the same dosage; however, efficacy was the same (Dziewanowska, 1992). In general, the British, Dutch and Scandinavian data are closer to those observed in the United States, with the German and Swiss data ‘least reactive’ and French, Italian and Spanish in between. As mentioned previously, severe ADRs in clinical studies tend to be the same; the major difference was in ‘minor’ adverse events, such as nausea, headache and so on. Thus, national temperament also may play a part in the expectation of efficacy and ADR. This finding was reflected in a study of attitudes of 4000 nurses from 13 countries to ethnic tolerance of pain...
(Davitz and Davits, 1981), that Jews, Hispanics and Italians appear to suffer more than Germans, Anglo-Saxons and Asians, but such difference may simply appear to be the socially acceptable level of expression of pain versus the actual pain severity itself.

In many African animist cultures, Western medicine may cure the disease but not the patient, who continues to languish. Western medicine is regarded in Africa in the same way that the Western world regards naturopathy – as ineffective, and this can cause the reverse placebo effect. This can be seen to the extreme in the severe mental function and physiologic systemic shutdown produced by a witch doctor’s curses, which seem totally unresponsive to antidepressant medication (Cannon, 1957), and the first author of this chapter has witnessed and successfully treated such an episode but had to use unconventional methods.

In addition, Third World patients who report seeing spirits and ghosts may not be equated to ‘hallucinating patients’, as in a Western culture, for they may be experiencing the prevailing expectations of their culture (Hartog and Hartog, 1983). Even within the United States, 70–90% of self-recognized episodes of sickness are managed outside the formal healthcare system (Zola, 1972). Thus, the incorporation of clinical social sciences is essential if physicians are to understand, respond to and help patients (Eisenberg, 1973); this is also applicable to the interpretation of clinical results.

18.5 The evolution of ICH topic E5

Background

In November 1991, in Brussels, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was held. A new topic was proposed to, and accepted by, the ICH Steering Committee. This was the thorny issue of tripartite mutual acceptance of ‘foreign’ data. It was assigned the prefix E5 (efficacy, fifth topic approved) but was to be one of the slowest to be resolved – as the reader by now will appreciate, slowly resolved because of its complexity, not because of ill-will. It is true that initially, mutual suspicion reigned, with regional rights and pride. This was quickly replaced by mutual respect, first amongst the regulators and then between the regulators and the pharmaceutical industry representatives. At a meeting in Washington in 1992, Professor Chikayuki Naito from Teikyo University, Japan, was handed perhaps the toughest job of ICH. He was appointed chairman of the E5 working party. He selected his working party members from the three regions, including this chapter’s first author. He then immediately set to work. One of the most interesting discussions was the topic’s title; should it be ‘ethnic’ or ‘racial?’ – so interwoven were these descriptors with cultural, religious and language differences. Eventually, ‘ethnic’ was selected, for it allowed more regional incursion than ‘racial’, which was too restrictive. Then tasks were assigned on a regional basis; the United States representative (the first author) to a literature search, review and compilation; Japanese members were to research the dosing differences between the three regions on the 80 common drugs, backed up where available by matching PK data; Europe was assigned two tasks, first to review of the European adverse event database (national variations) and second, through an independent third party (Center for Medical Research), review of dosage, efficacy and safety differences. The reports were issued in October 1993 at the ICH 2 Orlando meeting. Professor Naito reported for the Japanese delegation that, amongst 42 drugs examined, daily doses of β-blockers and ACE inhibitors in the United States and Europe were twice as high as in Japan. Hypolipidemic drugs were similar in all the regions but, surprisingly, the highest doses were in the EC. Similarly with antibiotics: higher maximum doses were prescribed in EC and also in the United States, than in Japan.

\( H_2 \) blockers, a protein pump inhibitor and NSAIDs showed no difference in daily doses in the three regions, but again, maximum and lowest doses allowed were all lower in Japan. They had also reviewed the PK factors in 80 drugs approved in the three regions but largely concluded that intra-ethnic variation in drug metabolism was as large or larger than interethnic differences; however, this variability was greater in the Japanese
population. Professor Naito concluded that, if the metabolism of a new drug was influenced by genetic polymorphism, then additional regional PK and dose-ranging studies might be required.

Dr S. Walker of CMR approached European and US companies for information on 21 drugs available in the three regions. Within this narrow sample, only one drug had genetic polymorphism, but even this did not translate to ethnic variations. Three other drugs showed regional variability in PK, but these were attributable to different formulations, different sample times and reduction of the initial dose. The CMR survey confirmed that the reported levels of adverse events were lower in Japanese patients, even when adjusted for dose – a cultural variation.

The US report on findings in the literature were given by the first author of this chapter and Dr. R. Williams of the FDA. Much of the earlier part of this chapter was drawn from these reports.

Deciding what to do about this complex issue took another four years! Two more conferences were needed to resolve the issue, but finally in July 1997, Step 3 was concluded, Europe and Japan referred it to their governmental bodies and the United States published the draft guidelines in the Federal Register. Phase IV acceptance by the ICH Steering Committee occurred in February 1998, and the final guidance document was implemented in the United States in June 1998 (Step 5) (Federal Register, 1998).

Outline of the ‘Guidance’ – E5

Overall, it will not be necessary to repeat the entire clinical drug program in each of the other two regions. Each regional authority will judge whether the clinical data fulfill their regulatory regional requirements (i.e. are a complete package). If so, can they be extrapolated to their population? If the authority is concerned that a drug could be subject to ethnic factors impacting on efficacy or safety, then limited clinical data gathered in people of that region may be required to ‘bridge’ the clinical data between the data generated in one region to those of the area in which the data were generated. If new data are required by the new region anyway (inadequate for regional requirements), the study could

What is a complete package?

Studies should be adequately well-controlled end points and medical and diagnostic definitions appropriate to the region. The specific needs are mostly covered in other ICH guidances GCPs (E6), dose response (E4), adequacy of safety data (E1 and E2), studies in elderly (E7), reports (E3), clinical trials (E8) and statistics (E9)). Occasionally, a region may feel that other studies are needed in areas that other regions are less concerned with; a different ‘golden’ standard as comparator, or at a dosage as approved in that region, as well as patients with renal or hepatic insufficiency, are given as examples.

Ethnic factors and population extrapolation of a drug

Some properties of a drug or its class may make it insensitive to ethnic factors. This will make it easier for extrapolation to different regions and reduce the need for ‘bridging’ clinical data. Properties that make it susceptible to ethnic influences see Table 18.1 will require bridging studies, sometimes of PK/dynamics studies or safety and efficacy either or both.

Assessing the potential sensitivity of a drug to ethnic factors

If a drug is of a known class, the sensitivity may already be determined, but by the end of phase I most of the PK and PD of a drug will be known. The properties of the compound that may indicate potential ethnic variation (ethnically sensitive) are

- nonlinear PK
- a steep efficacy and safety PK dose curve
- narrow therapeutic dose range
- highly metabolized, especially if through just one pathway (potential for drug–drug interaction)
- metabolism by enzymes known to show genetic
• a pro-drug relying on enzyme conversion subject to ethnic variation
• low bioavailability (ethnic dietary effects)
• projected common use in multiple co-medication
• potential for inappropriate use

Properties that reduce a drug’s potential for ethnic variation (ethnically sensitive) are the converse of the above, with the addition of low potential for protein binding and non-systemic use.

**Bridging data package**

This consists of information from the complete clinical data package selected for its relevance to the new region. PK, PD and early dose-response data should all be included. If a bridging clinical study between the foreign data and the new region’s population is needed, this may be a PK study, or PD demonstration of efficiency or a full center running a PK study additionally on volunteer patients. A bridging clinical study may not be needed (a regional regulatory decision). This is most likely where (a) the medicine is ethnically sensitive and medical practice and conduct of trials are similar, (b) if ethnically sensitive but the two regions have similar clinical make-up of populations, and (c) when extrapolation from drugs of a similar class can be made. If the drug is ethnically sensitive and clinical data are derived from dissimilar ethnic populations, provided that other non-physiological factors are similar, a simple PD dose–response study may suffice. This could utilize an endpoint predictive of clinical value (surrogate), for example blood pressure. If PK were also undertaken in the same study, dynamic effects may be directly reflected by the blood levels.

If the bridging study shows similarity to the dose–response study in safety and efficacy, this is usually sufficient, even if this study shows that a different dose is indicated. That is especially so if at that new dose (range) a similar safety and efficacy profile has been demonstrated.

Where the differences are greater (medical practice, a new drug class to the region, different con-

---

**Table 18.1** Classification of intrinsic and extrinsic ethnic factors (ICH Guidance, 1997)

<table>
<thead>
<tr>
<th>Intrinsic</th>
<th>Physiological and pathological conditions</th>
<th>Extrinsic</th>
<th>Environmental</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic</td>
<td>Age (children–elderly)</td>
<td>Climate</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>Height</td>
<td>Sunlight</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td>Bodyweight</td>
<td>Pollution</td>
<td></td>
</tr>
<tr>
<td>ADME</td>
<td>Liver</td>
<td>Culture</td>
<td></td>
</tr>
<tr>
<td>Receptor sensitivity</td>
<td>Kidney</td>
<td>Socioeconomic factors</td>
<td></td>
</tr>
<tr>
<td>Genetic polymorphism of the drug metabolism</td>
<td>Cardiovascular functions</td>
<td>Educational status</td>
<td></td>
</tr>
<tr>
<td>Genetic diseases</td>
<td>Diseases</td>
<td>Language</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical practice</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disease definition/diagnostic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Therapeutic approach</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug compliance</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smoking/alcohol</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Food habits</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stress</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Regulatory practice/GCP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Methodology/end points</td>
<td></td>
</tr>
</tbody>
</table>
from that of the region standard), a controlled, randomized clinical study for efficacy will be required. This might utilize shorter duration surrogate end points, rather than the clinical end points common to phase III studies.

The ICH issued a further Questions and Answers Guidance (US Food and Drug Administration, 2004) to provide further explanations of when bridging studies may be required following six years of experience.

**Bridging safety studies**

The new region may also have concerns regarding the relevance of the safety data of common serious adverse events and their incidence to their ethnic population. The guidance recommends that the clinical efficacy study should be powered to capture a 1% incidence of an event, namely 300 patients for six months on the new medicine. Additional patients will be needed for the control group in a controlled trial, given an expected dropout rate of 15–30%, dependent on disease and severity of efficacy depends on the balance of the groups (1:1, 1:2, 1:3). A small safety study might be done initially to assure the sponsor and the region that a high incidence of serious events is unlikely to be seen in the larger study.

**Practical implications to sponsors of new medicines**

Most major clinical pharmaceutical manufacturers recognize that it is not profitable to develop a drug just for one region. In the past, most drugs were introduced first in Europe, even by US-based firms for pricing reasons, often country by country, and in Japan even later. This has dramatically changed since the Prescription Drug User Fee Act, which speeded up US approvals and the introduction of the ‘centralized procedure’ of Application for Europe. Frequently, firms will conduct multicentre studies in both the United States and Europe and submit them almost simultaneously to the FDA and EMEA. This was not possible to do for Japan; now it is! Indeed, Japan now can conduct studies in other regions on their drugs and combine them with confidence into their own more extensive clinical data package for foreign submission. Differences of Japan’s chemical manufacturing and quality control section (CMC) still have to be resolved before full interchangeability (mutual recognition) of their Common Technical Documents occurs. Many firms now do PK and PD dose–response studies on Japanese patients in Japan. In addition, even if not needed, they conduct a controlled local comparison clinical study to expand the database and for sound marketing reasons.

In the United States, because of legislation previously discussed, data on major ethnic groups are collected and analyzed and may in general provide reassurance that the most obvious ethnic differences are observed. This is of less concern to the other regions.

For many years, the FDA has encouraged a wide geographic distribution of phase III multicenter studies. This can be used to enroll minority and cultural ethnic groups, because they tend to congregate in regional clusters, for example Hispanics in Miami and New York. Placement with a physician investigator of similar ethnic origin can enhance the enrollment, for frequently they will attract patients of that group. It should be noted that ‘hispanic’ analysis has been dropped as a requirement unless culturally relevant.

The current regulatory position of the three regions has been outlined in the notes for The Guidance for the Mutual Use of Foreign Data in the EC, Japan, and US, Part 1. The ADME concern has been well defined and quantified in separate reports.

**Does it matter? The reality**

Despite this huge list of possible factors influencing the drug development and assessment process, the following realities are emerging.

- For most drugs the therapeutic range is broad, and rarely is an optimal dose so critical for effective treatment. Exceptions, such as cardiac glycosides, anticonvulsants, anticoagulants and so on, have a narrow therapeutic window and must be individualized by titration. Such drugs,
if not useful, are soon discarded (Benet, 1992). Despite the presence of multiple conflicting factors, the global dosage trend is toward a global ‘mean’. Over time, the same dosage range emerges in many countries, adjusting to the ‘real world’ as opposed to the narrow demographics of research or cultural expectations.

- Generally, where dosages are the same, the incidence of serious adverse events tends to be the same in the three regions (Edwards, 1993; Papaluca, 1993).

- Objective differences, when found, are largely due to physiologic influences (blood/body volume and metabolic intrapopulation differences) and less commonly due to ethnic variation. In the United States, an estimate of less than 5% of drugs subject to significant clinical ethnic variation was reported by participating companies in a USA/PMA Survey (Edwards, 1991) and confirmed by the retrospective surveys undertaken for ICH 2 (Harvey and Walker, 1993; Natio and Yasuhova, 1993).

- Data are more interchangeable between the United States and Europe than between Japan and the United States, or between Japan and Europe, but this is less often due to PK differences, body size and diet but more often to the even larger differences in medical and cultural attitudes of Japan, Europe and the United States which influence dose selection and data compatibility.

18.6 The future

Technology, television, transcontinental travel and international scientific and medical conferences continue to narrow the subjective variations. Differences in diagnosis, data measurement and interpretation will diminish with such exchanges. It is possible that methodology, study design and case report forms can be constructed that correct for culture, diet and at least some subjective factors, which will allow comparability of efficacy and adverse events on dose/mg/kg body weight measured between European, US and Japanese data.

In conclusion, most but not all differences will disappear and indeed, from such diversity, there may spring new understanding of both clinical and therapeutic mechanisms for the development and applicability of better medications.

Recommended further reading


References


Code of Federal Regulations 21 Foreign data. Section 314.106. Application for FDA approval to market a new drug or antibiotic.


Dziewanowska ZE. 1992. ‘International harmonization of clinical trials’. In Fifth World Conference on Clinical Pharmacology and Therapeutics, Yokohama, Japan, July.


Leiberman JA, Canoso RT, Egea E, Kane JM, Yunis J. 1990. ‘HLA-B38, DR4, DQW3 and clozapine-induced
agranulocytosis in Jewish patients with schizophrenia’. 
Arch. Gen. Psychiatry 47: 945–948.
Lin KM, Lesser JM, Poland RE. 1986. ‘Ethnicity and 
psychopharmacology culture’. Med. Psychiatry 10: 
151–165.
Lin KM, Mendoza R, Poland RE, et al., 1991. ‘Phar-
macokinetic and other related factors affecting psy-
chotropic responses in Asians’. Psychopharmacol. 
Metropolitan Life Insurance. 1999. Male, Female, 
Height and Weight Tables (www.metlife).
189: 14–17.
449–460.
Oster G, Huse DM, Deles TE, et al., 1987. ‘Cost-
effectiveness of labetalol and propranolol in the 
Papaluca M. 1993. ‘Ethnic factors and clinical respon-
siveness: basic concepts of the retrospective survey’. 
ES Workshop Report, ICH-2, Orlando.
York.
Rieder MJ, Sheer NH, Kanee A, et al., 1991. ‘Promi-
nence of slow acetylator phenotype among patients 
with sulfonamide hypersensitivity reactions’. 
Sleath B, Svarstad B, Rotes D. 1998. ‘Patient race and 
psychotropic prescribing during medical encoun-
treatment of Black American populations’. Psycho-
Takahashi R. 1979. ‘Lithium treatment in affective 
disorders: therapeutic plasma level’. Psychopharma-
100.
Factors in the Acceptability of Foreign Clinical 
Data – Questions and Answers (www.fda.gov/ 
cber/gdlns/iche5ethnic.htm).
Uchida K. 1988. ‘Acceptability of foreign clinical trial 
Vessell E. 1989. ‘Ethnic differences in reactions to 
21–37.
differences in drug response-altered sensitivity 
to and clearance of propranolol in men of Chinese 
descent as compared with American Whites’. 
metabolism in native Chinese, poor and extensive 
hydroxylators of S-mephenytoin: inter-ethnic differ-
ences in comparison with White subjects’. Clin. 
489: 10–17.
Zola IK. 1972. ‘Studying the decision to see a doctor’. 
In Advances in Psychosomatic Medicine, vol. 8, 
Drug development programs are obligated to consider whether specific dose adjustments, warnings or contraindications should be recommended in patients with varying degrees of hepatic or renal failure. In some regards the issues are analogous for patients with disease in one or other of these organs, and, indeed, renal failure can be secondary to hepatic disease (the reverse is more controversial). The objective here is to review the issues surrounding these special populations. In doing so, readers should also review the two excellent US Food and Drug Administration (US FDA) Guidances on these subjects (see Further reading list at the end of this chapter).

19.1 General principles

(a) The issues surrounding hepatic or renal insufficiency are obviously greater for drugs (or their active or toxic) metabolites that are eliminated by the liver, kidney or both.

(b) From a safety perspective, drugs whose effective doses are close to the harmful dose (a narrow ‘therapeutic ratio’) are more likely to have critical limits on exposure, and thus, in general, more likely to need careful study in patients with disease in these organs. A useful rule of thumb is: ‘If there is going to be a clinical assay for the drug, then watch out for renal and hepatic disease associated adverse effects’.

(c) Both renal and hepatic function can decline with age and differ with gender, pregnancy and so on. When studies are needed (see below), the appropriate controls are not the typical young, fit normal volunteers in phase I studies, but rather people who are age- and sex-matched as closely as possible to the patients with the disease state that will form the indication for the drug.

(d) Population kinetics can often provide much useful information, especially when the intended patient population is elderly and may well have varying degrees of hepatic or renal reserve within the ordinary phase III database. This requires documentation of each patient’s hepatic and renal status in ordinary clinical trials of unrelated diseases,
although each patient may provide only a sparse set of pharmacokinetic samples.

(e) For drugs administered chronically, consider carefully whether single-dose pharmacokinetics are truly predictive of the multiple-dose situation, not only in normal volunteers but also in patients with hepatic or renal disease. In case of any doubt, conduct the studies described below in patients with liver or kidney disease at steady state, or at least under conditions where the effects of the organ insufficiency can be assessed at both peak and trough drug concentrations.

(f) Be aware that pharmacokinetics and patterns of metabolism can change in patients with hepatic and renal insufficiency. With serious liver disease, many drugs’ eliminations convert from first-order to zero-order. With serious renal disease, new metabolites may appear in the circulation because the urinary excretion of unchanged drug or the fastest generated metabolites is reduced. Dialysis often causes the opposite phenomenon.

(g) There is a need to study the effect of varying degrees of hepatic or renal sufficiency on new drugs, according to the relevance of every degree to the promulgated indications. Almost all new drugs that will be administered to persons over 65 years of age will therefore need information about the effects of mild renal or hepatic insufficiency. Additionally, some drugs may need to be studied in patients with moderate or severe insufficiency(ies). In general, it is easier to quantify degree or severity of renal failure than hepatic failure.

(h) For drugs that are excreted entirely and unchanged by the lung (e.g. inhaled anesthetic gases), it is almost always possible to provide a rationale that hepatic and renal insufficiency studies are unnecessary. Similar arguments can often be made for single-dose drugs with wide margins between dose–response curves for wanted and unwanted effects, even if eliminated by either the kidney or the liver.

19.2 Renal insufficiency

The central question is whether the degree of renal insufficiency that exists in patients who are likely to be exposed to the drug of interest could have a sufficient effect as to warrant an alteration in dosing. Note that the kidney is also an organ of metabolism, and, therefore, renal disease (especially when severe) can affect clearance in multiple ways, not just in urinary excretion.

Are studies needed?

The resolution of this central question, and thus the perceived need for special studies, hinges on multiple factors:

(a) Is the reduced excretion likely to cause a pharmacokinetic effect that is likely to be associated with a deleterious pharmacodynamic effect (reduction in efficacy or increase in intolerability)?

(b) Is the drug and its indication likely ever to be administered to people with renal insufficiency, and, if so, then to what degree of the latter?

(c) Is there an active metabolite for which these considerations are more important than the parent drug?

(d) Can fluid overload or other factors that change plasma protein concentration, and hence binding, interact with the anticipated effects on renal excretion?

(e) Are there some rare, special factors that can even theoretically be imagined (e.g. drug-induced diabetes insipidus and lithium)?

Excluding an effect of renal failure

It is usually straightforward to conduct brief studies confirming the absence of any effect of renal failure that would impact pharmacodynamics. This
is usually done when the circulating concentration response relationship for the wanted effects of the investigational drug is well understood, of orthodox sigmoid form, when there is no active metabolite(s), and when the dose or concentration–response relationship for unwanted effects is also well understood and a long way to the right of the curve for efficacy. Small studies with dense sampling, or population kinetics with sparse sampling during the phase III program can accomplish this. Note that the latter cannot be accomplished when renal failure has been a routine exclusion criterion during the clinical development program. When study sponsors are confident, then a small study (say $n = 4–6$ subjects with severe renal insufficiency) may serve to exclude an effect on the drug.

**Quantifying the effect of renal failure**

Assuming that studies are needed, then patients with mild or moderate renal failure (estimated creatinine clearances 50–80 and 30–50 ml min$^{-1}$, respectively) must be studied. Age-, sex-, diet- and smoking-matched controls for the disease state being treated should be used, rather than young, fit volunteers, in order to avoid false-positive study conclusions.

A single-dose study will usually be acceptable to regulatory authorities, provided that there is clear evidence elsewhere in the dossier/NDA that single-dose data can predict multiple-dose pharmacokinetics. If multiple-dose studies are needed then these should include an observation period at steady state. The study size (i.e. number of patients per group) will be determined by a power calculation using the known variability of the pharmacokinetic parameters of the drug in question; in practice there is seldom the need for more than 15 subjects per renal function stratum, unless a population kinetics approach has been preferred. The nonlinear and non-compartmental modeling procedures for use in a population kinetics scheme are beyond the scope of this chapter, and should certainly be discussed in advance with the relevant regulatory authorities.

When possible, pharmacodynamic assessments should be made in conjunction with the pharmacokinetic estimates. The reason for this is that it can check that there has not been some supersensitivity state induced in the biophase by the disease causing the renal insufficiency, and thus to exclude a false-negative conclusion when purely pharmacokinetic data are analyzed.

**Assays** will usually be on plasma and urine. Plasma protein binding should be estimated simultaneously because renal disease can alter plasma protein binding of some drugs.

**Note on estimation of creatinine clearance**

Formal measures of glomerular filtration rate (GFR), using intravenous inulin or radio-iodinated sodium iothalamate, will not have been performed on most patients with relative renal failure in ordinary clinical practice. Of several alternatives in adults, creatinine (Cr) clearance (CrCL) is probably the most commonly employed, and uses the familiar formula:

$$\text{CrCL} (\text{ml min}^{-1}) = \frac{([\text{Cr}]_{\text{urine}} (\text{mg dl}^{-1}) \times \text{urine excretion rate (ml min}^{-1}))}{[\text{Cr}]_{\text{plasma}} (\text{mg dl}^{-1})}$$

This requires a timed urine sample (e.g. a 24-h collection). The Cockroft–Gault estimate of CrCL uses only a point measure of serum creatinine and currently enjoys wide acceptance by regulatory authorities.

For men, the Cockroft–Gault estimate is:

$$\text{CrCL (ml; min}^{-1}) = \frac{[140 \times \text{age (y)}] \times \text{weight (kg)}]}{[72 \times \text{serum creatinine (mg dl}^{-1})]}$$

For women, the Cockroft–Gault estimate is the same as for men, except that the result is multiplied by 0.85.

In infants, the Cockroft–Gault estimate is inaccurate. Currently, the US FDA Guidance for
children is:

Under 1 year: \( \text{CrCL} \ (\text{ml min}^{-1}) = \left[ 0.45 \times \text{length (cm)} \right] / \text{serum creatinine (mg dl}^{-1}) \)

1 – 12 years: \( \text{CrCL} \ (\text{ml min}^{-1}) = \left[ 0.55 \times \text{length (cm)} \right] / \text{serum creatinine (mg dl}^{-1}) \)

**Dialysis**

Lastly, end-stage renal disease is characterized by the need for routine dialysis. These are the patients with renal failure for whom an increase in dosing may be necessary to compensate for drug/active metabolites being lost into the dialysate. Understanding the pharmacokinetics of the drug during dialysis is essential unless it is not anticipated that such patients will be treated with it. Even then, knowing whether a drug can or cannot be dialyzed is helpful in providing advice to clinicians dealing with overdoses or poisonings after the drug has been marketed.

**Labeling**

The US FDA Guidance provides several specimen pieces of wording for use by those drafting product labeling. They are highly recommended. Generally speaking, if renal insufficiency causes a change in pharmacokinetics that exceeds the latitude granted to generic copies of previously approved drugs, then careful consideration to adding specific dosing recommendations for patients with renal insufficiency to the product labeling. Currently, this latitude is for the mean \( C_{\text{max}} \) to lie outside a range of 70–143\% of the control mean, with the simultaneous mean AUC to lie outside 80–125\% of the control mean.

**Assessing severity of hepatic dysfunction**

Most widely accepted by regulatory authorities (i.e. you have to have a good reason not to use it) is the Child-Pugh scoring system. This was originally developed as a method for assessing anesthesia/surgical hazard in patients with varying degrees of hepatic disease. It is a point-scoring system, according to Table 19.1.

The only other commonly used alternative is the Maddrey Discriminant Function (MDF) which was developed to assess acute alcoholic hepatitis. This is more easily calculated than the Child-Pugh score as:

\[
\text{MDF} = [4.6 \times \text{prothrombin time (s)}] + \text{serum total bilirubin (mg dl}^{-1})
\]

Disease was labeled not severe when MDF < 54, severe at 55–92 and probably lethal at ≥ 93. In practice, most modern clinical trials will document differences. Firstly, hepatic disease causes secondary renal failure more often than the other way round. Secondly, it is more difficult to quantify severity of insufficiency of the liver than for the kidney. This section of the chapter is again based upon the excellent US FDA Guidance (see Further reading below).

The literature contains literally hundreds of reports on the influence of liver disease on drug elimination. Most commonly the patients in these studies have various degrees of fatty degeneration or cirrhosis (the former often associated with alcohol or diabetes, and the latter most commonly due to hepatitis viruses, alcohol, but sometimes obliterator biliary disease or autoimmune disease). These diseases are more often associated with intrinsic alterations in pharmacodynamic responses, for example liability to seizure is common in patients suddenly withdrawn from chronic alcohol abuse, and the encephalopathy associated with elevated circulating concentrations of ammonia or superimposed acute hepatic disease or gastrointestinal bleeding.
both the Child-Pugh score and the MDF at all relevant time points.

Methods that involve studying the disposition of some exogenously administered agent (e.g. indocyanine green, antipyrine, galactose or dextromethorphan) have now been superceded by functional (often multicomponent) tests. Monoethylglycinexylidide formation has not found wide acceptance. More complicated Cox proportional hazards models may exist for other liver diseases, but are only used specifically for them (e.g. the Mayo Clinic Survival Model for primary biliary cirrhosis; see the US FDA Guidance).

When studies are needed

In general, studies are needed for all drugs to which the liver is exposed, unless

- drug excretion is entirely renal
- hepatic metabolism accounts for <20% of clearance and the drug has a clearly demonstrated wide therapeutic window or
- the drug is volatile and it (and its metabolites) is readily excreted by the lung

Most regulatory authorities allow some relaxation of the requirement for studies when the drug is for single-dose only, and when adverse events are $C_{\text{max}}$ rather than AUC-related (because $C_{\text{max}}$ usually varies little with reduce rate of clearance under these conditions).

Study design

Generally, there should be a clear understanding of the pharmacokinetics of the drug of interest in all three Child-Pugh classes of liver disease, unless the Sponsor is willing to accept strong labeling against administration in severe liver failure (and then has to study only the other two grades of severity). The size of each treatment group depends upon the variability in the pharmacokinetics of the agent, although, regardless of this fact, the US FDA Guidance recommends that there should be at least six patients. As before, single-dose studies may suffice when there is reason to believe that all the stages of liver disease that are being studied, the pharmacokinetics of a single dose are indeed predictive of the multiple dose/steady state situation. When drugs are being developed for more than one route of administration, then usually one can be chosen that provides the maximum information, and the need to study the second route is obviated. Population kinetics approaches are also sometimes feasible if incorporated into phase III development schemes, and when appropriate nonlinear and non-compartmental models can be defined.

Conclusions of no effect are based upon the pharmacokinetic tolerances accorded to generic versus innovative products. However, small numbers of patients usually make this quite difficult.

In general, regulatory authorities are keen to provide advice on particular study designs that are appropriate on a case-by-case basis, and this should always be an agenda item at end-of-phase II

| Table 19.1 Child-Pugh Point-scoring system |

<table>
<thead>
<tr>
<th>Points scored</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Encephalopathy grade</td>
<td>0*</td>
<td>1 or 2</td>
<td>3 or 4</td>
</tr>
<tr>
<td>Ascites</td>
<td>None</td>
<td>Slight</td>
<td>Moderate</td>
</tr>
<tr>
<td>Serum bilirubin (mg dl$^{-1}$)</td>
<td>&lt;2</td>
<td>2–3</td>
<td>&gt;3</td>
</tr>
<tr>
<td>Serum albumin (mg dl$^{-1}$)</td>
<td>&gt;3.5</td>
<td>2.8–3.5</td>
<td>&lt;2.8</td>
</tr>
<tr>
<td>Prothrombin time prolongation (s)</td>
<td>&lt;4</td>
<td>4–6</td>
<td>&gt;6</td>
</tr>
</tbody>
</table>

*0 = normal; 1 = restlessness 5 Hz waves on EEG; 2 = lethargic, disoriented, asterixis; 3 = somnolent/stuporous rigidity; 4 = unrousable coma (each grade >0 can have other symptoms). Total points: good operative risk: ≤6; moderate risk: 7–9; poor risk: >9 points.
meetings in the United States, or during scientific advice procedures in the European Union.

**Labeling**

The US FDA Guidance provides specimens for labeling. In practical terms, another useful approach is to review some recent product labels in commonly used compendia (*Physician’s Desk Reference*, *Drugs Sheet Compendium*, *Rote List*, etc.) to find the sorts of wordings that national regulatory authorities have recently found to be acceptable.

**Further reading**


20 Drug Interactions

Anthony W. Fox and Anne-Ruth van Troosteburg de Bruyn

20.1 Definition

A drug interaction is an effect observed with two or more drugs, which is not seen with one drug alone. The effect can be qualitative or quantitative. Drug interactions can constitute clinical hazard or be exploited for therapeutic benefit.

In modern clinical settings, patients often receive multiple drugs. Every physician will be aware of the benefits of pharmacodynamic interactions of medications—such as additional effects on blood pressure when combining ACE inhibitors, calcium antagonists or beta blockers to treat hypertension. The interactions of these drugs result in additional blood pressure lowering effect, which can be both wanted or unwanted in its magnitude. Equally, all physicians will be aware of the potential for adverse effects of commonly used drugs, such as warfarin, when another drug is introduced at the same time. Care needs to be taken, in both cases, when either the target of the mechanism of action is the same for two drugs, or one drug alters the pharmacokinetics of the other.

The purpose of this chapter is to offer a description of drug interactions in a systematic manner. It is impossible to remember all drug interactions, and information technology and ready-reference manuals should always be used. But, within the realm of pharmaceutical medicine, additional aspects that must be borne in mind are to understand how interactions may be described and quantified on paper, whether in product labeling, regulatory submissions or scientific reports.

20.2 Description and quantitation of drug interactions

Drug interactions may be described as additive, antagonistic or synergistic (or potentiating). These three categories are regardless of whether the underlying mechanism is pharmacodynamic or pharmacokinetic in nature.

Drug interactions may be quantitated and illustrated using isobolograms. An isobologram is simply a method of illustrating data with three variables in two dimensions, that is on the surface of a piece of paper. This form of plotting should not be unfamiliar. Analogous examples of such plots are found (three dimensions) on topographical maps (latitude, longitude and elevation above sea level) and meteorological charts (e.g. latitude, longitude and barometric pressure); in both cases the third variable is shown by the contours. In the
simple case of an interaction between two drugs, the three variables are the dose of drug A, the dose of drug B and size of effect; the last of these being shown by the contours.

Additivity is where two drugs have the same effect, and neither potentiates or antagonizes the other. The isobologram has contours that are parallel line segments (see Figure 20.1). If the adverse effects are different then this tactic can minimize clinical hazard without sacrificing efficacy. Antibiotic combinations frequently are additive.

Antagonism is an interaction where one or other drug reduces the activity of the other. The contours of the isobologram are convex away from the origin of the plot (Figure 20.2). Several examples of antagonistic interactions are discussed below in connexion of the locus where such interactions take place.

Synergy or Potentiation is where the combination of two drugs has an effect that is greater than simply additive. The contours of the isobologram are concave toward the origin of the plot (Figure 20.3). In most cases, an effect with this

\[ ay + bx = kE_c \]

Figure 20.1  Isobologram illustrating simple additivity. The lines connect equal amounts of drug effect \( (E) \), with each having the general equation \( ay + bx = kE_c \), where \( a, b \) and \( k \) are constants, and \( c \) is the percentage of maximal effect on the dose–response curve (in this case \( a = b = k = 1 \))

Figure 20.2  A classical isobologram illustrating antagonism. Using the same notation as in Figure 20.1. The broken lines show how a combination of four units of drug A plus four units of drug B has an effect that is much less than \( E_8 \) (as would be the case if the interaction was additive). The formulae for the contours are \( ay + bx < kE_c \)
type of drug combination can exceed the effect that is achievable with even maximal doses of either alone. Combination of antihypertensive therapy or chemotherapy is a good example.

More complicated isobolograms exist. The N-acetyl cysteamine dosage algorithm is an isobologram with time and acetaminophen (paracetamol) plasma concentration on the axes in the plane of the paper and a two-step measure in the third dimension (probability of toxicity that requires treatment). Somewhat as famous is Professor Herxheimer’s depiction of the interaction between coffee and wine: two glasses of each provide the maximum possible beneficial effect (the effect being ‘happiness’). The contours are thus of a hill on a plane.

20.3 Systematic consideration of drug interactions

The key to considering the potential for drug interactions lies in considering all the places that drug molecules may occupy. In this section, we shall present a repertoire of drug interactions sorted by locus, which the reader may like to consider, and those sitting the Diploma in Pharmaceutical Medicine might like to be able to deliver to the examiners. The full set of drug loci are the sites of drug storage, absorption, distribution, action, metabolism and excretion, plus, in some cases, the presence of the drug in blood and urine samples that reach the clinical laboratory; clearly there are exceptions. For example, some drugs act at the site of absorption, and others are excreted unchanged.

Prior to administration: drug storage

These interactions are always unwanted. A good example is the inappropriate mixing of insulins. Slower release insulins are complexed with protamine zinc in excess, while the conjugation of insulin with such adjuvant takes place slowly, especially in the relatively low temperature of a refrigerator. Drawing up the lente insulin first, and then sticking the needle into the soluble insulin,
gradually transfers the excess protamine zinc into the soluble insulin, thus converting it into lente insulin. Other examples include almost any drug in blood or elemental foodstuffs. Also, heparin is the most acidic drug in common usage, and it chelates almost everything; for some reason penicillins are reported as the most chelated combination in the infusion bag.

Site of absorption

There are common examples of both wanted and unwanted drug interactions at the site of absorption. Examples include activated charcoal/any overdose (wanted), metoclopramide–naproxen (the absorption of the latter being hastened by the former for improved efficacy when treating migraine acutely), lipid or olefin fecal emulsifiers and fat-soluble vitamins (the latter being unabsorbed, an unwanted interaction) and tetracyclines – calcium-containing drugs (e.g. milk, an unwanted interaction because of the calcium-chelating properties of tetracyclines). Note that the epinephrine–lidocaine (adrenaline–lignocaine) interaction can be both wanted or unwanted; in most injection sites localized vasoconstriction reduces the rate of systemic absorption, prolongs local anesthesia and reduces the potential for central nervous system adverse effects (i.e. a wanted interaction). However, in tissues that form a salient (fingers, toes, nose, ear pinna, penis) the vasoconstrictor can cause necrosis because of the absence of collateral circulation.

Drug distribution

Most of these drug interactions involve displacement of drug from plasma proteins, thus increasing the free/bound ratio for drug concentration. When the free moieties are those that are pharmacologically active, then unexpectedly exaggerated responses result from standard doses. Most (but not all) such interactions are unwanted. Almost any nonsteroidal anti-inflammatory drug (NSAID) displaces warfarin, thus enhancing its anticoagulant effect and rendering the patient liable to unexpected ecchymosis or more serious hemorrhagic adverse events. Similarly unwanted are the interactions between phenytoin and thyroxine (sedation and thyrotoxicosis), and salicylates with tolbutamide (hypoglycemia). Oral contraceptives compete for albumin-binding sites, and phenytoin doses may need to be adjusted when the former are introduced. A rare example of a beneficial drug interaction at this locus are the use of NSAIDs with some glucocorticoids, where enhanced anti-inflammatory effects of the latter can result, even though a relatively low dose has been administered.

Drug interactions at the site of action are manyfold and familiar. All receptor antagonists, when used in the face of an agonist challenge, are clinically desirable. Obvious examples include naloxone for opioid overdose and physostigmine for reversal of tubocurarine in anesthesia. Note that succinylcholine paralysis during anesthesia is only made worse with anticholinesterase administration (an adverse drug interaction at the receptor, beloved by multiple-choice question setting examiners!).

Sequential biochemistry interactions also fall within this category. Sulfamethoxazole and trimethoprim inhibit different stages of the folate metabolism pathway. Concomitant administration reduces the probability that a bacterial strain can mutate in any single step to evade the antibiotic effects of both drugs.

Physiological interactions are a subset of site of action interactions. Adding spironolactone to furosemide (frusemide) provides no extra diuresis, but does antagonize the potassium loss that occurs when the latter drug is used alone. Both progestagens and estragens (progesterones and estragens) such as ethinyler estradiol and levonorgestrol inhibit ovulation and uterine deciduation, thus being positive or wanted interactions, albeit acting at different receptors.

Unwanted interactions at the site of action classically include the highly undesirable concomitant use of tetracyclines and penicillins. The latter are bacteriocidal when the organism is dividing because they obstruct cell wall manufacture, and thus expose the new bacterial membrane to osmotic destruction. Bacteriostatic compounds, such as tetracyclines, reduce the rate of bacterial division and thus reduce the effectiveness of penicillins.
Other nonreceptor site of action interactions include MAOIs – pethidine (acute dystonias), ethanol – benzodiazepines (synergistic sedation and respiratory depression), cocaine – amphetamines (hypertensive crisis) and dihydrocodeine – morphine (the former is a partial agonist and reduces the efficacy of the full agonist).

As far as drug metabolism is concerned, it is essential to understand some of the basic biochemistry before being able to anticipate the interactions that can occur at this locus. Mobile omnivore mammals are constantly exposed to xenobiotics, many of which can be toxic. An efficient defence against these toxins resides in the gut and the liver, with the general aim of metabolizing such toxic molecules into smaller and less toxic metabolites; these are generally more water-soluble and thus more capable of excretion, thus reducing the exposure of the rest of the body to high concentrations of the parent toxin. Drugs fall foul of the same defence mechanisms.

Cytochromes are a diverse class of enzymes, and are so named because they are brightly colored when in solution. This color is because these enzymes contain heme groups and transition metal ions (e.g. Fe^{2+}, Cu^{2+}, etc.). As they are colored, these enzymes may be classified by the wavelength of light which they absorb maximally. Although a comprehensive discussion of cytochrome classification is beyond the scope of this chapter, suffice it to say that cytochrome class P enzymes, with a maximal absorption of 450 nm (CYP450), are the most important for drug metabolism. These CYP450 enzymes themselves exist as several hundred isoenzymes, denoted by code letters and digits, for example CYP450 2D6. Each isoenzyme has a preferential substrate. Different species (including *H. sapiens*) exhibit different patterns of isoenzymes in their phenotype, and there may be further variation in the activity of particular isoenzymes between individuals, whether or not this is predictable on the basis of membership of particular ethnic groups.

CYP450 isoenzymes usually reside on the smooth endoplasmic reticulum, and are classic examples of mixed-function oxidases (or oxigenases); these enzymes oxidize and reduce two substrates simultaneously, and atoms from molecular oxygen usually are incorporated into one of the substrates. Alternatives include the loss of hydrogen atoms or alkyl groups, with the corresponding formation of water or formate. The loss of hydrogen atoms (i.e. a substrate that becomes less reduced) is another form of molecular oxidation within the Lowry-Brønstein formulation. Thus, drug metabolism by CYP450 can involve hydroxylation, dealkylation, aromatic oxidation, sulfation, ring opening with hydroxylation and so on. Sometimes, the isoenzyme itself is oxidized, and in this case it is usually regenerated by reduced nicotinamide adenine phosphate (NADP-H).

When thinking about interactions at the site of metabolism, one must therefore think about classical enzymology, and from the enzyme’s point of view. Drugs can be substrates, inhibitors or enzyme activators (i.e. inducers or promoters). Competition by two drugs for saturated enzyme is mutual competitive antagonism and elimination times for both will increase. Drugs that are enzyme inhibitors will prolong the elimination time for another substrate, but the pharmacokinetics of the inhibitor itself will not change (unless the drug is itself not only an inhibitor but also a substrate for the enzyme). Some drugs (e.g. rifampicin, barbiturates and cigarette smoke) are enzyme inducers. In molar terms per gram protein, the concentration of enzyme increases during exposure to the inducing drug a period of several days and there is secondarily hastening of the metabolism of some other drug substrate. Barbiturates (barbitals) are classic enzyme inducers; by enhancing the elimination of warfarin, anticoagulant effect can be lost. Some drugs (e.g. opiates) auto-induce their own isoenzyme, and this is one reason why doses tend to escalate in palliative care (note that there is no adaptive reduction in the gut, and oral opiate-induced constipation under these conditions gets only worse because this is a local effect at the site of absorption which is unprotected by hepatic metabolism of absorbed drug).

For a census of commonly prescribed drugs, the predominant CYP450 isoenzyme for drug metabolism is 3A4 (about 55% of all prescribed drugs). Next comes 2D6 (25%). About 15% of drugs are metabolized by isoenzyme 2C9 (although this number probably includes small contributions by
2C10, 2C18 and 2C19, as well). A few percent of all drugs are metabolized by either CYP450 1A2 or 2E1 isoenzymes in humans.

Genetic polymorphisms in CYP450 isoenzymes are common. Among whites, 5–10% of the population carries a mutation of CYP450 2D6, causing them to be ‘slow metabolizers’ of debrisoquine, mephenytoin, quinidine, metoprolol and dextromethorphan; standard doses are more likely to be associated with adverse events as a consequence, especially when a second substrate drug is interacting.

The elderly have livers that are functionally less effective than younger adults; CYP450 enzyme activity reduces correspondingly. The newborns have relatively reduced CYP450 capability, although this is uneven, and glucuronidation of bilirubin at birth is especially poor. The human fetus uniquely expresses CYP450 3A7; this disappears soon after birth, for reasons that are unknown.

Wanted interactions at the site of metabolism include acetaminophen (paracetamol)–N-acetyl and cysteamine; note above the comments that this is an atypical isobologram.

‘Methylated spirits’ are used as a fuel for lamps or heating in some places, and is a mixture of methanol and ethanol. The methanol component is supposed to deter ethanol abusers, but, nonetheless, methylated spirits are still drunk in pursuit of intoxication, especially by the indigent. Both alcohols are substrates for the same dehydrogenases. Formaldehyde is more toxic than acetaldehyde, and formate is more toxic than acetic acid, with the optic nerve being an especially vulnerable tissue to these toxins. Thus, treating methylated spirit toxicity with pure ethanol can save the patient’s eyesight because, at the expense of greater acetaldehyde exposure, enzyme competition will lead to increased excretion of unchanged methanol.

Site of excretion

The principal site of excretion that is liable to drug interactions is in the kidney. The classic example is forced alkaline diuresis using intravenous sodium bicarbonate solution to hasten the excretion of aspirin. Aspirin is freely filtered by the glomerulus into the nephron, and is then reabsorbed across the lipid membrane into the renal parenchyma, and thence the renal vein. When not ionized, resorption across the lipid membrane is more than when salicylate is ionized. Salicylate (like sulfate, nitrate, etc.) is the ion resulting from dissolving an acid. Making the urine alkaline increases the proportion of salicylate that is ionized, reduces its resorption and hence increases its urinary excretion. Note also that this all works vice versa. Metamphetamine (like other compounds ending-amine) is a base: its excretion can be hastened by acidifying the urine by using oral ammonium sulfate. These interactions are also beloved by multiple-choice question composers.

The techniques of forced diuresis must be contrasted with the tactics that can be employed to alter the excretion of drugs that are actively secreted into the postglomerular nephron. Acidic drugs (e.g. penicillin) are good candidates for these transporters. The coadministration of another organic acid (classically a redundant analgesic called probenecid), by competing for the acid transport mechanism, can reduce the urinary excretion of penicillin, and hence enhance its residence in the body. Historically, this was used for economy of penicillin supplies when this drug was very precious during the Second World War; today, the same tactic can be used for single-dose treatment of gonorrhea.

There are rare, alternative examples for drug interactions at other sites of excretion. For example, volatile general anesthetics are exhaled, and drugs that reduce minute ventilation (e.g. benzodiazepines perioperatively) consequently reduce the rate of excretion of isoflurane. Arguably, because one might also consider these as sites of absorption interactions, drug excretion rates in the stool can be increased using oral polyethyleneglycol to reduce the absorption of oral poisons (wanted), and oral paraffins (used for constipation) can increase fat-soluble vitamin excretion (unwanted).

The clinical laboratory is the final place where drug interactions can occur, although only a small proportion of false-positive, false-negative and inaccurately quantitated clinical laboratory results
are those of interference by concomitant drugs. One somewhat historical example is that for some of the older, less specific antibodies, spironolactone, vitamin D and carbamazepine can all interfere with digoxin radioimmunoassays; this remains a problem in less wealthy countries.

20.4 Preclinical investigations and clinical trials to investigate interactions

Development plans for new drugs should include screening for potential drug interactions at an early stage. Structural chemistry and other chemical properties will give a broad idea of how the drug may be absorbed, transported, metabolized and excreted. Mechanistic studies to elucidate the mechanism of action will give indications for possible interactions with other drugs acting at the same site. In vitro and in vivo investigations on hepatic enzyme systems can be carried out to investigate the substrate potential and/or capability for inhibition or induction of liver enzyme systems; this information can then be used to guide investigations of metabolic interactions that may be of eventual clinical significance. The animal toxicokinetics may also provide information about what can be expected in humans.

These batteries of preclinical tests will often generate questions that can only be answered by studying potential interactions in humans. Understanding whether a new drug will interact with other drugs that are likely to be co-prescribed for the disease of interest is essential for good product labeling. Oral contraceptives are used by about 50% of women in their reproductive years in the developed world, and must always be considered as a concomitant medication.

Clinical trial design for drug interactions

Drugs in development usually have to undergo a number of human interaction studies before they can be administered to patients (often on stable co-medications), whether in phase III clinical trials or after marketing authorization was obtained. It is hard to generalize about the number and type of interaction studies that are needed for new drugs because these depend on so many aspects of the preclinical profile and target disease (see above).

The design of individual studies that address possible interactions through the CYP450 metabolic pathway are, although often somewhat stereotypical, never completely standard. Usually these are phase I healthy volunteer studies which have primary end points of a pharmacokinetic nature. The studies can usually be done in an open-label fashion and without the use of placebo, because the end point is objective: drug concentrations reported in the laboratory cannot be influenced by investigator bias.

Prior to study design, the available data need to be examined to understand, whether the study drug is expected to be an inhibitor or inducer of any important CYP450 isoenzyme, or is a substrate competing for one of them. If there is a priori understanding of the putative metabolic pathway(s), then it can be possible to design a single study which screens broadly across all those isoenzymes that are commonly involved in drug metabolism in humans.

Enzyme competition or inhibition occurs quickly and can often be demonstrated with a single-dose design. Inhibition tends to be very specific for a given isoenzyme. Offset of inhibition can be fast or slow. Straightforward substrate competition wears off as quickly as the fastest of the interacting drugs is eliminated. However, covalent binding of drug to the receptor or enzyme of interest is irreversible. A good example is proton-pump blockade, where recovery requires regeneration of the proton transporter, and takes several days. Many inhibitory effects are dose-dependent and only reach clinically significant levels of inhibition at greatly supra-therapeutic doses. It is, therefore, important in first interaction studies to plan for more than one dose level.

Enzyme induction is usually dose-dependent and typically needs 10–14 days of repeat dosing to develop to its full extent. Enzyme induction is generally less specific than enzyme inhibition and can be observed across a broad range of
Isoenzymes simultaneously. Barbiturates (barbiturals), rifampicin and cigarette smoking are all well-known enzyme inducers, and can affect the metabolism of a wide variety of drugs. A redundant nonsteroidal agent (known as antipyrine), was the classical probe drug for enzyme induction, and its metabolism is increased compared to baseline when a 14-day challenge by an enzyme-inducing drug is administered. Modern 'cocktail' studies have now superseded antipyrine.

Substrate 'cocktails' are now used so as to efficiently study the effect of the test drug on several CYP450 isoenzymes at once. The cocktail comprises a mixture of drugs where each is metabolized wholly by a sole and different isoenzyme. Several established 'cocktails' have been published. For example, the 'Indiana Cocktail' contains (isoenzyme) caffeine (1A2), tolbutamide (2C9), dextramethorphan (2D6) and midazolam (3A4). All such studies need to have adequate monitoring for safe administration of drugs in place – such as oxygen saturation monitoring when midazolam is given. Acute attention to detail and timing is vital in order to obtain reliable, interpretable results. In particular, the timing of blood sampling for drug concentrations must be carefully designed in accordance with the known pharmacokinetic profiles of each drug administered and executed with the greatest precision.

For studies of CYP450 isoforms involving large phenotypical differences in humans, prescreened volunteers, with known isoenzyme activity and capacity, are needed. In this way, experimentally induced extreme plasma concentrations and the consequent clinical hazard can be avoided (e.g. due to preexisting slow metabolism).

Two typical phase I drug interaction clinical trial designs are shown in Figure 20.4. Pharmacokinetic profiles are found within each subject for each substrate with and without concomitant exposure to the study drug. These designs are applicable to both enzyme induction and inhibition effects (Figure 20.4, upper half). The same study schematic can be used to study the effects of inhibitors or inducers on the study drug as a substrate for CYP450 systems (as illustrated in the lower half of Figure 20.4).

Some drug interaction studies must be done in patients and use longer durations of exposure, and these are usually conducted in small groups of patients (rarely more than 12). These investigate not only pharmacokinetic interaction considerations but also the potential for interference with the efficacy of a proven agent. For example, drugs in development for rheumatoid arthritis must undergo an interaction study with methotrexate prior to the execution even of phase II clinical trials, because it is essential to assure that the new agent neither interferes with the therapeutic effect of methotrexate nor potentiates its adverse effects. These studies are more complex and need to be designed carefully on a case-by-case basis.

![Figure 20.4](image-url) Two typical designs for a phase I drug interaction clinical trial. The horizontal arrow represents time, at a scale of several days. Above the horizontal line is a typical screening study, where the test medication (Study drug) is being screened for any sort of interaction (inhibitory or inducing) with a known isoenzyme substrate; note that a cocktail of several substrates can also be used with this design. Below the horizontal arrow is a study design testing whether elimination of the test medication is itself susceptible to enzyme induction or inhibition by some other drug (inducer/inhibitor); note that the roles of the known and unknown drugs have essentially been reversed.
20.5 Regulatory considerations of drug interactions

This chapter has concentrated on drug interaction studies during the development of new drugs. Just as important is that the development of a drug does not stop after marketing authorization has been obtained because new information on a marketed drug can emerge at any stage of its lifespan. Marketing Authorization (MA) or New Drug Application (NDA) holders are obligated to monitor this emerging information for its relevance to prescribers and patients. This includes any new information on the potential for drug interactions.

When drug interaction information emerges late in the product life cycle, it is almost always a matter of clinical importance. This information must be made available to prescribers and patients, and can be communicated by inclusion into the product labeling, or, more quickly for issues of serious hazard, as a ‘Dear Healthcare Professional’ letter. All such new information to be included in the label is subject to regulatory scrutiny and approval, and the initiating entity can be the MA or NDA holder or regulatory authorities themselves. However, the pharmaceutical physician should be aware of the important differences between regional regulatory systems.

In the United States, pharmaceutical companies have the option of including important new safety information (such as a relevant drug interaction) in the label and sending a notification with the new label text to the FDA. The changed label will come into effect at the time of sending the notification to the agency. This ‘Changes being effected’ notification is justified on the grounds of an immediate improvement in notifying product hazards. Usually, the relevant FDA medical reviewer will communicate with the NDA holder and state whether the label change was accepted or whether he/she considers the change subject to prior approval. The latter allows the FDA reviewer more time and the option to adapt the proposed label text. In any case, this is a quick and effective way to ensure communication to all relevant parties in a minimum amount of time.

In the European Union matters are slightly more complex. Whether products have been approved using the central or mutual recognition procedures, the MA will have harmonized the product labeling across all EU Member States. European regulations require that all changes to product labeling must have prior approval. Thus, important new drug interaction findings will require the submission of a type II variation to the MA and a (albeit abbreviated) Common Technical Document. The Summary of Product Characteristics and Patient Information Leaflet must all be changed accordingly, and approval by the regulatory authority(ies) will inevitably take several months. For very significant clinical hazards, a more rapid and direct communication of such important new information from the MA holder to prescribers and patients will be needed.

Prospectus

As in many areas of drug development, the amount of information about drug metabolism in children is limited: more work on the ontogeny of drug metabolism systems will be needed in the future. Regulatory authorities are actively encouraging this with certain incentives both in Europe and the United States, which generally find support not only from academic societies of pediatric medicine but also from MA and NDA holders themselves. Studies of drug interactions will form a part of this pediatric metabolic research, and should be able to exploit these regulatory initiatives.

Furthermore, as more information is wrung from the human genome, it is likely that many drug interactions that we currently view as idiosyncratic will acquire mechanistic explanations. This form of personalized medicine, with the capability to predict a pharmacokinetic or pharmacodynamic interaction by knowing the patient’s phenotype in advance, will be a powerful therapeutic tactic in the interests of patient safety and optimization of therapy.
21 Orphan Drugs

Bert Spilker

21.1 Introduction

In the United States, ‘rare disease’ is defined as a disease with a prevalence of less than 200,000 patients. Some countries have defined a rare disease based on a prevalence of 0.1–0.5% of the population. A rare disease is sometimes referred to as an orphan disease. An ‘orphan drug’ is defined as a drug to treat a rare disease. The term ‘orphan drug’ originated from the belief that there were drugs that no pharmaceutical sponsor wanted to develop and market, and thus they were like homeless orphans.

There are an estimated 4000–8000 rare diseases, but no one has actually counted them. Many of these diseases involve genetic problems and often are related to birth defects that are poorly characterized or involve permanent defects of nerve, muscle or bone which cannot be corrected with drugs.

Almost all marketed drugs are used to treat some rare diseases. A few examples among the largest selling drugs in the world include propranolol, which is used to treat idiopathic hypertrophic subaortic stenosis (in addition to the more well-known cardiovascular diseases), cimetidine, which is used to treat Zollinger–Ellison Syndrome (in addition to duodenal ulcers), and all antibiotics used to treat rare bacterial infections, in addition to common ones.

21.2 Principles

One of the most important principles about orphan drugs is that they are a very heterogeneous group of drugs. In fact, they are as heterogeneous as any other group of drugs and, in most cases, should not be considered as a separate group. Orphan drugs are heterogeneous for the reasons given in Table 21.1.

Pharmaceutical companies have always developed orphan drugs. This did not change suddenly when the Orphan Drug Act was passed in 1983 in the United States, but the Act stimulated the development of more such drugs.

If one compares orphan drug status with a patent, either a compound or use patent for a
new drug is preferable for a company. However, there are some exceptions to this rule, depending on the degree of patent coverage and the number of years left at the time of initial marketing. There are also various states of a patent to consider. For example, patent status may be characterized as nonpatentable, applied for, in interference, under final rejection, approved but not issued, approved and issued or another scenario may apply.

Drugs are either investigational or marketed, and orphan drugs are no different. They may be used to treat only rare diseases, or both rare and common diseases. They are deemed orphan only for the rare disease indication.

The clinical value of drugs being developed for rare diseases varies along the same spectra that exist for all drugs. This runs from having no clinical efficacy or medical value (for any of many reasons) to extremely high medical value that will revolutionize medical practice.

Development costs, time to market and commercial potential vary enormously among orphan drugs, as with all drugs. It is usually meaningless to develop an orphan drug if a generic is available on the market or will be shortly (i.e. before the company can launch its product). Even if the generic version is not officially indicated for treating the rare disease, it is likely that the generic version will be used for the treatment of the rare disease.

### Table 21.1 Reasons why orphan drugs are a heterogeneous group

<table>
<thead>
<tr>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orphan drugs differ according to:</td>
</tr>
<tr>
<td>1. medical value</td>
</tr>
<tr>
<td>2. patent status</td>
</tr>
<tr>
<td>3. investigational or marketed status</td>
</tr>
<tr>
<td>4. availability in a generic equivalent form</td>
</tr>
<tr>
<td>5. use for a common disease too</td>
</tr>
<tr>
<td>6. costs of development</td>
</tr>
<tr>
<td>7. commercial (and profitability) potential</td>
</tr>
<tr>
<td>8. disease prevalence (stable, increasing or decreasing)</td>
</tr>
<tr>
<td>9. availability of alternate therapies</td>
</tr>
<tr>
<td>10. manufacture by conventional or biotechnological methods</td>
</tr>
</tbody>
</table>

Although classification of orphan drugs may be made along several lines, no single classification has been accepted as universally acceptable. In fact, several classifications have been proposed (Spilker, 1991). This section briefly mentions the criteria on which a classification scheme could be based and describes a simple classification based on economic value combined with medical value.

The major criteria that may be used to create a classification of orphan drugs include the following:

1. Therapeutic or disease area of the drug.
2. Marketed status of the drug (i.e. marketed or investigational).
3. Patent status of the drug (e.g. patent issued and in force, patent expired, nonpatentable, patent pending).
4. Generic drug availability (yes or no). Availability in the same dosage form, strength, with same excipients, and any other factors that are relevant to consider.
5. Size of patient population. This refers not only to those in the parent country, but in other countries as well. Considerations of closely related subsets of patients must be considered because it is not possible to obtain orphan drug designation in the United States if the drug can be used by a closely related subgroup of patients [e.g. one type of epileptics vs. another; or a large number of moderately ill who can readily benefit from a drug as well as a small number (under 200,000) of severely ill patients with a particular disease].
6. Can drug development costs be recovered through sales? Although this criterion was very important in the original Orphan Drug Act of 1983, it was eliminated a short time later. This could be considered important for both legislators as well as pharmaceutical companies that are considering developing orphan drugs.
7. Are alternative treatments available? The competitive position of the disease area must be considered. There are several categories of whether alternative treatments may be used to treat the rare disease (e.g. none exist, all alternatives are highly toxic, alternatives are very expensive, alternatives are limited in availability, alternatives only work in a small number of patients).

8. Medical value of the drug. In the author’s opinion, this is the most important criterion to judge (or classify) orphan drugs. If the drug does not have, or is not expected to have, high medical value, there are very few instances where its development would make sense. A classification of medical value may be as simple as high, medium and low.

9. Potential use in a more common disease, as well as in a rare disease. This is often difficult to know at the outset of development, but almost every drug that reaches the market is tested by the medical community in many other diseases to evaluate its efficacy.

10. Type of drug. This category considers whether the drug is a biotechnology-derived and produced drug or a conventional pharmaceutical synthesized in a laboratory.

11. Patient support group. If a patient support group exists, it may facilitate the development of the drug by notifying its members about participation in clinical trials. The group could also have its members write letters on behalf of the product to increase awareness in the medical community.

21.4 Economic classification of orphan drugs

An economic classification is one of the most relevant alternative classifications to consider, particularly for companies considering the development of orphan drugs. Five categories of drugs can be described. These are as follows.

1. **Drugs with little commercial potential, but with high medical value.** The commercial value may be subdivided as to whether the product will lose money and never pay back its development costs or whether the sales are expected to be below an arbitrary hurdle rate (e.g. internal rate of return) and achieve less profit than desired for new projects added to the company’s portfolio. In the former case, only wealthy companies that wish to perform a community service, or have other reasons than profits for developing the drug, could undertake the development of a money-losing drug. If the drug has high medical value and will not lose money, there are companies that would at least consider developing it if it met their other criteria (e.g. a therapeutic area of interest).

2. **Drugs of moderate or high commercial value and high medical value.** If a few caveats were met, this category of orphan drugs would never have a problem finding a sponsor to develop the drug. For example, it is important there is no generic drug on the market, or else pharmacies would fill prescriptions with the generic. If a generic was available, the commercial potential of a new brand name drug would only be theoretical. This category is meant to imply that the commercial potential would be real if the product was to reach the market.

3. **Variable commercial potential and low medical value.** This category is a very realistic description for many, if not, most drugs at an early stage of their development, before the clinical efficacy and safety profile of the drug are well understood. The most wise and educated person or group of experts can only guess the value of a drug before it is tested and its profile is known. One exception to this principle is drugs that are developed in a new dosage form, but whose activity and safety are well known.

Nonetheless, a drug of low medical value will rarely be developed unless a company knows that the commercial value is significant. A ‘me-too’ drug is an example of a drug in this category.
4. **Unprofitable drug for a common disease.** This category of drug is described in the orphan drug legislation and could refer to tropical diseases that are not prevalent in the United States or to a drug that may be medically important for a subset of patients with a common disease but would not be expected to recoup the company’s investment. Few drugs of this category have been developed.

5. **Variable commercial potential for both a rare and common diseases.** Virtually every pharmaceutical company that develops an orphan drug hopes that the drug will be found useful in treating a more common disease, but this seldom occurs.

### 21.5 The interested parties

Eight groups involved in orphan drug development and use are briefly discussed. These include patients as well as both public and private institutions. These parties have a variety of motives for their interest in this area.

#### Legislatures

National, provincial and potentially other levels of legislatures can become involved in orphan drug development, primarily through creating new legislation. They primarily influence development through incentives that provide tax benefits or grants, or otherwise incentivize pharmaceutical companies to develop and market such drugs.

#### Regulatory authorities

Their motivation is usually to improve and protect the public health of the community they serve. This is most obviously apparent through the approval of orphan drugs for marketing. These authorities are primarily motivated by their perception of the drug’s medical value and less by whether the drug is considered to have orphan drug designation or the potential to help only a small number of patients.

#### Patient associations

These groups focus primarily on one specific disease or one type of disease process (e.g. inborn errors of metabolism, muscle disease, glycogen storage diseases, autoimmune diseases) or serve as umbrella organizations representing the interests of their specific rare disease association members [e.g. National Organization of Rare Disorders (NORD)]. Their goal is to stimulate the discovery and development of new treatments for their specific diseases. Another important function of many of these groups is to provide patient information to their members, and often to the public as well.

#### Pharmaceutical companies

The motivation of these organizations is not solely profit oriented in most cases, as they usually accept social responsibilities for the patients they serve with their more profitable drugs. In addition to the small amount of profit they may make on orphan drugs, there is an enhancement of the company’s image, which is becoming more and more important in our critical society.

#### Trade associations

Professional trade associations representing pharmaceutical companies or other groups are concerned with the image of the industry, as well as providing social benefits through publicizing the products of their members. The Pharmaceutical Manufacturers Association had a ‘Commission on Drugs for Rare Diseases’ that focused on issues relating to orphan drugs for many years.
Patients and families

The motivation of those with the disease or those with relatives with the disease is clear – they want better treatments that are affordable and will improve the quality of life for the patient.

Physicians and other healthcare providers

The motivation of these people is also clear – they seek to find better treatments for their patients and are often willing to test new drugs in clinical trials.

Academicians

Orphan drugs offer research opportunities for scientists and clinicians. Another important motivating factor are the opportunities presented for career enhancement.

21.6 Specific sources of information on orphan drugs

The Food and Drug Administration (FDA) publishes an annual list of orphan drugs that have been approved for marketing since the signing of the Orphan Drug Act in 1983. They also publish a monthly list of drugs that have received orphan drug designation within the last month and an annual cumulative summary of the current designations. There is also a home page on the Internet and an annual publication of grants to evaluate orphan drugs in clinical trials.

Most specific disease organizations, as well as umbrella disease organizations, provide information of relevant diseases for members and sometimes for researchers, and the public. These groups may also provide current scientific information. For example, the NORD database is a valuable source of information for many groups of people interested in a particular disease.

21.7 Discovery, development, marketing and distribution of orphan drugs

The process of discovering new orphan drugs is not different from that used to discover drugs for more common diseases (Spilker, 1994). This is a broad topic and will not be discussed further.

As with discovery, the methods used to develop drugs for rare diseases do not differ from the methods used to develop drugs for more common diseases in terms of strategies created, methodologies used and criteria for success (see Chapter 2.2). However, certain differences in quantity of data exist. If there are only 500 patients with a specific disease, it is probably impossible to have two randomized, well-controlled placebo trials. Nonetheless, the quality and amount of manufacturing data required for regulatory submissions do not differ for orphan drugs than for more common drugs.

The same marketing tools are available to market orphan drugs and non-orphan drugs. Probably the greatest difference between orphan and non-orphan drugs from a marketing perspective is that the amount of money spent on orphan drugs will be significantly less than that for non-orphans. Although the same mix of marketing tools can be and are often used, the number of symposia to be held and the number and size of advertisements will usually be fewer. Another exception is that the use of sales representatives to promote a new orphan drug may be nonexistent. However, a large company may in fact be developing the orphan drug so that the sales representatives can discuss the orphan drug (and non-orphans too), whereas a small company may have decided to develop an orphan because sales representatives are not necessary to promote the product.

Distribution methods differ more between orphans and non-orphans more than the other categories discussed in this section. Conventional drugs are generally sold through wholesalers, as well as
directly to institutions. Orphan drugs more often use what are referred to as alternative distribution techniques. These include mail order pharmacy and direct sales to patients, physicians and institutions.

### 21.8 Marketing benefits to sell orphan drugs

Most pharmaceutical companies that market their own products can benefit from marketing orphan drugs. These benefits include the following.

1. It is useful for sales representatives to use orphan drugs as an entrée to see physicians. In this busy world, physicians want new and important medical information and are not as willing to see sales representatives as they used to be. Thus, a sales representative who can discuss an important new treatment, even for a rare disease, is likely to have better access to physicians.

2. It is useful to develop orphan drugs to keep competitors out of a therapeutic or disease area of importance to a company. A company may choose to develop a drug to prevent competitors from doing so and not because they want to develop an important orphan drug.

3. It is possible to bundle products more easily if you have a whole portfolio of products in a given therapeutic area. Several companies that have merged in recent years initially felt that some of the smaller products would be divested or merely dropped from the portfolio because of their small size. However, they soon realized that there was value in even the smaller products, and that the sum of their value was much greater than the sum of their sales, particularly when the company approaches managed care or other groups (with formularies) with a wide selection of products.

4. Image enhancement of the company is likely to occur through development of drugs for rare diseases. Reporters can easily write heartwarming stories of patients with rare diseases who are helped by orphan drugs. Word of mouth and other public relations methods also help enhance a company’s image.

5. It may be possible to have a patient support group promote a drug by telling their members, writing articles in their newsletter or in the popular press, or informing the regulatory agency about the need to have the product available for patients to use.

### 21.9 Common issues for a company to consider when developing an orphan drug

1. Should the company obtain an approved indication or should it allow off-label use of the drug to provide whatever commercial value it obtains? This is often viewed as an exercise in cost accounting, whereby the company totes up all the costs and resources used to obtain the indication and compares the total with the potential sales and profits that would accrue with each approach. It is important to consider the opportunity cost of working toward an approved indication (i.e. if one spends $x$ dollars and uses $y$ staff months to obtain the indication, then those staff cannot be working on other projects and the money cannot be applied elsewhere).

2. Should a company attempt to obtain an orphan indication or a more common indication first? Assume that the orphan indication can be obtained in a much shorter time than the more common one and that the time to submit the New Drug Application (NDA) is less for the orphan indication. In this situation, there is a tradeoff between the smaller amount of sales that will come sooner with the orphan indication along with the possibility of off-label use for the more common indication. The tradeoff is with waiting longer for the larger indication that will be much more important commercially. Initially, many people think that the orphan drug development route is preferable, but a regulatory authority
will have much less pressure to approve the more common indication when the NDA is submitted and approved for the orphan indication because of the availability of another form of the product. This means that during this period, the company will not be able to promote the drug for the common indication. Thus, it is usually preferable to try to obtain regulatory approval for the more commercially important indication first. There are some important exceptions to this rule. For example, start-up companies have limited funds and may seek approval for the rare indication first out of necessity.

Another consideration regarding this issue is that a company seeking an orphan approval and hoping for off-label use for a more common disease may find a strong regulatory backlash when the company’s strategy becomes apparent. There are real cases where a company submitted an NDA for a rare disease and then shortly thereafter submitted an IND for a more common disease. The FDA realized the company’s ploy and significantly raised the standards for approving the rare disease indication.

21.10 Benefits of orphan drugs from a development perspective

The most obvious benefit for a company is that the number of clinical trials and the quantity of clinical data required for marketing approval will be usually less for an orphan drug. This is primarily based on the limited number of patients available for clinical trials. Even though the numbers are fewer, the data must be convincing and the standards of trial design are often unchanged. The standards of clinical trial design may be modified for extremely rare diseases where a company may be limited to obtaining a number of individual case studies.

A possible benefit in some drug development programs is that less toxicology data may be required. A regulatory requirement for less toxicology data is based both on the difficulty of obtaining the data as well as the benefit risk ratio for getting the product to market rapidly.

A more rapid regulatory review may be anticipated for products of high medical value. This results from the medical need of society for the drug, the smaller application (dossier) compared to other drugs with substantially more data and the high priority of the application. In most circumstances, there will be a waiver of administrative fees charged (e.g., user fees) for orphan drugs to be reviewed.

Standards of manufacturing and quality control for orphan drugs are identical to those of non-orphan drugs. In some situations, a few differences are that fewer validation batches may be required and the duration of stability tests may be addressed while the drug is being evaluated by the regulatory authority, or in exceptional cases, after the product is on the market. Thus, the time to develop the chemistry and the technical package of data for the regulatory submission may or may not differ from that needed if the drug was for a common disease.

Orphan drugs do not have medical value simply because they are orphan drugs. Most drugs that could be used for rare diseases do not have great medical value in terms of safety, efficacy or practical reasons (e.g., number of doses required per day, unpleasant taste, cost).

The opportunity costs of developing an orphan drug must always be considered. In considering whether or not to undertake this activity, most large companies have indirectly said that they will not develop orphan drugs because they have implemented financial hurdles ($x million dollars in sales per year) that extremely few orphans could meet. As a result, companies usually have specific reasons for developing orphan drugs.

An approved indication is not always necessary in order for a marketed drug to capture a rare disease market for which it is also found to be active. Patients may use a marketed drug to treat a disease in some countries before it is approved by the regulatory authorities for that use. This is often understood and accepted by the regulatory authority. For example, the FDA did not approve acyclovir for Herpes encephalitis for over five years after the NDA was submitted because they said it was
already the drug of choice for that disease and that everyone was already using it and that it would even possibly be viewed as malpractice not to use it. Nonetheless, the company could not promote the drug for this use or mention it in publications. This was not a commercial issue, as the FDA’s views were correct, and moreover, there were very few cases of Herpes encephalitis each year.

The speed of regulatory review depends on the number of drugs in the queue in front of it, the medical value of the drug and the quality of the submission in addition to regulations. Another factor that few companies would want to try to influence is the pressure from outside sources on a regulatory authority. The US Congress pressured the FDA to approve valproic acid for seizures in children many years ago, even before the company was ready to make its submission.

The medical value of a drug may be independent of the efficacy and rarity of the disease. For example, for Wilson’s disease there are several products on the market that are effective and yet additional ones are still being developed. Penicillamine is often effective, but often causes serious adverse reactions. Zinc acetate and trientine are newer products and molybdenum is being evaluated for the same indication.

21.11 Disincentives and obstacles for orphan drug development

There is no limit to the number of disincentives and obstacles that could be described for developing orphan drugs, several of which have already been mentioned. Selected examples will be given to illustrate several that are commonly encountered. Disincentives include the following:

1. The tax credit offered in the United States for developing orphan drugs is not much more than the tax credit for research and development of any new pharmaceutical.

2. Resources of the company could be applied to developing more profitable drugs.

3. Development may not be required if the drug is already marketed for a more common use. This implies off-label use, which is more easy to do in some countries and very difficult or impossible in others.

4. Because the safety and quality standards of manufacturing are the same, it may create too many technical problems and costs for the development of a specific drug.

5. The medical need for the drug may not be great and/or the medical effectiveness of the drug may not be strong.

6. The regulatory authority may require more data than the company thinks are warranted.

7. The liability risks may be unacceptably high. A drug to treat patients with a rare disease that causes a serious adverse event could increase the exposure of the company to a major court suit.

8. Difficulty in finding a small number of patients widely dispersed through the United States (or other countries) for conducting clinical trials or for marketing products.

Additional obstacles may include lack of a patent or other proprietary position, availability of a generic equivalent, large amount of competition, technical difficulties in any area of formulation, analytical, stability, scale-up or other related issues. Manufacturing issues or costs of any aspect of the manufacturing, from obtaining the raw products to final manufacturing and packaging to distribution, are other possible disincentives.


The Orphan Drug Act was signed by President Reagan of the United States in 1983. In its original form, the Act provided for the following:

1. A seven-year period of exclusivity for designated drugs.
2. Established the Orphan Products Board within the US government.

3. Allowed tax credits for certain expenses in clinical trials.

4. Authorized a grant program that included medical foods and medical devices, although medical foods and medical devices cannot obtain orphan designation.

5. Provided assistance to corporations and academic investigators by the FDA.

It is important to note that medical foods and medical devices were not eligible for orphan drug designation or for the marketing exclusivity provisions of the Act. The Act was originally designed for unprofitable and unpatentable medicines only.

Amendments to the Orphan Drug Act

In 1984, an amendment to the Act changed the standard for orphan drug designation from profitability to prevalence, which was set at less than 200,000 patients in the United States. The requirement of unprofitability was dropped from the Act.

In 1985, another amendment to the Act made it possible for patented and patentable medicines to receive orphan drug designation (a pre-marketing classification) and orphan drug status (a post-NDA approval classification).

In 1988, a further amendment established the time period for filing for orphan drug designation. This clarified that the designation must be prior to filing the NDA.

In 1990, the US Congress passed a fourth amendment that would have allowed shared exclusivity for companies that developed an orphan drug virtually simultaneously and to lose exclusivity under certain conditions. However, this amendment was vetoed by President G. Bush, in whose judgment it was anticompetitive.

In 1991, a proposed amendment was proposed that would have established a sales cap after which an orphan drug would lose its exclusivity. This and other amendments to the Act, proposed in 1992 and 1994, have not passed the Congress.

The benefits of the Act as it now exists actually emanate both directly from the Act itself, as well as from outside the Act.

Within the Act itself, the four major benefits are (1) the period of marketing exclusivity, which may be considered as a type of patent; (2) the tax benefits on clinical trials between the date of orphan drug designation and NDA approval; and (3) the FDA’s Office of Orphan Products Development grants to support clinical trials on orphan drugs. A fourth benefit of protocol assistance, from the FDA, was always available for important new drugs (as well as others) and is important, but not necessarily new. Nonetheless, it is useful to call attention to this provision.

The benefits from outside the Act (i.e. unofficial benefits) are as follows:

1. Potential for more rapid regulatory review of NDAs. This is considered extremely important by many companies, but the author believes that it is medical value of the treatment, rather than the number of patients treated, that influences the speed of regulatory review.

2. Enhancement of the company’s image by developing important orphan medicines. This often can be parlayed into publicity that usually is extremely important to the company.

3. Build a portfolio of products. Orphan drug benefits may enable a company to develop and market a new drug and help build a portfolio of products in a therapeutic area of importance to them.

4. Hope for a larger market. It is always possible that a new use for an orphan drug may be found that may give the medicine greater commercial potential than originally believed.

5. Help fill important gaps in the company’s development. There are often gaps in a company’s portfolio that orphan drugs could fill.
This would provide a wide variety of benefits to a company, including the stimulation of staff who recognize the medical importance of the product.

6. Have a new message and product for sales representatives to give to physicians.

This may be an entry of importance to the company.

21.13 Unintended consequences of the Orphan Drug Act

When Congress passed the Act, there were several different factions and intentions of those who wanted an Act passed. All sides had to make compromises, but everyone knew that some incentives had to be given to pharmaceutical companies in order for the Act to have any impact or to influence behavior. Nonetheless, the incentives worked too well in some people’s opinion in that some of the Act’s loopholes were exploited or were found to benefit companies in unintended ways.

For example, companies with orphan drug protection sometimes charge very high prices, which raised questions of appropriateness. In situations where the medicine had a reasonably strong patent, such as with Retrovir (zidovudine, azidothymidine), the orphan drug designation and exclusivity was not of consequence to the company, at least not for market protection. For drugs such as growth hormone, erythropoietin, pentamidine and Ceredase, orphan drug designation and resultant exclusivity on FDA approval were essential. To some people, the high price of the drug represented an abuse of the Act.

An important issue for politicians was that the Medicare and Medicaid programs had to pay large sums of money for protected medicines. One final issue to some people outside the pharmaceutical industry, and also a few companies affected by the issue, was the inability of a second company to market a drug with an approved NDA. Of course, this was clearly known for the entire history of the Act and was the obvious consequence of marketing exclusivity.

A current trend is that more biotechnology products (see Chapter 2.11) are applying for orphan drug designation. The main reason for this phenomenon is that biotechnology patents are so difficult to obtain and orphan drug protection is valuable, while the inventors wait to see if a strong patent will issue.

21.14 Establishing prevalence or incidence of a disease

The FDA recognizes any authoritative evidence to support the prevalence of less than 200,000 patients in the United States. The major sources of evidence include the following:

1. Peer-reviewed literature.
2. Textbooks.
3. Surveys by patient support groups.
4. Data from the National Disease and Therapeutic Index.
5. Hospital discharge data based on ICD codes or other clear classifications.
6. Data from the Centers for Disease Control.
7. Data from the National Center for Health Statistics.
8. Data from IMS or other reliable market data organizations.
9. Sales data of companies.
10. Testimony of a few experts, based on evidence from their (or other) hospitals or practices.
11. The weakest data is testimony of experts based on personal experience unsupported by hard evidence.
21.15 Establishing differences among medicines

It is often important to establish that a company’s medicine for which it desires an orphan drug designation differs from another medicine. There are a number of principles that will help a company establish a difference.

1. Different chemical structures. If it is unequivocally shown that two structures differ and it makes a biological or clinical difference, both will be given orphan drug designation. However, if the chemical difference is minor (e.g. one amino acid difference in a protein or the terminal carbohydrate portion of a large molecule) and no clinical differences can be shown, they will usually be viewed as the same product.

2. Differences in clinical effects. This is often a very difficult criterion to demonstrate, but if it can be shown, a difference would be established.

3. Contribution to patient care. If a marketed dosage form of a medicine cannot help certain patients with a problem, or not help them adequately compared to a different dosage form (e.g. parenteral), then the parenteral form would be eligible for orphan drug designation.

4. New production methods to purify a drug. If such methods lead to a difference in safety or efficacy, this would qualify for orphan drug designation. A real example is a new Factor IX.

5. New excipients. Differences in excipients that lead to a difference in clinical safety or efficacy would qualify for orphan drug designation.

Rear-Admiral Marlene Haffner MD MPH FRCP, Director of the FDA’s Office of Orphan Products Development, has summarized this issue best by saying 'For a difference to be a difference it must make a difference' (personal communication). A lower cost of a second form of a medicine, or of the same dosage form, is not a criterion to establish a difference between two drugs, even if the original is considered extremely expensive and a new breakthrough allows the new product to be sold at a markedly reduced price.

21.16 What is an orphan drug indication?

It is obvious that arthritis, epilepsy, depression, asthma and other similar diseases are not rare and drugs to treat them do not qualify for orphan drug designation. But would a medically plausible subset of each disease qualify as an orphan indication if there were fewer than 200 000 patients with, for example, a severe form of the disease? The FDA’s principle in addressing this common question is to ask the question: ‘Could (and would) patients with less severe forms of the disease use the new treatment?’ If so, then the FDA says that the indication is not a true orphan and usually denies the application for orphan designation.

A rare variant of depression, asthma or other common disease might qualify as an orphan indication if it is deemed to be a medically plausible separate indication. In this situation, it is possible that the company may receive the designation, but the reviewing division of the FDA may impose much higher standards for regulatory approval of an orphan drug for marketing if they believe it will be widely used in medical practice. For example, a drug to treat a rare rheumatological disorder that could also be useful in rheumatoid arthritis would likely have to provide much more data to obtain approval than if the drug were limited to treating a very small patient population. On the contrary, a toxic medicine that could only be used to treat severe cases of patients with a common disease (because of benefit to risk considerations) could receive orphan designation and regulatory approval for marketing as an orphan drug, with relatively little data. This assumes that there was a significant medical benefit to using the medicine in patients with severe forms of the disease.
21.17 Rating the effects of the Orphan Drug Act in the United States

With over 650 active designations and over 120 orphan drugs approved for the market, plus numerous grants awarded since 1983, it is clear that the Act has been very successful and has been a major stimulus for certain pharmaceutical companies. The fact that some blockbuster drugs have been approved under this legislation is a controversial topic for reasons relating to drug cost. The tax credit for clinical trial costs has been very modest and does not represent a significant sum of money to most companies.

The number of designations have increased in recent years not only because of the incentives of the Act but also related to advances in science and medicine, increased investments made in research and development by companies and academic institutions, increased competition within the pharmaceutical industry and an increased interest in this legislation by the biotechnology industry.

21.18 Lessons of the Orphan Drug Act for Europe

By 1996, a number of European countries and organizations started to pay much more attention to this issue than before. The United States experience offered a number of lessons for the Europeans to consider as they discussed and considered numerous issues.

1. True incentives for the pharmaceutical industry are required in order for any orphan drug legislation to be successful. Without true incentives, the legislation will have little, if any, effect. The major incentive required is a period of exclusivity for marketing. Without this incentive, industry is not likely to modify its activities in this area. A 10-year period of marketing exclusivity rather than seven at in the U.S. is appropriate and is not excessive if the potential abuses of the legislation are prevented. Other incentives are secondary and are not really necessary for legislation to be successful.

2. Abuses of the law by the pharmaceutical industry must be prevented. The simplest way of avoiding abuses is to have a sales cap. This means that the market exclusivity disappears when the cumulative sales of a drug reach a predetermined level. This amount of money should be set at a fair value to incentivize the companies and to protect the government or other groups that pay the bill for excessive charges.

3. All potential medicines for indications or diseases meeting prevalence numbers should qualify for designation and a drug’s potential profitability should not be a barrier to receiving orphan drug designation.

4. A specific regulatory group must be in place to decide on ‘gray’ issues. There will always be issues to resolve, such as determining whether or not an indication is real or represents salami (wurst) slicing of a larger one. Another commonly encountered ‘gray’ issue is to decide whether or not a new dosage form qualifies for designation. The Committee on Orphan Medicinal Products within the EMEA is now well established.

5. Regulatory review of orphan drugs should be based on the drug’s medical value and medical need and not on whether or not an official orphan drug status is present.

References

SECTION IV
Applied Aspects of Drug Development

Introduction

Having covered in Sections I and II the strictly clinical, more orthodox aspects of drug development, we now turn to some applied aspects. In general, these reflect relatively modern sophistications in the development process, compared with, for example, many types of clinical trial design, which have been available for decades.

These modern aspects of drug development are rarely optional. All are crucial for the success of a product in the marketplace. Several of the next chapters will also describe methodologies that also teach us, on new dimensions, about properties that are intrinsic to drugs. Some (e.g. pharmacoeconomics) are also becoming of increasing importance in the regulatory approval process.
22.1 Introduction

The objectives of this chapter are to describe what biotechnology products are, and where their regulation is similar or different from chemically synthesized, small molecule drugs. It is a common assumption that biotechnology has sprung from nothing, de novo, within a small number of recent years. This is not the case, and we shall show how the recent growth of this field actually has a basis which is, in many ways, common and interconnected with development of all other types of drugs. We shall also explore, briefly, how the science of pharmacogenomics interfaces with the development of biotechnology products.

22.2 Definition

Biotechnology products are those that are prepared using biological organisms, rather than the usual types of industrial chemical synthesis. Biological organisms may be used in vivo, ex vivo or in vitro to make these products.

Biotechnology products are diverse, including polypeptides, biological organisms themselves (living, dead or attenuated), genes, any type of fermented product (even when these may be alternatively synthesized chemically) and antisense compounds. To date, the peptides have formed the largest group among these, themselves being functionally very diverse: hormones, antibodies, cytokines (including interferons) and immune adjuvants (including nonmammalian examples, such as Key-hole Limpet (Megathura crenulata) hemocyanin).

Biological products have a longer history than is generally assumed. At one time small pox accounted for 10% of deaths in some countries. The development of cow pox vaccination in 1796, and later the Variocella vaccine, has led to small pox being the only infectious disease ever to have been eradicated from the planet; the final outbreak was after a laboratory accident in 1979, leading to a small number of cases.

It is beyond the scope of this chapter to discuss all potential applications and all present technologies associated with biological drugs. We wish to concentrate here on the newer technologies that are actually used on either an investigational or approved basis in human beings, and can only provide an overview. Thus, vaccines, fermented antibiotics, blood products, diagnostic products (e.g. antibody-based assay systems) and devices
using biotechnology products will not be covered, although they could be classed as biological products. Similarly, pluripotent stem cells are currently investigated for the manufacture of tissues for grafting, but these are not biotechnology therapeutics themselves.

There are approximately 1250 biotechnology companies in the United States and Canada, about half that number in Europe and smaller but growing numbers throughout the rest of the world (especially Israel, Korea and Australasia). These companies are usually much smaller than the large, fully integrated ‘pharmaceutical’ companies (‘large pharma’) on the East coast of the United States or in Switzerland. Small companies’ research activities may be restricted to the preclinical discovery and early-stage clinical investigation of compounds; therefore, their business environment and practices differ from large pharma. On the other hand, all of the less numerous but much bigger pharmaceutical companies are engaged in biotechnology, one way or another. Somewhat arbitrarily, we shall use the term ‘Biotechnology Company’ rather loosely in this chapter to mean this type of small organization. One wag in the investment community has given a further definition: a biotechnology company is a pharmaceutical company without revenues! The term ‘Biotechnology Products’ refers to the compounds themselves, regardless of the size of the organization developing them.

Before we turn to the products themselves, however, we would like to draw attention to when biotechnology brings special ethical aspects to the clinical trial. As we shall see below, some of these therapies require extraordinary procedures, such as the deliberate immunization of normal volunteers to foreign blood groups, or the introduction of exogenous genes into patients. Ensuring that consent is truly informed is sine qua non, even though, sadly, this was not the case in a recent disaster when a patient in an early-phase gene therapy study died. We return to ethical issues at the end of the chapter because they must be considered in relation to the technical aspects of investigational biological products; nonetheless, these should be foremost and not afterthought.

22.3 Regulatory considerations

In most countries regulation of drug and biological compound development and marketing has usually derived from governmental response to crisis.

US perspective

The initial legislation affecting biologics was the Safe Vaccines and Sera Act of 1904, the focus of which was the development of safe, pure and potent vaccination preparations. At that time this was the responsibility of the Department of Agriculture. This was somewhat superceded by the Public Health Service Act (1944), written principally with blood products and prevention of the transmission of disease by infusion in mind.

It was not until 1972 that biological products were brought under the same regulatory framework as chemically synthesized, small molecule drugs. The Food and Drug Administration (FDA), a single branch of the Public Health Service, then accepted the responsibility for biologics, upon their transfer from the Department of Agriculture; within the FDA, a designated Center for Biologics Evaluation and Research (CBER) was created. This unified approach progressed further in 2005, when most (but not all) biological products were transferred within FDA from CBER to the Center for Drug Evaluation and Research (CDER), the latter comprising the ordinary reviewing divisions with which readers will be familiar. Similar historical events stimulated other models in other countries.

In the United States and elsewhere, evidence of this convergence of biological and nonbiological products is evidenced by:

- IND regulations (there are no unique regulations for biologics undergoing experimental study)
- Similar good clinical practices guidelines
- Various International Conference on Harmonization initiatives
- Good manufacturing practices
‘Fast Track’ designations for accelerating review and approval

However, in the United States, illogicalities still persist. For example, the Waxman-Hatch legislation gave authority for generics and provided patent term exclusivity for drugs, but not for biological products licensed prior to 1972. Similarly, the pediatric ‘exclusivity’ that the Act initiated also only pertained to the drugs with unexpired patent or Orphan Drug exclusivity. Lastly, the Centers for Disease Control remains involved with compensation issues for pediatric vaccines, a unique administrative arrangement.

22.4 Biotechnology versus conventional drug products

There is a widespread, but largely unreasonable, perception that biotechnology products differ in their properties to conventional small molecule drugs. For example, it is widely believed that simple pharmacokinetic models cannot adequately describe the behavior of biological agents in vivo. Although quantitative data relating to the intracellular distribution of these agents may not be known or easy to measure, the underlying principals of absorption, distribution, metabolism and excretion (ADME) are the same, even though new paradigms and different quantitative models may be required to describe the properties of biological compounds. However, Table 22.1 lists the factors that need to be considered when modeling pharmacokinetic (PK)–pharmacodynamic (PD) relationships for the extreme case of gene therapy products, most having correlates with features of orthodox drugs.

While biotechnology products have complicated PK–PD relationships, this can also be the case for orthodox drugs (e.g. antidepressant therapies, where three weeks or more is usually needed before any therapeutic response may be seen, or angiotensin converting enzyme (ACE) inhibitors that remain antihypertensive after several months of therapy, even after serum ACE activity has been restored). Likewise, both corticosteroid therapy and gene therapies require access to the cell nucleus; the intercompartmental transfer coefficients (serum/cytosol/nucleus) are complex and immeasurable in human beings in both cases. In contrast, complexity among biotechnology products include antibody complement fixation, cellular attack may be an all-or-none phenomenon, DNA lysis in sputum may not require drug absorption at all and clot lysis may depend on a wide range of endogenous plasma proteins, each with its own concentration–response relationships. The problems and analysis of tachyphylaxis are common to both orthodox and biotechnology products.

22.5 Manufacturing issues

Manufacturing changes are more likely to affect the clinical profile of biological compounds than small chemical entities. Small changes in the three-dimensional folding, posttranslational modification or glycosylation of proteins can significantly

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Absorption</td>
<td>DNA vector distribution</td>
</tr>
<tr>
<td>Distribution</td>
<td>Vector fraction target cell uptake</td>
</tr>
<tr>
<td>Distribution</td>
<td>Genetic material traffic in organelles</td>
</tr>
<tr>
<td>Metabolism</td>
<td>DNA degradation</td>
</tr>
<tr>
<td>Metabolism</td>
<td>mRNA production</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Protein production – quantity</td>
</tr>
<tr>
<td>Excretion</td>
<td>Protein production – stability</td>
</tr>
<tr>
<td>Metabolism, excretion</td>
<td>Protein production – compartmentalization</td>
</tr>
<tr>
<td>Excretion</td>
<td>Protein production – secretory fate</td>
</tr>
</tbody>
</table>
alter biological activity. The potential for the replication of viruses or bacteria in fermenters, and their persistence in finished drug product raise additional safety concerns arising from the manufacturing process for such compounds. For the clinical trialist, this leads to a generality: when studying biologicals there is usually a greater need for early-stage test medications to be as similar as possible to the eventual marketed product than for ‘orthodox’ small chemicals. The same reasoning is the current concern of regulators when trying to understand and approve ‘generic’ biologicals that have not been subjected to large-scale clinical trials demonstrating bioequivalence.

### 22.6 Product classes and resultant clinical trial issues

Many of the principles outlined in other chapters for phase I and II studies of these compounds are equally applicable to the testing of most biotechnology products. The same basic principle of demonstrating clinical tolerability as a priority over proving efficacy must apply. Other chapters also discuss some specific toxicology and drug discovery aspects of biotechnology products.

The general design of a development program for a biological product has the same principles as for ordinary drugs, and this should be familiar to the competent clinical trialist. The development program should be determined by the nature and needs of the disease; often the pharmacological activity of a biological product is likely to be very precise. For example, an antibody will bind to a previously identified narrow range of antigens, and the pathogenesis or source of antigen presentation will have a fixed relationship to a well-described disease or set of diseases. Equally useful in the case of biologics is to begin development with an agreed, desirable package insert or product information leaflet. That document can then be used to define the development strategy. Only those tactics (i.e. clinical trial designs, milestones and product-killing findings) that are justified or validated by that strategy should be implemented.

The nature and seriousness of the disease being treated is just as important as in more orthodox clinical trials. The degree of lethality or morbidity associated with the disease treated with existing therapies is correlated positively with the degree of intolerability of the test agent that may be accepted.

The trialist’s first general concern, of course, is tolerability. Most biological products carry a higher probability of antigenic immune response, compared with small molecules, because of their large size. However, the range of target-organ toxicities is usually narrower, and directly related to the specific receptors (using that term in a loose sense), to which the product is targeted. Clinical trialists should also be careful not to ignore the toxicological potential of the often large amounts of vehicle, with unusual ionic strengths, buffering materials, nonphysiological pH or unusual preservatives (e.g. cresols for insulin) which may be required to maintain complex peptides in a stable form. These ‘inactive’ product ingredients can have their own nephrotoxic, hepatotoxic and allergenic properties.

The clinical trialist who switches to a biological product will nonetheless use familiar tactics to prove efficacy. With ‘breakthrough’ agents that offer the potential for a new type of therapy, clinical trials can be conducted comparing the trial agent to a placebo. The central ethical consideration will usually be about whether standard treatment (if any) can be withheld, and the debate is not about the use of placebo in an absolute sense. Dose–response relationships need to be evaluated for biological agents prior to approval even when the biological response is an ‘all or nothing’ type of response (e.g. serological conversion, when the proportion of responding patients may be the end point of interest). It should be remembered that dose–response relationships must be understood for populations, as well as for the range among individuals. Therapies like vaccines need also to be evaluated in different racial populations, and in other types of special populations, such as the elderly.

### 22.7 Peptides

For a long time, interest in biotechnology centered on the production and properties of administered
hormones ranging from tripeptides, for example corticotrophin-releasing factor (CRF), through cyclic nonapeptides like vasopressin analogs, to longer polypeptide chains, for example insulins and growth hormones. As the length of the polypeptide increases, the three-dimensional structure becomes an important determinant of in vivo activity and properties.

However, there are also important advantages that an increase in protein size can bring. Single peptide mutations become less important as protein size increases. The scope for posttranslational modification is also greater in large polypeptides than in small ones. Good illustrations of this are the nonapeptides with large qualitative changes in pharmacology of the single amino acid that distinguishes arginine–vasopressin (the human antidiuretic hormone) from human oxytocin, or the marked differences in pharmacodynamics between calcitonin and calcitonin gene-related peptide, which are both encoded by the same gene.

Immunologic adverse events can be viewed as either active or passive, that is firstly what the drug does to the patient (histamine release, B lymphocyte proliferation, etc.) and secondly what the patient does to the drug (enhanced clearance, peptide cleavage, hapten formation, etc.). The clinical correlates of these cellular processes range from tachyphylaxis (need for ever increasing doses to maintain biological effect) to the acute emergencies of anaphylaxis. For example, around 13% of patients given aglucerase (indicated for Type 1 Gaucher disease) develop IgG antibodies to the enzyme, and of those so immunized, approximately 25% of these have clinical symptoms of hypersensitivity.

**Hormones**

Insulin is an early and classic example of a biotechnology product. It illustrates some of the general problems that are associated with peptide drugs and how modern technology leads to improved therapy. Prior to the production of human insulin by cell-based fermentation processes, treatment was with pancreatic extracts of porcine or bovine origin. Many patients developed insulin resistance, and this correlated with specific antibody responses directed against the insulin of the species of origin. Patients then had a ‘career’ of increasing insulin dose, punctuated by hypoglycemia when changing from one animal source to another without changing dose size. Some patients became so competent at clearing bovine or porcine insulin that they needed extracts from exotic species such as whales. The modification of recombinant chimeric or pure cell lines to secrete human insulin, the development of large-scale fermenters to multiply such cultures and the ability to purify cell-free insulin from other materials in the broth have led to a sufficient supply of exogenous, but human, insulin. Now in use by almost all patients with diabetes in the western world, immune responses to this molecule are much rarer than before, and dose sizes tend to remain more stable.

In addition to insulin, various other hormones made by recombinant methods have been approved or are under development. The most commonly prescribed examples at present include growth hormone (somatrem, Protropin, Genentech, Inc.) or erythropoietin (epoeitin alfa, Epogen; Amgen, Inc.). The EMEA has chosen three molecules from this class (insulin, somatotropin and human growth hormone) as worked examples (‘product-specific’) guidances on demonstration of biological equivalence (issued in final form March 2006). Erythropoietin will probably be next. Accompanied by a more general guidance, these documents set out the EMEA’s requirements for follow-on (i.e. quasi-generic) biological products. Furthermore, these guidances clarify matters concerning scale-up and technology transfer between production plants, which should benefit the developers of innovative and follow-on biologics, alike. At the time of writing (March 2006), similar guidances are awaited from the US Food and Drug Administration (US FDA), which have been at least two years in the writing so far. Active litigation in the United States Federal Court, by the developer of one follow-on biological product whose Biological License Application seems to have stalled without any request for further technical information, is doubtless complicating this advance in regulatory practice.
Enzymes

Several peptide drugs are enzymes. Dornase alpha (Pulmozyme; Genentech, Inc.) is an example, which is used to improve the management of chest infections and pulmonary function in patients with cystic fibrosis. It works because the rate of DNA release from dead and dying leukocytes is sufficient to significantly increase sputum viscosity. The enzyme (inhaled through a nebulizer) digests this released DNA, thus liquifying the sputum, and enhancing expectoration. The clinical trials of this product were generally of orthodox design, using dose–response analysis and placebo-controlled designs. The fact that the product is made by fermentation of genetically engineered Chinese hamster ovary cells containing DNA encoding for the native human protein, deoxyribonuclease I (DNAase), was essentially irrelevant to the design of the clinical development program.

Other enzymes in clinical use, manufactured using similar processes, include tissue plasminogen activator, other thrombolytic agents and aglucerase (Ceredase, Genzyme Corp.) for Type 1 Gaucher disease. These illustrate the diverse clinical applications that enzymes may find.

Antibodies

Because antibodies bind to antigens, their function is often to augment intrinsic clearance mechanisms as well as potentially exerting definitive therapeutic effects. It is not surprising, therefore, that the therapeutic targets for antibody therapy are extremely broad, ranging from antitumor therapy to specific immunological diseases, for example rheumatoid arthritis.

Antibodies can be targeted more or less specifically, either against a single or a variety of antigens. An example of a ‘broad-spectrum’ antibody therapy is anti-Rhesus antigen antibody (WinRho) which has been used postpartum for many years to prevent rhesus immunization of an Rh− mother by an Rh+ neonate. There are at least 60 known epitopes of the rhesus D antigen. The product is made from pooled plasma of Rh− male volunteers who have been deliberately challenged with small Rh+, ABO-compatible blood transfusions. The resulting product binds to red cells from 99.7% of all Rh+ blood donors.

Specific targeting of single, infrequently expressed antigens forms the basis of the large number of monoclonal antibody therapies that are either in development or in the market. These are generally manufactured by mammalian cell fermentation process, as described above (see the chapter by Dr Reno for issues relating to the manufacturing process and viral contamination of these products). Rituximab (Rituxan; IDEC Pharmaceuticals) is a highly targeted antibody that binds principally with CD-20-positive B lymphocytes that characterize one form of non-Hodgkin lymphoma. More recently, clinical trials on this agent have been conducted evaluating its effects on other putatively B lymphocyte-mediated diseases such as rheumatoid arthritis. Another example of a specific therapeutic is anMuromonab-CD3 (Orthoclone OKT3; Ortho Pharmaceuticals) used to reverse acute rejection of transplanted kidneys. The presence of single antigen targets in or on tumor cells can be further exploited by conjugating the antibody to a radioactive or cytotoxic molecule. For example, human milk fat globule I monoclonal antibody complexed with 90Yttrium (Theragyn) is under development for the treatment of ovarian carcinoma by Antisoma, PLC.

Antibody development radics can be learned by reviewing the product labeling for some agents mentioned. Antitumor necrosis factor alpha (infliximab; Enbrel; Amgen, Inc., Wyeth, Inc.) has revolutionized the treatment of rheumatoid arthritis, even if its labeling, in small font, occupies both sides of a small poster.

Cytokines

Cytokine responses to infection or tumors are thought phylogenetically to be the most ancient form of immune response. Cytokines are generated in response to antigen challenge and now have a large impact in the clinical management of many diseases. However, unlike antibodies, cytokine responses are nonspecific, and their principal
biological effect is to enhance general, lymphocyte-mediated attack on the antigen-bearing cell.

Cytokines include the large and ever increasing set of interleukins, various interferons, trophic factors such as tumor necrosis factor and the many growth factors. Granulocyte macrophage colony stimulating factor (GMCSF; sargramostim, Leukine; Immunex Corp.) is used for myeloid reconstitution after bone marrow ablation, exploiting its eponymous property, which was initially identified in vitro. Interleukin-2 (aldesleukin, Proleukin, Chiron Corp.) is approved in the United States for the treatment of renal carcinoma and metastatic melanoma. Platelet-derived growth factor can be used to heal diabetic foot ulcers, presumably by imitating normal physiology that is blunted in patients with diabetes (gel becaplermin, Regranex; Ortho-McNeil/Chiron, Inc.). Pegylated interferon alpha has revolutionized the treatment of hepatitis due to virus type C.

Because cytokines have nonspecific effects, existing biological products often find additional indications. Similarly, their adverse effects also reflect their nonspecificity with symptoms such as fever, myalgias, flu-like symptoms and rhabdomyolysis.

## Immune adjuvants

Immune adjuvants can be classed as:

- Nonspecific, for example BCG vaccine for bladder cancer
- Specific, for example Salk vaccine for polio prevention
- Genetic, to elicit cytokine responses (see below)

Traditionally, vaccines have been directed against the prevention of specific infectious diseases. Vacca is the Latin nominative for a cow, and vaccines have been used widely in medicine since Jenner’s pioneering work. Live, live-attenuated and killed microorganisms may all be used as antigens to elicit cellular and humoral responses. They may be viewed as adjuvants because it is the enhancement of endogenous physiology which protects against the pathogen, and not the vaccine itself.

The great scope for preventing infectious disease remains, and there is a continuing need for worthwhile research programs. Current challenges include malaria, sleeping sickness, HIV and prion-mediated disease. The last of these may (controversially) also be regarded as an ‘autoimmune’ or ‘congenital’ disease, if it turns out to be truly due to the derepression of prion genomes, which lurk dormant in many normal mammals, including human beings. Drug resistance, occurring in numerous microorganisms ranging from staphylococcus to malaria, is another field which could conceivably be conquered by taking the biological approach. A current ethical problem is that diseases that plague tropical countries and the developing world are in great need for drug development and research, but offer little financial incentive to the traditional pharmaceutical industry.

Not surprisingly, there is considerable interest in using adjuvant tactics for the prevention or treatment of noninfectious disease. Spontaneous tumor regression (although observed clinically only very rarely) and the development of rare tumors in immunocompromised patients (such as Kaposi sarcoma in patients with AIDS) are both consistent with the usefulness of endogenous host mechanisms to either prevent or retard cancer. Tumor-specific antigens may be used as therapeutic targets for exogenous therapy.

## Antisense drugs

Antisense drugs are exogenous oligonucleotides that bind to specific endogenous nucleic acid sequences. Binding to mRNA prevents the construction of proteins by ribosomes and similarly, binding to specific gene sequences on DNA can prevent transcription (i.e. inhibit mRNA synthesis). The application of antisense technology is broad as this approach can be used to inhibit the production of a wide range of proteins including stimulatory and inhibitory molecules.

Although the synthesis of antisense molecules using modern combinatorial chemical approaches is easily automated, the delivery of these molecules to
the appropriate intracellular and intranuclear sites is more difficult. The first antisense drug to be approved is for the treatment of cytomegalovirus retinitis in patients with AIDS (fomivirsen; Vitravene, ISIS Pharmaceuticals, Inc.). The route of administration of this drug is by direct intraocular injection, illustrating well the ADME complexities associated with some biotechnology products.

To date, most regulatory authorities have treated antisense drugs in much the same way as any other biological product, and without the additional constraints that apply to gene therapies. As these oligonucleotides have specific binding activities, safety considerations are usually dependent on the potential for nonspecific effects of protein synthesis inhibition. At present, with the current limited experience, there would appear to be sound in vitro methods for the testing of the specificity of antisense drugs to be predictive for their tolerability in man. Furthermore, when the properties of the protein which is inhibited are discrete and consistent across individuals, then it is likely that the potential adverse effects will be predictable.

22.8 Gene therapy

Gene therapy may be defined as the administration of exogenous DNA, in the form of intact gene(s) for therapeutic purposes. There are some a priori characteristics for diseases that are likely to be attractive targets for gene therapy, and a fundamental contrast between the gene therapy of protein replacement, in comparison with protein synthesis regulation.

The absolute or relative deficiency of a particular protein needed for health may be correctable, for example the enzyme needed to reverse Gaucher disease. If the gene product can be manufactured and administered effectively and tolerably, then the need for a gene therapy is reduced.

However, there are also congenital disorders involving relative deficiencies of a particular protein, and, where, importantly, therapeutic-induced overexpression can be as harmful as underexpression. Attempting to regulate gene expression then becomes more difficult than merely inducing it. The thalassemias are a priori a good example of this problem. Overproduction of the missing hemoglobin chain is unlikely to be helpful to the patient. Similarly, when the principal desired target for gene therapy is a specific target organ, then overexpression of genes in other tissues may create tolerability problems.

Gene therapies usually have two major components, the DNA molecule itself (the ‘construct’), and an administration adjuvant (the ‘vector’). In some cases constructs are injected directly, without a vector (termed ‘naked DNA’), but vectors are usually necessary because genes are large, hydrophilic molecules that do not readily cross lipid membranes. Vectors may be viral or nonviral.

Viral vectors include:

- Potentially pathogenic DNA viruses. These include adenoviruses and pox or vaccinia viruses. Both virus types can replicate in mammalian cytoplasm, whether or not the host cell is in mitosis or quiescent, and usually elicit a host immune response.

- Herpes simplex virus I (HSV1) also contains double-stranded DNA, but it replicates in the nucleus of cells that are successfully infected, again without need for mitosis.

- Nonpathogenic adeno-associated viruses. These paroviruses carry single-stranded DNA and are able to integrate into a broad range of nondividing cells.

- Retroviruses. These RNA-containing viruses exist in an envelope derived from host cell membrane, and thus do not usually elicit vigorous immune responses. Retroviruses also tend to replicate only in dividing cells.

It is perhaps surprising that naked DNA can cause gene expression at all. Current examples where this concept has been proven include genes injected into skeletal and smooth muscle. DNA–protein conjugates can also be administered without a vector, and seek to be internalized into the cell by specific receptors during the ordinary processes of endocytosis. Gold-coated DNA may also be inserted into cells by a ‘gene gun’, where electrostatic or gas
pressure powered displacement from a plastic matrix occurs.

Nonviral vectors are mostly liposomes of one type or another. Liposomal envelopes can transport substances across cell membranes which would otherwise be repelled by the hydrophilicity of the gene construct. Liposomes may be constructed that are either anionic or cationic. Complex liposomes, coated with antibodies that will target specific antigen presenting cells, can also be designed.

Human gene transfer experiments in lymphocyte marking studies began in 1989. These early studies showed that gene transfer was feasible and could be well tolerated although there was no demonstrable therapeutic benefit. The first human gene therapy clinical trial was in 1990, in a patient with adenosine deaminase (ADA) deficiency; initial responsiveness proved not to be uniform when the series of cases was extended, possibly due to the fact that the disease phenotype could be elicited by a variety of genotypes.

Two-stage delivery systems for gene therapies are also under development. This usually requires manipulating somatic tissue ex vivo. A good example would be following the transformation of bone marrow biopsies. The gene therapy can be introduced into the biopsy material ex vivo using either a viral or a nonviral vector. Successful expression can then be definitely demonstrated in vitro, following which the transformed marrow biopsy can be infused as an autologous transplant, with the intention of its proliferation and generation of the desired protein product in vivo.

The pharmacokinetics of gene therapy, and its relationship to dynamic effects, are very different from the orthodox pharmaceutical situation (Table 22.1). Ledley and Ledley (1994) have proposed a corollary of traditional PK–PD modeling, predicated upon the specific events in the cellular response to gene uptake and activation. These authors have developed a six-compartment model, which appears to have general applicability, to evaluate the apparent kinetic properties of a therapeutic gene product. This leads to the possibility of designing dosing regimens and relating them to measurements of expression and efficacy responses.

Acquired disorders may also be amenable to gene therapy. Stimulating the production of some cytokine that is a normal response to a tumor might be one strategy, using an appropriate gene and vector. Another example might be the differential sensitization of cells in a tumor to a particular cytotoxic drug, thus obtaining enhanced therapeutic response, permitting the use of lower doses of cytotoxic, and minimizing dose-limiting systemic adverse effects.

There are two areas of specific tolerability concerns associated with gene therapies, related to the expressed gene product and the vector. Both are immunological in nature, and may lead to therapeutic ineffectiveness.

If the gene therapy causes the production of a protein that was previously absent in the body, then an immune response to the novel protein is likely. Resistance to gene therapy can result from immunization against either the construct or the vector. The former is analogous to the patients who used to become resistant to xenobiotic insulins (see above), and is also seen in the case of human factor VIII in some patients with hemophilia. Escalating doses may be needed to maintain efficacy, or efficacy may be eventually lost. On the other hand, viral vectors are liable to replicate and also to elicit immune responses, just as for any vaccination, creating many of the same problems.

One approach has been to develop strains of many of the viruses listed above as ‘replication defective’ or ‘replication incompetent’. These viruses are mutations that are cultured initially in conditions that provide some crucial nutrient or element of the replicating machinery that neither the virus nor, importantly, the patient can synthesize. These strains of virus are therefore replication incompetent after human administration. There is nonetheless always the concern that after injection the virus will find some way to overcome its incompetency, for example by recruitment of the host cell machinery for this purpose.

Safety issues in gene product development

Although issues surrounding sterility, mutagenicity, stability and carcinogenicity, and the attendant GLP and GMP issues are much the same for
gene and other biotechnology therapies in principle, there is often greater complexity associated with the former. These complexities include uncertainties with preclinical toxicology and the potential for germ cell line incorporation.

Firstly, the toxicology of any gene therapy needs to be considered as a combination of three products: the construct, non-genetic elements in the construct (e.g. pharmaceutical adjuvant-stabilizing materials) and thirdly the vector.

Secondly, there is a need to test in animals the possibility of incorporation of the therapeutic gene into the germ cell line. Many constructs contain multiple genes: not only is the therapeutic gene present, but also genes to assist in manufacturing, for example those conferring antibiotic resistance to the microorganism that is being used for production, or a gene for a marker enzyme. All these genes require toxicological assurance that they do not incorporate into the germ cell line, and thus will not be replicated in the offspring of the treated patient. This is a special field of toxicology that is still in its infancy; in some cases clinical trials have to be restricted to surgically sterile patients in the absence of this information.

Regulatory issues specific to gene therapies

In the United States and Europe gene therapy protocols attract an additional degree of regulatory review. Not only must an IND be approved by the US FDA, but also the protocol must be approved by the Recombinant DNA Advisory Committee of the National Institutes of Health (the ‘RAC’). To date, many dozens of such protocols have been approved, with the largest group for therapies that are designed to increase production of a specific cytokine in a specific tissue location. In Europe there is no equivalent to the RAC, and regulatory requirements are handled within the national regulatory authorities reviewing research protocols for investigational agents. There is no anticipation of product licence applications in Europe. Gene therapies are also exempt from the time limits that usually apply to the review of clinical trial protocols by national competent authorities in Europe.

22.9 Cell and tissue products

There are various clinical conditions where administration of cultured whole cells or tissue may be desirable. The sources of these tissues are as diverse as the disease targets. For example, cultured fibroblasts from human prepuces are being developed as ‘artificial skin’ for the treatment of leg ulcers and burns (Advanced Tissue Sciences, La Jolla, California; Smith and Nephew, Romford, UK). Other companies are developing implantable pancreas generated from isolated pancreatic islet cells. Unlike matched transplantations, such therapies may involve treatment of large numbers of patients from a limited or sole initial human source or may be autologous albeit after some \textit{ex vivo} manipulation and culturing of the cell mass before reimplantation. \textit{Ex vivo} therapeutic strategies may take different forms. Chronic lymphocytic leukemias have been treated for long periods of time by using cell separators to reduce the burden of lymphocytosis, and to permit red cell transfusion. Laser-directed cell sorters may be used to select appropriate sub-populations of lymphocytes, which are then transfected with an appropriate gene product \textit{ex vivo} and returned to the patient, where these cells will hopefully target some diseased tissue such as widespread melanoma. Expense, availability of therapy and the duration and specificity of effect currently limit the widespread application of these approaches.

22.10 General ethical issues

The modern advances of biotechnology create numerous ethical issues. Care should be taken in relating directly the therapy type and the ethical issue. Moreover, ethical standards vary among highly respected ‘experts’. Indeed, it can be said that, to some extent, everyone is an ethicist, and those involved in biological product development certainly should be.

It is easy for those without technical training to extrapolate that all biological products have the same range of ethical issues which actually only affect some of these therapies and because
of misunderstanding. For example, the cloning of mammals (sheep at Roslin Therapeutics, Scotland; mice at the University of Hawaii) forces the consideration of cloning of humans. On one hand, much of this technology can be used for genetic screening of fetuses to exclude an inherited disease. On the other hand, the same techniques could be used to provide parents with a deliberate choice of the sex of their next baby. Science is likely always to be ahead of the lay public and politicians in creating these dilemmas in the absence of agreed guidelines or consensus. The biggest problem for the lay public to grasp is there is always an ethical continuum, without bright lines of demarcation or absolute limitations.

If it is the ethical continuum that is the central difficulty, then there are nonetheless analogies in the ‘pregenetic engineering’ era of medicine. Consider, for example, the parents of a child who needs a kidney transplant, and who find themselves without any suitable living donor. Without any modern technology at all, they may choose to have another baby with the hope or intent that the new child can serve as a suitable donor for their existing child. In this case, tissue proliferation ex vivo and implantation seem to be a simpler ethical situation than parents having offspring by entirely ordinary means. Consensus guidelines are needed, but in our opinion they must remain flexible in order to deal with ever faster technological innovation that is not going to stop, and they must also be consistent with guidelines that have wide acceptance in other areas of medicine and have cross-cultural flexibility.

**Informed consent**

More prosaically, the difficulties of explaining the nuances of biotechnology products to potential clinical trials subjects may be more difficult than for orthodox small molecule drugs. Often, candidate clinical trial patients will be experiencing life-threatening disease, and the apparent novelty of, say, a gene therapy, could, under the wrong conditions, create undue hope and bias in deciding to provide what should be truly informed consent. It is crucial that the same principles apply for biotechnology as for conventional drugs; the protocol and therapy must still be clearly explained in a non-coercive manner that do not raise false hopes in the patient. Let us not forget that this type of, major ethical lapse resulted in the death of Jessie Gelsinger during a clinical trial of a biotechnology product in the United States.

**22.11 Pharmacogenomics as it applies to biotechnology product development**

At the time of writing (March 2006), it is estimated that about a third of all investigational new drugs are the result of pharmacogenomic research. The science of pharmacogenomics may be defined as the exploitation of the human genome for the identification of candidate polypeptides that can serve either as drugs themselves or as therapeutic targets. It is contemplated that pathological deficiencies of such candidate polypeptides might be repaired or replaced by exogenous administration, abnormal excessive candidate polypeptide production might be antagonized or suppressed or that some normal candidate polypeptide might be overexpressed to supra-physiological levels in the effective treatment of disease. The science of pharmacoproteomics is exactly analogous, except that the database of human proteins (which exceeds in number the catalog of human genes and which roughly equates to one definition of phenotype) is the thing that is exploited.

This new science has three or four basic components: the map of the human genome (which was essentially completed in 2004), research that relates genes to proteins (the old one-gene-one-protein dictum has now been completely abandoned), the regulation and pharmacodynamics of posttranslational protein modification and integrative approaches to identify structural motifs of putative therapeutic agents. When there is capability to predict phenotype accurately (without waiting for drawn-out growth experiments), then the potential to accelerate process of biological drug discovery seems to be greatest.

An intrinsic part of the pharmacogenomic enterprise is the capability to analyze vast datasets, and
to integrate these with observable (pharmaco) epidemiology. This demands computational expense that would have been unimaginable even in the mid-1990s. Many phenotype databases are now online and in the public domain, including those for popular nonhuman experimental models, such as for worms (e.g. *C. elegans*), yeast, maize and mouse. There is also a human rare metabolic disease phenotypic database available (http://www.ramedis.de). These allow a reverse approach, namely using phenotypes (or translated proteins) as a marker for gene function, with the hope that the latter can be influenced by novel therapies in the future. These sorts of approaches can also be used to develop ontologies, and thus identify novel appropriate animal models for pharmacological testing in preclinical drug development. Pharmacoenomics is now a well-populated subspecialty among statisticians, engineers and mathematicians.

While unlikely to be directly involved in this type of molecular biology research, it will become the task of the typical practitioner of pharmaceutical medicine to develop drug candidates generated by pharmaco- or proteonomic research. *Vice versa*, those conducting this specialized form of research are unlikely to regard themselves as practitioners of pharmaceutical medicine. Thus, we cannot offer a comprehensive discussion of this field in this chapter, nor shall that be the case in the rest of this book. The interested reader is encouraged to consult the huge literature on this subject, which now includes some useful general textbooks (see below).

**Acknowledgments and Further reading**

The authors thank David Feigal, MD, MPH, Medical Deputy Director of the Center for Biologics Evaluation and Research of the US FDA for providing us with information relating to the regulations of drugs and biologics and the current regulatory issues. For a comprehensive description of the science of pharmacogenomics, the authors recommend:


Increased competition makes it imperative to hold down healthcare costs while maintaining or increasing quality. This has dictated changes in the traditional drug development path. For most of the past 40 years, the development of most pharmaceutical products has followed a predictable path from discovery to preclinical and clinical development, approval and marketing. To maximize the commercialization and clinical use of a product, successful drug development today must now focus on measuring other outcomes of a pharmaceutical intervention. Capturing data that document clinical response is no longer a sufficient objective of drug development programs.

Economic and humanistic outcome evaluations are now made as part of healthcare governance. The information gained from valid outcome measures can be used on a national level to allocate expenditures for treating various sectors of the population (e.g. the elderly, neonates, etc.) or to determine which programs will receive financial resources (e.g. vaccine programs vs. acute influenza treatments). Outcome information can be used to help make decisions regarding the inclusion or exclusion of drugs on formularies. Complete information about the economic, humanistic and clinical impacts that medications have on specific patients can help healthcare providers make better prescribing decisions.

Decision makers, including prescribers, providers, payers and patients, all want to maximize the value received for the money spent. Value to a prescriber might mean achieving a desired clinical impact for the cost of drug; value to a payer could mean spending more for a drug that reduces the number of days in a hospital, thus reducing the total economic impact of a condition. Value to a patient or employer might also be making sure that the drug prescribed maintains quality of life (QOL) or worker productivity. To be successful, the pharmaceutical developer must address the needs of all these decision makers. To do this, it is imperative that drug development programs today include quantitative measures of economic, clinical and humanistic value of the drugs they develop. It is never too early to begin to think about how the value of a product will be demonstrated.

The intent of this chapter is to help pharmaceutical developers and researchers understand how to document the economic and humanistic value of pharmaceuticals through appropriate pharmacoeconomic development programs.
Outcomes research is the study of the end results of medical interventions: Does the healthcare intervention improve the health and well-being of patients and populations?

The field of outcomes research emerged from a growing concern about which medical treatments work best and for whom. Outcomes span a broad range of types of intervention, from evaluating the effectiveness of a particular medical or surgical procedure to measuring the impact of insurance status or reimbursement policies on the outcomes of care. Outcomes research touches all aspects of healthcare delivery, from the clinical encounter itself to questions of the organization, financing and regulation of the healthcare system. Each of these factors plays a role in the outcomes of care or the ultimate health status of the patient. Understanding how these factors interact requires collaboration among a broad range of health service researchers, such as economists, sociologists, physicians, nurses, political scientists, operations researchers, biostatisticians and epidemiologists (Foundation for Health Sciences Research, 1993).

Health economics offers basic tools and criteria with which to analyze these issues of efficiency and the distribution of healthcare. These tools include techniques of optimization and the determination of equilibrium situations (e.g., predicting change in demand for services). The set of criteria is used to determine whether someone is better or worse off as a result of a particular action. Health economics tools are often used to evaluate how much money should be allocated to a healthcare program or service. To the extent that health economic analyses can clarify the costs of alternative medical treatments and make the values underlying those alternatives explicit, it is a useful approach to the study of medical care (Feldstein, 1983). Health economics focuses on all aspects of healthcare and as such can be very useful for generating data to make policy decisions involving multiple healthcare programs and systems. While some health economists take a 'big-picture' or macro-view and focus on issues involving healthcare policy, others may focus specifically on pharmaceutical industry issues such as drug pricing, or the cost of drug development.

Pharmacoeconomics is defined as the science that identifies, measures and compares the costs and consequences of pharmaceutical products and services (Bootman et al. 2005). As such, pharmacoeconomics focuses primarily on pharmaceuticals, and attempts to evaluate the economic and humanistic impact of drug therapy. Pharmacoeconomic tools are derived from a variety of sources, including the fields of economics and outcomes research. Quite often, the pharmacoeconomist will bring to the development team skills and experience in assessing QOL, patient satisfaction and other patient-centered measures. Health economists and pharmacoeconomists differ (while the terms are sometimes used interchangeably), in having stronger backgrounds in the theoretical and applied aspects of health economics, respectively. A researcher with solid pharmacoeconomic skills may not be a very good health economist and vice versa. When hiring pharmacoeconomists or health economists, first determine what they will do, then evaluate their skills and experiences to make sure that they will be able to deliver what is needed for your specific drug development program.

Healthcare used to be constrained mainly by the technologies available to assist in delivering care. As technology becomes increasingly sophisticated, its cost is potentially outpacing the resources available to pay for such care. Which patients should get which treatment? How should healthcare be allocated, or in some cases rationed?

Health outcomes are the measured end results of a medical intervention. They represent what happened to patients. Being cured of an illness is an outcome, as is succumbing to it. However, this rudimentary, epidemiological distinction tells us very little about the current functional status of the patient. Being alive but relying on a respirator...
to breathe is very different from being alive and fully functional. Additionally, intermediate outcomes (e.g. alleviation of pain or other symptoms of arthritis) are sometimes as important an outcome as the final outcome.

The measurement of outcomes is critical to the conduct of pharmaceutical research. Clinical outcomes (efficacy and safety) are the hallmarks of Food and Drug Administration (FDA) approval of a product for marketing. Clinical outcomes are necessary but no longer sufficient as a sole consideration in weighing decisions, and for reimbursement in socialized healthcare systems (where reimbursement essentially governs marketability).

Patients have become more involved in their own healthcare decisions, and economic considerations have increased in importance. All have contributed to the movement to extend outcomes measured beyond the traditional clinical outcomes associated with pharmaceutical research. Healthcare decision makers are pressed to know more than simply the safety and efficacy parameters of an intervention. It is important for them to know how a specific intervention will impact budgets and use of other resources, and how it will impact the patient from the patient’s perspective.

Pharmacoeconomic information demands are often not anticipated early enough in the clinical development program. For example, several million people in the United States are taking antihypertensive medications to lower their blood pressure, something we would generally think of as good, as the medications can possibly extend life by reducing the risk of stroke and coronary artery disease. However, in some cases the potential benefits of antihypertensives may not outweigh the negative effects of the drugs on QOL; one study reported that the health of a person treated with antihypertensive medication is comparable to that of an otherwise similar person 5–15 years older. Clearly, trade-offs between the side effects and benefits of the medications should be presented to patients so they can make informed decisions about treatment (Lawrence et al., 1996).

If a pharmaceutical company is developing a new antihypertensive medication targeted for chronic use, then preparing a submission with a goal of having the drug prescribed is an accomplishment. But it is also necessary to convince patients to take the drug on a regular basis, as well as to ensure that patients understand the pros and cons of taking the medication from their quality-of-life (QOL) perspective. An astute pharmacoeconomic researcher incorporates a QOL component into appropriate comparative studies, so that patient-derived and patient-reported aspects of treatment are considered in addition to the management of physiological symptoms such as blood pressure reduction.

Although clinical outcome is critical, it is no longer the sole factor reviewed in making a decision to use an intervention. Just as the information requirements increased from safety to safety and efficacy in the 1960s, the bar has been raised once again, and these requirements now include not only clinical (safety and efficacy) but also economic and humanistic outcomes. This paradigm shift has been represented in a model termed the ECHO (economic, clinical and humanistic outcomes) model, described by Kozma et al. (1993). Economic outcomes include direct medical resources used to provide a service or achieve an outcome, including healthcare providers’ time, laboratory services and diagnostic procedures. Patient productivity is also an economic outcome. Humanistic outcomes include health-related QOL, patient satisfaction with interventions and patient preferences.

Under the new paradigm for decision making, all decision makers will increasingly be forced to take into account the perspectives of the other players affected by their decisions. Prescribers will no longer consider just the clinical impact, but also the economic impact their decision will have on the payer, and the QOL impact the decision will have from the patient’s perspective. The payer and patients will need to consider the impact of their decisions on the rest of the system. Successful drug developers now evaluate three-dimensional outcome data as early as possible in the product development life cycle. This information will also be useful to investors who are making decisions regarding the ultimate potential for success or failure of a newly discovered therapeutic product.

Table 23.1 provides examples of clinical, economic and humanistic outcomes. Each outcome type is not mutually exclusive, for example pain
could be a clinical or a humanistic outcome, but only needs to be measured once in a study.

23.3 Pharmacoeconomics in development programs: advantages, disadvantages and challenges

Pharmacoeconomic tools will not make a decision, but are useful as an aid to decision makers regarding the appropriate use of a product. While typically considered to aid the end user, pharmacoeconomic data also have great applicability at the drug development level. This is not an entirely altruistic concern for the pharmaceutical company: if incorporated early into the development of a drug, a strategic advantage due to a more complete package of outcomes information is available at the time of product approval.

Pharmacoeconomic tools can also assist in selecting an area of preclinical exploration, choosing which drugs should move forward into humans, and whether to progress a drug from phase II to phase III research. An understanding of the current burden of the illness or condition, in terms of its natural history, resource use and QOL profile, can help a research team put the estimated development costs and the desired return on investment in proper perspective. A drug that ‘cures’ an illness that is common but not very debilitating is not likely to be seen as worthy of a premium price by many formulary committees. This does not mean that the drug should not be developed, but the expected return on the drug must be put in the appropriate context. Early research can also identify targets for comparative studies – a must under the new paradigm. If research is conducted in the most severe patients with a particular condition, but they constitute only 5% of the treatable population, then the perspective of those patients needs to be put in context with other patients who suffer a less severe form of the same condition. This will help to demonstrate how patients with less severe forms of the disease might respond to treatment and to determine what the impact of the condition is on their QOL.

Must pharmacoeconomic research delay development programs? A perception exists that disadvantages of incorporating pharmacoeconomic parameters into the development program necessarily delays the filing of the new drug/product licence application (NDA/PLA), while gathering data that will not be ‘useful’. First of all, the same statements could apply to any clinical measure, and every efficacy end point is carefully considered before incorporation into a study or program. Similarly, not every program requires all conceivable pharmacoeconomic components. Acute treatments (e.g. antibiotics for otitis media) may not require QOL components; ‘me-toos’ (e.g. a new β-blocker or a NSAID) may only require a simple cost comparison study.

Drugs for chronic use should be considered as a prime target for pharmacoeconomic study. If a disease is not going to be cured, and the patients are expected to take a product for the rest of their lives, there should be some message that can be provided to the patients that will support their use of the product in a compliant fashion for a number of years.

It must be remembered that the ultimate objective of the pharmaceutical company is the successful launch of a worthy new product. If phase III studies are already completed by the time pharmacoeconomic components are considered, the likelihood of having any outcomes data beyond traditional safety and efficacy at product launch is small and/or delay to gather such data is obligatory. A strategic advantage for the product will have

### Table 23.1 Examples of outcomes

<table>
<thead>
<tr>
<th>Type of outcome</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical</strong></td>
<td>Symptoms, diagnosis&lt;br&gt;Adverse events&lt;br&gt;Drug interactions</td>
</tr>
<tr>
<td><strong>Economic</strong></td>
<td>Hospitalizations&lt;br&gt;Physician visits&lt;br&gt;Prescription drugs&lt;br&gt;Productivity</td>
</tr>
<tr>
<td><strong>Humanistic</strong></td>
<td>QOL&lt;br&gt;Satisfaction with treatment&lt;br&gt;Preference for one treatment versus another</td>
</tr>
</tbody>
</table>
been lost. One of the most frequently requested pieces of information by formulary committees and reimbursement agencies is, ‘What is the impact on my budget?’ and from patients is ‘What will be the impact on me? Will I feel better?’ It is tempting to ignore pharmacoeconomics under the guise of ‘it is not required by the agency’ or ‘it will slow things down’.

The challenges associated with successfully incorporating pharmacoeconomic components into a clinical development program include making sure the right people are involved early enough, so that delays do not occur. Adding pharmacoeconomic components to clinical development programs does not have to be rate-limiting, but will automatically be so when the project team fails to bring the pharmacoeconomist into the project at an early stage, that is phase I. Early involvement will enable the pharmacoeconomist to understand the characteristics of the investigational drug and the targeted conditions, and as the trial program is laid out, pharmacoeconomic components can be selected that are the most appropriate for the studies in the program. A thoughtful and documented pharmacoeconomic development plan should be made available at the same time as the clinical and marketing development plans. Only then will all the three plans be coordinated and support one another.

23.4 Value-added versus traditional clinical development programs

The magnitude of the challenge of incorporating pharmacoeconomics into a traditional clinical development program will depend on the type of program being studied, the willingness of the research team to be open to new types of outcome measures and the capability of the pharmacoeconomist. As research-orientated companies avoid ‘me-too’ products, and forge new areas of unmet medical needs, the need for value-added development programs with scientifically valid pharmacoeconomic outcome data will increase. When the need to demonstrate value has been discussed long enough, the real debate should be why to exclude pharmacoeconomic measures, not whether to include them. Including pharmacoeconomic measures should be the default.

Training and experience of the pharmacoeconomist will impact the conduct of how well value is added to a drug development program. Does the pharmacoeconomist understand the clinical trial process? Is the goal to have a pharmacoeconomic message useful to marketing? Does the pharmacoeconomist understand what messages a sales representative can communicate and what materials can be disseminated as promotion? Has the pharmacoeconomic scientist interacted with the FDA and other regulatory agencies? Will he/she be able to develop a pharmacoeconomic strategic plan that will complement the clinical and marketing plans and fulfill the goals of the company? All these questions should be asked before selecting a staff or consultant pharmacoeconomist and embarking on a value-added development program.

23.5 Pharmacoeconomic baseline

The important first step in developing a pharmacoeconomic strategic plan is to start by finding out what is currently known about the disease and the economic and humanistic burden that it has on patients, payers and providers. The best place to start is with a review of the literature and the Internet to determine what has already been accomplished. This may entail a review of the epidemiology and clinical aspects of the condition to verify that pharmacoeconomic components would be a worthwhile addition to a clinical program. After this review the pharmacoeconomist should then formulate the plan for measuring economic and humanistic outcome, and this will ultimately become a component of the full development plan.

If adequate baseline measures do not exist, then an important part of the strategic plan will be to research and document the baseline burden of illness as it is currently being treated (or not treated, if this is the case). This can be done separately from the clinical trials that are taking place, although placebo-treated patient measures may also be
important in finding this baseline. The goal is to identify a benchmark, documenting the *status quo*. This baseline is critical to being able to show the impact (improvement) that the new drug will have.

Table 23.2 lists some of the important questions to consider when documenting the baseline burden of illness. Answers will not be available for every question, neither will perfect data be always available for those answers that can be provided. The risk–benefit assessment of taking the time to answer each question thoroughly versus applying some ‘quick and dirty’ estimates to the questions should be considered. Not every program requires a large-scale major prospective study to answer each question, for many of the reasons discussed above. However, in the long run, it is usually less costly in terms of time and money to research the unknown issues before committing to the pharmacoeconomic development plan. The *post hoc* piecemeal approach almost always fails.

**Case study: data sources**

A study to document the outcomes of epilepsy treatment, conducted by Hirsch and Van Den Eeden (1997), illustrates some of the challenges associated with collecting burden of illness data. The traditional clinical measure of seizure frequency is no longer considered appropriate as the sole measure of outcome of treatment or surgical intervention. The additional variables to document the burden of illness that were found illustrate the gap between the type of data desired and what is available. Hitherto, QOL had been assessed in epilepsy patients using no fewer than 12 different instruments (both disease-specific and general). The economic impact of epilepsy had previously been assessed at a national level and in a few small studies.

These authors wanted to describe the overall disease impact for patients with chronic epilepsy, using a retrospective cross-sectional design in a managed care organization. Multiple data sources were required, as no single data base served as a repository for the various types of data required, and included administrative databases, medical charts, pharmacy databases, outpatient databases, hospitals, laboratories, outside services, memberships and so on. They found that all the identified sociodemographic variables were available in at least one automated database, as were two of the clinical variables, and 26 of the economic variables. None of the humanistic variables were available in any database.

In this case, about half of the data desired were available electronically, most of which were related to health as heavily weighted toward economic information. To gather the remaining desired data the investigators needed to collect prospectively humanistic as well as some additional clinical variables (Hirsch and Van Den Eeden, 1997). It is quite typical that clinical data available electronically are often not complete and therefore not very useful, and that humanistic data are missing completely from the databases held by Health Maintenance Organizations.

When setting out to document the burden of illness, it is critical to ensure that the patients in the databases really are patients with the disease. In some cases, the ICD-9 codes are known to be inaccurate regarding patient capture, and means other
than electronic databases must be used. One advantage of using clinical trial patients is the certainty of having patients with the condition of interest – the trade-off being a concern for the generalizability of information to the larger population.

Pharmacoeconomic baseline data should not be considered in isolation, but as one aspect of data that must be considered as a part of the whole. Once the burden of illness information is collected and analyzed, the development team must move to plan for ways to measure and document the clinical, economic and humanistic impact of the new pharmaceutical entity or other intervention.

23.6 Studies within clinical trials: techniques

The information generated from the burden of illness component of a pharmacoeconomic strategy will serve as a useful guide for the design of pharmacoeconomic components within clinical trials. Obviously, this must be factored against the prior judgment of whether or not disease-specific QOL instruments are required at all. Healthcare resource use, measures of lost productivity and indirect financial cost measures may be all that is required. The process of incorporating pharmacoeconomic measures into clinical trials should begin before a draft protocol is ever created.

Both the quantity and the types of data able to be collected will be affected by the nature of the clinical study: patients may be inpatients or outpatients, and this in turn will govern the nature of pharmacoeconomic data that can be recorded. It is also important whether a clinical trial is intended as a pivotal trial for registration or not: if a study is pivotal, then a clinical efficacy measure will have to be the primary end point. Pharmacoeconomic parameters can still be incorporated into such a study as secondary end points, and still provide valuable information. If, on the other hand, the clinical research addresses a health system delivery issue, then the pharmacoeconomic end points may well be primary, and the study design need not be constrained by FDA-mandated requirements for the double-blind, placebo-controlled aspects of proof of efficacy.

Early phase: feasibility/late phase: data. As the development moves from early phase II through to phase IV, the rationale for incorporating pharmacoeconomic parameters into studies should evolve. Initially, measures may be used in studies with small sample sizes to gain experience with certain instruments, or to determine which instrument is preferred for use in larger studies. Early on, the project team may think that everything conceivable (‘all but the kitchen sink’) is being included in a study. In some cases, the instrument feasibility study could be done as a separate study, but the costs in terms of additional patients needed, and other resources required, need to be carefully considered before a decision to reject the inclusion of several pharmacoeconomic instruments in one early clinical study.

As the product moves from phase II into phase III, the number of seemingly redundant instruments should decline as the obvious choice, or best guess should rise to the top. If the goal of phase III studies is to file an NDA or gain regulatory approval, the studies may not be appropriately designed to capture the additional information deemed necessary for the product’s success. In some cases, separate pharmacoeconomic studies may be needed prior to marketing.

Good advice is to prioritize at this stage of development: which pharmacoeconomic components critical and which are not for product launch or shortly thereafter? Thus, there is usually a need to strike a balance between getting information in a timely fashion, meeting regulatory demands and meeting demands of the marketplace; that balance may often have to be struck pragmatically.

Confidence and validity of data

As in any other scientific endeavor, the validation of the database is as important as its interpretation; pharmacoeconomic variables require two degrees of confidence, that is in the accuracy and the validity of what has been measured.

Consider two opposite examples of pharmacoeconomic measurement. In one case, patients could describe their impression of the impact of an intervention on their QOL following completion of a
two-week, open-label course of treatment. At the other extreme, a randomized controlled trial (RCT), using a double-blind, placebo-controlled protocol and a 12-month follow-up in several hundred patients, could use a statistically validated QOL instrument. The results of the latter would probably inspire more confidence than the ‘informal’ scenario, all other things being equal. However, it does not mean that the answers given using the informal method are wrong; it simply requires an appreciation of the trade-offs involved in how data are collected. Furthermore, the former method might be of more use than the latter in exploratory pharmacoeconomic research conducted in the earliest stages of drug development.

The RCT, while regarded as a gold standard in much of drug development, offers real challenges to the pharmacoeconomist. The RCT is costly, time-consuming, and may not always be ethical (12 months of placebo?). Some types of outcomes, such as compliance, do not lend themselves to double-blind designs because such designs mask one of the effects being measured. RCTs generally strive to maintain high levels of internal validity at the risk of reducing external validity. Biases to internal validity affect the accuracy of the results of the study, as they apply to those who participated in the study (e.g. patient selection bias, crossover bias and errors in measurement of outcomes). Biases to external validity affect how well the results may be generalized to the public at large. Obviously, the choice of study design must take potential biases into account. These factors are somewhat analogous for pharmacoeconomic and traditional clinical research.

Selecting a QOL instrument

It is always important to select an instrument that has adequate reliability and validity. Although many instruments have been published, many of these have little supporting validation. Another source of information include the Medical Outcomes Trust (2001; http://www.outcomes-trust.org). Some instruments, such as the MOS-SF-36, a generic QOL instrument, seem to be gaining popularity, and it is tempting to routinely incorporate these into clinical studies. Many experts in the field recommend that both a disease-specific and generic instrument should be used in each study, in order to capture the broadest QOL information. Yet, excess burden on patients can defeat the accuracy and completeness of what is collected. Generally, if resources or patient burden threatens, then most experts would argue for retention of a disease-specific instrument when it is only possible to use a single measure.

Standard operating procedures and quality analysis should be a part of every study in which the company invests money to collect end points, be

**Table 23.3** Points to consider: incorporating pharmacoeconomic measures in clinical trials

- Document the pharmacoeconomic objectives, methodology and analysis plan within the study protocol.
- Measure outcomes in the most appropriate and most disaggregate units. Categories can always be collapsed at a future time, but is impossible to split out variables beyond their original units. The sources of process and outcomes data may vary.
- Clinical data may be captured from providers, patients and medical records.
- Resource use data may be obtained from patient, administrative databases, providers or charts.
- QOL data should come from the patient. In some cases (very young, very old, mentally unstable) patient proxies are used, but the patient should be considered the optimal choice.
- The study design can affect the *types* of outcomes that can be reliably collected, and the *manner* in which the outcomes can be collected.
- Study design affects several parts of the evaluation process:
  - Cost of evaluation
  - Time required to conduct the evaluation
  - Accuracy of the information gained
  - Complexity of administering the evaluation
  - Ease of defending subsequent decisions made, based upon the evaluation
they traditional or pharmacoeconomic end points. The handling and analysis of pharmacoeconomic data should follow good clinical practices (GCP) guidelines. Data collection instruments need to be selected, or created and incorporated into case report forms, just as for any other end point. Data analysis plans should be created prospectively. The statistical analysis plan should be prospective, and should help put the pharmacoeconomic measures in the context of other properties of the test medication (Table 23.3). Are they included to test a hypothesis or is this a hypothesis-generating study for the pharmacoeconomic measures? Is the goal to evaluate patients, discriminate between patients or predict how patients might act? The type of data collected should drive the level of analysis (continuous vs. categorical data). If there is an investigators’ meeting for the study, the pharmacoeconomic components should be presented at the meeting so the investigators and/or the study coordinators fully understand their role in data collection. As the study is ongoing, appropriate levels of monitoring should be conducted. Queries that arise during the study and reconciliation of the data afterward should be handled in the same manner in which clinical queries and data reconciliation are handled.

23.7 Reporting and publications

Most companies have some form of standard operating procedure by which they generate clinical study reports. Pharmacoeconomic data should be handled and reported in the same way. In some cases it may be appropriate to issue the pharmacoeconomic component of a study as an appendix to a larger clinical report. This will depend on the level of pharmacoeconomic involvement in the study and how closely related the end points may be to the pathological measures. If there were just a few pharmacoeconomic measures that were being tested, an appendix to a clinical report might be appropriate. In contrast, for example where recovery from anesthesia is measured by ‘street fitness’ (the humanistic outcome) and neurological measures of balance and coordination (the physiological end point), then it could be cogent to report these two types of data together, and to examine how well they correlate; this would not be suited for an appendix for the humanistic data.

External reports are most likely going to be manuscripts submitted to peer-reviewed journals. Placement of pharmacoeconomic articles in non-specialty journals is important but difficult. Some editors do not understand the intrinsic properties of pharmacoeconomic data, and some reviewers will blindly apply statistical constraints that are inappropriate or not valid to humanistic outcomes (e.g. power calculations to measures of the adverse effects of drugs on QOL measures).

The basic principles of scientific writing and reporting apply to pharmacoeconomic research, and little need be said here. The structure of the paper is the same (Introduction, Methods, Results, Discussion, etc.). It is important to be consistent and appropriate in the use of terminology (e.g. ‘costs’ is not synonymous with ‘charges’, and cost-effectiveness is not a cost–benefit analysis; Sanchez and Lee, 1994). New mediums such as the Internet offer new possibilities for publication, dissemination and debate (Medical Outcomes Trust, 2001 (www.outcomes-trust.org); American College of Clinical Pharmacy, 1996).

It must be said that how such information gets disseminated is controversial in the United States. A good recent example is an investigation of atovaquone versus i.v. pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia. This report included a decision tree to estimate the costs and cost-effectiveness of atovaquone versus pentamidine for cotrimoxazole-intolerant patients (Zarkin et al., 1996). Clinical outcomes were based on data from a previous phase III RCT, which compared the two medications. Economic outcomes were based on treatment algorithms derived from discharge data, published reports and clinical judgments by the co-authors. The clinical data were from a randomized, double-blind study. A sensitivity analysis was conducted. The major conclusion of the study was that there were significant cost savings to be had from treating Pneumocystis carinii pneumonia on an outpatient basis. An FDA representative, during a platform presentation of this paper, even indicated that these data could be used in promotion.
23.8 Current and future uses of pharmacoeconomic outcomes

The future for pharmacoeconomics is promising in the current healthcare environment. However, like any discipline, pharmacoeconomics has its limitations (Jennings and Staggers, 1997):

1. *Competing perspectives create tension*, for example pharmacoeconomics versus clinical importance. Differences in perspective may be irreconcilable because they relate to a perceived encroachment: ‘turf wars’ can erupt between clinical, marketing and pharmacoeconomics departments within the same company, in spite of all three professing the same goal, that is to successfully market a worthwhile drug in a proper fashion.

2. *Need for rapid response*. Protocol in two weeks versus six weeks? Sometimes it takes longer to develop the pharmacoeconomic portion of a protocol. There may be fewer people to do it, there are more likely to be unknowns and there may be a need to decide which instrument to use; worse yet, there may be no baseline data to validate any chosen instrument. Studies that examine efficiency are especially likely to require more planning.

3. *Lack of prototype*. Some groups want these studies to be pragmatic and relevant to everyday practice, yet there is no prototype to delineate the basic tenets of such studies, meaning that the data may be riddled with inaccuracies and misrepresentations. Additionally, the regulatory agencies may be more concerned with internal validity than the pragmatic approach would allow.

4. *Performance measure pitfalls*. What gets measured reflects system values. If clinical groups are measured on the ability to meet target-filing dates, then peak sales potential will be ignored. Relevant clinical indicators of performance may not be known, neither is it the best combination of data.

5. *Dearth of patient-centered outcomes measures in traditional drug development*. Physicians are usually relied upon for clinical data. Data from the patient are sometimes perceived to be ‘soft’. Patient perspectives may also be missed when the traditional clinical focus may be disease- or organ-dominated.

6. *Discrepancies in terminology*. A new lexicon is emerging. The lexicon must be carefully and precisely translated in its application to healthcare to avoid miscommunication. Marketing may ask for a CHA and not know the difference between a CHA and a CEA. They may not understand the approaches, but will only latch on to the buzzwords.

7. *When to measure*. A major challenge for clinical studies is when to measure. At what point in the process is the end point reached? The decision can significantly affect the cost and time of conducting a study. Unfortunately, there are no obvious guides, but there should be sufficient proximity between process and outcome measures to believe the linkage.

8. *Value*. To what extent is value related to quality? If there is no standard definition of quality, quality may be overridden by cost. It is difficult to quantify nonmonetary value into a neat formula. The challenge is to propose quality indicators that allow calculating a balance of quality and cost.

9. *Absence of clearly delineated perspective(s)*. Outcomes can be categorized in a variety of ways, including disease, patient, provider and organizational. There will likely be multiple perspectives, but it still needs to be orderly.

10. *Outcomes are not processes*. Patient care and quality dimensions of outcomes must be considered.

This applied discipline of pharmacoeconomics is slowly evolving. Despite its lack of maturity, many people and systems are embracing it as a savior. Although pharmacoeconomics is an important...
addition to decision making, it does need to be put in appropriate context. It is a new and essential part of older and previously less sophisticated processes of drug development and product selection. Used appropriately, pharmacoeconomic research can assist in rational decision making at every level of drug development and drug therapy.

References


Medical Outcomes Trust. 2001. www.outcomes-trust.org 617 426 4046 MOTRUST@worldnet.att.net.


Further reading


The specialty practice of preventive medicine extends into the realm of pharmaceutical medicine just as deeply as better-recognized disciplines such as clinical pharmacology or toxicology. Pharmaceutical physicians may often be found practicing preventive medicine under the guise of clinical research or regulatory affairs, or in separate departments of pharmacoepidemiology, health economics or outcomes research, as well as the perhaps more predictable aegis of drug safety and pharmacovigilance.

Preventive Medicine/Public Health physicians, alias pharmaco economists and pharmacoepidemiologists, are trained in the core sciences of public health – epidemiology and statistics along with their nonphysician pharmacoepidemiology colleagues. But, being physicians, they are also steeped in pathophysiology, diagnostics, therapeutics and behavioral sciences. Additionally, specialization in preventive medicine requires detailed education in environmental health and general management and behavioral science skills. Many of these areas of expertise are shared with other types of pharmaceutical physicians, for example clinical trialists. It is not uncommon to find professionals moving (or oscillating) between pharmacoepidemiology and other departments within the same company or regulatory agency.

Public health physicians use all these tools to identify, and control, public health hazards. In the pharmaceutical sector, these skills extend to such hazards associated with pharmacotherapy. Pharmacoepidemiologists have an additional dimension to their work, in that they may study drugs not only as a potential hazard to the public health (perhaps through drug surveillance programs) but also as a potential benefit to the public health (e.g. in large-scale interventional, clinical outcomes or economics studies). Identifying the types of patients who are most likely to benefit (or be harmed) by a therapeutic intervention is merely an extension of the orthodox world in which the public health physician practices. Thus, preventive medicine physicians may be found in pharmaceutical companies, CROs, academic, governmental and international political environments.

24.1 Epidemiology

The word has three components, from the Greek epi, upon; demos, the people; and logos, the study. These elements describe the fundamentals of what epidemiology is all about, the application of scientific principles to the understanding of health issues which are ‘upon the people’. All pharmaceutical
physicians need an understanding of the fundamentals of this field, in order to understand and harness the value that epidemiology, and epidemiologists, can bring to drug development and product surveillance programs. Epidemiology is taught in all schools of public health and, in varying depth and quality, in schools of medicine. Epidemiological techniques are used by many people who would not describe themselves as epidemiologists. Board certification in preventive medicine requires a Master’s degree with a large epidemiology component, and further tough examinations.

Such epidemiology training emphasizes observational research methodology as the core approach of the field. However, emphasis is also given on building expertise in clinical trials design and biostatistics. These disciplines require expertise and experience in the management of huge quantities of data and the attendant expertise in scientific computing/informatics. These are skills that find natural places in phase III and phase IV clinical study design and conduct within industry, and evaluation within the regulatory environment. However, it is in the understanding of the applications (and often more importantly the limitations) of the nonexperimental/observational method that the epidemiologist brings special value addition to the pharmaceutical sector.

It is important to remember that epidemiology represents another set of tactics to address the same underlying motive as others working in and with the development enterprise. Just as much as a molecular biologist or clinical pharmacologist, the epidemiologist is trying to find out which set of conditions causes a particular disease or benefit or adverse event (AE). The additional perspective of the impact on actual populations (the actual effectiveness) complements the emphasis on the experimental subject (the efficacy) of much of clinical research. The epidemiologist is faced with the substantial challenge of observational approaches. Without the benefits (comforts) of randomization and blinding afforded by the experimental method, only rarely can the epidemiologist imitate the pharmacologist, who can premeditate an intervention in a confined population, and then prospectively observe its effect. However, even when constrained by the observational approach, the epidemiologist is like other scientists in that findings are in the context of comparison among various structured observational groups, differing in their known exposures or outcomes (Strom, 2005; Hartzema, 2006).

24.2 Epidemiological methodologies

Prospective cohort studies

A prospective cohort epidemiological study approximates to a parallel-group clinical trial in its scientific basis, and epidemiologists will be as aware as clinical trialists of the bias that can be introduced if the study groups do not contain comparable, well-balanced and homogeneous groups of people. Although the experimentalist uses exclusions, randomization and blinding as tools to control for unseen biases, the epidemiologist is, rather, required to measure and document attributes and control for those that may lead to skewed results, by selection in ascertainment and stratification in analysis. Furthermore, like others calling themselves drug surveillance specialists, the epidemiologist will be well aware that the size of the groups that must be studied increases with the rarity of the phenomenon that is sought. The latency of the effect (e.g. the duration between exposure to an unsuspected atheromatous stimulus and coronary artery disease) can define the desirable duration of follow-up, in a manner analogous to the study of the probability of AEs arising only after prolonged multiple-dose drug exposure. Often, rather, the size of the available population and the duration for which it has already been followed (e.g. for other, administrative or clinical purposes) will dictate the extent to which an observational study is able to state the level of certainty of its observations.

1For a more extensive discussion of the field of pharmacoepidemiology, the reader is referred to the two most widely cited textbooks in the field.
Case–control study designs

These were developed to provide information more rapidly than when cohorts are followed for prolonged periods of time, using traditional hands-on methods; case-based research is, however, necessarily retrospective. Analysis begins with the characterization of a group of people that already have the disease of interest, the ‘cases’. Control subjects are then drawn from a population with exactly the same attributes as that from which cases are selected (often a very difficult task!). The antecedent demographic, therapeutic and environmental factors of both groups are documented, often by a combination of record abstraction and interview. If differences are found in the proportion (rate) for some factor between the two groups, then this becomes suspected as an etiological agent for the disease of interest. This suspicion is strengthened when either the discovered factor corresponds with a predictive hypothesis at the start of the study, or when there is consistent evidence that would support its identification (perhaps a biochemical link between the factor and the disease).

24.3 Drug risk as an epidemiological problem

Drug-related epidemics have occurred, mercifully relatively infrequently. However, with each unfortunate episode, there is inevitably a variety of regulatory and clinical fallout. Indeed, the illnesses associated with ingestion of glycol-tainted linctus led to the Food, Drugs and Cosmetics Act in the United States, and the disastrous association of phocomelia with thalidomide propelled reforms of drug regulations worldwide. Other famous examples include, of course, practolol-induced ocularnucocutaneous syndrome, and, more recently, fenfluramine-induced myocardial fibrosis, isotretinoïn-associated birth defects and unexpected heart complications with long-term use of Cox-2 inhibitors.

The major driver for the field of pharmacoepidemiology is the nature of the drug development process itself. Relatively small and often quite carefully selected clinical trials populations are followed for only limited periods, during and after exposure to the agent under study, in the populations that comprise typical product license applications and NDA safety summaries. This leaves, for the post-approval scientific environment, the challenge to apply methods that can detect AEs with relatively low frequency or relatively specific risk situations. Those who call for transfer of these burdens to the pre-approval environment would benefit from training in epidemiology, with the associated understanding that the only way to understand the real world is to study the real world!

Pharmacoepidemiology and pharmacovigilance do not pretend to be able to eliminate the occurrence of drug-associated epidemics. The challenge is to detect and quantitate problems as rapidly and accurately as possible, so that changes in the benefit–risk balance, as understood at the time of approval, can be quickly recognized and possible public health actions considered. Thus, pharmacovigilance may be understood as ‘epidemiologic intelligence’. And thus, in turn, the physician pharmacoepidemiologist is a strong contributor to drug surveillance departments in industry and drug safety groups in regulatory groups. Typically, these epidemiologists will be supervising and/or providing expert counsel to groups of less specialized or highly trained health scientists who implement the day-to-day running of these programs. Teamwork becomes an indispensable skill.

Consideration about the need for and technical considerations regarding one or more structured observational studies is a frequently recognized contribution of the epidemiologist in this enterprise. Less frequently extolled are the great contributions which epidemiologists make to consideration of approaches which, seductive because of their apparent simplicity, will not be likely to contribute, as options for reducing uncertainty around estimates of possible risk are considered. Observational science is very complicated, and the opportunities of failure of study are considerable! When epidemiological studies are undertaken, and results are known, it falls to the physician epidemiologist to put on the public health hat and recommend whether an intervention in the interests of public health might be needed,
and if so, then to suggest what its parameters might be.

24.4 The ‘wired’ epidemiologist

It probably goes without saying in the cybernetic environment of the twenty-first century that effective epidemiology of all types, including pharmacoepidemiology, can only be seriously conducted with the addition to the armamentarium of the epidemiologist, of the skillful use of large, automated, multipurpose, population-based systems (the LAMPS) – known by shorthand as ‘the databases’. Often these databases have been developed wholly outside the research context, with a primary intent of creating economic efficiency, quality assurance or management controls within organized systems of healthcare. Hence, in the United States, the organizations that construct these databases include insurance companies, hospitals, health maintenance organizations and other companies in the healthcare business. In Canada, and increasingly in Europe, such databases are emerging from provincial/regional or national reimbursement programs. If the database is equipped with patient identifiers (e.g. a unique membership number), then hospitalizations, prescriptions and combinations of healthcare transactions can be linked to a single individual across components of the system and over time: a so-called ‘record-linkage’ system. More recently, the evolution of a powerful clinical management tool, the electronic medical record, further powers the availability of linked data for entire populations under care. Such databases render it feasible to assemble cohorts of drug-exposed individuals and computer-matched comparator populations from historical (extant) data and observe them (using cohort analyses) forward over the time in the database (often decades) for evidence of excesses of events under study. Similarly, case-control methods may assemble cases and comparators, and use the powerful databases as the source of the antecedent information, so elusive in hands-on methods.

Recent regulatory efforts on behalf of the needs to protect patient privacy have established a long and successful record of systems that protect patient privacy while assuring access to necessary population-level, individual-linked data. The recent, excellent policy positions on data privacy protections of the American College of Epidemiology (ACE) and the International Society for Pharmacoepidemiology (ISPE) stand as evidence of this competence. The reader is referred to the websites of these organizations.

It is to be emphasized that such database work is often complicated, and requires a team of professionals comprising physician and nonphysician pharmacoepidemiologists, statisticians and specialists in information technology. Perhaps one of the greatest contributions that a clinician can make to such a team is to provide relevance to the hypotheses that are tested and as a reality check on the results that the computers generate, and which those less close to the field tend to regard automatically as ‘fact’.

Despite the deserved enthusiasm for the contribution of the LAMPS to epidemiology, more traditional hands-on, structured observational studies, with enrollment of cohorts of persons exposed to an agent under study and proper comparator populations, and selection of cases (e.g. from medical records) and appropriate controls, still have specific applications in pharmaceutical medicine, thus characterizing part of the activity of pharmacoepidemiologists.

24.5 Definitions

The pharmaceutical physician, epidemiologist or not, must understand the concepts of prevalence and incidence sine qua non. Prevalence is the frequency of disease in a defined population, at any one moment. Incidence is the frequency of new cases of a disease in a defined population during a defined time interval.

Thus, influenza may have an incidence of 15% for the months December–April 1999 in the United Kingdom, whereas the prevalence of influenza in the United Kingdom probably ranges between 0 and 10% on any given day. Perinatal (and maternal) mortality rates are usually stated annually and for specified country or region.
These are thus measures of incidence. The proportion of a population that will experience at least one seizure or one migraine attack in their lives is a measure of incidence and would likely be expressed as a number per thousand (or per hundred thousand) person-years, whereas the proportion of a population suffering from epilepsy or migraine during the year 2000 is an expression of prevalence.

In pharmacovigilance terms, the ‘true frequency’ in a treated population in a specified period, if it was known, of an AE observed in a marketed product, would be considered an incidence. All too often, the frequency of reported AEs (definitely not the complete or even estimated numerator), perhaps weighed against known sales (scarcely a true denominator), is mistakenly used to calculate a rate and called an ‘incidence’. At best, such spontaneous reports data should be termed ‘reports rates’.

Other, more complex terms are defined and described in standard textbooks of epidemiology and statistics (q.v.) and included in two excellent lexicons, the Dictionary of Epidemiology (Last, 2001) and, more recently, a very useful Lexicon from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

24.6 Epidemiology in drug development

The complexities of drug development include a decision web that is inevitably informed by incomplete information. Although past, focused research may comprise some of the information for the next step, epidemiological information can be of valuable assistance. The capturing and extension of population-based studies, often concerning the natural history of disease rather than the pharmacological properties of the test agent itself, can guide the choice of indication, market strategy and even the viability of an entire project. Furthermore, the place of existing therapies, in the context of the natural history of disease, can also be investigated epidemiologically. ‘If they don’t need it, we can’t sell it; then let’s not pursue it’ is an aphorism: but whether they need it is, of course, an epidemiological challenge.

Population-based measures of burden of disease involve a formal quantitation of the opportunity for a new drug. These measures vary among organ systems, but typically involve the interaction of lifestyle interference, duration of disease, prevalence, incidence, effectiveness and adverse effects associated with existing therapies, and reduction in lifespan. Such objective measures can be ascertained from population-based studies and existing national databases, for example from major ongoing population health surveys, and can often allow the pharmacoepidemiologist to contribute a substantial and useful evidence base to inform the difficult and emotion-laden decisions which must be made by senior executives in drug development.

During phases II and III, an additional capability can be offered to the development team that might hitherto be comprised purely of clinical department staff – Are infrequently observed but highly dangerous AEs being seen in a clinical trials program within the expected range for that study population? If so, then entire development programs in jeopardy could be saved; if not, appropriate actions may be undertaken more rapidly and decisively.

Under some circumstances, in the United States, widespread distribution of an investigational agent prior to NDA approval, involving large-scale populations, is permitted. Under these conditions it is, of course, necessary to monitor safety in such broader use, and usually with greater scrutiny that might ordinary apply after product approval. Thus, the best practice is to structure such programs as observational studies. AEs are bound to occur; thus providing an ideal opportunity for early detection of infrequent but important adverse reactions; conversely, trouble-shooting these, in the context of a sound epidemiological and clinical understanding of AEs associated with the disease itself, and with alternative therapies, is also often needed to protect against false conclusions. Such interpretations also eventually are translated into labeling, either by exclusion or inclusion.


### 24.7 Epidemiology in drug registration and licensing

During the registration process, there is typically repeated interaction between an NDA/PLA sponsor and the regulatory authority. Often these interactions revolve around whether the tolerability of the new drug is sufficiently well characterized, and the criteria for the inclusion and exclusion of particular observed intolerabilities in labeling, as well as the weight that should be applied to each (e.g. AE list, warning, contraindication or, rarely, precluding drug approval). Often the question ‘What level of risk is acceptable?’ becomes quickly answered with ‘Acceptable, compared to what?’ These considerations are clearly based on an insight into public health decision making and are often well served by inclusion of epidemiologists working with and/or consulting with regulators and sponsors.

Furthermore, the scientific proof of a negative is virtually impossible when fewer than an infinite number of patients have been studied. The more elusive problem, then, is to define acceptable uncertainty. Some of these decisions are based on precedent rather than observation. Pharmacoepidemiology is often a useful source of precedents, as well as available for further, future study in the post-approval period to clarify residual questions and/or reduce the remaining uncertainty.

### 24.8 The emerging world of risk management

Although many of the activities described can then be orientated towards support of registration with fair and balanced labeling or education that is useful to the prescriber, recently regulators have requested and sponsors have proposed programs of ‘risk management’ under circumstances in which an unacceptably serious risk has been identified or can reasonably be anticipated and risk factors or situations can be specified which, if addressed, can reduce that risk to a level which, balanced against anticipated benefits, could be accepted for clinical use. To manage such situations, sponsors are asked to develop, test and field interventions with the provider, distributor or consumer to accompany the marketplace activities with a drug with a residual safety concern. Recently, FDA has issued official guidance regarding action programs to minimize such risks (RiskMaps) (US FDA, 2005) and the European drug regulatory authority, EMEA has followed suit (EMEA, 2005). Expectations regarding these programs likewise include documentation of the effectiveness of the intervention, once again a challenge for the public health researcher, that is, the pharmacoepidemiologist.

#### Post-marketing surveillance studies

Approval (especially in the United States) to introduce a drug into the market is now often contingent on the agreement of the sponsor to conduct one or more post-marketing surveillance studies. Typically conducted on a scale of 5000 or more patients, the design of such studies poses classic epidemiological challenges: the choice of control cohorts (if any), appropriateness of historical controls, power calculations, the nature and range of confounding variables among others. Many of these may be addressed using the databases described above. It should be noted that post-marketing surveillance studies are often implemented by companies without any imposed regulatory requirement, simply due to the value that they bring in understanding a new product that may formerly only have been tested in several hundred patients. The strategic or forward thinking company will initiate such studies well in advance of the appearance of a signal of a potential problem, recognizing that large-scale and long-term studies need to be in place before a problem emerges if they are to be of use in clarifying the extent and nature of that problem in time to be of use, particularly in a closely regulated and often adversary environment.

#### General pharmacovigilance

Whether or not a post-marketing surveillance study is used, all drugs undergo pharmacovigilance when in the marketplace. This can be especially
challenging but vital during the early period after launch. The assessment of pharmacovigilance findings, particularly the initial few reports of AEs with low incidence, has obligatorily to include an epidemiological component. The epidemiological interpretation of a finding of excess prevalence requires the sophisticated epidemiological understanding of baseline, or population-expected risks and application of this understanding to the vagaries of uncertain ascertainment which characterize spontaneous reports. The usual disposition of a ‘signal of a potential problem’ from pharmacovigilance is introduction into the product’s core safety information (‘product label’). However, further, recent product withdrawals provide a litany of more extreme example that need not be repeated here, but average one or two major products and several minor ones each year. Product withdrawals are often misunderstood, particularly by the lay press hungry for a scandal. It is neither feasible nor desirable to ‘know everything about a product’ at the time of approval. But judicious product withdrawal, based on substantial evidence properly collected and analyzed in the post-marketing environment, is a classic example of a robust and balanced system, with each component functioning as it should. Pharmacoepidemiology contributes to the pursuit of the best-informed decision making, with the shared goal of optimization of the balance between patient benefit and the inevitable patient adversity.

**Prescription-event monitoring (PEM)**

This is essentially an extension of traditional, hands-on epidemiology, which assembles all patients that are prescribed a drug into a cohort which is then followed. In the United Kingdom, for example, through the Drug Safety Research Trust, all or a sample of this cohort is assembled from the records of the prescription pricing authority, generally within the first year or two of initial marketing of the product. Each patient can be followed up with a confidential enquiry for serious AEs using a form that, in the United Kingdom, is popularly called by its appearance: the ‘Green card’ (this term has an entirely different meaning in the United States, and, curiously, describes a pink document!). It is a classic example of an observational as opposed to an experimental method, in which all uses and all outcomes (events) are observed, generally without a simultaneously collected comparison population. Thus, data stemming from these sorts of activities are fraught with analytical and methodological traps. However, PEM is a good method for generating hypotheses for further testing, usually after reconciliation with the known pharmacology of the drug of interest, other drugs in the same class, and the natural history of the disease and kindred disorders. These, of course, shed further light on these data, and may be gathered, for example, from the spontaneous reports system. Indeed, sometimes this is also the first evidence of an unsuspected drug intolerability, perhaps in a previously unsuspected subset of the treated patient population. The ability in certain European areas and New Zealand to aggregate prescriptions from entire countries or regions, often as part of the reimbursement system, is obviously strategic to this approach.

**Pregnancy registries**

Pregnancy registries (or, more properly, pregnancy follow-up studies) are being recommended with increasing frequency for products that are likely to be used in women with child-bearing potential. Inevitably, all new drugs have not been studied in women who are, or become, pregnant, and equally inevitably, labeled warnings to that effect do not prevent exposures of embryos and fetuses to new drugs. The anticipated, spontaneous incidence of anomalies detectable post partum is in the range 3–7%. This wide range is cited because of the wide variations in criteria such as severity (e.g. is a minor birthmark a ‘birth anomaly’?), degree of scrutiny (follow-up until the age of four years or beyond is needed to detect some anomalies; some types of inguinal hernia presenting in adulthood are even thought to be congenital), geography, concomitant disease or toxin exposures (including tobacco, illicit drugs and alcohol), and socioeconomic status. The key to a successful pregnancy registry is that pregnancies should be
registered before their outcome is known: the diagnosed birth anomaly can cause bias in reporting frequency, and converts a prospective approach into a retrospective one. The choice of comparison population is highly complex. In general, the assumption of such registry studies is that the appropriate comparison is the general population, effectively a prospective cohort-controlled approach. Thus, the objective of such studies is to detect increases of specific defects over the expected rates in the general population. However, the detected occurrence of defects is a function of follow-up method and definition, and may be influenced by many (undocumented or even unknown) factors. Therefore, the conduct of registries and development of such comparisons must be done with great caution. Guidance on these matters has recently been proferred by the US FDA (2002).

24.9 Balancing benefits against risks

Critical to understanding the evolving picture of risk with a marketed product is to recognize that such risks emerge with progressively greater experience in increasingly broad and diverse populations over time. These experiences which include patients who differ in age, underlying disease state and stage or even indication from those who were studied in the development process. These uses will have varying impacts and may materially change the benefits profile from that in the approved product information. Often these issues become particularly important when a newly identified risk may appear to change the balance of benefits against risks to an unacceptable extent precipitating consideration of possible regulatory withdrawal.

Thus, a program of ongoing research may well be needed which calls upon the skills of the pharmacoepidemiologist, observational studies of drug utilization patterns, often tied to medical outcomes.

The professional epidemiologist is the first to caution against cavalier approaches to such effectiveness research. Without the protections of randomization and blinding, many of the biases which have plagued clinical research since its inception can creep in to such studies and render them uninterpretable, or, perhaps worse, lead to wrong interpretations. Thus, the research team contemplating the use of observational follow-up studies to understand effectiveness, particularly as part of a revised benefit to risk assessment, needs a pharmacoepidemiologist on board.

24.10 Training to be a pharmacoepidemiologist

No parent has ever heard the statement: ‘Mummy (or Daddy), I want to be a pharmaceutical physician pharmacoepidemiologist when I grow up’! Few physicians and very few pharmaceutical physicians choose this route. But what is along that route? The ‘high road’, in the United States at least, is graduation from medical school, obtaining at least one year of intense clinical postgraduate training (often leading to internal medicine or other primary care boards, the equivalent of MRCP in the United Kingdom), and then to undertake a further formal residency training program that leads to certification by the American Board of Preventive Medicine. Residencies are inspected and approved by the Board, and may be in one of four areas: public health, general preventive medicine, occupational medicine or aerospace medicine. Various concentrations in medical management are also becoming recognized. In the United Kingdom, registrar positions in most of these specialties are advertised, and the Diplomas in Occupational or Public Health, membership of the Faculties of Occupational or Public Health and the Diploma in Aviation Medicine would provide equivalent experience and certification.

In the United States, the academic equivalent of these, which can often be pursued in parallel, is to obtain the additional degree of Master of Public Health (MPH). Board certification through a preventive medicine residency requires such formal academic training and an MPH
degree as well as at least one year of structured training or ‘practicum’. Again, European equivalents exist. A four to five-year program following graduation in medicine can accomplish all of these. Additionally, those interested in pharmaceutical matters which involve epidemiology, but who do not aspire to board certification, can often attend specialized courses, and use case studies in this area to fulfill their academic requirements, or, of course, at least enroll in a MPH degree program. Many of these now exist as ‘off-campus’ (so-called executive) degree programs, particularly for physicians.

Complicating the training challenge for the physician pharmacoepidemiologist has been the relative paucity of academic centers of excellence specializing in this field. Thus, as part of the FDA Modernization Act of 1997 in the United States, the Congress created, and the agencies working together have jointly developed, a network of Centers for Education and Research on Therapeutics, with particular emphasis on outcomes research and the capacity in pharmacoepidemiology. For further details, the reader should consult the CERTs website. The International Society for Pharmacoepidemiology maintains a registry of academic centers currently training and conducting research in Pharmacoepidemiology (website: pharmacoepidemiology.org).

More commonly, if not the ‘high road’, a pharmaceutical physician will stumble into this area by lateral transfer within a company, or due to the chance happening of being assigned a development project that requires extensive pharmacoepidemiological support. Such physicians can supplement their training with ad hoc programs in statistics and epidemiology that are commonly offered on a short-term or part-time nondegree basis by many universities and training groups, or an executive MPH.

All physicians seeking to be ‘credentialed’ in Pharmaceutical Medicine will have, as part of the required core competencies for the field, extensive and substantial orientation to the broad field and approaches of pharmacoepidemiology, so that they may be effective demanders and intelligent users of the fruits of pharmacoepidemiology and partners with their physician pharmacoepidemiologist colleagues.

### 24.11 The future

Pharmacoepidemiology has proved itself over the last 25 years, and will only grow during this new century. It is unlikely that society as a whole will understand the subtle but vital nuances of the concepts of risk and uncertainty any better in 25 years time than it does now. Governments and the general public will require the pharmacoepidemiologist to protect their interests, and to accurately assess the hazards that today’s powerful drugs will also bring. And tomorrow’s drugs, driven by the genomics revolution, will only further underscore the need for epidemiology, to help us map the genome to the ‘phenome’, that is, the population manifestations of our genomic make-up. Although it is by no means clear where our earliest experiences with genetic alteration will lead, it is clear that any efforts in this arena will require long-term population-based follow-up. Cost containment will become increasingly a constraint on pharmaceutical medicine, and we must ensure that it does not bring its own hazard. And risk management, with its accompanying accountability, is emerging as a classic epidemiological challenge. The future for the pharmacoepidemiologist trained in both epidemiology and medicine is bright indeed. The lucky men and women who choose pharmacoepidemiology will be highly fulfilled in this subspecialty of pharmaceutical medicine.

## References


25.1 The scientific method and the role of the scientific experiment

The purpose of science is to explain natural phenomena by uncovering the natural laws that give rise to them.

The scientific method is a three-step process: (a) formulating theories as explanations of phenomena, (b) making predictions based on these theories and (c) testing the theories through experimentation.

Most people engage daily in the first two activities. Explaining the environment in which we live is an innate human urge. However, people rarely subject their theories to testing by experimentation.

What makes the scientific method unique is that it does not accept an explanation as valid until it has been validated through testing. However, a scientific experiment can never prove a theory. At best, it can provide evidence for the usefulness of the theory in predicting the consequences of given experimental conditions and help to define more precisely the relationship between these conditions and their consequences.

The greatest value of a scientific experiment is in its ability to disprove a theory or identify limits of its applicability, either of which is key to scientific advances. An experimental finding inconsistent with a theory suggests that a theory should be revised or rejected. Popper (1959) states that a necessary condition for a valid theory is the condition of falsifiability. That is, it must be capable to generate predictions that can be tested experimentally. Experimental outcomes contradicting the theoretical predictions necessitate a reassessment of the theory and lead to a revision or rejection. In other words, a scientific theory is always tentative and entirely dependent on experimental verification. Theories that are not falsifiable may be the subject of religious or philosophical discourse but not of scientific investigation, according to Popper.

Experiments designed to confirm a theory (or to falsify it) are called confirmatory, and those designed to merely accumulate information and generate hypotheses are termed exploratory. Exploratory experiments are a useful first step in the process of formulating scientific theories. Either type must follow strict methodological procedures and adhere to a detailed experimental protocol describing the conditions of experimentation, the methods of measurement and all other aspects that might affect the results. The experimenter must record the raw data prior to any analysis and document any protocol deviations, documenting all aspects of the experiment such that another scientist can precisely repeat it.

Principles and Practice of Pharmaceutical Medicine, 2nd Edition
Edited by L. D. Edwards, A. J. Fletcher, A. W. Fox and P. D. Stonier
25.2 The statistical method: making decisions under conditions of uncertainty

The scientific method runs into difficulties when applied to the study of random phenomena. A random phenomenon is one where the outcome cannot be predicted with certainty from the experimental conditions. One cannot guarantee the repeat of a coin toss, no matter how hard one tries to keep the conditions constant. Neither can one expect a drug to produce an identical effect in the same patient under identical conditions on separate occasions. Such phenomena can be described probabilistically. That is, one can assign numerical values describing the likelihood, or probability, of the possible outcomes. Because of the uncertainty, an isolated failure of a drug to produce an expected therapeutic effect does not prove that the drug is non-efficacious. Similarly, an isolated successful drug treatment outcome does not prove that the drug is efficacious.

Unfortunately, it is impossible to design an experiment that will totally disprove a theory based on random phenomena. Various outcomes may occur, some of which may be unlikely but not impossible. Thus Popper’s falsifiability condition does not apply. The statistical method advocated by Fisher (1956) attempts to overcome this problem by substituting ‘unlikely’ for ‘impossible’ but otherwise follows the principles of the scientific method. With this substitution, Fisher and others proposed conceptual structures for testing theories and scientific hypotheses under conditions of uncertainty that are analogous to the scientific method. However, these approaches, although being very useful in practice, have raised a host of conceptual issues that are the subject of ongoing debates.

Let us illustrate the statistical method with an example.

A pharmaceutical company has developed an antihypertensive drug that is theorized to lower diastolic blood pressure when given to subjects with moderate to severe hypertension. If the diastolic blood pressure were constant under given conditions, then failure to lower diastolic pressure by any amount in any human subject treated with this drug under a constant set of conditions would disprove the theory. In reality, the subject’s blood pressure is a random phenomenon. It varies with or without treatment. Thus, administering the drug to one subject and measuring the resulting change in blood pressure cannot be used to prove or disprove the hypothesis that the drug has no efficacy. How can one tell whether the difference in blood pressure before and after treatment is due to the effect of the drug or due to the natural randomness of blood pressure? To answer this question, one must (a) have knowledge of degree of the natural variability of diastolic blood pressure and (b) determine whether the change in blood pressure is likely to result from natural variability. Measuring variability requires the study of more than one subject. Thus, a statistical experiment always consists of the study of groups of subjects rather than individual ones.

A typical experiment might look like this: Subjects are selected from a target population to participate in the study. They are assigned to one of two groups, A and B. Group A receives no treatment or a placebo. Group B receives the test drug. A quantitative variable that is hypothesized to be affected by the drug (e.g. diastolic blood pressure), the efficacy variable, is measured in all subjects before treatment and at some time point when the drug effect should be measurable if the drug is efficacious. Mean change in the efficacy variable is compared between the groups. If the difference appears random, the drug is probably ineffective. If the difference appears nonrandom, it is probably due to the effect of the drug. The starting point for the experimenter is the hypothesis that the drug is ineffective. Thus, smaller the probability that the observed difference is due to randomness, the more confidence the experimenter has that the hypothesis of no efficacy is incorrect.

The above example illustrates the basic steps in statistical research methodology. (a) A scientific question is posed (‘The drug effect is to reduce blood pressure’). (b) An experiment is designed that in the absence of randomness would yield distinctly different outcomes (‘Treat one group of subject with the supposedly active drug and another with inert substance, or placebo’) and a
The mean change in the pretreatment to posttreatment blood pressure'. (c) A statistical hypothesis is formulated, that is the scientific hypothesis is formulated in terms of the test variable ('The mean reduction in blood pressure in the group treated with the new drug is greater than that of the placebo-treated group'). (d) A decision criterion is formulated. That is, which outcomes of the experiment would lead to the rejection and which to the acceptance of the hypothesis. (e) The experiment is conducted, and the data are collected and the test variable observed in the experiment is calculated ('The mean change in pretreatment to posttreatment blood pressure is calculated for the two groups of subjects'). (f) A decision is made using the decision criterion.

The key difference between the statistical method and the scientific method is that statistically the result, no matter how unlikely, is not impossible. Therefore, any decision to confirm or reject a hypothesis is liable to error. Two types of error are possible, as summarized in Table 25.1.

25.3 The statistical test: the null hypothesis, error probabilities, statistical power

Seemingly, the decision whether a drug is efficacious or not, is a dichotomy. In reality, however, it is a continuum. If we consider the measurable effect \( E \) of our drug in lowering diastolic blood pressure, then lack of efficacy corresponds to \( E = 0 \). Positive efficacy corresponds to \( E > 0 \), which contains a continuum of possibilities depending on the magnitude of the effect. Thus, the hypothesis of no efficacy is very specific in terms of the size of the effect and is called a simple hypothesis, whereas a hypothesis corresponding to a range of values is called a composite hypothesis.

As we have seen, both the scientific method and the statistical method are designed to prove a claim false rather than true. In drug testing, the statistical experiment is designed to reject the null hypothesis – the hypothesis of lack of efficacy, or that there is no difference between the treatments being tested. Table 25.1 mentioned above is applied to the null hypothesis.

Type I error: Rejection of the null hypothesis when it is true (an ineffective drug is judged effective).

Type II error: Acceptance of the null hypothesis when it is false (an effective drug is judged ineffective).

Type I error is often also called ‘False Positive’ and type II error ‘False Negative’. Because rejection of the null hypothesis enables one to make the scientific claim that the study was performed to prove, statisticians label such a rejection as significant. When the result of a test is declared significant, the only error that could occur is type I error. Clearly, the smaller the probability of type I error, the more secure one is in rejecting the null hypothesis. The probability of a type I error is called the significance level of the test and is denoted by \( \alpha \). The probability of a type II error is denoted by \( \beta \); \( 1 - \beta \) is called the power of the test, often expressed as percent. Thus, the power of the test is the probability of rejecting the null hypothesis when it is false. When the null hypothesis is that the drug is not efficacious, the power is the probability that the test would declare the drug as efficacious when indeed it is so. The null hypothesis is usually a simple hypothesis. Therefore, \( \alpha \) is usually a single number. The alternative to the null hypothesis, however, is typically a composite hypothesis. In our antihypertensive drug testing example, this alternative was the whole region \( E > 0 \). In this case, the value of \( \beta \) and the power \( 1 - \beta \) depend on the specific value of \( E \). Thus, it is meaningless to talk about the power of a statistical test without specifying the alternative for which it applies. In our example, the power of the test at \( E = 10 \) is the
probability that the statistical test would be significant if the effect of the drug is to reduce the diastolic blood pressure by 10 mmHg on average.

It is desirable that a statistical test should have as small \( \alpha \) and \( \beta \) (i.e. low type I error and high power) as possible with regard to alternatives of interest. The perfect test would have \( \alpha = \beta = 0 \). However, as we will see, this is not possible in practice due to the fact that all experimental measurements involve errors. If, in our example, the clinician estimates that the drug should lower diastolic blood pressure by an average of about 10 mmHg, the statistician would want \( \alpha \) to be small, say \( \leq 0.05 \), and \( 1 - \beta \) to be large, say \( \geq 0.95 \), for the alternative \( E = 10 \). Can the statistician design a study such that the test would have any desirable \( \alpha \) and \( \beta \)? Generally, yes, by selecting an appropriate sample size; that is, by including a sufficient number of subjects in the study. Once the sample size is fixed, the relationship between \( \alpha \) and \( \beta \) is determined. A reduction in \( \alpha \) must be compensated by an increase in \( \beta \), and vice versa. For a given study design, the only way to decrease \( \alpha \) and \( \beta \) simultaneously is by increasing the sample size. We will discuss this topic in greater detail in Section 25.10.

25.4 Causality

The ultimate goal of clinical research is to establish causality – to determine efficacy outcomes that are due to the drug and to measure their magnitude and to identify adverse effects caused by the drug.

How does one know whether an effect A (e.g. giving a particular drug at a particular dose) causes an event B (e.g. diastolic blood pressure is reduced)? Two conditions must be satisfied. First, A must precede B. Second, whenever A occurs, B must occur too. These, of course, are not sufficient, as both A and B could be caused by an effect C. In addition, therefore, a theory is required that links A to B. This requirement is the Achilles Heel of ‘causality’, as all theories are necessarily tentative. In an experimental science such as pharmaceutical research, the second condition can be established by conducting an experiment both when effect A is absent and when effect A is present, whereas all other conditions remain unchanged. If B requires the presence of A, then one can conclude that A causes B. However, if B is present regardless of A, then no causality is proven.

In studying drug effects in humans, the controlled clinical trial is the preferred method to establish causality. In its simplest form, a controlled clinical trial is an experiment in human subjects in which some subjects are treated with an investigational drug and some are not, whereas all other conditions remain the same for the two treatment groups. In this way, differences in clinical outcomes can be attributed to the investigational drug [Controlled Clinical Trials (CCT) will be discussed in greater detail in Section 25.6 below].

25.5 Variability – the source of uncertainty

Virtually no drug has an identical response in all patients. For example, an effective antibiotic will almost certainly be ineffective in some patients, possibly because such patients are infected with a resistant strain or have a deficient immune response. Variability in response introduces uncertainty in establishing cause and effect. The fact that administering a drug to a given subject has not resulted with the desired therapeutic effect does not necessarily imply that the drug is ineffective. Causality in the strict sense discussed in the previous section can no longer be established when outcome of an experiment is subject to variability. However, one can still talk about causality in a probabilistic sense by modifying the requirement that ‘whenever A is present B must be present too’ necessary for the establishment of causality, to ‘the probability that B will occur is greater in the presence of A than when A is not present’.

Another issue is that when the measurement of efficacy is variable, it is impossible to determine what part of the measured outcome is due to the effect of the drug and what part is due to variability unrelated to the drug effect. The size of a drug effect is called the ‘signal’, whereas the variability associated with it is referred to as the ‘noise’.
Clearly, the larger the ‘signal-to-noise ratio’, the easier it is to establish a causal relationship. Thus, in a clinical drug trial, it is equally important to measure both noise and signal. How are these measured? The nature of variability is that the effect of interest is random. When we measure the blood pressure of an individual subject repeatedly, the measurements will be dispersed around some central value in a random fashion; some will be larger and some smaller. The effect, however, is systematic. If, for example, we measure the blood pressure of an individual repeatedly before and just after administering an antihypertensive drug, the pretreatment and posttreatment measurements will be dispersed around different central values, the posttreatment value lower than the pretreatment value. The magnitude of the effect (signal) is usually calculated as the mean of the individual effects in a population of subjects. The variability (noise) is usually calculated as the standard deviation.

Example: Suppose 10 hypertensive subjects are treated with a novel antihypertensive drug. The subjects’ blood pressure is measured at 8:00 a.m., just prior to the administration of the drug, and then again 1 h later. Data are as shown in Table 25.2.

The first and the second rows of the table give the diastolic blood pressure of subjects before and after treatment, respectively. The third row gives the change \((D)\) in diastolic pressure (value in row 1 minus the value in row 2). The mean, given in the last column, is 12.8 mmHg. On the face of it, 12.8 looks like an impressive effect. However, as we have discussed earlier, we cannot assess its significance without considering the inherent variability, the noise. Indeed, the values of \(D\) range from \(-4\) to \(33\), a substantial range. To assess \(D\)’s variability, we calculated the deviations of the values of \(D\) about their mean 12.8. These values are given in the next row. Naturally, as the mean is a value somewhere in the middle, some deviations are positive and others are negative. One property of the mean is that the sum of these deviations is always zero. Thus, the average (mean) of the deviations around the mean is always zero, and therefore is not useful as a measure of the variability. Instead, we calculate the mean of the squares of the deviations about the mean as a measure of variability. This measure is called the variance. The variance is an average of nonnegative numbers and it is, therefore, always a nonnegative number. It is equal to 0 if and only if all the deviates are equal to zero, meaning that all the measurements are the same and thus equal to their mean, that is, there is no variability at all. The standard deviation (S.D.), the most commonly used measure of variability, is the square root of the variance. In our case S.D. = \(\sqrt{110.16} = 10.50\). The advantage of using the standard deviation over the variance is that it is measured with the same units as the mean. The mean does not represent the response to treatment of any particular individual. It does, though, give us an idea of the magnitude of the response to treatment produced by the drug. Can we conclude, then, that the drug is efficacious? If the drug is ineffective, then there should be no systematic change in blood pressure measurements taken 1 h after treatment as compared to pretreatment measurements and thus the mean change should equal approximately to zero. The observed mean change of 12.8 mmHg is then due entirely to chance. Statistical theory shows that the likelihood that a sample of 10 numbers drawn at random from a set of numbers with mean zero (in our example,
the set of all possible posttreatment minus pretreatment blood pressure measurements) with standard deviation of 10.5 would have a mean of 12.8 or larger is less than 0.15% (or 15 in 10000). Although this outcome is not impossible, it is highly unlikely. Thus, it is more prudent to conclude that the drug is efficacious and that the observed mean of 12.8 is due to a systematic effect caused by the drug rather than to chance.

The above example encapsulates many of the ideas and concepts behind the theory of statistical inference. The standard deviation quantifies how widely a measurement is expected to deviate from a theoretical typical value of the variable being measured. In our example, the variable being measured is the change between pretreatment and posttreatment in a patient’s diastolic blood pressure. So, if the drug is ineffective, any change is due entirely to chance and therefore one would expect the change to be zero. This expected typical value is theoretical. In reality, blood pressure is affected by a variety of factors independent of the treatment and therefore actual measurements will not necessarily be zero. The standard deviation enables us to calculate the probability that the measurements will fall close or far away from zero. For example, the probability is 95% that a measurement will fall within $\pm 2$ S.D. That is, assuming the drug is ineffective and the standard deviation is 10.5, 95% of patients treated with the drug should have a change in their pretreatment and posttreatment diastolic blood pressure between $-21$ and $+21$. This is a fairly large range and indeed all but two of the measurements in our example are within this range. This observation does not contradict our previous conclusion that the drug is effective. This is because our conclusion that the drug is effective was based on the mean of 10 measurements rather than on a single measurement. The mean change is also associated with experimental error. If we calculate the mean change for another set of 10 measurements obtained from different patients, it is unlikely that the result will be 12.8. However, the variability associated with a mean is smaller than that of a single measurement. The standard deviation associated with the mean is called the standard error of the mean (SEM) and is smaller than the S.D. by a factor equal to the square root of the number of measurements used to calculate the mean. In our example, \( SEM = \frac{10.5}{\sqrt{10}} = \frac{10.5}{3.16} = 3.22 \). Thus, in our experiment, the probability is 95% that the mean change will fall between $-6.64$ and $+6.64$. The mean of 12.8 is well outside that range. In fact, \( \frac{12.8}{SEM} = 3.85 \). The probability of observed sample mean to be as a distance of 3.85 SEMs or more from the actual population mean is approximately 0.15%.

To summarize, statistical methods are not intended to establish a cause and effect relationship between treatment and the response of any individual subject; rather, it is to establish a cause and effect relationship in the aggregate response (e.g. the mean) of a population of subjects. The key to this is the fact that by considering aggregates, one can control the variability of a measured quantity. By increasing the sample size, one can reduce the standard error of the mean to a level that would make it possible to determine whether a signal is likely or unlikely to be due to chance and thus decide whether a causal relationship is likely or unlikely to exist.

### 25.6 The Controlled Clinical Trial: basic design elements

#### Randomization

The CCT is the scientific tool for demonstrating causality. Two essential elements characterize the CCT: (a) it contains a control group and an experimental group, and (b) with the exception of treatment, all other conditions and procedures to which the subjects are exposed during the trial are constant. These two characteristics of the CCT enable the researcher to establish a causal relationship between treatment and the outcome of the trial. The tool for standardizing the trial is the study protocol, the document defining the subjects eligible for inclusion in the study, the study procedures and schedules.

A key element is the method of allocating subjects to the treatment groups. Subjects may possess a variety of characteristics that could influence
their response to treatment. These could be related to the subject demographic background, such as age, sex and ethnic origin, genetic disposition or other prognostic variables. The method of allocating subjects to treatment must make sure that the resulting treatment groups are balanced with respect to such factors. The most effective way to achieve this is by randomization. That is, assign each subject to a treatment group using a chance mechanism. Of course, one could achieve the desired balance by using a systematic, nonrandom allocation scheme that will force the balance. Randomization, however, has some important advantages. Any nonrandom method inevitably involves a decision by the individual making the allocation. This potentially could result with the preference of a certain type of subjects for one of the treatments that may not be reflected as an imbalance in any of the identified prognostic variables. Furthermore, there might be some other variables which affect the response to treatment and which are either unrecognized as such at the time the study is planned or are impossible to balance for logistical reasons. A random allocation, at least in large trials, can typically protect the investigator against such problems.

To achieve a completely random allocation, one could use a mechanism such as a simple toss of a balanced coin or anything equivalent to it and assign a subject to receive treatment A if the coin lands on Heads (‘H’), say, and treatment B if the outcome is Tails (‘T’). Although the result of a coin toss is a perfect random sequence of ‘H’s and ‘T’s, the number of ‘H’s in any finite sequence of coin tosses is rarely equal to the number of ‘T’s. Thus, the result of using a coin toss mechanism for treatment allocation would typically result in an imbalance among the treatment groups, an undesirable statistical design property. The most common method of randomization that will guarantee that approximately equal number of subjects is allocated to the different treatment groups is the randomized blocks method. Let us illustrate this for a trial with three treatment groups: A, B and C. Blocks containing the letters A, B and C in a random order, with each letter repeated the same number of times, are generated. Such a block of length 6 might look like (B, B, A, C, C, A). The requirement that each letter appears in the block as frequently as any of the other two letters implies that the length of the block must be a multiple of 3. Thus, for the case of three treatment groups, the block size must be 3, 6, 9 and so on. The number of such random blocks generated must be such that the number of letters in the resulting string equals or exceeds the number of subjects to be enrolled in the trial. Subjects are then assigned sequentially to the treatment group corresponding to the next unassigned letter in the randomization string. Because each individual block contains the same number of each of the letters, the treatment assignment sequence obtained from the randomized blocks method is not exactly a sequence of random numbers. However, the method has the advantage that it guarantees a maximum balance in the resulting sizes of the treatment groups. In fact, the number of subjects allocated to two treatment groups cannot differ by more than the number of times each treatment is repeated within the block.

**Bias and blinding**

Statisticians routinely use data obtained from a sample to estimate a parameter of interest. The estimate is subject to variability inherited from the data. Thus, using different and independent samples would result in different values of the estimate that are distributed around a mean value. Bias is the difference between that mean value and the quantity it intends to estimate. The bias, then, is a measure of the magnitude by which a statistical estimation method is overestimating or underestimating the parameter it is designed to estimate. We refer to this type of bias as statistical bias. Clinical researchers often use the term ‘bias’ in a broader, though less precise, fashion. They refer to bias as the effect of any factor, or combination of factors, resulting in inferences, which lead systematically to incorrect decisions about the treatment effect. Although this usage has the appeal that it corresponds to our intuitive understanding of the word ‘bias’, it cannot be quantified because of its imprecision. It is, nevertheless, useful in discussing problems that could result from a faulty design or inadequate conduct of a trial.
The most common source of bias is one resulting from subjects being selected to the different treatment groups in a way that creates an imbalance in one or more prognostic variables. This type of bias, known as selection bias, is usually the result of unconscious action on the part of the investigator or other people involved in the enrolment of subjects into the trial, or of a faulty treatment allocation method. Randomization is designed to take the treatment assignment decision away from the enrolling investigator and place it in the hands of chance. Unfortunately, it is not foolproof. An investigator who has a personal preference for one treatment over another for a particular type of subject may decide to postpone enrolling a subject until the ‘right’ treatment comes up on the randomization schedule. Also, there are many other ways, that are not affected by randomization, in which the investigator can influence the trial outcome. A simple talk with a subject reinforcing the subject’s confidence in the efficacy of treatment can often have a real or transient effect on the subject’s response to treatment.

Another potential source of bias is the subject himself/herself. Often, the mere expectation that the drug will have a therapeutic effect produces an effect. This effect is known as the placebo effect, and in some cases, it could be considerable.

To counteract these types of bias, CCTs are generally blinded. That is, the identity of the treatment is concealed from everybody who can influence the treatment assignments and any procedure that could impact the trial outcome. When the treatments are masked from both the investigator and the subject, the trial is called double blind. In drug trials, blinding is accomplished by using placebo, an inert substance, as a non-active control and identically looking packaging, for the different treatments with labels that do not reveal the identity of the drug.

The use of double-blind randomized clinical trials has become the gold standard for good clinical research. However, it is not always possible to mask the treatments. A trial designed to compare the effectiveness of two surgical procedures, for example, cannot be blinded. Another example is a trial comparing an intravenous drug to an oral drug. In principle, one could blind such a trial by delivering an inert substance (e.g. saline) intravenously to the oral drug group and an oral placebo to the intravenous group. However, this procedure might be controversial because subjects are exposed to additional risk, albeit small, without direct potential benefit to them. When the comparators have distinct characteristics that would identify them, blinding can be achieved by using the so-called ‘double-dummy’ method unless it is ethically unacceptable. The ‘double-dummy’ method means that all subjects receive identically looking treatments only one of which is active and the others are placebos. For example, in a comparison of two oral drugs, one of which is a tablet and the other a capsule, each subject receives a tablet and a capsule, one of which contains the treatment assigned to that subject and the other is placebo. Sometimes even the ‘double-dummy’ method is not helpful. The drug might have a characteristic profile, such as identifiable smell, taste, or a specific adverse event or other biological effect that would reveal the identity of the treatment either to the investigator or to the subject or both no matter how the drug is packaged or labeled. When blinding is not possible, special efforts must be made to minimize the possibility of introducing bias by incorporating appropriate bias prevention methods in the study design. Once bias is introduced, it is very difficult and sometimes impossible to adjust for it at the analysis stage.

**Stratification**

An efficient study design is one that maximizes the ‘signal-to-noise ratio’. Thus, controlling the ‘noise’, or variability, is an important aspect of a good design. Consider the following example.

A graduate student in Public Health is conducting a research project on the health-related habits of the students at her University. As part of the project, she measured the resting heartbeat of 20 student subjects. The results are listed in Table 25.3.

The mean and standard deviation are 56.8 and 3.57, respectively. The student further divided the subjects into two groups: Group A consists of subjects who do aerobic exercises regularly and
Group B of those who do not. The results are presented in Table 25.4.

We notice that the two groups of subjects have different means and different standard deviations. Both standard deviations are smaller than the one obtained before separating the subjects into subgroups. That is, the two groups are more homogeneous than the original group. When one combines the standard deviations into so-called pooled standard deviation, the result is $S.D_{\text{pooled}} = 2.47$ which is substantially lower than the standard deviation of the original combined group. The reason for this is that when we calculated the mean of the combined group, we ignored the fact that the group consisted of two subgroups with different means. Thus, the calculated mean was in fact, a mean of the two subgroups’ means. Indeed, the overall mean 56.8 equals the average of the means of the two subgroups, that is, $56.8 = (54.2 + 59.4)/2$. The standard deviation, therefore, represented the sum of two sources of variation: the intra-group variability represented by the two subgroups’ standard deviations, and the intergroup variability represented by the difference between the two subgroups’ means. In general, if one combines two groups of measurements with the same number of measurements in each group and if the standard deviations of the two groups and the combined group are denoted by $S_1$, $S_2$ and $S$, respectively, and if the means of the two groups are denoted by $M_1$ and $M_2$, respectively, then the following relationship holds:

$$S^2 = \frac{1}{2} (S_1^2 + S_2^2) + \frac{(M_1 - M_2)^2}{2}$$

The variance of the combined group is the sum of the two parts: The first is the average of the variances of the two individual groups, and the second is one half of the square of the difference between the means of the two groups. The first part represents the intra-group variation and the second the intergroup variation.

### Table 25.3 Heartbeat measurements of 20 students

<table>
<thead>
<tr>
<th>Student</th>
<th>Heartbeat</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
</tr>
<tr>
<td>3</td>
<td>56</td>
</tr>
<tr>
<td>4</td>
<td>56</td>
</tr>
<tr>
<td>5</td>
<td>56</td>
</tr>
<tr>
<td>6</td>
<td>57</td>
</tr>
<tr>
<td>7</td>
<td>56</td>
</tr>
<tr>
<td>8</td>
<td>52</td>
</tr>
<tr>
<td>9</td>
<td>63</td>
</tr>
<tr>
<td>10</td>
<td>51</td>
</tr>
<tr>
<td>11</td>
<td>59</td>
</tr>
<tr>
<td>12</td>
<td>63</td>
</tr>
<tr>
<td>13</td>
<td>55</td>
</tr>
<tr>
<td>14</td>
<td>58</td>
</tr>
<tr>
<td>15</td>
<td>56</td>
</tr>
<tr>
<td>16</td>
<td>53</td>
</tr>
<tr>
<td>17</td>
<td>64</td>
</tr>
<tr>
<td>18</td>
<td>56</td>
</tr>
<tr>
<td>19</td>
<td>58</td>
</tr>
<tr>
<td>20</td>
<td>55</td>
</tr>
<tr>
<td><strong>Mean</strong></td>
<td><strong>56.8</strong></td>
</tr>
<tr>
<td><strong>S.D.</strong></td>
<td><strong>3.57</strong></td>
</tr>
</tbody>
</table>

### Table 25.4 Heartbeat measurements of 20 students by exercise status

<table>
<thead>
<tr>
<th>Subject</th>
<th>Heartbeat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>53</td>
</tr>
<tr>
<td>Mean</td>
<td>54.2</td>
</tr>
<tr>
<td>S.D.</td>
<td>1.81</td>
</tr>
<tr>
<td>Group B</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>58</td>
</tr>
<tr>
<td>Mean</td>
<td>59.4</td>
</tr>
<tr>
<td>S.D.</td>
<td>2.99</td>
</tr>
</tbody>
</table>
The above example illustrates well the idea behind stratification. The study population is usually quite heterogeneous. If one measures the effect of treatment by calculating the overall mean effect in the population, although this mean represents an estimate of the treatment effect in this population, it might be associated with a large measurement error which could make it difficult to distinguish the signal from the background noise. In other words, the overall mean may be an estimate of the treatment effect, but an inefficient one. If one can identify a priori certain subgroups, or strata, in the study population which are more homogeneous with respect to the efficacy variable of interest in the trial, then by estimating the effect within each of these strata and combining these estimates one may increase substantially the power of the analysis because the noise masking the effect of interest is reduced. It is well known, for example, that in multicenter trials, the measured effect often differs between investigators. This could be a result of the physician’s procedures, his or her instruments, the method of evaluating the subject’s response or a myriad of other reasons, especially when the measurement has a great degree of subjectivity. Sometimes the difference is due to the characteristics of subject populations from which the different investigators draw their subjects. Whatever the reason, it is often common practice to stratify the subjects by investigators. It is also wise to identify important prognostic variables and design the trial so as to stratify according to them. Examples of some common stratification variables are sex, race, age, disease severity, Karnofsky status score in cancer studies, disease staging and so forth. When strata are identified, it is recommended that the randomization process will be done within the strata. This helps to equalize the number of subjects in the various treatment groups within each of the strata and balance them with respect to the stratification variables. The drawback is that as the number of important prognostic variables increases, the number of strata increases by multiples, thus complicating the trial’s logistics. For example, if one wants to stratify by sex and race when sex has two categories (male and female) and race has four (White, Black, Hispanic, other), the number of strata is 8. Adding another variable with three categories, such as disease severity at baseline (mild, moderate, severe), will bring the number of strata to 24. If, in addition, investigator is a stratification variable, then this would mean that each data center performing the randomization will have to manage 24 randomization tables for each investigator, one for each stratum, which is utterly impractical. For a study of moderate size of 100–500 subjects, a large number of strata may mean that some strata may contain very small number of subjects, which complicates the statistical analysis and its interpretation.

In summary, stratification is a very useful tool for noise reduction, but it has its limitations. Usually, the one stratification variable used in multicenter trial is the investigational site. More than one additional variable can introduce serious logistical and methodological difficulties. If one is not concerned about the investigator’s effect, then central randomization procedures can be very useful in situations of complex stratification requirements. Computerized central randomization procedures are now available that make complex stratification schemes possible.

**Blocking**

Another common method employed to decrease the background variability is blocking. Like stratification, blocking involves the subdivision of the subject population into homogeneous subgroups. The experimenter defines block of subjects and randomizes the subjects within each block to the study treatments such that the same number of subjects are assigned to each treatment within each block. The blocks are defined so that the intra-block variability is minimal. For example, to determine whether a drug is carcinogenic, rats of the same litter are randomized to receive several doses of the drug or placebo. This way, effects due to genetic variation are minimized.

To take advantage of the block design, the treatments are compared within each block and then the information is pooled across blocks. When the ‘within-block’ or ‘intra-block’ variability is substantially smaller than the ‘between-block’ or ‘inter-block’ variability, blocked designs could be
very efficient in the use of subject resources. One disadvantage of blocked designs is that they do not allow for missing data. If data from one subject in the block are missing, the entire block may be disqualified.

A variation on the idea of blocking is the crossover design. Here, each block consists of one subject who receives the study treatments in a random order. Crossover experiments are frequently used in bioavailability and pharmacokinetic studies. The reason is that the pharmacokinetic parameters which determine the absorption, distribution, metabolism of the drug in the body and its elimination form the body depend on the biological makeup of the subject and vary, often considerably, from subject to subject. Thus, the inter-subject variability is typically much higher than the intra-subject variability. In crossover studies, the treatments are compared within each subject and then summarized across subjects. The crossover design is different from the blocked design described above in that each block consists of a single subject, which means that measurements within each block are not independent of each other. Furthermore, it is possible that a residual effect of one drug carries over to impact the effect of another drug administered subsequently. Statistical analytical methods are limited in their ability to adjust and correct for such effects. This is why the use of crossover designs in clinical research is limited.

In summary, the design of a clinical trial incorporates methods of minimizing noise and the prevention of bias. This is done through the use of appropriate subject allocation procedures, such as randomization and blinding or through the use of stratification and blocking.

25.7 The study population: inclusion and exclusion criteria

Generalizability

The study of the pharmaceutical effect of a drug is always done in reference to a population of prospective patients. For example, the clinical dose to be recommended for an older patient is often different than for a younger patient. Thus, the target population for the study must be well defined in advance. Obviously, it is impractical to study the entire patient population of interest. Fortunately, this is also not necessary. Statistical sampling methodology enables us to draw conclusions from a sample to the population from which the sample had been drawn, to any desirable degree of accuracy and confidence. But, there is one important caveat to this ability: The sample must be ‘representative’ of the population of interest; meaning that the sample must preserve all the relevant characteristics of the population. That is, samples should have the similar proportions of men and women, similar racial composition, similar numbers of hypertensive patients and so on. Clearly, the creation of an exact replica of the population on a small scale is an impossible task. However, statistical sampling methods can produce very close to representative samples with very high probability. These are the methods utilized by pollsters to make highly reliable predictions and inferences on the population from relatively small samples.

In clinical research, the random selection of subjects to be included in the trial from the target population is not practical. Subjects are usually selected from the patient pools available to the investigators participating in the trial. This, in and of itself, is problematic. The subject pool available to a particular center usually reflects the population in the geographical area where the center is located which may not represent the general potential patient population. To complicate things even further, some of the subjects available at a given center may not be suitable for enrollment in a trial with an experimental drug. The investigator may wish to exclude certain subjects because of certain known or unknown risks. The possible effects of drugs on the unborn fetus are often unknown, and thus pregnant or lactating women are usually excluded. Potential subjects may be excluded if they are taking another medication, which can potentially interact with the study drug. Also, some potential subjects may refuse to participate
in the trial for one reason or other. Finally, for the purpose of studying the efficacy of a drug, it is desirable to enroll only subjects who are most likely to have a measurable response to treatment. Thus, every trial protocol contains a list of inclusion and exclusion criteria defining the subject population to be studied. Obviously, such a population is hardly ever fully representative of the target population. This raises a question regarding the generalizability of the trial’s conclusions.

When defining a set of inclusion and exclusion criteria for a trial, the issue of generalizability must be kept in mind. The rule is that the more restrictive the criteria, the less generalizable the results. On the contrary, setting criteria for eligibility to participate in the trial provides the investigator with an important tool for controlling the variability. Thus, the choice of eligibility criteria must guided so as to balance the efficiency of the trial design against the need to assure that the result are generalizable. Some of the guiding principles for defining subjects’ eligibility are listed below.

**Homogeneity**

Homogeneity of the subject population is an important factor in controlling variability. The more homogeneous the subject population generating the data, the more informative it is. Thus, fewer subjects are required to achieve the desired control of the statistical errors when a study is conducted in a homogeneous subject population as compared to when the subjects are drawn from a heterogeneous population. The problem is that the more homogenous the group of subjects, the less representative of the general potential patient population it is. In the early stages of drug development, where the goal is to establish the general perimeters for the drug safety and efficacy, and provide information for the design of future studies, studies are usually carried out on a limited number of subjects. In these early trials, it is the subjects’ safety that is of primary concern, and the question of efficacy is secondary. The scope of the efficacy-related questions is limited to the ‘proof of principle’, that is, a demonstration of clinical activity, the identification of a safe dose range and information leading to the choice of dose and regimen for further studies. Subjects are selected who are most likely to respond to treatment, present no obvious potential safety risks and are as similar as possible. Later stage studies such as confirmative phase III trials, those providing pivotal information for the proof of the drug’s efficacy and safety, are generally less restrictive.

**Safety**

The safety of the subjects enrolled in the trial is always the primary concern of the researcher. Individuals at high or unknown risk to treatment with the drug are excluded from the study. For example, women of child bearing potential are usually excluded or required to use an acceptable method of birth control. Similarly, patients who are taking medications that might interact with the experimental drug, or who have medical conditions that place them at increased risk, are also excluded from participation.

**Selection of subjects – maximizing the signal-to-noise ratio**

Clinical trials are very expensive undertakings. Also, because they involve human subjects, there is always an ethical imperative to use the subject resources judiciously. Often, the researcher has only one chance to conduct a trial designed to answer a given question. Thus, the efficiency of the trial design is critical. In other words, the design must be such that the signal-to-noise ratio is maximized. The selection of subjects by specifying certain inclusion and exclusion criteria may go a long way in this direction. The exclusion of patients with poor prognosis who are unlikely to respond to treatment, the inclusion of only patients with more than minimal severity of their condition and similar measures are often used to achieve this goal. Again, one must be careful not to narrow the subject population to the extent that the results could not be generalized to a broader patient population.
The placebo effect

Placebo is the preferred control in the double-blind Randomized Controlled Clinical Trial (RCCT). Although placebo is not supposed to have any relevant biological activity, it is well known that it often produces remarkable therapeutic responses. This phenomenon occurs across the therapeutic board. It seems that mere knowledge that the subject is being treated for its condition often produces a measurable favorable response (Bok, 1974; Gribbin, 1981). A high placebo response will tend to mask the response of the experimental drug. Since placebo is rarely used outside the clinical research setting, some people argue that the comparison with placebo tends to show lower response rates for the drug than would later be observed in general use. Thus, goes the argument, the placebo-controlled trial puts the test drug at a disadvantage. The counter argument is that what one sees in the clinic is perhaps the combination of the placebo effect plus the drug’s biological effect, and therefore, establishing the residual effect of the drug over its inherent placebo effect should be the true objective of the trial. Whatever the case might be, the placebo effect invariably results in decrease in the signal-to-noise ratio. Therefore, measures are often taken to select subjects whose placebo response is low or nil. One way of accomplishing this is by treating prospective subjects with placebo for some time prior to randomization. Patients whose response during this screening phase is high or very variable are then disqualified from participating in the trial.

In summary, the selection of subjects to be enrolled in the trial using a list of entrance criteria is an important tool that helps to sharpen the signal-to-noise ratio. Therefore, measures are often taken to select subjects whose placebo response is low or nil. One way of accomplishing this is by treating prospective subjects with placebo for some time prior to randomization. Patients whose response during this screening phase is high or very variable are then disqualified from participating in the trial.

The statistical model

The statistical model is the mathematical framework in which the statistician operates. It provides the statistician with the tools to quantify the information obtained during the trial and defines relationships among the various measurements. It provides a framework for evaluating the properties of the statistical methods used to analyze the data and answer the questions the study is designed to address.

What is a statistical model?

A statistical model consists of a set of assumptions about the nature of the data to be collected in the trial and about the interrelationships among various variables. These assumptions must be specific enough that they could be expressed by a set of mathematical expressions and equations. For example: In a placebo-controlled clinical trial for testing a new analgesic for treatment of migraine headaches, the key efficacy variable is the number of subjects whose headache is eliminated within 1 h of treatment. A statistical model appropriate for this situation is as follows:

Let \( p \) denote the probability that a subject treated with a drug will have their headache disappear 1 h after treatment, following an episode of migraine headache. If the responses of different subjects are independent of each other, this probability can be expressed as

\[
\text{Prob. (no. of responses } = k) = cp^k(1 - p)^{(N - k)}(0 \leq k \leq N)
\]

where \( N \) is the number of subjects treated and \( c \) is a constant representing the number of possible combinations of \( k \) elements out of \( N \). This model is known as the Binomial Model.

The trial objective is to determine if the new drug is more efficacious than placebo. Within the context of this model, one could declare the drug as ‘more efficacious’ if \( p_d > p_p \), where \( p_d \) is the probability of response for a subject treated with the new drug and \( p_p \) the probability of response of a placebo-treated subject.

The data collected during the trial will provide information about \( p_d \) and \( p_p \), enabling the
statistician to test the null hypothesis $H_0 : \Delta = p_d - p_p = 0$ against the alternative hypothesis $H_1 : \Delta = p_d - p_p > 0$.

This very simple model provides sufficient structure for the statistician to design a statistical test to test these hypotheses. As was discussed in Section 25.3 above, the statistical test is a device providing a rule for decision-making associated with possible errors. The study design must be such that the error probabilities are properly controlled. In other words, the researcher must decide on acceptable levels of $\alpha$ and $\beta$, the probabilities of type I and type II errors. Typically, $\alpha$ is chosen to be 0.05, or 5% and $\beta$ between 0.05 and 0.20, depending on how serious the consequences are of committing a type II error (‘False Positive’). As the type II error probability is calculated under the assumption that the alternative hypothesis is true, it depends on the value of $\Delta$. The investigator must specify a value of $\Delta$ for which the type II error should be calculated. This value is the smallest clinically important $\Delta$. In our example, the clinician might consider an increase in the probability of response, of less than 50% not clinically meaningful. So, if it is known that 15% of patients treated with placebo report the disappearance of their headache, $\Delta = 0.075$, or 7.5%. Using the model and this information, the statistician can calculate the number of subjects required in the trial to guarantee that the statistical test will have the desired power, say 90%, to detect this increase if it is true, while maintaining the type I error below a desired low level, say 5%.

Another commonly used statistical model is the Linear Model, which represents a family of models of a similar structure. The most commonly employed linear model is the analysis of variance model (ANOVA). We shall illustrate this model using the simplest case, the one-way ANOVA model.

The model is used to describe continuous data such as blood pressure. The model assumes that the observed variable of interest $Y$ (e.g. diastolic blood pressure) can be expressed as a sum of a number of factors:

$$ Y = \mu + t + \epsilon $$

Here $\mu$ represents the overall mean diastolic blood pressure in the population under study, $t$ represents the increase (or decrease) of the blood pressure due to treatment and $\epsilon$ represents a random error. The model makes two additional assumptions:

(a) $\epsilon$ behaves like a Normal (Gaussian) variable with mean zero and some (unknown) standard deviation, and

(b) the measurements obtained from different subjects are independent of each other.

The quantities $\mu$ and $t$ are called the model parameters, sometimes referred to as the independent variables. There is one additional parameter in this model which is the standard deviation of the random error $\epsilon$. It is not explicitly evident from Equation (1) above but is implicit in assumption (a). The model parameters are unknown quantities that must be estimated from the data. The data here are represented by the symbol $Y$, sometimes referred to as the dependent variable. The relationship between the data and the model parameters is expressed by the linear equation (1), hence the name Linear Model.

Linear models can be quite complicated when additional structure, parameters and assumptions are introduced. For example, one may include another term $c$ in the model to account for the effect of the investigator (center) on the measurements, or another parameter $t* c$ to account for the interaction between the treatment and the investigator effect. We will discuss this important parameter in some detail in Section 25.12 below.

There are two common features to all linear models: The relationship between the data and the model parameters is always assumed to be linear, and the errors are assumed to be Normal.

It is important to remember that all the statistician’s quantitative work and calculations are model dependent. That is, their application to real life depends on the extent to which the model assumptions are satisfied in reality. Much of the work the statistician does in planning the trial, in discussing the nature of the efficacy and safety variables, randomizing, blinding and so forth, is expressed in the model. Obviously, the more complex the
model and the more specific the model assumptions, the more the final results of the analysis will depend on it. Statisticians are advised to always start the statistical analysis by performing certain diagnostic procedures on the data to check to what extent the model assumptions are supported by the data. This process involves a certain level of subjective judgment, and different statisticians may reach different conclusions looking at the same data. Statisticians have at their disposal certain tools by which they can manipulate the data so as to conform better to the model assumption. For example, the distributions of measured pharmacokinetic (PK) parameters is typically skewed. The assumption of Normality of the distribution implies that the distribution is symmetric. It turns out that if one calculates the PK parameters using the natural logarithms of the blood concentrations rather than the raw measured concentrations, the distributions of the estimated parameters are less skewed. The choice of model is part of the study design. It is, therefore, done before any data are available. It is not uncommon that at the analysis stage, it becomes evident that the model assumptions are grossly violated. It may become necessary to use different methods that are not as dependent on the model assumptions to analyze the data. This should be done with great care so that spurious patterns in the data would not lead the researcher to reach wrong conclusions. Additionally, changing the analysis methods after an inspection of the data could result in an introduction of bias if the statistician is aware of the treatment assignments. For this reason, it is prudent to perform these diagnostic examinations of the data without revealing the treatment assignments. In blinded studies, this means that these procedures are executed prior to the breaking of the blind. The statistical guidelines issued by the International Conference on Harmonization (ICH), which were adopted by the Food and Drug Administration (FDA) and the European regulatory authorities, address this issue as follows:

The [statistical] plan should be reviewed and possibly updated as a result of the blind review of the data . . . and should be finalized before breaking the blind. Formal records should be kept of when the statistical analysis plan was finalized as well as when the blind was subsequently broken. If the blind review suggests changes to the principal features stated in the protocol, these should be documented in a protocol amendment. (ICH, E9, 4.1)

It is important to remember that the question is not whether the statistical model is true or false. The statistical model is a theoretical construct, and thus it is always false. The question is how well it approximates the situation under study. Or, in the words of a famous statistician, ‘All models are wrong, but some are useful’.

25.9 Statistical inference

Hypothesis testing revisited: the $p$-value; power

In Section 25.3 above, we discussed the concept of the statistical test and defined some basic terms. In this section, we take a closer look at this idea and see, through an example, how this is actually done. Let us look at the data presented in Table 25.4 earlier in the chapter. The graduate student who generated the data did not, in fact, study 20 randomly selected students. The purpose of her study was to demonstrate that engaging in aerobic workout on a regular basis has a beneficial effect on the cardiovascular system, including the slowing down the heart rate. To do this, the researcher set out to test the null hypothesis (H0) that the mean heart rate of exercising students, $\mu_A$, is the same as the mean of the non-exercising students, $\mu_B$. The alternative hypothesis (H1) is that $\mu_A < \mu_B$. In order to test $H_0$ against $H_1$, one would need to identify a variable (or a statistic), the distribution of which is sensitive to the difference between the heart rates of the different groups. Such a statistic is the signal-to-noise ratio,

$$T = \frac{\bar{X}_B - \bar{X}_A}{SE(\bar{X}_B - \bar{X}_A)}$$

where the signal is the difference between the sample mean of Group B, $\bar{X}_B$, and the sample mean of Group A, $\bar{X}_A$, and the noise is the standard error of the difference $\bar{X}_B - \bar{X}_A$. 

25.9 STATISTICAL INFERENCE 327
We have seen in Section 25.5 that the standard error of the mean is \(1/\sqrt{N}\) times the sample standard deviation. The variance of the difference \(X_B - X_A\) is the sum of the variances of \(X_B\) and of \(X_A\). Therefore, from Table 25.4 we obtain:

\[
\bar{X}_B - \bar{X}_A = 59.4 - 54.2 = 5.2
\]

\[
\text{VAR}(\bar{X}_B - \bar{X}_A) = \frac{1.81^2}{10} + \frac{2.99^2}{10}
\]

and thus,

\[
\text{SE}(\bar{X}_B - \bar{X}_A) = \sqrt{1.81^2 + 2.99^2} = 1.105
\]

Therefore, \(T = 5.2/1.105 = 4.7\).

Statistical theory teaches that under the assumption that the population means of the two groups are the same (i.e. if \(H_0\) is true), the distribution of variable \(T\) depends only on the sample size but not on the value of the common mean or on the measurements population variance and thus can be tabulated independently of the particulars of any given experiment. This is the so-called Student’s \(t\)-distribution. Using tables of the \(t\)-distribution, we can calculate the probability that a variable \(T\) calculated as above assumes a value greater or equal to 4.7, the value obtained in our example, given that \(H_0\) is true. This probability is \(<0.0001\). Thus, if \(H_0\) is true, the result obtained in our experiment is extremely unlikely, although not impossible. We are forced to choose between two possible explanations to this. One is that a very unlikely event occurred. The second is that the result of our experiment is not a fluke, rather, the difference \(\mu_B - \mu_A\) is a positive number, sufficiently large to make the probability of this outcome a likely event. We elect the latter explanation and reject \(H_0\) in favor of the alternative hypothesis \(H_1\).

The steps we have taken in the above example are quite generic. They could be summarized as follows:

Step 1: Describe a statistical model and identify the variable measuring the effect of interest.

Step 2: Define the statistical hypothesis to be tested.

Step 3: Define the test statistic to be used for testing \(H_0\). This test statistics is always the signal-to-noise ratio.

Step 4: Perform the experiment and collect the data.

Step 5: Calculate the value of the test statistic based on the data.

Step 6: Calculate the probability under the assumption that \(H_0\) is true, that the test statistic will assume a value equal or greater than the value obtained in the experiment. If this probability is small enough for you to decide that the value obtained in the experiment is highly unlikely, declare the test as statistically significant and reject \(H_0\).

Step 6 reflects the logic driving statistical inference. It is based on the expectation that if an event occurs in an experiment it is not an unlikely event.

The probability that the test statistics will assume a value as large or larger than the value obtained in the experiment is called the significance probability of the test, or the \(p\)-value. In our example, the \(p\)-value was less than 0.0001. Most people would consider such a value extremely unlikely and declare the test statistically significant. The question what values should be considered small enough to declare statistical significance is a matter of judgment. Over the years of statistical practice, the number 0.05 became the standard cutoff point. Any \(p\)-value smaller than 0.05 is considered significant, and any \(p\)-value greater than 0.05 is considered not significant. It should be emphasized, though, that this is an arbitrary value and that there is no real difference between a \(p\)-value of 0.049 and a \(p\)-value of 0.051; although, if one follows the cutoff rule of 0.05 to the letter, one will declare statistical significance in the former but not in the latter case. This is, of course, absurd. These two \(p\)-values should not lead the researcher to conclusions with such diametrically opposed consequences. A choice of any other cutoff value will lead to a similar situation if followed strictly. A good measure of common sense is always useful. There is, of course, no reason...
why anyone should not use a cutoff point other than the customary 0.05 if he or she feels it is more appropriate. But as in any other situation when one deviates from a standard, one must explain the reasons for doing so before the experiment is performed and before the data are known.

The statistical testing setup, as we have already seen, is geared toward the declaration of statistical significance. When a test is significant, we draw a conclusion about the cause of the effect of interest. If we decide to reject the null hypothesis, the \( p \)-value is the type I error associated with this decision. Therefore, the level of confidence in the correctness of the decision depends on the \( p \)-value; the smaller the \( p \)-value, the more confident one is that the decision is correct.

What if the statistical test is not statistically significant? If one accepts the null hypothesis in this case, the error to be concerned about is the type II error (see Table 25.1). At the design stage of the trial, the statistician usually ascertains that the test to be employed at the end has desired power at clinically important alternatives. As the power is 1 minus the probability of type II error, a well-designed study has built-in protection against making a type II error when one of these alternatives is true but generally does not have this protection at other alternatives. In fact, for most statistical models used in practice, for alternatives close to the null hypothesis, the probability of type II error is near \( 1 - \alpha \), where \( \alpha \) is the significance level of the test. As the alternative hypothesis is usually composite, not all alternatives can be protected uniformly. Thus, accepting the null hypothesis when the test fails to achieve statistical significance is a decision associated with uncontrolled probability of type II error. For this reason, statisticians prefer to declare the test as inconclusive when it fails to achieve statistical significance.

### Confidence intervals: precision and confidence

Testing statistical hypotheses is a decision-making tool. The outcome of the test is a dichotomy; either the test is declared ‘statistically significant’ or it is not. The test provides directly very little information on the magnitude of the effect of interest. In the example of the heart rate data of Table 25.4, we have declared the test statistically significant and rejected the null hypothesis that the effect is zero. But we have not identified how large the effect is. It is often important to take the next step and estimate the magnitude of the effect. The obvious starting point is the ‘signal’ \( D = \bar{X}_B - \bar{X}_A = 5.2 \). This value is an estimate of the difference between the two population means, \( \Delta = \mu_B - \mu_A \), and as we have already seen, it is associated with a certain amount of variability measured by its standard error. This means that if the experiment was to be repeated under exactly the same conditions, it is most likely that a value different than 5.2 is obtained. But how different? How much should one expect the values obtained from repetitions of the experiment to spread about the true \( \Delta \)? This information is provided by the standard error.

A method of simultaneously providing information on the magnitude of the estimated parameter and the range of likely values of the estimate is the confidence interval. The key idea rests on a fundamental mathematical fact that if \( \bar{X}_k \) is a sample mean of a variable calculated from \( n \) independent samples of a variable, whose population mean and standard error are \( \mu \) and \( \sigma \), respectively, then the quantity

\[
Z = \frac{\bar{X}_n - \mu}{\sigma/\sqrt{n}} \tag{2}
\]

has approximately Standard Normal distribution (Gaussian distribution). The Normal distribution has the familiar bell-shaped curve and is tabulated in almost any elementary statistics textbook. The word ‘approximately’ here means that the actual distribution of \( Z \) may be different from the Normal distribution, but it becomes closer and closer to it as the sample size \( n \) increases. For all practical purposes, when the sample size is greater than 30, performing probability calculations on \( Z \) using the Standard Normal Distribution tables, will result in only minor errors.

Using the Standard Normal Distribution tables, one can find for every number \( 0 < \gamma < 1 \), a pair of numbers \( Z_1(\gamma) \) and \( Z_2(\gamma) \), such that

\[
\text{Prob.}\{Z_1(\gamma) \leq Z \leq Z_2(\gamma)\} = 1 - \gamma \tag{3}
\]
For example, for \( \gamma = 0.05 \), then \( Z_1(0.05) = -1.96 \) and \( Z_2(0.05) = 1.96 \).

As long as \( \gamma < 0.5 \), we can always find a value \( Z(\gamma) > 0 \) such that \( Z_1(\gamma) = -Z(\gamma) \) and \( Z_2(\gamma) = Z(\gamma) \) so that Equation (3) holds.

Now, by substituting the definition of \( Z \) in expression (2) with \( Z(\gamma) = Z_2(\gamma) = -Z_1(\gamma) \) and rearranging terms, the inequality \( Z_1(\gamma) \leq Z \leq Z_2(\gamma) \) can be re-written as

\[
L_\gamma = \bar{X}_n - Z(\gamma)\sigma/\sqrt{n} \leq \mu \leq \bar{X}_n + Z(\gamma)\sigma/\sqrt{n} = U_\gamma
\]

(4)

Now, let us take a closer look at expression (4). The value at the center, \( \mu \), is the population mean, which is the unknown quantity we are estimating. Expression (3) assigns a probability \( 1 - \gamma \) that (4) holds. The interpretation of this is that if we conduct an experiment and calculate the lower and upper limits of the interval, \( L_\gamma \) and \( U_\gamma \), respectively, then the interval \( (L_\gamma, U_\gamma) \) will contain the true (and unknown!) population mean with probability \( 1 - \gamma \). The interval (4) is called a confidence interval for the population mean, and \( 1 - \gamma \) is called the confidence level of the interval, often expressed as a percent.

Let us illustrate these ideas using the data of Table 25.4. Suppose we wish to estimate the difference \( \Delta \) between the population means of the non-exercising and the exercising students by constructing a confidence interval with confidence level 95%. Then substituting \( D \) for \( \bar{X}_n \) and \( SE_D \) for \( \sigma/\sqrt{n} \) in (4), and recalling that \( Z(0.05) = 1.96 \), we obtain the confidence limits

\[
L_{0.05} = D - SE_D \times Z(0.05) = 5.2 - 1.105 \times 1.96 = 3.03,
\]

and

\[
U_{0.05} = D + SE_D \times Z(0.05)
= 5.2 + 1.105 \times 1.96 = 7.26.
\]

Thus, the interval (3.03, 7.26) is a 95% confidence interval for the effect \( \Delta \). It should be emphasized that the probability statement about the confidence level of 0.95 does not relate to the specific interval (3.03, 7.26), as this specific interval is an outcome of the specific sample used for the calculation and either contains the parameter \( \Delta \) or does not. It is a theoretical probability pertaining to a generic interval calculated from a sample following the steps we described above. Thus, if we could repeat the experiment many times, each time calculating a confidence interval in the way we have just done, we should expect approximately 95% of these intervals to contain the true mean effect \( \Delta \). Of course, when calculating a confidence interval from a sample, there is no way to tell whether or not the interval contains the parameter it is estimating. The confidence level provides us with a certain level of assurance that it is so, in the sense we just described. One might ask, why not choose \( \gamma \) to be a very small number such as 0.01 or 0.001 and thus obtain an arbitrarily large confidence level? One can see from the way \( Z(\gamma) \) is defined that it increases as \( \gamma \) decreases. For example, \( Z(0.01) = 2.58 \) and \( Z(0.001) = 3.25 \) which would correspond to the confidence intervals (2.35, 8.05) and (1.54, 8.86), respectively. So the answer becomes self-evident: Yes, one can choose an arbitrarily high confidence level but this will come at the price that the resulting confidence interval will be so wide that it becomes meaningless. In other words, there is a tradeoff between confidence and accuracy. It seems that 95% confidence achieves a satisfactory balance between the two in most cases.

Confidence intervals are often calculated after performing a statistical test. When the test is statistically significant, we have reason to believe that the effect is real. The confidence interval gives us additional information as to the size of the effect. Confidence intervals are also calculated during exploratory analyses. The purpose of such analyses is to explore the data, identify possible effects and generate hypotheses for future studies rather than make specific inferences. Confidence intervals are extremely useful tools toward this goal.

Another common use of confidence intervals is in the establishment of equivalence between two treatments. Here 'equivalence' is not synonymous with 'equality'. It means that the difference, if any, between the effects of the two treatments is
not considered to be of material importance. Let us illustrate this with the following example: Suppose one is interested in determining whether two antihypertensive drugs are equivalent in their effect on diastolic blood pressure after four weeks of treatment. Let $\mu_A$ and $\mu_B$ denote the mean change from the pretreatment baseline for patients treated with drug A and drug B, respectively. Let $\Delta = \mu_A - \mu_B$. Blood pressure varies from measurement to measurement, even when the measurements are taken within minutes from each other so that measurements within $\pm 3$ mmHg are not considered to be clinically different. Therefore, as long as the two means are within $\pm 3$ mmHg, the two drugs are considered as having equivalent effectiveness. A trial to establish whether the two drugs are equivalent must be then designed so that a confidence interval for $\Delta$ with confidence level of 0.90 or higher (or another level considered by the researcher to be adequate) will have width not exceeding 6 mmHg. When the trial is concluded, the confidence interval is constructed. If it is entirely contained within the interval $(-3, +3)$, the two drugs are considered equivalent. Otherwise, they are not. It is possible to design a trial so that a desired confidence interval of a given confidence level will have a desired width. The width of a confidence interval for a parameter is the estimate’s precision. It depends on (a) the confidence level, (b) the inherent variability of the data and (c) the sample size. The inherent variability of the data can be controlled only to a limited degree. For a fixed sample size, the width of the confidence interval is determined by the confidence level. As we have seen in the previous example, the researcher can increase the precision of his estimate only by lowering the confidence level associated with the confidence interval and vice versa. The only way to guarantee an acceptable level of confidence and precision is to include sufficiently large number of subjects in the trial. In our example, if the interval’s width is larger than 6 mmHg, the trial could never establish equivalence because the criterion for this cannot be met. However, it could establish the lack of equivalence if the entire confidence interval is either larger than 3 or smaller than $-3$.

To summarize, when estimating the magnitude of a parameter is an important objective of a trial, thought must be given at the design stage to what levels of confidence and precision are considered acceptable and make sure that the trial is designed to enroll sufficient number of subjects to accommodate these requirements. There are no hard and fast rules about what levels of confidence are considered acceptable. However, rarely do researchers go below 80%, and more typically, they require a confidence level of 90% or higher. The desired level of precision depends entirely on the particular situation.

### 25.10 Study design: determining the sample size

We have already seen through a number of examples the interplay between sample size, variability and the performance of the statistical procedures employed to analyze the data. The sample size determines the amount of information that will be available at the end of the trial. Therefore, the determination of an adequate sample size is one of the most important aspects of the trial design. A trial accumulating inadequate amount of information is hopelessly flawed, as it will not enable the researcher to answer the questions the trial is intended to answer.

The determination of the sample size is intimately related to the trial objectives, the inferences the researcher wants to be able to make and the error probabilities in the case of hypotheses testing or the confidence and precision in the case of estimation that the researcher is willing to tolerate. The following example illustrates the process of determining the required sample size for a clinical trial.

Suppose one wishes to conduct a trial to test the efficacy of a new antihypertensive drug. The clinical research physician plans to enroll a certain number of subjects with mild to moderate hypertension and randomize them to receive either the experimental drug or placebo. The primary efficacy variable is the decrease in the diastolic blood pressure as compared to a pretreatment baseline.
The subject’s diastolic blood pressure is measured twice: once prior to treatment when the subject is free of any antihypertensive medication, and once following the administration of treatment (experimental drug or placebo). The change in diastolic blood pressure between the two measurements is the primary efficacy variable. The researcher knows that for the drug to be sufficiently efficacious to justify further development, it must reduce the subject’s diastolic blood pressure by at least 10 points. So, if we denote the mean decrease in diastolic blood pressure for the drug group by \( \mu_D \) and the corresponding decrease for the placebo group by \( \mu_P \), then the null hypothesis the researcher is set to test is:

\[
H_0 : \mu_D = \mu_P, \quad \text{or} \quad H_0 : \mu_D - \mu_P = 0,
\]

versus the alternative hypothesis

\[
H_A : \mu_D > \mu_P, \quad \text{or} \quad H_A : \mu_D - \mu_P > 0.
\]

One particular alternative of interest is

\[
H_{10} : \mu_D = \mu_P + 10, \quad \text{or} \quad H_{10} : \mu_D - \mu_P = 10.
\]

In order to guarantee that the statistical test of \( H_0 \) will have a significance level \( \alpha \) and power not less than \( 1 - \beta \) at the alternative \( H_\Delta : \mu_D = \mu_P + \Delta \), each of the two treatment groups must have at least \( N \) subjects, where \( N \) is given by the formula:

\[
N = 2(Z_{1-\alpha/2} + Z_{1-\beta})^2 (\sigma / \Delta)^2 \quad (5)
\]

\( \sigma \) is the standard deviation of the raw measurements (i.e. the decrease in diastolic blood pressure). For simplicity, we assume that it is the same for both treatment groups. \( Z_{1-\alpha/2} \) and \( Z_{1-\beta} \) are two constants depending on \( \alpha \) and \( \beta \), that can be obtained from tables of the standard normal distribution. If in our case, we assume that \( \sigma = 12, \ \Delta = 10, \ \alpha = 0.05 \) and \( \beta = 0.10 \), then \( Z_{1-\alpha/2} = 1.96, \ Z_{1-\beta} = 1.28, \) and (5) yields \( N = 30.23 \). That is, a sample size of at least 31 subjects per group is required. Expression (5) is specific to situations similar to our example. In general, the sample size required is calculated by a formula that looks like expression (6) below:

\[
N = C_{\alpha,\beta}(\sigma / \Delta)^2 \quad (6)
\]

where \( C_{\alpha,\beta} \) is some constant depending on \( \alpha \) and \( \beta \).

There are a number of important observations implied by Equation (6):

(a) The sample size is proportional to \( \sigma^2 \), the measurements variance. That is, the more variable the measurements, the larger must be the sample size to enable one to distinguish the effect of interest from the noise.

(b) The sample size is inversely proportional to \( \Delta^2 \). That is, the smaller the effect of interest, the larger must the sample size be to enable us to separate it from the background noise.

(c) The sample size depends on the squares of the parameters \( \sigma \) and \( \Delta \); meaning that if we are able to reduce the noise in the experiment by half, the payoff is that the clinical trial will require one-fourth of the number of subjects. Similarly, if we wish to build in sufficient power to detect half of the effect, the clinical trial would have to enroll four times as many subjects.

During the design phase of the trial, the statistician will typically ask the clinical researcher questions leading to the determination of \( \sigma \) and \( \Delta \). The anticipated standard deviation is often very difficult to estimate, and the best way of arriving at a useful number is to look for such an estimate either in the published scientific literature or estimate it from data obtained similar studies performed by the pharmaceutical company. Underestimating \( \sigma \) can result in an underpowered study resulting with unacceptable errors rates leading to ambiguities and an inability to make reliable inferences. For this reason, it is always preferable to overestimate \( \sigma \) rather than underestimate it when information on \( \sigma \) is scanty. The value of \( \Delta \), the minimal clinically important effect, is usually arrived at by the clinician based on past clinical experience.
The abuse of power: pitfalls of over-design

Equation (6) is expressing \( N \) in terms of \( \sigma \) and \( \Delta \). It is very easy to rewrite this equation and express any of the three parameters \( N \), \( \sigma \) and \( \Delta \) in terms of the other two. If we express \( \Delta \) in terms of \( N \) and \( \sigma \), we could see that by increasing \( N \), the statistical test could have high power to detect very small differences. Thus, it is sometimes tempting to ‘over-design’ the study; that is, to enroll more subjects than required so that if the drug is not quite as efficacious as one hopes, the statistical test would still be significant at the end; sort of buying an ‘insurance policy’. By enrolling a large number of subjects, one can assure that the statistical test is so powerful that it would declare very small and possibly meaningless differences as statistically significant. This approach is not only wasteful but may also lead to false inferences, and is outright unethical in the drug development arena. Clinical trials are very expensive enterprises, and it is typically not feasible to repeat a trial to demonstrate that the results are reproducible. Furthermore, in studying therapies for life-threatening diseases, a trial resulting with a significant outcome often precludes the possibility of conducting a second confirmatory trial. The variables studied in clinical trials are random, thus there will always be differences between the treatment groups that are due to chance. An over-powered study could find such differences statistically significant and lead the researcher to a false conclusion that a drug is efficacious when it is not, or that it is harmful when it is not. In the absence of a second chance, these finding may never be repudiated.

An underpowered trial is wasteful and unethical for a different reason. Such a trial may not have enough power to detect clinically meaningful differences resulting in missing clinically important medical advances. The subjects enrolled into such a trial, are exposed to the risks involved in all clinical trials using experimental drugs, without the anticipated benefit to themselves and to society.

For these reasons, it is important that the size of the trial is just right: not too small and not too large. The discussions taking place among the project research team leading to the appropriate choice of the sample size are therefore very important, and although at the end, it is the statistician who performs the calculations, the input from the other team members is critical.

25.11 Issues in statistical trial design

Multicenter trials

Most phase III clinical trials are multicenter trials; that is, they are conducted in more than one clinical center. The number of centers participating in a clinical trial can vary greatly.

There are a number of good reasons to conduct phase III trials as multicenter trials. The most obvious is an administrative and logistical reason. Spreading the burden of subject recruitment among many centers will reduce the duration of the subject enrollment phase of the trial. This is an important reason considering that often the key to commercial success or failure of a new drug is the timing of its introduction to the market. There are also important scientific reasons to conduct the trial as a multicenter trial.

Noise reduction

Different centers often draw subjects from different types of patient populations. Also, different centers may utilize different procedures and medical practices that are not controlled by the study protocol. It is, therefore, reasonable to expect that the within-center variability is smaller than the overall variability. In a multicenter trial, the center often serves as a stratification variable, thereby reducing the variability and increasing the efficiency of the trial design. In order to take advantage of this aspect of the multicenter trial, the number of subjects per center cannot be too small so that the estimate of the intra-center variability is stable. A rule-of-thumb is that the number of subjects per treatment group within each center will be at least 5.
Generalizability

A multicenter trial may be viewed as a number of identical small trials each conducted at a different center. From this perspective, each center can be viewed as repeating the study conducted in other centers. In addition, different centers draw their subjects from different geographic areas and thus a multicenter trial is more likely to enroll subjects who are representative of a cross-section of the general population. Consistency of the results among the different centers adds to the level of confidence that the results could be replicated anywhere. It is possible that the results across centers are inconsistent. There are two types of inconsistencies.

(a) The magnitude of the effect is different across centers. When the magnitude of the response to treatment is different across centers, the relative effect between the two treatments is approximately constant, treatment, referred to by statisticians as 'center effect'. The existence of a center effect means that the different centers contribute differently to the measured effect of treatment, but this contribution is the same for both the experimental treatment and the comparator. This situation is illustrated in Figure 25.1 below.

Figure 25.1 shows schematically the effects of two treatments across six centers. The magnitude of the treatment differs from center to center, but the difference between the effect of treatment A and treatment B is the same. Such a situation does not present a problem in comparing the treatments. It makes it impossible, though, to talk about the absolute magnitude of the treatment effect, as it is not constant. Observing a center effect is not unusual in clinical trials. The reasons for this may be many. It could be the result of a difference in the type of patients seen at the different centers, the center procedures and general nursing care, subjects compliance in taking their medication, the equipment used in the different centers and so on.

(b) Treatment-by-center interaction: This is the type of inconsistency that may cause an invalidation of the entire study. Here, the relative response to the different study treatments is different across centers. There are two situations that present qualitatively different levels of difficulties:

(i) Quantitative interaction. We say that the interaction is quantitative if the relative effect of the different treatments is in the same direction across centers, although the magnitude may be different. Figure 25.2 illustrates this type of interaction. This type of interaction means that the relative efficacy of the treatments is different in different centers, but the direction is always the same. That is, treatment A is more efficacious than treatment B at all centers, but the magnitude of the difference between the treatment effects is different in different centers. When this type of interaction occurs, one can say that one treatment is more efficacious than the other, but cannot say by how much because the relative efficacy of the two treatments is not constant.

(ii) Qualitative interaction. The type of interaction is the one that could invalidate the entire study. This occurs when the relative efficacy of the two treatments is different across the different centers both in magnitude and direction. This is illustrated in Figure 25.3. Here, treatment A produces a
larger effect than treatment B in some centers and a smaller effect in other centers. If the researcher cannot find the cause of this interaction and correct for it, the study will be inconclusive. This type of interaction would occur if, for example, the data center mislabeled the treatments for some centers. This would be easy to rectify. However, often there is no reasonable and acceptable explanation for this, and the entire study has to be invalidated.

The ICH guidelines address this issue as follows:

If heterogeneity of treatment effects is found, this should be interpreted with care, and vigorous attempts should be made to find an explanation in terms of other features of trial management or subject
characteristics. Such an explanation will usually suggest appropriate further analysis and interpretation. In the absence of an explanation, heterogeneity of treatment effect, as evidenced, for example, by marked quantitative interactions implies that alternative estimates of the treatment effect, giving different weights to the centers, may be needed to substantiate the robustness of the estimates of treatment effect. It is even more important to understand the basis of any heterogeneity characterized by marked qualitative interactions, and failure to find an explanation may necessitate further clinical trials before the treatment effect can be reliably predicted. (ICH, E9, 3.2)

**Multiplicity**

Clinical trials always include multiple end points and/or multiple comparisons between treatments. For example, in a clinical trial of a new drug for asthma, one may want to analyze the change in the Forced Expiratory Volume in 1 s (FEV₁) as well as the change in the total asthma symptoms score, the subject’s morning and evening symptoms severity scores, the investigator’s global improvement score and perhaps other end points. In a dose–response trial with placebo, low dose, intermediate dose and high dose, the investigator may want to compare the three dose groups to the control and perhaps the different dose groups with each other.

The issue of multiplicity is that when performing multiple statistical tests, the error probability associated with the inferences made is inflated. To see this, let us consider a simple situation where one is interested in performing two statistical tests on independent sets of data, each at a significance level of 0.05. Thus, the probability that each of the two tests will be declared significant erroneously (type I error) is 0.05. However, the probability that at least one of the two tests will be declared significant erroneously is 0.0975. The probability that at least one of the tests of interest will be declared significant erroneously is called the experiment-wise error rate. If we perform three 0.05 level tests, the experiment-wise error rate increases to 0.143. In practical terms, this means that if we perform multiple tests and make multiple inferences, each one at a reasonably low error probability, the likelihood that some of these inferences will be erroneous could be appreciable. To correct for this, one must conduct each individual test at a decreased significance level with the result that either the power of the tests will be reduced as well, or the sample size must be increased to accommodate the desired power. This could make the trial prohibitively expensive. Statisticians sometimes refer to the need to adjust the significance level so that the experiment-wise error rate is controlled, as the statistical penalty for multiplicity.

The need to control the experiment-wise error rate may not apply to exploratory analyses. Statisticians often perform formal statistical tests for exploratory purposes. So, no formal hypotheses are stated and no inferences are made based on them. Even though the act of performing formally an exploratory test involves the same steps as inferential testing, it is conceptually different because of the absence of a null hypothesis. The *p*-value obtained in such a test should be viewed as a measure of the level of inconsistency of the data with the underlying assumptions of the test rather than error probabilities involved in making causal inferences.

In summary, one should limit the number of inferential tests to be performed to the minimum necessary for making the desired causal inferences. They must be specified in the study protocol and the appropriate adjustments to the error probabilities must be made. Similarly, one should remember that when multiple tests are performed without adjustment, as the case would be in exploratory testing situation, one should expect to see spurious statistically significant results that may or may not be meaningful. This last comment applies particularly to statistical tests performed on adverse events and laboratory data. Adverse events reported in a study are often summarized by reporting their incidences summarized by body system. Often, dozens of categories are listed. When formal statistical tests are applied to these data, some of these tests will result with *p*-values less than the customary 0.05. The researcher should be cognizant of this issue and not jump to conclusions. It is strongly advisable to specify in advance the particular safety tests to be performed inferentially.
is a known or suspected safety concern with the drug or the class of drugs tested.

**Interim analysis**

Long-term clinical trials in life-threatening disease areas or in diseases involving serious morbidities, or in the study of drugs with possible serious toxicities, it is imperative to monitor the data on an ongoing basis and perform periodic interim analyses.

Interim analyses are performed for a variety of reasons. Some of the main reasons are as follows:

(a) Stop the development of an ineffective treatment.

(b) Stop the development of a toxic treatment.

(c) Terminate a trial in a life-threatening disease as soon as enough evidence accumulates to conclude that one treatment is significantly more efficacious than the other.

(d) Interim design adjustment (e.g. verification of assumptions on variability, power recalculation and sample-size adjustment; verification of assumptions on expected drug or control group response rate).

(e) Plan additional trials.

(f) Plan for capital expenditures and product launch.

(g) Make a regulatory submission for a short-term portion of a long-term trial.

(h) Other regulatory reasons (e.g. opening the trial to previously excluded high-risk subjects).

The first three reasons in the list include the possibility of terminating the trial based on an interim inferential analysis. The fourth reason can potentially alter the trial’s conduct. The other reasons should not, in principle, impact the trial.

Essentially, there are two separate issues involved in performing an interim analysis: a statistical issue and an administrative or trial management issue. The statistical issue is similar to the multiplicity issue discussed in the previous paragraph and applies to (a), (b) and (c) above. If we perform an interim inferential test, the overall error probability is inflated. Therefore, if one contemplates to perform an interim analysis with the option of making inferences early and possibly terminating the trial before its planned end, the procedure used for making this determination must be planned in advance and documented in the study protocol just as any other inferential procedure. As we discussed above, there will be a statistical penalty in the sense that each of the interim analyses and the final analysis will have to be performed at a lower level of significance than the overall type I error rate. The statistical penalty depends on the decision-making procedure to be used.

Interim analysis for the purpose of reassessment of the design assumptions and sample size recalculation has become a rather common place especially in large, long-term phase III trials. The assumptions driving the design of these trials are typically based on published or unpublished previous exploratory research or on extrapolations from preclinical work. These assumptions often involve a great deal of uncertainty. To reduce this uncertainty, an interim analysis at some time point early in the trial is planned, the sole purpose of which is to use the data accumulated thus far and estimate the parameters used to perform the power calculations and make appropriate adjustments to the trial design. Recalculation of the sample size is the most typical purpose of such analysis. A number of procedures for an interim sample-size adjustment were proposed in the statistical literature in recent years. One such approach is to calculate the probability that the trial, when continued as planned, will result in a significant outcome conditioned on the accumulated data. When this probability is calculated under the alternative hypothesis, this (conditional) probability is called the **conditional power**. If the conditional power is equal or higher than the power used in the original design of the trial, the trial will continue as planned. If the conditional power is smaller, the sample size will be increased. The increase of the
The sample size may not depend solely on statistical considerations but also on budgetary or other considerations. Although there is no reason in principle why one would not allow reducing the sample size if it turns out that the trial is overpowered, all the methods for sample-size adjustment allow only for increasing the size of the trial. The reason is a practical one. As the trial sponsor has already committed the resources to conduct the trial as designed, they would rather use them all and have a more powerful trial rather than saving and risking that the trial may be underpowered. Clearly, if one incorporates the option of an interim sample-size adjustment, at the outset, the expected sample size of such a trial will be larger than a trial designed without such an option using the same design assumptions. Therefore, if the criterion for statistical significance at the end of the trial is the same, such a design will result in a more powerful trial than if this option was not available. This gain comes, of course, with a price tag: the type I error probability is increased as well. Therefore, the inclusion of an interim redesign must be planned as an integral part of the trial design and proper adjustments must be made to ensure that the resulting decision procedure has the desired power while still properly controlling the type I error rate.

The timing of an interim analysis for reassessment of the sample size is very important. One would want to conduct this analysis after sufficient amount of data have accumulated so that the estimated design parameters are stable and reliable. However, one would also not want to wait too long either. For a typical large trial, when a sample-size adjustment procedure is planned after 30–50% of the data are available, the estimates are reasonably stable and the statistical penalty involved in the p-value adjustment is relatively small. Also, some procedures leading to an early decision to stop the trial for lack of efficacy, or a futility analysis also involve the calculation of conditional power. The same calculations involved in sample-size adjustment can be used to assess futility. If the conditional power is very low (which would lead to a substantial increase in the sample size, should the trial continue), the sponsor may want to consider terminating the trial and reallocating the unused resources to more promising investigations.

The administrative issue involves the potential for the introduction of bias. Any interim analysis, regardless of whether or not it is done with the intention to affect the ongoing trial, involves the possibility of introducing bias if the analysis requires the breaking of the blind. The FDA is particularly wary about these types of analyses because even if every step and decision is well documented, it is impossible to anticipate the impact on the trial that a partial, even preliminary, knowledge of the efficacy results might have. For this reason, it is imperative that such analyses, regardless of their declared purpose, will be performed with strict guidelines as to who will be unblinded, and how the results will be disseminated. It is important to make sure that individuals directly involved in the trial conduct and management, such as investigators, monitors and other project personnel, should remain blinded to the data and the results of the interim analysis. It has become standard practice in the pharmaceutical industry to appoint a Data Monitoring Board consisting entirely of people uninvolved in the trial conduct to review the interim data and analyses and make recommendations. The Pharmaceutical Manufacturers Association published a position paper discussing in details the various aspects of the issue as it relate to the specific circumstances of new drug development (PMA Biostatistics and Medical Ad-Hoc Committee on Interim Analysis, 1993). The ICH guidelines address this issue as well.

The execution of an interim analysis should be a completely confidential process because unblinded data and results are potentially involved. All staff involved in the conduct of the trial should remain blind to the results of such analyses, because of the possibility that their attitudes to the trial will be modified and cause changes in the characteristics of patients to be recruited or biases in treatment comparisons. This principle may be applied to all investigator staff and to staff employed by the sponsor except for those who are directly involved in the execution of the interim analysis. Investigators should be informed only about the decision to continue or to discontinue the trial, or to implement modifications to trial procedures.
Any interim analysis that is not planned appropriately (with or without the consequences of stopping the trial early) may flaw the results of a trial and possibly weaken confidence in the conclusions drawn. Therefore, such analyses should be avoided. If unplanned interim analysis is conducted, the clinical study report should explain why it was necessary and the degree to which blindness had to be broken, and provide an assessment of the potential magnitude of bias introduced and the impact on the interpretation of the results. (ICH, E9, 4.5)

25.12 Issues in data analysis

Clinical trials present unique problems during the analysis phase that other experiments do not. The inherent complexity of the clinical trial is compounded by the fact that it uses human subjects, and therefore it is governed by a set of ethical rules, paramount of which is the voluntary and informed participation of the subjects in the study. Subjects are required to sign an informed consent form prior to their enrollment in the study in which they confirm their understanding of the trial procedures, the potential risks and benefits, and state their voluntary agreement to participate. Notwithstanding the informed consent form, subjects can at all times exercise their free will and choose to terminate their participation, refuse to undergo a procedure, skip a visit or violate any of the study protocol procedures without penalty. The result is that clinical trials rarely are conducted exactly as planned. Some of the issues resulting from this are discussed below.

Noncompliance, dropouts and missing data

Noncompliance

In testing the efficacy of a new drug, or studying a dose–response relationship, it is of critical importance that subjects take their medication as prescribed in the protocol. Most drugs exhibit a direct dose–response relationship in terms of the drugs efficacy and safety. Noncompliance with respect to the schedule and dose of the study medication may have serious impact on the researcher’s ability to determine the recommended dose or even to show efficacy. When subjects under-dose themselves, the drug efficacy may be missed and the true adverse event pattern of the drug may be underestimated. Clinical researchers always try to build in mechanisms into the trial’s procedures designed to maximize compliance. However, it is not uncommon that despite such efforts, some subjects will miss some doses.

It is impossible to adjust for noncompliance at the analysis phase without making assumptions about the dose–response relationship, which is often not well understood and might vary greatly from one subject to another. It is always important to assess the level of compliance at the end of the trial so that one might gain some appreciation, qualitative and incomplete as it may be, of what one should expect when the drug is taken as prescribed.

Another type of noncompliance is the subjects’ adherence to the protocol procedures and schedules. It is the role of the investigator to make sure that the protocol is adhered to. Lack of adherence to the protocol complicates the analysis and may make the result difficult to interpret.

Dropouts

Subjects may drop out of the trial for a variety of reasons. Some could be unrelated to the trial such as relocation, but others, such as experiencing adverse events, the perception of no efficacy or perception of well-being, could be strongly correlated with the study drug effect. The result is that some subjects will have no data to evaluate from some time point onwards. When the reason for dropping out are treatment related, the patterns of dropouts will be typically different between the different treatments, and ignoring the missing data will introduce bias into the analysis. There are a number of methods for handling dropouts, none of which is entirely satisfactory. One common way is to use the Last-Observation-Carried-Forward
(LOCF) method. In this method, the last available value is substituted for all missed measurements. The problem with this approach is that it assumes that had the subject not dropped out, he or she would continue to respond exactly the same way they did on their last visit before dropping out. This assumption is never verifiable and often unreasonable. Another approach is to substitute the worse possible value for the missing data. The rationale for this approach is that the results of the analysis will show ‘worst case scenario’ and if the drug passes this test and can be labelled safe and effective, it would still be so had subjects not dropped out. This rationale is certainly plausible. The trouble is that efficacy of important and moderately efficacious drugs may be missed, or mildly toxic drugs may end up with unnecessarily serious safety warnings on their labels. There are other methods of statistical ‘imputation’ where a value is calculated using some algorithm and is substituted for the missing value. The reasonableness of these procedures must be judged on a case-by-case basis by examining the underlying assumptions and judging their appropriateness in the given situation.

**Missing data**

Dropouts present one type of missing data; namely, data are not available from a certain time point onward. Data could be missing in many other ways. A subject may miss a visit, a sample could be invalid or a subject may fail to fill out a form or questionnaire. When data are missing at random, the effect is generally some loss in the power of the statistical analysis. When data are missing according to some pattern, bias can be introduced in addition. Some statistical study designs are particularly sensitive to missing data. Crossover designs are such designs. In crossover designs, each subject is randomly assigned to a sequence of treatments administered at certain time interval apart. The reason for using these designs is that each subject serves as his own control, and the comparisons between treatments are done within subjects. When the within-subject variability is substantially smaller than the between or inter-subject variability, the crossover design may be quite powerful and offer great savings in the utilization of subject resources. The loss of one value in a crossover study may result in a loss of the entire sequence. Some designs require certain balances among the treatments and schedules of treatment. Missing data can destroy such balances, seriously handicapping the statistician’s ability to analyze the data. Here too, imputation, with all the caveats going along with it, is the method of ‘correcting’ for the missing data. When much data are missing, say 20% or more, one should seriously question the validity of the conclusions drawn from the study, as they might be over-influenced by the assumptions made how to handle the missing data than by the data themselves.

**Intent-to-treat analysis**

One possible way of handling protocol violations, noncompliance, missing data, dropouts and so on is to remove all subjects whose violations are considered to be serious from the analysis and analyze only the data obtained from the subjects who reasonably complied with all the requirements stated in the protocol. Such analysis is sometimes referred to as per-protocol analysis (PP). The problem with this approach is that the effectiveness of the randomization process as a mechanism to bestow balances among latent on non-latent prognostic factors, and set the stage for making causal relationship inferences, is disturbed. Also, if the reasons for these violations are not independent of treatment or the subject’s condition, the removal of these subjects for the analysis may introduce a bias in the analysis. Therefore, it is customary to always perform an intent-to-treat-analysis (ITT) in which all subjects randomized, or all subjects randomized who received at least one dose of study medication, are included. The proponents of this approach argue that in addition to the preservation of the randomization process, the ITT reflects ‘real-life’ results. They argue that in ‘real-life’, as opposed to the artificial setup of the clinical study, neither patients nor their physicians follow a specific rigorous protocol. So, if the outcome of noncompliance, for example, is reduced efficacy, this is what one should expect to see when the drug
is used in clinical practice. The use of the ITT is required by the FDA as one of the analyses to always be presented to them. The problems we highlighted earlier in this section present challenges to the data analyst that can be addressed at the analysis phase only to a limited extent. It is impossible to design a trial so that these problems will be prevented entirely. However, a careful design of the trial and diligent execution and monitoring of the trial can minimize them.

### 25.13 The dissemination of clinical trials results

Clinical trials are complex and expensive scientific endeavors. For this reason, most clinical trials are supported by either pharmaceutical companies or government. Pharmaceutical companies conduct clinical trials not only as part of their clinical development of new therapies but also to discover new indications or special features of their approved drugs as part of their marketing activities. The results of trials conducted as part of the drug approval process are summarized and submitted to the FDA. In addition, the FDA requires sponsors to summarize and submit the results of all other studies of the drug conducted by the sponsor or that were published in the scientific literature. This information becomes part of the public knowledge after the drug is approved. Studies conducted outside of the New Drug Application (NDA) process are treated quite differently. As these studies are conducted for the purpose of promoting the sales of the drug or in exploration of additional indications, there is no requirement to submit the results to any governmental agency unless the company decides to submit a supplementary NDA. Many such trials result with negative outcomes and the sponsors as well as the clinical investigators have little or no incentive to expend the resources of analyzing data from trials and publish the results. Contributing to this is the fact that scientific publications must make editorial decisions as to what they will and will not accept for publication. Negative studies are often found uninteresting scientifically and are refused publication. The result of this is that the information available to the medical community is selective and incomplete. This might have serious public health consequences, as it could influence medical practice. Medical practitioners may not be aware of certain adverse effects of a drug they prescribe, the usefulness of drugs in the treatment of certain conditions may not be known, or worse, treatments proven ineffective may continue to be employed. This problem has been recognized and a federal law was passed in 1997 requiring the sponsors of clinical trials to report the existence and result of their trials to the FDA to be included in a trial registry and available to the public. The law has been largely ignored by the pharmaceutical industry, and the FDA did little to enforce it. A registry was established in 1998 but only a small percentage of industry-sponsored trials were posted in it. This issue came to the attention of the American public recently after it became known that one of the nation’s major pharmaceutical manufacturers has been withholding information of serious adverse events of one of their antidepressants in children and adolescents. (Bloomberg Business News, 2004; The Washington Post, 2004a, 2004b). It seems that the publicity given to this issue may encourage sponsors to be more diligent in making the results of their trials known and the FDA enforcing this requirement.

### 25.14 The statistician’s role

Information derived from data collected in a clinical trial is the ultimate product of the trial. Every aspect of the trial from its conception to its execution impacts the quality of the data and the information they contain. The final step in the process, the analysis, is nothing but the application of statistical methods for organizing the data, summarizing them and extracting relevant information; that is, separating the signal from the noise. The statistician’s ability to make up for design deficiencies and for noisy data is limited, and the same rule defining good practice of medicine applies here as well: the best treatment of a disease is to prevent it. The statistician’s greatest impact
could, therefore, be at the front end – during the trial planning – rather than the back end – at the analysis phase.

The study protocol and case report forms (CRF)

A clinical trial is a complex scientific undertaking that requires the collaboration of many people: clinical investigators, subjects, study coordinators, data managers, statisticians, programmers and many more. It is, therefore, of critical importance that a study plan, procedures and conventions will be laid out clearly in advance in a document so that all the participants in this journey will follow the same road map. The study protocol is this road map. Like any good road map, the study protocol must be very clear about the ultimate goal and direction of the journey – the study objectives. Often, the clarity of the study objectives in the protocol determines the coherence of the rest of the protocol. Clearly and specifically stated objectives will help identify when the primary measures of efficacy, for example, are inadequate, or when the design is flawed, or when superfluous data, which will not contribute anything to answer the questions posed in the objectives, are going to be collected.

The creation of the study protocol is a multidisciplinary and collaborative effort. Every aspect of the protocol impacts all other aspects. A medical procedure may impact the response of subjects to treatment, their compliance or other important aspect that ultimately will impact the data and the conclusions that can be drawn from them. For this reason, every member of the study design team must assume responsibility for the entire protocol. The statistician may be responsible directly for writing the statistical design considerations and the analysis plan, yet his or her involvement in all other aspects of the design that feed into it are equally important.

The CRF is the data collection tool for the clinical trial. Often, the design of the CRF is viewed as a technical task auxiliary to the trial, and the statistician may not see it until the trial is ongoing and the data start coming in for processing. The CRF design is an important activity that can make a difference in the quality of the data obtained in the trial. It should be viewed as an integral part of the protocol development process, and input from the clinician, the clinical monitor, and the statistician must be obtained. The CRF is a multipurpose instrument. It serves the investigator as the tool for recording the data obtained in the trial, must facilitate the review of the data by the clinical monitor, and is the document used by the data manager to build the database for statistical analysis. The organization and structure of the CRF, the way the questions are phrased, the use of codes, all impact the data quality.

Since the early 1980s, technology has been available for electronic transfer of the data from the investigational sites to the data center. However, this technology had very limited use until recently. Electronic data collection (EDC) systems have become very powerful and attractive in the last few years due to the maturity and growing power and speed of the Internet. The use of EDC systems can speed up the data processing and thus ultimately reduce the entire new drug development process. The procedures involved in the use ECD systems are still evolving, but one can predict with certainty that these methods will become the dominant mode of data acquisition in the not too far future.

Analysis and reporting

The analysis of the data at the end of the trial is, of course, the statistician’s domain. A successful analysis is one that reaches unambiguous conclusions, not necessarily the ones the clinical researcher is hoping for. As we emphasized earlier, the success of the analysis depends entirely on the way the trial was conducted and monitored, and the way the data were generated and collected. The statistician’s role is to utilize the appropriate tools designed to most effectively extract the information from the data. The analysis tools do not create information. We emphasized the need to prepare for the analysis at the design stage. It is also important to think one step ahead and consider the need to analyze the
data obtained from a number of different studies. A new drug application usually consists of many different studies. The approval of the application is not based on any single study rather on the synthesis of the information obtained from all the studies. Data from some studies will have to be combined and analyzed. Such an analysis, called meta-analysis, must be planned for in advance, too. Two examples of meta-analysis are the integrated summary of safety (ISS) and the integrated summary of efficacy (ISE). These analyses must be planned for just as if the combined database represented data from a new study. Ideally, plans for meta-analyses should be made at the time the individual studies are planned. This is not always possible, but this is the best way to assure that the meta-analysis database used for the analysis is coherent. For example, if the adverse events information is collected in two studies using different data collection forms, the combination of the individual databases may be difficult and some information may be lost.

Epilogue

An anonymous cynic once said that there are three types of liars: liars, damned liars and statisticians. This statement reflects the discomfort many researches feel when working with statisticians. The image of the statistician taking the data to his or her dark room, performing incomprehensible manipulations behind closed doors and coming back with results, charts and magic numbers, throwing around vaguely understood terms, is unfortunate. It is my hope that this chapter helps to disperse the haze and clarify the statistician’s role and mode of thinking. The statistician is neither a liar nor a magician; rather, the statistician is a professional trained in scientific methods devised to establish causal relationships under conditions of uncertainty. My goal in writing this chapter was not to turn the reader into a statistician. Instead, it was to bring the statistician out of the dark room into the open, and by reviewing the issues he or she is concerned about and clarifying basic terminology, to facilitate communication between the statistician and the rest of the study team.

References and additional reading

Pharmaceutical research and development is a lengthy (8–12 years) and costly process (approximately $500 millions in 2001). It starts from discovery of the compound, biological screening, animal toxicological studies, formulation, assay development/validation, clinical pharmacology, stability testing, clinical trials, data management, statistical and clinical evaluation, new drug application and promotional marketing. At each stage of the research and development, data are generated, processed and validated before being subject to statistical analysis. Data management plays a significant role in assuring the government agency and consumers that the database represents a pool of information that was accurately collected and processed and logically presented. With the advancement of pharmaceutical technology in identifying new compounds, and improved efficiency in software support and information processing, the duration of exclusivity enjoyed by a new drug has been drastically reduced before a competitive drug of the same or a similar class reaches the market. For example, the duration of exclusivity (PhRMA, 1997) for several major drugs is summarized in Table 26.1.

Because of the accelerated shortening of the duration of the exclusivity, the pharmaceutical companies tend to initiate clinical trials in several countries simultaneously to obtain worldwide clinical data. This strategy will give the pharmaceutical companies a chance to market the drug in many countries simultaneously and recover as much cost as possible before the competitors join in. To collect worldwide data and pool them together presents a special challenge to data management professionals. It is necessary to consider differences in culture, medical practice, laboratory standards/units, classifications of disease and medication, drug reactions, religion, self-medication, drug interactions and so on. Therefore, a detailed and coordinated data management plan, standard operation procedures, quality control (QC) and quality assurance (QA) are essential to produce a reliable database.

26.1 Obtaining the project material

To develop a data management plan pertinent to the project, a checklist of the project material is necessary to enhance the planning. The items to be collected include the protocol, annotated case report forms (CRFs), literature, log-in and tracking forms, file structures, coding rules, CRF review conventions, query handling procedure, required edit checklist, central laboratory address/file format, laboratory normal ranges, clinically...
significant ranges, timelines, QC rules, QA sampling, error analysis, criteria to release the database, disaster recovery plan and so on. Most of these rules and conventions are preliminary and are collected from earlier studies. These rules and conventions will be discussed by the project team from time to time to make them pertinent to the current studies.

### 26.2 Formation of the project team

Pharmaceutical companies usually assign a project manager to coordinate the formation of the project team (Table 26.2). The project manager works closely with the functional department heads to select the team members. The team usually includes representatives from the departments of regulatory affairs, clinical research, medical writing, biostatistics, data management, programming and document supports. The project manager should coordinate the activities to make sure that the team has adequate resources; the project information is distributed in a timely fashion; the status is issued; milestones are reached at each stage; and the team members have a clear and detailed instruction of the priorities of the various protocols. For multinational projects, the quality of CRFs varies from country to country. It requires a great deal of management skill on the part of the project manager to balance national pride and quality requirements without sacrificing the quality of the final database.

### 26.3 Project setup

From the data management perspective, the clinical data coordinator (CDC) is the central team member receiving and distributing data-related information to the project team members. The CDC meets with the project team members to review the project material collected and to elicit the rules and special requirements from the statistician, clinician, safety officer, medical writer and regulatory associates. These project materials, rules and special requirements will be considered in conjunction with data management requirements to develop the data management plan. The CDC should prepare the following documents before the clinical trials are initiated:

- Data creation flow chart (Figure 26.1)
- Project team personnel list (Table 26.2)
- CRFs log-in sheet (Table 26.3)

#### Table 26.1 Duration of exclusivity for some major drugs

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Year approved</th>
<th>Exclusivity (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inderal</td>
<td>1968</td>
<td>10</td>
</tr>
<tr>
<td>Tagmet</td>
<td>1977</td>
<td>7</td>
</tr>
<tr>
<td>Capoten</td>
<td>1980</td>
<td>5</td>
</tr>
<tr>
<td>Prozac</td>
<td>1988</td>
<td>4</td>
</tr>
<tr>
<td>Diflucan</td>
<td>1990</td>
<td>2</td>
</tr>
<tr>
<td>Recombinate</td>
<td>1992</td>
<td>1</td>
</tr>
<tr>
<td>Invirase</td>
<td>1995</td>
<td>0.25</td>
</tr>
</tbody>
</table>

#### Table 26.2 Project team personnel list

<table>
<thead>
<tr>
<th>Protocol No.</th>
<th>Project team coordinator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of drug</td>
<td>Directory location:</td>
</tr>
<tr>
<td>1. Regulatory associate:</td>
<td></td>
</tr>
<tr>
<td>2. Clinician/medical writer:</td>
<td></td>
</tr>
<tr>
<td>3. Primary statistician:</td>
<td></td>
</tr>
<tr>
<td>4. Secondary statistician:</td>
<td></td>
</tr>
<tr>
<td>5. Scanner</td>
<td></td>
</tr>
<tr>
<td>6. Primary CDC</td>
<td></td>
</tr>
<tr>
<td>7. Secondary CDC</td>
<td></td>
</tr>
<tr>
<td>8. Data entry screen designer</td>
<td></td>
</tr>
<tr>
<td>9. Edit check programmer</td>
<td></td>
</tr>
<tr>
<td>10. Quality assurance</td>
<td></td>
</tr>
<tr>
<td>11. Data entry</td>
<td></td>
</tr>
<tr>
<td>12. Data verifier</td>
<td></td>
</tr>
</tbody>
</table>

#### Table 26.3 CRFs log-in sheet

<table>
<thead>
<tr>
<th>Protocol No.:</th>
<th>Name of drug:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Clerk name:</td>
<td></td>
</tr>
<tr>
<td>1. Log-in date:</td>
<td></td>
</tr>
<tr>
<td>2. Investigator number and name:</td>
<td></td>
</tr>
<tr>
<td>3. Patient number/initial:</td>
<td></td>
</tr>
<tr>
<td>4. Book/visit number:</td>
<td></td>
</tr>
<tr>
<td>5. Batch name:</td>
<td></td>
</tr>
<tr>
<td>6. Comments:</td>
<td></td>
</tr>
</tbody>
</table>
CRFs COLLECTED BY CRAs

Step 1
- LOG-IN TRANSMITTALS
- PREPARE
- SCAN

Step 2
- VERIFY SCANNING
- INDEX
- INDEX QUALITY CONTROL

Step 3
- REVIEW & ANNOTATE CRFs
- ENTER INITIAL REVIEW QUERIES

Step 4
- KEYING OF CRFs
- VERIFICATION OF CRFs (double entry)

Step 5
- ENTER “DATA ENTRY” QUERIES
- ENTER “EDIT CHECK” QUERIES

Step 7
- PROCESS RETURNED QUERIES
- CORRECT IMAGES & DATABASE

Step 8
- INVESTIGATE & CORRECT

Step 9
- AUDIT OF CRC DATA

Step 10
- FINAL DATABASE

CLIENT / CRO / CRA

INDEX ISSUE RESOLUTION

Figure 26.1 Data creation flow chart
26.4 Data processing

Log-in and scan process

To prepare the CRFs to be scanned into the computer, do the following:

1. Verify the shipment of CRFs from clinical research department to the inventory of data management department (Table 26.3).

2. Check the CRFs to assure that the header information is accurate and complete.

3. Prepare the CRF file folder with the cover page (Table 26.4), which carries the following information: batch number, site, patient ID, visit number, log-in date and the initials of the person who logged the CRFs. This will ensure that the scanner will assign the patient information to the correct fields of the electronic image files.

4. Scan CRFs into the computer image files.

CRFs image review process

This process is to ensure that unexpected data problems or unusual interdata relations in various data fields are identified. It is a very important step in the data process: many companies have encountered data quality problems because of the lack of this step, which is not included to replace the computer edit check but rather to enhance it. The basic principles for the image review are checking...
the ‘accuracy’, ‘completeness’ and ‘consistency’ of the data within a subject and across subjects. This review and timely computer edit checks will provide feedback to the monitoring staff concerning a problematic investigator or CRF page, so that corrective action of monitoring practice or enhancement of the computer edit checks can be implemented promptly. The review should include the following:

1. Are there missing header information, missing pages and visits.

---

### Table 26.6 Data query sheet

<table>
<thead>
<tr>
<th>Protocol No.:</th>
<th>Data submitted:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of drug:</td>
<td>Date returned:</td>
</tr>
<tr>
<td>CDC name:</td>
<td></td>
</tr>
<tr>
<td>Site/pat. no.</td>
<td>Logged (no.) (%)</td>
</tr>
<tr>
<td>Investigator signature:</td>
<td>Date:</td>
</tr>
<tr>
<td>CRA signature:</td>
<td>Date:</td>
</tr>
</tbody>
</table>

### Table 26.7 Data process status

<table>
<thead>
<tr>
<th>Protocol No.:</th>
<th>Logged (no.) (%)</th>
<th>Reviewed (no.) (%)</th>
<th>Keyed (no.) (%)</th>
<th>Verified (no.) (%)</th>
<th>Audited (no.) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of drug:</td>
<td>Site/inv.</td>
<td>Total:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDC name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 26.8 Audit sheet

<table>
<thead>
<tr>
<th>Protocol No.:</th>
<th>Audit sheet programmer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of drug:</td>
<td>Version date:</td>
</tr>
<tr>
<td>Name of CDC:</td>
<td>Revision date:</td>
</tr>
<tr>
<td>CRF Page 1:</td>
<td>Visit date: 02/10/97</td>
</tr>
<tr>
<td>Eligibility criteria:</td>
<td>Initial: RLD</td>
</tr>
<tr>
<td>Inclusion criteria</td>
<td>1 2 3 4 5 6 7</td>
</tr>
<tr>
<td>1 1 1 1 1 1 1</td>
<td></td>
</tr>
<tr>
<td>Exclusion Criteria</td>
<td>1 2 3 4 5 6 7 8 9 10 11</td>
</tr>
<tr>
<td>2 2 2 2 2 2 2 2 2</td>
<td></td>
</tr>
<tr>
<td>CRF Page 2:</td>
<td>Visit date: 02/10/97</td>
</tr>
<tr>
<td>Infection history:</td>
<td>Initial: RLD</td>
</tr>
<tr>
<td>Number of infections in past year: 3</td>
<td></td>
</tr>
<tr>
<td>Therapy for infection in past year: 2</td>
<td></td>
</tr>
<tr>
<td>Medication: Drug aaa</td>
<td>Effective: 1</td>
</tr>
<tr>
<td>(etc.)</td>
<td>Complete med.: 1</td>
</tr>
</tbody>
</table>
2. Are randomization numbers allocated sequentially?

3. Are blanks are properly answered?

4. Check adverse events and prematurely discontinued subjects, with special attention to the comments for hidden information.

5. Has clinically significant laboratory abnormality has been followed by the investigator?

6. Does the drug inventory match the number consumed?

7. Clarify all text items, for example adverse events, concomitant medications, physical examinations, ECG, progress notes and so on.

**Data entry and double entry using CRF images**

- Autocode the data using structured glossaries, including drug class, body system, preferred term and verbatim term.
• Manual code the ‘no-hit’ terms and update the glossary.

• Run computer edit checks (Table 26.5) and generate queries. Reconcile the discrepancies between the queries generated by manual review and computer edit check. Issue the queries (Table 26.6) to the investigators.

Query resolution and database update

When the answers to the queries are returned, the CDC updates the database and CRF images. This is a continuous process during the course of the clinical trials.

Create test datasets for various analysis population

To make the adequate inferences of the efficacy and safety of the study drug, Federal Register (1996) should be followed: in Section 11.1, ‘Data Sets Analyzed’, it states:

Exactly which patients were included in each efficacy analysis should be precisely defined, e.g. all patients receiving any test drugs/investigational products; all patients with any efficacy observations or with a certain minimum number of observations; only patients completing the trial; all patients with an observation during a particular time window; or only patients with a specified degree of compliance. It should be clear, if not defined in the study protocol, when (relative to unblinding of the study) and how inclusion/exclusion criteria for the datasets analyzed were developed. Generally, even if the applicant’s proposed primary analysis is based on a reduced subset of the patients with data, there should also be, for any trial intended to establish the efficacy, an additional analysis using all randomized (or otherwise entered) patients with any on-treatment data . . . A diagram showing the relationship between the entire sample and any other analysis groups should be provided.

Therefore, an algorithm has to be developed to precisely define how each analysis population of the dataset is defined. For example, there are at least four analysis population datasets, for example the intent-to-treat (ITT) population, the per-protocol (PP) population, the safety population and the microbiological population, as indicated in the diagram (Figure 26.2). During the derivation of various analysis populations, it may be necessary to issue new queries and update the database, based on the resolution of the queries.

Status reporting (Table 26.7)

1. From the image files and the database, a weekly production report is generated.

2. A cross-check of milestones and progress achieved should be made and the status reported to the department heads for review and action.

3. The department heads may adjust the resources, depending on the progress report.

Create audit sheet for audit

The computer-generated audit sheet (Table 26.8) should be formatted in the same sequence as the fields in the CRFs. This will enhance the speed of the audit task. The QA auditor will check the audit sheet against the CRF images.

Issue interim audit document and audit summary

When 10% of the CRFs have been scanned and entered into the computer, the interim audit should be conducted in order to tune up the CDC review manual and edit-check programs. Findings regarding the quality of the database should be given to the head of the data management group for possible action. The audit document (Table 26.9) should include patient ID, the initials of the keyer and verifier, CDC, editing programmer, type of audit, number of errors, description of errors. It is a tool to find out which records tend to produce more errors and
Figure 26.2 Derivation of study population
Figure 26.2 (Continued)
who tends to make most of the mistakes. Is CDC
review adequate? Are the programs written for
the computer edit checks sufficient? Did the
data entry verifier find the problems of the
keyer and fixed them? Once the CDC review
manual and computer edit checks have been
improved, a second interim audit should be
repeated when 50–60% of the CRFs have been
scanned and entered. Final audit should be per-
formed when all the CRFs are scanned and
entered. In addition to the audit memo issued
during the interim audits, an audit summary
report (Table 26.10) should be issued to sum-
marize the quality of the final database. This
will also give management an index of the
error rate, which measures the confidence level
of releasing the database.

### Database release memo

Once all the queries have been resolved and
updated to the image files and database, the data-
base is officially locked. A database release memo
(Table 26.11) should be issued to the project sta-
tistician, all other team members and management.

The project statistician will then merge the file of
the randomization codes to the database to generate
the analysis datasets.

### 26.5 Disaster recovery plan

The data files and the completed CRFs generated
from the clinical trials are more precious than the
hardware. In addition to daily and monthly back-up, pharmaceutical companies should have
a detailed recovery plan in case of unexpected
disaster. The disaster recovery plan should include
the following:

1. **Key personnel contact list**, with home telephone
   and pager numbers listed.

2. **List of critical applications and operations.**
   It should be a company’s policy to set up an off-
site processing center with the same hardware–
software setup. This should be able to be made
operational within 2 h should it become necessary
if a disaster strikes the data center. Critical appli-
cations and operations include upcoming NDA
studies, safety database, NDA summaries.

3. **Off-site storage.** In order to be operational at the
   off-site process center for critical applications,
   the files that need to be updated to the off-site
   center are master files for all completed projects,
daily back-ups for ongoing studies, monthly
   system files, monthly glossary updates, monthly
   safety monitoring, NDA files and production job
   streams. The protocols, CRFs, regulatory docu-
   ments, rules and manuals should also be stored
   off-site. A drill of the disaster recovery plan
   should be put to test at least every 6 months to
   reveal any unanticipated problem.

### References

ICH. 1996. ‘International Conference on Harmoniza-
tion: Guideline on Structure, Content and Clinical
Study Reports; availability; notice’. Federal Regis-
ter 61(138): 37326.

27 Patient Compliance: Pharmonics, a New Discipline

Jean-Michel Métry

27.1 Summary

Patient noncompliance with prescribed drug regimens is a long recognized, but until recently poorly analyzed, aspect of ambulatory healthcare. It was only in 1987 that objective, satisfactory methods became available for compiling drug-dosing histories in ambulatory patients, which is the cornerstone for measuring compliance. Since then, much new information has been gained. The term *pharmonics* refers to the new branch of the biopharmaceutical studies, namely the study of what patients do with the medicines they have been prescribed.

It is important to have sound terminology for pharmonic studies. *Adherence* is a blanket term that covers the three phases of ambulatory pharmacotherapy. The first phase is *acceptance*, that is, whether or not the patient accepts the principle and regimen of the prescribed treatment. If acceptance is forthcoming, the patient commences to engage with the drug-dosing regimen. The second phase is conveniently called *execution*, the quality of which is indicated by the parameter called *compliance*, which is the extent to which the patient’s dosing history corresponds to the prescribed dosing regimen. The third phase is called *discontinuation*, that is, when the treatment ceases – whether because the prescriber called for it to cease, or because the patient stopped engaging with the dosing regimen and either stopped the treatment altogether or dropped his/her drug intake to levels so low as to be therapeutically inconsequential. It is convenient to use the term *persistence* for the length of time between the first-taken dose and the last-taken dose in a course of ambulatory pharmacotherapy. The reason for separating these three phases is that the first and third phases are binary, or dichotomous, phenomena, in that they either happen or they do not. The second phase, however, is continuous and capable of varying from day to day, sometimes quite widely. One cannot have a single parameter that describes both dichotomous and continuous phenomena, and for that reason, the term *adherence*, which has a certain convenience, is inherently nonquantitative. Someone, for example, can be accurately termed a ‘poor adherer’, either because of nonacceptance, because of acceptance but poor quality of execution or because of short persistence, with either good or poor compliance during the period of time that the patient was engaged with the drug-dosing regimen.

From a methodological point of view, the most challenging of the three phases of ambulatory pharmacotherapy has been execution, which is the subject of this chapter.
Subjective methods usually used to assess patient compliance in drug trials or medical practice grossly overestimate patient compliance. Reliable measurements of drug exposure in ambulatory patients require methods that make it difficult for patients to censor evidence for delayed or omitted doses. Electronic monitoring has emerged as the gold standard method for measuring drug exposure in ambulatory patients. One mission of pharmionics-guided measurements is to accelerate and improve clinical developments of new drugs for ambulatory patients. Another mission is to improve clinical outcomes of ambulatory pharmacotherapy. The basis for doing both is the provision of full and reliable knowledge of drug exposure.

27.2 Introduction

A major reason for poor compliance is simple negligence. Neither good intention nor a professional level of understanding of medicine and pharmacology competes well for priority in busy lives: 35–40% of well-informed, cooperative patients frequently delay or omit scheduled doses. The resulting range and patterns of drug intake are remarkably similar, essentially irrespective of drug, disease, prognosis and even symptoms. Yet, although the dosing patterns are similar, their medical and economic consequences vary widely, depending on drug, disease and severity of disease and comorbidity. Thus is created varying needs for intervention, which, to be cost-effective, requires proper targeting to those patients who stand to incur big problems and high costs if their poor compliance is not improved, or other steps taken to minimize its consequences.

Thus, two very basic factors are (a) reliable detection of poor compliance and (b) reliable measurement of the consequences of steps taken to improve it. Given that clinical identification of poor compliance is so strongly biased toward underestimation, electronic monitoring, done in real time, is now the accepted standard.

Several levels of feedback of dosing history data to patients probably have future roles. A basic maneuver can be audible or visual status alerts for patients. A more intensive approach is modem- or pager-mediated error alerts for professionals willing to assume responsibility for pharmaceutical care. Obviously, the latter must be focused on well-defined, high-risk situations, in which the consequences of delayed or omitted doses are severe and costly, and actions taken are cost-effective.

27.3 What does ‘compliance’ mean?

Prior to the methodological advances, patient compliance had only a vague definition: ‘following the instructions of the health care provider’. With the advent of electronic monitoring methods, described below, it became practical to use a definition of compliance that has pharmacological meaning, in terms of drug exposure: ‘the degree for correspondence between the actual time history of dosing and the prescribed regimen’. The time history of dosing expresses drug exposure, not only in quantity but also in respect to the timing of individual doses. In order to get full therapeutic benefit from the drug, with least toxicity, certain standards must be met in respect to the quantity of drug taken and the timing of doses. Each drug, depending on its pharmacokinetics and pharmacodynamics, has its own standards, which are scientifically definable in properly conducted dose-response studies.

27.4 Methods of evaluating compliance

There are two categories, direct and indirect.

Direct

The most basic, direct method is to measure the concentration of drug in plasma; unfortunately, this method is usually biased because in most instances its reflection of prior dosing history is limited only to a day or two prior to the time that blood is drawn for the analysis. These problems arise because
most drugs are eliminated from the body with plasma half-lives of 12 h or less (Feely et al., 1987; Pullar et al., 1991), such that the measurement of a drug level in plasma reflects dosing only during the past day or two. Moreover, a prominent feature of patients’ dosing behavior is an improvement in compliance in the day or two prior to a scheduled examination the so-called ‘white-coat compliance’, which is a considerable improvement in compliance in the day or two prior to a scheduled visit to the physician (Feinstein, 1990). Thus, for most drugs, the measurement of drug concentration in plasma at the time of a scheduled examination reflects dosing only during a period of frequently atypically good compliance. For those few drugs that have exceptionally slow turnover, however, periodic measurement of drug concentration in plasma gives a view comparable to that provided by the low-dose, slow turnover markers described next. One could, of course, contrive to do unannounced sampling of blood, but it is very costly, often impractical and intrusive. Certainly the finding of zero concentration of drug in plasma is clear evidence that the patient has not taken any drug during a prior period of time equal to four half-lives of the drug in plasma, for example, 48 h for a drug with a plasma half-life of 12 h.

A useful but rather cumbersome direct method is based on the use of a slow turnover chemical marker substance incorporated into the drug dosage form. With a low dose of phenobarbital used as the marker, for example, the turnover is slow enough so that a single measurement of marker concentration in plasma is indicative of dosing over a period of a week or more. Marker methods do not, however, indicate the actual timing of doses but only aggregate dosing during a time window defined by the pharmacokinetic turnover of the marker. Another disadvantage, of course, is that a series of blood samples are needed if one desires a longitudinal record of aggregate drug intake over an extended period of time.

Indirect

Prior to 1987, the indirect methods in use were those that made it easy for patients to censor evidence for delayed or omitted doses: history, diaries and counts of returned dosage forms. They have repeatedly been shown to be unreliable, giving results that, as Pullar et al. (1989) put it, ‘grossly overestimate compliance’ in both trials and practice. Other authors have drawn the same conclusion in other kinds of study situations.

In 1987, the first electronic monitor for solid dosage forms was introduced (Norell, 1984; Pullar and Feely, 1990; Cramer, 1995; Urquhart, 1997). This device monitors the opening of the drug package, by means of time-keeping microcircuitry that registers the time and date of each opening and closing of the package. With this system, the date and hour at which the package is opened and closed, as well as the interval between each pair of opening/closing events during the whole observation period can be determined. Its only disadvantage is that the actual intake of the drug cannot be confirmed, except with a rather complex combination of pharmacokinetic projection of the time-course of drug concentration in plasma with periodic direct sampling to assess the reliability of those projections (Urquhart, 1997). In addition, experience has shown that patients not wishing to take their medicine rarely go to the length of opening the drug package at scheduled times, but not taking the medicine, day in and day out, throughout the whole course of prescribed treatment.

27.5 Compliance during clinical trials

A growing consensus supports the measurement, by reliable means, of compliance with the protocol-specified regimen during clinical trials. This consensus is reflected in comments by leading biostatisticians – Paul Meier (1991), Bradley Efron (1991, 1998), Donald Rubin (1991, 1998) and Sir David Cox (1998). The gold-standard method for evaluating patient compliance is now accepted to be electronic monitoring (Cramer, 1995; Kastrissios and Blaschke, 1997; Urquhart, 1997), and the nature of the data found with electronic monitoring is well summarized in (Urquhart and de Klerk, 1998). The difficulties of trying to interpret data from unreliable methods, for example, counting returned, unused
tablets, which are confounded by the high incidence tablet-dumping by poorly/partially compliant patients, are documented in various ways by the following studies (Rudd et al., 1989; Waterhouse et al., 1993; Pocock and Abdalla, 1998). Readers of Pocock and Abdalla (1998) should take note that the authors were seemingly oblivious to the well-documented fact (Pullar et al., 1989; Rudd et al., 1989; Waterhouse et al., 1993) that a substantial fraction of patients discard some or all of their untaken dosage forms before returning the tablet container to the investigator.

But what are the advantages of measuring compliance in the different phases of development of a drug?

The past decade of research with electronic methods for compiling dosing histories in ambulatory patients has taught a number of notable lessons, which can now be incorporated economically and with little risk into phase II testing (Sheiner, 1997; Urquhart, 2002). The main lessons have to do with the reliability of interpreting what are inherently observational data, derived from patients’ reliably compiled actual dosing patterns and their clinical correlates. Novel statistical methods (Loeys and Goetghebeur, 2003), new insights into the impact of drug holidays on the actions of drugs and astute use of data on time-sequence of events, together create the opportunity to greatly enrich the yield of pragmatic information from phase II ambulatory trials.

27.6 During early phases of drug development (phase I and II studies)

- The implementation of a pharmionic program to compile dosing histories electronically in ambulatory patients can simplify the design and can reduce the variance of PK/PD studies.

- For studies, in which present practice calls for volunteers to be confined in a hospital-type setting, a pharmionic program could allow shorter periods of confinement. Once the initial safety issues are resolved, the pharmionic approach can provide reliable measurement of external drug exposure, without the need for ongoing confinement, thus reducing costs, facilitating recruitment of volunteers and allowing longer periods of follow-up.

- For population PK studies, well-controlled intensive sampling days are recommended to assess the PK profile at what is often erroneously assumed to be a steady state. A pharmionic program exposes this error and its negative impact on the results and the time and costs of analysis. One can, with reliably compiled drug-dosing histories, reduce the number and length of intensive sampling periods. Reduced costs of patient reminders, such as phone calls can also be expected. The time involved in trying to extract information on drug exposure from diary entries can mostly be avoided, as such data are mostly useless (Vrijens, 2002; Vrijens et al., 2003).

With the information available today, it is not yet possible to determine to what extent between-patient variance can be reduced, but within-patient variance can be reduced by 55% (Vrijens et al., 2003). Thus, based on current evidence, we expect that a pharmionic program will result in considerable reduction in study costs while improving the quality of the collected data and the resulting definition of pharmacokinetic parameters.

- The implementation of a pharmionic program will enhance the quality and the relevance of collected data.

- The determination of the optimum dose (i.e. a dose that is likely to be both safe and effective) is often compromised by unrecognized underdosing by the subjects involved in dose-ranging studies, some of which is caused by simple forgetfulness, and some of which occurs because patients tend to ‘auto-adjust’ their exposure to prescribed therapy. It is not unusual that patients receiving the highest dose intentionally reduce their drug exposure due to perceived side effects. Adherence to prescribed therapy across different doses in dose-ranging
studies is thus not necessarily the same across the different dose groups. This self-selection of drug exposure by the patients involved in dose-ranging studies makes it hard to find the optimal dose in the absence of a reliable measure of external drug exposure.

- The erroneous assumption of perfect compliance when fitting PK models to observed concentration measures leads to a poor fit, often accompanied by non-convergence and seriously biased results. However, when drug intake times are electronically recorded over the course of the study, the appropriate hierarchical model for nonlinear effects over time can translate the data into accurate estimates.

- Patients vary the dosing interval, and electronic monitoring of a wide range of over- and under-dosing patterns has been a neglected opportunity to observe and model realistic concentration–time–effect relationships. Underdosing, drug holidays and undetected early cessation of dosing are common features of clinical trials, and likely are frequent sources of low response and high variability in response to the protocol-specified dosing regimen. Especially for non-linear PK/PD estimation, not only bias can be reduced but also higher precision can be attained from the same number of data points when irregular drug intake times occur and are captured by electronic monitoring, even in well-controlled studies. Estimators of PK/PD parameters gain in robustness when they are based on the actual, rather than assumed, external drug exposure.

- By a better characterization of the dose-response characteristics of a product candidate, the program will bring two major advantages to drug development:

  - Allow development of the drug at the appropriate dose and avoid potential, post-marketing and post-pricing dose reductions as are occurring today for more than 22% of products (Cross et al., 2002; Heerdink et al., 2002).

  - The improved quality of the recorded exposure data is expected to have the net effect of significantly reducing the workload of the PK/PD group.

- The number of queries for outlying concentrations will be reduced to a minimum. Typically, when relying on the assumption of steady state, more than 20% of observed concentrations have to be queried. Electronic compilation of dosing histories will reduce this proportion of queries to a <2%.

- Consequently, the time needed to remove the observation points based on above queries, as well as the time to justify that some patient data were removed, will be reduced.

- The time needed to arrive at a satisfactory PK/PD model will be reduced.

- A sound pharmionic program will reduce by half the amount of time needed to process a population PK/PD study.

- Ultimately, a pharmionic program will hasten and improve the ‘Go/no-Go’ decision to start the development phase (phase III).

- A pharmionic program will allow an earlier and a better characterization of the dose–time–response surface in the target population.

- It will deliver faster and greater insight than is now possible for dose selection in dose-ranging studies.

- It will facilitate a degree, not now possible, of ‘bullet-proofing’ against post-marketing/post-pricing reductions of the ultimately recommended dosing regimen. This consideration grows in importance as pharmaceutical prices increase.
It will provide a much more robust basis than presently possible for simulations of phase III clinical trials, because they will be based on actual rather than assumed dosing histories and on oversimplified pharmacodynamic characterizations.

27.7 During drug development (phase III studies)

- A pharmionic program can be implemented to enhance patient adherence, based on the principle that ‘what is measured can be managed; what wasn’t measured didn’t happen’. In a confirmatory trial, it is crucial to guarantee that patients get the optimal exposure to the test drug.

- In placebo-controlled studies, this approach will guarantee a greatest average improvement in the response of the test drug compared to the placebo effect.

- In positive-controlled studies, the assurance of good exposure to the test drug is essential for maximal assay sensitivity, to guarantee that the claim of equivalence is not related to a lack of drug exposure.

- Having reliable pharmionic data avoids the increase in variance of the response that arises from variable execution of the prescribed dosing regimen – widely recognized as a leading source of variance in drug response. In engineering terms, having reliable pharmionic data converts ‘noise’ into ‘signal’.

- The implementation of such a program could thus result in an increase of study power or equivalently in a smaller sample size needed to achieve a given level of statistical power, resulting in a shorter and less expensive confirmatory phase.

- Supportive pharmionic analysis in addition to conventional intention-to-treat (ITT) analysis. As another supplement to the ITT analysis, a pharmionic program will allow robust estimates of:

- the treatment response that can be expected within the subpopulation of patients who dose essentially correctly, as estimated by current methods of causal inference;

- dosing errors that have the greatest potential to undermine effectiveness;

- dosing errors that have the greatest potential to create hazard (e.g. rebound effects after sudden cessation of dosing, recurrent first-dose effects, emergence of resistance to anti-infective agents and the like).

Against the background of firm knowledge of the impact of particular patterns of on–off–on dosing, the full benefit of the drug can thus be estimated and be used as supportive data.

- Confirmatory studies that could fail due to the usual patterns and prevalence of non-adherence to prescribed therapy could instead succeed through a pharmionics-based supportive program bringing adequate statistical power for a successful phase III program.

In conclusion, the economic advantages of faster product development and earlier termination of inherently weak product candidates (Urquhart and Chevalley, 1988; Urquhart, 2001) are well understood. So are the economics of bringing products of superior therapeutic power to the marketplace. The expression of these basic facts in specific programs of drug development are frequently obscured or confounded by the biggest single source of variance in drug response, which is unmeasured but highly variable compliance of ambulatory patients with protocol-specified drug regimens. Historically, variable patient compliance has had vague recognition, mainly because the then-available methods for quantifying drug exposure in ambulatory patients were grossly inadequate. That situation has changed, and it is now possible to measure and manage patient adherence to
prescribed therapy, and, if necessary, adjust for variable exposure to the test drug.

**Phase IV**

More robust outcomes studies because of an optimized degree of forgiveness for the more common errors in dosing.

**Commercial use**

Seamless transition to proven programs that enhance patients’ persistence with their use of product meant for indefinitely long use for higher revenues, lower marketing costs and much higher profits (Delmas et al., 2003; Eastell et al., 2003; Vrijens et al., 2003).

### 27.8 Compliance standards for analyzing real-time compliance data

For the analysis of the observation period, the data saved in the electronic monitors are transferred via a communicator to a personal computer or to a secure website. With few commands, the patient’s medication history can be visualized on the PC screen and then printed as a compliance report.

**The compliance report**

The central part of the compliance report is a quantitative and qualitative evaluation of the real-time compliance data.

**Calendar plot**

The calendar plot shows the number of daily dose units taken by the patient as illustrated in a monthly calendar.

This form of illustration facilitates the assignment of the drug intake to certain days, for example, the last days before the consultation (recognition of white-coat compliance) or weekend compliance (recognition of drug holidays). Moreover, account can be taken of the patient’s regimen behavior when evaluating reported effects and adverse effects.

An exact analysis of the temporal relationship between separate applications is given in the ‘chronology diagram’.

**Chronology**

The chronology diagram shows the dose units applied in a graph with a system of coordinates. The abscissa shows the observation period in days, the ordinate the hours of the day from 0:00 to 24:00 h. Every point in the diagram represents an application of the medication. The time interval between the doses corresponds to the regularity of the applications and permits an easier evaluation of the treatment result and also of adverse effects of the prescribed medication.

**Therapeutic coverage**

The therapeutic coverage is the percentage of time during which the patient had a therapeutically adequate effect of medication in the observation period, based on the interplay between the drug’s measured duration of therapeutically effective action, after a last-taken dose and the patient’s dosing history (Urquhart, 2000).

A useful consideration is captured in the term ‘forgiveness’, which relates to a given pharmaceutical product’s ability to continue to provide therapeutic drug action in the face of the most common errors in dosing. Forgiveness is specifically defined as the post-dose duration of therapeutically effective drug action minus the recommended interval between doses. Obviously, when an interval between doses exceeds the drug’s post-dose duration of action, there begins an accumulation of ‘uncovered hours’, during which drug action is inadequate. Therapeutic coverage is the percentage of a period of observation during which therapeutic action of the drug was maintained.
For the patient, knowledge of therapeutic coverage heightens the understanding of the impact of a particular level of compliance. For the doctor and the pharmacist, instruction of the patient is facilitated and the possibility is provided to praise patients with good compliance and to increase motivation in patients with poor compliance.

Calculation of the shortest and longest intervals between two doses, the percentage of days with correct number of doses taken and the distribution of intervals between doses complete the compliance report.

27.9 How is compliance classified: typical pattern

Full Compliance

The patient executes the prescribed dosing regimen to a high degree of punctuality. The limits of deviation from strict punctuality vary from one pharmaceutical product to another depending on the forgiveness of each (Urquhart, 1998). Thus, there are no fixed percentages of prescribed doses taken that can realistically provide a blanket definition of ‘full’ vis ‘partial’ compliance. Moreover, as discussed above, some pharmaceutical products enter the market with the prescribed drug-dosing regimen calling for considerably more drug to taken than is necessary. With such products, patients may omit half or more of prescribed doses and still end up with a good outcome of treatment. Of course, from a strictly behavioral point of view, patients can stray quite far from the prescribed dosing regimen, but the over-riding consideration is whether the pharmaceutical in question provides enough forgiveness to allow the patients to have good clinical outcomes, despite the omission or delay of many doses.

Partial compliance

The best definition of ‘partial compliance’ is a dosing history that provides a level of drug exposure that is sufficient only to elicit a partial therapeutic response. With exceptionally unforgiving drugs, a patient can take 100% of prescribed doses, but nevertheless have an inadequate therapeutic response simply because of erratic timing of doses taken. It is a product-specific matter, dependent on the forgiveness of the product in question. Note that we use the term ‘product’ instead of ‘drug’, because the formulation of some drugs can make a big difference in forgiveness, based on the use of controlled-release formulations.

Noncompliance

It is useful to recognize a level of drug exposure that could properly be called ‘de minimis’, that is, too little to matter. Again this is a product-specific matter. In the absence of reliable data on forgiveness, one might reasonably assume that an intake that, over time, averaged less than 50% of what was prescribed could be called ‘noncompliance’. Obviously, one level of noncompliance that is quite clear is zero intake.

Overcompliance

This term is used when there is evidence that the patient has taken more than the prescribed amount of medication. The outcomes of overcompliance are product specific, but can be expected to include increased numbers and severity of adverse effects, with or without increased levels of therapeutic action.

Bottom line

From the perspective of treatment outcomes, questions of how much compliance is enough, not enough and too much are product specific. From the behavioral perspective, one might set up arbitrary bounds, based simply on how far one strays from the instructions given. A common error made by many clinical researchers is to confuse the two, and mistakenly use the behavioral limits as determinants of treatment outcomes.
Which forms of partial compliance and noncompliance are particularly relevant?

White-coat compliance

The patient’s compliance in the observation period is predominantly inadequate. A few days prior to the consultation with his doctor, he improves his compliance and with it also most of the clinical parameters. This leads to the doctor wrongly assuming that the patient’s long-term treatment with the prescribed medication is adequate.

A high blood pressure, for instance, can become normal within a few days after regular short-term treatment with many antihypertensive agents. The regression of left ventricular hypertrophy (diminution of a dangerous increase of the mass of heart muscle due to an illness) can however only be achieved through regular intake of the medication over a prolonged period of time.

Drug holidays

This term implies that the patient discontinues the intake of his medication for three or more consecutive days. These so-called ‘drug holidays’ may tend to occur on days on which the patient changes his usual daily activities, that is chiefly at weekends, holidays and vacations.

Studies by Dr. W. Kruse and Prof. Dr. E. Weber, Heidelberg, have shown that approximately 50% of patients observed had at least one treatment-free phase within a four weeks of treatment period. According to these studies ‘drug holidays’ occupied 15% of the entire observation period (Kruse et al., 1990).

If a ‘drug holiday’ occurs shortly before a medical consultation, the doctor may have the impression that his patient is not under satisfactory control with the medication so far prescribed. The consequence may be an increase in dosage or an unnecessary change of medication.

Skewed dosing

The statistical distribution of drug exposure among ambulatory patients is strongly skewed downward, with relatively little overdosing, but a great deal of underdosing, relative to the prescribed dosing regimen. The consequences of this prevalent pattern of drug exposure for treatment outcomes are product specific.

Skipped dosing

The patient omits a scheduled dose. For example, if the prescription is ‘twice daily’, the patient often takes the medication once a day; if the recommended dosage is one tablet daily, he often takes one tablet every second day. Again, the consequences of this frequent error are specific to each pharmaceutical product, varying according to the frequency and timing of skipped doses and the products forgiveness.

Timing noncompliance

The daily intake of the medication is not at a regular, set time but with large temporal deviations or completely unstructured. This type of noncompliance may fail to ensure adequate therapeutic coverage, depending on the product’s forgiveness.

Actions to enhance compliance and persistence

The prevalence of suboptimal compliance in all fields of chronic, ambulatory pharmacotherapy is well established. This fact prompts the question: How to insure good outcomes in a world of imperfect compliers? Also, there is the crucial question, for chronic-use medicines: How long a patient will continue to take the prescribed medicine?

Drugs can only exert their full benefit if they are taken within certain limits of compliance with the recommended regimen. These limits are, for most
drugs, undefined, though progress is being made with studies that define these limits. The key, of course, is to know the drug’s forgiveness. The difficulty is the measurement of drug action.

In this effort, the patient holds a key position, as his/her ability to cope with the prescribed regimen is crucial for good compliance and, through good compliance with rationally prescribed medicines, good outcomes. Health professionals have an important role to play in helping patients comply properly and thus get the fullest possible benefit from their prescribed medicines. When compliance is insufficient, the outcome of the treatment is put in jeopardy and the costs of care rise due to the needless addition of second or third agents, dose escalations or diagnostic tests to ascertain the nature of a clinical problem that has been created by persistent, clinically unrecognized poor compliance.

Many studies have shown that patients undergoing long-term treatment in particular do not succeed in taking their medication correctly over a long period of time (Jones et al., 1995; Caro et al., 1999; Catalan and LeLorier, 2000; Benner et al., 2002).

Some figures may serve to demonstrate the dimensions of this problem:

- Fifteen percent of the prescriptions of general practitioners are not dispensed at the pharmacy.

- Fifty percent of all patients do not take the prescribed medication or do not take it correctly, mostly due to early, complete discontinuation of dosing, otherwise known as short persistence.

- Seven to eight percent of hospitalizations have been attributed to noncompliance; but on close review, this turns out to be hospitalizations for excessive drug intake. We now know that there are four times as many errors of dose omission than errors of excess dosing, which can result in clinical complications that mimic worsening disease. Thus, there is probably a higher percentage of hospitalizations attributed to noncompliance, but these are usually misinterpreted clinically as a worsening of the patient’s disease(s). We do not yet have good studies to quantify this aspect of the noncompliance problem.

Many patients fail to realize that it is important to take medication regularly and that they can make hazardous mistakes in the application of their medication. Moreover, many patients are for various reasons prejudiced against the prescribed treatment measures, including the prescribed medication. Problems with incomprehensible or disturbing package leaflets are only one of the aspects. The compliance of the patient is influenced by a large number of different factors. It is not a static process but a dynamic one, yet two groups have recently presented evidence that future compliance can be modeled and faithfully simulated during future months, based on 30–60 days of electronic monitoring data on the patient (dosing history). Such simulations may be sufficiently reliable at the group level to be useful for predicting group results in trials, but they cannot predict actual day-to-day dosing patterns in individual patients. Thus, they are not helpful for the practitioner, who inevitably deals with individual patients, one at a time.

The quantitative, objective analysis of the conduct of the patient in taking medication is obviously a first step toward an effective improvement of compliance, for reliable measurement is the keystone of effective management.

### 27.12 Improve compliance: but how?

The crucial step is to use the objective record of the patient (prior dosing) as a management tool to allow the patient to see what errors were made and to discuss options for how to avoid such errors in the future. This step is wholly new, for prior efforts to improve compliance have relied on patients’ self-reported compliance, which is subject to errors due to imperfect memory, mixed feelings about the treatment program and a desire to please the physician.

1. If the results of treatment are unsatisfactory, the following questions must be answered:
Is the cause pharmacological, due to failure of correctly taken drug to work as hoped, or is the cause due to inadequate compliance?

2. The compliance is not a static quantity but a dynamic process.
   Many studies have clearly shown that the compliance of most patients deteriorates as treatment progresses. Particularly in diseases with few or no symptoms, one sees a high rate of partial compliance and/or early discontinuation must be reckoned with after a few months of treatment. If the treatment results are inadequate, the doctor must judge whether the disease is taking a progressive course, whether the drug is losing its effect with prolonged treatment (which pharmacologists call ‘tachyphylaxis’) or whether the cause lies with inadequate compliance.

3. The compliance of the patient is not predictable by clinical examination.
   Studies have shown that even experienced doctors often fail to recognize partial compliance or noncompliance in their patients. There is no proven relationship between compliance behavior and parameters such as age, sex, educational background and social status, specific drugs, adverse effects of medication and nature or severity of the disease.

4. Compliance monitoring with feedback of the results to the patient enhances compliance.
   The review of the past dosing record with the patient is a powerful tool to help the patient recognize when he/she has made errors in dosing likely to undermine efficacy or cause safety problems. This review can be done by the prescribing physician, the pharmacist, a nurse or other paramedical staff, depending on the local circumstances. It is not a single review, but an ongoing process, so that the patient understands that, at the next visit, the dosing record during next interval will be the subject of review, and that the only way to compile a correct record is to pay careful attention to the prescribed regimen and link it closely to established routines in daily life. Yet, despite the disciplinary aspect of the review, most patients regard the review as a logical extension of the interest of the prescribing physician in their care. Furthermore, knowledge of the compliance behavior of the patient gives the pharmacist and the doctor the possibility of turning attention to the patient with compliance problems, of re-explaining the aim of treatment, of clearing up misunderstandings about the regimen and of reducing possible prejudices against treatment. Compliance monitoring moreover permits an individualization of the treatment, as the treatment regimen can be optimally adapted to the habits of the patient, thereby facilitating his correct execution of the agreed-upon dosing regimen. To do such adaptation effectively, it is essential to understand how much forgiveness the prescribed product allows. Without such knowledge, the process of adapting the regimen to the habits of the patient may stray outside the bounds of doses and dose-timing consistent with full therapeutic effectiveness.

**27.13 Who are the potential players involved in the field of real-time compliance?**

Every healthcare professional who has, direct or indirect, contact with the patient is a potential player (Comte et al., 2004). In the forefront is the physician who has to make sound decisions about the prescription, basing such judgment in part on average values coming out of clinical trials, but tempering judgment with understanding of the patient’s individual characteristics. During the past two decades, much has been learned about many of the various influences on drug absorption and metabolism that arise from dietary factors, concomitantly prescribed drugs and changes in renal or hepatic function. Yet, a major but hitherto inaccessible component of this dynamic process is the patient’s actual dosing history, which has the potential to influence the clinical manifestations of drug response over its full range.
Thus, the physician who has a reliable measure of the patient’s dosing history can interpret the patient’s response to the drug in far more realistic manner than the physician who can only guess at the patient’s actual drug intake. Such guesses are usually skewed toward overestimating patients’ actual drug intake. Obviously, the prescriber’s perception of the drug’s reliability and overall value will be diminished by patients who appear to the prescriber to be nonresponders but who in fact have taken too little drug to produce a clinically useful response (Vanhove et al., 1955; Milgrom et al., 1996). For example, Burnier and Brunner found that slightly over half the patients referred to their hypertension clinic for evaluation of ‘drug refractory hypertension’ turned out to be clinically unrecognized non-compliers, whose noncompliance only came to light when the first step in their diagnostic evaluation was 60 days of electronic monitoring of their intake of each of the three antihypertensive drugs that most of them had been prescribed by their primary physician (Urquhart, 1991; Burnier et al., 2001).

Another facet, obviously, is to deal with the patient whose compliance has been substandard and take effective action to make as much improvement as possible in drug intake, and to switch, if necessary, to the agent whose therapeutic actions are least influenced by lapses in dosing. These are, of course, new issues that have previously not been considered in drug evaluation, for the simple reason that reliable measures of patient compliance have not previously been available. The potential roles of pharmacists, nurses and other health professionals remain to be defined as this new information and its implications become available and integrated into clinical thinking.

Needless to say, the economic consequences of poor compliance will sooner or later attract serious attention of insurers and other payors for healthcare. Prescription drugs, after all, are a principal interventional arm of modern medicine, and their actions are invariably dose- and time dependent, so their ineffective or suboptimal dosing represents an inefficiency in medical care that is potentially remediable. In considering this prospect, one should recall the words of one of the pioneers in compliance research, Stefan Norell, who wrote in 1980: ‘... the aim of “improving” compliance is not to achieve perfect agreement between behavior and prescription, but to increase compliance only to the level where the satisfactory outcome of treatment is assured. In practice, however, this level is often unknown...’.

Awakening to these realities has already begun, as several pharmaceutical firms are making promotional claims for products, based on their having an exceptional degree of ‘forgiveness’ for the more common errors in compliance: delayed doses, skipping a single dose and skipping two sequential doses.

### 27.14 What are the facts which demonstrate the importance of compliance?

There are various perspectives from which to answer this question.

#### Science

Every study done with reliable measures of patients’ actual drug exposure in both trials and practice shows a marked skew toward underdosing. A prominent finding is the ‘holiday’ pattern of dosing – sudden halts in dosing, followed by a sequence of days during which no doses are taken, followed by an abrupt resumption of dosing. First described by Prof. Michael Kass and his colleagues in patients with sight-threatening glaucoma (Kass et al., 1986; Cramer et al., 1989, 1990), the medical and economic consequences were projected by Urquhart and Chevalley already in 1988. Of particular concern are drugs with hazardous ‘rebound’ effects when dosing suddenly halts. In 1990, Psaty et al. reported a four- to six-fold increased risk of incident coronary heart disease in poorly compliant hypertensive patients prescribed the most widely used beta-blockers. This class of drugs has long been known to have hazardous rebound effects, but the presumption always had been that it was matter of concern only when
the physician decided to stop treatment. Now we see that the one patient in five who is 'holiday-prone' is abruptly stopping treatment on a more or less monthly basis!

Urquhart has pointed out that pharmacological evaluation of new drugs is strongly biased toward studies of the onset of drug action as dosing commences, ignoring the offset of drug action as dosing stops. As we now see the frequency with which sudden stops in dosing occur, it is time for pharmacologists to rebalance their scientific focus on the stopping as well as the starting of drug dosing and their associated pharmacodynamical consequences.

Another consideration is drugs that have so-called 'first-dose' effects: dosing cannot begin at the full therapeutic level, but must be gradually increased from a low, initial dose. Some of these agents may be especially hazardous in the holiday-prone patient, as longer holidays permit the patient to return far enough toward the drug-naive state, with overdose toxicities developing in the wake of sudden resumption of full-strength dosing as the drug holiday ends.

Statistics

Numerous studies show that methods which afford patients easy ability to censor evidence for poor compliance consistently result in gross overestimates of compliance (Waterhouse et al., 1993). This finding poses a major challenge to contemporary clinical trials design and analysis. The prevailing statistical policy of ITT analysis is to ignore all information on actual drug exposure and simply average drug responses in all patients randomized to receive drug, irrespective of how much drug they took, or whether they took any at all. ITT analysis is far more seriously biased than previously believed by the pharmacodynamic skewing arising from, not only simple underdosing, but erratic patterns of dosing likely to trigger recurrent rebound effects or first-dose effects. If clinical trialists have been slow to grasp the implications of these dosing patterns, the problem has certainly attracted the attention of the biostatistical community, leading to a series of symposia throughout the 1990s and into the next decade. Statistical research done under the rubric of 'causal inference' is at the forefront of the effort to integrate drug exposure information and its clinical correlates into clinical drug development.

Diversity of electronically monitored packages

Several firms are beginning to provide electronically monitored packages: vials, blisters and nebulizers.

Pharmaceutical industry

Several major pharmaceutical firms have begun to address the issue defined by Norell, which might be paraphrased as answering the question 'how much compliance is enough?' (Urquhart, 1993). The answer to this question can support comparative claims for superiority in maintenance of therapeutic action in the face of common lapses in compliance. This is a therapeutically sound and potentially important new area of comparative pharmaceutical advantage. It can be expected to grow as a marketing issue, driven by the increasing orientation toward the outcomes of pharmaceutical care.

Packaging industry

For the packaging industry, the incorporation of compliance monitoring into packaging has value-added potential, the realization of which depends on many factors. The key factor, naturally, is the definition of cost-effectiveness of providing compliance information in specific therapeutic areas.

As usual with an emerging medical capability, there is an element of 'chicken–egg' impasse that has to open up in order for volume to increase, costs of goods to fall and perceived value of the information to grow. Obviously, high prices can hinder growth and diminish the perceived value of the information, but pricing linked to cost-of-goods
is volume dependent, and volume is limited by pricing. For this reason, most of the work done to date with electronic monitoring of compliance has been in the clinical trials arena, where per-patient costs are high and the premium is on the yield of reliable information. One hopeful sign that the ‘chicken–egg’ impasse is beginning to break is the emergence of four companies in the past year competing in the provision of monitored packaging for solid dosage forms. Another hopeful sign is the adoption of the ‘forgiving drug’ logic in pharmaceutical promotion by several firms.

An informative bit of related history is the development of glucometers for use in the management of insulin-dependent diabetes mellitus (IDDM). As glucometers began to appear in the early 1980s, they held the promise of making a marked improvement in the quality of metabolic regulation in IDDM, supplemented by measurements of glycosylated hemoglobin. Yet use of these new methods required patients to shift from a single daily injection of mixed short- and long-acting insulins to multiple fingersticks per day for glucometry plus multiple injections per day of short-acting insulin. Moreover, the cost of glucometry-guided insulin administration approximately trebled the costs of care for IDDM. What drove the market in this direction was the promise that improved metabolic control would make a major reduction in the risk of the many long-term complications of IDDM; blindness, renal failure, peripheral nerve disorders and atherosclerosis, all leading to excessive morbidity and premature death. Definitive proof of that promise was not forthcoming until 1993, with the publication of a meta-analysis and two randomized, controlled trial of the two modes of managing IDDM.

A noteworthy aspect of IDDM management is that a new professional entity, the ‘diabetes educator’, emerged to help patients grapple with the veritable flood of metabolic data generated by glucometry, in relation to patients’ particular levels of diet and exercise. Neither physicians nor pharmacists rose to the occasion to confront the new data and guide patients to use this new information in their daily lives. It is an object lesson in how emerging technologies can force changes in professional arrangements, when the professionals involved resist change.

### 27.15 What is the relevance of compliance in daily practice?

About one-third of patients appear to underdose to an extent that is likely, for most drugs, to be clinically relevant. About 50% of the patients comply well enough, if not perfectly, to get full benefits of the prescribed treatment. Only one patient in about six is strictly punctual. How much compliance is enough is a key question in order to secure full therapeutic benefit.

A striking finding from post-1987 research on compliance is that poor or partial compliance occur to a remarkably similar extent across many fields of chronic pharmacotherapy, irrespective of disease severity. A compelling example is the consensus among organ transplantation experts that poor compliance with immune suppression regimens is a leading cause of transplant rejection (Didlake et al., 1988; Rovelli et al., 1989; De Geest et al., 1998; Nevins et al., 2001).

Diagnostic confusion and hospital admission are the direct consequences of poor or partial compliance with medically crucial prescribed drug regimens. The associated economic problems have, for most part, not yet been quantified, although some initial efforts have been made (Urquhart, 1999).

Here, it is important to re-emphasize that the clinical signs of overdosing are often recognizable, but the clinical signs of underdosing – which is far more common – are usually misinterpreted as worsened disease, with ensuing lack of responsiveness to the pharmaceutical in question.

### 27.16 What should interactive packaging offer to improve patient compliance?

It is clear that patients have individual preferences and needs, and so will decide what fits them best: audible, visible alerts, integrated or not with the phone system. Technology is available to meet foreseeable preferences. It seems highly unlikely that a single type of electronically monitored packaging will accommodate the whole range of
patient needs. Instead, one can expect a variety of electronically monitored packages to emerge as the recognized need for such information grows.

Consider the following scenario: a 60-year-old patient is diagnosed as having high cholesterol levels and is prescribed a once-daily cholesterol synthesis inhibitor, essentially life-long therapy. The patient has a certain tendency to forget doses, which can be minimized by use of a simple reminder device. Perhaps, with practice, the patient develops a strong routine of drug intake, linked to some regular routine in his life. If that occurs, the reminder device becomes superfluous, although it has served its purpose during the start-up phase of treatment, to make the patient aware of the frequency of missed doses. Meanwhile, the consequences of missing an occasional dose of cholesterol-lowering drug are, as far as anyone knows, negligible. After a decade of treatment, however, the patient develops coronary heart disease with congestive heart failure, and now is in a situation where the punctual maintenance of a strict regimen is essential to prevent hazardous retention of fluid. In this setting, the types of errors that had little or no consequence for cholesterol regulation can create major problems: omission of the daily diuretic dose for as few as three days in sequence can trigger acute pulmonary congestion, requiring hospitalization that costs on the order of $10,000. If the patient’s condition is additionally complicated by chronic obstructive pulmonary disease, the impact of fluid retention is all the more severe, with even less latitude for error.

In this rather common scenario of disease progression, one sees how the changing nature of drugs, diseases, severity of diseases and comorbidity can radically change the medical and economic implications of compliance errors.

The type of devices needed to accommodate this particular patient can be as follows:

- A device with an acoustic or visual reminder for the patient and a memory capability so the treating physician will get that patient’s actual history of dosing. When a strong routine exists, then this device may be used only sporadically to check if the patient is continuing to dose satisfactorily.
- For elderly patients with multiple diseases and multiple medications, an electronic dose organizer may help them cope with the more complex regimens.
- An effective program of medication management may prevent the patient’s having to abandon home-based care: an obvious issue in both the economics of care and the quality of life.

Of course, some patients will not agree to any kind of monitoring, but the hazards and costs of suboptimal care have, as they become well understood, a way of shaping human decision making. One looks back at the way in which patients with diabetes switched from a single needlestick each day to as many as four injections of insulin and four additional needlesticks for blood sampling, hardly something one would do unless there were compelling reasons.

What about the patient?

In this world of technology, the patient should come before, not after, the technology. Technology by itself will not solve all the problems created by erratic compliance. Technology is a tool that can help healthcare professionals identify, track and potentially solve many of the issues created by partial and poor compliance. The patient will decide which type of intervention or what level of monitoring he/she wants to have. It will not be helpful to have the patient forced into a world that he/she does not understand. When all is said and done, the patient will have to perceive the value of available services, adopt one of them and adapt to it.

What about the health professionals?

Physicians

Physicians will have to heighten their index of suspicion of partial or poor compliance when drug responses are disappointingly small or absent. One might reasonably expect that the clinical
detection of poor compliance will improve as the use of electronic monitoring expands. There have been many examples in the past of how increasing use of a new, objective measurement resulted in a concomitant improvement in doctors’ abilities to recognize problems on clinical grounds alone. A more uncertain matter is how physicians can best intervene to improve compliance, or whether they will allow this problem to pass into the hands of other health professionals, as occurred, for example, with glucometry in IDDM.

**Pharmacists**

Compliance management opens up a potential opportunity for pharmacists to become directly engaged in pharmaceutical care and not allow the linkage between measurements and care to default to another professional group, as occurred in IDDM. If pharmacists correctly position their compliance-related activities, they could develop a much stronger partnership with the prescriber, though it will require a clear definition of the roles of the physician and the pharmacist (Métry and Meyer, 1999).

**Transition from in-hospital to in-home care**

Medication monitoring can help smooth the transition from the hospital to the home, to be sure that the patient is able to cope with the prescribed regimens at home. It will require a close link between hospital and community pharmacies.

**SIAC: systems integration in ambulatory care**

Several published RCTs show that frequent telephone contact with patients considerably reduces resource utilization in CHF and other chronic conditions. Thus far, however, the phone maneuvers lack an objective measure of the patient’s dosing history, which, in most instances, is the most important variable in disease management.

How much more efficient would these interventions be, if one could confidently rule in or out drug regimen noncompliance as the main focus for intervention? Hence, the SIAC program. SIAC provides a convenient upload link from the patient’s electronic dosing monitor(s) to a website, where the dosing history is analyzed and a specific plan formulated to guide the patient toward punctual dosing. Analysis and plan are downloaded to the prescriber, pharmacist or phone-interventionist for implementation. The cycle can occur daily via automatic downloading of dosing data from an in-home modem link, or at weekly/monthly intervals from downloading in the pharmacy or clinic. Class III and IV CHFs need daily review, but in other conditions, the complications of noncompliance are slower to occur, allowing weekly, monthly or quarterly analyses.

### What will be the reaction of third-party payers?

Studies will be needed to provide data on the cost-effectiveness of such approaches. One must approach these cautiously, because there is much to be learned before engaging in the kinds of confirmatory studies that can define the actual economic value of a new approach. Studies done prematurely, before the ‘learning curve’ has been substantially traversed, will only confuse and delay matters. A key step, as emphasized earlier, is the targeting of high-risk patients, whose well-being depends very directly on maintenance of the dosing schedule. Moderate–severe congestive heart failure appears to be one such situation; chronic hormonal receptor blockade in hormonally dependent tumors is probably another. Still another is immune suppression in organ transplant recipients. Yet another is moderate-to-severe epilepsy, especially at the time the patient is being evaluated for escalation from monotherapy to two-drug therapy, or from two-drug to three-drug therapy, to be sure that seizure recurrences are the consequence of inadequate drug action, not inadequate drug dosing.

The field of therapeutics is vast and complex, with many areas in which special problems arise
due to seemingly inadequate response to the prescribed drug regimens. If there is one lesson taught by the past decade of research on patient compliance, it is to put uppermost the question: nonresponder or non-complier? The economic opportunities for value-added packaging are to be found in our growing understanding of the medical and economic advantages of correctly answering this basic question in situations where the wrong answer is very costly in both medical and economic terms.

### 27.18 Conclusion

Almost two decades ago, the problem was how to measure drug intake in ambulatory patients (Averbuch et al., 1990; Kruse and Weber, 1990). That problem has been solved by a variety of approaches which integrate time stamping, recording microcircuitry into a variety of drug packages, to record times when the package is used in the manner needed to provide a dose of drug for the patient. Electronic monitoring is, to be sure, an indirect method of measuring drug intake by ambulatory patients, in that it does not show actual ingestion of the dose but has the unique virtue of being a method that does not require the patient to do anything exceptional and that provides continuity of data flow over long periods of time, and has proved itself in a variety of settings to be the superior method of measurement (Wagnet, 2002). Naturally, it must be used with common sense, for it does have certain ‘blind spots’ that can occur if, for example, the patient removes doses at times remote from actual ingestion, or if the patient uses a second, non-monitored package for one reason or another. However, these are errors made mainly by patients who are striving for full compliance, not the errors of the negligent, who often seek to minimize the errors they make. Thus, if one includes some appropriate questioning of the patient, these ‘blind spots’ can be identified and avoided.

The key question facing us today is how best to target the methods now in hand, so that they improve care and reduce costs. Some suggestions to that end are provided above (World Health Organization, 2004).

## References


women with osteoporosis: improving the measurements of persistence on actonel treatment: the impact study’. In European Calcified Tissues Society Meeting, Rome, 8–12 May.


28 Monitoring Drug Concentrations in Clinical Practice

Anthony W. Fox

28.1 General principles of therapeutic monitoring

Measuring drug concentrations, for example, in urine or blood is quite a small part of the general, laudable clinical goal of monitoring therapy. Therapeutic monitoring comes in many guises, ranging from the absence of reattendance of the patient with the same complaint (presumptive but not certain treatment success!), through various types of quantitative efficacy monitoring (e.g. activated prothrombin time and/or partial thromboplastin time for warfarin therapy; Nowak, 2001). Clearly, all prescribing should be accompanied by some sort of therapeutic monitoring, and good product labeling will explain how. While the pursuit of pharmacokinetic information is an obligatory part of drug development in general, this chapter focuses on the situation when drug concentration measurements become part of ordinary clinical practice. Above all, even when drug concentration has been measured, treating the patient rather than the laboratory report is paramount; no drug has a single target plasma concentration.

28.2 Why monitor drug concentrations?

The following reasons can justify the need to monitor drug concentrations in plasma or urine:

- Avoidance of adverse effects for drugs with narrow ‘therapeutic windows’
- Maximizing probability of efficacy (e.g. avoiding too low a dose of a prophylactic drug)
- Checking for compliance
- Detection of exposure (e.g. environmental risk studies; Lange and Dietrich, 2002)
- Treatment decision making (e.g. paracetamol/acetaminophen overdose)
- Avoidance of drug interactions
- Dose adjustment for special populations (e.g. the elderly, children, renal failure)
The biggest practical issue is taking the sample at the correct time: these times differ for digoxin (6 h post-dose), gentamicin (peak and trough), lithium (12 h post-dose), phenytoin (no specific timing) and cyclosporine (trough). The timing of samples for acetaminophen/paracetamol and salicylates is discussed below. Using the wrong tube is another error: read the laboratory request because some assays require serum, plasma or whole blood. (Reynolds and Aronson, 1993).

It is useful to consider these same criteria during drug development. Should the product label carry information about, and should the risk management program include, plasma concentration monitoring? A few worked examples may be of use.

**Narrow ‘therapeutic window’**

Theophylline is a classic example. Its bronchodilator effects are related to plasma concentrations in the range of 5–20 mg l\(^{-1}\), while higher concentrations are associated with tachyarrhythmias and other serious adverse effects. This is a drug with a narrow ‘therapeutic window’. Elderly patients commonly have several risk factors that can lead to unexpectedly high serum concentrations after administration of standard doses: reductions in renal clearance, reduced volume of distribution and an increased probability of concomitant disease and other therapies (Ohnishi et al., 2003). Monitoring plasma levels is thus helpful in avoiding the adverse effects of theophylline.

**Maximizing probability of efficacy**

Itraconazole is an antifungal agent of the triazole class (Buchowsky et al., 2005). This drug is commonly employed in patients with immunocompromise, and thus patients for whom it is prescribed have a substantial burden of concomitant disease and other therapies. Furthermore, itraconazole has several pharmacokinetic complexities: there is substantial inter- and intrapatient variability in the dose–plasma concentration relationship, plasma protein binding is substantial, there is at least one active metabolite, this drug is a CYP 3A4 substrate and it is compatible with P-glycoprotein transporta-

plasma concentration and efficacy is quite variable, levels above 250 ng ml\(^{-1}\) are more often associated with efficacy. Thus, this is a drug where the multiplicity of factors, both predictable and idiosyncratic, is so great that it can be worth checking that the appropriate dose has been chosen for effective plasma concentrations.

**Antiepileptic drugs**

There is no doubt that selective drug level monitoring can help reduce seizures and minimize adverse events when using antiepileptic drugs (AEDs). Glauser and Pippenger (2000) have enumerated the five situations when this is useful: finding a baseline efficacious concentration for comparison when things go awry later on, evaluating lack or loss of efficacy, evaluating intolerability, judging when to change AED(s) and providing some information as to the scope and latitude for changing dose size. For example, for clozapine nonresponsive patients might benefit from dose increase beyond a threshold concentration of 350–400 ng ml\(^{-1}\) (Bell et al., 1998). Zonisamide has a therapeutic range of 10–40 \(\mu\)g ml\(^{-1}\), although the dose required can vary when concomitant phenytoin or carbamazepine is being administered, as well as *vice versa* (Mimaki, 1998).

**Acetaminophen/paracetamol**

Overdose with this over-the-counter drug is such a public health hazard that some mention of it must be made here. In the European Community and North America, this is the most common of all drugs taken in overdose, and this injury probably creates the largest number of candidates for transplantation of precious donor livers. Jones and Dargan (2001) provide a definitive, condensed account, and rightly term this a ‘deceptive’ poisoning. Evidence of hepatic injury, sadly, may only arise 24 h or more after ingestion, by which time opportunities to limit absorption of the overdose will have been lost. Renal injury can also occur.

The toxicity of acetaminophen/paracetamol is plasma concentration dependent. However, it should be remembered that plasma concentra-
time since ingestion is also predictive of toxicity. Furthermore, concomitant drugs and chronic alcohol abuse can lower the threshold for toxic plasma concentrations. The curvilinear nomogram indicating risk of hepatic injury in patients deemed to be of low or high risk according to concomitant factors such as alcohol abuse, starts at 100–190 mg l\(^{-1}\) (about 0.7–1.2 mmol L\(^{-1}\)) at four hours post-overdose. Plasma concentrations measured prior to four hours are probably a waste of time because measures to reduce absorption should take priority and there is no real estimate of the size of the exposure.

\(N\)-acetylcysteine is a relatively well-tolerated drug (anaphylactoid reactions can be treated by halting the infusion for half an hour and administering an antihistamine). Thus, administration of \(N\)-acetylcysteine can be recommended on an ‘err on the safe side’ basis, when comparing plasma concentrations of the toxin with the nomograms on the package insert of the antidote. Similarly, overdoses taken in two parts, with some time interval in between them, should not cause concern when interpreting the plasma level: simply assuming that the whole overdose had been taken on the first occasion when using the nomograms will again safely bias the treatment decision. For these reasons, the nomogram for high risk falls to plasma concentrations of zero when measured 24 h after the overdose; thus, not only very early after overdose, but also much later, plasma concentration measurements are pointless.

Oral methionine is probably now an anachronistic treatment even in the absence of peripheral venous access (intravenous drug abusers). The importance of treating acetaminophen/paracetamol overdose easily justifies the hazards of a subclavian cannula.

**Salicylates**

Mention of salicylate overdose is made here, even though its popularity seems to be in decline. Its treatment, presuming hemodialysis is not indicated, includes a classic type of beneficial drug interaction that is different from that of a specific antidote (cf. \(N\)-acetylcysteine, above). Furthermore, the combination of respiratory alkalosis promoting drug excretion by altering urine pH, have long attracted Machiavellian examiners setting multiple-choice questions!

Overdoses greater than 150 mg kg\(^{-1}\) (i.e. 20–40 tablets weighing 325 mg each) cause toxicity, although fatality is related not only to overdose size but also to the patient’s general condition; children are sensitive to salicylates disproportionately to their body weight, and are also liable to more serious metabolic acidosis.

There are usually more acute clinical signs and symptoms in serious salicylate poisoning (hyperventilation, arterial blood gases, complaints of tinnitus, agitation, coma seizures, etc.). Although plasma salicylate concentrations become interpretable at about four hours post-overdose, there is a greater need to interpret these in the context of the clinical picture than when acetaminophen/paracetamol has been ingested (see Jones and Dargan, 2001). Identifying the peak plasma salicylate concentration can be achieved with venous samples every three hours. CNS toxicity, in particular, indicates serious poisoning, regardless of the plasma concentration of salicylate.

Hydration to promote diuresis is recommended in all salicylate overdoses. Urine alkalinization is generally recommended at plasma concentrations above 600 mg l\(^{-1}\) salicylate, or half that in children and the elderly. Even this, however, has its limits, and hemodialysis at salicylate concentrations of >800 mg l\(^{-1}\) in adults (half in children and the elderly), or regardless of plasma concentration when there are signs of CNS toxicity, is the treatment of choice.

The acid–base aspects to salicylate poisoning are the following:

- **Salicylate** is an organic acid (as the suffix indicates):
  - It is less ionized in acidic environments.
  - It crosses lipid membranes in a concentration-dependent fashion more easily when not ionized.

- **Acidosis** must be aggressively treated:
  - An acid urine inhibits salicylate excretion.
  - Acidosis enhances CNS sequestration of
- Blood gases indicate a mixed picture:
  - pH is low, and HCO₃⁻ is low, due to the direct acidotic challenge of the toxin.
  - pCO₂ is low due to hyperventilation (Kussmaul respiration, and possibly also a direct effect of salicylate).
  - pO₂ is typically normal.

- Excretion of salicylate is principally in the urine and can be enhanced by alkalinization because:
  - Salicylate is filtered in the glomerulus and this is pH independent.
  - Resorption of salicylate in the nephron is substantial because of the concentration of the toxin.
  - The nephron is a lipid membrane and in an alkaline environment more salicylate is ionized.

Lastly, remember that basic drugs are excreted more vigorously in a urine that is acidified with oral ammonium sulfate. A common and popular drug of abuse at the moment in California is methamphetamine; the suffix again tells us it is a basic drug, and the same logic applies, but in reverse.

### 28.3 When is plasma concentration monitoring irrational?

Drugs for which concentration assays are clearly unsuited include acute therapies (i.e. not used at steady state), those with extraordinarily short half-times (e.g. injected or intranasal polypeptides) and those for which either treatment is indicated regardless (late acetaminophen/paracetamol overdoses, see above), or when adverse events are almost automatic and should be monitored in other ways, for example CNS toxicity with salicylates (see above) or liability to bone marrow suppression with cytotoxic agents. Furthermore, the efficacy and tolerability of some drugs are known to be unrelated to circulating concentrations (e.g. penicillin anaphylaxis), which also makes plasma concentration monitoring pointless.

It is also important to remember that just because a clinical laboratory offers a plasma level for a particular drug, this does not mean that it will be universally useful. For example, plasma levels of antiviral drugs used in the treatment of HIV infection are now inferior to CD4 lymphocyte counts and RNA measures of viral load when monitoring for efficacy (e.g. Back et al., 2000). Another good example is the case of many antidepressant drugs. If the patient is also using a potentially interacting, concomitant therapy, if there is doubt as to treatment compliance or if there is some other special clinical feature, then a plasma level of, say, amitriptyline can be very useful. A plasma level might also be very useful in the emergency department for the diagnosis of an intoxicated patient. But studying lower concentrations of amitriptyline when treating depression is of almost no practical value in predicting efficacy (e.g. Ursolak, 1989). Although much is known about the pharmacokinetic interactions of selective serotonin reuptake inhibitors (and indeed some are even used as probes in clinical pharmacology studies), this does not extrapolate to their routine plasma level monitoring in the clinic (Sproule et al., 1997). Thus, routine venesection of patients in psychiatric clinics is likely to have a relatively low yield of useful information and may not be cost-effective.

### 28.4 Concentration monitoring in other biological fluids

#### Urine

Urine is commonly screened for evidence of illicit drug use or alcohol consumption. This may be viewed as a drug concentration monitoring procedure, even if only of a qualitative type. It remains controversial whether poppy-seed bagels can lead to positive urine screens for opioids!

Materials such as radioactive sodium iothalamate or inulin can be regarded as drugs. These
provide examples of quantitative urine concentration monitoring, and enable an assessment of the glomerular filtration rate (GFR). The GFR can measure renal injury with a greater degree of sensitivity than measuring serum creatinine or urinary protein excretion.

Cerebrospinal fluid (CSF)

It is a widely held myth that drug in the CSF has crossed the ‘blood–brain barrier’. This demonstrates an ignorance of basic anatomy and physiology. If a drug has appeared in the CSF it may have got there by filtration or secretion by the choroid plexi in the lateral ventricles, or by diffusion from the circulation directly. It is, therefore, rash to assume that drug concentration in the CSF is a good surrogate for actual brain exposure (Davson, 1967; De Lange and Danhof, 2002). Vice versa, when a drug is not found in the CSF, to assume that it is not present in the brain parenchyma presumes an absence of sequestration. Buprenorphine is a good example, where absence of detectable drug in the CSF (and venous blood) correlates with a prolonged analgesic effect.

Quite apart from the so-called ‘blood–brain barrier’ (and where it is lacking, e.g. some parts of the pituitary, hypothalamus and brain stem, i.e. the chemoreceptor trigger zone), there are many other factors which govern equilibration of drug concentration between CSF and the parenchyma of the brain itself. The differential effects of P-glycoprotein saturable active transport can govern the CNS sequestration in a manner that is completely unrelated to relative lipophilicity or ambient drug concentration.

Lastly, there are obviously more technical and clinical obstacles to obtaining CSF for pharmacokinetic purposes than when sampling venous blood or urine. These illustrate the topographical complexities of measuring CSF concentrations. In animal studies, after systemic drug administration, drug concentrations in the CSF can be unequal between ventricles and the subarachnoid space. Clinically, CSF from the cisterna magna and from around the corda equina can also differ in drug concentration. It is for this reason that preclinical scientists often resort to intracerebral microdialysis, and this is also why magnetic resonance spectroscopy and positron emission tomography are now being pursued more commonly for drug studies. The scope for useful CSF concentration monitoring in the ordinary clinical situation remains vanishingly small.

28.5 Summary

In this chapter, the measurement of drug concentrations in humans has been placed into the context of ordinary clinical practice, rather than the research environment. This is, therefore, a chapter that impinges on product labeling and risk management plans, and not necessarily pharmacokinetics or the quantification of drug interactions in normal volunteers. The general criteria for when plasma concentration monitoring may or may not be worthwhile have been reviewed. The essentially qualitative nature of urine monitoring, unless measuring GFR, and some fundamentals about CSF drug concentrations have also been reviewed.

References


Generic drugs are drugs that are sold under their generic name rather than a particular brand name. Generic drugs are usually approved via an abbreviated approval process using a branded drug as a reference product. Rather than going through the long and expensive process of demonstrating safety and efficacy of the product in animal and human trials, the generic company simply needs to show that its product is identical or bioequivalent to the previously approved reference product. Generic approval and launch, however, are subject to patents and various regulatory exclusivity periods that provide incentives for innovator companies to develop new drugs.

Generic drugs have been with us for a long time. Aspirin is an example of a century-old compound for which basic patent protection has long expired and that has been sold generically ever since. The generics business rivals in size that of the branded drug business. Currently in the United States, sales of generic drugs are about 40% that of the market. In some countries the numbers are much larger.

29.1 The great compromise – history of generics versus big pharma in the United States

Excluding sales of botanicals, ‘traditional medicine’ and so on, the pharmaceutical industry can broadly be divided into ‘Big Pharma’ and Generics. The business model for Big Pharma is the discovery of new medicines, the sales of which are protected by patents. During the life of the protective patents, the sale prices of these new medicines are well in excess of their manufacturing costs, which is justified by Big Pharma because of the need to reinvest these profits in the Research and Development needed to find the next new medicines. The business model for generics is to sell only medicines which are ‘off-patent’. As the manufacturing costs for these medicines can be quite low, as the market has already been developed by the Big Pharma company which has been selling the medicine for years and as there are virtually no advertising costs, the off-patent medicines can be
sold at a considerably lower cost (70–90% below is typical) than the brand product. The above description was painted with a broad brush; many variations and exceptions exist. Some companies have both generic and branded businesses; some branded companies sell primarily off-patent drugs. However, it is accurate enough for the purposes herein.

In the late 1970s and early 1980s, these two sides of the pharmaceutical industry petitioned the US Congress for relief from two perceived injustices. Big Pharma complained that what the government gave with one hand it took away with the other. Specifically, although an innovator company could get a patent on a new pharmaceutical invention, it was unable to profit from the invention and the patent because sales of the product were barred until regulatory approval was first obtained. The company had to file a New Drug Application (NDA) which contained proof in the form of the results of large-scale human studies that the new drug was both safe and efficacious for its intended use. The approval process could be quite lengthy, often taking many years. The regulatory agency involved is the Food and Drug Administration (FDA), which is under no legal obligation to clear new drugs under a rigid timetable. Thus, after the innovator company had complied with all demands for data from the FDA, it then waited for the bureaucratic process to decide on approval, rejection or a request for more data. All the while the life of the patent was ticking away. There was a solution to this ‘injustice’, albeit not a satisfactory one. After FDA approval, innovator companies could petition the civil courts for relief and argue about their lost sales. In some cases this actually resulted in patent term extension. However, it was an uncertain process as the court was not always convinced that any actual harm had befallen the company or, if relief was appropriate, how long the patent term extension should be.

Generics had a totally different complaint. Before they could bring their drugs to market, they also had to obtain FDA approval. Unfortunately for them, virtually none of the experimental work needed to file an NDA could be done prior to the expiration of the innovator’s patent. Quite simply, they could not manufacture the compound needed for all the required testing because such manufacture would be an act of patent infringement. Thus, they argued, the patent owner was de facto getting a period of exclusivity far beyond that provided by the patent because of the need for FDA approval. Also, it seemed unnecessary to regenerate all the safety and efficacy data, as these had already been obtained by the innovator and was already in the hands of the FDA.

The result of these competing petitions for relief was the Drug Price Competition & Patent Term Restoration Act of 1984, known simply as Hatch-Waxman.

Under Hatch-Waxman Big Pharma received a guaranteed extension for its pharmaceutical patents if it could demonstrate that there were FDA delays in approving a new drug, that is the FDA would have certain time constraints put upon it and if these were exceeded the innovator was granted an extension on its patent term. The term of extension was fact-dependent for each drug approval, but could be as long as five years. The procedure was administrative; no civil court action was necessary.

Generics also received significant relief. Under Hatch-Waxman, a generics company now files an abbreviated NDA (ANDA). The ANDA requires no safety and efficacy data; it relies on the data already in the FDA’s possession. What is required, however, are bioequivalence data, that is proof that when the brand drug and the proposed generic drug are administered, the same amounts of active ingredient are available to the patient. These data are much less costly and time-consuming to generate than safety and efficacy data. The last major hurdle for a generics company is the ‘Certification’.

Part of the ANDA is a certification of one of four things; the first three of which are easy. The first three certifications are that: (a) there was never a patent on the drug; (b) there was a patent but it has expired and (c) the date on which the patent will expire and a request that the approval be given for the day after patent expiration.

It is the Paragraph IV certification that is the most problematic. The generics company may certify that there is a patent but that either the proposed drug will not infringe the patent or that the patent is invalid. This certification is defined as an act of
patent infringement and provides the patentee 30 days in which to defend its patent by suing for patent infringement. The lawsuit prevents the FDA from approving the generic drug, pending resolution of the infringement action.

What is the value to the generics company from making a Paragraph IV certification, as it will certainly soon (within 30 days) be a defendant in a costly lawsuit for patent infringement? It can be considerable. If it is successful and the patent is held to be invalid, the generics company is granted a period of exclusivity for six months to sell its drug, with competition only from the innovator company. When the period ends, other generics companies will undoubtedly enter the market and the drug’s price will drop to about 10–30% of the brand drug price. However, during the period of exclusivity, the price drops to only about 70%, a handsome reward for invalidating the patent. These price drops are not dictated by law, just by the marketplace.

Although Hatch-Waxman is limited to the United States, laws in most other countries have some things in common with the US system – providing abbreviated approval processes for generic drugs, creating safe harbors from infringement to allow for development and clinical trials of generic drugs prior to patent expiry and providing patent term extension and/or data exclusivity periods to ensure a reasonable period of exclusivity to the innovator company. The Paragraph IV challenge and pre-launch patent litigation process, however, is unique to the United States. Consequently, outside the United States, the patent owner must usually wait until the launch of an infringing product to enforce its patents.

29.2 Seeking generic approval in the United States

In the United States, there are two main routes to approval of a generic drug.

The more common route is via an ANDA. An ANDA requires that the generic product contains the same active ingredient and has the same dosage and route of administration as the reference drug. It must also be for the same indication. The applicant must show that the generic product is bioequivalent to the reference product, with respect to its pharmacokinetic and pharmacodynamic properties. Bioequivalence can be shown by demonstrating that the formulations are so similar that no difference would be expected, or by a small trial in healthy volunteers, measuring the blood levels of the active pharmaceutical in patients receiving the generic formulation compared to the reference formulation. Measuring blood levels to demonstrate bioequivalence is usually appropriate for oral formulations, but may be unsuitable for drugs that have a primarily local activity, such as inhaled or topical drugs, or for certain injectable drugs.

The second route to generic approval in the United States is the so-called ‘paper NDA’. This type of application is used when the product or its use is not the same as the reference drug. Although an ANDA is reviewed by the Office of Generic Drugs in the FDA, the paper NDA is treated as a regular NDA. The trials carried out by the applicant, which may include trials going well beyond simple bioequivalence in healthy volunteers, are supplemented by reference to a previously approved drug product or to published data. The exact nature of the data and trials required for approval is determined on a case-by-case basis. This type of application may be used by the originator company for line extensions as well as by generic companies. Drug products approved via this route may or may not be ‘AB-rated’ that is they may or may not be considered bioequivalent, and thus fully substitutable for the reference drug.

Generic drugs are subject to quality assurance and manufacturing requirements similar to branded drugs, for example for approval, they must meet batch requirements for identity, strength, purity and quality, and they must be manufactured in accordance with the FDA’s good manufacturing practice (GMP) regulations.

Regardless of whether the generic applicant seeks approval via the ANDA route or the paper NDA route, it must provide the patent certification as described above. Moreover, approval of generic drugs is subject to registration data exclusivity periods. No generic versions of a new chemical entity can be approved until after five years from
the first approval of the new chemical entity. For new indications and new formulations of a previously approved active agent, the data exclusivity period is three years. These periods may be extended by six months when the drug has undergone additional FDA-requested trials for pediatric uses. Data exclusivity periods are only applicable against a generic company that wants to rely on another company's drug as a reference; they do not apply when the generic company has generated a complete data package of its own.

The relevant data exclusivity periods for each approved drug product, as well as any applicable patents on the product or its use, are listed in the 'Orange Book', which is published by the FDA and also available electronically on the FDA's web site.

**29.3 Generic approval process outside the United States**

In most countries, generic drugs may be approved via an abbreviated procedure similar to the ANDA procedure in the United States. The applicant generally must show that the generic product has the same dosage of the same active substance and the same pharmaceutical form as the reference medicinal product. As in the United States, the applicant must demonstrate bioequivalence to the reference product.

All World Trade Organization (WTO) countries are required under the General Agreement on Tariffs and Trade (GATT) accords to provide some sort of registration data exclusivity periods. Europe has data and marketing exclusivity rules which, in their latest embodiment, preclude launch of a generic product until 10 or 11 years after first approval of the active substance. For products approved prior to the new rules, there is six or ten years of data exclusivity depending on the country. Approval may be either through the regulatory agencies in the individual countries or via a central procedure. In Japan, data exclusivity is normally six years for new chemical entities. As in the United States, clinical trials carried out by generic companies in support of regulatory approval are excluded from patent infringement in both the European Union and Japan. However, there is no procedure in Europe or Japan comparable to the US Orange Book listing and Paragraph IV challenge procedure described above. Consequently, patent holders must usually wait until launch of an infringing product to enforce their patents.

The relative strength of the generic industries in various countries is largely a function of differences in government regulation of prices and generic-for-branded substitution, as well as differences in the patent laws. In France and many southern European countries, there are strict price controls from the outset on the branded products, so that the branded products are already relatively cheap and there is less impact on price when the patent expires. Brand loyalty also tends to be relatively high, resulting in a large proportion of 'branded generics' products, which are not patent-protected but rather sold as branded products by a company other than the innovator. In Japan, the prices for branded products are initially relatively high, although prices are regulated down post-launch. As the higher-priced branded products are more profitable for pharmacists than generic drugs and there are few incentives to substitute generic drugs for branded drugs, the generic drug industry in Japan is relatively small. In northern Europe (e.g. the United Kingdom and Germany), there are no price caps as such, but pricing is strongly influenced by government reimbursement levels, which are reduced when generics become available, resulting in significant market share for generic companies. The United States is the most open of the large markets, with very high prices for branded drugs, together with strong market incentives on the part of pharmacies and insurance companies to encourage generic substitution, resulting in potentially very large profits for the first generic on the market. Once there are multiple generic products in the market, however, the intense competition among generic companies results in rapid and dramatic price erosion. Finally, the generics industry is also strong in countries that have historically had weak patent protection for pharmaceuticals. Although these countries are typically poor and have low prices for branded and generic pharmaceuticals alike, limiting the value of the domestic market, these countries in some cases provide a manufacturing base and launching pad...
for products to be sold in countries with stronger patent protection.

29.4 Biopharmaceuticals

There is one type of medicine which does not fit into the regulatory schemes described above: biopharmaceuticals, also known as biogenerics. Unlike the typical drug, which is of relatively low molecular weight (referred to as ‘small chemical entities’), these massively large compounds are not easy to either synthesize or describe down to the individual atoms. They include compounds such as growth hormone, interferon, erythropoietin and somewhat over 100 additional products, with a very tempting projected generic market in the billions (US$). However, they present a two-fold problem for the generics industry. Unlike the Hatch-Waxman type of regulatory schemes, there is no generally agreed-upon approval process for biopharmaceuticals; specifically, what must be shown to prove bioequivalence. In the absence of a method to prove this, a generic company would be faced with the expensive task of running full safety and efficacy tests, the very thing that Hatch-Waxman and the similar non-US schemes were designed to eliminate. Second, the very high manufacturing costs associated with these drugs will preclude capturing market share by under-pricing the brand drugs by 70–90%, as can be done with small chemical entities. Just these two hurdles will make inroads by the generics companies into this market slow for the foreseeable future.

29.5 Blurring the lines

The pharmaceutical business is described above as composed of Generics and Big Pharma, each with its own business model. The distinction does not hold up in all cases. Although selling at a premium under the protection of a patent is Big Pharma’s modus operandi, many patents are also obtained by generics companies. This is for two reasons, at least. First, because of the competition from all the other generics houses, a patent on a new formulation, manufacturing process or polymorphic form of an old compound can be quite valuable; clearly not as valuable as Big Pharma’s original patent but valuable enough in a very competitive marketplace. Of course, as with any other patent, the value of these patents depends on whether or not they protect some economically desirable innovation. Second, at least some generics companies can be seen as having aspirations of becoming Big Pharma or, at least, of developing and selling their own branded medicines, that is they have research facilities to discover their own innovative medicines. Adding to the blur, Big Pharma has itself been in the generics business for some time. They have done this directly as by owning generics subsidiaries. (‘Ownership’ can take various forms depending on the desire of the owning company and national law.) They have also entered into many types of partnering/licensing relationships with generics companies, that is no actual ownership but a sharing of the sales of certain products. This can be useful, for example, if a product is about to go off-patent but the patentee does not wish to sell the product generically. If the patentee has valuable know-how relating to the product, it might license this know-how to a generics company, which thereby will gain an advantage over all its competitors.

29.6 The future

Many of the Big Pharma houses very well known in the 1950s–1980s have now disappeared, their businesses having been consolidated by merger or acquisition into fewer and fewer, larger and larger pharmaceutical operations. A similar pattern has been emerging in the last decade in the generics business. The reasons for this are undoubtedly the same as for other industries: economics of scale and the desire to expand both geographically and in breadth of product line. There is no reason to believe that this trend will stop anytime soon. Undoubtedly, one or more of these ever larger generics companies will become an acquisition target for a Big Pharma company.
Complementary medicines are very widely used. Their relevance to pharmaceutical medicine is the following:

- Many patients in clinical trials will be using complementary therapies (and we often omit to ask on the case report form)
- Many are pharmacologically active
- Some risk well-described drug interactions or other adverse events
- People uncritically pay for worthless therapies (e.g. the laetrile scandal)
- Pharmaceutical physicians are rarely trained in this area

Geographical and cultural factors are as important as in any aspect of medicine; for example, there are especially strong complementary therapy traditions in places as different as Germany and Utah. Furthermore, the popularity of drugs varies between places: for example, the United Kingdom apparently has the greatest faith in garlic. The market for complementary therapies is huge: the Nutrition Business Journal reported as long ago as 1999 that in the United States alone, about $14.7 billion (i.e. $14.7 thousands of millions) of complementary therapies are sold each year, and that it is a growing market.

Historically, complementary therapies were the only therapies available. Some orthodox drugs have their origin in complementary medicine: Withering’s discovery of digoxin was long after the gypsy had been using it for dropsy, and the Revd Edmund Brown’s willow bark extracts were the result of his belief in the doctrine of similarities. Much of the Third World has little allopathic medicine available to it, and complementary therapies continue to be offered for a wide variety of diseases. Even in the developed world, most good hospices will have complementary therapists on staff.

The ethical aspects of this area of medicine are as varied as the therapies themselves, and could be debated almost ad infinitum. Thus, the purpose of this short chapter is to alert pharmaceutical physicians about this topic, discuss the most commonly encountered therapies (recognizing that this changes with time) and describe their regulatory status (which is generally quite simple).
The Cochrane Collaboration defines ‘complementary medicine’ as:
‘Complementary and alternative medicine (CAM) is a broad domain of healing resources that encompass all health systems, practices, accompanying theories and beliefs, other than those intrinsic to the politically dominant health system of a particular society or culture, within a defined historical period. CAM includes all such practices and ideas self-defined by their users for prevention or treatment of disease, or promotion of health and well being. Boundaries within CAM and between the CAM domain and that of the dominant system are not always sharp or fixed’.

The term ‘alternative medicine’ is often now avoided in western developed countries, because it (often erroneously) suggested a mutual exclusivity between these therapies and conventional or ‘allopathic’ approaches. However, most of the diverse disciplines now prefer ‘complementary medicine’, so as to emphasize that the patient can benefit from a combination of orthodox and alternative approaches. There is no reason why complementary therapies may not be subject to evidence-based analysis, although there are very few such published examples, in comparison to orthodox medicine (see Critchley et al., 2000).

The factor in common to all complementary therapies is that they are prescribed or recommended by practitioners who approach the patient as a whole (holistic practitioners). It might be said that so does any good general practitioner. However, the clinical variables used by complementary therapists are often unquantitated, may lack an orthodox clinical correlate or, occasionally, even defy translation into English, for example the clinical variable ‘slipperiness’ that is used in oriental medicine. Zollman and Vickers (1999) have pointed out that the same patient may be described with deficient liver Qi by an acupuncturist, as having a pulsatilla constitution by a homeopath or having a peptic ulcer by a western physician. It might also be noted that, in the United Kingdom, the General Medical Council has begun to discipline practitioners who prescribe complementary therapies wrongly (Ernst, 2004).

Complementary therapists may or may not be graduates of orthodox medical schools. Other complementary therapists are organized professionally, if separate from orthodox medicine (the United Kingdom operates a General Chiropractic Council that regulates chiropractors in a manner exactly analogous to the General Medical Council). Other complementary therapists are trained privately, or in more informal ways, such as by experienced older relatives. Chinese traditional medicine is codified and relies on the cumulated experience of both ancient and modern practitioners (Cheng, 2000).

The complementary therapies themselves also vary in their degree of characterization. Less well-characterized therapies include some forms of over-the-counter products (especially in the United States), aromatherapies, crystal therapies and various forms of psychotherapy. This is a book about drugs, and non-pharmacological therapies (e.g. the well-regulated areas of acupuncture and physiotherapy) are beyond the scope here. ‘Herbal medicines’ (a term widely used in the United States) are basically unregulated pharmaceuticals; confusingly, materials that are not of vegetable origin (e.g. shark cartilage, oyster calcium or selenium) are often included under the category of herbal medicines. ‘Alkaloid’ is an older term referring to any drug with a plant origin (e.g. digoxin, aspirin and warfarin), including both orthodox and complementary therapies. Incidentally, opiates are alkaloids (e.g. morphine, codeine) and opioids are semisynthetic or synthetic drugs such as diacetylmorphine or pentazocine. ‘Pharmacognosy’ is the science of plant-related, pharmacologically active materials.

Homeopathy is the art and science of the treatment of disease using microscopical drug doses. Homeopaths believe that the most potent homeopathic products are those that have been most extremely diluted: in many cases, calculations based on Avagadro’s number and the number of sequential dilutions suggest there may not be a single alkaloid molecule left in the administered dose. However, it is believed that the pharmaceutical method, which is at least as rigorous as for the manufacture of allopathic drugs, creates an emergent property in the administered vehicle that still has the
therapeutic effect. Homeopathic medicines are available with and without prescriptions. Homeopathic prescribing resembles orthodox, if historical, prescribing. Homeopathic drugs are identified using the Latin terms for the (usually alkaloid) starting materials, and a set of apothecaries’ symbols for dose size, dose frequency and the number of dilutions required before dispensing. In the United Kingdom, homeopaths are regulated by law, and there is a Faculty of Homeopathy within the Royal Colleges in an analogous manner to the Faculty for Pharmaceutical Medicine. Associate members of the Faculty of Homeopathy may include any clinician with statutorily registered qualifications; the Licence of the Faculty is available by examination, again to all clinicians, usually after study at any of five nationally recognized homeopathic colleges. Membership of the Faculty is by examination and restricted to medical practitioners, and dental and veterinary surgeons; Fellows are selected from among the more prominent members. The Royal Household includes one or more homeopathic practitioners.

### 30.2 Common complementary medicines

The nine most commonly used complementary medicines that are in use in most of Europe and North America are derived from St. John’s Wort, Saw palmetto, *Ginkgo biloba*, Black cohosh, glucosamine/chondroitin, SAM-e, Ephedra, Ginseng and Kava. Although there is a certain amount of contemporary fashion that seems to govern which products sell best, all have a long tradition in complementary therapy.

The popularity of these preparations has caused a serious blight to the natural populations of some of the plant species in which they are found (especially *Panax ginseng*, *Cimicifuga racemosa* and *Kava kava*). The World Health Organization (WHO) has issued guidelines on good agricultural and collection practices for many of these species. Cultivation of these species on nonnative continents can seriously harm the tenuous economies of the original suppliers, who usually live in underdeveloped countries. For example, *Harpagophytum procumbens* (or Devil’s Claw, used for arthritis) was originally sourced from Namibia in quantities of about 200 tonnes per annum; foreign competition has driven down the price paid to its African growers by about 85% in the last 10 years, according to the WHO (Anonymous, 2004).

These complementary medicines are not without adverse effects (Tomlinson *et al.*, 2000 and see below).

*Extracts of St. John’s Wort* (*Hypericum perforatum*) are used for the prevention of migraine, depression and anxiety. The clustering of indications for neurological purposes suggests that it contains an active alkaloid or alkaloid mixture. The remittent, relapsing nature of these diseases make assessment of the limited reports of its efficacy difficult, but there are one or two fairly sound papers concerning migraine and depression. Most formulations of St. John’s Wort can reduce rates of absorption of antiviral drugs. Serotonergic drugs (antimigraine agents, antidepressants, whether serotonin-specific uptake blockers or not) ought to be most likely to interact with St. John’s Wort, while, on its own, St. John’s Wort can cause photosensitivity. Pharmaceutical physicians should investigate herbal drug use whenever this unusual adverse event arises (see also kava, below).

*Saw palmetto* (*Palmito caroliniensis*) is the State tree of South Carolina, being the only palm indigenous to the east coast of North America. Its seeds (which are used to derive the pharmaceutical) are rich in fatty acids, their esters and sterols. The extract of these seeds is recommended for mild symptoms referable to the prostate, without any pharmacological rationale. A recent clinical trial has confirmed the uselessness of Saw palmetto for this indication (Bent *et al.*, 2006), and, furthermore, the danger is that patients will use the product to temporize for symptoms that could lead to an earlier diagnosis of malignancy. The doses administered are usually insufficient to reduce the absorption of oral fat-soluble drugs, but it would seem wise to separate the administration of vitamin D, warfarin and so on, and this lipophilic complementary therapy.

*Ginko extract:* The robust tree *Ginkgo biloba* has remained essentially unevolved for far longer than almost all other tree species. For this reason it is
also known as the ‘Fossil tree’ in the Far East, where most of its fossils are found. A specimen of *G. biloba* was the only living thing to survive at ground zero, Hiroshima, recovering its stature from the surviving root within about 10 years. The product is used for memory loss and mental alertness, without good clinical trial evidence, but it has enjoyed this reputation for centuries in Asia, and now worldwide. Ginkaloids are antioxidants, but how this mechanism relates to its proposed neurological and cardiovascular effects is unclear. Some *G. biloba* extracts increase both the antiplatelet properties of aspirin and the anticoagulant properties of warfarin, perhaps suggesting that the interaction takes place at the level of plasma protein binding; which flavanoid or terpene lactone is responsible for this is unknown, and perhaps it is due to some other unidentified component of these particular formulations. Hydrolyzed amino acids from cow brain are recommended for the same indications in Central Europe (e.g. Cerebrolyticu in Romania).

**Black cohosh** (*Cimicifuga racemosa* or ‘Bugbane’) is native to the eastern United States and was first identified by the Algonquin tribes as an aid to inducing labor, and treating peri- and postmenopausal symptoms. Separation scientists have found no factors with known estragenic activity. It would therefore be illogical to impute beneficial effects of this material on prevention of coronary heart disease or osteoporosis.

**Glucosamine/chondroitin** combinations are promoted as ‘optimal support for joint health’, and to ‘repair joint cartilage’ in the United States. Both materials may be prepared either from bovine or ovine sources, which reputable manufacturers usually obtain from herds that are free from scrapie or bovine spongiform encephalopathy prions. Glucosamines are also found in chitin (the material giving strength to insect exoskeletons and the shells of marine arthropods) and some plant cell walls. Patients with allergies to crabs and lobsters are also liable to be allergic to glucosamine formulations derived from these sources. Chondroitin is a sulfated mucopolysaccharide found in mammalian cartilage or tendons. Glucosamine, in large doses, can increase insulin requirements in diabetics. Chondroitin increases the likelihood of relative overdose with warfarin, probably by competition for plasma protein binding sites and increase in free warfarin concentrations.

**SAM-e** recently became popular in North America, although it has been used for much longer in Europe. It is recommended for the kindred syndromes of fibromyalgia and chronic fatigue syndrome, as well as unrelated diseases such as osteoarthritis and Parkinson disease. SAM-e is also recommended for depression and anxiety, which can obviously be either primary or secondary to the other indications. Pure SAM-e is (usually) the S-isomer of adenosyl (L-) methionine, but it is often formulated with B vitamins; endogenous adenosyl methionine is found in the mammalian liver, and thus swallowing 200 mg per day (a typical dose) may not be able to materially change the biological economy of this substance. Perhaps by extrapolation from the known detoxicating properties of sulfydryl-containing amino acids, it proposed that SAM-e removes ‘harmful metabolites’ and that these, in turn, are responsible for the diseases for which the drug is indicated. It is also proposed that SAM-e can ‘optimize the synthesis of neurotransmitters, glutathione and cartilage’; as glutathione is synthesized in many mammalian tissues at high concentration, always from glutamate, cysteine and glycine, these claims cannot be entirely correct. One manufacturer’s trade mark for SAM-e is ‘Nature’s Wonder’ and sells SAM-e formulated with unidentified ‘methylation factors’ as a ‘complete methylation support formula’.

**Ephedra spp.** (known as ‘ma huang’ in Chinese medicine) are a large genus of woody, jointed, desert shrubs. These shrubs appear to be leafless from a distance but, on close inspection, possess scale-like leaf structures at the nodes. Ephedrine, pseudoephedrine and related alkaloids are the active principles. Ephedra is marketed for many logical purposes, for example as decongestants, bronchodilation and so on. Less appropriate uses are to heighten awareness, remain awake when studying for examinations and a street-sold alternative to illegal amphetamines. The predictable adverse events are hypertensive episodes, stroke, cardiac arrhythmias, malignant hyperthermia and seizures, many of which occur in young people.
and after doses as low as 1–5 mg, reported at an incidence rate of more than 100 cases per year to the US Food and Drug Administration (US FDA). During general anesthesia, unexpected hypertensive problems occur due to supra-additive interactions. Renal stones have been reported to be associated with ephedra use in one or two case reports, although a causal relationship must be viewed, at present, as uncertain. It would be illogical to recommend ephedra to patients with glaucoma, diabetes, hyperthyroidism and any other condition that would usually cause contraindication of sympathomimetic agonists. In the United States, the collapse of a professional sportsman on a televised field, as well as some injuries and deaths among military recruits during training led to governmental concern about ephedra-containing products. After the usual period of public comment (which was overwhelmingly supportive when from medical and scientific organizations), in 2004 the FDA implemented a ban on nonprescription ephedra-containing products. At the time of writing, the manufacturers and distributors of these products are pursuing legal avenues to reverse this regulatory action.

Ginseng is an extract of *Panax schinseng* (China) or *P. quinquefolius* (North America). It is a five-leaved herb with red berries. The part used for making complementary therapies is the aromatic root. Ginseng is recommended for holistic measures of good health, usually stated, at their most specific, as enhancing resistance to stress and improving sexual function. There are one or two case reports that ginseng can antagonize the effects of warfarin, but otherwise this herbal medicine does not have a reputation for intolerability. Ginseng is more widely used in North America and the Far East than in Europe.

*Kava* is an Australasian shrubby pepper (*Piper methysticum*). Amidst much ceremony, its crushed roots are made into an intoxicating beverage by the aboriginal people of the Molucca Islands and the Northern coast of Australia. In the west, kava is usually recommended for anxiety; it appears to have sedative and extrapyramidal effects, in common with some anticholinergic and antidopaminergic drugs. Its sedative effects are synergistic when administered with benzodiazepines, barbiturates (barbitals), alcohol and some antiepileptic and antipsychotic drugs. Kava makes Parkinsonism worse, and can cause drug rash, photosensitivity and itching.

*Other complementary medicines:* There are many thousands of other complementary medicines. These range from large doses of vitamins or minerals to extracts of many other plants and animals. Most are not characterized toxicologically or pharmacologically; the properties of the simplest may be anticipated with a good clinical biochemistry textbook at hand.

In Hong Kong, limited regulatory control of many traditional medicines has been found to be necessary due to their toxic nature. These regulations extend over root extracts from several *Aconitum spp.* (containing C19 terpionoid sodium channel blocking drugs), various herbs containing anticholinergic substances, toad venoms (which contain Na–K ATPase inhibiting bufotoxins) and preparations from the more familiar genera *Impatiens, Rhododendron* and *Euphorbia* (Tomlinson et al., 2000). The view through the window of a Chinese pharmacy, in the ‘Chinatown’ of any city in Asia, Europe or the United States, may cause different emotions in the pharmaceutical physician and pharmacologist. Although both may feel daunted, the true pharmacologist also beholds an almost inexhaustible new supply of drug development leads!

### 30.3 Adverse effects due to complementary therapies

It should be noted that almost all fundamental types of adverse event have been described, including those mentioned above. These include agonist–antagonist interaction, protein-binding competition, metabolic adaptation and pharmacodynamic synergy.

The general public seems to have a preconceived notion that drugs with ‘natural’ origins, or those which may be bought without prescription, are automatically safe. This notion is often accompanied by an uncritical assumption that there is no need to rigorously prove efficacy *a priori*, and that, as individuals, people can find out ‘if it works for them’.
It is a curious assumption, and illogical that a complementary therapy could have sufficient pharmacological activity to improve health (however imprecisely that may be defined), and yet these properties are automatically insufficient to cause harm. Part of the problem is that adverse reactions to ‘natural’ therapies are not reported in the same way as for orthodox drugs (Barnes et al., 1998). Reporting bias also tends toward the association of adverse effects with the condition being treated rather than from the ‘harmless’ over-the-counter or herbal remedy that has been administered. The only complementary therapies that are safe in overdose are those that are homeopathic, with even these carrying the clinical hazard of under-treatment.

30.4 Regulatory aspects

Homeopathic drugs are regulated in much the same way as allopathic drugs; there are some over-the-counter formulations, but most are prescribed and can only be dispensed by a pharmacist in the United Kingdom. Chinese medicines are essentially unregulated; as in mediaeval Europe, these can be prescribed by both a Chinese medical practitioner and a Chinese pharmacist (using the term Chinese to describe their disciplines, not their nationality), and much responsibility rests on the pharmacist for identification of the correct plants, resisting the purchase of cheap materials from unreliable suppliers and knowing what to look for in quality control. Other forms of herbal remedy (including all nine discussed above) are freely available in supermarkets and pharmacies in most jurisdictions. Mail order, using the worldwide web for advertising, is increasing, and will undoubtedly cause legal issues with cross-border commerce and transportation in the future.

In the United States, most herbal manufacturers simply write a letter to the US FDA to notify when a new product is being introduced, sometimes providing an example of the labels and tablets for identification purposes. The Food, Drug and Cosmetic Act has been interpreted as almost totally inapplicable in this situation, and is certainly not enforced. FDA does maintain adverse event registers for all forms of drug through the usual Medwatch forms.

Further reading

Ernst E. 2004. The GMC is right to come down hard on doctors who wrongly prescribe complementary medicine. Guardian 15.
SECTION V
Drug Regulation

Introduction

Sections I and II have covered fairly orthodox aspects of drug development. This Section now turns to applied aspects of research and regulation. These usually reflect newer aspects of the pharmaceutical enterprise, both from the point of view of product development and the regulatory responses that accommodate them. Both these are also rarely optional.
31 United States Regulations

William Kennedy

31.1 The Food and Drug Administration: how we got to where we are

Once upon a time . . . there was no FDA. However, the history of food and drug regulation began well before any modern government administration, anywhere in the World. Drugs and foods have only become distinguished from each other in the relatively recent past, and, it can be argued, as yet incompletely in the United States.

The ancient Greeks, Romans and Arabs all regulated food and drugs. Principally, their concern was with product purity, one of the three pivotal concepts that still form the basis for drug approval today. The typical penalty in ancient times for violating the standards was the loss of the dominant hand that had made the adulterated product. The Arabs were probably the most conscientious of regulators, with standards for about 2000 drug products, and, like today’s FDA, they were the first to establish a professional staff of food and drug inspectors. Their penalty for a baker of underweight loaves exceeded that of the drug adulterer: the bakers went summarily into their own ovens.

In 1202, the first English regulation was identified, traditionally, as the Assize of Bread. In fact, this assize had been held by manorial lords for a lot longer than this, and the lords were often also the exclusive owners of the ovens. To remedy this small aspect of local despotism, presumably with skepticism about self-regulation, the new national law forbade the incorporation of ground peas or beans in the flour meal. Meanwhile, the London Grocers had organized, and formed their own guild, again with self-regulation of a wider range of foodstuffs. In the seventeenth century, the London apothecaries (makers of medicines and also licensed medical practitioners in their own right) devolved from the Grocers. The Worshipful Society of Apothecaries of London still exists, can still award a medical license (although this is quite rare among British physicians) and is now the largest of all the London guilds.

What with 1776 and all that, the British jurisdiction of food and drug regulation ceased to obtain in what were to become the United States. The apothecaries were still people who had trained mostly in London or Germany, or had graduated to professional status by apprenticeship. But, there

---

1The paragraphs about the year 2005, immediately preceding the Summary to this chapter, were inserted after going to press by the Editors; the Editors are also grateful to Dr Tim Franson for his perspective on pediatric issues.
was a void in national regulation of food and drugs. British patents, which had already been awarded to American drug recipes, also became null and void.

Over-the-counter (OTC) medicines (or ‘patent’ medicines) thrived in this void. The American patent process was also undeveloped, so these became what we would perhaps view as trade secrets held by named apothecaries and their apprentices. There were also no inspectors. Moreover, the British were not quickly mollified by the new political reality: European medicines were included in the embargo, and yankee ingenuity began to be expressed to the full. The problem quickly evolved: Who was to say that the ‘eye of newt’ in the Scottish witches’ potion was not actually a bit of chicken?

It has been said that the drug law in the United States developed in the eighteenth and nineteenth century with all the red, white and blue of the aniline dyes that quickly became available. Regulations in this country rapidly developed in a characteristically idiosyncratic manner.

Sewers and food do not mix. This was the era of rapid expansion of Boston, Philadelphia, New York, Baltimore and eventually Washington, DC itself. Massachusetts regulated food for the first time in 1784, but this again was a feeble attempt to control purity. No attempt was made to address the potions used to treat ineffectively the infectious diseases that were rampant.

‘Dr Feelgood’ potions, typically named after the apothecary who compounded them, had eponymous effects. These potions usually contained alcohol and morphine, were used indiscriminately and at least made people feel good. One of these survives, ironically enough in England, and is called ‘Dr John Collis-Brown’s Compound’.

The American geography constrained the regulatory environment. First, there was a lot of pioneer activity in the West: trained professionals were not the first to climb on the covered wagons. Second, new religions were being spawned at a rate far faster than had ever occurred in any European country. Third, worthless medicines were being distributed and used over millions of square miles with, at best, only rudimentary communications. The promotion of medicines became a form of entertainment, by bogus professors, showmen, fakers and embezzlers in Desert Gulch! Meanwhile, little opportunity was taken to learn from the Native Americans, whose herbals were often quite well developed with active pharmacognosy. But the national government was not stirred into action until its own interests were directly affected: soldiers in the Mexican American War were poisoned by ineffective antimalarials south of the Rio Grande.

And so it was, in 1848, that the first drug regulation was established in the United States. It simply banned the import of impure drugs. The medicine man shows were left to local regulation (a legislative omission that is still with us today). And so it was that in 1850, the State of California became the first to enact anything resembling a comprehensive drug regulation.

By 1900, it is estimated that about $40 million per annum was being spent on drug advertising. This was mostly in newspapers, which were thus only too happy to ally with potion makers in stirring up public opinion against the national regulation of their products. Medicines (some up to 50% alcoholic tinctures) became the only source of alcohol in some communities where religion forbade wine and whisky. For the more adventurous, morphine, opium, cannabinoids and cocaine were available, even in some of the earliest formulations of Coca-Cola, although not, of course, today.

Harvey Wiley was a hero among the villains. He headed the Federal Bureau of Chemistry, and began calling for national regulation in 1890. His ‘poison squad’, the forerunners of the Inspectorate Branch of FDA today, began documenting and on occasion prosecuting the makers of fake and poisonous drugs. The convictions were usually for things that were very egregious, probably because Dr Wiley could only prosecute under the general laws. Unlike today’s FDA inspectors, the members of this squad were expected to sample the questionable product themselves, and then give first-hand evidence of the adverse effects that they experienced!

Specific regulation began in 1902, and concerned the purity of serums and vaccines to be used in humans; The Center for Biologics Evaluations and Research (CBER) thus has a longer history than its colleague center for drugs (CDER).
Part of United States food and drug regulatory lore includes, at this point, an unlikely convergence of two famous characters. One was President Theodore Roosevelt, nationalist ex-‘rough-rider’, soldier in Cuba and hero of San Juan Hill. The other was Upton Sinclair, United States’ first published communist, and author of ‘The Jungle’, intended as an exposé of North American capitalism at its worst. Sinclair’s book was being serialized in the DC newspapers, which the President habitually read during his high-cholesterol breakfast, which always included sausages. In one daily episode of the book, Sinclair described the use of offal, floor-waste and other abominations at the end of the daily sausage run, in the attempt to maximize profits. Dr Wiley had his political ally, and the Pure Food and Drug Act (PFDA) and Meat Inspection Act were the result (1906).

The PFDA banned adulterated or misbranded drugs from interstate commerce, and this remains the legal basis for FDA actions to this day. Today’s definitions of ‘adulterated’ and ‘misbranded’ are also those of nearly a century ago. The philosophy, however, has long been forgotten: if you made bad drugs, then you had to sell them within your own community, and the local law enforcement people should have found you out fairly easily for themselves. This is, arguably, a survival of the Anglo-Saxon principle of frankpledge within the twentieth century US laws.

From among the wide variety of dyestuffs available in the north-eastern factories before the First World War, just seven were authorized for human consumption by the Certified Color Regulations (1907). This brought dyestuffs within the canon of interstate commerce law. This is not as incongruent as it might seem because among these dye-stuffs were the first, primitive antibiotics.

But, then as now, the US Supreme Court was not averse to getting involved in unprecedented situations. In 1911, the Court held that the 1906 Act did not prohibit false or misleading therapeutic claims, but was strictly to be interpreted in terms of purity and composition. PFDA was thus amended in 1912, to include specifically false therapeutic claims. However, the Act now required proof of intent to be fraudulent: it was essentially a criminal matter. This need for proof of intent made the Act hard to enforce, and few could be punished or made to change their ways. In 1914, a further amendment defined the presence of poisonous or adulterated substances was specifically a violation of the Act, although the definitions of precisely what was a poisonous or adulterous substance would have to be developed on precedent.

It was not until 1924 that a further PFDA amendment that made mere statements potentially a violation under the Act. For the first time, exaggerated claims of therapeutic effectiveness could be proscribed. This amendment went further to specify that even true statements that nonetheless deceive or misinform would henceforth fall foul of the Act (malt vinegar without any written claim to be apple cider vinegar, but with an apple depicted on the label, was cited as an example of how this situation could arise).

Ever since 1906, there had been many challenges to the Act and its amendments, and this consumed much administrative time and money. The innovation of 1930, expansion of the Bureau of Chemistry into a renamed Food and Drug Administration, was designed to relieve this administrative burden. The new Agency introduced a Bill into Congress, that was designed to invigorate and modernize the by now patchwork and creaking amended PFDA.

Once again, there was resistance to the Bill. However, communications were modernized, and public opinion was molded not only by newspapers but also by radio: and radio could be heard hundreds of miles away. One small fly in the proverbial ointment, however, was that Teddy Roosevelt’s nephew, Franklin Roosevelt, was now President; the President was wheel-chair bound due to polio, and believed in the therapeutic value of hot springs and other complementary therapies.

At about this time (1931), an OTC potion called ‘Jake’ poisoned hundreds of people. It was probably a peripheral neurotoxin due to an adulterant in an extract of Jamaican ginger: ‘Jake-leg’ became a recognized syndrome. While Jake ‘the Peg’, with an extra leg (i.e. an axillary crutch), became famous, it needed a much bigger disaster to move legislative and public opinion.

Domagk demonstrated in 1935 that sulfonamide-containing dyes could protect mice from infection;
he became a Nobel laureate in 1938. The nostrum artists could hardly believe their luck: now they could peddle a drug that actually worked! The favored formulation at the time was an elixir, probably a holdover from evasion of alcohol restrictions due to religion, or the earlier flirt with prohibition. In any case, one Company, supposedly laudably, searched for a nonalcoholic solution for their sulfonamide. They chose diethylene glycol. In four weeks of marketing, the product was not a success: only 353 patients drank it; of these, 107 died. They were mostly children, and there was no renal dialysis in 1936. Thousands could have been killed had the Company’s market analysis been accurate.

But finally, there was sufficient groundswell, and FDA obtained passage of the Food, Drug and Cosmetic Act (FD&C Act) in 1938. Thus, the FD&C Act added safety as the second pivotal leg of drug approval.

There was still no requirement to prove product efficacy. But in 1941, with most of the world at war, an often overlooked piece of US legislation was passed. The FD&C Act was amended, to reflect an FDA proposal. Henceforth, FDA was empowered to certify the potency of insulin. This required a bioassay, and for the first time FDA was able to regulate pharmacodynamics. It was a short step to therapeutic efficacy.

In 1943, the Supreme Court again got involved. In an otherwise obscure case, it held that FDA was empowered to establish standards for products labeling. The four principal arms of drug approval were finally concentrated in the hands of a single agency: purity, safety, efficacy and labeling. To this day, much of the power of FDA is exercised by its control of what a label says, and not by the pharmacological characteristics of the particular drug in question. To Europeans this is sometimes a surprising concept, but in fact the principal extends to other areas of American commerce: for example, cars may be imported into California depending not upon whether the vehicle meets the emissions standards, but rather upon whether it is labeled as meeting those standards.

In the 1950s, the Delancy Amendment to the FD&C Act authorized an investigation into the new dyes, flavorings and preservatives that were becoming available in an era of unprecedented chemical innovation. There was already a clear need to update the FD&C Act, and the Food Additive Amendment of 1958 was one result, which, among other things, prohibited carcinogenic materials from foods and drugs. This required a method to establish carcinogenicity, which is now an important element in the toxicology package for an overwhelming majority of approved drugs. There are now exceptions. Antineoplastic drugs are often themselves carcinogenic, and the absolute restriction on such materials is somewhat tempered. Furthermore, we now understand the dose relationships for chemical carcinogenesis, and how to measure it, very well; high-school exercises now routinely exceed limits of detection available in the 1950s. But the principle had been established in law. November 1958 saw FDA recalling the entire cranberry crop, just before the Thanksgiving holiday, because there was a fear that weedkiller contamination which they had established was a carcinogen in animals!

The other major piece of legislation in the 1950s was the Durham-Humphrey Amendment to the FD&C Act. Humphrey (unsuccessful Presidential candidate and later Vice-President) had been a pharmacist; he wanted to clarify what should and should not be an OTC drug. Hitherto, the only reason to get a prescription from a physician and have it filled by a pharmacist was because the patient did not know of an OTC drug to meet his or her need, and the prescription was one which needed to be compounded by a professional. The amendment provided, perhaps artificially, that when a disease or a drug side effect needed a physician’s attention, then any treatment required a prescription, and that only a licensed pharmacist could fill a prescription. Some view this as the genesis of general diagnostic education by the pharmaceutical industry, and, in turn, the origins of direct-to-consumer advertising designed to drive patients into their doctors’ offices.

In the late 1950s, there were also many other reasons to seek reform. FDA's ability to regulate efficacy assessments was still restricted to a small number of highly specialized products, and modern advertising techniques were getting under way. As usual, there was public resistance, and it
required a big disaster to get things done. To be precise, thalidomide.

Dr Frances Kelsey had the thalidomide application on her desk. She was busy and had simply not got around to it. Then from Europe she heard about a question of peripheral neuropathy, and possibly thyrotoxicity; at that point she made an active decision to hold up the approval. It was an Australian dermatologist who identified drug-induced phocomelia, and the rest is well known. Only nine cases of phocomelia were reported in the United States, from an exposure of about 4000 women of childbearing potential, most of whom were pregnant. Kelsey received a medal from President Kennedy.

Amazingly enough, the 1962 amendments would still not have kept thalidomide off the market in the United States. The precise strain of rodent that would have been required to identify the lesion was not in common use, and the adverse event frequency in neonates, in the average-sized NDA of the day, might not detect adverse events of such low frequency. However, the 1962 amendments required, in the general case, that drugs should be demonstrated to be effective prior to approval, for the first time.

The 1962 Kefauver-Harris amendments provided further capability to FDA. They set forth the requirements of the IND process. The FDA was empowered, for the first time, to seize a drug and cause it to be withdrawn. Adverse event reporting to FDA became mandatory. Labeling and advertising requirements were clarified, and transferred that responsibility to FDA from the Federal Trade Commission. Inspections of manufacturing sites were also facilitated by these far-reaching amendments.

In 1966, it was estimated that there were about 4000 drugs available which had been approved on pre-1962 criteria. FDA commissioned the National Academy of Sciences/National Research Council (NAS/NRC) to review these ‘grandfathered drugs’ against the modern standards. Some of the reviews lasted 15 years, and were contentious, while other drugs felt to be important had to be transferred to new manufacturing sites. The abbreviated NDA (ANDA; mostly thought of today in connection with generic drug approvals) was invented in 1970 for the latter purpose. The NAS review was extended to OTC drugs in 1972. Meanwhile, devices came under the FDA aegis in 1972, and biologics and vaccines were subsumed under the FDA umbrella in 1972.

As regulations increased, so did the risk of drug development. Complaints were loud that rare diseases, offering small potential markets, were increasingly ignored because the costs of drug development to address those markets had become so high as to deter research and development by the pharmaceutical manufacturers. After much debate, a compromise was reached in the Orphan Drug Act (1983). If it could be demonstrated that the incidence of the disease in question was fewer than 200 000 persons per year in the United States, then Orphan Drug designation would be allowed. This provided tax credits and exclusivity guarantees, should an eventual NDA succeed. Currently, there is criticism that this absolute number of 200 000 patients has not been raised with time, as the US population is now greatly increased since 1983, and, unless amended, this legislation will eventually become moot. Meanwhile, there is also often debate with FDA on borderline cases of calculation of incidence. Several drugs that are in the market in Europe are denied to Americans by reason of FDA not granting Orphan Drug designation, and there being no other method for gaining exclusivity for at least the seven years that the Orphan Drug Act provides.

The Waxman-Hatch Amendment (1984) traded off patent term restoration for innovative drug development with generic drug ANDA approval. The contents of the ANDA were clearly stated for the first time. Furthermore, FDA review times could be added to the patent-awarded period of exclusivity. Currently, FDA compares these review periods in a highly conservative manner: the review period is compared to the period that the drug company has been conducting IND research, and the public is led to the view that FDA review is a trivial component of total development time. Furthermore, FDA stops this artificial clock every time they send a question about the NDA back to the sponsor, even though review activities at the Agency continue. In one case, in the 1990s, when these procedures had been well established,
30 months elapsed between NDA submission and approval, but the patent term restoration was only nine months; no new clinical trials or toxicology studies were needed during this review.

The generic scandal of the 1980s involved pharmaceutical companies making, and FDA staff accepting, bribes in the interests of rapid generic drug approval. No new legislation resulted, even though two Vice-presidential commissions (one Republican, the other Democratic) inquired into the matter. Similarly, there was no new legislation following the massive Clinton initiative; drug pricing was probably the principal missed target on that occasion. It is arguable whether or not these vents triggered the subsequent spate of mergers and acquisitions within the pharmaceutical industry.

The Prescription Drug Users Fee Act (PDUFA, 1992) traded off fees paid upon NDA submission for performance standards on the part of FDA. This was the first time that any effective accountability had been applied to FDA, somewhat reversing the orientation of the Agency. PDUFA is due for reauthorization in 2002, and an analysis of its effect is being conducted by several industry and government organizations.

The last major revision of Food and Drug Law took place in 1997, coincident with the first reauthorization of PDUFA. The Food and Drug Administration Modernization Act (FDAMA) of 1997 was only the third major overhaul of the original 1906 Act. It was the first to occur without the impetus of a disaster or perceived disaster. After a troubled start in 1996, FDAMA received overwhelmingly positive support in both houses of the US Congress, getting 98 of 100 votes in the Senate, and a unanimous vote in the House.

The perceived need for FDAMA by Congress, the industry and ultimately the FDA was the recognition that while the law and the regulations had changed little from the 1962 Amendments, the requirements made by the FDA of the industry had increased dramatically. Part was due to advances in technology and medicine, but part was due to FDA reviewer preferences. Both of these contributed to the phenomenon known as ‘regulatory creep’ that was demonstrated by wide variances across the FDA in requirements. Although there were some significant break-throughs that advanced healthcare and the regulatory process, a major portion of the legislation focused on the formalization of ‘best practices’ that existed within the FDA and making these the standard throughout the FDA.

Some of the major breakthroughs of FDAMA included

- formalization of the evidence needed from pharmacoeconomic studies;
- authorized and regulated the dissemination of information on unapproved uses of approved products to healthcare providers by pharmaceutical companies;
- enhanced the availability of labeling information for use in pediatric patients by recognizing the difficulties of developing drugs for this group and providing an incentive to undertake this work.

Examples of modernization which were the result of identifying ‘best practices’ within FDA and making them the standard include

- improving access to unapproved drugs;
- clarifying the definition of ‘substantial evidence of efficacy’ to include only one pivotal study provided there is adequate confirmatory evidence. This had long been used for the approval of oncology drugs, but was now able to be applied more widely;
- formalization of various administrative aspects of the IND and NDA process.

Although PDUFA and FDAMA offered significant opportunities to improve the drug development process and make more drugs available to more people, more quickly, for the most part, the promise has yet to be fully realized. There are two reasons for this, both acknowledged before the legislative changes were initiated. The first reason is that the ‘regulatory creep’ that was being corrected was something that took place over the period 1962–1997. It would be unrealistic, not to mention
unsound, to expect 35 years of change to be corrected overnight, and at the same time, maintain a productive regulatory agency. Congress allowed for an implementation period. The second reason flows from the first. The drug development process is long and resource-intensive. It is difficult to turn midstream. Once the FDA starts changing, the industry will have to respond with changes in the development process. This takes even more time. Simply stated, many of the changes have just not had sufficient time to get into the process.

31.2 Economic considerations

FDA has jurisdiction over about 20–25% of the gross national product (GNP) of the United States. In 1996, the FDA-regulated industries comprised about $1750 billion (i.e. $1.75 \times 10^{12}$), thus dwarfing the US Department of Defense budget by about a sixfold difference. This is about 150% of the entire GNP of the United Kingdom. These regulated industries include all medical devices, all drugs, many other OTC or in vitro diagnostic materials and almost all food (meat is still the responsibility of the Department of Agriculture under Teddy Roosevelt’s 1906 Act). These activities are all mandated by the FD&C Act and its various amendments.

In addition, FDA engages in various cooperative projects with organizations such as the National Institutes of Health, the Centers for Disease Control, the Drug Enforcement Agency and the US Public Health Service (many of whose officers serve attachments to FDA). A certain amount of independent research is supported in the FDA budget, as well as international liaisons. FDA, too, conducts lobbying and legislative functions.

31.3 Organizational aspects

FDA is part of the Department of Health and Human Services, which is represented at Secretary level within each President’s cabinet. The secretary appoints a commissioner to head the FDA, and this is usually a political appointment (i.e. not held by a career civil servant). The commissioner appoints assistants or deputies to head the following centers or offices:

- CDER
- CBER (now with a far smaller remit than previously)
- Center for Food Safety and Applied Nutrition
- Center for Devices and Radiological Health
- Center for Veterinary Medicine
- Office of Regulatory Affairs
- Office of Orphan Product Development
- National Center for Toxicological Research

The assistant and deputy commissioners might be either political appointees or career civil servants. Each of these subdivisions is typically further subdivided. For example, CBER has offices of Management, Compliance, Therapeutic Research and Review, Vaccines Research and Review, Establishment Licensing and Product Surveillance, Blood Products and Communications and Training. Each are typically led by career civil servant Office Directors, although, currently, the Office of Orphan Product Development is headed by a Rear-Admiral from the US Public Health Service.

CDER has a larger product development responsibility than CBER, and thus has five Therapeutic Review Divisions, each led by a career civil servant Division Director. But the other divisions are similar to the CBER model, with divisions for Epidemiology and Statistics, Compliance, Pharmaceutical Sciences (including a specialized office of New Drug Chemistry), Biopharmaceutics and Generic Drugs. It seems likely that an Office for Toxicology will soon be established.

Most centers or offices have access to a network of field-based inspectors. These inspectors operate worldwide, and audit both animal and clinical studies, as well as manufacturing processes and premises. Such audits can be ‘for cause’, for example a complaint from the public or an
emergent safety issue, or ‘routine’. Pivotal clinical trials in a submitted NDA or BLA will usually garner an inspection of the clinical trial sites and statutory documentation.

This inspection process has recently been augmented with the establishment of an Office of the Inspector General (OIG) which reports at the level of the Secretary, not the FDA Commissioner. One of the first announced targets of the OIG, selected from the entire realm of foods and drugs that FDA regulates, is clinical trials. In particular, the OIG is actively investigating informed consent documents, and also has notified institutional review boards (the US equivalent of the ethics committee) that they are in for close scrutiny.

Make no mistake. One big difference between the EMEA and FDA is that the FDA is also the police (and often the judge and jury, as well). Do not take lightly the appearance of your name on Form 1571.

### 31.4 Investigational new drugs (IND)

The student is urged to read the Code of Federal Regulations with this title, beginning at 21CFR310.

The legal basis for an IND was set up in the 1962 amendments. It is unlawful to transport an unapproved drug across state lines unless FDA has issued an exemption. The IND is technically an exemption from the requirements of an NDA. Drugs labeled ‘Not for human use’ are also exempt from the NDA requirements, before being transported, but carry regulatory restrictions. Note that technically and legally these regulations apply just as much to noncommercial research physicians, for example in universities, as to pharmaceutical companies.

The structure of an IND application is contained in the regulation and is quite easily followed. Almost all pharmaceutical companies, contract research organizations and universities have templates for the writing of these documents. All the animal data, the proposed clinical study protocol, a clinical investigators’ brochure and the chemistry and manufacturing controls must be described. Once an IND is active, then it can be amended with further clinical protocols, additional toxicology data and so on, as the development program proceeds.

The IND differs in a number of ways from its European counterparts. First, it is much longer; a typical IND is of at least 1000 pages, and for drugs with foreign human experience, often many multiples of this number. The UK Clinical Trials Certificate, used very rarely for this reason, and not the Clinical Trials Exemption (‘CTX’), would be the nearer comparison. Second, an IND is required for all human exposure to INDs, and this includes normal volunteer studies. Third, all being well, there is only a 30-day wait between filing and commencement of the clinical study; no news from FDA after this time period has elapsed is presumptive evidence that the study may proceed (most FDA divisions will, in fact, issue affirmative letters that this is the case, within 30 days). Fourth, once an IND has become active, there is no subsequent 30-day wait when further clinical protocols are submitted.

FDA is at liberty to impose partial or total clinical holds on any protocols that it receives. Partial holds might limit, for example, the maximum dose that can be employed, prevent commencement until additional safety monitoring measures have been instituted or restrict dose frequency.

It is no longer the case that an IND is needed merely for the export of an investigational agent to another jurisdiction, provided that the regulations that obtain in that jurisdiction are adhered to. This was one former peculiarity of the restriction on transportation of unapproved drugs across state lines.

There are variants of the IND process. These are described in the chapter entitled Special INDs.

### 31.5 Meetings with FDA

Many Europeans are surprised at the access that pharmaceutical companies have to the reviewing divisions of FDA. The typical investigational drug will be the subject of a pre-IND meeting, which FDA will provide at its discretion and for which the agenda may be set by the prospective
applicant. These meetings can also be held by telephone conference, and FDA is getting quite good at accepting electronic files of data. An IND is, however, only allotted a number upon its submission.

It is fair to say that US companies differ in their approach to pre-IND meetings. Most companies probably view pre-IND meetings as desirable. However, under the law, proprietary information is only required to be kept confidential by FDA when it is the subject of an IND. No known major disclosure has happened, but companies would have little recourse if FDA leaked information following a pre-IND meeting. The other problem is that without an IND in place, FDA has no obligation to meet with clinical trial sponsors: reviewers up against a PDUFA deadline on another project are unlikely to prepare thoroughly for a pre-IND meeting, and may entirely change their views after the IND, when they become obligated to adopt a position. Some companies file the IND first, with a simultaneous request for a meeting.

Typically, during phase I and II development there will be sporadic communications between the IND sponsor and FDA. These might be to clarify issues over post-IND clinical protocols, reach agreement on compatibility of toxicology data with clinical study design, carcinogenicity testing requirements (typically starting at this time due to their long duration and the necessity for their completion before filing the NDA) and the many technical matters associated with the scale-up of the chemistry and production processes.

It is typical to hold an end-of-phase II meeting (EOP2). At this meeting, the FDA will review the current phase I and phase II clinical data, and the state of the toxicology program. The objective is to reach agreement on the design of the phase III studies that will support NDA approval, as well as to identify any further problems that may be ameliorated without delaying the NDA. FDA can also begin planning for the resources needed when the NDA arrives.

A pre-NDA meeting is typically held as the phase III clinical trials are concluding. The principal objective is to check how the issues identified at the EOP2 meeting have been resolved. At this meeting, the entire structure of the forthcoming NDA can be agreed, and technicalities surrounding electronic submissions can also be arranged.

31.6 The new drug application (NDA)

The best NDAs have a table of contents before the EOP2 meeting, and are built as the various component nonclinical and clinical study reports become available. Most companies do this both electronically and as paper hard copy. At present, FDA requires the submission of both, although PDUFA requires FDA to be able to accept just an electronic version by 2002. The structure is well described in the regulation, which the student is again urged to read.

Two sections of the NDA are markedly different from a European submission. These are the Integrated Summaries of Efficacy and Safety. In some respects, these are the biggest intellectual exercises that are encountered during the NDA process. These documents require the pharmaceutical physician to have thoroughly reviewed and understood the other sections of the NDA. But further than this, these summaries require risk–benefit assessment, crystal clear arguments for choice of dose size and a full justification of how the NDA data place the new drug into the current understanding of the pathology and indication. The new drug must also be reviewed in comparison with the pharmacology and toxicology of kindred drugs. Justification for every statement in proposed labeling must also be provided. These integrated summaries, in contrast with a European expert report, are often 300–400 pages long.

Assembling an NDA is a long process. Usually there is a cut-off date for data that by then may be accruing from all over the world, but which are not pivotal for NDA approval.

The Integrated Safety Summary is then supplemented four months after NDA submission. This usually provides a significant increase to the safety database either from ongoing studies that are rapidly accumulating patients in phase IIIB, or from marketing data from foreign countries where the drug may be already approved. The FDA requires updating on all safety information.
that has been gathered subsequent to the filing of the NDA.

Federal law requires that FDA issue a notice of action within 180 days of filing the NDA. There are three forms of action: approval, approvable, or non-approvable. Approvable letters must indicate all the deficiencies that FDA has identified that can, upon rectification, lead to approval. If such deficiencies require the submission of additional data, however slight, then FDA has another 180 days to review the application. If the deficiencies are administrative (e.g. debate over the precise wording in labeling), then the FDA must act within 90 days of a resubmission. Lack of agreement on labeling is the major reason for issuance of an approvable letter rather than an approval letter. Although most FDA reviewing divisions will only negotiate the proposed label, word for word, after the issuance of an approvable letter, some companies have been able to go directly to an approval letter as the first action by a combination of good communication with the FDA and the submission of a realistic package insert. The labeling negotiation itself will often be done by fax and counter-fax, possibly culminating in a face-to-face meeting at FDA premises.

NDA approval is sometimes contingent on the sponsor making various commitments. Most recently, the Company is being asked to conduct post-marketing surveillance studies for safety issues that may be more or less well defined. Post-NDA safety report frequency will also be agreed prior to approval. Occasionally, there may be a toxicology study that FDA regards as outstanding but not crucial to drug launch. There may also be stated requirements for additional indications that have been refused by the Company at the initial NDA approval.

### 31.7 Sources of guidance

Both CDER and CBER have published a large number of guidance documents that are now also available at the www.fda.gov web site. Some of these are simply ICH documents in English. However, FDA has gone far beyond this, in supplying a large amount of valuable information. Guidances are not binding (on either sponsor or FDA), but it would be fair to say that clear reasons would have to be enunciated by FDA when requiring the guideline to be exceeded, and by the sponsor when suggesting a variance from them.

One of the difficulties in dealing with FDA is that reviewing divisions interpret these guidances differently. These differences can be profound. The term ‘adequate and well-controlled studies’ is used to describe the requirement for complying with the need to demonstrate drug efficacy. Most reviewing divisions in CDER still tend to interpret this to mean two independent, large-scale phase III clinical trials despite the clarification in FDAMA. Yet, CBER will approve drugs with a single phase III study and some consistent phase II data. Similarly, although the ICH guideline states that drugs used for intermittent, acute therapy do not need to have lifespan carcinogenicity tests, there can still be different interpretations within FDA regarding the definition of ‘intermittent’. Anesthetic drugs are usually exempt from these long and resource-intensive animal studies; but should this apply to acute treatments for disease, labeled for a maximum of three doses per week, and with relatively short half-times of elimination, or not?

Another example was the Computer Assisted NDA (CANDA). The Cardiorenal division within CDER embraced this technology rapidly and developed its own guidelines as to the technical parameters for this innovation. When the rest of CDER caught up (several years later), it was clear that consistency with an established and successful CANDA format was not on the agenda.

A further example relates to the pre-IND meeting. Some FDA divisions do not like them, and if reviewers attend, they have a tendency to provide less valuable information than they would for an EOP2 meeting or a pre-NDA meeting, the so-called ‘entitled meetings’. But, within the industry, there are a number of companies who have similar attitudes about the value of pre-IND meetings. The notable difference is that the FDA has to go to the pre-IND meeting if scheduled. The companies who see little value merely do not schedule them.

The bottom-line is that guidances are merely that – guidances. Individual reviewers at FDA are unlikely always to agree with what are essentially consensus documents.
CBER has innovated further with documents entitled ‘Points to Consider’. These rank below guidances in terms of their gravity. These are designed to accommodate rapidly developing technologies, which, to be fair, is probably a greater challenge for CBER than CDER. These ‘Points to Consider’ are almost completely outside the ICH process, and have been very well received by the regulated industries.

FDA has also been keeping its eye on the public. Advisory committee hearings are typically held by the reviewing divisions prior to any significant NDA approval. These hearings are open to the public, and specifically include an agenda item that provides for public commentary, quite apart from the dialog that goes on between FDA staff, their recruited outside experts and the NDA sponsor (again, all in public). FDA has also begun to publish its policy statements. The AIDS community, in particular, has been especially effective in deflecting FDA from its otherwise default-mode course in the review of investigational and new drugs.

31.8 Influences on FDA activities

The FDA, like any other branch of the US government, is subject to the oversight of Congress. It is Congress that writes the laws that FDA must implement as regulations. FDA must understand the Congressional intent in any law, or will find itself called before them to justify their actions. FDA is also dependent upon Congress for its budget, which it must get approved yearly. The court of public opinion has had more of an influence on the FDA in the past 20 years than any other time in its history. This influence is directly focused at the FDA, or indirectly through interaction with Congress or the media. The AIDS community broke the ground in this arena in the 1980s when they demanded access to more drugs for this dreadful disease more quickly. Fueled by the success of their actions, other patient groups have challenged FDA authority since then. Groups such as the American Association of Retired People have voiced their concern on a wide range of activities. The American Academy of Pediatrics continues to fight for more drugs for children. A number of cancer patient groups seek the ear of the FDA on a regular basis. Pharmaceutical trade associations are also active voices.

Other recent regulatory developments, which are covered elsewhere in this book, include legislation regarding risk management as a forthcoming integral part of all NDA approvals (see also below), and new requirements for studying potential cardiotoxicity (which is the subject of a valuable ICH guidance).

Although the special nature of children in clinical trials is dealt with elsewhere in this book, it should not be forgotten that the FDA has been influenced to make regulatory changes specific to this age group as well. The victims of the sulfanilamide elixir tragedy that drove the 1938 Food, Drug and Cosmetic Act were mostly children.

The Food and Drug Modernization Act (1997) again explicitly encouraged IND sponsors to study children earlier in their development programs than had been the case previously. A six-month extension of product exclusivity upon NDA approval was the incentive, and pediatric research guidelines were issued (see http://www.fda.gov/cder/pediatric). In 1998, a mandatory rule requiring studies in children for certain therapeutic areas was introduced, and in 2002 the Best Pharmaceuticals for Children Act renewed these provisions as a matter of law, and expanded them on certain pharmacovigilance technical matters. The Pediatrics Research Equity Act (2003) constituted a separate Pediatric Advisory Committee within the FDA, and further codified the requirements for studies in children for almost all new molecular entities. European regulators have done likewise in 2005.

All these regulatory innovations have improved labeling for clinicians using drugs for children, and have increased the frequency of pediatric clinical trials manyfold. By January 1, 2006, some 720 pediatric clinical trials had been specifically requested by FDA in connexion with new product approvals, and of these 35% have been for efficacy and safety, 29% for pharmacokinetics and safety, 15% solely for safety, 9% for PK–PD assessments and 12% for various others. These trials were reckoned to be in children with 117 different diseases, distributed among 15 specific therapeutic areas.
31.9 Developments during 2005

The year 2005 was tumultuous at the FDA for numerous reasons. However, there was one event that is likely to have a particularly long-lasting impact on researching investigational drugs and the approval of NDAs. This was the recognition by FDA that certain cyclo-oxygenase-2 specific (‘COX-2s’), nonsteroidal anti-inflammatory agents (NSAIDs) carried an excess risk of cardiovascular adverse events in patients. In the case of rofecoxib (Vioxx), this led to its voluntary withdrawal from the market by its manufacturer.

Stereotypical behaviors resulted. Medical journal editors were prolix. Professional pharmaceutical industry bashers were given yet more cause for their wrath. Congress and the newspapers severely criticized the FDA. Plaintiffs’ lawyers salivated.

This adverse event potential had been known for 2–3 years at least, judging by the publications in medical journals. But lost in the cacophony was that the underlying reason for this problem was the disappearance of an appropriate risk–benefit balance when prescribing such drugs. Undoubtedly, there are many patients with arthritis and other inflammatory conditions for whom other NSAIDs are either ineffective or intolerable. However, the volume of sales of the ‘COX-2s’ would suggest that indiscriminate use of these agents as all-purpose analgesics had been taking place; famous, direct-to-consumer television and newspaper advertisements of these drugs by trade name undoubtedly increased this product demand.

The regulatory and industry responses to this crisis have been numerous, and are probably not complete at the time of writing (January 2006). These include

- a voluntary embargo by several pharmaceutical companies on advertising newly approved drugs (probably to be followed by regulations nonetheless);
- a vigorous debate on making risk management plans an intrinsic part of all NDA approvals and their continuing status;
- reorganization and bolstering of FDA pharmacovigilance departments;
- in the opinion of some, an inordinate new imbalance in regulators’ practices, leading to evidence of intolerability excessively outweighing efficacy when making both IND study and NDA approval decisions.

Direct-to-consumer advertising of prescribed drugs by trade name now exists only in the United States (it was banned in May 2005 in its only other locale, New Zealand). Congressman Waxman, among others, is publicly opposed to this practice in the United States. This debate will play out before the next edition of this textbook appears.

31.10 Summary

No apology is made for the extensive historical narrative that opened this chapter. Dealing successfully with the FDA requires an understanding of how the institution thinks, and how the individuals within it are constrained. The way the FDA thinks is predicated on its legislation, and how and why that legislation has evolved, mostly in reaction to crisis, but, at last, recently, in progressive negotiations with the industry and patient groups to bring about change that is of mutual benefit. The FDA has a complicated structure, and remains the most stringent regulatory authority in the World. We are likely to see further changes in the years to come.
32 Special US Regulatory Procedures: Emergency and Compassionate INDs and Accelerated Product Approvals

Anthony W. Fox

32.1 Introduction

The special types of IND and New Drug Application (NDA) probably represent the greatest differences in regulatory practice between Europe and the United States. These differences reside not only in the particular procedures themselves but also in the philosophy of regulatory authorities. Emergency INDs, Treatment INDs and accelerated approvals are essentially of United States interest, and the Code of Federal Regulations, Title 21, Chapter I (21CFR) is where most of these rules are published (the orphan drug regulations may, perhaps, also be seen as a special type of IND or NDA, and are described elsewhere in this book). It is probably fair to say that these procedures have created quite a revolution in the US drug approval process, and have helped drug developers. Their careful and gradual introduction has not damaged the public health. This chapter covers the following topics:

- Emergency INDs
- ‘Compassionate Use’: The Treatment IND
- Accelerated approvals: serious and life-threatening diseases
- Accelerated approvals: ANDAs and generic drugs

It should be noted that an ‘investigator’s IND’, or ‘physician’s IND’, is not a specific practice defined by regulation, and that these are orthodox INDs. It is true, however, that these IND submissions are usually smaller than those from pharmaceutical companies (see Section 32.3 below).

32.2 Emergency INDs

The IND in the United States is based legally on the notion that Food and Drug Administration (FDA) permission is needed to convey investigational (i.e. unapproved) drugs across state or international boundaries. This defines the jurisdiction of the Federal government in comparison to the state governments in all matters of commerce, not just drug development. The FDA imposes control over this process by requiring information of appropriate quantity and quality, before granting its permission. Much of the documentation is judged by how well it supports a proposed clinical protocol; the latter is one of the most important pieces of information that FDA quite properly demands.
Unapproved drugs in clinical research are termed investigational drugs or biologics.

Normally, a 30-day waiting period applies when an IND is submitted that describes the initial clinical study with an investigational drug or biologic. Thereafter, FDA must be notified (by filing an IND amendment) of further clinical protocols, newly developed toxicology information and changes to the chemistry, manufacturing or controls. However, there is no mandatory review period for IND amendments, and the changes to the IND that have been notified can usually be implemented immediately. Of course, FDA may impose clinical holds on particular dosing regimes, patient populations, protocols or entire projects, at any time when safety issues present themselves. For a detailed discussion of the typical IND, see the separate chapter in this book, and Fox (1996).

The Emergency IND (21CFR para 312.36) is designed to permit a physician to treat a particular patient with an investigational drug with an urgency that precludes the writing and filing of an IND, or even of a clinical protocol. An Emergency IND does not require the 30-day waiting period. Part of the philosophy behind the perceived need for this regulation is that the federal government does not wish to interfere directly in the relationship between an individual physician and an individual patient. The emergency procurement of materials that are unapproved for human use would be illegal, without this regulation.

When the need for an investigational drug is too urgent for the filing of an IND, then the procedure is for the patient’s physician to identify a source of the desired compound, and then telephone the FDA for Emergency IND permission. For biologics, the telephone number is (301) 443-4864 (the Center for Biologics Evaluation and Research, HFB-230), and for all other drugs (301) 443-1240 (the Center for Drug Evaluation and Research, HFD-53; note that the telephone number published in the 1995 Edition of 21CFR is out of date). Out of ordinary office hours (08:00–16:00 Eastern Standard Time), FDA’s Division of Emergency and Epidemiological Operations maintains a 24-h availability on (202) 857-8400. A confirmation will be provided to the requesting physician either with a number, or by a named FDA officer. The physician may then notify those details to the pharmacy or pharmaceutical company holding the investigational agent, and the drug may then be legally shipped. This information is also available by Internet (http://www.fda.gov). It should be noted that this permission can only be obtained by the treating physician him/herself; the pharmaceutical company cannot obtain an Emergency IND on behalf of a treating physician. It should also be noted that a paper IND must follow within reasonable time afterwards.

It should be noted that ‘off-label’ use of approved products (i.e. prescribing lawfully marketed products for indications other than those stated in their labeling) does not require an Emergency IND, under 21CFR paras 312.2(b)(i)–(v), provided that the intended use

(a) is not designed to support a forthcoming NDA or Supplemental NDA for a new indication;

(b) is not designed to support promotional materials;

(c) does not involve a significantly greater risk than the usual use of the agent (although not defined more precisely, large increments in dose, strange routes of administration or special patient populations would all violate this provision);

(d) the ethical provisions of the Declaration of Helsinki still apply, and informed consent (which need not necessarily be in writing) has been obtained, that is, the patient is fully informed of the unusual drug usage;

(e) no representations of safety or efficacy, and no monetary charges (ordinarily) are made (21CFR para 312.7); and

(f) the usage is not prolonged beyond the time period needed to reasonably ascertain its failure.

It may be noted that in anesthetics, pediatrics and intensive care medicine, in particular, drugs are used ‘off-label’ almost routinely; and in practice, it is doubtful that physicians in these specialties are
even aware of these nuances in the IND regulations. Reimbursement systems in the United States will, however, often refuse to pay for drugs used 'off label', and use these regulations as their justification.

The contrast in philosophy between these arrangements in the United States and the emergency use of unapproved drugs in Europe was succinctly put by one German pharmaceutical physician recently: ‘We don’t need any of that, I can prescribe cyanide if I want to!’ Although an exaggeration, this comment is nonetheless telling. Compared to the United States, there has always been a tendency for European regulatory authorities to place more discretion and responsibility on pharmaceutical companies and individual physicians when using investigational materials. For example, although recently changed by the Clinical Trials Directive, the former absence of the need for a CTX for normal volunteer studies in the United Kingdom, and indeed the CTX procedure itself (in comparison to Clinical Trials Certification), as well as the limited review of investigational drug dossiers after filing in Germany, are examples of this difference in philosophy. In the United States, the regulatory process, like much else in other areas of government, is conceived in terms of full disclosure of data in their final form, enforcement and affirmative acts of the granting of permission by the government.

32.3 ‘Compassionate Use’: the Treatment IND

Although the term is in common usage, ‘Compassionate Use INDs’ do not exist. The Treatment IND aims to make an investigational new drug available to patients with a defined disease state that is serious (usually life threatening), and for which there is no alternative therapy. This application may be made whether or not an NDA is to be filed at a later date.

There are several criteria which must be met for a Treatment IND to be acceptable to FDA, under 21CFR paras 312.34(b)(i)–(iv). Within these criteria are several terms that further require definition or justification to the reviewers:

- The disease process must be serious or life threatening.
- There must be no feasible alternative therapy.
- The drug is already under investigation in an orthodox IND.
- The sponsor of the drug must be actively pursuing marketing approval of the drug with all due diligence.

Treatment INDs are thus for pharmaceutical companies, not for individual physicians. All the usual clinical hold provisions apply.

There must already be information about the investigational drug supporting the proposed use, although this needs only to be ‘promising’ and not as definitive as would be needed for an NDA. The judgment of what is and what is not ‘promising’ is by the relevant reviewing division of FDA; in practice, it is usually the reviewers that have been responsible for an antecedent, ordinary IND that make this recommendation.

Frequently, circumstances arise during the interval between NDA submission and approval which make it desirable for the (still) investigational drug to be made more widely available. The ‘Treatment IND or the Emergency Use IND (21CFR para 312.36, see above) generally accommodates this need (21CFR paras 312.34 and 312.35).

The stated objective of this section of the regulation, under 21CFR paras 312.34(a) and (b) can, however, often be achieved using an intelligently designed ordinary IND. A seriously interested physician can make this application himself or herself, and pharmaceutical companies can cooperate by notifying the FDA that the physician may cross-reference to the chemistry and toxicology sections of their own ordinary IND. By quoting these cross-references, the physician’s IND becomes abbreviated. The clinical protocol for the physician’s IND need only use an open-label design, in pursuit of tolerability information. Inclusion and exclusion criteria can be kept broad and to the
minimum needed to assure patient safety. These abbreviated INDs are otherwise of orthodox composition (21CFR para 312.23), and have the advantage that the complexities of the Treatment IND, demonstrating ‘promising’ efficacy, can be avoided. Furthermore, even with a rudimentary case report form, the pharmaceutical company can gather tolerability information by this means, even for products approved for other purposes, because the exemptions of 21CFR paras 312.2(b)(i)–(iv) have not been exploited (see above). Pharmaceutical physicians can use template word processing files for these physician’s INDs, can complete the details for the particular physician over the phone, and mail it to him or her for signature and forwarding to FDA. The administrative burden, once this is set up, can be relatively light, and is often very much quicker and easier than navigating the complexities of a de novo Treatment IND.

32.4 Accelerated approvals: serious and life-threatening diseases

In the United States, there are numerous, active, nonmedical communities that are interested in the treatment of human immunodeficiency viruses (HIV), age-associated or Alzheimer syndrome, and, to a lesser extent, emergency medicine and various rare genetic diseases. Another community has formed to support the availability of generic drugs, because of concern about healthcare costs (with drug prices as a small but highly visible part of this). These communities have accomplished a very rare thing: using various parts of the political process, they have brought about change in FDA, causing alterations, and acceleration, in the drug approval process.

The structure and format of NDAs that may be submitted under these regulations are the same as that for ordinary NDAs (see the earlier chapter in this book). But the reviewing practice can be very different for these types of accelerated approvals.

Sub-Part H. The accelerated approval of new drugs for serious or life-threatening illnesses is provided for in 21CFR314.500–560 (‘Sub-Part H’). This practice dates from 1992, and applies to all types of drug, including antibiotics and biologics. Under Sub-Part H, it is stated that

If the Secretary determines, based on relevant science, that data from one adequate and well-controlled clinical investigation and confirmatory evidence (obtained prior to or after such investigation) are sufficient to establish effectiveness, the Secretary may consider such data and evidence to constitute substantial evidence...

For example, zidovudine (azidothymidine) was approved under these regulations as a treatment for AIDS after an NDA that contained only one well-controlled trial in its support, and various in vitro and uncontrolled human data as confirmatory; moreover, CD4 lymphocyte counts were accepted as a surrogate end point in the clinical trial.

Surrogate end points are not as radical as it may first appear. Antihypertensive drugs are approved using blood pressure as the surrogate end point; and, until recently, none of the large number of studies approved that antihypertensive had been demonstrated to actually reduce strokes or myocardial infarctions. This concept of surrogate end point should also be familiar to early-phase clinical trialists. The selection of development candidates at the IND stage, and assessing their worth during phase I or II clinical investigation often requires development decisions based on surrogate end points, again because these are usually quicker to obtain than (for example) mortality data in support of the proposed indication for the drug.

Thus, the differences in reviewing practice for accelerated approvals, in comparison to more typical NDAs, are that the regulations specifically permit FDA to

- judge efficacy on the basis of surrogate end points,
- grant marketing permission on condition of greater degrees of monitoring for safety than the norm, and
- to control promotional practices more stringently than usual.
It is also specified how FDA may withdraw approval, which is usually threatened when the sponsor fails to conduct post-marketing research to which it committed as a condition of approval.

Sub-Part E. 21CFR312.80–88 (‘Sub-Part E’) also provides for expedited approvals, when reviews can be accelerated for ‘drugs intended to treat life-threatening and severely debilitating illnesses’. This is generally understood to be disease states where there is no effective, alternative therapy. Sub-Part E anticipates flexibility, but continued observance of the statute, as for all drugs. Such products are officially termed ‘Fast Track Products’. The target NDA review time is reduced from the ordinary 10 months to 6 months under these provisions.

Within Sub-Part E, there is no specific anticipation of a relaxation of the requirement for two adequate and well-controlled studies. These regulations prescribe meetings and schedules, and simply suggest that there ought to be more flexibility in the application of the existing regulations to this type of drug.

What is ‘life threatening’ within the meaning of these regulations? This definition is not repeated in the accelerated approvals regulations. Thus, the presumption is that these definitions are similar to those provided elsewhere in the IND regulations (21CFR para 312.32(a), 21CFR para 312.34 and the previous Chapter on US regulations). One problem that arises is in the interpretation of regulations couched specifically in terms of adverse events or justification of a Treatment IND, and how these apply to NDA approvability or the clinical definitions of a disease process. ‘Life threatening’ usually is taken to mean that the patient’s life is actually under threat by the currently observed disease process (or adverse event), and not that the same type of disease or adverse event, but in worse degree than that actually observed in the patient, could be life threatening. Clearly, the burden of proof for demonstration that a disease is serious or life threatening, and thus an NDA may be considered for accelerated approval, falls squarely with the pharmaceutical company, and FDA will certainly need to be convinced of this as part of its judgment whether to accept the NDA application under these regulations.

Post-marketing impact of accelerated approvals. Safety monitoring, after NDA approval, is required for almost all drugs in the United States (21CFR para 314.98). The difference in practice with accelerated approvals is that almost always, specific post-marketing safety studies (and sometimes efficacy studies) will be required as a condition of approval. These post-marketing safety studies range from agreement on drug surveillance procedures in detail, through the maintenance of patient registries, to specific studies with protocols. In February 2007, FDA announced that a new routine 18 month post-approval safety review will also be introduced.

Post-marketing safety studies are considered in their own chapter of this book. However, it should be noted here that patient registries have been associated with grave jeopardy of litigation in the United States, and not necessarily on a sound scientific basis. On more than one occasion, pharmaceutical companies have been deterred from marketing new drugs when FDA has required a patient registry as a condition of NDA approval.

The greater control over promotional practice, under the accelerated approval process, usually places less burden on an ethical company than the post-marketing safety requirements. Promotional materials must be submitted for review before NDA approval, with the obviously desirable intention that promotion should not be any broader than the approved indication, which under these special circumstances is likely to be narrower than usual. Furthermore, the package insert should usually quantitate how narrow or broad the tolerability experience with the drug might be; frequent labeling revisions and NDA supplements should be planned for.

These special arrangements create two unusual situations where withdrawal of an NDA approved on an accelerated basis is more likely than for an ordinary NDA. First, the approval may be conditional on further clinical studies; FDA can withdraw NDA approval, if these studies turn out to be inconsistent with that (those) in the original NDA. Usually, the interim reporting frequency for these studies will be agreed as part of the NDA pre-approval meeting. Second, as mentioned above, post-marketing research commitments must be pursued in good faith.
and with all due diligence. Regulators often have no experience of clinical study management, and the difficulties of studying the disease in question may be substantial. Thus, there can be controversy on what does and does not constitute due diligence under these conditions. Third, failure to adhere to agreements over promotional materials can also lead to NDA withdrawal; this is under the pharmaceutical company’s control, and is far more predictable than the results of post-marketing studies. All the usual reviewing and appeals processes are available to both FDA and pharmaceutical companies when NDA withdrawal becomes a possibility.

In practice, good NDA sponsors find that post-marketing studies lead to package insert changes much more often than withdrawal of the entire NDA. There is also no evidence, so far, that the accelerated approval process has led to any serious threat to the public health. This new reviewing practice that appears to be working well.

32.5 Accelerated approvals: ANDAs and generic drugs

The Abbreviated New Drug Application (ANDA) is another form of accelerated approval, for which FDA is separately authorized under Section 505(j) of the Food, Drug and Cosmetic Act (as amended), which is reduced to regulation at 21 CFR paras 314.3 and 314.92 through 314.99. This process applies to generic products that are bioequivalent to previously approved, innovative drugs. In this case, the submission document is not of the same structure as an ordinary NDA, and this is quite unlike the accelerated approval for serious and life-threatening diseases described above. Approval acceleration in this case is accomplished by a massive reduction in the documentation needed for FDA review and approval.

For all practical purposes, the generic equivalent will challenge a trademark drug, probably by price competition, in the market place. However, there are rare situations where a trademark drug may have been withdrawn from marketing for purely commercial reasons. Although absent from the market, such a drug could still be followed by an ANDA from another company. The commonest case is where a large company withdraws an innovative, but off-patent drug due to insufficient market size. For strategic reasons, the innovator company may wish neither to license the product to some other company nor to continue its manufacture. The niche thus created can be filled by a small generic company for whom that small market size can still comprise a large fraction of their financial revenues.

The FDA publishes a current list of drugs which it considers suitable for ANDA applications. This may be obtained from the Superintendent of Documents, US Government Printing Office, Washington, DC, 20402, USA, Tel.: +1 (202) 783-3238, and will shortly be available on the World Wide Web. This includes both antibiotics and orthodox drugs within the Center for Drugs Evaluation and Research (CDER).

At the time of writing (January 2006), for reasons relating to manufacturing complexity, FDA does not believe that it can approve an ANDA for a ‘generic’ (or, more properly ‘follow-on’) biologic. However, this question is currently being litigated in the Federal Courts after the submission of the first abbreviated biologic application.

Supporting information. An unusual aspect of the ANDA is that there are two ways to apply. The first is to file a straightforward ANDA, which describes a copy of an approved drug. The second way is to file a petition for a drug that is not identical but may be sufficiently similar for the ANDA process to apply. The FDA is committed to reviewing complete ANDAs within six months.

The straightforward ANDA demonstrates that the generic drug is identical in its route of administration, active components, dosage form, strength and stability. The previously approved drug must be identified specifically [21 CFR para 314.93(d)], or, exceptionally, the applicant can demonstrate that the new product falls within the range of previously approved specifications among several antecedent products. The Freedom of
Information Act, which provides free access to the Summary Basis of Approval document for all approved drugs in the United States, facilitates this exercise.

If one has a close, but not identical, copy of a drug, then the second way to an ANDA is to file a petition under 21CFR para 314.93(b), identifying what the differences may be from the approved product, and making a case why the new drug should be the subject of a forthcoming ANDA. Successful examples have included differences in excipients, minor differences in *ex vivo* dissolution studies, and other matters which can be argued not to have much clinical impact. FDA will rule on this petition, and there are various appeals procedures if the ruling is unfavorable. The checklist of matters to cover in the petition is as follows:

- Identity of active ingredients.
- Expectation of the same therapeutic effect.
- Failure of the new product to meet the definition of a ‘New Drug’ under 21CFR para 314.1 and Section 201(b) of the Federal Food, Drug and Cosmetic Act (21USC, 301–392).

It should be noted that the therapeutic equivalence expectation is precisely that no comparative clinical studies are required. A phase I pharmacokinetic study, in support of the therapeutic equivalence, may be helpful but need not contribute any pharmacodynamic data. With a favorable ruling on this petition, the ANDA may then follow.

The overall structure of the ANDA is described in 21CFR para 314.94. Its component parts are as follows:

- Application Form
- Table of contents
- Basis of the ANDA, covering either the question of identity, or the results of a petition, as described above
- Description of the conditions of use, and showing its similarity to the previously approved drug (usually best done simply by plagiarizing large sections of the previous package insert)
- Description of the active ingredients
- Route of administration, dosage and strength
- Bioequivalence data
- Previous drug’s label and proposed labeling
- Chemistry, manufacture and controls
- Samples for testing in FDA’s own laboratories
- Other information
- Patent certification

In practice, in comparison to an NDA, the chemistry, manufacturing and controls section of an ANDA is just as long, but all the other sections are much abbreviated from an ordinary NDA. The issue of patents is covered elsewhere, but template wording for the certificates is provided, according to the various types of patent, in 21CFR paras 314.94–314.95.

*Post-marketing requirements* for an ANDA are similar to those for an orthodox NDA, and not as stringent as for an accelerated approval for a serious or life-threatening disease (see above). The usual processes are available for amending ANDAs, either before or after approval.

The ANDA process has permitted large numbers of generic drugs to be provided to the general public at lower cost. The process was created at the same time as the orphan drug procedures, and the Waxman–Hatch Act in the United States Congress. Many view the ANDA and the orphan drug initiatives as *quid pro quo*, and certainly both were the subject of negotiation with the US pharmaceutical industry.

**Final comments.** The intent of this chapter has been to provide the context and philosophy behind these special procedures. All these special IND and NDA procedures are now widely used.
by pharmaceutical companies, and they have all been developed with a lot of industry input. By these measures, they can be judged to have been successful.

It should be noted that regulatory practices with FDA are constantly evolving. Pharmaceutical physicians should always check the current edition of the 21CFR.

References

Code of Federal Regulations. 1997. Title 21, Chapter I, various paras as mentioned above.
Federal Food, Drug and Cosmetic Act, Title 21, sections 201–901.
33.1 The evolution of human medicines control from a national to an international perspective

‘The past shapes the present’. It is this that justifies the study of history, as without it we cannot truly appreciate the present or shape the future.

From classical times to the end of the eighteenth century

To few belongs the privilege of being credited with the invention of a medicinal formulation that endured the test of time for 2000 years. Belong it does, however, to Mithridates VIth, King of Pontus, surnamed Eupator (Geddie and Geddie, 1926). He succeeded to the throne about 120 BC as a boy of 13 years, had received a Greek education, and it was claimed that he could speak 22 languages. He subdued the tribes who bordered on the Euxine as far as the Crimea and made incursions into Cappadocia and Bithynia, which were then in the Roman sphere of influence. In the First Mithridatic War, he defeated the Romans and occupied Asia Minor, but in 85 BC he was defeated by Flavius Fimbria and compelled to make peace with Sulla, giving up all his conquests in Asia Minor, surrendering 70 war galleys and paying 2000 talents in reparations. In the Second Mithridatic War, which endured from 83 to 81 BC, Mithridates was wholly successful.

In the Third Mithridatic War, 74–64 BC, Mithridates VI was finally defeated on the banks of the Euphrates by Pompey the Great. New schemes of vengeance by Mithridates upon the Roman Republic were frustrated by his son’s rebellion in 63 BC. When he found himself under siege by his own son, he killed his wives and concubines and then committed suicide.

Pontus abounded in medicinal plants, and Mithridates acquired considerable knowledge of them. Like every despot of that period, Mithridates lived in fear of being assassinated by poisoning, in consequence of which he sought the universal antidote to all poisons. Mithridates proceeded along a simple line of reasoning. Having investigated the powers of a number of single ingredients, which he found to be the antidote to various venoms and poisons...
individually, he evaluated them experimentally on condemned criminals. He then compounded all the effective substances into one antidote, hoping thereby to produce universal protection. A daily dose was taken prophylactically to give the immunity he sought.

After Mithridates VI's defeat by Pompey, a store of his writings containing detailed information on medicinal plants was captured. Pompey instructed a freed slave, Lenaeus, to translate these writings into Latin. It was said that Pompey did a greater service to the Roman Republic by the value of these writings than by his military prowess. Our knowledge of these writings of Mithridates (Watson, 1966) has come down to us in the writings of Pliny and Galen, as the translation by Lenaeus has been lost. Pliny writes:

By his unaided efforts Mithridates devised the plan of drinking poison daily after first taking remedies in order to achieve immunity by sheer habituation. He was the first to discover the various antidotes, one of which is even known by his name.

So effective was Mithridates' formulation that he tried unsuccessfully to commit suicide by poisoning, and finally killed himself with a 'Celtic sword'.

Galen, writing in the second century AD at a time when he was physician to the Roman Emperor, Marcus Aurelius, refers to 'mithridatium' and a formulation derived from it by one Andromachus, Nero's physician. It is said that Andromachus removed some ingredients from Mithridates' formulation and added others, particularly viper's flesh. To this new product he gave the name 'galene', which means 'tranquillity'. Galene became known as theriac. Details of various theriaces, including mithridatium and galene, were given in Galen's 'Antidotes I' and 'Antidotes II'. In Galen's 'Antidotes I', he distinguishes three kinds of antidote, those that counter poisons, those that counter venoms and those that counter ailments. Some will counter all three, and Galen claimed that to this class belong mithridatium and galene. According to Galen, mithridatium contained 41 ingredients and the galene of Andromachus 55 components.

The preparation of galene was simple, in that its ingredients were free of fractional measures. Four vipers, cut down small, were placed in a solution of sal ammoniac, about 1 gallon, to which were added nine specified herbs and Attic wine, together with five fresh squills, also cut down small. The pot was covered with clay and set upon a fire. When the vapor came out of the four small holes left in the clay seal, dark and turgid, the heat had reached the vipers and they were cooked. The pot was left to cool for a night and day. The roasted matter was taken out and pounded until all was reduced to powder. After 10 days, the powder was ready for the next stage of manufacture.

At the final stage, the prescribed quantities of 55 herbs, previously prepared by various processes, along with the prescribed quantity of squill and viper flesh powder (48 drachms), were added to hedychium, long pepper and poppy juice (all at 24 drachms); 8 herbs including cinnamon and opoponax (all at 12 drachms); 18 herbs including myrrh, black and white pepper, and turpentine resin (at 6 drachms); 22 others and then Lemnian earth and roasted copper (at 4 drachms each); bitumen and castoreum (the secretion of beaver); 150 drachms of honey and 80 drachms of vetch meal. The concoction took some 40 days to prepare after which the process of maturation began. Twelve years was considered by Galen the proper period to keep it before use. Galen records that Marcus Aurelius consumed the preparation within two months of its being compounded without ill effect.

Mithridatium was similar, but contained fewer ingredients and no viper, although it did contain lizard! The other differences were that the opium content of Andromachus' theriac was higher than that of mithridatium, which also differed in containing no Lemnian earth, copper or bitumen and 14 fewer herbal ingredients.

Both mithridatium and galene were taken orally with water or wine, but were also used topically on the skin, or even in the eye. The theriac, galene, was also used by Galen to treat quartan fever (malaria), which was prevalent in the Pontine Marshes near Rome. Aetius (first century AD) stated that beyond question the best remedy for venomous bites is theriac of Andromachus, applied as a plaster—'The patient should also drink this theriac or mithridatium or some similar compound'.
Paul of Aegina was the last of the physicians of the Byzantine culture to practice in Alexandria, which fell to the Arabs in his professional lifetime in 642 AD. He refers to both mithridatium and theriac. Paul of Aegina was a link between Greek medicine and Mohammedan medicine. His book was used by Rhazes (854–930 AD), one of the greatest of the Arab physicians. Avicenna (980–1037 AD) approved of mithridatium as an antidote to poisons, and Maimonides, a Jew born in Moslem Spain, was also familiar with mithridatium. Mithridatium re-entered Western medicine culture by two routes. A Saxon leechbook of the eleventh century records that Abel, the Patriarch of Jerusalem, sent mithridatium or theriac to King Alfred the Great, who died on 26 October 899 (Stenton, 1947).

The *Leechbook of Bald* (Rubin, 1975) is the most important piece of medical literature to have survived from the Saxon period. The document is in two parts or leechbooks; the first contains 88 chapters and the second 67 chapters. They were written circa 900–950 AD from an earlier ninth century Latin text. Following them is a third book, consisting of 73 sections, written in the same hand, but which is nevertheless a separate and additional work. It, too, is of similar age and likely to be a copy of earlier material. A verse at the end of the second leechbook suggests that these books belonged to a physician or leech called Bald, and were written down by a scribe called Cild. These three leechbooks were obviously intended as manuals of instruction for the treatment of a variety of illnesses, injuries and mental states, together with instructions for the preparation of herbal mixtures. Interspersed with these remedies are sections dealing with rites, charms and invocations. Christian and residual heathen practices are represented, the latter including Greek and Roman traditions in addition to Germanic and Celtic folklore, which the Saxons had either brought with them from their homeland or found persisting on their arrival in Britain. There can be no doubt that these leechbooks were intended to be consulted in the physician’s everyday practice. Certain phrases and remedies can be traced to classical times, for example the sixth century Alexander of Tralles, and the fifth century Marcellus Empiricus. A most important passage is contained in the second leechbook and concerns King Alfred. It refers to his request that the Patriach Elias of Jerusalem send him remedies which the prelate had found to be effective. A theriac formulation appears in this leechbook.

The second route was when the works of the Greek and Roman medical writers again became available in Italy, possibly via Spain or through the university at Salerno. Theriac appears to have been more greatly favored than mithridatium as a remedy for poisons. In the twelfth century, theriac was being manufactured in Venice and widely exported. In England it became known as ‘Venetian treacle’ (‘treacle’ is a corruption of theriac). Theriac became an article of commerce, with Venice, Padua, Milan, Genoa, Bologna, Constantinople and Cairo all competing. The manufacture of these theriacs took place in public, with much pomp and ceremony.

It was commonly thought by those in authority that if mithridatum or theriac did not produce the desired cure, this was due to incorrect preparation (perhaps with adulterated or poor-quality materials) or to incorrect storage after use. As the only cause for therapeutic failure therefore lay with the pharmacist who compounded the mixture, the remedy lay in careful scrutiny of manufacture, which should be in public. Any misdemeanor should then be detected and immediately punished.

The earliest written code of quality control in Britain seems to be the *Ordinances of Guild of Pepperers of Soper Lane* in 1316. The Pepperers in the twelfth century took over the distribution of imported drugs and spicery (which includes spices, sugar, confections and fruit). They were not always easy to distinguish from the Spicers, who themselves became intermingled with or perhaps succeeded by the Grocers. The *Ordinances* of 1316 possibly included the Apothecaries and the Spicers and forbade the mixing of wares of different quality and price, the adulteration of bales of goods or falsifying their weight by wetting.

For the next several hundred years, the story is a confused one, containing the roots of the later separation of the Apothecaries as a craft guild and their emergence, first as compounders of medicine and then as a division into those who ultimately became general medical practitioners and those who, together with the emergent chemists
and druggists, founded the pharmaceutical society and became the pharmacists as we know them today. The Apothecaries were originally part of the Guild of Grocers and unsuccessfully petitioned Elizabeth I in 1588 for a monopoly of selling and compounding of drugs. It was not until 1607, however, that James I was to grant a Charter to the Grocers, who recognized the Apothecaries as a separate section. Ten years later, in 1617, James gave the Apothecaries a Charter to separate them from the Grocers as ‘The Worshipful Society of the Art and Mystery of Apothecaries’.

The story over this period and for much later is that of a long fight with the physicians, and as early as 1423 the ‘Commonalty of Physicians and Surgeons of London’ appointed two apothecaries to inspect the shops and their colleagues and bring any who offended in the quality of their wares before the Mayor and Aldermen.

The College of Physicians was founded in 1518 by Henry VIII, and in 1540 one of the earliest British statutes on the control of drugs was passed (32 Henry VIII c.40 for Physicians and their Privileges), which empowered the physicians to appoint four inspectors of ‘apothecary wares, drugs and stuffs’. Section 2 of the Act gave the physicians the right to search Apothecaries’ shops for faulty wares, with the assistance of the ‘Wardens of the said mysterie of Apothecaries within the said City’. If the search showed drugs that were ‘defective, corrupted and not meet nor convenient to be ministered in any medicines for the health of man’s body’, the searchers were to call for the Warden of the Apothecaries and the defective wares were to be burnt or otherwise destroyed.

This Act of Henry VIII was obviously incorrect in defining the Apothecaries as a separate body, and was corrected later in the reign of Queen Mary by an Act of 1553 (1 Mary sess 2 c.9), in which it was enacted:

for the better execution of the searche and view of Poticarye Wares, Drugges and Compositions according to the tenour of a Statue made in the Two and Thirtieth yeare of the Reigne of the said late King Henry Eigth that it shall be lawfull for the Wardeins of the Grocers or one of them to go with the say’d Physions in their view and searche.

It is revealing that, whereas the penalty for refusing to have wares examined was 100 shillings in Henry’s day (of which he took half), by Mary’s day this had been raised to £10. The wording of the Act was also changed slightly, in that under Henry the Wardens were to be called for, but under Mary they had to go. Henry was also determined that the 1540 Statute would be obeyed and an errant apothecary punished and not allowed to make excuses:

... in the Kings Court ... no wager of law, esoin (excuse) or protection shall be alloweth ... apothecaries to sell or prescribe any poisonous substance or drug ... to the body of any man, woman or child save on the written prescription of a physician or upon a note in writing from the purchaser.

The Apothecaries hotly disputed this Order and there is no record of any action being taken on it. They asked the physicians to tell them of specific abuses and that they would then cooperate in reforming them. The Apothecaries said that others, such as druggists, grocers and chandlers, could sell poisons quite freely and many craftsmen used them daily. The Apothecaries further said that to restrict them to providing poisons solely at the request of the physicians would take away their livelihood and interfere with the liberty of the subject to have free use of all medicines.

In England, after the founding of the Royal College of Physicians in 1518, the making of theriac and mithridatium was made subject to supervision under the Pharmacy Wares, Drugs and Stuffes Act of 1540. In the reign of Elizabeth I, the making of theriac was entrusted to William Besse, an apothecary in Poultry, London. He had to show the finished product to the Royal College of Physicians. In 1625, three apothecaries made respectively 160, 50 and 40 lb of mithridatium when London was stricken with plague.

Another technique to control the quality of drugs is the issue of a pharmacopoeia (Greek ‘pharmakon’, a drug; ‘poiaia’, making). The official and obligatory guide for the apothecaries of Florence was published in 1498 and is generally regarded as the first official pharmacopoeia in Europe in the modern sense, that is of a specific political unit. Other cities soon followed in the publication of
obligatory formularies: Barcelona in 1535 (Concordia Pharmacolorum Barcinonesium); Nuremberg in 1546 (Dispensatorium Valerii Cordis). Similar compilations were also issued in Mantua in 1559; Augsburg, 1564; Cologne, 1565; Bologna, 1574; Bergamo, 1580; and Rome, 1583. Britain was somewhat slower, and it was not until Elizabethan times that it became obvious that there was a need for such a pharmacopoeia or formulary. This was first considered by the College of Physicians in 1585. However, work proceeded very slowly and the Pharmacopoeia Londinensis was not published until 1618. There were two issues: one on 7 May, and the first ‘official’ edition on 7 December. This latter was by no means a reprint of the earlier one and was substantially enlarged and changed. The publication of the London Pharmacopoeia in December 1618, setting out detailed formulations of theriac and mithridatium, had made supervision easier and the manufacture was clearly no longer entrusted to a single apothecary.

Nicholas Culpepper, in his Dispensatory (1649), refers to both mithridatum and ‘Venetian treacle’. References in English literature to theriac always refer to it as treacle. Miles Coverdale translated balm as treacle in his Bible of 1538. This was repeated in the Matthew Bible and Bishops’ Bible of 1568. Jeremiah 8 v 22 therefore reads: ‘Is there no treacle in Gilead? Is there no physician there?’.

In 1665, the Great Plague of London broke out and Charles II turned to the Royal College of Physicians for advice. It was eventually published as ‘Advice set down by the College of Physicians (at the Kings Command) containing certain necessary directions for the cure of the Plague and preventing infection’. The streets were to be kept clean and flushed with water, in order to purify the air, fires were to be lit in streets and houses and the burning of certain aromatic materials, such as resin, tar, turpentine, juniper, cedar and brimstone, was enjoined. The use of perfumes on the person was recommended. Special physicians, attended by apothecaries and surgeons, were appointed to carry this out. The main internal remedies for the plague that were recommended were London treacle, mithridatium, galene and diascordium, a confection prepared from water germander. Victims of the plague who developed buboes were treated with a plaster of either mithridatium or galene, applied hot thrice daily.

**Inspection in the 18th century extended to all manufacturers**

In December 1720 The College of Physicians of London approved the President’s draft of a petition to Parliament regarding the difficulties which the servants of the College met when they collected, at the place of execution, corpses of malefactors to which their Elizabethan Charter gave them a right. On 25 June 1723 Sir Hans Sloane, as President, proposed that a Bill should be promoted to make the procuring of bodies easier: but the College was then led by the President and Censors to combine this with clauses about searching apothecaries’ shops. The Bill was drafted by Mr Mead, the College attorney, who worked in the new point that the censors were empowered to search shops of all persons selling medicines, as they already did for apothecaries’ shops and the right of search was to be extended from the City of London, to which it had hither to been confined, to an area of 7 miles radius around the City. Various attempts were made to insert other clauses to the Bill. The Apothecaries wished to require that the concurrence of the Apothecaries would be necessary before any medicines were destroyed. Other attempts to exempt warehouses from the search were unsuccessful. However, all medicines made by virtue of letters patent were exempted. This exemption was made because of a clause submitted by a Licenciate of the College, Dr Joseph Eaton, who had patented a styptic and who wished it to be exempt from search. Another clause exempted any Physician from search. The physicians’ self-interest thrived!

The Bill became Law in April 1724 as 10 Geo 10 c 20, but strangely the original purpose of the Bill, i.e. procurement of corpses for dissection, was lost [23].

Records of ‘visitations’ of apothecaries shops and premises from which medicines were sold exist in The College Library for the years 1724–1754. It is clear from these records that the College Censors...
wasted no time in enforcing their new powers outside the City of London [24]. The following is a synopsis of their visitations over this period:

On 27 May 1724, 28 premises in the Strand, Pall Mall, St James, and German (Jermyn) Street were inspected. Mr James Goodwin of Haymarket was found to have manufactured Venetian treacle which was described as ‘almost very indifferent – reprimanded’. The Censors were back on 7 June 1724 and several medicines condemned to be burnt in public before the doors of Mr Goodwin’s shop. Goodwin had two shops, one in the City and the other in Haymarket – the latter was searched the second time in the owner’s absence, two assistants being in charge. Goodwin claimed that the censors behaved with ferocious violence and had condemned five lots of his medicine including his stock of Venetian treacle. Mr Goodwin was not a Freeman of the Worshipful Society of Apothecaries and was clearly targeted by the College and the Society. Goodwin, however, took advantage of new appeal procedures, but at a special meeting of the full Comitia of the College the Fellows compared specimens of the condemned medicines with type-specimens from Apothecaries Hall and they upheld the decision of the Censors unanimously. A few days later the Censors destroyed the condemned medicines before his door, and continuing their visitation found and destroyed several more medicines.

James Goodwin nursed his grievance and made representation to the House of Lords in a pamphlet ‘Brief for James Goodwin, Chymist and Apothecary, upon his Petition to the House of Lords’ 1725, but his protests came to nothing.

The College Censors were diligent in their extended powers. On 22 June 1724 they conducted 15 visitations in the Borough, Southwark and London Bridge area and destroyed Venetian treacle confiscated from the shops of Mr Snaggs and Mr Thomas Pont. The visitations of 20 July 1724 record the inspection of 18 premises in the same area, eight of which belonged to surgeons. One of these surgeons, Mr. J. Wood, was found to be in possession of defective Venetian treacle.

The 1724 Act was originally drafted to run for 3 years; its scope was extended in 1727 for a further 3 years. After 1731 the Act was not extended and the Censors had to operate within the terms of the Acts of Henry VIII and Mary I, but with their area of inspection extended beyond the City.

In the 30 years of visitation for which records exist only two apothecaries raised objection to being inspected.

Also, Sir George Clark in his History of the Royal College of Physicians of London (1966) [25] records that the Worshipful Society of Apothecaries tested the strength of the College by a calculated defiance. Robert Gower, a trainband colonel, and Master for the second time, refused to show his medicines to the Censors. The College comitia of 1727 was informed and sought Counsel’s opinion. No opinion has been found in the College archives, so no further light can be obtained from the Society’s history [19]. The answer probably lies in the fact that the joint inspections by the College Censors and the Society’s Wardens continued for another 150 years until these powers were revoked under the Food and Drugs legislation of 1872, although the last joint visitation had taken place in the 1850s. In the 10-year period 27 May 1724 to 30 July 1734, 791 shops were visited in the course of 37 inspection days, giving an average of 21 premises per day’s inspection. In subsequent decades the College Censors were not quite so active (see Table 33.1).

On a typical visitation day, the four censors of the College of Physicians and two Wardens of the Society of Apothecaries assembled at 10.00 h.

<table>
<thead>
<tr>
<th>Years</th>
<th>Number of visitations</th>
<th>Number of premises visited (average per visitation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1724–1734</td>
<td>37</td>
<td>791(21)</td>
</tr>
<tr>
<td>1734–1744</td>
<td>22</td>
<td>384(17)</td>
</tr>
<tr>
<td>1744–1754</td>
<td>18</td>
<td>325(18)</td>
</tr>
<tr>
<td>1756–1757</td>
<td>4</td>
<td>56(14)</td>
</tr>
</tbody>
</table>

At this period the Julian Calendar, the New Year’s Day 25 March, was in use. From visitation of Apothecary, Chymist and Druggist Shoppes, College of Physicians of London, in three volumes: Vol. 1 1724–1731; Vol. 2 1732–1747; Vol. 3 1748–1754. The final volume also contains records of four visitations for 14 April 1756, 21 June 1756 and 10 August 1756, at which Willob Heberden was one of the four Censors, and the last recorded visitation of 9 June 1757.

Source: Griffin (2004).
After their round of inspections the group retired to a hostelry where at 16.00 h they sat down to dinner, at the College’s expense, with the President, Registrar and Treasurer of The College of Physicians.

Inspections were as frequently commenting on products absent from premises as products that were defective. Products frequently reported as defective were Venetian treacle/Mithridatum/Theriac Andromachus, Tincture of Rhubarb, cinnamon, helleboris niger, absinth, aloes, jalop and most frequently, Peruvian bark.

Three areas were noted where apothecaries’ premises were most likely to be the source of problems. The Southwark/Borough/London Bridge, Whitechapel/Houndsditch/Aldgate and Clerkenwell areas seem to have figured large as areas of poor-quality shops. Surgeons’ premises were frequently described as very bad, particularly in Southwark!

Mr Bevan’s shop in Plough Court, the predecessor of Allen and Hanbury’s (now part of Glaxo Smith Kline) was singled out for very favourable comment on several inspections. For example, on 11 September 1728 it was described as ‘extra ordinary good’. The College of Physicians exerted their privilege to search apothecary shops up to the early 19th century. It is interesting to note that when the Censors visited Allen and Hanbury’s (then William Allen and Co.) in the 1820s, they noted it was ‘an excellent house’.

Doubts as to whether theriac and mithridatium were the universal panacea had been voiced by Culpepper and other physicians such as Dr John Quincy, who died in 1722. The real attack on these two long-standing remedies came from Dr William Heberden (1745) in a 19 page pamphlet entitled Antitherica: Essay on Mithridatium and Theriac. Heberden concludes his attack on the lack of efficacy of these products with the words:

Perhaps the glory of its [mithridatium’s] first expulsion from a public dispensary was reserved to these times and to the English nation, in which all parts of philosophy have been so much assisted in asserting their freedom from ancient fable and superstition, and whose College of Physicians, in particular, hath deservedly had the first reputation in their profession. Among the many eminent services which the authority of this learned and judicious body hath done to the practice of Physic, it might not be the least that it had driven out this medley of discordant simples . . . made up of a dissonant crowd collected from many countries, mighty in appearance, but in reality, an ineffective multitude that only hinder one another.

In William Heberden’s entry in Munk’s (1878) Roll it is stated that he was always ready to attack the ‘idle inventions of ignorance and superstition’.

William Heberden was born in 1710, entered St John’s College, Cambridge University, in 1724.

Table 33.2  The development of concepts of medicines regulation in England as illustrated by the history of mithridatium and theriac

<table>
<thead>
<tr>
<th>Regulatory measure</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality and inspection</td>
<td>1423, 1540, 1723</td>
</tr>
<tr>
<td>Fines for breach of Regulations</td>
<td>1540, 1553, 1617</td>
</tr>
<tr>
<td>Specified composition</td>
<td>1586</td>
</tr>
<tr>
<td>Licensing of specific manufacturer(s)</td>
<td>1586, 1625</td>
</tr>
<tr>
<td>Destruction of faulty product</td>
<td>1540, 1723</td>
</tr>
<tr>
<td>Pharmacopoeial monograph</td>
<td>1619, 1650, 1721, 1746, 1788</td>
</tr>
<tr>
<td>Fraud prevention</td>
<td>1688</td>
</tr>
<tr>
<td>Multidisciplinary scrutiny</td>
<td>1723</td>
</tr>
<tr>
<td>Appeal procedures</td>
<td>1723</td>
</tr>
<tr>
<td>Exemptions from legislation</td>
<td>1723</td>
</tr>
<tr>
<td>Efficacy</td>
<td>1745</td>
</tr>
<tr>
<td>Ideas of regulatory scrutiny prior to marketing</td>
<td>1799</td>
</tr>
</tbody>
</table>

Source: Griffin (2004).
at the age of 14, graduated BA in 1728, became an marketing authorization (MA) in 1732, and obtained his MD in 1739. Heberden published his Essay on Mithridatium and Theriac in the same year as he obtained his FRCP. William Heberden founded the Medical Transactions of the Royal College of Physicians in 1767 and in the first three volumes, 1768–1785, he published 16 papers. Heberden is known for his description of Heberden’s asthma (cardiac asthma) and Heberden’s nodes, which are calcipic spurs on the articular cartilage at the base of the terminal phalanges in osteoarthritis. He made the clear point that they had no connection with gout, which was the main and highly fashionable arthritic ailment of his time. Heberden died in 1801 and was buried in Windsor Parish Church, where there is a memorial plaque to him and his son William Heberden Junior, who was physician to George III during his years of insanity, which we now believe was due to porphyria.

The 1746 London Pharmacopoeia was the last in which mithridatium and galene appear; they were absent from the 1788 edition. The Edinburgh Pharmacopoeia, first published in 1699, dropped mithridatium and galene from the 1756 edition. Not all Western European countries were so quick to expunge these formulations, for galene with its vipers appears in the German Pharmacopoeia of 1872 and in the French Pharmacopoeia of 1884. With the disappearance of mithridatium from the French Pharmacopoeia, the long-used complex remedy attributable to an experimental toxicologist from the first century BC came to an end.

Prior to the doubts on the efficacy of mithridatium raised by a number of English physicians, including Culpepper and Quincy, and culminating in William Heberden’s attack and condemnation of these products, there had been occasions when these formulations had been noted to be ineffective. In all these circumstances, it was believed that the formulations had been inadequately compounded; or that the quality of the ingredients was suspect (the quality of cinnamon was frequently raised); or even the species of viper used in theriac was questioned. These concerns to maintain the quality of mithridatium and theriac led to the introduction of strict controls over the quality of ingredients and blending. For example, the manufacture had to be done in public in Venice and the ingredients had to be open to inspection. Pharmacopoeias were produced, which laid down standards, not only for mithridatium and theriac, but for other therapeutic substances. Perhaps, in the final analysis, the contribution of mithridatium and theriac to modern medicine was that concerns about their quality stimulated the earliest concepts of medicine regulations.

The Medical and Physical Journal, one of the earliest to supply regular information on new work in medicine, pharmacy, chemistry and natural history, suggested in its first volume in 1799:

> ...we would submit to the legislature the propriety of erecting a public board composed of the most eminent physicians for the examination, analysis and approbation of every medicine before an advertisement should be admitted into any newspaper or any other periodical publication and before it should be vended in any manner whatsoever.

By the end of the 18th Century all the ingredients for an efficient regulation of medicines had been conceived, but in a piece-meal fashion (see Table 2). What was missing was the integration into a single scheme. This would have to wait until the passing of the Medicines Act (1968) and its implementation on 1st September 1971.

### 33.2 The nineteenth and twentieth centuries to the Medicines Act 1968

Compulsory vaccination against smallpox was established by the Vaccination Act of 1853 after the report compiled by the Epidemiological Society on the state of vaccination following the first Vaccination Act of 1840. The 1840 Act had provided free vaccination for the poor to be administered by the Poor Law Guardians.

Under the Vaccination Act of 1853, all infants had to be vaccinated within the first three years of life, default of which meant the parents were liable to fine or imprisonment. New legislation incorporated in the Vaccination Act of 1867 made it
compulsory for children under the age of 14 years to be vaccinated, and encouraged the notification of default by doctors by providing financial inducements for compliance and penalties for failure.

The law was further tightened in 1871, when the appointment of vaccination officers was made compulsory for all local authorities. A House of Commons Select Committee, set up in 1871 to investigate the efficacy of the compulsory system, was concerned by a report by Dr Jonathan Hutchinson, who gave an account of the transmission of syphilis in two patients by arm-to-arm inoculation of the material from the pustule of one patient to the arm of another. The use of calf lymph vaccine did not become standard until 1893, when a commercially available preparation was introduced. Prior to this, it had been impossible to standardize the material used for vaccination.

In 1858, the Medical Act created the General Medical Council, one of whose duties was to compile an official pharmacopoeia for the whole of the United Kingdom to supersede the three current ones for London, Edinburgh and Dublin. The first British Pharmacopoeia was published in 1864 (the 1958 and 1993 editions were published by the Health Ministers on the recommendations of the Medicines Commission; vide infra).

It has to be acknowledged that there was little momentum during the nineteenth century concerning the general requirement for scrutiny of medicines for safety and efficacy, in addition to the quality requirements already in existence, before products were marketed in Britain. A few attempts were made to do this and, as far back as 1880, a British Medical Association (BMA) working party investigating sudden deaths occurring in chloroform anesthesia had suggested the establishment of an independent body to assess drug safety. Chloroform was first used as an anesthetic in 1847 and, as its use increased, it was found that occasionally people died unexpectedly during the induction of anesthesia. In 1877, the BMA appointed a committee to investigate this and the final report was published in 1880. They found that chloroform not only depressed respiration but had a deleterious effect upon the heart in very small doses and could cause cardiac arrest. This was the first major collaborative investigation of an adverse reaction to a drug ever carried out.

This study had very little impact on generating public or political concern to set up a regulatory authority. However, the appearance of two publications by the BMA concerning certain proprietary medicines, entitled Secret Remedies (1909) and More Secret Remedies (1912), caused a Parliamentary Select Committee on Patent Medicines to be set up. This Select Committee reported in 1914, but World War I intervened and all the proposed legislation was shelved. It is worth listing several of the recommendations of this Committee, some of which had to wait until the Medicines Act (1968) controlled and kept standards under review, and many of these became internationally recognized.

Recommendations

- 56(1). That the administration of the law governing the advertisement and sale of patent, secret and proprietary medicines and appliances be coordinated and combined under the authority of one Department of State.

- 56(5). That there be established at the Department concerned a register of manufacturers, proprietors and importers of patent, secret and proprietary remedies . . .

- 56(6). That an exact and complete statement of the ingredients . . . and a full statement of the therapeutic claims made . . . be furnished to this Department . . .

- 56(7). That a special Court or Commission be constituted with power to permit or prohibit . . . the sale and advertisement of any patent, secret or proprietary remedy . . .

- 56(12). That inspectors be placed at the disposal of the Department . . .

- 58(2) That the advertisement and sale (except the sale by a doctor’s order) of medicines purporting to cure the following diseases be
prohibited: cancer, consumption, lupus, deafness, diabetes, paralysis, fits, epilepsy, locomotor ataxy, Bright disease, rupture.

- 58(3 and 4) That all advertisements ... [of] diseases arising from sexual intercourse or referring to sexual weakness ... [or] abortifacient ... be prohibited.

Still, little attention was paid to the efficacy of drugs and treatment. The Venereal Disease Act of 1917 and the Cancer Act of 1939 prevented the public advertisement and promotion of drugs for these conditions, to prevent sufferers from inadequate or unsuitable treatment and from fraudulent claims. It was necessary to wait until the Medicines Act was in force before further consideration was given to efficacy (but see Therapeutic Substances Act), but it may be noted here that this was a foretaste of control of advertisement and promotional literature for medicines.

The antisyphilitic drug arsphenamine (Salvarsan) had been discovered in Germany in 1907 and was imported into Britain until the outbreak of World War I, when the Board of Trade issued licenses to certain British manufacturers to make it. Each batch had to be submitted to the MRC for approval before marketing. The problem was that, although synthetic, and hence the chemical identity of the product was known, highly toxic impurities could only be detected by biological testing.

It began to be realized also that the increasing use of potent biological substances and the extension of immunization were raising new questions of proper standardization of such preparations and of the competence of manufacturers. The only law at this time concerned with the purity or quality of drugs was the Food and Drugs Act of 1875, and this had a very limited application.

Control of biological substances was difficult to contain within a pharmacopoeial monograph, for it demanded the use of biological standardization, as the purity and the potency of these substances could not be measured by chemical means. The Therapeutic Substances Act (TSA) aimed to regulate the manufacture and sale of such substances and to provide standards to which they must conform, to regulate their labeling and, to a certain extent, their sale. The principal substances to which the Act applied were vaccines, sera, toxins, antitoxins, antigens, arsphenamine and related substances, insulin, pituitary hormone and surgical sutures. Certain suture material had been found to be contaminated with Clostridium welchii, and this was the reason for inclusion of sutures under the TSA. It provided for a licensing system, with the Minister of Health as the Licensing Authority for England and Wales, the Department of Health for Scotland and the Minister of Home Affairs for Northern Ireland. The TSA also recognized that the competence of the employees of the manufacturer and the conditions under which they worked were equally as important as the tests applied to the end products. Factory inspections and in-process control therefore played a large part in supervision by the Licensing Authority. Records of sale also had to be kept by the manufacturer, and the container had to identify both the manufacturer and the batch.

This Act began modern concepts of safety. Further regulations issued between 1925 and 1956 brought more substances under control and kept standards under review, and many of these became internationally recognized. The whole TSA was revised and consolidated in 1956, but has now been superseded by the Medicines Act (1968).

The Biological Standards Act (1975) established the National Biological Standards Board. This Board, appointed by the UK health ministers and funded by the Health Department, is responsible for standards and control of biological substances, that is substances whose purity and potency cannot be adequately tested by chemical means, such as hormones, blood products and vaccines. The Board operates through the executive arm, the National Institute for Biological Standards and Control.

33.3 Thalidomide and its aftermath

The story of thalidomide is too well known to bear much repetition here but, as it was the stimulus that laid the ground rules on which the Medicines
Act in the United Kingdom and most other modern European states’ legislation, including the European Community’s Directive 65/65EC, was built, it is relevant to summarize these events.

Thalidomide first went on sale in 1956 in West Germany and enjoyed good sales, both there and in other countries, as a sleeping aid and as a treatment of vomiting in early pregnancy, because of its prompt action, lack of hangover and apparent safety. Adverse reports of peripheral neuropathy and myxoedema appeared in the literature in late 1958 and 1959, associated with thalidomide. In 1961, reports began to be made of a remarkable rise, in West Germany since 1959, in the incidence of a peculiar malformation of the extremities of the newborn. This condition was characterized by the defective long bones of the limbs, which had normal to rudimentary hands or feet. Owing to its external resemblance to a seal’s flipper, it was given the name ‘phocomelia’. This condition had previously been very rare in West Germany but whereas no cases had been reported in the 10 years 1949–1959, there were 477 cases in 1961 alone. In the United Kingdom, 400–500 cases were reported during 1959–1961. The public and government were not prepared for these unforeseen consequences of the therapeutic revolution that had been taking place for 30 years. This complacency was now shattered, public concern was vocal, and the government was galvanized into action.

The joint subcommittee of the English and Scottish Standing Medical Advisory Committees, under the chairmanship of Lord Cohen of Birkenhead, made recommendations regarding future legislation for the control of medicines, in addition to the immediate establishment of the Committee on Safety of Drugs, which came into operation in 1963 and whose function was to review the evidence on new drugs and offer advice on their safety. The Committee consisted of a panel of independent experts from various fields of pharmacy, pathology and so on. The Committee was serviced by a professional secretariat of pharmacists and medical officers, who undertook the assessment of the submissions and presented these to the committee and various subcommittees.

The Committee on Safety of Drugs was set up in June 1963 by the Health Minister, in consultation with the medical and pharmaceutical professionals and the British pharmaceutical industry, with the following terms of reference:

1. To invite from the manufacturer or other person developing or proposing to market a drug in the United Kingdom any reports they may think fit on the toxicity tests carried out on it; to consider whether any further tests should be made and whether the drug should be submitted to clinical trials; and to convey their advice to those who submitted reports.

2. To obtain reports of clinical trials of drugs submitted thereto.

3. Taking into account the safety and efficacy of each drug, and the purposes for which it is to be used, to consider whether it may be released for marketing, with or without precautions or restrictions on its use; and to convey their advice to those who submitted reports.

4. To give to manufacturers and others concerned any general advice they may think fit.

5. To assemble and assess reports about adverse effects of drugs in use and prepare information thereon which may be brought to the notice of doctors and others concerned.

6. To advice the appointing ministers on any of the above matters.

The Committee had no legal powers, but worked with the voluntary agreement of the Association of British Pharmaceutical Industry and the Proprietary Association of Great Britain. They promised that none of their members would put on clinical trial or release for marketing a new drug against the advice of the Committee, whose advice they would always seek.

The joint English and Scottish Standing Medical Advisory Committee also recommended that there should be new legislation regarding many aspects of drug safety, and after a review and consultation,
a White Paper, *Forthcoming Legislation on the Safety, Quality and Description of Drugs and Medicines* (Cmd 3393), was published in September 1967, and the Medicines Act, based on these proposals, received the Royal Assent in October 1968. The Act is a comprehensive measure replacing most of the previous legislation on the control of medicines for human use and for veterinary use. The first provisions laid down in the Act, regarding licensing of medicinal products and other aspects of control, came into effect on 1 September 1971. The Act was administered by the health and agriculture ministers of the United Kingdom, acting together or in some cases separately, as the health ministers or the agriculture ministers in respect of human and veterinary medicines, respectively.

The Medicines Commission was appointed by ministers to give them advice generally relating to the execution of the Act. A number of expert committees with specific advisory functions were appointed by ministers after considering the recommendations of the Commission, as proposed in Section 4 of the Medicines Act.

Under the Medicines Act (1968), the Licensing Authority consists of the Secretaries of State for Health and Social Services, the Secretary of State for Agriculture and the Secretaries of State for Wales, Scotland and Northern Ireland. The Medicine Act (1968) was implemented to operate from September 1971. The day-to-day administration of the Act for human medicines was conducted by the Medicines Division of the Department of Health and Society Security (DHSS) and was managed jointly by an under-secretary and the professional head of the Division, who held the rank of Senior Principal Medical Officer.

In 1988, the DHSS was split into two departments, the Department of Health (DoH) and the Department of Social Security (DSS). Following the Evans–Cunliffe report, from April 1989, the Medicines Division of the DoH became the Medicines Control Agency (MCA) under a director, and was expected to self-fund its operation from fees commensurate with the services provided. The UK MCA in 1997 had 458 staff, of whom 150 approximately worked in licensing, 130 in post-licensing, including pharmacovigilance, 75 in licensing inspection of manufacture and enforcement, and 28 on the *British Pharmacopoeia* and the United Kingdom contribution to the *European Pharmacopoeia*. This has now increased to 600 staff in 2002.

On 12 September 2002, the then Health Minister, Lord Philip Hunt, announced that the MCA would merge with the Medical Devices Agency (MDA) with effect from 1 April 2003. The merged agencies would be known as the Medicines and Healthcare Products Regulatory Agency (MHRA).

The Licensing Authority is advised by expert committees, appointed by ministers, as advised by the Medicines Commission under Section 4 of the Medicines Act. These advisory committees consist of independent experts, such as hospital clinicians, general practitioners, pharmacists and clinical pharmacologists, not the staff of the DoH, and are appointed by ministers on the advice of the Medicines Commission. Since 1971, the relevant advisory committees have been the Committee on Safety of Medicines (CSM); the Committee on Review of Medicines (CRM), which was set up in 1975 and disestablished on 31 December 1994; the Committee on Dental and Surgical Materials (CDSM) was established in 1975 and disestablished on 31 March 1992; the *British Pharmacopoeia* Commission (BPC) and the Veterinary Products Committee, which is administered through the Ministry of Agriculture, Food and Fisheries (MAFF). There are proposals out for consultation which suggest the merger of the Medicines Commission with the Committee on Safety of Medicines, implementation of such a proposal would require Primary Legislation to change the Medicines Act 1968.

The licensing of new medicines

The United Kingdom joined the European Community (EC) in 1973, but the data requirements for granting MAs has, as the implementation of the Medicines Act (1968), been in accordance with *EC Directive 65/65* and the subsequent *Directive 75/318*, which elaborated on the requirements for preclinical testing, pharmaceutical quality and manufacture. Both these Directives and the Medicines Act (1968) envisaged that MAs issued on the basis of these requirements would be valid for five years and subject to review and/or renewal.
During the period 1971–1981, after the implementation of the Medicines Act (1968), the Licensing Authority granted 204 MAs for new chemical entities (NCEs), granted 3665 marketing approvals for new formulations and 6898 variations of marketed formulations (Griffin and Diggle, 1981). In the period 1971–1994, there were 525 NCEs approved for marketing, 30 new biological entities (NBEs) and 28 products of biotechnology (Jefferys et al., 1998). Of these new active substances, 35 product licenses were surrendered by the manufacturers and a further 22 were withdrawn for safety reasons.

National MAs were intended to be phased out after 1 January 1998, but it is likely that national approvals for marketing will continue beyond that date. The future foresees that all MAs within the European Union (EU) will have been issued under the rules governing medicinal products in the EC by virtue of the centralized procedure or the so-called ‘mutual recognition’ or ‘decentralized procedure’ (vide infra).

Controls on conduct of clinical trials in the United Kingdom

In the United Kingdom, when the Medicines Act (1968) came into operation, all clinical trials in patients had to be covered by a clinical trial certificate (CTC). Under the Medicines Act, studies on normal healthy human volunteers (phase I studies) were exempt.

A clinical trial in the terms of the Medicines Act (1968) is an investigation, or series of investigations, consisting of the administration of one or more medicinal products, where there is evidence that they may be beneficial to a patient by one or more doctors or dentists for the purpose of ascertaining what effects, beneficial or harmful, the products have. The Licensing Authority does not lay down rigid requirements concerning the data, which must be provided before authorization can be given for the clinical trial of a new drug. It issues guidelines for applicants.

By the late 1970s, it had become apparent that the need to apply for a CTC and the regulatory delay that this caused was driving clinical research out of the United Kingdom. The Secretary of State for Social Services approved the introduction of a new scheme in 1981, the details of which were announced by Griffin and Long (1981). The new procedures allowed for a clinical trials exemption (CTX) from the need to hold a CTC; the applicant company was required to produce a certified summary of data generated to support the proposed clinical studies, signed by a medically qualified advisor or consultant to the company. The regulatory authority has 35 days to respond to the notification, but can in exceptional circumstances require a further 28 days to consider the notification. If the CTX is refused, the applicant can apply for a CTC, in which circumstances complete data have to be filed. If the CTC application is refused, the statutory appeal procedures come into play if the applicant company wishes to avail itself of this provision. These appeal procedures are identical with those for marketing applications.

The basis of the CTX scheme is that, together with a detailed clinical trial protocol, summaries of chemical, pharmaceutical, pharmacological, pharmacokinetic, toxicological and human volunteer studies may be permitted instead of the additional details normally required for a CTC or product license application. This CTX scheme is based on the requirement that (a) a doctor must certify the accuracy of the data; (b) the supplier undertakes to inform the Licensing Authority of any refusal to permit the trial by an ethical committee; and (c) the supplier also undertakes to inform the Licensing Authority of any data or reports concerning the safety of the product.

Speirs and Griffin (1983) described the effect of the CTX scheme in attracting clinical studies on NCE in the first year of operation of the scheme. In 1980, there were 87 applications for CTC; in 1981, the first year of the CTX scheme, there were 210 applications for CTX, of which 79 were for NCEs. Speirs et al. (1984) studied the effects of the CTX in encouraging inward investment into research in the United Kingdom; 23 companies had increased their research investment by 100%.

Doctor’s and dentist’s exemption

This is an exemption which is available to doctors or dentists who are undertaking clinical trials.
initiated by them but not at the request of a pharmaceutical company. Outline information about the trial is required and a decision is made by the Licensing Authority within 21 days. Where the product to be used is unlicensed or is complex, further information may be requested and the 21-day time period is extended.

**Clinical trials on marketed products**

Where a clinical trial is proposed with a marketed product, then the applicant can submit a copy of the trial protocol, provide information on the investigators and, depending on whether or not the applicant is the MA holder, information on the procedures for reporting adverse drug reactions (ADRs). It is only possible to use this procedure for United Kingdom marketed drugs. It does not apply to unauthorized products manufactured specifically for trial, nor to products which may be licensed in other countries but are not in receipt of a MA in the United Kingdom.

The various member states of the EU were surveyed by Griffin (1987); the United Kingdom, Eire, The Netherlands and Italy did not have legislation requiring regulatory approval for studies affecting human (non-patient) volunteers; in Germany, Denmark and Sweden, legislation did impose controls on such studies. This survey indicated that a clear definition of what was meant by a ‘human volunteer’ was also lacking between national regulatory authorities in Europe. As clinical trial provisions vary greatly between EU member states, therefore the EC, in accord with their prevailing philosophy of ‘harmonization’, wishes to change this.

With a view to harmonizing the conduct of clinical trials across the EU, Directive 2001/20/EEC was finally agreed on 14 December 2000, and was formally adopted in May 2001 with a three-year transition for its implementation.

The EU Clinical Trials Directive contains specific provisions regarding the conduct of clinical trials, including multicenter trials, on human subjects. It sets standards relating to the implementation of good clinical practice and good manufacturing practice (GMP), with a view to protecting clinical trial subjects. All clinical trials, including bioavailability and bioequivalence studies, must be designed, conducted and reported in accordance with the principles of good clinical practice.

It defines ‘clinical trial’ as any investigation on human subjects intended to discover or verify the clinical, pharmacological and/or other pharmaco-dynamical effects of one or more investigational medicinal product(s), and/or to identify any adverse reactions to one or more investigational medicinal product(s), and/or to study absorption, distribution, metabolism and excretion of one or more investigational medicinal product with the object of ascertaining its (their) safety and/or efficacy, and it defines ‘subject’ as an individual who participates in a clinical trial as a recipient of either the investigational medicinal product or a control. Thus, healthy volunteer studies are included.

Member states have 60 days to consider a valid request from an applicant to conduct a clinical study, in the case of trials involving medicinal products for gene therapy or somatic cell therapy or medicinal products containing genetically modified organisms an extension of a maximum of 30 days may be allowed. If the request to conduct a study is refused by the competent national authority, the sponsor may on one occasion only modify or amend the protocol to take account of the objections raised. No further appeal mechanism is provided.

Premises where clinical studies are to be conducted are open to inspection by the GCP Inspectorate set up by the MHRA in accordance with the EU Directive on good clinical practice. The inspectorate is required to give a preliminary oral report at the conclusion of the inspection and a written report within 30 days.

Various sectors of the pharmaceutical industry have lobbied hard against the Clinical Trial Directive, particularly the industry based in the United Kingdom that have objected to the inclusion of phase I studies involving healthy volunteers being brought under legislation. These objections are based on the negative effects on research conducted in the United Kingdom by CTC scheme introduced by the Medicines Act 1968, and the subsequent deregulation achieved by the CIX scheme had on United Kingdom clinical research.
A negative effect on phase I clinical research was being reported in the United Kingdom by Clinical Research Organisations (CROs) and Academic University Departments by the Autumn of 2004.

The review of products on the market pre-1971

At the start of product licensing in the United Kingdom in 1971, products already on the market were granted Product Licences of Right (PLRs), which were subject to review. Between 1971 and 1982, 22,376 lapsed or were revoked or suspended, and 598 had been converted to full product licenses. The Committee of Review of Medicines was deemed to have completed its work in 1991 and was disestablished on 31 March 1992.

All member states of the EC were similarly required to review the quality, safety and efficacy data of products on their market. Various dates were set for the completion of such national reviews, and the time schedule had to be revised on a number of occasions due to slow progress of the exercise. The various national review processes have not led to harmonized marketing approvals for these older products within Europe.

Pharmacovigilance and the adverse reactions voluntary reporting system

One of the most important aspects of the UK regulatory system is the scheme provided by the voluntary reporting of adverse reactions to a marketed drug. As most serious ADRs are rare events, they are unlikely to be detected in early clinical trials. The problem is essentially one of numbers, as relatively small numbers of patients are exposed to a new drug before it is released on to the market. Marketing may, therefore, be the first adequate safety trial. The main functions of the adverse reactions reporting system are:

1. to provide an alerting signal of a risk due to a particular drug;

2. to provide confirmation of an alert detected by some other method;

3. to provide data to assist in the evaluation of comparative risks of related drugs.

The spontaneous adverse reaction reporting system in the United Kingdom is based on the submission of ADR reports by doctors and dentists by means of reply-paid ‘yellow cards’. The system was introduced in 1964 by Professor Witts, the first chairman of the Adverse Reactions Subcommittee of the original Committee on Safety of Drugs (CSD). The system has continued unchanged to the present time, and the number of reports and fatal reactions each year of the scheme’s operation is shown in Table 33.3.

Membership of the EU and the establishment of the European Medicines Evaluation Agency (EMEA) has imposed a European dimension on ADR monitoring and given it a new title – ‘pharmacovigilance’. The requirements of the European dimension can be summarized as obligations for Regulatory Authorities and obligations for the pharmaceutical company holding a MA:

Agency granted under the centralized procedure (the Agency referred to is the EMEA) and member state responsibilities:

- Receive all relevant information about suspected adverse reactions to medicinal products authorized by the centralized procedure.

- MA holders and member states are required to provide such information to the Agency.

- Member states must record and report to the Agency within 15 days all suspected serious adverse reactions.

- The Agency is responsible for informing national pharmacovigilance systems and the establishment of a rapid network for communication.

- The Agency shall collaborate with WHO on international pharmacovigilance issues and submit information on community measures
which are relevant to public health protection in Third World countries.

MA holder’s responsibilities:

- To have a qualified person responsible for pharmacovigilance.

Table 33.3 Annual input of adverse reaction reports to CSM and total number of fatal reports

<table>
<thead>
<tr>
<th>Year</th>
<th>Total ADR reports</th>
<th>Total deaths</th>
<th>Fatal reaction as a percentage of total ADR reports</th>
</tr>
</thead>
<tbody>
<tr>
<td>1964</td>
<td>415</td>
<td>86</td>
<td>5.9</td>
</tr>
<tr>
<td>1965</td>
<td>3987</td>
<td>169</td>
<td>4.2</td>
</tr>
<tr>
<td>1966</td>
<td>2386</td>
<td>152</td>
<td>6.4</td>
</tr>
<tr>
<td>1967</td>
<td>3563</td>
<td>198</td>
<td>5.7</td>
</tr>
<tr>
<td>1968</td>
<td>3486</td>
<td>213</td>
<td>6.1</td>
</tr>
<tr>
<td>1969</td>
<td>4306</td>
<td>271</td>
<td>6.3</td>
</tr>
<tr>
<td>1970</td>
<td>3563</td>
<td>196</td>
<td>5.5</td>
</tr>
<tr>
<td>1971</td>
<td>2851</td>
<td>203</td>
<td>7.1</td>
</tr>
<tr>
<td>1972</td>
<td>3638</td>
<td>211</td>
<td>5.8</td>
</tr>
<tr>
<td>1973</td>
<td>3619</td>
<td>224</td>
<td>6.2</td>
</tr>
<tr>
<td>1974</td>
<td>4815</td>
<td>275</td>
<td>5.7</td>
</tr>
<tr>
<td>1975</td>
<td>5052</td>
<td>250</td>
<td>4.9</td>
</tr>
<tr>
<td>1976</td>
<td>6490</td>
<td>236</td>
<td>2.6</td>
</tr>
<tr>
<td>1977</td>
<td>11255</td>
<td>352</td>
<td>3.1</td>
</tr>
<tr>
<td>1978</td>
<td>11873</td>
<td>396</td>
<td>3.3</td>
</tr>
<tr>
<td>1979</td>
<td>10881</td>
<td>286</td>
<td>2.6</td>
</tr>
<tr>
<td>1980</td>
<td>10179</td>
<td>287</td>
<td>2.9</td>
</tr>
<tr>
<td>1981</td>
<td>12357</td>
<td>303</td>
<td>2.5</td>
</tr>
<tr>
<td>1982</td>
<td>14701</td>
<td>340</td>
<td>2.3</td>
</tr>
<tr>
<td>1983</td>
<td>12689</td>
<td>409</td>
<td>3.2</td>
</tr>
<tr>
<td>1984</td>
<td>12163</td>
<td>340</td>
<td>2.8</td>
</tr>
<tr>
<td>1985</td>
<td>12652</td>
<td>348</td>
<td>2.8</td>
</tr>
<tr>
<td>1986</td>
<td>15527</td>
<td>403</td>
<td>2.6</td>
</tr>
<tr>
<td>1987</td>
<td>16431</td>
<td>390</td>
<td>2.4</td>
</tr>
<tr>
<td>1988</td>
<td>19022</td>
<td>410</td>
<td>2.2</td>
</tr>
<tr>
<td>1989</td>
<td>19246</td>
<td>475</td>
<td>2.5</td>
</tr>
<tr>
<td>1990</td>
<td>18084</td>
<td>377</td>
<td>2.1</td>
</tr>
<tr>
<td>1991</td>
<td>20272</td>
<td>541</td>
<td>2.7</td>
</tr>
<tr>
<td>1992</td>
<td>20155</td>
<td>478</td>
<td>2.4</td>
</tr>
<tr>
<td>1993</td>
<td>18066</td>
<td>480</td>
<td>2.7</td>
</tr>
<tr>
<td>1994</td>
<td>17546</td>
<td>412</td>
<td>2.3</td>
</tr>
<tr>
<td>1995</td>
<td>17668</td>
<td>467</td>
<td>2.6</td>
</tr>
<tr>
<td>1996</td>
<td>17191</td>
<td>393</td>
<td>2.3</td>
</tr>
<tr>
<td>1997</td>
<td>16637</td>
<td>455</td>
<td>2.7</td>
</tr>
<tr>
<td>1998</td>
<td>18062</td>
<td>529</td>
<td>2.9</td>
</tr>
<tr>
<td>1999</td>
<td>18505</td>
<td>560</td>
<td>3.0</td>
</tr>
<tr>
<td>2000</td>
<td>33094</td>
<td>610</td>
<td>1.8</td>
</tr>
</tbody>
</table>

- Establishment and maintenance of a system for collection, evaluation and collation of all suspected adverse reaction information so that it may be accessed at a single point in the community.

- Preparation of six monthly scientific reports and records of all suspected serious adverse reactions for the first two years after marketing, annual reports for the next three years and thereafter at renewal of the authorization.

- Reporting to the member state concerned within 15 days of receipt information on all suspected serious adverse reactions within the community.

- Reporting to member states and the Agency within 15 days of all suspected serious unexpected adverse reactions occurring in Third World countries.

GMP

Manufacturers’ licenses were issued by the UK Licensing Authority from the inception of the Medicines Act to cover all manufacturing operations, including those previously embraced by the TSA. The Medicines Inspectorate laid down standards in its Guide to Good Manufacturing Practice, otherwise known as ‘The Orange Guide’; the most recent edition was issued in 1997. Although the issue of manufacturers’ licenses remains a national regulatory function, it is governed by the standards set in EC Commission Directive 91/356 EEC, which can be summarized as follows.

The Directive lays down the principles and guidelines of GMP to be followed in the production of medicines, and requirements to ensure that manufacturers and member states adhere to its provisions. Manufacturers must ensure that production occurs in accordance with GMP and the manufacturing authorization. Imports from non-EC countries must have been produced to standards at least equivalent to those in the EC, and the importer must ensure this. All manufacturing processes should be consistent with information provided in the
MA application, as accepted by the authorities. Methods shall be updated in the light of scientific advances, and modifications must be submitted for approval.

Principles and guidelines for GMP

- Quality management – implementation of quality assurance system.

- Personnel – appropriately qualified, with specified duties, responsibilities and management structures.

- Premises and equipment – appropriate to intended operations.

- Documentation.

- Production – according to pre-established operating procedures with appropriate in-process controls, regularly validated.

- Quality control – independent department or external laboratory responsible for all aspects of quality control. Samples from each batch must be retained for one year, unless not practicable.

- Work contracted out – subject to contract, and under the same conditions, without sub-contracting.

- Complaints and product recall – record keeping and arrangements for notification of competent authority.

- Self-inspection – by manufacturer of his own processes with appropriate record keeping.

- Good manufacturing standards are enforced by the Medicines Inspectorate of the Medicines Control Agency. The United Kingdom has been involved in the Pharmaceutical Inspection Convention since its inception and, through the Orange Guide, set standards which are now reflected in the EC Directives.

Wholesale dealers’ licenses

This activity, established under the Medicines Act 1968, still remains wholly within the remit of national regulatory authorities but in accordance with Directive 92/25 EEC on the wholesale distribution of medical products for human use (Official Journal L113/1–4 30 April 1992).

Routes of sale and supply

In the United Kingdom, the Medicines Act 1968 assumes that all medicinal products will be sold through a pharmacy unless it is decided by the Licensing Authority that supply of the product should be limited to being dispensed only on a registered medical practitioner’s prescription. Such products appear on the Prescription Only Medicines List and their packaging is marked ‘POM’. Certain products are also available through outlets other than pharmacies and are designated as General Sales List (GSL) products and listed as such. Additional restrictions on supply are imposed by the Misuse of Drugs Act 1971, and the Misuse of Drugs Regulations substances that have a potential for abuse are scheduled under three categories, classes A, B and C:

- Class A includes alfentanil, cocaine, dextromoramide, diamorphine (heroin), dipipanone, lysergide (LSD), methadone, morphine, opium, pethidine, phencyclidine and class B substances when prepared for injection.

- Class B includes oral amphetamines, barbiturates, codeine, ethylmorphine, glutethimide, pentazocine, phenmetrazine and pholcodine.

- Class C includes certain drugs related to the amphetamines, such as benzphetamine and chlorphentermine, buprenorphine, diethylpropion, mazindol, meprobamate, pemoline, pipradrol and most benzodiazepines. Cannabis and cannabis resin have been rescheduled as class C, but were class B until 2003.

The Misuse of Drugs Regulations 1985 define the classes of person who are authorized to supply and
possess controlled drugs while acting in their professional capacities, and lay down the conditions under which these activities may be carried out. In the regulations, drugs are divided into five schedules, each specifying the requirements governing such activities as import, export, production, supply possession, prescribing and record keeping which apply to them:

- **Schedule 1** includes drugs such as cannabis and lysergide, which are not used medicinally. Possession and supply are prohibited, except in accordance with Home Office authority.

- **Schedule 2** includes drugs such as diamorphine (heroin), morphine, pethidine, quinalbarbitone, glutethimide, amphetamine and cocaine. They are subject to the full controlled drug requirements relating to prescriptions, safe custody (except for quinalbarbitone), the need to keep registers and so on (unless exempted in Schedule 5).

- **Schedule 3** includes the barbiturates (except quinalbarbitone, now in Schedule 2), buprenorphine, diethylpropion, mazindol, meprobamate, pentazocine, phentermine and temazepam. They are subject to the special prescription requirements (except for phenobarbitone and temazepam) but not to the safe custody requirements (except for buprenorphine, diethylpropion and temazepam) nor to the need to keep registers (although there are requirements for the retention of invoices for two years).

- **Schedule 4** includes 33 benzodiazepines (temazepam is now in Schedule 3) and pemoline, which are subject to minimal control. In particular, controlled drug prescription requirements do not apply, and they are not subject to safe custody.

- **Schedule 5** includes those preparations which, because of their strength, are exempt from virtually all controlled drug requirements other than retention of invoices for two years.

There is no ‘harmonized’ comprehensive legislation to control drugs of abuse under an EU Directive.

---

### 33.4 The European controls of medicinal products

**Directive 75/319** laid down the legal basis for the establishment of the Committee on Proprietary Medicinal Products (CPMP). This met for the first time in November 1976, at which time there were nine member states in the EC. Each member state was represented at the CPMP by its named representative and specified alternate.

At this time, a procedure was laid down in **Directive 75/318**, a scheme for ‘mutual recognition’ of MAs. Article 9 of this Directive envisaged that

The member state which has issued a marketing authorization for a proprietary medicinal product shall forward to the Committee a dossier containing a copy of the authorization, together with particulars and documents specified in Article 4 second paragraph of Directive 65/65, if the person responsible has requested the forwarding to at least five other Member States.

This was later changed to ‘at least two other member states’ in **Directive 83/570** to encourage the use of the procedure, which was initially very slow in taking off.

This ‘mutual recognition procedure’, initially called the ‘CPMP procedure’, has had several other names attached to it, for example the ‘multistate procedure’ and the ‘decentralized procedure’. Manufacturers could choose the country that they would wish to be the initiating or reference country to forward their dossier into the multistate procedure. Some countries were more popular than others (see Table 33.4).

In December 1986, the Council Directive on the approximation of national measures relating to the placing on the market of high-technology medicinal products, particularly those derived from biotechnology (87/22/EEC), was published. This Directive introduced the concept of two classes of high-technology medicinal product.

Annex A. Medicinal products developed from the following biotechnological processes:

- Recombinant DNA technology.
Controlled expression of genes coding for biologically active proteins in prokaryotates and eukaryotates including transformed mammalian cells.

Hybridoma and monoclonal antibody methods.

Annex B

Other biotechnological processes.

Medicinal products administered by means of a new delivery system which, in the opinion of the competent authorities, constitutes a significant innovation.

Medicinal products containing a new chemical entity.

Medicinal products based on radioisotopes.

Medicinal products the manufacture of which employs a significantly novel process.

This Directive required that products covered by the Annex classification had to be referred to the CPMP for an opinion before a MA could be granted in any member state. This process became known as the ‘concentration procedure’ or the ‘central procedure’. Products covered by Annex B could, at the request of the manufacturer, be dealt with by the concentration procedure or by an individual national authority, and then achieve entry into other EU member states markets if requested by means of the multistate procedure. In the concentration procedure, the opinion given by the CPMP was not binding on the member states.

Directive 2309/93 introduced further changes. It established a new body that is based in London, established on 1 January 1994, and two procedures for the obtaining entry to the markets of the member states, namely the ‘multistate or decentralized or mutual recognition procedure’ and the ‘centralized procedure’; see Figures 33.1 and 33.2, which show schematically the procedures which became operative on 1 January 1995.

Under the mutual recognition procedure, the applicant company would receive a number of national MAs from national drug regulatory authorities. Under the centralized procedure, the applicant company would receive a single marketing approval from the EMEA, valid in all EU countries.

<table>
<thead>
<tr>
<th>Country</th>
<th>CPMP procedure</th>
<th>Multistate procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Country of origin</td>
<td>Recipient country</td>
</tr>
<tr>
<td>Belgium</td>
<td>5</td>
<td>33</td>
</tr>
<tr>
<td>Denmark</td>
<td>7</td>
<td>26</td>
</tr>
<tr>
<td>Germany</td>
<td>5</td>
<td>25</td>
</tr>
<tr>
<td>Greece</td>
<td>–</td>
<td>12</td>
</tr>
<tr>
<td>Spain</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>France</td>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td>Ireland</td>
<td>–</td>
<td>24</td>
</tr>
<tr>
<td>Italy</td>
<td>–</td>
<td>38</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>–</td>
<td>37</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>–</td>
<td>35</td>
</tr>
<tr>
<td>Portugal</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>UK</td>
<td>16</td>
<td>18</td>
</tr>
<tr>
<td>Total</td>
<td>41</td>
<td>263</td>
</tr>
</tbody>
</table>

dossiers/applications

Table 33.4 The distribution of work to the rapporteur countries under the former CPMP procedure (Directive 75/319/EEC) 1978–1986, and the multistate procedure (Directive 83/570/EEC) 1986 to October 1992
Centralized procedure

In the centralized procedure, products falling within Annex A have to be processed by this route, products in Annex B may be processed by this route at the discretion of the manufacturer. Applicants using the centralized procedure may nominate a member of the CPMP to act as rapporteur and co-rapporteur. However, the final choice of rapporteur and co-rapporteur remains within the remit of the CPMP. The membership of the CPMP has been made so that it is now a technically expert committee which advises the EMEA. The opinions of the CPMP are referred to member states, who have a period of time to comment back to the CPMP. Thereafter, an opinion is issued which is binding on the member states.

Tables 33.5 and 33.6 show the work of the EMEA in terms of centralized procedure applications dealt with since the inception of the current scheme on 1 January 1995 to 19 December 1999. Table 33.5 shows the new applications submitted to the EMEA under the centralized procedure, and Table 33.6 shows the number of variations to MAs granted under the centralized procedure. It can be envisaged that variations are going to comprise the major part of EMEA’s workload, in the same way as it does for national drug regulatory authorities.

The MCA (now the MHRA) has remained the dominant regulatory authority regarding the share of work conducted under the two revised community procedures, for example in March 1996, the Annual Report of the MCA for 1995/96 states: ‘The MCA was responsible for eight of the 21 mutual recognition procedures that had been successfully completed (38%) and was the reference member state for 10 of the 23 procedures in progress at that date’. The United Kingdom was also the rapporteur or co-rapporteur for 19 of 81 applications made to the centralized procedure in 1997 (European Agency for the Evaluation of Medicinal Products, Third General Report 1997). The distribution of work on centralized applications by the member state is shown in Table 33.7. The processing times for centralized applications is shown in Table 33.8.

Decentralized or mutual recognition procedure

Table 33.9 shows the use of the ‘decentralized’ or ‘multistate’ or ‘mutual recognition’ procedure

---

**Figure 33.1** Centralized procedure for biotech (mandatory) and high-tech (optional) medicines (from 1 January 1995). *Source:* Griffin and O’Grady (2006)
During 1997. In this procedure, the initial or reference member state that granted marketing approval forwards the necessary documents for registration to the other member states where the manufacturer wishes to market his product, and a copy is also sent to the EMEA/CPMP. If one or more member states raise objections, the applicant had the right, until 31 December 1997, to withdraw his request for a MA in that member state. Thereby, the applicant avoided the application being forwarded to the CPMP for arbitration (Table 33.10).

Application for marketing approval

Application for marketing approval, using either the centralized or decentralized procedure, has to be accompanied by three expert reports, which...
cover (a) chemistry, pharmacy, manufacturing route; (b) preclinical aspects, including pharmacology, safety pharmacology, pharmacokinetics, single and repeat-dose toxicological evaluation, reproduction studies, mutagenic potential and carcinogenicity; (c) clinical studies covering phase I–III studies; ADRs notified to the company during clinical studies. If the product has been marketed, then all post-marketing experience should be assessed. Expert reports are not a promotion platform for the product but an assessment of the data generated, an explanation of the results and an interpretation. An expert report should not normally exceed 25 pages of A4 size. The expert reports should also make clear whether or not the studies submitted have been conducted according to GLP standards and whether the clinical studies have been conducted to GCP principles and in accord with the Declaration of Helsinki. A statement of the environmental effects of the product is also necessary.

DG XXIV Scientific Committee on medicinal products and medical devices

In a communication to the Council and European Parliament on ‘Consumer Health and Food Safety’

<table>
<thead>
<tr>
<th>Table 33.5</th>
<th>Centralized marketing applications to EMEA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Part A</td>
<td>20</td>
</tr>
<tr>
<td>Part B</td>
<td>40</td>
</tr>
<tr>
<td>Withdrawals</td>
<td></td>
</tr>
<tr>
<td>Part A</td>
<td>3</td>
</tr>
<tr>
<td>Part B</td>
<td>4</td>
</tr>
<tr>
<td>Opinions adopted by product</td>
<td></td>
</tr>
<tr>
<td>Part A</td>
<td>6</td>
</tr>
<tr>
<td>Part B</td>
<td>19</td>
</tr>
<tr>
<td>Opinions adopted by substance</td>
<td></td>
</tr>
<tr>
<td>Part A</td>
<td>6</td>
</tr>
<tr>
<td>Part B</td>
<td>13</td>
</tr>
</tbody>
</table>

*These figures include negative opinions given for seven products (representing four substances), and for two variations.

<table>
<thead>
<tr>
<th>Table 33.6</th>
<th>Variations and line extensions to marketing applications processed by centralized procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I variations</td>
<td></td>
</tr>
<tr>
<td>Part A</td>
<td>57</td>
</tr>
<tr>
<td>Part B</td>
<td>52</td>
</tr>
<tr>
<td>Type II variations</td>
<td></td>
</tr>
<tr>
<td>Part A</td>
<td>19</td>
</tr>
<tr>
<td>Part B</td>
<td>28</td>
</tr>
<tr>
<td>Extension and abridged applications</td>
<td></td>
</tr>
<tr>
<td>Part A</td>
<td>32</td>
</tr>
<tr>
<td>Part B</td>
<td>2</td>
</tr>
</tbody>
</table>

*These figures include negative opinions given for seven products (representing four substances), and for two variations.
[COM(97) 183 Fund], the European Commission emphasized that high-quality scientific committees are an essential foundation for EC rules in this area.

It was decided in August 1997 that DG XXIV Consumer Policy and Consumer Health, now renamed the Health Directorate in 1999 Protection, should set up a number of eight new advisory committees, including a Scientific Committee on Medicinal Products and Medical Devices. These committees are expected to meet 10 times per year, and the Committee on Medicinal Products and Medical Devices met for the first time on 10–14 November 1997. The European Drug and Device Report stated: Feathers are understood to be ruffled in the EU’s Committee for Proprietary Medicinal Products; however, up to now, the CPMP has largely held a monopoly on scientific opinion.

The Commission said the new Scientific Committee will not overlap CPMP and there does appear to be a role for both panels.

Unlike the CPMP its minutes would be public.

Drug companies have feared that the committee would lean more toward consumers than industry.

The interaction between CPMP (which reports to the Enterprise Directorate, formerly the Commissions DG III Industry Affairs) and the new Medical Products and Medical Devices Committee, which reports to the Health Directorate, formerly DG XXIV Consumer Policy, is very uncertain. It has to be borne in mind that the objective of Directive 65/65 was to advance the

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of times a country has been rapporteur or co-rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>17</td>
</tr>
<tr>
<td>Denmark</td>
<td>25</td>
</tr>
<tr>
<td>Germany</td>
<td>34</td>
</tr>
<tr>
<td>Greece</td>
<td>2</td>
</tr>
<tr>
<td>Spain</td>
<td>19</td>
</tr>
<tr>
<td>France</td>
<td>37</td>
</tr>
<tr>
<td>Ireland</td>
<td>25</td>
</tr>
<tr>
<td>Italy</td>
<td>18</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>6</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>33</td>
</tr>
<tr>
<td>Austria</td>
<td>12</td>
</tr>
<tr>
<td>Portugal</td>
<td>12</td>
</tr>
<tr>
<td>Finland</td>
<td>15</td>
</tr>
<tr>
<td>Sweden</td>
<td>36</td>
</tr>
<tr>
<td>UKa</td>
<td>36</td>
</tr>
</tbody>
</table>

*aUK has been rapporteur for 21 applications.*

---

Table 33.7 Distribution of work on centralized procedure applications among EC member states

<table>
<thead>
<tr>
<th>Country</th>
<th>Number of times a country has been rapporteur or co-rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>17</td>
</tr>
<tr>
<td>Denmark</td>
<td>25</td>
</tr>
<tr>
<td>Germany</td>
<td>34</td>
</tr>
<tr>
<td>Greece</td>
<td>2</td>
</tr>
<tr>
<td>Spain</td>
<td>19</td>
</tr>
<tr>
<td>France</td>
<td>37</td>
</tr>
<tr>
<td>Ireland</td>
<td>25</td>
</tr>
<tr>
<td>Italy</td>
<td>18</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>6</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>33</td>
</tr>
<tr>
<td>Austria</td>
<td>12</td>
</tr>
<tr>
<td>Portugal</td>
<td>12</td>
</tr>
<tr>
<td>Finland</td>
<td>15</td>
</tr>
<tr>
<td>Sweden</td>
<td>36</td>
</tr>
<tr>
<td>UKa</td>
<td>36</td>
</tr>
</tbody>
</table>

*aUK has been rapporteur for 21 applications.*

---

Table 33.8 Processing times (days) of centralized applications to EMEA, 1995–1999

<table>
<thead>
<tr>
<th>Year</th>
<th>Assessment phase</th>
<th>Decisions process</th>
<th>EMEA post-opinion phase</th>
<th>Company clockstop</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>189</td>
<td>45</td>
<td>119</td>
<td>59</td>
<td>412</td>
</tr>
<tr>
<td>1997</td>
<td>169</td>
<td>40</td>
<td>79</td>
<td>119</td>
<td>407</td>
</tr>
<tr>
<td>1997</td>
<td>178</td>
<td>32</td>
<td>86</td>
<td>139</td>
<td>435</td>
</tr>
<tr>
<td>1998</td>
<td>185</td>
<td>42</td>
<td>83</td>
<td>109</td>
<td>419</td>
</tr>
<tr>
<td>1999</td>
<td>183</td>
<td>38</td>
<td>70</td>
<td>148</td>
<td>439</td>
</tr>
</tbody>
</table>

---

Table 33.9 Total number of finalized mutual recognition procedures by type, August 1995–December 1997

<table>
<thead>
<tr>
<th>Type</th>
<th>Number</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>New active substance</td>
<td>77</td>
<td>31.5</td>
</tr>
<tr>
<td>Generics</td>
<td>45</td>
<td>18.4</td>
</tr>
<tr>
<td>Line extensions</td>
<td>29</td>
<td>11.9</td>
</tr>
<tr>
<td>Fixed combination</td>
<td>20</td>
<td>8.2</td>
</tr>
<tr>
<td>OTC</td>
<td>6</td>
<td>2.6</td>
</tr>
<tr>
<td>Herbal</td>
<td>2</td>
<td>0.8</td>
</tr>
<tr>
<td>Others</td>
<td>65</td>
<td>26.6</td>
</tr>
</tbody>
</table>

*aThe number includes multiple procedures (total = 244).*
free movement of goods within the EC, that is an industrial/commercial objective. In the future, it might be more logical for the functions of EMEA to be the responsibility the Health Directorate rather than the Enterprise Directorate.

The CPMP and European harmonization of data requirements and ICH

It might not be immediately apparent that the drive toward ‘harmonization’ of regulatory requirements had its birth at the first meeting of the CPMP in November 1976. The CPMP at that juncture had been established to operate a ‘mutual recognition’ procedure, laid out in Directive 75/318, but it had no work to do initially. It was, however, immediately clear to the CPMP that the data requirements laid down for registration were being interpreted differently by individual member states’ regulatory authorities. For example, there was no agreement on requirements for reproduction studies, carcinogenicity, studies and so on. At that first meeting, two expert working groups on safety and efficacy were established to draw up guidelines (later, other expert working groups were established). A great deal of international harmonization of requirements and thought was achieved, and this could clearly be extended beyond the confines of the EC.

By June 1984, the EC Commission decided that a meeting with the Japanese authorities, attended by Mr Fernand Sauer and the Chairmen of the Safety and Efficacy Groups J.P. Griffin and J.M. Alexander should take place in Tokyo. As a result of this, a second meeting with the Japanese authorities (the JPMA), the EC Commission and EFPIA representatives took place. This was the stimulus for EFPIA, JPMA and the PMA, as it then was in the United States, to press for wider consultation. From such a start, the International Conference on Harmonization (ICH) was born. The ICH Steering Committee established expert working groups (EWG) to discuss areas where harmonization was possible and to produce universally acceptable guidelines. Thus, under the auspices of the ICH, a considerable number of guidelines have been issued in the areas of quality, safety and efficacy, with the objective of achieving harmonization of requirements for registration between regulatory authorities, and thus reducing the need for duplicating studies. It must be made clear that these documents should be regarded as guidelines, not requirements. These guidelines are not at the cutting edge of science but represent acceptable compromises. Guidelines will need updating, and this must be coordinated, otherwise there will be ‘regulatory drift’ toward disharmony.

If harmonization can be achieved, as it has been, across sufficiently broad areas of quality, safety and efficacy, there is no logical reason why a common technical document (CTD) or dossier cannot be prepared that would be acceptable to all drug regulatory authorities. Movement to a CTD would appear to be the next step toward further internationalization.

The ICH guidelines and details of their evolution can be obtained in the Proceedings of the First, Second, Third and Fourth International Conferences on Harmonization, held in Brussels (1991), Orlando, USA (1993), Yokohama, Japan (1995) and Brussels (1997), published by the Queen’s University of Belfast and obtainable

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>New applications</td>
<td>275</td>
<td>48</td>
<td>210</td>
<td>2</td>
</tr>
<tr>
<td>Type I variations</td>
<td>695</td>
<td>90</td>
<td>625</td>
<td>0</td>
</tr>
<tr>
<td>Type II variations</td>
<td>254</td>
<td>109</td>
<td>292</td>
<td>2</td>
</tr>
</tbody>
</table>

*The number includes multiple procedures.*
from the IFPMA Offices, 30 Rue du St Jean, P.O. Box 9, 1211 Geneva 18, Switzerland.

The clinical guidelines applicable to the EC may be obtained from the MHRA, EuroDirect Guideline Service, Room 1615, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK. Tel.: +44 (0) 171 273 0352/0228.

Mutual recognition of established products and line extensions

The bulk of national licensing activities relates to new formulations of older products, generics and line extensions. However, over the years, the indications, contraindications, warnings, dosages and so on of even well-known products differ significantly from member state to member state. The national reviews required of older products that were conducted by each member state of the EC were not accompanied by any international concentration of effort and did not lead to harmonization within the EC. This has made it difficult for companies to use the mutual recognition procedure for the introduction of generic products, as the summary of product characteristics (SPC) differs between member states. The same problem can affect the originator of an established chemical entity when the company wishes to introduce a line extension, because even under the operation of the mutual recognition procedure, where the CPMP opinion was not binding, there were differences in dosages, indications, contraindications and warnings between member states.

In 1996, the Swedish government proposed a solution to the impasse affecting the use of the mutual recognition procedure for generic products, as the summary of product characteristics (SPC) differs between member states. The same problem can affect the originator of an established chemical entity when the company wishes to introduce a line extension, because even under the operation of the mutual recognition procedure, where the CPMP opinion was not binding, there were differences in dosages, indications, contraindications and warnings between member states.

In 1996, the Swedish government proposed a solution to the impasse affecting the use of the mutual recognition procedure for generic products, as the summary of product characteristics (SPC) differs between member states. The same problem can affect the originator of an established chemical entity when the company wishes to introduce a line extension, because even under the operation of the mutual recognition procedure, where the CPMP opinion was not binding, there were differences in dosages, indications, contraindications and warnings between member states.

In April 1997, the EC Commission announced that, rather than change the Directives to allow the ‘core SPC idea’ as advanced by Sweden, it would ‘reinterpret’ them. In practice, this means that generic companies would, from 1 January 1998, be able to use the mutual recognition procedure only when the originator’s SPC was identical in all member states, that is the originator’s product had mutual recognition status or a centralized license. In practice, this means that generics will have to use national procedures ‘which were due to be phased out on 31 December 1997’. Line extensions of existing products, that is new dosage forms and so on, would logically be caught in the same net as generics if the initial product did not have an identical SPC in all member states. Currently, some companies are withdrawing products from the market and replacing them with a new salt of the same active substance in an attempt to thwart generic products entering the market.

Changes ahead for European regulation?

Possible changes to the centralized procedure

In view of the increased membership of the EU, in future years, if standards of granting MAs for medicines are not to decline, measures will have to be taken to preserve the standards that operated in Northern Europe prior to 1994. It could be conceded that all NCEs should be handled through the centralized procedure. This could only be acceptable in terms of consumer safety if the competence of advice available to the EMEA was increased. EMEA staff themselves must be technically competent to do the assessment work currently done by those national drug regulatory authorities, appointed to act on behalf of the rapporteur and co-rapporteur. The use of national drug regulatory authorities to do the work of rapporteur and co-rapporteur would cease. The staff recruited to the EMEA to do this expert work should be recruited on the basis of quality, rather than having regard to the adherence of ‘national quotas’ of staff. The CPMP, currently composed of one member from each of the 25 member state’s regulatory authority, should be disbanded. The technical
advisory committee serving the EMEA should be served by expert panels, covering chemistry and pharmacy, pharmacology, and toxicology, and multiple clinical panels of experts, covering for example cardiovascular, respiratory, diabetic and endocrine disorders, oncology and so on, on the pattern used by the US Food and Drug Administration (FDA). This would be a way forward, with synthesis of an overall view done by a standing expert committee. It would have to be recognized that not all EU member states would be involved in every committee or expert panel. Although attempts should be made to involve all member states at some level in the procedure, it must be accepted that, in the public interest, expertise should predominate over national representation. The role of selection of the experts to serve on this standing committee and expert panels should be the role of the EMEA Management Board, and nominations should be made by the Ministers of Health of the member states of the EU, on a similar basis to the way the membership of the British Committee on Safety of Medicines is drawn together.

Possible changes to the decentralized or mutual recognition system

The current mutual recognition system is cumbersome and could be improved. A true mutual recognition system for marketing applications that did not involve a NCE could be devised, drawing on the system operating in the medical devices area, where authorization by one regulatory agency leads to an EU-wide approval, provided that marketing in all EU member states is identical with the approval granted in the reference member state. A single chemical entity MA number would be used to cover the authorization in all member states of the EU. Applicant companies would be wise to select a credible national drug regulatory authority to process such a mutual recognition. In fact, it might be better if the scheme were to designate competent national regulatory bodies (not all national authorities would necessarily qualify).

Single assessment/single marketing approval

Both systems, modified as outlined, would lead to a single EU-wide marketing approval, following a single assessment.

33.6 Conclusion

The European system for granting MA for medicinal products will continue to evolve and change; however, like the advice given to the man seeking directions (I would not start from here if I were you), we do not have an option. Finally, it has to be understood that the EU is not a country – it is a collection of member states, and there continues to be much fertile ground for continuing debate and dissent.

References


### Recommended information sources


### List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABPI</td>
<td>Association of British Pharmaceutical Industry</td>
</tr>
<tr>
<td>CEP</td>
<td>European Pharmacopoeia Certificate of Suitability</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for Human Medicinal Products</td>
</tr>
<tr>
<td>CIOMS</td>
<td>Council of International Organizations of Medical Sciences</td>
</tr>
<tr>
<td>CMC</td>
<td>Chemistry, Manufacturing and Controls</td>
</tr>
<tr>
<td>CMS</td>
<td>Concerned member state(s)</td>
</tr>
<tr>
<td>COMP</td>
<td>Committee for Orphan Medicinal Products</td>
</tr>
<tr>
<td>CP</td>
<td>Centralized procedure</td>
</tr>
<tr>
<td>CPMP</td>
<td>Committee for Proprietary Medicinal Products</td>
</tr>
<tr>
<td>CTA</td>
<td>Clinical trial authorization</td>
</tr>
<tr>
<td>CTD</td>
<td>Common technical document</td>
</tr>
<tr>
<td>CVMP</td>
<td>Committee for Veterinary Medicinal Products</td>
</tr>
<tr>
<td>EEA</td>
<td>European economic area</td>
</tr>
<tr>
<td>EFPIA</td>
<td>European Federation of Pharmaceutical Industries’ Associations</td>
</tr>
<tr>
<td>EMEA</td>
<td>European Medicines Evaluation Agency</td>
</tr>
<tr>
<td>EPAR</td>
<td>European Public Assessment Report</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GCP</td>
<td>Good clinical practices</td>
</tr>
<tr>
<td>GLP</td>
<td>Good laboratory practices</td>
</tr>
<tr>
<td>GMO</td>
<td>Genetically modified organism</td>
</tr>
<tr>
<td>GMP</td>
<td>Good manufacturing practices</td>
</tr>
<tr>
<td>GSL</td>
<td>General sales list</td>
</tr>
<tr>
<td>HCMP</td>
<td>Committee for Herbal Medicinal Products</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference of Harmonization</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational medicinal product</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>MA</td>
<td>Marketing authorization</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Drug Regulatory Activities</td>
</tr>
<tr>
<td>MRFG</td>
<td>Mutual Recognition Facilitation Group</td>
</tr>
<tr>
<td>MRP</td>
<td>Mutual recognition procedure</td>
</tr>
<tr>
<td>MS</td>
<td>Member state(s)</td>
</tr>
<tr>
<td>P</td>
<td>Pharmacy</td>
</tr>
<tr>
<td>PA</td>
<td>Protocol assistance</td>
</tr>
<tr>
<td>PAGB</td>
<td>Proprietary Association of Great Britain</td>
</tr>
<tr>
<td>PIL</td>
<td>Patient information leaflet</td>
</tr>
<tr>
<td>POM</td>
<td>Prescription only medicine</td>
</tr>
<tr>
<td>PSUR</td>
<td>Periodic Safety Update Report</td>
</tr>
</tbody>
</table>

---

*Principles and Practice of Pharmaceutical Medicine, 2nd Edition*


Edited by L. D. Edwards, A. J. Fletcher, A. W. Fox and P. D. Stonier
34.1 The European regulatory framework

The Treaty of Rome (1957) created a single community out of several European countries with diverse cultures and histories: Belgium, France, Italy, Luxembourg, the Netherlands and (then) West Germany. Among other things, this began a process of harmonization of regulations and technical requirements for the marketing authorization (MA) of medicines, within a European common market. The United Kingdom, Denmark and Ireland joined in 1973, Greece in 1981, Spain and Portugal in 1986 and Austria, Finland and Sweden in 1995. On May 1, 2004, 10 more nations joined: Cyprus, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia and Slovenia. While the European Union (EU) was formalized by the treaty of Maastricht in 1992, already by 1975, the fundamental directives concerning medicines had been issued.

34.2 The European legislative mechanism

Directives are issued by the European Commission and the Council, and are binding as to their objectives and results. MS are obligated to transpose Directives into national law, with prescribed timelines for doing so. In the case of medicines regulation, this happens not only in the 25 countries of the EU but also, on a voluntary basis, in the additional countries of the European economic area (EEA) (Norway, Liechtenstein and Iceland) and even, to some extent, in Switzerland.

Regulations are laws of immediate application for all MS and overrule national law. Regulations are typically issued by the many agencies of the EU, and may be viewed as interpretations, or more practical descriptions of how Directives are to be implemented.

EU decisions are directed at and are binding upon named addressees, and are not necessarily applicable throughout the EU. Addressees can be individual MS, particular economic sectors or even single organizations.

Opinions and recommendations are not legally binding, being designed to enunciate governmental views and current thinking on particular topics. Often, opinions and recommendations form the basis for future decisions, regulations or even directives.

Guidelines provide technical interpretations of the law, and usually set out what is thought to be acceptable to regulatory authorities (RAs), for example the European Medicines Evaluation Agency (EMEA). In the field of medicines regulation, guidelines can be published by individual scientific committees within an agency, for example the Committee for Human Medicinal Products (CHMP). Although guidelines are not legally binding, they do constitute an official reference or precedent. Any deviation from such guidelines must usually then be explained with sound scientific justification. Special types of guidelines, quite unlike the practices of the United States, are those relating to a formal request laid down by a Directive or Regulation; these guidelines are published by the European Commission and are legally binding; a recent example is the Note for Guidance on Transmissible Spongiform Encephalopathies, and is restrictions on bovine components in pharmaceutical products.
The legal basis for medicinal product marketing authorization

The aim of the many directives and regulations been issued over the years is to harmonize medicine regulations across EU MS. This harmonization includes uniform requirements and decision-making criteria not only for MA but also for post-marketing surveillance processes throughout the EU.

The very first Directive issued was Council Directive 65/65 concerning ‘The approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products’. It was a milestone in the quest to provide the same opportunities in healthcare to all EU citizens, through the removal of local, legal, technical and regulatory barriers.

Directive 65/65 defined Quality, Safety and Efficacy as the sole criteria for approval of medicines in the EU, and for awarding MA. It established that product approvals are granted on purely technical basis, without political or economic implications.

Ten years later, a pair of Directives extended the provisions of 65/65. Directive 75/318 defined testing and protocol standards, while Directive 75/319 introduced the Committee for Proprietary Medicinal Products (CPMP) and what is now known as the ‘mutual recognition procedure’ (MRP) for MA (see below). Nine years later, the structure of the CPMP was adjusted by Regulation 726/2004, and now forms the CHMP (see below). These three fundamental Directives represent the basis of pharmaceutical regulation that is common to the whole of Europe; the creation of the EMEA in 1995 (by Regulation 2309/93, two years earlier) provided the machinery that implements these Directives.

Most recently, all these relevant legal requirements for human medicines (other than those foreseen by Regulation 2309/93, and replacement Regulation 726/2004) have been collected together in Directive 2001/83 entitled ‘Community code relating to medicinal products for human use’. This, together with Directive 2003/63, standardizes the components of each technical section of the marketing application dossier for different product categories (such as chemical synthesis products, biologics, plasma derivatives, fixed combinations, radiopharmaceuticals, vaccines, homeopathic, herbal and orphan medicinal products). European regulations and guidelines that support the European pharmaceutical legislative framework are collected in the 10 volumes of ‘The Rules governing medicinal products in the European Union’, edited by Eudralex:

Vol 1 Pharmaceutical legislation (human)
Vol 2 Notice to Applicants (human)
Vol 3 Guidelines (human)
Vol 4 Good Manufacturing Practices (human and veterinary)
Vol 5 Pharmaceutical legislation (veterinary)
Vol 6 Notice to Applicants (veterinary)
Vol 7 Guidelines (veterinary)
Vol 8 Maximum residue limits (veterinary)
Vol 9 Pharmacovigilance (human and veterinary)
Vol 10 (forthcoming) Clinical trials

The International Conference on Harmonization (ICH) process

In recent years, the pharmaceutical industry has displayed an increasing tendency to globalize the market, particularly for innovative medicines. The differences of requirements in different geographical areas often caused duplication of clinical trials or other research, with consequent waste of time and resources. This added to the escalating costs and telescoping timelines of research and development. Uniformity of approach across the EU has the potential to eliminate these redundancies. The Clinical Trial Directive (2001/20, required to be implemented by MS on May 1, 2004) pursued this aim further. The Directive requires a uniform approach toward investigational drug oversight, creates international standards of pharmacovigilance and establishes a common European adverse event (AE) database.

Taking these concepts further, it was quickly realized that even wider international harmonization could benefit pharmaceutical research and
development. This led to the collaborative project involving Europe, Japan and the USA known as the ‘International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use’ (ICH). The ICH aims to provide harmonized guidelines acceptable to regulatory authorities in all three places.

The ICH process involves participation by both national regulatory authorities and the pharmaceutical and biotechnology industries. These parties form Steering Committees which address selected technical issues. ‘Working parties’ are often used to prioritize the issues that Steering Committees must address. Many ICH guidelines have now issued on matters of drug quality, safety and efficacy. Some of these have led to everyday working tools, for example, the Medical Dictionary for Drug Regulatory Activities (MedDRA), or the common technical document (CTD, mandatory July 2003), which is a guideline for the structure, format and content of dossiers that are submitted to the regulatory authorities for product license approval.

Within this framework, we provide below an overview of the current regulatory procedures in Europe. We address the practical aspects of regulating drug development, the MA processes and other activities such as advertising regulations in the EU.

34.5 The European Medicines Evaluation Agency

The EMEA is an advisory body reporting directly to the European Commission. It is located at London. Its structure and responsibilities are defined by Regulation 726/2004, and these are primarily 'coordinating the existing resources put at its disposal by the MS for the evaluation, supervision and pharmacovigilance of medicinal products'.

The underlying objectives, driving the work of the EMEA, are to

- protect and promote public health by mobilizing the best scientific resources in the EU;
- facilitate quicker access and free circulations of medicines within the EU;
- collaborate in harmonizing scientific requirements to optimize pharmaceutical research worldwide;
- develop efficient, effective and responsive operating procedures.

In pursuit of these aims, and in response to Regulation 726/2004, the main practical tasks of the EMEA are to

- provide MS and the Community institutions with the best possible scientific advice on questions concerning quality, safety and efficacy of medicinal products for human and veterinary use (note that this does not include medical devices);
- establish multinational scientific expertise through mobilization of existing national resources;
- organize rapid, transparent and efficient procedures for the authorization, surveillance and, when necessary, withdrawal of medicinal products in the EU;
- provide scientific advice to the sponsors of pharmaceutical research;
- draw up scientific opinions concerning evaluation of medicinal products or of the starting materials used in their manufacture at the Commission’s request;
- reinforce the supervision of existing medicinal products by coordinating national pharmacovigilance and inspection activities;
- improve cooperation between the EU government, MS, international organizations and third countries;
- provide assistance on information of medicinal products to physicians and the public;
- create and maintain a European database of medicinal products accessible to the general public.
- transmit and make publicly available assessment reports, Summary of product characteristics (SmPC), product labeling and package information leaflets for medicines subject to community procedures;
- coordinate verification of compliance with good manufacturing, good laboratory, and good clinical practices guidelines (GMP, GLP and GCP, respectively).

The EMEA comprises (Figure 34.1)

- a Management Board that approves the Agency’s work program and approves the budget;
- an Executive Director, legal representative of the Agency and responsible for the overall working of the Agency;
- a Secretariat that provides technical, scientific and administrative support to the scientific committees;
- the Scientific Committees, responsible for the scientific opinions delivered by the Agency:
  - Committee for Human Medicinal Products (CHMP; formerly CPMP)
  - Committee for Veterinary Medicinal Products (CVMP)
  - Committee for Orphan Medicinal Products (COMP)
  - Committee on Herbal Medicinal Products (HCMP)

Standing working parties and ad hoc expert groups support these committees. Some 3500 European experts have been listed and will support on request the scientific work of the Committees. The list is published on the EMEA web site.

In addition, there can be pilot project teams. For example, one such team is currently testing whether Therapeutic Advisory Groups (TAGs)

---

**Figure 34.1** The organizational structure of the EMEA
can usefully provide independent clinical expertise on products under evaluation by the CHMP without, of course, removing the final responsibility for the scientific opinion with the latter. Such TAGs (currently in oncology, infective diseases and diagnostic agents) have core members who are appointed by the CHMP, and can appoint ad hoc external experts, when necessary.

### 34.6 Current European regulatory practice

**Clinical trials: Directive 2001/20**

This Directive was to be implemented by all EU MS by May 1, 2004. As a result, approval of clinical trials is no longer based on the former uneven laws of individual MS, but rather on how each state has implemented this Directive, which is much more uniform.

The scope of Directive 2001/20 is broad. All clinical studies of medicinal products involving human subjects (both patients and normal volunteers) fall within its remit, unless the trial is merely observational and noninterventional. This applies equally to the pharmaceutical industry, academia, government research institutes and all others.

The Directive

- sets standards for the protection of study subjects, including especially vulnerable groups such as children and incapacitated adults;
- requires every MS to have a central governing body that oversees ethics committees;
- mandates that national licensing authorities must now affirmatively permit clinical trial initiation;
- prescribes standards for the manufacture, import and labeling of all investigational medicinal products (IMPs);
- establishes an inspection system to ensure compliance with good manufacturing practices (GMP) and good clinical practices (GCP);
- focuses particularly on the safety monitoring of participating subjects in trials and sets out procedures for doing so;
- mandates safety reporting to a pan-European pharmacovigilance database.

The National Competent Authority (NCA) in each MS (e.g. the BfArM in Germany or the MHRA in the United Kingdom) reviews proposed clinical trials within their jurisdictions; if satisfied with the information provided, then the NCA notifies the study sponsor that it has no grounds for objection. The Directive sets a timeline for review of up to 60 days for most trials, as well as for substantial protocol amendments, although there are options to extend this timeline under special circumstances, such as for gene therapy studies, where there is no time limit at all. The authorization granted by the regulatory authority (RA) – a clinical trial authorization (CTA) – is issued study-by-study, with affirmative notifications being needed for every protocol separately; this is an important difference from the IND regulations in the United States.

The Clinical Trials Directive requires the integration of the GCP guidelines into the national law of all MS (which had not been the case in some MS before May 2004). Local regulatory authorities now carry the burden of inspecting for compliance with both GCP and the GMP guidelines for investigational drugs. Inspections take place at both sponsor’s facilities and clinical trial sites.

All research involving human subjects (apart from wholly noninterventional, observational studies), including academic research and Clinical Pharmacology studies in healthy volunteers, fall within the scope of the Directive. The latter, hitherto, had a much lighter administrative burden or even no regulatory oversight at all in some MS. The need now to provide the same amount of information and be subject to RA review just as much as later phase clinical research has led to some complaints, especially in the academic community.

The European Commission issued a set of detailed guidelines on the requirements and format of the CTA application for use by NCAs and ethics committees, as well as templates for application forms. Directive 2001/20 has also added a small but
significant new administrative aspect: every applicant for a CTA, in any EU MS must now have a legal representative who is domiciled in Europe, through whom all activities and communications pass. Non-European applicants for a CTA must, therefore, name a representative, resident in the EU (this includes Swiss study sponsors, and there is an analogous requirement in the United States).

The pan-European clinical trial database (EuDRACT)

The EuDRACT enables the various European regulatory authorities to track all clinical trials taking place anywhere in the community using a single source of information. Every clinical trial in the EU must be registered with this database and has a unique registration number (the EuDRACT trial number), even when the study is taking place in multiple EU countries. Sponsors can register their clinical trials online, and must have a system in place to guarantee that duplicate EuDRACT numbers are not requested. The EuDRACT database is for the sole use of RAs and its contents cannot be accessed by trial sponsors or the general public.

The information that needs to be provided about the clinical trial at the time of registration in EuDRACT is similar, but less extensive than that provided in the CTA and includes the following:

- The title of the trial
- The identity of the sponsor
- The type of application
- The trial monitoring and central facilities
- Information about the IMPs
- Information about the placebo
- The manufacturer or importer of the IMPs
- Information about the trial design and procedures
- Details of the trial subjects;
- Information about the overseeing ethics committee

The applicant has no access to the information, once it has been registered with the database; only the regulatory authorities can alter the database.

Ethics committees

Directive 2001/20 has also led to a set of detailed Guidance documents, to help MS interpret the Directive and implement appropriate ethical committee oversight. The ‘Detailed Guidance on the Application Format and Documentation to be Submitted in an Application for an Ethics Committee Opinion on a Clinical Trial for a Medicinal Products for Human Use’ (April 2003) is self-explanatory. This document includes a table that collates each special requirements of MS, and it is designed to be used with the national Guidances, where they exist.

All proposed clinical trials in Europe now have to receive an affirmative favorable opinion from a properly constituted ethics committee, before commencement. In the case of multinational, multicenter trials, only a single ethics committee opinion is needed in each MS. There is nonetheless the capability for individual sites, with additional ethics committees, to reject a clinical trial. But a negative opinion from the local ethics committees would only stop the trial at the particular site, and not affect the overall approval given from the lead ethics committee in the relevant MS.

Both sponsors and investigators are empowered to apply for the ethics committee opinion. The Directive states that the applicant can choose to make parallel applications to the NCA and the ethics committee, or do it sequentially. However, in practice national preferences will vary in whether sequential applications may be preferred. It is important to make sure that the version of the reviewed documents at the ethics committee and the RA match.

The National Competent Authority and ethics committee initially validate the application and the sponsor is informed that the application is valid (i.e. the format is appropriate and that the application appears prima facie to be complete and accurate). Ethics committees have the same review clock as regulatory authorities, including the special situations with extended or eliminated timeframes (see
above). Note that the guidance foresees the possibility for sponsors to supply further information once without extension of the review timeframe (under ideal circumstances). Clinical trial can only begin when the favorable opinion of both the ethics committee and the RA’s notification of no grounds for objection (see above) have been received in writing.

### Protocol amendments

Usually, if, in the course of a trial, a substantial amendment to the protocol becomes necessary, then a repeat opinion of the ethics committee must be sought before implementing any change. Substantial amendments are defined as amendments to the terms of the research ethics committee’s (REC’s) application, or to the protocol or any other supporting documentation that is likely to affect to a significant degree:

- the safety or physical or mental integrity of the subjects of the trial;
- the scientific value of the trial;
- the conduct or management of the trial or
- the quality or safety of any IMP used in the trial.

Note, however, that amendments that are made to reduce an immediate clinical hazard to the trial participants may be implemented immediately, and remains the primary responsibility of the designated medical monitor for the study, without prior written approval from the ethics committee. However, the investigator is under obligation to inform the ethics committee, the sponsor must inform the RA, both as soon as possible and in any case within 72 h (see European Commission Directive 2003/94/EC, 2005/28/EC).

Minor amendments – also called ‘administrative amendments’ – do not have to be approved by the ethics committee or RA, although most research sites choose to notify the ethics committee of such changes on a periodic basis. These would include, for example, typographical errors, amended contact information, appointment of new support staff and changes in the logistical arrangements for storing or transporting samples.

Lastly, the guidance also lays out the procedure of informing the ethics committee at the termination of a trial, and lists the required documentation to be submitted.

### Clinical trial authorization (CTA) by national competent authorities

The relevant Guidance is the ‘Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments, and declaration of the end of the trial’ (April 2004).

The CTA procedure became mandatory on May 1, 2004 (existing trial authorizations from the pre-Directive period, for example in the United Kingdom a CTX, CTC or DDx, retained their validity, and automatically became CTAs). The CTA application process is a relatively straightforward written procedure, and requires no extensive preparatory meetings with the regulators.

The information on the IMP in the CTA is necessarily not as complete as in a MA, and the overall intent is that the extent of information should be proportional to the clinical phase of the protocol, while complying with the new Guidance document for Good Manufacturing Practices as they apply to IMPs (Annex 13, Rev 1 of the document). A further guideline is forthcoming on the requirements to the chemical and pharmaceutical quality documentation concerning IMPs in clinical trials (see European Commission Directive 2003/94/EC).

The core of a CTA application in all MS includes the following, which is submitted both to RAs and ethics committees:

- Covering letter
- EuDRACT number
- Application form
- Investigator’s brochure
- Protocol and amendments
- Protocol summary
- List of competent authorities to which the application was submitted, and their decisions

The supporting documentation, submitted only to the RA, comprises

- IMP dossier or simplified IMP dossier for known products
- SmPC*
- Ethics committee approval*
- Outline of all active trials with the same IMP
- IMP manufactured in EU: copy of manufacturer authorization
- IMP not manufactured in EU: QP statement that site complies with EU GMP (or at least equivalent to EU GMP)
- IMP not manufactured in EU: copy of importer authorization
- Certificate of analysis for test product where impurities are not justified by the specification*
- Examples of IMP label
- Viral safety studies
- Authorization for GMO, radiopharmaceuticals (in the United Kingdom: ARSAC approval)*
- Transmissible Spongiform Encephalopathy (TSE) certificate*
- Declaration of GMP status of active biological substance
- Manufacturing licence (on request)
- Authorization for contract research organization to represent sponsor*

Documents which need to be submitted to the ethics committee only are the following:

- Informed consent form
- Subject information
- Recruitment procedures, including advertisements and so on, and informed consent
- All information to be provided to the subject, for example questionnaires, diaries and so on
- Peer review of trial*
- Ethical assessment made by the principal investigator
- Suitability of site and adequacy of facilities
- Suitability of investigator and key staff; CVs; name and address of investigator; information on key staff
- Funding and possible conflicts of interest
- Compensation statement
- Sponsor indemnity
- Investigator’s insurance
- Payment to subjects
- Agreement between sponsor and investigator
- Publication policy and investigator’s access to data, if not in protocol

After receipt of the application, the submission is first validated, and then the review clock starts. The review clock stops when a query is raised, and begins again with the sponsor’s response. The procedure will end with an affirmative decision (one way or the other). Sponsors cannot, however,
presume CTA approval in the absence of receiving objections within the 60 days specified by the Directive. Many regulatory authorities have responded to the needs of the industry to shorten the review times and have agreed to review trials in shorter time periods, for example the MHRA in the United Kingdom aims to review all CTA applications for phase I trials within 14–21 days.

**Radioactive IMPs**

In this special case, additional approval is needed from the national authorities overseeing radiation safety. For example, in the United Kingdom this is the Administration of Radioactive Substances Advisory Committee (ARSAC). Application to ARSAC only requires a summary of the study protocol, but a careful scientific justification of the amount of radiation employed and the number of subjects exposed. The EU Directive 97/43/EurATOM sets dose limits for healthy subjects and patients.

**Good clinical practices**

The European clinical trial directive has the central objective of protecting subjects taking part in medical research. The principles within Declaration of Helsinki (as amended) are now integrated into the legal framework by inclusion in the GCP guidelines (and also the GMP guidelines, see next section). Briefly, these principles are the following:

- Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki (as amended), and that are consistent with GCP and the applicable regulatory requirements.
- Before the trial is started, foreseeable risks and inconveniences should be weighed against the anticipated benefit for the individual trial subject and society. [However, the Declaration has a central tenet that civilians must not be subjected to undue clinical hazards, without any potential for benefit themselves, but in order to benefit society at large.]
- The rights, safety and well being of the trial subjects are the most important considerations and should prevail over interests of science and society.
- The available nonclinical and clinical information on an IMP should be adequate to support the proposed trial.
- Clinical trials should be scientifically sound and described in a clear, detailed protocol.
- The trial should be conducted in compliance with a protocol that has received ethics committee(s) and competent authority’s approval.
- The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility of a qualified physician or dentist.
- Each individual involved in conducting a trial should be qualified by education, training and experience to perform his or her respective tasks.
- Freely given informed consent should be obtained from every subject prior to clinical trial participation.
- All clinical trial information should be recorded, handled and stored in a way that allows its accurate reporting, interpretation and verification.
- The confidentiality of records that could identify subjects should be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirements.
- Investigational products should be manufactured, handled and stored in accordance with applicable GMP. They should be used in accordance with the approved protocol.
- Systems with procedures that assure the quality of every aspect of the trial should be implemented.

For a fuller discussion, please see the chapters specifically on ethics, elsewhere in this book.
Good manufacturing practices

Directive 2001/20 required that compliance with GMP guidelines was introduced into the national laws of all MS and (see European Commission Directive 2003/94/EC). GMP inspections have long been standard for all companies at the time of a MA application, but there had previously been no such requirement for IMPs. This gap has now been closed.

Briefly, the components of GMP are

- a quality assurance system (Article 6);
- appropriately qualified personnel with training documentation, organizational charts and job descriptions that define roles, responsibilities and hierarchy (Article 7);
- premises and equipment appropriate and documented (Article 8);
- documentation system for all processes with appropriate record keeping; up to date and free of errors (Article 9);
- production to pre-established standard operating procedures and appropriate, validated in process controls (Article 10);
- a quality control system and independent audit staff. Samples from each batch must be retained for testing and archiving, if at all practicable (Article 11);
- any out-contracted work is subject to the same conditions and cannot be further delegated; precise contracts must define roles and responsibilities (Article 12);
- a system in place for complaints and product recall and notification of the RA (Article 13);
- self-inspection by the manufacturer with appropriate record keeping (Article 14).

Directive 2001/20 also requires that any site where IMPs are manipulated (other than pure administration to the trial subjects) should have a valid manufacturer’s license for GMP-compliant IMP preparation. Hospitals, health centers or registered pharmacies are exempt from needing an IMP manufacturer’s license, provided that changes to the IMP are done under the supervision of a doctor or pharmacist for use at that site. A further exemption is when manipulation of the IMP is simply a reconstitution activity directly prior to drug administration (e.g. adding diluent to a lyophilized injectable). Contract research organizations (CROs) and commercial phase I units are not exempt from these requirements, but can apply for a manufacturer’s license in the usual way, and are subject to inspection. The regulatory authorities issue IMP manufacturer’s authorizations after a comprehensive GMP inspection of the applicant.

Importation of IMPs from non-EU countries is also strictly regulated by Directive 2001/20. Directive 2001/83 defines rules and circumstances under which retesting or recertification of manufactured products have to be performed, whether manufactured within the EU or imported from elsewhere.

Qualified persons (QPs)

A holder of a manufacturer’s license must have a QP. The QP’s central role is to authorize batch release. The QP must be qualified by training and experience, and the manufacturer must notify the competent authority of the name of the QP with supporting documentation for his/her qualification to fulfill this role.

Scientific advice and protocol assistance

Scientific advice

Scientific advice is provided by regulatory authorities so that sponsors can design drug development plans that eventually are likely to satisfy the reviewers for MA. The individual national competent authorities offer scientific advice, on written request, and does the EMEA through the CHMP.
Requesting scientific advice from the CHMP can be sought irrespective of whether the product licence application will be made using the ‘centralized’ or ‘mutual recognition’ procedures (see below). For products that are not required to pass through the centralized procedure (CP), careful, case-by-case consideration is needed when deciding which authority to approach with a request for scientific advice.

Scientific advice can be requested on Chemistry, Manufacturing and Control (CMC), preclinical testing or clinical development of a medicinal product. Regulatory authorities generally require that the issues raised should not be already covered by existing guidelines, unless the sponsor wishes to deviate from published guidance and present a justification for doing so.

Scientific advice is not, and should not be regarded as a pre-submission review. The advice given by the RAs is not binding on either the RA or the sponsor.

The timing of a scientific advice request should be carefully planned. The CHMP and national authorities recommend that scientific advice requests are best when made early in the development of a drug; follow-up questions on the advice provided and renewal of questions throughout the development process are possible and encouraged.

Application procedures: scientific advice from EMEA (EMEA/H/4260/01/Rev. 2)

The role and responsibilities of the Scientific Advice Working Group (SAWG), within the CHMP are published. The highly structured, formal procedure does not necessarily include a face-to-face meeting between the company and the SAWG, and there is a substantial fee (unless the IMP is a designated under the orphan product regulations, see below), although this varies according to the nature and extent of the questions on which the advice is sought. In generating its scientific advice response, the SAWG first presents a draft response to the CHMP. The final advice is provided to the sponsor in writing. The procedure provides for follow-up requests after the original written scientific advice response has been issued.

The SAWG is a multidisciplinary group and comprises a Chair and 17 other members (including 2 COMP members). The Chairperson of the SAWG is nominated by the CHMP for a term of three years, and is eligible for renomination. The Chair may or may not be a member of the CHMP. The Vice-Chairperson is elected by and from amongst the SAWG members for a term of three years, again renewable. The CHMP appoints 15 members for a term of three years upon proposal of CHMP delegates. The SAWG can also co-opt members from outside the EMEA, from among a prequalified panel of external experts. The overall aim is to maintain a comprehensive expertise, because scientific advice and protocol assistance (PA) may involve pharmaceutical development, toxicology, methodology and statistics, pharmacokinetics, other therapeutic fields as appropriate.

Scientific advice from national regulatory authorities

Scientific advice from individual national authorities is also available. Applicants contact the national authority prior to sending the formal request for scientific advice, and the rest of the procedure, in most MS, is similar to that in the EMEA procedure. With less administrative effort and more frequent presence of key members at the national authorities, scientific advice at the
national level is often quicker to obtain, and the costs are considerably lower than that for the CHMP. However, national authorities will decline to give scientific advice when it has also been requested from the CHMP, viewing the effort as duplicative and redundant.

34.8 Product registration

European controls on medicinal products were originally laid out in Directive 65/65, but it was Directive 75/319 that established the CPMP as the pivotal review committee within the EMEA. With the major revision of the medicines regulation and the enlargement of the EU to 25 MS in May 2004, the CPMP has now been restructured, and renamed as Committee on Human Medicinal Products (CHMP). The CHMP now comprises a representative from each MS, as well as nonvoting representatives from the EEA countries (Norway, Iceland and Liechtenstein). Currently, the CHMP meets during the third week of each month at the EMEA headquarters in London.

The format of the submission dossier and the technical requirements are the same in all cases: the CTD has been made compulsory in Europe for all submissions since 2003.

The common technical document

The CTD format is described in ICH Guidance M4, and is organized in the following five modules (see also Figure 34.2):

- **Module I** is specific to the region in which the application is made (the EU in this case) and is, technically, not part of the CTD. It contains regional administrative information, a submission table of contents, the SmPC (i.e. the draft package insert), the patient information leaflet (PIL) (if any) and translation of the labeling into all relevant languages (in the case of a CP application this is now required in 22 languages).

- **Module II** contains the CTD summaries. These are introduced with a table of contents for Modules II–V and an introductory document. The summaries cover manufacturing and quality control, nonclinical information (including toxicology) and a clinical overview (comparable to the ‘expert report’ in previous forms of European submissions).

- **Module III** contains the detailed manufacturing and quality data: it starts with its own table of contents, and then continues with the organized body of data and any applicable literature references.

- **Module IV** contains the nonclinical study reports. Like Module III, it has its own table of contents, and then all the study reports and relevant literature references.

- **Module V** then contains the clinical study reports – again starting with a table of content for the module. A tabular summary of the studies is useful when inserted before the study reports themselves.

For most applications, English can be used for Modules II–V. However, for national applications, some authorities require a national language and should be checked with the RA well in time before submission. The EMEA web site provides administrative details concerning submissions, such as formats for electronic submission in each MS, numbers of hard copies required and so on.

Marketing authorization

Directive 65/65 established that a medicinal product can only be marketed after being authorized by the competent authority. Such obligation is reiterated in article 6 of Directive 2004/27 and article 3 of regulation 726/2004.

Regulation 726/2004 covers biotech products and other innovative products as specified in the relevant annex; main consequences of the changes of this regulation will be introduced in the chapter relating to CP.

Article 2 of Directive 2004/27 states that ‘this Directive shall apply to medicinal products for
human use intended to be placed on the market in MS and either prepared industrially or manufactured by a method involving an industrial process’, whereas, according to article 3, the following products are not included in the scopes of the Directive:

1. Any medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient (commonly known as the magistral formula).

2. Any medicinal product which is prepared in a pharmacy in accordance with the prescription of a pharmacopoeia and is intended to be supplied directly to the patients served by the pharmacy in question (commonly known as the officinal formula).

3. Medicinal products intended for research and development trials, but without prejudice to the provisions of Directive 2001/20/EC.

4. Intermediate products intended for further processing by an authorized manufacturer.

5. Any radionuclides in the form of sealed sources.

6. Whole blood, plasma or blood cells of human origin.
Criteria for granting a MA refer to quality, safety and efficacy, which, according to the new law, ‘should enable the risk–benefit balance of all medicinal products to be assessed both when they are placed in the market and at any other time the competent authority deems this appropriate’.

In fact a MA shall be refused if (article 26):

- the risk–benefit balance is not considered to be favorable
- the therapeutic efficacy is insufficiently substantiated by the applicant
- the qualitative and quantitative composition is not as declared

Authorization shall likewise be refused if documents submitted in support of the application do not comply with directive requirements.

Article 26 of the Directive and article 17 of the Regulation also state that ‘the applicant or holder of the MA shall be responsible for the accuracy of the documents and of the data submitted’: this strengthens and formalizes the close relationship that must exist between Regulatory and Quality Assurance.

A MA may be renewed after five years, based on a reevaluation of the risk–benefit ratio, and after that the MA “shall be valid for an unlimited period, unless the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with an additional five-year renewal.

An authorization will cease to be valid if the authorized product is not put in the market within three years after the authorization has been granted, or if an authorized product is not present on the market for three consecutive years. Exemptions may be granted on justified reasons.

**National application procedure**

To obtain a national marketing authorization, an application is submitted to the competent authority of the MS. The documentation is the same as required for the MRP and the technical assessment should be completed within 210 days. Since January 1998 independent national applications are limited to products that are to be authorized in not more than a single MS.

**Mutual recognition procedure**

The legal basis for this procedure is Directive 2001/83, as amended by Directive 2004/27, which became mandatory in all MS on October 30, 2005. The procedure requires MS to recognize assessments done by any one of them, provided that no risk to the public health can be identified. Risk to the public health is a broad term, and can include any quality, safety or efficacy issue within a particular national context. The MRP cannot be used for all products: the CP is compulsory in some cases (see below).

Sponsors initially submit their dossiers to a single MS. That MS conducts the initial review, and is termed the reference member state (RMS). When sponsors then request mutual recognition by other MS, the latter are termed concerned member states (CMS). The RMS is selected by the sponsor.

The RA in the RMS then evaluates the dossier and prepares an assessment report. All being well, the RMS then grants MA and agrees to the text of a final SmPC, and the labeling of the product.

Following this initial approval, the RMS will then facilitate communication between the applicant and the CMS. The CMS may offer comments and suggestions for changing the SmPC. When there are opinions that diverge between the RMS and the CMS, and if efforts to compromise fail, arbitration may be requested by CMS, or even (rarely) by the applicant. All CMS must check the correct translation of the SmPC and labeling in their national language. The RMS refers an application to arbitration by the CHMP if needed. The RMS later handles all post-marketing issues, such as variations and renewals.

**The decentralized procedure**

The new Directive (2004/27) introduces a distinction between the MRP and the decentralized procedure. The decentralized procedure allows the
applicant to submit an identical dossier for a new application, before any marketing authorization has been granted, in selected MS, asking the RMS to prepare a draft assessment report, a draft SmPC, label and package leaflet and forward them to the CMS and applicant within 120 days after receipt of a valid application. Thereafter, the procedure will not be different from the MRP and should be completed within 90 days, totaling the 210 days as foreseen for all national applications.

The MRP can be used for both full-length and abridged applications. Variations to an authorization obtained through the MRP or the decentralized procedure follow the same regulatory pathway. The MRP cannot be used for products that have received a negative opinion or have been withdrawn from the CP (see below), except by submitting a completely new dossier.

Figure 34.3 provides a flowchart and timelines for the MRP (see also Vol. 2A of the Notice to applicants: Procedures for Marketing Authorisation...
To start an MRP, the applicant requests an assessment report of the dossier on which the MA has been granted, or the updating of an existing report from the licensing authority. Then the applicant requests the RMS to send the report to the CMS; the assessment report should be made available within 90 days. Possible changes and additions to the original dossier should be processed through the variation procedure. If a large volume of data is involved, a suitable timetable should be agreed with the competent authority of the RMS.

The applicant then submits the dossier to the CMS. The application must be accompanied by a declaration that all the dossiers filed as part of the procedure are identical, including the SmPC. The SmPC is the fundamental document on which mutual recognition is based. The applicant also informs the EMEA that MRP is started, but a full dossier is only sent to the EMEA in case of arbitration.

In all cases, the appropriate fees for the national applications must be paid and all necessary translations provided, at the time of the MRP submission. Chapter 7 of the Notice to Applicants provides, for each MS, the administrative details such as number of hard copies of the dossier, specified languages, samples of active substance and finished product, electronic formats and so on.

Each CMS submits the application to a check-in validation procedure, and the MRP starts when the dossier is found valid and the assessment report has been sent to CMS. The MA granted by the RMS should be recognized within 90 days.

By day 50 of the procedure, CMS must communicate any objections to the RMS and the sponsor. The sponsor is allowed to discuss his position verbally or in writing. Objections are only permitted for major concerns for public health (see European Commission, 2005), and arbitration to the community should be an exception to the general rule of mutual recognition. The MS who fail(s) to recognize the MA must provide an in-depth justification of its position, also indicating what could be done to correct the identified deficiencies. The sponsor is not allowed to present additional studies during the procedure; however, it is acceptable to present additional data from studies already included in the dossier.

If by day 90, disagreements have still not been resolved, the matter may be referred to the EMEA for arbitration.

The applicant is entitled to withdraw the application in any particular MS, and so avoid arbitration. It must be noted, though, that after withdrawal of the application from a CMS, no independent national application in that MS is permitted.

Whenever an arbitration procedure is initiated, the result is a decision by the European Commission, with the same pathway as for the CP (see below). The CHMP reaches its opinion, and if negative, the applicant has the opportunity to present an appeal, after which the Commission makes the final decision. The Commission’s decision is binding on the RMS and all the CMS involved, and must be implemented within 30 days of issuance. Beginning November 20, 2005, these Commission decisions are being made publicly available. Any CMS that had previously approved the RMS assessment report, the SmPC and the labeling can, at the request of the applicant, authorize the product within its territory without waiting for the outcome of the arbitration procedure. Nonetheless, if the arbitration procedure leads to a negative outcome, then this national approval must be revoked within the 30-day implementation period. MS should set off the MRP on receipt of a national application for a product that has already been approved in another MS (Article 18, Directive 2004/27). After the 90-day agreements CMS should grant the national registration within 30 days. Experience shows that there are often substantial delays.

The MRP has several advantages. The processing time for applications is relatively rapid, and there are several elements of flexibility for the applicant (choice of RMS and CMS, and provision of a draft report). The MRP also allows for approvals to include different trade names in different countries for the same product, unlike the CP (see below). Furthermore, the MRP can be activated repeatedly and incrementally, so as to gradually expand the product application into increasing numbers of MS. It should be noted, however, that MS can differ in their recognitions in classification for supply (prescription-only, over-the-counter, etc.).
**Coordination group**

An informally instituted coordination group recently replaced the formal Mutual Recognition Facilitation Group (MRFG) that had been active since 1995. The MRFG issued many guidances, SOPs, recommendations and position papers to help initiation and development of the MRP. The Coordination Group is composed of one representative per MS and is entitled to examine any question relating to MA of a medicinal product in two or more MS.

**Centralized procedure**

The CP provides for a single application to result in a single MA decision that applies to the whole EU. The CP concerns itself purely with the scientific and technical assessment of quality, safety and efficacy of the product. Pricing, classification for supply and marketing aspects (e.g. advertising) are left to the individual MS after CP approval. Thus, starting from an approved pan-European SmPC, for each MS, MA holders may select from the approved indications, pack sizes, PILs and so on that fit the national health system. The main objective of the CP is that of creating a harmonized European environment for innovative products, through a highly qualified single assessment made on a single dossier, resulting in the same recommendations for use of the product throughout the EU, and thus ensuring the same safeguard for all EU citizens.

The CP is *compulsory* for products, which are (Regulation 726/2004)

- manufactured using recombinant DNA technology;
- synthesized through controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes (including transformed mammalian cells);
- produced by hybridoma or other monoclonal antibody biosynthesis;
- veterinary products, intended primarily for use as performance enhancers in order to promote the growth of treated animals or to increase yields from treated animals;
- containing a new active substance(s) intended for the treatment of
  - AIDS
  - Cancer
  - Neurodegenerative disorder
  - Diabetes
  - Autoimmune diseases, other immune dysfunction and viral diseases (after 20 May 2008)
- orphan medicinal products (see below).

Any medicinal product not included in the above list *may*, but is not obligated to, use the CP if

- ‘the medicinal product contains a new active substance which, on the date of entry into force of the regulation, was not authorized in the community’ or
- ‘the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization in accordance with this regulation is in the interest of patients or animal health at community level.’

Abridged applications are possible for new applications regarding products that have previously been approved through the CP.

The CP is divided into the following phases:

1. Pre-submission
2. Submission and validation of the dossier
3. Scientific evaluation
4. Decision-making process
5. Post-authorization provisions
**Pre-submission activities**

Four to six months before a planned CP submission the applicant has to notify the EMEA of the intention to file an application and provide an estimate for the date of submission. The notification should include information on the product (a draft SmPC), the legal basis for the application (whether complete or abridged), proposal for classification for supply, justification for request of MA using the CP, information on manufacturing and batch release arrangements that may be linked to pre-authorization inspections, the proposed product trade name and a stated preference regarding Rapporteur and Co-rapporteur (see below).

Only one trade name can be proposed within the CP (unlike for the MRP, see above), although a second may exceptionally be permitted when there is good reason to show that a single name cannot be used throughout the EU. Trade name proposals can be submitted to the EMEA even 12 months before filing the application, in case of any doubt on this point, where they are evaluated by the Name Review Group (NRG), which will check with national authorities whether the name may be misleading for its therapeutic use or could otherwise generate confusion, create safety problems or offend against local antipromotional regulations.

The NRG ignores any aspect relating to intellectual property rights. CP applications without suitable trade names can be filed using a generic or chemical name, together with the name of the manufacturer.

Pre-submission meetings are held with the Agency, primarily to receive advice on preparing a submission in compliance with procedural, regulatory and legal requirements. These meetings are also an important opportunity to establish a good working relationship with the personnel who will handle the application and, in particular, the project manager who will coordinate all the review activities.

Next, three to four months before submission, the CHMP will appoint the Rapporteur and Co-rapporteur. These are the members of the CHMP who will be responsible for the scientific assessment of the dossier. The preference of the applicant, the specific expertise of CHMP members and the overall workload distribution among the CHMP members are taken into account for the appointment of the Rapporteurs. The sponsor cannot appeal these appointments.

**Submission and validation of the dossier**

The submission date should be agreed with the EMEA and planned in such a way as to match, following the predefined review schedule, with CHMP meetings. The applicant must submit one full copy of the dossier, two copies of Module I (including the draft SmPC). The proposed labeling must be submitted in each of the 22 official languages of the EU plus Norwegian and Icelandic. This information is also submitted in electronic format. For EMEA applications, the dossier is first validated, and then identical copies are sent to the Rapporteur and Co-rapporteur (see below). The Agency will not begin validating the application until receipt of its fees.

Applicants for a MA must have a legal representative resident within the EU. Furthermore, the application must identify persons with the following responsibilities (including relevant addresses and phone numbers):

- QP for pharmacovigilance
- A responsible person for scientific communications and in overall charge of the information on the product
- QP responsible for batch release and contact person for product defects and recalls

If the application is for a product containing or consisting of genetically modified organisms (GMOs), then it is also required to provide

- evidence that the relevant competent authorities approve of the use of the GMO for this research and development purpose and
- the complete technical dossier for the GMO itself (per Directive 2001/18) together with the environmental risk assessment.
The EMEA will validate the dossier within 10 working days. The project manager will consult with the Rapporteur or Co-rapporteur for the need for GMP and GCP inspections, necessity for an *ad hoc* expert group and so on. The applicant provides any additional information, on request, within a specified time limit. If the application is found valid, the applicant is notified in writing and a timetable for the evaluation is set. However, if the dossier is found severely deficient, the applicant will be requested to either collect it or indicate whether it should be destroyed by the EMEA. In the latter case, the EMEA will retain part of the fee (less for an abridged application) as an administrative charge, but otherwise return the application fee.

**Scientific evaluation**

The CHMP renders its scientific opinion with an overall deadline of 210 days. The Rapporteur and Co-rapporteur prepare draft assessment reports during the first 70 days, and send them to the CHMP, the EMEA secretariat and the applicant. After exchange of comments and opinions between the Rapporteurs and the CHMP, a collated list of questions is sent to the applicant by day 120. The review clock is stopped at this point, and restarts with the applicant’s response. If the applicant believes that more than six months are needed to answer the list of questions, then the application should be withdrawn.

On the day when written responses are received the review clock restarts with day 121. The Rapporteurs assess the responses, and submit their final assessment report by day 150. The final assessment is again sent to the CHMP, the EMEA and the applicant. CHMP members have until day 170 to file any comments. Outstanding issues are discussed at a CHMP meeting by day 180.

If any unresolved issues remain at this stage, then the CHMP or the applicant can request a meeting for oral explanation. The review clock is stopped (usually not for more than a month), so that the applicant can prepare for this meeting.

After the oral explanation the clock is restarted at day 181. The applicant sends the final draft SmPC, package leaflet and labeling (revised as needs may be) to the Rapporteurs, the CHMP and the EMEA. The CHMP adopts a final opinion, either positive or negative, by a single majority vote at a CHMP meeting on or before day 210.

In case of a positive opinion, between days 210 and 240, the applicant prepares the final SmPC and labeling in all the 22 required languages. Between days 240 and 300 the European Public Assessment Report (EPAR) is finalized in agreement with the applicant. The EPAR is published, after the Commission decision, on the EMEA web site.

A negative opinion may be subject to appeal. The EMEA informs the applicant of the reasons for an unfavorable conclusion and provides details on the divergent opinions of the CHMP members (if any). The applicant then has 15 days within which to notify an intent to appeal to the EMEA. The detailed grounds for the appeal must then be provided within 60 days, and the applicant may also request a meeting at the CHMP to provide justification for the appeal. The CHMP may or may not appoint new Rapporteurs, and within 60 days of the receipt of the grounds for appeal will consider whether the opinion can be revised. No meeting is granted within this 60-day time frame. During the appeals process, no new study can be presented, and a revised opinion may only be issued concerning the same data as originally presented.

**Decision-making procedure**

The European Commission (or when relevant the Council) converts the scientific opinion of the EMEA into a legally binding decision for the MS. In this last phase of the CP the Commission is assisted by its Standing Committee of Medicinal Products, whose members, appointed by MS, receive the documents. The draft decision must occur within 15 days of receipt of the EMEA opinion (Regulation 726/2004), and is forwarded to MS and the applicant. Verification of the draft decision must then be completed in 22 days.

A MS may still raise objections to the Commission’s draft decision, and ask for a meeting of the Standing Committee of Medicinal Products. If the objections identify important issues not addressed
in the EMEA opinion, then the decision-making procedure is suspended, and a new opinion is requested of the EMEA. A further Standing Committee review follows the EMEA reply. A favorable opinion of the Standing Committee is adopted as a decision within 15 days and is published in the Official Journal.

Very rarely, the Commission, being politically and legally responsible for the approval decision, may disagree with the scientific opinion adopted by the EMEA even after Standing Committee review. In this case, the decision is submitted to the Council. If within three months of submission the Council has not made a decision, then the Commission will adopt its own proposed decision.

**Post-authorization provisions**

**Application withdrawals:** Applicants withdrawing their dossiers do so at some cost. An explanation why the dossier is being withdrawn must be provided to the EMEA, and this information will be published. The EMEA will also publish assessment reports if prepared at this time.

**Expedited reviews:** The new Regulation foresees the possibility of an expedited procedure of only 150 days duration, for products of major interest for public health, which are addressing an unmet medical need. Also, a conditional approval may be granted, which would be reviewed yearly.

**Exclusivity:** All medicines approved through the CP will be granted an eight-year period of data protection and a ten-year period of marketing protection (see below). This period can be extended to 11 years if, during the first 10 years, a major new indication is developed.

Once a product has been approved through the CP, all further regulatory activities, such as license variations, labeling changes, new indications and so on must be CP submissions.

**Community referral**

The European pharmaceutical legislation includes mechanisms whereby a Community arbitration may be triggered on the basis of specific articles of Directive 2001/83, as amended. The arbitration ends up in a binding decision, issued after a scientific evaluation of the matter involved. The CHMP is responsible for the evaluation and will endorse the referral as admissible when the issue to be discussed can be framed in the relevant articles of Directive 2001/83 EC.

A referral may be started not only for a particular medicinal product but also for a specific class of products. Community referrals are contemplated in cases foreseen by the following articles of Directive 2001/83 EC:

**Article 29 – mutual recognition referral:** This applies whenever a concerned MS, during a MRP, considers that a product may present a risk to public health.

**Article 30 – divergent decisions referral:** This article applies whenever divergent national decisions are taken by MS concerning authorization, suspension or withdrawal of a medicinal product.

The procedure covers purely national MA or MA issued following a MRP in cases, for example, where

- indications significantly diverge in different MS;
- a product is suspended or withdrawn in one or more but not all concerned MS;
- a national authorization is varied, introducing a divergence versus other national authorities.

The referral may be started by any MS, the Commission or by the MAH.

**Article 31 – community interest referral:** This article applies to conditions where the interest of the Community are involved. This may especially refer to public health issues related to a product marketed in the EU, in the light of new data emerged on quality, safety, efficacy or pharmacovigilance.

The referral may be started by MS, the Commission or the applicant/MAH.

**Articles 35, 36, 37 – follow-up referrals:** These articles refer to arbitration mechanisms aimed at resolving divergences after harmonization has
been achieved on a particular product already submitted to a community procedure and a
MS considers that a change/variation, suspension
or withdrawal of a harmonized MA may become
necessary for protection of public health. Likewise,
by reference to article 5(11), 6(12), 6(13) of
Regulation 1084/2003, one or more MS may
not recognize a draft decision of the Reference
MS on a variation. In this case, therefore, the
CHMP will issue an opinion on the variation to
the terms of a MA, its suspension or withdrawal,
where such actions are justified by public health
issues.
These referrals may be started by the MS or the
MAH.

Procedure

To start a referral procedure different forms must
be used, according to the type of referral; such
forms are annexed to the Guideline included in the
Notice to Applicant Volume 2A – Procedures for
Marketing Authorization – Chapter 3 – Community

Before starting a referral procedure a notification
should be sent to the EMEA, stating

- the intention to submit a referral;

- information on the medicinal product con-
cerned;

- clear and concise formulation of the questions to
be discussed;

- proposal on the documentation to be provided;

- where appropriate, request for a meeting with the
EMEA to deal with issues linked to the referral.

The scientific opinion on the referral questions
will be provided by the CHMP and all the pertinent
documentation should be submitted by the MS or
applicant/MAH.

Where the referral follows the suspension or
withdrawal of a product from the market in a MS,
this MS should immediately inform the CHMP
members, the authorities of the other MS and the
EMEA of the action taken.

If the referral is started by an applicant/MAH,
the documentation submitted should include the
expert reports updated with the data supporting
the reasons for referral.

Timeframe for the referral

The CHMP issues a reasoned opinion within
90 days of the referral. This period may be
extended to 180 days in case of articles 30, 31, 36
and 37 referrals. The timetable is described in
detail in Volume 2A of the above guideline.

The clock of the procedure may be stopped to
allow the applicant to prepare explanations, to be
submitted or discussed in a hearing.

The opinion of the CHMP may be subject to
appeal; the intention to appeal should be notified
to the EMEA within 15 days after the opinion has
been issued, and within 60 days the detailed
grounds for appeal must be forwarded to the
EMEA. A final opinion will be adopted by the
CHMP within the following 60 days, together
with an assessment report, stating the reasons for
the conclusions reached. In the event of an opinion
in favor of granting or maintaining a MA the op-
inion will include a draft SmPC, the proposed label-
ing and any condition deemed to be relevant for the
safe and effective use of the product. This opinion
will be sent within 15 days to MS, Commission and
the applicant/MAH.

The subsequent Commission’s decision-making
procedure is essentially the same as for the CP. But
the decision is not only addressed to the applicant
but also to the MS concerned in the referral, who
are required to take actions, such as grant, suspend
or withdraw a MA, as established in the decision
within 30 days following its notification. The MS
are also required to inform the Commission and the
CHMP of the measures taken.

Consequences of the decision

The decision following a referral is only applicable
to the products and MS involved in the procedure.
In case that an article 29 referral (mutual recognition referral) relates to a product with MA in MS other than those involved in the procedure, a new article 30 referral can be triggered for those MA to pursue harmonization of the SmPC. This is also applicable to cases where a MA is pending for the product submitted to referral: the MS are obliged to grant or reject the MA in conformity with the community decision. Subsequent applications for the same medicinal product must follow the community decision and use the harmonized SmPC.

**Stopping of the referrals**

In case of article 29 referral (a mutual recognition referral), an application may be withdrawn by the applicant at any time in any MS where it has been submitted. This action may avoid the referral. However, if an issue of community interest is identified, MS or the Commission may then start an article 31 referral.

For referrals relating to articles 30, 31 and for follow-up referrals, the procedure can only be stopped if the applicant/MAH withdraws the concerned product from all the EU markets. In such case the CHMP may decide to close the referral procedure, or to proceed in spite of the withdrawal, where public health issues are considered to need continuing discussion.

**Unilateral actions by MS in urgent cases**

MS may take unilateral urgency measures, such as suspending the marketing and use of a medicinal product, whenever such action is deemed necessary to protect public health, and until a final decision is adopted. EMEA must be informed on the following working day, and the matter is discussed in the following CHMP meeting. A referral procedure, where appropriate, may be triggered by either a MS or the Commission.

Overall, these procedures have not been extensively used. As to article 29 referral, applicants have preferred, in most cases, to withdraw the application in the countries unwilling to accept the mutual recognition, rather than go through the CHMP arbitration and face possibly unfavorable consequences.

However, it should be remembered that such procedures have to be regarded in the perspective of the general scope of achieving the highest possible degree of harmonization within the community.

### 34.9 Orphan medicinal products

Orphan medicinal products are defined as those diagnosing, treating or preventing life threatening or very serious conditions that affect no more than 5 per 10,000 persons in the EU.

Regulation EC 141/2000 established the COMP formed by one representative from each MS, three from various patients groups and three from EMEA to liaise with CHMP. The role of COMP is to:

- help sponsors to prepare orphan designation applications through free pre-submission meetings;
- provide scientific advice on the development of the product after orphan designation has been granted;
- examine applications for designation of orphan drug status and
- assist the European Commission on development of orphan drug policies.

The incentives for orphan products are: market exclusivity for 10 years after the marketing authorization even if a previously authorized product is now developed for a new orphan indication; PA (scientific advice on development and dossier preparation); access to the centralized registration procedure; fee reduction for all types of regulatory activities (applications review, inspections, variations, scientific advice, etc.) and provide a limited amount of EU-funded research grants for orphan products.

Orphan designation can be applied for at any stage of the development with appropriate scientific justification. The designation of an orphan product is preliminary to application for a MA and
entitles the sponsor to the above listed incentives for development of the drug.

Sponsors need to notify the EMEA of the intent to file an application for orphan designation. A pre-submission meeting with COMP will be arranged, if viewed as desirable. The submission is usually validated within 10 days of receipt, and then COMP will assess the submission within a further 60–90 days. When the COMP has adopted an opinion, it is sent to the European Commission, whose binding decision is issued within a further 30 days. Orphan drug designations are published in the Official Register on the EMEA web site, after applicants have had the opportunity to review a draft and redact proprietary information.

34.10 Generic medicinal products

Directive 2004/27 provides the following definition of generic medicinal product (Article 10, 2. (b)): ‘generic medicinal product shall mean a medicinal product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference pharmaceutical product, and whose bioequivalence with the reference medicinal product has been demonstrated’. As a result of various recent treaties, Europe, like the rest of the world, recognizes patent protection on all new inventions for 20 years after the patent application is filed. However, in the special case of medicinal products, where the long development cycle allows a product into the market only late in the life of the patent, a supplementary patent protection for a maximum of five years can be applied for, under certain circumstances. Although detailed discussion of European patent law is outside the scope of this chapter, we shall adopt a general definition for a ‘generic drug’ as one that is approved as a bioequivalent product after the innovator’s patent has expired.

Nomenclature

Dossiers for generic products must be as complete for all quality and manufacturing aspects as any innovator product. However, a generic drug dossier can merely reference an innovator’s dossier for data concerning product safety and efficacy. For this reason the application for a generic product is also known as an ‘abridged’ application.

The innovator’s product is termed a ‘reference medicinal product’ for the same reason. This is a product that has a legally valid MA in a (some) MS, which was granted on the basis of a full-length dossier.

Application to market a generic medicinal product can be made in one MS even when the reference product is only authorized in a different MS. In this case, the MS in which the reference product is marketed can be asked to transfer a copy of all the relevant documents by the MS holding the generic application. There is a one-month deadline for this.

Quite apart from patent protections, innovator products are granted eight years of data protection and ten years of market exclusivity (see above), plus a further year of market exclusivity if a major new indication is registered. This means that a generic medicinal product can be placed on the market only 10 (or 11) years after the original authorization, although experimental activities to prepare the dossier, in particular to conduct bioequivalence studies, can start two or three years earlier.

Following the CTD format, a generic application must contain Module I (administrative information), Module II (overviews and summaries) and Module III (quality). Bioequivalence data, as they refer to clinical experimentation, are submitted in a separate binder, following the numbering system of Module V (Section 5.3.1.2).

Drug substance

Different salts, esters, ethers, and derivatives of the same active moiety from acceptable generic products, are permitted provided that they have the same characteristics of safety and efficacy. Proof of absence of significant differences must be supplied by the applicant through appropriate studies, the extent and content of which has to be decided on a case-by-case basis.

The use of different synthetic pathways by different manufacturers may also be acceptable. It is
the generic applicant’s responsibility to define the impurity profile (if any), provide impurity levels, their characterization and biological qualification according to current guidelines. However, the presence of a toxic impurity, or an impurity endowed with a particular biological activity, and which is not present in the reference product, will make the latter’s dossier an inappropriate reference. Toxicity of impurities should be discussed in the nonclinical overview, with cross-references to the quality overview.

Whenever an active substance is the subject of a pharmacopoeia monograph, suitability of the monograph for the substance must be controlled. On request of the active substance manufacturer the European Pharmacopoeia issues Certificates of Suitability (CEP), which replace the information of the corresponding sections and allow reference to the pharmacopoeia monograph. Any technical characteristics not covered by the certificates must be supplied as additional information.

**Drug product**

A generic product should comply with the following characteristics:

- Same qualitative–quantitative composition of the active ingredient as the reference product.
- Known excipients of established use.
- Same pharmaceutical form. Oral solid pharmaceutical forms of immediate release, such as tablets and capsules, are regarded as the same dosage form.
- Bioequivalence with the reference product.

The note for guidance CPMP/EWP/QWP/1041/98 on investigation of bioavailability and bioequivalence sets the criteria for showing pharmacokinetic equivalence and thus permits waiver of extensive clinical trials for demonstration of efficacy.

Two products are considered bioequivalent when the drug substance, in the same molar concentration, is absorbed at the same rate and extent. Authorization of a generic product is essentially based on demonstration of identical bioavailability that is defined as the rate and extent at which an active ingredient is absorbed and becomes available at the site of action.

In the great majority of cases, medicines are intended for a systemic therapeutic activity. Therefore, being difficult or impossible to measure the quantity of active substance at the site of action, it is accepted that equivalence of levels in the systemic circulation, or other biological fluids, are accepted as surrogates of therapeutic equivalence.

For the typical generic application, a bioequivalence study against a reference product in a crossover, single and/or multiple dose design in healthy volunteers (or patients wherever appropriate) is used to demonstrate bioequivalence. The CPMP ‘Note for Guidance on Investigation of Bioavailability and Bioequivalence’ provides details on design and conduct of studies, statistical and analytical aspects, selection of subjects and conditions for study standardization. The number of subjects to be included depends on many factors, such as the variability of the primary characteristic to be assessed, the predetermined significance level and the required power. In any case, not less than 12 subjects should be used. Clinical therapeutic bioequivalence must always be documented for oral modified release and transdermal dosage forms.

Rarely, waivers from human bioequivalence can be granted, although these are only under the most straightforward situations imaginable. The commonest case is that of a generic, intravenous (IV), aqueous solution containing the same active drug at the same concentration. The same concept can be extended to intramuscular (IM) and subcutaneous injectables, when the test and reference products consist of the same type of solution with the same or comparable excipients. This does not extend to topical products, however, when a bioequivalence study must always be carried out if a systemic action is expected.

Different problems are encountered for approval of ‘copies’ of biotechnologically derived products. The issue is of practical relevance as the patent of many biological products has or is going to expire. Biotechnology derived products may represent a
scientific and regulatory challenge, insofar as the synthetic process takes place inside a living organism. The synthetic process cannot be controlled directly and this fact alone introduces a series of aspects linked to factors, which are certainly more difficult to control and standardize. Years ago the regulatory thinking for biotech products was based on the paradigm ‘the process defines the product’, implying that changes in manufacture could result in changes in the product difficult or impossible to detect, with the risk of nontherapeutic biological responses. This excluded, in practice, the possibility of generic applications for biotech products.

Now, there has been a substantial change in attitude toward biotech products: technological improvement and higher sophistication of analytical methodology make it possible to design integrated control strategies allowing physicochemical characterization to begin to shift the focus from the process to the product.

In any case, Article 10 of Directive 2004/27 introduces the concept of ‘similar products’ as follows:

‘Where a biological medicinal product, which is similar to a reference biological product, does not meet the conditions in the definition of generic medicinal product, owing to, in particular, differences relating to raw materials or differences in manufacturing process of the biological medicinal product and the reference biological medicinal product, the results of appropriate preclinical tests or clinical trials relating to these conditions must be provided. The type and quantity of supplementary data to be provided must comply with the relevant criteria stated in Annex 1 and the related detailed guidelines. The results of other tests and trials from the reference medicinal product’s dossier shall not be provided’.

Note that the Directive makes two important points: (a) similar biological products are legally admitted and (b) at least partial reference to the originator dossier is acceptable, making it possible to prepare a dossier based on ‘bridging studies’, to be decided on a case-by-case basis. A corresponding Guidance has also been published (EMEA/CPMP/BWP/3207/00/Rev.1, EMEA/CPMP/3097/02/final).

When considering how extensive the comparative studies must be, the following factors are relevant:

- Stage where the manufacturing change is introduced
- Potential impact of the change on product characterization
- Suitability of analytical techniques to detect potential modifications
- Relationship between established quality criteria with safety and efficacy results based on the overall preclinical and clinical experience

Where similarity to an already authorized product is claimed, the nonclinical and clinical data to be submitted will probably be decided on the basis of the following considerations:

- The extent to which the product may be characterized
- The nature of the changes in the new product compared to the reference product
- The observed/potential differences between the two products
- The clinical experience with the particular class of products

One critical issue may be that of immunogenicity. This must always be investigated, and a plan for a post-marketing monitoring must be included in any ‘generic biological product’ application.

34.11 Herbal medicinal products

Herbal medicinal products represent a large market in the EU, although unevenly distributed across MS. Although there is a separate chapter on complementary medicines in this book, we must here consider the special regulatory approach that is taken toward these distinctive products within the
The following definitions are from the Guidance CPMP/QWP/2820/00:

1. **Herbal medicinal products** are medicinal products containing exclusively herbal drugs or herbal drug preparations as active substances.

2. **Herbal drugs** are mainly whole, fragmented or cut plants, part of plants, algae, fungi and lichen in an unprocessed state, usually in dried form but sometime fresh. Certain exudates that have not been subjected to a specific treatment are also considered as herbal drugs. Herbal drugs are precisely defined by the botanical scientific name according to the binomial system (genus, species, variety and author).

3. **Herbal drug preparations** are obtained by subjecting herbal drugs to treatments such as extraction, distillation, expression, fractionation, purification, concentration or fermentation. These include comminuted or powdered herbal drugs, tinctures, extracts, essential oils, expressed juices and processed exudates.

Differences in criteria and methods of assessment of the characteristics and properties of herbal products may represent a risk for consumers and an obstacle to their free circulation within the Community. Therefore, in 1997, an ‘ad hoc working group’ was established at the EMEA, which was tasked with addressing the problems of demonstration of quality, safety and efficacy. Subsequently the group became a permanent Working Party of the CPMP and developed a set of guidelines on the requirements and assessment of herbal medicines.

The revised legislation (Regulation 726/2004) established a new committee within the structure of the EMEA named the Committee on Herbal Medicinal Products (HCMP). This committee has the task to provide ‘the MS and the institutions of the Community with the best possible scientific advice on any question relating to the evaluation of the quality, safety and efficacy of medicinal products’, as well as advising interested parties on the conduct of the various tests and trials necessary to demonstrate quality, safety and efficacy.

The complex composition of herbal medicines makes quality a fundamental and critical aspect, that have been dealt with in two guidelines:

1. **Note for Guidance on Quality of Herbal Medicinal Products** – CPMP/QWP/2819/00.


The first guideline addresses special quality issues of herbal products because of the difference to products containing chemically pure, well-defined active substances. This document should be read in conjunction with Annex 7 ‘Manufacture of Herbal Medicinal Products’ of Volume 4 of the Rules governing Medicinal Products in the EU. GMP recommendations should be respected and consistent quality can only be assured when

- starting materials are defined in a rigorous and detailed manner, including the specific botanical identification, geographical origin and the conditions under which the herbal drug is obtained and

- the manufacturing process of the finished product, starting from a herbal drug or a herbal drug preparation is described in a detailed manner, including in-process controls with details of test procedures and limits, as defined in the ‘Note for Guidance on Manufacture of the Finished Dosage Form’ (Vol. 3 of the Rules governing Medicinal Products in the EU).

The second guideline provides the general principles for setting specifications for herbal drug preparations, as required to build up an application for a MA of a herbal medicinal product. The document, therefore, defines the criteria to be followed and reports a list of physicochemical and biological tests relevant for an overall quality control strategy and consistency of quality and characteristics of herbal drugs, herbal drug preparations and herbal medicinal products.
Traditional herbal medicinal products

A MA for a herbal medicinal product may be submitted, as for any medicinal product, through a full application with new tests and trials, whenever the application refers to a new product or a therapeutic innovation. Alternatively, for a well-established drug (defined in Directive 99/83) a bibliographic application may be submitted, when safety and efficacy for a given indication, dose and patient population are satisfactorily described in the published literature.

There is, however, a large number of herbal products that, in spite of having been used for a long time, are not supportable by data that qualify for well-established use with recognized efficacy and acceptable safety. The political decision was made that, within limits, the public interest in keeping these products in the market could outweigh imposing a burden of clinical experimentation, while also eliminating differences in requirements and regulations in different MS that could cause distortions in commerce. Thus, recently, Directive 2004/24 was issued, which amends Directive 2001/83 and the Community Code relating to medicinal products for human use. This new Directive creates a category of ‘Traditional Herbal Medicinal Products’ as well as provides for a simplified procedure for their MA. Even when the definition of herbal medicinal product, herbal drug and herbal preparation are actually the same as those mentioned above, the Directive also allows the presence of vitamins and minerals, if of well-documented safety, in the composition of herbal products, provided that their action is ancillary with respect to the herbal ingredient.

A ‘traditional herbal medicinal product’ should comply with the following characteristics:

- indication does not require the supervision by a medical practitioner for diagnostic purposes or for prescription or monitoring of treatment;
- administration according to a specified strength and posology;
- administration exclusively by oral, external and/or inhalatory route;
- bibliographical or expert evidence to the effect that the product itself, or a corresponding product, has been in medicinal use throughout a period of at least 30 years preceding the date of the application, including at least 15 years within the Community;
- data on the traditional use sufficient to prove that the product is not harmful in the specified conditions of use and the pharmacological effects or efficacy are plausible on the basis of long-standing use and experience.

The simplified procedure for registration of traditional herbal medicinal products includes full administrative information and a complete pharmaceutical dossier on the assumption that the quality of the product is independent of its traditional use. Nonclinical data are not necessary where information on the traditional use proves that the product is not harmful in the specified conditions of use. However, where concerns are raised with regard to the product’s safety, the competent authorities may ask for additional data necessary to assess safety. The dossier will, therefore, include a bibliographic review of safety data, and additional data where required, together with an expert report.

No clinical data are required provided that efficacy is at least plausible on the basis of long-standing use and experience. The dossier will also include information on any authorization obtained in another MS or in a third country, and details of any decision to refuse to grant an authorization.

The labeling must state that the product is a traditional medicinal product for use in specified indications exclusively based upon long-standing use. The same statement must also accompany any advertisement. Furthermore, the labeling must indicate that the user should consult a doctor if symptoms persist or if adverse effects not mentioned in the labeling occur.

The Committee for Herbal Medicinal Products (HCMP) has been given the task of preparing a list of herbal substances, herbal preparations and combinations thereof to be used in traditional herbal medicinal products. The list will contain for each substance the indication, strength, posology, route
of administration and any information necessary for the safe use of the traditional herbal medicinal product. Where an application will refer to a product included in that list, it will not be necessary to provide proof of long-term use, or evaluation of safety data.

The new Directive became effective on March 31, 2004 and implementation was mandatory in MS by October 30, 2005. For traditional herbal medicinal products already in the market, these new provisions become effective by March 31, 2011, thus providing a seven-year transitional period for manufacturers to comply with the minimal regulatory requirements of the Directive.

### 34.12 Labeling

**Summary of product characteristics**

The SmPC is amongst the most crucial documents in the marketing authorization application, as it forms the basis of the MA and consequently is the basis for the labeling of the product. Any statement in the SmPC must be supported by experimental data in the dossier. It is defined during the development of the drug and finalized through a scientific discussion with the RA, and therefore constitutes a reference that cannot be changed, unless new experimental data are made available, approved and authorized. The SmPC represents the basic element of communication for the company; in fact any information on the drug, including labeling and advertising, is bound to this document that also plays a fundamental role in the MRP.

Directive 2001/83/EC as amended by Directive 2004/27, specifies the required information for the SmPC and the PIL.

In the guideline on SmPC the exact layout and the contents are defined. Additional guidelines issued by central bodies as well as national regulatory authorities provide recommended wording for specific text in various different classes of medical products in the jurisdiction of the RA (e.g. the MHRA document ‘generic’ overdose sections for selected SmPCs, Feb 2004).

Separate SmPCs for each pharmaceutical form and strength of a medicinal product are required. Reasonable merging of multiple SmPCs into one for advertising of a single product is permitted.

The headings in the SmPC are as follows:

1. Name of the medicinal product (Trade) name of product, strength and pharmaceutical form
2. Qualitative and quantitative composition for the active substances
3. Pharmaceutical form (standard terminology per the European Pharmacopoeia and Section 1 of the SmPC)
4. Clinical particulars

#### 4.1 Therapeutic indications

4.2 Posology and method of administration, including advice on pediatric experience, or lack thereof with reference to section 5.3; dose adjustments (e.g. in renal insufficiency)

4.3 Contraindications (pregnancy only to be mentioned if actually contraindicated)

4.4 Special warnings and precautions for use (in the order: relative contraindications, warnings and precautions) including special populations at risk. Warnings about excipients and hypersensitivity are mandatory in this section. However, interactions, pregnancy, lactation and ability to operate machines do not belong in this section

4.5 Interaction with other medicinal products and other forms of interactions, with recommendations for contraindication of concomitant use, mechanism of interaction (if known)

4.6 Pregnancy and lactation. It must be made clear what extent of experience in pregnancy or lactation, or the lack of experience, exists. Relevant preclinical details should be given in Section 5.3. Further recommendations about women of childbearing potential and lactation

4.7 Effects on ability to drive and use machines
4.8 Undesirable effects. The precise wording prescribed for expression of frequencies of adverse effects is given in the guideline

4.9 Overdose

5. Pharmacological properties

5.1 Pharmacodynamic properties

5.2 Pharmacokinetic properties

5.3 Preclinical safety data

6. Pharmaceutical particulars

6.1 List of excipients

6.2 Incompatibilities

6.3 Shelf-life – as packaged for sale, after reconstitution (if applicable), after first opening of packaging container

6.4 Special precautions for storage

6.5 Nature and contents of container

6.6 Instructions for use and handling, and disposal

7. Marketing authorization holder

8. Marketing authorization number(s)

9. Date of first authorization/renewal of authorization

10. Date of revision of the text

Products authorized through the CP carry a ‘blue box’ on the package label, containing information specific to the MS in which the product is marketed. This is the only part of the label that can vary for those products, and is the result of retained national authority for decisions on package size, pricing and classification of centralized authorized products.

**Package labeling and patient information leaflet**

The PIL and the label of the drug container itself are as precisely regulated as the SmPC. Changes in any of these documents have to be approved by the RA (see license variations below).

Directive 2001/83, the Community Code sets the standard for labeling and PIL.

IMP labeling is regulated by the GMP guidelines. These labels should include:

- name of the sponsor;
- pharmaceutical dosage form, route of administration, quantity of dosage units (and name/identifier of the product and strength/potency in case of an open trial);
- the batch and/or code number to identify the contents and packaging operation;
- the trial subject identification number, where applicable;
- directions for use;
- ‘for clinical trial use only’;
- the name of the investigator (if not included as a code in the trial reference code);
- a trial reference code allowing identification of the trial site and investigator;
- the storage conditions;
- the period of use (use by date, expiry date or retest date as applicable) in month/year;
- ‘keep out of reach of children’, except when the product is for use only in hospital.

If the outer packaging of the IMP contains all of the above listed items, the immediate packaging needs to carry only the first five items; there are further specifications on the labeling of various immediate
packages (addressing blister packs, ampoules, etc.).

**34.13 Marketing authorization variations, renewals and reclassification**

**License variations**

Most of the work of the national regulatory authorities concern license variations, line extensions and license renewals. The application will follow the same approval procedure in which the original authorization was obtained. As many products currently licensed have been licensed through national procedures, before the mutual recognition or CP were available, many of the applications are still undergoing the national approval process in each MS separately.

Since October 1, 2003, the European variations regulations came into force, which introduced a newly revised Annex I to Directive 2001/83. The relevant Commission regulations 1084/2003/EC and 1085/2003/EC concern mutual recognition and CPs, respectively. The MRFG has issued a Best Practice Guide, which implements the directive and gives guidance to MA holders on how to apply for the variations under national or MRP. Guidance on variations in the CP can be found in the CPMP document on post-authorization guidance (human medicinal products), February 2004.

License variations are divided into three main categories termed ‘Type I variation’, ‘Type II variation’ and ‘extensions’. The main changes introduced by the new legislation are:

- a new category of minor variation (Type IA notification) with a 14-day timeline and requiring only scientific validation;
- the former revised Type I minor variation categories are now classed as Type IB notifications, and have a 30-day review timeline;
- RMS act on behalf of all CMS for products approved by the MRPs for Type I minor variations;
- flexibility of timelines for Type II variations (extension for new indications and reduction for safety variations);
- introduction of a process of appeal by MA holders when Type IB and Type II variations are rejected;
- streamlined decision making for centralized notifications;
- new Annex II of the variations regulations and definition of extension applications.

Frequently, MA holders find it difficult to classify the requested labeling change into Type IA, IB and so on. The ‘Notice to applicants of the EU Commission – Guideline on the categorisation of new applications versus variations applications, Jan 2002’ aims to clarify these issues, and it has now been supplemented (July 2003) by the ‘Guidance on dossier requirements for Type IA and IB notifications’ which lists all foreseen variations, their classification and the documentation required. Revisions of the former are expected in late 2005.

In general, Type IA and IB variations are, for example, changes of administrative nature like the address of the MA holder; changes in batch sizes within limits; minor changes in test procedures. These contrast with ‘Extension’ applications, which are necessary when the following has occurred:

- changes to the active substance(s);
- changes to the indications;
- changes to strength, pharmaceutical form and route of administration;
- changes specific to veterinary medicinal products.

Any of these changes have to undergo a full scientific evaluation as for any new marketing application. An exception to this rule is the annual human influenza vaccine, which, although a change to the
active substance, can be applied for as a Type II variation.

In the United Kingdom, variation applications are sent to the MHRA Variation Processing Division. The application and supporting data should be submitted in a clearly laid out dossier applying the headings and numbering of the CTD format. There is a reduction in fees for bulk applications, incorporating multiple changes (fees are published on the RA’s web site).

The application documents for any variation are:

- Cover letter – which clearly states the product license numbers involved, the reason for the change, for example if it has been requested or is as a result of harmonization and whether the application is national or a mutual recognition variation.

- The list of dispatch dates – for mutual recognition applications where the United Kingdom is the RMS.

- Confirmation that the appropriate fee has been paid.

- A table of contents.

- The variation application form dated and signed by the official contact person. All changes proposed should be clearly explained in the scope of the variation.

- Supporting data relating to the proposed variation.

- Update or Addendum to quality summaries, non-clinical overviews and clinical overviews (the former ‘expert reports’) as may be relevant. When nonclinical or clinical study reports are submitted, their relevant summaries should also be included in Module II.

- In cases where the changes affect the SmPC, labeling and/or PIL the revised product information must be submitted. Mock-ups are required of proposed labels and PILs, and both annotated, old as well as the proposed, final versions of the labeling are required.

‘Complex’ Type II variations require a higher fee, as the review involved is more extensive; the timeline is also longer. The following changes are usually regarded as ‘complex’:

- new or amended indication(s);
- reformulation of the product introducing a novel excipient that has previously not been included in medicinal products;
- a new route of synthesis that has not previously been assessed and a Ph Eur Certificate of Suitability is not available*;
- new method of sterilization of a product*;
- new container materials for a sterile product*;
- new active ingredient manufacturer, not previously approved to manufacture the active ingredient concerned, and who does not hold a Ph Eur Certificate of Suitability for the substance concerned;
- for flu vaccine – new manufacturer or process;
- reformulation of a product that is supported by bioavailability studies;
- change in the product’s preservative system;
- change in excipients which significantly affect the pharmaceutical or therapeutic properties.

If a company submits a variation application that needs to be newly assessed because it is supported by the results of clinical trials or other data (including pharmacological and toxicological tests as well as extensive evidence from post-marketing experience or publications), the RA will classify it as a Type II complex variation. The calculation of fees is complicated.

*Specific to the active ingredient
License renewals

MAs are granted for five years in the first instance, after which a renewal is necessary. This requires submission of a review of all the product experience since the drug was first marketed. Essential parts of this review are the periodic safety update reports (PSURs), required every six months during the first two years of marketing, and annually thereafter. Normally, after the five-year renewal, further PSURs are required every five years. Under special circumstances more frequent PSURs may be required for products, which the authorities wish to keep under closer review. There is never any relaxation of the requirement for expedited reporting of serious, unexpected AEs.

For most products, the revised regulation foresees only one renewal based on a reevaluation of the risk–benefit balance, after which the validity of the MA is unlimited. However, at its discretion, national regulatory authorities can still require subsequent five-year renewals (article 24 of Directive 2004/27 and article 14 of Regulation 726/2004).

Reclassification

Reclassification (e.g. an ‘over-the-counter switch’) remains the responsibility of each national RA. The EU guideline on changing legal classification for the supply of medicinal products (The rules governing medicinal products in the European Community – Vol. IIIb) sets out the standards that must be fulfilled in order to change the legal classification of a medicinal product.

New products, when first licensed, are usually approved as ‘prescription only medicine’ (POM). With increasing experience in the use of the medicine, it might seem likely that a medication is safe for use with pharmacy supervision only; then, the NCA may remove the prescription requirements and allow sale or supply from a pharmacy without prescription, that is the medicinal product is reclassified as Pharmacy (P). If further experience shows that access to professional advice is not required for safe use of the medicine, it may finally be reclassified as general sales list (GSL) to allow sale from a wider range of retail outlets on an over-the-counter basis.

In the United Kingdom, the post-licensing division of the MHRA deals with all reclassification requests. By law, all medicines are P unless they meet the criteria for POM or GSL. Pack size restrictions for GSL products are listed in the Medicines (Sale or Supply) (Miscellaneous provisions) Regulations 1980. For all licensed medicines, legal status is ultimately determined by the MA.

Directive 2001/83 provides that prescription control is applied to any product which:

- is likely to present a direct or indirect danger to human health, even when used correctly, if used without the supervision of a doctor or dentist; or
- is frequently and to a very wide extent used incorrectly, and as a result is likely to present a direct or indirect danger to human health; or
- contains substances or presentations of substances of which the activity requires, or the side effects require, further investigation; or
- is normally prescribed by a doctor or dentist for parenteral administration.

Exemptions from prescription control may be made with regard to

- the maximum single dose;
- the maximum daily dose;
- the strength of the product;
- its pharmaceutical form;
- its packaging or
- other circumstances relating to its use that would be specified when reclassification is determined.

After the national RA has received and validated an application, it classifies the application into one of three types: standard, complex or ‘me-too’ applications not supported by full data.
Complex applications require initial committee referral. Therefore, the procedure takes 180 days; a full fee is charged for review.

Standard applications are generally reviewed within 120 days, and only if issues arise that require referral to a full committee review will this timeline be lengthened; the applicant may also be approached to clarify details of the application. An initial full fee has to be paid by the applicant; if the procedure passes without referral to the full committee, the RA will refund half of the fee to the applicant.

A ‘me-too’ application, for a product, which has analogous products with the classification applied for already in the market, is handled as standard Type II variation, and the corresponding fee is charged.

After an application has been filed, it is published for consultation with interested parties for a 4–6-week period – immediately in case of a standard application (based on the reclassification summary), or after the committee’s advice for reclassification, in case of a complex procedure. The consultation period is not included in the timelines for approval.

The documentation necessary for a valid reclassification application is listed below:

- Reclassification application form
- Reclassification summary – a comprehensive summary in a set format, which will form part of the information provided for the public consultation (two pages A4)
- Safety and efficacy summary – supporting safety and where necessary efficacy data
- Patient information – full details of leaflets and labels and an indication of the advertising plans
- Training and education – a summary of what provision has been made for appropriate education and training
- Clinical expert report – a critical evaluation of the proposed pharmacy product demonstrating that none of the prescription criteria (see above) apply

Crucial issues that must be addressed in the expert report of the application are the ease of self-diagnosis of the target disease, whether the substance is a narcotic or a psychotropic substance, if there is a risk of abuse leading to addiction and whether the substance has a potential for misuse for illegal purposes.

If the maximum dose is restricted when the medicine is supplied P or GSL to protect against adverse effects from correct or incorrect use of the medication, it is important to prove that the restricted dose is still as effective and keeps the same benefit–risk relationship, as the original full dose.

GSL can be considered for those medicines which can, with reasonable safety, be sold or supplied without the supervision of a pharmacist. The following classes of products are excluded from GSL:

- Anthelmintics
- Parenterals
- Eye drops
- Eye ointments
- Enemas
- Irrigations used wholly or mainly for wounds, bladder, vagina or rectum
- Aspirin or aloxiprin for administration wholly or mainly to children

**Product recall**

The GMP Directive requires each manufacturer to have a system for complaints and product recall readily in place. Section 8 of the Directive requires review of any complaint about potentially defective products following a written procedure and if necessary the effective and prompt recall of defective products from the market. It is a requirement to inform the QP and the quality control department during the review and analysis of all
product complaints which need to be thoroughly investigated.

In order to allow effective tracking of products, record keeping of product distribution is necessary. Sufficient information on wholesalers and/or directly supplied customers with precise batch numbers and quantities supplied together with contact numbers and addresses must be available and up to date. The process of the recall must be recorded including reconciliation between delivered and returned quantities of the products.

A designated person in the company needs to be responsible for execution and coordination of product recalls. This person should be independent from the sales and marketing personnel. The QP of the company must be made aware of the product recall. Furthermore, it is required to inform the regulatory authorities of any recall action.

**34.14 Safety reporting and pharmacovigilance**

The assessment of safety in the use of medicinal products starts before the first administration to humans and continues throughout the development of the medicine to the MA for the lifetime of the drug. It is governed by a set of comprehensive rules, which are published in Volume 9 of the rules governing the use of medicinal products in the EU, notice to applicants (see boxed item above). These rules have seen several major updates in the time since the first publication in 1986, and a comprehensive review is currently ongoing. The nonclinical aspects of product safety are discussed elsewhere in this book.

Directive 2001/20 had a major impact on pharmacovigilance in Europe because it demanded the creation of a pan-European safety database for all medicinal products in the market and extending to IMPs. The system was named EudraVigilance. The EuDRACT system (clinical trials registration, see above) was created as part of it. The detailed guidance about reporting of adverse reactions to IMPs, whether licensed or not, was issued in April 2004.

**Safety monitoring in clinical trials**

The sponsor of an IMP or the MA holder in the case of a clinical trial using a licensed medicine is responsible for the ongoing safety assessment, compliance with reporting timelines and distribution of reports to all concerned parties. Furthermore, the sponsor of a trial now also has the responsibility to report serious adverse drug reactions occurring in the use of active comparator products, even if the sponsor of the trial is not its MA holder. The guidelines recommend that the sponsor also inform the MA holder about the reported case.

An AE is defined as: any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.

A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose:

- results in death;
- is life threatening;
- requires inpatient hospitalization or prolongation of existing hospitalization;
- results in persistent or significant disability/incapacity;
- is a congenital anomaly/birth defect;
- is an important medical event that may require intervention to prevent the above five conditions or may expose the subject to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.

*The term ‘life threatening’ refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.*
In clinical trials of IMPs without a MA, sponsors must report all serious unexpected suspected adverse drug reactions (SUSARs) within eight calendar days if they were fatal or life threatening, and within fifteen days for other serious cases. The initial report has to be followed up within seven days for fatal or life-threatening cases and within fifteen days for other serious reports. These expedited reporting requirements mean that the treatment code in blinded trials must be broken, as it is otherwise impossible to decide which treatment the patient received and, therefore, impossible to determine whether an event could possibly be a reaction: if a patient received placebo, then there is no suspicion of a possible adverse reaction to the IMP and authorities do not require expedited reporting (unless the AE could have been a reaction related to an excipient present also in the placebo).

‘Expected’ adverse drug reactions in clinical trials – even if serious – are not reported in an expedited fashion. An ‘Expected’ adverse drug reaction is one that is mentioned in the SmPC (in the case of a licensed product) or in the investigator’s brochure in the case of an IMP. It is important to understand that expectedness is solely referring to experiences made with a given individual product – class reactions, if not observed with an individual medicinal product or reactions relating to the underlying disease are not ‘expected’ for the given product and if considered possibly related to the medicinal product, must be reported in an expedited fashion, if fulfilling the criteria for expedited reporting.

**Figure 34.4** Flowcharts for reportability assessment: (a) assessment of expedited reportability (Europe): investigational medicinal products (IMPs); (b) assessment of reportability of individual case safety reports (ICSRs) in Europe: post-marketing
Figure 34.4 illustrates the evaluation of a reported case for reportability.

Clinical trial sponsors also have the obligation to report safety information to investigators and ethics committees in a timely fashion. Ethics committees can be informed in an unblinded fashion within the same timeframe as the regulatory authorities, or in reasonable, regular intervals (commonly quarterly). The investigators can be updated periodically in a blinded fashion, provided that no compelling safety reason to unblind have emerged.

Annual update reports for all clinical trials are required to be sent to regulators and ethics committees. For short trials (up to six months), or trials involving less than 50 subjects, this can be combined with the notification of end of trial.

Clinical trials constitute well-monitored environments, in which most events (whether related to the IMP or not) can be collected and added to a database which will gradually outline the safety profile of the drug, allowing for a risk–benefit assessment that will form the cornerstone of any marketing application. After MA has been granted, the population exposed to the drug usually increases exponentially, while the conditions of product use become suddenly less well controlled. Thus, new safety issues often surface immediately after MA.

The MAH is, therefore, required to provide with the application for MA a pharmacovigilance plan, outlining the intentions and systems in place to further evaluate and strengthen the risk–benefit analysis of the medicinal product under review. During the early phases of drug development, safety assessments in clinical trials are generally viewed as ‘hypothesis forming’ – broadly applied systems to collect as much useful data that might

---

### Alternative sources of ICSRs

- **Consumer**
  - Healthcare professionals or scientific literature
  - Is case valid?*
    - Yes
    - No
  - Yes
  - No

- **Clinical study**
  - Serious and Rx related?
    - Yes
    - No
  - Yes
  - No

- **Sponsor’s Licensed Product**
  - Event Expected?
    - Yes
    - No

- **Placebo**
  - Determine treatment
    - (e.g. break Rx code for clinical trials cases, if needed)

- **Other Active Comparator(s):**
  - proceed as for active comparators in Investigational Medicinal Products algorithm

- **Has case arisen in EEA?**
  - Yes
  - No

- **Expeditied SUSAR Report to RA in country of origin**
- **Expeditied SUSAR report to RA in each EEA country and to EMEA**

---

*S Requires real patient, identified reporter, drug name, and adverse event type.

**With rare exceptions, for example excipient-induced anaphylaxis

---

**SUSAR:** Suspected unexpected serious adverse event

**Rx:** treatment

**EEA:** European Economic Area

**RA:** Regulatory authority(ies)

---

**Figure 34.4 (Continued)**
help to identify special issues or problems with a given drug. In later development, the profile of the product must be investigated more in depth in those areas that previously might have given rise to attention (e.g. hepatic issues, gastric bleedings or other special issues a drug might present during initial clinical trials). The pharmacovigilance plan aims at outlining the risk management procedures planned and will usually contain a series of planned studies or observations, preclinical or chemical test programs aimed at characterizing the drug further and help to understand the true risk–benefit profile of the medicinal product.

**Post-marketing authorization**

Pharmacovigilance in the post-marketing authorization period is tightly regulated. As in North America and Japan, Europe has adopted the ICH guidelines with a few, relatively minor additions. The MA holder must have systems and qualified personnel in place to fulfill all his obligations for the monitoring of the safety of its medicinal products.

Similarly to the QP for GMP, MAH is required to identify to the authorities an individual to take the role of the QP for pharmacovigilance. The QP must be fully versed in all aspects of pharmacovigilance and carries personal responsibility for compliance with all applicable regulations. The QP is therefore responsible to ensure that the MAH is diligently collecting safety information on all its marketed products and adheres to obligations taken with the regulatory authorities (e.g. commitments made in the pharmacovigilance plan at time of MA). Regular surveillance over many different sources of information must be maintained (e.g. medical journals, spontaneously reported cases, ‘Yellow Card’ schemes, etc.) and reportable information identified and processed in a timely fashion.

The competent national authorities have received the power of inspection of the pharmacovigilance system of any MAH, similarly to the long-standing GMP or newly introduced GCP inspectorate, and are now equipped with considerable power extending to MA suspension and criminal prosecution of the QP, if critical findings are made and not sufficiently addressed. Pharmacovigilance inspections particularly focus on the systems employed to ensure comprehensive collection of any serious adverse drug reactions and the adherence to reporting obligations and timelines. Companies are expected to audit the pharmacovigilance procedures internally and create a record of compliance.

In addition to the periodic reports (see above), all serious adverse drug reactions reported spontaneously, identified in the worldwide scientific literature or through post-marketing safety studies have to be reported in an expedited fashion. Again, fatal or life-threatening reactions have to be reported within eight calendar days and other serious reactions within fifteen days if emanating within the EU. For cases arising from outside the EU, only the unexpected serious ones must be reported in an expedited fashion.

Companies with co-licensing agreements have to prepare detailed contracts about exchange of safety information and reporting responsibilities, as duplication of reports are unacceptable to the regulatory authorities.

**Periodic safety update reports**

As described earlier in this chapter, the MAH is required to submit regular safety updates to the competent authorities for each licensed product. Combination products can either be submitted as separate PSURs or enclosed in one PSUR covering all indications, strengths and license variations of a given medicinal product. The PSUR reports licensing and marketing status of the product, estimates exposure during the reporting period and cumulatively since the first launch of a product. Any regulatory action or changes to the Core Company Safety information on the compound (CCSI) must be listed in detail. All reported adverse reactions from any source are listed, serious and nonserious, reactions of special interest for a given compound, overdoses, congenital abnormalities, interactions and newly received clinical trial data must be presented in detail and discussed.
Most companies elect to prepare six-monthly reports and when the reporting intervals to the RA prolong, to submit a number of reports together with a brief bridging report. Please note that data are always only presented for the reporting period and not cumulatively since launch of a product.

The timing of the PSUR is governed by its international birth date: the date of first launch of the product.

**Individual case safety reports (ICSR)**

The bases for all expedited, but also cumulative or periodic reports are individual case reports. The accepted reporting format for individual case reports is the Council of International Organizations of Medical Sciences (CIOMS) form. However, all other forms are acceptable in principle, as long as they contain the necessary information. Cases must fulfill minimum requirements to qualify for reporting: a reporter, an event, a drug and a patient must be identifiable. In the EU, the reporter can only be a healthcare professional, unlike in the United States, where the Food and Drug Administration (FDA) accepts reports from consumers.

All European RAs have access to the Eudravigilance database. (EudraV) Electronic transmission of ICSRs into the EMEA has been made mandatory since 2004, electronic reporting to national authorities and electronic receipt of case reports from any authority are mandatory since November 20, 2005. RAs and pharmaceutical companies alike prepare to set up electronic gateways to exchange safety information and compile it in Eudravigilance. Until all competent authorities are fully capable of electronic data exchange, ICSRs can be submitted as hard-copies (have access to the EudraV).

**34.15 Regulation of advertising and promotion**

Advertising and promotion are again covered in detail elsewhere in this book. Here we shall just briefly discuss some of the European regulatory aspects.

Directive 2001/83 sets the framework for the regulation of promotion and advertising in the EU. The European Federation of Pharmaceutical Industries’ Associations (EFPIA) has produced the European Code of Practice for the promotion of medicines and requires each MS to establish a committee to deal with complaints. This committee must include independent members. Despite the Directive and the European Code, the regulation of promotion and advertising of medicinal products is still not harmonized throughout the EU. Every MS can make individual additions to the code and, as always, the Directive gives only general guidance with room for individual interpretation.

Voluntary codes of practice have been in use in many MS for many years. For example, in the United Kingdom, the *ABPI Code of Practice* is applicable to prescription medicines, and the Proprietary Association of Great Britain (PAGB) ‘*Code of Standards of Advertising Practice*’ for over-the-counter medicines.

The general principles of advertising and promotion are the following:

- It is an offence to issue a false or misleading advertisement or representation about a medicinal product; in particular, the advertisement has to comply with the approved SmPC.
- The product must be presented objectively and without exaggeration, to encourage its rational use.
- It is an offence to issue an advertisement about a non-authorized indication, and no promotion of a medicinal product is permitted before it is granted MA.
- The advertising of POMs to the consumer (the patient) and thus the general public is prohibited.

In the United Kingdom, copies of all advertisements must be submitted to the RA every 12 months. Furthermore, it is a requirement that the approved SmPC is supplied within 15 months of an advertisement. Meanwhile the British pharmaceutical industry provides a compendium of SmPCs.
to every practising physician and pharmacist in the
country as one mechanism to comply with the
regulation.

Many of the promotional activities of the phar-
maceutical industry are directed at professionals in
the healthcare market (doctors, pharmacists, hospi-
tals, etc.), as advertising POM medications directly
to the patient is prohibited. However, companies are
receiving an increasing number of enquiries directly
from patients about their products. This has neces-
sitated the provision of a regulatory Guidance for
companies on how to answer such direct requests for
information from the general public.

Pharmaceutical companies are now permitted to
answer general inquiries in a non-promotional way.
However, promotion to the public is specifically
permitted only in the case of P or GSL medicinal
products.

Disease awareness campaigns are a recognized
and approved way for pharmaceutical companies
to communicate with the general public. Disease
awareness campaigns may make reference to treat-
ment options, but need to carefully avoid high-
lighting any specific medicinal product, as this
would be viewed as promotional. Any promotion
of a particular medicinal product will bring the
campaign within the scope of the Community
Code (Directive 2001/83), and violate the law.

Promotional aids, gifts, hospitality, supply of
free samples and the conduct and training of med-
ical representatives all fall as squarely within the
regulations as printed and audiovisual promotional
materials.

### 34.16 Medicines regulation in
Switzerland

Switzerland is a federation of cantons. Each canton
governs its own regional issues, while the national
Swiss government is concerned with overarching
matters. Democracy extends to a yet smaller scale
in Switzerland because, even within the cantons,
individual villages or cities retain varying degrees
of independence. The result is a fascinating legal
mosaic: a system of great diversity within the
national borders of a relatively small country.

Switzerland lies outside of both the EU and the
EEA. Nevertheless, the Swiss RA has adopted all
the ICH guidelines and requires MA applications
in the CTD format. Modules II–V can be submitted
in English; while the country-specific Module I has
to be submitted in one of the Swiss languages
(German, French, Italian or Romansch; however,
informally, the RA discourages the last of these).
The SmPC and PIL must provide information in
German, Italian and French, unless for some pecu-
liar reason, the product will only be distributed in
cantons using just one of these languages. Switzer-
land does not automatically ratify European MA.
However, because of its special relationship and
national status, marketing applications that have
been ratified in Liechtenstein can lead to simpler
application processes at the Swiss RA (named
‘SwissMedic’).

Although SwissMedic functions as an RA for all
of Switzerland, there are nonetheless parts of med-
icines regulation that are governed by cantonal laws,
and not centrally harmonized across the whole
country. For example, the GMP and GCP inspecto-
rate and distribution of medicines is a cantonal, not
national, responsibility, even though the GMP and
GCP guidances are promulgated nationwide by
SwissMedic. It is advisable to talk to the relevant
personnel (e.g. the cantonal pharmacist for GMP
and medicines distribution issues) at the cantonal
administration, when applying for MA.

As in the EU, an inland legal representative is
needed for all non-Swiss applicants. These legal
representatives are as valuable to sponsors for navi-
gating this complicated situation, as to SwissMedic
as a point of contact and communication.

### 34.17 Medical devices and drug/
device combinations

All medical devices are subject to regulatory
review and MA similar to the medicinal products.
In the United Kingdom the national regulatory
authorities for devices and medicinal products
were merged in 2003. However, note that the
EMEA, CHMP and COMP do not regulate medical
devices, unlike their US equivalents.
The Medical Device Directive 93/42 defines medical devices and products, which combine a drug with a device. For regulatory purposes, the latter are subdivided and dealt with as follows:

- Where device and drug are supplied separately (e.g. syringes marketed empty), the device is subject to devices controls and the medicine is subject to medicines control.

- Integral, non-reusable products intended solely for use in the given combination (e.g. syringes marketed prefilled) are subject to medicines control, but the device feature must satisfy the relevant essential requirements of the directive relating to safety and performance.

- Devices incorporating a drug where the action of the drug is ancillary to that of the device (e.g. anticoagulant-coated catheters) are subject to devices control, but the drug must be verified by analogy with medicines control criteria and the medicines licensing authority must be consulted.

References and resources

World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects (as amended).
Regulation 726/2004 of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.
Directive 92/28/EC (advertising and promotion).
Medical Device Directive 93/42/EEC.
Directive 89/105/EEC of December 21, 1988, relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion within the scope of national health insurance systems (transparency of price and reimbursement).
EC Commission. Detailed guidance on the application format and documentation to be submitted in an application for an ethics committee opinion on the clinical trial on medicinal products for human use. April 2003 (Brussels, ENTR/F2/BL D (2003)).
EC Commission. Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the
end of the trial, April 2003 (Brussels, ENTR/F2/BL D (2003)).

EC Commission. Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use, April 2004, revision 1 (Brussels ENTR/CT3).


Commission Regulation (EC) No 1084/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal products for human use and veterinary medicinal products granted by a competent authority of a member state (mutual recognition variations).


Regulation 540/95 arrangements for reporting suspected unexpected adverse reactions which are not serious.


Summary of product characteristics for benzodiazepines as anxiolytics or hypnotics (Eudralex Vol. III BC1A).

Summary of product characteristics for ACE inhibitors (Eudralex Vol. III BC2A).

User leaflet for oral contraceptives (Eudralex Vol. III BC3A).

Summary of product characteristics for antimicrobial medicinal products (Eudralex Vol. III BC4A).

Summary of product characteristics for antibacterial medicinal products (Eudralex Vol. III BC5A).

CPMP/108/99 SARG role and responsibilities.

SOP 2072/99 on scientific advice by the CPMP.


CPMP Joint Pharmacovigilance plan for the Implementation of the ICH E2B M1 and M2 requirements related to the electronic transmission of individual case safety reports in the community.

Conduct of pharmacovigilance for medicinal products authorised through the mutual recognition procedure EMEA, June 1997.

Conduct of Pharmacovigilance for centrally authorised products EMEA, April 1997.

CPMP SOP 986/96 Rev 1 (Trade mark review).

Commission Regulation (EC) No 847/2000 of April 27, 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts ‘similar medicinal product’ and ‘clinical superiority’.


CPMP note for guidance (CPMP/EWP/QWP/1401/98) on the investigation of bioavailability and bioequivalence.

CPMP/3097/02. Guidance on the comparability of biotech derived proteins as active substances in medicinal products.
Notice to applicants of the EU Commission – guideline on the categorisation of new applications versus variations applications Jan 2002 (currently under revision to reflect the new regulations in force since Oct 2003).


The Prescription Only Medicines (Human Use), Order 1997 (The POM Order).

The Medicines (Products other than Veterinary Drugs) (General Sale List), Order 1984 (the GSL Order).

The Medicines (Pharmacy and General Sale – Exemption) Order.

The Medicines (Sale or Supply) (Miscellaneous Provisions) Regulations.

The Medicines Act 1968 (as amended).

MHRA document ‘generic’ overdose sections for selected SmPCs, Feb 2004.


COREC New Operational procedures for NHS RECs, guidance for applicants to Research Ethics Committees.


Supplementary remarks of the BfARM in addition to the Joint Notification by BfARM, BgVV and PEI of Sept 4, 1998 – guide for applicants (national scientific advice).

CIOMS IV form for reporting of serious unexpected suspected adverse drug reactions: www.cioms.ch.

ABPI Code of Practice 2003.


Prescription medicines code of practice authority, constitution and procedure, operative from July 1, 2001.

Presentation notes from MHRA breakfast meeting, Thursday, February 26, 2004.

EMEA web site: www.emea.eu.int

EuDRACT database homepage: http://eudract.emea.eu.int

ICH web site: www.ich.org

BfArm web site: www.bfarm.de

Swissmedic web site: www.swissmedic.ch

MHRA web site: www.mhra.gov.uk

COREC web site: www.corec.org.uk

The ABPI web site: www.abpi.org.uk


European Commission. Detailed guidance on the European clinical trials database (EuDRACT Database). April 2003, and successor documents CT 5.1 Amendment describing the development of EUDRACT-Lot 1 (May 1, 2004) and CT 5.2 EUDRACT core dataset.


European Commission Directive 2005/28/EC. Principles and detailed guidelines for good clinical practices as regards investigational medicinal products for human use as well as the requirements for authorization of the manufacturing or importation of such products.

EMEA. Guidance for companies requesting scientific advice and protocol assistance, June 2008. EMEA/H/4260/01/Rev.2.


Japan is a country of 128 million inhabitants, just a little larger than California or almost one half of the United States. It has 270 000 medical practitioners (2004), and is the second largest drug market in the world. Economically very attractive, it remains for Westerners a country difficult to understand and to communicate with. A strong Dutch, then German, influence during the eighteenth and nineteenth centuries, respectively, opened Japan to Western medicine; it then developed its own techniques to become internationally recognized as one of the most advanced countries in the world of biological and medical sciences with an average life expectancy of 82 years. However, Japan, land of contrast, also preserved its traditional therapies of Chinese origin: herbal medicine (‘kampo’) is still popular and commonly co-prescribed with ethical drugs. Such co-prescription seeks to add different pharmacological effects at low doses without inducing adverse drug reactions (ADRs). It is unethical for a physician to be responsible for iatrogenic incidents, and drug safety has long been a priority to the detriment of efficacy. Japanese regulators developed the most severe guidelines regarding drug safety studies in animals and, paradoxically, clinical development remained, until recently, a pragmatic approach totally in the hands of medical doctors, at times hierarchical for clinical drug investigation. Nowadays, the rules regulating clinical trials recommend the use of international standards, and Japan became the leader of several topics at the International Conference on Harmonization. It has been a full member since 1991. This chapter will present the main preclinical and clinical regulations governing drug development on Japanese territory.

35.1 Organization of Japanese Health Authorities

General organization

Under the authority of the Minister and the Vice-Minister, the Ministry of Health, Labor, and Welfare (MHLW or Koseirodosho in Japanese) is responsible for social security, public health and the promotion of social welfare. For such purposes, the organization includes (Figure 35.1) the following:

- A main body (central offices).

An advisory body: the Pharmaceutical Affairs and Food Sanitation Council (PAFSC), involved in New Drug Application (NDA) review.

The main body of the MHLW is divided into three branches:

1. *The core administration*, which consists of the Secretariat (including the Statistics and Information Department), and 11 bureaus, which are as follows: Health Policy Bureau; Health Service Bureau; Social Welfare and War Victim’s Relief Bureau; Health and Welfare for Elderly Bureau; Equal Employment, Children and Families Bureau; Insurance Bureau; Pension Bureau; the Pharmaceutical and Food Safety Bureau (PFSB), which plays a major part in drug regulations; and the Director-General for Policy Planning and Evaluation. Around 2000 officials work full-time in the central offices.

2. *Regional branches*. Each prefectural government (47 prefectures) offers a local branch of the Health Authorities and Labour Bureaus: the Regional Medical and Pharmaceutical Affairs offices, and the District Narcotics Control offices. New drug applications are made through the regional office of the prefecture where the company is situated.

3. *Affiliated institutions*. In the present organization, national hospitals such as the National Cancer Center and three affiliated institutions operate under MHLW supervision:

   (a) The National Institute of Health Sciences, performing tests and research on drugs, food and chemical substances.

   (b) The National Institute of Infectious Diseases, conducting research on pathogenicity, etiology, prevention of certain diseases, and tests and research on vaccines and blood products.

   (c) The National Institute of Population and Social Security Research, training public health technicians, conducting surveys related to public health and so on.

More than 50,000 officials are working for the MHLW general organization.

**Pharmaceutical administration**

The PFSB, the Health Policy Bureau, with the assistance of the PAFSC, and the Pharmaceuticals and Medical Devices Agency (PMDA or Kiko in Japanese) represent the managing authorities of Japanese pharmaceutical administration, in charge of reviewing drug application for approval, reexamination or reevaluation.

**The PFSB**

The PFSB consists of a Secretary General, five divisions and one office. It ensures safety and efficacy of drugs, quasi-drugs and medical devices, editing as well policies regarding blood supplies, blood products, narcotics and stimulants.

*General Affairs Division*. This division coordinates all activities of the PFSB, enforces the Pharmaceutical Affairs Law (PAL), manages questions related to the PAFSC, and provides guidance and supervision to the PMDA. Two offices attached to the Planning Division are as follows:

1. The Office of Access to Information, ensuring publication of information held by administrative organization.
2. The Office of Drug Induced Damages, which supervises the PMDA and the administration of work related to ADRs damages.

Evaluation and Licensing Division. This division surveys and coordinates regulation of production, research and trade of drugs, quasi-drugs and medical devices. Many other services are provided by this division: licenses for manufacturing or import of drug and medical devices, designation of orphan drugs and medical devices; guidance to the PMDA; supervision of standards and specifications for drugs, quasi-drugs and cosmetics; guidance for the Japanese Pharmacopoeia (JP); Reexamination and reevaluation of drugs and medical devices.

Safety Division. The responsibility of this division is to ensure the safety of drugs, quasi-drugs, medical devices and cosmetics. The Office of Appropriate Use of Drugs, attached to this division, collects and evaluates information related to ADRs and promotes the appropriate use of drugs.

Compliance and Narcotics Division. The role of the division is to control and inspect, looking for quality issues, faulty labeling, unlicensed drugs, quasi-drugs, medical devices and cosmetics. It gives guidance for advertising, testing, official certification and good manufacturing practice (GMP). It supports the enforcement of the Narcotics and Psychotropics Control Law, Cannabis Control Law, Opium Law and Stimulants Control Law.

Blood and Blood Products Division. This division regulates blood collection, proper use of blood products, and production and distribution of biological products.

The Health Policy Bureau

The Health Policy Bureau handles promotion of R&D, drug, quasi-drugs, medical devices and sanitary materials production and distribution policies. It is divided in two divisions, the Economic Affairs Division and the Research and Development Division, both having relationship with the pharmaceutical industry.

The PAFSC

The PAFSC, an advisory organ of the MHLW, investigates and discusses important matters related to pharmaceutical affairs and food sanitation. The PAFSC members are experienced specialists in the field of medicine, pharmacy, biology, dentistry and veterinary medicine, coming from universities, public hospitals and research institutes; there are 55 permanent members and about 400 temporary members, function of the topics to be discussed. Major subjects treated by the PAFSC include the following:

- Revision of the JP.
- Determination of standards for drugs.
- Evaluation of the relevance of allowing import or manufacturing of drugs.
- Review of NDA.
- Designation of drugs to be submitted for reexamination and reevaluation.
- Judgments concerning the payment of relief funds under the provisions of the ADR Relief and Research Promotion Fund Law.

For such purpose, the PAFSC is organized into 16 committees and 21 subcommittees.

The Pharmaceuticals and Medical Devices Agency (PMDA or Kiko in Japanese)

In 2005, there were significant revisions to the Japanese PAL, requiring Third Party certification systems for new low-risk and priority high-risk medicines and devices.

In preparation for this, in April 2004, the Pharmaceutical and Medical Device Evaluation Center (PMDEC), the Japan Association for the Advancement of Medical Equipment (JAAME) and the Organization for Pharmaceutical Safety and Research (OPSR) were merged and integrated in the National Institute of Health Sciences. This
consolidated a unified organization for the regulation of pharmaceuticals, biologicals and medical devices, and thus now became the Pharmaceuticals and Medical Devices Agency (PMDA) (see Figure 35.2).

The main activities of the PMDA are to offer the pharmaceutical industry consultations with regard to clinical trial protocols and drug and medical devices development plans, to conduct new drug application review and to confirm the quality of the submitted data. The PMDA, or Drug Agency, is composed of 15 offices to conduct different services (see Figure 35.3).

Main offices related to new drug application, approval review, drug safety issues, reexamination and re evaluation are as follows.

**Office of New Drug I.** This division takes in charge anti-HIV agents, anti-malignant tumor agents, anti-bacterial agents and related drugs.

**Office of New Drug II.** This division operates review of cardiovascular drugs, metabolic disease drugs when in combination with other drugs, reproductive system drugs, anal and urogenital drugs, and diagnostics and radiopharmaceuticals for in vivo use.

**Office of New Drug III.** This division takes care of hormonal agents, metabolic disease drugs when not in combination with other drugs, dermatologic agents, gastrointestinal tract agents, central and peripheral nervous system drugs, sensory organ agents, antiallergy drugs, respiratory tract drugs and narcotics.

**Office of Biologics.** This department reviews files for biological products, and cell- and tissue-derived products. It is also involved in agents used in gene therapy.

**Office of OTC and Generics.** This division reviews applications for approval of generics, non-prescription drugs (OTC), quasi-drugs and cosmetics.

**Office of Medical Devices.** Medical devices and in vitro diagnostics are reviewed by this department.

**Office of Safety.** This office collects, organizes and analyzes safety information from drugs and medical devices, in collaboration with some other offices from the ministry, and participates in the dissemination of the safety information.

**Office of Compliance and Standards.** In this department, data compliance to good laboratory practice (GLP), good clinical practice (GCP) and good post-marketing surveillance practice (GPMSP) is carefully controlled. Applications are checked to determine if they were prepared according to the Criteria for Reliability of Application Data.

PMDA covers a wide range of other services, such as guidance for the development of orphan drugs, communication with drug consumers, guidance on the necessity of different types of certificates. One of the most important services is the ‘Kiko consultation’. Starting 1 April 1997, with the Drug Organization, PMDA carries on today several types of consultations (19 subtypes) for the pharmaceutical industry. The main consultations for drug development are

- on initial plans for clinical trials (phase I);
- at the end of phase Ia and at the end of phase Iib;
- before filing (dealing with long-term trials or pre-NDA consultation, checking the acceptability of the NDA);
- on protocols.

Fees of ¥0.5–3.3 million are charged for consultation services; records of the guidance and advices
are kept and can be used as attached data for a new drug application.

35.2 Japanese pharmaceutical laws

Japanese pharmaceutical administration has a long story; it started during the reign of Emperor Meiji, a period during which Japan reopened its frontiers to Western countries. The first law, enacted in 1874, dealt with pharmaceutical sales and handling, but it was limited to three areas (Tokyo, Osaka and Kyoto). Fifteen years later, the law covered the whole country and was merged with another law, the Patent Medicine Law, in 1925; it was then renamed the ‘Pharmaceutical Affairs Law’ in 1943.

The Pharmaceutical Affairs Law (PAL)

The first ‘modern’ law was born in August 1960, when it was split into the PAL and the Pharmacists’ Law. The original goal of the Law is to ensure the quality and safety of drugs. Following the evolution of medicines, technique, quality standards and so on, the Law was revised and amended several times in order to incorporate new regulations, such as the GCP. Nowadays, the PAL and the Enforcement Regulations of the PAL regulate drugs from production and development to marketing and distribution, its scope covering new drugs, quasi-drugs, cosmetics and medical devices. It was further revised in 1996, and the first physician was appointed to the Regulatory Authorities in 1997. Last amendments were made in 2002 mainly to improve post-marketing surveillance (PMS) policy and revision of the approval and licensing systems; it includes provisions for safety measures for biological products, investigator-initiated clinical trials, rationalization plan to establish the PMDA and revision of the review system, and provisions related to manufacturing and distribution business.

The Law contains 11 chapters and 89 articles. Surveying this Law in brief, we observe the following:

Chapter 2. *Pharmaceutical Affairs Council.* The PAFSC is established, as well as local prefectures councils.

Chapter 3. *Pharmacies.* Defines license standards and supervision of the pharmacies.

Chapter 4. *Manufacture and import of drugs and so on.* Here it is specified that import or manufacture of a drug needs official review by the PMDA and approval, and that the drug should be reexamined and then reevaluated after a certain period of marketing.

Chapter 5. *Selling drugs and medical devices.* Deals with licenses for sales and restrictions.

Chapter 6. *Standards and tests for drugs and so on.* Establishes the JP and other standards.

Chapter 7. *Handling of drugs and so on.* Specifies the handling of poisonous and powerful drugs, drugs requiring prescription, package inserts, containers, labeling, sales and manufacturing restrictions.

Chapter 8. *Advertising of drugs and so on.* Regulates advertising of drug and handling of biological products.

Chapter 9. *Supervision.* Defines on-site inspection and potential sanctions, orders for improvement, cancellation of approvals and licenses, and so on.

Chapter 9.2. *Designation of orphan drugs and orphan medical devices.*

Chapter 10. *Miscellaneous provisions.* Deals with data submission and the handling of clinical trials, and so on.

Chapter 11. *Penal provisions.* Defines and fixes the penalties for violation of different articles of the Law.

The Law generally describes the frame of the regulations; for most of the articles, more details and complementary information are provided by the Enforcement Regulations of the PAL, which regulates most of the drug development. These regulations will be reviewed in the next chapters.

### Other pharmaceutical laws

Separated from the main Law in 1960, the Pharmacists’ Law deals with the activities of pharmacists, examination, licensing and duties; the Law concerning the Organization for Pharmaceuticals and Medical Devices was recently revised. Several other laws are involved in pharmaceutical administration. Their scope is restricted to limited areas and most of them aim at preventing drug abuse and health damages. They are the Poisonous and Deleterious Substances Control Law, the Narcotics and Psychotropics Control Law, the Cannabis Control Law, the Opium Law, the Stimulants Control Law, and the Blood Collection and Blood Donation Services Control Law.

### 35.3 Drug development regulations overview

In order to clarify the following sections, some regulations have been artificially separated. For Western people not familiar with Japanese regulations, these rules, delivered through hundreds of notifications from the Pharmaceutical Affairs Bureau, are a huge maze. We have tried to simplify this review, and we apologize for the lack of precision consequently induced.

### Generalities

**Marketing approval, manufacturing and import approval**

To be authorized to market a new drug in Japan, it is necessary to obtain a drug approval and a manufacturing or import approval for the drug. Drug Approval is an official confirmation, based on scientific data, that the drug is effective and safe. The Approval is granted for a drug to a person or a
juridical person. The manufacturing or import approval for a given drug is granted after ensuring that the applicant is healthy and sane, legally competent, and that the personnel, facilities and equipment comply with the Pharmaceutical Law requirements and quality standards in order to be able to manufacture or import the approved drug properly. The manufacturing approval is granted for a specific drug to the facilities where the drug will be manufactured. Manufacturing approval can be transferred to legally authorized manufacturers, for example through contracts or mergers.

**In-country caretaker system**

Approval might be obtained by either a domestic company or directly by a foreign company settled abroad, since the revision of the PAL in May 1983. However, clinical data establishing efficacy and safety should be generated in Japanese patients, on Japanese territory; therefore, if the foreign company has no means of conducting these clinical trials on its own, it should appoint an in-country caretaker, domiciled in Japan. A clinical research organization (CRO) is allowed to perform such clinical development in respect to the PAL; the CRO may be subject to spot inspections or other specific requests from the MHLW, such as report submission regarding ADRs. The CRO should be able to take necessary measures to prevent the occurrence or spread of health damages induced by the drug under investigation (for more information about CROs in Japan, please refer to Bentley, 1997).

**Substances and devices regulated by the PAL**

**Main groups defined by the law**

Four groups are defined, which usually need an Approval to be marketed in Japan, unless specifically designated by the MHLW:

1. Drugs, including substances listed in the JP, substances for diagnosis, treatment or prevention of human and animal diseases, and substances affecting any structure or function of the human or animal body. Apparatus or instruments are, of course, excluded. This group can be divided in prescription drugs (or ethical drugs) and non-prescription drugs.

2. Quasi-drugs are substances that exert a mild action on the body, such as drugs used to prevent nausea, bad breath, body odor, hair loss, heat rash and so on.

3. Cosmetics are substances also having a mild action or no action on the body, but are for external use, applied by rubbing or spraying on the skin or hair, and are used for cleaning or beautifying.

4. Medical devices are instruments or equipment used for the diagnosis, treatment or prevention of human or animal diseases. They are designated by ministerial ordinance.

**Drug classification**

The four groups above include numerous subclasses, which vary according to the function of different parameters: for example, approval procedures, approval authorities, handling of standards, list of data to be submitted. Regarding drugs and data to be submitted for approval, Figure 35.4 gives a good example of a possible classification.

**Orphan drugs**

Within the ethical drug class, a particular group should be distinguished: orphan drugs. Orphan drugs status was originally defined in 1993 as follows: a drug is designated as orphan by the MHLW after recommendation by the PAFSC, when efficacy is scientifically established and when it can benefit less than 50 000 patients. Orphan drugs are subject to financial aid, priority review and extension of the reexamination period from 6 to 10 years.
According to Notification 481 from the PMSB, dated 8 April 1999, the whole original list of data required for a NDA should include from April 2000:

(a) Data on origin, details of discovery, use in foreign country and so on:
   1. Data on origin and details of discovery.
   2. Data on use in foreign countries.
   3. Data on characteristics and comparison with other drugs.

(b) Data on physical and chemical properties, specifications, testing methods and so on:
   1. Data on determination of structure.
   2. Data on physical and chemical properties, and so on.

(c) Data on stability:
   1. Data on long-term storage test.
   2. Data on severe test.
   3. Data on acceleration test.

(d) Data on acute toxicity, sub-acute toxicity, chronic toxicity, teratogenicity and other toxicity studies in animals:
   1. Data on single dose.
   2. Data on repeated dose.
   3. Data on mutagenicity.
   4. Data on carcinogenicity.
   5. Data on reproduction.
6. Data on local irritation.

7. Other safety data.

(e) Data on pharmacological action:

1. Other safety data.

2. Data on efficacy (mechanism of action).

3. Data on safety (general pharmacology).

4. Other animal pharmacology data.

(f) Data on pharmacokinetics (PK):

1. Data on absorption.

2. Data on distribution.

3. Data on metabolism.

4. Data on excretion.

5. Data on bioequivalence.

6. Other PK data.

7. Data on the results of clinical trials.

Some of these requirements are omitted when applying for a new dosage, a new indication, a new route of administration or a new formulation with regard to a drug already approved, or may vary according to drug classification, non-prescription drug (Notification 0827003 from PSFB, 27 August 2003), quasi-drug or cosmetic.

Quality standards

Quality standards for substances and devices regarding properties, technical specifications and test methods

1. The Japanese Pharmacopoeia (JP). The main and the oldest document specifying standards for drugs is the JP, first published in 1886. The JP is established by law (Article 41). It aims at regulating quality for important drugs used in healthcare and specific standard test methods. The JP is revised by law every 10 years; but in practice, the revision is carried out every 5 years. The fourteenth edition was published in 2001 and already contains some monographs harmonized with the US and European Pharmacopoeias. The fifteenth edition was issued in 2006.

2. For drugs not mentioned in the JP, Article 42 of the PAL indicates that the MHLW can lay down necessary standards for drugs and so on, requiring particular cautions. The following standards for drugs have been gazetted through ministerial ordinance:

(a) Standards for Biological Materials (MHLW Notification 210, 2003).

(b) Minimum requirements for biological products.

(c) Minimum requirements for blood grouping antibodies.

(d) Radiopharmaceutical standards.

Other standards were published for quasi-drugs (e.g. sanitary products standards), cosmetics (e.g. standards for the quality of cosmetics) and medical devices (e.g. standards for blood donor sets, for cardiac pacemakers, for medical X-ray apparatus).

3. For substances not mentioned in the JP and not covered by Article 42 of the Law, additional standards were notified by the MHLW, for example, the Japanese standards for pharmaceutical ingredients, standards for crude drugs, standards of raw materials for clinical diagnostics and so on.

4. Finally, for drugs having particular manufacturing technology and test methods, such as biotechnological products, a government certification based on ‘batch tests’ is necessary.
Quality standards for data, facilities and functional organizations

These standards cover different fields describing ‘good practices’ ensuring the quality of the drug, the quality and reliability of the data generated with the drug and, finally, warrant the efficacy and safety of a given drug for a given disease, with respect to scientific and ethical considerations for both humans and animals.

**GMP.** Enforced in 1976, GMP establishes the requirements ensuring drug production of a high and constant quality. Ordinances 92 and 95, revised in May 2003, contain guidance on the following:

- Manufacturing control and quality control (GMP software).
- Duties of the Control Manager (self-inspection, education and training, etc.).
- Standards for buildings and facilities for manufacturing plants (GMP hardware).

In 1988, GMPs for medical devices were also enforced. A group of inspectors attached to prefectorial government perform regular on-site inspections of manufacturers, importers and distributors in order to check their compliance to GMP.

GMP compliance certificates for Japanese drug plant have been issued since 1982; today bilateral agreements have been signed with the United States and EU since May 2003, with regard to GMP compliance recognition.

**Regulations for Imported Drug Management and Quality Control.** Also related to drug quality, the standards for Quality Assurance of Imported Drugs and Medical Devices were notified in 1993, establishing basic quality assurance requirements with which the drug importer should comply. The MHLW ordinance 62 of June 1999 today regulates drug import to Japan.

**GLP.** In order to ensure the reliability of animal data, GLP standards were published by the PAB in March 1982, enforced one year later and revised in October 1988. GLP describes standards for personnel and organization (management, quality assurance unit, etc.) for animal care facilities and equipment, standard operating procedures for the operation of testing facilities, test and control articles, the conduct of a study, the study report, and the storage of the raw data.

These standards originally concerned animal safety studies; today, they are applied to all animal studies, for example, toxicology, pharmacology and animal PK. GLP was legalized as an MHLW Ordinance in 21 March 1997, requiring in particular to establish SOPs and the preparation of protocols and study reports. PMDA is conducting GLP compliance reviews and on-site inspections of testing facilities.

GLP applies to foreign data when attached to the NDA. Mutual GLP agreements have been signed between Japan and the United States, EU and Switzerland.

**GCP.** Written in 1985, Japanese GCP standards were notified by the MHLW in 1989 for a general application from October 1990. They laid down rules for conducting a clinical trial properly from an ethical and scientific standpoint:

- Definition of the respective role and responsibilities of the sponsor, the investigator and the medical institution.
- The contract for a clinical trial between the sponsor and the hospital conducting the study.
- The institutional review board (IRB) in each medical institute, its role and organization.
- The informed consent of patient to participate into the trial, which was not originally a ‘written’ consent.
- The storage of the study records (source data) during a certain period of time.

These rules, however, were to be applied to a clinical development organization specifically in Japan, and were very different from our Western ones (cf. section on ‘Clinical Development’, below). Within the framework of the International Conference on Harmonization (ICH), GCP were re discussed for several years and finally concluded
in 1996. New harmonized GCP standards are now applicable to the United States, Europe and Japan as well, but they require profound changes of the Japanese system to be fully applied; the PAL had to be amended in order to permit the enforcement of the new GCP from April 1997. These had a major impact on new study starts, the need for informed consent being the largest reason.

The main changes for the Japanese clinic (Takahashi and VandenBurg, 1997) include the following:

- New obligations for the sponsor, such as the preparation of the clinical protocol and the writing of a clinical study report.
- The abolition of the ‘chairman’ of the investigator steering committee (see Figure 35.5).
- The designation by the medical institution of an IRB which can be outside the hospital, such as an academic society, and which will compulsorily have a member from outside the institution.
- The sponsor must establish an independent monitoring system in order to conduct an adequate evaluation of progress of the clinical trial, safety information and efficacy end points. This means that Japanese companies will now have to hire medical doctors to handle medical matters.
- The informed consent becomes a written consent and necessitates true and complete information for the patient, including risk and compensation for damage to the health of subjects.

The new GCP standards are, of course, similar to those of the US and European GCP, to which the reader should refer for detailed regulations.

The GPMSP. The PMS system is a well-established system in Japan for collecting safety data in order to prepare the documentation requested for reexamination which will be described in the section on ‘Post-approval activities’, below.

GPMSP standards were enforced in April 1994 after revision of the text published in May 1993. It became a law in 1997, and was further revised in 2000, to add the ‘Early Post-Marketing Surveillance’, applying to new drug in the first six months of marketing. These standards specify the rules to be observed by the manufacturer in order to ensure the reliability of the PMS data, mainly the following:

- The manufacturer shall establish a PMS department independent of the marketing division and shall employ sufficient staff.
- PMS managers shall prepare standard operating procedures for PMS in order to collect information on drug use, assess this information and take appropriate measures, undertake surveys and special surveys when necessary, perform post-marketing clinical trials, conduct self-inspections, train and educate PMS personnel,
contract-out PMS works, and store the information records properly.

- ADR and Infections Reporting System are following ICH rules for reporting within 15 and 30 days. From October 2003, it became mandatory to use MedRA for individual adverse event report.

**Specific guidelines for drug development**

In addition to the Law and Quality Standards, specific guidelines have been notified for both preclinical and clinical studies. They regulate the preparation of the data to be submitted for approval by the authorities and they should generally be strictly followed. These guidelines explain what kind of data have to be produced and indicate the methodology to generate these data; many of these guidelines were discussed at the ICH, and most of them are already harmonized and implemented on Japanese territory.

Other guidelines or recommendations regulate the administrative procedures surrounding development works, such as the import or labeling of the study drug. The PAL directly describes the procedures for notifying clinical trials in its section ‘handling of clinical trials’. These regulations will be reviewed with the next section.

**35.4 Drug development procedures**

After the chemical research and screening test periods, the development of a new chemical entity (NCE) follows preclinical and clinical steps similar to Western ones. It takes 8–10 years to establish the efficacy and safety for a new drug and to prepare the documentation required for a NDA.

Regarding the development of a new drug in Japan that is already approved in a foreign country, even if preclinical data were harmonized up to 95%, six to eight years are still necessary in order to conduct clinical development on the Japanese territory on Japanese subjects and patients from phase I to phase III. New regulations, such as ‘ICH E5’ implementation in Japan, offer potential strategies to reduce the development time, using foreign data; however, in practice, acceptable cases are rather limited.

**Preclinical studies**

*Physicochemical properties, specifications and test methods*

Basic chemical data, identification, purity and test methods should follow the Guidelines ‘Setting Specifications and Test Methods of New Drugs’, notified in May 2001. Several others dealing with analytical validation, impurities or residual solvents were established on the basis of ICH agreements. When available, standards published in the JP or other quality standards (cf. section on ‘Quality standards’) represent the references for specifications and test methods.

**Stability studies**

Stability data on the active principle and on the formulation(s) are required on three batches, according to the Stability Test Guidelines issued in April 1994. These guidelines are now harmonized between the three ICH regions, implemented in Japan with the New Stability Test Guidelines, June 2003. Long-term data and tortured conditions test data should be submitted for new drug application; accelerated conditions tests only are necessary for applications regarding new dosages or new indications of a drug already registered.

**Animal safety data**

In May 1980, Notification 698 from the MHLW specified the type of data required for the evaluation of safety in animals and Guidelines for Toxicity Studies were subsequently established in 1984. It is necessary to generate data on acute, sub-acute and chronic toxicity, effect on reproduction, dependence, antigenicity, mutagenicity, carcinogenicity and local irritation.
After several revisions, including ICH agreements in 1993 and 1999, the present Guidelines for Toxicity Studies cover almost all these items, describing the tests methods to be conducted for:

- single-dose toxicity study;
- repeated-dose toxicity study, 1 or 3 months and 6 or 12 months administration, and guidance for toxicokinetics;
- reproductive and developmental toxicity studies;
- drug dependence studies were notified in 1975 by the Narcotic Division (for drugs having a pharmacological effect on the central nervous system);
- antigenicity studies;
- skin sensitization and skin photosensitization for dermatological preparations;
- genotoxicity studies;
- carcinogenicity studies (requirements and dose selection for carcinogenicity study has been harmonized).

All toxicity studies supporting a new drug application should comply with GLP standards.

Pharmacology

Pharmacological data should include two different types of data:

- ‘Specific pharmacology’ data provide information regarding the main effects on the target disease in animal models and try to clarify the mechanism of action as far as possible. There are no guidelines for specific pharmacology.

- ‘General pharmacology’ studies are conducted to assess the overall pharmacological profile and to obtain information about the effects on the main physiological functions and potential adverse events. Three dose levels are studied (low, intermediate and high or very high doses) in a battery of tests exploring the main body functions. General pharmacology studies are regulated by guidelines notified in January 1991.

In 2001, general pharmacology data have been classified in ‘efficacy pharmacology, secondary/safety pharmacology, and other pharmacology’. All pharmacological studies should also comply with the GLP standards.

Animal PK

Data on absorption, distribution, metabolism and excretion in animal are necessary to clarify the drug’s biological fate in the body and to establish an appropriate dose regimen in animal studies, and ultimately in man.

The guidelines for nonclinical PK studies were notified in January 1991. They request those studies to be performed after single and repeated administration. Japan was traditionally the only country to systematically conduct a two- or three-week administration test in order to detect tissue accumulation.

Recently, the ICH-harmonized tripartite guideline, Guidance for Repeated Dose Tissue Distribution Studies, opened the door for such repeated-dose studies, but recognized that there was no consistent justification to conduct these tests systematically. In June 2001, new guidelines on nonclinical PK studies were notified.

Clinical development

Efficacy and safety data supporting a NDA approval does not differ fundamentally from the Western clinical data package. They are generated through similar phases, which are:

- human pharmacology studies (phase I)
- therapeutic exploratory studies (dose determination studies, phase II)
- therapeutic confirmatory studies (safety and efficacy studies vs. a reference drug, phase III)
However, Japanese clinical trials show some differences in their organization and methodological approaches, which are still in practice in spite of regulations requesting the application of internationally validated standards.

**Clinical trials regulations**

*The PAL and its Enforcement Regulations* establishes some basic rules for clinical trials, that is, in summary, it is necessary

- to conduct preclinical tests (toxicity, pharmacology, etc.) before starting human administration;

- to request in writing to an adequate medical institution to conduct a clinical trial;

- to inform the patient before his/her enrollment into the trial;

- to submit to the MHLW information regarding the clinical protocol for each study, with information regarding the study drug and a summary of the preclinical tests.

Each change in the study course should be notified to the authorities by filling specific administration forms (protocol modification, study suspension, study completion).

*Notification 698 of May 1980* does not provide much more information regarding clinical trials, requesting to submit ‘at least 150 cases in at least five institutions’ for a new ethical drug application for approval.

*Two guidelines notified in 1992* brought more detailed guidance on the purpose, methodology and assessment of the three clinical development phases:

- Guidelines for the Statistical Analysis of Clinical Study Results (May 1992)

- General Considerations for the Clinical Evaluation of New Drugs (June 1992)

- And, including ICH standards, the General Considerations for Clinical Studies (April 1998)

**Phase I** should estimate a range of safe dose levels up to a maximum tolerated dose, and characterize the PK profile of the study drug in humans. Generally, a single-dose study and a one-week repeated-dose study are conducted in a small number (six to eight) of healthy male volunteers. Food effects, drug interactions and bioequivalence studies nowadays belong to this clinical pharmacology phase, as well as PK in the elderly and studies in subjects with poor kidney or hepatic function.

**Phase II** is traditionally divided in two sequences: Phase IIa or early Phase II; and Phase IIb or late Phase II. Phase IIa is generally an open study with three or four arms, performed to explore efficacy and safety of three or four doses in patients, and it should also bring supplementary information regarding PK parameters. This is different from conventional phase IIa, which is Proof of Concept Study (POC). Phase IIb is a double-blind study comparing the effects of two or three doses to placebo effects, aiming at the determination of the optimal dose and dose regimen for a specific indication. It should be noticed that placebo use is not mandatory, but is used ‘if necessary’. The final galenic formulation and dosage forms of the study drug is required for the conduct of phase IIb.

**Phase III** should confirm the efficacy and safety of the optimal dose and dose regimen in a large group of patients under the usual therapeutic conditions. A large randomized double-blind trial should be conducted versus a reference drug (traditionally, a reference drug in Japan has been marketed for at least six years, and its efficacy and safety has been confirmed through the reexamination procedure).

Long-term trials have now to be conducted and meet international standards, the Extent of Population Exposure to Assess Clinical Safety (it was difficult in the past to obtain long-term data). Some open phase III trials might be added to study particular patient subgroups, for example the elderly, or a specific subgroup of the disease.

The guidelines on statistics indicate how to analyze the study results properly and introduce international and validated standards for the statistical evaluation.
Specific guidelines. With regard to certain pharmacological or therapeutic classes, several specific guidelines have been published since 1980, describing the type of data necessary for a NDA and how to generate these data. Twelve guidelines have been published, in different clinical fields; guidelines for clinical trials on urinary tract infections and on dysuria are to be announced soon; other therapeutic fields should be covered in the coming years.

ICH guidelines. In addition to these Japanese original guidelines for clinical development, internationally harmonized guidelines are now implemented in Japan:

- Clinical Trials in Special Population (Geriatrics)
- Dose–Response Information to Support Drug Registration
- The Extent of Population Exposure to Assess Clinical Safety
- Clinical Safety Data Management (Definition and Standard for Expedited Reporting)
- Clinical Study Reports: Structure and Content
- Clinical investigation in Pediatric population
- Choice of Control Group and Related Issues in Conducting Clinical Studies

International Good Clinical Practices. Finally, all clinical studies supporting a drug registration should comply with the harmonized Good Clinical Practices, which were enforced in April 1997.

Other development rules and practices

1. Regarding the clinical development organization, some aspects were unique to Japan (Labbé, 1995). Traditionally, an investigators’ committee will take full charge of the clinical development from Phase I or Phase IIa through Phase III. The committee consisted of a chairman, a senior leader in his specialty, chosen by the pharmaceutical company. The chairman recommended key investigators and well-known experts to the sponsor (See fig. 35.5).

Each of the five or eight key investigators recommend several medical institutions, public or private, where the investigators performed the clinical trial. The investigators’ committee was supposed to write the clinical protocol, to follow the study progress and to propose action when something wrong happen (serious adverse events for instance), to decide whether to keep or reject a case report form before statistical analysis, and to write the clinical study report. They met and worked under the supervision of a government controller (often a clinical pharmacologist).

There is usually, for one indication, one study per phase from phase IIa, and all trials are multi-center studies. Regulations required around 100 patients for phase II and 200 for phase III; however, 1000–1500 cases are commonly submitted to date in the NDA; as one investigator may produce only one, two or three case reports, 30, 80 or more investigators may consequently be involved in a phase II or III trial.

Clinical development has to progress step by step, according to the general guidelines; after each phase, the steering committee of investigators decided whether the study results justified whether or not to proceed to the next step. It was surprising to notice that the placebo was not considered as mandatory in dose determination studies (always mentioned in the protocols as ‘placebo if necessary’), and it was never used in phase III studies, for ethical reasons, unless no reference treatment is available. This is still true today.

These specificities and many others are changing with the implementation ICH guidelines, for example, the enforcement of the new GCP abolishes the traditional Steering Committee of Investigators, the ‘controller’ is only responsible to warrant the ‘blindness’ of the trial. However, it generally takes a long time in Japan to modify such strong traditions, and they will probably still be in practice for some years more.

2. Foreign data could be helpful to reduce the six to eight years necessary for clinical development
in Japan. However, the clinical development of a foreign drug has to be duplicated in Japan from phase I to phase III, because of potential genetic differences, diet and medical practice differences. Key data in the NDA are Japanese data; the foreign clinical data package is only considered as complementary information, only used when safety issues are raised during the approval process.

Some clinical pharmacology studies only can be accepted as key data, such as drug interaction studies or kinetic studies in renal or hepatic insufficiency. The topic ‘Ethnic factors in foreign data acceptability’ (E5) was passed in 1998 in Japan and ended after six years of discussions; it is now recognized that cultural factors are far more important than genetic differences (ICH 2 Proceedings, 1993; ICH 3 Proceedings, 1995).

This allows for a regulated mutual recognition of clinical data, which should significantly reduce the number of useless duplications of clinical studies and consequently save development resources (see Chapter 18).

3. The import of a foreign study drug is strictly regulated: imported amount of bulk and/or pharmaceutical form should be clearly justified and limited to the exact quantity necessary for the development. When a clinical trial protocol is available, a copy has to be submitted for approval by a customs officer with a Drug Import Report Slip (Form 12) and a copy of the invoice. When the protocol is not available, a certificate from the Inspection and Guidance Division must be obtained after submission of the following documentation: an Import Report Form (Form 1), a Drug Import Report Slip (Form 13), a Memorandum (Form 2), a protocol outline, a Memorandum stating that the protocol will be submitted within three months and a copy of the Drug Import business license.

The labeling of the study drug should mention, on the drug packaging, container or wrapper, the fact that the drug is for study purposes, the name and address of the institution, the chemical name or symbol, the manufacturing code number, storage instructions and expiry date.

The anticipated brand name, indications or effects, and directions for use and doses of the trial drug should not be mentioned on the drug container or wrapper or on any document attached to the trial drug.

### 35.5 New drug approval process

#### Content of the New Drug Application (NDA)

Once the clinical development is completed, four to six months are necessary to prepare the presentation of the NDA, which should be as perfect as possible. The content of the NDA is defined by the notification of April 1999, ‘Approval Application for Drugs’. The ICH agreement induced several revisions in July 2001 and June 2003, to describe the preparation of the CTD, enforced in April 2005.

**Module I:** Regulatory information such as application forms and information on attached documentation. Module I is region specific.

1. Table of content.
2. Approval application (copy).
3. Certificates.
5. Background of origin, discovery and development.
6. Data related to conditions of use in foreign countries.
7. List of related products. Comparison of the main characteristics of the drug with those of similar drugs already registered in Japan.
9. International Non-proprietary Name (INN) and Japanese Accepted Name (JAN) publications.
10. Data for review as powerful, poisonous drug and so on.

11. Draft plan and protocol for PMS.

12. List of attached documentation.

13. Other documents.

Module II, Data Summaries (the GAIYO in Japanese), and Module III, Quality, Module IV, Safety, and Module V, Efficacy, are common to the ICH Regions. Please refer to the ICH M4 guidelines.

Foreign data attached to the NDA are not necessarily translated in Japanese. They may be submitted in English, with a Japanese summary; this is not mandatory however, for original English entries of the CTD.

Review process

Before submission of the NDA to the Authorities, the dossier is carefully checked because no other data, unless specifically required by the MHLW, can be added after submission. No clinical trial with the study drug is allowed on Japanese territory once the review process has started, unless authorized by the Authorities.

The application for approval is submitted to the Health Authorities through the prefectural branch of the MHLW (Figure 35.6). The 2006 total application fees (MHLW+PMDA fees) are ¥16,881,800 (around $140,000) for the first dosage of a new ethical drug, and ¥4,235,300 for each further dosage (about $35,000), ¥12,018,400 (around $100,000) for the first dosage of an orphan drug and ¥3,011,100 (around $25,000) for each further dosage, ¥441,300 to 655,300 (around $4,500) for a generic drug, ¥129,600 (around $1,000) for a non-prescription drug.

The NDA is transmitted to the PMDA which first conducts a reliability and a GLP compliance review. When the data quality is confirmed, specialized team of experts review the NDA data and prepare a list of requests and questions addressed to the applicant. After receiving the answers from the applicant, a review report is prepared. Samples of the active principle might also be requested, for analytical control by the National Institute of Health Sciences.

A meeting with Clinical Experts is then organized with the review team members of the PMDA (Specialists Meeting) to discuss key issues of the

![Figure 35.6 Approval process overview](image-url)
At this stage, within six months after application, a hearing is generally held between the reviewers and the sponsor, which may today be accompanied by its own experts.

Another ‘follow-up’ meeting is organized between the reviewers and the specialists, and a second review report is finalized. The report is transferred to the Evaluation and Licensing Division of the PFSB. After a careful reading, the report will be circulated to the Committee on New Drugs of the PAFSC.

When the subcommittees are satisfied with the review report, the dossier goes back to the PFSB with a recommendation for approval. The minister will officially grant the New Drug Approval to the pharmaceutical company, through the prefecture. Around 18–24 months are necessary to obtain a new drug approval if there are no special issues, 6 months for a quasi-drug, 3 months for cosmetics and 12 months for a medical device.

A New Drug Approval Information Package is prepared from this report, and is published, available to medical institutions.

**Summary of the product characteristics**

The data sheet is called the ‘package insert’ in Japan, as it can be found in the drug packaging. The data sheet is drafted by the company and checked and completed by the authorities after the NDA review and the recommendation for approval. The content has been defined by the MHLW notification, and was revised in May 1997. Besides general information on the product, the most important entries are warnings, precautions and contraindications, and a list of adverse events quantitatively reported. These entries will be revised if necessary, with the safety data regularly analyzed for the periodic safety update report; however, an ad hoc revision is made at any time in case of serious events.

**NHI price fixing**

Prescription drugs are listed on the National Health Insurance Drug Price List in order to be reimbursed under the National Health Insurance Program. The price is fixed by a commission, including medical doctors, consumers, Central Social Insurance Medical Council representatives (‘Chuikyo’ in Japanese). Recent available treatments serve as price references and premiums of 3–100% are added to compensate for novelty and clinical advantages. The NHI price needs two to three months after the drug approval to be listed on the drug tariff. The product can be launched the following day.

### 35.6 Post-approval activities

From the first day of its launch, the drug enters the PMS period until the end of its marketing life cycle. Besides phase IV trials, the regulation of which are under reorganization and which should meet GCP standards, post-approval activities mainly aim at ensuring the new drug safety and efficacy. For such purposes, a surveillance system has been settled by the PAL. It consists of three different types of investigations: the ARD collecting system; the Reexamination and the Re-evaluation. Quality standards for those three activities are defined in by GPMSP (cf. earlier section in this chapter).

**PMS organization**

Several systems allow the collection of drug adverse events and their assessment by the MHLW as shown in Figure 35.7:

- **ADR Monitoring System**. Voluntary reports on ADRs are sent to the MHLW from around 3000 facilities designated by the MHLW, including national hospitals, and university and municipal hospitals; it is also called the ‘hospital monitoring system’.

- **Pharmacy Monitoring System**. This is a similar system, collecting ADRs related to non-prescription drugs, by designated pharmacies. Around 2800 pharmacies report ADRs to the MHLW.
- **Medical Device Monitoring System.** Another similar system reports to the MHLW the problems encountered with medical devices.

- **Manufacturers (and wholesalers)** should also report ADRs to the MHLW, according to the Law.

The type of ADR to report and the time limits are defined by the international guidelines on Safety Data Management. In addition, periodic safety update reports are sent to the MHLW with respect to these international standards. Traditionally, in Japan, ADRs are classified into three grades (mild, moderate, severe), according to severity criteria, and into function of the body apparatus.

The MHLW collects and exchanges ADR information through other sources:

- **WHO International Drug Monitoring Program.**

- Relations with foreign health authorities, such as the FDA in the United States and the EMEA in the European Union.

- Survey of medical journals.

- Relations with universities and national institutes, and so on.

The safety information collected on a drug is assessed by the PAFSC (subcommittee on ADRs evaluation), and when necessary, the MHLW instructs the manufacturer to take measures such as

- the revision of the data sheet (warning, dose, etc.);

- to conduct new investigation in animals or in humans;

- to discontinue import or manufacturing;

- to recall drugs from the market.

**Reexamination**

The Reexamination system is part of, and complementary to, the PMS. After a certain period of marketing, safety and efficacy data are reexamined in the light of data collected during this period, which is

- six years for new drugs (extension up to 8 years update discussion), combined drugs and new administration route;

- four years for a new indication, or a new dosage;

- ten years for orphan drugs.
Reexamination aims at confirming the conclusions from the drug approval and particularly the daily recommended dose, treatment duration, safety in long-term use, and so on. The manufacturer should apply a reexamination file three months before expiration of the six-year period for a new drug.

The dossier contains data from case report forms collected from hospitals. The number of cases is around 3000–4000 observations, reporting prescriptions on a routine basis (survey of use). Safety information comes from this particular survey and from spontaneous ADR reporting (serious events reports and the synthesis of the periodic safety update reports). Of course, information on measures taken during the period should be added (modification of the data sheet, etc.), as well as updated information regarding approval of the drug in foreign countries.

The Safety Division is in charge of reviewing the application; subcommittees and committees of the PAFSC will carry out the scientific assessment of the data and will either confirm the usefulness of the drug or ask for modification of the data sheet.

**Reevaluation**

The spirit of the Reevaluation system is different from that of reexamination. Here, the efficacy and safety are reconsidered in the light of the evolution of medical sciences and regulatory progress. The reevaluation is nowadays periodical, that is, every five years after the reexamination (Figure 35.8); however, ad hoc reevaluation can occur at any time upon request of the MHLW, when efficacy or safety is questioned for some therapeutic groups. Reevaluation is done for each drug designated by the MHLW; drugs are usually grouped by therapeutic categories for reevaluation; consequently, it may happen that for a given drug, reevaluation is performed just before the reexamination, as reevaluation is not directly dependent on the approval date. Additional studies might be requested by the MHLW to keep the drug on the market if the available data are not consistent with the present regulations and/or medical knowledge. If a drug designed by the MHLW does not undergo reevaluation or does not show evidence of usefulness, the drug approval is cancelled.

So, from approval to market withdrawal, the drug dossier is a ‘living substance’, regularly completed by the pharmaceutical company and periodically revised by the health authorities.

### 35.7 Conclusion

Japanese regulations regarding drug development and PMS were recently amended, because of the progress of the ICH program, and for other reasons, such as recent incidents related to contaminated blood infusion and a fatal interaction between an antiviral and an anticancer drug, which most probably prompted the changes. However, there is a strong will from the Japanese authorities to apply international standards to drug development, particularly in the clinical field. The introduction of new GCP and GPMSP rules deeply modifies the background of the traditional Japanese R&D: the industry has to modify its structure and take over new responsibilities, hiring medical doctors in order to organize
medical departments for clinical R&D and to assess ADRs. The predominant role of the investigators will decrease. The drug evaluation system by the authorities will have to be modified as well, it already shows however a strong will to a more scientific evaluation with the creation of the Japanese Drug Agency (PMDA).

The move is not limited to drug research and development. Many other fields are involved in this general evolution of the Japanese healthcare system: for example, the separation of prescription from dispensing (‘bungyo’) made recent progress; an important NHI price reform is under discussion, which could be a step toward a large change of the health insurance system.

In conclusion, the rapid evolution of the drug regulations may invalidate this chapter within a few years, but it is important for the pharmaceutical industry to understand that the whole drug environment moves toward international standards under the pressure of the scientific progress, quality requirements and economical issues. It represents a chance to integrate Japan in the conception of the global dossier, for which ICH has already laid the foundations.

References


36 Drug Registration and Pricing in the Middle East

Edda Freidank-Mueschenborn

36.1 The market

Commercial and cultural background

The Middle East is comprised of 14 independent countries located on the Arabian peninsula: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates (UAE), Yemen, Syria, Lebanon, Israel, Palestine, Jordan, Egypt, Iraq and Turkey. The peninsula is bound by three bodies of water: the Mediterranean Sea to the north, Red Sea to the west and the Arabian Sea to the east and south.

The region is not homogeneous. Individual countries differ significantly in government, economics, per capita income, size, population and religion. For example, Saudi Arabia is the largest country with 2 million km², cf. Bahrain with only 711 km². Yet Bahrain is the most densely populated country (917 people/km²) with Oman at the other extreme (9 people/km²). Absolute monarchy is found in Kuwait and complete democracy in Lebanon. The distribution of Islam, Christianity and Judaism will be familiar, with some countries almost totally one or other, whereas others are more mixed (e.g. 40% of the Lebanese population is Christian).

In many Middle Eastern countries, the economy pivots on the sale of oil. However, phosphate production and tourism (Jordan), aluminium and textiles (Bahrain), citrus growing (Israel) and so on are less well known. Gross domestic product (GDP) per capita per year ranges from $1527 in Yemen to more than $26 000 in UAE.

Arabic is an official language used by all regulatory authorities in the Middle East. However, some will also accept documents in English or French, and Israel also accepts documents in Hebrew.

For most of these countries, health systems are very modern and up-to-date. There is an average of one physician for every 500 people in the region as a whole, and in some countries, especially the wealthier oil states, medical service and medicine is free. There are exceptions however, usually being the poorest and least peaceful states in the region.

An important difference between the Middle East and other high-quality medicine regions, however, is the population served. Only 30% of the population in the Middle East is over 30 years of age, unlike the inverted age ‘pyramids’ found in Europe and North America.

Important authorities/organizations

Authorities

The competent regulatory authorities in the Middle East region are the Ministries of Health (MoH) in
each country. These control the whole process of product approval from application formats to pricing. A small exception is in Egypt, where the regulatory authority is subdivided; the National Organization for Drug Control and Research (NODCAR) works together with the Central Administration for Pharmaceutical Affairs (CAPA) and the Drug Policy and Planning Centre (DPPC), all being within the Ministry of Health and Population (MoHP).

Realizing the benefits of harmonization, the following countries now accept a standard format marketing application: Saudi Arabia, Bahrain, Kuwait, Oman, Qatar and UAE. These are coordinated by the Gulf Central Committee for Drug Registration (GCC-DR). In August 2004, applications could be submitted to the GCC-DR, and a two-year transition to this becoming mandatory was under discussion. Otherwise, nation-by-nation applications within the GCC-DR territory are made, and most companies taking this regulatory route prepare their dossiers to a standard acceptable in Saudi Arabia, which probably has the most rigorous review system in the region (see also the Appendix).

**Other organizations involved in regulatory affairs and health policy**

The *Levant Industry Group*, founded in 1995, is headquartered in Amman, Jordan.

Its objective is to represent the pharmaceutical industry in dialogue with governments in healthcare issues. Its membership includes pharmaceutical companies that are active in Cyprus, Jordan, Lebanon and Palestine.

The *Pharmaceutical Research and Manufacturing Affiliates* (PhRMAG) was founded in 1999, and is based in Dubai (UAE). Its objective is to represent the pharmaceutical industry in dialogue with governments in healthcare issues and to communicate the value of innovation and research. Its membership is mainly the Middle East affiliates of European and American pharmaceutical companies that are active in the five Gulf States (Kuwait, Bahrain, Qatar, UAE and Oman).

The *Middle East Regulatory Conference* (MERC) was founded in 1995 by the pharmaceutical industry. It meets annually in different countries by rotation (most recently Dubai, Cyprus, Bahrain and Egypt). The objectives of the MERC are to facilitate communication between the regulatory authorities and the industry, to understand and discuss registration requirements and their relevance, to provide updates on new trends and concepts, to align perceptions of both the industry and authority, to facilitate discussions on current and key issues, to seek solutions, and generally to continue to build trust and partnerships between industry and authorities.

### 36.2 Company and product registration

The registration process of pharmaceutical products in the Middle Eastern countries differs from all other regions of the world in that an additional company registration is required in addition to individual product applications. The company registration includes documentation for each manufacturing site and all the relevant company subsidiaries. In some countries, this company registration must be approved prior to product registration (Saudi Arabia, Bahrain, Oman, Syria, Iraq and Yemen), whereas elsewhere company and product registration applications can be filed in parallel (Egypt, Kuwait, Qatar, UAE, Jordan and Lebanon). Some countries (e.g. Saudi Arabia and Yemen) make inspections during or after the company registration process. Applicants in these countries can expect to pay the costs for two or three inspectors for the duration of that inspection, which usually lasts for about a week.

**General requirements for company registration**

Documentation for submission:

- Application form/questionnaire, which is country specific. Information pertaining to the company size, staff, equipment, production and quality control.
- Company profile.
Good Manufacturing Practice (GMP) compliance.

Research & Development (R&D) activities.

Product information.

There are no time limits for the review of company registrations by the regulatory authorities, and long delays are commonly experienced (up to three years, especially in Turkey and Oman). Furthermore, the bureaucratic process is also not streamlined. Legalizations by the equivalent of a Notary Public are obligatory for many certificates, confirmations and leaflets. Sometimes, it seems that no piece of paper moves without a rubber stamp.

**Drug registration (see Figure 36.1)**

Product classification: As a first step, the relevant Ministry of Health (MoH) classifies the new drug into one of

- Prescription only medicine (POM), for e.g. new chemical entities or narcotics.

**General process**

**Process in Egypt, Kuwait, UAE, Jordan and Qatar**

*Figure 36.1* Flow chart for the company and product registration process in the Middle East. During examination of the application, many interim responses are usual to meet the requests of the Health Ministry (MoH) concerned.
Pharmacy only, and there are differences (with sub-classes for over-the-counter (OTC) products and herbal medicines.

Food supplements or cosmetics.

The regulatory application requirements are different for each category, with most needed POM products, and least for food supplements or cosmetics.

General requirements for product registration

Documentation for submission

- A country-specific application form.

- Certificate of a Pharmaceutical Product (CPP) according to the format issued by the World Health Organization (WHO).

- Dossier with administrative data, pharmaceutical, pharmacological–toxicological and clinical documentation.

The dossier should include the following:

- Documentation similar to that specified in the Notice To Applicants (NTA).

- Stability data (which are probably more stringent than elsewhere in the world); three batches must be tested at three different temperatures/humidities for the complete shelf life: 25 °C/60%RH and 30 °C/70%RH. Additionally, six months, 40 °C/75% RH must be studied.

- Specific documentation with regard to pharmaceuticals containing alcohol, which usually have the most difficulty during the registration process (especially in Saudi Arabia). Special declarations, confirmations and statements of interest are necessary to convince authorities which prefer the traditional absolute ban on alcohol.

- Expert reports on pharmaceutical, pharmacological–toxicological and clinical data.

- Supporting literature from any source.

- Price certificate, which is country specific, sometimes in three forms, Cost Insurance Freight (CIF) price, wholesale price, retail price.

- Finished product samples with Certificate of Analysis (CoA).

- Packaging (leaflet has to be part of the CPP for some countries, e.g. Jordan, Israel).

- Reference substances with CoA.

Pricing

Pricing is part of the registration process, and in some countries, pricing is strictly tied to some other parameter, for example, the lowest price in Europe or elsewhere in the Middle East region (see also Appendix).

Product launch

After approval, the registered product must be launched within a certain time period – usually one to two years. At the time of launch, in most countries, the product supply must meet a definition of ‘fresh’, that is, that at least two-thirds of the product’s shelf life must be remaining. Usually, the product must also be registered and sold in the country of origin. It should have the same trade name, composition, shelf life (confirmation often required as an attachment to CPP, e.g. UAE) and leaflet. Exceptions are possible; often it depends on good contact with the partner in the country.

Labeling

The package insert must be like the leaflet of the country of origin, pending an officially approved translation in some countries (Saudi Arabia, UAE,
Jordan and Oman). Otherwise, the language can be English and/or Arabic. Nonetheless, inadvertent offence must be avoided in these religious countries. Objections to labeling can come from unexpected quarters in a region where there are cultural obstacles to the use of terms such as ‘naturally powerful’ or ‘uses the knowledge of nature’ in advertising, which will not be acceptable in Saudi Arabia and some other countries because of an underlying presumption within the concept that only Allah is all knowing, and therefore that only Allah is powerful.

**Line extensions**

Line extensions, for example, an alternative route of administration, are approved with similar requirements for documentation to primary applications for new chemical entities.

### 36.3 Summary

The Middle East is a complicated region for the inexperienced regulatory affairs officer. A local affiliate, who will act as an intelligent professional partner and can manage the product registration details with the Ministries of Health, is a major advantage for doing business in this region. Business plans and financial models must anticipate the possibility of long approval times, and direct contact between applicant and regulatory authority, or between Ministry and Marketing Authorization Holder (MAH) is unlikely. Lastly, during Ramadan (currently mid-October to mid-November in the European calendar), most regulators’ offices, pharmaceutical companies and distribution channels operate with minimal activity.

### Appendix: application process

#### New application

This requires classification as to prescription-only, and so on.

#### ‘Variation’

The documentation depends on the kind of change:

<table>
<thead>
<tr>
<th>Change</th>
<th>Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composition</td>
<td>CPP, updated documents, stability, samples</td>
</tr>
<tr>
<td>Shelf life</td>
<td>CPP, stability data, samples</td>
</tr>
<tr>
<td>Leaflet</td>
<td>CPP, updated leaflet</td>
</tr>
<tr>
<td>Pack size</td>
<td>CPP, stability data, samples</td>
</tr>
<tr>
<td>Price</td>
<td>Price certificate</td>
</tr>
<tr>
<td>Analytical methods</td>
<td>Updated pharmaceutical documents</td>
</tr>
</tbody>
</table>

CPP: Certificate of a Pharmaceutical Product.

#### Renewal

Most countries have a re-registration system. Approvals are valid for five years. Three to six months before the expiration date of the marketing authorization, an updated file must be submitted. In some countries, it is sufficient to submit only a new CPP, such as in Lebanon.

#### Certification/legalization procedures

As mentioned in Section 36.2 of the chapter, legalizations or notarizations play a major role in the registration process in Middle East countries. Even if, as a premise, a relationship based on trust and honor exists between the authority, partner and applicant, Ministries will still insist on several confirmations, certifications, declarations and so on, additional legalization may also be required from the Embassy of country of the product’s origin. A common request for a declaration is to give a statement that the product does not contain any substances from animal sources (especially pork) or that products are alcohol free.

Difficulties also arise in unexpected quarters. Regulatory authorities may have a particular respect or regard for some forms of notarization and not others. Thus, the identity of the notarizing entity can count for as much as the notarization itself. Furthermore, even when the notarizing entity is
well respected, the very form of the notarization can cause concern. For example, Jordan only accepts documents from the German regulatory authority (BfArM) when they bear the old-fashioned rubber stamp with its image of an eagle. Personal contacts and people with deep local experience become mandatory under such conditions.

**Pricing**

For pricing, the classification is necessary to determine if the product fits into a category that needs price fixation, or not. Normally, for all prescription products and some OTC products, a price fixation is obligatory. For OTC products, it depends on the active substance and the indications mentioned for the product itself. No price fixation is necessary for products that are herbals and food supplements, nor for cosmetics.

For pricing, the process starts by submitting a legalized certificate for the specific product with the following information on it:

- Name of the manufacturer or marketing authorization holder.
- Name and address of the local partner.
- Wholesale price in the country of origin.
- Registered price in neighbor countries (if available).
- Suggested CIF in the specific country.

Such a certificate has to be signed by the manufacturer and must be legalized by the Chamber of Commerce and the Embassy of the concerned country. Innovative products will generally receive a price that is higher than for a follow-on product with the same, or similar, active ingredient. Generics must accept a lower price. The basis for price finding is always evolving, and an average price, using the three lowest prices from the region itself, is a recent development.

The time needed to obtain a price is usually about months, depending on the MoH.

Saudi Arabia has a separate pricing committee, which considers ex-factory wholesale price, public price in the source country, export price to Saudi Arabia, and export price of some 30 other countries. Normally, the lowest price found will then be awarded.

**Tender**

Governmental companies or institutions, for example, army or hospitals, offer tender business throughout the Middle East, on an *ad hoc* or annual basis. It is even possible that unregistered products can be tendered for, especially when serious diseases or the need of huge amounts of medicines exist. Every company can apply for a tender; the government will choose the most appropriate one, depending on quality and price.

**The GCC-DR**

The member states are as follows:

- Saudi Arabia
- Kuwait
- UAE
- Oman
- Bahrain
- Qatar

The executive office for the health ministers is located in Riyadh, Saudi Arabia. The committee consists of a chairman, two members of each of the six member states and a secretariat. The responsibilities of GCC-DR are as follows:

- Registration of pharmaceutical companies.
- Registration of pharmaceutical products.
- Inspection of pharmaceutical companies concerning GMP compliance.
Approval of quality control laboratories.

Review of technical and post-marketing surveillance reports.

Responsible for the program of bioequivalence studies as a part of quality assurance.

The aim of the GCC-DR is to harmonize company and product registrations between the member states.

Applications to the GCC-DR for company registration (original plus six copies) must include the following:

- Application Form
- GMP certificate (needs legalization, preferably from Saudi Arabian Embassy, but the other member states are also accepted)
- Manufacturing license
- Product information table
- Research summary
- In case of subsidiaries, certificates issued by the parent company
- Confirmation of payment of fee

After a positive evaluation, the company must prepare for the three-person inspection from the authority.

Documents which have to be submitted for the GCC-DR Product registration (original plus six copies) include the following:

- Application Form
- Certificate of Pharmaceutical Product (CPP)
- Dossier
- Fifteen finished product samples (with CoA)
- Fifteen samples of packaging material (labeling needs health authority approval, leaflet should be in Arabic and/or English)
- Animal source information, percentage of alcohol (if applicable)
- List, in which countries the product is registered
- Confirmation of payment of fee

The GCC-DR review of the dossier

At the first stage, two member states make a review and compile an evaluation report, which is then reviewed by the committee. Afterwards, the preliminary technical and pricing approval follows.

The second stage includes the laboratory analysis (only performed in Saudi Arabia, Kuwait or UAE). Then, a GCC-DR registration certificate is issued. Thereafter, each member state issues its own national license, usually after receiving payment of fees.

References

Auswaertiges Amt, Deutschland (July 2004), www.auswaertiges-amt.de.
Deutsche Gesellschaft für Regulatorische Angelegenheiten e.V. (2003)
RAJ August 2001, Sabih R Kukhun, Registration in Saudi Arabia, p 645 ff
RAJ September 2000, Taha Gihan, Registration of medicinal Products in Egypt, p 318 ff
SECTION VI
Medical Services

Introduction

This section covers the area that is typically termed ‘Medical Affairs’ in pharmaceutical companies. The specific areas of knowledge and capability are described in the following chapters, but a few words on the less tangible aspects of this subspecialty might be offered here.

Firstly, the term is somewhat of a misnomer: many different professions contribute to an effective Medical Affairs department. The tasks of such departments are diverse and include everything that has any, even tangential, clinical implication. These may include developing old drugs for new indications, post-marketing commitments for newly approved products, pharmacovigilance, marketing, promotion, price negotiations and so on.

Secondly, these diverse tasks bring diverse responsibilities. Very often, those working in Medical Affairs departments will find themselves in the role of an in-house ombudsman. It is here that ebullience in the Marketing department must be tempered with realities of labeling, where pharmacovigilance signals are sifted and corporate responses to them are designed, and the clinical impact of manufacturing deviations must be assessed. If the Company must defend itself in litigation, then it will be the medical affairs specialists who will have to ensure that the lawyers are properly educated. These can sometimes be lonely roles, because insistence on their performance is often counter to short-term financial aspirations elsewhere in the Company.

The best medical affairs specialists are those with long experience. Although these chapters contain a useful knowledge base, nothing can replace several years’ experience ‘in the trenches’ of a vigorous Medical Affairs department. The role can be the most stimulating of any in the industry, and it suits well the versatile generalist.
37 Medical Affairs

Gregory P. Geba

37.1 Introduction

The role of clinical trials in evaluating efficacy and safety of drugs extends well beyond the regulatory environment of registration with health authorities. Due to the tremendous costs and time associated with drug development, the strategy involved in drug registration is one that employs a process that favors taking the most direct route to answer specific clinical efficacy and safety questions that would allow health authorities to judge the benefit–risk profile of a drug and secure marketing approval for specific indications. It is, however, rare that a drug has only one use, and almost every new medicine can be employed in different clinical scenarios, in different patient populations, be studied to assess different clinical outcomes and compared to other drugs of the same or other classes in already approved indications. Such studies are usually the focus of clinical research departments that are organized under the rubric of ‘Medical Affairs’ to distinguish them from ‘Clinical Development’ departments that are focused on the submission of the New Drug Application (NDA).

Medical Affairs divisions are usually fully capable research organizations housed within large pharmaceutical companies, that are comprised of medical, clinical and managerial staff (usually healthcare-oriented clinical staff including physicians, pharmacists, public health experts and statisticians), as well as very extensive support staff that includes clinical research associates (in-house or field-based personnel who are the direct contacts for investigational site interactions and communications), scientific liaisons, data analysis, medical writing, regulatory and legal personnel. The goal of such organizations is to allow pharmaceutical companies to most effectively conduct clinical trials or statistical analysis, prepare and submit data and claims to regulatory authorities and disseminate information via meetings and symposia, and peer-reviewed journals of high scientific value, enhancing understanding and public health impact of marketed medicines.

Medical Affairs departments are frequently capable of conducting various types of clinical research. The type of research culminating in the further categorization of the efficacy and safety of a new medicine can take the route of conventional phase III clinical development, sometimes conducted by a Medical Affairs division, whereby a new indication is sought. Another approach is to perform necessary clinical trials and seek approval to promote features of benefit–risk that are supported by clinical data, with or without requesting change of registered label use. This phase of
research is often referred to as phase IIIb, if conducted prior to or after dossier submission, but prior to marketing approval. Other approaches include the design and execution of clinically important trials whose results are disseminated principally via their scientific publication to more or less targeted, broader clinical audiences. These approaches have in common the necessary requirements to adhere to principles of good clinical practice (GCP) and clinical trial ethics. Clinical trials for any reason need to comply with the principles outlined by the Belmont Report, the Declaration of Helsinki and the International Council for Harmonization (ICH) guidelines, and thus are hypothesis-driven studies that appropriately take into consideration the risk and benefit of clinical trial participation, and assure adequate statistical power to maximize the likelihood of obtaining a result that is scientifically rigorous and interpretable.

Other objectives of later phase clinical research include addressing health authority commitments after the drug has been approved (phase IV commitments) which can focus either on safety or efficacy questions that were not fully addressed in the registration package, or the establishment of patient registries to exclude the possibility of very rare adverse events that require a very large population-level exposure to reliably exclude specific adverse outcomes. Clinical trials of this sort, in the phase IV environment, are pursued to provide further information to health authorities and clinicians as to the long-term safety and efficacy of drugs that otherwise have been demonstrated in earlier clinical research phases in trials of generally shorter duration. This includes the provision of data showing efficacy and safety in pediatric populations, if this had not been the focus of the original registration of the drug. The process, thereby, accelerates the availability of valuable new medicines, while at the same time fostering design and execution of additional research to further categorize the drug via the conduct of these later stage clinical trials or monitored use programs.

Additional research efforts conducted at the Medical Affairs divisions of pharmaceutical companies include the study of Health Economics and Clinical Outcomes Research, which examines the effect of drugs on the cost of healthcare delivery, as well as effects on patient-reported outcomes such as quality of life. In addition, useful summaries of efficacy and safety can result from data mining of pooled databases, conducted by clinical and statistical personnel in Medical Affairs divisions, often in collaboration with external scientific advisors, to provide further information concerning the safety and efficacy of marketed drugs.

### 37.2 Phase III and phase IIIb studies

Clinical trials falling under the rubric of phase IIIb are those that are performed with all the rigor of the phase III registration program, but for a different purpose. Most commonly, such studies, designed while the phase III program is nearing completion and often initiated prior to NDA submission and conducted during agency review, are performed for the purpose of data dissemination during or just after launch of the new drug. The type of study that is often performed is a randomized double-blind comparator study to assess the safety or efficacy of a drug, compared to another of its or another class which is indicated for a specific medical condition. Hence, these trials usually employ the same outcome measures used in the phase III program. Many other types of designs can be employed including, but not limited to, single-blind studies, open-label trials, crossover studies and other types of clinical trials that aim to provide additional efficacy or safety information that would assist clinicians in assessing the value of the new drug in their medical practice. Importantly, this is not the same as increasing potential market uptake of pharmaceuticals through ‘experience’ trials which are not scientifically driven, but rather represent hypothesis-driven clinical trials with clear scientific rationale that are prespecified and adequately powered for, as documented in final study protocols.

The form of planned data dissemination will often influence the type of trial conducted. In the past, such choices could have included methods of communication from simple data sharing at invited scientific symposia to disclosure of research via publication in peer-reviewed scientific journals. As a response to the increasing scrutiny of medical
research at all levels, the approach today is much more robust and defined, largely driven by industry-initiated efforts to make access to clinical trial results more transparent. As this is not mandated by federal laws, but has been guided by academic groups interested in effective communications and clarity about the roles of listed authors on manuscripts (i.e. CONSORT guidelines), the approach can vary slightly from company to company, but usually takes the form of both online communication usually via company-sponsored web sites as well as disclosure by publication in abstract form with presentation at national scientific meetings.

Because the publication of a paper describing the results of a clinical trial is not guaranteed by journals, which accept papers for publication based on interest to the readership as well as the scientific methodology involved, the full communication of trial results in the form of a peer-reviewed manuscript may be delayed for some time after receipt of the final statistical report. Moreover, sometimes the data are available, the focus is commonly on preparation of abstracts for scientific meetings, which need to be submitted as early as one year prior to their presentation, and on the preparation of a detailed clinical study report (sometimes several hundred pages in length), containing all data from the trial, which are incorporated into the dossier submitted to regulatory agencies. Thus, communication in the form of abstracts and online publications, as well as the full disclosure of clinical trial results to regulatory agencies has acquired increasing importance in the process of data communication. In addition the use of public web sites to provide access to additional trial information has been recently implemented (see below).

In addition to such forms of publication, it should be noted that health authorities in the United States and other countries are also informed as to the design and goals of all clinical trials conducted by pharmaceutical companies, and are sent final protocols prior to the study investigator meetings. This allows time for these health authorities to comment on the same and suggest modifications to the design of trials, if needed, based on their specific scientific goals. In addition, communication of safety information from clinical trials beyond phase III is incorporated into Annual NDA Safety Updates which are also submitted to health authorities for purposes of ongoing safety monitoring of newly marketed drugs.

Another purpose of conducting clinical trials in phase IIIb is to provide practicing physicians with information concerning efficacy or safety of drugs soon to be in the market relative to other drug comparators. Trials of this sort, if performed with prespecified aims, outlined in a clinical study protocol, conducted via GCP standards and meeting prespecified study hypotheses relevant to the disease state being treated, can be submitted to a division of FDA which has responsibility for drug promotion – the Division of Drug Marketing, Advertising and Communications (DDMAC). This agency also regulates direct-to-consumer advertising and is responsible for approving presentation to the public of clinical trial data via promotional materials.

The usual procedure for obtaining regulatory approval for the dissemination of promotional detailing information that can be presented by sales associates directly to physicians is for the clinical trial results to be submitted to DDMAC along with proposed language, advertisements or detail aids which describe the study results. Such descriptions need to demonstrate balanced presentation of the efficacy and safety in treatment of indicated medical conditions. Analogous to the registration of drugs for marketing approval, the process can be lengthy, requires careful review of the dossier, often with input from the division originally responsible for approval of the NDA, supplemented by interactions in the form of discussions among scientific, regulatory and commercial associates and DDMAC. The final output usually takes the form of a pamphlet or handout which can be left with the physician by the sales or marketing personnel, which details the clinical trial results. Alternatively, trial results can be incorporated into direct-to-consumer advertising efforts, as appropriate. FDA can also require various types of action if promotional efforts are deemed inappropriate. This sometimes takes the form of letters which are directed to consumers or to practicing physicians, developed in order to
provide the necessary clarification and may represent corrective action.

### 37.3 Phase IV studies

Clinical trials conducted by Medical Affairs divisions that are categorized as phase IV studies are those that are conducted while the drug is already in the market. This can include safety and efficacy questions that arise on further experience with the drug, or the pursuit of clinical trials to examine the efficacy of the drug relative to newer agents entering the market. The two main types of studies that are performed are those that are pursued to respond to specific requests of health authorities which were stipulated in the initial approval of the drug (phase IV commitments) and those studies conducted to answer medical questions that are raised while the drug is being used in the clinic. The former can be considered studies analogous to phase IIIb studies which are conducted at a different time point in the product cycle, while the latter are usually the results of extensive discussion with health authorities aimed to answer specific questions raised by the agency itself or by members of advisory committees responsible for providing guidance to the health authority at the time of initial evaluation of drugs for approval.

Phase IV commitments can be varied in aims and scope. In order to expedite the market availability of novel drugs that can improve human health, health authorities make qualitative assessments of the value of delaying approval versus requesting more efficacy or safety information. A process that allows novel drugs to enter the market while assuring further safety and efficacy monitoring is to approve drugs with stipulations as to the types of additional studies a company will commit to performing in a reasonable time period after drug approval. These phase IV commitments generally take the form of longer trials assessing safety, or trials which address efficacy in specific patient populations which may be at greater risk of side effects or have the potential to experience a greater degree of efficacy, but were not studied in the program designed for original registration, as the latter usually focuses on patient population in which the drug would most likely be used.

The design of phase IV commitments can include the traditional approach of a randomized, double-blind, placebo-controlled study, an open-label trial or can be approached via the establishment of patient registries. In the case of comparative trials in a phase IV environment, drugs are much more commonly compared to other approved therapies. The use of placebo arms is much less common due to the desire to allow the most ‘real-world’ use of the drug (where placebo is not given). The vast majority of such trials are conducted blinded to study allocation to reduce the chance that identification of study drug biases the perceived benefits in favor of the novel medicine. There are, however, examples of phase IV studies that are conducted as ‘open-label’ trials, whereby both drugs can be identified by both patients and treating physicians. The ability to make definitive conclusions concerning relative safety and efficacy can be compromised by the potential for bias, particularly if the outcome measures chosen are patient- or physician-reported. Nevertheless, this type of trial can be reasonably conducted in evaluating the effect of therapy using more robust outcomes that would not be affected necessarily by knowledge of drug allocation, such as blood glucose levels, blood pressure measurements or time to myocardial infarction and so on.

Often the size of clinical trials in a phase IV environment, which provides sufficient power to assess outcomes between two drugs shown previously to be effective, is large. Thus, in this setting, perhaps more than any other, patient recruitment and retention are key to the successful enrollment and ultimate interpretability of trial results. Pharmaceutical, governmental (i.e. NIH) and academic groups sponsoring such phase IV studies often require additional staff to resource these trials adequately. An industry has developed to assist sponsors in the conduct of clinical trials, and can be of particular benefit to smaller companies which do not have the internal resources to conduct clinical trials on their own, or by larger companies whose resources are occupied in other trials. These include Contract Research Organizations (CROs) which can design, implement,
analyze and report the results of clinical trials, and Site Management Organizations (SMOs), which in large part participate in the recruitment and monitoring of randomized patients at individual or small groups of clinical research centers without the necessary staff to adequately follow clinical trial subjects.

Phase IV studies can also take the form of patient registries to determine the effect of a new drug on very rare outcomes. Such studies can be regarded as a form of industry-sponsored prospective cohort study. Generally these registries are established to exclude the possibility of rare adverse events which require very large sample sizes to detect. Registering users of the new medications while in the market and following outcomes as they occur with simple questionnaires is one way such research can be conducted. Within the cohort being followed, ‘nested’ case control studies can also be conducted to understand the association of very rare outcomes with drug exposure, adjusting for factors that could theoretically influence outcomes.

Because of the size of phase IV studies and particularly for those focused on adverse events, some special form of safety monitoring is generally indicated. Although this is more common in the phase III environment, where the safety and efficacy of the drug are less well known, with broad exposure of patients and large clinical trials even for phase IV trials, the potential exists for a large number of adverse events to occur prior to full analysis of the data, which would otherwise provide a signal as to a side effect meriting further evaluation. If trials are especially large or are enrolled very rapidly, this is especially useful.

Thus the creation of data and safety monitoring boards (DSMB) has become routine in pharmaceutical and government-sponsored trials. The responsibilities of DSMB are generally documented in a charter which stipulates the leadership and membership, as well as their roles and responsibilities. The main reason to establish a DSMB is to determine whether any safety signal is recognized sufficient to change the course of a clinical trial. Other reasons can include the establishment of a group of ‘disinterested’ individuals who are not directly connected to the trial to assess trial progress in regard to outcomes such as efficacy or safety end points that could lead to a sample size recalculation or protocol amendments. Usually these boards are comprised of prominent clinicians and clinical trialists in the field, epidemiologists and statisticians. There is usually also at least one ‘unblinded’ statistician with knowledge of treatment allocation, allowing analysis of data based on the treatment in order to assure that any adverse reactions can be reported to the DSMB according to treatment allocation, if appropriate. The DSMB is led by a Chairperson who organizes the board and establishes a schedule of meetings based on clinical trial metrics or time intervals. Decisions of the DSMB are communicated to the clinicians primarily responsible for trial conduct, which can include simply continuing the trial, modifying it via amendment or even potentially halting it.

37.4 Data mining in the phase IV environment

Phase IV studies can also take the form of retrospective pooled analyses which are designed to reflect the totality of clinical research experience with a new drug which is usually obtained via analysis of pooled clinical trial databases. Such ‘data-mining’ efforts should not be considered inferior to data obtained from the conduct of an individual clinical trial. In fact, there are substantial benefits of such an approach, as the results of a given trial, especially if the end point is not prespecified to be primary because of power limitations, can be a function of chance. To assure that the results obtained from pooled analyses are not biased, a prespecified data analysis plan is often formulated as the first step, outlining the clear goals of the proposed analysis as well as its methodology. Key to this type of analysis is the definition of the outcome measure. Both efficacy and safety measures can be the focus of these types of analyses.

Pooled analyses are commonly used to assess the safety of drugs that have been already evaluated on an individual subject level by adjudication committees. Such committees are usually comprised of a combination of clinicians, epidemiologists and statisticians, who meet to discuss the specifics of prespecified, suspected adverse events, in order to
provide the greatest precision in diagnosis. Typically if an adjudication committee is established to evaluate safety outcomes, detailed information concerning the adverse event of interest is requested of the clinical investigator shortly after the event occurs to assure that necessary and most accurate, complete clinical information is available for each event, which allows the committee to assess and categorize adverse events. Pooled analyses of data that are adjudicated across a large clinical program can provide the most robust assessment of drug safety. The strength of the approach lies in increasing the sample size available for the analysis, which increases substantially the ability to make more definitive statistical inferences. Because the sample size and, hence, power of the analysis is substantially greater, this approach can replace large clinical trials that would be very costly and time consuming. If the analysis is performed according to rigorous statistical methodology, the results can sometimes serve as a substitute for specific phase IV commitments.

37.5 Practitioner and investigator interaction

Medical Information and communications unit

Another major function of the Medical Affairs department is that of providing information about a company’s products. Their customers range from fellow healthcare professionals to the public and internal company clients. The frontline is usually comprised of nurses and registered pharmacists who respond to telephone and written requests for medical information about products, spanning clinical safety and efficacy questions. Companies often offer this service as needed and most can respond to clinical questions within 24 h of a request with specific and detailed information. A frequently asked question document is prepared to enhance rapidity of response. If this document does not provide the needed information, further research by Medical Information specialist, often in collaboration with internal clinical staff, is pursued to yield the necessary response. Callers are frequently retail pharmacists and physicians asking about potential drug–drug interactions and unsolicited requests for information on ‘off label’ use, which may have been described in a medical journal or at a medical meeting. The staff often provide articles that describe results from clinical trials, or information from studies conducted to assess ‘off label’ use that is clearly marked so that the clinician does not confuse this with approved use of the drug.

Medical writing unit

The Medical Information department may have its own medical writers dedicated to phase IV (post-approval) publications, booklets and pamphlets. Many large companies have a specific Medical Writing department usually reporting into the Research department, who will assist in writing clinical reports, publications and help prepare the clinical investigational brochure or NDA annual safety reports. These associates usually have science degrees and have been trained in technical and medical writing.

Drug safety and epidemiology unit

In many companies, even medium-sized companies, this unit reports into Medical Affairs. This is because it is responsible for tracking the safety record of the drug and because the largest use of a new drug or device will be after postmarketing. Rare serious adverse events occurring at the incidence of one in 10 000 patients will not be found in the average NDA database of 2000–3000 patients. A clear ‘signal’ may not emerge until many thousands of patients have been exposures which would allow discrimination from ‘background’ incidence of rare clinical adverse events. The mechanism of safety monitoring usually takes the form of adjudication of adverse events that occur in the setting of ongoing clinical trials by a blinded (usually external) committee and compilation of adverse events from pooled databases or by analysis of MedWatch reports provided via the Adverse
Events Reporting System (AERS) of the FDA which also continuously assesses the safety of marketed drugs. This is often supplemented by internal safety databases that are maintained by pharmaceutical companies separately from governmental databases.

Advertising, promotion and training overview

This activity often described as ‘The Medical and Social Conscience of a company’ largely resides in the Medical Affairs department. In most large- and medium-sized pharmaceutical companies this responsibility lies with Medical Affairs. The review of all materials, whether detail pieces provided in person to physicians in practice, slide sets for speakers on behalf of the company, general promotional material that is disseminated via print, radio, TV or web must be reviewed and approved by internal committees comprised of Medical Affairs staff, regulatory and legal personnel. In addition to the company review, this material must be sent to FDA at least by the first day of use. Review by FDA’s DDMAC should be sought for TV advertisements.

In addition, any Field Sales instructions, Public Relations, Financial Analysts Statements and Press Releases should be reviewed for appropriateness and approved or modified. Such review will also involve both the Legal and Regulatory Affair departments. Moreover, materials for medical liaison activities, communications to third party insurers and responses to other inquiries should be reviewed prior to release. This is an important role, given the significance for the company and timeline pressures.

Medical science liaison (MSL) function

MSLs were introduced by the Upjohn Company in the 1970s, initially as a scientific communication tool to academia. The function has subsequently been refined and now incorporates the dual functions of scientific communication to key opinion leaders (KOLs) and interaction with the same, facilitating more direct and consequential interaction of the scientific community with pharmaceutical companies. KOLs can be recognized on an international, national, regional or district basis, and their involvement in increasingly earlier stages of development enhances the relevance and focuses the direction of pharmaceutical research.

MSL officers are scientists with MD or PhD or PharmD qualifications. They are usually specialized in an area of research, and thus, are often experts in their own fields. Because they are usually Medical Affairs employees, they do not report to Sales and their job metrics are not determined by commercial success. The separation of Sales and MSL activities is important as otherwise would lead to regulatory and legal ramifications.

Continuing medical education (CME) activities

CME and associated credit requirements have to be earned by health practitioners in most westernized countries to ensure that physician knowledge and practice are up to date. The providers of this education may be universities, professional associations or not-for-profit firms or departments that are separate from sales organizations within pharmaceutical companies. Pharmaceutical manufacturers may provide funding for these events, but may not be involved in other aspects of the programs. In the United States, the courses must comply with the relevant accrediting bodies, and are subject to scrutiny and monitoring.

Pharmaceutical companies are often requested to financially support these programs. These monies must not be disbursed by the company to a given individual, but to the organization responsible for the CME program (though this is often administered by a third party, independent of either provider or sponsor). In order to maximize independence, often the budgets have been taken out of Marketing and Sales and placed under the Medical Affairs department, with an oversight committee that ensures appropriateness of the grants. Speakers at meetings are required to disclose any real or potential conflicts of interest, including financial
relationships with commercial entities for full transparency.

### 37.6 Access to ongoing clinical trial information

Increasing scrutiny of clinical trial data emanating from the industry, academic and government sectors has led to an important evolution in access to information concerning ongoing clinical trial data and knowledge of the status of publication of completed clinical trials. Dialogue amongst the three major entities involved in these types of studies has led to new processes that have been established by pharmaceutical companies to assure increased transparency of clinical trial conduct and communication of results. This has taken the form of three related methods of communication of trial metrics.

A web site has been established by the FDA whose informational and timing provisions were outlined in Section 113 of the Food and Drug Administration Modernization Act (FDAMA), provides continuously updated information concerning the existence and purpose of federally and privately supported clinical trials, such as those conducted at pharmaceutical companies (www.clinicaltrials.gov). The trials listed are those that are ongoing or had been completed since January 2004. Information available includes the name and purpose of the study, brief entry or exclusion criteria indicating who may participate, participating investigative sites including contact information and status of enrollment.

A second source of information regarding clinical trials was established with a different goal by the Pharmaceutical Research and Manufacturers Association (PhRMA). In 2004 PhRMA launched a Clinical Results Database (www.ClinicalStudyResults.org) to provide a central repository for clinical trial results, positive or negative, of ‘hypothesis testing’ clinical trials involving marketed drugs. The goal of this industry-initiated effort was to have substantial information available via electronic database concerning all studies completed after October 1, 2002. As full publication clinical study results may be delayed by the complicated process of manuscript acceptance by journal editorial boards, the purpose of this repository database was to enhance the transparency of clinical trial results and expedite their communication. By July 1, 2005 all new studies meeting the criteria established by PhRMA, and by September 13, 2005, all ongoing clinical trials were to be listed.

A final source of information for the public concerning the status of clinical trials was established by individual pharmaceutical companies to allow prospective patients’ access to knowledge concerning the availability of clinical trials. The exact web addresses can be obtained by searching company-specific web pages. Such web sites fill a third need – to help an individual patient make an educated decision about participating in a clinical trial. Usually these web sites include a listing by disease and study number of ongoing clinical trials, a brief description of the precise disease category being studied, the purpose of the trial, the key entry and exclusion criteria and the treatment arms and duration. In addition links are provided to study specific web sites, and supplemental information about the disease being studied, its manifestations and how it is diagnosed are included. Questionnaires are also often available which can be completed by patients to identify eligible patients and provide information concerning the nearest location of a clinical trial site.

### 37.7 Summary

Medical Affairs departments design valuable and often extremely creative trials that provide important later phase information about clinical research conducted with soon-to-be-marketed or already marketed drugs in regard to their relative efficacy compared to others of its class, new information concerning efficacy in related indications and additional safety and efficacy data that supplement the core data which led to original approval. Because the type of research conducted in this later phase is often in response to residual questions about safety as part of phase IV commitments agreed to upon original approval,
or is performed to understand the relative efficacy and safety of drugs compared to other newly available marketed medicines of the same class or of other classes also used for the same indication, such studies can have extremely high-value public health value. Finally, the ability to pool data sets, conduct specific outcomes research, assess real-world use, benefit–risk and pharma-coeconomics, critical for formulary and access decisions, makes these departments indispensable to pharmaceutical companies and clinicians who depend on an ongoing stream of clinical data.

Further reading


38.1 Introduction

The purpose of the drug label is stated succinctly in the Japanese guidelines:

Package insert statements should generally contain information essential to using the specified drug for approved indications and within the range of approved dosage and [route of] administration. However, other important data regarding any use of the drug should also be evaluated and described. (PAB Notification No. 606, 25 April 1997)

In other words, the drug label is the summary of all that is learned during drug development plus that which is inevitably discovered during post-marketing surveillance. The terms ‘drug label’ and ‘package insert’ (the former in common use in North America, the latter in Europe and Japan) are used interchangeably in this chapter.

The intent of this chapter is to review drug labels in North America, Europe and Japan. The philosophy of these differing types of labeling will be explored. The reader can easily access local examples of current, approved labeling; these will not be reproduced here, and could, in any case, become rapidly out of date. Much of the content of drug labeling is the subject of other chapters in this book, the approach here will avoid redundancy.

38.2 Drug labeling in Japan\(^1\)

The Ministry of Health and Welfare has a subordinate organization known as the Pharmaceutical and Medical Safety Bureau, which supervises drug labeling in Japan. This bureau has prescribed a standard set of subtitles for drug labeling which must always appear (Table 38.1).

As can be seen, the structure of a Japanese drug label is a standard format that would also be familiar to physicians in Europe or North America.

The one major difference, however, is that a separate regulation (PAB Notification No. 607, 25 April 1997) governs how precautions should be displayed in drug labels, and is quite elaborate in comparison to European or North American counterparts. The Warnings and Contraindications sections of the drug label (items 6 and 7 in Table 38.1) are required to contain, under this regulation, the following subsections (Table 38.2).

Although most of these subtopics (Table 38.2) would have stand-alone counterparts in drug

\(^1\)Acknowledgment to Dr Hiroko Sakai, Yamanouchi Pharmaceuticals, Tokyo, Japan.
labeling elsewhere in the world, this regulation emphasizes drug tolerability, consistent with the approach taken with much of regulatory affairs in Japan. The visual presentation of the precautions subsections goes further to make this point: Warnings are printed in red within a red box, whereas contraindications are printed in black, and again within a red box. Lastly, contraindications for co-administered drugs must be printed as a table within a red box.

Japanese labeling regulations require that animal data and data from other members of the same chemical or pharmacological class of drugs should be included, even when these allude to adverse effects that have not actually been observed for the product that is labeled. When direct drug attributability of an adverse event has not been established, it remains a requirement that other indirectly obtained information must still be included; this would include epidemiological information or pharmacodynamic effects observed in normal volunteer studies. Adverse event frequencies (Section 38.4, Table 38.1) may be presented in a table, usually for all adverse event types reported with frequencies >5%, between 0.1–5 and <0.1%.

### Table 38.2
Subsections of ‘precautions’ in Japanese drug labeling

<table>
<thead>
<tr>
<th>1. Warnings</th>
<th>7. Use in the elderly</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Contraindications (Do not administer to the following types of patients)</td>
<td>8. Use in pregnancy, delivery and lactation</td>
</tr>
<tr>
<td>3. Careful administration (Administer with care to the following patients)</td>
<td>9. Pediatric use</td>
</tr>
<tr>
<td>4. Important precautions</td>
<td>10. Effects on clinical laboratory tests</td>
</tr>
<tr>
<td>5. Drug interactions:</td>
<td>11. Overdosage</td>
</tr>
<tr>
<td>(i) Contraindicated co-administrations</td>
<td>12. Precautions concerning use</td>
</tr>
<tr>
<td>(ii) Precautions for coadministration</td>
<td>13. Other precautions</td>
</tr>
<tr>
<td>6. (i) Clinically significant adverse events</td>
<td></td>
</tr>
<tr>
<td>(ii) Other adverse events</td>
<td></td>
</tr>
</tbody>
</table>

### 38.3 Drug labeling in the United States

The Food and Drug Administration (FDA) is, among other things, probably the most stringent controller of drug labeling of all the world’s regulatory authorities. Typically, drug labels are agreed with pharmaceutical companies at meetings shortly before product approval, where the proposed label is debated line by line. Such meetings
often include not only the reviewing Division Director but also his or her superior, the Office or Center Director. The relevant parts of the Code of Federal Regulations (CFR) are authorized by the Food, Drugs and Cosmetics (FD&C) Act (21 United States Code 321). Although the licensing of drug products (21CFR310 and 314) and biologicals (21CFR601) are different, their labels are governed in a similar manner. It should be noted that promotional materials are considered to be a form of labeling in the United States, and the FDA regulates these as stringently as the package insert (21CFR201.1). All magazine advertisements and so on, have to be accompanied by a complete copy of the approved package insert adjacent to the published promotional materials. The package insert in the United States is usually much longer than in any other country. A recent label for an injectable treatment for rheumatoid arthritis (etanercept; Enbrel<sup>1</sup>, Amgen and Wyeth) can only be described as a poster, being 58 cm × 63 cm, and filled with print on the whole of both sides in mostly 10- and 11-point font!

The general principles that apply to all US drug labeling (whether a package insert or an advertisement) are as follows:

- Consistency with approved package insert
- Absence of misleading information
- Fair balance
- Absence of relevant omissions
- Defensibility from the clinical trials database

A specific division of FDA (the Division of Drug Marketing, Advertising and Communications; DDMAC) reviews all promotional materials prior to product launch and must be provided with all subsequent advertising. Companies can (and frequently are) ordered to recall promotional materials, as well as being required to take corrective measures after promulgating advertising that the Agency views as misleading.

The FDA uses black boxes around the text in labeling to indicate major hazards associated with marketed products. Most drugs that are ‘black-boxed’ in the United States usually remain on the market pending the Sponsor’s compliance not to engage in any further promotion of the product. However, this does not apply to certain opioids, muscle relaxants and cytotoxic drugs, all of which are black boxed, when these are promoted to specialist physicians (in these cases, anesthesiologists/anaesthetists and oncologists, respectively).

Drugs that are extemporaneously compounded from legally obtained starting materials, by individual pharmacists per physician’s prescription, are not subject to the same regulations (see 21CFR216). Among other things, these regulations nonetheless contain a list of drugs which are prohibited from compounding, usually in response to corresponding product withdrawals under the orthodox regulations (e.g. dexfenfluramine, chlorhexidine, tetracycline, for any, topical and pediatric uses, respectively). However, this relatively anachronistic part of pharmacy practice is also prohibited from engaging in widespread promotion.

The components of United States package inserts are provided in 21CFR201–202. Related matters (e.g. imprinting of tablets, labeling of controlled drugs, use of official and trade names, etc.) are governed by regulations scattered between 21CFR206–299. Spanish translations of drug labels are permitted (especially for products sold in California, Florida, New York and Puerto Rico), and some mandatory, equivalent Spanish vocabulary appears in the regulations (e.g. 21CFR201.16). The various sections of a US drug label will not be reprinted here: the reader is advised to look in the current edition of the Physician’s Desk Reference for models to follow. Most European physicians comment on the greater technical detail and length of US labels, in comparison to those in Europe.

A central legal term in the United States is ‘misbranding’ of an approved drug, meaning that the provisions of the NDA (as it might have been amended) have been breached. Such breaches may include the following: (a) when FDA has determined that the drug is being promoted for indications, dose sizes or routes of administration that are outside the approved labeling; (b) unapproved
Ingredients have been used in manufacture; (c) approved ingredients have failed some quality control that is specified in the NDA; or (d) the Sponsor has violated some previous agreement with FDA about how the drug should be marketed. Almost any infraction perceived by FDA will be termed misbranding. Comparative statements (‘Drug X was better than Drug Y’), and active-comparator clinical trials data in a proposed package insert, are especially likely to meet with disapproval by FDA.

FDA enforcement actions may be listed in escalating order of severity:

1. Warning letter from FDA to the manufacturer, requiring a specified corrective action within a reasonable time frame.

2. Mandatory issuance of a ‘Dear Doctor’ letter to the medical profession.

3. Black boxing of drug product (usually with agreement not to promote).

4. Product recall (although, in practice, most of these are voluntary on the part of the Sponsor).

5. NDA withdrawal.

6. Product seizure and establishment closure.

FDA can take these actions independently. For example, although a product seizure can be appealed against in Federal Court, the product remains seized, and sales remain halted while the legal process takes place, usually over at least several months. This prolonged period per se is often sufficient to kill the product in the marketplace, even if agreement for its reintroduction is eventually reached. The more serious enforcement actions are also punishable with prison terms and fines under the FD&C Act. A large, decentralized inspectorate is distributed throughout the United States and around the world as part of FDA’s enforcement arm.

Typically, FDA requires that post-marketing surveillance of new drugs is reported at less than annual intervals. Usually, after three- or four-year market experience, annual reports can then be agreed. A review of the labeling is made on each of these occasions, which, for nonurgent matters, is when a Sponsor or FDA might suggest amendments to it. All advertising materials that have been used during the year must be filed with these annual reports, even though they were sent to DDMAC at the time of their introduction.

It is surprising that these strict regulations and their energetic enforcement apply only to approved drugs. The United States currently has a vigorous market in so-called ‘natural products’. Thus, oral proteoglycans ‘to repair joint cartilage’, *Gingko biloba* extracts ‘to improve memory’ or the ‘anti-aging effect’ of oral, powdered shark cartilage may yet be advertised to the general public with impunity, and purchased by the general public without prescription. Legally, this creates a paradox because manufacturers want people to believe that these drugs are effective, and yet therapeutic effectiveness is tantamount to one criterion for bringing drugs within the jurisdiction of the Food Drugs & Cosmetic Act. However, at present, there is strong political support against extending FDA jurisdiction over such products.

FDA has just announced a new rule for label format, to be implemented in June 2006 for all NDAs, and a longer timetable for revisions of older products. The principal innovation is a summary section, intended to draw attention to important ‘highlights’ such as important contraindications, likely adverse drug interactions. The overall aim is to improve patient safety when prescribing. There is a set of four guidances that accompany the new rule. This move is not without controversy: at the time of writing, several States have mounted legal challenges to the new rule, and some patient advocacy groups are also vocal critics.

### 38.4 European labeling

There is reasonable similarity across the countries of the European Union, and these labels are collated into national compendia such as the *Rotte Liste* in Germany or the *Data Sheet Compendium* in the United Kingdom, to which the
reader is referred. Consistency between countries is likely to increase now that drug licensing has been centralized at the European Medicines Evaluation Agency (EMEA). Many of the headings within European labeling correspond to those shown for Japan (Table 38.1 above) and the United States.

American or Japanese physicians are frequently surprised at European drug labels. The brevity and the relative scarcity of quantitative data reflect a very different philosophy. Such labels arise from a regulatory milieu which itself has a different philosophy, expecting product manufacturers to assume responsibilities that would be accepted by the regulatory authorities in the United States and Japan. There is no European equivalent of the worldwide enforcement arm of the FDA.

There can be no doubt that the principles that underlie European labeling are the same as those enumerated in other jurisdictions. Consistency of promotional materials with the approved package insert, the absence of misleading information in package inserts, fair balance, absence of relevant omissions and defensibility of all statements from the clinical trials database are also characteristic of good European labeling.

However, there is a widely expressed sentiment in Europe that the long and technical labels promulgated by FDA are unlikely to be read by the ordinary prescriber. Thus, European labeling aims for concise and well-balanced summary information. For this reason, European labels are usually more difficult to write than, say, American ones, and are much more likely to be debated among the physicians in a company’s medical affairs department, and between the company and the regulatory authority on subjective, interpretative grounds.

These fundamental differences between European and American drug labels also lead to unexpected, tangential difficulties, especially for international corporations. The corporate lawyers in the United States live in a more litigious environment than their European or Japanese colleagues. Plaintiffs’ litigation often makes the claim that a patient has experienced an adverse event that had not been disclosed in the package insert. Companies are also sued in America for adverse events that occur in Europe, and plaintiff’s counsel will often wish to exploit the differences that exist in drug labels between different jurisdictions. Thus, the company lawyers in the United States usually would usually like two things: (a) any and all adverse event types to appear in labeling, so that the company cannot be accused of failing to disclose any relevant information; and (b) consistency of such information in all drug labels around the world so that a picture cannot be painted suggesting to a jury that the company was willing to warn Americans but not Europeans of a particular adverse event type. Given the typical inability to assign drug attributability to low-frequency adverse events, and the philosophy of European labeling, foreign subsidiaries often object to the inclusion of (probably irrelevant) minutiae in their labeling.

### 38.5 Final words

The real key to understanding drug labeling is to work with it, for real. Almost all entry-level medical affairs positions can provide this if the post-holder expresses appropriate interest. Similarly, almost all successful drug development (i.e. phase I–III) positions are guided by draft labeling. When writing labeling, the first thing to do is to seek out a recent model, for a drug that is already approved (indeed, such models can also serve as guides to clinical development plans at the very start of drug development). When making judgments about how to amend labeling and what may or may not be an acceptable précis when converting a US label to a European label, remember to seek the advice of those with experience, both within the medical, regulatory and legal departments.
The primary duty of a drug monitoring system is less to demonstrate dangers or to estimate incidences than to initiate suspicions... (Finney, 1982)

Drug safety monitoring is relevant to a wide audience (e.g., patients, prescribers, regulators and lawyers). Patients gain most from enhanced prescribing information or removal of products no longer considered to be safe, as a result of pharmacovigilance by companies and regulatory agencies. Prescribers benefit by being able to prescribe the most appropriate medicine for a given patient. Regulators continuously watch over the adverse events reported by manufacturers and independent reporters, add newly reported events to existing safety databases for analysis, and are often in a position to make comparisons between different members of the same pharmacological class. Lawyers both within companies and in the litigation bar, are interested in whether the local prescribing information is up to date as far as adverse event reporting is concerned.

On the supply side, safety monitoring is a shared responsibility. Monitoring the safety of medicines is a shared responsibility involving, among others, the pharmaceutical industry, physicians and regulatory authorities. The primary responsibility must belong to the individual pharmaceutical company, which knows the most about the drugs and has the greatest interest in the proper and safe use of the drugs and in maximizing the usefulness of their products to patients.

Pharmacovigilance is the name of the art, science and tools to identify new adverse events or safety signals. Manufacturers need to analyze adverse events both individually and in aggregate fashion. Pharmacovigilance can be formalized as periodic safety update reports, ad hoc increased frequency reports, scientific publications and other types of safety analysis. Most countries also require formalized reporting of serious adverse drug reactions (ADRs) and aggregate periodic safety update reports to regulatory authorities. There are many hurdles to overcome, as history shows.

For both the creators and the users of this information, the passing to signal from noise is crucial. Useful clinical information must always be disclosed, but optimally this should not be amongst heaps of the irrelevant because that, too, will fail to communicate useful information.

### 39.1 Reasons for monitoring safety post-marketing

The safety profile of a drug is only at an early stage of evolution when the NDA/PLA is approved, and
changes over time thereafter. In order to ensure continued patient protection, it is therefore necessary to monitor the safety profile of marketed drugs continuously for new signals of concern that might prompt revisions in prescribing information.

### Sample sizes

Clinical trials designed to prove the safety and efficacy of drugs are limited by sample size and strict enrollment criteria. As such, ADRs occurring at fairly low rates (e.g. 1 in 1000) or those occurring in patient subpopulations not studied during clinical investigations may not be identified during clinical trials and can only be identified post-marketing. New rare, serious events may be reported only after large numbers of patients take a new drug, often after several years of marketing experience (Kessler, 1993). One rule of thumb is that for a clinical development program containing a known number of patients exposed at appropriate doses and for appropriate periods of time, there is 95% confidence level that at least one specified type of adverse event will have been observed if it has a frequency greater than three times the reciprocal of the sample size. Thus, a clinical development program with 3000 appropriately treated patients (perhaps larger than average) would be very likely to include patients with adverse events occurring at a frequency of 1 in 1000 or greater.

Adverse events are sometimes termed type A (usually pharmacologically predictable, relatively frequent, seldom fatal and usually identified during clinical trials) or type B (unpredictable idiosyncratic reactions which are usually infrequent but can be very serious or fatal) (Rawlins and Thompson, 1977; Venning, 1983). Post-marketing ADR monitoring usually identifies the more serious, type B reactions. The sample size needed in clinical trials to detect differences between an incidence rate of 1/10 000 and 2/10 000 is about 306 000 patients (e.g. for a placebo comparison of chloramphenicol-induced aplastic anemia, which occurs in 1/30 000; Lasagna, 1983). Clinical trials at this scale are simply impractical.

Spontaneous or unsolicited ADRs reported post-marketing may contain limited, unclear or imperfect information. It is the responsibility of the manufacturer to try to obtain as much relevant information as possible so they can be clinically assessed, particularly those that are serious.

### Drug interactions

Potentially harmful drug interactions may not be identified during controlled clinical trials, due to the exclusion of patients taking concomitant medications, which are not allowed to be taken during a study. For example, terfenadine, a novel non-sedating antihistamine which was found to cause a serious and potentially fatal cardiac arrhythmia, *torsades de pointes*, when administered with ketoconazole or erythromycin, and this could not realistically have been expected to be identified in the clinical trial setting. The mechanism of this adverse drug interaction was found to be due to cumulation of unmetabolized terfenadine, due to inhibition of cytochrome P-450 (CYP) by ketoconazole or erythromycin; the parent terfenadine molecule is usually cleared very rapidly when there is no concomitant CYP inhibitor.

### 39.2 Council for International Organizations of Medical Sciences (CIOMS) initiatives

Recognizing that drug surveillance was a global problem, and that international standardization would assist the assessment of large numbers of patients, the CIOMS of the World Health Organization (WHO) began meeting in 1986 (CIOMS Working Group I, 1990; Gerald *et al.*, 1990). The original CIOMS I ‘working party’ consisted of representatives from six regulatory authorities and seven multinational pharmaceutical manufacturers. This group had the goal of developing a uniform adverse event reporting form (the CIOMS I form) that would be acceptable internationally. A system of expedited reporting of serious adverae events (SAEs) to regulatory authorities...
was also proposed. This group had no official authority, but it was hoped that the members would influence their respective government agencies to enact regulations which would improve safety reporting, based on the CIOMS initiative.

The CIOMS I working party’s efforts were highly effective. Today, every regulatory authority in the developed world has endorsed expedited SAE reporting, usually within 15 working days of receipt by the company. The CIOMS form, in its later editions, is also now ubiquitous.

In 1989, the CIOMS II ‘working group’ took up the matter of a uniform approach to aggregate periodic safety update reporting (CIOMS Working Group II, 1992). Like CIOMS I, the second working party consisted of representatives from regulatory agencies and multinational pharmaceutical companies, again without authority to mandate changes in national regulations. The CIOMS II Working Group (1992) developed a standardized periodic safety update report template which could be used by all countries with periodic reporting requirements. The International Conference on Harmonization (1994; ICH E2C, see below) later adopted the CIOMS II report format with minor modifications and proposed that it be used globally.

A third CIOMS ‘working group’ was established to propose guidelines for preparing core clinical safety information on drugs (CIOMS Working Group III, 1995). The Core Data Sheet (CDS) was defined as:

A document prepared by the pharmaceutical manufacturer, containing [among other things] all relevant safety information, such as adverse drug reactions, which the manufacturer requires to be listed for the drug in all countries where the drug is marketed. It is the reference document by which ‘labeled’ and ‘unlabeled’ are determined [for the purpose of international ADR reporting]. . .

Safety information was noted to be described in various sections of a CDS, including ADRs (undesirable effects), warnings, precautions and contraindications. As there were questions pertaining to what information should be included in a CDS, and how the information should be updated, along with no internationally agreed standards for preparing this information, the CIOMS III working party proposed several guidelines for production of the safety section of the CDS (also termed ‘core safety information’). Topics such as the first core safety information, frequency of updates, together with the anticipated national differences in product presentation, use, excipients and package inserts were also described.

**Benefit–risk evaluation**

No drug is 100% safe in 100% of patients. Comparative evaluation, or benefit–risk balancing of pharmaceutical products is inevitable. Furthermore, there are no absolute or arithmetical standards for this; it is part of the art of practicing medicine, if at a large than usual scale of conducting what is essentially an n = 1 clinical trial every time a prescription is written. Thus, the definitions and terms chosen depend entirely on the context in which they are used, and on the user, in a case-by-case manner. These complexities are not always obvious to information users, such as patients and their lawyers. But again, the factors influencing benefit–risk assessments include

- the audience of the information;
- the nature of the clinical hazard;
- the drug, its indication and population under treatment, and, to be realistic
- economic issues.

The CIOMS IV ‘working group’ discussed benefit–risk evaluations under circumstances when there is a known, significant clinical hazard associated with a particular drug (CIOMS Working Group IV, 1999). Benefit should be assessed when compared with alternative therapies (medical and surgical) or no treatment at all. Analogously, risks should be compared between the subject drug and alternative or no therapy. Methods are suggested by the CIOMS IV working group for balancing the benefits against the risks for each of these therapies, and for identifying subsets of patients at relatively
greater risk than others. If specially planned studies can help, then the protocols should be outlined. The final selection should be based on a review of the ‘pros’ and ‘cons’ and likely consequences of each option, including the quality and quantity of any subsequent evidence that would influence the decision.

The CIOMS V ‘working group’ presented pragmatic approaches to good case management and focused on four main topic areas (Lumpkin, 2000; CIOMS Working Group V, 2001):

- Sources of individual cases
- Good case management practices
- Good summary reporting practices: beyond PSURs
- Determination and use of population exposure data

The CIOMS VI ‘working group’ moved away from the realm of post-marketing surveillance, discussing issues related to reporting of safety during the conduct of clinical trials and described concepts important to managing safety information from clinical trials (CIOMS Working Group VI, 2005; Stephenson, 2005). The final document includes discussions of:

- ethical considerations for clinical trial safety management;
- good pharmacovigilance and risk management practices; systematic approach to managing safety during clinical development;
- collection and management of safety data during clinical trials;
- identification and evaluation of risk from clinical trial data;
- statistical analysis of safety data in clinical trials;
- regulatory reporting and other communication of safety information from clinical trials.

- The CIOMS VII ‘working group’ is currently discussing development periodic safety reporting recommendations.

39.3 ICH initiatives

The ICH was formed in 1989 (Secard International Conference on Harmonization, 1994; Worden, 1995). It provides a forum for discussions about the internationally varied technical requirements for product registration and identifies where modification and mutual acceptance of research and development procedures could lead to more economical use of resources. Ostensibly harmonizing only between the United States, the European Union and Japan, several other national regulatory authorities send representatives to these meetings, and the ICH lead is thus followed widely around the globe.

ICH has various code-numbered committees and subcommittees, which generate reports on practical matters. One of these, the ICH E2 working group, had the goal of harmonizing adverse event reporting requirements between manufacturers and regulatory agencies in the United States, Europe and Japan; three subcommittees then took on various parts of this large task, that is reporting of individual adverse experience reports (ICH E2A), electronic transmission of individual case reports (ICH E2B) and periodic safety update reporting (ICH E2C). In contrast to CIOMS, the vision of ICH is to lead to the enactment of specific local regulations; the European and US regulatory authorities usually adopt ICH reports verbatim when designing new regulations or guidance documents.

The ICH review process proceeds through five steps:

- **Step 1**: Preliminary discussion and draft report.
- **Step 2**: Draft is submitted to three regulatory agencies (United States, EU, and Japan) and industry representatives for consultation and comment.
• **Step 3:** Comments are collected and incorporated and drafts referred to the ICH steering committee.

• **Step 4:** Final draft is discussed within the ICH steering committee and adopted by the three regulatory parties.

• **Step 5:** The full recommendations are incorporated into domestic regulations.

ICH E2 (1994) described clinical safety data management. The now familiar definitions and standards for expedited reporting of individual adverse events when serious, unexpected and treatment associated are the result of ICH E2 (and the regulatory transcriptions, e.g. 21 CFR 312.32).

ICH E2 defined an adverse event (or adverse experience) as ‘any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment’. An ADR reported in the marketplace, that is post-NDA/PLA approval was defined as ‘a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease, or for modification of physiological function’.

Minimum reporting criteria defined by ICH for initial reports of adverse events are when:

• a specific individual patient is reported;

• a specific suspected medicinal product;

• an identifiable reporting source, and

• an event or outcome that is serious, unexpected and reasonably treatment associated.

An SAE (or experience, or reaction) is defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

An adverse event is *unexpected* when its nature or severity is not consistent with information in the relevant source document(s)’. Relevant source documents include the investigator’s brochure for investigational drugs, and the master data sheet or core safety data sheet, or local product labeling for marketed products. The determination of whether an adverse event is unexpected usually resides with the company that sponsors the clinical trial or markets the product.

The *causality* or *treatment relatedness* of clinical investigation cases is determined by the reporting healthcare professional or the sponsor, and is based on a ‘reasonable suspected’ causal relationship between patient exposure to the suspect drug and the occurrence of the adverse event. Spontaneous reports about marketed products are always taken to imply that the reporter has assessed an adverse event with causality by the reported product (and are thus also always adverse events *per se*).

ICH recommended that fatal or life-threatening unexpected ADRs should be expedited to regulatory agencies as soon as possible, but no later than seven calendar days after first being known to the Sponsor. As complete a report as possible is recommended within eight additional calendar days. All other serious unexpected ADRs should be reported within 15 calendar days.

### 39.4 Spontaneous case reports

These are unsolicited adverse events that are reported to the company after the drug is on the market. Their sources include consumers, their relatives, clinicians (whether nurses, pharmacists or prescribers) and, occasionally, lawyers or sales representatives (the last even being from other companies).

Although of limited value in isolation, these reports can be important in aggregate. By definition, spontaneously reported adverse events are deemed possibly treatment related by the reporter, even when the motivation is to inquire into the possibility that the subject drug could be associated with the adverse event type that has been observed
in a particular patient. Occasionally, a case report, even from a patient, will describe fully his/her adverse event, including positive rechallenge, and this is very important information in relation to the safety profile of the drug.

Spontaneous case reports can reassure a company if a report describes a large accidental overdose with no serious adverse effects. They can also provide reassurance, when reviewed in aggregate, when no reports for drug x causing event y over time period z have been received. Clusters of similar spontaneous reports should be meaningfully analyzed for consistency in time to onset post-dose, pattern of presentation, rechallenge and dechallenge, to identify a signal and to get a feel for its significance.

The main advantage of spontaneous case reports is that they can provide important signals when reviewed collectively. Although it would be wrong to underestimate their occasional individual importance, it is the consistency of time to onset and pattern of presentation that is important. The spontaneous case report database cannot be used to give an accurate incidence rate of even the Type B adverse reactions, because not all cases are reported (Fletcher, 1991; Kessler, 1993). Nor do spontaneous case reports lend themselves to meaningful comparisons between different drugs. Not only are all cases not reported for either drug but also the reporting pattern varies with the time from launch (the reporting rate generally peaks one to two years after marketing) (Weber, 1984; Sachs and Bortnick, 1986), and also the reporting rate for a particular adverse reaction tends to increase after publication of a signal.

Pharmaceutical companies, individual regulatory authorities and the WHO have databases which facilitate this overview. The use of a standard coding dictionary of adverse event terms is essential for this sort of analysis, and one, MedDRA (Medical Dictionary for Regulatory Activities) has been accepted as the ‘gold standard’ to be used. Nevertheless, routine review of individual cases by responsible, experienced reviewers is the most essential factor in identifying new signals and ensuring patient protection.

### 39.5 Causality assessment

It is often difficult to assess causality or treatment association. For individual patients, factors such as polypharmacy and multiple events occurring during therapy can interfere with the causality assessment of ADRs. In one study, three clinical pharmacologists independently evaluated 500 untoward clinical events. There were broad differences in interpretation in causality of adverse events (Koch-Weser et al., 1977).

The factors influencing causality assessments are as follows:

- What is the background incidence of the event independent of any treatment?
- Is there evidence that the incidence in users of the drug is greater than the background incidence?
- What is the chronology of the occurrence of the reaction?
- Is the chronology consistent between reports?
- Is the reaction biologically plausible, based on what is known about the pharmacodynamics and pharmacokinetics of the drug?
- Is there evidence of a drug–drug interaction?
- Is there an alternative or more plausible explanation (e.g. natural history of disease, concurrent conditions, other therapies, other exposures)?
- Is the reaction known to occur with other drugs in the same class or with similar structure?
- Is the reaction commonly associated with drugs in general?
- Is there any supporting evidence from clinical trials, post-marketing surveillance studies or animal studies?
- Are there any cases which reoccurred on rechallenge?
39.6 Labeling

Product labeling describes currently known relevant information about a drug and is intended to aid in evaluating the risk versus benefit of a drug when a prescriber is confronted by an individual patient. The labeling is often in the form of a package insert or compendium of information, such as the Rote List, Drug Sheet Compendium or Physicians’ Desk Reference. As the safety profile of a drug changes over time, the product labeling is modified in order to convey up to date information.

39.7 (Sub)populations

Different subpopulations may react differently to drugs, due to a variety of reasons affecting metabolism. Factors that could influence patient susceptibility include multiple drug therapies, multiple disorders and severity of disease, types of drugs prescribed, altered pharmacokinetics, pharmacogenetics, altered pharmacodynamics and the age of the population treated (Nolan and O’Malley, 1988).

Differences in metabolism among patients can lead to differences in susceptibility to adverse events. Classic examples are patients with

- abnormal pseudocholinesterase levels have prolonged apnea after receiving succinylcholine;
- low activity of N-acetyl transferase (‘slow acetylators’) are more likely to develop lupus-like reactions to procainamide, hydralazine and isoniazid; and
- variants of the cytochrome P-450 family of enzymes can lead to altered metabolism of a variety of drugs, including antidepressants, antiarrhythmic agents, codeine, metoprolol terfenadine, cyclosporine, calcium channel blockers and others (Peck et al., 1993).

The pharmacological action of drugs in children may differ from adults, and may invoke a different pattern of adverse events (Gustafson, 1969; Collins et al., 1974). However, there is little systematic pediatric pharmacoepidemiological data (Bruppacher and Gelzer, 1991). Post-marketing safety surveillance may be the only way new signals can be detected in this population.

There may also be ethnic differences in susceptibility to adverse event frequency and reporting. Corzo et al. (1995) identified an association of alleles of the HLA-B and DR loci with increased risk of clozapine-induced agranulocytosis. Patients with abnormal pseudocholinesterase levels have prolonged apnea after receiving succinylcholine. Patients with low activity on N-acetyl transferase are more likely to develop lupus-like reactions to procainamide, hydralazine and isoniazid (Peck et al., 1993). In some countries, the reporting of adverse events is reduced because of cultural biases against upsetting the prescriber.

39.8 Pregnancy

Fetal injury and death can result from the use of certain drugs by the mother, and decisions regarding risk versus benefit must be made when no alternative treatment is available. Certain drugs are specifically contraindicated during pregnancy, for example angiotensin converting enzyme (ACE) inhibitors, used by a mother during the second and third trimesters of pregnancy to treat hypertension or congestive heart failure, can lead to fetal injury and death (FDA, 1992). Thalidomide was found in the early 1960s to cause fetal limb abnormalities (phocomelia) in the children of mothers who took thalidomide as an antiemetic or sedative during pregnancy.

39.9 Post-marketing surveillances studies

During clinical trials, investigators are instructed to collect all adverse events reported by patients enrolled in the study, which are tabulated. During final study reports or product marketing applications, adverse event data are analyzed and compared among treatment arms. Overall analyses of
results are restricted to statements regarding the specific patient populations studied and the sample sizes available (see above).

Post-marketing surveillance studies attempt to study toxicity under conditions of actual use. These studies differ from early phase investigations in several ways (Wardell et al., 1979). Larger sample size, lower cost nonrandom assignment, lack of control over subgroups, long-term open-ended studies and no formal regulation may all be exploited. Longitudinal studies investigate nonrandomized groups(s) using a specific drug, and follow cohorts of patients through time to see if a specific event occurs. Case–control studies investigate nonrandomized groups of subjects with and without an adverse event, reviewed retrospectively to determine which drugs the subjects took; in this case, the two or more patient groups are matched for incidental features such as age or race.

39.10 The need for better communication to the prescribers and patients

The most important responsibility of the pharmaceutical industry is to ensure that safety messages are communicated clearly and effectively to prescribers, and sometimes also to patients. Adding to the core safety information is pointless when it is not known whether such messages reach the target audience. This is particularly relevant to contraindications, precautions and warnings. It is also presumably the responsibility of the regulatory authorities to identify and counsel any prescriber who they identify may have misprescribed a drug to the detriment of a patient. These mistakes may not be deliberate, but in view of the volume of literature received by busy physicians, it is essential that important information concerning the administration and safety of drugs is read and understood.

Modern technology should help. For example, pharmacists are developing databases that help them to identify drug interactions. In the future, the medical history of a patient could be added to a card which could be used by a pharmacist to ensure that the patient’s prescribed medicine is appropriate. It would also be possible to input safety data on drugs to computer systems already used by prescribing physicians to store their patients’ records. The physician would then be alerted to any contraindications, warnings or precautions that may be relevant to individual patients if prescribed the drug.

39.11 Summary

In this chapter, we have outlined the principal motives and methods that pertain to good pharmacovigilance. We have also tried to show how, in particular, risk–benefit analysis must always be on a case-by-case basis, and how it relies, ultimately, on the judgment of those experienced in this field rather than some automatically applicable arithmetic algorithm. Large-scale patient exposures will always trump clinical trials databases for rare types of adverse event, and this continues to be demonstrated by cases such as thalidomide, terfenadine and rofecoxib.

References and Resources


Data mining has been defined as ‘The nontrivial extraction of implicit, previously unknown and potentially useful information from data’ (Frawley et al., 1992). However, an easier way to grasp the concept of data mining is to think of it as a process that uses automated, analytic tools to search large databases, in order to discern useful information.

40.1 Introduction

The goal of data mining is to simplify the process for sorting through vast amounts of data to generate valuable and actionable information in support of a business proposition. Given the large volume of data that is collected in a variety of industries and the speed with which it is being accumulated, digging through those databases to get to the kernels of knowledge may be impossible if done manually. The development of powerful computers, along with software that contains data-mining algorithms, provides the individual with an additional tool to better do his/her job.

Some common uses of data mining are in the marketing of specific products to customers who show a propensity for purchasing a particular product. Although it may be intuitive that customers who buy a particular product may be more apt to purchase a similar type of product if it is marketed to them, searching for hidden correlations between disparate products (e.g. soap and tea purchases) may generate new avenues to co-market or at least place products in close proximity to one another. Additionally, high-value customers can be segmented from the general customer population to allow for a more focused marketing approach to these customers.

Data mining has been used in several industries and in many different ways, including banking to detect credit card fraud, by retailers in direct mail marketing campaigns and in the sales of goods from wholesalers to retailers. In the pharmaceutical industry, data mining has been used in sales and marketing to focus on the types of customers the company wants to focus on, in reviewing sales force performance, in examining clinical and non-clinical toxicology data for potential claims to pursue and now in the review and assessment of post-marketing safety surveillance data. This last topic will be discussed in depth, later in this chapter.

As important as it is to define what data mining is, it is equally important to state what it is not. Data mining is not a panacea for business problems. It is simply another tool to be used in seeking solutions to business problems. There will still be a need for
analysts and healthcare professionals with the ability to assess the validity of the results generated by a data mining algorithm. Additionally, data mining is not data dredging, which is a pejorative term used to imply the repeated evaluation of a data set, usually involving multiple comparisons with no prior defined method, to find some ‘statistically significant’ event. Given the statistical problems associated with conducting multiple comparisons, such a ‘statistically significant’ event may merely be a random finding that only gets noted due to the multiple comparisons, or data dredging.

40.2 Methods

Before any data mining algorithms or models are used on a database, it is important to first make sure that the data have been collected appropriately and that they have been organized and checked for accuracy. Subsequently, there is a choice from among multiple data mining methods that can be used. Among these are the Multi-Item Gamma Poisson Shrinker (MGPS) algorithm, which generates an Empirical Bayesian Geometric Mean (EBGM) score, the Proportional Reporting Ratio (PRR) method and the Bayesian Neural Network approach Du Mouchel (1999); Evans et al. (2001); Bate et al. (1998). Both the MGPS and PRR methods will generate similar drug–event combinations for further investigation when the observed number of cases with the drug–event combination is greater than 20 or the expected number of cases with the drug–event combination is < 1.

EBGM is a statistical measure of disproportionality, comparing the observed and expected reporting frequency within a database. The determination of the expected reporting frequency assumes complete independence of cases associated with either a drug or an event. Thus, in a hypothetical database of 100 cases, if Drug Z represented 20 cases in the database and there were 10 cases of rhabdomyolysis, the expected reporting frequency would be 20/100 (probability of Drug Z) × 10/100 (probability of rhabdomyolysis) × 100 cases (total database size) = 2 expected cases. If the observed number of drug–event cases was 8, then the relative reporting ratio (RR) would be 8/2 (N/E) = 4 and the EBGM would be about 4, depending on the amount of ‘shrinkage’ that occurs based on the model (see Figure 40.1).

The larger the number of adverse event (AE) reports for a particular drug (for a drug that has

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>The observed number of cases with the combination of items.</td>
</tr>
<tr>
<td>E</td>
<td>The expected number of cases with the combination.</td>
</tr>
<tr>
<td>RR</td>
<td>Relative reporting ratio (the same as N/E). Observed number of cases with the combination divided by the expected number of cases with the combination. This may be viewed as a sampling estimate of the true value of observed/expected for the particular combination of drug and event.</td>
</tr>
<tr>
<td>EBGM</td>
<td>Empirical Bayesian Geometric Mean. A more stable estimate than RR; the so-called ‘shrinkage’ estimate.</td>
</tr>
<tr>
<td>EB05</td>
<td>A value such that there is less than a 5% probability that the true value of observed/expected lies below it.</td>
</tr>
<tr>
<td>EB95</td>
<td>A value such that there is less than a 5% probability that the true value of observed/expected lies above it.</td>
</tr>
<tr>
<td>90% CI</td>
<td>The interval from EB05 to EB95 may be considered to be the ‘90% confidence interval’.</td>
</tr>
</tbody>
</table>

Figure 40.1 Empirical Bayesian Geometric Mean (EBGM) terms
been in the market for a long time and may have a lot of AE reports in the database) and/or the larger the number of cases of a particular AE (a common AE), the larger the expected ‘E’ will be. The larger that ‘E’ is, the smaller the EBGM will be. A new drug or a very rare AE would represent lower proportions of the total database and thus the expected ‘E’ would be lower.

40.3 Safety surveillance

As discussed in the chapter on Drug Surveillance, the safety surveillance mission is to implement the systematic review of spontaneous post-marketing data for proactive risk identification and assessment. In general, signal generation is done using clinical trials data, the medical literature, knowledge of class effects and spontaneous reports.

There are numerous challenges with spontaneous report databases, including the fact that they are numerator-based, subject to many reporting biases, can be hard to place in population context, clearly dependent on coding practices and given the granularity of the MedDRA Dictionary, there can be a dilution of the signal.

Additionally, spontaneous post-marketing safety surveillance databases were developed for regulatory reporting, as such, differences that exist with the national reporting requirements can alter the type, frequency and number of post-marketing safety surveillance reports that get entered into a database. Also, different companies may interpret the regulations differently, resulting in differential reporting of post-marketing safety surveillance reports. Furthermore, changes take place over time with dictionary version, with reporting standards and with product labeling. Data migration may cause sufficient changes to take place so that data conversion and legacy data can be lost. Moreover, causality assessment is rarely consistent.

There are several factors that affect both the quality and quantity of postmarketing reports. This is sometimes referred to as the ‘Weber effect’, where the newness of a drug to market results in a peak in post-marketing reports during the second year of being marketed. Additionally, if a drug is the first in its class to be marketed, as opposed to being the second or third drug in a class to be marketed, there can be higher reporting rates of post-marketing safety surveillance reports. In addition, items such as publicity, whether it is from a regulatory action such as a Dear Doctor Letter, litigation or coverage in the media, can all result in increased post-marketing reports.

In addition, there are some countries like the United States, which allow for consumers to report AEs, whereas other countries only allow healthcare professionals to make such AE reports. This can result in higher numbers of reports, though the information that is received may not be completely valuable or beneficial when searching for safety signals. Consumer reports can also be increased as a result of direct consumer advertising, especially when consumer hotlines are published.

There are two key approaches to safety surveillance. First, the intraproduct signaling, which seeks to identify changes in the overall AE pattern for specific products over time. This monitors selected AEs for a specific product over time to determine changes in the frequency and severity of AE reports. The other type of approach is the interproduct signaling which compares a specific product with all products in the database.

This interproduct signaling is data mining and essentially it determines a disproportionality score to detect drug–event combinations that are distinct or stand out from the background rate. Both approaches should be used to systematically screen large data sets to identity and analyze drug–event associations. These are, however, hypothesis-generating approaches and the idea is to search for new, preventable, serious AEs with potential public health importance. In addition, the surveillance program should be set up to evaluate new and emerging safety issues.

Intraproduct signaling essentially looks at a company’s own database to determine whether the frequency of a particular AE has been increasing, after appropriately adjusting for sales. Interproduct signaling uses computer-assisted application of statistical algorithms to measure disproportionality. It tries to identify drug combinations that occur more frequently than expected. It is important to remember that such signal scores are measures of statistical
associations and do not necessarily imply a clinical or a causal association.

As discussed, there are several disproportionality analyses that can be conducted, but essentially an observed rate is compared to an expected rate. Following the calculation of an EBGM or a PRR, there is an ability to generate a case series and then to characterize that case series. As a result of the surveillance process, hypotheses are generated. These hypotheses may then need to be evaluated using additional quantitative methods as appropriate, looking at the company’s database, or requiring stimulated reporting, or enhanced surveillance, or epidemiological studies to try and evaluate these hypotheses.

Thus, it is clear that the safety surveillance process is an iterative one. It looks at multiple data sources, whether screening large regulatory databases, looking at company databases or looking at manufacturing Lot related AEs for potential problems. The surveillance process screens the data using both the intraproduct and the interproduct methods. The object is to identify topics for further review to develop case definition, to compile a case series and then to characterize that case series.

### 40.4 Data mining in safety surveillance

Data mining is used in the review of safety surveillance data to try and detect strong, consistent associations that occur at higher-than-expected frequencies. Data mining usually uses AE safety databases that lack denominator data. It detects frequency of drug event combinations in post-marketing reports. It also determines the relative frequency that the drug–event combinations are reported for drug X than for any other drug. Data mining attempts to quantify the strength of potential drug–event association, whereby signal scores are calculated and represent the relative reporting rate for AEs.

Data mining does not equal data dredging. It is a systematic screening for drug–event combinations that are being reported disproportionately. It is essentially a quantitative signal detection method.

The data mining method that is currently being used widely in the United States, by both the FDA and the pharmaceutical industry, is the MGPS, which adjusts for the multiplicity of drugs and events per record. The MGPS generates an EBGM, which is an estimate of the relative reporting ratio. It is the ratio of the observed over the expected counts. A 90% confidence interval is calculated around the EBGM covering the lower 5% and the upper 95% of the confidence interval.

Amongst the major challenges that data mining has had is the belief that this is simply data dredging and that this is not a worthwhile scientific endeavor. However, data mining is a scientific, statistically valid method that encompasses a quantitative computer-assisted method of trying to determine safety signals. Both of the FDA’s post-marketing safety surveillance databases, the Adverse Events Reporting System (AERS) and the Vaccines Adverse Events Reporting System (VAERS) are used in safety signaling and data mining, along with the World Health Organization’s (WHO) AE database. The FDA’s databases contain all US reports along with serious, unlabeled reports from outside the United States. The WHO database contains reports from more than 65 national authorities, including the FDA’s databases.

The FDA’s Spontaneous Reporting System (SRS) was in operation from 1968 to October 1997. The reports were transitioned to the AERS, which has been used from October 1997 to the present. A publicly released version can be purchased on a quarterly basis. It is a passive surveillance system where direct volunteer reporting accounts for 10% of reports from healthcare professionals and consumers. Ninety percent of reports in the FDA’s post-marketing safety surveillance databases come from pharmaceutical companies, as they are mandated by regulations to report AEs that they receive. The combined SRS + AERS database currently contains more than 2.7 million reports and is growing rapidly, at about 465,000 reports on an annual basis. The number of reports has more than doubled in the last 10 years and because the FDA is interested in serious, unlabeled reports, that has grown as a percentage of the total number of reports submitted to the FDA.
Some of the limitations of the FDA’s AERS database are that the lag time can be several months, there is underreporting and there can be increased reports as a result of stimulated reporting. Additionally, there can be biased reporting due to a number of factors, including publicity, regulatory letters and so on, and because of the differential interpretation of the reporting regulations, reports may differ by country and company. Additionally, duplication, coding errors, variable historical data, poor quality of information and changes over time are all limitations to information recorded in the AERS database.

The data mining output is similar to the safety surveillance output in that hypotheses are generated and these may need to be evaluated with additional quantitative analyses as appropriate, using the company database, stimulated reporting, enhanced surveillance or they may require the conduct of epidemiological studies.

40.5 Case study

Rhabdomyolysis and statins

Introduction

In this case example, the FDA’s SRS + AERS database, through the end of the second quarter of 2005, was data mined to determine the lower 95% confidence interval limit of the EBGM scores (denoted as EB05), a measure of disproportionality, for rhabdomyolysis associated with the use of statins. The drugs of interest were atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin. The event of interest was rhabdomyolysis.

EB05 guideline

A guideline that has been used for identifying a signal score for pairwise combinations as higher-than-expected is an EB05 ≥ 2. This criterion ensures with a high degree of confidence that, regardless of count size, the particular drug–event combination is being reported at least twice as often as it would be if there was no association between the drug and the event (Szarfman et al., 2002).

Data source

This report contains the most currently available cumulative data from the FDA’s SRS + AERS database, through the end of the second quarter of 2005. This database contains approximately 2.7 million patient records. It includes branded and generic prescription products that are marketed in the United States. The database contains both US reports (including consumer reports) and a subset of non-US reports (AEs that are both serious and unexpected, which are not contained in the US package insert).

All data were retrieved utilizing Lincoln Technologies WebVDME 5.2, which is a data mining application used in post-marketing safety surveillance to support product risk management. Unless specified, individual case reports were not specifically checked for duplicate reporting. However, the vendor does implement an algorithm to screen the database for duplicates as part of standard data cleansing. Searches were conducted based on ‘drug mentions within a report’. This means that all case reports where the selected drug is classified as either a concomitant or suspect drug are included.

Data output

Figures 40.2–40.5 show the frequency and EB05 scores, both total and cumulative by year, of rhabdomyolysis associated with the use of the statins. AEs in the FDA database are codified using the MedDRA dictionary. It is important to note that a single case report may contain more than one preferred term.

The color of the bar represents a measure of disproportionality, that is ‘how disproportionate’ is the observed report frequency of the AE–drug combination compared to what might be expected, if all AE–drug combinations in the database were independent. The color scale ranges from a light...
gray, which represents low disproportionality, that is the observed frequency is not substantially different from the expected, while the darker gray represents AE–drug combinations with higher measures of disproportionality.

**Interpretation**

Figures 40.2–40.5 show the frequency and EB05 scores, both total and cumulative by year, of rhabdomyolysis associated with the use of the statins. Although all the statins have an $\text{EB05} \geq 2$ for rhabdomyolysis, and this is a well-recognized AE associated with the use of statins, both the frequency (5280) and the EB05 (10.93) noted with cerivastatin are significantly higher than any of the other statins. This clearly suggests an association between cerivastatin and rhabdomyolysis that required further investigation, with possible regulatory action.

The clinical importance of these observations could have been explored through other
A case series of rhabdomyolysis associated with cerivastatin could have been constructed and analyzed to evaluate the company’s post-marketing experience, and clinical trial data could have been examined if additional follow-up was required.

**Summary**

An evaluation of the FDA’s SRS + AERS database, through the end of the second quarter of 2005, showed that there was an increased risk of rhabdomyolysis associated with the use of all the statins. The frequency and EB05 were significantly higher for cerivastatin, compared to the other statins. On August 8, 2001 the FDA had announced that cerivastatin was being voluntarily withdrawn from the US market by its manufacturer, because of reports of sometimes fatal rhabdomyolysis.

**Caveats**

**Data source caveats**

Reports may be submitted using either a drug’s generic or brand name. As brand names may differ among countries, all standard signaling activities are performed using the generic drug name, as it appears coded in the database. Reconciliation among different names/formulations does not occur on a routine basis.

It should be noted that drug mentions are used to determine concomitant and co-suspect medications. This means that duplicate mentions of a drug within a specific case may result in double counting. Thus, all drug mentions should be considered approximations.

Important limitations of this regulatory database include general underreporting of post-marketing events and reporting bias. Factors such as publicity, length of time the drug is on the market and...
regulatory action can influence the rate of reporting as well as the types of events reported. In addition, this database can contain duplicate reports because of multiple potential reporters, and the same case may come from different reporters. Also, a single case report may contain more than one preferred term.

**Data interpretation caveats**

Lincoln Technologies, the company that prepares the data, prepares it for WebVDME without changes to the reports.

These signaling data are generated by computer-assisted algorithms based on relative ratio – the ratio of the observed event for the specific drug as compared with the expected occurrence based on other drugs within the database. A potential signal is generated when an AE–drug combination has a disproportionately high occurrence compared with the background. It is important to stress that an elevated ratio is a measure of statistical association and not a clinical association between an AE and a drug.

These identified AE–drug combinations are hypotheses for further testing; follow-up may be necessary to determine whether they represent a potential drug safety issue. Further evaluation may include a query and review of the company’s safety database, review of the scientific literature and preclinical data and consultation/discussion with internal and external experts. If a product safety issue was identified, next steps would include the development of a risk management and risk communication plan.

It is important to note that the numerator reflects only reports in the database. The actual number of patients exposed to the drugs is generally not known, so it is not possible to calculate the true incidence of an AE from this database. Thus, comparing EB05 scores across drugs should not be done as a surrogate calculation for incidence. Incidence data are not available from this database; there are too many factors that could influence the EB05 in an asymmetric manner, for example

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pravastatin</td>
<td>1.88</td>
<td>5.658</td>
<td>6.42</td>
<td>5.333</td>
<td>5.494</td>
<td>4.63</td>
<td>3.943</td>
<td>2.935</td>
<td>2.434</td>
<td>2.399</td>
<td>2.368</td>
<td></td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>0.96</td>
<td>1.31</td>
<td>1.326</td>
<td>1.475</td>
<td>1.644</td>
<td>2.343</td>
<td>2.973</td>
<td>3.063</td>
<td>3.325</td>
<td>3.356</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>2.156</td>
<td>3.068</td>
<td>2.206</td>
<td>1.67</td>
<td>1.736</td>
<td>1.84</td>
<td>1.834</td>
<td>2.209</td>
<td>2.309</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carisvastatin</td>
<td>33.73</td>
<td>38.86</td>
<td>38.162</td>
<td>27.299</td>
<td>17.405</td>
<td>10.902</td>
<td>10.929</td>
<td>10.929</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.332</td>
<td>4.375</td>
</tr>
</tbody>
</table>

Figure 40.5 The cumulative annual disproportionality score (EB05) of cases of rhabdomyolysis in the AERS database associated with the statins.
coding and the lack of ex-US, serious, labeled reports, making this an invalid comparison.

Since the signaling data sources are post-marketing reports, factors that influence reporting will affect the signaling output. With rarely reported AEs, a disproportionality will become magnified, because even one reported case against an expected background of zero may be statistically significant even though its clinical significance may be unknown.

Special caution should be exercised with any comparison of reporting ratios across different products, for example comparison with competitor drugs. Differences in company interpretation and applications of the international health authority regulations, coding and case processing standards and practices, and factors such as time on the market, labeling, product publicity and total patient exposure may be important factors in explaining apparent differences. The latency between agency receipt of data and public availability of the data may obscure differences between older and newly marketed products.

Data obtained by proportional reporting evaluations or EB05 scores should be reviewed in light of clinical experience with the product and, in general, should be validated using an external source of data such as exposure estimates, clinical trial results, review of the scientific literature and clinical and epidemiological studies.

For all of these reasons, these types of reports should be used solely for the purpose of initial signal identification. Causality cannot be determined using this instrument, and its primary utility is for generating hypotheses for further evaluation. These data cannot be used alone to make safety decisions or recommendations about safety issues, as signal analysis cannot prove or disprove a causal association between a specific drug and an AE, in the absence of other compelling evidence. Appropriate regulatory and legal guidance should be sought concerning other uses of these types of reports.

40.6 Regulatory guidance

According to two FDA guidance documents issued in 2005, and presented in synoptic form below, applying data mining techniques to large AE databases, such as FDA’s AERS or VAERS, can enhance risk identification and assessment. Data mining, by systematically examining reported AEs, may be able to provide additional information about the existence of an excess of specific AEs reported for a product, warranting further investigation. FDA Guidance for Industry (2005).

This technique can be used to supplement existing signal detection strategies, but does not establish a causal association between the drug–event pairs being studied. However, it can be used for assessing patterns, time trends and events associated with drug interactions. Data mining can be improved by adjusting for aspects of reporting (e.g. cumulative reporting by year) or characteristics of the patient (e.g. age or gender), or limiting the analysis to drugs of a specific class or for those used to treat a particular disease. The score generated by data mining quantifies the disproportionality between the observed and expected values for a given product–event combination.

Although it is recognized that all of these approaches are inherently exploratory or hypothesis generating, they may provide insights into the patterns of AEs reported for a given product relative to other products in the same class or to all other products. The FDA urges caution when making such comparisons among products, because voluntary AE reporting systems such as AERS or VAERS are subject to a variety of reporting biases.

As of now, the use of data mining techniques is not a required part of signal identification by regulatory authorities; however, if data mining results are submitted to the FDA, it is expected that they will be presented in the larger appropriate clinical epidemiological context, to include

- a description of the database used;
- a description of the data mining tool used (e.g. statistical algorithm, and the drugs, events and stratifications selected for the analyses) or an appropriate reference;
- a careful assessment of individual case reports and any other relevant safety information related to the particular drug–event combination of
interest (e.g. results from preclinical, clinical, pharmacoepidemiologic or other available studies).

Data mining techniques should always be used in conjunction with, and not in place of, analyses of single case reports. Data mining techniques facilitate the evaluation of spontaneous reports by using statistical methods to detect potential signals for further evaluation. This tool does not quantify the magnitude of risk, and caution should be exercised when comparing drugs. Further, when using data mining techniques, consideration should be given to the threshold established for detecting signals, as this will have implications for the sensitivity and specificity of the method (a high threshold is associated with high specificity and low sensitivity). Confounding factors that influence spontaneous AE reporting are not removed by data mining.

### 40.7 Privacy

Privacy concerns are becoming more important as data mining becomes more common. Besides issues of data ownership, there are questions that abound on who has access to the data, the amount of identifying information that is present in the database and how the results of the data mining will be used.

Furthermore, there are laws both in the United States and Europe which regulate data privacy, and in addition the FDA has separate rules on data integrity and traceability. All of these issues will have an impact on the way data are collected, data mined and how these results are used.

The European Union’s Directive on Data Protection bars the movement of personal data to countries that do not have sufficient data privacy laws in place. Additionally, the US Health Insurance Portability and Accountability Act (HIPAA) sets national standards for the protection of health information, as applied to the three types of covered entities: health plans, healthcare clearinghouses and healthcare providers who conduct certain healthcare transactions electronically. HHS OCR HIPAA Privacy (2003). This law was enacted in recognition of the fact that advances in electronic technology could erode the privacy of health information.

The discussion about data mining and privacy is just the beginning. There will be increased scrutiny of data mining and its impact on privacy in the years to come. This is especially true as consumers and lawmakers become more aware and concerned about the potential for data mining, if used improperly, to violate the privacy rights of individuals. At the same time, however, governments are actively engaged in data mining for national security and law enforcement purposes, as they too begin to recognize the tremendous value of using this powerful technique. Nevertheless, as long as the data that are collected contain any potentially identifying information, legal, ethical and privacy questions will need to be addressed.

### 40.8 Limitations

The biggest limitation with data mining is the quality of the data. Simply put, the results of the analyses are only as good as the data from which they are derived. The best databases are those that are relevant, complete, have rich-quality data, are large and get updated frequently. Unfortunately, many databases are designed for purposes entirely different than what they are being used for, when they are data mined.

Additionally, as errors can easily occur in databases, it cannot be assumed that the data they contain are entirely correct. Even after ‘data cleaning’ – a process to remove obvious errors and duplicates – there may be inherent errors or misclassification in the data being collected, particularly if there is subjectivity involved in the measurement that is used. Furthermore, in large, constantly changing databases, there must be rules in place for the data mining algorithm to capture the most current data.

Lastly, because the results obtained from the data mining process can be difficult to interpret, it is extremely useful for the results to be presented in a graphical form that allows the user to interact with both the data and the results. This allows the end user to further explore and better understand the results obtained. By being able to go from a
broad perspective to a fine focus, this ability for the user to ‘drill down’ to the level of detail in which he/she is interested can be helpful. Furthermore, a graphical display of the data can help to identify data problems, provide insights not achievable with mere tables and demonstrate new relationships.

40.9 Summary

Data mining does not supplant traditional pharmacovigilance methods. Instead, it supplements safety surveillance methods and allows a systematic identification of potential safety signals. The promise of data mining using large regulatory safety databases is that the huge size and diversity are the primary advantages because they enable multiple comparisons and provide valuable information whether one is looking in groups of events or classes of drugs. Essentially it allows the review of all of the data and is very sensitive in detecting safety signals.

The interpretations of data mining results need the expertise of safety reviews and medical officers to analyze and interpret data appropriately. Data-mining signals by themselves are not indicators of problems, but are indicators of possible problems. Moreover, caution must be exercised with any comparison of disproportionality ratios across different products, for example comparison with competitor drugs because of the various limitations that exist when making these kinds of comparisons.

Finally, all signals should be evaluated recognizing the possibility of false positives. In addition, the absence of a signal does not mean that a problem does not exist.

References


41 Risk Management in Product Approval and Marketing

Anthony W. Fox

41.1 What is it?

- In general terms: Identification and implementation of strategies to reduce risk to individuals and populations

- For individual products: A plan oriented towards the known risks of the product, and identifying methods not only to minimize risk to the individual patient, but also to define further the product’s safety profile as it reaches a wider population.

adapted from remarks by Markku Toivonen MD PhD (February 2003)

Risk management in product approval and marketing is an extension of the practice of pharmacovigilance, and translates the observations of that discipline into actions that reduce clinical hazard. This is the art and science of getting the right drug to the right patient at the right time.

Clinical hazard has two aspects. The most obvious aspect is avoiding the inappropriate exposure of a patient to a potentially harmful drug. But let us not forget that clinical hazard can also be created by restrictions on product distribution channels; if these are too rigourous, then the drug might never reach a patient who could experience benefit beyond that from any alternative therapy.

This chapter begins with the regulatory basis for risk management programs, as far as is needed beyond the previous chapters on European and American regulations. Practical examples will then be considered.

41.2 Regulatory frameworks

Of all areas of regulatory science, the regulations concerning risk management programs are amongst the least internationally harmonized. It can be argued that this is good: as we shall see below, special risk management programs work best when tailored to the specific characteristics of the product, its indication and the venue of its use. Flexibility of approach may be required to adapt a risk management program to different geographical and cultural contexts, even when the same product and indication are under consideration.

The ordinary case. All Sponsors/Marketing Authorization Holders are required to implement pharmacovigilance programs for all marketed products. Reports to regulatory authorities of the findings of these programs are usually required.
more frequently in the early part of the product life cycle than later on. The least restrictive ordinary situation is when clinical hazard is seen as being so slight that prescription is judged unnecessary. Products can then be licensed for over-the-counter use, with or without pharmacist oversight. In the opposite direction, ‘black box’ labeling might recommend restriction of the distribution of the product to practitioners with specific training (e.g. in the United States, neuromuscular junction blocking drugs to anesthesiologists, and cytotoxic agents to oncologists and rheumatologists). ‘Black box’ warnings might also draw attention to particularly serious adverse event types, and restrictions on advertising and marketing can thereby also attach.

These common situations are discussed in the previous chapters on regulatory affairs. They can be viewed as the default set of risk management programs to be implemented in the absence of any special clinical hazard.

Special regulatory provisions: United States. Subchapter D of the Code of Federal Regulations (CFR) authorizes the Food and Drug Administration (FDA) to approve new drug products on an accelerated basis, provided that the indication is for a serious or life-threatening condition (see: 21 CFR 314.500–560, also known colloquially as ‘Sub-part H’ because of where it resides in the Subchapter). This regulatory innovation took place in 1992, with a minor amendment in 1999. The candidate new drug product must also offer ‘meaningful clinical benefit’ to be approved under these provisions; FDA must be able to anticipate that there are patients for whom alternative treatments are clearly inferior, either through lacking efficacy or risking substantial intolerability.

Accelerated, Sub-part H, approvals rely less on clinical data than an ordinary approval. On the efficacy side, this might include, for example, the use of a surrogate end point instead of a disease outcome (for example, an antihypertensive drug can be approved without a p-value for reduction of stroke). On issues of tolerability, an accelerated approval almost always means a database with fewer patients than would be otherwise desirable. It is in this latter case that FDA will mandate a special risk management program. The Agency will review and approve a specific program design, to which the Sponsor must agree, before issuing the product approval.

The design of these special risk management programs may involve one or more components. In general, these components fall into the following categories:

(a) Restriction in product distribution (location, medical procedure or quantity of dispensing).

(b) Need for special training of prescriber or pharmacist before authority to prescribe or dispense.

(c) Need for special education of patient prior to dispensing.

(d) Specific clinical tests prior to patient eligibility.

(e) Documentation of patient’s informed consent prior to dispensing.

(f) Mandated patient registries.

(g) Targeted post-marketing clinical studies.

The term ‘access program’ is often used when publicizing these special measures. The Sponsor’s performance according to the agreed plan becomes a condition for the approval to remain active; however, if the FDA does wish subsequently to withdraw approval for failure to follow a post-marketing risk management plan, then the Sponsor is entitled first to a hearing.

Special regulatory provisions: European Economic Area (EEA). The components of risk management programs in Europe have been similar to those listed above. However, it is probably fair to say that, overall, there has been less experience with these programs in Europe than in the United States.

Pan-Community, both the European Commission and the EMEA have interests in risk management programs for pharmaceutical products. Both organizations are interested in the safety of the general public and also in ensuring equal access to pharmaceutical products across the Community. The Commission tends to take a more economic
view; for example, expressing concern about special programs that drive product costs upward and when these costs are absorbed by the national health services more easily in large countries than in small ones. Within the EMEA, there are multiple departments and divisions with responsibilities that impinge on different aspects of risk management programs; the CHMP maintains a Pharmacovigilance Working Group, the COMP wants to assure access to drugs for patients with rare diseases, and the groups dealing with labeling have the daunting task of ensuring that written descriptions of how to mitigate drug hazards, mean the same thing in more than 20 languages.

At the national level within Europe, the situation becomes yet more complicated for both regulatory and less tangible, cultural reasons. Each member state has a National Competent Authority (NCA) regulating pharmaceutical product price, label and distribution. Each NCA can mandate product withdrawal within its boundaries, and notify others about its concerns. But such a decision is never binding in any other part of the EEA, and there is certainly no obligation for one member state to implement a risk management program that has been mandated at the national level elsewhere.

Academic, cultural (including religious), ethical and medical attitudes also diverge within the EEA. For example, with the exception of clinical trial participation, in many European countries a requirement for written informed consent is seen as unethical: no informed consent means no therapy, and therefore the patient may be under duress, or provide uninformed ‘consent’ in order to gain access to medical treatment. Furthermore, the notion that some of the burden of responsibility for drug exposure could shift to the patient can also be seen as an abrogation of the responsibility of the prescriber or pharmacist.

Patient registries and databases also run into problems within the EEA. Regardless of whether or not these rely on public funding, they are seen as potential violations of patient confidentiality. In some European countries, this is emphasized by national privacy legislation. The entry of an identifiable patient into a registry, as a condition of drug supply, can be seen as a situation where it is a registry administrator, checking inclusion and exclusion criteria, that ultimately decides whether a patient is treated; this is seen as de facto interference with the clinician–patient relationship. For all these reasons, it can be impossible to operate the same risk management program in every European country.

### 41.3 Practical examples

What sorts of drugs and indications have special clinical hazards and need special risk management programs? At the pan-European level, the EMEA now considers risk management plans more or less routinely prior to Marketing Authorization. But in general, the products for which detailed risk management plans will almost always be required are:

- biological products;
- new chemical entities with novel mechanisms of action;
- significant changes in indication for older products;
- new target populations;
- major issues of intolerability;
- products undergoing the prescription-only to over-the-counter ‘switch’; and
- Orphan Medicinal Products (where clinical trials patients are automatically few).

Although most of the ‘Sub-part H’ examples in the United States fall into these categories, these are good, general criteria which should stimulate Sponsors to consider implementing detailed risk management programs, regardless of whether or not this is being mandated by a regulatory authority.

**Abuse liability.** Psychotropic drugs with abuse and dependence potential, and the associated restrictions on product distribution (i.e. ‘Scheduling’ under a Controlled Substances Act or equivalent) form a well-established system of risk
management programs. Most countries recognize the need for four or five degrees of scheduling with graded increases in product restrictions, thus forming a usefully flexible system. This is also now harmonized internationally by the signatories to the United Nations Psychotropic Drugs Convention, which covers opioids, thebaine derivatives, barbitals (barbiturates), amphetamines, the natural and semi-synthetic products of *Erythoxylon coca* and *Ephedra* spp., as well as other drugs with both medical purposes and abuse liability.

Even in the most extreme case of risk management program, where the risk-benefit assessment is deemed to be so hopeless that a drug is absolutely banned, there can be a lack of international harmonization. The easy illustration within this class of drugs is diacetylmorphine (diamorphine, ‘heroin’). In the United States, this is a Schedule 1 controlled substance, defined as being without any medical value; prescribing and dispensing is absolutely prohibited. In contrast, several European countries value this drug for the treatment of pain in terminally ill patients, and for its greater solubility than morphine (making large doses of opioid easier to swallow). In the EEA, this is achieved by a lower grade of ‘Scheduling’ than in the United States, although prescription, storage and dispensing nonetheless require greater storage security and accountability than for ordinary prescription-only medicines.

Note, too, that this well-established type of risk management program has indirectly led to competitive advantage in at least one case. One manufacturer of a modern product for insomnia advertises in the United States that this drug ‘is not a narcotic’. Simplicity in prescribing and dispensing, and a perception of the relative safety of an unscheduled product, is attractive to physicians, pharmacists and patients with insomnia, alike.

**Major issues of toxicity: thalidomide.** The story of thalidomide in the 1960s is too well known to need any repetition here. The full spectrum of its pharmacology and toxicology is still not fully understood, but in addition to its supposed antiemetic effects during pregnancy, this drug is also immunomodulatory. In the 1990s, interest in this latter property grew, and thalidomide (often in combination with dapsone) was found to be effective for erythema nodosum in patients with Hansen’s Disease (leprosy) and without peripheral neuritis. What has been the response, in terms of risk management programs, to allow patients to have access to this teratogenic drug?

In the United States, thalidomide was approved in 1998 under the ‘Sub-part H’ provisions. The product label carries no fewer than seven different ‘Black Box Warnings’, some of which appear twice. These describe precisely the teratogenicity and risk management plan associated with this drug. More or less every component from the list above is deployed, in what is known as the System for Thalidomide Education & Prescribing Safety (the ‘STEPS Program’), including the following:

- Product supply chain to a small number of registered pharmacies (fewer than an average of one per State).
- Dispensing permitted-against prescriptions written by only a small number of named, specially-registered physicians.
- Requirements for special training of these registered physicians and pharmacists.
- Documented informed consent by patients, emphasizing contraception, pregnancy testing and the risks of teratogenicity.
- For minors, documented informed consent from parents or guardians.
- Mandatory regular pregnancy testing for women of child-bearing potential.
- Maximum one-month supply per prescription, with no refills permitted.
- Mandatory patient registration by name and location prior to dispensing.
- Close pharmacovigilance of all registered patients with frequent FDA reporting.

Erythema nodosum associated with Hansen’s Disease is a rare disorder in the United States, and the manufacturer of thalidomide enjoys the exclusivity
provided by orphan drug status. This might be a rare situation where the toxicology of an orphan drug product is well known due to its severity, relatively high incidence and prior exposure to a larger patient population for a previous, failed indication. But, thus far, there have been no reported disasters.

European views about STEPS-type programs are very different. First, there is conflict between patient (and probably clinician) registration and privacy laws in many countries. Second, the patient registers and documentation of informed consent is seen as interfering with the doctor–patient relationship. Thirdly, there is the potential for iniquity of drug distribution; some of Europe, including areas where leprosy is to be found, is only sparsely provided with physicians and pharmacists, and those that are unregistered for this special purpose effectively block access for a proportion of the EU population. Fourthly, for the cultural reasons described above, the patient registries would probably have to be at the national level; the cost–benefit ratio of these schemes might be less attractive to smaller countries than large ones, again creating iniquity. Fifthly, there is skepticism that the required documentation can automatically correspond with the quality of education imparted to clinicians and patients alike (this concern applies more widely to many matters of continuing medical education and revalidation in Europe). Lastly, the STEPS Program can be seen as one where the Marketing Authorization Holder actually decides whether a patient is eligible to receive the treatment, and whether a doctor is qualified to prescribe it, thus pre-empting those who would otherwise be duly empowered to do so, either by reason of ethics or by law. In Europe, no risk management program has been implemented, and there is no marketing authorization for thalidomide.

**Major clinical hazard: mifepristone.** This prostaglandin analog is capable of inducing abortion of a uterine pregnancy of less than 49 days duration when administered orally. In 2000, it was approved in the United States amidst controversy associated with the cultural aspects of pregnancy and its termination.

The risk management program that has been deployed for mifepristone is less restrictive than that for thalidomide. The use of the product is restricted to those physicians who are capable of determining the duration of pregnancy, and who can identify ectopic implantation. Availability and training in the use of ultrasound is therefore required. Doctors who prescribe the drug must also be able to provide surgical intervention in cases of incomplete abortion or severe bleeding, although it is unclear whether this includes (for example) the situation of an endocrinologist prescriber who works with a gynecologist in a closely coordinated environment, or whether the prescriber and the surgeon-in-reserve has to be the same person.

At the time of writing, about four years have elapsed since product launch. The most widely reported serious adverse events during those four years have been four cases of fatal sepsis, a clinical hazard that is much smaller than the general risks associated with pregnancy to full term.

This is an example of a risk management program that currently appears to have been scaled appropriately for the minimization of direct clinical hazard. Cultural aspects of this form of therapy continue to provoke protest at product availability, and reported adverse events are also used to keep these protests in the public eye.

**Examples of International disharmony.** The examples of diacetylmorphine and thalidomide (see above) are examples of pharmaceutical products that are available either only in Europe or only in the United States, respectively. Within Europe, the existence of National Competent Authorities provides further scope for nonuniform risk management plans.

A good example is cisapride, a propulsive gastrointestinal drug, which was found (especially in the context of drug interactions) to cause prolongation of the QT interval and predispose to **torsade de pointes** ventricular tachyarrythmia. This information caused some of the National Competent Authorities in Europe to suspend marketing authorization for this drug. The CHMP within the EMEA subsequently reviewed the pan-European pharmacovigilance data on this product. Cisapride has now been returned to the marketplace with various restrictions having been placed on national authorizations, including a
variety of nonharmonized risk management programs.

Similarly, sertindole. In this case, the marketing authorization for this anti-psychosis agent was initially suspended by a single member state (some would claim with too little advance notice). This was followed by complete withdrawal of the product, on a voluntary basis, by the Marketing Authorization Holder. Again, a CHMP/EMEA pan-European review took place for all the pharmacovigilance data that was available. Again, the product has now been reintroduced, albeit with risk management programs of different designs in various European countries.

Intra-County (sic) problems implementing risk management programs. If there was ever any need to emphasize the need for flexibility of approach in risk management programs, then no better illustration could be than dealing with problems that can arise within a single county! San Diego County is the most southwestern within the 48 contiguous United States, bordering on Mexico and the Pacific Ocean. It is quite a large county (about the size of the country of Lebanon) and has substantial Spanish-speaking, Italian-speaking, Mandarin-speaking, Anglophone, Roman Catholic, Protestant, Buddhist and non-religious communities.

Pity, then, the San Diego pediatrician trying to cope with the nationally designed risk management program for isotretinoin when used in adolescent girls with acne vulgaris. Advice to avoid sunlight, given the local climate and architecture might be somewhat pro forma. But the ability to hold effective discussions about contraception and repeated pregnancy testing with supposedly under-aged, tattooed, Californian, surfers, as well as conservative, teenage Latinas accompanied by their mothers, can only inspire awe.

41.3 Summary

Risk management programs are not a new invention (e.g. ‘Scheduling’ of drugs with abuse liability). There are classes of drugs for which risk management programs are clearly indicated beyond those that are routinely required for product approval and marketing. The menu of measures that can be used is long, and should be scaled against the clinical hazard that has been identified or is suspected. Political, national and cross-cultural factors have a large impact on the success of risk management plans; the most effective ones are likely not to be internationally harmonized.

Acknowledgments

For this chapter, much is owed to analysis offered by the following experts at the 5th Scripps-BIO Drug Development Conference (La Jolla, California, February 2003): Rear-Admiral Marlene E. Haflann USPHS MD MPH FRCPR (US Food and Drug Administration), Professor P. Kurki MD (National Agency for Medicines, Finland), M. Toivonen MD PhD (CHMP, EMEA), H. Greenaway MD (Scripps Clinic, California), and R. Wagner PharmD (Kaiser Permanente, USA). The views expressed at that conference were those of the experts themselves, and were not necessarily those of their employers.

Further reading


42 Publishing Clinical Studies

Anthony W. Fox

42.1 Introduction

This chapter has three objectives. First, it is necessary to discuss the ethics and desirability of publishing clinical trials, and the biases that may be involved with that process. Second, younger clinical trialists may benefit from some discussion of classic parts of an orthodox clinical trial report in a peer-reviewed journal, and some clues for effective oral presentations. Third, alternative forms of publication are discussed, including isolated abstracts and posters, electronic publication and press releases. The scope of this chapter is strictly formal publications: regulatory documents (which are typically not published and are a different form of clinical trials reporting) and marketing materials are dealt with elsewhere. Also, although the term ‘publishing’ is used to describe the electronic submissions to regulatory authorities, that subject belongs to another chapter of this book. A summary and prospectus closes this chapter.

42.2 Ethics in publishing clinical trials

For all forms of publication, the objective usually goes beyond the mere reporting of clinical trials data. In some way or another, the pharmaceutical physician will interpret his or her data to reach conclusions, and will want to urge some change in the behavior of the target audience. These changes might include prescribing habits, healthcare resource utilization, public health policy or regulatory practices.

Whatever the form of publication, the only tools available to persuade people to make these behavioral changes are the well-created document, audiovisual presentation, press release and so on. Often, the actual dissemination of these materials takes place at a time or place remote from the writer’s supervision. Publications must be well made for stand-alone use.

Conclusions that extrapolate beyond the range of available data are as inappropriate in scientific
publications, and nor do they belong in regulatory
documents or marketing materials. Omissions of
details in methods and results pursuant to a concise
presentation will always be subjective, and there is
a close link between the appropriateness of this
subjectivity and the integrity of the author(s).

The pressures on the clinical trialist, whether
writing himself or herself, or when guiding specia-
list medical writers, are many, sometimes contrary
to common standards of integrity, and often ema-
inate from powerful people who lack the training
needed to assess data objectively. Such people will
include journalists who oversimplify or sensatio-
onalize, marketing department staff wanting to
amplify positive messages and silence negative
ones, and corporate officers who want to use pub-
ications as vehicles for enhancing the share price
or negotiating better financial arrangements on
Wall Street. Rarely, even government politicians
get involved, whose tactics include those used by
journalists, the diligent application of complete
ignorance, and the forced fit of technical informa-
tion to a predetermined political position.

The publication of clinical trials, then, is one
example where the clinical trialist (acting as pub-
licist or medical writer) may become an agent for
social change (Gray, 1994). Even when he or she
acts solely as a medical writer, authors physician
must understand their ethical responsibility to repre-
sent the material in a fair, balanced, and, above all,
accurate manner. While an ombudsman-like role
may help in finding compromise among the various
pressures that are applied to this process from
diverse outside parties, the author of a clinical trial
report may inevitably (but hopefully only occasion-
ally) find himself or herself as the sole repository of
integrity in this process; this can feel lonely, but
nobody else is going to fulfill this role.

42.3 Desirability of, and biases
in, the publication
of clinical trials

Everybody finds the publication of an ideal clinical
trial to be highly desirable. Clinical development
departments find it efficient to mail out reprints in
response to clinicians’ inquiries and to append
them to Investigators’ Brochures and IND amend-
ments. Regulators controlling promotional prac-
tices need only satisfy themselves that the
publication accurately reflects the report that has
been submitted to the approved PLA or NDA.
Marketing departments can use these publication
for promotional purposes, knowing that the data
is cast-iron, the message is unarguably positive,
and that the self-evident benefits of the drug will
be understood by the most skeptical clinician
meeting the least adept sales person. Lastly, senior
management can bask in the glory of its contribu-
tion to the public health, and direct observers on
Wall Street to the appearance of its clinical trials
in the world’s most respected medical journals.
For small companies, this might even be life
saving. How on earth could such a laudable activ-
ity go wrong? The answer, of course, lies in the
fact that many clinical trials are less than ideal
candidates for publication. These poor publication
candidates may be trials that did not result in a
positive outcome, or those that generated data
about some prosaic aspect of drug action (e.g.
tolerability in a special population). Studies repli-
cating a positive finding are often a regulatory
requirement, but me-too papers do not find
homes in prominent journals. Lastly, some good
studies are less than ideal publication candidates
solely because the manuscript has been drafted
badly.

Negative trials are rarely accepted for publica-
tion by good journals unless their results seriously
despel some previously held belief, or contradict
previously published studies. Some areas of ther-
peutics are notorious for the high proportion of
negative clinical trials results (e.g. pharmacologi-
cal treatments for depression). However, the
majority of negative clinical trials are those
where either drug efficacy is simply not evident
or where no difference is found between two active
treatments. Negative data are the inevitable result
of conducting clinical trials that are true experi-
ments; there is nothing dishonorable in such a
result, even if it is disappointing. However, the
failure to publish such studies risks waste of further
resources and duplication of the patient hazard,
needed for an independent study group to discover
later the same negative result. Chalmers (1990), somewhat hyperbolically, has actually characterized underreporting of clinical trials data as scientific misconduct.

If this underreporting is suboptimal, then those who publish clinical trials must take their share of the blame. Incongruously, it is the same journal editors who have traditionally been least likely to publish negative data that are making the most noise about the unsatisfactory performance of the pharmaceutical industry in failing to publish the data (e.g. Horton and Smith, 1999; Tonks, 1999). This author cannot agree with Dickersin et al. (1992) who wrote: ‘Contrary to popular opinion, publication bias originates primarily with investigators, not journal editors...’ because the busy clinical trialist is unlikely to waste his or her time writing a paper that he or she knows has little chance of being published.

The establishment of clinical trials registries may be one way to overcome the bias against reporting of negative clinical trials. This is not a new idea (e.g. Simes, 1986) and several worthwhile attempts have been made to accomplish this. The National Health Service in the United Kingdom (Peckham, 1991), an amnesty for the publication of clinical trials offered by some journals (Roberts, 1998), and specialized databases (especially in the areas of malignant disease and AIDS) have been partial responses to the many pleas for registration of clinical trials. Two large pharmaceutical companies have taken an initiative to register their own clinical trials (e.g. Sykes, 1998), but have been ungratefully criticized both for doing too much and for doing too little: some think that the registered information is insufficient, whereas others believe that this creates a commercial disadvantage (Horton and Smith, 1999).

A further bias in clinical trials publishing is the selective reporting of subsets of secondary end points. This is usually associated with active-comparator trials having a primary objective of demonstrating the superiority of one treatment over the other. All too often, the primary objective of the trial is not achieved: the authors then selectively publish a few of the many secondary end points that did support their hypothesis. The ‘if you have 100 end points and \( z = 0.05 \), then, at random, five end points will be statistically significant’ principle supervenes; fallacious treatment differences are claimed after reporting only those five end points. Solutions to this problem could include an independently prepared summary of the protocol, with its prospective objectives and complete list of end points, perhaps in mini-type, at the end of such papers, as well as sensitization of reviewers to this potential problem. Journal editors sometimes approach this ideal by asking for protocols to accompany the submitted manuscripts; some companies view their protocols as confidential, and one wonders whether this is one of the reasons why.

Thus, there are multiple ways in which publication bias may be created by study sponsors, publicists, medical writers and those who control journal content. Clinical trial registries still do not exist in any comprehensive fashion. Those constructing meta-analyses from published studies should beware.

### 42.4 The classic components of a clinical trial report in a peer-reviewed journal

The publication of clinical trials in peer-reviewed journals normally follows the same format as for any other paper: title, authors, sponsorship, abstract, introduction, methods, results, discussion, concluding paragraph, acknowledgments, references, tables and figure legends, with each figure attached on a separate sheet labeled on the reverse. The overall philosophy is also the same as for any other paper, namely that there should be enough information for the study to be replicated in independent hands, should the need arise. It is beyond the scope of this chapter to teach how to write a scientific paper: there are many other books, manuals and journals that can devote enough space for this purpose (succinct examples include Skelton, 1994; Bonk, 1997; Fromter et al., 1999).

All journals publish guidelines describing the formats for the often diverse types of article that will be considered. The corollary is that the writer should identify the target journal before putting
pen to paper, and judge whether the quantity of material supports a whole paper, a brief report or even more than one paper.

Authorship on papers is a matter of substantial debate. Under some circumstances, literally dozens of coauthors will clamor to be listed, and this phenomenon is not restricted to the publication of huge multicenter clinical trials. Clinical trials are a specific case of this general, perennial problem, to which Rafal (1991) has provided a somewhat humorous guide. There are two solutions.

The first solution is the prospective promulgation of a set of criteria that every author must meet. Many journals publish their own specific guidelines or criteria, and these do not differ greatly in qualitative terms. In the practicality of publishing clinical trials, the following would be typical:

(a) The principal investigator(s) is/are authors unless so numerous as to require a team designation (see below).

(b) The statistician(s) who personally accept(s) responsibility for the statistical analysis in the corresponding document(s) that is/are submitted to regulatory authorities should sign off on the paper and be named as author(s).

(c) Key members of the clinical team within the pharmaceutical company may (but not necessarily need to) be authors.

(d) All named authors should be able to personally defend the paper after publication, and be familiar with (but not necessarily have personally performed) all the methods employed in the clinical trial.

(e) There should be no circumstances where ‘guest authorship’ or ‘gratitude authorship’ is awarded; all authors’ participation must have been fundamental to the conduct and success of the clinical trial.

(f) All authors should be prepared to disclose all conflicts of interest and the sources of financial support for the clinical trial.

The second solution is to publish the paper under the name of the team that conducted the trial, rather than the personal names of the participants. The acknowledgments can then list all those who took part (e.g. The Subcutaneous Sumatriptan International Study Group, 1991). A hybrid variant is also sometimes used, where a one (or a few) lead author(s) is named and stated to represent the rest of the team (e.g. Cady et al., 1991)

The advantages of this tactic are that there is at least one person who accepts responsibility for defense of the paper after publication. A further advantage is that this can be used to motivate investigators in multisite studies: the protocol can state that the investigator who recruits the most completed patients, without violations, will be named the first author in any publication.

### Isolated abstracts and posters

An argument can be made that the isolated abstract format is not a good vehicle for the publication of clinical trials. Indeed, the inclusion and exclusion criteria in most clinical protocols alone exceed the word limit of most journal article abstracts. Too often, the publication of an abstract or poster is a criterion used by companies to justify the time and expense of sending staff to a conference: authors then generate and submit unimportant abstracts, principally for use as tickets to venues that attract them for ulterior reasons.

There are a few exceptions to this generalization, however. Legitimate retrospective analysis of the database of a clinical trial that has been previously published in full sometimes can make an isolated abstract, provided the full reference is provided, and an educated audience at, say, an academic conference, will be aware of the potential biases of this technique. Similarly, the open-label tolerability extension to a previously published controlled trial might be usefully published as a poster. But these are minor exceptions to the general principle that in order to assess the validity of a clinical trials report, far more detail is needed than

---

1See especially the footnote to the first column on page 2831 and the acknowledgments.
can be published in the small spaces of isolated abstracts and posters.

**Audiovisual presentations at academic meetings**

It is amazing that apparently intelligent people often attempt to speak to their peers at academic meetings with (a) disorganized speech (due to disordered thought processes and/or acute episodic dysartria) and (b) an inability to control a PowerPoint® projector that should by now have universally replaced the former chaos they created with 2" × 2" photographic slides. This ineptitude is displayed by all medical specialties (including clinical trialists), by most other nonmedical professions, and has shown no sign of improvement during the past three decades. One’s amazement is all the greater because these incompetent speakers must often have heard equally bad productions, and today’s projector controls are simpler than an hotel alarm clock.

The most important time when making oral presentations is before you even begin the talk. You should have the following three things **sine qua non**:

(a) An understanding of the audience and the vocabulary needed to communicate with them (the general public, a patient advocacy group, an academic society and an in-house department seminar all require very different approaches).

(b) A slide set that is cogent, organized and familiar.

(c) A look at the venue and the various pieces of equipment that will be at your disposal; think about how to match your speaking volume to the open-air or to the microphone (if any), where to stand so that you can see your slides without having your back to the audience, and how to use a laser pointer without imitating a demented insect.

For the actual talk itself, one useful checklist is as follows:

(a) What is the take-home message, in one simple sentence of the language of the conference? (e.g. ‘Drug X was superior to placebo in treating disease Y, in a patient population with characteristics A, B, and C, i.e. like the known epidemiology of the disease’).

(b) State the purpose of the talk at the beginning; usually, this will be to explain how one will defend the take-home message. (‘This talk is to describe the clinical trial that has led us to conclude that drug X is effective for disease Y in a patient population that is representative of the known epidemiology of this disease.’)

(c) Organize one’s slides in a manner that would be used sequentially to illustrate a written paper in a peer-reviewed journal (see above).

(d) Make sure all slides are legible (e.g. a minimum of bold 24 point text for a Microsoft® PowerPoint® presentation).

(e) Avoid tables of data in slides; if you cannot graph it, then it is probably not worth showing at all.

(f) Make the text of each slide concise (e.g. maximum of 30 words per slide).

(g) Create slides to be self-supporting; if you gave your set of slides to someone equipped with a projector, could they, without any further explanation, more or less work out your subject and principal conclusions?

(h) Plan to use about one slide per minute of time allotted.

(i) If you are an iconoclast and still using photographic slides, then at least number your slides with bright labels on the plastic holder (so that you can see or feel the bright label in near darkness). Use a consistent location for your label, and then use that label to orient the slide when loading the carousel. Usually, but not always, this is ‘right way round, wrong way
up’. Practice showing one slide before wrongly loading all of them.

(j) Relate the middle part of your talk to your take-home message (e.g. if disease Y is type I diabetes, then ‘As shown in this slide, the patient population included 30% adolescents because this group represents a relevant fraction of the whole population with type I diabetes’).

(k) At the end, repeat the scientific conclusions, briefly review the data that you have presented in their support, and then interpret these conclusions, once again, into your take-home message.

Most people are in an altered psychological state shortly after giving a talk, whether or not it seemed to go well. In this psychological state, they gladly accept thanks and congratulations, but are incapable of hearing constructive feedback. Feedback is essential to either improve the talk the next time round or to improve one’s presentation skills in general. Seek out this learning opportunity from friends, and tell them in advance that you will be asking for this feedback, probably a few days after the event.

Newer forms of clinical trials publication

Electronic publishing is relatively new and is not yet in any standardized form. It is important to understand, however, the main classes of electronic publication, before taking the big step of committing your clinical trial report to it. Only then can the central question be answered for that clinical trial: Would electronic publication make these data more easily available to the audience that can best use them (Geddes, 1999)?

The CD-ROM versus the textbook is probably the most primordial form of the digital versus analog debate. This battle has probably now been fought to a standstill, with winners and losers on both sides. Example replacements include the approximately two dozen annual volumes of Index Medicus, or both 37 annual volumes of Headache and 17 annual volumes of Cephalalgia, by single CD-ROM disks. This replacement saves trees, speeds search times, and has lower production and shipping expenses, but requires readers to have access to a computer at the same place as the disk. Clinical trial databases can be usefully placed on CD-ROM, and this can facilitate explorations beyond the prospective trial objectives. Epidemiological studies, where huge numbers of patients are often studied, may be especially suited to this form of publication.

Many traditional journals have sprouted electronic limbs. The most common form at present is probably the distribution of electronic facsimiles of printed papers, usually in pdf format which can be read using Adobe Acrobat software that can be downloaded without charge. Access to these facsimiles is usually restricted to those who also have a subscription to the paper version of the journal and thus represents a duplication of or extension to paper publication, rather than its replacement. In some cases, journals publish electronically a wider selection of submitted papers than can be accommodated in their paper versions, or restrict new electronic material to correspondence that does not appear in print (Chalmers, 1999; Delamothe and Smith, 1999; McConnell and Horton, 1999).

Song et al. (1999) have suggested that electronic journals can reduce publication bias (see above) principally by accommodating and providing access to greater quantities of published materials. Chalmers (1999, and see above) is an enthusiast, so presumably this is correct. Chalmers and Altman (1999) have even proposed that not only will publication bias be reduced but also that the intrinsic quality of clinical trials themselves could be improved as a result of electronic publication; this remains to be proved. However, this enlarged volume of publications also mandates a different peer-review system, or even no peer-review at all. It is possible that electronic publications may come to be suspected as both providing higher quantities of information but possibly with lower quality than more orthodox publications.
Press releases

Pharmaceutical physicians in large pharmaceutical companies will only very rarely be exposed to the need for press releases concerning their clinical trials. In contrast, the small entrepreneurial pharmaceutical company may live or die on the outcome of a single clinical trial. The rapid dissemination of the results of such a clinical trial to the appropriate audience (shareholders and investment community) is legally required when material to the prospects of a small, public company. The press release then becomes an important tool for publishing clinical trial results.

When writing press releases, absolutely no technical knowledge can be assumed on the part of the recipient. Often their questions parse simply to ‘Did the drug work or not?’ Extended detailed explanations can actually create the false impression that the drug did not work, when in fact the trial outcome was quite satisfactory for product registration purposes. Equally, when clinical trials fail, ingenious but scientifically meaningless explanations by corporate officers can create the false impression that the outcome was better than it was. A good example is the often used: ‘We still have confidence in our ability to register Drug X; Drug X performed as we expected, but it was just that the placebo response rate in this [pivotal] study was unexpectedly high.’

Clinical trialists may often want to avoid involvement in the drafting of press releases altogether. However, this creates a liability that one’s independent comments may not then dovetail with the company’s press releases, causing harm not only to the company but also to one’s longevity within it!

The best advice on press releases may be two-fold. First, avoid scientific nuance and technical detail. State clearly whether or not the primary objective of the clinical trial was met. Whenever the case, then state clearly the implications of these data to the clinical development plan: if it needs redirection, the state what that redirection is, and the implication for the registration timeline.

Copyright

Copyright exists to prevent the exploitation of a publication (or trade mark) by anyone other than the publisher. This protection of the right to exploit a publication is central to the promotion of publishing per se, and thus an incentive to disseminate free speech.

In most developed countries, copyright can exist in two forms. First, for a fee, the protected publication can be registered with the national office of copyright. Second, the copyright holder can simply assert in the publication ownership of copyright under the Common Law. Both forms may use the familiar © symbol. The registered copyright is easier to enforce in court because the date of registration and priority of first publisher are on independent record and can be compared to the behavior of the alleged infringer. The Common Law alternative can also be legally enforced, but requires the development of a set of evidence; an infringer usually has at least an initial defense that due search of the national register failed to locate the alleged infringed copyright.

It is a peculiar and remarkable aspect of academic journals that their publishers make a profit while receiving almost all their copy entirely for free. Almost all journals require transfer of copyright from authors to publisher upon acceptance of submitted manuscripts. Technically, this requires that an author needs specific permission from the publisher to use his own manuscript later; in practice, this permission is routinely granted upon written application. A few journals now seek only exclusive licenses from authors, one condition of which preserves the author’s right to personally use his own work, and which leaves copyright ownership with the author(s); the license can also become void if the publisher fails to exploit it, and can yield royalties to the authors. In practice, this license removes the administrative burden of granting routine permissions by the publisher, and royalties on journal reprints are either nominal or absent.

But there are exceptions. Copyright for publications is not universal. In the United States,
manuscripts from federal employees cannot be claimed as proprietary because their work product is deemed always to belong to the general public, whether published or not. Most journals operate a copyright exemption system for this purpose. In many Third World countries, copyright, if it exists at all, is unenforceable.

Reprints disseminated for medical information or marketing purposes should be those purchased from the publisher. Alternatively, photocopying license fees can be paid, and in the United States a national clearing house exists for this purpose.

Every website page can potentially be copyrighted. Few are actually registered, although assertion of Common Law copyright is common. So far, there has been insufficient litigation to delimit the copyright aspects of electronic publishing.

**Summary and prospectus**

In summary, the construction of a clinical trial report for use in the peer-reviewed literature is much like that for any other scientific paper; it must contain most of the things that would appear in the executive summary of a clinical report used for regulatory purposes. Clues for effective oral presentations are also provided. Systems for publication of clinical trials are currently neither comprehensive nor universally available to the relevant target audiences. Pharmaceutical companies and journal editors both introduce publication bias; the former is likely only to expend resources in reporting, and the latter is likely only to publish clinical trials with positive outcomes. Registration of clinical trials was suggested more than 15 years ago, as one method for avoiding the bias against publication of negative trials. Some pharmaceutical companies are beginning to provide such registries for their own work, but no internationally coordinated or funded agency has yet emerged except in specialized areas with relatively small academic audiences. It is possible that electronic publication can improve this situation, but, at present, there is more optimism than proof that this is the case.

**References**


Rafal RB. 1991. ‘A standardized method for determination of who should be listed as authors on scholarly papers’. *Chest* 99: 786.


43 Organizing and Planning Local, Regional, National and International Meetings and Conferences

Zofia Dziewanowska and Linda Packard

Using scientific meetings appropriately can be one of the most powerful tools for the promotion and phase IV development of corporate assets. Other types of meeting, crucial in the development process, are investigators’ meetings, pan-corporate international staff meetings and conferences to resolve issues of harmonization or standardize clinical trial methodology. Almost all clinicians working in the industry will, from time-to-time, find themselves taking part in such meetings, whether as speaker, attendee, reporter or chairperson.

Most clinicians lack formal training in meeting planning. Hands-on experience is always the best tutor, but perhaps here we can provide some clues and frameworks for how meetings take place.

In what follows below, we shall concentrate on large meetings. Small meetings will obviously only require a subset of all this.

43.1 Goals, types of meetings and participants

It is usually best to start with the goals of the proposed meeting. This will dictate the type of meeting, its duration and participants. Organizational approval of these goals is a sine qua non and should be obtained early. Table 43.1 provides some examples.

With the goals of the meeting in place, the format and content of the meeting can then be designed. Usually, this works best if a meeting chairperson or central organizer can be identified. This should be a person who is experienced in the type of meeting that is envisaged, and who can clearly enunciate a vision for the future meeting to the many and varied people who will eventually have to implement the plan. In the case of large meetings (Table 43.2) there may be separable parts, and desirable chairpersons for each part may well differ in their background and experiences (Table 43.3).

Large meetings inevitably require professional organizers, whereas small ones might simply use volunteers. One way or the other, these people deserve good leadership, and it will be your meeting that will suffer if those deployed are not put to good use. Professional organizers will obtain the relevant physical space for the meeting, get the meeting advertised (if appropriate), coordinate the preparatory materials and their distribution, handle the catering contract(s), manage registration, handle the social and companion programs, and basically do everything that you do not want to do. Getting a local meeting professional is always
best: they will know the management of the facility itself, as well as the potential for local tours, activities and so on.

The schedule of the scientific program is usually pivotal in a large meeting, and everything must fit in around it. It goes without saying that scientific chairpersons must themselves be thought-leaders in the meeting’s topic(s). However, another vital qualification is that this eminent person must also be somebody who is willing to cooperate with lesser mortals, and who is decisive, consistent and communicative. The advisory board, if there is to be one, should generate comments on a draft of the scientific program that the scientific chairperson provides early. With that advice, the scientific chairman can finalize the program and then recruit the speakers and moderators.

The key word for speaker and moderator recruitment is balance. Balance should be sought not only in diverging scientific opinion but also in the geographical origins of the speakers and moderators. The latter must be people who can broach no subversion of accurate time keeping yet impose that discipline on speakers politely.

*Time and place.* For a large-scale conference, if you start less than 18 months in advance, then you are usually headed for disaster. Every effort must be made at this early date to avoid dates that conflict with other conferences that may attract the same audience, and thus compete, with yours. This planning interval can become smaller as meetings become smaller, but a six-investigator protocol meeting can usually not attract all the required participants with less than three or four months notice.

Constructing (or purchasing) a mailing list should be the next early step. Contact details for known participants and define a set of characteristics for desirable unknown participants. For the latter, until registrations are received, advertising in relevant journals may be the only way to contact them.

Geographical location for the meeting is the next decision. This can be an iterative process when it turns out that there is no suitable meeting facility in the place which would minimize the aggregate travel time and costs for the participants. Again, the larger the facility required, the longer the lead time. Convention halls in major cities are often booked years in advance; one rule of thumb is to start booking one year ahead of the event for every 100 attendees expected, up to a maximum of five years. Small meetings in university towns can often collide with events such as graduations or

---

**Table 43.1** Typical goals of conferences and meetings

- To exchange scientific opinion and information
- To educate a target audience
- To secure consistency of clinical trial conduct and evaluation
- To obtain peer/opinion leader review input
- To obtain drug recognition among relevant clinicians
- To launch a new drug with a sales force
- To promote a new drug, or a new indication for an old drug

**Table 43.2** Types of meeting depending upon meeting goals

- Multicenter investigators’ meeting
- Advisory board/consultants’ meeting
- Intracompany product launch meeting
- Satellite symposia at meetings of academic societies
- Regulatory presentations
- Therapeutic review conferences
- International Conference on Harmonization subcommittees

**Table 43.3** Leadership of separable components of large meetings

- Chairman of the scientific program
- Chairman of the social program
- Collaborators and advisory board
- Moderators of individual sessions
- Speakers and panelists
- Judges of presentations
- Poster display organizer
- Organizers of registration and attendees’ services
- Audiovisual coordinator
- Director of supply and serving food and beverages
- Partnering meetings coordinator
(in the United States) sporting events, and accommodations in even small hotels may be unavailable or highly expensive. When the location is known and the facility is booked, then this is material for a press release and another round of conference announcement mailings if it is a large, commercial meeting.

**Budgets.** If the meeting is purely company sponsored, then the meeting organizer should determine the size and location of the meeting, calculate the costs and present the budget for approval. If that budget is cut back, then the number of attendees can be adjusted downwards accordingly. If there would appear to be no compromise between a budget that is too small and the number of attendees desired, then do not forget to consider breaking the meeting into two smaller ones at different geographical locations; reductions in travel costs can compensate for the economy of scale that might be achieved with a single large meeting.

Satellite symposia usually come with fixed price tags payable to the sponsoring academic society. If the budget will not support it, then shop around; almost every discipline has more than one annual meeting of interest. Furthermore, contracting for a satellite symposium at each annual meeting for the next three years can obtain a volume discount, but you should reserve the right to retail those that you have paid for, just in case you do not need them.

If the meeting planned includes paid registrations, then seek professional help with the budget. The process will be much more complicated, and depend on the rates of registration, both actual and projected, in order to trim the meeting expenditures where it may be necessary, and avoid going broke!

**Promoting the meeting.** The mailings, fliers, email reminders and press releases should begin 8–12 months before the event. A schedule for regular promotions should be set out at the beginning of the planning process.

**Licenses and permits.** Usually, the facility that you have chosen will be able to tell you whether any of these are needed. Usually, applications made six months before the event are sufficient.

**Registrations.** Opening early-bird registration five months before the event is usually effective, and a motivating discount is usually good for early cash flows. The outline program should be ready at this point, even if some of the participants have either not yet replied to the invitation or are to be determined. Calls for papers and abstracts can also begin at this time. Both early-bird registrations and scientific submissions should have deadlines, and it is best if these are rigidly adhered to. Otherwise, you will be bombarded by supplicants for exceptions and special treatment!

**By one month before the event,** all the programs should be finalized, and the definitive version printed. All audiovisual bookings and menus should be contracted. The remnants of the hotel room reservation block can then be released (those registering at the door can fend for themselves). This is a good time to send out reminder postcards with basic information: where and when is registration, location and directions to the facility, and the name of the nearest airport or railway station. The publication plan should also be agreed at this point.

**Two weeks before the event:** Most caterers will want final numbers on food and beverages being served. The meeting staff should be taught how to find their way round the facility, and where, nearby, such things as business services, restaurant advice and traveling essentials may be obtained.

**Half a day before the event:** Train the registration desk staff, make friends with the audiovisual people and test all their systems. Set up the message board, and signage to all the conference rooms.

**Feedback.** During the conference, ask the attendees what they think about it. In some cases, for example where medical education credits are offered, there will probably be a formal mechanism required for the scientific content. However, even a small meeting might engender unexpected opinions on the hotel rooms, the food or the travel arrangements, and these can only add to your own experience as well as contribute to the success of the next meeting that you are planning.

**The first to arrive and the last to leave.** The meeting staff will probably be required to remain at the facility for at least a day and a half after the final gavel. Dismantling display materials, finalizing invoice arrangements with vendors, and getting the proceedings publication started are common tasks. There should also be a time for general recovery and celebration; the latter will enhance
morale, and, if you can retain them, make next year’s conference easier.

In summary, large meetings are tough and time consuming. Patience, ability, decisiveness and good communication under pressure are essential. But the rewards, both personally and professionally, can be great, and the payback for the sponsor will make it all worthwhile.
44 Drug Withdrawals From the Market – Causes and Consequences

Ronald D. Mann

44.1 Introduction

From the point of view of a pharmaceutical company, the worst way in which things can go wrong is when the marketing authorization for a major product is threatened with revocation or suspension due to reports of serious or fatal adverse drug reactions.

The losses involved in such a disaster can be so sudden and so damaging that the threat polarizes the Managing Director, the Medical Director, the Marketing Manager and the rest of the Executives, and sets them apart from one another. In most cases it also bewilders them, for it is highly unlikely that any of them will have previously faced such a situation.

The relevant literature that might provide useful examples and guidance is pretty sparse. Micturin (terodiline hydrochloride) was withdrawn from sale in 1991 after it was discovered that its use was associated with serious cardiac arrhythmias, most notably a rare and sometimes fatal form of ventricular tachycardia known as torsades de pointes. As we shall shortly see, other drugs have been withdrawn for the same reason but the story of terodiline was written up by the physician who was Medical Director of the relevant company at the time. This account (Wild, 2002) should be read by anyone who may become involved in a sudden drug withdrawal due to toxicity, for it represents one of the few such firsthand accounts in the literature. A comparable account of the withdrawal of nomifensine due to the unexpected occurrence of hemolytic anemia has also been published (Stonier and Edwards, 2002) and, again, this account records the views and experience of the physician who was Medical Director of the relevant company at the time of the crisis and drug withdrawal.

It is a staggering fact that in the present state of scientific knowledge we cannot prevent the loss, after marketing, of licensed pharmaceuticals that are found to produce unexpected grave toxicity. This has been known for virtually 40 years and yet the pharmaceutical industry has not seen fit to organize itself collectively to protect companies that suffer these unexpected and damaging drug withdrawals. Drug regulatory bodies were set up in Europe in response to the thalidomide disaster of the very early 1960s. In the United Kingdom drug regulation began with the Committee on Safety of Drugs which was chaired by Sir Derrick Dunlop. This Committee (the forerunner of the Committee on Safety of Medicines) functioned from January 1, 1964 until it provided its last report for the combined years of 1969 and 1970. The experience of those six or seven years led the Committee, in its...
final report, to make the following quite remarkable statement:

‘No drug which is pharmacologically effective is entirely without hazard. The hazard may be insignificant or may be acceptable in relation to the drug’s therapeutic action. Furthermore, not all hazards can be known before a drug is marketed: neither tests in animals nor clinical trials in patients will always reveal all the possible side effects of a drug. These may only be known when the drug has been administered to large numbers of patients over considerable periods of time’.

Thus, we can try to prevent these drug disasters to the maximum extent possible, we can try to identify and diagnose them at the earliest possible date (and so minimize the number of patients hurt or disadvantaged), but, in the present state of scientific knowledge, we cannot eliminate drug withdrawals due to unexpected toxicity.

A list of 39 drugs withdrawn due to major safety concerns in the United Kingdom between 1975 and 2005 has recently been published elsewhere (Mann, 2005). This list can be summarized in Table 44.1.

<table>
<thead>
<tr>
<th>Reason for withdrawal</th>
<th>Number of drugs withdrawn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatotoxicity¹</td>
<td>9</td>
</tr>
<tr>
<td>Cardiovascular²</td>
<td>5</td>
</tr>
<tr>
<td>Arrhythmias³</td>
<td>4</td>
</tr>
<tr>
<td>Skin and mucus membrane lesions⁴</td>
<td>4</td>
</tr>
<tr>
<td>Gastrointestinal lesions⁵</td>
<td>2</td>
</tr>
<tr>
<td>Blood disorders⁶</td>
<td>2</td>
</tr>
<tr>
<td>Anaphylaxis⁷</td>
<td>2</td>
</tr>
<tr>
<td>Others (singles only)⁸</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td>39</td>
</tr>
</tbody>
</table>

Key:
1: benoxaprofen, clomacran phosphate, perhexilene, dilevalol, pemoline, troglitazone, tolcapone, trovafloxacin, kava-kava.
2: fenfluramine, dexfenfluramine, droperidol, amfepramone phentamine, rofecoxib.
3: terodiline, sertindole (license restored), grepafloxacin, cisapride.
4: practolol, fenclofenac, feprazone, valdecoxib.
5: indoprofen, Osmosin.
6: nomifensine, remoxipride.
7: zomepirac, Althesin.
8: polidexide, zimeldine, suprofen, metipramolol eye drops, triazolam, temafloxacin, remoxipride, mibebradil, Alec, cerivastatin, coproxamol.

It is notable that 11 (28%) of these withdrawals were due to causes which appeared only once in the 30 years considered in the table. Examples are polidexide, withdrawn in 1975 as the formulation contained impurities, and coproxamol, withdrawn in 2005 as it was frequently used in suicides. The most common single cause of withdrawal was hepatotoxicity (nine drugs withdrawn), but adverse cardiovascular events, if grouped with arrhythmias, were equally conspicuous. Drugs which challenge liver function would seem poor candidates for development and it seems reasonable to suggest that prolongation of the QTc interval clearly needs to be carefully excluded before new drugs move very far along their path of development.

44.2 Prevention is better than cure

It is now well understood that post-marketing surveillance (PMS) must be undertaken when newly licensed drugs enter everyday clinical usage. The data available at the time of marketing speak far more fully to the efficacy and quality of the drug than they speak to its safety. This is because the number of patients included in the clinical trials is small compared with the number of patients who can be exposed once the drug is available for prescription; additionally, the populations are very different, because the prelaunch program will have been conducted in patients with only one disease, whereas the drug, once licensed, will often be used in an older population of patients with more than one disease. Thus, the PMS program should emphasize populations covering the age ranges appropriate to the indications for the drug; it should also include appropriate drug–drug interaction studies and studies in any special populations, such as children, who may receive the drug once it is in everyday clinical usage. Clearly, the PMS program needs to include studies intended to resolve any queries or questions that have been noted in the animal safety evaluation studies or the earlier studies in man.

A great deal of guidance is now available and is, in its essentials, common to all areas of the
developed world. The fundamentals are given in the Guidance for Industry – Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessments (http://www.fda.gov/cder/guidance/index.htm). This document outlines the methods of obtaining and assessing observational data regarding drugs; it considers the methods of detecting signals of adverse effects, assessing and interpreting these signals and planning effective PMS. A second similar document is entitled Guidance for Industry – E2E – Pharmacovigilance Planning. This is available on the same web site and is, in essence, concerned with the generation and review of a formal plan for the conduct of a well thought out PMS or pharmacovigilance program. The third document in this series is entitled Guidance for Industry – Development and Use of Risk Minimization Action Plans. This document, like those of other regulatory authorities, has arisen from discussion over recent years and it accepts that there is a risk, and plans to discuss the risk and minimize it. Not to plan and conduct an effective pharmacovigilance and risk minimization program is clearly negligent.

### 44.3 When the balloon goes up

The threat to the marketing authorization usually develops very rapidly and often in response to an event which grossly biases the data. Typically a few worrying reports have been trickling in and then one of the regulatory bodies makes an announcement seeking additional data – and this produces a flood. Doctors and other reporters remember a case they could not make up their minds about, but the announcement, however gentle, makes up their minds for them and they report. The trickle becomes a flood and the company is put on notice that action of some sort is likely to have to be taken. There is no sacred text that tells the officers of a company what to do, but the following steps should, experience suggests, be considered:

1. Organize a task force of appropriate in-house experts and specialists supported by outside consultants who have lived through the presenting kind of problem before. Support the task force by obtaining the advice of two or three national specialists whose expertise is directly relevant to the problem. The task force should be chaired by the Chief Executive Officer and have the Research Director, Medical Director, Legal Advisor, Head of Regulatory Affairs and the Principals dealing with the product in question on it. It should meet frequently, have an organized agenda and record minutes.

2. Advise the regulatory authority who is on the task force and who is its Technical Secretary and contact point. This will reassure the regulatory people with whom it is essential to establish professionally trustworthy relationships.

3. If any information has leaked out (e.g. by requests for additional data), prepare a sensible and comprehensive press release. This should emphasize that these problems cannot be prevented as rare events but they can and are being controlled. Have one Press Liaison Officer and allow no other press contacts. Any evidence of a ‘cover-up’ provides the press with a story in its own right and this is best avoided by openness.

4. In an organized way reexamine the molecular structure of the drug and the known adverse effects of related molecules. In the same way, revisit the animal safety evaluation data and the clinical trials data to make sure, in the light of the new suspicion, that nothing has been missed.

5. Get full but anonymized copies of the suspected Adverse Drug Reaction Reports in the hands of the regulatory authority. Eliminate duplicate and triplicate reports (as these can swell the numbers in an alarming way). Do everything possible to ensure that the reports have been followed up properly and the final diagnosis established. Make sure that patients suffering from inborn errors of metabolism are not being included just because they are receiving the drug in question. Look for clustering, for
example several reports coming from the same doctor or practice (is the so-called hepatotoxicity really a local outbreak of viral hepatitis or due to some strange doctor still giving aspirin to children and causing Reye syndrome).

6. Carefully reassess the balance of benefit and risk and determine if this has changed and, if so, in what way. The ADR data (yellow cards in the United Kingdom) form the numerator. The company is in the best position to know the number of patients treated (the denominator). Has the ratio changed? What is the indication for the drug (rare, severe adverse effects may be acceptable in an effective anticancer agent, whereas almost total safety would be demanded for an oral contraceptive used in fit, healthy people early in adult life). If the drug is withdrawn what remedies remain for the management of the indication – and what is the picture of their comparative toxicity? Make quite sure that the problem is not arising from some new, previously undescribed iatrogenic disease (e.g. the oculomucocutaneous syndrome with practolol); in a similar way rule out long-latency adverse reactions (e.g. sclerosing peritonitis – again with practolol). Be careful to determine what other drugs the patients were receiving (is the problem a drug–drug interaction).

7. Consider whether the current pharmacovigilance program is adequate to deal with the new issues arising. The situation may have greatly changed – new data may focus attention on one specific adverse effect and, for example, a case control study on that reaction might need to be established with the General Practitioner Research Database (GPRD), or some other database, as a matter of extreme urgency. It is now known what the cases must be in such a study and that changes the picture completely. Any such study must almost always need to be conducted in an existing database as time and the urgency of the situation will not permit any study which requires the prospective acquisition of data.

44.4 Escaping from the maze

Although escape may be impossible, and the drug has to be withdrawn in the best interests of the patients, there have been survivors. The techniques used have included the following:

1. **Focussed surveillance:** The classic example is clozapine and the Clozaril Patient Monitoring Service. Clozapine is a valuable antischizophrenic agent used in patients unresponsive to other antipsychotic agents. Its side-effect profile includes fatal agranulocytosis, myocarditis and cardiomyopathy. Because the drug can be effective in severe schizophrenia when other remedies have failed it was desired to maintain it in clinical use despite the known incidence of uncommon blood dyscrasias and cardiac adverse reactions. This was accomplished by establishing the Clozaril Patient Monitoring Service with which the patient, prescriber and supplying pharmacist must be registered before the drug will be supplied. The monitoring service ensures that leukocyte and differential blood counts, plus other observations, are undertaken at suitable intervals. The scheme has been highly effective and similar schemes have been established by other pharmaceutical houses supplying the drug. Clearly, this kind of intense focussed management can be used only when it will prevent withdrawal of a uniquely valuable therapeutic agent active against life-threatening disease.

2. **Contraindication in a susceptible subpopulation:** Aspirin (acetylsalicylic acid) has been associated with the occurrence of Reye syndrome and, as a result, the Committee on Safety of Medicines has advised that aspirin-containing preparations should not be given to children and adolescents under 16 years of age unless specifically indicated, for example for Kawasaki syndrome. Establishing this contraindication, relating to what is probably the most widely used medicine known, involved educating the whole community and represented one of the most remarkable therapeutic achievements of the late twentieth century. The
literature on the difficulties that are encountered in getting doctors to observe new contraindications is very extensive and it is clear that this procedure is not to be lightly undertaken.

3. **Consider the formulation:** Osmosin was a modified release preparation of indomethacin. It was designed to release the active drug under osmotic control. Instead it allowed its potassium content to be released in a way that caused perforation of the small bowel distal to the duodenum. The drug provides an example of the formulation causing the problem, and the drug serves as a reminder that consideration needs to be given to the formulation as a possible cause of trouble which can be remedied by reformulation.

4. **Get the dose right:** Problems readily arise if the development program gets locked into the wrong dose range early on. It is important to titrate dose ranges down to lessen Type A side effects and to make sure that domiciliary patients are not treated with a dose that is appropriate for seriously ill, hospitalized subjects.

5. **Consider the indication:** Very little will be tolerated, in terms of side effects, for oral contraceptives or other drugs to be used in young, fit people early in life. The situation is different in respect of anticancer drugs used late in life in patients who have a disease with a poor prognosis. Trimming down the indications and claims made for the drug can materially affect the benefit-to-risk ratio. In assessing this ratio, consideration has to be given to the treatability of any side effects, the drugs available to treat the indication if the suspect drug is withdrawn and the fate of those many patients using the suspect drug with benefit and without complaint.

6. **The availability of additional data:** The first year after launch can be a difficult time as very few of the important data sources are fully functional apart from the yellow card scheme. Thus, the Medical Department needs to monitor the Drug Analysis Print very carefully and review all Adverse Drug Reaction reports received by the company with equal diligence. One cannot set up case control or similar studies until one knows what cases are relevant. Even then it needs to be remembered that the GPRD covers only a minor proportion of the population, so cases may be few and far between in the first months of the life of the drug. Prescription-Event Monitoring (PEM) also tends to start fairly slowly as there is a delay before the Prescription Pricing Authority sends the first batches of prescriptions to Southampton; then there will be a delay of perhaps six months before the first batches of the green form questionnaire are sent out. Doctors in Scotland tend to be cautious about prescribing new drugs so the record-linkage programs of the Medicines Evaluation and Monitoring Organization (MEMO) also tend to get off to a slow start. The point is that the yellow card data and the Drug Analysis Prints need to be watched like a hawk. It has been suggested that the DAP data should be reanalyzed to make their clinical significance easier to understand and this exercise may well be worth the time devoted to it (Mann, 2005). In respect of matters in the United Kingdom the GPRD is of special value, and one needs to know, at reasonably short intervals, how many reports of the new drug on the database and what those reports comprise; it is a major feature of the database that its data were collected before any alert appeared – the data can be divided into two: before and after the alert, that is before and after gross bias distorted the picture.

7. **Consider the legal position carefully:** The tests are now onerous, because one must consider not only negligence but also the Product Liability Directive and the Consumer Protection Act with its requirement that the product must be as safe as the consumer might reasonably expect it to be. Amongst others, the medical people need expert and objective legal guidance. If one reads nothing else in preparation for dealing with responsibilities in this area it is wise to quietly read through the approved judgment of Mr Justice Mackay in the oral contraceptive litigation (Neutral Citation No: (2002) EWHC 1420 (QB)).
References


Mackay, The Honourable Mr Justice. 2002. In the High Court of Justice, Queens Bench Division, Approved Judgment. Case No: 0002638.


SECTION VII
Legal and Ethical Aspects of Pharmaceutical Medicine

Introduction

Ethical conduct in both drug development and ordinary clinical practice is obviously *sine qua non*. This section brings together aspects of this essential prerequisite with some of the mechanisms that are used to enforce it.

In drug development, the rare clinical disasters that are well publicized almost always turn out to have an ethical component during the investigations that follow. Although neither academic institutions nor governments are entirely free of ethical lapses during clinical trials, it is the pharmaceutical industry that usually garners most negative press, perhaps disproportionately.

Although, on its face, this book would not seem to be about clinical practice, let us not forget that pharmaceutical companies, disease management enterprises, economists, third-party payers, regulators of formularies, whether local committees or national bodies such as the National Institute for Health and Clinical Excellence (NICE) in England and the Scottish Medicines Consortium, and politicians, among many others, all have an indirect hand in shaping that ultimate clinical activity: prescribing. Arm’s-length influence over clinical practice is no excuse for ignoring the ethical implications of one’s indirect actions.

The law, it can be argued, is the enforcement aspect of ethics, among other things. Respect for intellectual property (seen especially in Japan where patent litigation is almost unknown), appropriate prescribing, and the detection and punishment of those who unethically invent ‘paper’ patients or alter research data are the subjects of other chapters in this section. This may seem pessimistic. However, there is a yet stronger argument to be made: the law can be a rather blunt tool for dissecting ethical issues, and may not be able to right a wrong when it is somebody’s personal health that has been damaged. Moreover, if we did not exercise our best ethical judgment at all times, then the law, in any case, could only ever address a small minority of cases that would arise.

Clearly, other chapters in this book could have appeared in this section. An early chapter in this book is on ‘informed consent’; its location is designed to indicate the supervening importance of that particular application of autonomy, beneficence and equipoise. Ethical behavior is also at the very centre of ‘good clinical practices’. The chapter on ‘publishing clinical trials’ also examines some of the ethical aspects of that activity. Dr Belsey also enters into this area with his chapter on ‘advertising and marketing’.

Ethics and the law are thus presented in conjunction in this section.
45.1 Introduction

Discourse on ethics dates back at least as far as the Ancient Greeks and Romans and undoubtedly has much earlier origins, in both religious and secular systems of thought. Bioethics may be viewed as a subdivision of ethics, from which it borrows most of its tools and concepts, albeit with refinements. Bioethics developed rapidly during the twentieth century, corresponding with the recent era of growth in medical technology and research, and has been defined as:

‘A discipline dealing with the ethical implications of biological research and applications, especially in medicine’¹

‘The study of moral issues in the fields of medical treatment and research’²

‘The study of ethical issues concerning the life sciences and the distribution of scarce medical resources’³

‘The branch of ethics that studies moral values in the biomedical sciences’⁴

Most people in clinical research and medicine think that they have a good grasp on ethics and ethical principles, and that acting ethically is simply a matter of doing ‘the right thing’. Thus, those with little formal training in bioethics (probably most people) feel perfectly capable, most of the time, of making appropriate ethical decisions in the conduct of pharmaceutical medicine. Personal and professional ethics probably derive from a variety of sources, for example:

- One’s personal beliefs
- One’s professional code of practice
- State or federal law
- Intuition – one’s innate sense of ‘the right thing’

Most bioethical decisions are of the straightforward ‘right versus wrong’ type. These decisions usually require no formal tools of bioethics. But decisions are more difficult when they involve ‘right versus right’ (dilemmas). Parsing the notions of ‘right’ and ‘wrong’, four broad categories of bioethical dilemma have been listed⁵:

¹Merriam-Webster at http://www.m-w.com/.
²Many sources, including http://www.bioethics-singapore.org/resources/body_useful.html.
³Adapted from the University of Penn, Center for Bioethics, http://www.bioethics.upenn.edu/.
Self or small-group interest versus community or large-group interest

Short-term interest versus long-term interest

Loyalty versus truth

Mercy versus justice

In the highly regulated environment of the pharmaceutical industry, ‘ethical’ approaches often seem to be predetermined by local legislation and regulation (or ‘fiat’). Additionally, we are guided by voluntary national guidelines, as well as international codes of practice (see below). Nonetheless, merely relying on these alone is dangerous. A decision may be within the letter of the law and be covered by all such voluntary codes and yet still may arguably be unethical. Shannan Muskopf has written:

Science asks ‘Can we’?

Law asks ‘May we’?

Ethics asks ‘Should we’?

Thus, while regulations help ensure minimum ethical standards, they do not necessarily ensure the highest ethical standards. Increasingly, therefore, the medical and pharmaceutical research and practice environments face a growing need for a formal approach to ethics, and particularly to bioethics.

45.2 Basic tools of bioethics

The process of analyzing and solving ethical problems involves

- recognition of the relevant ethical issues;
- analysis of the subcomponents of these ethical issues;
- finding appropriate tools to help solve these issues and their subcomponents;
- applying those tools;
- checking that the selected tools have indeed met the recognized bioethical need.

The two fundamental types of bioethical tools are deductive and inductive reasoning. There are, however, complexities and adaptations for both of them. Let us first consider the two fundamental systems and then examine their complexities.

**Deductive reasoning**

Deductive reasoning is the process of concluding that something must be true because it is a special case of a general principle that is known to be true. It relies on the establishment of laws or rules that are generally applicable. It can be summed up as top-down reasoning: one moves from the general to the specific(s). Much of medicine uses deductive reasoning: a general law, such as a fractured tibia heals best when immobilized in the correct position, is applied frequently to individual patients in the Emergency and Accident departments.

Emmanuel Kant (1724–1804) can probably be credited with enunciating best the classic approach to deductive reasoning. Kant believed that the moral worth of an action was based on the ultimate outcome of the action, but rather on the motive behind that action. Kant described morality as being governed by universal laws that he termed categorical imperatives – these are duties that are inescapable. Perhaps the most famous of his categorical imperatives is that one has a duty always to tell the truth. Kant took the hypothetical example of a would-be murderer seeking to kill one’s friend. If the friend is hiding in one’s house, then when the murderer knocks on the door one has an absolute duty to answer truthfully his inquiry whether the friend is inside. This truthfulness, according to Kant, might not, however, preclude shouting the answer loudly, thus giving the friend the chance to escape. There was no such thing as a ‘white lie’ for Kant.

---

Inductive reasoning

Inductive reasoning is the process of concluding that a general principle is true because the special cases you have seen are true. This is the opposite to deduction, and may be thought of as bottom-up reasoning. One moves from the specific(s) to the general. Clearly, the likelihood that inductive reasoning is ‘correct’ improves with the cumulation of larger numbers of special cases. Inductive reasoning can thus generate the general laws that can later be applied deductively.

One might assume that deductive reasoning is superior—as it would appear to offer mathematical-style ‘proof’. But a ‘law’ is only as good as the premise on which it is based. Virtually, all scientific laws are derived inductively—from observation. But once the ‘law’ is established, it is then applied deductively. However, when the original ‘law’ turns out to be flawed it has usually been disproved inductively. Thus, in bioethics (as in science), the best approach is often a mixture of deductive and inductive reasoning.

Utilitarianism

Utilitarianism is a doctrine, enunciated by Jeremy Bentham (1748–1832) and John Stuart Mill (1806–1873): it is the search for ‘the greatest happiness for the greatest number’ or, more eloquently, the ‘quantitative maximization of some good for society or humanity . . . a form of consequentialism’. Consequentialism is the belief that what ultimately matters in evaluating actions or policies of action are the consequences that result from choosing one action or policy rather than the alternative. Thus, utilitarianism is a direct counter to the motivation-based categorical imperatives (essentially a deductive approach) of Kant.

Casuistry

Casuistry is an inductive method: it is the task of deriving principles from cases. Moral dilemmas can be addressed by comparing them with ‘agreed responses to pure cases’. Its main weakness is that there can be inadequate selection of suitable comparative cases, which may be by omission or commission (the latter being especially common amongst politicians). Occasionally, there is also obscurity concerning the specifics of what the ‘agreed responses’ might be.

Feminist bioethics

Feminist bioethics deals with bioethical issues that particularly affect women. Controversially, it has been asserted by some that women approach ethical dilemmas differently to men, because of dissimilar contexts. The ethic of care is proposed as a ‘female’ trait, while the ethic of justice or rights is supposedly more ‘male’. A common illustration of this is when a married couple is asked to include a clause in their wills concerning the disposal of property in the case of their simultaneous deaths: the wife will often propose a scheme dividing joint property unequally and according to need and number of all their relatives; the husband frequently sees the situation as requiring a simple 50–50 split between their two families.

The golden rule

Another important principle is ‘The Golden Rule’, which states ‘Do unto others as you would have others do unto you’. This is also called the Ethic of Reciprocity. Note that this is not the same as ‘tit-for-tat’ or ‘an eye for an eye’ which describes post hoc responses and vengeance, rather than prospective guidance of behavior by an ethical, golden rule

---


standard. Again, this is principally a deductive approach, and not very far from Kant’s categorical imperatives.

**Objectivism versus subjectivism**

A final consideration is whether ethical principles are relative or absolute. *Ethical objectivism* (Kant’s categorical imperatives fall under this heading) asserts that ethical solutions are always absolute. In contrast, *ethical subjectivism* maintains that ethical solutions are never absolute. *Ethical relativism* (cultural relativism) provides a compromise, which may or may not be ‘correct’, that ethical behavior should be judged relative to the norms of one’s culture: what may be wrong for one society may be right for another, and this is clearly a utilitarian principle; an example may be the difference between civilian and military healthcare. In the civilian world, ‘every patient deserves the very best treatment’ is the ideal, and is an absolute ethical objective. At a field dressing station, where medical staff and their equipment may be suddenly overwhelmed, triage is practiced with the aim of providing the greatest benefit for the greatest number. Thus, on the battlefield it will not be the case that every wounded soldier gets the best medical care, and this is an example of utilitarianism and ethical relativism. Both medical practices are ethically sound (or ‘correct’), and the term *universal prescriptivism* was formulated by R.M. Hare (1919–2002) to describe such combinations of Kantianism and utilitarianism.

**Four basic principles**

When using these formal tools, there are four basic domains of bioethics wherein they are applied. These are the following:

- **Beneficence**: Is every action oriented toward the benefit of the individual?

- **Nonmaleficence**: Is any action not oriented toward the benefit of the individual? (note that nonmaleficence is included under ‘beneficence’ in the Belmont Report)

- **Autonomy**: Does every individual agree with every action applied to him or her?

- **Social justice**: Is every action compatible with the standards of the population?

Although these principles are particularly relevant to the conduct of clinical studies (see below), they may also apply to the ordinary practice of medicine and, indeed, all situations where one human being has a responsibility to care for another human being. Let us not forget that the fundamental goals of healthcare, even in this age of rapid technological progress, are to cure sometimes, relieve often and comfort always, and this should not be violated in the context of clinical studies.

**45.3 Ethics of human experimentation**

Protection of the research subject in clinical trials poses a number of bioethical questions. We have already mentioned beneficence (the anticipation of some benefit), nonmaleficence (freedom from harm), autonomy (free participation without coercion) and social justice (whether or not there is a duty for people to participate in clinical studies, as benefactors of those who have previously volunteered). Each of these needs further discussion. These domains were egregiously violated by various governments during the twentieth century (German Nazis, Tuskegee, etc.). It was the Nuremberg code that first provided for the protection of the research subject, and the Declaration of Helsinki, as amended, is its successor.

Above all, the rights of the individual must be seen to trump any need or possibility of scientific advance. The duty toward the individual must always have a far higher priority than some intangible benefit that might attach to the population as a whole in the future. In protecting the research subject, the first principle is ‘informed consent’.
Informed consent

As the term implies, subjects must be fully informed about the nature of the experiment, the known benefits and risks and the possibilities of unknown risks to which they will be exposed. Consent must be given autonomously and obtained without any coercion – direct, indirect or perceived.

Already, a number of problems are evident. Fully informing a patient as to the nature of an experiment and its attendant risks, known and unknown, is an arduous task. The language used must lack ambiguity, and understanding must be real – even for those who cannot fathom the technical issues.

It has been shown repeatedly that humans are notoriously bad at assessing personal risk. As Beecher has suggested, although many patients are willing to help their doctors, their fellow humans and science to improve medical care, most are not willing to assume significant risk in this endeavor, and few would be willing to risk serious injury or death. Yet, such outcomes nonetheless continue to occur, and analysis of recent disasters has often centered on whether subjects have fully understood the nature of their consent, rather than on the actual clinical procedures being implemented.

Henry Beecher (1904–1976) discussed the key concepts in human research of consent and autonomy, and the inherent difficulties in achieving these. People in positions of dependency may be termed ‘vulnerable groups’; these can include minors, prisoners, employees and family members. Conversely, Beecher established that there is no duty to participate in clinical research – an example in which public or societal good cannot outweigh personal risk.

The primacy of truly informed consent is such that it deserves its own chapter, elsewhere in this book.

Clinical equipoise

Benjamin Freedman (1951–1997) defined clinical equipoise as ‘a state of genuine uncertainty on the part of the investigator [or – present or imminent controversy in the clinical community] regarding the comparative therapeutic merits of each arm in a trial’. Freedman continued that ‘at the start of the trial, there must be a state of clinical equipoise regarding the merits of the regimens to be tested, and the trial must be designed in such a way as to make it reasonable to expect that, if it is successfully conducted, clinical equipoise will be disturbed’.

Clinical equipoise and informed consent raise issues of beneficence and nonmaleficence, both of which may be violated by participation in the study. However, if there is intent to do good and to avoid harm, then arguably these concerns are satisfied.

45.4 Ethics of animal experimentation

Public disagreement surrounds the use of animals in research – which occurs primarily to benefit humans, although some agricultural and veterinarian studies are carried out to benefit animals themselves. Three distinct approaches are offered here:

- ‘Duties Toward Animals’ (Immanuel Kant)
- ‘A Utilitarian View’ (Jeremy Bentham)


Kant argues that we do not have a direct duty to animals, and, therefore, killing them for food is acceptable. On the other hand, being cruel to animals is undesirable because it diminishes us morally.

Bentham argues that use of animals for human good, if carried out as humanely as possible, is justified if it results in an overall benefit to humans. Thus, harm inflicted to one species is justified if it results in overall benefit to another. This justification assumes an inherent moral superiority of humans over the animals being experimented upon. Such arguments meet their greatest challenge when the test subjects are necessarily primates (e.g., HIV research); a degree of self-awareness can be deduced in these species, and yet their consent is obviously absent.

Singer, in contrast to Bentham, believes all animals (humans included) are morally equal, and that Bentham’s arguments are ‘speciesist’ (although Bentham does question the inherent superiority of humans, tending toward Singer’s viewpoint).

45.5 Further issues of concern to the pharmaceutical industry and medical research

Ethical violations in human experimentation

There is a long history of unethical human experiments. King George I of England offered pardons to inmates of Newgate Prison (London), in return for inoculation with smallpox, as part of a variolation experiment. We delude ourselves if we assume that such ethical violations are now a thing of the past. In 1966, Beecher reviewed a series of unethical medical experiments. These included problems with consent, the withholding of known effective treatment and studies to improve medical knowledge but without obvious benefit (and with inherent risk) to the participants. A sample of more such studies is offered here, in addition to those of the egregious government of Nazi Germany, mentioned above.

In 1932, the Tuskegee Syphilis Study began, sponsored by the US Health service. Over the next 40 years, 399 rural African American men, living in Tuskegee, Alabama, were enrolled in the study. The study participants received regular medical examinations, but were not told they had syphilis, and were left untreated. The unethical aim of the study was to observe the natural history of the disease, and the study continued until 1972—long after the discovery of a proven treatment, penicillin, in the early 1940s.

In 1996, Nicole Wan, a student at the University of Rochester, underwent bronchoscopy as a healthy volunteer. She collapsed at home shortly afterwards and died at home two days later. The cause of death was an excessive dose of lidocaine administered to help the procedure. An investigation determined a failure to establish safe dosage guidelines for lidocaine administration during these procedures.

In 1996, an antibiotic study of bacterial meningitis was conducted in children in the city of Kano in Nigeria—a strife-torn city suffering an epidemic of bacterial meningitis. In a study organized by a pharmaceutical company, 100 children received the antibiotic trovafloxacin (which had not yet been approved for use in children), and another 100 children received ceftriaxone (a well-established antibiotic). Eleven children died—five taking trovafloxacin and six taking ceftriaxone. Subsequent investigations suggested that the study had not been properly approved, that the dose of ceftriaxone was too low, that informed consent had

19Sources include http://www.mindfully.org/Industry/Pfizer-Trovan-Nigerian-Suit.htm.
not been obtained and that families were not told that an alternative and effective nonexperimental antibiotic, chloramphenicol, was being administered free in the same hospital.

Jesse Gelsinger\textsuperscript{20} suffered from a rare genetic disorder called ornithine transcarbamylase deficiency, which, while requiring cumbersome treatment with diet and drugs, was not a life-threatening disorder for him. In 1999, he volunteered for a phase I experimental gene therapy at the University of Pennsylvania; his personal goal, it is thought, was to help the treatment of babies with this disorder rather than to benefit himself. He was injected with corrective genes incorporated into an adenovirus vector, despite animal data suggesting toxicity of the vector. Three days later, he was dead from multiple organ failure, apparently due to an overwhelming inflammatory reaction to the vector which had unexpectedly regained its virulence. Bioethical concerns raised afterwards included inadequacy of the informed consent (failure to fully reveal toxicity in previous animal experiments), bending of the rules (Jesse’s ammonia levels exceeded the upper limits set by the protocol) and conflict of interest (one of the investigators had a significant financial interest in the study outcome).

In 2001, Ellen Roche, a volunteer in a phase I study at Johns Hopkins University, died after an experimental inhalation of hexamethonium.\textsuperscript{21} Two major ethical lapses have been suggested. Firstly, the toxic nature of the inhalant had been underestimated by the clinical investigators, in spite of (admittedly decades old) literature demonstrating this toxicity. Secondly, the volunteer had been an employee in the laboratories of the same University, thus presenting a potential for coercion to take part in the study.

**Allocation of resources**

Resource allocation is a bioethical concern for all aspects of medicine, for instance, how limited resources should be allocated among different groups. It applies to the pharmaceutical industry and its allocation of funds for drug research and development. Such issues include

- exotic therapies versus cheaper more widely useful therapies;
- therapies for old versus young, rich versus poor, one ethnic group versus another and so on;
- public need versus profitability.

Allocation of scarce resources can be decided in a number of ways, for example by the principles of utilitarianism (such as by using medical criteria to select those most likely to benefit) or by random choice.

**Ethics committees**

Robert Pearlman,\textsuperscript{22} a bioethicist and physician at the University of Washington, asks a series of questions about hospital ethical committees and Institutional Review Boards (IRBs) that may be easily generalized to other settings:

- Membership – Who should sit on an ethics committee?
- Roles – Advisory or mandatory?
- Outcomes – What to do if consensus is impossible?
- Ethics education for committee members – Content?
- Hospital [or company] policies on ethics – What should these be?
- Quality assurance – How to measure?

\textsuperscript{20}Sources include http://www.frenchanderson.org/history/biotech.pdf.
\textsuperscript{21}Sources include http://www.ahrp.org/informail/0701/19.php and http://medicine.creighton.edu/idc135/2004/group2b/.
It is true that in the hospital environment, such committees’ activities may have greater scope than a clinical trial IRB. Robert Veatch,23 a bioethicist at Georgetown University, has pointed out that hospital ethics committees

- make specific patient-care decisions;
- make broad policy decisions;
- provide counseling and support;
- establish likely prognosis.

All of these can impinge, directly or indirectly, on the autonomy of patients, and deflect hospital care from the best principles of beneficence for each individual case. Furthermore, Bernard Lo,24 a physician and bioethicist at UCSF, discusses possible pitfalls of ethics committees: There can be excessive pressure to reach agreement, impairment rather than improvement of decision making and the broader dangers of ‘Group-think’, that is attraction toward consensus overcoming the voicing of independent, and possibly discordant, points of view.

Bioethicists in the pharmaceutical industry

Although it is true that most of the egregious violations of bioethics have resulted from the actions of governments and academic institutions, we should nonetheless ask a pivotal question: Is there now a need for formal recognition of bioethicists as an integral part of the pharmaceutical medicine ‘team’?

This question has many aspects. Who can be a bioethicist? – should it be only someone with a degree from one of the now numerous university departments of bioethics? Increasingly, bioethics awareness, training and expertise is needed throughout the pharmaceutical industry and related regulatory and research areas. Or is the increasing use of data safety monitoring boards, together with their approval of the protocols they monitor, a better way to go?

These are unsettled questions with able protagonists on all sides. We may hope that, in the future, there ought to be sufficient flexibility to adapt the necessary safeguards to the type of clinical study. A ‘one size fits all’ approach is hardly likely to be useful.


46 Pharmaceutical Medicine and the Law

Sarah Croft and Timothy Pratt

46.1 Introduction

In this chapter, we introduce basic legal principles and some of the legal concepts most relevant to the pharmaceutical physician. The central topics, touched upon here, are expanded upon elsewhere in this section.

46.2 Individual or corporate responsibility?

The circumstances in which a pharmaceutical physician will personally be sued under the civil law are relatively infrequent. The individual doctor or pharmaceutical physician, who is usually an agent of the company, does not fall within the definition of a ‘producer’ or ‘manufacturer’, although the pharmaceutical company usually will. Therefore, the individual pharmaceutical physician is unlikely to have proceedings brought against him or her personally, except in rare circumstances. It is much more likely that the company will be a defendant to an action by an individual patient or by another company, whether in tort or in contract. The deeper pockets of the company, in comparison to the individual pharmaceutical physician, practically guarantee that this is also the case in the United States. It is possible that criminal sanctions could be applied to the individual, but such proceedings are not common. As discussed elsewhere in this book, both the UK and US regulations make it an offence for an applicant (i.e. the company) to give false information in connection with an application for a licence for a pharmaceutical product. Most regulations, however, also provide that where a company makes a misrepresentation and it can also be shown that the misrepresentation was committed with the consent and connivance of, or attributable to the neglect of any director, manager or similar officer of the company, those individuals may also be personally liable. This may obviously affect the pharmaceutical physician, who is a director or equivalent in the company, who may be the signatory to advertising materials, for example.

It is sometimes the case that the company and the pharmaceutical physician are sued for negligence, where the allegations include specific acts for which the pharmaceutical physician is responsible, such as the warnings in a data sheet or the reports from a clinical trial. Regardless of who might be held legally responsible, an understanding of the relevant legal framework is essential.
46.3 Criminal and civil law distinguished

Generally speaking, law is broken down into two separate components – criminal law and civil law. A crime is an offence or wrongdoing against the State and is punishable by the State. Civil law concerns the breach of a private right or duty. Thus, in contrast to criminal cases, most civil actions are not brought by the State but by private individuals or other legal entities, such as corporations. In some instances, an individual’s actions can give rise to both a criminal offence and a civil liability, for example, an assault can result in a prosecution by the State and a claim by the victim for damages for personal injury.

Another important distinction between criminal and civil cases is the threshold ‘burden of proof’ that must be reached in order to prove the case against the defendant. In a criminal case, the State must prove its case ‘beyond a reasonable doubt’. In civil actions, the plaintiff must prove his/her case ‘on a balance of probabilities’. The standard of proof for criminal matters is higher, essentially because an individual’s life or liberty may be at risk.

46.4 Criminal law

Fortunately, instances where pharmaceutical physicians face criminal prosecution are rare. There are a number of specific ways, however, in which the criminal law can affect pharmaceutical companies and their physicians. One significant area is in the regulatory context, which may vary from country to country. For example, in the United Kingdom, the Medicines Act of 1968 creates some statutory offences, such as providing false information when applying to license a product.

In the United States, the Food Drug and Cosmetics Act (FDCA) also creates statutory offences for certain actions or inactions. For example, it is not permissible to sell a misbranded drug or device, or one with labeling that is false, misleading or fails to bear adequate directions for use. In addition, an adulterated product may not be introduced, such as one that has been modified from its intended use.

The US Supreme Court has observed that an offence is committed ‘by all who do have such a responsible share in the furtherance of the transaction which the statute outlaws’. Furthermore, the Court has interpreted the FDCA as imposing ‘not only a positive duty to seek out and remedy violations when they occur but also, and primarily, a duty to implement measures that will insure that violations will not occur’. The Prescription Drug Marketing Act of 1987 (PDMA, part of the FDCA) was enacted to address marketing practices that contribute to a second-hand market for drugs, such as distribution of free samples, coupons for reduced or free drugs and deeply discounted drugs. The PDMA, makes it a crime to knowingly sell, purchase or trade a prescription drug sample. This Act also prohibits the resale of any prescription drug previously purchased by a healthcare entity. The Anti-Kickback Statute, as the name suggests, prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration in order to induce business payable by a healthcare facility or program that is federally funded (for example, through Medicaid).

Another area where potential criminal liability may occasionally emerge is fraud or forgery during the course of a clinical trial. In the United States, the Office of Research Integrity investigates allegations of scientific misconduct in federally funded research. Pharmaceutical physicians, who are involved in designing and monitoring clinical trials will be aware of the need to build in various safeguards to protect against the possibility of these offences. Courts expect foresight and diligence from individuals who voluntarily assume positions of authority in enterprises that affect the health and well-being of the public.

46.5 Civil law

The two main areas of civil law that may affect the pharmaceutical physician are the law of contract and the law of tort. Essentially, a contract is a legally binding agreement between individuals (or other legal entities such as corporations), where one of the parties assumes an obligation or makes a promise to the other. Usually, the parties to
the contract have obligations and gain rights under
the agreement. The law of contract regulates the
enforceability of such agreements and the steps
that can be taken if the contract is broken. Perhaps
the most fundamental feature of contractual liabil-
ity is that it is strict and not fault based. This
means, broadly speaking, that it does not matter
whether a party to the contract acted reasonably or
not; what matters is whether the contract has been
broken.

The pharmaceutical physician will be very
familiar with certain types of contracts, depending
on his/her role within the company. Examples
include agreements with contract research organi-
sations, contracts for the sale of the finished phar-
maceutical product and licensing or distribution
agreements.

Generally, there is no contract between the phar-
maceutical company and the patient who is pre-
scribed the product by a doctor. In the United
Kingdom, it has been held that where a product is
prescribed under a National Health Service
scheme, it is not prescribed as a result of a contract
between the pharmaceutical company and the
patient because legislation exists that requires a
pharmacist to supply the product on the production
of a valid prescription. For nonprescription, ‘over-
the-counter’ (OTC) products, there is a contract
between the retailer and the consumer who pur-
chases the pharmaceutical product, but there is still
usually no direct link in contractual terms to the
manufacturer of the product. It may be, however,
that the contract between the manufacturer and the
retailer contains an indemnity provision. Then, in
the event of a successful claim for breach of con-
tract made against the retailer by the customer, the
manufacturer would effectively be required to
reimburse the retailer for the amount ordered to
be paid in compensation to the customer.

In the United States, as in the United Kingdom, a
contractual right of action generally exists only
between parties to the contract. This is known as
the rule of privity. Courts in the United States have
recognised that, in a mass-consumption society,
there is little real privity between manufacturers
and consumers: Manufacturers are remote to the
ultimate consumer, sales are accomplished through
intermediaries and products are marketed through
the use of advertising media. Some courts, how-
ever, have carved out an exception to the privity
rule for contract claims, recognising, for example,
that in certain circumstances consumers may bring
breach of express warranty claims against pharma-
cutical companies, based on statements made in
the package insert as well as promotional literature
and advertisements.

For the individual pharmaceutical physician,
arguably the most important contract will be
his/her own contract of employment with the com-
pany. This is likely to contain terms which, if
broken by the individual, could give rise to a
claim being made against him/her and, of course,
*vice versa*. The contract of employment may cover
matters such as confidentiality and restrictive cov-
nants, as well as defining the individual’s role and
responsibilities within the company. Distinct from
the law of contract, the law of tort serves to regulate
standards of behavior, operating to deter conduct
that may cause injury or damage and to remedy the
consequences of such actions. This area of law
includes the tort of negligence. An important and
well-known case in the development of the tort of
negligence in the United Kingdom is the case of
Donoghue v Stevenson, which involved a woman,
Mrs. Donoghue, who was unfortunate enough to
drink from a bottle of ginger beer containing the
remains of a snail. There was no contract between
Mrs. Donoghue and the manufacturer of the ginger
beer, so she could not claim a breach of contract.
However, the court held that the company actually
had a ‘duty of care’ to the ultimate consumer of its
product to take reasonable care in the manufacture
of its product.

The main elements of negligence have been
distilled from this statement in various cases over
time. In order for a person (the ‘plaintiff’) to prove
negligence by another (the ‘defendant’), he/she
must show:

1. that the defendant owes the plaintiff a duty of
care;

2. the defendant has breached the duty of care; and

3. the breach of duty caused damage that the plain-
tiff alleges he/she suffered.
In order to succeed in a claim of negligence, a plaintiff must prove all three elements. It is not enough to show that the defendant had a duty of care and was in breach of it. There must be proof that the breach caused the plaintiff’s alleged injury, which is often the most difficult task for a plaintiff, especially in claims concerning pharmaceutical products, where there may be other possible causes of the plaintiff’s condition.

In the law of tort, including negligence, liability is fault based. It must be proved that the defendant was at fault in that he/she acted wrongfully and as a result violated a right of the plaintiff, causing harm to him/her. The requirement of fault differentiates a genuine accident from a negligent act for which the injured person can be compensated.

Liability can result under other laws in the United States, such as the False Claims Act, which provides for civil proceedings to punish healthcare fraud when a person knowingly causes a false claim to be made to a government agency. A lawsuit can be filed by the government or by a citizen, who then receives a portion of the monetary recovery.

To complicate matters in some countries, liability may also arise in tort without proof of fault. This is known as strict liability. An important example of strict liability for pharmaceutical companies is what is commonly referred to as the ‘European Products Liability Directive’, which introduced a Europe-wide scheme of strict liability for defective products. (see Chapter 52 on ‘Pharmaceutical Product Liability’). As liability is strict, the defences that are available in the legislation are most important. The UK legislation, for example, includes a ‘development risk defence.’ This essentially means that, if the state of scientific knowledge was such that the producer could not have discovered the defect, this will provide a defence to the claim.

The United States has also adopted a theory of strict liability. This theory imposes liability on the seller of a product that is unreasonably dangerous because of a defect in its design, manufacture or warnings. There are special provisions carved out for pharmaceutical products because of their value to society and the fact they are “unavoidably unsafe”. Such products need to be accompanied by an adequate warning. Under strict liability, a pharmaceutical company is unquestionably subject to strict liability as a ‘seller’ of a pharmaceutical product. A pharmaceutical physician, however, is generally not subject to this type of liability.

46.6 The legal framework for regulating pharmaceutical products

As any pharmaceutical physician is well aware, the development, manufacture, marketing and safety of pharmaceutical products are subject to close governmental control in most countries through specific regulations on the sale of medicines and medical devices. Pharmaceutical physicians play a key role in ensuring that, at each stage in the life of a pharmaceutical product, the regulatory requirements have been met. As discussed above, there may be criminal implications if certain requirements are not fulfilled. Also, in a negligence action against the pharmaceutical company, the failure by the company or by one or more individual employees to comply with the regulations may be relevant to the question of whether or not a company has acted reasonably. Indeed, in the United States, some courts have held that a company failing to comply with government regulations may be presumed to be negligent; known as ‘negligence-per-se’, it essentially lessens the plaintiff’s burden regarding the standard of care owed by the defendant. Negligence-per-se focuses on the defendant’s actions, whereas in strict liability, the focus is on the product and whether it was defective.

In the United Kingdom, regulation is derived from the Medicines Act of 1968, which provides a comprehensive system of licensing affecting most aspects of the sale of medicinal products. It also contains provisions on related matters, such as pharmacovigilance and the requirements for the reporting of adverse events (AEs). The Medicines Act encompasses measures contained in European Community Directives, including the first on the control of medicines, introduced in 1965. The Medicines Act led to the creation of various
regulatory bodies to carry out the functions outlined in it, including the following:

(a) The Licensing Authority, which decides whether licences for medical products should be granted.

(b) The Medicines Commission and the Committee on the Safety of Medicines, which are examples of independent bodies set up under the Act to advise the Licensing Authority.

As well as domestic legislation, there is extensive European legislation governing member states. The European Community has over the years established measures to harmonize the regulation of medicines throughout Europe. In 2001, all European Community Directives adopted between 1965 and 1999 on the regulation of medicines were consolidated into a ‘Community Code’. At the time, the Code could not incorporate the new Clinical Trials Directive harmonizing EU controls on the approval and conduct of clinical trials (i.e. Directive 2001/20/EC). The Community Code has, however, since been amended to take into account the Directive’s ethics.

It was through this series of, now codified, Directives that a Europe-wide Committee for Proprietary Medicinal Products was created, now known as the Committee for Medicinal Products for Human Use (CHMP). Its role is significant. In conjunction with the European Medicines Agency (EMEA) established in February 1995, which it advises, it is responsible for overseeing the procedures established for the regulatory harmonization of pharmaceutical products throughout Europe, namely:

- The ‘centralised procedure’, which involves one application made to the EMEA. This has been mandatory for biotechnology products since January 1995, and has been extended to further categories since then.

- The ‘mutual recognition’ procedure (or the ‘decentralised procedure’), which is in essence a national registration recognised by the other member states.

In the centralised procedure, it is the CHMP which initially decides if the new product should be authorized and gives its ‘opinion’ to the EMEA. Also, through the mutual recognition procedure, it is the CHMP which resolves any disputes. Thus, there are two ways in which a drug may be granted a license in the United Kingdom; via the EMEA (be it through the centralized or mutual recognition procedure) or through its own MHRA.

The above procedures were reevaluated in 2001 as required in the originating legislation. The European Commission concluded that the main structures should remain but more flexibility was needed in pharmaceutical legislation. Issues considered were the need to provide European citizens with the highest level of healthcare, the need for an increase in the availability of innovative medicinal products and the then imminent enlargement of the EU. The findings of the Commission plus the intervening introduction of the ‘Community Code’ prompted the replacement of Regulation 2309/93 by Regulation 726/2004. The new regulation was drawn up to improve the previous version taking into account practical experience and to update all references to Directives since codified. The regulation also sets out the EMEA’s other tasks such as coordinating existing resources for the evaluation, supervision and pharmacovigilance of medicinal products.

One of the new developments of the European legislation above is the introduction of financial penalties for failure to comply with obligations and the ‘naming and shaming’ of offending companies. The United Kingdom, Medicines Act (1968) places responsibility on the applicant for a licence, which in most cases is a company, not on an individual within the company. The legal responsibility is thus that of the company (and those in positions of leadership and authority) to comply with the various regulations under the Act. Under certain circumstances, the regulatory authority (i.e. the government) may be sued if it was allegedly somehow at fault in granting or failing to withdraw a licence for the product that supposedly caused harm.

In the United States, pharmaceutical products are the most heavily regulated of all consumer products. The Food and Drug Administration
(FDA) is the primary regulatory agency and the Food and Drug and Cosmetic Act (FDCA) is the principal statute governing pharmaceutical products. The FDCA requires FDA approval of prescription medicines as ‘safe and effective’ before they may be sold in the United States (emphasis added). Regulations relating to pharmaceutical products address the safety and efficacy of pharmaceuticals and range from initial testing of a drug to post-marketing surveillance. The law regarding the conflict or balance between state and federal laws – called ‘pre-emption’ – is convoluted and is the source of extensive legal debate (see Chapter 52).

In the United States, as elsewhere, labeling is a crucial issue in litigation. The FDA’s regulation on labeling covers all written materials attached to or accompanying the product or container, as well as journal, television and radio advertising. The labeling used to inform physicians about the drug’s uses and risks is a crucial element for the FDA’s determination of drug approval. The FDA regulates all such labeling, including ‘all written, printed, or graphic matter’ used in advertising the drug. After FDA approval, a manufacturer may sell and advertise the drug in accordance with the approved uses on the drug label. ‘Off-label’ use is any use for the drug that is not approved by the FDA.

As in other countries, the US federal regulation of a drug does not end with the approval of the drug and the company being granted a license for it. The FDA requires drug manufacturers to engage in post-market surveillance of the approved drugs and can include revisions to the labeling. A manufacturer must report to the FDA and investigate any adverse events (AERs) in accordance with FDA regulations. Further, FDA regulations require a manufacturer to issue subsequent warnings whenever there is ‘reasonable evidence of an association of a serious hazard with a drug; a causal relationship need not have been proved.’ Pharmaceutical litigation in the United States and elsewhere often centers on the manner in which clinical trial data and AERs are processed and reported and how such information is incorporated into labeling changes. The pharmaceutical physician will often be central to this process.

### 46.6 Legal procedures

Although most legal procedures are not directly relevant to the work of the pharmaceutical physician, there are some procedural considerations worth acknowledging. When pharmaceutical litigation ensues against a pharmaceutical manufacturer, the manufacturer has a legal obligation to preserve documents, including electronic correspondence, that is related to the litigation. All employees should heed such notices to preserve documents and email correspondence. Failure to do so may result in the company being sanctioned by the court. It is worth bearing in mind that memoranda, email and other types of internal documents can become evidence in a lawsuit.

### 46.7 Data protection

An important area which will impact on a pharmaceutical company, however, is the law as to data protection. Governed in the United Kingdom by the Data Protection Act of 1998 (enacted to comply with EC Directive 95/46/EEC), this wide-ranging piece of legislation was designed to allay privacy concerns as technology developed allowing widespread availability of information relating to individuals. In the context of a pharmaceutical physician or company, the main concern will be data collection in clinical trials. The Act is based on eight ‘principles’ by which all ‘personal’ data must be processed. Thus, the processing of personal data is not prohibited, provided these principles are adhered to and the Information Commissioner is notified. Where data is considered ‘sensitive’, however, extra safeguards are added. The Act also establishes certain rights of the data subject. On a practical level, the Clinical Trials Directive has introduced ‘EudraCT’, a European database for interventional clinical trials with the aim that information on clinical trials should be shared between all member states. However, both this and the Health Service (Control of Patient Information) Regulations 2002 which apply to confidential patient information expressly provide that they should not be interpreted in a manner inconsistent
with the 1998 Act. It should be noted that breach of
the Act could result in criminal penalties.
In the United States, federal legislation called the
Health Insurance Portability and Accountability
Act of 1996 (HIPAA) to make patient information
more strictly protected than before. Although most
pharmaceutical companies have limited access to
patient names and other health information, any
patient information must be carefully guarded to
avoid violation of HIPAA statutes, which address
the use and disclosure of individuals’ medical infor-
mation by ‘covered entities’, and set standards for
individuals’ rights to control the use of their med-
ication information. Violations can result in fines and/
or, in some instances, imprisonment.

46.8 Pharmaceutical industry voluntary codes

In addition to the provisions of the UK Medicines
Act (1968), European Directives and other similar
mandates, the pharmaceutical industry also carries
out a measure of self-regulation through its industry
bodies. In the United Kingdom, for example,
the Association of the British Pharmaceutical
Industry (ABPI) is the trade association for around
100 companies in the United Kingdom producing
prescription medicines. The Association’s Code of
Practice for the Pharmaceutical Industry (‘the
Code’) is operated by the Prescription Medicines
Code of Practice Authority (PMCPA), which was
established by the ABPI as an independent author-
ity. The Code applies to the promotion to UK health
professionals and National Health Service man-
gerers of medicines for prescribing, and to informa-
tion made available to the general public about
such medicines. It does not cover the promotion
of OTC medicines when the object is to encourage
purchase by the public.

Voluntary codes are not legally enforceable in
the same way as a statute. However, it is a condition
of membership of the ABPI that the pharmaceuti-
cal companies abide by the Code. In addition, the
Code contains a number of sanctions that may be
imposed against member companies. Complaints
are made to the PMCPA, and if it is decided that
there has been a breach of the Code, the company
concerned has 10 working days to provide a written
undertaking to discontinue the promotional activ-
ity in question, with an ‘administrative charge’
levied. The amount depends on the breach. There
are also other sanctions available to the PMCPA,
such as auditing the company in breach of its proce-
dures to comply with the Code or reporting
it to the Board of the ABPI, which has the authority
to publicly reprimand the company or revoke its
membership to the ABPI. All complaints and their
outcomes are reported in a quarterly review.

Some provisions of the Code are of particular
importance to pharmaceutical physicians. Clause
14, for example, requires that promotional material
be certified by two senior officials in the company,
one of whom must be a registered medical practi-
tioner. The other is usually a pharmacist. The pro-
motion must be certified to be in accordance with
the Code; it must confirm that the material is accu-
rate, balanced, fair, objective and unambiguous
and based on an up-to-date evaluation of all the
evidence and be in no way misleading. Certificate
renewal is required every two years.

The US equivalent is the Pharmaceutical
Research and Manufacturers of America
(PhRMA), a trade association founded in 1958.
PhRMA is a nonprofit scientific and professional
organization of more than 100 pharmaceutical man-
ufacturers. The Association promulgates voluntary
standards (‘Guiding Principles’) for producers,
encourages product research and prepares and dis-
semnates information on behalf of the industry. The
Association also publishes consumer-orientated
informational materials on drug utilisation. Volun-
tary standards proposed in 2005 include initiatives
regarding direct-to-consumer advertising of pre-
scription medicines, use of an electronic system to
track pharmaceuticals from the place of manufac-
ture to the place where dispensed, and broader dis-
semination of clinical study data.

46.9 Conclusion

Caution and compliance are the bywords for
pharmaceutical physicians. He or she must be
knowledgeable about the many laws and regulations that directly affect pharmaceutical manufacturers and their employees. Sanctions for failing to comply with these requirements, may be severe, both for the manufacturer and for the individual. Consequently, pharmaceutical corporations need to develop, implement and maintain effective compliance programs and related training and pharmaceutical physicians should stay informed of the regulations and laws relevant to the industry in order to ensure compliance. Regulatory compliance and effective internal communication can avert potential problems and potential legal liability for both the manufacturer and its employees.

References

‘...a manufacturer of products which he sells in such a form as to show that he intends them to reach the ultimate consumer in the form in which they have left him with no possibility of intermediate examination and with the knowledge that the absence of reasonable care in the preparation or putting up of the products will result in an injury to the consumer’s life or property, owes a duty to the consumer to take that reasonable care’ (per Lord Atkin at p. 599).

Pfizer Corp. v. Ministry of Health (1965). 1 All ER 450, HL.

U.S. v. Dotterweich, 320 U.S. 277 (1943) (finding president of company individually guilty for shipping misbranded and adulterated drugs).


Zubulake v. UBS Warburg LLC, 220 F.R.D. 212 (S.D.N.Y. 2003); and Stevenson v. Union Pacific Railroad Company, 354 F.3d 739 (8th Cir. 2004).

Zubulake v. UBS Warburg LLC, 220 F.R.D. 212 (S.D.N.Y. 2003); and Stevenson v. Union Pacific Railroad Company, 354 F.3d 739 (8th Cir. 2004).

21 CFR Section 1.3(a).

21 CFR Section 201.57(e).

21 USC Section 331.

21 USC Section 353(c)(1).

21 USC Section 353(c)(3)(A).

21 USC Sections 301–393.

21 USC Sections 301–393.

21 USC Sections 331(t) and 333(b).

21 USC Sections 355(d) and 393(b)(2)(B).

31 USC Section 3729 et seq.  

31 USC Section 3730(d)(1)–(2).

42 USC Section 1320a–7b(b) (remuneration includes discounts, gifts, free supplies, equipment or any item of value).


By Council Reg. 2309/93 and formerly known as the European Medicines Evaluation Agency but shortened to the European Medicines Agency by Reg. 726/2004 (see following footnote).


Council Reg. 2309/93.


EC Directive 2001/83/EC.

EC Directive 2004/27/EC.


EC Directive 85/374/EEC.

For definition of ‘sensitive personal data’ see Schedule 2. The extra safeguards relating to the First Principle are contained in Schedule 3.

For example, in the UK the government was a defendant in actions brought by haemophiliacs alleging contamination with the HIV virus through use of blood products.

Implemented in the UK by the Medicines for Human Use (Clinical Trials) Regulations 2004 SI 2004/1031.


See Staples v. Merck & Co., Inc., et al., 270 F. Supp. 2d 833 (N.D. Tex. 2003) (consumers sued clinical researcher and research facility for strategic procedural purposes in lawsuit against manufacturer). Although originally sued, the clinical researcher and facility were eventually dismissed from the case.


See Part II of Data Protection Act 1998 generally.

See Pub. L. 104-191; 42 USC Section1320d-5; Pub. L. 104-191; 42 USC Section 1320d-6. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA faces a fine of $50,000 and up to one-year imprisonment. The criminal penalties increase to $100,000 and up to 5 years imprisonment if the wrongful conduct involves false pretences, and to $250,000 and up to 10 years imprisonment if the wrongful conduct involves the intent to sell, transfer or use individually identifiable health information for commercial advantage, personal gain or malicious harm. Criminal sanctions will be enforced by the Department of Justice.

See Schedule 17 of Act for notification requirement.

See, for example, Community Code 2001/83/EC and amending Directives 2003/63/EC (implemented in the UK by SI 2003/2321) and 2004/27/EC (implemented in the UK by SI 2004/3224).

See, generally, Andrew E. Costa, “‘Negligence per se Theories in Pharmaceutical & Medical Device Litigation,’” 57 MELR 51 (2005).

The advisory role of the CHMP in the EU is similar to the advisory role of the Committee on the Safety of Medicines in the UK.


The new Reg. 726/2004 now makes the authorisation procedure compulsory for orphan medicinal products and medical products for human use containing an entirely new active substance for the treatment of AIDS, cancer, neurodegenerative disorder or diabetes. See Annex to Regulation listing all products now requiring Community authorisation and those needing it as of 2008.

This is a simplification of a complex area of law for the purposes of this introduction. These themes are explained more fully in subsequent chapters.

With thanks to N. Leverett in Shook, Hardy and Bacon LLP Houston and E. Bolton Shook, Hardy and Bacon International LLP, London.
Product liability is one of the fastest growing and most economically significant applications of tort law. Products liability actions against pharmaceutical companies are among the most widely publicized classes of suits in the United States and Europe, and this has prompted large pharmaceutical companies to lobby vigorously for tort reform. (Nace et al., 1997). The liability burden of pharmaceutical companies has been described as grossly disproportionate to their sales in comparison with other manufacturing industries (The Progress & Freedom Foundation, 1996, p. 101). Direct comparisons, however, are difficult because the market for ethical pharmaceuticals is unlike the usual market situation, where consumers have choices among competing products on the basis of quality and price. In the case of ethical pharmaceuticals, a physician generally selects the specific drug, and the consumer bears only a fraction of the cost burden, as health insurance defrays a significant part of the cost (Mossialos et al., 1994). The recent increase in product liability actions against pharmaceutical companies as well as healthcare professionals has also been described as having an impact on the practice of medicine itself (Pendell, 2003).

The social and public policy implications of expanding pharmaceutical products liability litigation have made this area a focus of academics and politicians. These groups seek to balance incentives for improved product safety against the benefits of new and existing products on the other (Moore and Viscusi, 2001). High-liability costs occur under a regulatory regime that is exceedingly stringent compared with that in place for other consumer products. In the presence of such stringent regulatory criteria, one wonders why the pharmaceutical industry has been the object of such extensive litigation. This chapter will introduce the basic concepts of
pharmaceutical product liability law, review recent developments and emerging trends among pharmaceutical companies and product liability lawyers, and discuss how they might impact the industry as a whole in the future.

47.1 Principles of product liability law

The origins of product liability law can be traced to cases brought before British courts shortly after the onset of the Industrial Revolution in the first half of the nineteenth century. Since then, an ever-increasing volume of product liability cases have been brought before the courts in industrialized countries. In the United States alone, product liability lawsuits have increased from over 2000 cases in 1975, which marked the first crisis in the product liability insurance market, to over 13 000 cases in the late 1980s (Epstein, 1995). Although approximately 60% of this increase resulted from cases involving exposure to asbestos, a large fraction of the remainder have been brought against pharmaceutical companies.

In general terms, ‘product liability’ refers to the liability of a seller of a product which, because of a defect, causes damage to its purchaser, user, or sometimes a bystander. Responsibility for a product defect that causes damage lies with all sellers of the product who are in the distribution chain including the product manufacturer, manufacturers of component parts, wholesalers and retail stores that sold the product to the consumer. Laws in most countries and jurisdictions require that a product meet the ordinary expectations of the consumer. When a product has an unexpected defect or danger, that product cannot be said to meet the ordinary expectations of the consumer. Product liability law is primarily based on precedent case law that varies among jurisdictions. For example, in the United States, there is no federal product liability law per se. Typically, product liability claims are based on state laws and relevant commercial statutes, modeled on the Uniform Commercial Code (UCC), that pertain to warranty rules that govern manufacturers and their products. Classically, for product liability to arise, at some point, the product must have been sold in the marketplace resulting in a contractual relationship, known as ‘privity of contract’, between the person injured by a product and the supplier of the product. However, in most countries and jurisdictions today, the privity requirement no longer exists, and the injured person does not have to be the purchaser of the product in order to recover. Any person who foreseeably could have been injured by a defective product can recover for his or her injuries, as long as the product was sold to someone.

Pharmaceutical companies are increasingly being named as defendants in product liability suits. Pharmaceutical manufacturers have a duty to appropriately test their products before releasing them into the market, based on criteria from regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA). These criteria are regarded as industry standards, but the fact that a drug was properly licensed by the FDA or EMEA has no effect on the manufacturer's liability to an injured plaintiff, if the drug proves to be otherwise defective. A drug manufacturer has a duty to warn of side effects of a drug when such effects are understood to occur, but is not expected to warn of unknown dangers. Often the manufacturer discharges this duty by providing the necessary information to the patient’s prescribing physician or to the pharmacist. There is no duty to warn of possible reactions in unusually susceptible consumers, but just because a reaction is rare does not mean the manufacturer has no duty to warn about it. As with almost all medical products, with the exception of over-the-counter drugs, there will usually be a ‘learned intermediary’ between a drug’s manufacturer and the ultimate user. This can be the doctor who prescribes a drug, a nurse who instructs the patient on its proper use or the pharmacist who fills the prescription. The key role of these health professionals in the use of pharmaceutical products gave rise to the ‘learned intermediary doctrine’ which has been used by pharmaceutical companies as a primary defense in failure to warn claims. Under the doctrine, a pharmaceutical company is relieved of its duty to warn a patient of side effects associated with a drug when the company has provided an adequate warning to the patient’s physician. How-
ever, as more information about drugs have become available to the consumer and as plaintiffs’ lawyers continue to search for new theories on which to base claims against pharmaceutical companies, the learned intermediary defense has come under greater attack (Garbutt and Hofmann, 2003).

Product liability law, generally and as it pertains to pharmaceutical companies, is broadly based on legal principles involving contract law, the law of torts and the relevant statutory provisions of the country or jurisdiction where the action is brought (Jones, 1993). However, there are three fundamental legal principles under which a seller of a product can be liable for damages incurred from the use of that product: strict liability, warranty and negligence.

**Strict liability**

Strict liability is a principle of both tort law and contract law (i.e. purely under civil law), which provides that a seller of a product is liable without fault for damage caused by that product if it is sold in a defective condition that is unreasonably dangerous to the user or consumer. Thus, strict liability would mean that pharmaceutical companies would have to pay damages in some cases, even when they had researched their drugs impeccably (Hunter, 1993). Strict product liability similarly applies not only to the product’s manufacturer but also to its retailer and to any other party in the distribution chain. However, a product would not give rise to strict liability if it is found to be ‘unavoidably unsafe’. This has direct relevance to pharmaceutical companies, in that most courts have agreed that a product will not give rise to strict liability if it is unavoidably unsafe, as described by labeled descriptions of adverse events, and if its benefits can outweigh its dangers. Furthermore, most courts have also held that the existence of ‘unreasonable danger’ and ‘defectiveness’ should be based on the state of scientific knowledge and technology at the time when the product is sold and not on the date when the resulting product liability case comes to trial. The courts have taken a similar approach to ‘failure to warn’ claims in that if the state of scientific knowledge and technology at the time of manufacture is such that the defect or danger is neither known nor knowable, not only is the manufacturer protected from ordinary strict liability, but the manufacturer is also relieved of his duty to warn of the unknowable danger.

**Warranty**

Warranty is a principle of both tort law and contract law, that allows a purchaser of a product to bring a cause of action against the immediate seller of that product if he/she can demonstrate that the seller expressly or implicitly made representations or warranties about the quality of the product that were ultimately false or misleading, without the need to demonstrate negligence on the part of the seller. Thus, the seller may have reasonably and honestly believed that his/her representations or warranties were true, and could not possibly have discovered the defect in the product, and yet the plaintiff may nonetheless recover. Many countries have enacted statutes that apply to such warranties and resulting product liability actions. For example, in the United States, the UCC includes provisions regarding warranties and forms the legal basis for product liability actions brought under the principle of warranty. UCC Section 2-313 provides that an express warranty may be produced by an ‘affirmation of fact or promise’ about a product by a description of that product or by the use of a sample or model. The existence of a warranty as to the quality of a product may also be inferred from the fact that the seller has offered the product for sale. The UCC also imposes several implied warranties as a matter of law. The most important of these is the warranty of merchantability under UCC Section 2-314 which states that the warranty that goods shall be merchantable is implied in a contract for their sale if the seller is a merchant with respect to goods of that kind. Similarly, a retailer who did not manufacture a product is nonetheless held to have impliedly warranted its merchantability by virtue of the fact that he has sold it, assuming he deals in goods of that kind. In addition, under UCC Section 2-315, a seller of goods may also implicitly warrant that goods are ‘fit for a particular purpose’ if the seller knows that the purchaser wants the goods for a particular purpose, and the purchaser relies on the seller’s judgment to purchase the goods in question.
Negligence

Negligence is a principle of tort law that may be defined as the breach of a duty of care owed by one party, the defendant, to another party, the plaintiff, which results in damage to the plaintiff. The concept of duty of care serves to define the interests protected by the tort of negligence by determining whether the type of damage suffered by the plaintiff is actionable. The plaintiff must also demonstrate that there is a sufficiently proximate causal connection between the defendant’s negligence and the damage incurred. The damage in question may arise through misfeasance or nonfeasance and may consist of personal injury or damage to property, which are categorized as pure economic loss under civil law. Manufacturers, retailers, bailers and other suppliers may be liable to plaintiffs under the principles of negligence if they are found to have breached a duty of care.

47.2 Types of product defects

Under any theory of liability, a plaintiff in a product liability case must prove that the product that caused injury was defective, and that the defect made the product unreasonably dangerous. There are three types of defects that might cause injury and give rise to manufacturer or supplier liability: manufacturing defects, design defects and marketing defects. Manufacturing defects involve a product where the particular item that causes damage to the plaintiff is different from other similar items manufactured by the defendant, and the difference is attributable to the manufacturing process for the item in question. However, very few pharmaceutical product liability claims allege manufacturing defects because quality control standards are closely regulated and have traditionally been extremely high in the pharmaceutical industry (European Federation of Pharmaceutical Industries and Associations, 1999).

Design defects involve a product where all similar items manufactured by the defendant are the same, and they all bear a feature whose design is defective and unreasonably dangerous. Most design defect claims are further categorized as involving either structural defects, absence of safety features or suitability for unusual purposes. These design defect claims often involve allegations of negligence on the part of the defendant even though they may be based on strict liability principles in that the plaintiff often alleges that the manufacturer should have been aware of the safety attributes of his/her design and, in failing to do so, breached his/her duty of care. Finally, marketing defects are flaws in the way a product is marketed, such as improper labeling, insufficient instructions or inadequate safety warnings. A negligent or intentional misrepresentation regarding a product may also give rise to a product liability claim. Manufacturers and suppliers of unavoidably unsafe products must give proper warnings of the dangers and risks of their products so that consumers can make informed decisions regarding whether to use them.

47.3 Legal defenses in product liability cases

The defenses available to manufacturers in product liability actions vary, based on the respective common law or statutory provisions of jurisdiction in which the action is filed. However, certain legal principles commonly constitute a full or partial defense to product liability actions.

Regulatory compliance

The issue of regulatory compliance as a defense in product liability actions, especially those involving pharmaceutical companies, generally arises in connection with allegations of design or manufacturing defects or of failure to comply with federal labeling requirements. In the United States, the general rule is that, unless Congress intended to preempt the states from requiring stricter or different warnings, the defendant’s compliance with regulatory requirements does not preclude liability (McCartney and Rheingold, 1996). However, several states, such as New Jersey, have enacted
statutes that allow regulatory compliance as a valid defense in pharmaceutical product liability actions (N.J Code Section 2A:58C-4). A handful of other states have also adopted modified versions of a regulatory compliance defense which, for example, bar punitive damages for drugs approved by the FDA or create a rebuttable presumption of non-liability in light of FDA approval (Lifton and Bufano, 2004). Similarly, in the United Kingdom, Section 4(1) of the Consumer Protection Act of 1987 provides a valid defense if the defect is attributable to compliance either with a domestic enactment or with European Community law (Heuston and Buckley, 1992).

**Disclaimers**

With regard to product liability actions brought under the principles of warranty, a defendant may assert a defense based on a disclaimer from a warranty associated with the purchase or use of the product in question. For example, in the United States under UCC Section 2-316(2), a seller of a product may make a written disclaimer of the warranty of merchantability if it is conspicuous. However, it should also be noted that the Magnuson–Moss Federal Trade Commission Improvement Act of 1974, 15 USC Section 2301, et seq., provides that, if a written warranty is given to a consumer, there cannot be any disclaimer of any implied warranty.

**Contributory negligence**

A defense of contributory negligence asserts that a plaintiff who is him/herself negligent in that he/she does not take reasonable care to protect him/herself from damage, and whose negligence contributes proximately to his/her injuries, is either entitled only to reduced recovery from his/her damages, or in some countries, is totally barred from recovery (Heuston and Buckley, 1992). In these cases, the plaintiff is held to the same standard of care as the defendant, which is that of a similar reasonable party under similar circumstances. Although a plaintiff’s contributory negligence will be a defense in product liability actions brought under the principles of negligence, virtually all courts have agreed that in most actions brought under the principles of warranty or strict liability, contributory negligence may not be a viable defense. For example, if a plaintiff’s contributory negligence lies in a failure to inspect the product or a failure to become aware of the danger from that product, virtually all courts agree that this is not a defense. However, if the plaintiff learns of the risk and voluntarily assumes the risk in purchasing and using the product, contributory negligence may be a defense to strict liability. Similarly, if the plaintiff’s contributory negligence consists of his/her abnormal use or misuse of the product in question, this may be a defense to strict liability, depending on the degree of foreseeability of the abnormal use or misuse.

**47.4 International issues**

In recent years, pharmaceutical companies have faced increased litigation from overseas claimants because of the international differences in product liability laws that make them easier targets. Such differences include the absence of discovery mechanisms, jury trials, legal contingency fees and variations in the learned intermediary doctrines in many foreign jurisdictions. Lawsuits are also being filed in the United States because foreign parties are not able to get justice in their own country. This represents a marked reversal in the ‘foreign non-convenience rule’, which was originally adopted to protect defendant companies from being sued in some distant location where it had a small operation. Now, the very rules that used to help multistate or multinational corporations are being turned against them, on the theory that it is not convenient for these foreigners to sue in their own country because they do not have a claim there or they are not able to have their case heard for many years. Similarly, the plaintiffs’ bar has become increasingly sophisticated in using global regulatory inconsistencies to their clients’ advantage during discovery and at trial. During the course of litigation, pharmaceutical companies are now routinely faced with discovery requests,
designed to identify documents and data relating to their dealings with foreign regulatory agencies. Plaintiffs’ counsel regularly point to differences in labeling and product design resulting from a pharmaceutical companies’ compliance with foreign regulations as evidence of ‘defectiveness’ in similar or identical products marketed in the United States (Moore and Cullen, 1999). Thus, in overview, the global marketing of pharmaceuticals has had significant product liability implications resulting from jurisdictional issues, maintaining records for different regulatory agencies and compliance or noncompliance with regulatory requirements in different marketing venues.

47.5 Landmark cases

In contrast to the ostensibly uniform framework of product liability law that defines drug-induced tort, the history of high-profile pharmaceutical injury litigation shows that the practical prosecution of drug-related injury claims is broadly varied as it reflects the many possible types of drug-induced injuries. Although the breadth of potential harms from the use of pharmaceuticals is, in theory, limitless, adverse drug effects generally fall into one of seven groups: (a) toxic effects, where the drug causes an undesired pharmacologic effect on the body; (b) allergic effects, where the drug has an unpredictably severe or harmful effect on hypersensitive individuals; (c) dependence, where users of the drug develop a psychological or physiologic need for the drug; (d) indirect injury, where the drug interferes with mental or physical functions, resulting in collateral injuries; (e) interactions, where ingesting the drug in the context of other drugs or foods causes injury; (f) inefficacy, where the drug fails to perform its intended function; and (g) socially adverse effects, where a drug (usually an antibiotic) is overused by a population of patients, resulting in the rise and spread of resistant microorganisms (Dukes et al., 1998). The following discussion of several high-profile product liability cases shows how plaintiffs, corporations, attorneys and courts have applied product liability jurisprudence to varied types of pharmacological injury.

Thalidomide

The drug thalidomide caused one of the most vivid and widely publicized tragedies in the history of medicine (Bernstein, 1997). Thalidomide is a piperidinedione hypnotic derived from a naturally occurring amino acid, glutamic acid. Thalidomide was first synthesized in West Germany in 1953 by Ciba A.G., but it was initially abandoned after tests in laboratory animals revealed neither a beneficial nor a toxic effect. A few years later, chemists at another West German pharmaceutical company, Chemie Grunenthal A.G., deduced from thalidomide’s piperidinedione structure that it might have an anticonvulsant effect, and they experimented with giving thalidomide to epileptics. The ensuing studies revealed that thalidomide was ineffective as an anticonvulsant, but showed that it acted as a mild hypnotic or sedative. On the basis of these data, Chemie Grunenthal A.G. brought thalidomide to market under the trade name Contergan in October 1957 (Robertson, 1972). Thalidomide was an early success because it acted quickly to cause deep, natural-feeling sleep, and the drug soon became a favorite sleeping tablet for over-the-counter consumers and for institutions. Promoted as a safe tranquillizer, suggested uses of thalidomide included mild depression, flu, stomach disorders, menstrual tensio, and even stage fright (Allen, 1997). Also an antiemetic, Contergan was commonly prescribed for the nausea of pregnancy (Sherman, 1986; cf. Burley, 1986).

Although thalidomide showed no toxicity to laboratory animals when tested by Ciba and Chemie Grunenthal A.G., potentially irreversible peripheral polyneuritis was soon identified in patients following long-term use of thalidomide. Symptoms

\[1\] Bernstein notes that thalidomide quickly entered the lexicon as metaphor for poison and evil. ‘For years I have heard the word Wait!’ wrote Martin Luther King Jr in his famous Letter from Birmingham City Jail (1963). ‘It rings in the ear of every Negro with a piercing familiarity. This “Wait” has almost always meant “Never.” It has been a tranquilizing thalidomide, relieving the emotional stress for a moment, only to give birth to an ill-formed infant of frustration.’

\[2\] Burley argues that there is no evidence that thalidomide was neither useful nor prescribed as an antiemetic, and thus it had no place in the management of the nausea of pregnancy.
included burning pain in the feet, cramping pain in the calves, loss of ankle and knee reflexes, and tingling in hands (Crawford, 1994). Other reported toxicity symptoms included severe constipation, dizziness, hangover, loss of memory and hypotension (D’Arcy, 1994). Chemie Grunenthal A.G. initially defended thalidomide as a safe product and attributed the reports to overdosage and prolonged use. A pharmacologist at the FDA at that time, Dr Frances Kelsey, noticed this discrepancy and requested more data from the drug’s manufacturers to show that it was safe (see D’Arcy, 1994).³ In what has been heralded as ‘one of the FDA’s finest hours’ (see D’Arcy, 1994), Dr Kelsey withheld FDA approval of thalidomide until it became clear that the reports on neurotoxicity were valid and that, in addition, thalidomide was adversely affecting unborn children. In 1961, physicians in Germany realized with alarm that the growing number of otherwise rare severe congenital malformations, including phocomelia (defective development of limbs) and amelia (absence of limbs), could be attributed to the use by women of even a single dose of thalidomide during the critical first few weeks of their pregnancy (Wiedemann, 1961).⁴ Over the next years, it became clear that thalidomide was one of the most potent teratogens in the medical pharmacopoeia. Almost 100% of women who took thalidomide during the sensitive period (days 21–36 of gestation) produced malformed infants (D’Arcy, 1994). The spectrum of malformations was also notable for its breadth. In addition to phocomelia, thalidomide babies suffered from spinal cord defects, cleft lip or palate, absent or abnormal external ears, and heart, renal, gastrointestinal or urogenital malformations (D’Arcy, 1994; see also US HHS, 1997⁵). Before the epidemic ran its course, over 12 000 infants were born with deformities attributable to thalidomide (Sherman, 1986; see also Szeinberg, 1968;⁶ see also Flaherty, 1984⁷).

In 1971, 62 of the estimated 430 British children injured by thalidomide sued Distillers Co., the British marketer of the drug (Dworkin, 1979⁸). The thalidomide plaintiffs’ strongest argument under strict product liability was that thalidomide was defective in its design (Cook et al., 1991). To prevail on this theory, plaintiffs had the burden of showing that, based on testing procedures and scientific knowledge available at the time of manufacture, the drug’s danger to unborn fetuses was known or knowable by the defendant.⁹ In the 1950s, though, it was not common practice for drug companies to test new drugs on pregnant animals (Ferguson, 1996). Furthermore, even if tests on pregnant animals had been conducted, differences between animal and human metabolism of the drug would likely have hidden the drug’s teratogenic effects.¹⁰

Realizing the difficulties in establishing the elements of a design defect case against Distillers Co., the thalidomide plaintiffs pled in the alternative that Distillers Co. had negligently breached a duty of care it owed to all potential consumers of the drug, including the then unborn plaintiffs. This

³Dr Kelsey was also particularly conscious of the potentially harmful effects of drugs on a fetus having been involved with a malaria project during World War II in which quinine (another teratogen) was studied.

⁴During the 1960s, virtually every pediatric clinic in Germany had at least one child born with phocomelia or amelia.

⁵Although it is possible that thalidomide caused this heterogeneous group of deformities by acting through several different toxic mechanisms each targeting a different organ system, it is more likely that thalidomide has a single or few disruptive effects that can manifest themselves pleiotropically, depending on what stage the embryo had reached when the drug was introduced.

⁶Szeinberg estimates that 10 000 deformed babies were born in Germany, 1000 in Japan, 400 in England and 280 in Scandinavian countries.

⁷Flaherty estimates that approximately 20 thalidomide babies were born in the United States; most of these to women who had received thalidomide from their husbands who were stationed in Europe.

⁸Distillers advertised thalidomide as a treatment for morning sickness that could be given ‘with complete safety to pregnant women. . .without adverse effect on mother or child’.

⁹This rule is embodied in the Restatement (Second) of Torts, Section 402A, comment k, which provides that the supplier of an ‘unavoidably unsafe product’ is liable only if it was not accompanied by a warning of dangers that the manufacturer knew or should have known about.

¹⁰This conundrum of adequate drug testing persists even today; although more complete and rigorous laboratory testing protocols are now required by pharmaceutical regulatory agencies, many drug dangers like the action of thalidomide as a teratogen can be uncovered only post-marketing monitoring of drug toxicity because of the obvious ethical bar on drug testing using human subjects.
claim, too, was questionable, however, in light of the contemporaneous Hamilton v. Fife Health Board (1993) decision, holding that a child could not suffer ‘personal injuries’ while still a fetus. Reasoning that unborn children are not ‘legal persons’, Lord Prosser ruled that antenatal personal injuries did not give rise to a cause of action for damages. Although the Hamilton case was subsequently overruled by the legislature in the Congenital Disabilities (Civil Liability) Act of 1976, additional uncertainty would certainly have arisen from the empirical difficulty in proving that thalidomide was the teratogenic cause for each plaintiff given the spontaneous risk of abnormality inherent in human embryonic development (see Ferguson, 1992). Indeed, proof of causation would most likely have rested on equivocal statistical analysis of epidemiological data.

In light of the clear hurdles to establishing a successful strict liability or negligence claim, the thalidomide plaintiffs’ lead counsel advised that the plaintiffs’ chance of success at trial was ‘slightly less than even’ (The Sunday Times, 1973). Upon this advice, the thalidomide plaintiffs initially agreed to a £3.5 million settlement. Over the next decade, public pressure forced Distillers Co. to increase the settlement amount to £20 million, but it is estimated that this fund will be exhausted by 2012 (Waterhouse, 1995). Although the settlement agreement provided some timely compensation to the thalidomide plaintiffs, the fact that the case was settled out of court made it impossible to determine which, if any, of the plaintiffs’ claims would have been successful at trial. The legacy of the thalidomide tragedy thus was not a clarification of drug product liability law. Instead, thalidomide focused the attention of lawmakers and scientists on the potential risks of all medications. This legislative mandate ultimately led to stronger and more effective drug regulations worldwide, including in the United States.11 Bernstein (1997) quotes various sources stating that the German Pharmaceutical Law of 1976 and the Japanese Drug Side-Effect Injury Relief Fund Act of 1979 were indirect products of the thalidomide experience. Drug manufacturers in Sweden adopted voluntary regulations, and drug legislation in Canada was tightened in sympathy with the new laws in the United States (which set up the framework for current FDA regulations regarding new drugs).

Diethylstilbestrol (DES)

DES is a synthetic analogue of estrogen, first manufactured in the United Kingdom in 1937. The inventor’s altruistic decision not to patent DES led to the drug’s manufacture by more than 300 companies (Ferguson, 1996). Arguments in favor of the use of DES at the time of its introduction were largely theoretical, but although few rigorous clinical trials were performed to evaluate its efficacy, physicians began to promote the use of DES in pregnancy to treat threatened abortion or to prevent habitual abortion. The FDA licensed DES in 1947 for the prevention of early miscarriage. Due to vigorous support by physicians, acceptance by the FDA, and low cost, between 3 and 4 million women in the United States ingested DES; and between 20 000 and 100 000 fetuses were exposed to DES in utero, each year, for 20 years (Dutton, 1988).

In retrospect, it is questionable whether DES had any meaningful therapeutic effect. Beginning approximately 15 years after the peak of DES use, doctors found that female children of mothers who had taken DES during their gestation tended to develop preneoplastic vaginal and cervical changes in adolescence or adulthood. Male and female DES children also showed an increased incidence of fertility disturbances after puberty (Dukes et al., 1998). In 1984, the World Health Organization estimated that hundreds of thousands of pregnancies, especially in the United States and The Netherlands, were potentially affected (Buitendijk, 1984).

Since the early 1980s, thousands of pharmaceutical product liability cases have been brought against the manufacturers of DES. These plaintiffs had a stronger strict liability design defect claim than those for thalidomide because DES, marketed to prevent miscarriages, had no demonstrable

11Public outcry over thalidomide is credited for the 1962 amendments to the Federal Food, Drug, and Cosmetic Act (FFDCA).
clinical benefit. In Barker v. Lull Engineering Co. (1978), a California court adopted a ‘risk–benefit’ test to assess whether a product was defective. This test for defectiveness required a court to weigh a drug’s benefits against its potential risks, in light of evidence that the drug could have been designed more safely, or that other drugs were available that confer the similar benefits with less risk. A drug with no therapeutic benefit, like DES, would, under the risk–benefit test, be held defective in design.

Although drug manufacturer liability under a theory of design defect tort law was relatively easy to prove, especially in courts adopting the Barker risk–benefit test, some DES plaintiffs were barred from recovery by limitations placed on the unborn plaintiff liability doctrine that originated with the thalidomide cases. Although thalidomide’s teratogenicity affected only fetuses exposed during gestation – the second generation – increasing evidence showed that DES could cause injury to third-generation plaintiffs, the grandchildren of the woman who originally ingested the drug. In one such case, Enright v. Eli Lilly & Co. (1991), the plaintiff claimed that her cerebral palsy resulted from deformities in the reproductive system of her mother, which had been caused by her grandmother’s ingestion of DES during pregnancy. Stressing the need to limit manufacturers’ exposure to tort liability, the New York State Court of Appeals decided that a cause of action could be brought only by ‘those who ingested the drug or were exposed to it in utero’ (Brahams, 1991).

Although the two-generation limitation excluded a relatively few plaintiffs outright, the most important hurdle facing the remaining DES plaintiffs was establishing specific causation to prove that one specific manufacturer of DES produced the pills that were ingested by their mothers. This burden of proof created difficult logistical problems because of the two- to three-decade delay between ingestion of the drug and manifestation of injury. The loss of medical and pharmacy records due to death or other causes made it difficult in most cases for plaintiffs to establish their mothers’ use of a DES preparation made by a specific manufacturer. Also, anecdotal evidence suggested that pharmacists commonly dispensed DES from different manufacturers fungibly (Schreiber and Hirssh, 1985).

A lasting common law legacy of the thousands of DES cases litigated in the United States are novel theories of causation invented by activist courts to allow plaintiffs who could not prove specific causation to hold one or more of the manufacturers of DES liable for their injuries. Among these theories, the four most commonly and successfully invoked are (a) alternative liability, where a plaintiff sued all of the manufacturers of DES and the court placed the burden on the defendants to prove that they were not the manufacturer of the injuring drug;12 (b) concerted action, where the plaintiff showed express or implicit agreement among defendants to commit the tort, all defendants are equally liable;13 (c) market share liability, where the plaintiff is required only to show that the defendants benefited from a substantial share of the drug market, to shift the burden to the defendants to show that they did not produce the particular injuring drug;14 and (d) Hymowitz theory, where the court focused on the fact that all manufacturers of an injurious product increase the risk to the general public, and thus held each defendant liable in proportion to its share of the drug’s nationwide market, regardless of whether the defendant could prove that it did not make the actual preparation that injured the plaintiff.15

12Alternative liability originated in the landmark case, Summers v. Tice (1948), where the plaintiff was shot in the eye by one of two negligent hunters who had shot in his direction. The doctrine is now memorialized in the Second Restatement of Torts: ‘Where the conduct of two or more actors is tortious, and it is proved that harm has been caused to the plaintiff by only one of them, but there is uncertainty as to which one has caused it, the burden is upon each actor to prove that he has not caused the harm’ [Second Restatement of Torts, Section 433B(3)].

13See, e.g. Bichler v. Eli Lilly & Co. (1982); concert of action found among DES defendants who pooled information on the basic chemical formula and model package inserts.

14See Sindell v. Abbott Laboratories (1980); market share liability introduced by the California court specifically in response to the difficulties in proving causation faced by DES plaintiffs.

15See Hymowitz v. Eli Lilly & Co. (1989); this decision by the highest court of New York State is considered by many to be radical.
Recent cases and developments

Since the thalidomide and DES cases, a growing number of drugs have been the subject of product liability actions including Accutane (acne), Baycol (high cholesterol), Bextra (pain and inflammation), Crestor (high cholesterol), Celebrex (pain and inflammation), Fen-Phen (weight loss), Rezulin (Diabetes), Propulsid (acid reflux), Trovan (bacterial infections), Vioxx (pain and inflammation) and Zyprexa (schizophrenia). Among these, the cases which have developed most quickly and arguably have the greatest potential size, scope and visibility involve Baycol, Fen-Phen and Vioxx. It is important to note that litigation involving many of these drugs is ongoing, and new developments can occur on an ongoing basis which may materially alter the landscape of other pharmaceutical product liability actions.

Baycol (cerivastatin)

Baycol (cerivastatin) was developed by Bayer A.G. and approved by the FDA for use in the United States in 1997. It is a member of a class of cholesterol-lowering drugs that are commonly referred to as ‘statins’. Statins such as Baycol lower cholesterol levels by blocking a specific enzyme in the body that is involved in the synthesis of cholesterol. Although all statins have been associated with very rare reports of rhabdomyolysis, a muscle disorder, cases of fatal rhabdomyolysis in association with the use of Baycol have been reported significantly more frequently than for other approved statins. On 8 August 2001, Bayer announced that it was voluntarily withdrawing Baycol from the US market because of reports of sometimes fatal rhabdomyolysis.

Since Baycol’s withdrawal, numerous lawsuits have been filed against Bayer. As of January 2004, Bayer estimated that it had settled over 2000 Baycol-related claims out of court, and still faced over 10 000 existing lawsuits in both federal and state courts including putative class actions. The actions in the United States have been based primarily on theories of product liability, consumer fraud, medical monitoring, predatory pricing and unjust enrichment. These lawsuits seek remedies including compensatory and punitive damages, disgorgement of funds received from the marketing and sales of Baycol, and the establishment of a trust fund to finance the medical monitoring of former Baycol users. As of March 2004, without acknowledging any liability, Bayer had settled 2224 cases resulting in settlement payments of approximately $63 million. As of July 2005, three individual US cases had been tried, and all resulted in a verdict in Bayer’s favor.

Fen-Phen (pondimin/phentermine)

Until the late 1990s, fenfluramine and the other drug that made up the Fen-Phen regimen, phentermine, had been on the market in the United States for over 20 years. Fenfluramine is an appetite suppressant that was sold by A.H. Robins Inc., and Wyeth-Ayerst Laboratories Co., divisions of American Home Products Corp. Phentermine is a type of amphetamine that has been sold under many names and made by many companies. Fenfluramine is thought to cause weight loss by increasing the levels of a brain chemical, serotonin, which suppresses appetite. Phentermine, which acts on another brain chemical, dopamine, increases the body’s metabolism and is thought to have a role in reducing minor side effects caused by fenfluramine. Both drugs were approved by the FDA as short-term diet aids, but they were never approved for use together as part of a weight reduction regimen.

The Fen-Phen combination regimen started in 1992 after the publication of an article that showed dramatic weight loss when both drugs were taken together. In 1995, the FDA was asked to approve a new diet drug, dexfenfluramine or Redux. Developed by Interneuron Pharmaceuticals Inc., a Massachusetts company, Redux is a purified form of fenfluramine. However, prior reports had linked fenfluramine use with primary pulmonary hypertension (PPH), a rare but potentially fatal cardiopulmonary disease. The FDA finally approved fenfluramine and Redux went on the market in April 1996. In July 1997, the Mayo Clinic released results from a study that found 24 cases of heart
valve damage in Fen-Phen users, all of whom were women. The FDA subsequently issued a warning about heart valve problems associated with the use of Redux and Pondimin. The FDA warning and the publication of the Mayo Clinic study in the New England Journal of Medicine, led to the withdrawal of Pondimin and Redux from the market in September 1997.

Product liability litigation involving American Home Products (now called Wyeth) has continued since then, with Wyeth being named as a defendant in numerous legal actions alleging that the use of Redux and/or Pondimin, independently or in combination with phentermine, caused certain serious conditions, including valvular heart disease and PPH. For Fen-Phen litigation alone, Wyeth recorded litigation charges of $4.5 billion in 2004, $2 billion in 2003 and $1.4 billion in 2002. Payments to the nationwide class action settlement funds, individual settlement payments, legal fees and other items were $850.2 million, $434.2 million and $1.307 billion for 2004, 2003 and 2002, respectively.

Vioxx (rofecoxib)

Vioxx (rofecoxib) was developed by Merck & Co. Inc. (Merck) and approved by the FDA in May 1999, for the treatment of osteoarthritis, menstrual pain and the management of acute pain in adults. Vioxx belongs to a class of nonsteroidal anti-inflammatory drugs that block the enzyme, cyclooxygenase-2, commonly referred to as ‘Cox-2’. On 30 September 2004, Merck announced that it was voluntarily withdrawing Vioxx from the market worldwide after results from a clinical trial indicated that Vioxx users may have an increased risk of suffering a heart attack, stroke or other cardiovascular event. The risk–benefit profile of Vioxx and other Cox-2s has been widely debated since then. On 16–18 February 2005, the FDA held a joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The committees discussed the overall benefit to risk considerations (including cardiovascular and gastrointestinal safety concerns) for Cox-2 selective nonsteroidal anti-inflammatory drugs and related agents. On 18 February 2005, the members of the committees were asked to vote on whether the overall risk versus benefit profile for Vioxx supported marketing in the United States. The members of the committees voted 17 to 15 in support of the marketing of Vioxx in the United States. Even with the FDA Advisory Committee meeting and vote, federal and state product liability lawsuits involving individual claims, as well as several putative class actions were filed against Merck with respect to Vioxx. As of 31 January 2005, Merck was aware that it had been named as a defendant in approximately 850 lawsuits, which include approximately 2425 plaintiff groups alleging personal injuries resulting from the use of Vioxx. Product liability litigation related to Vioxx is expected to continue for a number of years to come.

47.7 Conclusions

This chapter has provided a brief overview of the doctrinal framework of products liability law that is applied in pharmaceutical injury cases. Though a full explication of the theories, definitions and defenses involved with products liability law is quite complex, this chapter summarizes these elements as they most specifically relate to pharmaceuticals. Though the drug industry is heavily regulated in the United States by the FDA and abroad by analogous agencies, products liability tort in the forms discussed here constitutes an increasingly prominent parallel regulatory means by which defective products can be removed from the market and negligent manufacturers can be censured. Despite the increase in products liability litigation, plaintiffs such as those who brought suits in the thalidomide and DES litigations frequently face unpredictable and difficult hurdles to recovery under existing legal theories. This makes the area of pharmaceutical products liability an especially productive area for new theories of liability and for defense from liability. Ultimately, it is the responsibility of courts to approve or disapprove of these novel theories and to strike the right balance between deterring irresponsible drug manufacturers and encouraging beneficial drug development.
References

Allen DK. 1997. ‘The return of thalidomide: are we ready to forget images like this and give the drug another chance?’ St. Louis Post-Dispatch: 28 September; 01B.
Barker v. Lull Engineering. 1978. 20 Cal. 3d 413, 573 p. 2d 443, 143 Cal. Rptr. 225.
Harris Interactive Inc. 1993. Pharmaceutical Liability Study commissioned by the U.S. Chamber Institute for Legal Reform, Washington, DC.
Summers v. Tice. 1948. 33 Cal. 2d 80, 199 P. 2d 1.
Gabriel Lopez

The realities of modern international corporations and the international marketplace for pharmaceuticals demand a global view of patents and other forms of intellectual property. Because patents are territorial, that is, they only protect an invention within the borders of the issuing country, the inventor must think of protecting an invention in countries other than in the home country. National patent applications are very frequently extended to other countries, as we will see below. Therefore, although the discussion to follow concentrates on the United States, which is the largest and most profitable market for pharmaceutical products, this chapter will also reference international patent concepts.

Even if it was limited to US law, this chapter would not be intended to be a learned treatise on patent law, given the enormity of the subject. Rather, it is designed to expose those in the pharmaceutical industry only to some general principles. It is biased toward pharmaceutical patent practice; meaning that issues totally different from those discussed herein might arise if the invention was a computer program, an electric switch, or a device for milking yaks. Also to be remembered is that, as in most fields of law, both the substantive and procedural aspects of the subject are always changing, either by legislative act, judicial ruling or international treaty. This constant change will make today’s statements on substance and procedure, not necessarily obsolete, but certainly dated in the not too distant future.

As a simple example, the life span of a US patent used to be easy to calculate: US patents used to last 17 years, calculated from the date of issue. But US patents filed after 7 June 1995 now last 20 years, calculated from the date of filing (which has been typical outside the United States for many years). Also, a form of tax, known as a maintenance fee, is now imposed on US patents. If the patentee does not pay each fee as it becomes due, the patent lapses. Lastly, patents can be extended via two different mechanisms. Under the rules of Patent Term Restoration, certain patents, mostly pharmaceuticals, can be extended for up to five years. The theory is that the patentee has suffered an injustice because he or she was essentially denied a portion of the patent’s life and not allowed to earn potential profit from the patented invention because of the need to first obtain regulatory (e.g. FDA) approval before bringing the product to market. Under the rules of Patent Term Adjustment, extensions can also be obtained for certain procedural delays during the prosecution of a patent application. The actual term extension for each patent is determined by its specific facts. These two calculations are independent of one another.
Patent Term Adjustment is not limited to pharmaceutical patents. ‘When does this U.S. patent expire?’ used to be, but no longer is, a trivial question to answer.

### 48.1 Intellectual property

*Types of intellectual property.* Patents are just one of a class of intellectual property rights; that is, rights to intangible property (as contrasted to the right to real property, such as the deed to a house). These intellectual property rights are Patents, Copyrights, Trademarks, Trade Secrets and Seed Protection. Each ‘right’ differs from the others primarily in the type of property it protects, how it is obtained and the length of protection. Some of their characteristics are as follows:

1. **Copyrights:** These protect the expression of an idea. Protection may be obtained by marking the work, as with the symbol ©. The term is typically for the life of the creator plus a number of years. Articles in medical journals are usually copyrighted.

2. **Trademarks (and the related service marks):** These protect logos, company names, container shapes, color patterns and so on. Drug trade names are usually protected by trademarks.

3. **Seed protection:** These protect agricultural seeds.

4. **Trade Secrets:** These protect information which is not publicly available and not divulged to anyone unless there is a confidentiality relationship therewith. Trade secret protection has no statutory life span; protection lasts as long as divulgation is prevented. Whether the divulgation occurs innocently or through intent, error or malice is irrelevant; once the secret is out, it is out and protection ends. There may be monetary recovery through court action against a malicious or divulger, who may also be punished under the penal codes if malicious. But this is usually small comfort to the previous trade secret owner.

5. **Patents:** These protect designs, asexually produced plants, things, processes and business methods. Pharmaceutical patents typically protect new chemical entities, synthetic processes, formulations and methods of treatment. (Designs, plant patents and business methods are not further discussed.) Protection is obtained by filing and then successfully prosecuting a patent application which discloses the invention. The patent term is typically 20 years from date of the filing.

Note that Patents and Trade Secret are antithetical types of protection. To protect by Trade Secret, the invention must never be disclosed; whereas to protect by Patent, disclosure at the time of filing is essential. The patent applicant receives a monopolistic right for a period of years in exchange for putting the invention in the hands of the public. (For ‘public’ read ‘competitor’.) *This exchange of monopoly for divulgence is at the core of the patent concept.* Failure of the inventor to fully disclose an invention has led to patent invalidation.

**Selecting the type of protection.** Although the subject matter which is intended to be protected largely dictates what type of protection is available and/or preferable (e.g. one could obtain copyright protection but not trademark protection for a new song), there can be overlaps. Probably most common is the overlap between Patents and Trade Secrets. If an invention can be commercialized without divulging the invention and without risk of its being back-engineered, then the innovator should seriously consider not seeking a patent at all, but rather keeping the invention secret. Possibly the longest kept such trade secret is the formula for Coca-Cola®, which to this day has been neither stolen, divulged nor back-engineered. A patent for this formulation would have described this invention in detail and would have expired decades ago.

It is not always easy to make the correct decision among alternatives when seeking to protect inventions. The inventor who decides on trade secret protection may regret that decision in a few years when the secret is inadvertently or maliciously revealed or when some analytical tool is developed which allows back-engineering of the invention. In the area of pharmaceuticals, trade secret protection
in not likely to be sought by the inventor, as a new chemical entity is often the invention that needs protection and such an invention necessarily must be publicly divulged. Two types of pharmaceutical inventions, however, are often kept as trade secrets: manufacturing process improvements and screening assays.

48.2 Short history of patents

Patents are not a new concept. They were granted at least as far back as ancient Greece and Babylon. Nor are they the product of only one form of government. Essentially every country has some form of patent protection, albeit not necessarily as strong as that in the United States and the other industrialized countries. Patent laws have long existed even in the noncapitalist systems, such as the former USSR. That intellectual property is a highly valued concept that can be no better demonstrated than by the observation that there are only two rights (Patents and Copyrights) which are specifically mentioned in the US Constitution. (The much-praised Bill of Rights was a group of 10 amendments added to the basic document.) Section 8, para 8 reads:

To promote the progress of science and the useful arts by securing for limited times to authors and inventors the exclusive rights to their respective writings and discoveries.

Limitations on patent rights. Patents, however, are not free of their detractors. As they are a form of monopoly and because monopolies have been subject to abuse (e.g. granting the king’s cousin a monopoly on the local water well), anti-monopoly laws (e.g. restraint of trade, anti-trust, etc.) exist which can be used to limit a patentee’s rights. Another limitation on patent rights is simply prohibiting the grant of patents on certain types of inventions, typically based on ethical or economic considerations. There are arguments against ‘patenting life’, as a result of which some types of biotechnology inventions are unpatentable in many countries. Among these can be included patenting transgenic animals, pieces of the human genome and, of course, human clones. Many countries prohibit methods of treating humans. Another, older, prohibition is that against granting patents to pharmaceuticals per se. Although their numbers are diminishing, many countries have allowed only limited patent protection on pharmaceuticals. Typically what can be patented in these countries is a process to synthesize the compounds but not on the compounds per se. These, so called, ‘process countries’ are mostly nonindustrialized. They have argued that they would be at an economic disadvantage if they were to grant compound per se protection because they do not have the in-house infrastructure to invent/patent such compounds themselves. All such patents would be granted to foreign, international pharmaceutical houses, as a consequence of which, moneys would always be flowing out of these countries to pay for vital pharmaceutical drugs. Many ‘process’ countries have already amended or have agreed to amend their laws to include compound per se protection. The subtleties of these ethical and economic debates are beyond the scope of this discussion.

48.3 Patent protection

Fundamental patent rights. A patent is a monopoly for a period of time (20 years) which gives the patentee the right to exclude others from making, using, selling or offering to sell the patented invention. Patents are limited geographically, temporally and by the rights of others. Because others may have superior rights, a patent never gives the patentee a right to practice the invention. This is a basic concept which is often unappreciated by the non-practitioner.

Patent licensing. Thus, the oft-heard, ‘We just licensed in the right to make Compound X’, when a patent license has been negotiated, is legally incorrect. It would imply that the right conveyed by the license is actually greater than that possessed by the licensor. However, the licensor does not have the right to make Compound X, only the right to deny that right to others. What is generally conveyed by a patent license, and depending on the wording thereof, is (1) protection from a patent infringement suit by the licensor or (2) the right to sue others for patent infringement.
A relatively simple example explains this concept. A manufacturer has obtained a patent for and wishes to sell a chair with two armrests and a wheel under each of its four legs. However, he cannot make such a chair because there is already a patent to another which very broadly claims ‘a chair having a flat sitting surface mounted atop four legs’. Although the earlier patent does not claim the armrests and wheels, it will ‘dominate’ the later patent, assuming the later chair has a flat sitting surface atop four legs. The first patentee has the right to exclude others, including the later patentee, from making a four-legged chair with a flat sitting surface atop four legs. The first patentee has the right to exclude others, including the later patentee, from making a four-legged chair with a flat sitting surface atop four legs, but, after the second patent issues, cannot itself make a chair with two armrests which has a wheel under each of its four legs, as this is the subject of the later patent. How can this matter be resolved, without costly court battles?

(1) The manufacturer can attempt to negotiate a ‘freedom to operate’ license from the first patentee, which will protect it from patent infringement suit by the patentee.

(2) If armrests and wheels produce a much more marketable product, it might be in both patentees’ interests to cross-license their respective patents, as neither patentee could sell the more desirable chair without an accommodation with the other.

(3) The manufacturer could also buy chairs from the first patentee and then modify them by adding armrests and wheels, as the sale exhausts the patentee’s patent rights in the goods sold. However, this may be economically unfeasible if the purchasing and modification costs cannot be passed on to the consumer by charging a higher price.

The situation can quickly become more complicated if we now add a third party who also has a patent, this one on a chair with two armrests but no wheels. The license negotiated, as described above between the first and second patentees, does not protect either patentee from suit by this third patentee, who is not a party to the license. Note that if this third patentee attempts to sell a green, two-armed, wheeled, four-legged chair with a flat sitting surface, both the first and second patentees could sue for patent infringement under their respective patents, even though neither of them mentioned ‘green’. In some technologies, especially those involving biotechnological inventions, multiple-party cross licenses and ‘freedom to operate’ licenses are common.

### 48.4 Patentable subject matter

Patentable subject matter covers a very broad range of the terms ‘things’ and ‘processes’. These include compounds per se (i.e. new chemical entities), compositions (e.g. a chemical entity and a pharmaceutically acceptable carrier or two chemical entities), life forms (e.g. a purified, newly discovered microorganism, a constructed microorganism or a region of DNA), devices (e.g. a surgical appliance), chemical syntheses, screening assays and methods of using a compound or composition. Shorter than to define what is the patentable is to define what is legally unpatentable. Generally, unpatentable subject matter includes products of nature (i.e. naturally occurring articles), scientific principles and some inventions related to atomic energy and nuclear material. The prohibitions against patents on methods of human treatment and compounds per se have been discussed above. In the ‘process countries’ (see above) patents can be obtained on a process to make a compound, but not on the chemical entity itself. Inherently, this is a more limited patent right, as (a) it may be very difficult to prove that a particular process is being infringed, and (b) alternative manufacturing processes may be developed which do not infringe.

### 48.5 Criteria for obtaining a patent

There are three criteria for obtaining a patent. The claimed invention must be (1) novel, (2) obvious, and (3) useful or utile. There are somewhat subtle differences in what these concepts mean in different countries, which can lead to different
outcomes when the inventor tries to obtain patent protection for the same invention in different countries. But generally, these three criteria are universally accepted. Of these, novelty and utility are usually the easiest criteria to deal with.

**Novelty.** An invention is novel if it was not part of the 'prior art' before the priority date (see below) of the patent application which claims the invention. The 'prior art' comprises all oral or written information publicly available before the priority date of the application. This criterion is essentially absolute everywhere except in the United States, where there is a ‘grace period’ of one year within which one can file a patent application even if the invention has been earlier divulged either by the inventor or by another. Novelty is fairly strictly interpreted; that is, the destruction of novelty requires a specific prior description of the invention being claimed. Thus, one can obtain a patent on a compound even if it is within the scope of the generic formula in an earlier publication which teaches multiple substituents on a core structure but which does not specifically show the now-claimed compound. To determine novelty one compares the date of invention (under US law) or priority filing date with the divulgation date of the supposed prior art. If the subject matter is the same and the divulgation date of the publication precedes the invention/filing date, then the invention fails the first test and cannot be patented.

In the United States, one further twist on divulgation dates is that a US patent is a reference as of its earliest US filing date. As a US patent application used not to be publicly available until the patent issued and since the allowance of a patent could be delayed either by a prolonged prosecution in the Patent Office (which could include appealing an adverse determination by the Examiner both within the Patent Office and then to the courts) or by the filing of one or more continuation applications, a US patent could become a reference as of its earliest US filing date many, many years after said filing date. Such patents (sometimes referred to as 'submarine patents') can be used as weapons in litigation to invalidate competitors' patents, the applications for which were filed after said earliest filing date. Now that the United States has joined the rest of the world in publishing applications 18 months after filing, ‘submarine patents’ are becoming much less of an issue.

**Utility.** An invention is utile if it has a practical end use. The requirement can be met by a statement of what the invention can be used for and how to use it; for example, ‘This compound is useful for the treatment of asthma when administered at a dose of 0.1–5.0 μg/kg per day’. A more complete teaching would include modes of administration, dosage forms, delivery systems and so on. The utility must be currently available. Although commercial availability is not necessary, mere assertions such as ‘these are therapeutic agents’ or ‘they are for pharmaceutical purposes’ are generally insufficient. If the asserted utility is believable on its face to persons skilled in the art in view of the state of the art as of the filing date, then the burden is upon the Examiner to give adequate support for rejections for lack of utility. As stated by Commissioner Lehman at a hearing on 17 October 1994: ‘In other words, if an applicant presents a scientifically plausible use for the claimed invention, it will be sufficient to satisfy the utility requirement’. Two types of inventions that tend to fail the utility test are perpetual motion machines (the Patent Office wants to see working models of these) and ‘unbelievable’ cures without supporting experimental data (e.g. a cure for AIDS).

**Unobviousness.** The third, and most difficult, criterion is unobviousness, or inventive step, as it is known outside the United States. The process for deciding whether or not an invention is obvious was succinctly stated in a US court decision (the Deere case). According to the Deere decision, the Patent Examiner should determine obviousness using a three-prong approach:

1. Determine the scope and content of the prior art;

2. Ascertain the differences between the prior art and the claims; and

3. Resolve the level of ordinary skill in the pertinent art.

Although Deere is a US decision and is only binding therein, the principle enunciated is followed, more or less, by most patent offices worldwide.
Of course, this three-prong approach is much easier to enunciate than to practice. Consequently, much time and effort is typically spent during the prosecution of a patent application trying to convince the Examiner that the rejection of the claims on the basis of obviousness is incorrect because one or more of the Deere prongs has failed. Steps (1) and (2) of the Deere analysis tend to be fairly straightforward. However, it is in the third step that a judgment call must be made by the Examiner which presents the most problems. Even if the applicant and Examiner agree on steps (1) and (2), the conclusion to be drawn therefrom is rarely easily agreed upon. Obviousness, like beauty, appears to be more often than not in the eye of the Examiner-beholder. The matter is made worse by the organization of patent applications, which are usually drafted by first stating the background of the invention, which may include a description of the closest prior art and some unresolved problem therewith, followed by a statement of the invention. It should not be too surprising that an Examiner, presented with both a statement of a problem and the solution to the problem, would respond by concluding that the solution is obvious. Most of us have probably had a similar response upon being shown the solution to a trivial geometric puzzle, which, of course, up to that moment had completely baffled us. Hindsight in deciding the question of obviousness, as in many other endeavors, is 20/20. (In Europe, the Examiner’s approach to a determination of obviousness is based on ‘the problem to be solved’. The problem/solution organization just described makes it easier for the European Examiner to find the claims ‘lacking in inventive step’.)

The task then is to convince the Examiner to reconsider the obviousness rejection. Many approaches are possible. (In the following examples, the claimed invention is a compound and the prior art discloses structurally similar compounds. However, analogous arguments can be made for process claims, composition claims, etc.)

The simplest arguments are based on structural differences. For example, the reference compound contains an alkyl substituent at the position where the claimed compound contains an aryl group. The argument is that alkyl does not suggest aryl. Similarly, arguments can be made that ‘C’ does not suggest ‘S’; ‘2-phenyl’ does not suggest ‘3-phenyl’; ‘S’ does not suggest ‘O’; ‘S’ does not suggest ‘SO2’ and so on.

An argument based on structural differences becomes more compelling if related to physical properties such as biological activity. For example, the reference compound had no activity, had a different activity, had the same but less activity or had a side effect not exhibited by the claimed compound. Note that as the rejection is based on what is disclosed in the prior art, the applicant can use what is disclosed in the art to construct an argument. Thus, if the reference discloses that the compound has an ED50 of 100 µg/kg and the claimed compound has an ED50 of 10 µg/kg, an argument based on the enhanced activity of the claimed compound can be made without actually having to generate data to determine the already disclosed ED50 of the reference compound.

Another argument may be that the prior art actually taught away from the invention; for example, the compounds were known to be toxic or unstable, or there was a progression in the references away from the invention (e.g. the claimed compound contains a methyl substituent, whereas the earliest of three references cited against the applicant teaches an alkyl group at the same position of 4–7 carbons, the second reference teaches 10–15 carbons and the latest reference teaches 20–30 carbons).

Another, albeit weaker, approach is to argue from ‘secondary considerations’. It brings in such secondary considerations as the commercial success of the invention, that there was a long-felt need in the art for a solution to some problem, the failure of others to solve whatever problem the invention solves, and so on.

Any of the above arguments can be made, and usually are, in combination with some limitations on the scope of the claimed subject matter. More often than not, the allowed claims are narrower in scope that those that were initially filed.

Failing to convince by mere argumentation, the applicant may choose to introduce tangible evidence, which is typically in the form of a signed declaration which presents the results of comparative testing, that is, a side-by-side
comparison in some assay of the prior art and claimed compounds.

48.6 Short biography of a patent application

With the understanding that there really is no typical patent application, the following is an attempt to describe a typical and highly simplified patent application life span. The setting is an international pharmaceutical corporation.

The inventor prepares an Invention Disclosure describing the invention. The Disclosure is reviewed/approved by Research and forwarded to a Patent Committee for further review. If it is decided that the invention is worthy of patent protection, a patent application is drafted, finalized and filed within several months after approval by the Committee. (In the United States, patent applications can only be filed by inventors, and patents are only granted to inventors. Outside the United States, however, non-inventors can be applicants. These applicants are usually the organizations which hired the inventors, but they could be others.)

In about one year from filing, a Patent Examiner takes up the application and communicates (usually in the form of a Rejection) with the patent attorney handling the application. Issues of novelty, utility and obviousness are argued back and forth and after about another year or two, the application is either allowed (in which case an Issue Fee is paid and the patent is granted) or the Examiner issues a Final Rejection, to which the response is an Appeal. Appeals are handled by a three-person Board which reviews all the arguments presented by the Applicant and the Examiner. Favorable decisions by the Board of Appeals result in an allowance. Unfavorable decisions can be appealed to the courts or simply result in abandonment of the application by the inventor. Board decisions are currently taking about two years from the time the Applicant’s Brief and the Examiner’s Answer are submitted to the Board. This process is what is meant by patent prosecution; that is, the give-and-take between the applicant (more typically, applicant’s agent or attorney) and the Patent Office, which results in granting or denying the grant of a patent.

In parallel with the above, about 9–10 months after filing the application, a decision must be made by the Patent Committee about if, where and how to Foreign File the application, which must be done by one year from the filing date if the applicant is to claim the benefit of the Paris Convention (see below).

The foreign filing decision-making process varies from organization to organization (sometimes even differing from subsidiary to subsidiary within the same company) but is often in the form of a committee comprising members from Research, Marketing and Patents, preferably armed with a tiered country list. An extremely potent new drug, marketable worldwide, with a high likelihood of being patented is a candidate for global foreign filings. An invention of lesser value might be filed on a more-limited basis [e.g. United States, European Community (EC), Canada and Japan] while still protecting a significant amount of sales. An invention of very little continued interest might (1) either be made publicly available as by allowing the application to publish at 18 months after the priority date but then allowing the application to lapse by nonresponse to the next Patent Office letter, or (2) not published at all as by expressly abandoning the pending application.

If it is decided to proceed with national filings, the application is sent to an agent in each country with instructions to file the application by the one-year anniversary date.

If a Patent Cooperation Treaty (PCT, see below) filing is decided, the application can be filed by the applicant in the PCT Receiving Office of the US Patent Office. Decisions then have to be made shortly before 30 months after the initial filing date with regard to national filings, as described below in the section on ‘PCT’.

National filings, whether directly or through the PCT, are handled by each country’s Patent Office. There are a multitude of statutory, formalistic and stylistic differences among all the Patent Offices, resolved with the help of the local patent agents. However, typically there is a review by an Examiner, amendments and arguments by the Applicant, and either an Allowance or an Appeal (i.e. a
procedural system similar to that in the United States). In the EPO, Japan and many other countries, an Allowance does not automatically result in the granting of a patent. In these countries, when the Examiner decides there is patentable subject matter, the allowed claims are published for Opposition. During the Opposition period (six to ninth months), anyone can protest the granting of the patent. Opponents present their written arguments which the Applicant attempts to rebut. If the matter is not resolved after a period of arguments and counterarguments, the matter is orally argued before and decided by an Opposition Board. As with a US patent application involved in an Interference (see below), ultimate issuance of a patent may take years in the case of a vigorously contested Opposition.

Finally, after the patent has issued, it must be ‘maintained’. Maintenance fees must be paid periodically to each country in order to keep the patent in force. Failure to pay results in a lapsed patent.

### 48.7 International treaties

Although patents are territorial, that is, they are granted by and enforced in individual countries, several international treaties have had a major impact on patent practice on a global scale. Although the lists of signatory countries are not identical for all treaties, essentially all major countries are signatories to all the treaties described herein (with the exception of the EPC).

#### The Paris Convention

The first and most important of these treaties is the Paris Convention for the Protection of Industrial Property of 1883. ‘The Convention’ allows an applicant to file a patent application in any of the Convention countries and then, no more than one year after the filing, to file corresponding patent applications in any, or all, of the other Convention countries and to claim the benefit of the filing date of said earlier patent application.

The significance of the Paris Convention cannot be overstated. The first filing date, ‘the priority date’, shuts off the prior art, not only in the country of original filing but in all the other signatory countries. As absolute novelty is the rule everywhere except the United States, it is very advantageous to the applicant to be able to fix a date certain after which no later publicly available information can be cited as prior art, either by a Patent Examiner during prosecution or by opposing counsel in litigation (i.e. in a courtroom) in any Convention country. (Actually, multiple related patent applications (typically, each an expansion of and/or a more detailed version of the prior) can be and often are filed within the ‘Convention Year’. Each of these establishes a different priority date for whatever is newly disclosed therein. However, it is simpler, to confine the rest of discussion to a single priority filing and a single priority date.)

There is a great economic advantage to this arrangement, as the applicant need only file one application to stop the prior art. The applicant then has one year in which to evaluate the invention and decide if additional, that is ‘foreign’, filings are warranted.

#### The European Patent Convention

This is the treaty under which the EC created the European Patent Office (EPO) to receive and prosecute patent applications with jurisdiction over the whole EC. Only EC countries can be signatories to the EPC. This system works in parallel with the European national patent offices, which have not been closed. In fact, on filing an EPO patent application, the applicant designates in which of the EC countries patent protection is sought. If the application is successfully prosecuted, the applicant is then granted a patent by each of the designated countries; that is, each signatory country has agreed to have the EPO determine patentable subject matter and then grants its own patents based on the EPO’s favorable decisions. If one wishes to file a patent application in Europe, there are three routes to choose from: (1) file nationally (i.e. country-by-country), (2) file in the EPO and (3) simultaneously file nationally and in the EPO. (Route 3 is an expensive alternative and little used.) Unless the country list is very small,
EPO filing has several advantages. Procedurally, it is the simplest, as there is only one filing, one prosecution and one set of allowed claims. The entire proceeding can be handled in any one of the official languages (English, German and French). The cost of translating into the nonofficial languages can be deferred until the end of prosecution. If there is an adverse decision or if the application is abandoned because the subject matter is no longer of interest to the applicant, there are no translation costs. The EPO route does suffer from the ‘all your eggs in one basket’ problem, which, of course, does not exist if one files nationally. This is not viewed by most as a significant impediment.

The Patent Cooperation Treaty

The PCT of 1970 created an extremely practical and economic mechanism for worldwide patent filing which has been steadily gaining in popularity. The treaty created the World Intellectual Property Organization (WIPO), which is headquartered in Geneva and which administers the provisions of the treaty. As with an EPO application, when filing a PCT application, one initially designates those countries, or regional patent offices such as the EPO, in which patents are to be sought at a later date, during the ‘National Phase’. The PCT application is itself not a patent application. Instead, it reserves the right to file national patent applications in the future in the designated countries. A PCT filing comprises both an international phase and a national phase.

International Phase: The PCT filing results in an International Search and the issuance of an International Search Report, a Written Opinion (which comments on the three aspects of patentability (novelty, obviousness and utility) as they apply to the claims, and possibly comments on other matters as well), and an International Preliminary Examination Report (IPER). WIPO will also publish the patent application 18 months after the priority date. The designation ‘WO...’ in the upper right hand of what many call a ‘patent’ actually indicates that the document is only a published PCT patent application, not a patent. The PCT patent application is itself never prosecuted to allowance. The filing allows an applicant to defer further action (and cost) until 30 months from the priority date, giving the applicant some time to consider both (1) the value of the invention (Does it work? Is it marketable?) and (2) the contents of the Search Report, Written Opinion and International Preliminary Examination Report (How close is the prior art and how likely is it that it can be overcome?). There is clearly a great advantage both in time and cost (no national filing fees, agents’ fees or translation costs) resulting from deferring national filing until 30 months after the priority date.

National Phase: Mechanically, this means filing a patent application (through one’s patent agents) in each of those countries initially designated, and still of interest, and advising each national Patent Office that the national application is based on the PCT filing. It is WIPO’s responsibility to forward all the documents from the international phase to these national offices. Prosecution of each application is then handled by each country independently of what any other country may be doing with a corresponding application. As each national patent office must act in conformity with the patent laws of that country, the Written Opinion and IPER cannot control and there is a broad range of reactions from the national patent offices to the Written Opinion/IPER during the national prosecution stage. Some offices appear to totally abdicate responsibility and incorporate the results reached during the international phase into their own decisions, whereas others appear to disregard them in whole or in part. In any case, the applicant is in a much more desirable position if a favorable and well-reasoned decision was reached during the international phase. Ultimate allowance or rejection proceeds on a country-by-country basis.

The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure

There is an inherent problem with many biotech inventions which was eloquently, if somewhat presciently, stated by Mr. Joyce Kilmer: ‘...But only God can make a tree’. This is not a theological argument against ‘patenting life’ but rather
recognition that present day science has its limitations. Until the better microscope is built (and patented), we simply cannot describe every atom in very complex organic structures, for example an *E. coli* cell, and thus cannot teach how to make one. If an invention requires such a cell, the applicant cannot meet the obligation to disclose the invention in a patent specification; that is, there is no way to put the invention in the hands of the public without also giving the cell to the public. However, the cell is likely to be a valuable asset, and the applicant will probably not wish to divulge it unless a patent has issued.

One solution to this problem is to make a restricted deposit of the cell in a public depository, which provides a unique accession number identifying the deposit. By agreement with the depository, the restriction is lifted in the future, for example, when a patent issues referring to the cell. The applicant can then meet the disclosure requirement by providing the deposit’s accession number in the specification. This approach works best if only one country is involved but does not work as well with multiple international filings, as the patent office in each country may have its own rules as to what constitutes an acceptable depository, acceptable restrictions on access to the public, and so on.

The Budapest Treaty resolves these issues by providing a list of approved depositories throughout the world and one set of deposit conditions, which include restricted access to a deposit by the public prior to patent grant. The inventor need make only one deposit under one set of rules to enable the invention and the public gets disclosure of the invention under certain restricted conditions prior to patent grant.

**General Agreement on Tariffs and Trades (GATT)**

GATT is one of the latest attempts at global patent harmonization, that is, amending patent laws everywhere so that they are more or less alike, mostly more. For example, as a result of GATT, many ‘process countries’ have agreed to grant compound *per se* patents. This recent (1994) treaty has had significant impacts on US patent practice, most of which are procedural and too arcane for discussion herein.

It was GATT that brought about the change in US patent terms. As discussed above, prior to 8 June 1995, US patents lasted 17 years from grant. Now the United States has adopted the worldwide standard and US patent last 20 years from first US filing. According to US Patent Office figures, the average chemical patent application is pending slightly less than two years. Therefore, the new 20-year patent has a slightly longer patent life than the old 17-year patent. However, this computation ignores the practical reality that many pharmaceutical patent applications are rarely simply just filed and then granted in two years. Rather, many initial pharmaceutical patent applications are the first of a string of related filings, the last of which may occur many years after the first. Under the new rules, patents issued from these later-filed applications all expire 20 years from first the filing date. This results in a considerably reduced patent life versus a comparable 17-year patent.

GATT did not remove one peculiarity of US patent law: interference practice (see below). However, it did bring about one change, concerning the place of invention. Prior to GATT, one could only prove the date of invention by reference to acts committed in the United States. Non-US inventors had long complained about the favoritism of this rule, as it gave US inventors a clear advantage, for example in deciding the earlier inventor during an interference. Under GATT, non-US acts can now be used as part of the proof of the date of invention, thus, somewhat leveling the international playing field.

### 48.8 Interference practice

Unlike the rest of the world, US patent practice is a ‘first-to-invent’ rather than ‘first-to-file’ system, the argument being that the Constitutional basis for the patent system was to secure rights for inventors not for hasty filers. This occasionally leads to a quasi-judicial proceeding known as an interference.

An interference arises when two (or more, but this complicates matters even further) patent
applications are filed in the US Patent Office at about the same time and much the same subject matter is determined by the Examiner to be allowable in each application. (In the first-to-file countries, the second application is simply rejected over the first. This ends the matter, unless the second applicant can successfully argue that the Examiner has misunderstood either of the inventions, that is, that in fact there is no overlapping subject matter, or that there is some fundamental error in the first application, for example, that the first application does not actually teach what it appears to teach.) Usually, the determination of overlapping subject matter occurs while both of the applications are still in prosecution, but it can also occur if one has already been granted and a patent has issued.

The declaration of an interference can either be the result of an internal check at the US Patent Office of pending applications or as the result of provocation by an applicant. This occurs when the applicant sees a patent issue with overlapping subject matter based on an application filed by another within certain time limits. There does not have to be a complete overlap in allowable subject matter, merely some overlap. The applicant then ‘copies claims’ from the patent for purposes of having an interference declared. As the Examiner must first determine that the applications contain otherwise allowable subject matter, interferences take place only at the end of the prosecution stage.

The interference is referred to as quasi-judicial because, as in a trial, two opposing sides argue against each other and present evidence either in support of their side or to contradict the other. The US Patent Office sets up a schedule for exchanging proofs, calling witnesses and so on. Ultimately, a decision is made by a panel of Administrative Patent Judges as to which party is the first to invent and is be to granted a patent. This decision is binding on both parties; however, it can be appealed to the civil courts.

Interference practice is defended by many as the only way to assure that the true (read ‘first’) inventor is granted a patent in accord with the Constitutional intent. It is also attacked by many as a costly and time-consuming proceeding that serves no real purpose, as ‘inventor’ can just as easily be defined as the one who files first, independently of when the invention was actually is made. Interestingly, most decisions are rendered in favor of the first applicant. There is pressure from the international community for the United States to adopt a first-to-file system but, for now, interferences will continue.

48.9 Biotechnology

Biotechnology (hereinafter, biotech) can loosely be defined as the science of very large and very complicated living molecules. The patent concepts that have developed over the decades to deal with a myriad of inventions covering organic compounds (i.e. ‘small molecules’) can generally be, and have been, adapted to cover biotech inventions. However, biotech inventions have two basic types of problems: one technological, the other societal.

Technological. One of the issues on the technological side is the question of enablement. This has been discussed in part in the section dealing with ‘The Budapest Treaty’ (see above). But even if the inventor tries to put the invention or a precursor of the invention in the hands of the public as by a Budapest deposit, the public may still not be able to reproduce the invention; for example, because of an inherent instability in the deposited material.

Another technological question is how to fully describe the invention. Analogously to a description of a piece of real property (i.e. land) found in a deed, the ‘metes and bounds’ of the invention must be described in a patent application in such clear and concise terms that a potential infringer would be able to figure out what acts are infringing and which are not. In the biotech area, it is often not easy to fully describe the thing that has been invented. The stick formulas used to describe classical pharmaceutical compounds are rarely of any value. The physical properties of biotech inventions are often ‘fuzzy’. An expression such as ‘...having a molecular weight of 75–95 kD’ may be the best the inventor can provide but it is not very precise. Each type of biotech invention presents its own technological difficulties which must be resolved using whatever tools are available when preparing a patent application.

Societal. On the societal side, there is the understandable concern about ‘patenting life’. This is
another example of the difficulties which arise when technology races ahead of society’s capacity to even understand that there is a potential new problem. Although plant patents and other protections for agricultural inventions (all of which were known to be living organisms) had been granted for many years, patent offices had simultaneously refused to grant patents for inventions of living, non-plant organisms. This all began to change with the 1980 US Supreme Court decision in the Chakrabarty case, where the invention was a modified microorganism. The sole issue before the Court was whether an invention could be denied patent protection solely because the claimed material was alive. The Court said ‘No’, and the biotech industry exploded onto the scene.

No one today complains about patenting microbes. However, the intensity of the debate is understandable when the inventions involve human DNA, as these are seen by some as endangering our humanity. Today, the major issues relate to patenting transgenic mammals, pieces of the human genome and human clones. Tomorrow, the great issue of the day may be patenting cyborgs; that is, organisms comprising synthetic and human components. Undoubtedly, some of these issues will be resolved soon and some will be hotly debated for a long time; at least, until a hotter issue emerges.

### 48.10 The value of patents

Patents are clearly of great economic value to the patentee because they can be used to block competition, because they can be licensed out, thus producing a revenue stream even if the patentee has no interest in actually selling the patented product, or because they can be bargaining chips in cross-licensing arrangements, just to name a few. For a start-up company, the mere granting of a patent can add tens of millions of dollars to the value of the enterprise, somewhat independently of what the patent actually covers. This converts into more-ready access to additional funding from venture capitalists and the price of the company’s stock when a public offering is made.

Patents may be of value for only a few years in rapidly developing technological areas; that is, until the next ‘big thing’ makes the patented technology obsolete. Patents are also arguably of lesser value than a well-recognized trademark, which does not expire in 20 years.

Pharmaceutical patents in particular have come under attack in recent years, largely due to the perceived high costs of medicines. Thus, in the United States, there is pressure to allow the importation of foreign-purchased drugs, even though a US patent exists which would normally be expected to bar such importation. In the EC, there is no barrier to the free movement of goods within the EC. So, if a drug is not covered by a patent in a first EC country, it can be purchased there (presumably at a cheaper price) and moved to a second EC country, even though there is a patent in the second country that covers the drug. The ability of the patentee to bar these importations at the border has been eliminated.

Another diminution in the value of patents in the United States is the result of the Hatch–Waxman Act. This law provides a significant economic incentive to generics companies to attack the validity of US patents. (See Chapter 29 for a more complete discussion on this subject.)
49.1 Introduction

Research misconduct strikes at the very heart of scientific objectivity. It raises doubts about the integrity of the science and our trust in the work of others. We must be able to believe in the reliability of scientific research.

There has been much published on the incidence, detection and prosecution of publication fraud, rather less on fraud and misconduct in clinical research, but we should be equally concerned about research fraud. The Consensus Conference on Misconduct in Biomedical Research convened by the Faculty of Pharmaceutical Medicine and the Royal College of Physicians of Edinburgh in 1999 defined research misconduct as ‘behavior by a researcher, intentional or not, that falls short of good ethical and scientific standards’. Frank Wells, co-founder of MedicoLegal Investigations Ltd., the only specialist research fraud investigation company in Europe, prefers ‘the generation of false data with the intention to deceive’.

49.2 How common is research fraud?

Carelessness is common, research fraud less so, but both are almost impossible to quantify. The US Food and Drug Administration (FDA) has offered estimates of around 5% of clinical trials. Some authorities suggest a rate of 1%, some up to 7%. My experience suggests a figure around the 3% mark. The number of clinical trials running at any one time must be in the hundreds of thousands, leaving potential for an unacceptable number of studies producing data that are unreliable or even fabricated. More than 70% of the audiences of two separate international clinical research conferences within the last two years agreed they had seen clinical research fraud. Most had done nothing about it.

49.3 Fraud or misconduct?

It is tempting to use the words fraud and misconduct almost interchangeably, but in most cases, they can be differentiated. In broad terms, research fraud is defined as wilful behavior that breaches the principles of good practice in research. Fraud must have an element of deliberate action: true fraud is not an accidental act.

The definition of research malpractice provided by the Wellcome Trust is a useful starting point, and it makes clear the element of intent:

‘The fabrication, falsification, plagiarism or deception in proposing, carrying out or reporting results of
research or deliberate, dangerous or negligent deviations from accepted practices in carrying out research. It includes failure to follow established protocols if this failure results in unreasonable harm or risk to humans, other vertebrates or the environment and facilitating misconduct in research by collusion in, or concealment of, such actions by others. It also includes intentional, unauthorized use, disclosure or removal of or damage to research-related property of another including apparatus, materials, writings, data, hardware or software or any other substances or devices used in or produced by the conduct of research. It does not include honest error or honest differences in the design, execution, interpretation or judgement in evaluating research methods or results, or misconduct unrelated to the research process. Similarly, it does not include poor research unless this encompasses the intention to deceive.

Another method of differentiation relates to those affected. Others are always harmed by fraud, whereas in some cases of misconduct there may be no obvious victims. Foremost among those harmed by fraud are patients or research subjects who may have received unnecessary treatment, not had full safety assessments while taking an experimental drug or been entered into a study about which they knew nothing. Patient records may have been altered to show untrue diagnoses to make them appear eligible for the study: this often remains uncorrected.

Sponsoring pharmaceutical companies are harmed if they have paid for fraudulent data that they cannot subsequently use or if a drug is delayed in gaining a licence, and the families of fraudulent doctors who lose their licence to practice when prosecuted and found guilty also suffer financially. Journal editors who unknowingly publish the fraudulent results can be harmed, as happened to Prof Geoffrey Chamberlain in the Pearce case discussed later in this chapter.

All fraud is also misconduct by definition, but misconduct *per se* is not so clear-cut. It could be accidental, for example missing the due date for patient assessments, or carelessly completing case record forms, but the point where carelessness becomes misconduct and misconduct becomes fraud is indistinct. A safety assessment might be omitted because the research team forgot about it or the research subject did not present himself or herself to the laboratory to have the blood drawn. Equally, it might be because a researcher decided not to do it because of too much work or because he decided it was not important. Serious but non-fraudulent misconduct might be the inappropriate delegation of study tasks to an inexperienced member of the study team without input or supervision from the Principal Investigator.

Distinction must be drawn between clinical research that is of poor quality and that which is fraudulent. Errors are common, represent lack of attention to detail, pressure of work and time, inadequate or overcomplicated case record forms or plain carelessness. By contrast, immaculately completed record forms may prove to be too good to be true.

### 49.4 What constitutes research fraud?

There are many types of research fraud, and this list is not exhaustive, but it is useful to consider the various categories.

#### Fabrication: the deliberate invention of research data/results, or the deliberate fabrication of laboratory analysis

An eminent UK gynecologist, Malcolm Pearce, published two papers in the British Journal of Obstetrics and Gynaecology in 1994, one claiming to have successfully reimplanted an ectopic fetus, the second being an extensive series of case studies in a syndrome so uncommon that a major referral center was seeing only one or two new cases a month. Over three years, Pearce reported on 191 women he claimed to have seen and on whom he had run a battery of complex tests, including karyotyping both the women and their partners. Pearce was an editor of the journal and the Editor in Chief, Professor Geoffrey Chamberlain, was his head of department and named as co-author of one of the papers. Chamberlain’s role in the work is not known, but he was quoted by a newspaper as...
saying, ‘The head of department’s name is always put on reports out of politeness. I was not part of this work, but I have always trusted Mr Pearce’. When the fraud was discovered, thanks only to a whistleblower, both men found their careers effectively ended.

The most commonly fabricated documents are consent forms and patient diary cards. The diary cards allegedly submitted by the patients of a general practitioner (GP) in northern England were all immaculately completed and in pristine condition. This marked them out from the cards collected from other investigational sites, which were dirty and showed signs of frequent handling. Additionally, the handwriting on all diary cards was very similar, and an idiosyncratic mark made by the investigator when he wrote was noted many times on the diary cards. The doctor was found guilty of fraud and his licence to practice medicine was withdrawn.

Falsification: the deliberate distortion or omission of undesired data/results, including the dishonest misinterpretation of results

William McBride, an Australian obstetrician, wrote a letter to the Lancet in 1961 in which he suggested that the drug Thalidomide, when given to pregnant women, was causing severe limb deformities in their babies. Nobody else had raised concerns at that time about the dangers of this drug. McBride’s hypothesis was based on limited anecdotal observations, but he was subsequently shown to be right and thalidomide was removed from the market. In 1982, he published research that showed that the active substance in Debendox, a drug for morning sickness of pregnancy, caused birth defects in rabbits. The manufacturers took the drug off the market, but no researchers could reproduce his work. It later transpired that McBride had altered research results, and Debendox had no teratogenic effects. Ten years later, McBride was found guilty of scientific fraud by a medical tribunal and removed from the Medical Register.

Manipulation of data is seen when attempts have been made to show larger differences between groups than really exist, to reduce the variability of results or to invent extra data. In a study of diabetic neuropathy, the results showed that there was significantly better pain relief with the active treatment than with placebo. However, at one site the patients worst affected by the disease all received active medication, while those least affected were apparently randomly allocated to placebo. Analysis of the patients at this site showed statistically significant improvement on the study drug, whereas analysis of the other sites excluding that one site did not. It was found that the investigator had a means of accessing the randomization code so that he could allocate the patients to what he had decided was the ‘correct’ medication, thus skewing the data to support his hypothesis.

Plagiarism: the deliberate unacknowledged presentation/exploitation of the work and ideas of others as one’s own

The culture in schools and universities seems increasingly accepting of a certain amount of plagiarism. A recent survey in the United Kingdom showed that 16% of respondents had plagiarized work more than once and that a further 9% had plagiarized once, most commonly by copying material for essays from the Internet. The detection rate was only 3%. Although not actively condoned, plagiarism is not always dealt with as firmly as one might hope. Submitting another’s essay as one’s own work may well amount to fraud, and if it seems to have been accepted, one barrier to committing further fraud has been removed. Given the low rate of detection compared with the rate of plagiarism, it would seem that there needs to be significant attention paid to the education of tomorrow’s researchers as to what constitutes good scientific and ethical behavior. This underlined by the fact that 24% of those students who replied to the survey claimed to have received no guidance as to what constituted plagiarism. Education of students and scientists as they enter their research career must, therefore, include the concept of research honesty and ethics, as well as trial design and methodology.
Deception: the deliberate concealment of a conflict of interest or inclusion of deliberately misleading statements in research funding proposals or other documents

Kimon Angelides ran a university laboratory in the United States when he was found to have intentionally falsified data in five grant applications submitted to the National Institutes of Health, seeking a total of $4 million in research funds. Initial concerns were raised by his departmental head who noticed inconsistencies in grant applications. On being investigated, Angelides conceded that elements of his grant applications were false, but attempted to deflect responsibility by accusing two members of his laboratory (a graduate student and a postdoctoral fellow) of deceiving him by providing the falsified data. Other false information, particularly those appearing in the published papers, he claimed to be matters of data interpretation or simple errors.

Recruiting and consenting patients without ethics approval

Independent ethical review of clinical research is central to the protection of the rights of patients. It can sometimes be a time-consuming process. Using modern scanners and copying equipment, it is relatively easy to produce a document that appears to be ethics committee or Institutional Review Board approval to start a study. Studies may not start without ethical approval, and funding will not be forthcoming until it is given, so time is probably the driving force behind this type of fraud.

Failure to document consent appropriately

Forged consent forms are one of the most common types of research fraud. A monitor from a Contract Research Organization (CRO) took the trouble to lay out all the patient consent forms at one site side by side. She noticed that the patients’ signatures looked similar to each other and some of the letters resembled the handwriting of one of the study team. It transpired that none of the patients involved in the study had any knowledge of being in a trial. The study involved the women taking hormone replacement therapy (HRT) over several months, with a biopsy of their uterine lining being done before and after treatment. All had been supplied with the drug from the desk drawer of their GP, but none had given consent.

Misquotation or misrepresentation of the results of other researchers

This was how William McBride achieved the material for his infamous publication. Phil Vardy was a scientist working for McBride who discovered that the results of his experiments had been falsified. When he confronted McBride, he was sacked, and had to move away from the area to get another job, losing his marriage in the process. It was five years before Vardy was persuaded to publicize the fraud.

Noncompliance: the wilful failure to comply with statutory and sponsor and professional body obligations

Investigation of one case can show several different fraudulent practices. John Anderton, an exemplary and highly respected physician in Edinburgh, came under suspicion when the trial monitor noticed that the signatures of some patients on the consent forms did not seem to match other signatures in their hospital notes. It was found that electrocardiograms (ECGs) and nuclear medicine investigations were apparently reported on forms that had gone out of use some time before the start of the study. Records had been created documenting the effects of treatment before the patients were actually treated, and there were major discrepancies between the case record forms and the letters to patients’ GPs. Hospital registers did not record patients’ attendance for many of their stated visits, some patients were listed as attending hospital on public holidays when the outpatient department was closed, and
13 visit dates coincided with the investigator’s own holiday. Some of the ECGs and X-rays had been tampered with to remove dates and patient identification. Perhaps the most damning evidence was that patients at this site showed an apparent rise in drug metabolite levels at a time point when all other sites recorded a fall, and they reported one-eighth of the number of adverse events of other sites. Anderton had his name erased from the Medical Register after being found guilty of serious professional misconduct.

**Inappropriate attribution of authorship and gifted authorship on publications**

Of all the abuses of scientific research, gift authorship is the most common and the most lightly regarded. This is nowhere better illustrated than in the Pearce/Chamberlain case described above.

**Inciting others to be involved in research misconduct**

Robert Fiddes was an eminent researcher in the United States. In a lengthy and detailed fraud running over several years he changed patient notes to show that they had a specific false condition, and instructed his study staff to buy bacteria from a commercial supplier and send it to testing laboratories under the names of patients. He used cervical smears from other sources and entered the results into the patient notes, and used blood from employees, passing it off as being from patients. He made his staff wear Holter monitors and took ECGs from them, again claiming that they were taken from patients. Despite pharmaceutical company and FDA inspections, the fraud was only recognized when a former employee blew the whistle. Fiddes was sentenced to 15 months in prison, and fined almost a million US$.

**Collusion in or concealment of research misconduct by others**

The General Medical Council (GMC), the United Kingdom’s governing body for doctors, has made it clear that a doctor’s failure to report allegations or evidence of scientific fraud and misconduct to the appropriate body, if he or she suspects research fraud, will result in that doctor also facing disciplinary action. This happened to Prof Timothy Peters, who knew that a colleague, Anjan Bannerjee, had fabricated data in a clinical trial and did not report it. Both men were found guilty of serious professional misconduct: Dr Bannerjee was suspended and Prof Peters received a severe reprimand. His punishment was less than it might have been because of his previous exemplary career and because the case was already 10 years old.

However, it is not uncommon for those who expose the wrongdoing of others in any area to experience negative consequences, despite legislation to provide a framework and protection for them. Damage to whistleblowers who act in good faith can usually be avoided, but it is essential that they are properly assessed and managed by someone experienced in the role.

Perhaps this, in part, explains why more biomedical fraud is not exposed, even though it may have been recognized. For example, it took some years before Phil Vardy reluctantly blew the whistle on McBride. He was not the only whistleblower to become a victim. Dr David Edwards was a partner in Geoffrey Fairhurst’s General Practice in the United Kingdom when he reported Fairhurst to the GMC for research misconduct. There was a long wait for a hearing, during which his marriage came under extreme stress. After the guilty verdict on Fairhurst he had graffiti sprayed on his surgery door by angry patients, and was faced with financial ruin for some time.

**Malicious unfounded accusation of misconduct against another**

It is perhaps fear of being shown to be wrong that holds many back from making allegations of research fraud. The term of whistleblower does not have a good connotation and is being widely replaced by such euphemisms as ‘Open-Practice Policy’. It is in an attempt to minimize risk both to those who report suspected fraud and to those
accused of it that all National Health Service (NHS) Trusts and universities in the United Kingdom have published clear policies on such matters.

49.5 What is being done about handling research fraud?

Given the growing concern over research misconduct, a number of organizations have proposed that universities and other research institutions should safeguard public confidence in research by formulating good research practice guidelines and laying down clear and equitable procedures for investigating allegations of research misconduct. Increasingly, funding agencies are making it a condition of eligibility for research grants that institutions have in place agreed procedures for governing good research practice. Although the principles involved are not new, the presence and use of a published code of practice is widely regarded as the best preventative measure against research misconduct. Such policies have stepwise procedures describing how to proceed, including clarifying responsibilities at each stage and stressing the need for full documentation.

The United States

The United States was the first to take a stand on the detection and prosecution of research fraud. A national body was established in 1972 to ensure that research subjects had true protection. This organization became the Office for Human Research Protections (OHRP) in 2000. The OHRP, which falls under the jurisdiction of the Department of Health and Human Services (HHS), provides guidance, education and clarification on human research subject protection. It has implemented a program to supervise compliance to the Code of Federal Regulations, the legislation surrounding clinical trials in human subjects in the United States. Importantly, the OHRP reviews investigations undertaken by institutions of cases of alleged noncompliance with the regulations and determines with those institutions the action to be taken.

The United States has a second official body overseeing research and ensuring its probity: the Office of Research Integrity (ORI), which is part of the Office of Public Health and Science (OPHS). Its purpose is to promote integrity in biomedical and behavioral research projects supported by the Public Health Service (PHS) worldwide. It monitors institutional investigations of research, helps to develop policies and provides training and support to researchers.

The FDA plays a major part in the prevention and detection of research fraud and misconduct. The FDA carries out two different types of reviews. Study-orientated audits are conducted on clinical trial data itself, in order to ensure patient eligibility, and investigator-orientated inspections can be carried out either routinely or because a sponsor has concerns. If the inspectors have reason to believe that a site has not complied with regulatory requirements or has engaged in fraudulent activity – for which the definition in the Federal Code is very similar to that of the Wellcome Trust – they have the power to disqualify the investigator from taking part in further research, or severely restrict his activities. Such findings are widely publicized both within and outside the United States on the so-called ‘Black List’.

Europe

Although European countries take research fraud and misconduct seriously, most have no official sanctions in research fraud. The first research misconduct committees in the Nordic countries date from the early 1990s. Their roles may be both preventive and investigative, but they do not, for the most part, allow sanctions to be taken; that remains in the hands of the institutions.

Finland

First was the National Research Ethics Council of Finland, founded in 1991, under the auspices of the Department of Education. It does not itself investigate research fraud, but produces guidelines for the prevention, handling and investigation of
alleged scientific dishonesty. The responsibility for investigation and actions to be taken against those found guilty remains firmly with the universities and research institutes. All such cases are reported to the Council, which gives nonlegally binding advice.

**Denmark**

Denmark has had the Danish Committee on Scientific Dishonesty since 1992, chaired by a High Court Judge. This committee was charged with investigating cases and giving a formal opinion. After 1999 the committee was split into three, only one officially covering health and medical science, but the three groups often sit together to consider cases. The committees do not have sanctions as such, but can recommend sanctions to be taken, or can decide to make a report to the police.

**Norway**

There has been a National Committee for the Evaluation of Dishonesty in Health Research in Norway since 1994, charged with preventing and investigating scientific dishonesty, based heavily on the Danish committee. The committee reports findings to the institution and the involved parties, but again leaves any sanctions up to the employers.

**Sweden**

In Sweden, the institutions conduct their own investigations, with an expert advisory group, founded in 1997 and linked to the Swedish Medical Research Council (MFR), providing guidance. It too follows the Danish model of investigations. There have been proposals recently for a central committee to take over some of the elements of the investigation.

**Germany**

The largest academic research funding agency in Germany, the Deutsche Forschungsgemeinschaft (German Research Foundation, known as DFG) formulated ‘rules of good scientific practice’ in 1999 after a major scandal in which 47 published papers came under suspicion, with the aim of advising and assisting researchers nationwide. Every institution in Germany also has its own committee to investigate and suggest actions in cases of suspected research misconduct, and the federal Länder inspectors play a supportive role. The Committee of Inquiry on Allegations of Scientific Misconduct (Ausschuss zur Untersuchung von Vorwürfen wissenschaftlichen Fehlverhaltens) investigates allegations of scientific misconduct carried out by those who receive DFG funding and members of DFG bodies involved in consultation and decision-making processes. If scientific misconduct is established, the committee’s findings are forwarded to the central steering Joint Committee with a recommendation.

**France**

The principle medical body in France established a group of experts in 1999, the Délégation à l’Intégrité Scientifique, to focus on both the prevention of research fraud and the sanctions to be taken against individuals or institutions, although there have been few official reports of fraud. There are detailed sequential procedures to be followed, and much use has been made of the experiences of other countries.

**United Kingdom**

In the United Kingdom, a Joint Consensus Conference on Misconduct in Biomedical Research was held in Edinburgh in 1999 with all major stakeholders and interested parties represented. The panel’s main conclusion was that ‘a national panel should be established – with public representation – to provide advice and assistance on request’. The suggestions for the remit of this panel included the development of models of good practice, assistance with investigation of alleged misconduct and the collection and publication of information on incidents of research fraud and misconduct. It was only in 2004 that a National Panel for Research Integrity
(NPRI) received funding in a joint venture headed by UK Universities and the Department of Health/NHS. It is hoped that it will become operational in 2005, with potentially huge benefits to patients, the pharmaceutical industry and the medical profession, although its scope is not yet defined. It is not clear whether the actual body will have a direct investigative function, which could be a real deterrent to those who might be considering fraud, or will merely be a setter of standards. Any mechanism that unified response to and actions taken against clinical research fraud would be a major step forward, and the progress toward this will be watched closely and with much interest. It is widely hoped that such a national body will restore the United Kingdom’s position as a leading country in biomedical research.

In the United Kingdom, some groups involved in biomedical research are already subject to disciplinary action by their professional bodies. Doctors answer to the GMC, the Statutory Body registering doctors to practice, charged with the responsibility of monitoring standards and protecting patients. Nurses, health visitors and midwives are responsible to the UK Central Council. Over 20 doctors in the United Kingdom have been reported to the GMC in the last 10 years. All but one were found guilty of serious professional misconduct, and most were suspended or erased from the Medical Register, thus losing their licence to practice medicine. The GMC has made it clear that it regards research fraud as extremely serious and will punish it hard. Although other countries have official channels for its investigation, more cases have been reported in the United Kingdom, but there is no reason to suppose that the incidence of fraud here differs from other countries.

There have been many criticisms of the slowness of the process of bringing doctors to the GMC to account for their activities, and accusations that the process is not sufficiently transparent.

49.6 Why commit research fraud?

This is a difficult question to answer, and there is certainly more than one answer. The creation of fraudulent data probably takes as long – if not longer – than its legitimate counterpart. Money seems to be one motivator, others being vanity or arrogance and the need to achieve publications to further career aims. Peter Jay, co-founder with Frank Wells of MedicoLegal Investigations, lists greed, need and breed as the main tempters. The first is self-explanatory, the second category includes addiction to drugs, alcohol and gambling and the third acknowledges the adrenaline buzz achieved by lying, cheating and deceiving. (The GMC recognizes that ‘need’ is better dealt with under its health procedures.)

49.7 What will be the impact of European legislation?

The European Union (EU) Clinical Trials Directive came into force in May 2004, enacted in the Member States of the EU and so enshrining good clinical practice (GCP) in law, and giving for the first time specific legal standing to research in human subjects. Under the new laws, compliance with GCP becomes a legal obligation, and providing false information to an EC or the national authority issuing authority to carry out human research, therefore, by definition becomes an offence. Although the legislation does not specifically mention the investigation and prosecution of research fraud and misconduct, it does allow the ‘Competent Authorities’ – the bodies established by each Member State to authorize clinical research – to undertake inspections of sponsors and investigational sites, thus bringing Europe more into line with the United States and the FDA. It is too early at the time of writing this chapter to see the extent of any impact that this will bring, but it is widely hoped that the presence of a statutory framework for research will reduce the incidence of fraud. Some, though, point to the higher incidence of research fraud and misconduct in the United States, who have had their Federal Regulations, very similar to Europe’s new laws, for many years. One wonders if that is because there is more fraud per se, or because there are official bodies involved with proactive powers and roles to identify and investigate it.
49.8 What can be done to prevent fraud?

Research Governance

In 2000 in the United Kingdom, the Research Governance Framework for Health and Social Care laid down standards, delivery mechanisms and monitoring requirements for all NHS research in England and Wales. The stress is on the rights and well being of study participants, but it also actively promotes good quality research, which by definition excludes fraud. It puts stress on the need for the review of research at all stages, and this is seen as being a significant potential tool in the prevention of fraud.

Publications

The editors of scientific journals, vehemently expressing their abhorrence of research and publication fraud, established the Committee on Publication Ethics (COPE) in the United Kingdom in 1997. They recommend peer review and require all named authors to sign the letter of submission, coupled with clear declarations from all parties as to conflict of interest. Such procedures would have prevented Pearce’s fraud as the paper on the reimplantation of the ectopic fetus had not undergone peer review, and the co-authors were not required to detail their involvement.

Standard operating procedures (SOPs)

Adherence to SOPs has a major protective effect in suspected research fraud and misconduct. First, it enables an organization to make clear the consequences of research fraud to the researcher at the start of the research with the intent of preventing such dishonesty. Second, it gives a framework for the reporting and subsequent investigation of potential misconduct, and consequent legal protection for those following such guidelines, especially if the finding of the investigation is that there was no misconduct.

49.9 What can be done if fraud is suspected?

In general, the role of national bodies involved in the investigation of research fraud and misconduct is merely to advise and support the relevant institutions, but it is for those institutions themselves to decide whether to take action against those found to have acted dishonestly. The situation in the United States is somewhat different; the FDA can order the closure of institutions and circulates the names of wrongdoers on their ‘Black List’. The ORI can recommend the withdrawal of Federal funding, and the French authorities, too, can take direct action.

The system for dealing with doctors suspected of research crime in the United Kingdom revolves around the GMC, which stated in 1992 that their disciplinary committee would take a very serious view of proven clinical research fraud. Since 1990, 26 doctors accused of research fraud have been reported to the GMC, all but 1 being found guilty. The penalties imposed ranged from erasure from the Medical Register, to admonishment and limitation of future research. The GMC can only investigate suspected fraud or misconduct after a formal
complaint in the form of a Statutory Declaration is made, and they have no authority to deal with nonmedical research personnel. Nurses and midwives are responsible for their behavior to the UK Central Council, and other healthcare workers have their own governing bodies.

There are potential criminal sanctions against fraudulent researchers, but these are seldom, if ever, pursued. In most countries, there is no law specifically relating to fraud. One needs to draw elements from laws relating to deception, theft, offences against the person and forgery and counterfeiting. However, the police and judiciary would find it difficult to follow the intricacies of research fraud, and as the amount of money involved is usually relatively small, might not be particularly interested in following a case through. Perhaps, more importantly, the time that it would typically take for such a case to come before a criminal or civil court would allow even more fraud to be committed, and more patients to be put at risk.

The pharmaceutical industry has been extremely active in its efforts to prevent and detect research fraud and misconduct, and most companies are now comfortable taking action when appropriate. The Association of the British Pharmaceutical Industry (ABPI) has encouraged its member companies to do so and has provided much support and encouragement. The new European Directive on clinical trials and the International Conference on Harmonization (ICH) have both aided a growing understanding and awareness of the issue, and most pharmaceutical companies now have standard procedures for handling cases of suspected fraud. The interests of the industry lie partly in protecting patients, but also in protecting and maintaining the quality and integrity of clinical research.

Many of the doctors brought before the GMC for research misconduct have been involved with more than one pharmaceutical company, and the Medical Director of the ABPI has a process to bring together two or more companies with suspicions about the same doctor to enable a joint case to be made. A similar process exists in Germany. Sadly, there are, as yet, no sanctions if a company refuses to cooperate or investigate.

### 49.10 Conclusions

Research fraud is a reality, but in the past, healthcare professionals and academia have sometimes chosen to turn a blind eye, and pharmaceutical companies tacitly condoned it by choosing not to investigate fully and to bring prosecutions. The climate now is changing, driven by all those parties, but medical research is still vulnerable in the absence of any effective mechanism to combat and detect fraud.

To pretend that fraud does not exist is to condone it. To take no action when fraud is suspected or when blatant evidence is seen is not acceptable. The most vulnerable potential victims are the patients; whichever definition of fraud is used, the fact that patients have been exploited remains. This exploitation occurs when ethics committee authorization is not sought or is forged, denying patients the protection of review of the safety and ethics of the study. It occurs when safety data are not recorded or when patients are treated with inappropriate drugs. It occurs when drugs are licensed or withdrawn from the market using fraudulent data. It occurs when there are incorrect details on their patient notes.

The eradication of research fraud will not be easy. Research Governance will be a significant step toward eradication, but only if everyone accepts the possibility for the existence of fraud and is alert to its presence. SOPs provide a framework within which it is easier to follow up suspicions of fraud and misconduct, but they only work if everyone concerned has been trained in their use and remembers to use them: their presence alone is not a safeguard against fraud. Ethics committees too have their place in the fight against fraud. Again, they need to be aware of the possibility of fraud, and need to have a mechanism whereby they can report concerns, for example, of an inappropriate number of studies running at one site.

Three elements are necessary to improve the situation. There must be official bodies in each country with real powers to investigate and prosecute clinical research fraud. There must be a widespread and unequivocal acceptance that failure to act on suspicions of fraud is itself serious misconduct. And finally there must be an
acceptance of the application of the same rules, no matter who sponsors research, whether it be industry or academia.

Most clinical researchers, like most members of the public, are honest. However, to pretend that clinical research fraud and misconduct do not exist is to allow bad medicine, bad science and, above all, abuse of patients.

References


Fabrication, falsification, plagiarism, or other practices that seriously deviate from those that are commonly accepted within the scientific community for proposing, conducting, or reporting research’ (42 CFR 50.102).


Supplement 7: Joint Consensus Conference on Misconduct in Biomedical Research, Edinburgh Royal College of Physicians; 2000.
SECTION VIII
Business Aspects

Introduction

Contrary to popular opinion, governments and health services develop almost no drugs and discover very few. In the developed world, almost all of the therapeutic advances of the last half-century have been the result of the efforts of the pharmaceutical industry. This is actually also true in the underdeveloped parts of the world, although public health measures in those regions may also have greater scope for improving the human condition.

So how does the pharmaceutical industry do it? Compared with, say, the car manufacturing industry, drugs have long development cycles, huge development costs, high project failure rates, intense regulation, high compliance costs, shortened periods of patent exploitation, government-enforced price controls, numerous competitors and great product liability issues when a product does make it to the marketplace. This set of conditions is highly unattractive for an industry that might want to borrow money and attract investors.

And so, it becomes a fact of life for large pharmaceutical companies that they must fund their research and development activities themselves. Not only that, but one way or another, they must also fund development candidates that emerge from small pharmaceutical or biotechnology companies, too. The latter cannot afford phase III studies, and would find it impossible to recruit a sales force.

But research and develop we must. If we do not, then this industry will wither approximately at the rate of appearance of generic products. Such a withered industry will bring to an end almost all progress in medicine.

This section therefore concentrates on the financial aspects of pharmaceutical medicine. This may be an unattractive subject to the idealists. But Churchill once said: ‘Democracy is the worst form of government, except for all those other forms that have been tried from time to time’ (House of Commons, 11 November 1947). Perhaps we should replace the words democracy and government with the terms private enterprise and medical progress, respectively.
50.1 Cultural challenges

‘Culture’ has been defined as the ‘totality of socially transmitted behavior patterns, arts, beliefs, institutions and all other products of human work and thought typical of a population or community at a given time’ (Webster’s Dictionary, 1984). With respect to the multinational pharmaceutical corporation, culture can be thought of at three levels: (a) societal; (b) medical; and (c) corporate. At each level, culture has an omnipresent impact on drug development, prior to and after regulatory approval. Sensitivity to cultural considerations will help identify, conceive, present and respond to issues in drug development. It may also help to identify sources of competitive advantage.

Societal culture

Societal culture describes those attributes of culture pervading a population or community inhabiting a given geographical area. Individuals from the same societal culture share common values. A multinational corporation has to deal with many societal cultures, even, sometimes, within a single nation. Differences in societal culture will result in different responses to key issues. Table 50.1 indicates a range of culturally determined responses to important questions.

One can apply the concepts in this table to the pharmaceutical industry, for example, to management practices originating from one culture being applied in a different cultural setting. For example, companies in the United States tend to use control systems that exert more checks and balances on personnel than do European companies (a habit that may have historical origins in a Christian, non-conformist set of traditions emphasizing a belief that all people are intrinsically evil). Similarly, companies with development programs involving contraceptive drugs have sometimes aroused criticisms among their personnel, depending on country, religious background and personal beliefs.

Other cross-cultural differences revolve around the distinction between group goal seeking and individual goal seeking. Group goals are emphasized by those who see a lineal relationship of man to man as important; this contrasts with to those cultures of an individualistic disposition that emphasize individual goals (Japan versus the United States is a clear example of this dichotomy). Concern for the welfare of the extended family might result in the hiring of a close relative in one culture, but cause accusations of nepotism in another.
Medical culture

Differing perceptions of health and disease by patients, healthcare providers, and governing and regulatory bodies are the primary elements of medical culture (Riphagen, 1992). Aspects of medical culture of particular importance to the pharmaceutical industry are those affecting drug development, approval and marketing, including those that may determine whether a drug should have prescription or over-the-counter status. Other aspects of concern are the type of healthcare funding favored by a particular culture – private insurance or public funding through taxation.

An attempted convergence of medical cultures is currently under way in the area of drug development and regulatory approval, under the auspices of the International Committee on Harmonization (ICH). Note that this regulatory harmonization will probably have no influence whatsoever on increasing the uniformity of prescribing behavior. Convergent thinking is also seen in a worldwide effort to control healthcare expenditure. The various cost-cutting approaches have included

- decreased reimbursement for medicines;
- delisting of medicines from reimbursement lists;
- encouragement to parallel trade;
- control of overall company profitability;
- drug formularies;
- encouragement of generic substitution;
- encouragement of therapeutic substitution;
- assignment of pharmaceutical budgets to institutions and individuals.

Despite the prima facie attraction of cultural convergence in medicine, there are not only major differences in the incidence and prevalence of many diseases between countries but also in expectations of these different cultural groups of patients. Even in a relatively homogeneous region such as Western Europe, the incidence of adverse drug reactions to a standard therapy varies dramatically from country to country. The perception of

<table>
<thead>
<tr>
<th>What is the character of human nature?</th>
<th>Cultural approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is the relationship of man to nature?</td>
<td>Man is evil</td>
</tr>
<tr>
<td>What is the temporal focus of life?</td>
<td>Man is subject to nature</td>
</tr>
<tr>
<td>What is the modality of man’s activities?</td>
<td>Activity that gives spontaneous expression to impulse and desires</td>
</tr>
<tr>
<td>What is the relationship of man to man?</td>
<td>Lineal – group goals are primary and an important goal is continuity through time</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cultural approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>Man is evil</td>
</tr>
<tr>
<td>Man is a mixture of good and evil</td>
</tr>
<tr>
<td>Man is good</td>
</tr>
<tr>
<td>Man is in harmony with nature</td>
</tr>
<tr>
<td>Man is master of nature</td>
</tr>
<tr>
<td>Activity that emphasizes as a goal the development of all aspects of the self</td>
</tr>
<tr>
<td>Activity that is motivated primarily toward measurable accomplishments</td>
</tr>
<tr>
<td>Collateral – group goals are primary. Well-regulated continuity of group relationships through time</td>
</tr>
<tr>
<td>Individual – the individual goals are most important (modified from Kluckhohn and Strodtbeck, 1961)</td>
</tr>
</tbody>
</table>
the nature and significance of given disease states varies by country, and the trigger to seek professional assistance also varies. The ensuing doctor–patient relationships reflect not only the national medical culture but also broader societal culture in such practical matters as the patient’s ‘right to know’, freedom of information, tendency to litigation for malpractice and so on.

**Corporate culture**

In any company, the corporate culture permeates every aspect of the company’s activities, affecting promotion prospects, risk propensity, and individual and group behaviors.

The principal concern of the multinational corporation is the extent to which corporate culture conflicts or fits in with the societal and medical culture(s) in each country where the company operates. Corporate culture is evidenced by shared values about the conduct of business, and may be strong or weak.

The most successful corporate culture is one that can foster leadership that is responsive to potential conflict arising in multinational operations from cultural diversity. Organizations with such a culture express a clear vision that is understood and supported internationally. Such organizations benefit from an alignment of business values among employees worldwide, despite varied national and cultural backgrounds. Procter and Gamble is an example of a strong corporate culture that successfully crosses business and geographical boundaries.

Complexities can also arise when a multinational pharmaceutical company engages the services of another organization, such as a multinational contract research organization (CRO), with potentially different corporate cultures. In each country where the two multinationals collaborate, there is a need to reconcile their corporate cultures, while simultaneously being responsive to local societal and medical cultural considerations.

**Languages**

A multinational corporation necessarily conducts its business in many different languages, presenting challenges of internal and external communications. Companies with a weak corporate culture are paradoxically more likely to cause local tensions by insisting on a rigid mode of operation. Companies with a strong corporate culture are more likely to operate according to local cultural norms under the guidance of local management. For example, the ‘or not’, as in ‘would you like a drink or not’ can be regarded as aggressive when spoken in English in England, and yet is intended as a courtesy, indicating that the questioner is truly not trying to influence your decision, when spoken in English in Singapore.

**Societal, medical and corporate culture interplay**

Figure 50.1 depicts how the cultural responsiveness of a company in a given country is determined by the overlap of its corporate culture with local societal and medical cultures. The more that the circle corresponding with corporate culture overlaps those of societal and medical culture, the more the area available for culturally appropriate behavior is increased. Figure 50.1 also provides a framework for comparing central with national or subnational medical culture.
peripheral control of national affiliates. There are many determinants of the balance between the two. However, if a corporate culture is dissonant with the societal and medical cultural imperatives of a subsidiary or affiliate organization, yet is imposed upon that organization because of a policy of ‘centralization’, then a suboptimal outcome is likely. Conversely, a strong, responsive corporate culture that is consonant with local societal and medical values increases the likelihood of success.

A locally responsive corporate culture favors neither centralization nor decentralization – this will depend on many other considerations (e.g. size of operations, in-country management capability, etc.). However, it facilitates an appropriate devolution of managerial power, which might otherwise be difficult or even impossible. The challenge to the multinational corporation, therefore, is to have a strong corporate culture that is compatible with diverse societal and medical cultures.

50.2 The legal/regulatory framework for drug development in Europe and the United States

The International Conference on Harmonization (ICH) document General Considerations for Clinical Trials, seeks to do the following:

- Describe the internationally accepted principles and practices in the conduct of both individual clinical trials and the overall development strategy for new medicinal products.

- Facilitate the evaluation and acceptance of foreign clinical trial data by promoting common understanding of general principles and approaches, and also the definition of relevant terms.

- Present an overview of the ICH clinical safety and efficacy documents and facilitate the user’s access to guidance pertinent to clinical trials within these documents.

In Western Europe, in spite of the Clinical Trials Directive, there is still no uniformity in the order of approval/submission of documentation by the various parties involved. For example, although all countries now require review and approval of phase I clinical protocols, in some countries, approval of a study by the local or national ethics committee is required before documentation is submitted to the competent national authorities, whereas in others, this order is reversed. The documentation that is required to be submitted to the authorities is also quite variable (Table 50.2). Some countries require brief summaries of available information, whereas others require detailed information on the preclinical, pharmacy, chemistry and other clinical data to be submitted.

All European countries require, in common with the United States, and in conformity with the Declaration of Helsinki, that ethics committees (the European version of institutional review boards in the United States) review protocols from phase I–IV and the general conduct of trials outside the formal protocol document. However, there is wide variation in Europe as to how this procedure is enacted. In countries such as France, Spain and Germany, there is a national system of ethics committees that duplicate similar work at a local level. In the United Kingdom, there are a wide variety of ethics committees, such as commercial committees, those set up by the Royal College of Physicians, and those run by local area health authorities or hospital trusts.

Local medical and societal cultural factors impact on the ethics committee approvals, so that a study that is considered to be ethical in one country may be regarded as unethical in another. Examples of this may be the unacceptability of the use of placebo control in depression studies in Germany, whereas similar studies would be permitted elsewhere. Similarly, the common practice of extensive blood sampling in Belgium, especially in pediatric studies, would be regarded as excessive and hence unethical in other countries.

In the Central and Eastern Region (CEE) of Europe, the clinical trials approval system continues to evolve rapidly. In general, the regulations are converging towards the EU model of submission and approval, but local practices make
interpretation at the national level a necessity for the expedient approval of any clinical trial project or program.

Even insurance practices exhibit cross-cultural differences. The EU guidelines for patient protection lay down that there should be ‘sufficient’ insurance provision. However, some countries have taken this requirement a step further by laying down the actual sums for which individual patients, or, in the case of Germany, the total number of patients, must be covered. In the United States, patients and volunteers are in general insured by the institution in which the study is conducted; the fees for this are not directly reimbursed by the sponsor but form part of the overall study cost.

Apart from the administrative burdens and the financial implications of insurance, timing of the approval process is of the essence. There are wide variations from country to country, which depend not only on the approval times from the competent authorities but also on the ethical committee approval times.

The IND application system in the United States is often seen as more problematic for companies than the EU system. However, if the United States is a potential market for the product under investigation, there can be significant advantages to conducting studies under an IND, in parallel perhaps with other studies in Europe. An IND application is required in the United States before any new medicinal product may be introduced into humans, or before any established product is used in an experimental or novel way. This applies not only to a commercial sponsor but also to an independent physician wishing to conduct experimental therapy for his/her own purposes. In the United States, an IND application must be accompanied by a completed form FDA 1571, which consists of a number of sections:

- Table of contents
- Introductory statement
- General investigational plan
- Clinical investigator’s brochure
- Protocol(s):
  - Study protocol
  - Facilities data
  - Investigator data
  - Ethical committee data

Table 50.2  European requirements for submissions to competent authorities to obtain clearance for initiation of clinical trials

<table>
<thead>
<tr>
<th>Country</th>
<th>Protocol and supporting documents</th>
<th>EC (IRB) approval</th>
<th>Insurance certificate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>×</td>
<td>×</td>
<td>×</td>
</tr>
<tr>
<td>Denmark</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>×</td>
<td>×</td>
<td>×</td>
</tr>
<tr>
<td>Germany</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>Ireland</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>The Netherlands</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>×</td>
<td>×</td>
<td>×</td>
</tr>
<tr>
<td>Portugal</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
<tr>
<td>UK</td>
<td>×</td>
<td>×</td>
<td></td>
</tr>
</tbody>
</table>
Unlike in Europe, the US IND generally requires the submission of full-length study reports whether of clinical or preclinical studies, together with relevant summaries to guide the reviewer through the document. Although the writing involved in the preparation of an IND may be regarded as onerous, because the FDA reviewing staff views the 1571 form as a totality, its preparation should not be regarded as a routine exercise. Rather, it should be an occasion for a critical internal appraisal of the data available and how they support the proposed protocol. Clearly, this is how the FDA views the document. The FDA peer review is thus not just an administrative hurdle to be jumped but also is often a useful, confidential third-party review of the drug development program, and once studies have received IND approval, further protocols can be added with little trouble. Of course, the IND lays down responsibilities for sponsors, which include minimum reporting times for adverse events and completion of qualification forms for investigators, and so on. These steps add to the administrative load of the clinical drug development process. It is generally thought that it would be a bold company that submitted a NDA to the FDA without the FDA’s prior involvement via an IND. However, this has been done successfully in the past and will probably occur again.

A very important cultural difference between Europe and the United States, that impacts on drug development, is indirectly expressed at the stage when the regulatory authority examines the final submitted dossier. In the United States, the FDA adopts a bottom-up stance, in which it looks at the basic raw data and sees what conclusions can be drawn from it, using its own criteria for analysis and interpretation. In Europe, the authorities tend to take the opposite approach: they look at the conclusions of all the studies, as manifested in the proposed labeling, patient leaflets and summary of product information, and examining to what extent the data presented justify those conclusions. In Europe, considerable importance is placed on the role of independent experts, whose critical reports on the various sections of the dossier provide a sort of vade mecum for the reviewer. It is vitally important to understand in detail that the expert report required in Europe is not the same as the integrated summary required by the FDA.

In drug development, therefore, significant differences exist on a country-by-country basis in Europe as well as, to a far lesser extent, on a state-by-state basis in the United States. These differences manifest themselves not only in the legal/regulatory framework but also in the commercial practices that surround the conduct of clinical trials by licensed medical practitioners.

50.3 The medico-commercial environment in the United States and Europe

One of the major differences between the United States and Europe, as regards the conduct of clinical trials, is the financing of medical care in the two regions. Throughout Europe, medical care is largely funded by governments. In the United States, with some exceptions such as the State of California and in the case of military veterans nationwide, medical care is largely funded through private insurance, generally paid by a person’s employer. Coverage for many of those less able to pay, such as the indigent and the elderly, is provided by the government through the Medicare and Medicaid programs. Military veterans are eligible for medical treatment through the VA program. For patients without ready access to medical care, participation in a clinical trial may provide needed medical care.

CROs and site management organizations (SMOs) are organizations that run clinical trials, using physicians who are full-time, part-time or contract employees. The companies employ regulatory staff, for IRB filing, adverse event notification and so on, as well as site coordinators,
nurses and quality control personnel. SMOs might also recruit patients on behalf of their doctors, either from databases built up over the years, or by press and radio/TV advertising, and even by direct telemarketing. Nonphysician staff do initial screening of potential subjects on the telephone and in face-to-face interviews. Most SMOs exist in conventional treatment centers; others treat only patients who are enrolled into clinical studies, and have no other role than to run clinical trials, rather in the same way as phase I units.

The advantages for the sponsor are several: recruitment by sites is rapid, they are used to dealing with IRBs, monitoring is straightforward, the quality of data is good and the general service is cost-effective. For the patient, there is free medical care and medication, together with ‘compensation’ for inconvenience, which can add up to an appreciable sum ($500+).

Some hospital units in Europe have recently become more commercially minded and have set themselves up as profit centers within their own hospitals. As financial pressures increase, with the increased cost of medical technology and the unfavorable demographics of an aging population, we would expect more hospitals to go along this route.

This leads to one other clinical development arena that does appear different between the United States and Europe: clinical pharmacology. Europe has a long tradition of high-class, highly scientific clinical pharmacology. This has led to the setting up of a significant number of independent companies, which have been spun-off from, or were formed in association with, departments of clinical pharmacology in hospitals. Such units routinely carry out studies involving first administration to humans, rising dose tolerance, pharmacodynamics and sophisticated pharmacokinetics. In the United States, such studies are more likely to be carried out in the university hospitals themselves, with the phase I CROs, generally not associated with hospitals, carrying out the more routine bioequivalence and bioavailability work.

Differences in societal and medical cultures thus impact significantly on the development of novel drugs. The ICH process has, to a major extent, harmonized requirements but cannot and will not of itself influence how the data to fulfill these requirements are generated and collected. For the foreseeable future, the United States will be seen as the more prescriptive, litigious society – suspicious of the results, building conclusions from the evidence. Europe, in so far as it can be regarded as a unity, even today, has yet to accept the ever-present lawyer in all public contexts, so that to the American observer it will continue to look laissez-faire and superficial in its regulation of drug development.

References and resources

The process of developing a new pharmaceutical product incurs both significant costs and risks. On average, only 1 in 5000 pharmaceutical products tested is eventually approved for patient use, and only 3 out of 10 approved drugs in the United States generate enough revenue to meet or exceed average research and development (R&D) costs, currently estimated at $800 million to $1.7 billion per product (Certified Medical Representatives Institute, 2002; Mullin, 2004). The average lead time between patenting a new chemical entity and achieving approval for marketing is 12 years, but patent protection is only 20 years post-filing, typically leaving only 8 years of exclusive marketing to recoup the R&D costs. Furthermore, extending patent duration does not guarantee reduced competition as 90% of patented drugs have direct competitors (Australian Academy of Science, 1995).

Pharmaceutical companies in the United States spent $24 billion developing and testing new drugs in 2000, equivalent to about 21% of sales, and twice as much as computer software companies (Matthews, 2001). However, only 17 new drugs were introduced across the industry in 2002, compared to 53 in 1996, making it even more crucial that maximal sales are achieved for each new product. Marketing of older drugs under new names and indications is becoming more common as new drugs in the pipeline become less prevalent (Vogenberg, 2003). In the past six years, it has been claimed that 78% of ‘new’ drugs were classified by the FDA as being no better than those already in the market and in 60% there were no new active ingredients (Paukstis, www.amfar.org).

In 2000, 48.2% of the world pharmaceutical sales were in the United States, 16.2% in Japan, 23.7% in Europe, 6% in Latin America and 5.9% in Africa, Asia and Australia (Oxfam/Save the Children/VSA Joint Report, 2002). Unlike many industries, the pharmaceutical market is very fragmented. In the developed world, there are at least 390 pharmaceutical manufacturers, and no single pharmaceutical company has more than 8% of the overall market (Matthews, 2001).

This investment in R&D can only be turned to profit if sales of the new product are maximized, and that requires a successful marketing strategy. The efficiency of this process must be all the greater when there are exceptionally long development cycles, an absence of market dominance, high product–failure rates and unpredictable, staccato advances in technology.
51.2 What is marketing?

Marketing is a process of identifying the needs, wants and demands of customers and organizing the creation, offering and exchange of ideas, products and services of value to both the customer and the organization (James, 2004). Marketing requires a clear and specific focus on the market and the customer, so that promotional activity can be tailored as appropriately as possible to each customer group or segment. Marketing is ubiquitous, pervasive and extremely competitive in all industries. In most developed countries, the average person is exposed to 2000–3000 promotional messages a day (James, 2004).

51.3 Pharmaceuticals are different from other products

The pharmaceutical industry differs from other industries in that in many cases a third party (or ‘learned intermediary’) is responsible directly for the purchasing decision (prescribing) and indirectly for payment to the supplier. The prescriber chooses the drug and its quantity, subject in varying degree to audit by the dispensing pharmacist, who may point out drug interactions, and encourage alternative brands or generic equivalents of what was prescribed. Pharmaceutical wholesalers prefer to purchase from cheap suppliers. The organizations ultimately responsible for paying are governments, via state health providers such as the National Health Service in the United Kingdom, or insurers, whether federal (such as Medicaid and Medicare) or private in the United States (Kanavos, 2001). This all combines to provide a complex market facing increasing cost-containment restrictions globally.

There are other unique facets of the pharmaceutical market. Pharmaceuticals are seen as life-saving interventions, therefore, infinitely desirable, but with potentially serious side effects, leading to ethical dilemmas about their widespread use. This is particularly the case for antibiotics, where overuse leads to bacterial resistance. They can also be perceived as a tool for the unscrupulous manipulation of prescribers and patients by the multinational pharmaceutical industry.

There are strict laws to control quality of the products, and most countries have a national formulary in which all products must be included on if they are to be prescribed in that country. Advertising of products by brand name to the final consumer – the patient – is prohibited in all countries except the United States and New Zealand, and may well soon cease in the latter (James, 2004).

The pharmaceutical industry aims to produce effective drugs, but it needs to do this while meeting its main objective of profitability in a competitive environment. This can lead to an uneasy conflict with governments which are trying to contain costs of healthcare, in particular, of prescribing costs, even though these typically account for only about 10–15% of the entire healthcare budget. The relationship between the pharmaceutical industry, government and the NHS in the United Kingdom has been fairly stable, but initiatives such as the National Institute for Clinical Excellence (NICE), established in 1999 to promote cost-effective practice and prescribing, threaten this balance (Walley et al., 2000).

All European Union (EU) governments have taken measures to contain pharmaceutical spending, although so far with only minor, brief effect (European Pharmaceutical Research, 1997). These measures include promotion of innovative medicines which add therapeutic or cost-effective benefits, more effective prescribing and greater use of generic drugs where appropriate (EU Pharmaceuticals and Public Health in the EU, 2000). The World Health Organization also actively encourages development of drug policies based on the promotion of generic medicines. Competition among chemically different but therapeutically similar patented drugs can also reduce the prices of patented products, for example the price of antiretroviral products fell by 73% in five years once a number of products were available (WHO Medicines Strategy, 2000–2003). In the United Kingdom, the average NHS price of a generic prescription is £3.78 and that of a branded prescription is £13.04. In the United States, patented products cost three times as much on average as those for generics (Oxfam).
Despite this, the market is growing rapidly. Overall, in EU states, the proportion of total health-care costs accounted for by outpatient drug costs rose from 13.3% in 1980 to 15.3% in 1999 (Martikainen, 2002), a faster increase than overall health spending.

The pharmaceutical market is also very competitive. In England in 2003, almost 650 million prescription items were dispensed in the community, with a total net ingredient cost of over £7.5 billion (PCA, 2003). However, there were 390 pharmaceutical manufacturers competing for a share in this market (BNF 48, 2004).

### 51.4 Product versus brand

The pharmaceutical industry relies on patent laws to maximize its income from a new product (see above). However, patents were a late addition to pharmaceutical industry regulations, with many European countries only permitting patent protection after their industries had reached a degree of development – France in 1960, Germany in 1968, Japan in 1976, Switzerland in 1977 and Italy and Sweden in 1978 (Oxfam Briefing Paper, 2001).

Generic drugs were introduced in the 1980s, as cheap equivalents to branded drugs that outlived their patent protection. The R&D costs for generic products are much lower than for the original branded products, and unit production costs are very low. This means that once patent protection ceases and generic versions are in the market, sales of the more expensive branded product tend to fall. Pharmaceutical companies need strategies to cope with this limited time span of patent protection (Certified Medical Representatives Institute, 2002).

One strategy to deal with the competition from cheap generic drugs is to promote the concept of brand rather than product. Branding was originally used to denote product purity by the early pharmaceutical companies, in much the same way as other industries did (e.g. soaps). The term ‘Brand equity’ refers to the unique set of assets linked to the brand name, which adds value to the product and gives customers a reason to prescribe and use them. The brand is now seen as the only tangible unit of value in the pharmaceutical company and its greatest asset. Brands are also highly significant to patients as something in which to trust and of importance to their health (James, 2004).

Positioning is the process of establishing a brand in the mind of the target consumer so that the brand is seen to meet their needs. The attributes of the product are compared to the requirements of the consumer. Market leaders often show ideal positioning, when the product attributes are unique and highly relevant to customers (James, 2004).

### 51.5 The customers

Although the ultimate consumers of the product are the patients, customers include anyone who can make a decision about prescribing, spending money on or taking a drug, and as such each group requires a different marketing strategy (James, 2004).

Prescribers can be classed according to how rapidly they change their practice when faced with information about a new product. Those most willing to try something new are known as innovators or ‘early adopters’, and they generally account for 15% of the group. The next third are termed the ‘early majority’, followed by another third of the ‘late majority’, with the last 16% willing to change commonly, being called ‘laggards’ (James, 2004).

### 51.6 The product life cycle

Rapid penetration strategies around the launch of a new product tend to target early adopters and early majority prescribers. The next phase of the drug life cycle, the growth phase, is aimed at increasing perception of value and loyalty among users and recruiting new customers from nonusers. During the maturity phase the only new prescribers are laggards, and sales begin to fall due to new competitors and brand saturation. Finally, the product loses its patent, which usually results in a significant drop in sales (James, 2004).
51.7 Regulations regarding marketing of prescription drugs

The United States and Canada

The Food and Drug Administration (FDA) has regulated advertising of prescription drugs in the United States since 1962 under the Federal Food, Drug and Cosmetic Act and related regulations. Advertising for other products, including over-the-counter (OTC) products, is controlled by the Federal Trade Commission under different rules. It is the FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) which enforces these regulations and oversees promotional labeling and advertising of prescription drugs (Rados, 2004).

In the United States, direct-to-consumer (DTC) advertising of prescription drugs by brand name is permitted, but controlled by regulations to make sure that all information is accurate, balanced, with details of possible side effects as well as statements of benefits that could be expected. Details of how to access more detailed information must also be provided (US Department of Health and Human Services, 1999). The recent withdrawal for safety reasons of rofecoxib, which had been heavily promoted using DTC advertising in the United States, will probably increase scrutiny of this practice by those who regulate it. Meanwhile, Canada has banned DTC advertising of prescription drugs since 1949; nonetheless, most Canadians live quite close to the US border, and can view US television and radio advertisements (Palumbo and Mullins, 2002).

The United Kingdom and Europe

Medicines cannot be promoted in the United Kingdom until they have been granted marketing authorization from the UK Medicines Control Agency or the European Medicines Evaluation Agency. There are three categories of licensed medicines available in the United Kingdom: prescription-only (POM), pharmacy sale (P) and general sales medicines (GSL). The position of a medicine in one of these categories is on the decision of the Health Ministers on the advice of the Medicines Control Agency, the Committee on the Safety of Medicines and the Medicines Commission, based on the product’s possible use, any side effects and risk of its misuse. POMs and certain pharmacy sales medicines must not be promoted to the general public, but can be marketed to the medical profession. The Association of the British Pharmaceutical Industry (ABPI) Code of Practice regulates promotional activities (Association of the British Pharmaceutical Industry, 2001).

DTC advertising is prohibited within the EU, but is seen as inevitable to some extent anyway due to international access to the Internet and digital television (’t Hoen, 2003). This prohibition is to the extent that medical journals bearing drug advertisements on their covers cannot be mailed in see-through bags unless such advertisements are obscured with additional pieces of paper inside the wrapper.

International patent laws

Patent laws have recently been updated internationally via the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement. Adopted in 2001, this sets out minimal standards for the protection of intellectual property rights, which now lasts for at least 20 years from filing. The problem of developing countries being unable to afford necessary drugs, especially for HIV/AIDS, was addressed by the clause allowing countries to make or import generic versions of drugs under compulsory licensing, where the country’s own pharmaceutical industry is allowed to manufacture generic versions of essential drugs still protected by patent, or parallel trade, where branded drugs made more cheaply in other countries are imported at lower cost (’t Hoen, 2003).

51.8 Marketing budgets

In the United States in 1998, the pharmaceutical industry spent $12 724 million on promotion. Of this

- 86% was spent on the top 250 drugs,
- 52% was spent on the top 50 drugs,
$6602 million was spent on free drug samples to physicians,

$3537 million was spent on office promotion,

$1337 million was spent on DTC advertising (see below),

$705 million was spent on hospital promotion,

$540 million was spent on advertising in medical journals (Ma et al., 2003).

In 2001, this had increased to an expenditure of $20,000 per physician (Engler, 2003). Pfizer reported spending almost $2.9 billion on advertising in 2001, while Bristol-Myers-Squibb spent more than $1.4 billion on advertising and promotion with an additional $3.9 billion on marketing, selling and administration. Merck increased sales staff by 1000 in the United States alone in 2001, with 85% of its 78,000 employees engaged in non-research activities. Brand name drug manufacturers in the United States employed 81% more people in marketing than in research in 2001 (Families USA, 2002).

As in all business, 20% of the brands, 20% of the customers and 20% of the marketing activities generate 80% of the profit. Marketing and selling now typically takes up to 40% of sales revenue (James, 2004).

Strategies

For any product, there is a range of approaches for marketing. The most successful strategies are coordinated and clearly focused on the target audience and brand values.

Marketing strategy is the broad idea of how a company’s strengths are used to achieve its objectives and how to allocate resources to best meet sales targets. Understanding how the product compared favorably with its competitors, in terms of efficacy, safety, convenience or cost, is crucial. Increasingly, new products are modifications of older ones, in pursuit of greater efficacy or fewer side effects. However, selling branded products on the basis of cost is progressively more difficult with increased use of generics and cost-effectiveness strategies by prescribers. Pharmaceutical companies now tend to either use a highly focused clinical strategy showing the unique features of their brand which give it value to prescribers, or develop a unique set of conditions around a brand such as continuing medical education (CME) support or research funding, in order to create brand loyalty (James, 2004).

Strong marketing strategies target real segments of the potential market which have similar needs. The brand is promoted to these customers in a way that is designed to maximize its strengths and minimize its weaknesses. Prediction of the future market and uniqueness of approach are ways to beat the competition (Pharmaceutical Marketing Live, www.pmlive.com).

Marketing strategies have traditionally been built around the following four Ps:

- **Product** – development of the brand concept, plus other services associated with the brand such as diagnostic, monitoring, drug delivery and education support.
- **Price** – the only element to generate revenue, the crucial engine of market success and driver of profitability.
- **Place** – activities to ensure that the product is easily available and assessable to customers, including distribution channels and discount systems.
- **Promotion** – communicating customer benefits and building brand reputation and trust from customers (James, 2004).

Additionally, two new Ps are also relevant:

- **Political relationships** with organizations responsible for payment
- **Patients** – who have increasing economic input into their care and access to information (James, 2004)

Many pharmaceutical companies have weak marketing strategies (Pharmaceutical Marketing...
Live, www.pmlive.com). This is partly due to a desire not to limit the market by 'niche-ing' the product. Larger markets are easier to enter, but are also subject to more fierce competition, and co-marketing of one product by two or more pharmaceutical companies is an approach used more frequently. Marketing capability is largely based on the size of the sales force, which has been increasing since the early 1990s, but has now probably reached a size that is subject to the laws of diminishing returns. This drives a need for alternative approaches, such as online marketing.

One study of marketing activities for a branded drug in the United States found that marketing efforts generated 22% of prescriptions. Of this, television generated 12% details (sales people visiting prescribers) and face-to-face contacts generated 6%, print generated 3% and online activities 1%. Online activities accounted for 3% of total media expenses but generated 7% of marketing-driven prescriptions and was more responsive than TV or print; online costs are estimated at $11.33 per incremental prescription, compared with $17.12 for television adverts and $13.33 for print (DoubleClick Media Mix, www.doubleclick.net).

The range of marketing strategies is large, and includes

- advertisements to prescribers in medical journals and other publications;
- detailing to prescribers (face-to-face visits);
- free samples and gifts to prescribers;
- medical education activities for prescribers;
- DTC advertising to patients via general publications, radio and television;
- disease awareness campaigns, targeted at patients;
- Internet sites, targeting patients and prescribers;
- contributions to patient support groups;
- other activities.

### 51.9 Advertisements in medical journals

Advertising can be considered to be any representation by any means whatever for the purpose of promoting directly or indirectly the sale or disposal of any food, drug, cosmetic or device. Promotion of a drug prior to market authorization is not permitted as the proposed indications have not yet been verified (Health Canada, 2000).

Advertising should be undertaken when it provides the kind of reach and presence among existing and potential customers that other promotional options cannot do. Advertising can be used to project a brand in the market, to reward and encourage customers, to establish a presence and to give a personality or attitude to a brand. The campaign should be designed around the available marketing budget and needs a good, simple idea if it is to stand out from other messages and information (Pharmaceutical Marketing Live, www.pmlive.com).

Many medical journals rely on advertising to survive and sometimes this gives pharmaceutical companies a degree of influence over editorial content. US studies have shown that more frequent exposure of prescribers to advertisements heightened product and message awareness and increased prescriptions, as well as increased confidence in the claims made by the advertisements (Vitry, 1996). However, a UK study failed to show a clear association between extent of advertising and subsequent prescribing by GPs (Jones et al., 1999). This may in part be due to a perception that claims made in drug advertisements may be misleading (Villanueva et al., 2003).

GPs are increasingly using computers for accounting, prescribing and medical records, and screen advertising is an alternative to print. However, care must be taken that patients do not have access to the advertisements in countries where DTC advertising is prohibited (Nolan, 2000).

### 51.10 Detailing to prescribers

Face-to-face contact between pharmaceutical representatives and prescribers has long been the
backbone of marketing and has taken the bulk of marketing budgets. Attitudes to representatives vary from individual to individual. Pharmaceutical sales representatives have incentives to be overly positive when discussing their products with prescribers as they are interested in selling drugs not providing information (Rubin, forthcoming). It is estimated that 30–60% of GPs in the United Kingdom do not see representatives regularly or frequently, and those who do see representatives give them only a few minutes to promote their products. However, while rep numbers increased by 40% and their overall cost by 70%, face-to-face contacts increased by only 13% between 1994 and 2002 in the United Kingdom (Pharmaceutical Marketing Live, www.pmlivw.com). GPs in the United Kingdom who do see drug representatives perceive these visits as a good way of accessing new drug information quickly, and many feel they have the necessary skills to appraise the information provided (Prosser and Walley, 2003).

A US study found that pharmaceutical representatives thought certain services they offered were valued more by target physicians than did the physicians themselves, in particular product detailing, provision of research details, expert consultant role and recruiting physicians to participate in FDA approval drug studies. Physicians only valued free product samples and promotional meals as much as drug representatives did (Gaedeke et al., 1999).

51.11 Free samples and gifts

Standard marketing practice internationally includes samples, gifts, printed information and invitations in contact with prescribers, based on the principle of reciprocity to influence prescribing (Roughead et al., 1998). Giving prescribers free samples of drugs for their own use or to pass on to patients is a more common practice in the United States, where more patients have to purchase their medication at cost price than in the United Kingdom. Free sample availability has been shown to influence prescribing habits in the United States (Boltri et al., 2002).

The practice of giving free gifts to prescribers may also be viewed with suspicion by doctors and patients, and is subjected to regulation. A survey of psychiatrists in Canada in the 1990s found that they had received a median of one personal meeting, ten lunches, two promotional items and one drug sample in the past year, with a median value of gifts received of $20. Fewer than half of the doctors thought they would maintain the current contact levels with drug representatives if they did not receive promotional gifts. The more money and promotional items received, the more likely they were to believe that this did not influence their prescribing (Hodges, 1995). A survey of hospital doctors in the United States found that even those who thought that sponsored lunches and pens were inappropriate gifts had accepted such items. 61% of doctors thought that industry promotions and contacts did not influence their own prescribing, but only 16% thought that the prescribing of others was equally unaffected (Steiman et al., 2001).

51.12 Direct-to-consumer advertising

DTC advertising is the promotion of prescription medicines to the general public. The United States is now the only OECD countries which allow DTC promotion (see below). However, de facto DTC advertising may occur in other countries such as in advertisements about a specific disease or condition which does not include a drug name but bears a pharmaceutical company logo or name (Vitry, 2004).

DTC advertising of the modern type began in the United States in 1981 with an ibuprofen product, available at the time by prescription only, being advertised in a consumer-oriented magazine. Other manufacturers followed, leading to a moratorium from 1983 to 1985 imposed by the FDA. It was then decided that there was no evidence that DTC advertising was endangering consumers and the practice was allowed to continue without specific focused regulation. The first television DTC advertisement appeared in 1997 (Lee, 2001).
There are three types of DTC advertisements:

- Advertisements for specific prescription drugs are subject to strict regulations in the United States. They must contain a summary of risks and benefits, as well as detailing how customers can access more information about the drug. They must be fair and balanced, with no false or misleading information, and must not omit material facts.

- Disease awareness advertisements, which do not mention a specific drug, are not regulated by the FDA.

- Reminder advertisements, which just give the name of the product but not its uses, do not have to include risk information (Rados, 2004).

DTC advertising expenditure has been increasing sharply in the United States, with almost $2.5 billion spent in 2000, three times the level spent in 1996. However, this accounted for only 15% of all drug promotion (Rosenthal et al., 2002). Of this, 60% was spent on television, 37% on print and 3% on billboards and other media advertisements. Use of DTC advertising varies from one pharmaceutical company to another. In the first quarter of 2000, both Merck and the former GlaxoWellcome spent more on DTC than on professional advertising, while Eli Lilly and Novartis both spent less than one-tenth as much on DTC as professional promotion (Matthews, 2001).

DTC advertising is very effective. A study of the effects of DTC advertising in the United States concluded that a 10% increase in DTC spending would be expected to yield a 1% increase in sales of drugs in that class. The figures for 1999–2000 show that an estimated 12% of the growth in total prescription drug spending at that time was attributable to DTC advertising, a yield of an additional $4.20 in sales for every dollar spent on DTC advertising. This makes DTC an important, but not the major, driver of recent growth in drug sales (Kaiser Family Foundation, 2003). Proponents of DTC advertising claim that, although it can encourage more drug consumption, this can lead to overall cost cutting if it means that other, more expensive treatments are not needed later (Matthews, 2001).

In contrast, most physicians in the United States have negative feelings about DTC advertising, especially feeling that they do not provide enough information on cost, alternative treatment options or side effects. More than half thought DTC advertisements increased consultation length and encouraged patients to ask for specific medication, and only 29% thought they could be a positive trend in healthcare (Robinson et al., 2004).

Within the EU, member states are prohibited from allowing the advertising to the general public of medicinal products that are available on prescription only, and may prohibit such advertising where the product is eligible for reimbursement. However, OTC products may be advertised generally (European Commission, 2000). Despite this, it is possible to get a marketing message across to the public in other ways. The majority of people in the United Kingdom come into contact with 19 health stories each week, via the media, internet, mobile phones, celebrity gossip and in public places, as well as from advertising for other products such as foods. In addition, patients in the United Kingdom can be targeted legitimately by public relations activities, disease area advertising and patient support programs (Pharmaceutical Marketing Live, www.pmlive.com). The Medicines and Healthcare Products Regulatory Agency (MHRA) lifted some regulations in August 2003 to permit promotion of medicines such as cardiovascular disease prevention products such as statins (Pharmaceutical Marketing Live, www.pmlive.com).

### 51.13 Disease awareness campaigns (DACs)

While DTC advertisements are not permitted in most countries, DACs are legal on the basis that they advance public health. In the United Kingdom, MCA guidelines state that DACs must be aimed at increasing awareness of a disease and to provide health education information on the disease and its management. It must not be used to promote or stimulate public demand for the use of a particular product or to encourage patients to...
Contact their doctors to ask for specific medication. Treatment options can be discussed as long as patients are not encouraged to ask for one of these in particular. DACs should raise awareness of symptoms and risk factors, to encourage early diagnosis and treatment and to minimize progression and complications of the disease (Pharmaceutical Marketing Live, www.pmlive.com).

DACs can be successful when the company can capture a major share of the increased prescribing market, such as where there are few competing treatment options, or where a change in prescribing practice can be caused by tackling consumer inertia. This second approach is less likely to lead to increased sales. Customers can be motivated to respond to a campaign if they believe they are susceptible, that the disease might be serious and that it can be prevented. Mild fear can arouse interest, but too much fear may lead to denial (Pharmaceutical Marketing Live, www.pmlive.com).

### 51.14 Internet marketing

The Internet can provide the in-depth content seen in print advertising, the real-time impact of television, the immediate response of direct mail and the mass reach of outdoor advertising (Randle, 2003). It is estimated that about 25% of online information is related to health, over 50% of adults who use the Internet use it for healthcare information and a quarter of patients who go to disease-specific websites ask their doctors for a specific brand of medication in the United States (Matthews, 2001).

Online marketing includes:

- search engine optimization, where companies leverage search engine listings;
- V-detailing: most widely used in the United Kingdom, the GP views a content-rich interactive presentation on a condition and treatment;
- live-remote detailing: a real-time online interaction with a company representative;
- direct links to pharmaceutical companies’ websites and systems;
- messaging to GPs’ handheld computers (Pharmaceutical Marketing Live, www.pmlive.com; Worah and Bimbrahw).

The use of e-marketing in the pharmaceutical industry is still in its infancy and is subject to increasing regulations. E-detailing is used widely in the United States and increasingly in Europe, to provide doctors with secure online medical and product information. In 2001, six pharmaceutical companies out of 40 in the United States and 19 products out of 94 represented 80% of online advertising expenditure (Worah and Bimbrahw).

The Internet has been shown to be three times as effective as TV and six times as effective as print in reaching and maintaining target audiences (Estafanous, www.estomedical.com). GPs can spend 11–12 min in reviewing an e-detail, and 70% of GPs receive these at home. 80% of GPs say they would be prepared to alter their prescribing of a product following an e-detail. A US study showed doctors who received an e-detail as well as traditional promotional materials increased the market share of the product by 1% overall, with an increase in sales of $40 million and return on investment of 480% (Pharmaceutical Marketing Live, www.pmlive.com).

Internet-based campaigns now often run side by side with other media which can be used to promote websites. However, certain groups still have restricted access, so conventional approaches are still needed (Randle, 2003). Web sites may need to be different for prescribers and the public, with content checked constantly to make sure the information is current, complete and free of conflicts.
All communications need to be consistent with the overall marketing message, however. Web sites can also be used to coordinate activities prior to launch and ensure rapid spread of up-to-date materials and messages (Estafanous, www.estcomedical.com).

### 51.15 Patient support groups

Many pharmaceutical companies provide funding for patient groups, either without specifying what they money should be used for, or to sponsor a specific product for which the company has no direct involvement. The ABPI Code of Practice reflects UK and EU legislation which prohibits pharmaceutical companies from undertaking or sponsoring any activity, deemed to be promoting a prescription-only product to the public. Patient groups are independent voluntary organizations which usually prefer not to be controlled by a sponsor, but at the same time, they are charities which need to raise funds from a wide funding base. Companies must not sponsor any activity by patient groups that would breach the ABPI Code if they were to do so directly, and all funding arrangements must be transparent (Association of the British Pharmaceutical Industry, 2004).

### 51.16 Medical education activities

Pharmaceutical companies can become involved with medical education activities via sponsored meetings and conferences, as well as paying for the authorship of reference texts and peer-reviewed journal articles.

In the United States, activities performed by, or on behalf of, pharmaceutical companies which market relevant products are subject to FDA regulation, whereas activities supported by pharmaceutical companies but delivered by agencies otherwise independent from pharmaceutical industry promotional influences are not. This is so that constraints on advertising and labeling do not restrict freedom of speech of participants in scientific and educational activities, such as discussion about unapproved uses, which cannot occur in directly sponsored, promotional activities. However, it can be difficult to determine where the line is between these two levels of involvement of sponsors, especially when the industry has been taking a growing role in CME activities (US Department of Health and Human Services, 1997).

The Pri-Med 2004 CME Insight survey of US physicians found that 22% of doctors see industry sponsorship of CME as a good thing and 64% see it as essential to making CME events accessible and available. Almost three-quarters of primary care physicians surveyed were unwilling to pay more than $100 in fees to attend a CME event, and fewer than one-third would pay $1000(http://12.130.8.166/live/images/other/CME_Insight_Report_41504.pdf). In the United States, the evidence-based medicine movement has set up the ‘No Free Lunch’ campaign to point out the hidden marketing message in this sort of pharmaceutical marketing (Mason, 2003).

### 51.17 Other marketing strategies

Pharmaceutical companies are beginning to look to sports sponsorship to promote their products, such as Viagra (Major league baseball), Levitra (National football league) and Cialis (Professional Golf Association matches) in the United States. This is useful where a positive brand image associated with masculinity, speed, strength and youth is to be promoted (Colyer, www.brandchannel.com).

### 51.18 Monitoring the marketing strategy

Marketing campaigns need clear goals and targets and must be evaluated to determine their return on investment (ROI). Targets should be SMART (specific, measurable, achievable, realistic and timely). It has been suggested that 10% of the total budget be set aside for evaluation of the campaign. The findings must then be used to steer future campaigns (Pharmaceutical Marketing Live, www.pmlive.com).
51.19 Summary

Pharmaceutical products are a special category of merchandise, both due to exceptional business risks in development and the need for highly educated intermediaries to ensure their proper use. The marketing of pharmaceutical products is, rightly, highly regulated. Nonetheless, the efficient marketing of pharmaceutical products is crucial for the financial viability of the research-based pharmaceutical industry, without whose profits innovation will cease, albeit at the financial cost of their marketing practices.

References

Oxfam. Fatal side effects: medicine patents under the microscope.
Oxfam/Save the Children/VSO joint report. 2002. Beyond philanthropy: the pharmaceutical industry,
corporate social responsibility and the developing world.


Paukstis E. Crunching the numbers on pharmaceutical companies. www.amfar.org.


The objective of this chapter is to survey Asia and The Middle East, which actually comprises multiple different environments, and consider how these affect the practice of pharmaceutical medicine. The specific problems are related to fundamental differences from the West: culture, economics and epidemiology.

Medicine is a cultural activity that varies from country to country. The cultural context in which drugs are used varies among cultures. This is true in the Western world (e.g. the use of low-dose digoxin for cardiac asthenia in Germany), let alone in the East, where therapeutics may include, for example, natural products prescribed by alternative practitioners.

These regions are also different from, for example, the ICH territories, in that the economic resources that can be deployed to healthcare and drug purchases are limited. Factors which commonly encourage investment in the West (availability of skilled manpower, strong patent protections, highly developed drug distribution systems, socialized medical systems, private medical systems and affluent populations) are typically absent here. Yet, there are many physicians in these countries who may fairly be described as being pharmaceutical physicians. How does their environment cause their practice to differ from that in the West?

Many patients in the tropics have diseases that are familiar to Western-trained physicians, but it is the epidemiology that is often different. Comparing the AIDS populations in Los Angeles and Eastern Africa is an obvious example. Different practices in antiviral therapy prescription, distribution and drug pricing thus emerge in the two environments. Thus, pharmaceutical medicine becomes governed by epidemiology. Incidentally, and contrary to the assertions of some journalists and their editors, the pharmaceutical industry has made great and unprofitable efforts to increase such drug supplies to Africa. This is in spite of the fact that epidemics are typically halted by public health measures, not by antibiotics.

The range of pathology may be different when it is related to climate: it is for this reason that American and European universities have, for a long time, established schools and departments of tropical medicine. Probably the area of infectious disease is the best example, and malaria one of the clearest examples within the group. If pathology is specific to a region, then clinical trials almost always have to be conducted in those same geographical areas.
One real patient brings all these factors together. A middle-aged man in Nepal has had a diagnosis of pulmonary tuberculosis for about four years. He supports his family by subsistence farming. There are no telephones, and he walks about 10 miles for an unscheduled clinic appointment when his breathlessness interferes too much with his work. At each clinic appointment his pleural effusions are drained (thus improving his breathlessness, which he appreciates), and a small supply of antibiotics is prescribed, probably with little effect (at best) because he cannot afford to pay for the prescriptions that he has been given, even if rifampicin is in stock locally. He cannot be admitted to hospital for more intensive treatment: he has no adult children to help him in the fields, and his family would starve. How can the practice of pharmaceutical medicine adapt to this sort of environment?

52.1 Pharmaceutical business in the People’s Republic of China

Currently, the Chinese economy is the world’s third largest and is heading very rapidly to overtake Japan and the United States. Indeed, most observers strongly believe that, if China can hold its course, it may surpass the American economy to become the biggest in the world and become the greatest economy in history.

In the year 2025, China’s population will reach 1.6 billion, compared with United States’ 307 million and Japan’s 128 million. China’s overall growth rate is now 14%, and the province of Guangdong has even reached the highest growth rate in the world at approximately 28–30%. Foreign investment in China increased 17% from January to September 1993, which indicates investor confidence in the future of China’s economy. Greater China (People’s Republic of China + Hong Kong + Taiwan) imports in the year 2002, according to the World Bank’s prediction, will be $639 billion compared with $521 billion for Japan. GNP for China is expected to be $9.8 trillion compared to $9.7 trillion for the United States.

China offers a unique business opportunity for pharmaceutical and healthcare companies, including those involved in diagnostics and biotechnology. The following is a summary of the demographic and healthcare situation in China (statistics from China–Britain Trade Group, 1993).

- China has a population of 1.306 billion (CIA website, 2005).
- China has more than 2 million beds in more than 67 000 hospitals and 1.6 million medical doctors, major potential purchasers of medical goods and products.
- China is opening its economy to foreign investment and moving toward rejoining GATT, and was recently approved as one of United States’ ‘most favored nations for importation taxation’.
- China was admitted in to the World Trade Organization in December 2002.
- The pharmaceutical and medical market of China is growing very quickly. The size of China’s pharmaceutical market in 1992 excluding bulk drugs and traditional Chinese medicines, was ¥ 19.3 billion and $3.5 billion at the official 1992 exchange rate. This reflects overall growth of 92 and 30%, respectively, compared to five years previously. The pharmaceutical market grew by 30% in 1993–1994 to $10 billion.
- The liberalization of trade in China has facilitated negotiation and sales for foreign companies, leading to increases in sales volume.
- Chinese exports in 1991 were $72 billion; imports were $62 billion.
- The huge size of China’s healthcare system means that demands for imports of medical equipment and pharmaceuticals will continue. China has 200 000 medical centers and institutions, including 67 000 hospitals.
• These hospitals are potential customers. The US Department of Commerce estimated that the Chinese medical import market would be worth $1.1 billion by 1996. All agree that growth in the sector is approaching 25% a year; the lion’s share, an estimated 80%, is controlled by the United States, Germany and Japan. Each large hospital gets an annual global budget of foreign exchange to purchase supplies directly.

• There is no shortage of money to purchase new medical supplies. The state now allocates an estimated RMB 5 billion on the nation’s hospitals.

• Pharmaceutical joint ventures started in 1980 with China Otsuka Pharmaceutical Company (see Table 52.1).

• Spotty application of Intellectual Property Protection is still a concern now in 2006.

Clinical trials in China

All prescription-only medicines (POMs) must be subjected to local clinical studies prior to local marketing approval. Exceptions are rarely granted, even for ‘breakthrough’ drugs. This applies even to cough and cold remedies normally available without prescription in the rest of the world.

There is a system for applying for an IND certificate that allows study of medicines previously unregistered in China, and also a marketing authorization (NDA) process for a drug which is known in the country and which an individual company wishes to market. Applications for an IND are

<table>
<thead>
<tr>
<th>Year operational</th>
<th>Pharmaceutical plant</th>
</tr>
</thead>
<tbody>
<tr>
<td>1980</td>
<td>China Otsuka Pharmaceutical Company</td>
</tr>
<tr>
<td>1982</td>
<td>Sino-American Shanghai Squibb Pharmaceutical Ltd</td>
</tr>
<tr>
<td>1982</td>
<td>Sino-Swedish Pharmaceutical Corporation</td>
</tr>
<tr>
<td>1984</td>
<td>Tianjin Smithkline and French Laboratories</td>
</tr>
<tr>
<td>1985</td>
<td>Xian Janssen Pharmaceutical Co. Ltd</td>
</tr>
<tr>
<td>1987</td>
<td>Beijing Zhongrui Ciba–Geigy Pharmaceutical Co. Ltd</td>
</tr>
<tr>
<td>1987</td>
<td>Novarit and Beijing Zizhn Pharmaceuticals</td>
</tr>
<tr>
<td>1989</td>
<td>Chongqin Glaxo Pharmaceuticals Ltd</td>
</tr>
<tr>
<td>1989</td>
<td>Pfizer Pharmaceuticals Ltd</td>
</tr>
<tr>
<td>1991</td>
<td>Xian Jensen</td>
</tr>
<tr>
<td>1992</td>
<td>Second Ciba plant – joint venture with Beijing Pharmaceutical Factory No. 3</td>
</tr>
<tr>
<td>1993–1994</td>
<td>Merck Vaccines Plant</td>
</tr>
<tr>
<td>1994</td>
<td>Chugai – joint venture with Shanghai Xin Xing Medicine and Drug Development Centre</td>
</tr>
<tr>
<td>1994</td>
<td>Tanabe – joint venture with Tianjin Lisheng Pharmaceutical Factory</td>
</tr>
<tr>
<td>1994</td>
<td>Shanghai Pharmaceuticals and Schering Plough</td>
</tr>
<tr>
<td>1994</td>
<td>Second Otsuka Plant</td>
</tr>
<tr>
<td>1996</td>
<td>Takeda – joint venture with Lisheng Pharmaceutical Factory</td>
</tr>
<tr>
<td>1996</td>
<td>Upjohn – joint venture with Suzhou Pharmaceutical Factory No. 4</td>
</tr>
<tr>
<td>1995</td>
<td>Ranbaxy</td>
</tr>
<tr>
<td>1995</td>
<td>Hoechst and Huabei Pharmaceutical Factory</td>
</tr>
<tr>
<td>1995</td>
<td>Roche and Shanghai Sun Ve Pharmaceutical Corporation</td>
</tr>
<tr>
<td>1995</td>
<td>Zeneca</td>
</tr>
<tr>
<td>1995</td>
<td>HMR with Huabei Pharmol and Shanghai Int. Pharm Ltd</td>
</tr>
<tr>
<td>2002</td>
<td>Baxter and Xi Anlibang</td>
</tr>
</tbody>
</table>

From China Economic Review (May 1994).
made at both provincial and national level, and approval must be granted by both to be able to proceed to clinical studies. There is some rivalry between provincial and national bodies, and plans agreed with one may not be acceptable by the other. Applications may be made in any of the provinces and also in Beijing, Shanghai and Tianjin, cities that are considered ‘provinces’ for many administrative purposes.

**Requirements for authorization of clinical trials**

According to the provisions for an NDA, clinical studies on a new medicinal product in China are classified into two categories: clinical trials and clinical verification.

Clinical trials are divided into three phases. A phase I trial is carried out with 10–30 subjects, mostly healthy adults and a few appropriate patients, all on a voluntary basis, to find out the optimum dosage and route of administration. Early phase II trials are carried out as comparative studies, using double-blind methodology. Late phase II trials are carried out at medical institutions (not less than three) and more than 300 patients should be included and validated. Immediately after the new medicinal product has been approved by the Health Authorities for provisional production, phase III clinical trials should be carried out to conduct a community investigation and evaluation of the product.

Clinical studies in China may only be carried out after an application with supporting data, partly equivalent to those for a marketing authorization in many other countries, and are approved by the Bureau of Drug Policy and Administration, Ministry of Public Health. The application must be in accordance with the provisions of the Rules Governing the Approval of Clinical Trial of Foreign Drugs, and the studies must be conducted in compliance with these rules.

Within 30 days of approval of a clinical trial application, the medical institution in charge must submit a detailed clinical trial protocol to the Bureau of Drug Policy and Administration, with copies to the central Committee of Drug Evaluation and the regional Bureau of Public Health concerned. If no opinion on the draft protocol is expressed by the Bureau of Drug Policy and Administration after 40 days, the medical institution may start the clinical trial.

Clinical trials on new medicinal products in class 1, 2 or 3 are required to be approved by the central Bureau (see Table 52.2). Clinical verifications, mainly for products in classes 4 and 5, may be approved by a local Health Bureau.

There are 31 medical institutions designated as clinical pharmacology centers. Medical institutions are designated by the Authorities to conduct clinical trials on a new product, but the applicant may propose the name of the institute(s) to be involved in the studies. The requisite range of studies on a foreign product may vary, depending on its status in foreign countries.

In the case of a foreign product filed by a foreign applicant, the Bureau designates a coordinating agent, who may negotiate and sign the contract on behalf of the institutions performing the clinical studies with the foreign applicant and collaborate with the Bureau (IFPMA Compendium, 1994). The data that should be submitted to the Registration Authorities for a foreign therapeutic agents are as follows:

- Protocol for the clinical trial
- GMP Certificate
- Registration status of the drug in the country of origin or in other countries

**Table 52.2 Chinese classification of Western drugs**

| Class 1 | NCE not registered anywhere in the world |
| Class 2 | NCE for the first filing in China but registered elsewhere |
| Class 3 | Compound and fixed dose combination products |
| Class 4 | NCEs previously registered for import into China |
| Class 5 | Registered products for which a new indication is sought |
• Technical file re: quality control, manufacturing procedures, preclinical and clinical studies

The clinical investigator should receive the following data:

• Therapeutic indication, dosage and how the product is used.

• Pharmacodynamic and toxicological studies.

• The name of the person responsible and the place of the archives.

• Suspected adverse drug reactions (ADRs) and symptoms of intoxication.

• Sponsor’s name.

• Investigators in charge of preclinical studies.

Good clinical practice (GCP) guidelines are published and should be adhered to. Normal precautions should be applied to protect the safety and health of test subjects throughout the trial, with provision for emergency treatment and effective treatment against possible adverse reactions.

Chinese clinicians have the same competencies as any elsewhere in the world, but possibly few have any experience of working to GCP standards, and the administrators of hospitals are also not familiar with the concept. Thus, much time and energy needs to be directed at the training of investigators and those with power to ‘sell’ the concept of source data verification, and such a task must be done by a Chinese speaker because of the subtlety of the alphabet and the risk of misunderstanding.

All the provinces should hold equal sway in terms of their suitability for conducting studies, but Beijing and Shanghai have the greatest ‘value’ (see Table 52.3). Beijing, as the capital, has strategic influence, and Shanghai is comparatively wealthy and has value for pricing purposes. The latter is crucial, as the pricing granted at the time of licensing is the price that will remain in place during the selling period of the drug. Price increases are not allowed at all.

Table 52.3  Clinical trials in China – value of provinces

<table>
<thead>
<tr>
<th>Province</th>
<th>Influence</th>
<th>Cost Limit</th>
<th>Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beijing</td>
<td>Carries enormous influence over the rest of the country</td>
<td>Tends to set higher cost limits, thus is crucial from a reimbursement point of view</td>
<td></td>
</tr>
<tr>
<td>Shanghai</td>
<td>Has fiscal value</td>
<td>Tends to set higher cost limits, thus is crucial from a reimbursement point of view</td>
<td></td>
</tr>
<tr>
<td>Tianjin</td>
<td>Convenient for Beijing, but has little direct influence</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All 16 + 3 provinces (Beijing, Shanghai and Tianjin are also treated as provinces) should have equal influence, however.

Beijing carries enormous influence over the rest of the country, thus is a frequently chosen city.

Shanghai has fiscal value; tends to set higher cost limits, thus is crucial from a reimbursement point of view.

Tianjin is convenient for Beijing, but has little direct influence, although it has several excellent academic centers.

\[a\] Source: Dr David Blowers.

Approval of medicines (Table 52.4) is a two-stage, two-level process for both IND and NDA. Local approval is by the Bureau of Public Health and national approval is by the Ministry of Public Health (MOPH) for an IND. Within the body the recommendation for approval (Scientist Review) of Pharmaceutical new drugs, generic and over-the-counter (OTC) medicines is undertaken by the Center for Drug Evaluation (CDE). The Bureau must see pharmaceutical, chemistry, stability data, summaries of preclinical data and of clinical data to date. Full registration files will not be reviewed, even if available. The documents must be in Chinese. The Bureau will have views about the choice of study type(s) and also the investigators who should be used. They also like to attend investigator meetings, often unannounced, and can derail the progress of the meeting. They may well have views about the studies which differ from those expressed by the Ministry, and care must be taken to satisfy both groups. Patience, negotiation and compromise are some of the skills to be used in the meetings. They are open for discussion/negotiation, and time spent at this stage is well worth the effort.

Table 52.4  Approval of medicines in China

<table>
<thead>
<tr>
<th>Process</th>
<th>Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two-stage, two-level process for both IND and NDA, that is, approval to investigate and approval to market</td>
<td>Bureau of Public Health at regional level</td>
</tr>
<tr>
<td></td>
<td>Ministry of Public Health at national level</td>
</tr>
</tbody>
</table>

\[a\] Source: Dr David Blowers.
The Ministry meets only three times each year, thus
timing is critical if documents are to be reviewed
with optimal timing. The Ministry insist on seeing
all classes 1, 2 and 3 INDs, that is, all NCEs not
registered elsewhere in the world, NCEs new to
China, and any combination products. They also
review all NDAs (Tables 52.5 and 52.6) and the
Minister must issue approval for marketing. The
activities of the Ministry (Table 52.7) are some-
what secretive, and they are generally mistrusting
of company data, especially data analysis, often
seeking another review to ensure the quality of the
submitted data. The Ministry is mistrusting of the
independence of its own experts and provides them
with little lead time to review dossiers. It is often
the case that documents are only provided the night
before the meeting. In addition, decisions taken at
the provincial level may be overridden suddenly,
without explanation.

Table 52.5  IND review process – Bureau of Public
Health

| Wants: pharmaceuticals, chemistry, stability (some),   |
| that is, summary preclinical data, clinical data to   |
| date. NB full registration file will not be reviewed, |
| even if available elsewhere                            |
| May well have views about the type of studies and the |
| ‘best’ investigators – they may decide where the      |
| clinical trial is conducted                           |
| Wants a say in final study design                    |
| Likes to attend investigator meetings (usually      |
| unannounced)                                         |
| Often takes a different view to the Ministry of      |
| Public Health (e.g. comparators or placebo control)  |
| Potentially open for discussion/influence             |

Table 52.6  IND review process – companies

| Submit clinical proposals, including protocols       |
| Protocols sent to key opinion leaders for review,   |
| then to Bureau of Public Health, and to investigators|
| for clearance                                       |
| All centers endeavor to follow GCP, but monitoring  |
| is a problem                                        |
| Clinical records are not readily available          |
| Trained staff are few and far between               |

| Meets only three times/year                          |
| Needs several weeks’ lead time                      |
| Must see all classes 1, 2 and 3 INDs               |
| Must see all NDAs                                   |
| Rather secretive                                    |
| Does not trust company data analysis                |
| Does not trust the independence of its own experts  |
| Often reverses decisions taken by the provinces     |

*Class 1, NCE not registered anywhere in the world; Class 2, NCE registered somewhere; Class 3, combination products.

There are a few other minor issues that need to be
borne in mind about studies in China. For example,
adverse events are not dealt with in the same way as
in Europe. Complaints are often made by the
patient direct to the company (an obvious breach
of GCP regulations regarding anonymity of data),
and staff feel honor bound to offer some compen-
sation to the complainant, to save ‘face’ for the
company, even if there is limited merit in the
complaint. The recompense offered is usually a
small amount of money (for inconvenience
caused), medicine (to speed recovery) and some
food (to facilitate healing). This presents a night-
mare of assumed liability, but is very much the
norm in China.

Monitoring of clinical trials

External communications have improved immea-
surably over the last five years, but internally things
are not perfect. Monitoring is potentially a problem
unless there are staff located near to study centers,
and data retrieval from remote sites can be difficult.

Data entry and statistical analysis

There is a dearth of trained staff for either of these
tasks in China at present, and many companies
either ship data in bulk back to a central processing
unit or may transfer a team to China on a project-
specific basis. Both methods have their associated
problems, and the cost of the second option can be
considerable.
Dr David Blowers, an international pharmaceutical physician who has conducted and monitored clinical trials and studies exclusively in China, feels that:

- China is a land of opportunity;
- studies are necessary and are possible to reasonable standards;
- the rewards are probably worth the risks.

For a summary of information on clinical trials in China, see Tables 52.8–52.10.

**Table 52.8** Summary of the general information on clinical trials in China

<table>
<thead>
<tr>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Total number are normally 10–30 subjects (healthy volunteers)</td>
</tr>
</tbody>
</table>
| II    | 300 patients. This is divided into two stages:  
  First stage: to assess the efficacy, indications and adverse reactions of the new therapeutic agents  
  Second stage: similar to first stage, except increase in the number of cases and increase in the number of units where the clinical trial takes place to not less than three |
| III   | Post-marketing surveillance, i.e. ADRs and evaluate continued efficacy of the drug  
  Up to 2000 patients may be requested as a post-marketing commitment. |

**Useful addresses in relation to clinical trials and registration**

Bureau of Drug Policy and Administration, Ministry of Public Health, No. 44 Houhai Beiyuan, Beijing, China [Tel.: +86 (1) 401 2873; Fax: +86 (1) 401 2870].  
Address for documentation: Laws and Regulations, Bureau of Drugs Policy and Administration, Ministry of Public Health, No. 44 Houhai Beiyuan, Beijing, China [Tel.: +86 (1) 401 2873; Fax: +86 (1) 401 2870].

**Application data for clinical study**

**Documentation of general information**

- Name and related information
- Purpose of and reason for the selection
- Current state of research on new drug or a review of its production and usage

**Chemical and pharmaceutical documentation**

- Structure or composition
- Method of preparation
- Control of starting materials and related information

**Table 52.9** Clinical verification

Number of patients should not be less than 100  
Objective is the comparison of the new drug with an established drug by comparing the efficacy and ADRs

**Table 52.10** Clinical study requirements (No. of Patients)

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Study drug</th>
<th>Control</th>
<th>Total cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>300</td>
<td>300</td>
<td>600</td>
</tr>
<tr>
<td>2</td>
<td>300</td>
<td>300</td>
<td>600</td>
</tr>
<tr>
<td>3</td>
<td>100</td>
<td>100</td>
<td>200</td>
</tr>
<tr>
<td>4</td>
<td>100</td>
<td>100</td>
<td>200</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>100</td>
<td>200</td>
</tr>
</tbody>
</table>

*aPost-marketing surveillance requested up to 2000 patients.*
• Control of drug substance
• Control of the dosage for clinical use, with authentic specimens as reference control
• Stability (the first test)

**Toxicological and pharmacological documentation**

• Single-dose toxicity
• Repeated-dose toxicity
• Local toxicity
• Reproduction studies
• Mutagenicity
• Carcinogenicity
• Drug dependence

**Pharmacodynamics and general pharmacology**

**Pharmacokinetics**

• Impact of each ingredient on efficacy or toxicity of the combination product, where applicable

**Samples**

• Samples for clinical trials and its analytical report
• Clinical trial protocols and a review on pharmacodynamic and toxicological studies to be sent to clinical investigators

**Application data for manufacturing approval**

**Clinical documentation**

• Stability under ambient and severe conditions and expiry data where applicable
• Quality standards for production
• Clinical pharmacokinetics
• Bioavailability and a summary

**Special particulars**

• *Dosage form:* Packaging material, labeling material and draft package insert (PI).

• *Samples:* Sample for clinical trials, and three to five batches produced in succession, and their analytical data. Authentic specimens as reference or control (IFPMA Compendium, 1994).

**Producer information**

All medical products must be labeled on the container, giving the following detailed instructions:

• Name and strength of product
• Name of manufacturer
• Serial number of application data
• Lot number
• Active ingredients
• Therapeutic indications
• Usage
• Dosage
• Contraindications
• Side effects and ADRs
• Warnings and precautions
Summary of product characteristics (SPC), data sheet and PI

PIs should be included in each package. The draft leaflet, prepared by the medical profession, is required to be submitted to the authorities as part of the application data. The following information has to be included:

- Name
- Structural and molecular formulae
- Composition
- Pharmacodynamics and indications
- Directions and dosage
- Adverse reactions and side effects
- Contraindications
- Precautions and warnings
- Package quantities and strength
- Storage conditions
- Expiry date, marked clearly

Samples

There are no legal requirements regarding samples for the medical profession in government or private practices.

Pharmacovigilance, post-marketing surveillance and ADRs reporting

All pharmaceutical manufacturers and medical institutions are required by law to report any serious ADRs to the Bureau of Drug Policy and Administration or to regional competent authorities. There are central and regional ADR Monitoring Centres associated with the central and regional Health Bureaux. University/college hospitals and major medical institutions designated by the central and regional governments are obliged to conduct ADR reporting. The central Committee of Drug Evaluation undertakes the assessment of ADR reports. Actions and measures are taken by the Bureau.

Price controls

There is some government control over the price of drugs for domestic products. Pharmaceutical manufacturers may negotiate with the regional price agency concerned, based on a full-cost principle. Imported drugs are free in principle, but are worked out by the Bureau of Commodity Prices of China (BCPC) and the State Pharmaceutical Administration of China (SPAC). In 1991, the SPAC set up a national imported drug pricing balance group.

Reimbursement and health

The Medicare systems in China are as follows: government-paid medical service for state functionaries and university/college students; labor insurance medical service for employees of industrial, communication and other enterprises; and various forms adopted on a voluntary basis for rural populations. Under the reforms of the healthcare system proposed by the Ministry of Public Health, co-payments were introduced in 10 provinces and cities for employees of state-owned institutions and enterprises to pay for part of their treatment, including drugs (IFPMA Compendium, 1994). Approval of drugs can be revoked after two years if no part of manufacture occurs in China (usually packaging).

52.2 India – new opportunities

When Queen Victoria was proclaimed Empress of India in 1877, India was regarded as ‘the jewel in the Imperial Crown’. India was granted independence in 1947, and was divided into East and West Pakistan (the latter became the Independent State of Bangladesh), and the central larger land mass
was redesignated 'India', all this on religious majority divisions.

To India's north lie the fierce peoples of the Himalayan nations and the disputed territories of Jammu and Kashmir. To its south the Island nation of Sri Lanka (Ceylon) and the Maldives Islands.

India is only one third the size of the United States but has a population nearly four times as large, 1.05 billion people. It is made up of many peoples and cultures, and currently over 200 languages or dialects are spoken. The unifying language of English has become the language of Government, Science, Law and Medicine. The population is still growing at 1.8% each year, despite a low life expectancy of 51.4 years. It also has a high infant mortality rate of 90 deaths per 1000 live births.

Clinical abilities and opportunities

India has over 600,000 medical physicians, its thought leaders and key specialists have nearly all received their specialist training in Britain, Canada or United States. Most have been involved in research and are able to conduct clinical studies to a research standard, albeit supplemented by GCP training.

The major diseases are now AIDS and still TB and malaria, in addition, 8–10 million people are HIV positive. Among other disease prevalence, 8 million epileptics, 5 million rheumatoid patients, 34 million diabetics and despite the low life expectancy, 1.5 million patients are diagnosed with Alzheimer’s disease. As with other emerging nations, 15% suffer from hypertension and 2 million from cardiac-related diseases. Clearly a country with a large medical need and plentiful candidates for new medicine research, even of 'western' diseases (40 million asthmatics).

The health services in India have a centralized administrative structure (Figure 52.1) with the Drug Controller General of India DCGI under the Ministry of Health for Clinical Trials and Imported Clinical Materials. Although export of biological samples, which included bloods, tissues plasma assay material must be also approved by the

---

Figure 52.1 Multi-ministry role of clinical trial licenses
Ministry of Commerce. A further fragmentation occurs for Biological Recombinant DNA drug clinical trials which are processed through the Review Committee for Genetic Material, under the joint responsibility of the Ministry of Science and Technology and the Ministry of the Environment (Figure 52.2).

The Indian regulations for drugs and biologics

The Indian Drugs and Cosmetic Act was formed in 1940, and the rules framed in 1945. The rules for drug approval were found under Rule 36 until 1988 when Schedule Y amendment to the Drugs and Cosmetic Rules was applied. Yet again, these have recently been amended in 2005. For example, prior to 2005, clinical studies in India of ‘non-Indian’ origin, could only be tested at an earlier phase of development than in the rest of the world. Thus, if phase II studies were completed in the rest of the world, phase I must be repeated in India. Similarly, if phase III studies are being undertaken elsewhere, India could only conduct phase II studies. This has been abolished (January 2005) except for the Exclusion of First in Humans Studies with Non-Indian Drug New Chemical Entities.

Clearance for Clinical trials is given by a ‘No Objection Certificate’ (NOC). In addition a T Licence (Test Licence) for importation of Clinical Trial Supplies into India. These are then also free of customs duty. For further details, see Rule 122A of Drug and Cosmetics Rules. This T Licence is obtained by filling Form 12.

As with other authorities Protocol, CRF, investigator names and institutions must be supplied for approval of both NOC and T Licence.
For biological samples to be sent out of India, an export license must be applied to and issued by the Director General of Foreign Trade. This is valid only for six months, so a ‘year long study’ will require reapplication or samples are sent at end of study within a six-month window.

The ‘NOC’ takes at least three months to issue (usually six months), the T Licence, at least four months after submission and the export license for biologic samples three to six months.

Conduct of clinical studies

Amendments to Schedule Y require that study be conducted according to Indian GCPs (similar to ICH); allow concurrent phase II and III to be conducted concurrently; only allow phase I in India or Indian drugs.

Schedule Y contains various template formats to accompany applications.

Serious adverse events (SAEs) in phase II and III are expected to be reported to the Drug Controller promptly; but the time lines are not defined. Industry practice is to submit only ‘Triple Yes’ cases (serious related to drug and unexpected) routine reporting of SAEs is not yet the norm, even though Schedule Y would not appear to exempt these latter SAEs from reporting.

Pros and cons of development clinical research in India

Acceptance of Indian Data by US FDA, within the CTD format as part of the clinical data base is accepted, but as yet no pivotal (key) clinical studies totally conducted in India have been the basis of approval. Indeed the FDA GCP inspectors have not done any site inspections yet, though that is likely to change as increasing generic and new chemical entities are emerging from Indian facilities for the US market. Indeed Merck have announced that Dr Reddy Pharmaceuticals will manufacture Merck’s generic Zocor. (June 2006).

From an industry perspective the new Act passed in January 2005 by the Indian Parliament to recognize ‘and enforce’ intellectual property rights (sic Patents) together with the ability to get good GCP-compliant data and the abundance of patients, have increased the price of new clinical research.

The acceptance by the FDA and EMEA of Indian clinical data, especially that supportive of labeling, and, at present, the relatively low commercial costs of running studies prove to be additional enhancement. Particularly attractive is the opportunity especially with curative medications to provide free medicines to the poorer populations at the same time gathering additional efficacy and safety data. However, great care must be taken in these ‘vulnerable populations’ not to be seen as ‘exploiting poverty’. A special responsibility falls upon the physicians to review adequately and in detail such proposals for scientific and ethical soundness as well as measured risk–benefit assessments. For as was seen in a recent antibiotic pediatric study in Nigeria, when things go wrong companies are perceived as always in the wrong.

Other possible downsides are the relative paucity of ‘central laboratory’ facilities especially for assays, and that are accredited to International Standards and also both GLP and GCP compliant. Transport of clinical trial supplies, access of sites to monitoring visits may require days of rail transport rather than air with complications of humidity and temperature extremes on supplies and biological samples. Finally, sectarian violence can break out at any time causing disruption to monitoring of studies and possible danger to foreign monitors.

Over all, it would seem the pros outweigh the cons as 70% of US firms and most European firms are conducting studies in India and including them in their Common Technical Document and of course for approval to the Indian Government which requires data in Indian patients as part of their process.

52.3 The Middle East – land of plenty

The Middle East will generate revenue from oil for the next century at least. Currently,
two-thirds of the world’s proven oil reserves are from this area, and this makes these oil-producing countries some of the wealthiest in the world. With a population of some 270 million, the Middle East is the second largest single market after the European Union. Before we go further, we should answer the justified question: Why should the Middle East be singled out? The answer is very simple, as for Europe and the United States:

- it is the third largest export market;
- there are considerable trading advantages;
- their share of the market is rising;
- they have a wide range of goods and services that countries in the Middle East need to import;
- payment terms can be attractive, normally involving an irrevocable letter of credit (ILOC);
- opportunities for small firms are growing.

**Middle East pharmaceutical and healthcare market**

The Middle East is still an exciting marketplace for pharmaceuticals and healthcare products, and the range of opportunities in the Middle East for healthcare companies is enormous. Countries throughout the region have announced far-reaching development plans for their healthcare infrastructures and they have the ability to fund these developments.

Over much of the Middle East there is a great deal of activity taking place in terms of new hospital construction. Governments are increasing their budget allocations in the healthcare field. In short, the Middle East is currently one of the few places in the world where multinational pharmaceutical companies can expand their activities and be profitable. The Iranian government increased its fiscal year budget for 1992–1993 by 21% (7.15% of the total government budget), and one of the greatest increases in the allocation has been given to healthcare.

In Saudi Arabia, the massive King Fahd project calls for the provision of 2000 health centers across the country within the next five years and the Ministry of Health has announced plans to build an additional 18 major hospitals. The United Arab Emirates sees Dubai alone constructing 40 new clinics and 12 health centers, and creating almost 2000 extra hospital beds by the year 2005. The medical market for the Middle Eastern countries – Egypt, Turkey, Iran, Bahrain, Jordan, Kuwait, Syria, Saudi Arabia, United Arab Emirates, Oman and Qatar – represents 2% of the world market. The gross domestic product (GDP) in Turkey was 4% in 1991, rising to 5.5% in 1992. Healthcare expenditure in 1989 was $3 billion, representing 3.8% of GDP. Healthcare expenditure in 1991 in Iran was estimated at $1.4 billion, representing 7.8% of GDP. Over 30% of the current population is under 13 years old, indicating that pediatric services are likely to be in greater demand. It is obvious from all this activity that the Middle East presents an exciting marketing opportunity.

**Healthcare structure in Saudi Arabia**

- Saudi Arabia healthcare is controlled by the government and is free for all citizens.
- Expatriates working in the Kingdom are not eligible for free healthcare and are treated privately.
- To encourage investors in new private hospitals, government lends up to 50% of the cost.
- The Ministry of Health rents up to 15% of beds in private hospitals for state use.
- Saudi Arabia offers the most attractive marketing opportunity in the Middle East. It is difficult to find another country that is continuously spending large sums of money on healthcare. The market will hopefully remain dynamic for the foreseeable future.
Agency laws in the Middle East

The agent must be a national of the country concerned, or a company with a majority national shareholding. The agency agreement must be registered. The agreement must specify

- the rights and obligations of both parties;
- the type of agency;
- the date of signature and length of time for which it is valid;
- the provisions for the renewal;
- the territory to be covered;
- the products and services to be covered.

Typical agency in the Middle East

- Family owned.
- Most of the financial power is in the Chairman’s hands.
- Different departments, for example, marketing, registration and so on.
- Continuous support needed from the manufacturer to ensure
  - successful company and product registration; and
  - good clinical evaluation to generate local data.

What to look for when selecting an agency

- Personal rapport – essential if you are to work well together in the long term.
- Location – can the agent cover the right market area for you?

Business efficiency – you need information on the agent’s reputation and financial position.

Adequate facilities – has good facilities for storage and repairs.

Contacts – has the right contacts in government, purchasing organization, major companies and so on.

Administration – Does the agent have a good working knowledge of local laws, standard specifications and so on? Is he prepared to make routine arrangements for you – booking hotels, making appointments and so on?

Competition – Does the agent carry too many competing lines? Can he devote enough time to promoting your products?

Egypt pharmaceutical market

The pharmaceutical industry in Egypt was established in 1933–1934; The Hegazi Pharmaceutical Company was established in 1933, Memphis, MISR and CID companies followed in 1940, and what was to become a huge nationalized industry was born. The year 1952 was the turning point regarding drug policy in Egypt, as was true for the whole spectrum of socioeconomic development. At that time, the yearly drug consumption totaled $12.5 million with an average consumption of 55 cents/person. The local drug industry was in its infancy and constituted only 10% of total consumption. From organizational and historical points of view, there were four important stages that influenced drug policy in Egypt:

1. 1933–1961. At one stage there were 22,000 products available. The market was liberal, which led to fierce competition between foreign companies. The Directorate of Pharmacy, under the Ministry of Health (MoH), supervised local pharmaceutical companies and distributors.

2. 1962–1975. Egyptian pharmaceuticals were completely nationalized. The Egyptian Institute
for Drug, Chemical and Medical supplies (MHO), had total control over the whole pharmaceutical industry, with the aim of providing protection for the local industry. The value in 1971 was $220 million, 86% of which was produced locally. Public sector companies numbered 11 at the time. Several European companies had established manufacturing sites in Cairo. The quality center was set up in 1963.

3. **1976–1984.** The Egyptian Institute was abolished and replaced with the Egyptian Organization for Drug, Chemical and Medical Supplies. Its function included strategic planning, follow-up and performance evaluation of all pharmaceutical activities in the country. The public center remained as it was, but Squibb negotiated a deal to establish its own manufacturing site, I Egypt, with annual sales of around 26 million Egyptian pounds (E£).

4. **1985 to date.** The government has adopted and maintained a well-balanced policy, encouraging both the public and private sectors. This policy, plus the level of democracy and freedom that Egypt enjoys (there are three pro-government and seven opposition daily newspapers), has attracted huge foreign investment in pharmaceuticals and paved the way for the establishment of new pharmaceutical companies in the private sector, including EIPICO, Pharco, Amryia, Sedico and 10th of Ramadan Co.

In the past, only 1% of net profit from the local industry was invested in research and development, but this figure is steadily increasing. If the present policy continues, the future for the pharmaceutical industry, both public and private, looks rosy indeed. The local industry is regaining some of its lost ground, while at the same time, a more reasonable importation policy is ensuring that the private sector is encouraged and protected. Total pharmaceutical production for the public sector in 1991 was E£608 million and among companies enjoying their share of the market are MISR, EI Nile, Kahira, CID, ADCO Memphis and Alexandria Co.

### Private companies

The private pharmaceutical companies currently operating in Egypt include Pfizer, Swiss Pharma, Hoechst, Bristol–Myers Squibb, EIPICO, Pharco, Glaxo, ABI, MUP, Amryia, Sedico, 10th Ramadan, Mepaco, APIC, October Pharma and Amoun Pharmaceutical Industries. The total pharmaceutical turnover of the private sector in Egypt in 1991 was E£619 million. The total pharmaceutical turnover for the public and private sectors combined was E£1000 million (rate of exchange: E£ = $3.3).

### Tips for success in the Middle East

- Before traveling to the Middle East, read something about the area you are visiting to avoid culture shock.
- A sense of humor is acceptable in some parts and prohibited in others!
- Arabic is the official language, although English is widely spoken.
- Your investigator will shake hands frequently, may hug and kiss you on the cheek in the second visit. Do not be alarmed! This is the norm.
- Avoid using initials. People in the Middle East like to use their full names e.g. Ali Sayed Al-Qasimmi, NOT as A.S. Al-Qasimmi.
- Personal contact in the Middle East is of tremendous value.
- Avoid discussing clinical trials in Saudi Arabia at the Ministry of Health level. Leave the discussions to your local investigator.
- Tapes, videos, slides, and even newspapers and magazines could be screened at the airport.
- Drive slowly, and keep a letter in Arabic about yourself, your employer and the purpose of your visit.
- Think positively all the time.
- Watch your body language.
- Do not value people according to their fluency in, say, English or French.
- Avoid generalizations.

## 52.4 The Far East – the Asian Tigers

There are several reasons to focus on the Far East as part of our review of opportunities for the pharmaceutical industry abroad. In the Far East, there in concrete evidence of continuous rapid economic growth in the region; the Far East is the fastest growing pharmaceutical market in the world; there is an annual increase in healthcare budgets and spending in most of the Far Eastern countries; and the Far East is politically and economically stable.

### South Korea

**Managing the culture and business in healthcare and pharmaceuticals**

The Korean population is 42 million. Its capital, Seoul, is one of the world’s 10 largest cities, with a population of nearly 12 million. The general character of the country is mountainous and hilly. All available land is intensively cultivated; 20% of the population is engaged in farming and fishing. Korean economic growth since 1986 has been very impressive. South Koreans are proud of their economic achievement. The emphasis in the economy is on exports. South Korea identifies itself with the giant economic power, Japan, and believes it will be soon on the same level economically. In 1987, there was a surplus of around $10 billion – a remarkable achievement.

**Healthcare in South Korea**

Traditionally, pharmacies have played a leading role in providing medical advice to patients. Pharmacists dispense 70% of all pharmaceuticals consumed in Korea (ethical and OTC). Physicians, doctors and medical practitioners are concentrated in the capital, Seoul, and major big towns and cities. Doctors in Korea are now lobbying to separate prescribing, diagnosis and treatment from dispensing, so they aim to deprive the pharmacists of the therapeutic role they are playing. The government of Korea extended health and medical insurance to cover almost the whole population. Healthcare is free for those over 65 and under 18 years of age.

**Pharmaceutical industry**

Three hundred pharmaceutical companies are active in Korea, including multinationals, some of which operate on a joint venture basis: for example, Glaxo, Otsuka, Sandoz SK&F (SmithKline Beecham), Sanofi, Ciba-Geigy, Squibb, Rhone-Poulenc, Sterling, Bayer, Roche, Boehringer, Ingelheim, Janssen, Upjohn, Eli Lilly, Pfizer, Searle, Cyanamid, Schering AG and Syntex are examples of multinational companies with joint ventures in South Korea: foreign capital investment regulation, which came in 1981, has allowed a foreign company to hold an equity share in a joint venture. Up to 70% have attracted a number of multinationals. However, the pharmaceutical market in Korea is dominated by local companies; 30 of which account for over 75% share of the market. These companies include Korea Green Cross, Chong Kun Dang, Yu Han, Choong Wae, Dong A, II Yang, II Dong, Daewoo, Samsung, Lucky Gold Star.

There is a liberal policy adopted by the Korean government regarding importation of pharmaceutical raw materials; 50% of raw materials are imported and the rest manufactured locally. The South Korean pharmaceutical market is ranked 12th in the world in terms of production value.

The market size is $1700 million; 70% of pharmaceutical products are purchased directly from pharmacies. Koreans prefer locally manufactured medical products over imported foreign drugs. Traditional therapeutic herbal products are still widely popular. This applies possibly to most of
the Far Eastern countries. In 1986, the top 20 products on the market were all tonics, vitamins, ginseng and herbal products.

**Distribution of pharmaceuticals**

Most wholesalers are too small, and 37% of total pharmaceutical sales is through direct sale by the manufacturer to pharmacies, with only 26% of sales through wholesalers. Twenty-six percent of sales are direct to hospitals, 4% to other manufacturers and 4% are exported.

**Regulatory affairs and registration**

The Regulatory Authority is located at the Ministry of Health: Ministry of Health and Social Affairs, Government Unification Building 1, Choongang-dong Kwacheon-myun, Sihoog-gun Kyunggi-do, Republic of Korea (Tel.: Kyunggi 171–11).

The Ministry of Health in 1987 introduced a requirement for all multinational and other companies seeking approval for new indications for an existing substance, or for registration of a new chemical entity (NCE) to conduct clinical trials locally to support their application.

**Pricing of pharmaceuticals**

There is price control in both hospitals and pharmacies. In hospitals, products are eligible for reimbursement under the national health insurance scheme and are price controlled. In pharmacies, a standard retail price system is in force (30% mark-up on manufacturer’s plant delivery price). Patent protection has been available since July 1987.

**Thailand**

**Healthcare in Thailand**

Thailand operates public and private healthcare systems. There is free medical care, including pharmaceuticals for Thais earning below $80–100 per month. Village health centers provide essential drugs and basic medical services and there is one medical doctor per 6000 people. Bangkok has one-quarter of Thailand’s chemists (drugstores), although population-wise it is one-tenth; 30% of healthcare expenditure is contributed by the government, the remainder by the health insurance scheme. There is a national list of essential drugs sold in government hospitals and clinics at fixed prices.

**Pharmaceutical Industry in Thailand**

There are 193 registered manufacturing companies, of which 21 are joint ventures or foreign owned, and 424 pharmaceutical traders (importers). Three are contract manufacturing plants used by overseas companies. Local pharmaceutical companies are engaged in formulating and packing. Analgesics, vitamins, antacids and antibiotics are the largest categories; 90% of the pharmaceutical raw materials are imported; 30% of the market consists of imported finished products; and 60% of the multinational companies’ products are manufactured locally. The Government Pharmaceutical Organization (GPO) manufactures preparations in Thailand’s National List of Essential Drugs (130 substances, in approximately 420 presentations). The pharmaceutical market size is approximately $3300 million; 50% of the population prefer self-medication through drug stores, rather than visiting a medical doctor.

**Patent protection and intellectual property**

The United States removed Thailand from the priority foreign country list and threatened trade sanctions. Thailand remained on the priority watch list. Currently, there is pipeline protection for five years for pharmaceuticals.

**Business addresses in Thailand**

Thai Pharmaceutical Manufacturers’ Association, Rattapaitoon Building, 2884 New Petchburi Road, Bangkok 10310, Thailand.
Singapore

Singapore healthcare

Singapore’s population of 2.6 million is provided with a comprehensive medical service by the Ministry of Health and by many private practitioners and hospitals. There are about 10 government hospitals, with a total of 7898 beds. Another 2076 beds are available in 12 private hospitals. The latest state-of-the-art center is the 712-bed National University Hospital, set up at a cost of $18 million. The private 485-bed Mount Elizabeth Hospital, acquired by National Medical Enterprises of Los Angeles, with a specialist cancer unit, is the first of its kind in the region. Four of the government hospitals, namely Alexander Hospital, Singapore General Hospital, Tan Tock-Seng Hospital and Toa Payoh Hospital are designated as regional general hospitals. Kandang Kerbau Hospital is the largest hospital for obstetric and gynecology services. Woodbridge hospital specializes in psychiatry, and Trafalgar hospital is the only leprosarium in Singapore. The 200-bed Center for Communicable Diseases is the center for the treatment of AIDS and venereal diseases. Currently, there are 2700 doctors in Singapore, giving a doctor-to-population ratio of about 1:1000. Singapore will need a total of 4700 doctors by the year 2000.

Hospital development plan

In keeping with the Ministry’s policy of expanding and upgrading the quality of public healthcare, a modernization program was drawn up in 1978. The commissioning of the new Singapore General Hospital marks a new era of medical development in Singapore. This hospital has a total of 1651 beds, was constructed at a cost of $180 million and was equipped with the latest medical equipment; it was commissioned in 1981.

Another landmark in Singapore’s progress toward medical excellence is the newly completed National University Hospital, built in two phases, with a bed complement of 712, and opened in 1985. It is significant that this hospital has been given autonomy in management.

Community hospitals

The first 200-bed community hospital has been built in Ang Mo Kio and was completed in 1990. It provides rehabilitation services and basic laboratory and X-ray services.

Purchasing of medical equipment and supply

Government hospitals always buy on tender. The purchasing policy has been decentralized, the Pharmaceutical Department, 1 Jalan Bukit Merah, Singapore 0316, would call tenders for consumables; the Biomedical Engineering Department, c/o Singapore General Hospital, 6 Level 2, 7 Outram Road, Singapore 0316, for electromedical equipment; and hospitals would issue tenders themselves for capital purchases and replacement parts. Private hospitals and medical practitioners buy independently from local agents, who supply the equipment from their stock.

Privatization

The national University Hospital was privatized in 1986 as a pilot scheme. The experiment was successful, and the new system will be extended to the Singapore General Hospital and later to other hospitals. It will result in a substantial upgrade of equipment facilities and services in order to be competitive among autonomous hospitals.
**Distribution**

Most companies have their marketing, sales and distribution operated through a local agent and distributor. Some companies have their own regional offices. Leading distributors in Singapore are Zuellig, Diethelm, Summit and Guardian.

**Patent protection is available**

Foreign investment incentives are affected by Singapore government’s Economic Development Board as 5–10% tax-free status for new technology companies or those conducting R&D. An investment allowance of 50% may be used in R&D. There is a cash grant for training local staff and so on.

**Tips for success in the Far East**

Before traveling to the Far East, read something about the area you are visiting to avoid culture shock. A reasonable sense of humor is acceptable in most countries in the Far East. English is widely spoken, but learning the basics of the national language can open doors and hearts, and possibly minds. Shaking hands is a routine daily ritual before and after business meetings. Personal contact in the Far East is of tremendous value. Think positively at all times. Watch your body language. Do not value people according to their fluency in English, French and so on. Modify your ear to listen to English in a foreign accent and try to see the contrast in a positive way – do not expect English with an Oxford accent.

**Tips for registration dossier compilation**

Communicate with colleagues in the Far East well in advance. Plan well ahead to investigate whether the product is of significant value to the market. Start with documentation and certificates that need legalization to save time. The index of contents should be accurate and clear. Dossier format must be well presented, bound and clearly labeled. Health authorities’ registration guidelines, if available, should be requested and followed. Organize your work and start with priority markets first. The dossier is first checked for completeness, so do not forget any document needed in the requirement. Do not flood the authorities with unwanted information.

**Malaysia**

Trading with Malaysia holds many attractions. It is the most prosperous country in the Far East, after Japan. Economically progressive, it has plenty of natural resources, including timber, tin, rubber, petrol and gas, palm oil products, and spices. Indeed, one can say that Malaysia is also a land of plenty. It enjoys a parliamentary democracy, constitutional monarchy and freedom of the press. It has a well-structured healthcare system, and its registration regulations are tailored to encourage multinationals to invest in the country. Malaysia imports medicinal and pharmaceutical products worth in the region of £80 million a year. The United Kingdom’s share of this market is approximately 14%, with competition from the United States, Germany and Switzerland. Malaysia also has a growing domestic pharmaceutical manufacturing industry, mostly wholly owned subsidiaries or joint venture partnerships with foreign manufacturers, mainly from then United Kingdom and the United States.

Under the Control of Drugs and Cosmetics Regulation 1984, which came into force in November 1985, it is mandatory for all pharmaceutical products to be registered with the Drug Control Authority (established at the same time) before they can be imported, manufactured, sold or supplied. The regulation covers ‘a drug in a pharmaceutical dosage form or a cosmetic having a singular identity, composition, characteristic and origin’. Realistically, it was recognized that it would take some time for the authority to complete processing the registration applications for all types of medicines covered, and so the system is being introduced in stages. The first products...
required to be registered are prescription drugs, technically classified as poisons under the Malaysian Ordinance 1952. They are to be followed by OTC items and, finally, by traditional medicines and cosmetics.

Through their historic links with the United Kingdom, Malaysians are well acquainted with UK goods. The many doctors and pharmacists who completed their training in the United Kingdom are consequently well informed on British products and have a high regard for UK manufacturing standards. Glaxo is the leading pharmaceutical company, with a plant in Petaling Jaya, near Kuala Lumpur.

A newcomer to Malaysia can do business in the area through one of the large number of Malaysian companies which function as distributors and agents for overseas pharmaceutical manufacturers and suppliers. When appointing an agent, however, it is important to ascertain the equity structure of the company you are dealing with, or what alternative arrangements are in place for participating in government sector tenders. This is because, under the government’s New Economic Policy (NEP), which came into operation in 1970, government departments and agencies are obliged to deal only with Bumiputra companies, defined as those which have at least a 30% Bumiputra-controlled equity. Bumiputra, literally translated, means ‘son of the soil’ – that is, Malay. The NEP was brought in following serious racial rioting in 1969 to increase the modest Bumiputra share of the corporate sector to about 30% by 1990, principally through economic expansion.

When competing for Ministry of Health pharmaceutical tenders, Bumiputra companies consequently enjoy preferential treatment. However, most non-Bumiputra companies now have a Bumiputra partner or associate who processes the government tender applications on their behalf.

**Product registration**

Applications for product registration should be addressed to the Secretariat of the Drug Control Authority, National Pharmaceutical Control Laboratory, Ministry of Health, Jalan University, P.O. Box 319, 46730 Petaling Jaya, Malaysia, and made by the manufacturer or a locally incorporated firm or authorized by the manufacturer in writing to be the holder of the registration certificate. Application forms and guidelines can be obtained from the Drug Control Authority for a fee of M$250 (Malaysian dollars).

The documents that must accompany the application form are as follows: the applicant company’s incorporation certificate; a letter of authorization from the manufacturer; evidence of marketing of ‘existing products’; certificate of sale and good manufacturing practice (GMP) for imported products; and product information and data supporting documentation, sufficient to establish safety, efficacy and quality.

A separate application is required for each product. Where injectable pharmaceutical products are concerned, a separate registration application must be submitted for different packing or pack sizes.

Registration compilation is expected to be well presented and orderly. Important relevant articles, papers and reports should be enclosed, especially for new or little-known ingredients that are not subject of the current pharmacopoeias and standard references.

Applications must be in the national language (Bahasa Malaysia). All other data and supporting documentation, labels, PIs and summary of product characteristics (SPC) must be in Bahasa Malaysia or English.

**The Philippines**

**Healthcare in the Philippines**

PHC Project (Primary Health Care) was introduced in 1981. This provides basic medical care to rural areas through hospitals and health centers. District Hospitals and Provincial Hospitals act as referral hospitals. The Philippines’ Department of Health has allocated 60% of its budget to the running of government hospitals. The government spends $40 million on pharmaceuticals, amounting to 16% of the Department of Health budget, but
only 8% of the total pharmaceutical market. Recently, the government of Philippines has started issuing tenders for the purchase of essential drugs. Thirty-five million people are covered by the Medicare Health Insurance Scheme (government and private sector employees). Other private health insurance schemes also exist.

Pharmaceuticals in the Philippines

There are a number of contract manufacturers, for example, Interphil (subsidiary of Zuellig), and pharmaceutical manufacturers, which provide for 30% of the market; 95% of the pharmaceutical raw materials are imported, with finishing and packaging carried out locally.

There are 32 pharmaceutical manufacturers in the Philippines:

- Bio, Marsman, Hizon, Metro
- Drug makers and Interphil (Zuellig), engaged in contract manufacturing
- United Laboratories

Several multinational companies have local manufacturing plant in the Philippines.

Chem Field is a government pharmaceutical company with almost a monopoly in antibiotic manufacturing, especially ampicillin, amoxycillin and cloxacillin.

Philippines Pharmaceutical Industry Association (FFPI) is advising the government to set up raw material manufacturing plant, rather than producing finished products.

The pharmaceutical market

The Philippines’ pharmaceutical market is a small but lucrative. There are 50 companies which compete in the market, with a market size of $300 million, and 10,874 preparations are available (9,154 branded, 1,720 generic). The local Philippine pharmaceutical company, United Laboratories, dominates the market and has 22% of the market share. Foreign companies account for 60% of the market; no one has more than 5% share. Antibiotics form the largest proportion of imported drugs, followed by vitamins. Pharmaceutical exports from the Philippines are almost negligible.

Regulatory affairs and registration

The Bureau of Food and Drugs (BFAD) controls product registration. Their address is as follows: Bureau of Food and Drugs, Department of Health Compound, Albang. Muntinglupa, Metro Manila, Philippines.

Pharmaceutical manufacturing retail licenses are issued by BFAD. A local clinical trial must be carried out for new substances (new brands or new drugs), and registration is granted for one year initially. Post-marketing surveillance reports must be submitted twice a year to BFAD. Patent protection is available and implemented.

Clinical trials

Clinical trials can be conducted in the Philippines provided prior permission from the BFAD is granted. The application and protocol are submitted to BFAD. There is an approved list of clinicians from which investigators are selected. Clinical trials must be conducted in accordance with guidelines on GCP. Patients’ informed consent must be obtained, in accordance with the Declaration of Helsinki.

Indonesia

Indonesia is considered the fourth most populated country after China, India and United States. Two-thirds of the population is concentrated in Java, 19% in Sumatra, 8% in Sulawesi, 5% in Kalimantan and 6% on Eastern Islands off Indonesia.

Rural health services are provided through a network of health subcenters, health centers and district hospitals. Urban health services are provided through specialized and provincial hospitals, which are located in large cities. A health subcenter
is staffed by a full-time nurse who provides simple basic medical care, including maternal/child healthcare, vaccinations and nutrition.

**Health centers (puskesmas)**

There are 5800 centers in Indonesia. Health centers provide basic medical care, maternal and child health services. Some health centers have inpatient facilities (10-bed wards). They are staffed by GPs and nurses.

**Hospitals**

District hospitals support the primary healthcare facilities provided by the health centers, whereas general hospitals provide specialist services.

**Health workers**

There are 284 000 health workers in Indonesia in the government sector. These include physicians, dentists, pharmacists, paramedics, nurses and technicians. There are 40 000 health workers in the private sector.

**Pertamina and Indonesia Armed Forces**

Pertamina (State Oil Company) and the Armed Forces have their own medical services. These, together with the private sector, operate well-equipped hospitals.

**Pharmaceutical industry – distribution, pricing and market size**

There are approximately 900 pharmaceutical wholesales, 340 with limited local activities. Distribution is fragmented, due to Indonesia’s geography, thus sales figures are difficult to acquire. The wholesalers’ mark-up is 20%, whereas the pharmacy mark-up is 45%. The market size is approximately $400–500 million. The leading products in sales volume are antibiotics, vitamins and minerals, respiratory drugs, dermatology drugs, analgesics, hormones, cardiovascular drugs, psychotropic, anti-inflammatory drugs, anti-TB drugs and anti-spasmodics.

**Registration in Indonesia**

All medical products marketed in Indonesia must be registered and approved by the Ministry of Health through POM (Pengawasan Obat den MaKanan, the Food and Drug Authority). Applications are referred to a special committee, Panitia Penilai Obat Jadi (PPOJ), to examine the documents submitted. There are expert committees to review pharmaceuticals and medical products on behalf of PPOJ. The secretariat of PPOJ then prepares a report to the Directorate General and, if the product is approved, a registration number is issued by the Ministry of Health.

**Clinical research**

Clinical trials can be conducted in Indonesia, but prior permission must be obtained from the Ministry of Health.

**Pharmaceutical manufacturers in Indonesia**

The Indonesian pharmaceutical industry imports 95% of the pharmaceutical raw materials needed. Importation of finished products is not allowed, except for medical products not manufactured locally, for example insulin. There are 280 pharmaceutical manufacturers in Indonesia: (a) 40 large local companies, others small; (b) 40 foreign companies; and (c) State-owned companies. A foreign company must operate through a joint venture with an Indonesian firm. The Indonesian firm must have 30% equity in the shareholding. Several multinational companies operate in Indonesia.
Antibiotics assume the leading therapeutic category in Indonesia (25% of total market). They are followed by vitamins, minerals and tonics.

**Regulatory affairs and registration**

There is a long delay for products to be registered; sometimes it can take two to three years. Local companies are able to obtain registration as quickly as six months. The Regulatory Authority address is as follows: Directorate General of Drug and Food Centre, Ministry of Health, DIR. JEN. POM, Department Kesehatan R.I., JI Percetakan Negara 23, Jakarta 10560, Indonesia.

**References**


**Suggested reading**

Clinical trials are major budget items in drug development. The total costs vary according to therapeutic area, indication, duration of the study and numbers of subjects. Even for rapidly acting drugs in acute conditions (e.g. analgesics, infections), the cost of the clinical trial program is unlikely to be less than two-thirds of the entire development program, and chronic therapies (e.g. osteoporosis) might require a larger proportion yet.

The cost of a clinical trial arises from both internal and external costs. Internal costs are those incurred within the sponsor’s organization (personnel, office supplies, etc.); external costs are those incurred on such items as investigators, laboratories, travel and so on. Quantification of the internal costs, especially those associated with personnel, has proved a persistent challenge, as discussed below. The costs of a typical contract research organization (CRO) may be viewed as shifting costs from internal to external.

We have grouped the external costs of a clinical trial as follows:

- Investigator fees
- Laboratory charges
- Travel
- Clinical trial medication (when manufactured or packaged by a contractor)
- Ethics committees and Institutional Review Boards (EC/IRBs)
- Regulatory fees
- Consultancy
- Patient fees
- Equipment
- Finance
- Meetings
- Printing and copying

In addition, we have addressed the issue of internal costs and the use of CROs, particularly with respect to (a) obtaining and comparing CRO bids;
(b) assessing the financial stability of a CRO and (c) choosing the right type of contract.

## 53.1 Investigator fees

Fees paid to investigators to conduct clinical trials vary according to a number of criteria as follows:

- Therapeutic area
- Country/continent
- Protocol
- Phase of protocol
- Number of patient visits
- Type and number of procedures
- Affiliation and eminence of the investigator

In assessing investigator costs, the pivotal document is obviously study protocol, which governs the amount of time the investigator must devote to the patient and to the organization of the trial. Today’s principal investigators usually need assistance in implementing a clinical protocol, and they generally rely upon, and employ, junior doctors, research nurses and other paramedical staff. Managed investigational sites are also emerging, where investigators handle only the minimum of administration; it is the site organization which contracts with the study sponsor, and handles issues such as patient recruitment, informed consent, patient records, case record forms (CRFs), appointment keeping, financial accounting and so on; these are widespread in the United States and now more common in Europe (particularly the United Kingdom), too.

The protocol governs not only the time the doctor spends with the patient but also the quality of the time spent and the various procedures that are associated with the study. Some of these may not be supervised by the investigator, or at least only indirectly (e.g. X-rays, ECG, etc.), whereas others may need specialized medical training to be administered, for example endoscopy or surgical investigative procedures. In both Europe and the United States, institutions often have a varying pricing policy, depending on who, or which, organization requests the procedure. Thus, X-rays arranged via a professor may well cost less than those arranged directly by the sponsor. Increasingly, institutions attempt to separate out the cost of investigative procedures from the ‘true’ investigator fees, which account solely for the time spent by the investigator.

The therapeutic area or medical specialty also determines costs of studies. Information from DataEdge, PICAS database, indicates systematic variations in costs among different therapeutic areas (Figure 53.1).

Comparisons for total clinical trial costs can also be made between countries (Figure 53.2). Perhaps surprisingly, the United Kingdom, on the basis of this evidence, is the most expensive, although the relatively lower cost of Italy and Spain is more expected. Compared with Europe, the United States is generally the most expensive country for investigational procedures, and the premiums for these increase as the underlying price increases. The price ratios for common research procedures have been reported as in Table 53.1. Although in 1993, Eastern and Central Europe (the former communist countries) were cheaper than the rest of Europe (Hughes, 1994), there is now little difference (Hughes, 1997). Some sponsors insist that, within Europe at least, they will pay the same fee to all investigators, regardless of their country (this is also now a common practice for multicenter studies in various states of the United States). This overcomes the invidious situation of investigators comparing fees at investigator meetings, with the inevitable result that the lower paid feel short-changed. Japan is a special situation, where various scandals have led to a mandatory system where fees are paid to the national hospital institution, rather than to investigators themselves. These hospitals typically have a complex calculation chart (Table 53.2), which is used to calculate the fees. External costs in Japan are now more or less on parity with those in the United States.
Figure 53.1  Relative costs by therapeutic area

Figure 53.2  Relative costs by country

Table 53.1  Price ratios for common research procedures

<table>
<thead>
<tr>
<th>Procedure</th>
<th>United States</th>
<th>France</th>
<th>United Kingdom</th>
<th>Netherlands</th>
<th>Belgium</th>
<th>Denmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECG</td>
<td>256</td>
<td>81</td>
<td>100</td>
<td>66</td>
<td>90</td>
<td>96</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>335</td>
<td>114</td>
<td>100</td>
<td>144</td>
<td>121</td>
<td>119</td>
</tr>
</tbody>
</table>
Although not normally regarded as the remit of the ethics committee or IRB (at least in Europe and the United States), such bodies from time to time have indicated to sponsors that they feel that a particular fee paid to investigators for a particular trial is excessive. Such observations can be real or perceptual; sometimes there is ignorance of the effort needed to conduct a study, the ‘going rate’ for investigators’ hours and that sponsors often compete for a competitive and finite research resource. For this reason alone, the sponsor of the first trial in a particular area with a novel drug may gain a financial advantage over its industry competitors with later, me-too, drugs.

The affiliation of an investigator can influence the fees paid in two ways. First, investigators attached to prestigious universities or medical clinics may feel, perhaps justifiably, that they are deserving of higher fees, given that the prestige of their institution adds to the acceptability of the study to the regulators and, more importantly, the value of the study for eventual marketing purposes. Second, institutions now almost uniformly charge an overhead ranging from a few percent to over 100% of the basic investigator fees and procedure fees. In the planning stages of a clinical trial, ignoring such potential up-charges can lead to unpleasant financial surprises at a later date and require revisiting the initial budget.

### 53.2 Laboratory charges

The cost of laboratory analysis of specimens from patients can be a significant proportion of the overall cost of a clinical trial. For early studies, costs are high for GLP assays of blood, urine or plasma for parent drug and metabolite. Routine hematology and biochemistry at larger scale, then takes over in later trials. The overall cost is, however, not just the cost of analysis; the total cost may include elements such as sample kit design and manufacture, transport of kits to investigator sites, transport of kits to central analyzing
laboratories, interpretation of results, customs charges, data processing of results at the laboratory and transmission of the results to the data management center, as well as the actual cost of the analysis. Pharmaceutical physicians often miss an opportunity to reduce costs by using local laboratories in multicenter clinical trials. Regulatory authorities have openly stated that much of the laboratory data collected and submitted are superfluous or irrelevant, so that discussion with regulators of what precisely is to be measured in any particular study can result in significant savings.

The cost of the basic hematology and biochemistry varies from country to country, as well as being dependent on the institution carrying out such analysis. Purely commercial central laboratories, which carry out analysis only in connection with clinical trials, may, at first sight, appear expensive when compared with the cost of a local hospital or a doctor’s laboratory. However, the additional services provided by the central laboratory, together with the reduced necessity for both qualification and audit of a diverse group of regional laboratories, as well as the not insignificant cost of consolidating the data from these laboratories, should easily compensate for the apparent higher price.

53.3 Travel

Few studies are conducted at a single location, and travel by study monitors, CRAs, physicians and auditors can amount to significant expenditure. Major companies can ameliorate such costs by negotiating special rates with airlines, rental car companies and hotel chains. Indeed, companies may be able to pass such savings on to CROs working for them. Such savings may amount to 50% of the total travel budget.

Much is made of the savings that can be made by use of regional monitors — either as full-time employees or as exclusive or nonexclusive contract employees. At first sight, such arrangements can result in important savings; however, these can be offset by the need for additional project team meetings and training, greater use of telephone and video conferencing and, not infrequently, by site visits by more senior employees and auditors. Thus, it is often difficult to determine real savings made by a regional monitor policy.

What is apparent from the recent Central and Eastern European Study (Hughes, 1997) is that travel to these countries can be very costly, compared with the cost of travel within, for example, the United States. Likewise, travel to and within Scandinavia still remains a high-cost item.

53.4 Clinical trial medication

The sponsor must also account for the cost of preparing and providing appropriately packaged clinical trial medication to be used in its trials. This may include procurement or manufacture of comparator treatments and/or placebo medication.

Clearly, arrangements must be made early in the trial to ensure that an efficient supply chain is set up and the associated costs (which can be significant) taken into account. In recent years, sponsors have utilized methods such as minimization techniques (within the randomization process for controlled randomized trials) to help reduce waste of clinical trial medication and hence reduce the overall cost.

53.5 Ethics committees and institutional review boards

IRBs are increasingly requiring payment to evaluate protocols: when a single IRB can be used, this fee is likely to be insignificant. However, in Europe and the United States, multiple local research ethics committees often have to be consulted and, even if their individual fees are modest at rarely more than $2000 per protocol, the effect of dozens of such committees can be quite substantial. In Germany, there are usually two ethics committees that review each protocol — one local and one at the state level.

53.6 Regulatory fees

Very few places charge a significant administration fee for a clinical trial approval (although
Massachusetts is one example). In less developed countries it may prove necessary to pay true fees together with ‘consultation’ fees to government advisors. Sponsors will, however, need to take into account the costs associated with the effort of their internal regulatory staff in preparing CTX submissions (or their equivalent).

53.7 Consultancy

Consultants may be involved in clinical trials at various stages. At the planning stage they may be used to develop, refine or approve the protocol. Consultants may be used individually to advise during the course of the trial – the ‘principal investigator’ will often play an important role in the study design, although the distinguished individual usually chosen may not recruit any patients (in Germany the appointment of the principal investigator is a regulatory requirement, and the medical monitor is a signatory on form 1571 in the United States, and the Clinical Trials Application in European countries). Many major studies, particularly those of life-threatening diseases and those with mortality as an end point, have independent committees monitoring for safety and adjudicating efficacy end points. These also add cost.

53.8 Patient fees and clinical trial advertising

Although it is almost universal practice for healthy volunteers to be compensated (paid) for taking part in phase I studies, to date, it is very unusual for patients in phase II–IV studies to be paid more than token sums for transport and inconvenience. In both the United States and Europe, advertising for patients is generally acceptable (although it is much more common in the United States). Generally, approval of advertisements by local ethics committees is required. Mass marketing techniques and rapid recruitment of qualified patients by external agencies may well be highly cost-effective when clinical trials are planned or are under way.

53.9 Equipment

We have already noted that sample kits for clinical samples from patients may have to be designed and manufactured. Additional costs may be incurred, especially in less developed countries, by the need to provide investigators with items of medical equipment. Even in the United Kingdom, it is common for sponsors to provide random-zero sphygmomanometers, as well as equipment that would not normally be found in a doctor’s office, such as a centrifuge. In Central and Eastern Europe and Latin America, even basic medical equipment may be necessary or appreciated, while communications equipment, such as faxes, modems or even photocopiers, may markedly improve the logistics of a study.

53.10 Finance

A multinational trial can be a significant challenge to accounting departments of sponsors, and it is to be strongly advised that accounting/finance and purchasing personnel be involved at an early stage of the project. Such early involvement should allow the efficient financing of the project, not only from the formal budgeting process but also in ensuring that there is an efficient process for investigators and other subcontractors to be paid on time. The added international dimension of large trials can also be a challenge, particularly where fluctuating exchange rates are involved. Finance and purchasing departments should examine the need to hedge against currency variations which, over the life of a study, even in countries with relatively stable currencies, can introduce a variance of ±30% from the projected out-of-pocket fees.

53.11 Meetings

Investigators’ meetings are often regarded as indispensable to the success of a clinical trial, and can be efficient ways to train large numbers
of participants in the trial procedures and regulatory responsibilities. As with so many items, the expenditure on such meetings is far from insignificant. Apart from the hire of an appropriate venue, it is important not to overlook the cost of transportation and investigators’ time, as well as the time involved by the sponsor in both organizing and attending such meetings. Such meetings held prior to and during the trial are, however, invaluable for improving conformity of conduct of the study, as well as being strongly motivational for investigators. A final meeting or meetings can also be useful for binding in investigators for subsequent trials, drafting the study report and crafting a publication.

Table 53.3 Costing categories for a clinical Phase III project

1. Protocol design and development
2. CRF, patient information sheet, informed consent form design and development
3. Investigator identification and qualification
4. Initiation visits to study sites
5. Administration of ethics committee approvals
6. Regulatory approvals
7. Clinical trial supply labeling
8. Translation of study documentation
9. Set-up and attendance at investigators’ meetings
10. Study monitoring (including secondary in-house data cleaning and monitoring reports)
11. Administration of investigator payments
12. Identification, qualification and management of central laboratory(ies)
13. Administration of payments to central laboratory(ies)
14. Set-up and administration of central randomization system
15. Reporting of serious ADRs to regulatory authorities and sponsor (including written reports)
16. Distribution of all trial materials (documentation and study medication)
17. Reconciliation of study medication
18. Return of study medication to sponsor
19. Quality Assurance audits:
   (a) Clinical in-house
   (b) Clinical on-site
   (c) Database
   (d) Central laboratory(ies)
20. Database design (including validation plan and programming)
21. Double data entry and data management (including query generation and resolution)
22. Statistical plan and programming
23. Statistical analysis and reporting
24. Integrated statistical and medical report
25. Archiving of study documentation
26. Project management

53.12 Printing and copying

Clinical trials generate paper – at the beginning, during the study and as a final report. The cost of printing and distribution of printed materials in a large major study should not be ignored, but if undertaken by a sponsor internally, may easily be overlooked. The cost of production of multipart CRFs is only one of the costs involved for a major multinational study. With multiple patients, centers, investigators and IRB/ECs, many copies of protocols, patient information leaflets, investigator brochures, ethics committee submissions and so on will add to a printing and copying budget that may be insidiously doubled by these non-CRF
printing charges, which are often thought to be insignificant.

### 53.13 Internal costs

Apart possibly from investigators’ fees, in-house costs represent the greatest single item in a clinical trials budget. Table 53.3 lists many of the subdivisions of costing that could be regarded as internal, the vast majority of which could be outsourced to CROs or similar organizations.

In order that the true internal costs of a study can be calculated, it is necessary that a sponsor completes a similar exercise, using its own internal fully overheaded costs for each of the cost center personnel that are used. When sponsors’ estimates of internal costs are substantially less than those offered by CROs, it is frequently the case that understanding of the sponsors’ fully overheaded costs has been inadequate. This was borne out in a survey of 27 pharmaceutical companies (King, 1997), 41% of whom reported that they did calculate internal costs, 33% reported that they did not and, interestingly, 26% did not know!

Various methods can be used for the calculation of internal costs, two of which have been published widely; the Hoechst Marion Roussel Model (Hill and Hubbard, 1996) and the MSD BARDS Model (Papazian and Wise, 1995). A reliable and reproducible method must include the calculation of the cost of a full-time equivalent (FTE) employee at each level of seniority needed to execute and manage the project (Table 53.4). In an era of cost containment, such calculations can inform decisions about whether or not to outsource a study to a CRO; however, sponsors should not forget that there is no such thing as a turn-key project with a CRO, and that some internal costs for sponsors’ oversight and decision making will persist during such contracted studies (the MSD BARDS group has suggested that this typically amounts to 15% of the total contract cost; Papazian and Wise, 1995).

### 53.14 Use of CROs

CROs are now regarded as essential collaborators by many companies, and are no longer stop-gap resources to be used in an emergency. As a result, many CROs are keen to obtain preferred provider and strategic alliance relationships with sponsors. There are three major aspects to establishing the optimal sponsor–CRO relationship: (a) obtaining bids; (b) assessing financial stability and (c) choosing the right contract framework.

#### Obtaining and comparing CRO bids

This aspect of the contracting process is highly developed in all major pharmaceutical companies. Although much has been written and presented

---

**Table 53.4  Model for FTE cost calculation**

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual base salary + benefits (e.g. 35% of salary) + bonus (e.g. 5% of salary)</td>
<td>Total personnel costs + operational costs (e.g. 78% of total personnel costs) includes infrastructure support, overheads and administration = total personnel costs plus operational costs = total or fully overheaded FTE cost</td>
</tr>
<tr>
<td>Example calculation of daily FTE cost for an experienced CRA in the United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Annual base salary</td>
<td>£25 000</td>
</tr>
<tr>
<td>Benefits</td>
<td>£8 750</td>
</tr>
<tr>
<td>Bonus</td>
<td>£2 500</td>
</tr>
<tr>
<td>Total personnel cost</td>
<td>£36 500</td>
</tr>
<tr>
<td>Operational costs (78%)</td>
<td>£28 470</td>
</tr>
<tr>
<td>Total FTE cost</td>
<td>£64 970</td>
</tr>
<tr>
<td>Daily FTE cost (assuming 230 days/year)</td>
<td>£282</td>
</tr>
</tbody>
</table>

Clearly, the calculation of the total cost for completion of a project must rely on good forecasting of resource needs, in terms of number and type of staff required and number of hours/days required.
about the process of requesting CRO proposals (or RFPs, as they have become known), some useful ‘rules of thumb’ are the following:

- Request bids from no more than five CROs: The main issues here concern both the difficulty of comparing numerous bids and fairness to the CROs in terms of the probability of winning the business, when considering the degree of effort required on their part to put a proposal together.

- Brief the CROs as comprehensively and consistently as possible. Consistency is key here if bids are to be compared fairly.

- Give the CROs at least three weeks to prepare the bid.

- Provide the same bid template to all CRO competitors (Brancaccio, 1997).

- Request daily rate fees (i.e. FTE rates for each of the functional staff to be involved).

- Ask the CROs to document all assumptions made.

- Prepare yourself for the responses, for example construct a master spreadsheet with (internal) costs also inserted in for ease of comparison.

- Be available for clarifying questions from the CRO when making their bid: it is the best way to get an apples versus apples comparison.

Table 53.5 illustrates the comparative bids received from three CROs who were asked to bid for the partial (2000 patients from 50 centers in the United Kingdom) clinical management and complete data management, statistics and reporting for a 6000-patient multinational cardiovascular mortality study. The study parameters were as follows:

- 4–6-year treatment period
- 5-year follow-up
- 250-page CRF

### Table 53.5 Comparison of CRO bids (in £ sterling) for a mortality study

<table>
<thead>
<tr>
<th>CRO A</th>
<th>CRO B</th>
<th>CRO C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Selected daily rates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRA</td>
<td>500</td>
<td>550</td>
</tr>
<tr>
<td>Project manager</td>
<td>650</td>
<td>850</td>
</tr>
<tr>
<td>Physician</td>
<td>900</td>
<td>900</td>
</tr>
<tr>
<td>QA auditor</td>
<td>600</td>
<td>650</td>
</tr>
<tr>
<td>Data entry personnel</td>
<td>250</td>
<td>300</td>
</tr>
<tr>
<td>Data coordinator</td>
<td>360</td>
<td>350</td>
</tr>
<tr>
<td>Data manager/programmer</td>
<td>450</td>
<td>450</td>
</tr>
<tr>
<td>Statistician</td>
<td>450</td>
<td>650</td>
</tr>
<tr>
<td><strong>2. Selected task bids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator ID and selection</td>
<td>49 000</td>
<td>110 000</td>
</tr>
<tr>
<td>Monitoring</td>
<td>3 750 783</td>
<td>4 843 875</td>
</tr>
<tr>
<td>Auditing</td>
<td>130 604</td>
<td>177 000</td>
</tr>
<tr>
<td>Project management</td>
<td>1 556 824</td>
<td>4 995 535</td>
</tr>
<tr>
<td>Database design</td>
<td>11 610</td>
<td>12 000</td>
</tr>
<tr>
<td>Double data entry and management</td>
<td>3 031 824</td>
<td>7 291 000</td>
</tr>
<tr>
<td>Secondary CRF review and coding</td>
<td>325 000</td>
<td>1 900 000</td>
</tr>
<tr>
<td>Statistical analysis (interim and final)</td>
<td>87 000</td>
<td>56 770</td>
</tr>
<tr>
<td>Integrated report</td>
<td>25 000</td>
<td>25 450</td>
</tr>
<tr>
<td><strong>Total project bid (professional fees)</strong></td>
<td>9 340 945</td>
<td>20 057 380</td>
</tr>
</tbody>
</table>
The importance of the sponsor having already calculated its internal costs for executing the project cannot be overemphasized in this situation. In this example, despite the relative uniformity of daily rate fees across the three CROs, there are significant variations between the line item (or task) bids, as well as the ‘bottom-line’ or total bids. Only with the sponsor’s own estimate for comparison can sensible and informed revisions by the CRO be requested and, most importantly, it allows assessment of which of the CROs has provided the most realistic bid. Beware of the practice of simply choosing the lowest or average bid (i.e. on an empirical basis); it may well be that the highest bid is the only one that includes everything needed to successfully complete the study.

Assessing the financial stability of a CRO

The recent history of CROs shows few business failures and, in comparison with other service suppliers, CROs are remarkably stable and resilient. Assessment of the financial stability of a CRO is, in general, very difficult to accomplish. Most CROs are private companies whose accounting practices differ. Some of the large CROs are publicly quoted, and hence regularly publish their accounts and projection, but these account for less than 2% of the total number of CROs worldwide. This 2%, however, represents about half of gross revenues for the CRO industry.

Data on private companies are difficult to assemble, and financial checking on the CROs is not straightforward. When published at all, these companies’ accounts are often in abbreviated format, and can be out of date. Organizations such as Dun & Bradstreet may be able to provide useful information. However, it is likely that the best source of reassurance of financial stability of a CRO is via bankers’ references, obtained through the sponsor’s own finance department.

The data obtained from the aforementioned sources may be difficult for the average clinical project manager to interpret (this where the finance managers will indeed be helpful, if not essential). However, the importance of asking sensible questions of a CRO cannot be overemphasized; the responses to these questions are essential to completing the overall picture of a CRO’s financial situation, and may actually be more revealing than bald, out-of-date audited accounts. Questions to ask would include those listed in Table 53.6.

Lastly, it must be remembered that vice versa CROs are business entities, and they have a right to ask questions of prospective sponsors. Be ready to disclose your company’s financial situation and third-party payment history.

Choosing the right type of contract

An agreement on the overall budget for the project, although clearly an important milestone, does not actually form the whole of basis of the contractual relationship between the sponsor and the CRO. The two parties must also agree on the type of contract that best meets the needs of both parties.

There are four types of CRO–sponsor contracts that are in current use. Each has advantages and disadvantages to the sponsor and CRO (see Table 53.7), and the choice between them will depend on a series of factors, including length and complexity of the project, the functions/tasks to be contracted and the level of trust that already exists between the CRO and the sponsor (perhaps based on previous contracting experiences). The aim should be to create a win–win scenario, whereby the contract

| Table 53.6 Questions designed to elicit the overall picture of a CRO’s financial situation |
|------------------|----------------------------------|
| 1. What are your annual revenues – current and past? |
| 2. How are pass-through costs managed (e.g. investigator fees, etc.)? |
| 3. How many clients do you have? |
| 4. What percentage of your business is accounted for by each of your major clients? |
| 5. What is your average size of contract in financial terms? |
| 6. How much repeat business (in percentage terms) do you get? |
| 7. What is your business breakdown by service? |
| 8. Are there any pending legal cases? |
| 9. What insurance policies do you have and at what level? |
### Table 53.7 CRO contracts

<table>
<thead>
<tr>
<th>Type of contract</th>
<th>Characteristics</th>
<th>Sponsor perspective</th>
<th>CRO perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed price</td>
<td>Final price known</td>
<td>Good for documentation</td>
<td>Efficient gains are all profit</td>
</tr>
<tr>
<td></td>
<td>Fixed price for completion of project defined up front</td>
<td>and prediction of cash flow and for budgeting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clearly defined scope of work.</td>
<td>Pay only for results</td>
<td>Price quoted must be accurate in order to realize profit</td>
</tr>
<tr>
<td></td>
<td>Must have mechanism for changes in scope</td>
<td>CRO may have underbid, if making a loss may become lower priority within CRO</td>
<td>Can become a milestone</td>
</tr>
<tr>
<td></td>
<td>Typically paid according to predefined tranches</td>
<td>Pressure to deliver, for example final protocol, drug supplies, sample CRFs</td>
<td>Blank cheque!</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renegotiation is almost inevitable, maybe adversarial</td>
<td></td>
</tr>
<tr>
<td>Fee for service</td>
<td>Open-ended. Sponsor billed according to hours spent on project and FTE rate. The so-called ‘blank cheque’ scenario. Must be built on trust through experience. Often used for consultancy projects</td>
<td>Easy to work with Can benefit from CRO efficiency Difficult to control Encourages CRO inefficiency Can create atmosphere of mistrust</td>
<td>Allows flexibility in budgeting and scheduling of activities No incentive to increase efficiency, that is no financial benefit Can create atmosphere of mistrust</td>
</tr>
<tr>
<td>Fixed unit price – based</td>
<td>Sponsor and CRO agree definition and dimensions of task (e.g. monitoring visit, database design) and allocate price to the task unit. Sponsor pays according to number of units completed</td>
<td>Can compare CRO activities to internal activities Easy to understand how much additional tasks will cost Renegotiation less adversarial Protracted initial negotiations to agree definition of tasks Does not encourage CRO efficiency</td>
<td>Renegotiation (for extra tasks) easier Protracted initial negotiations to agree definition of tasks Does not encourage CRO efficiency</td>
</tr>
<tr>
<td>Fixed unit price – milestone/ deliverable based</td>
<td>Sponsor and CRO agree definitions of milestone (e.g. agreed number of investigators initiated, patients entered, database locked, etc.). Sponsor pays when milestone achieved</td>
<td>Pay only for results. Minimal renegotiation Encourages CRO efficiency: get paid quicker if work fast to achieve milestones Longer planning and negotiation phase</td>
<td>Rewards efficiency Longer planning and negotiation phase</td>
</tr>
</tbody>
</table>
is merely a reference document, rather than the controlling factor in the relationship.

At the end of the day, the decision to outsource a project is not based on purely financial considerations, and quality, experience, expertise and internal capacity are other key factors. But it remains important for functional managers to understand some of the financial issues that are integral to both the success of an outsourced project and the ability to plan for the future.

53.15 Conclusion

The financial aspects of clinical trials are wide ranging. The clinical studies, whether managed by in- or out-of-house personnel, represent 30–50% of the total development expenditure on any particular drug. Clinical scientists and research physicians will need much support from their qualified business and financial colleagues in order to manage these complex activities successfully.

References

The most dramatic change in the last 30 years of modern drug development is the trend toward extensive outsourcing of drug-development responsibilities to contract research organizations (CROs). Since 1994, the pharmaceutical industry has eliminated more than 40,000 jobs, many in R&D. The task of developing new products with smaller in-house staffs has led pharmaceutical companies to increase their reliance on CROs. It is estimated that more than 60% of all clinical studies now involve significant outsourcing (Getz, 2006a,b).

As pharmaceutical companies strive to increase productivity and decrease costs, they must improve their skills in dealing with CROs. This chapter examines the challenges of outsourcing clinical drug development activities and identifies critical success factors for working with CROs.

### 54.1 Pharmaceutical industry views of CROs

**‘Traditional’ view of a CRO**

The view that working with a CRO involves unacceptable risk is often expressed by pharmaceutical industry personnel. One project leader who had successfully developed several drugs commented: ‘There is significant risk in relying on CROs. I would rather use my own personnel’. The characteristics of this ‘traditional’ view of working with a CRO are shown in Table 54.1.

In-house staffing is based on long-term workload projections, which focus on the peaks rather than the valleys. The CRO is used as a back-up, when the workload exceeds projections, or when staffing levels fall due to a hiring freeze. The CRO is treated as an extension of in-house staff and may be asked to relocate its personnel to the sponsor’s site. In order to minimize risk, the sponsor contracts the minimum range of services and retains the critical activities for its own staff. The decision to use a CRO is delayed until all other options are exhausted. CRO evaluation and selection occurs at the eleventh hour in a ‘crisis’ atmosphere, where time is the major concern, rather than quality or cost.

Using a CRO in such a way often leads to disappointing results. Outsourcing failures can usually be traced to one of three causes:

- The sponsor selects the wrong CRO.
- The sponsor does not articulate its needs clearly.
- The sponsor does not manage the project.
The ‘modern’ view of a CRO

Success with outsourcing, however, has led senior executives to express such views as: ‘If I can contract out cafeteria and building maintenance, I can contract out clinical research’. Characteristics of this modern view of working with a CRO are illustrated in Table 54.2.

In this view, the composition of in-house staff is determined by ‘core’ needs – What will be needed to design the study, select the CRO and manage the program? The drug development plan includes a description of which studies and services will be contracted. A list of ‘prequalified’ CROs is developed by matching the sponsor’s anticipated needs with the range of services and therapeutic area expertise various CROs provide. The role of the sponsor’s personnel is redefined from conducting the project to managing the CRO. Its staff receive training on how to work with CROs. Advance planning and training enables the sponsor to direct its attention to assessing quality and cost of CRO services.

54.2 Deciding when to use a CRO

Strategies for using CROs typically fall into three categories:

- Tactical outsourcing
- Project outsourcing
- Strategic outsourcing

Tactical outsourcing

This is essentially the ‘traditional’ view of outsourcing. A sponsor maintains in-house staff levels capable of performing the projected workload. Individual studies or selected activities within a study are contracted to a CRO only when in-house

Table 54.1 ‘Traditional’ view of a CRO

| In-house staffing is based on expected workload |
| A CRO is used when in-house resources become inadequate |
| A crisis management atmosphere exists |
| The CRO is viewed as an extension of in-house staff |
| Time is a major concern |

Table 54.2 ‘Modern’ view of a CRO

| In-house staffing is based on ‘core’ needs |
| CROs are included in resource planning |
| CROs are prequalified, based on therapeutic expertise, range of services, and compatibility with the sponsor |
| Personnel are trained in CRO skills |
| Quality and cost are the major concerns |

Getz, 2005), and the balance sheets of publically quoted CRO corporations, provide ample evidence that outsourcing is expanding. Since 2000, the global headcount growth among major pharmaceutical and biotechnology companies has been flat, whereas that among CROs has increased by 6% annually. At the beginning of 2006, personnel from CRO companies nearly doubled the total number of drug development professionals (Getz, 2006a,b).

In addition, a wider range of services is being contracted. In 1992, sponsors were most likely to contract out site recruitment and study monitoring, whereas other activities were conducted in-house. By 1994, sponsors reported large increases in the use of CROs for data management, statistical analysis and medical writing. Today’s market for CRO services is driven by two distinctly different client bases. Large pharmaceutical companies account for approximately 60% of the CRO market. Much of this work involves large phase III studies. Small biotechnology companies, which make up nearly 40% of the market, outsource primarily phase I and early phase II (proof of concept) studies. CROs are also more likely to be involved in study design. Some sponsors now use multinational CROs to conduct entire global drug development programs.
resources become inadequate because of an unforeseen study or a reduction in staff.

Advantages to tactical outsourcing are that the sponsor can exert maximum control over the project. Risk is limited by outsourcing a minimum scope of services (e.g. study monitoring but not data management and analysis). Many sponsors believe it is less costly to use in-house resources, although Hill (1994) suggests that the costs of contracting out are roughly equivalent. A further advantage is that the sponsor maintains in-house drug development expertise.

However, tactical outsourcing has significant disadvantages. It is likely that in-house staff exceeds needs from time to time. If development of a poorly performing drug is terminated, the result may be layoffs, severance payments and relocation costs. A project in a new therapeutic area may require new personnel knowledgeable about that area. Staffing up for large phase III studies, which typically involve thousands of patients, is expensive and time consuming. Minimizing the work contracted to CROs provides little opportunity for the sponsor’s staff to acquire the necessary skills to work with CROs when they are needed. If the sponsor delays the decision to use a CRO until the last minute, finding and contracting with the CRO may delay the study and the NDA or Marketing Authorization Application. The pressure to select a CRO provides inadequate opportunity to define the sponsor’s needs and select the right CRO.

**Project outsourcing**

With this strategy, the sponsor outsources nearly all of its clinical development activities to CROs. Some pharmaceutical senior executives have expressed the desire to minimize in-house staff and outsource ‘everything’. Small companies may have minimal, if any, drug development staff and must rely extensively on CROs.

This strategy has the advantage of minimizing fixed costs and eliminates the need to acquire detailed expertise when the sponsor enters a new therapeutic area. However, there are many disadvantages to project outsourcing. Minimal sponsor involvement in a study may lead to deficiencies in quality, cost and timing. Contracting early phase II studies to a CRO reduces contact with investigators and may prevent the sponsor from learning important information about the drug. The sponsor risks losing in-house drug development expertise, which many consider to be a core competency, and has no ‘fallback’ option if it is dissatisfied with the CRO’s performance.

**Strategic outsourcing**

This approach uses a mix of in-house and outside resources. It is closest to the modern view outlined earlier. The sponsor conducts phase I and early phase II studies, and hires CROs to conduct larger and routine studies (e.g. late phase II and phase III). An important corollary of strategic outsourcing is that CROs are prequalified according to projected sponsor needs. Relationships are developed between the sponsor and certain CROs that can perform particular types of studies.

Advantages to strategic outsourcing include quick feedback from investigators during early studies and the focusing of in-house staff on ‘core’ needs, such as designing the clinical program, conducting initial studies and managing CROs. In-house drug development expertise is maintained. Because the sponsor uses in-house resources for early studies, there is more lead time to select and contract with a CRO. The two difficulties with this approach are (a) that personnel must be trained on how to work with and manage a CRO, and (b) that the sponsor must ensure compatibility between its standards and procedures and those of the CRO (e.g. ensure database compatibility).

People working in pharmaceutical companies are often unprepared for their new role of working with a CRO. Pharmaceutical drug development staff consist of highly skilled technical people, for example, physicians, clinical research associates (CRAs), data managers, statisticians, medical writers, who joined the industry to utilize their skills. Those jobs are increasingly located in the CRO industry. The new job – managing other people who are performing these tasks – is one
for which few, if any, people have been formally trained.

### 54.3 Frequent causes of sponsor/CRO problems

Problems with contracted studies can often be traced to one of three causes:

1. *The wrong CRO is selected.* Sponsors often make the mistake of assuming that a CRO that has performed well on one study will be equally capable of conducting a study in a different therapeutic area. Some sponsors mistakenly assume that all CROs are the same, and that it is not possible to determine which one will be most capable of performing a specific planned study.

2. *The sponsor fails to articulate its needs clearly.* Sponsors sometimes issue a request for proposal (RFP) with little more than a protocol outline, and expect CROs to guess what services and resources are required. The result of inadequate information is that CROs underestimate the sponsor’s needs, assigning insufficient numbers of personnel or inadequately trained staff to the study. This can result in errors, delays and cost overruns.

3. *The sponsor fails to manage the study.* Sponsors sometimes make the mistake of assuming that in-house resources are not needed once the study is outsourced. In most cases, the sponsor should continue to play a critical role in a contracted study, providing guidance to the CRO and ensuring that agreed standards and time-lines are achieved. There is no such thing as a ‘turn-key’ project managed by a CRO.

### Three critical steps to ensure success with a CRO

In order to ensure successful outsourcing, the sponsor should focus on three critical steps:

1. Determine accurate study specifications

2. Select the right CRO

3. Manage the study

The remainder of this chapter outlines the benefits of these steps and describes specific activities that sponsors should carry out to ensure successful outsourcing.

### 54.4 Determine study specifications

Study specifications are a list of activities required to initiate, conduct, analyze and report the results of a clinical study. They include tasks that will be performed in-house and those to be contracted out to one or more CROs (Vogel and Nelson, 1993).

#### Importance of accurate study specifications

Accurate study specifications are a critical tool for planning a study. They assign responsibility to the various disciplines involved in the study (e.g. clinical research, regulatory affairs, data management, clinical manufacturing, programming, statistics and medical writing). By comparing study specifications with internal capabilities, the sponsor can identify activities that must be contracted out. This analysis also provides useful criteria for selecting the right type of CRO, a niche provider or full-service CRO. Study specifications also enable the sponsor to make more accurate projections of study costs and timing.

Study specifications are an essential element of the sponsor’s RFP and the CRO’s proposal. Study specifications should be included in the RFP in order to familiarize CROs with the sponsor’s project and goals. Study specifications enable the CRO to break down the individual tasks and materials on which it is asked to quote cost and timing, and provides a useful format for the budget proposal.

Accurate study specifications enable the CRO to perform a ‘reality check’ on the sponsor’s expectations. Often, CROs add items to the study
specifications (e.g. activities or materials to be provided by the sponsor or other CRO services) that the sponsor may have overlooked. Moreover, CROs can and do decline to submit a proposal because they believe the sponsor’s study specifications describe an unachievable study plan (especially with small companies). The study specifications also enable the sponsor to conduct a ‘reality check’ on the CRO’s understanding of the study and to determine that the proposal covers the project scope. Study specifications facilitate comparison of proposals from different CROs and help ensure that the sponsor’s attention is focused on the resources the CRO will provide, as well as on the proposed budget.

Study specifications are also an important tool for managing the study. They help define the various in-house disciplines that will be interacting with the CRO and to project the level of sponsor involvement required. They help focus the sponsor’s attention on the deliverables and provide milestones and timelines to assist the sponsor in measuring study progress. Accurate study specifications promote a thorough evaluation of the CRO’s performance during, and on completion of, the study.

The study specifications worksheet

An example of a study specifications worksheet is shown in Figure 54.1. The first page of the worksheet, entitled Study Details, is designed to provide an overview of the study and includes information on key parameters, such as the number of patients, number of visits, expected enrollment rate and number of sites. It also includes information on the healthcare setting (e.g. academic medical center, private practice or managed care) and the regulatory status of the product. The Materials and Actions section of the worksheet is divided into 21 categories, chosen after consultation with several CROs and designed to be consistent with activities on which CROs base their bids.

In order to facilitate the process, sponsors should use the suggested categories. Within each category are several specific activities listed as examples. The sponsor may list as many specific activities as appropriate for the study. For each activity, the sponsor should indicate whether that activity will be the sponsor’s responsibility or the CRO’s responsibility by placing a check in the appropriate column. In those cases where the sponsor feels that the activity will be shared with the CRO, sponsors should examine the activity to determine whether it could be broken down into more discrete items. This will minimize confusion over who actually is responsible for the activity. The last section of the study specifications worksheet is entitled Project Timeline. It contains the sponsor’s projected dates for completion of study milestones. Dauntingly, 26 suggested milestones are listed; the sponsor may wish to modify the list according to its own milestones. However, attention to these milestones at the beginning of a study will pay ample dividends later.

Preparing study specifications

Study specifications are typically prepared by the sponsor’s project team or the project leader. Small companies may hire a drug development consultant or CRO to help prepare study specifications. Ideally, preparation of study specifications should begin four to six months before the study begins. Details of all activities may not be available at this point, but sufficient lead time must be given for identifying the necessary services, evaluating in-house capability and selecting a CRO. Details can be added as they are identified.

The three Cs of CRO selection

The three most important criteria for selecting a CRO are as follows:

1. Capability
2. Compatibility
3. Cost
## STUDY SPECIFICATIONS WORKSHEET

<table>
<thead>
<tr>
<th>Study details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Project leader:</td>
</tr>
<tr>
<td>5. Study objective:</td>
</tr>
<tr>
<td>6. Study design:</td>
</tr>
<tr>
<td>7. Total number of patients:</td>
</tr>
<tr>
<td>11. Number of visits (treatment phase):</td>
</tr>
<tr>
<td>13. Expected enrollment rate:</td>
</tr>
<tr>
<td>14. Number of study sites:</td>
</tr>
<tr>
<td>16. Healthcare setting:</td>
</tr>
<tr>
<td>_____ Academic</td>
</tr>
<tr>
<td>_____ Private practice</td>
</tr>
<tr>
<td>17. Regulatory status:</td>
</tr>
<tr>
<td>_____ New IND</td>
</tr>
<tr>
<td>_____ Phase III</td>
</tr>
<tr>
<td>_____ Phase IV</td>
</tr>
</tbody>
</table>

*Figure 54.1* Study specifications worksheet (Reproduced with permission from Vogel and Nelson, 1993)
The most important criterion is **capability**. Can the CRO provide the needed services? Are the CRO’s personnel well qualified, and do they have experience in the therapeutic area? If the CRO is not capable of performing the study, then it will likely fail to meet the sponsor’s expectations. A disastrous outcome could delay product development, have a negative impact on the sponsor’s economic well-being and harm the careers of sponsor staff.

**Figure 54.1 (Continued)**

![Table](image)
## STUDY SPECIFICATIONS WORKSHEET

<table>
<thead>
<tr>
<th>Activity</th>
<th>Sponsor's responsibility</th>
<th>CRO's responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>7. Site monitoring</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Conduct monitoring visits (at intervals of __ weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Maintain telephone contacts with study sites (at intervals of __ weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Provide written monitoring reports to sponsor (at intervals of __ weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. Communicate with sponsor via electronic mail</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>8. Site closeout</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Perform drug accountability audit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Dispose of unused clinical supplies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Provide closeout report</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>9. Regulatory auditing</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Audit study sites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Provide audit report</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10. Serious adverse event (SAE) reporting</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Submit SAE reports to sponsor</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11. Site management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Negotiate investigator grants/contracts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Manage investigator payments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Provide project status reports to sponsor at intervals of __ weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>12. Project management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Conduct project management meetings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Provide minutes of meetings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Provide project status reports</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. Provide data management reports</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13. Database design and validation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Design database</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Set up data-entry program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Create database</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Figure 54.1 (Continued)*
<table>
<thead>
<tr>
<th>Activity</th>
<th>Sponsor's responsibility</th>
<th>CRO's responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>14. Data cleanup</td>
<td>A. Write data management guidelines and edit specifications</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Run edit checks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Clean up case report forms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Perform Q.C. on ___% of CRFs</td>
<td></td>
</tr>
<tr>
<td>15. Data entry</td>
<td>A. Enter CRFs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Code adverse events and concomitant medications</td>
<td></td>
</tr>
<tr>
<td>16. Generation and review of tables</td>
<td>A. Prepare tables and listings</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Perform Q.C. on ___% of tables</td>
<td></td>
</tr>
<tr>
<td>17. Statistical plan and analysis</td>
<td>A. Generate statistical plan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Prepare shell tables and listings</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Perform analysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Write statistical methods</td>
<td></td>
</tr>
<tr>
<td>18. Integrated clinical and statistical report</td>
<td>A. Prepare integrated tables</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Write statistical methods</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Provide discussion of the significance of results</td>
<td></td>
</tr>
<tr>
<td>19. Manuscript preparation</td>
<td>A. Prepare draft manuscript</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Prepare up to ___ revisions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Prepare abstract</td>
<td></td>
</tr>
<tr>
<td>20. Drug packaging and distribution</td>
<td>A. Formulate and package drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Create randomization schedule</td>
<td></td>
</tr>
</tbody>
</table>
The second most important criterion is compatibility. Are the CRO’s procedures and practices compatible with the sponsor’s? Is the chemistry between the CRO and sponsor good? The sponsor should examine the CRO’s standard operating procedures (SOPs) and talk with CRO staff to determine not only whether the CRO is meeting the requirements of good clinical practices (GLP), but also whether its practices closely parallel the sponsor’s. CROs sometimes claim they can work ‘according to the sponsor’s SOPs’, but the results are likely to be disappointing if the two companies have vastly different approaches or use incompatible technologies.

The third important factor is cost. Equally important are the business terms. The sponsor must ensure that the CRO’s price and terms of agreement are acceptable. Sponsors are skeptical of low bids because they may result from the CRO underestimating the resources required to complete the project. High bids, however, may indicate that the CRO overvalues its services. Demands for large advance payment and imposition of severe penalties for cancellation should not be accepted.

Prequalifying CROs

Selecting a CRO requires effort by all sponsor disciplines involved in the study. Evaluating a large number of CROs is costly, time consuming and, in the short-term, unproductive. A more practical approach is to prequalify CROs to identify the most appropriate candidates for in-depth evaluation. This approach has several advantages. Not all CROs can perform the same range of services. Different CROs are experienced in particular therapeutic areas. Some CROs have more recent experience in conducting studies similar to that planned by the sponsor, or staff with special expertise. Promotional material received from CROs is often not very informative. Most CRO brochures look similar, make similar claims and do not enable the sponsor to differentiate among the large number of candidates. It is important for a sponsor to distinguish between ‘can do’ and ‘have done’. CROs are prone to claim they ‘can do’ whatever the sponsor wants. The sponsor should focus on what the CRO ‘has done’ and make its own predictions about what the CRO can do.

The automobile industry sets out an interesting model for the pharmaceutical industry to consider. Automobile manufacturers are essentially becoming design houses. The automobile industry has become highly adept at prequalifying suppliers of major components, while no longer putting out to bid each component for each assembly. Rather, they create specifications for major components, such as transmissions or braking systems, then turn to a small group of prequalified ‘first-tier’ suppliers.

<table>
<thead>
<tr>
<th>Materials and actions</th>
<th>Activity</th>
<th>Sponsor's responsibility</th>
<th>CRO's responsibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>21. Regulatory submissions</td>
<td>A. Prepare NDA/PLA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Prepare SNDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Prepare CANDA/CAPLA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. Prepare IND/NDA annual report</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>E. Prepare 120-day safety updates</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 54.1 (Continued)
## STUDY SPECIFICATIONS WORKSHEET

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Sign contract</td>
<td></td>
</tr>
<tr>
<td>2. Submit list of proposed study sites</td>
<td></td>
</tr>
<tr>
<td>3. Submit draft protocol</td>
<td></td>
</tr>
<tr>
<td>4. Enroll investigators</td>
<td></td>
</tr>
<tr>
<td>5. Protocol approval</td>
<td></td>
</tr>
<tr>
<td>6. Case report forms/MOPs approval</td>
<td></td>
</tr>
<tr>
<td>7. Hold multi-investigator meeting</td>
<td></td>
</tr>
<tr>
<td>8. Complete IRB approvals</td>
<td></td>
</tr>
<tr>
<td>9. Ship drugs/CRFs</td>
<td></td>
</tr>
<tr>
<td>10. First patient enrolled</td>
<td></td>
</tr>
<tr>
<td>11. Data management guidelines approved</td>
<td></td>
</tr>
<tr>
<td>12. 25% of valid patients completed</td>
<td></td>
</tr>
<tr>
<td>13. 50% of valid patients completed</td>
<td></td>
</tr>
<tr>
<td>14. 75% of valid patients completed</td>
<td></td>
</tr>
<tr>
<td>15. Last valid patient completed</td>
<td></td>
</tr>
<tr>
<td>16. Submission of first CRF to data management</td>
<td></td>
</tr>
<tr>
<td>17. Submission of last CRF to data management</td>
<td></td>
</tr>
<tr>
<td>18. Lock database</td>
<td></td>
</tr>
<tr>
<td>19. Transfer database to sponsor</td>
<td></td>
</tr>
<tr>
<td>20. Analysis plan and shell tables/listings</td>
<td></td>
</tr>
<tr>
<td>21. Draft statistical tables and listings available</td>
<td></td>
</tr>
<tr>
<td>22. Final statistical tables and listings available</td>
<td></td>
</tr>
<tr>
<td>23. Draft integrated study report</td>
<td></td>
</tr>
<tr>
<td>24. Final study report</td>
<td></td>
</tr>
<tr>
<td>25. NDA/PLA; SNDA; CANDA/CAPLA</td>
<td></td>
</tr>
<tr>
<td>26. Publication</td>
<td></td>
</tr>
<tr>
<td>27. Other (specify):</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 54.1  (Continued)**
to design, build and supply those components. Those on the cutting edge of drug development are moving in an analogous direction in their relationships with CROs.

**The request for information (RFI)**

This approach was first described by Vogel and Resnick in 1996:

- **Step 1.** From an in-house database, one of the various commercial directories of CROs, or a consultant’s database, the sponsor should select those CROs that offer the desired range of services and claim to have experience in the target therapeutic area.

- **Step 2.** The sponsor should contact each CRO and request the details of experience in the target therapeutic area. The CRO’s response should describe specific studies completed. For each study, the CRO should provide information on the range of services provided, the number of study sites, project enrollment, actual number of patients completed and the number of months required to complete the study. The CRO should also describe the expertise of personnel who are likely to be involved in the project.

- **Step 3.** The sponsor should review the responses from the CROs and select several of the most qualified ones for on-site visits.

**Leveraging CRO experience**

There are several advantages to prequalifying CROs and placing emphasis on the CRO’s expertise in the target therapeutic area. A CRO with such expertise may be able to provide valuable input to the study plan and should have a ready list of qualified investigators, which can save the sponsor’s time. The CRO will be able to make more accurate predictions of patient enrollment if those estimates are based on recent experience rather than optimistic projections from study sites. In addition, experienced CRO staff will likely be more efficient at study monitoring, problem solving, data clean-up and report writing.

It may be possible to leverage the skills of a number of different CROs with competencies in specific areas to create a ‘virtual’ drug development process. Ideally, highly specialized, narrowly focused companies provide their services along the value chain of drug development, leaving the sponsor’s role as one of initial discovery of the chemical entity, then management of the drug development process and the value chain. Today, most sponsors contract with full-service CROs and closely manage the project, but some are exploring the advantages of using multiple ‘niche providers’ as a ‘virtual’ CRO (Lightfoot and Vogel, 1996).

### 54.6 Requesting and evaluating proposals from CROs

After conducting on-site visits to prequalified CROs, a sponsor should select three to five CROs who will be invited to submit a proposal.

**Contents of the RFP**

The RFP consists of a cover letter, detailed instructions to proposers, a copy of the study protocol, the completed study specifications worksheet, a resource allocations worksheet and a copy of the sponsor’s standard CRO agreement. The cover letter should briefly describe the study goal, provide an overview of the clinical plan, specify the proposal due date, indicate that the CRO may be invited to present its proposal orally to the sponsor and specify the timing for the sponsor’s reply. The CRO should be given approximately two weeks to prepare a proposal, and the sponsor should expect to reply to the proposals within two weeks.

**Instructions to bidders**

Subjects to be covered in the instructions to bidders are listed in Table 54.3. Under the general
Table 54.3 Instructions to bidders

General requirements:
- Confidentiality
- Discrepancies and omissions
- Preparation costs
- Form of proposal
- Modification and withdrawal
- Contract award
- Return of documents
- Subcontracting

CRO’s qualifications:
- Capabilities
- Experience
- Key personnel
- Study plan
- Investigator recruitment plan
- Availability of patients
- Project management
- Communication with sponsor
- Business terms
- Insurance

CRO’s services and fees:
- Activities to be performed by the sponsor
- Services to be provided by the bidder
- Resource allocations
- Service fees
- Estimated pass-through costs

requirements section, the sponsor should specify the following:

1. **Confidentiality**: The CRO must treat all information in the RFP as confidential.

2. **Discrepancies and omissions**: The CRO is responsible for bringing these to the sponsor’s attention.

3. **Preparation costs**: The CRO bears the cost of preparing and submitting the proposal.

4. **Form of proposal**: The proposal must be in the format prescribed by the sponsor and must address all areas of the RFP.

5. **Modification and withdrawal**: The responder may modify or withdraw the proposal if the sponsor receives notice prior to the proposal due date.

6. **Contract award**: The sponsor has the right to select the successful proposal or not to award the contract.

7. **Return of documents**: The CRO must return the RFP if requested.

8. **Subcontracting**: The CRO may not subcontract services without the sponsor’s permission. The sponsor has the right to evaluate and approve the subcontractor.

In the section on CRO qualifications, the sponsor should ask the CRO to address the following:

9. **Capabilities**: Provide a brief description of the services offered and how they relate to the activities requested.

10. **Experience**: Summarize experience in the therapeutic area, including the number of prior studies conducted by personnel who are still on staff (for each study, include number of study sites, number of subjects, study duration and range of services) and cite the relevant experience gained by staff while in previous academic, industry or external positions.

11. **Key personnel**: Briefly describe the training and experience required for key positions that will be involved in the present study (e.g., project manager, medical director, CRA, data administration manager, database administrator, programmer, statistician, medical writer and regulatory affairs manager) and provide resumes of typical personnel in these positions.

12. **Study plan**: An overview of the study design and plan for implementation.

13. **Investigator recruitment plan**: How qualified investigators will be identified (e.g., database, previous study) and evaluate their appropriateness for the study.

14. **Availability of subjects**: How subjects will be recruited (e.g., subject database, advertising) and predict the enrollment rate.
15. **Project management**: An overview of the plan to coordinate sites and manage study initiation, execution, data cleanup, analysis, report preparation and regulatory services.

16. **Communication with sponsor**: The frequency and formats for periodic progress/status reports, ability to establish specific electronic links with the sponsor (e.g. e-mail, secure website) and meetings with the sponsor.

17. **Payment terms**: Terms and milestones for sponsor payments.

18. **Insurance**: A copy of insurance certificates for clinical trials insurance and forms of mutual indemnity.

The section on CRO services and fees should instruct the CRO to describe the following:

19. **Activities to be performed by the sponsor**: This is a list of the materials and activities the CRO expects the sponsor to provide.

20. **Services to be provided by the CRO**: This is a list of the materials and services the CRO will provide.

21. **Resource allocations**: This is a list of the types of personnel to be involved in the study, the estimated number of hours/FTEs for each skill level and the fee charged for each skill level (see the resource allocations worksheet described below).

22. **Service fees**: Identification of the cost for each category of service listed in the study specifications.

23. **Estimated pass-through costs**: Estimates for costs that will not be subjected to mark-up (e.g. travel, central laboratory, central IRB, investigator grants).

### The resource allocations worksheet

The principal criterion for selecting a CRO, **cap-** and amount of effort (hours/FTEs) the CRO proposes to use to conduct the study. Cost, which is another important selection criterion, is determined by the rates charged for each skill level. CROs should be required to summarize these data in a resource allocations worksheet (Figure 54.2; Vogel and Resnick, 1996).

The worksheet lists the same 21 service categories addressed by the sponsor in the study specifications worksheet. For each category, the bidder should list the types of personnel who will be involved in performing that service. For each type of personnel, the CRO should define the number of hours/FTEs, the rate charged per unit of time and the total cost for that person to perform that service.

Figure 54.3 shows two examples of resource allocations for protocol preparation. On the bottom, the CRO proposes a team, consisting of a project physician, project manager, statistician, CRA, medical writer and secretary, with a total cost of $39120. The top shows another proposal for the same activity, where the task of writing the protocol is assigned to a physician, who will be billed at $200/h, with a total cost of $52 000.

The resource allocations enable the sponsor to make a more critical evaluation of a proposal than if the cost of each service was simply listed. In both these examples, the cost of writing a protocol is about $52 000. However, most sponsors would agree that the ‘team approach’ is highly preferable to assigning the task to an individual physician. Without the resource allocations data, the sponsor would not have been able to differentiate between the two proposals.

The sponsor should circulate the proposals to staff who represent the disciplines for which the CRO will be expected to provide services. Each staff member should review the proposals and prepare written evaluations. A convenient way to compare several proposals is to use an evaluation form, such as that proposed by Vogel and Schober (1993), seen here as Figure 54.4.

After evaluating the proposals, the sponsor may decide to invite two or three CROs for a face-to-face meeting or a conference call, to provide an opportunity for each to present its proposal and
<table>
<thead>
<tr>
<th>ACTIVITY</th>
<th>PERSONNEL</th>
<th>EFFORT</th>
<th>RATE</th>
<th>TOTAL</th>
<th>ASSUMPTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. IND reporting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Protocol preparation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Case report form preparation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Pre-study preparation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Investigator meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Study initiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Site monitoring</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Site closeout</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Regulatory auditing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Serious adverse event (SAE) reporting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Site management</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Project management</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 54.2** Resource allocations worksheet (Reproduced with permission from Vogel and Resnick, 1996).
## RESOURCE ALLOCATIONS WORKSHEET - (Part B)

<table>
<thead>
<tr>
<th>ACTIVITY</th>
<th>PERSONNEL</th>
<th>EFFORT</th>
<th>RATE</th>
<th>TOTAL</th>
<th>ASSUMPTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>13. Database design and validation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Data cleanup</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. Data entry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16. Generation and review of tables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17. Statistical plan and analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. Integrated clinical and statistical report</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19. Manuscript preparation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20. Drug packaging and distribution</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21. Regulatory submissions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Figure 54.2 (Continued)*
## RESOURCE ALLOCATIONS EXAMPLES

<table>
<thead>
<tr>
<th>ACTIVITY</th>
<th>PERSONNEL</th>
<th>EFFORT</th>
<th>RATE</th>
<th>TOTAL</th>
<th>ASSUMPTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXAMPLE A  Protocol preparation</td>
<td>Project physician</td>
<td>260</td>
<td>150</td>
<td>39 000</td>
<td>Total = $39 000</td>
</tr>
<tr>
<td>EXAMPLE B  Protocol preparation</td>
<td>Project physician</td>
<td>80</td>
<td>150</td>
<td>12 000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Project manager</td>
<td>24</td>
<td>80</td>
<td>1920</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Statistician</td>
<td>48</td>
<td>100</td>
<td>4800</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CRA</td>
<td>120</td>
<td>80</td>
<td>9600</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical writer</td>
<td>160</td>
<td>50</td>
<td>8000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Secretary</td>
<td>80</td>
<td>35</td>
<td>2800</td>
<td>Total = $39 120</td>
</tr>
</tbody>
</table>

*Figure 54.3*  Resource allocations examples (Reproduced with permission from Vogel and Resnick, 1996).
CONTRACT RESEARCH ORGANIZATION BID EVALUATION FORM

<table>
<thead>
<tr>
<th>Selection parameter</th>
<th>CROs (Score 1–5)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CRO A</td>
</tr>
<tr>
<td>1. <strong>Bidder’s qualifications</strong>—is it likely that the bidder will be able to provide the services required by the study?</td>
<td></td>
</tr>
<tr>
<td>2. <strong>Experience</strong>—does the bidder have adequate experience in the therapeutic area?</td>
<td></td>
</tr>
<tr>
<td>3. <strong>Key personnel</strong>—do the personnel in key positions have adequate training and experience for these positions?</td>
<td></td>
</tr>
<tr>
<td>4. <strong>Study plan</strong>—do the bidder’s overview of the study design and plan for its implementation accurately reflect the sponsor’s needs?</td>
<td></td>
</tr>
<tr>
<td>5. <strong>Investigator recruitment plan</strong>—has the bidder presented a convincing plan (e.g. investigator database, list from recent study) for recruiting qualified investigators?</td>
<td></td>
</tr>
<tr>
<td>6. <strong>Availability of patients</strong>—does the bidder have a reasonable strategy (e.g. patient database, advertising) for recruiting patients and is the projected enrollment rate realistic?</td>
<td></td>
</tr>
<tr>
<td>7. <strong>Project management</strong>—Has the bidder described an appropriate plan for coordinating sites and managing the study?</td>
<td></td>
</tr>
<tr>
<td>8. <strong>Communication with the sponsor</strong>—are the proposed frequency and formats of written and telephone reports acceptable?</td>
<td></td>
</tr>
<tr>
<td>9. <strong>Activities to be performed by the sponsor</strong>—is the list of the sponsor’s obligations accurate?</td>
<td></td>
</tr>
<tr>
<td>10. <strong>Services to be provided by the bidder</strong>—does the list of materials and services to be provided by the bidder agree with the sponsor’s study specifications?</td>
<td></td>
</tr>
<tr>
<td>11. <strong>Resource allocations</strong>—for each activity to be performed by the CRO, are the types of personnel appropriate and are the estimated workloads (FTEs) realistic?</td>
<td></td>
</tr>
<tr>
<td>12. <strong>Costs</strong>—are the estimated costs reasonable?</td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL SCORE:</strong></td>
<td></td>
</tr>
</tbody>
</table>

Figure 54.4  Contract research organization bid evaluation form (reproduced with permission from Vogel and Schober, 1993).
54.7 Managing the sponsor–CRO relationship

Defining accurate study specifications and selecting the right CRO are critical to achieving success in an outsourced study. However, careful attention must also be paid to managing the study and the sponsor–CRO relationship. The sponsor may mistakenly assume that, once the study is contracted, its staff can be fully allocated to other projects. In fact, a significant in-house effort is needed to manage the project. Most sponsors report that managing an outsourced project requires at least 20% of the resources that would have been needed to conduct the same project in-house.

The sponsor should follow three principles for managing an outsourced project:

1. Clarify the roles and responsibilities of the sponsor and CRO.

2. Define and use ‘performance metrics’ to measure study progress.

3. Ensure efficient communication between the sponsor and CRO.

Sponsor roles and responsibilities

It is the sponsor’s responsibility to design the study, determine which materials and actions it provides and define the services it requires from the CRO. Accurate study specifications communicate this to CROs. The sponsor must also ensure that the CRO understands and agrees to its expectations. Evaluation of proposals by a multidisciplinary sponsor team, with special attention paid to proposed resource allocations, helps the sponsor verify that CROs understand its needs and provide a reasonable plan to meet them.

The study specifications and the contract with a selected CRO identify key study milestones and timelines. These help ensure that the study is completed on schedule. However, in practice, the intervals between milestones are too long to enable the sponsor and CRO to make mid-course corrections and keep the study on target.

The sponsor needs to monitor CRO accomplishments using objective outcome measures (see discussion of ‘performance metrics’ below). The sponsor must recognize red flags that signal the need for corrective action. If requested by the CRO, the sponsor should assist in resolving problems by providing needed information and, if appropriate, making amendment to the study protocol. Such assistance should be provided in timely fashion and should involve the appropriate level of authority at the sponsor.

Despite the sponsor and CRO’s best efforts to predict all aspects of the study, there often arise occasions on which the study requires CRO services that exceed expectations. In these cases, the sponsor must be prepared to negotiate a ‘change order agreement’ to cover the expenses of additional CRO services. In certain cases, the sponsor may approve a change order that amends the study timeline. Sponsor roles and responsibilities are summarized in Table 54.4.

CRO roles and responsibilities

The CRO should evaluate the feasibility of the sponsor’s study plan. If the sponsor has provided detailed study specifications and the CRO is experienced in the target therapeutic area, it will be possible for the CRO to compare its past experiences with the sponsor’s projections and to identify any inconsistencies. If the CRO believes it cannot achieve the sponsor’s expectation (e.g. enroll three patients/month at each site in an arrhythmia study), it is important to bring it to the sponsor’s attention and negotiate a more realistic goal.

The CRO has a responsibility to staff the study with adequate numbers of competent, well-managed personnel. This can present a challenge,

<table>
<thead>
<tr>
<th>Table 54.4</th>
<th>Roles and responsibilities of the sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Define the study specifications</td>
<td></td>
</tr>
<tr>
<td>Provide information to the CRO</td>
<td></td>
</tr>
<tr>
<td>Monitor results</td>
<td></td>
</tr>
<tr>
<td>Recognize ‘red flags’</td>
<td></td>
</tr>
<tr>
<td>Resolve problems</td>
<td></td>
</tr>
<tr>
<td>Approve changes in ‘scope’</td>
<td></td>
</tr>
</tbody>
</table>
especially in areas prone to high turnover, such as CRAs. The CRO must have an adequate training and evaluation program to ensure staff performance and must not promote inexperienced personnel to critical positions, such as project manager. It is the CRO’s responsibility to conduct the study activities as prescribed in the study specifications and the sponsor–CRO agreement.

Despite the CRO’s best efforts, problems will arise. Too often a CRO tries to solve a problem without bringing it to the sponsor’s attention. Valuable time may be lost if the sponsor, which could have provided useful information to the CRO, is not consulted. When a problem cannot be readily resolved, the CRO should bring it to the sponsor’s attention and present proposed solutions. The CRO should also ensure that proposed solutions are practical and cost-effective. The CRO’s experience with similar studies may be an asset in solving the problem. CRO roles and responsibilities are summarized in Table 54.5.

### Performance metrics

Identification and communication of problems requires that the two parties agree on what constitutes a true problem. Often a sponsor identifies what it believes to be a significant variance, yet the CRO fails to respond because experience tells it that the variance will not have an impact on the end result. The result of this miscommunication is that the sponsor loses trust in the CRO, and the relationship is harmed.

Performance metrics allow the sponsor and CRO to measure the same thing. Performance metrics are systematic and objective measures of CRO and sponsor performance. Their validity is established by demonstrating that they are related to achieving quality, ensuring timeliness and managing cost. Performance metrics should be negotiated between the sponsor and CRO prior to the study.

They can be established for the qualifications of CRO personnel (e.g. a senior CRA must have at least two years of clinical research experience); timing and content of reports (e.g. the CRA’s monitoring report must follow the format of the example given, and a copy of the report must be received by the sponsor within two weeks of the monitoring visit); patient enrollment (e.g. each site must enroll a minimum of 10 patients/month for the first four months of the study); cycle times (e.g. questions on case report form content, ‘queries’, must be generated within one week of receipt of the data by the CRO); database accuracy (e.g. the error rate as determined by comparing actual case report forms with the CRO database must be no more than 0.01); billing practices (e.g. the CRO will invoice the sponsor for the exact amount paid to investigators without a mark-up); and compliance audits (e.g. the CRO must have written, detailed, SOPs, for various activities and must be able to demonstrate that its staff routinely complies with the SOPs).

Performance metrics enable the sponsor to focus on the outcome (managing the CRO) rather than the process (micromanaging the CRO). Micromanaging the CRO by analyzing and monitoring its internal processes is disruptive and conveys a message of mistrust. Performance metrics help distinguish between the sponsor’s role, to verify that the CRO is achieving the agreed-upon standards and timelines, and the CRO’s role, to select the most appropriate processes to achieve these objectives. When performance metrics demonstrate that the CRO is failing to meet the objective, the sponsor and CRO have a shared responsibility to examine the process and agree on an appropriate solution. After corrective actions have been taken, the performance metrics help demonstrate that the desired effect has been achieved.

### The sponsor–CRO communication/decision-making model

The CRO’s team members are expected to carry out the study activities, whereas the sponsor’s team
functions as a resource to the CRO. Most interactions between the sponsor and the CRO will take place between the individual team members and their technical counterparts. Discussions between sponsor and CRO technical staff should focus on information exchange and issue identification. Team members should inform their respective project managers of all communications between sponsor and CRO personnel. The benefit of informing the project manager of all issues is that the project manager can compare input from different team members, relay information to other team members as necessary and detect issues that may not yet be apparent to the team.

Project managers are responsible for ensuring that their respective teams perform as expected. This may require them to negotiate with functional department heads to acquire needed resources, or to resolve a performance problem. Like any other human interaction, when a problem arises between the sponsor and CRO, project managers with a good relationship are most likely to negotiate a mutually acceptable solution and document the same in a change order, when appropriate. Technical team members should not independently negotiate changes with their counterparts.

54.7 MANAGING THE SPONSOR–CRO RELATIONSHIP

6. To define those changes that can be agreed upon informally and those that require a formal change order.

The meeting should begin with introductions of team members and their respective project managers. It is recommended that both sponsor and CRO senior managers make brief presentations, underscoring the importance of the study and reinforcing that the project managers have ‘bottom line’ responsibility. Additional activities include a review of the performance metrics, explanation of the responsibilities of the sponsor and CRO project managers, review of the responsibilities of the sponsor and CRO teams, description of the communication/decision-making process, and discussion of problem-solving procedures.

The meeting should include exercises designed to teach team members how to recognize behaviors that enhance and impair sponsor–CRO relationships. Participants should also engage in role-playing designed to teach efficient problem-solving techniques. In order to be most effective, the role-plays should be based on scenarios that are likely to occur in the planned study. Down-time (e.g. pre-meeting dinner and socialization in the hotel bar) can be invaluable in the long run.

**Sponsor–CRO study initiation meeting**

The sponsor and CRO teams should hold a ‘kick-off’ meeting prior to initiation of the study. The goals of the meeting are listed as follows:

1. To promote camaraderie and ownership of the study among team members.

2. To clarify the roles and responsibilities of the sponsor and CRO.

3. To identify the primary sponsor and CRO contacts.

4. To present the agreed-to performance metrics and audit procedures.

5. To define the approach to problem resolution.

**Sponsor–CRO periodic oversight meetings**

The sponsor and CRO should meet formally at an agreed frequency, and certainly not less than once every three months. The attendees should include the project managers and their respective team members, as determined by the status of the study and the topics to be discussed. The goals of periodic oversight meetings are listed as follows:

1. To review the status of the study milestones and timelines.

2. To review the budget in terms of cost-to-date, change orders executed and the latest projection for total cost.
3. To identify ways in which the sponsor and CRO have each significantly advanced the study.

4. To identify opportunities for improvement.

54.8 Identifying and resolving problems

Problems during the study always occur. The goal is to identify them an early stage, so that they have minimal impact on study cost, timing and quality. It is also important to address problems when they are small enough to be easily resolved. Earliest detection of problems will likely take place at the technical level. Members of the sponsor and CRO teams will readily perceive issues in their individual technical areas. It is important for a team member to inform the project manager of any issue before attempting to resolve it. This information will enable the project manager to determine whether the problem is an isolated case, which can be resolved at the technical level, or if it is part of a larger problem that needs to be addressed with the corresponding project manager.

Ten 'red flags'

Red flags are early warnings that may not require immediate action, but should be evaluated to determine whether a significant underlying problem exists. Each team member may wish to prepare a list of red flags for his/her individual technical area. Ten typical red flags and the possible significant underlying problems are as follows:

1. Selection of inexperienced investigators by the CRO: The CRO monitoring staff may be inexperienced.

2. Questions from the study site directed to the sponsor: The CRO may not have provided adequate training to site personnel.

3. Inadequate monitoring reports from the CRO: The CRO monitoring staff may not be receiving adequate training and supervision.

4. Enrollment of patients who do not fit the study criteria: The investigator may not understand the study protocol.

5. A higher screening-to-enrollment ratio at one site than at others: The investigator may be ‘padding the budget’ by performing unnecessary screening procedures.

6. Failure of the CRO to submit monitoring reports promptly after completing visits: The CRO may not have adequately staffed this study.

7. Frequent rescheduling of meetings and reports by the CRO: The CRO staff may be carrying excessive workloads.

8. Delays in cleaning up case record forms (CRFs): The CRO may be processing CRFs in batches, which can hide monitoring problems and delay study completion.

9. Changes in CRO personnel: The CRO may be experiencing labor problems.

10. Unscheduled request for payment by the CRO: The CRO may be experiencing financial problems.

Sponsor–CRO end-of-study meeting

The sponsor and the CRO should hold a formal meeting at the end of the study. The goals of this meeting are listed as follows:

1. To review the actual budget and timeline as compared to the sponsor’s and the CRO’s expectations.

2. To characterize the quality and timing of materials and activities performed by the sponsor and of the services performed by the CRO.

3. To discuss follow-up of any unresolved issues (e.g. cost overruns, incomplete services).
Conclusions

In summary, more effective contracting of clinical drug-development activities to CROs can be achieved by applying the following methods:

1. Use a strategic approach to outsourcing.

2. Follow the three principles for achieving success with CROs: define accurate study specifications, select the right CRO and manage the study.

3. Select CROs according to the three Cs: capability, compatibility and cost.

4. Evaluate the CRO’s resource allocations.

5. Define the performance metrics.

6. Ensure efficient communication with the CRO.

It is important to recognize that the roles and the responsibilities of the sponsor and the CRO are complementary. Dedication and skill are required of both the sponsor and the CRO team members to achieve successful outsourcing.

References


After rising sharply during the 1970s and 1980s, overall healthcare costs in the United States leveled in the 1990s, only to start soaring again in 2000, with projections to rise to unprecedented levels in future years. The control of healthcare costs during the 1990s has been attributed to the dramatic growth of managed care with tight cost management procedures. In fact, health plan premium increases were at a record low from 1994 to 1998. Conversely, health-benefit costs increased nearly 15% in 2002, while inflation was around 2% (PricewaterhouseCoopers, 2002). The paradigm shift from a largely fee-for-service (FFS) to a managed care environment in the late 1980s and early 1990s affected every aspect of the healthcare system, including the pharmaceutical industry. Managed care organizations (MCOs) brought healthcare costs under control through a variety of strategies, including controlled access to healthcare providers, health plan benefit limitations and restrictions, including pharmacy benefits and products, and capitated reimbursement systems.

Although satisfied with the results of slowed increases in healthcare costs, purchasers and consumers were less satisfied with restricted access to providers and benefit limitations and restrictions. This criticism received much media attention. As a result, purchasers and consumers have pressured MCOs to abandon procedures that worked in the 1990s. Furthermore, recent trends show a move away from tightly managed health benefit plans to more conventional indemnity plans. Official forecasts, however, conclude that a rapid departure of managed care principles would significantly increase the rising cost problem, and that developments in managed care will influence, at least to some extent, healthcare costs over the next five years. In addition to this increased consumer demand, other factors driving rising healthcare costs include drugs and medical advances; profit margins on healthcare products and services, rising provider expenses; government mandates and regulation; litigation and risk management; general inflation and other miscellaneous factors such as fraud and abuse (PricewaterhouseCoopers, 2002). Foremost among these cost drivers are drugs, medical devices and other medical advances, accounting for 22% of the overall increase, or $15 billion of the increase in premiums (PricewaterhouseCoopers, 2002).

With prescription medications continuing to account for an increasing proportion of total medical costs, MCOs are being forced to implement new drug benefit management techniques such as multilitered formularies, higher co-pays and deductibles. Traditionally, managed care impacted
pharmaceutical products after reaching the market through pharmacy benefit restrictions, limitations and product formularies. Today, managed care is influencing pharmaceuticals much earlier in the product life cycle. In many cases, the impact is being felt before a product even enters the market.

MCOs are a major customer to the pharmaceutical industry, with increasing leveraging and purchasing power. Therefore, MCOs have had a profound impact on how the pharmaceutical industry develops, markets, distributes and generates revenue for products. This impact will only increase in the future. This chapter will introduce basic concepts in managed care, discuss the impact of managed care on the pharmaceutical industry and conclude with a discussion of emerging trends in managed care and how they may impact the pharmaceutical industry in the future.

55.1 The concepts of managed care

The basic concepts of managed care have evolved and are continuing to evolve over time. To understand this evolution, a brief historical perspective is presented first, followed by discussions of the language and principles of managed care.

Historical perspectives

Surpassing traditional indemnity, or FFS health insurance policies, managed care health plans now represent the largest and fastest growing type of coverage for health and medical care in the United States. From a rather slow initial growth period, which began in 1929 with the establishment of the first prepaid group practice plan, managed healthcare has grown substantially over the last 25 years (Health Insurance Association of America, 1996). By the mid-1970s, approximately five million people were enrolled in prepaid group practice plans (MacLeod, 1993). As of 1997, over 83 million people were enrolled in health maintenance organizations (HMOs) alone (Hoechst Marion Roussel, 1998). According to the Health Confidence Survey (Employee Benefit Research Institute, 2001), approximately 90% of employees participating in employment-based health plans were enrolled in a managed care plan, up from 48% in 1992.

Concern over rapidly rising healthcare costs has been the driving force behind the rapid growth of managed care. Inherently, a FFS system, where reimbursement and compensation for services are directly related to delivery or utilization of services, has the potential to promote overutilization and drive costs upward. Alternatively, a managed care system, where payment for healthcare is typically prepaid or capitated, has more control over the utilization of services, and thereby costs. The potential of managed care to successfully control healthcare costs has long been recognized and supported by the federal government, starting with the HMO Act of 1973 to more recent healthcare reform initiatives, including the introduction, in 1998, of a Medicare Prospective Payment System (PPS) for nursing facilities.

In the managed care system, there are three major market segments – consumers, payers and providers – each with their own distinct groups. Individual health plan members or patients represent the consumer segment. Payers, who are largely defined by their purchasing power, include employer groups (e.g. larger employers, small employers, small business coalitions, cooperative purchasing arrangements, etc.), the government (e.g. government agencies, public insurance programs – Medicare and Medicaid, etc.) and MCOs (e.g. HMOs, preferred provider organizations (PPOs), etc.). Providers include healthcare organizations (e.g. accredited hospitals, ambulatory care centers, behavioral healthcare facilities, etc.), healthcare professionals (e.g. physicians, pharmacists, nurses, etc.) and, depending on their business model, may include MCOs.

Although each of these market segments and groups has unique concerns, they also share common goals, through which their collective actions are defining managed care. For example, managed care systems have an intrinsic conflict between prepayment for healthcare and underutilization of needed benefits and services. This conflict has given rise to a greater demand by consumers and providers for managed care to demonstrate quality.
of care, patient satisfaction and cost-effectiveness of selected services.

The language of managed care

To further explore the principles of managed care, an accurate knowledge of managed care terminology is essential. As managed care is an evolving paradigm, with new systems and models emerging continually, no single, universal definition exists for many of even the most basic managed care terms. Certain elements and characteristics, however, are commonly associated with each, in spite of variations in definition and interpretation by the various market segments.

A MCO is any type of system that integrates the financing and delivery of healthcare to voluntarily enrolled plan members. Common distinguishing characteristics of MCOs include

- arrangements with selected providers to deliver a comprehensive package of health plan benefits to enrollees;

- clear standards for selection of healthcare providers;

- a focus on wellness, preventive care and disease management to keep plan members healthy, and thereby reduce medical costs;

- formal quality improvement and utilization review programs.

Based upon how these healthcare delivery and financial management strategies are designed and implemented, MCOs are classified into different types or models — HMOs, PPOs, point-of-service (POS) plans and integrated service networks. In addition, pharmacy benefit management organizations provide specialized services to managed care.

A HMO is a type of MCO that offers comprehensive healthcare to voluntarily enrolled members, who prepay a fixed amount of money in exchange for access to a clearly defined package of health plan benefits. Generally, HMOs receive a fixed fee from members, regardless of whether healthcare services are utilized or not, that is they are prepaid on a capitated basis. A primary distinguishing characteristic of HMOs is that, upon enrollment, members are required to select a primary care physician (PCP), who not only delivers comprehensive care but also serves as the gatekeeper to specialty services, such as seeing a physician specialist. If a member seeks nonemergency services from an HMO provider without a referral from his/her PCP, or seeks services from a provider who is not affiliated with the HMO, then those services typically will not be covered by the health plan. With these two characteristics in common, HMOs are further characterized into basic models.

A staff model HMO owns its healthcare facilities and employs physicians and other providers to provide the healthcare services to its membership. All premiums and revenues accrue to the HMO, which compensates providers by salary and incentive programs. Alternatively, a group model HMO contracts with a group of physicians and other providers, who are organized as a partnership or professional corporation. The health plan compensates the medical group for contracted services at a negotiated rate, and then the group is responsible for compensating its physicians and contracting with hospitals and other providers for care of their patients.

A network model HMO is a health plan that contracts with many large physician groups and community pharmacies to provide care to its members. As with group model HMOs, network HMOs do not own their own facilities and typically compensate each provider group at a negotiated, capitated rate. Finally, an individual practice association (IPA) is an HMO model that contracts with independent physicians, pharmacies and providers in their own practice settings to provide medical services to its enrollees.

Recently surpassing HMOs as the most common type of MCO is the PPO. A PPO is an organization that contracts with providers to deliver healthcare services at a negotiated discount off of their standard fees or the usual and customary rate (UCR), which is the standard for those services in that geographical region. The PPO then encourages plan members to select providers from this network of preferred providers; however, it does not limit members to this closed panel of providers. By
selecting network providers, plan members pay lower co-payments and deductibles than if they were to select a nonnetwork provider. Also, unlike HMOs, plan members are not required to select a PCP. Typically, they may seek care from any network provider without penalty.

Another type of MCO is a POS plan, which is a hybrid between an HMO and PPO. Like HMOs, POS plans typically use PCPs to deliver the comprehensive set of health benefits and to serve as gatekeepers to control access or referrals to specialists. Like PPOs, POS plans also allow health plan members to use nonparticipating or nonnetwork providers at a reduced level of benefits (e.g. higher co-payments, higher deductibles, etc.). POS plans have emerged in response to needs and desires in both the consumer and payer market segments. Dissatisfied with both restricted access to providers in HMOs and higher premium costs associated with PPOs, consumers have responded favorably to the emergence of POS plans that blend the flexibility of PPOs with the lower costs of HMOs. HMOs have willingly developed such plans to gain competitive advantage over PPO plans.

A gradually increasing trend in managed care is the emergence of integrated services networks (ISNs). ISNs are large integrated organizations that incorporate facilities, providers and payers. These organizations provide patients with an array of healthcare services through providers who are affiliated under a single payment structure. Recent trends in managed care indicate increasing numbers of PPO, POS and IPA plans. This movement represents a shift from the more restrictive staff and group model HMO plans to the less restrictive types of managed care plans with open-ended coverage. According to the Health Confidence Survey (Employee Benefit Research Institute, 2001), 53% of managed care enrollees reported enrollment in PPO-type plans, compared to 37% in HMO-type plans.

According to 1997 statistics, 92% of HMOs engage a pharmaceutical benefit manager (PBM), that is a company to administer all or part of their pharmaceutical benefits and services (Hoechst Marion Roussel, 1998). Some of the basic functions provided by PBMs include dispensing, formulary management, mail-order drug dispensing, drug utilization reviews (DURs), prescription claims processing and academic or counter-detailing. Academic detailing supports formulary adherence through the use of educational interventions, such as telephone calls or letters, to prescribers. Among HMOs, over 90% of IPA and network models contract with PBMs, in contrast to 69.0% of staff model HMOs (Hoechst Marion Roussel, 1998). Overall, 86.9% of all managed care plans contract with PBMs for their prescription drug benefit claims processing services (Hoechst Marion Roussel, 1998) (Figure 55.1).

**Key principles of managed care**

Successful managed care systems deliver high-quality healthcare to their members, while maintaining low operating costs through effective application of basic principles of managed care. Three key issues addressed by these managed care principles include provider compensation, cost containment and quality of care.

Provider compensation includes the methods by which MCOs financially compensate or pay their providers. Provider compensation varies with the nature of the relationship between the MCO and the
provider (e.g. employer–employee, contractual agreements, strategic partnerships, joint ventures, etc.). Typically, payments are negotiated and may include a variety of methods, including the following:

- **Capitation**: The MCO negotiates with the provider, who agrees to provide a clearly defined set of healthcare services to plan members for a fixed amount per member per month (PMPM), regardless of the amount of services delivered.

- **Discounted FFS**: The MCO negotiates with the provider, who agrees to provide services to enrollees at a discount from their UCRs for FFS patients.

- **Per diem**: The MCO negotiates with a provider organization (e.g. accredited hospitals, ambulatory care centers, etc.), who agrees to deliver care for a fixed rate per day that an enrollee receives care.

- **Per case**: The MCO negotiates with the provider who agrees to deliver care for a fixed amount or rate of compensation per case for a specified illness or condition.

- **Risk-sharing**: The MCO negotiates with the provider, who agrees to deliver effective, efficient and high-quality care to all enrollees with some degree of financial risk.

Integral to these payment methods are their administrative methods. For example, two specialized approaches to assessing payment methods are carve-out and global costs. With carve-outs, the MCO negotiates with a specialized provider or service organization, such as a PBM, to provide a narrowly defined set of specific services. Reimbursement for these carve-out services, however, is usually on a capitated basis. With global costs, an MCO allocates all healthcare costs under one budget. Some MCOs may even negotiate with providers and healthcare facilities, who agree to receive a global fee for all professional services and institutional expenses for a particular episode of care or diagnosis, except optional benefits, such as medications. Typically, this global fee is capitated.

Although provider compensation methods are effective in controlling a significant proportion of managed care costs, they cannot work alone, as there are other priority issues that continually challenge managed care’s ability to deliver high-quality services, yet control healthcare costs. Cost-containment issues that influence business decisions in managed care include medical loss ratios (MLRs) and pharmacoeconomic and outcomes data.

The MLR is a cost:revenue ratio. It is calculated by dividing the total costs of delivering the health and medical care covered by plan benefits (i.e. total costs) by the total revenues received from members in the form of dues or premium payments (i.e. total revenues), and then multiplying by 100%.

\[
\text{Medical loss ratio} = \frac{\text{Total costs}}{\text{Total revenue}} \times 100\%
\]

From a business perspective, MCOs aim for low costs and high revenues, resulting in a small MLR. Managed care executives, however, must continually balance the demands of their various constituents to achieve an acceptable MLR, for example members want unlimited access to providers and the very best medical treatments with zero-to-low annual premium increases, while shareholders and investors want operating costs (e.g. medical costs, provider compensation, etc.) held to a minimum with annual premium increases. According to industry experts, these forces can be significant, as indicated by the sizable differences in MLRs for indemnity health insurance companies versus HMOs. For indemnity health insurance, the MLR is usually in excess of 90%. For cost-efficient HMOs, it is usually less than 80–85%.

When available, MCOs can use pharmacoeconomic and outcomes information to drive the choice for cost-efficient therapeutic alternatives. For this reason, pharmacoeconomic and outcomes data are becoming increasingly important to MCO decision makers, including formulary decision makers. Pharmacoeconomic and outcomes data tend to have the greatest impact on managed care decisions when the novel product or drug under consideration produces positive patient outcomes, or yields substantial cost savings within the first 6–12 months of initiation of
therapy, as compared to older, less expensive therapies. If positive pharmacoeconomic or patient outcomes are not seen until 2–5 years after initiating drug therapy, then the economic information tends to have a lesser impact on the MCO’s pharmaceutical benefit or drug therapy decisions.

Intrinsic to the principles of managed care is the conflict between the desire to control costs and the desire to promote quality of care. Two common measures of quality of care are health plan member satisfaction and health plan accreditation. Member satisfaction surveys assess the extent to which a managed care plan is able to satisfy the diverse needs of its members. Increasingly, member satisfaction is an important measure for MCOs because it can impact the ability of the plan to attract and retain new members, reduce turnover rates and achieve accreditation.

Accreditation of managed care plans is a relatively new process, driven by consumer demand for improved quality of care. In recent years, several nonprofit entities have developed mechanisms for evaluating and accrediting MCOs. The National Committee for Quality Assurance (NCQA) has emerged as the most recognized and respected among these. NCQA’s accreditation process is designed to assess, measure and report on the quality of care provided by managed care plans. To receive accreditation, a managed care plan must demonstrate the ability to provide consumers with protections required by the accrediting agency, and to continuously monitor and improve the quality of care for its members. Accreditation status is not an absolute guarantee of the quality of care that an individual plan member may receive, or that a network provider may deliver. As competition in the managed care market continues to stiffen, accreditation is becoming increasingly important to MCOs.

55.2 The impact of managed care on the pharmaceutical industry

In the late 1970s, pharmaceutical companies developed and marketed new products to physicians with minimal, if any, interference from third-party insurers and payers. Even in the mid-1980s, the pharmaceutical industry paid little attention to group- and staff-model HMOs because they imposed restrictions on sales representatives and demanded price concessions (Pollard, 1990). Over the last two decades, however, managed care plans have experienced sustained growth and consolidation and, in the process, demonstrated their ability to impact the pharmaceutical industry. For example, managed care plans have driven pharmaceutical costs down by demanding economic proof of a product’s cost-effectiveness, by measuring the impact of products on health status (e.g. patient outcomes, quality of life, etc.) and by integrating drug utilization into standard treatment protocols. Managed care plans represent a major customer base of the pharmaceutical industry and advancements in pharmacotherapy have had a profound impact on how pharmaceutical manufacturers develop and market products to MCOs.

To more fully understand the impact of managed care on the pharmaceutical industry, a look at managed care’s cost-containment strategies and continued movement toward multiple payers will be presented first, followed by the influential market dynamics of increased competition and changing demographics. Concluding the section will be a discussion of how these factors have impacted the pharmaceutical industry’s research and development priorities and product life cycles.

Managed care cost-containment strategies

According to current managed care industry estimates, prescription medications account for up to 15% of total medical costs for some managed care plans (Meyer, 1998). In addition, prescription drug costs are rising by 15–20% each year, much faster than other components of healthcare, for many managed care plans (Meyer, 1998). Furthermore, as the pharmaceutical industry introduces a rush of innovative and expensive drugs, MCOs are mounting defensive strategies to control prescription costs, yet maintain quality of care for their members. Managed care plans that have implemented integrated formulary and disease management...
programs, outcomes assessment and risk-sharing contracts have been more successful at controlling pharmaceutical costs than plans without such strategies.

Formulary management is the most common strategy used by managed care plans for controlling increasing drug costs and access to prescription medications. A formulary is a list of drug products that have been reviewed and approved for use in a particular medical setting. Typically, normal prescribing is restricted to drugs listed in the formulary. In general, drug products are classified into one of three categories: generic, preferred or non-preferred. A cost-containment strategy used by many MCOs is to encourage drug utilization of generic and preferred drug products only. A formulary system is a method of drug-use control that involves a systematic approach to evaluating drug products, providing guidelines for utilization, informing appropriate parties of current formulary status and policies, enforcing adherence to those policies and implementing the system.

Responsibility for developing, maintaining and enforcing formulary systems in managed care lies with the pharmacy and therapeutics (P&T) committee, which normally comprises health plan physicians and clinical pharmacists. Additional responsibilities of a managed care P&T committee may include development, implementation or maintenance of drug utilization policies, DUR programs, prescribing protocols, generic drug substitution policies and educational programs.

The formulary approval process for a new drug is a two-step process in managed care. Reimbursement status is determined in the first step; formulary inclusion in the second step. The decision for reimbursement usually occurs 0–6 months post-launch, and its purpose is to determine whether or not a product will be covered by the plan. Typically, this decision is made before the product is evaluated for formulary acceptance. An MCO will then determine whether or not the product will be included on the formulary by routing the new product through the plan’s formulary evaluation and decision process, which usually occurs 6–12 months after launch. This committee evaluates the new product and generally classifies it as either preferred or non-preferred. Therefore, under a managed care plan, US Food and Drug Administration (US FDA) approval of a new product is no longer a guarantee of unrestricted access to the product, as evidence of a drug product’s economic value is typically required prior to formulary acceptance.

In general, MCOs with formulary programs use a variety of methods to enforce formulary adherence to their preferred agents (i.e. generic and preferred drug products). These methods vary in their restrictions, and typically include financial incentives for both prescribers and patients. Table 55.1 lists and defines typical restriction methods, such as prior authorization and treatment limitations. Table 55.2 lists commonly used enforcement strategies and financial incentives, including switch programs, differentiated/tiered co-payments and education programs.

Of particular interest is the multitiered formulary with increasing differentials among the

| Table 55.1 Drug utilization restrictions used by managed care organizations |
|-----------------------------|-----------------------------------|
| Restriction                | Definition                                      |
| Prior authorization        | A physician or patient must receive authorization by the plan before the drug will be covered |
| Quantity limitations       | The amount of medications prescribed/dispensed is limited to a prespecified quantity (usually a monthly limit) |
| Specialist-only            | Only specialists are allowed to prescribe medication |
| Treatment limitations      | Treatments are limited on a per-member or per-year basis |
| Step protocols             | Treatments are restricted to a specific step in a protocol (i.e. a second- or third-line treatment in a protocol) |
| Patient criterion          | Patient must qualify for treatment by meeting specific criteria (usually used in conjunction with a prior authorization program) |
various product tiers. Tiered formulary benefits typically have three tiers with increasing patient co-payments. For example, generics may have a $5, preferred drug products a $15 and non-preferred agents a $25 co-payment. Depending on the product category, patients are responsible for paying the corresponding co-payment fee when purchasing their prescription. This cost-sharing system was designed to combat rapidly growing expenditures and to make consumers more accountable and involved in their healthcare decisions. With patient out-of-pocket drug costs rising and co-pay differences between tiers widening, the pharmaceutical industry can expect more patients to raise financial questions about branded products that their physicians prescribe. Accordingly, health plan members will increasingly be forced to make choices as financial priorities affect the traditional doctor–patient relationship (Studin, 2004).

An emerging trend in formulary management is the decline in the utilization of enforcement and restriction strategies such as switch and prior authorization programs (Litton et al., 2000). These programs typically have high administrative and internal resource costs, significant time consumption, limited success on drug utilization and dissatisfaction among patients and providers (Olson, 2002). Instead, MCOs are expanding their use of multtiered co-payment systems, and increasing the co-pay differentials between the tiers. When multtier systems were first developed, generally only a few dollars differentiated each level of tiers. Currently, it is not uncommon to see $15–$30 differences between single-tier levels (Fendrick et al., 2001). The benefits of using this type of system over switch or prior authorization programs are multifaceted in that the multtiered system is simple and economical to administer, offers patients a choice in making decisions without restrictive access to medications and provides a reasonable level of satisfaction compared with other programs (Olson, 2002).

In addition to use of multtiered co-payment systems to control costs, MCOs are frequently using generic incentives and mail-order delivery systems. Typical generic incentives are financially based, either being the lowest tier in a tiered system or having coupons offered to cover the co-payment for a one-month utilization. Audit reports have demonstrated that a mere 1% increase in generic utilization

Table 55.2 Formulary enforcement policies used by managed care organizations

<table>
<thead>
<tr>
<th>Enforcement policy</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Switch programs</td>
<td>Whereby physicians are called and asked to switch to a specific formulary product</td>
</tr>
<tr>
<td>Risk sharing</td>
<td>Policies whereby the physician (usually the primary care provider (PCP)) is placed at financial risk for providing services (including prescription drugs) to the patients</td>
</tr>
<tr>
<td>Financial penalties</td>
<td>Physicians are financially penalized for prescribing non-formulary products</td>
</tr>
<tr>
<td>Differential/tiered co-payments</td>
<td>Member’s prescription co-payments are higher for non-formulary products</td>
</tr>
<tr>
<td>Out-of-pocket payments</td>
<td>Members pay for non-formulary drugs (either a fixed amount/co-payment or the fee-for-service (FFS) cost of the prescription)</td>
</tr>
<tr>
<td>Education programs</td>
<td>Education programs for physicians (usually the PCP) to educate physicians on formulary products and selection criteria</td>
</tr>
<tr>
<td>Report cards/performance records</td>
<td>Monthly or quarterly reports comparing and evaluating physicians’ prescribing patterns are generated and distributed to all participating physicians</td>
</tr>
<tr>
<td>Intervention programs</td>
<td>Telephone calls and/or letters are sent to physicians prescribing non-formulary drugs</td>
</tr>
</tbody>
</table>
can result in a multimillion dollar savings to the plan (Olson, 2002). Mail-order service is another cost-containment strategy that MCOs use, including PBMs. Mail service pharmacy covers maintenance medications for up to a 90-day supply of medications at a reduced co-payment. Advantages of mail-order services include discounts on dispensing fees compared to retail pharmacies/networks; home delivery convenience for patients and the opportunity to manage cost and compliance (Pharmacy Benefit Management Institute, 2000).

With individual health plan members in a unique position to make independent purchasing decisions, the cumulative impact of increasing cost differences between product tiers and the availability of a broad array of generic products presents a marketing challenge to the branded pharmaceutical industry. Accordingly, the managed care business units of pharmaceutical manufacturers may need to address consumer-member marketing if they are to realize market share success and sustained product growth at the plan level (Studin, 2004).

The pharmaceutical industry has long challenged the necessity of formularies and related enforcement policies that restrict a prescriber’s choice. In response, pharmaceutical companies have engaged a number of their own strategies to counter managed care’s cost-containment practices. For example, they are funding pharmaco-economic, quality-of-life and other outcome studies to demonstrate the economic and societal value of a drug product, and thereby influence formulary acceptance by managed care decision makers. In general, MCOs view pharmaceutical industry-sponsored economic evaluations as useful in comparing therapeutically similar products; however, sponsor bias and applicability of study results to a plan’s population are major concerns (Luce et al., 1996). Out of all the research conducted by MCOs, economic studies have the greatest potential to guide formulary decisions.

Another increasingly important strategy for the pharmaceutical industry is assessing whether a new product’s therapeutic category is on the MCO’s ‘radar screen’. Criteria for inclusion of a product’s therapeutic category on an MCO’s radar screen include the following:

- The current budget and resources allocated for patients with the target disease;
- the ability of the plan to realize a significant return on investment if the disease is managed (i.e. cost-effectiveness) appropriately;
- the ability of the plan to provide staff for development and implementation of disease management programs;
- the ability of the plan to effectively measure the impact of a disease management program.

Because of increased difficulty in getting a new drug on an MCO’s formulary, it is now common for pharmaceutical companies to collaborate with managed care decision makers in ‘round table’ or ‘advisory board’ meetings. These discussions, which normally occur before product launch or as early as phases II and III of clinical development, are helpful in determining reimbursement status and identifying potential barriers and restrictions that may be placed on the product, once approved.

Disease management programs represent another pharmaceutical industry strategy to counter managed care cost-containment efforts. Offered by pharmaceutical manufacturers to MCOs to demonstrate the clinical merit and cost-effectiveness of their drug therapy, disease management is ‘a collaborative process which assesses, plans, implements, coordinates, monitors and evaluates options and services to meet an individual’s health needs through communication and available resources to promote quality cost-effective outcomes’ (Care Management Society of America, 1995). MCOs are increasingly adopting disease management programs to provide comprehensive medical care and improve patient outcomes at a lower cost (Schulman et al., 1996). Today, virtually all managed care plans offer a disease management program for asthma to prevent costly emergency department visits and hospitalizations.

Some MCOs have even forged partnerships with pharmaceutical manufacturers to allow the sponsoring company to track patient outcomes, to gauge a disease management program’s effectiveness and to access scientific and financial support for the
program. Other disease management programs involve risk-sharing contracts between the MCO and the pharmaceutical company, through which both parties share in the financial risks and rewards of doing business. Package pricing (i.e. special discount on a product line) and rebate programs that reward an MCO for achieving a certain market share of the product are two other contracting strategies that have been adopted by the pharmaceutical industry.

In addition to integrated formulary and disease management programs, outcomes assessment and risk sharing contracts, MCOs are implementing a variety of other services and programs to minimize costs, modify provider behavior, enhance patient outcomes and differentiate themselves in the marketplace. The pharmaceutical industry has responded to its managed care customer base needs by offering a variety of innovative, value-added services, including medication compliance programs, patient education programs and call center services.

Multiple payer influence in managed care

In addition to cost-containment strategies, managed care is impacting the pharmaceutical industry through a continued movement toward multiple payers of healthcare. The make-up of the payer market is changing as increasing numbers of MCOs are doing business with the government and large employers. These payer market segments are exerting a greater influence on the scope of their health plan benefits and treatment decisions.

Both the federal government and state agencies are moving increasing numbers of Medicare and Medicaid recipients, respectively, into managed care plans, to control healthcare expenditures, including drug costs. Clearly, the impetus has been the ability of managed care plans to reduce healthcare expenditures, which is accomplished by shifting the focus of healthcare away from incident-driven delivery to preventive and coordinated care. State Medicaid agencies have actively promoted managed care plans to recipients. Likewise, Medicare actively encouraged enrollees participation in Medicare managed care plans, resulting in steady increases in the 1990s. Although some MCOs initially offered prescription drug benefits as an incentive to attract Medicare enrollees, drug benefits were often capped or eliminated due to escalating costs, and traditionally, prescription drugs have not been covered on an outpatient basis under Medicare. To fill this gap, beginning January 1, 2006, outpatient prescription drugs will be covered under Part D of Medicare, as enacted by the Medicare Prescription Drug, Improvement and Modernization Act of 2003.

Under the Part D Prescription Drug Benefit, Medicare beneficiaries will be able to obtain a prescription drug benefit by one of three means: a traditional Medicare FFS plan with a separate prescription drug plan (PDP), an enhanced FFS plan that provides an integrated PDP or a Medicare Advantage plan (the program that will replace Medicare + Choice from January 1, 2006). HMOs that offer a Medicare Advantage plan must ensure that their drug benefits at least match those of the standard package (Grubert et al., 2004). Prior to the Part D Prescription Drug Benefit, Medicare-endorsed drug discount cards were available during a transitional phase from 2004 to 2006. Accordingly, MCOs that have already established the capacity to administer pharmacy benefits over a broad area should have a significant advantage in negotiating for PDP contracts to cover Medicare beneficiaries. Those MCOs with experience in Medicare risk contracting, marketing and brand strength, and pharmacy management capabilities will be in the best position to take advantage of the new Medicare reforms (Grubert et al., 2004).

Although the effect of employers on the pharmaceutical industry continues to evolve, employers are significant purchasers of managed care health plans and, as such, in a position to significantly impact the pharmaceutical industry. Driven by cost-sharing motives, the shift to tiered coinsurance with consumers financing a portion of the cost will enable employers to better estimate member costs and budget more appropriately. Market dynamics indicate that in the future, large employers or employer groups will work directly with buyers and providers of healthcare, thereby challenging managed care for contracts with employers. In addition, employers may require
MCOs to use fewer carve-out services, like PBMs, to encourage a more global perspective in caring for their employees. Responding to the needs of both payers – employers and MCOs – the pharmaceutical industry is positioned to sponsor wellness and preventive care programs to help differentiate MCOs from their competitors and facilitate contracts with employers. Finally, the influence of employers in improving quality standards, patient safety and affordability of healthcare is gaining momentum through initiatives such as The Leapfrog Group, a national consortium of Fortune 500 companies, and other large private and public employer healthcare purchasers.

One of the most unprecedented strategies by an MCO to reduce drug costs involved the switch of the nonsedating antihistamine loratadine (Claritin) to over-the-counter (OTC) status. Traditionally, pharmaceutical companies have petitioned the US FDA to switch their products from RX to OTC to extend patent life and create new markets for their products, thus increasing revenue. In 1998, Wellpoint (one of nation’s largest health insurers) petitioned the FDA to switch second-generation antihistamines from RX to OTC status (Food & Drug Letter, 2002). In its petition, Wellpoint argued that second-generation antihistamines were safer and more effective than traditional sedating antihistamines currently sold OTC. Further, by making the class available OTC, Wellpoint would save about $90 million – $45 million from prescription costs and $45 million in for co-pays (Food & Drug Letter, 2002). Faced with competition from other manufacturers to launch generic versions of OTC Claritin and an FDA Advisory Committee’s overwhelming recommendation supporting the OTC switch, the manufacturer agreed to file a supplemental NDA to move their product to OTC status. For the first time, a party other than a pharmaceutical company petitioned the FDA for OTC switch approval (Food & Drug Letter, 2002). To further discourage prescription antihistamine use and reduce cost, some PBMs have shifted existing second-generation antihistamines to a more expensive tier, thus requiring a higher co-payment by the patient.

Finally, consumers, or individual health plan members, represent another payer group within managed care. Consumers pay for healthcare through health plan premiums, deductibles and benefit-specific co-payments, including prescription drug co-payments. To address consumer needs, as well as to expand market share, many pharmaceutical companies have invested significant resources in direct-to-consumer advertising (DTCA) campaigns. Furthermore, because the FDA relaxed advertising regulations in 1997, pharmaceutical companies can now make product-specific health claims and link it to treatment of the indicated disease, as long as they disclose the major risks and side effects of the product. As a result, spending by the pharmaceutical industry on DTCA in the United States has steadily increased over the last several years from $1.2 billion in 1998 (IMS Health Web Site, 1999) to $4.2 billion in 2004 (NOP World Health, 2005).

Consumer advocate groups contend that DTCA has the potential to alert patients to potentially serious medical conditions and available drug therapies. Within the pharmaceutical industry, drug product managers see increased use of their product by better-informed consumers. MCOs have responded less enthusiastically to DTCA, due to its potential to increase drug costs through overutilization of prescription medications. In support of this position, a recent Yankelovic patient awareness survey found that 15% of consumers discussed an advertised drug with their physicians, and 8% visited a doctor specifically to discuss an advertised product (Headden and Melton, 1998). Critics further contend that DTCA increases the overall costs of medical care, that therapeutic alternatives and side effects of the medication are often inadequately presented and that information may be misleading (Gandy, 1992). Despite the resistance, DTCA is a powerful tool that the pharmaceutical industry continues to use to increase product awareness and market share in a multiple-payer managed care system.

**Managed care market competition**

A managed care market dynamic that has impacted the pharmaceutical industry is increased competition. With the managed care market becoming
increasingly competitive due to market saturation, many MCOs are employing innovative strategies to recruit and retain members. One such strategy is to offer enrollees multiple products and expanded health plan benefits. In a US national survey of managed care health plans, Gold and Hurley (1997) found that MCOs are providing a selection of benefit programs in response to customer interests and to ease the transition to more traditional managed care, especially in consumer markets with low managed care penetration; 71% of the plans in their sample offered at least two products, and a majority of plans with multiple products offered three or more options.

In highly penetrated managed care markets, health plans are strategically expanding benefits and services to foster loyalty and improve member retention, largely in response to the realization that it costs five to seven times more to recruit a new health plan member than to keep one (Edlin, 1998). Health Net, based in Woodland Hills, California, and a subsidiary of Foundation Health Systems, automatically enrolls members in their WellRewards program, which offers discounts of 20–50% on quality health-related products and services, including vitamins and supplements, sports and fitness equipment, veterinary services, pet care supplies and medically supervised weight management (Edlin, 1998). Prudential HealthCare of South Florida offers members nicotine patches at a discount through its smoking-cessation program, Committed Quitters, and bicycle helmets for $10 through its bike helmet program for members and nonmembers (Edlin, 1998).

This expansion of health plan benefits and availability of multiple product offerings has created new opportunities for the pharmaceutical industry, for example pharmaceutical manufacturers with drug products in therapeutic areas not traditionally covered by managed care, such as smoking cessation, weight loss and infertility, are now targeting plans with expanded benefits in those areas to promote their products. Another strategy employed by the pharmaceutical industry is to offer a portfolio of value-added services associated with a product, rather than promoting the therapeutic benefits of an individual drug, to help managed health plans achieve market differentiation and a competitive advantage.

Within the managed care industry, increased market competition has led to the emergence of the sales and marketing director and the benefits director as key decision makers, with increasing influence on medical decisions, including pharmacy benefits and formulary coverage. To effectively communicate with and sell to these stakeholders, the pharmaceutical industry has developed specialized sales teams, and expanded the responsibility of the managed care sales force to identify and target these directors for selected sales promotions.

Industry-wide consolidations, acquisitions and mergers are also affecting managed care market competition. Since the early-1990s, mergers and acquisitions among MCOs and insurers have occurred at a record pace. In late 1998, Aetna US Healthcare, formed by an $8.9 billion acquisition of US Healthcare by Aetna in 1996, announced plans to acquire Prudential Healthcare for $1 billion, making the combined entity the largest managed care company in the United States with 18.4 million members (Aetna US Healthcare Web Site, 1998). One evident outcome of consolidation among MCOs and insurers is that the pharmaceutical industry is now dealing with fewer, larger customers, who are gatekeepers for member services. As managed care market consolidation continues, it will become increasingly important for the pharmaceutical industry to identify and understand the role of the gatekeeper in formulary decisions, monitor product utilization through provider pharmacies and health systems and develop strategies to link inpatient and outpatient drug use to coordinate pharmaceutical care.

In response to consolidations throughout the entire healthcare industry, as well as to increasing drug development costs, the pharmaceutical industry has also experienced a series of mergers and acquisitions in the last decade. Since the late 1990s and in the early part of the new millennium, horizontal integration in the pharmaceutical industry has produced giant drug conglomerations, such as AstraZeneca, Sanofi-Aventis, GlaxoSmithKline and Pfizer (comprising legacy companies Warner-Lambert and Pharmacia). These transactions enable economies of scale in research and marketing to better compete with rival firms. In addition,
merging companies claim they will benefit from enhanced research and development capacity and better access to global markets (Bond and Weissman, 1997).

Since the 1990s, another aspect of market competition that has caused even greater concern to MCOs and payers than pharmaceutical manufacturer consolidations was the pharmaceutical industry’s trend toward vertical integration through the acquisition of PBMs. Because they manage drug benefits for approximately half of the US population, PBMs have significant buying power, and therefore represented a real threat to a pharmaceutical company’s market share and profits (Bond and Weissman, 1997). In 1993, Merck & Co. paid a record $6.6 billion to purchase Medco, and less than 1 year later, SmithKline Beecham acquired Diversified Pharmaceutical Services (DPS) and Eli Lilly bought PCS Health Systems. Despite allegations from consumer advocate groups that the transactions were made to preserve each acquirer’s market share and profits from brand name products, the pharmaceutical companies contended that vertical integration of a PBM has enabled each to deliver integrated pharmaceutical care and compete more effectively in the managed care arena. While the Merck–Medco alignment had generated robust sales for Merck products that might otherwise have been spent on competitors’ products, Lilly struggled to increase its market share of brand name products on the PCS formulary. In the fall of 1998, Lilly announced that it was leaving the PBM business and selling PCS to Rite Aid, one of the nation’s largest pharmacy chains. In 1999, SmithKline Beecham announced the divestiture of its PBM subsidiary DPS to sharpen its focus on pharmaceuticals and consumer healthcare. While Merck had a successful run of the PBM market for nine years, it too followed suit in 2002 by divesting its Medco subsidiary to concentrate on its core business strategy of discovering, developing and marketing pharmaceuticals.

Finally, with increased consolidation in the managed care and pharmaceutical industries, as well as throughout the healthcare industry, comprehensive, integrated data management systems will be needed to enable industry partners to collect, manage, analyze and disseminate medical and utilization information in a comprehensive and standardized manner. Integrated data management systems are critical for healthcare consumers, payers and providers, because they enable each group to evaluate treatment selections or use decisions, identify substandard utilization patterns, provide comprehensive and accessible medical records for plan providers and identify risk factors for chronic and expensive urgent-driven healthcare needs. A complete, integrated management system allows pharmaceutical companies to demonstrate how prescription medications may decrease costs and optimize the quality of care provided to an MCO’s members.

**Population and managed care market demographics**

The US population and managed care market demographics are changing significantly, largely due to increased life expectancies and an aging ‘baby boom’ generation (i.e. individuals born during 1946–1964). As this generation reaches retirement age, there will be a larger geriatric market than ever before, as an estimated 10,065 Americans turn 50 years old each day, according to US census data.

The 2000 Census counted nearly 35 million people in the United States 65 years of age or older, about one of every eight Americans. By 2030, demographics estimate that one in every five Americans will be age 65 or older . . . Those age 85 or older, the ‘oldest-old’, are the fastest growing segment of the elderly population . . . This group is of special interest to healthcare planners because those 85 or older are more than likely to require health services (Himes, 2001).

While Medicare beneficiaries have not enrolled in managed care plans at rates seen in the employer market, trends have mirrored the employer market. Enrollment in Medicare managed care increased steadily in the 1990s, peaking with 6.3 million enrollees in 2000. Plan withdrawals, reduced benefits and higher premiums resulted in a downward trend from 2000 to 2003 (Kaiser Family Foundation, 2004). Cost management and oversight will
become increasingly important in this expanding senior market, due to the expanded benefits created under the Medicare Prescription Drug, Improvement and Modernization Act of 2003, including prescription drug coverage, low-income assistance and preventive benefits. Additionally, as growing numbers of people move into the senior care market, increasing incidence of chronic diseases, including Alzheimer’s disease, arthritis and osteoporosis, will influence healthcare markets and managed care plan dynamics. Sloane et al. (2002) predicted no ‘less than a threefold rise in the total number of persons with Alzheimer’s disease between 2000 and 2050’. Riggs and Melton (1995) estimated a fourfold increase in the global fracture rate over the next 50 years, reaching 6.25 million hip fractures by 2050. Exemplifying the influence of chronic diseases on healthcare and managed care, a one-time ‘Welcome to Medicare’ physical exam, cardiovascular screening and bone mass measurements are among the new and current preventive services available to beneficiaries covered under Medicare. New Medicare Specialty Plans provide more focused healthcare to manage a specific disease or condition. Both this growing geriatric population and managed care plans with significant numbers of Medicare enrollees will continue to drive the demand for better treatment options.

The pharmaceutical industry has started to respond to the increasing geriatric market with increased research and development for products for the treatment of chronic diseases. Some pharmaceutical firms have even established geriatric-focused research departments to identify and address the special needs of the elderly.

**Pharmaceutical research and development**

In addition to the influence of a growing geriatric market segment on pharmaceutical industry research and development, each of the other managed care and market influences – cost-containment strategies, multiple payers and market competition – have collectively impacted pharmaceutical research and development. The pharmaceutical industry is highly competitive and heavily invested in research and development. For example, recent consolidations among pharmaceutical companies are due, in part, to the enormous risk and expense in bringing a new drug to market and the desire to spread development costs over a larger revenue base (Pollard, 1990). Increased global competition has also influenced pharmaceutical industry research and development. Finally, MCOs and PBMs, focused on cost-containment strategies, are resisting expensive drugs that lack explicit advantages over older, less expensive therapies. They are forcing the pharmaceutical industry to focus on drug candidates with the largest potential for financial return, a move that has raised concerns about which drugs get developed. Therefore, there is increasing concern that clinical research in the United States is being threatened by the proliferation of managed care.

One indication of this concern over pharmaceutical research and development is that pharmaceutical manufacturers are shifting clinical investigations from costly academic medical centers (AMCs) to less expensive private study centers and third-party contract research organizations (CROs), to reduce both drug development time and costs. In 1988, AMCs accounted for 80% of investigators and 10 years later, that percentage had dropped to 46% (Lightfoot et al., 1999). Some MCOs are reluctant to refer members to AMC-conducted trials, even if the research is pharmaceutical industry-sponsored, due to concerns of higher patient care costs and litigation over unexpected adverse events. Critics contend that the managed care practice of restricting patient access to AMCs for specialized care has accelerated declining physician revenues, which directly affects the ability of an AMC to engage in clinical research (Burnett, 1996). Furthermore, declining AMC patient care revenues and the pharmaceutical industry’s cost-saving strategy of shifting studies to CROs are contributing to a lack of funding for training future research investigators.

Despite MCO concerns over patient costs and liability issues, the number of research studies is steadily increasing in the managed care setting. Many investigators believe that the managed care setting is ideal for conducting clinical research, because care is standardized and easier to control, potential study patients can be easily identified
through centralized databases and the population is representative of the real world, especially for post-marketing and safety surveillance studies. In fact, most MCOs are more interested in establishing the effectiveness of a product, that is how well the drug performs under real-world conditions, than in determining a product’s efficacy through rigorously controlled clinical trials. Although rare, some firms will halt development of a compound as early as phase II trials if there appears to be no perceived economic value. Conversely, pharmaceutical companies with favorable outcomes and pharmacoeconomic (i.e. cost-effectiveness) data at the launch of a new product have assisted MCOs in their formulary decision processes and have had successful launch campaigns. Indeed, prelaunch research participation may help an MCO gain a competitive edge, by integrating experimental care into clinical practice and offering new treatment options to their members.

Pharmaceutical product life cycles

In addition to its influence on pharmaceutical industry research and development, managed care has significantly impacted product life cycles. Drugs identified as preferred products by managed care health plans have a steeper, or faster, uptake and initial growth period, as shown in Figure 55.2, than products that are covered, non-formulary. MCO-preferred products reach their sales peak earlier and experience a longer, sustained maturation phase. Covered, non-formulary products never reach as high a maturation peak as preferred products. However, once a preferred product’s patent expires, there is a rapid decline in sales, as most health plans routinely switch the formulary choice to a generic equivalent. In addition to identifying preferred products for reimbursement, MCOs are implementing disease management programs to foster increased utilization of the preferred product over similar, but competitive, products.

Pharmaceutical companies are adopting a number of strategies to maximize market share of a new product in a managed care environment. Achieving formulary acceptance by MCOs is the first step for ensuring a successful life cycle for a prescription product, as shown in Figure 55.3. To positively influence formulary decisions and gain preferred product status, pharmaceutical companies are generating pharmacoeconomic and outcomes data. Once accepted by the managed care health plan’s P&T Committee, pharmaceutical companies may invest in pull-through programs to increase market share and appropriate utilization of the product. Pull-through programs may involve special contracting agreements or comprehensive disease management initiatives to highlight the clinical and economic value of a specific product. In addition to pull-through programs and value-added services, such as patient education materials, pharmaceutical companies are discounting targeted prescription drug products or entire product lines where competition is fierce.

Figure 55.2 Impact of managed care on pharmaceutical product life cycle
The value of evidence-based medicine as the new ‘gold standard’ for clinical practice is poised to play a greater role in driving the market share success of pharmaceuticals, particularly in the managed care and Medicare environments. Although the pharmaceutical industry agrees that evidence-based medicine improves quality in medical practice, critics contend that it tends to commodify products by holistically categorizing them based on class effect and product interchangeability, thereby minimizing individual product differences (Studin, 2004). To address an emerging evidence-based commodity environment, it is suggested that the pharmaceutical industry promotes the adoption of consensus guidelines and protocols to standardize treatment approaches. The new horizon for managed care marketing will be defined by increased product commodification justified not by cost but by quality. Accordingly, pharmaceutical manufacturers will need to address quality-driven commodication imperatives (Studin, 2004).

Finally, to maintain a healthy product life cycle until patent expiration, pharmaceutical companies are engaging business strategies, including risk-sharing contracts, DTCA and co-marketing partnerships. Pharmaceutical companies are developing co-marketing partnerships in record numbers to achieve maximum global market penetration, by leveraging research and marketing strengths in key therapeutic areas. Co-marketing partnerships are being formed through joint ventures, licensing agreements, strategic alliances, traditional mergers and acquisitions (Kaniecki and Goldberg-Arnold, 1993).

### 55.3 Emerging trends in managed care and their impact on the pharmaceutical industry

Diverse factors will continue to influence managed care in the future, and subsequently impact the pharmaceutical industry. Managed care consumers, payers and providers will continue to be the key facilitators of change. Key areas in which these distinct, but interconnected market segments will drive change include the recent trends in importing prescription drugs, an increased need for pharmacoeconomic and outcomes research and the repurposing of PBMs.

### Importing prescription drugs

To overcome high prescription drug prices in the United States – the highest in the world – individual consumers, along with city and state agencies, are buying or developing plans to import prescription...
drugs from Canada, despite a federal ban to do so. Citing a recent Kaiser Family Foundation and Harvard School of Public Health survey, Barry (2004, July) reported, ‘Eight out of 10 Medicare beneficiaries believe the law should be changed to allow Americans to import drugs from Canada’. Individual consumers support this position as a way to pay for the prescription drugs they need and at prices they can afford. The position of the US FDA is that the safety and efficacy of the drugs cannot be guaranteed. City and state agencies, however, argue that they can save millions of dollars in the face of substantial budget deficits, the drug regulations and practices of Canadian and European nations are typically more stringent than the United States and US policy is antifree market and pro-pharmaceutical industry. Although no American citizens have been prosecuted for importing medicines, and no states have actually done so, to date, at least 24 are considering plans to purchase prescription drugs from Canada and a number are challenging the federal policy in various ways, such as in court or by directing residents to web sites of pre-screened foreign pharmacies (Barry, 2004 October). A number of cities already purchase drugs from Canada. A similar trend is occurring south of the border, with increasing numbers of older Americans traveling to Mexico to purchase generic prescription medications at prices significantly less, in some cases up to 75% less, than in US pharmacies (Shelvelove, 2002). With prescription drugs accounting for an increasing proportion of healthcare spending, the policy debate and all of these actions are likely to heighten. The ability to resolve this debate will be critical to ‘giving Americans the best healthcare at the lowest possible cost’ (Times Argus, 2004).

Increased need for pharmacoeconomic and outcomes research

To plan and implement successful launch campaigns, the pharmaceutical industry will increasingly need to meet managed care’s need for practical pharmacoeconomic and outcomes data to assist in formulary decision-making processes. Therefore, in the future, the pharmaceutical industry may conduct prelaunch clinical trials in MCOs to address the economic and outcomes issues associated with new products in real-world settings. This will provide the added advantage of introducing the product to managed care physicians and providers prior to launch. In the future, the pharmaceutical industry will need to develop MCOs into research-ready sites for gathering and analyzing outcomes data, to address specific managed care clinical and economic issues.

In addition, the Academy of Managed Care Pharmacy (AMCP) has developed a set of guidelines called the AMCP dossier, which is a tool for MCO decision makers to use in assessing useful clinical and economic data that will enable a P&T Committee to make formulary decisions. An AMCP formulary dossier should include the following components: (a) product information; (b) supporting clinical, economic and humanistic information; (c) impact model report; (d) clinical value and overall cost and (e) supporting information: bibliography, checklist and appendices. The additional information that is required by this dossier (as compared to typical formulary kits) includes the economic, humanistic, modeling and value components. Increasingly more MCOs are requiring AMCP dossiers at product launch. This trend is requiring pharmaceutical companies to conduct pharmacoeconomic and outcomes research during drug development to meet an MCO’s needs.

Evolution and repositioning of PBMs

As managed care moves toward globalization of all medical care expenditures, including pharmaceutical products, PBMs will be at-risk, as they are typically viewed as a carve-out expenditure. To remain viable and to protect themselves from integration and competition, PBMs will have to reposition themselves in the marketplace. They will need to offer more than pharmacy management services. In response to this emerging trend, a few PBMs are offering additional services, such as managed care-based pharmacoeconomic research centers, to expand their client base to include the pharmaceutical industry and academic institutions. Other needed services that PBMs may offer include call center-based services, patient
compliance programs, CROs and disease management programs.

The repositioning of PBMs in the managed care market could have a tremendous impact on the pharmaceutical industry. Pharmaceutical companies should continue to outsource a larger proportion of their research studies to CROs, due to both corporate downsizing and the lack of specialized expertise. Coupled with the increased demand for managed care-based outcomes research, PBMs could become an important vendor to pharmaceutical companies, especially for tracking long-term outcomes and the costs of disease. A PBM that offers pharmacoeconomic consulting or CRO research services could be a cost-effective solution to the information gap between what MCOs need and what the pharmaceutical industry can fulfill. To facilitate this process, the pharmaceutical industry will need to establish an information system through which they can enhance their understanding of new PBM services, and develop methods of marketing to this newly positioned customer.

Another evolution dynamic of the PBM market is the formation of specialized PBMs. In order to survive in a highly competitive, cost-sensitive market, many PBMs have specialized and targeted specific customer segments. Some regionally based PBMs have been very successful at attracting small to mid-size insurance companies, third-party administrators (TPAs), unions, self-insured and insured employers. They have found a niche market in these customer segments that the larger PBMs do not target. Additionally, some PBMs directly target the Medicaid segment. As rising health costs have impacted the state Medicaid programs, many have turned to third parties to assist in the development, adjudication, implementation and assessment of their prescription drug programs. Traditional PBMs have not had the capacity, systems, resources, experience or incentive to target state Medicaid programs. This opportunity has been seized by a very few PBMs which offer services such as claims adjudication, prior authorization, IT support, health management, formulary/clinical review, real-time claims scrutiny and other services. In this specialized segment, less than five PBMs provide pharmacy benefit services to all 50 state Medicaid programs in the United States.

### 55.4 Summary

Managed care has surpassed traditional indemnity or FFS health insurance to become the predominant form of coverage for health and medical care in the United States. Concern over rapidly rising healthcare costs has been the driving force behind the rapid growth of managed care in recent decades. Through effective application of key managed care principles of restricted access to healthcare providers, defined health plan benefits and services, and capitated reimbursement, MCOs have demonstrated their ability to control healthcare costs. In the process, managed care has affected every aspect of the healthcare industry, including the pharmaceutical industry.

With medications accounting for an increasing proportion of total medical costs, MCOs have been forced to implement cost-containment strategies to managed pharmacy benefits, including integrated formulary and disease management programs, pharmacoeconomic and outcomes research and risk-sharing contracts. In addition, MCOs have become a major customer base to the pharmaceutical industry, with increasing leveraging and purchasing power. Therefore, managed care has had a significant impact on the way the pharmaceutical industry develops, markets, distributes and generates revenue. Two aspects of the pharmaceutical industry that have been impacted the greatest are pharmaceutical research and development and product life cycles.

Finally, diverse factors will continue to influence managed care into the future, and subsequently, the pharmaceutical industry. Emerging trends include the importing of prescription drugs, increasing need for pharmacoeconomic and outcomes research and the repositioning of PBMs. Therefore, the pharmaceutical industry must be positioned to maximize sales of targeted products and services and return on investment (ROI) in an increasingly managed healthcare system.
References


Hoechst Marion Roussel. 1998. Managed Care Digest Series. Hoechst Marion Roussel: Kansas City, MO.


Since our textbook’s first edition, the worldwide web has continued to expand exponentially, and the plethora of web sites of relevance to pharmaceutical medicine has grown commensurately. While web sites change constantly and while the choices are enormous, the following collection is again offered as those the editors have found useful. Note that many of these links offer links to still more sites. Although great care has been taken, please accept our apologies for choices with which you disagree and for any outdated links.

Regulatory links:

Australia – Therapeutic Goods Administration:

Canada – Health Protection Branch (HPB):
http://www.hc-sc.gc.ca/

European Agency for the Evaluation of Medicinal Products (EMEA):
http://www.emea.eu.int/

European Confederation of Medical Devices Associations:
http://www.eucomed.be/

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH):
http://www.ich.org

International Federation of Pharmaceutical Manufacturers & Associations (IFPMA):
http://www.ifpma.org/

Japan – Ministry of Health and Welfare (Koseisho):
http://www.mhlw.go.jp/english/

Pharmaceutical Research and Manufacturers of America (PhRMA) Regulatory Affairs:
http://www.phrma.org/

RAPS (Regulatory Affairs Professional Society):
http://www.raps.org/

US Code of Federal Regulations:
http://www.gpoaccess.gov/cfr/

or, with better layout:
http://www.law.cornell.edu/cfr/

US Code of Federal Regulations, Title 21: Food And Drugs:
http://www4.law.cornell.edu/cfr/21cfr.htm#start
U.S. Food and Drug Administration (FDA): http://www.fda.gov/


Worldwide Regulatory Affairs Information: http://www.rainfo.com/

Pharmaceutical-related societies


Drug Information Association (DIA): http://www.diahome.org/

Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom: www.fpm.org.uk

International Federation of Associations of Pharmaceutical Physicians (IFAPP): www.IFAPP.org

International Federation of Pharmaceutical Manufacturers Associations (IFPMA): http://www.ifpma.org/


Pharmaceutical Research and Manufacturers of America (PhRMA): http://www.phrma.org/

Other Medical Societies and Organizations

American Medical Association (AMA): http://www.ama-assn.org/

Association of American Medical Colleges (AAMC): http://www.aamc.org/

Centers for Disease Control and Prevention (CDC): http://www.cdc.gov/

National Institutes of Health (NIH): http://www.nih.gov/


Pharmaceutical Companies


Contract Research Organizations

Listing of CROs: http://www.dataedge.com/cro_info.htm

Ethics in Clinical Research


Bioethics information (from the University of Pennsylvania Center for Bioethics): http://www.bioethics.net/


ICH Guideline for Good Clinical Practice: http://www.ich.org/LOB/media/MEDIA482.pdf

Multiple Bioethics Links (provided by the New Jersey law firm of Sherman, Silverstein, Kohl, Rose & Podolsky): http://www.sskrplaw.com/bioethics/
Nuremberg Code:
http://ohsr.od.nih.gov/guidelines/nuremberg.html

Office of Human Subjects Research:
http://ohsr.od.nih.gov/

World Medical Association Declaration of Helsinki (2000 Update):
http://ohsr.od.nih.gov/guidelines/helsinki.html

Miscellaneous

Cochrane Collaboration:
www.cochrane.org

General Information for Pharmaceutical Medicine Professionals:
http://www.medilexicon.com/

PERI Pharmaceutical Medicine Certificate Program:
http://www.peri.org/pharm_courses.cfm

Pharmacy Information on the Internet:
http://www.pharmweb.net/

Post-Graduate Programme in Pharmacology and Pharmaceutical Medicine:
http://www.ulb.ac.be/medecine/pharmed/PROGRAMME/PROGRAMME%202005-2006/programme.htm
Abbreviated New Drug Applications (ANDAs) 382, 399, 412–14
component parts 413
supporting information 412–13
abstracts, isolated, publishing of clinical trials in 568–9
Academy of Managed Care Pharmacy (AMCP) formulary dossier 741
accelerated approvals for ANDAs and generics 412–14
post-marketing impacts/studies 411, 413
for serious and life-threatening diseases 410–12
accounting, clinical trial costs 694
acetaminophen/paracetamol 376–7
acetylation (metabolic) pathways, ethnic differences 234, 541
N-acetylcysteine 377
actual-use (‘slice-of-life’) studies 187, 188
additivity of drugs 256
adherence 355
see also compliance
Administration of Radioactive Substances Advisory Committee (ARSAC) 452
adverse drug reaction (ADR) reporting system
Europe 133, 429–30, 477–80
Japan 504–5
adverse events (AEs)
in complementary therapies 391–2
definition 133, 477, 539
EBGM scores 546–7
in elderly people 194–5
European database 445, 477
first known investigation 423
gender differences 213
handling/dealing with 35–6, 581–2
ICH GCP guidelines for reporting 133, 538–9
reportability assessment flowchart 478–9
reporting and recording 133, 148, 150, 151, 477–80, 535–43
in China 673
electronic reports 132–3
ethnic differences 239–40
in UK 425, 429
in USA 133, 524–5, 548
type A and type B 536
types 610
advertising
clinical trial subjects 134, 200, 694
pharmaceutical
Medical Affairs Department’s responsibilities 525
in medical journals 657, 658
regulation of 481–2, 525, 531, 656
US spend 657
aerosols 56
agencies
Malaysia 684
Middle East 678
aging population
impact on society 194
see also elderly population; geriatrics
agonist–antagonists, pharmacodynamics 90
agonists, full 90
alcohol effects, ethnic differences 237
alkaloids 388
allometric scaling 83, 86
in drug discovery process 86–9, 95
alternative liability 613
alternative medicine see complementary medicine(s)
Alzheimer’s disease 48, 194, 198
American Academy of Pharmaceutical Physicians (AAPP), career satisfaction survey 5
analgesic, concentration–time effect modelling 92
analysis-of-variance (ANOVA) model 326
analytical methods, for dose and plasma determinations 65–6
animal experimentation, ethics 591–2
animal models 48, 49, 66, 499
antagonism between drugs 256
Anti-Kickback Statute 596
antibodies, as biotechnology products 284
antidotes, early developments 415–17
antiepileptic drugs 206, 207–8, 376
antisense oligonucleotides 47, 285–6
Apothecaries 395, 417–18
inspection of shops 419–21
appraisals, training 17–18
archiving of documents 133, 141, 152, 168
audits 174–5
Argentina, postgraduate education 23
Armitage (‘sequential analysis’) clinical trial design 110
arthritis 198
ascending dose-ranging cohort design 108–9
Asia, pharmaceutical medicine in 680–7
aspirin 105, 204, 205, 381
pediatric use 582
Association of the British Pharmaceutical Industry (ABPI), Code of Practice 425, 601, 640, 656, 662

Principles and Practice of Pharmaceutical Medicine, 2nd Edition
Edited by L. D. Edwards, A. J. Fletcher, A. W. Fox and P. D. Stonier
INDEX

audiovisual presentations, at academic meetings, publishing of clinical trials using 569–70
audit(s)
certificate 168
closing meeting for 167
communication during 167
correspondence 166
data management 173, 349–50, 351, 354
of external providers 175
follow-up 168
notes/evidence/findings/conclusions 167
opening meeting for 167
plan 166
program 165–6
report 168
systems audits 172–5
team 166–7
tools 167
trial-related audits 169–72
types 169–75
auditing 140, 164
training for 163
auditors see quality assurance (QA) auditors
Australia, GCP guidelines/regulations 154
autonomy 75
Bahrain 509, 510, 514, 677
Bayesian trial designs 114–15
Belgium, postgraduate qualifications 4, 20,
21–2
benefit–risk analysis 115–16
and informed consent 116, 147
mathematical approaches 116
Bentham, Jeremy 589, 592
benzodiazepines 95, 96, 194, 212
bias, statistical 102, 319–20
Bentham, Jeremy 589, 592
bias, statistical 102, 319–20
avoidance in minimization trials 111
sources 103, 320
binomial model 325–6
bioavailability 85
in pediatrics 226
bioequivalence
generic drugs 54–5, 122, 382
trials/studies to demonstrate 121–2, 136
bioethicists 594
bioethics 587–94
basic tools 588–90
casuistry 589
deductive reasoning 588
‘golden rule’/Ethic of Reciprocity 589–90
inductive reasoning 589
objectivism vs subjectivism 590
utilitarianism 589
definition 587
dilemmas listed 587–8
feminist bioethics 589
biological therapeutics 279–90
biopharmaceuticals 385
biotechnology companies 280, 290
biotechnology products 14–15, 279–90
classes 282–8
clinical trial issues 282
compared with conventional drug products 281
definition 279–80
ethical issues 288–9
generic products 467–8
informed consent for 280, 289
manufacturing issues 281–2
patent issues 629–30
regulatory considerations 280–1
‘black box’ labeling 531, 558
black cohosh (Cimicifuga racemosa) 390
blinding procedures 153–4, 320
blocking (statistical) method 322–3
body surface area
body weight relationship 86, 87
in pediatric dose calculations 226
branded products 655
Brazil, postgraduate education 23
bridging data/studies
ethnic issues in drug registration 243–4
‘similar’ biological products 468
British Association of Pharmaceutical Physicians (BrAPP) 20
British Pharmacopoeia (BP) 423, 426
Budapest Treaty 627–8, 629
budgets
clinical trials 689–96
conferences and meetings 577
marketing 656–8
burden of illness
considerations when documenting baseline 296
data sources (case study) 296–7
business aspects 643–744
calendar plot (for compliance) 361
Canada
export of drugs to USA 741
GCP guidelines/regulations 154
regulation of marketing 656
carcinogenicity studies 71–2, 499
case-control studies 305, 542
case reports
CRFs 31, 36–7, 105, 132
selection of 32, 142
audits 169, 349, 351, 354
cover sheet 348, 348
data creation from CRF images 347, 348–56
data entry using CRF images 347–50
image review process 348–50
log-in sheet 346, 348
scan process 348
summary of information on
case report forms (CRFs) 31, 36–7, 105, 132,
141–2, 342
audits 169, 349, 351, 354
cover sheet 348, 348
data creation from 347, 348–56
data entry using CRF images 347–50
image review process 348–50
log-in sheet 346, 348
scan process 348
case reports
considerations when documenting baseline 296
data sources (case study) 296–7
business aspects 643–744
calendar plot (for compliance) 361
Canada
export of drugs to USA 741
GCP guidelines/regulations 154
regulation of marketing 656
vulnerability 227
classification of Western drugs 668
clinical trials 667–72
documentation required 671–2
monitoring of 670
requirements for authorization 668–70
summary of information on 671
demographics 666
healthcare situation 666–7
IND procedure 670
manufacturing approval, data/information required 672–3
Ministry of Public Health 669–70, 670
NDA procedure 669
pharmaceutical joint ventures 667
Chinese medicine(s) 388, 392
chronology diagram (for compliance) 361
cisapride 561–2
citrus fruits, scurvy treated with 104–5
civil law 597–9
compared with criminal law 596
Class A/B/C drugs 431
clinical data coordinator (CDC) 346
documents to be prepared by 346–8
clinical development plans (CDPs) 27–8, 64, 105
clinical equipoise 75, 591
clinical hazard 557
see also risk management
clinical investigator(s) 129
fees 690–2
responsibilities 143
selection of 32, 142
clinical outcomes 293, 294
clinical outcomes research 520
clinical pharmacology 651
overlap with pharmaceutical medicine 14
clinical protocols 28–31, 105, 141, 342
clinical research
current rules for conducting 139–40
in Medical Affairs departments 519
clinical research organizations (CROs), in Japan 493
clinical studies/trials
biotechnology products 282
in China 667–72
closing down 36
costs 689–700
definition in European legislation 428
design(s) 28, 29, 51, 106–9
dissemination of results 341
doctors’ and dentists’ exemption 427–8
documentation 34
ethnic differences 236–7
European database 449, 477, 602
INDEX 751

European requirements 649
financial aspects 689–700
gender differences 204–5
historical examples 104–5
in India 675–6
initial 64
internal costs 695, 696
interpretation 102–4
Japanese regulations 500–1
medication costs 693
monitoring 34–5, 141, 144, 146, 148
patient screening/recruitment/retention 133–4, 199–200, 227, 694
pediatrics 226–8
pharmacoeconomic measures incorporated into 297–9
pivotal studies 115
public access to ongoing information 526
publishing 565–73
reports 37–8, 341
audits 171–2
role of statistician 341–3
safety issues 35–6, 113
setting up 140–2
sources of bias 103
stopping 113–14
on efficacy grounds 113–14
on safety grounds 113
training of staff for 26–39
see also phase II and phase III clinical studies; phase IV (post-marketing) studies
clinical trial authorization (CTA) 448, 450–2
application documentation 450–1
guidance on procedure 450
Clinical Trials Certification (CTC) 402, 409, 427
Clinical Trials Directive 55, 64, 128, 140, 155, 160, 409, 428, 445, 448, 599
effect on fraud 639
effect on phase I studies 429
Clinical Trials Exemption (CTX) 402, 409, 427
Clozaril Patient Monitoring Service 582
Cockroft–Gault estimate of creatinine clearance 251
Code of Federal Regulations, Title 21 (21CFR) 407, 531
cohort studies 304
combinatorial chemistry 49
Committee for Medicinal Products for Human use (CHMP) 444, 447, 453–55, 459, 462–65, 599
Committee for Orphan Medicinal Products 447, 465–66
Committee on Publication Ethics (COPE) 639–40
Committee on Safety of Drugs (CSD) 425, 579–80
Committee on Safety of Medicines (CSM) 426, 599, 656
adverse reaction reports 429, 430
common cold, treatment of 180
common technical document (CTD) 438, 455, 456
compassionate-use INDs 409–10
competency-based education and training system (CBETS) 26
competency-based training 25–39
capabilities and knowledge 26–39
capabilities and knowledge 26–39
conducting clinical research 33–7
general clinical capabilities 26–7
planning clinical development 27–33
reporting clinical research 37–9
vendors of training programs 39
complementary medicine(s) 387–92
common medicines listed 389–91
market value 387
regulatory aspects 392
relevance to pharmaceutical medicine 387
terminology 388–9
compliance 355–73
actions to enhance 363–4
classification 362
in clinical trials 357–61
data analysis of 361–2
definition 161–2, 356
deviation from 339
effect of interactive packaging 368–70
in elderly population 199
electronic monitoring of 356, 357, 367, 371
factors affecting 363, 364
facts demonstrating 366–8
how to improve 364–5, 368–70
involvement in 365–6
methods of evaluating 356–7
relevance in daily practice 368
compliance management 356, 370
compliance monitoring 356, 357, 365
collaboration report 361
Computer Assisted New Drug Applications (CANDAs) 207, 404
certified systems validation (CSV), audits 173
concentration monitoring 375–80
in cerebrospinal fluid 379
in plasma 375–8
reasons for 375–8
in urine 378–9
concerted action (for liability) 613
conditional power 337–8
conferences, organizing and planning 575–8
confidence intervals 329–31
confirmatory experiments 313
congenital abnormalities 206
constituents of a drug/medicine 52–3
consultancy costs 694
consumers 655
direct advertising 398, 406, 654, 656, 659–60
contemporaneous independent treatment allocation 111
continuing medical education (CME) activities 525–6, 662
continuing professional development (CPD) 18–19
contraceptive precautions, failure rates 207
contract of employment 597–8
contract law 597
contract research organizations (CROs) 522–3, 650, 696–700, 701–23
assessing financial stability 698
comparing bids/proposals 697–8, 714, 718
identifying and resolving problems 722
instructions to bidders 712–14
Internet listing 746
leverage skills and experience 712
‘modern’ view 702
obtaining bids/proposals 696–7, 712–14
performance metrics 720
prequalifying 702, 710, 712
reasons for failures/problems 701, 704
request for information (RFI) 712
requests for proposal (RFPs) 697, 704, 712
resource allocations examples 714, 717
worksheet 714, 715–16
role in drug development 702
roles and responsibilities 719–20
selection criteria 705, 707, 710
sponsor–CRO relationship 719–22
communication/decision-making model 720–1
end-of-study meeting 722
periodic oversight meetings 721–2
study initiation meeting 721
sponsor’s responsibilities 719
strategies for using 702–4
project outsourcing 703
strategic outsourcing 703–4
tactical outsourcing 702–3
study specifications 704–5
worksheet 706–10, 711
‘traditional’ view 701–2
types of contract 698–700
contributory negligence, as defense in product liability actions 608
‘controlled’ drugs 432
controlled clinical trial (CCT) elements 318–23
limitations 105
copyright 571–2, 620
coronary heart disease 197
cost effectiveness, compliance management 570–1
cost–utility techniques 13
Council for Education in Pharmaceutical Medicine (CESPM) 20
Council for International Organizations of Medical Sciences (CIOMS), initiatives and guidelines 140, 157, 536–8
creatinine clearance rates 251–2
criminal law 596–7
compared with civil law 596
...
INDEX

crossover studies 109, 323, 340
Culpepper, Nicholas 419, 421, 422
culture, definition 645
customers (prescribers) 655
cyclo-oxygenase-2 (COX-2) anti-inflammatory agents 406, 615
cytochrome P450 enzymes 234, 259, 260, 541
cytokines, as biotechnology products
culture, definition 645
Culpepper, Nicholas 419, 421, 422
database(s) 36–7
data sheet 504
data and safety monitoring boards (DSMBs) 31, 36–7, 141–2, 150–2, 342
gender data 217
data collection 31, 36–7, 141–2, 150–2, 342
data analysis, problems encountered 339–41
data dispersal, clinical trials 520–1
data management 36–7, 132–3, 345–56
data collection 31, 36–7, 141–2, 150–2, 342
data analysis, problems encountered 339–41
data mining 545–55
data queries
decisive reasoning 588
deductive reasoning 588
degradants 52
denmark
clinical trial costs 657, 735
drug concentration monitoring 375–80
drug clearance 80–1
drug concentration monitoring 375–80
drug discovery and development 41–189
drug discovery and development 41–189
algorithms 277–392
basic combined with applied research 45–7
biomolecular approach 13, 47–8
drug discovery and development 41–189
algorithms 277–392
basic combined with applied research 45–7
biomolecular approach 13, 47–8
drug discovery and development 41–189
algorithms 277–392
basic combined with applied research 45–7
biomolecular approach 13, 47–8
drug discovery and development 41–189
algorithms 277–392
basic combined with applied research 45–7
biomolecular approach 13, 47–8
depression in elderly population 198
gender differences 212
detailing to prescribers face-to-face contact 658–9
via Internet 661
developmental defects, causes 209, 399, 425
diacylformine 560
dialysis 252
dietary effects, ethnic differences 237–8
disease awareness campaigns 482, 660–1
disease management programs 733–4
disease management programs 733–4
disproportionality measure 546
disclosure, as defense in product liability
disparate recovery plan 354
dispersed required items 345–6
project setup 346–8
project team 346
status reporting 349, 351
data mining 545–55
case study (rhabdomyolysis and statins) 549–54
caveats 551–4
data interpretation 550–1, 552–3
data output 549–50
data source 549, 551–2
EB05 guideline 549
definition 545
limitations 554–5
methods 546–7
in phase IV studies 523–4
privacy concerns 554
regulatory guidance 5512
in safety surveillance 548–9
uses 545
data processing 141
data protection considerations 601–2
and data mining 554
data and safety monitoring boards (DSMBs) 523
data sheet 504
see also summary of product characteristics
dbbase(s) 36–7
adverse drug reactions 583
audits 171
clinical studies 449, 477, 526
release memorandum 351, 354
debraisoquine–sparteine oxidative pathway, ethnic differences 234
Declaration of Helsinki 75, 139, 158, 160, 169, 452, 590
deductive reasoning 588
degradants 52
Denmark
clinical trial costs 691
prevention of research fraud 637
drug ‘holidays’ 363, 366–7
drug interactions 255–63
at site of absorption 258
at site of action 258–9
at site of excretion 260–1
at site of metabolism 259–60
definition 255
during storage 257–8
in elderly population 195
information on 524
in post-marketing monitoring 536
regulatory considerations 263
studies 123–4, 261–2
systematic considerations 257–60
types 255–7
drug labeling 529–33, 541
european 532–3
in Japan 504, 529–30
in USA 530–2, 533
drug metabolism 69
drug regulation 393–515, 648–50
european 415–85, 599–600, 648–9
history 395–401, 415–24
in India 675
in Japan 487–507
legal framework for 599–601
in Middle East 509–15
in USA 395–414, 600–1, 649–50
drug safety and epidemiology unit 524–5
drug surveillance 535–43
drug withdrawal from market 579–84
causes 580
consequences 581–3
prevention better than cure 580–1
dry powder inhaler 60
dyestuffs 397
e-marketing 661–2
economic, clinical and humanistic outcomes
cause (ECHO) model 293
economic outcomes 293, 294
economics 291–301
orphan drugs 267–8
education and training 4–5, 15–19
audits 174
in various countries 20–3
efficiency 89–90
OTC drugs 182
and stopping of trials 113–14
efficiency variable 314
Egypt 510, 677, 678–9
elderly population(s)
adverse drug reactions 194–5
demographics 193–4
diseases 197–8
drug research in 193–201
industry response 197
practical and ethical issues 195, 198–200
regulatory response 195–6
ICH guideline 191, 196–7
see also aging population; geriatrics
electronic data capture 132–3, 342
see also data collection
electronic monitoring, of patient compliance 356, 357, 367, 371

INDEX

Food and Drug Administration (continued) ‘monograph’ (pre-approval) system for OTC drugs 183–4
herbal medicinal products 52–3, 388, 468–71
and FDA jurisdiction 532
quality guidelines 469
traditional products 470–1
hexachlorophene, safety issues 13–14
Higher Medical Training (HMT) programmes 5, 21, 22
historical background 7–8
holistic practitioners 388
impurities in drugs 52, 65
importing of drugs, into USA 740–1
immigrants, healthcare costs 194
hypothesis testing 315, 327–9
hypothesis forming 479–80
hypertension
ethnic differences in treatment 236
in older population 197
hypothesis forming 479–80
hypothesis testing 315, 327–9
immigrants, healthcare costs 194
importing of drugs, into USA 740–1
impurities in drugs 52, 65
in vitro data 79
in vitro + in vivo preclinical data, prediction using 80–6
incidence, meaning of term 306–7
independent review boards see institutional review boards
India 673–6
health services 674–5
major diseases 674
individual case safety reports (ICSRs), import of drugs 502
Indonesia 685–7
induction training 16–17
in quality assurance 163
inductive reasoning 589
inflammatory disease treatment 45–6
informed consent 75–8, 106, 141
and benefits/risks 116, 147
biotechnology products 280, 289
elderly population 198–9
ethical basis 75, 144, 591
forged forms 634
information to be provided prior to
147–8
in pediatric studies 228
principles 146
responsibility of parties 77–8
surrogate 77
unwritten 76–7
verification of 151, 171
when not possible 77
written 76
inhaled route of drug administration 56–7
injectable formulations 58–9
innovation in pharmaceutics 59–60
inspections 135–6, 164–5
institutional review boards (IRBs) 27, 142–4, 145–6, 593–4
costs 693
member 144
in pediatric studies 228
insulin, as biotechnology product 283
insulin-dependent diabetes mellitus
(IIIDDM), management of 368
integrated service networks (ISNs) 728
intellectual property
legislation covering 656
types 620–1
see also copyright; patents
intent-to-treat analysis 340–1, 367
interim analysis 113, 337–9
internal consulting 164
International Conference on Harmonization
(ICH) 39, 63, 231, 438, 445
on adverse-event reporting 133, 538–9
on carcinogenicity studies 71, 72
clinical development guidelines 501, 648
on document storage 133
‘elderly’ drug guidance 191, 196–7
on ‘foreign’ data 232, 241–2
implications for sponsors 244
practical realities 244–5
Good Clinical Practices (GCP) guideline
25, 27, 140, 157, 160, 161, 162, 164, 168
on audits 164, 168
on quality assurance 160, 161, 162,
164, 168
guidelines 157, 445
on mutagenicity studies 68
on nasal sprays and aerosols 57–8
on pediatric studies 228
on pharmacovigilance 120, 122
on reproductive toxicology studies 71
Stability Test Guidelines 498
statistical guidelines 327, 335–6, 338–9
on toxicity studies 41, 63, 66, 68, 498–9
International Federation of Associations of
Pharmaceutical Physicians (IFAPP)
20
Internet links 745–7
contract research organizations 746
ethics in clinical research 746–7
medical societies and organizations 746
pharmaceutical companies 746
pharmaceutical-related societies 746
regulatory links 745–6
Internet marketing 661–2
intranasal formulations 57–8
intravenous formulations 58
investigational medicinal products (IMPs)
31
audit of procedures 173–4
costs 693
packaging and labeling of 31–2, 35, 59,
152, 188, 472–3, 502
storage of 170
supply requirements 35, 65, 152–3
see also study medications/devices
investigational new drug (IND) application
128, 402, 649–50
in China 670
Emergency IND 407–9
Treatment IND 409–10
investigative procedures, costs 690, 691
investigative site(s)
audits 170–1
basic infrastructure 128–33, 136
clinical aspects 133–6
deficiencies 137
FDA audits 135–6
financial aspects 134–5
gender bias 209
for geriatric patients 199–200
management of 127–38
performance criteria 136–7
selection of 142
types 127–8
see also study sites
investigator see clinical investigator
investigator fees 690–2
investigator meetings 33
costs 694–5
Investigator’s Brochure (IB) 28, 70, 105
Iran 677
Ireland, postgraduate qualifications 22
ISO standard(s)
on audits 166, 168
on quality management systems 160, 161,
162, 166
isotretinoin 562
Italy
clinical trial costs 690, 691
postgraduate qualifications 23
itraconazole 376
Japan
clinical fees calculation 690, 692
drug development
procedures 498–502
regulations 492–8
drug labeling 504, 529–30
drug regulation 487–507
generic drugs approval procedure 384
Health Policy Bureau 489
as ICH member 25, 63, 231, 438, 445,
487
import of study drugs 502
legislation
other pharmaceutical laws 492
Pharmaceutical Affairs Law
491–2
Ministry of Health, Labor and Welfare
(MHLW) 489–90
new drug approval process 502–4
Pharmaceutical Affairs and Food
Sanitation Council (PFSB) 489
Pharmaceutical and Food Safety Bureau
(PFSB) 488–9
Pharmaceutical and Medical Safety
Bureau 529
Pharmaceuticals and Medical Devices
Agency (PMDA) 489–91
population demographics 233, 487
post-approval activities 504–6
Japanese Pharmacopoeia (JP) 495
Jordan 677
patents 619–30
  criteria for obtaining 622–5
  extensions 619–20
history 621
  interference practice 628–9
  international treaties 626–8
value 630
patient compliance see compliance
patient fees (for phase I clinical studies) 694
patient information leaflets 472, 673
patient registries 523, 559
patient support groups 662
patients, influence on healthcare provision 8–9
pediatrics
  clinical studies 226–8
  physiological variations 225–6
peer-reviewed journals, publishing of
pharmacoeconomics 291–301
pharmacoeconomic data, reporting of
pharmacokinetic/pharmacodynamic models
pharmacokinetic parameters, prediction for
pharmacogenomics, in biotechnology
pharmacokinetics
  definition 89–90
  complex and time-dependent models 91–5
  involvement in drug discovery process 95–6, 97
  link/effect-compartment model 92–3
  single-compartment, time-independent models 90–1
pharmacokinetic studies 69
  nonclinical 499
  for special populations 196, 225, 226–7
pharmacokinetics 79
  gene therapy 281, 287
pharmacokinetics/pharmacodynamics (PK/PD), ethnic differences 234–5
pharmacology data 499
pharmacopoeias, early examples in Europe
  418–19, 423
pharmacovigilance 122, 305, 308–9, 429, 480, 535, 581
  audits 174
  in China 673
  see also risk management
pharmacy-sale products 475, 656
pharmacies 51–61
pharmaceutical benefit managers (PBMs) 728
  acquisition by pharmaceutical companies 737
  evolution and repositioning of 741–2
pharmaceutical industry
  bioethicists in 594
  business cycle 10
  clinical research education and training 25–39
  compared with other industries 653
  and contract research organizations 701–2
  ‘Generics’ vs ‘Big Pharma’ 381–3, 385
  Internet links 746
  and managed care organizations 730–40
  meetings with FDA 402–3
  mergers and acquisitions 736–7
  objectives 294
  overlap with academia 14
  and patient compliance issues 367
  research and development costs 10–11, 11, 12, 738–9
  special populations in studies 197, 214–15
  voluntary codes 602–3
pharmaceutical medicine
  definition 8
  disciplines covered 4
  as medical specialty 3, 7–23
  practitioners 3–4
  sciences involved 9
pharmaceutical product liability 605–17
Pharmaceutical Research Manufacturers of America (PhRMA) 601
  Clinical Results Database 526
Pharmaceutical Research and Manufacturing Affiliates Group (PhRMA, Middle East) 510
pharmacoeconomics 291–301
  baseline data/measures 295–7
  in clinical trials 297–9
  definition 292
  in development programs 294–5
  future uses 300–1
  limitations 300
  use by managed care organizations 729–30, 741
pharmacoeconomist(s), training and experience of 295
pharmacoepidemiologist(s)
  training 310–11
  use of electronic data by 306
pharmacoepidemiology 303–12
  in drug development 307
  in drug registration and licensing 308
  future developments 311
pharmacogenomics, in biotechnology
  product development 289–90
pharmacogeny 49, 388
pharmacokinetic parameters, prediction for humans 88
pharmacokinetic/pharmacodynamic models 89–95
  basics 89–90
  complex and time-dependent models 91–5
  use of EEG data by 306
pharmacy
  action if successful 98
  audits 172
  in China 668, 671
clinical trials in 567–8, 639–40
costing categories 695
design 106–9, 333–9
Japanese regulations 500, 501
multicenter trials 333–7
pharmacoeconomic measures incorporated into 297
toxicoLOGY studies 66–70
phase II and phase III clinical studies 101–17
  in China 668, 671
  compliance during 358–60
  for drug interactions 261–2
  exclusion of women 204
  future improvements 98
  industry practice 208–10
  investigative sites 128
Japanese regulations 500
pharmacokinetic questions 96
toxicoLOGY studies 66–70
phase IIb studies 520–2
phase IV (post-marketing) studies 119–25, 520, 522–3
  in China 668, 671
  clinical–legal interface 124–5
  clinical–marketing interface 124
  comparative superiority trials 120–1
  for special populations 123
  compliance during 361
data mining in 523–4
  drug interactions studies 123–4
  equivalence trials 120, 121–2
  goals 120, 520
  mega-trials 120, 122
  for new formulations 123
  for new indications 120, 122–3
  open-label studies 120, 121
  practical aspects 120
  for prescription-to-OTC switch 185
  safety monitoring in 523
  safety surveillance trials 122
  types 119–24, 522
phases of drug development, blurring of distinctions 101–2
Philippines 684–5
phacomelia 399, 425, 611
physicians, role in society 7
placebo controls in pediatric studies 228
  and phase IV studies 522
  regional differences 237
placebo effect 320
plagiarism 634
plague, treatment of 419
Plan ‘B’ 186
point-of-service (POS) plans 728
pooled analyses 523, 524
population demographics 233–4
population pharmacokinetics 228
Portugal, postgraduate qualifications 22–3
posters, publishing of clinical trials in 568–9
postgraduate qualifications 4–5, 20–3

758
INDEX
post-marketing authorization period, pharmacovigilance during 480
defenses in legal cases 608–9
post-marketing safety monitoring 535–43
contributory negligence 609
reasons for 535–6
post-marketing studies 119–25
example cases 610–15
see also phase IV studies
type 608
post-marketing surveillance (PMS) 308, 541–2
of accelerated approvals 411
in China 673
of good practice standards 497–8
FDA’s requirements 404, 601
and re-evaluation 505–6
and re-examination 505–6
and re-examination 505–6
potency 89
post-marketing surveillance (PMS)
and re-evaluation 505–6
and re-examination 505–6
and re-examination 505–6
power of test 315
in Japan 504–5
preclinical studies 79–100, 128
preclinical studies 79–100, 128
preclinical studies 79–100, 128
prescribers, as customers 655, 658–9
prescribers, as customers 655, 658–9
prescribers, as customers 655, 658–9
prescriber–patient communications 542
preferred provider organizations (PPOs)
pre-marketing phase 41
preferred provider organizations (PPOs)
pre-marketing phase 41
preferred provider organizations (PPOs)
pre-marketing phase 41
preferred provider organizations (PPOs)
pre-marketing phase 41
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
pregnancy
in clinical trials 207
drugs contraindicated during 71, 206, 224, 399, 424–5, 541
registries/follow-up studies 309–10
as immunomodulatory drug 560–1
number of infants affected by 611
theophylline 576
therapeutic agents, influences in adoption of 9–10
therapeutic coverage 361–2
therapeutic monitoring
general principles 375
see also concentration monitoring
Therapeutic Substances Act 424
therapeutic ‘window’ 181, 376
theriac (antidote, aka ‘treacle’) 417, 420, 421
timing noncompliance 363
tissue products 288
TMF audits 169–70
topical formulations 58
tort, law of 598, 608
toxicokinetic data 69
toxicology
acute toxicology studies 67
chronic toxicology studies 71
expert reports 73
in pediatrics 226
preclinical studies 63–73, 106
product licence/NDA requirements 72–3
special studies 72
trade names 461, 620
trade secrets 620–1
trademarks 620
traditional herbal medicinal products 470–1
trainees 16
training
audits 174
courses/programmes 20–3
of pharmacoepidemiologist(s) 310–11
records 19
sources 19, 525
transdermal formulations 58
travel costs 693
Treatment IND 409–10
treatment withdrawal, in clinical trials 112–13
Treaty of Rome 444
see also European Union
tuberculosis 194
Turkey, healthcare expenditure 677
type I errors 315, 326, 329
type II errors 315, 326, 329
UK
clinical trial costs 690, 691
clinical trials certification system 402, 409, 427
data protection legislation 601–2
drug regulation in 425–6, 599
early history 417–24
GCP guidelines/regulations 155
postgraduate qualifications 4, 20–1
prevention of research fraud 638, 639, 640, 641
R&D expenditure 11
regulation of advertising and marketing 481–2, 656
uncertainty, source(s) 316–18
Uniform Commercial Code (UCC) 606, 607, 609
United Arab Emirates (UAE) 509, 510, 514, 677
unmet prescriptivism 590
unobviousness, as criterion for patent 623
USA
clinical trial costs 690, 691
data protection legislation 602
drug labeling in 530–2, 601
drug regulation 395–414, 600–1, 649–50
history 395–400
special procedures 382, 399, 407–14
see also Food and Drug Administration
elderly population 193
GCP guidelines/regulations 155–7
generic drugs approval procedure 382–4
as ICH member 25, 63, 231, 438, 445, 487
import of drugs 740–1
IND application 128, 402, 649–50
medico-commercial environment 650, 651
population demographics 233
prevention of research fraud 636–7
regulation of marketing 656
Social Security benefits 194
utilitarianism 589
utility, as criterion for patent 623
vaccination, legislation on 422–3
vaccines 285
vaginal candidiasis 179–80, 187
vaginal pessaries 58

value for money, maximization of 291
value-added development programs 295
variability 316–18
Venetian treacle (aka theriac, antidote) 417, 420, 421
volumes of distribution 84
prediction in humans 84
volunteer studies, young participants 209–10
warfarin 93–5, 105, 194
interactions with other drugs 195, 258
warranty 607
Waxman–Hatch legislation 281, 399
Weber effect 547
weight/dose relationships
ethnic differences 238
gender differences 211
in pediatric use 224
‘white-coat’ compliance 357, 363
whole tissue studies 48–9
wholesale dealers’ licenses 431
Wiley, Dr Harvey 396, 397
willow bark extracts 105, 387
see also aspirin
withdrawal of drugs from market 579–84
causes 580
consequences 581–3
prevention 580–1
women
drug development research in 203–21
government agency responses 213–14
pharmaceutical industry practice
214–15
enrolment in clinical studies 64, 215–16, 217
as percentage of total population 203–4
potential childbearing population 216–17
representative population 205, 210, 216
see also gender differences
World Health Organization (WHO),
guidelines 140, 157–8
World Intellectual Property Organization (WIPO) 627
World Medical Association (WMA) guidelines 158
see also Declaration of Helsinki